<SEC-DOCUMENT>0000950170-23-006493.txt : 20230307
<SEC-HEADER>0000950170-23-006493.hdr.sgml : 20230307
<ACCEPTANCE-DATETIME>20230307171117
ACCESSION NUMBER:		0000950170-23-006493
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		102
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230307
DATE AS OF CHANGE:		20230307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39852
		FILM NUMBER:		23713619

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sclx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-07T13:28:23.6012+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:sclx="http://www.scilexholding.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_6463cc28-8d65-4f96-95bf-abffbc67ff81" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="C_0eb4f5f3-217e-4d32-9df0-0de97d9de853" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9210ffe7-39a4-4a0e-a307-01b932158bee" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e4a5c6db-30ef-462c-82dd-288b64103342" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="C_0eb4f5f3-217e-4d32-9df0-0de97d9de853" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_0bf5a962-5b24-48b1-9002-e5c81894ca56" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_6647079d-3f50-46e5-afdd-7cb5fff7d6ba" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b5b86b27-0532-49c1-b76c-6f887f0a63fc" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_aefe8b43-5bdf-4327-b2fa-26db087baf25" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_bc2eaed7-a292-4f4d-8ddb-007ba59ac15f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_29c766bb-4fce-4dbc-b8e4-92a68d84c25f" name="sclx:AccrualForTransactionCostsRelatedToTheBusinessCombination" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b54e17bc-61af-4171-b620-195b9f60d357" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_b620909f-073f-4a76-8775-805e21b71726" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_adf58944-3511-4a6c-9e5d-eeee7d745bfb" name="sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization" contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_54523a10-c706-4fd9-8164-2c0bfdbbf91a" name="sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d7029d50-a9ef-4592-9ed0-d44a967cfa64" name="dei:CurrentFiscalYearEndDate" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" format="ixt:datemonthday">12/31</ix:nonNumeric><ix:nonFraction id="F_6ef1b2d1-d409-4de2-8c2d-7363847d2a82" name="sclx:AccrualForTransactionCostsRelatedToTheBusinessCombination" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_708be5d4-a9d0-4908-bbbe-b2da444eaa07" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_a527389d-306f-4919-bfea-9e278fdd7f82" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_53016aa0-3b61-4375-bbc0-41251f062de2" name="sclx:TransactionCostsObligationAssumedBySorrento" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_557d651b-062c-47e0-8442-4e8146558b5a" name="sclx:OtherLongTermLiabilities" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3ea715ce-1b17-4fc1-b25f-7f625140097e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_7c048ae5-b63f-448b-ac5e-16d9e9290785" unitRef="U_shares" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b1071206-0591-4a2e-8730-fb93dbb2b787" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_9b930bf6-320d-4b6c-af8c-5aa608240d49" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_2e14ac05-2d70-479b-834b-0da0a2e27285" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039">http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction id="F_ac4101a1-c5ee-4706-a1b3-9f3fcddd0896" name="sclx:TransactionCostsObligationAssumedBySorrento" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_caaad943-62b2-4ebc-80c9-006fe6443079" name="dei:EntityCentralIndexKey" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291">0001820190</ix:nonNumeric><ix:nonFraction id="F_174a237b-3e62-4fa6-915e-8a53d0d37000" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a2bc1cc5-c1e7-43cf-a6f8-b4f4facf181d" name="sclx:OtherLongTermLiabilities" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_4a367a12-e012-4165-b149-5a78dbe3c071" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb">http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction id="F_41f57cde-2f51-43b9-9298-50e67016606a" name="sclx:DerivativeWarrantLiabilityPrivateWarrants" contextRef="C_da474804-4de4-46da-8eb7-10fd79d64919" unitRef="U_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction><ix:nonFraction id="F_7653d5f4-622c-4e12-b949-15400631d4f1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_170226e9-c00b-474c-bd4f-5a9963f10134" unitRef="U_shares" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a0f75d3a-9e10-4019-b021-87432668c6ac" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_8c37c057-4848-462d-ada1-a24a6cad00dd" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c168d39c-2871-42e8-b79d-b3ce199f3e7b" name="sclx:DistributionToSorrentos" contextRef="C_1b29efe1-913c-4907-b34e-894a0a2002b7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3ae621a8-3f3f-4d53-a551-5225faec3ab9" name="sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue" contextRef="C_9b930bf6-320d-4b6c-af8c-5aa608240d49" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_1b42e5e5-376a-4619-9690-cb8f5630cc07" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb">http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction id="F_bdcbe9bc-f5de-47ee-9b21-0cb6f9049bc6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_e5358be9-d8b5-4ee2-b332-0a8d62231dd7" unitRef="U_shares" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d7125064-9b76-4c9c-9019-5e82b70b444a" name="sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_14d9603c-d453-4443-95d8-8db6986dc87a" name="sclx:EffectOfBusinessCombinationInValue" contextRef="C_d123794d-4e0e-4ed2-bb14-c7d85afb939f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_29bd1289-b520-4e29-8ba1-ad024d26bcc3" name="dei:AmendmentFlag" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction id="F_728917e1-629e-4287-882c-0bb9e7bb1bc9" name="sclx:RecapitalizationDueToTheBusinessCombinationValue" contextRef="C_d123794d-4e0e-4ed2-bb14-c7d85afb939f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_11cebda7-8f87-4267-ac10-7be6b1acda18" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_0271b23c-aafd-4698-bd7b-106ba0477b32" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_8c37c057-4848-462d-ada1-a24a6cad00dd" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_61c0eef7-6384-452f-89b2-2406931de476" name="sclx:RecapitalizationDueToTheBusinessCombinationValue" contextRef="C_6bf9409a-d416-4d1d-a445-b90863d1d1c6" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_13bda9ef-a43d-4945-8aa9-0cae0d8d0725" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_00732d84-d8e8-4024-abae-db67a18b5da3" unitRef="U_shares" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a4cda2f0-ffce-4c0e-ae35-a6cbdae92144" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_18bdd4e4-1c39-4997-8142-276300487882" name="dei:DocumentFiscalPeriodFocus" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291">FY</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sclx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_cea31b52-db39-4e74-9ef9-00fbadd09e8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7eb481bd-4d9b-4545-b52a-3d1554edfd5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8af3e27b-97dd-4b7e-8523-2366035accc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:LegacyScilexCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4eac9786-7af1-498b-ade8-18ab32ec037e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sclx:InducementPlanAxis">sclx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ee0f0fb-af92-4b7b-b642-acfabbcf105e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-05</xbrli:startDate><xbrli:endDate>2018-10-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36afe8fd-cd95-4f09-aed3-b9387cac7efb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e229956a-eca3-48a8-a9c3-297169d09bc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffc67561-e990-47ce-8a93-35879897d05b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49abe51e-8cd0-4386-b0ec-79317162d36d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c80b9c46-2554-4fc5-8b0f-919a277a3868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27408945-d0d7-44d3-b555-007ee69f44da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67497c23-14fc-4051-a630-4c59813052eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_305b4be4-c15c-4501-b464-80c28ee532ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bed26af-6062-4ef5-8277-06de00c7bdeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:AardvarkAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbf37b66-c5d5-46d3-bd3a-c9a534d9acd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e325ed31-26e8-4093-8e73-8b5f019c9102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb34a34f-10db-4900-ac2a-b95cc1252ca0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a527389d-306f-4919-bfea-9e278fdd7f82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5024e079-7880-4bc6-b897-722b2e854e4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01d3fa20-46b6-4e6b-9289-84ca49a349a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a74f725-b9ea-4b81-818b-1b7c312abf01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51878a55-90f9-402f-b4db-e8e5f31208c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8ba7d57-830b-450b-b045-491a8e4913bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:SorrentoTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_560e4782-7a8f-459f-9609-b04f9e8ab33f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de43cc1f-2fdb-4769-8c7b-6c7cef7cb9b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea7b3fbf-8dd6-49a4-a28c-adc88beeb0ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a251053-d0ea-4cdf-85a7-8504f3883048"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ecb841e-8811-42ee-b52f-1ff866488d24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a1e9628-d82e-4638-abce-1a2d0888da09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da474804-4de4-46da-8eb7-10fd79d64919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83eae59f-9d4a-4170-b358-a33c0ee64291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d26ddb1f-b0fe-4faf-b8a1-857c9dd18019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e6b294a-07c5-4bc3-b0f8-28ef1bba9112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_646df392-6d69-4b69-80f2-861bf594ef6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a5560ce-e23e-4368-8572-860644a67abb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_906ba0ae-005a-42a4-a051-5cdede4e78db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:AdministrativeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9da5d773-9803-4cb9-b88b-b575366eed3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:EquityPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60091fdd-6400-442e-a7a0-8a096195f3d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-03</xbrli:startDate><xbrli:endDate>2022-06-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fac2033-f8b3-4b66-9e60-cd16541fd776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d23acd9a-b5cb-47a5-b3c3-5c16f3f1a346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecondAmendedCertificateOfIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a7981fc-b448-47e6-bbe7-0f3aa97fb3c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99d36902-bfd3-4b3d-847f-f4e34de66d2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ca01e5c-64ba-4811-8dd0-2596f60a100f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00732d84-d8e8-4024-abae-db67a18b5da3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d25b0fa-f232-49d1-bb07-eac65211d5f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:LegacyCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47fbaa34-ba91-4f95-8043-9f86ce21361b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2648accc-f3dc-426e-92a2-db64ebe17309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b7ed203-c059-4dea-8727-86670689b7cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c47f53f-c811-4186-9ff5-419aa14184c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e55c840-7ba5-4068-b9ac-a6ab3b619797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-01</xbrli:startDate><xbrli:endDate>2015-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ca10b55-83d0-43b1-ba2e-ab5f1c28907e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffce1a83-cdb6-4f8b-8ce0-60c88047dbe7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6647079d-3f50-46e5-afdd-7cb5fff7d6ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc5b8987-1bb7-4130-9b7a-6a3c9e569fde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-08</xbrli:startDate><xbrli:endDate>2023-02-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4cbb81e-b3d2-4016-bb84-fc0e80fe9230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-22</xbrli:startDate><xbrli:endDate>2018-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a481e148-6651-4f1b-8127-50bb57bdbf62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b0d5c8f-c285-4b81-adfe-90ae2f642ce4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ffc6a81-2d13-4ca4-89ec-8c611943a526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sclx:FrequencyOfPaymentsAxis">sclx:MonthlyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10bd7df9-bc0a-460b-b471-0b07966dbf8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:FundingCommitmentLetterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f187651-0980-4146-8085-29b42623f970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c57207b1-14a7-41a8-8d5b-1a183f1fb11b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43ab2205-1c3d-4a4c-81af-b8effc0a8d3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd06b1ee-3d7a-4324-8584-ffe7cba561aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ca96e60-bf56-4765-9420-632b08ad825f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:VickersDebtAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b6f23f6-2673-4fcb-bf14-d6a9163b7497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_509f938b-6ead-4be2-8bdc-b00905b87017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c64fc25e-92ac-443f-a2c8-1c627ddec5c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0205795c-8a73-4b30-885d-bfc720c71093"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7cfc2da8-8fde-41ac-99ad-52a0a1ee5813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9f1e9c3-d961-4504-8da6-3bd4eb3c8fbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-02</xbrli:startDate><xbrli:endDate>2022-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b29efe1-913c-4907-b34e-894a0a2002b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74765fdd-abd5-4a48-b447-771ee939f2e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd0b590c-8ba4-42a9-a808-760e195081f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bd18d66-7285-40d4-8961-714fd8c2eb8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5358be9-d8b5-4ee2-b332-0a8d62231dd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bf41c40-384d-4879-a540-39666147391f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-14</xbrli:startDate><xbrli:endDate>2022-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d38defbd-6d26-448d-a459-d2d7ff5e7a40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6adfa385-28e2-4bb5-b8a7-8b66dc48c7de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02f580e6-c788-4eef-9f36-799127c833b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-02-01</xbrli:startDate><xbrli:endDate>2013-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b97057d7-7304-4fd2-8467-c5db2179660a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c394325-8608-4ec1-8f78-11dd10ae9413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1803839-1bed-4d8d-a474-a5546b31743c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc7d0f2d-5bbb-46cf-929e-8eb3fbe1169a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4216d375-5857-4658-937f-eb7e215cb19f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26f9a78f-d20f-4189-8bc1-b3bfc1c9e6c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a8702ad-037a-48f2-8a73-f2f31cbe072b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b6804ad-db9d-442b-8365-1912fdf47899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:LegacyCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85fddfc8-ede1-4821-8070-f8272993162e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5732eb05-268c-4927-ab42-4931ac50cee6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fac449c-067b-401a-bdcc-4e3e9932dff4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb4e9c2d-4697-4133-b0c7-df08bcc87742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:VickersDebtAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b5ecdb8-3bc8-4088-bf74-05a8fbd7c323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3377c481-f9db-4160-b872-f87f6e365001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21eb1f4e-32ad-4b44-99ff-e9ffd99b9aa5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e32c9b3-9d19-4265-8164-574e03766785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2416c551-e9fc-44d6-b78f-4b72a1263fbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a56b9b5-0e8c-4c4c-a42e-683ebcaf8d04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8bd7dfd-bf6a-41eb-a0d6-21c0c0e518ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-15</xbrli:startDate><xbrli:endDate>2022-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed6ebbfe-7582-45c9-a505-88a5349d8983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64b784b2-80c2-40ef-8826-8180d2f928c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a7ce1a3-b831-4b91-8f43-85fae241ba37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_635fb103-c71a-477c-8c47-7047957e404b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:EquityPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-17</xbrli:startDate><xbrli:endDate>2022-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cf5091c-7b41-4d84-af4b-27015818f063"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16948957-8702-4576-aa50-3b0b402e4d82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3313f304-eb89-4d42-83ee-725fd81202b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bf9409a-d416-4d1d-a445-b90863d1d1c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44ed269a-dde2-4886-8ee5-2f9c77ffdde5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecondAmendedCertificateOfIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42d227b9-ddaf-4601-acc3-2ee568156933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-02</xbrli:startDate><xbrli:endDate>2022-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc2eaed7-a292-4f4d-8ddb-007ba59ac15f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42dde953-1de3-4888-9e2a-9a55861296bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:VickersDebtAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b620909f-073f-4a76-8775-805e21b71726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccca58d1-1a9c-4f4b-8d50-efc7509df65b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1bc45ab-d342-4c18-b196-5098efc938e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:RelatedPartyNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbd32b12-fb83-432d-9c2d-e70a0b209ce4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a476f78c-ccf8-4bfe-b276-63e339cbc4fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97b73263-30f4-4653-9e9d-edde5c0042df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a917c50-4370-49ab-9afd-58aaa9a10804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efd6a36c-f68c-4a10-8867-54bd97146b01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46761a2f-b18a-4aaa-8269-68342d732dc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:RelatedPartyNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e69aafa-547e-45e9-bdf7-d87792ef197d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52e1afd8-0dd3-4e45-8542-1b0396bc18c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ItochuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a34d7e4b-75b0-46b3-9b67-fb0bd31b0200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0720b69-b850-4e33-b843-ca514f86a042"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ItochuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1a7d0f1-3664-4a42-9233-282dd426f358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8af8c6e1-609d-44ef-9f26-2b6bd7056a94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bef67e9a-4b76-4019-893d-8f19c877187f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5350c734-a3ef-4fd1-88d3-af11b48f40cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a5c0b06-915d-455f-9fc7-0f9a23843003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a708aae3-4854-410d-ab82-fbfc4a130c97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cfa11ab-3c88-4cef-9e78-7b5083e4ce05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a25c562-96ff-46d5-bbd4-d140bf78fd97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05185b29-2199-41ac-97f8-a22476c305be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sclx:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01b3c958-391f-4745-a694-8e6d618b12d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0de8b1c-7d16-427b-aa57-833ab07979da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecondAmendedCertificateOfIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e39da0e0-163c-455f-965a-58ab13bf9d84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-07</xbrli:startDate><xbrli:endDate>2018-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_935d8df9-59c4-47da-a78c-46dc24743107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_464851d6-2036-40d8-94d5-168fe9bff9ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a4759f2-8d65-4ebd-9e91-79f879ffa0f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbd5dc57-1898-456c-9638-93bc81132559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c97eb44-901a-46bb-99e9-b42a24cc2386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3710aa11-fcfc-4dcd-aacb-4c89272492cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32ab59f7-6a30-49d8-81a3-b2690ed7e60b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b50d45e3-e036-46e1-88f2-6346a47e412b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc227406-9649-405a-abe9-80c403455490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef14117d-6b86-46ed-956e-d73420b1a933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3829a111-1d2a-42cf-8ef3-8eee8d13b455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-28</xbrli:startDate><xbrli:endDate>2022-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6337de38-c2dc-48a8-b488-04cc48d9be24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3faac18-7970-4d6f-9b9f-ebaa1c4bc17f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6afef57-8906-4dde-a3a5-2e46d3fa8a04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb7297d5-c3c9-4562-83bf-bfeaeab23e3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3354e157-13ff-4e9f-bfd3-3f7a68647739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-12</xbrli:startDate><xbrli:endDate>2022-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0acf01dd-c0f8-474b-86b7-9a4ee39ecb2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:EquityPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-17</xbrli:startDate><xbrli:endDate>2022-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7de5b4e3-ff7d-4a25-8702-760a6461c79b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b13cd8e3-7db7-4217-8072-5fe48b25740e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae30ee0d-8ccb-47a5-834c-471e858d4c23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e23bb04d-0ba8-4323-a7aa-cc2b64211427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5afaea6d-9fb4-41dc-9415-7c291b048f12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-28</xbrli:startDate><xbrli:endDate>2022-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e8d69bd-8277-4214-b3a2-0f8215199def"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b8c6875-5daf-4b8b-bbe3-c55418e62301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-05</xbrli:startDate><xbrli:endDate>2018-10-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8f61138-8d7f-420c-9c8d-08f6643abad5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6462068b-60b7-499d-ac23-4f81f11e97d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1cafa60-e7b5-445c-b9e8-7dc034751dc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ItochuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d408965d-1291-4b37-9b62-a779f1f46c23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58cd7445-cfd3-4b6c-9853-77975484a3f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52b44a02-592f-4ce7-8c2c-3d786b8c7f58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c4a15ab-7f26-41bf-ba84-63b74afb22cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8219a545-34c9-4750-80f1-f7f2e16e64f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81a151cb-066d-45a5-8264-1e0d16707f77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76b68a36-8bf6-4b4f-ba40-ee105d4ec879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c37c057-4848-462d-ada1-a24a6cad00dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c1f3d78-c5e0-4b4b-93a7-3c1f21841465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_456895c8-fe6d-4068-beff-13288c8937f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43387abc-3f9a-4d01-8539-0e8a069d288c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_218d96e4-ea4f-4f86-8b2f-c64a6bcff94a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40562d01-6462-499f-a04a-47153823c26b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-02-01</xbrli:startDate><xbrli:endDate>2013-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_461cdc24-bee6-49eb-825f-a615ecb35d40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d79b6ca-f817-4000-9690-57cda2cd8b96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sclx:FrequencyOfPaymentsAxis">sclx:MonthlyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34aca91d-0225-49d8-82d3-b112cf786117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a447a6e2-4ac3-4afb-95ec-8bfbc792b678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_422ae92b-12d6-4a4a-b618-0c2fa63c8e57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5202eaa2-94ce-4852-a791-98e95950e6e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:FirstAmendedCertificateOfIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d2870e1-119e-419e-9885-26f2174d6332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7a078e2-6aea-4910-9389-223a17cbe1d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5431b419-860c-45a2-bb9a-fd5a0ef55758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-08</xbrli:startDate><xbrli:endDate>2023-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cce805c3-34ca-4d41-82ac-e95225784312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55510dfd-6682-410d-b6b4-4d16606f2bde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2cce05e-1a26-43e6-8f1f-e439a7aa2acd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d123794d-4e0e-4ed2-bb14-c7d85afb939f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b930bf6-320d-4b6c-af8c-5aa608240d49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edcc144e-d7f7-43da-bd1b-72d518cd963f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c048ae5-b63f-448b-ac5e-16d9e9290785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_170226e9-c00b-474c-bd4f-5a9963f10134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a36dab1-2630-4e69-8371-8793ba9072bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-14</xbrli:startDate><xbrli:endDate>2022-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6202898d-9295-4896-a66a-61c32e1f4b3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:AardvarkAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98ba01df-597b-4318-aca4-8f7bf10d4909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:LegacyScilexStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb1d9fe2-1ba9-49c8-9a85-dcf2896bdf52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:EquityPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47ef1e97-f5b2-4965-919e-b1ad07eae683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33d1eca1-5b22-4cf6-bc73-83bb4af8df1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_478baeaf-44cf-43d3-a89f-f421fb630ec5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-02</xbrli:startDate><xbrli:endDate>2022-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_777530a8-90c5-459f-8a78-9891fb3b3069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5033dffd-d662-4f5b-9fe3-88e68279b972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e6757a4-23e1-4b86-9c56-e99208d69c95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0eb4f5f3-217e-4d32-9df0-0de97d9de853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0ff95ef-24d5-464a-957b-98f6e31fc5f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17686498-39e6-4eca-a9d9-732664349cdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ItochuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1e465a4-3408-4232-a9fe-97ae297cdf9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe20fc93-e090-4257-8aea-e4facd17edbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cbfb5ab-baf8-419e-afef-9b3373e009f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:FirstAmendedCertificateOfIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e39411dd-ee32-4564-9103-dfccf71f4ba3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3d7eb79-4633-4e48-bbe1-9c972c6e1a38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9922975f-1d41-4752-92b7-f2ec2c047e71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-02-01</xbrli:startDate><xbrli:endDate>2013-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_efe1a9a6-58f4-4735-a3c3-cf9c01c9b525" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.996%;"></td>
    <td style="width:96.004%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_5269e161-f1d0-44d3-a47d-581709f9f4f1" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended: </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0e317b2-65f6-4ad5-8814-db0bff27a8b3" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5c0d9927-878f-4b08-9d89-b9859313cddb" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.996%;"></td>
    <td style="width:96.004%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_3e44c532-fc70-4029-a22b-51996ac39baa" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                  </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the transition period from                to</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3a7cfb6b-b0e6-49b0-9561-38dfb3b674d6" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39852</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6cdee382-bbf2-4606-a892-36366d7d4d33" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Holding Company</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact Name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b24830a1-e261-416d-846a-20ff83f31353" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b4b7d034-878d-4867-80ce-db60af085964" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92-1062542</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporation or Organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d99b021f-8c31-45c1-a7b4-a591b8b0b8e8" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">960 San Antonio Road</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f0f16efd-ee96-45f9-9116-d9c4f988d09c" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Palo Alto</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e414a74c-2b71-4ed6-9788-06d5105a1397" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;94303</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4cbef0c2-a9df-4421-bdc5-f883c8f129c9" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94303</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_22d1f716-d5c9-42d5-b4ec-42111a01a4bd" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2a6d9990-bb60-4096-a549-b35dc26c8ea0" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">516-4310</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Registrant&#x2019;s telephone number, including area code)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.991%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of exchange on which registered</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b47a529d-625b-42b0-82e9-e2ef4fa4a7da" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8414da00-804a-4be8-bf22-26941ca74d72" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCLX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cc35dcbd-01a7-460f-b4b8-21be601af1b4" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Stock Market LLC</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCLXW</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Stock Market LLC</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Yes     </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0dcd4b4-ddbe-4bfb-aa7b-0056e575b8c5" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or  Section 15(d) of the Exchange Act.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes      </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746; </span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e182a69c-1860-4476-ba3c-7eb4f96e0e21" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_edaa7a10-87a4-4f67-a1a4-4ddd76ea54b0" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">     </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746; </span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3fb2259a-3dea-49bc-b399-0331d4a60fc7" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">      </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.889%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:55.844%;"></td>
    <td style="width:1.058%;"></td>
    <td style="width:20.096%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:2.105%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e8e86531-519b-41c6-ab67-2218ffbd16a0" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_cfd0e12d-dd68-4e8a-84bf-075699b69174" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntitySmallBusiness" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_d4c36710-9dec-46c4-a12b-9e05a00103f4" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e4bdf706-ed4f-428f-8fc1-59b7cb0f0015" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_66571ff9-5e67-4495-ab30-1b3e78bb4296" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). &#9744; Yes     </span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0fe5b75c-cd26-47f6-a5d2-cea7bb6fad9c" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of voting stock held by non-affiliates of Vickers Vantage Corp. I (&#34;Vickers&#34;), our predecessor, is calculated based upon the closing sale price of the common stock on June 30, 2022 (the last trading day of the registrant&#x2019;s second fiscal quarter of 2022), as reported on the Nasdaq Capital Market, was approximately $</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa9d9e67-e8e8-4a71-a988-a9494f0efc97" contextRef="C_8af8c6e1-609d-44ef-9f26-2b6bd7056a94" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">99.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At March 3, 2023, the registrant had </span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c1386de-03ea-4c76-9d19-d099df31ebd9" contextRef="C_3ca10b55-83d0-43b1-ba2e-ab5f1c28907e" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">145,800,574</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock outstanding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7bd9bf5b-1927-49ac-bf66-3038ddc22733" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant&#x2019;s fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCILEX HOLDING COMPANY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT ON FORM 10-K</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FISCAL YEAR ENDED DECEMBER 31, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.004%;"></td>
    <td style="width:76.998%;"></td>
    <td style="width:11.998%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page No.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#market_for_registrant"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#mda"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">179</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#financial_statements_and_supplementary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">179</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">179</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">179</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">182</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">182</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">182</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#certain_relationships_and_related"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">182</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">182</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item15"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">183</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item16"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">188</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCILEX HOLDING COMPANY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As used in this Annual Report on Form 10-K, unless the context requires otherwise, references to the &#x201c;Company&#x201d;, &#x201c;Scilex&#x201d;, &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;, and similar terms refer to Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;), and its consolidated subsidiary. References to &#x201c;Legacy Scilex&#x201d; refer to the private Delaware corporation that is now our wholly owned subsidiary and named Scilex, Inc. (formerly known as &#x201c;Scilex Holding Company&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 10, 2022, we consummated the previously announced Business Combination pursuant to the Agreement and Plan of Merger, dated as of March 17, 2022 (as amended by Amendment No. 1 to Agreement and Plan of Merger, dated September 12, 2022, together, the &#x201c;Merger Agreement&#x201d;), by and among Vickers, Vantage Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a wholly owned subsidiary of Vickers, and Legacy Scilex. Pursuant to the terms of the Merger Agreement, a business combination (herein referred to as the &#x201c;Business Combination&#x201d; or &#x201c;reverse recapitalization&#x201d; for accounting purposes) between Vickers and Legacy Scilex was effected through the merger of Merger Sub with and into Legacy Scilex with Legacy Scilex surviving as Vickers&#x2019;s wholly owned subsidiary. In connection with the Business Combination, Vickers changed its name from Vickers Vantage Corp. I to Scilex Holding Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless otherwise noted or the context requires otherwise, references to our &#x201c;Common Stock&#x201d; refer to our common stock, par value $0.0001 per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain statements contained in this Annual Report on Form 10-K may constitute &#x201c;forward-looking statements&#x201d; for purposes of federal securities laws. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements appear in a number of places in this Annual Report on Form 10-K including, without limitation, in the sections titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as &#x201c;plan,&#x201d; &#x201c;believe,&#x201d; &#x201c;expect,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;intend,&#x201d; &#x201c;outlook,&#x201d; &#x201c;estimate,&#x201d; &#x201c;forecast,&#x201d; &#x201c;project,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;possible,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;should,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar words and expressions (including the negative of any of the foregoing), but the absence of these words does not mean that a statement is not forward-looking.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These forward-looking statements are based on information available as of the date of this Annual Report on Form 10-K and our management&#x2019;s current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks and uncertainties and other factors, many of which are outside the control of the Company and our directors, officers and affiliates, that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K. There can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forward-looking statements in this Annual Report on Form 10-K may include, but are not limited to, statements about:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      our public securities&#x2019; liquidity and trading;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      our ability to raise financing in the future;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      the outcome of any legal proceedings that may be instituted against us;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      our ability to attract and retain qualified directors, officers, employees and key personnel;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      our ability to compete effectively in a highly competitive market;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;   the competition from larger biotechnology companies that have greater resources, technology, relationships and/or expertise;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      the ability to protect and enhance our corporate reputation and brand;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      the impact from future regulatory, judicial and legislative changes in our industry;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      our ability to obtain and maintain regulatory approval of any of our product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      our ability to research, discover and develop additional product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      our ability to grow and manage growth profitably;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      our ability to obtain and maintain intellectual property protection and not infringe on the rights of others;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      our ability to execute our business plans and strategy;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      the impact of the COVID-19 pandemic and other similar disruptions in the future; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;      other factors detailed under the section of this Annual Report on Form 10-K titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk Factors.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should one or more of these risks or uncertainties materialize or should any of the assumptions made by our management prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the continuing COVID-19 pandemic, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update, add or to otherwise correct any forward-looking statements contained herein to reflect events or circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span id="part_i"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span><span id="business"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he Company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are developing our late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate, and a Phase 1 candidate that is expected to enter Phase 2 studies in 2023. Our commercial product, ZTlido</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">&#xd2;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) for the relief of neuropathic pain associated with postherpetic neuralgia (&#x201c;PHN&#x201d;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. We license the rights to ZTlido from and rely exclusively on Oishi Koseido Co., Ltd. (&#x201c;Oishi&#x201d;) and Itochu Chemical Frontier Corporation (&#x201c;Itochu,&#x201d; and together with Oishi, the &#x201c;Developers&#x201d;) pursuant to the Product Development Agreement and Commercial Supply Agreement. We have acquired two FDA approved non-opioid pain products for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults, which we plan to commercialize in the U.S. in 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our three product candidates are (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (&#x201c;SEMDEXA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">&#xd4;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; (ii) SP-103 (lidocaine topical system) 5.4%, (&#x201c;SP-103&#x201d;), a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (&#x201c;LBP&#x201d;); and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (&#x201c;SP-104&#x201d;), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2023. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 14, 2022, we entered into a License and Commercialization Agreement (the &#x201c;Romeg Agreement&#x201d;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#x201c;Romeg&#x201d;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1) the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States, and (2) an exclusive, transferable license to use the trademark &#x201c;GLOPERBA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">&#xd2;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;. GLOPERBA is an FDA-approved, oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain and can be disabling with tenderness, warmth and swelling. Non-steroidal anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S. is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. We have a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S. For more information on Scilex, please see the section titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business &#x2014; Material Agreements &#x2014; Romeg License and Commercialization Agreement.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; On February 12, 2023, we acquired from BioDelivery Sciences International, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Collegium Pharmaceutical, Inc. the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (celecoxib oral solution) and the commercialization thereof in the United States and Canada. ELYXYB</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.  We are planning to commercialize ELYXYB</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the U.S. in 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are focused on identifying treatment options for pain management with established mechanisms that have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of these pipeline product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our marketed product, ZTlido, has multiple advantages over currently available prescription and over-the-counter (&#x201c;OTC&#x201d;) lidocaine patches, of which over 147 million and 136 million of such patches were sold in the United States in 2021 and 2020, respectively, according to Symphony Healthcare. We have sold 6,336,032 and 7,011,112 ZTlido patches in the United States in 2020 and 2021, respectively. We acquired SP-102 from Semnur Pharmaceuticals, Inc. (&#x201c;Semnur&#x201d;) in March 2019 and are developing SP-102 to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by off-label epidural steroid injections (&#x201c;ESI&#x201d;), which are administered over 12 million times annually in the United States. See the section titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business &#x2014; Material Agreements &#x2014; Semnur Merger Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; for a description of our acquisition of Semnur and our ongoing obligations to Semnur&#x2019;s former equityholders. SEMDEXA&#153; has been granted fast track designation by the FDA and, if approved, could become the only FDA-approved ESI for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over 4.8 million patients would suffer from sciatica in the United States in 2022. SP-103 has also been granted fast track designation by the FDA and, if approved, could become the first FDA-approved lidocaine topical product for the treatment of acute LBP. We are developing SP-104 as a novel delayed-release formulation of low-dose naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used off-label to treat fibromyalgia. There are no low-dose formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. We believe our currently approved product and future product candidates, if approved, could uniquely address what we believe are the significant unmet needs of the targeted populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section7">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Marketed Product and Pipeline</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following chart illustrates our current commercial product and novel product candidates, for which we have worldwide commercialization rights, except with respect to Japan for ZTlido and SP-103.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_0.jpg" alt="img248422670_0.jpg" style="width:624px;height:311px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section8">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our vision is to become the leading pain management company delivering novel non-opioid and non-addictive treatments to provide safe, effective and durable relief of multiple pain conditions. To accomplish this, the principal elements of our strategy are the following:</span></p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maximize the commercial potential of ZTlido.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We have assembled an integrated commercial organization using a dedicated sales force and sales management, marketing and managed care capabilities to support continued uptake of ZTlido. We leverage a sales force of approximately 60-70 people, targeting over 10,000 primary care physicians, pain specialists, neurologists, and palliative care physicians who we believe treat the majority of PHN patients. Additionally, we are utilizing direct-to-patient marketing strategies to expand awareness and utilization of ZTlido. Our managed healthcare account executives have extensive experience in negotiating contracts and have already achieved significant uptake by adding ZTlido to key formularies such as CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem Blue Cross Blue Shield (&#x201c;BCBS&#x201d;), BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota.</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercialize and successfully re-launch GLOPERBA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for gout in the U.S.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We will utilize our current commercial infrastructure comprised of our sales, marketing, and managed health care functions to promote GLOPERBA&#174; for gout to approximately 3,000 healthcare providers (&#x201c;HCPs&#x201d;) in the U.S. market. We anticipate a good degree of overlap between the current HCPs </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:10.0%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that we target and HCPs who prescribe colchicine for gout, allowing for efficient dual promotion of Gloperba and ZTlido. The principal elements of the GLOPERBA strategy are as follows:</span></div></div>
  <div style="margin-left:18.13%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5417124709905945%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Educate the market on the need for and value of simplified and precise colchicine dose adjustments to allow individualized, patient-by-patient therapy. Scilex will leverage its in-person sales forces, medical affairs teams, and omni-channel HCP engagement campaigns to drive awareness of GLOPERBA&#x2019;s features and benefits. In addition, target providers, rheumatologists and primary care physicians treating various comorbidities, will be provided with tools to help them identify and prescribe GLOPERBA to appropriate patients.</span></div></div>
  <div style="margin-left:18.13%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.5417124709905945%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase access to GLOPERBA for subsets of patients in prophylactic treatment of gout, specifically those with comorbidities and GI intolerance. Our managed healthcare account executives will negotiate contracts with key payer and pharmacy customers to achieve uptake of key formularies.</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Develop and commercialize SEMDEXA as a novel epidural injection for the first approved treatment of sciatica.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used off-label. Many of these products contain potentially neurotoxic preservatives and particulates, and are administered over 12 million times annually despite a warning on the label of serious neurologic complications, including loss of vision, stroke, paralysis and death. These products carry warnings required by the FDA that the safety and efficacy of epidural administration has not been established. SEMDEXA has received fast track designation from the FDA and, if approved, could become the first FDA-approved epidural steroid product with long-term patent protection, which we also believe would create significant barriers to entry. Due to the novelty of our formulation as well as the associated patents and trade secrets, future potential competitors could be required to conduct extensive preclinical studies and costly comparative clinical trials. A full 6-month data analysis was completed in February 2022 and we have recently completed a pivotal Phase 3 study with final results received in March 2022, which results reflect achievement of primary and secondary endpoints. We believe these final results are supportive of a breakthrough therapy designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program leading to market approval. We have extensive clinical and pre-clinical data (including those obtained from multiple Phase 2 clinical trials) with the novel viscous gel formulation of SP-102. We expect to present the robust data collected over the course of our multi-year clinical development program to the FDA as part of a New Drug Application (&#x201c;NDA&#x201d;). We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022.</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursue clinical development of SP-103 for the first approved topical treatment in patients with acute LBP.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are developing SP-103 as a triple-strength lidocaine topical system for the treatment of acute LBP, to be used where we believe a high-dose strength and superior adhesive qualities of a topical system may provide a greater therapeutic benefit than currently available therapies. SP-103 is designed to use ZTlido&#x2019;s delivery and adhesion technology to deliver a dose of lidocaine that is threefold higher than any other approved lidocaine topical products. We initiated a Phase 2 trial in acute LBP in the second quarter of 2022. SP-103 has been granted fast track designation by the FDA and, if approved, could become the first FDA-approved lidocaine topical product for the treatment of acute LBP.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursue clinical development of SP-104 for the treatment of fibromyalgia, which has very few approved therapies that are marginally effective and have unpleasant side-effects.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are developing SP-104 for fibromyalgia. Low-dose naltrexone hydrochloride delayed-release capsules are routinely used off-label to treat fibromyalgia and other chronic pain conditions such as complex regional pain. SP-104 addresses the shortcomings of using the high-dose commercial products and pharmacy-compounded products by delivering a low-dose of naltrexone hydrochloride (approximately 11 times less than the commercial product) in a delayed-release formulation that bypasses the stomach and releases the drug in the gut (upper intestine). These product characteristics mitigate against the known safety issues associated with the high-dose commercial products and immediate release pharmacy-compounded products, and the overall reliability issues associated with pharmacy-compounded products. SP-104 has completed two Phase 1 studies to characterize the pharmacokinetics and safety of the product, and we expect to commence Phase 2 studies in 2023.</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expand our product portfolio by developing or acquiring non-opioid assets that leverage our novel delivery and adhesion technologies or our existing commercial infrastructure.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are continuously evaluating opportunities to leverage our research and development experience to develop non-opioid therapeutics for pain management indications that are not adequately served with existing treatment options. We also seek to in-license or acquire non-opioid therapeutics that can both complement our existing product portfolio and benefit from our existing commercial infrastructure. In evaluating marketed and clinical-stage expansion opportunities, we intend to pursue therapeutics that address markets served by our established target physician audience and that can be commercialized by our existing sales force.</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leverage our management team&#x2019;s experience to further develop and commercialize its current and future product portfolio.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our management team has held senior positions at leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd. (&#x201c;Teva&#x201d;), Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. Our team has substantial experience in rapidly progressing new drugs to clinical proof of concept, completing successful pivotal registration programs and successfully commercializing products.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#x2019; lives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section9">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Management Team</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have assembled a management team of experienced biopharma industry veterans, who have deep scientific, business and leadership expertise in pharmaceutical industry, in addition to strong transactional and business development track records.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management team is led by our Chief Executive Officer and President, Jaisim Shah, with strategic guidance from our Executive Chairperson, Henry Ji, Ph.D. They collectively have over 60 years of global biopharmaceutical and biotechnology experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jaism Shah has over 30 years of industry success in leading product development &amp; commercializing innovative therapies and creating companies with documented success in development and commercialization of some of today&#x2019;s most recognized pharmaceutical brands. He is a seasoned life science executive and board director with extensive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accomplishments at Bristol-Myers Squibb, Roche, PDL Biopharma, Sorrento, Pfizer/Upjohn, Scilex, and start-ups such as Elevation and Semnur Pharmaceuticals. Mr. Shah has been Chief Executive Officer and President of Semnur Pharmaceuticals (acquired by Scilex Pharmaceuticals) since its inception in 2013. He has served as Chief Executive Officer and President of Legacy Scilex and Scilex Pharmaceuticals since March 2019 and of Scilex since November 2022. Mr. Shah also serves on the board of directors of Sorrento Therapeutics Inc. and Scilex Holding. Most recently, Mr. Shah served as Chief Business Officer of Elevation Pharmaceuticals where he focused on financing, business strategy, mergers and acquisitions, and business development. He led the sale of Elevation to Sunovion Pharmaceuticals in 2012. At Facet Biotech and PDL BioPharma, he served from 2000 to 2009 as Chief Business Officer and also held the position of senior vice president of marketing and medical affairs. During this time, he completed numerous licensing/partnering and strategic transactions including with Roche, Bristol-Myers Squibb, Otsuka, and Biogen Idec. His leadership in marketing and portfolio management including leading the commercial enterprise helped the company make large improvements to meet its profitability potential. At Bristol-Myers Squibb, as vice president of global marketing from 1997 to 2000, Mr. Shah received the &#x201c;Presidents Award&#x201d; for completing one of the most significant collaborations in the company&#x2019;s history. Prior to working with Bristol-Myers Squibb, Mr. Shah led international marketing for oncology and virology and was global business leader for corporate alliances at Roche from 1991 to 1997 with Genentech and IDEC, and prepared products for worldwide launch and pre-launch at F. Hoffman-La Roche AG in Switzerland. He has played a key role in the formulation of long-range plans and pre-launch and launch strategies for such brands as Abilify&#174;, Pegasys&#174;, and Rituxan/MabThera&#174;, each of which have generated well over $1 billion in sales. Dr. Henry Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento Therapeutics, Inc.&#x2019;s (&#x201c;Sorrento&#x201d; and, together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries), the &#x201c;Sorrento Group&#x201d;) intellectual property. Our Chief Financial Officer, Elizabeth Czerepak, has more than 35 years of finance and operational expertise across pharmaceuticals, biotechnology and venture capital. Our research efforts are guided by highly experienced scientists and experts. Our management team contributes a diverse range of experiences from leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. With this leadership, we believe we are well positioned to achieve our vision of becoming the leading pain management company delivering novel non-opioid and non-addictive treatments to provide safe, effective and durable relief of multiple pain conditions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we are supported by impressive teams across all levels of the organization. We hire and develop world-class talent from diverse backgrounds in biopharma, academia, technology and finance to ensure we have all of the capabilities to design and deliver effective first-class pain management therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section10">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Product Portfolio</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZTlido</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our marketed product, ZTlido, is a lidocaine topical system approved for the relief of neuropathic pain associated with PHN. ZTlido was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. We launched ZTlido in October 2018 with an integrated commercial organization and we believe its differentiated therapeutic profile, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated sales growth and increased market uptake.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prescription Lidocaine Patch Market Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief of neuropathic pain associated with PHN. PHN is a chronic neuropathic pain syndrome that results as a complication following an infection of herpes zoster, also known as shingles. Herpes zoster symptoms resolve after a few weeks, but the pain caused by the nerve injury can persist for months to years surrounding the affected area. According to Evaluate Ltd., there were over 3.5 million people living with PHN conditions in the United States in 2021. Lidocaine patches have also been used in patients with other types of pain, such as diabetic neuropathy, osteoarthritis and pain associated with surgery, cancer or trauma, and often in patients with LBP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, there were more than 147 million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. Of this, five lidocaine patch manufacturers accounted for approximately 92% of the total prescriptions, according to Symphony Healthcare. We believe that the PHN market will continue to expand with the introduction of our lidocaine topical system, ZTlido, which is supported by our commercial organization, by prescribing trends away from opioid use, and by continued growth in the population of patients aged 45 years and older who are at greater risk of suffering from PHN. Unlike Lidoderm, the FDA has not determined that any other products are therapeutically equivalent to ZTlido, and accordingly, a prescription for ZTlido may not be able to be substituted by a generic product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current Treatment Landscape and Limitations of Existing Treatments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recommended first-line treatment for the relief of neuropathic pain associated with PHN includes topical lidocaine, gabapentinoids (which have been associated with the potential for abuse as well as numerous adverse events), antidepressants and a multi-modal approach. Topical lidocaine and gabapentinoids are preferred for combination therapies due to their low propensity for drug-to-drug interactions. For example, an eight-week combination use with pregabalin (Lyrica) has been proven to reduce pain in half for patients who had inadequate relief on monotherapy, despite titration of pregabalin to effect. This efficacy boost was achieved without tolerability issues or adding to side effects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A survey analyzing treatment patterns for neuropathic pain associated with PHN found that recommended first-line therapeutics were used in only 29% of patients examined from 2010 to 2014, while the remaining patients were started on various off-label treatments, including nonsteroidal anti-inflammatory drugs (&#x201c;NSAIDS&#x201d;) and opioids. These drugs can have adverse effects, especially on elderly patients, which represent the majority of PHN patients. For example, opioids carry a well-characterized risk of abuse and misuse and the potential for serious side effects, such as respiratory depression, constipation and others, including death. According to the Centers for Disease Control and Prevention, over 75% of the 100,306 drug overdose deaths during the 12-month period ending in April 2021 involved opioids. Similarly, tricyclic antidepressants, which can be effective in managing the neuropathic pain associated with PHN, can result in significant systemic side effects and cardiotoxicity, posing risks to the elderly and patients with heart disease, epilepsy or glaucoma. These side effects make topical lidocaine products an attractive first-line treatment option from a safety perspective.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The safety of lidocaine patches is well-supported in medical literature. Unlike transdermal medications that are designed to achieve systemic drug levels via absorption through the skin or mucosal membrane, leading to effects away from the application site, topical lidocaine has a local effect at the site of application. Because drug application is localized to the immediate area surrounding the patch, systemic absorption from a topical patch is low, reducing the risk of systemic side effects and lowering the potential for drug interactions relative to other systemic pharmacologic therapies. Due to the low systemic exposure and minimal systemic side effects reported in clinical trials, we believe a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">topical lidocaine patch is well-suited for patients being treated with multiple medications or at a higher risk of side effects, including the elderly or those with chronic conditions. As a localized treatment, lidocaine patches have been used concomitantly with other medications in patients for whom monotherapy is inadequate. Furthermore, we believe medication administered topically rather than orally can improve patient compliance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While lidocaine patches have certain advantages over the treatment alternatives discussed above, certain patches have limitations that may impact efficacy. For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System (&#x201c;FAERS&#x201d;). Because the drug is incorporated in the adhesive for these products, patches must maintain adhesion or risk compromising the ability to deliver their full drug dose. As a result, establishing strong adhesion is a key factor for patient compliance and satisfaction. In draft guidance issued in July 2021, the FDA recommended that developers of topical and transdermal delivery systems (&#x201c;TDSs&#x201d;) conduct studies to characterize the adhesion performance of the product with suggested data requirements. Likewise, the FDA issued a draft guidance in October 2018 outlining the adhesion data requirements for generic TDSs. This guidance, along with Scilex&#x2019;s past experience with regulatory agencies, shows the FDA&#x2019;s interest and the importance of adhesion performance of these products. There are also dermal safety requirements that force developers to carefully balance adhesion performance against dermal safety. ZTlido is the first TDS product approved by the FDA that was able to demonstrate the targeted adhesion performance with an overall benign dermal safety profile.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following figure depicts data derived from FAERS as of December 31, 2021:</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_1.jpg" alt="img248422670_1.jpg" style="width:609px;height:293px;" />&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For many of the competing lidocaine patches, a common drawback is the usage of hydrogel technology that limits the overall pharmaceutical efficiency of the product, requiring more total drug to be loaded into the patch to deliver sufficient drug to achieve a therapeutic effect. For example, Lidoderm has a drug load of 700 mg drug but only delivers 3&#xb1; 2% of that drug load. Consequently, adhesive thickness must be increased in order to have a drug load sufficient to deliver a therapeutic dose of drug to the skin. As adhesive thickness increases, the product&#x2019;s pliability can be compromised to the extent that the patch loses adhesion as the skin moves and wrinkles through normal patient activity. The weight of the hydrogel patches (largely due to high water content) further contributes to the challenge in maintaining adhesion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The greater drug load also poses a risk of accidental exposure. For example, with a bioavailability of 3 &#xb1; 2% of the 700 mg drug load for Lidoderm, there is over 650 mg of drug remaining on the patch at the end of the 12-hour administration period, as captured in a bolded warning on the product label. If improperly disposed of, the residual drug poses the potential risk to children, pets and others of accidental exposure to a toxic amount of lidocaine, although we believe the risk with this formulation has not been evaluated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to prescription lidocaine patches, there are commercially-available OTC topical lidocaine products in the market, but none of these OTC products have been reviewed or approved by the FDA. Notably in 2003, the FDA proposed amending the tentative final monograph for OTC external analgesic drug products to clarify the status of patches (and poultices and plasters), noting that the dosage forms had not been determined to be generally recognized as safe and effective for any analgesia at that time. Therefore, the FDA would likely not consider these OTC products to be compliant with the monograph and do not have legal marketing status.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our novel adhesion and delivery technology provides significantly improved adhesion compared to Lidoderm, manufactured by Endo Pharmaceuticals, and generic alternatives marketed by Mylan N.V. (&#x201c;Mylan&#x201d;), while providing bioequivalent delivery of lidocaine via an efficient drug delivery system. Our product is lighter, thinner and provides for a better patient experience without compromise to dermal safety and with no presentation of dermal sensitization. Below is a comparison of the key advantages of ZTlido to Lidoderm and generic lidocaine patches manufactured by Teva and by Mylan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Key Advantages of ZTlido vs. Lidoderm and Associated Generics</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_2.jpg" alt="img248422670_2.jpg" style="width:608px;height:401px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note: DIA = Drug-in-adhesive</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Source: A Scilex-sponsored head-to-head comparative adhesion study (SCI-LIDO-ADH-003)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido has been strategically designed to address poor adhesion, a leading complaint associated with other currently marketed topical lidocaine products. ZTlido uses an advanced hot-melt technology, which uses premixing and hot-melt mixing of various excipients and lidocaine, followed by current Good Manufacturing Practices (&#x201c;cGMP&#x201d;) compliant coating, lining, cutting and filling processes. In clinical studies, the technology provided significantly improved adhesion over Lidoderm</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (a branded, prescription 5% lidocaine patch product) (&#x201c;Lidoderm&#x201d;) and Mylan&#x2019;s generic lidocaine patch at 12 hours after application. In a head-to-head study of 44 subjects, ZTlido showed statistically significant adhesion at all-time points compared to Lidoderm. Further, ZTlido maintained greater than 90% mean adhesion over the labeled 12-hour administration period while Lidoderm fell below this benchmark within 3 hours. ZTlido also showed superior adhesion when compared to Mylan&#x2019;s generic lidocaine patch. In this head-to-head study, ZTlido maintained greater than 90% mean adhesion throughout the labeled 12-hour administration period, while Mylan&#x2019;s generic product had a mean adhesion score of only 80% immediately after application, which progressively worsened over time. The formulation components are also carefully selected to achieve the target adhesion profile without creating dermal sensitization and maintaining a benign irritation profile.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In two separate studies, adhesion performance of ZTlido was compared to Lidoderm (with 44 subjects) and to Mylan&#x2019;s generic lidocaine patch (with 24 subjects), as depicted in the diagrams below. Both studies were performed with healthy volunteers using a standard clinical adhesion protocol where adhesion could not be enhanced (i.e., no reinforcement, pressing or reattaching). The level of adhesion was measured immediately after application (Time 0), and at 3, 6, 9 and 12 hours after application. ZTlido was the only lidocaine product to achieve over 90% adhesion over 12 hours after application in these studies. Maintaining 90% adhesion was a requirement for ZTlido&#x2019;s NDA approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_3.jpg" alt="img248422670_3.jpg" style="width:576px;height:264px;" />&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The proprietary adhesive system utilized for ZTlido allows for a more efficient delivery of the drug from the patch to the skin. This was supported by a clinical study in which our product achieved a bioequivalent dose of lidocaine while using a reduced drug load (36 mg for ZTlido versus 700 mg for Lidoderm). The drug delivery efficiency of ZTlido lessens the danger of accidental exposure. After 12 hours after application, ZTlido contains approximately 18 mg of residual lidocaine. In comparison, each Lidoderm patch leaves over 650 mg in the patch at the end of the 12-hour administration period. If improperly disposed of, the residual drug poses a risk of accidental exposure to a toxic amount of lidocaine to children, pets and others, although the risk with this formulation has not been evaluated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The drug delivery efficiency of ZTlido also enables it to be manufactured as a thinner product relative to Lidoderm and Teva&#x2019;s generic lidocaine patch. We strategically leveraged this property of ZTlido by utilizing a thin patch design with a nonwoven backing cloth that allows for better adhesion of the product. The improved adhesion performance, thinner profile and incorporation of a flexible backing material allows for a product that maintains contact with the skin in contoured areas of the body, when encountering torsional strains arising from normal body movements and during contact with clothing and bedding. While Mylan&#x2019;s generic lidocaine patch is also thinner than Lidoderm, it incorporates a film backing material that makes the product inflexible with body movements, contributing to its rapid loss in adhesion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The adhesion profile of ZTlido allows the product to be used under moderate exercise conditions (tested in 4 sessions of 30-minutes of stationary bike exercise, cumulatively 2 hours) as captured in the ZTlido label. No ZTlido patches fell off during the entire 12-hour administration period. Lidoderm and the associated generics have not produced any public data on the use of their products by active pain patients under such conditions. ZTlido is also labeled to allow patients to shower and bathe while wearing the patch, which is supported by an adhesion or pharmacokinetic study showing that, while some degree of lifting is observed in these environments, the patches were able to be pressed back down or reattached in the cases where the product completely detached, with no clinically meaningful change in pharmacokinetics. In contrast, Lidoderm and the associated generics are labeled with the effects of water exposure being unknown.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although ZTlido, Lidoderm and the associated generics are all labeled to not be used with heat (e.g., heating pad or blanket), the FDA-approved ZTlido label states that users may apply ZTlido to a treatment site after moderate heat exposure, such as after 15 minutes of heating pad use on a medium setting. This authorized use of ZTlido is of value as heat therapy is widely used in treating pain. In contrast, Lidoderm and the associated generics are not labeled for use with heat.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe ZTlido has other favorable features compared to Lidoderm and associated generic lidocaine patches such as the inclusion of a perforated release liner and the absence of cold flow. The perforated release liner allows for easier removal of the liner before application, which we believe provides convenience to patients who have dexterity challenges. In contrast, Lidoderm and generic lidocaine patches incorporate a single-sheet release liner, requiring patients to pick at the corners and edges to breach and remove before application. Cold flow is the propensity of the adhesive to migrate from the edges of the product under normal conditions, either in the product envelope or while on the skin. This can lead to difficulties in removing the product from the envelope and/or movement of the product, while on the skin, away from the intended administration site.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We launched ZTlido in October 2018 with support from an integrated commercial organization using a dedicated sales force and sales management, marketing and managed care capabilities. We market ZTlido through a dedicated 65-person sales force, targeting over 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We are utilizing a multi-channel marketing strategy to expand awareness and utilization of ZTlido. Our managed healthcare account executives have achieved success in adding ZTlido to key formularies, including CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem BCBS, BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We believe the benefits of ZTlido, combined with our competitive pricing strategy and our active direct marketing efforts, have driven, and will continue to drive, accelerated sales growth and increased market uptake.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to support several investigator-initiated research studies to explore the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-102 (SEMDEXA)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102 (SEMDEXA) is a Phase 3, novel, injectable viscous gel formulation of a widely used corticosteroid for epidural injections to treat sciatica. No ESIs are currently approved by the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sciatica Market Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A particularly debilitating complication of back pathology is sciatica, which is a condition caused by mechanical compression of the nerve root, or by the effects of inflammatory mediators arising from a degenerative disc that results in inflammation and damage to the nerve roots. This nerve root compression in the lumbar segment of the spine causes shock-like or burning low back pain (&#34;LBP&#34;) combined with pain radiating down along the sciatic nerve through the buttocks and down one leg, sometimes reaching the foot. This often severe and debilitating leg pain is usually associated with symptoms of neuropathy-like numbness and tingling. The estimated lifetime incidence of sciatica ranges from 10% to 40% of the U.S. population, and about one-third of these cases will develop symptoms lasting over a year. According to a report by Decision Resources Group, it was estimated that over 4.8 million patients would suffer from sciatica in the United States in 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current Treatment Landscape and Limitations of Existing Treatments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the U.S. population ages, the incidence of sciatica and the need for interventions are expected to continue to increase. For example, from 2000 to 2018, ESIs in Medicare beneficiaries increased by more than 125%.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although there are numerous etiologies of sciatica, and therapies may differ based on the etiology, pain management interventions for sciatica are usually multi-modal. Among the pain management interventions, ESI is considered to be efficacious and has been widely used by physicians across multiple specialties, including anesthesiology, physical medicine and rehabilitation and pain medicine. However, there is no ESI therapy approved by the FDA for sciatica to date, and particulate formulations of glucocorticoids have been associated with severe adverse events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients with sciatica have a wide range of invasive and non-invasive treatment options. Surgical intervention options include vertebroplasy, spinal laminectomy, discectomy, microdiscectomy, foraminotomy, intradiscal electrothermal therapy, nucleoplasty, radiofrequency denervation, spinal fusion and artificial disc replacement. These options are generally the last line of treatment because they can result in prolonged recovery time, may not be successful in reducing pain or addressing the underlying cause, and may result in permanent loss of flexibility. For these reasons, less invasive interventions are usually implemented first. Less invasive interventions may include (i) nonpharmacological therapies such as physical therapy, stretching exercises, spinal manipulations or chiropractic therapy, traction, acupuncture, transcutaneous electrical nerve stimulation, and biofeedback&#x37e; (ii) oral pharmaceutical therapies such as NSAIDs, muscle relaxants, opiates, antidepressants, and anticonvulsants&#x37e; and (iii) injectable pharmaceutical therapies such as off-label use of ESIs or nerve blocks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESIs for various back pain syndromes are one of the most common procedures performed in the United States and lumbosacral radicular ESI procedures represent 88% of total ESI procedures. ESIs are used when a patient&#x2019;s pain is inadequately controlled with oral pain medications, topical systems or interventions such as physical therapy. ESIs have demonstrated efficacy in reducing pain, restoring function, reducing the need for other health care and avoiding</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">back surgery. However, in addition to not being FDA-approved for the treatment of lumbosacral radicular pain, currently-used ESIs also present various risks and challenges.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When administering an ESI, many physicians use a particulate steroid (including methylprednisolone acetate, triamcinolone acetonide, or betamethasone sodium phosphate or betamethasone sodium acetate) instead of a non-particulate steroid (dexamethasone sodium phosphate) because early studies suggested that the duration of pain relief was longer with the particulates and fewer repeat injections were required, even though dexamethasone is considered an otherwise potent and therapeutically beneficial therapy. Particulate in injectable products is defined as extraneous undissolved particles present in injectable solution products. An example of such particulate is precipitate of insoluble drug form, or suspended drug particle. These steroid particles or their aggregates have at least two mechanisms for neurological damage: (1) they can act as emboli if injected into an artery and are of sufficient size to block small terminal arterioles supplying the brain or spinal cord&#x37e; and (2) several particulate steroids have an immediate and massive effect on microvascular perfusion because of formation of red blood cell aggregates. These emboli can cause rare but catastrophic neurologic injuries including stroke and spinal cord injury that can result in increased pain, severe permanent disability or death. In addition, fungal meningitis has occurred from the injection of steroids manufactured in a compounding pharmacy that did not adhere to sterility standards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has been evaluating serious neurologic events with ESIs since 2009, and in 2014, the FDA required a class warning on the currently off-label use of injectable corticosteroids to include information about the risk of serious neurologic events with ESIs. The warning on product labels for all injectable glucocorticoids states that the product is to be used for intramuscular or intravenous purposes only, and specifically includes a warning for serious neurologic adverse reactions with epidural administration. These serious neurologic events have been reported with and without use of fluoroscopy. The class warning also includes a statement that safety and effectiveness of epidural administration of these corticosteroids have not been established.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain third-party payors have also provided limited coverage of ESIs to date. Based on coverage criteria established by different health care plans and certain Medicare Administrative Contractors, an ESI is considered medically necessary and therefore reimbursable only when certain specific criteria are met.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing SP-102 to address problems associated with currently available corticosteroid products that are used in practice but not approved for epidural injection or the treatment of lumbosacral radicular pain. SP-102 is a Phase 3 sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a pre-filled glass syringe for delivery via an epidural injection. SP-102 allows for the use of the potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is also formulated without the use of preservatives and packaged in a pre-filled syringe, so as to confer greater physician convenience.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently-used steroids carry a class warning and are not approved to be administered epidurally for the treatment of sciatica. In fact, there are further warnings that the safety and efficacy of the use of these products following epidural administration has not been established. Their formulations include neurotoxic preservatives, surfactants, suspensions or particulates that carry risks of serious neurologic complications. Unlike currently-used steroids, SP-102 does not contain neurotoxic preservatives, surfactants, suspensions or particulates that carry risk of serious neurologic complications, which we believe may improve safety and the extent of pain relief. By using dexamethasone sodium phosphate, the soluble form of the potent dexamethasone, we believe SP-102 may substantially reduce the risk of embolic events in case of inadvertent intra-arterial administration and enable repeat injections. We expect the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injectable viscous gel product, SP-102, which uses a biocompatible, biodegradable, novel excipient and is protected by multiple patents and patent applications and trade secrets, to prolong the residence time at the injection site and result in extended local activity. We believe SP-102, if successfully developed and approved, has the potential to reduce the disability related to lumbosacral radicular pain and help delay or avoid spine surgery.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If approved, SP-102 could become the first FDA-approved ESI product. We believe an FDA-approved therapy for the treatment of sciatica could potentially benefit from first-to-market advantage if it can be shown to reduce or delay the need for expensive and potentially risky interventions such as spinal surgery and decrease the use of opioids. SP-102 benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible viscosity-enhancing excipient sodium hyaluronate in SP-102. Our complex manufacturing process, specialized equipment and know-how for sterile viscous product candidates are also key to our competitive edge.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently evaluating data on SP-102 from a pivotal Phase 3 Corticosteroid Lumbar Epidural Analgesia (&#x201c;CLEAR&#x201d;) trial, which was designed to evaluate the safety and efficacy in the proposed indication. The CLEAR clinical trial is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica at over 40 sites across the United States, with a primary objective to evaluate the analgesic effect on average leg pain (as measured by the Numeric Pain Rating Scale in the affected leg) following a single epidural injection of SP-102, compared to an intramuscular injection of placebo over four weeks. A full 6-months data analysis was completed in February 2022 and we announced final results from the study in March 2022, which results reflect achievement of primary and secondary endpoints. We believe these final results are supportive of a breakthrough therapy designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program leading to market approval. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 3 CLEAR trial summary results, which results reflect achievement of primary and secondary endpoints, are as follows:</span></p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102 (SEMDEXA&#153;), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy), demonstrated a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with improvement against placebo over the first 4 weeks, following a single transforaminal injection, LS Mean (SEM) difference -1.08 (0.17), with a p-value &lt; 0.001.</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102 (SEMDEXA&#153;) showed continued reduction of pain beyond one month, and the median time to open-label repeat injection was 99 days (95% CI: 78, 129 days) according to a Kaplan-Meier estimation. By contrast, off-label injectable steroids typically provide pain relief for periods ranging from less than a week and up to one month, and then a repeat injection may be required.</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The key secondary endpoint of Oswestry Disability Index, the gold standard for measuring degree of disability and estimating quality of life, showed a 28% improvement at 4 weeks on SP-102 (SEMDEXA&#153;) compared to baseline (minimal clinically meaningful improvement 8%-12%)15. The LS Mean (SEM) difference as compared to placebo was -6.28 (1.49), with a p-value &lt; 0.001.</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no adverse events (&#x201c;AEs&#x201d;) of special interest reported, such as paraplegia, hematoma, or infection at the injection site, which events are associated with the off-label use of non-approved injectable steroid preparations. Of the 354 patients receiving at least a single injection of SP-102, there were 125 (35.3%) patients experiencing treatment emergent adverse events (&#x201c;TEAEs&#x201d;), with 32 (9.0%) patients experiencing treatment-related AEs, 16 (4.5%) patients experiencing medication-related AEs, 23 (6.5%) patients experiencing procedure-related AEs, four (1.1%) </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:10.0%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patients experiencing serious AEs, and one (0.3%) patient experiencing AEs related to early withdrawal. Of the 47 patients only receiving a single placebo injection (and no repeat injection of SP-102), there were 14 (29.8%) patients experiencing TEAEs with (i) two (4.3%) patients experiencing treatment-related AEs, (ii) two (4.3%) patients experiencing medication-related AEs, (iii) one (2.1%) patient experiencing procedure-related AEs, (iv) one (2.1%) patient experiencing serious AEs, (v) one (2.1%) patient experiencing AEs related to early withdrawal, and (vi) one (2.1%) patient death. TEAEs occurring in &#x2265; two percent of patients were headache (SP-102: 13 (6.4%), 17 events&#x37e; placebo: 11 (5.5%), 11 events), injection site pain (SP-102: 4 (2.0%), four events&#x37e; placebo: zero (0.0%), 0 events), upper respiratory tract infection (SP-102: two (1.0%), 2 events&#x37e; placebo: four (2.0%) events), sinusitis (SP-102: 4 (2.0%), four events&#x37e; placebo zero (0.0%), 0 events) and hypertension (SP-102: four (2.0%), four events&#x37e; placebo: one (0.5%), two events). The C.L.E.A.R trial also established the safety of repeat injections, as patients who experienced moderate-to-severe radicular pain between 4 and 23 weeks were allowed to receive open-label additional SP-102 (SEMDEXA&#153;) injection. The safety analysis was comparable between treatment groups through 4, 12 and 24 weeks of study period.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section11">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3 SP-102 C.L.E.A.R Trial - Primary Endpoint</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_4.jpg" alt="img248422670_4.jpg" style="width:507px;height:231px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_5.jpg" alt="img248422670_5.jpg" style="width:507px;height:305px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-103</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing SP-103 to be a triple-strength, non-aqueous lidocaine topical system for the treatment of acute LBP. SP-103 leverages the same adhesive drug delivery formulation and manufacturing as ZTlido along with comparable backing material, perforated release liner and container-closure system. The increase in drug load is offset by a corresponding decrease in the adhesive diluent.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acute LBP Market Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The safe and effective treatment of acute LBP addresses a high unmet need and creates large market opportunities. LBP affects about 70% of people in resource-rich countries at some point in their lives. Acute LBP can be self-limiting, however. One year after an initial episode, as many as 33% of people still have moderate-intensity pain and 15% have severe pain. Acute LBP has a high recurrence rate with 75% of those with a first episode having a recurrence. Although acute episodes may resolve completely, they may increase in severity and duration over time. Americans spent approximately $134.5 billion in 2016 on treating LBP and neck pain, which was the highest expenditure among 154 conditions studied by the Department of Institute for Health Metrics and Evaluation at the University of Washington.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current Treatment Landscape and Limitations of Existing Treatments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">According to the Centers for Disease Control and Prevention, in 2018, 28.0% of men and 31.6% of women aged 18 years old and older had lower back pain in the past three months. The percentage of women who had lower back pain increased as age increased. Among men, the percentage increased with age through age 74 years and then decreased. Women in the age groups 18 - 44, 45 - 64, and 75 years and older were more likely to have lower back pain in the past three months than were men in the same age groups, but percentages were similar between men and women in the age group 65-74 years. Although most patients recover quickly with minimal treatment, proper evaluation is imperative to identify rare cases of serious underlying pathology. Certain red flags should prompt aggressive treatment or referral to a spine specialist, whereas others are less concerning. Serious red flags include significant trauma related to age (i.e., injury related to a fall from a height or motor vehicle crash in a young patient, or from a minor fall or heavy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lifting in a patient with osteoporosis or possible osteoporosis), major or progressive motor or sensory deficit, new-onset bowel or bladder incontinence or urinary retention, loss of anal sphincter tone, saddle anesthesia, history of cancer metastatic to bone and suspected spinal infection. Without clinical signs of serious pathology, diagnostic imaging and laboratory testing often are not required. Although there are numerous treatments for nonspecific acute LBP, most have little evidence of benefit. Patient education and medications such as nonsteroidal anti-inflammatory drugs, acetaminophen and muscle relaxants are beneficial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our triple-strength SP-103 is an investigational, non-aqueous lidocaine topical system undergoing clinical development in acute LBP conditions. If approved, we believe that SP-103 could become the lidocaine topical product for acute LBP indications. All current uses of topical lidocaine products for LBP are off-label. This program builds on the learnings from ZTlido because both products share the same adhesive drug delivery formulation and manufacturing technology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing SP-103 to deliver a dose of lidocaine that is at least threefold higher than any approved lidocaine topical products (including the approved ZTlido, which has a drug load of 36 mg lidocaine). We manufacture SP-103 to have a drug load of 108 mg lidocaine in a similar adhesive formulation as ZTlido, along with comparable backing material, perforated release liner and container-closure system.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-103 has demonstrated delivery of threefold the level of drug of ZTlido, and consequently delivers threefold the level of drug of Lidoderm and associated generics by extrapolation. SP-103 has been granted fast track designation by the FDA and, if approved, could become the first FDA-approved lidocaine topical product for the treatment of acute LBP. We believe SP-103, if successfully developed and approved, may be able to address the limitations of prescription lidocaine patches in treating acute LBP by delivering a higher dose of lidocaine to the application site, but with systemic exposure of drug remaining well below established safety thresholds. SP-103 has three times the drug load of ZTlido (108 mg versus 36 mg) in the adhesive system and can potentially deliver threefold the level of the drug within a targeted area, with the convenience of a single topical system. This level of dosage for SP-103 is comparable to the maximum approved daily dosage of ZTlido, or three topical systems for up to 12 hours during a 24- hour period. By contrast, delivering higher levels of drug with other lidocaine patches is encumbered by the underlying hydrogel technology that constrains the level of drug that can be loaded into the adhesive of those products. The level of drug product in such patches can be increased only with a thicker adhesive layer, which can result in a loss of adhesion performance and flexibility. Further, increasing product dimensions can allow delivery of the drug over a larger area, but does not increase drug delivery to a localized area under the topical system.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the acute LBP market presents an attractive commercial opportunity due to the large patient population, lack of any approved drugs and high level of unmet medical need. We believe developing and commercializing a topical non-opioid product targeting this segment of the pain population represents a commercially attractive strategy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend initially to evaluate SP-103 in a Phase 2 trial in subjects who have acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, two-period cross-over, multicenter study of SP-103 and placebo in subjects with acute LBP. The study consists of a 7-day open-label run-in period where all subjects receive active treatment. Responders to treatment then will be randomized to blinded Treatment A, consisting of 30 days treatment with SP-103 or Treatment B, consisting of 30 days treatment with placebo patch with no lidocaine. We initiated the Phase 2 trial in the second quarter of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-104</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing SP-104 for the treatment of fibromyalgia. Low-dose naltrexone hydrochloride delayed-release capsules are routinely used off-label to treat fibromyalgia and other chronic pain conditions such as complex regional pain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fibromyalgia Market Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fibromyalgia affects an estimated 10 million people in the United States and an estimated 3% to 6% of the world population. While it is most prevalent in women, it also occurs in men and children of all ethnic groups. Fibromyalgia is the second most common disorder that rheumatologists encounter, seen in 15% of evaluated patients. Approximately 8% of patients cared for in primary care clinics have fibromyalgia. Prominent fibromyalgia researchers and specialists estimate the economic burden of fibromyalgia in the United States to be between $12 billion to $14 billion each year and the condition accounts for a loss of 1% to 2% of the national overall productivity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Potential Complications of Fibromyalgia</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is a non-exhaustive list of complications of fibromyalgia:</span></p>
  <div style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extreme allodynia with high levels of distress&#x37e;</span></div></div>
  <div style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">opioid or alcohol dependence&#x37e;</span></div></div>
  <div style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">marked functional impairment&#x37e;</span></div></div>
  <div style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">severe depression and anxiety&#x37e;</span></div></div>
  <div style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obesity and physical deconditioning&#x37e; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:4.857%;font-size:0;margin-top:6.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">metabolic syndrome.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although fibromyalgia is frequently grouped with arthritis-related conditions, there is no apparent inflammation or damage to the joints, muscles or other tissues. The diagnostic criteria for fibromyalgia are detailed in the chart below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_6.jpg" alt="img248422670_6.jpg" style="width:542px;height:424px;" />&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently approved products for pain in fibromyalgia, including duloxetine, pregabalin and milnacipran, have limited efficacy. Responders applying such products can only demonstrate a 27% to 40% reduction of symptoms, which is far below the commonly accepted threshold of 50% to prove efficacy in treating fibromyalgia. In light of this, we believe new treatments with higher efficacy are needed to improve management of fibromyalgia.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-104 has key clinical data supporting its use in fibromyalgia. There are investigational trials that support use and development of SP-104 for fibromyalgia. Currently there are no low-dose formulations (i.e., less than 5 mg) available. Physicians currently use the commercially available high-dose tablets (50 mg) and have compounding pharmacies aliquot lower doses for patients. Pharmacy-compounding is inherently inaccurate and does not involve analyses to confirm that the aliquoted product has the target level of drug, and there is no assurance as to content uniformity within a batch as well as other quality attributes critical for pharmaceutical product performance. This approach can lead to errors in dosing and challenges with titration. The commercial products and pharmacy-compounded products also allow for the immediate release of the drug in the stomach, which can lead to compliance challenges due to severe side effects. Common side effects for naltrexone include hyperalgesia, dysphoria, insomnia and anxiety. All these issues culminate into patient compliance issues and result in the eventual abandonment of an otherwise viable therapy to treat this debilitating disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our SP-104 uses delayed burst release technology that bypasses the stomach and releases the drug in the gut (upper intestine). When taking SP- 104 at night before bed, peak drug levels are achieved at night during sleep, allowing the patient to avoid conscious perception of hyperalgesia and other side effects. The combination of the delayed-release and administration at night may also maximize efficacy as most endorphin/ enkephalin release is during sleep, which maximizes the product&#x2019;s potential to elicit compensatory response.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are committed to develop SP-104 for fibromyalgia. Phase 1 studies are designed to characterize the pharmacokinetic and safety profile of SP-104, and Scilex intends to initiate a Phase 2 study in 2023. If successful, we believe SP-104 can become a pivotal treatment for management of fibromyalgia, which represents a large commercial opportunity with high unmet demands.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section12">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercialization and Market Access</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales &amp; Marketing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have built a robust and integrated commercial infrastructure using a dedicated sales force and sales management, marketing and managed care capabilities, to maximize the potential of our current marketed product, ZTlido, and our two other FDA-approved products, GLOPERBA and ELYXYB, and to commercialize our product candidates, if approved. We are focused on achieving accelerated sales growth and increased market uptake for ZTlido in the topical lidocaine product market, where we believe we have the only actively promoted product. Our dedicated 65-person sales force has broad experience in pain management and is exclusively focused on promoting ZTlido. Our sales representatives leverage their established relationships to call on over 10,000 target pain specialists, neurologists, select primary care providers and palliative care physicians who Scilex believes treat the majority of PHN patients. We believe these same call points provide treatment for the sciatica and acute LBP patients that could benefit from SEMDEXA and SP-103, if approved. Our sales representatives typically have over 10 years of experience in promoting a broad scope of pain management products that Scilex intends to leverage as our product candidates are commercialized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, ZTlido had gained approximately 11.4% market share of the lidocaine patch prescription market across the territories we cover in the United States. The total prescriptions of ZTlido for the year ended December 31, 2022 grew by more than 50.4% over the year ended December 31, 2021, according to Symphony Healthcare&#x2019;s national prescription data. Our experienced sales representatives and managers are supported by our marketing team, whose members have successfully launched over 20 products with large pharmaceutical, biotechnology and specialty pharmaceutical companies. Our marketing team has developed a multi-channel marketing strategy to promote the continued uptake of ZTlido by highlighting its significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. We are also promoting ZTlido with a marketing campaign that engages patients seeking relief for neuropathic pain associated with PHN through social media and medical and consumer journals. Further, our marketing function is supported by an experienced analytics team that leverages its experience in forecasting and analytics to draw insights from healthcare databases to inform our marketing strategy. As part of our broader commercial strategy, our marketing analytics team is conducting market research to support the launch of SP-102, SP-103 and SP-104, if any of these candidates is approved. We believe that our sales force, supporting commercial infrastructure and established relationships with our targeted physician audience will provide a strategic advantage in pursuing potential partnerships to commercialize other non-opioid pain management therapeutics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Market Access</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have established a patient-centric market access function with robust capabilities across the market access continuum, including payor sales, contracting and marketing strategies, supplemental patient assistance programs and responsible drug pricing to support patients&#x2019; access to ZTlido. Our team of managed healthcare account executives has demonstrated experience in establishing products on formularies and have currently prioritized and targeted select payor accounts representing approximately 275 million of the over 300 million lives, with the remaining 25 million to be considered in the future. Currently, ZTlido is covered for over 200 million lives in the United States and coverage continues to improve. As of January 2023, we have secured coverage for ZTlido on CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem BCBS, BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We continue to negotiate coverage with large payors and pharmacy benefit managers in all books of business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section13">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido Formulary Coverage - Over 90% of Lives Covered or In Negotiation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_7.jpg" alt="img248422670_7.jpg" style="width:578px;height:277px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We utilize an outside vendor to administer a patient assistance program directed at patients with commercial insurance or those paying out-of-pocket. With the copay assistance program, qualifying patients do not have to pay any copayment for their ZTlido prescription. We utilize an external vendor and train the sales force to work proactively with clinician office managers in completing required forms for prior authorization for ZTlido.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section14">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Development Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZTlido</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Trial Highlights</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have evaluated ZTlido in over 600 subjects in clinical trials to support marketing approval and promotional campaigns for the relief of neuropathic pain associated with PHN in the United States. Our studies sought to investigate the bioequivalence of ZTlido compared to Lidoderm, adhesion performance and the dermal safety and tolerability of ZTlido under a range of application times and settings. Based on these studies, we concluded that ZTlido:</span></p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">demonstrated bioequivalence to Lidoderm in study SCI-LIDO-PK-002A&#x37e;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">showed greater than or equal to 90% adhesion in over 90% of the subjects at the end of the 12-hour administration period in study SCI-LIDO-ADH-001&#x37e;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">showed superior adhesion to Lidoderm and Mylan&#x2019;s generic lidocaine patch in studies SCI-LIDO-AHD-002 and SCI-LIDO-ADH-003&#x37e;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was not meaningfully impacted by heat or exercise in study SCI-LIDO-HEX-001&#x37e;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was able to be used under showering and bathing conditions in study SCI-LIDO-ADH-004&#x37e; and</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.041111111111111%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">did not show clinically meaningful dermal irritation in study SCI-LIDO-DERM-001.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZTlido Study Details</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pivotal Bioequivalence Study </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- SCI-LIDO-PK-002A</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted a comparative single-dose pharmacokinetic (&#x201c;PK&#x201d;) study between ZTlido and Lidoderm designed as a two-way cross-over in 54 healthy subjects. In this trial design, each subject received a single dose of three ZTlido or three Lidoderm patches followed by a washout period and the administration of the other product. The purpose of this study was to establish bioequivalence between the products, which was determined by the statistical comparability of Cmax and AUC as shown in the figure below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This was considered the pivotal clinical trial for ZTlido, as it provided the pharmaceutical bridge between the two products and showed that ZTlido had comparable safety and efficacy to Lidoderm. As a result of successfully establishing the pharmaceutical bridge, no stand-alone clinical efficacy studies were required by the FDA to determine ZTlido&#x2019;s analgesic effects for ZTlido&#x2019;s approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section15">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mean Lidocaine Plasma Concentration Time Profiles - Semilog Scale</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_8.jpg" alt="img248422670_8.jpg" style="width:487px;height:327px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pivotal Adhesion Study</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - SCI-LIDO-ADH-001</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted an open-label, single-treatment, single-period, single-application adhesion performance study in 54 healthy, human subjects to assess the adhesion performance of ZTlido over the 12-hour administration period of the product. The study also investigated whether ZTlido met an FDA established adhesion performance benchmark of greater than or equal to 90% adhesion in greater than or equal to 90% of subjects in the study at the end of the administration period. At the end of the 12-hour administration period, over 90% of the subjects (49 out of the 54 subjects) maintained greater than or equal to 90% adhesion, with no adverse events reported during the study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section16">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido Maintained Greater Than 90% Adhesion Over the 12-Hour Time Period</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_9.jpg" alt="img248422670_9.jpg" style="width:526px;height:281px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This study was considered the pivotal adhesion study for marketing approval and is summarized in the product label.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Head-to-Head Adhesion Study versus Lidoderm </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- SCI-LIDO-ADH-002</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted an open label, single-treatment, three-period, single-application adhesion performance study in 44 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of Lidoderm over a 12-hour administration period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In this study, ZTlido demonstrated significantly superior mean adhesion scores compared to Lidoderm at 3, 5, 9 and 12 hours after application. ZTlido maintained a mean percent adhesion performance greater than 90% over the 12-hour administration period, while Lidoderm fell below 90% mean adhesion within three hours.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section17">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido Demonstrated Superior Adhesion Compared to Lidoderm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_10.jpg" alt="img248422670_10.jpg" style="width:456px;height:305px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Head-to-Head Adhesion Study versus Mylan&#x2019;s Generic</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - SCI-LIDO-ADH-003</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted an open-label, single-treatment, two-period, single-application adhesion performance study in 24 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of a generic lidocaine patch 5% manufactured by Mylan over a 12-hour administration period. The purpose of this study was to compare the adhesion performance of ZTlido against a topical lidocaine product involving a non-aqueous formulation. We selected Mylan&#x2019;s generic lidocaine patch as a comparator because it has similar product characteristics, including a non-aqueous polymer drug-in-adhesive system allowing for a thinner patch and a lower drug load as compared to Lidoderm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In this study, ZTlido demonstrated significantly superior adhesion performance compared to Mylan&#x2019;s generic lidocaine patch. ZTlido maintained a mean adhesion greater than 90% over the 12-hour administration period, while the generic product had a mean adhesion score of only 80% immediately after application, which declined to a mean adhesion score of 27% at 12 hours after application.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section18">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido Demonstrated Superior Adhesion Compared to Mylan&#x2019;s Generic Lidocaine Patch</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_11.jpg" alt="img248422670_11.jpg" style="width:496px;height:411px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PK and Adhesion Study under Exercise and Heat Conditions </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- SCI-LIDO-HEX-001</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted an open-label, randomized, three-treatment, three-sequence, three-period, cross-over, PK and adhesion performance study of three ZTlido topical systems applied to separate areas in 12 healthy, human subjects during physical exercise, exposure to heat and under normal conditions, respectively. The three treatment periods were as follows:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.693432091613477%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment A sought to assess the PK and adhesion performance of ZTlido under physical exercise conditions. In this treatment period, subjects were instructed to perform exercise for 30 minutes on a stationary bike achieving a heart rate of 108 beats per minute, with continuous heart monitoring during exercise. Subjects were instructed to perform exercise immediately after the application of the topical system and at 2.5, 5.5 and 8.5 hours following application of the topical system.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.693432091613477%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment B sought to assess the PK and adhesion performance of ZTlido under heat conditions. In this treatment period, a heating pad adjusted to the medium setting was applied for 20 minutes immediately after application of the topical system and at 8.5 hours following application of the topical system.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.693432091613477%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment C sought to assess the PK and adhesion performance of ZTlido under normal conditions. In this treatment period, topical systems were applied to the mid-lower back and worn for 12 hours.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In treatment A, adhesion and PK performance were not compromised by exercise, as reflected in the product label. In treatment B, heat had an effect on PK but had no effect on adhesion. In Treatment C, normal PKs were observed and greater than 90% of subjects showed greater than 90% adhesion. No meaningful irritation was observed across all treatments across all time points in any of the subjects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The impact of heat and exercise on PK is presented in the figure below. It was observed that heat had an effect on Cmax, but the drug returned to normal levels after removal of heat and there was no clinically meaningful observed effect on AUC. Heat did not appear to have a deleterious or catastrophic effect on topical system performance, either as a dose-dump (i.e., immediate and complete release of all drug from the product), or as reduced drug delivery (i.e., much lower systemic exposure). There was no significant effect on PK observed with exercise when compared to subjects under normal conditions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section19"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido Demonstrated Consistent* PK Performance under Exercise and Heat Conditions</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_12.jpg" alt="img248422670_12.jpg" style="width:446px;height:337px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Defined as no clinically meaningful changes by meeting bioequivalence criteria</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dermal Sensitization and Irritation Study</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - SCI-LIDO-DERM-001</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted a provocative dermal sensitization and irritation human clinical trial, also referred to as a repeat insult topical system test, intended to elicit the worst-case dermal safety of ZTlido by extended wearing of the product over multiple days. In this trial, we compared the sensitization potential, and the overall irritation profiles of ZTlido and Lidoderm in 218 normal and healthy subjects. We used a 7-point scale where a score of 0 indicated no irritation and a score of 7 was considered a strong reaction spreading beyond the application site.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In this study, results showed that the adhesion quality of ZTlido did not compromise dermal safety. The study reported that ZTlido did not show potential for dermal sensitization and showed an overall benign irritation profile. Both ZTlido and Lidoderm had a mean irritation score well below 1, which is defined as barely perceptible erythema. This study allowed for the ZTlido label to adopt the same local tolerance language as labeled for Lidoderm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Photoallergy and Phototoxicity Studies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - SCI-LIDO-PHOT0-001 and SCI-LIDO-PHOTO-002</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted a 6-week randomized study, SCI-LIDO-PHOTO-001, to evaluate the potential of ZTlido and its comparator, Lidoderm, to induce a photoallergic skin reaction in 54 healthy volunteers. In this study, we observed that ZTlido was not photoallergenic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted a 4-day, randomized study, SCI-LIDO-PHOTO-002, to evaluate the irritation potential of ZTlido and its comparator, Lidoderm, when application to skin is followed by light exposure in 32 healthy volunteers, using a phototoxicity patch test. In this study, we observed that ZTlido was not phototoxic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Studies for ZTlido</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Water Stress Study (Shower and Swimming)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - SCI-LIDO-ADH-004</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted a single-dose study in 24 subjects to examine the adhesion and lidocaine delivery (pharmacokinetics) of ZTlido when it is exposed to two separate water stress conditions of (1) showering (10 minutes) and (2) swimming (15 minutes). The study showed that while some degree of product lifting was observed, the product could be pressed back down or reattached with no further diminished adhesion performance or drug delivery. This study led to a change in the product label indicating that patients may use the product while showering or bathing. This provides significant patient convenience as Lidoderm and the associated generics are labeled to avoid contact with water such as bathing, swimming or showering, as these products may not stick if they get wet. With ZTlido, patients can engage in these activities within the 12-hour administration period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investigator-Sponsored Studies</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to support several investigator-initiated research studies to evaluate the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102 (SEMDEXA)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recently conducted a Phase 3 pivotal study of SP-102. The Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (&#x201c;CLEAR&#x201d;) study is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica to compare the epidural administration of SP-102 to placebo. We announced final results from this study in March 2022. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Trial Highlights</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102 has been evaluated in a number of preclinical studies and clinical trials as a potential treatment for sciatica. Key findings from the preclinical studies and clinical trials include:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repeat injections of SP-102 showed continued pain reduction with no unexpected adverse events based on preliminary results from the SP-102-03 study&#x37e;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102 showed an extended local activity with epidural administration in the ES-1504 study&#x37e;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102 showed an extended residence time and tolerability in the 1014-1512 and the 1014-2847,  preclinical studies&#x37e; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The introduction of SP-102 into blood vessels did not result in neurological complications in the UPD003-IS21 preclinical toxicology study.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-102 (SEMDEXA) Study Details Phase 3 Pivotal Clinical Trial - CLEAR</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recently conducted a pivotal, randomized, double-blind, placebo-controlled Phase 3 trial, CLEAR, that enrolled 401 patients with sciatica at over 40 sites across the United States. The study includes an open-label extension where subjects will be followed for up to 24 weeks after treatment to evaluate the safety of administering SP-102 in a larger patient population. After week 4, subjects who met certain pain criteria received open-label SP-102 to investigate the safety of repeat injections and the duration of pain relief following injection. This well-controlled, randomized trial was designed to demonstrate evidence of the analgesic effect and safety of SP-102. The schematic of this Phase 3 trial is demonstrated in the flowchart below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary objective of this study was to evaluate the analgesic effect of SP-102 on average leg pain, measured using the Numeric Pain Rating Scale (&#x201c;NPRS&#x201d;) following a single transforaminal injection. These results were compared to an intra-muscular injection of placebo over a four-week period. The secondary objectives of this study include (i) evaluation of the degree of disability over time as measured by the Oswestry Disability Index&#x37e; (ii) characterization of the change of the subject&#x2019;s radiculopathy symptoms and overall condition, using a combination of PainDETECT, modified Brief Pain Inventory, Clinical Global Impression of Change, and Patient Global Impression of Change and (iii) evaluation of the safety of a single and repeat SP- 102 injections.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section20">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schematic of CLEAR - SP-102 (SEMDEXA) Phase 3 Pivotal Trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_13.jpg" alt="img248422670_13.jpg" style="width:614px;height:267px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment was completed in the second half of 2021. We announced final data from this study in March 2022. The Pivot Phase 3 trial has met the primary efficacy and key secondary efficacy endpoints:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the primary endpoint of change in average daily pain (as measured by the Numeric Pain Rating Scale) in the affected leg over four weeks following the initial injection, the LS Mean (SE) group difference of -1.08 (0.17) compared to placebo with a p-value less than 0.001.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The two key secondary endpoints assessing Oswestry Disability Index (&#x201c;ODI&#x201d;) and Time to open label repeat injection have been demonstrated for SP-102. The LS Mean (SE) group difference in ODI compared to placebo at week 4 was -6.28 (1.49) with a p-value less than 0.001. A Cox proportional hazard model showed significantly longer duration of initial SP-102 (SEMDEXA) treatment compared to placebo Hazard Ratio (95% CI) 0.49 (0.36, 0.65), with a p-value less than 0.001.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2 Repeat Dose Study</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - SP-102-03</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted an open-label, single-arm, pharmacodynamics (&#x201c;PD&#x201d;) and safety study of repeat epidural injections of SP-102 in patients with sciatica. We conducted this study to characterize repeat dose PD with respect to hypothalamic-pituitary-adrenal suppression using plasma cortisol levels, white blood cell count and blood glucose levels.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The study enrolled 19 subjects, of which 15 received repeat SP-102 epidural injections 4 to 8 weeks after the initial injection. Four of the subjects did not experience recurrent pain and thus did not require a repeat injection. The daily average, current and worst pain in the affected leg and back showed continuous reduction throughout the 28-day observation period for both treatments. Based on a preliminary review of the results, SP-102 injections were generally well-tolerated and there were no new unexpected adverse events observed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section21">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mean Percentage Change in Sciatica-Related Leg Pain as Measured by NPRS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_14.jpg" alt="img248422670_14.jpg" style="width:529px;height:247px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1 Trial of SP-102 (SEMDEXA) Compared to Reference Listed Drug</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - ES-1504</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted an open-label, single-arm, two-period, fixed sequential-dose study to evaluate the PK, PD and safety of SP-102 when administered by epidural injection. SP-102 was compared to intravenous dexamethasone sodium phosphate injection in subjects with lumbosacral radiculopathy. There were 12 subjects enrolled in this study, all of whom received SP-102 followed by the intravenous dexamethasone sodium phosphate injection (Reference Listed Drug) administered one month later. A Reference Listed Drug is an approved drug product to which new versions are compared to show that they are bioequivalent. The purpose of this study was to establish the pharmaceutical bridge between SP-102 and the Reference Listed Drug. The Tmax observed with the administration of SP-102 was four hours, compared to 15 minutes observed with intravenous dexamethasone. The PD parameters and safety results of both products were similar, and SP-102 did not prolong cortisol suppression time. SP-102 also maintained analgesic effects throughout a one-month observation period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The overall systemic exposure of dexamethasone was similar, whether administered as SP-102 or injected intravenously, with a mean AUCinf of 0.916 &#x3bc;g*h/mL (observed with SP-102) compared to 0.943 &#x3bc;g*h/mL (observed with intravenously-administered dexamethasone). Notably, there was a 16- fold increase in the time to maximum serum concentration (&#x201c;Tmax&#x201d;) following epidural injection of SP-102. The median Tmax was 4.00 hours for SP-102 compared to 0.25 hours for the comparison group. All 12 subjects with sciatica showed continuous reduction in back and leg pain during the one-month observation period following a single epidural injection of SP-102.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This study demonstrated that at an equivalent initial dose of dexamethasone, the systemic exposure to dexamethasone following epidural injection of SP-102 did not exceed the exposure following intravenous injection of the Reference Listed Drug. The PD effects, measured as white blood cell count, cortisol levels and glucose levels, as well as the safety profile, were similar between the two treatments. SP-102 injections were generally well-tolerated and did not result in new unexpected side effects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Toxicology Studies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - Study Nos. 1014-1512 and 1014-2847</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted PK and toxicology studies in two non-rodent animal species to assess SP-102 administered via epidural and intrathecal routes with single and multiple dose regimens. Pharmacokinetically, a prolonged increase in the active dexamethasone metabolite was consistent with the extended residence time of the viscous gel formulation of SP-102 at the site of injection. There were no new unexpected toxicology findings apart from well-characterized toxicity findings commonly observed with administration of dexamethasone sodium phosphate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Toxicology Study</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - UPD003-IS21</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted a preclinical toxicology study designed to simulate the accidental introduction of epidural steroids into arterial blood vessels providing blood supply to the spinal cord, which is a major cause of neurological complications associated with current administration of suspension steroids containing particulates.A2 mL (10 mg of dexamethasone) injection of SP-102 was injected over 1-2 minutes into the vertebral artery of large animal species.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre- and post-dose angiography showed no remarkable changes and all animals survived for approximately 24 hours until euthanasia. The veterinary animal health report and the pathology report concluded there were no vascular, spinal cord or brain injuries associated with injection into the vertebral artery of the animals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Hydrodynamic Study</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - SP-PC002</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted a hydrodynamic study of SP-102 in non-rodent animal species, which showed that epidural administration of SP-102 demonstrated an increased local residence half-life and a decreased flow from the injection site.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intravascular Injection Study</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - SEM-005</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted a study to evaluate the accidental intravascular injection of SP-102 into the vertebral artery of non-rodent animals. There were no adverse clinical signs associated with the accidental intra-arterial injection of SP-102 following a 24-hour survival period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-103 (lidocaine topical system) 5.4%</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-103 is an investigational, non-aqueous lidocaine topical system undergoing clinical development in acute LBP. As a higher strength topical lidocaine system, SP-103 will build on the learnings from ZTlido because both products share the same adhesive drug delivery formulation and manufacturing technology. The clinical program involves evaluating the safety and efficacy of SP-103 for the treatment of acute LBP. A Phase 1 study was completed that demonstrated bioequivalent pharmacokinetics between the administration of a single SP-103 and the administration of three commercial ZTlido. The study also showed linear kinetics among multiple applications of SP-103 (i.e., 1, 2 or 3 patches) over a 12-hour administration period. Adhesion performance was assessed and found to be comparable between SP-103 and ZTlido.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specifically, we plan to evaluate SP-103 in the following studies:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-103-02 is a Phase 2 study of SP-103 in subjects with acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, two-period, cross-over, multicenter study of SP-103 versus placebo. The study is expected to consist of a 7-day open-label run-in period where all subjects receive active treatment. Responders to treatment will then be randomized to receive blinded treatment of either SP-103 or placebo. This study will inform on the pivotal Phase 3 study design to support market approval.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to a pivotal Phase 3 program, we intend to perform a 3-day PK study of SP-103, an adhesion performance study of SP-103 and an investigational study to evaluate the effects of heat and exercise on the PK and adhesion of SP-103 to support the NDA submission.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 2 trial of SP-103 was initiated in the second quarter of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-104 (4.5mg, low-dose naltrexone hydrochloride delayed-release capsules)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Two Phase 1 trials have been completed for SP-104 at investigative sites in New Zealand:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-104-01 is a food effect and bridging pharmacokinetic study comparing SP-104 to Naltrexone HCL Tablets conducted on approximately 18 healthy adult subjects. The study is designed to be an open-label, three-period, three-treatment, randomized study to characterize the PK and safety and tolerability of SP-104 under fasting and fed conditions. Subjects are randomly administered a single dose of one of three treatments and followed for PK and safety for a period of time followed by a washout period before receiving one of the other treatments. All subjects receive all three treatments. The study characterize the single-dose clinical studies and ultimately the commercial label. The study also serves as a &#x201c;pharmaceutical bridge&#x201d; between SP-104 and the commercial reference listed drug (the &#x201c;RLD&#x201d;) (Naltrexone HCI tablets, USP 50 mg) to support the eventual Section 505(b)(2) NDA. Assuming that the rate and extent of drug exposure for SP-104 will be lower than that observed for the RLD, this study allows us to rely upon the FDA&#x2019;s findings of safety for the RLD instead of having to perform extensive nonclinical animal safety toxicology studies and establish an extensive clinical safety database. Our development program can focus on establishing efficacy of SP-104 in the treatment of fibromyalgia.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-104-02 is a Phase 1 study of SP-104 conducted on approximately 52 healthy human subjects. The study is designed to be a double-blind, randomized, two-period, two-treatment crossover study to evaluate the safety of SP-104, compared to immediate release naltrexone capsules. The primary purpose of the study is to test the hypothesis that, when taken at night, the delayed release of 4.5 mg Naltrexone mitigates</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> against adverse events known for the drug and could affect patient compliance in maintaining treatment for their fibromyalgia. In a small (n=52) cross-over trial in healthy volunteers comparing SP-104 (naltrexone hydrochloride delayed-release 4.5 mg) to naltrexone hydrochloride immediate release 4.5 mg (the &#x201c;compared drug&#x201d;), there were no serious adverse effects, no AEs leading to discontinuation, no meaningful differences in physical examinations, vital signs, or laboratory parameters between treatments, no severe AEs for either treatment. Of the 52 patients receiving at least a single injection of SP-104, there were 21 (40%) patients experiencing at least one TEAE, 14 (27%) patients experiencing at least one treatment-related TEAE, 12 (23%) patients experiencing at least one treatment-related TEAE within 72 hours after first administration of SP-104. Notable AEs of special interest were nausea and headache within 72 hours after first administration of SP-104. SP-104 administered at night before bed resulted in a lower number of subjects with at least one AE (p = 0.0414), and an even lower number of subjects with at least one AE within 72 hours after the first administration of SP-140 when compared to the compared drug. There was a lower number of subjects with AEs of special interest within 72 hours after administration of SP-104 (n=9&#x37e; 12 events) versus the compared drug (n=15&#x37e; 20 events). Notable AEs of special interest observed within 72 hours after administration of the applicable drug are nausea (SP-104: n=0&#x37e; the compared drug: n=3) and headache (SP-104: n=6&#x37e; the compared drug: n=12). The study randomized subjects to one of two treatments followed by a washout period and then receipt of the other treatment, which allows all subjects to act as their own control. The study will support intellectual property, inform on clinical study design and contribute to safety characterization to support market applications.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We completed both studies in the second quarter of 2022. We plan to use data collected from these studies to support an Investigational New Drug application with the FDA, which is expected to enable further clinical development and initiation of a planned multi-center placebo-controlled registration trial in the field of fibromyalgia. The registration trial is designed to be a Phase 3, randomized double-blind, placebo-controlled, parallel group, multicenter study that meets the regulatory requirements of an &#x201c;adequate and well-controlled&#x201d; study to establish the efficacy of SP-104 in the treatment of fibromyalgia. Depending on the outcomes, this registration trial alone may be efficient in supporting market approval of SP-104 or as an additional Phase 3 study may be required.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section22">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Medical Affairs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Medical Affairs team includes in-house medical expertise, health economics and third-party payor support. The Medical Affairs team works with our clinical team to identify sites for clinical trials, support the investigator teams and develop publication plans for clinical and real-world ZTlido data and our product candidates. Our Medical Affairs team also works with Key Opinion Leaders, professional societies and patient advocacy groups to educate on and support the appropriate use of pain therapeutics, including topical pain products. Further, our Medical Affairs team provides our sales organization with therapeutic knowledge and product training. The Medical Affairs team and Promotional Review Committee review all promotional materials for scientific accuracy. Medical Affairs team also develops lifecycle planning and works with our clinical team to determine registration or supportive studies, oversee post-approval studies and support investigator-sponsored trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section23">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing and Supply Chain</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. Our technical team has extensive pharmaceutical development, manufacturing, analytical, quality and distribution experience and is qualified and capable of managing manufacturing and supply chain operations. Our Quality System, Standard Operating Procedures and contract manufacturing organizations (&#x201c;CMOs&#x201d;) comply with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cGMP and regulatory requirements. We selected our CMOs for specific competencies having met our development, manufacturing, quality and the FDA regulatory requirements. These CMOs manufacture our clinical supplies and commercial batches. We currently have no plans to build our own manufacturing or distribution infrastructure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZTlido</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido is a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi Koseido Co., Ltd. (&#x201c;Oishi&#x201d;) in Japan. We have exclusive worldwide rights to Oishi&#x2019;s proprietary formulation and manufacturing technologies except with respect to Japan. ZTlido is manufactured using premixing and hot-melt mixing of various excipients and lidocaine, followed by cGMP compliant coating, lining, cutting and filling processes. ZTlido is packaged as a carton of 30 topical systems, into individual child-resistant envelopes. See the section of this Annual Report on Form 10-K titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business - Material Agreements - Itochu and Oishi Product Development Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and &#x201c;Business - Material Agreements - Itochu and Oishi Commercial Supply Agreement&#x201d; for additional information regarding the manufacturing and supply chain of ZTlido.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once production is complete, commercial product shipments are sent to the United States, where our exclusive third-party logistics distribution provider, Cardinal Health 105, LLC (&#x201c;Cardinal Health 105&#x201d;), ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on the same day, or within 24 hours. We currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson Corporation (&#x201c;McKesson&#x201d;), Cardinal Health 110, LLC (&#x201c;Cardinal Health 110&#x201d;) and AmerisourceBergen Corporation (&#x201c;AmerisourceBergen&#x201d;). Distributors have agreements in place that provide us with access to large retail chains, including CVS, Walgreens, Rite Aid and Walmart, as well as independent pharmacies. In addition to all order fulfillment, Cardinal Health 105 performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December 31, 2020, 2021, and first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such periods.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. We currently hold wholesaler licenses and commenced selling directly to our main distributor customers as well as pharmacies from the second quarter of 2022. In April 2022, we discontinued our use of &#x201c;title model&#x201d; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-102 (SEMDEXA)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102 is a Phase 3 sterile dexamethasone sodium phosphate injectable viscous gel drug product containing dexamethasone sodium phosphate equivalent to 10 mg dexamethasone in a pre-filled glass syringe with a 2 mL deliverable volume. SP-102 also contains sodium hyaluronate, which is a novel, biocompatible, viscosity-enhancing excipient and is listed in the European Pharmacopeia. We have an exclusive supply agreement for sodium hyaluronate for SP-102 from the manufacturer and supplier.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102 is manufactured by a single-source manufacturer, which supports the clinical development, including the completed Phase 3 clinical trial of SP-102. In March 2022, we announced final results of the Phase 3 clinical trial, satisfying the primary efficacy and key secondary efficacy endpoints. The manufacturing process is proprietary and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">includes trade secrets. We plan to engage our existing contract manufacturer, Lifecore, for the commercial production of SP-102, if approved. We plan to use the biocompatible proprietary excipient supplied by Sanofi-Aventis U.S. LLC (&#x201c;Sanofi&#x201d;) sodium hyaluronate, pursuant to the Genzyme Supply Agreement, and engage Sanofi for commercial supply of dexamethasone sodium phosphate for SP-102, if approved. See the section of this Annual Report on Form 10-K titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business - Material Agreements - Genzyme Supply Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business - Material Agreements - Lifecore Master Services Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; for additional information regarding the manufacturing and supply of the proprietary excipient and contact manufacturing of SP-102 product, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-103</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-103 contains 5.4% lidocaine (108 mg lidocaine) and is manufactured for clinical supply by Oishi, using the same manufacturing processes as used for ZTlido. If our Phase 2 and Phase 3 trials are successful, we plan to submit the SP-103 manufacturing protocols in a supplemental new drug application.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-104</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing SP-104, a novel low-dose, naltrexone hydrochloride delayed release formulation for treating fibromyalgia. SP-104 is 4.5 mg, low-dose naltrexone hydrochloride delayed release capsule product in clinical development, currently undergoing Phase 1 studies. It is manufactured by a contract manufacturer, Tulex Pharmaceuticals Inc. (&#x201c;Tulex&#x201d;), located in Cranbury, NJ.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section24">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our industry is highly competitive and subject to rapid and significant technological change. The large size and expanding scope of the pain management market makes it an attractive therapeutic area for biopharmaceutical businesses. Our potential competitors include pharmaceutical, biotechnology and specialty pharmaceutical companies. Many of these companies have drug pipelines, readily available capital, and established research and development organizations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido and our product candidate, SP-103, if approved, face and will likely face competition from prescription, generic, and OTC topical lidocaine patches, including Lidoderm and generic lidocaine patches manufactured by Teva, Mylan and Par Pharmaceutical, Inc. Additionally, SP-103, if approved, will likely compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants and anticonvulsants, particularly as we seek approval for the treatment of acute LBP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102, if approved, has the potential to become the first FDA-approved epidural steroid product for the treatment of sciatica. While there are currently no FDA-approved ESIs indicated for the treatment of sciatica, we are aware of certain non-steroid product candidates in development. SP-102, if approved, will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the off-label and unapproved use of branded and generic injectable steroids.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of certain non-opioid therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, SP-104, will likely face direct competition from these candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that the market will become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in: developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining the FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates and launching, marketing and selling product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The key competitive factors affecting the success of ZTlido, SP-102, SP-103 and SP-104 are likely to be their efficacy, durability, safety, price and the availability of reimbursement from government and other third-party payors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section25">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Material Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Itochu and Oishi Product Development Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are party to the Product Development Agreement with Oishi Koseido Co., Ltd. (&#x201c;Oishi&#x201d;) and Itochu Chemical Frontier Corporation (&#x201c;Itochu,&#x201d; and together with Oishi, the &#x201c;Developers&#x201d;). Pursuant to the Product Development Agreement, the Developers agreed to develop, exclusively for us, lidocaine tape products, including ZTlido and SP-103 (the &#x201c;Products&#x201d;). Pursuant to the Product Development Agreement, we obtained the rights to market, sell and distribute the Products in global markets outside of Japan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In carrying out the development responsibilities, the Developers agreed to, among other things, (1) source and provide the active pharmaceutical ingredient for the Products for manufacturing, (2) develop a stable final dosage form of the Products suitable for regulatory approvals, (3) conduct product development activities necessary to support the filing of applications for regulatory approvals for the Products and (4) conduct manufacturing scale-up activities and preclinical studies for the Products. We are responsible for, among other things, (a) conducting all pivotal human clinical trials for the Products, (b) completing all regulatory filings, correspondence and meetings with the FDA or other applicable governmental authorities with respect to the Products and (c) commercially launching the Products. We maintain the ultimate responsibility and decision-making control with regard to the marketing and pricing of the Products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The parties agreed to cooperate in good faith to determine whether to seek or maintain patent protection with respect to the Products, the active pharmaceutical ingredient, any associated method of use, method of manufacturing, or any other invention that could reasonably be expected to affect the commercialization or value of the Products. The Developers have the first right to pursue patent protection for any invention by them. All parties will jointly agree on the appointment of the patent representatives in each country outside of Japan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until the expiration or termination of the Product Development Agreement, the Developers granted us an exclusive, royalty-free, sublicensable, worldwide license (except with respect to Japan) under its current and future intellectual property rights relating to the Products and the lidocaine in such Products. As consideration for the Developers&#x2019; development obligations under the Product Development Agreement, we agreed to pay a contingent quarterly royalty between 25% and 35% to the Developers based on the net quarterly profits of the Products. In the event that the net profits of any of the first four calendar quarters after the commercial launch equals a negative amount (a &#x201c;Net Loss&#x201d;), we are allowed to carry over such Net Loss to apply against all future calendar quarters until such Net Loss is covered, all calculated in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Under the Product Development Agreement, if our total net profits for ZTlido and SP-103 are equal to or less than five percent of our net sales of ZTlido and SP-103 for a period of four or more consecutive quarters, the Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement. As of the date of this Annual Report on Form 10-K, our net profits for ZTlido and SP-103 have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this Annual Report on Form 10-K, neither Oishi nor Itochu has exercised its right of termination. Additionally, if we receive any licensing fees from any third-party sublicensees, we are obligated to pay the same proportions of such licensing fee to the Developers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The current term of the Product Development Agreement will continue until October 2, 2028, which is the 10th anniversary of the first commercial sale of ZTlido. Afterwards, the agreement will renew automatically for subsequent successive one-year renewal periods unless we or the Developers terminate it upon six-month written notice. In addition, we or the Developers may terminate the Product Development Agreement if (1) the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within 180 days after notice requesting to cure&#x37e; (2) the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts&#x37e; (3) the market conditions are such that (a) our total net profits of the Products are equal to or less than five percent of our net sales of the Products for a period of four or more consecutive quarters, or (b) the Products&#x2019; economic viability is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us and the Developers, and the parties are unable to resolve the concerns under the foregoing clauses (a) and (b) after 30 days of good-faith discussion&#x37e; (4) the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated&#x37e; or (5) we or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Additionally, we may terminate the Product Development Agreement if (i) any of the pivotal human clinical trials for any of the Products fail, or (ii) the FDA issues a &#x201c;Refusal to File&#x201d; for any of the Products&#x2019; regulatory approval application and, after reasonable consultation with the Developers, we believe that it is commercially unreasonable to re-file. The Developers may terminate the Product Development Agreement if we fail to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Product Development Agreement, we and the Developers have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (1) any breach of our respective representations,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">warranties or obligations under the Product Development Agreement, (2) any failure by either of us to comply with all applicable laws, or (3) our respective negligence or willful misconduct.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing is a summary of the material terms of the Product Development Agreement and its amendments in the forms filed as exhibits to this Annual Report on Form 10-K. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Itochu and Oishi Commercial Supply Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective February 16, 2017, Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;) entered into the Commercial Supply Agreement with Itochu and Oishi (the &#x201c;Commercial Suply Agreement&#x201d;). Pursuant to the Commercial Supply Agreement, Oishi agreed to manufacture, store, handle and perform quality control testing of the Products (as defined in the Product Development Agreement) at its facility in Japan. Itochu agreed to purchase Products from Oishi and handle the shipping of the Products. Both Oishi and Itochu agreed to provide us with certain technical support regarding the Products as reasonably requested by us, including but not limited to analytical test methods, method development, physical and chemical properties, and use of the Products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Itochu and Oishi Commercial Supply Agreement, we pay per item transfer prices for ZTlido, ZTlido professional samples and ZTlido placebo samples, in each case subject to certain minimum order quantities. We are required to provide a 12-month rolling purchase forecast of the estimated quantities of the Products in writing on a monthly basis. Oishi is required to promptly notify us and Itochu if it lacks the capacity to meet the forecast. All Products ordered by us will be in the form of a firm written purchase order. During the years ended December 31, 2022, 2021 and 2020, we purchased inventory in the amount of $6.7 million, $5.7 million, and $0.8 million, respectively, under the Itochu and Oishi Commercial Supply Agreement. The significant increase in inventory purchased in fiscal year 2021 was largely due to an excess of in stock inventory in fiscal year 2020 that was sold throughout fiscal year 2020 and the early part of fiscal year 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Itochu and Oishi Commercial Supply Agreement will remain in effect until the termination of the Product Development Agreement. Additionally, either we or the Developers may terminate the Itochu and Oishi Commercial Supply Agreement (1) if the other party is in material breach of the agreement and the breach is not substantially cured within 60 days after receiving written notice specifying the nature of the breach, or (2) in the event of any of the parties&#x2019; insolvency, bankruptcy or assignment for the benefit of creditors. Any third-party claim arising out of a breach by a party of any representation, warranty or obligation under the Itochu and Oishi Commercial Supply Agreement, or a failure by a party to comply with applicable laws, or the negligence or willful misconduct of a party, will be subject to and governed by the Product Development Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing is a summary of the material terms of the Itochu and Oishi Commercial Supply Agreement and its amendments in the forms filed as exhibits to this Annual Report on Form 10-K. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Genzyme Supply Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 17, 2015, through our wholly owned subsidiary, Semnur, we entered into that certain exclusive Supply Agreement (the &#x201c;Genzyme Supply Agreement&#x201d;) with Genzyme Corporation (&#x201c;Genzyme&#x201d;), an affiliate of Sanofi-Aventis U.S. LLC. Pursuant to the Genzyme Supply Agreement, Genzyme agreed to produce and provide sodium hyaluronate, one of the excipients for SEMDEXA, and we agreed to purchase 100% of our clinical and commercial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements for sodium hyaluronate in specified territories, including the United States and all countries of the European Union (&#x201c;EU), exclusively from Genzyme.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Genzyme Supply Agreement, we agreed to pay a per gram price for clinical supply of sodium hyaluronate. For commercial supply, the price will depend on the quantity of order. The pricing for both the clinical supply and the commercial supply of sodium hyaluronate is subject to readjustments each year on January 1, provided that in no case will the price be increased by more than 5% each year.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Genzyme Supply Agreement provides for a five year exclusivity period in favor of us and will remain in effect until 10 years after the effective date unless earlier terminated in accordance with the terms thereof, with automatic renewal for additional five year periods (on an exclusive basis), if the respective requirements for exclusivity are met by us as set forth therein, and for additional two-year periods thereafter unless either party gives notice of a termination not less than 18 months prior to the expiration of the then-current term. Either party may terminate the Genzyme Supply Agreement if (1) the other party is in material breach of the agreement and fails to cure within 30 days, or (2) if the development of SEMDEXA is ceased or we do not file for regulatory approval for SEMDEXA by January 1, 2020. Additionally, Genzyme may terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#x2019; notice. We did not file for regulatory approval for SEMDEXA by January 1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with Genzyme&#x2019;s right terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons, Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement, effective as of May 31, 2024. Although we are currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an alternative supplier of sodium hyaluronate on commercially reasonable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Genzyme Supply Agreement, we and Genzyme have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (1) any material breach of our respective representations, warranties and obligations thereunder, or (2) our respective gross negligence or willful misconduct. In addition, we have agreed to indemnify Genzyme against any third-party liabilities arising out of the development, manufacture, storage, handling, use, marketing, distribution, offer for sale, sale, promotion or other commercialization of sodium hyaluronate by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing is a summary of the material terms of the Genzyme Supply Agreement in the form filed as an exhibit to this Annual Report on Form 10-K. You should read the form of the agreement for a complete understanding of all of its terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lifecore Master Services Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 27, 2017, through our wholly owned subsidiary, Semnur, we entered into that certain Master Services Agreement (as amended, the &#x201c;Lifecore Master Services Agreement&#x201d;), with Lifecore Biomedical, LLC (&#x201c;Lifecore&#x201d;). Pursuant to the Lifecore Master Services Agreement, Lifecore is responsible for clinical trial material manufacturing and development services for SEMDEXA as set forth in each separate statement of work (each a &#x201c;Lifecore Statement of Work&#x201d;).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The parties entered into a Lifecore Statement of Work on January 27, 2017, pursuant to which Lifecore agreed to provide, among other things, (1) project management support, (2) development services, (3) clinical trial materials,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and (4) stability studies. We paid Lifecore for the development and clinical trial material manufacturing services, which was invoiced at the completion of each service.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the purposes of Lifecore&#x2019;s development and clinical trial material manufacturing obligations, we granted Lifecore a nonexclusive, worldwide and royalty-free license under our owned or controlled intellectual property rights necessary to manufacture SEMDEXA, without additional right, title or interest in our intellectual property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Lifecore Master Services Agreement contains customary reciprocal indemnification obligations for Lifecore and Semnur.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Lifecore Master Services Agreement expired on December 31, 2022, and we are currently negotiating a new agreement with Lifecore.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing is a summary of the material terms of the Lifecore Master Services Agreement and the amendment thereto in the forms filed as exhibits to this Annual Report on Form 10-K. You should read the form of the agreement and its amendment for a complete understanding of all of their respective terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Semnur Merger Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 18, 2019, Legacy Scilex acquired Semnur pursuant to an Agreement and Plan of Merger with Semnur (as amended, the &#x201c;Semnur Merger Agreement&#x201d;), Sigma Merger Sub, Inc., a wholly owned subsidiary of Legacy Scilex (&#x201c;Sigma Merger Sub&#x201d;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#x201c;Semnur Equityholders&#x2019; Representative&#x201d;), and for limited purposes, Sorrento. Pursuant to the Semnur Merger Agreement, Sigma Merger Sub merged with and into Semnur (the &#x201c;Semnur Merger&#x201d;), with Semnur surviving as Legacy Scilex&#x2019;s wholly owned subsidiary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with transactions contemplated by the Semnur Merger Agreement, Sorrento and each of the other holders of outstanding shares of capital stock of Scilex Pharma, contributed each share of Scilex Pharma capital stock it owned to Legacy Scilex in exchange for one share of common stock of Legacy Scilex (&#x201c;Legacy Scilex Common Stock&#x201d;), par value $0.0001 per share (the &#x201c;Contribution&#x201d;). As a result of the Contribution, and prior to the consummation of the Semnur Merger, Scilex Pharma became a wholly owned subsidiary of Legacy Scilex and Sorrento became the owner of approximately 77% of Legacy Scilex&#x2019;s issued and outstanding capital stock. As a result of the Semnur Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of Legacy Scilex.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the closing of the Semnur Merger, Legacy Scilex issued to the holders of Semnur&#x2019;s capital stock (the &#x201c;Semnur Equityholders&#x201d;) and options to purchase Semnur&#x2019;s common stock, upfront consideration with a value of $70.0 million. The upfront consideration was comprised of the following: (i) a cash payment of approximately $15.0 million, and (ii) $55.0 million in shares of Legacy Scilex Common Stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#x201c;Stock Consideration&#x201d;). A portion of the cash consideration otherwise payable to the Semnur Equityholders was set aside for expenses incurred by the Semnur Equityholders&#x2019; Representative, and 4,749,095 shares of Legacy Scilex Common Stock otherwise issuable to Semnur Equityholders were placed in escrow with a third party as security for the indemnification obligations of the Semnur Equityholders under the Semnur Merger Agreement. The expense fund and escrow have since been released per the terms of the escrow agreement. The Semnur Equityholders that received the Stock Consideration were required to sign an exchange and registration rights agreement with Legacy Scilex, which is further described below. Following the issuance of the Stock Consideration, Sorrento ownership in Legacy Scilex was diluted to approximately 58% of Legacy Scilex&#x2019;s issued and outstanding capital stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Semnur Merger Agreement, and upon the terms and subject to the conditions contained therein, Legacy Scilex also agreed to pay the Semnur Equityholders up to $280.0 million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0 million payment that will be due upon obtaining the first approval of a NDA of a Semnur product by the FDA and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (i) a $20.0 million payment upon the achievement of $100.0 million in cumulative net sales of a Semnur product, (ii) a $20.0 million payment upon the achievement of $250.0 million in cumulative net sales of a Semnur product, (iii) a $50.0 million payment upon the achievement of $500.0 million in cumulative net sales of a Semnur product, and (iv) a $150.0 million payment upon the achievement of $750.0 million in cumulative net sales of a Semnur product. As of the date of this Annual Report on Form 10-K, none of the foregoing payments have been triggered.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Semnur Merger Agreement also provided that following the consummation of Legacy Scilex&#x2019;s first bona fide equity financing with one or more third-party financing sources on an arms&#x2019; length basis with gross proceeds to Legacy Scilex of at least $40.0 million, certain of the former Semnur optionholders will be paid cash in lieu of: (i) the 352,972 shares of Legacy Scilex Common Stock otherwise issuable to such former Semnur optionholders pursuant to the Semnur Merger Agreement, and (ii) any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Semnur Merger Agreement, with such shares in each case valued at $1.16 per share. The Semnur optionholders subsequently agreed, under the terms of the Exchange Agreement (as defined and described below) to forego the foregoing right to any such payment in exchange for the right to participate in the Share Exchange (as defined below).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2019, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with Legacy Scilex (as amended, the &#x201c;Exchange Agreement&#x201d;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within 18 months following the closing of the Semnur Merger, 100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital stock on a major stock exchange that met certain requirements, then holders of the Stock Consideration could collectively elect to exchange, during the 60-day period commencing the date that was the 18 month anniversary of the closing of the Semnur Merger (the &#x201c;Share Exchange&#x201d;), the Stock Consideration for shares of Sorrento&#x2019;s common stock with a value of $55.0 million based on a price per share of Sorrento&#x2019;s common stock equal to the greater of (a) the 30-day trailing volume weighted average price of one share of Sorrento&#x2019;s common stock as reported on The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) as of the consummation of the Share Exchange and (b) $5.55 (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#x201c;Exchange Price&#x201d;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento and the Semnur Equityholders&#x2019; Representative on September 28, 2020, on October 9, 2020, Sorrento paid $55.0 million in cash to the Semnur Equityholders in lieu of issuing $55.0 million of shares of Sorrento&#x2019;s common stock at the Exchange Price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing is a summary of the material terms of the Semnur Merger Agreement (including the amendment thereto) in the forms filed as exhibits to this Annual Report on Form 10-K. You should read the Semnur Merger Agreement (including the amendment thereto) for a complete understanding of all of their respective terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Aardvark Asset Purchase Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, Sorrento entered into an asset purchase agreement (the &#x201c;Aardvark Asset Purchase Agreement&#x201d;) with Aardvark Therapeutics, Inc. (&#x201c;Aardvark&#x201d;), pursuant to which, among other things, Sorrento acquired Aardvark&#x2019;s Delayed Burst Release Low Dose Naltrexone (DBR-LDN) asset and intellectual property rights, for the treatment of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the &#x201c;SP-104 Assets&#x201d;), which includes a Statement of Work dated November 18, 2020 (the &#x201c;Tulex Statement of Work&#x201d;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of SP-104 for Sorrento.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to SP-104 and on May 12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#x201c;Bill of Sale&#x201d;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the SP-104 Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and Legacy Scilex assumed all of Sorrento&#x2019;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the &#x201c;SP-104 Acquisition&#x201d;).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the SP-104 Acquisition, Legacy Scilex issued a promissory note in the aggregate principal amount of $5,000,000 to Sorrento (the &#x201c;Promissory Note&#x201d;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and (b) the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#x201c;Consideration Shares&#x201d;) or any combination thereof, at Legacy Scilex&#x2019;s sole discretion, and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within 60 days of the issuance of such Consideration Shares.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy Scilex&#x2019;s sole discretion) (the &#x201c;Development Milestone Payment&#x201d;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#x201c;Commercial Product&#x201d;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of the date of this Annual Report on Form 10-K, none of the foregoing payments have been triggered.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with its acquisition of the SP-104 Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tien-Li Lee, MD, a member of our board of directors (the &#x201c;Board&#x201d;), is the founder, chief executive officer and a member of the board of directors of Aardvark.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing is a summary of the material terms of the Aardvark Asset Purchase Agreement, Bill of Sale and Promissory Note in the forms filed as exhibits to this Annual Report on Form 10-K. You should read the forms of these agreements for a complete understanding of all of their respective terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tulex Master Services Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As described above, in connection with the SP-104 Acquisition, Legacy Scilex acquired the Tulex Statement of Work, pursuant to which Tulex, among other things, develops, tests and manufactures clinical supplies of SP-104 for Legacy Scilex. The Tulex Statement of Work is governed by the terms of a master services agreement (the &#x201c;Tulex Master</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services Agreement&#x201d;). The Tulex Master Services Agreement was novated to Legacy Scilex on June 15, 2022 and will remain in effect until five years after the effective date, unless terminated early by either party. Either party may terminate the Tulex Master Services Agreement or a Tulex Statement of Work by written notice (1) if the other party is in material breach of the agreement or a Tulex Statement of Work and fails to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable Tulex Statement of Work) or (2) in the event of the other party&#x2019;s insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any Tulex Statement of Work (1) without cause upon 30 days prior written notice to Tulex or (2) immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. A termination or expiration of a single Tulex Statement of Work will not cause the automatic termination of the agreement or of any other Tulex Statement of Work.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each party under the Tulex Master Services Agreement agreed to indemnify the other party, its affiliates and each of their respective officers, directors, employees, contractors and agents against any third-party liabilities arising out of (1) such party&#x2019;s breach of the Tulex Master Services Agreement or a Tulex Statement of Work or (2) the negligence or willful misconduct on the part of such party, its officers, directors, employees, agents or other representatives in connection with the Tulex Master Services Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing is a summary of the material terms of the Tulex Master Services Agreement in the form filed as an exhibit to this Annual Report on Form 10-K. You should read the form of the agreement for a complete understanding of all of its terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Shah Investor LP Assignment Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2013, through Semnur, we entered into an Assignment Agreement (the &#x201c;Assignment Agreement&#x201d;) with Shah Investor LP (&#x201c;Shah Investor&#x201d;). Mahendra Shah, Ph.D., who served on our board of directors from March 2019 to October 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned to us certain intellectual property related to pharmaceutical compositions of corticosteroids (the &#x201c;Assigned IP&#x201d;). As consideration for the Assigned IP, we agreed to pay a contingent quarterly royalty in the low-single digits to Shah Investor based on the quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed utilizing the Assigned IP (a &#x201c;Royalty Product&#x201d;). We expect that SEMDEXA, if approved, will constitute a Royalty Product. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as a Royalty Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the first Royalty Product in the United States, whichever is longer. We also agreed to use commercially reasonable efforts to maximize the scope and coverage of the patents contained in the Assigned IP. As of the date of this Annual Report on Form 10-K, no royalty payments have been made as we have not yet commercialized any applicable products and therefore such payments have not been triggered.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Assignment Agreement will remain in effect on a country-by-country and product-by-product basis until royalties are no longer due on any Royalty Product. Either party may terminate the Assignment Agreement upon sixty days&#x2019; prior written notice, in the event the other party seeks to avoid a provision of the Assignment Agreement by asserting that such provision is invalid, illegal or otherwise unenforceable, unless such assertion is eliminated and the effect of such assertion cured within such sixty day period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing is a summary of the material terms of the Assignment Agreement in the form filed as an exhibit to this Annual Report on Form 10-K. You should read the form of the agreement for a complete understanding of all of its terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Romeg License and Commercialization Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective June 14, 2022, we entered into a License and Commercialization Agreement (the &#x201c;Romeg Agreement&#x201d;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.). Pursuant to the Romeg Agreement, Romeg granted to us (1) the right to manufacture, promote, market, distribute and sell the Licensed Products (as defined below) in the United States and (2) an exclusive, transferable license to use the trademark &#x201c;GLOPERBA&#x201d;.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Romeg Agreement, among other things, Romeg granted us (1) a transferable license, with the right to sublicense, under the patents and know-how specified therein to (a) commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#x201c;Initial Licensed Product&#x201d;) in the United States (including its territories) (the &#x201c;Territory&#x201d;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#x201c;Licensed Products&#x201d;) and commercialize any such products and (c) manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory&#x37e; and (2) an exclusive, transferable license, with right to sublicense, to use the trademark &#x201c;GLOPERBA&#x201d; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The license to know-how is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the royalty term, but is otherwise non-exclusive. The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July 1, 2027 and, thereafter, is co-exclusive with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i) expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii) the tenth anniversary of the date of the Romeg Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the license under the Romeg Agreement, we agreed to pay Romeg (1) an up-front payment of $2.0 million, (2) upon our achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0 million and (3) certain royalties, at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by us during the royalty term.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Romeg Agreement will remain in effect until it is terminated in accordance with the terms thereof. We may terminate the Romeg Agreement (1) upon written notice to Romeg, if we elect (or are required) to withdraw the Initial Licensed Product from the market as a result of serious adverse reactions from use of such product, which termination will be effective 30 days following the date of such notice or (2) at any time, without cause, upon written notice to Romeg, which termination will be effective 120 days following the date of such notice, provided that a termination fee of up to $2.0 million shall be paid to Romeg depending on when during the 10 year period following the date of the agreement any such termination notice set forth in the immediately preceding clause (2) has been provided. Romeg may terminate the Romeg Agreement (a) upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we has made such payment in full or delivered such quarterly report within such 30 day period&#x37e; (b) immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities&#x37e; or (c) by written notice to us if sales of Licensed Products do not commence or continue within specified periods agreed to by the parties. In addition, either party may terminate the Romeg Agreement (1) in the event the other party materially breaches the agreement, unless the breaching party has cured any such breach within 60 days after any notice thereof was provided or (2) in the event the other party (a) files in any court or agency a petition in bankruptcy or insolvency, (b) is served with an involuntary petition against it in any insolvency proceeding and such involuntary petition has not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">been stayed or dismissed within 90 days after its filing, or (c) makes an assignment of substantially all of its assets for the benefit of its creditors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Romeg Agreement contains customary reciprocal indemnification obligations for Romeg and us. Additionally, we agreed, subject to certain exceptions, to indemnify Romeg against any loss arising out of the manufacture or commercialization of any Licensed Product by or on behalf of us or our affiliates, marketing partners, sublicensees or subcontractors on or after the date of the license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing is a summary of the material terms of the Romeg Agreement, which is in the form filed as an exhibit to this Annual Report on Form 10-K. You should read the form of the agreement for a complete understanding of all of its terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section26">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our novel adhesion and delivery technology, inventions, improvements and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates, their methods of use and processes for their manufacture, and any other inventions that are commercially important to our business. We also rely on trade secret protection of our confidential information and know-how relating to our novel adhesion and delivery technology, platforms and product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the PTO in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. We cannot provide any assurance that any patents will be issued from our pending or future applications or that any patents will adequately protect our product or product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our patent portfolio, consisting of owned and/or licensed IP as of  December 31, 2022 contains approximately sixteen issued and unexpired U.S. patents, six pending U.S. patent applications, and one pending Patent Cooperation Treaty (PCT) application. Our portfolio also includes certain foreign counterparts of these patents and patent applications including Australia, Brazil, Canada, China, Hong Kong, India, Indonesia, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Russian Federation, Singapore, South Africa, Taiwan, Ukraine, and certain countries within the European Patent Convention.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to ZTlido and SP-103, our patents and patent applications cover compositions and methods of treatment. With respect to our product candidate SEMDEXA, our patents and patent applications include formulations and methods of treatment. The patents are U.S. Pat. Nos. 10,500,284, 10,117,938, and 11,020,485, all of which expire in 2036. With respect to SP-104, our pending Patent Cooperation Treaty application is WO 2022/076470 (and all patents and patent applications that claim priority rights thereto), which covers oral delayed burst formulations of low-dose naloxone or naltrexone and related methods of treatment. We continue to seek to maximize the scope of our patent protection for all our programs. We have six issued U.S. patents and two pending U.S. patent applications relating to lidocaine topical system compositions and methods of treating pain with lidocaine topical system compositions. The patents are U.S. Pat. Nos. 9,283,174, 9,925,264, 9,931,403, 10,765,749, 10,765,640 and 11,278,623 all of which expire in 2031. Related to GLOPERBA, our licensed patents include U.S. Pat. Nos. 9,907,751, 10,226,423, 10,383,820, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,383,821, which relate to liquid colchicine formulations for oral administration and associated methods of use. U.S. Pat. No. 10,226,423 expires in 2037. The remaining patents related to GLOPERBA expire in 2036. We believe that we have certain know-how and trade secrets relating to our technology and product candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future product candidates. However, trade secrets can be difficult to protect. We seek to protect our trade secrets, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, service providers, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trademarks, Trade Secrets and Other Proprietary Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We file trademark applications and pursue registrations in the United States and abroad when appropriate. We own registered U.S. trademarks for the marks &#x201c;SCILEX,&#x201d; &#x201c;ZTlido&#x201d; and &#x201c;RESPONSIBLE BY DESIGN.&#x201d; We also own pending trademark applications for &#x201c;SEMNUR PHARMACEUTICALS&#x201d; and &#x201c;SEMDEXA&#x201d; in the United States. We also license the GLOPERBA trademark as discussed in relation to the Romeg Agreement described above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how, we rely on trade secret protection and confidentiality agreements to protect our interests. Our policy is to require each of our employees, consultants and advisors to execute a confidentiality and inventions assignment agreement before beginning their employment, consulting or advisory relationship with us. The agreements generally provide that the individual must keep confidential and not disclose to other parties any confidential information developed or learned by the individual during the course of the individual&#x2019;s relationship with us except in limited circumstances. These agreements generally also provide that we will own all inventions conceived by the individual in the course of rendering services to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEMDEXA benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible excipient with no generic equivalent. Our complex manufacturing process, specialized equipment and know-how for sterile viscous product candidates are also key to our competitive edge. We believe that our competitors will be required to conduct lengthy and costly preclinical and clinical trials to establish products with comparable safety and efficacy to SEMDEXA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section27">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation and Product Approval</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities in the United States at the federal, state and local levels, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are marketing and developing. SP-102, SP-103, SP-104 and any other product candidate that we develop must be approved by the FDA or otherwise authorized for marketing before they may be legally marketed in the United States and by the corresponding foreign regulatory agencies before they may be legally marketed in foreign countries. The processes for obtaining marketing approvals, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Drug Development Process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates drugs under the FDCA and implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval, may subject an applicant or its products to a variety of administrative or judicial sanctions, such as inspection scrutiny, the FDA&#x2019;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, or reimbursements, restitution, disgorgement of profits or civil or criminal penalties. The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices (&#x201c;GLPs&#x201d;) or other applicable regulations&#x37e;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an Investigational New Drug Application (&#x201c;IND&#x201d;), which must become effective before human clinical trials may begin&#x37e;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an institutional review board (&#x201c;IRB&#x201d;) covering each clinical site before each trial may be initiated&#x37e;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials according to the laws and regulations pertaining to the conduct of human clinical trials, collectively referred to as Good Clinical Practice (&#x201c;GCP&#x201d;) requirements to establish the safety and efficacy of the proposed drug for its intended use&#x37e;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an NDA or other marketing application (collectively, an &#x201c;NDA&#x201d;), for a proposed new drug, including its specific formulation and labeling&#x37e;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable&#x37e;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with the FDA&#x2019;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity&#x37e;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential FDA audit of the preclinical study and clinical trial sites that generated the data in support of the NDA&#x37e; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before testing novel compounds with potential therapeutic value in humans, the drug candidate enters the preclinical testing stage, also referred to as preclinical studies. Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug candidate. The conduct of the preclinical studies must comply with federal laws and requirements including GLPs. The IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, and any available clinical data or literature, to the FDA as part of the IND. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns, non-compliance, or for additional reasons. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the drug candidate to healthy subjects or patients with the target disease under the supervision of qualified investigators, generally physicians not employed by the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, subject selection and exclusion criteria, dosing procedures, and the parameters to be used to collect data and to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and investigators for suspected adverse reactions that are serious and unexpected. Clinical trials must be conducted in accordance with applicable statutes, the FDA&#x2019;s regulations and GCP requirements. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to and signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until it is completed. In some instances, additional oversight boards, such as a data safety monitoring board, are required to evaluate interim data and determine whether a study should continue or be modified or terminated. Information about many clinical trials is required to be publicly reported on www.ClinicalTrials.gov or similar databases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing may be conducted only in patients having the specific disease</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The drug is administered to an expanded patient population in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm the safety and efficacy of the product for potential approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. Generally, at least two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. In some cases, the FDA may approve a drug based on the results of a single adequate and well-controlled Phase 3 trial for excellent design and which provided highly reliable and statistically strong evidence of important clinical benefit.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-approval studies, also referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Progress reports detailing the status of drug development and results of the clinical trials must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for suspected adverse reactions that are serious and unexpected (including increased rate of occurrence of such adverse reactions), findings from other studies that suggest a significant risk in humans exposed to the drug, or any findings from tests in laboratory animals that suggests a significant risk for human subjects or patients. Phase 1, Phase 2 and Phase 3 clinical trials may not yield positive results, or may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to study subjects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the Phase 3 clinical trials that they believe will support approval of the new drug.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FDA Review and Approval Processes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of product development, preclinical studies and clinical trials for the claimed indications are incorporated into an NDA. The FDA may grant deferrals for the development and submission of pediatric data or full or partial waivers after the initial submission of a pediatric study plan following an end of Phase 2 meeting. In addition, descriptions of the manufacturing process and controls, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are also submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees and a waiver of such fees may be obtained under certain limited circumstances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#x2019;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (&#x201c;PDUFA&#x201d;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#x201c;filing&#x201d; of a standard, original NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#x201c;filing&#x201d; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accepting an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the drug approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (&#x201c;REMS&#x201d;) is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving an NDA, the FDA will generally inspect the facilities at which the product is to be manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require post-approval studies, referred to as Phase 4 testing, which involves clinical trials designed to further assess a product&#x2019;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA administers a number of different programs that enable the agency and sponsors in various ways to expedite the development or agency review of a new drug product. Among these, the FDA has a fast track designation that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. New drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. As an example of the modified processes available to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review applications with priority review designations within six months of the filing date as compared to ten months for review of other NDAs under its current PDUFA review goals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform additional adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-use submission of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#x201c;breakthrough therapies&#x201d; that may be eligible to receive breakthrough therapy designation. A sponsor may seek the FDA designation of a product candidate as a &#x201c;breakthrough therapy&#x201d; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work with the sponsor to expedite the development and review of such drug.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With passage of the 21st Century Cures Act in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have obtained fast track designation for SEMDEXA for the treatment of lumbosacral radicular pain and have applied for breakthrough therapy designation for the treatment of lumbosacral radicular pain based on the top-line results obtained from the pivotal Phase 3 trial, which results reflect achievement of primary and secondary endpoints. We have also obtained fast track designation for SP-103 for the treatment of acute LBP. We may seek additional designations for SEMDEXA, SP-103 or our other product candidates. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown risks or problems with a product may result in labeling changes, restrictions on the product or even complete withdrawal of the product from the market. After approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any drug products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences or quality issues with the product, providing the FDA with updated safety and efficacy information, satisfaction of post-approval requirements or commitments, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, among other things, standards for direct-to-consumer advertising, prohibitions against promoting drugs for uses, or in patient populations, that are not described in the drug&#x2019;s approved labeling, which is known as &#x201c;off-label use,&#x201d; rules for conducting industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to comply with post-approval requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant, manufacturer or product to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Hatch-Waxman Amendments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 505 of the FDCA describes three types of NDAs that may be submitted to request marketing authorization for a new drug, the first being a 505(b)(1) NDA. A 505(b)(1) NDA is an application that contains full reports of investigations of safety and effectiveness. A 505(b)(2) NDA likewise contains full reports of investigations of safety and effectiveness relevant to a product, but some of the data are not owned by or licensed to the applicant. Section 505(j) establishes an abbreviated approval process for generic versions of approved drug products through the submission of an abbreviated new drug application (&#x201c;ANDA&#x201d;). An ANDA generally provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form, and with the same labeling and route of administration as the listed drug and has been shown to be bioequivalent to the listed drug. ANDA applicants are required to conduct bioequivalence testing to confirm chemical and therapeutic equivalence to the branded reference drug. Generic versions of drugs can often, and sometimes must, be substituted by pharmacists under prescriptions written for the branded reference drug.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. This regulatory pathway enables the applicant to rely, in part, on the FDA&#x2019;s findings of safety and efficacy for an existing product, or published literature, in support of its application. Additional preclinical and clinical data may also be submitted. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, or for any new indication sought by the 505(b)(2) applicant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA at least one of the following (1) no patent information on the drug product that is relied upon by the ANDA or 505(b)(2) NDA (known as the reference drug) has been submitted to the FDA&#x37e; (2) such patent has expired&#x37e; (3) the date on which such patent expires&#x37e; or (4) such patent is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the drug product for which the ANDA or 505(b)(2) NDA is submitted. This last certification is known as a Paragraph IV Certification. If the NDA holder for the reference drug or patent owner(s) asserts a patent challenge to the Paragraph IV Certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the Paragraph IV Certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#x2019;s favor or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#x2019;s or patent owner&#x2019;s decision to initiate patent litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to, and distinct from the patent protection provisions, the Hatch-Waxman Amendments establish periods of regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2) application that relies on the branded reference drug. For example, the holder of an NDA may obtain five years of exclusivity upon approval of a new drug containing a new chemical entity that has not been previously approved by the FDA. The Hatch-Waxman Amendments also provide three years of marketing exclusivity to the holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for drugs that include the innovation that required the new clinical data, but generally allows the approval for non-protected characteristics and labeling.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA for the drug for the rare disease or condition. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication not protected by the exclusive approval, but that could be used off-label in the orphan indication. The FDA also has authority to withdraw exclusive marketing rights if the holder of an approved orphan drug cannot assure the availability of sufficient quantities of the drug within a reasonable time to meet the needs of patients with the disease or condition for which the drug was designated. Once withdrawn under such circumstances, exclusive approval may not be reinstated for that drug.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third-Party Payor Coverage, Pricing and Reimbursement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, sales of a product will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for the product. Third-party payors include government payor programs at the federal and state levels, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication, and which can change over time. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs, in order for the company&#x2019;s products to be considered as a formulary option. Nonetheless, product candidates may not be considered by individual payors to be medically necessary or cost-effective. A payor&#x2019;s decision to provide coverage for a product does not imply that a preferred formulary position or an adequate reimbursement rate will be approved. Further, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as our products and the product candidates that we are developing and could adversely affect our net revenue and results. See the discussion below under &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Healthcare Reform&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and regarding the Inflation Reduction Act for further information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Different pricing and reimbursement schemes exist in other countries. In the European Economic Area (F&#x201d;) (which is currently comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">healthcare systems that fund a large part of the cost of those products to consumers. Some countries in the European Economic Area (&#x201c;EEA&#x201d;) operate positive and negative list systems under which some medicinal products are selected for coverage (positive list) and others are explicitly listed as excluded from reimbursement (negative list). To obtain reimbursement or pricing approval, some of these EEA countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product to currently available therapies. Other EEA countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for products will allow favorable reimbursement and pricing arrangements for any of our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Healthcare Reform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2020 (the &#x201c;ACA&#x201d;) was enacted, which is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, and which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impact the U.S. pharmaceutical industry. The ACA, among other things, (1) subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework for follow-on biologic products, (2) prescribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, (3) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, (4) established annual nondeductible fees and taxes on manufacturers of certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, (5) established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D, (6) expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability, (7) expanded the entities eligible for discounts under the 340B Public Health Service Act program, (8) created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research, and (9) established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been judicial, Congressional and Administrative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, legislation affecting the implementation of certain taxes under the ACA has been signed into law. The TCJA included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to as the &#x201c;individual mandate&#x201d;. Further, the Bipartisan Budget Act of 2018 (the &#x201c;BBA&#x201d;), among other things, amended the ACA, effective January 1, 2019, to increase from 50% to 70% the point-of-sale discount that is owned by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#x201c;donut hole&#x201d;. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#x201c;donut hole&#x201d; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is unclear how additional healthcare reform measures of the Biden administration or other efforts, if any, to modify or invalidate the ACA or its implementing regulations, or portions thereof, will impact our business. Any health care reform measures will likely take time to unfold, and could have an impact on coverage and reimbursement for healthcare items and services. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or other policy or the impact of potential legislation or other policy on us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative and administrative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. For example, the Budget Control Act of 2011, among other things, in connection with subsequent legislation, reduced Medicare payments to providers, on average, by 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020, through May 31, 2022, due to the COVID-19 pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. Moreover, on January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may impact the ability of relevant agencies to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. On May 16, 2019, CMS adopted a final rule that, among other things, will require Part D plans to adopt Real Time Benefit Tools that are capable of integrating with electronic prescribing or electronic health record systems and have the capability to inform prescribers when lower-cost alternative therapies are available under a beneficiary&#x2019;s prescription drug benefit. Similarly, since 2021, Part D Explanation of Benefits transmittals to members</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are required to inform Part D beneficiaries about drug prices and lower cost therapeutic alternatives. On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which among other things, contains two specific provisions affecting pricing for drugs and biologics. The first provision allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#x2019; annual out-of-pocket drug expenses at $2,000. The second provision imposes a requirement that pharma manufacturers provide a rebate to Medicare, if the manufacturer increases price at a rate higher than the measured inflation rate. Medicaid has had a rebate program for several years, but Medicare did not. The intent is to limit price increases. The new rebate applies to drugs covered by Medicare under Part B or Part D . The rebate obligation applies if the average sales price (for Part B) or average manufacturers price (for Part D) of a single source drug or biologic increases more than the rate of inflation (as measured by the index for urban consumers). The rebate amount is the total number of units sold in Medicare coverage multiplied by the amount by which the price exceeds the inflation adjusted price. The base year against which the inflation adjustment is measured is 2021. If the price exceeds the inflation adjusted price, the difference is multiplied by the units sold in Medicare and that amount is to be rebated. A failure to pay the rebate is subject to a penalty of 125% of the original rebate amount. The provision for Part D takes effect in 2022, with rebates to be paid beginning in 2023. The provision for Part B takes effect in 2023. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. In some cases, states appear interested in public policy designed to encourage drug importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenue. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other U.S. Healthcare Laws and Compliance Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector General), the United States Department of Justice and individual United States Attorney offices within the Department of Justice, and state and local governments. For example, various activities, including but not limited to sales, marketing and scientific/educational grant programs, must comply with the anti-fraud and abuse provisions of the Social Security Act, the federal Anti-Kickback Statute, the federal False Claims Act and similar state laws, each as amended. Failure to comply with such requirements could potentially result in substantial penalties to us. Even if we structure our programs with the intent of compliance with such laws, there can be no certainty that we would not need to defend against enforcement or litigation, in light of the fact that there is significant enforcement interest in pharmaceutical companies in the United States, and some of the applicable laws are quite broad in scope.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute prohibits any person, including a pharmaceutical manufacturer (or a party acting on its behalf), from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. The term &#x201c;remuneration&#x201d; is not defined in the federal Anti-Kickback Statute and has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability. The government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below) or the civil monetary penalties statute, which imposes fines against any person who is determined to have presented or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Additionally, many states have adopted laws similar to the federal Anti-Kickback Statute, and some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third-party payor, not only the Medicare and Medicaid programs in at least some cases, and do not contain safe harbors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment of government funds, or knowingly makes, uses, or causes to be made or used a false statement material to a false or fraudulent claim, or knowingly conceals or knowingly and improperly avoids, or decreases an obligation to pay money to the government. The qui tam provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has increased dramatically. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program. There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The False Claims Act has been used to assert liability on the basis of inadequate care, kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper promotion of off-label uses (i.e., uses not expressly approved by the FDA in a drug&#x2019;s label), and allegations as to misrepresentations with respect to the services rendered. Our activities relating to the reporting of discount and rebate information and other information affecting federal, state and third-party reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases, among other activities, may be subject to scrutiny under these laws. We are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the cost of defending such claims, as well as any sanctions imposed, could adversely affect our financial performance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The healthcare fraud provisions under the U.S. federal Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (&#x201c;HIPAA&#x201d;) impose criminal liability for, among other things, knowingly and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">willfully executing, or attempting to execute, a scheme to defraud any health care benefit program, including private third-party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to, or our marketing activities may be limited by, data privacy and security regulation promulgated by both the U.S. federal government and the U.S. states in which we conduct our business. For example, under HIPAA, the U.S. Department of Health and Human Services imposes upon &#x201c;covered entities&#x201d; (broadly, healthcare providers, health plans and healthcare clearinghouses) and their respective &#x201c;business associates&#x201d; (individuals or entities that create, receive, maintain or transmit protected health information on behalf of a covered entity) privacy obligations; requirements to implement appropriate administrative, physical and technical safeguards to ensure the confidentiality, integrity, and security of electronic protected health information; and breach response notification obligations. We are not subject to HIPAA, as we are neither a covered entity nor business associate.  The Federal Trade Commission (the &#x201c;FTC&#x201d;) also requires companies to take appropriate steps to keep consumers&#x2019; personal information secure and to make accurate statements regarding how they secure personal information under their custody or control, such as in a privacy notice. The FTC also expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of personal information it holds, the size and complexity of its business, and the cost of available tools to improve data security and reduce vulnerabilities. Individually identifiable health information, which we process, is considered sensitive data that merits stronger safeguards. Violations of the foregoing FTC requirements may constitute unfair or deceptive acts or practices under Section 5(a) of the Federal Trade Commission Act (the &#x201c;FTC Act&#x201d;). While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce public privacy statements as it interprets them. Further, events that we cannot fully control, such as data breaches, may also result in civil penalties, FTC enforcement or enforcement by U.S. state attorneys general or other regulators. . Various U.S. states have implemented privacy laws and regulations that regulate the use and disclosure of health information and other personal information. For example, the California Consumer Privacy Act and its implementing regulations (the &#x201c;CCPA&#x201d;), established a privacy framework for covered businesses by, among other items, expanding the definition of personal information, establishing new data privacy rights for consumers that are resident in the State of California, imposing rules on the collection of personal information from minors, and creating a statutory damages framework for violations of the CCPA, including for failure to implement reasonable security procedures and practices to prevent data breaches. Penalties for violations of the CCPA include civil penalties and may result in related legal claims. The California Privacy Rights Act (&#x201c;CPRA&#x201d;), most provisions of which became operative on January 1, 2023, introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency (the &#x201c;CPPA&#x201d;). Similarly, the Virginia Consumer Data Protection Act took effect on January 1, 2023; the Colorado Privacy Act will take effect on July 1, 2023; the Utah Consumer Privacy Act will take effect on December 31, 2023; and the Connecticut Data Privacy Act will take effect on July 1, 2023. The foregoing U.S. state privacy laws impose many similar obligations as the CCPA on our processing of personal information. Other U.S. states are considering similar privacy legislation, and industry organizations regularly adopt and advocate for new standards in these areas. The uncertainty, ambiguity, complexity, and potential inconsistency surrounding the implementation and interpretation of the CCPA and other enacted or forthcoming U.S. state privacy laws exemplify the vulnerability of our business to the evolving regulatory environment related to the privacy, security and confidentiality of personal information and protected health information. We may be subject to fines, penalties, or private actions in the event of non-compliance with such laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our activities outside of the U.S. implicate local, state, provincial, and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for non-compliance. Such laws may also restrict the access, use and disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers, or to remediate issues caused by such breaches. Compliance with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">these laws is challenging, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In addition to this federal requirement, a number of individual states and foreign jurisdictions require detailed reporting and often public disclosures concerning transfers of value to physicians, other health care providers and family members. Effective January 1, 2022, these reporting obligations are extended to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, or register their sales representatives, as well as prohibiting pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales and marketing practices. These laws may affect our sales, marketing and other promotional activities by imposing administrative and compliance burdens on us. If we fail to track and report as required by these laws or otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Where our activities involve foreign government officials, they may also potentially be subject to the Foreign Corrupt Practices Act (&#x201c;FCPA&#x201d;). If we seek to have a product paid for with federal funds under the Medicaid programs or Medicare Part B, various obligations, including government price reporting, are required under the Medicaid rebate provisions of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended, which generally require products to be offered at substantial rebates/discounts to such programs and certain purchasers. Government price reporting may also be required with respect to average sales price, which serves as the basis of reimbursement under Medicare Part B. In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Many of our current as well as possible future activities are potentially subject to federal and state consumer protection and unfair competition laws. We must also comply with laws that require clinical trial registration and reporting of clinical trial results on the publicly available clinical trial databank maintained by the National Institutes of Health at www.ClinicalTrials.gov. We are subject to various environmental, health and safety regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous substances. From time to time, and in the future, our operations may involve the use of hazardous materials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private &#x201c;qui tam&#x201d; actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts, integrity oversight and reporting obligations to resolve allegations of non-compliance, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Marketing Exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Hatch-Waxman Exclusivity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications of other companies seeking to reference another company&#x2019;s NDA. If the new drug is a new chemical entity subject to an NDA, the FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. This definition is currently under FDA review. During the exclusivity period, the FDA may not accept for review an ANDA or a Section 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, such as new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pediatric Exclusivity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to any existing exclusivity period or patent term. This six-month exclusivity may be granted by the FDA based on the completion of a pediatric clinical trial in accordance with provisions of the FDCA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Europe/Rest of World Government Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials, pricing and reimbursement, anti-bribery, advertising and promotion, data privacy and security and any commercial sales and distribution of our future products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EEA, for example, a clinical trial application (&#x201c;CTA&#x201d;) must be submitted to each country&#x2019;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with the EU Clinical Trials Directive 2001/20/EC (the &#x201c;Clinical Trials Directive&#x201d;) and the related national implementing provisions of the relevant individual EEA country&#x2019;s requirements, the clinical trial described in that CTA may proceed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (the &#x201c;Clinical Trials Regulation&#x201d;) was adopted. The Clinical Trials Regulation entered into force on January 31, 2022. The Clinical Trials Regulation is directly applicable in all the EEA countries, repealing the prior Clinical Trials Directive. The new Clinical Trials Regulation allows a sponsor to start and conduct a clinical trial in accordance with the Clinical Trials Directive during a transitional period of one year after the application date, i.e. January 31, 2022. The transition period for the trials ongoing at the moment of applicability will be a maximum of 3 years after the date of application of the Clinical Trials Regulation. Clinical trials authorized under the current Clinical Trials Directive before January 31, 2023 can continue to be conducted under the Clinical Trials Directive until January 31, 2025. An application to transition ongoing trials from the current Clinical Trials Directive to the new Clinical Trials Regulation will need to be submitted and authorized in time before the end of the transitional period. The new Clinical Trials Regulation is intended to simplify and streamline the approval of clinical trials in the EEA. The main characteristics of the regulation include: a streamlined application procedure through a single entry point, the &#x201c;EU portal&#x201d;&#x37e; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors&#x37e; and a harmonized procedure for the assessment of applications for clinical trials, which is divided into two parts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For other countries outside of the EEA, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCP, applicable regulatory requirements of each jurisdiction and the medical ethics principles that have their origins in the Declaration of Helsinki.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EEA, medicinal products can be commercialized only after obtaining a Marketing Authorization (&#x201c;MA&#x201d;). There are several procedures for requesting marketing authorization which can be more efficient than applying for authorization on a country-by-country basis. There is a &#x201c;centralized&#x201d; procedure allowing submission of a single marketing authorization application to the European Medicines Agency (the &#x201c;EMA&#x201d;). If the EMA issues a positive opinion, the European Commission will grant a centralized marketing authorization that is valid in all EEA countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The &#x201c;centralized&#x201d; procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The &#x201c;centralized&#x201d; procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is also a &#x201c;decentralized&#x201d; procedure allowing companies to file identical applications to several EEA countries simultaneously for product candidates that have not yet been authorized in any EEA country and a &#x201c;mutual recognition&#x201d; procedure allowing companies that have a product already authorized in one EEA country to apply for that authorization to be recognized by the competent authorities in other EEA countries. Under the &#x201c;decentralized&#x201d; procedure, an identical dossier is submitted to the competent authorities of each of the EEA countries in which the MA is sought, one of which is selected by the applicant as the Reference Member State (&#x201c;RMS&#x201d;). If the RMS proposes to authorize the product, and the other EEA countries do not raise objections, the product is authorized in all the EEA countries where the authorization was sought. Before granting the MA, the EMA or the competent authorities of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EEA countries make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In many countries outside the United States, procedures to obtain price approvals, coverage and reimbursement can take considerable time after the receipt of a MA. Many EEA countries periodically review their reimbursement of medicinal products, which could have an adverse impact on reimbursement status. In addition, we expect that legislators, policymakers and healthcare insurance funds in the EEA countries will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some EEA countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment (&#x201c;HTA&#x201d;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EEA countries, including those representing the larger markets. The HTA process, which is currently governed by national laws in each EEA country, is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EEA countries. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EEA countries, although the HTA Regulation, which aims to harmonize the clinical benefit assessment of HTA across the EEA, will apply from January 12, 2025. If we are unable to maintain favorable pricing and reimbursement status in EEA countries that represent significant markets, our anticipated revenue from and growth prospects for our products in the EEA could be negatively affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside the United States, interactions between pharmaceutical companies and physicians are also governed by strict laws, such as national anti-bribery laws of EEA countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#x2019; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EEA, the advertising and promotion of our products are subject to laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#x2019;s Summary of Product Characteristics (&#x201c;SmPC&#x201d;), as approved by the competent authorities in connection with a marketing authorization approval. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EEA. Other applicable laws at the EEA level and in the individual EU Member States also apply to the advertising and promotion of medicinal products, including laws that prohibit the direct-to-consumer advertising of prescription-only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care professionals. Violations of the rules governing the promotion of medicinal products in the EEA could be penalized by administrative measures, fines and imprisonment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to data privacy and security regulations in the United States, we may be subject to, or our marketing activities may be limited by, data privacy and security regulations in the EEA, Switzerland, or the United Kingdom (&#x201c;UK&#x201d;), where the legislative and regulatory landscape continues to evolve. There has been increased regulator attention to privacy and data security issues that could potentially affect our business, including through legislation such as the EEA General Data Protection Regulation (&#x201c;EEA GDPR&#x201d;) and UK General Data Protection Regulation (&#x201c;UK GDPR,&#x201d; and together, the &#x201c;GDPR&#x201d;), which each imposes strict obligations on the processing of personal data, including the transfer of personal data from the EEA, Switzerland, or UK to third countries that the European Commission has determined does not ensure an adequate level of protection, such as the United States. If we violate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the GDPR, we may face significant penalties of up to EUR 10,000,000 or 2% of our total worldwide annual, or for more serious violations, up to EUR 20,000,000 or 4% of our total worldwide annual turnover.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The GDPR and other EEA and UK data privacy and security regulations generally restrict the transfer of personal data from the EEA, United Kingdom and Switzerland, to the United States and certain other third countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards on which companies may rely to import or export personal data from had been the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks administered by the U.S. Department of Commerce. However, the EU-U.S. Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union (the &#x201c;CJEU&#x201d;) in a case known as &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Schrems II</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d; Following this decision, the Swiss Federal Data Protection and Information Commissioner (the &#x201c;FDPIC&#x201d;) announced that the Swiss-U.S. Privacy Shield does not provide adequate safeguards for the purposes of personal data transfers from Switzerland to third countries that are deemed as not providing adequate protection, including the United States. While the FDPIC does not have authority to invalidate the Swiss-U.S. Privacy Shield regime, the FDPIC&#x2019;s announcement casts doubt on the viability of the Swiss-U.S. Privacy Shield as a compliance mechanism for Swiss-U.S. data transfers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The CJEU&#x2019;s decision in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Schrems II</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> also raised questions about whether one of the primary alternatives to the EU-U.S. Privacy Shield, namely the European Commission&#x2019;s Standard Contractual Clauses, can lawfully be used for personal data transfers from Europe to the United States or other third countries that are not the subject of an adequacy decision of the European Commission. While the CJEU upheld the adequacy of the Standard Contractual Clauses in principle in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Schrems II</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, it made clear that reliance on the Standard Contractual Clauses alone may not necessarily be sufficient in all circumstances. Use of the Standard Contractual Clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses and/or applicable European law, the decision in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Schrems II</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and subsequent draft guidance from the European Data Protection Board (the &#x201c;EDPB&#x201d;) would require the parties to that transfer to implement certain supplementary technical, organizational and/or contractual measures to rely on the Standard Contractual Clauses as a lawful &#x201c;transfer mechanism.&#x201d; However, the draft guidance from the EDPB on such supplementary technical, organizational and/or contractual measures appears to conclude that any combination of such measures may not be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#x201c;in the clear&#x201d; to recipients in countries where the power granted to public authorities to access the transferred data goes beyond that which is &#x201c;necessary and proportionate in a democratic society&#x201d; - which may, following the CJEU&#x2019;s conclusions in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Schrems II</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on relevant powers of United States public authorities and commentary in draft EDPB guidance, include the United States in certain circumstances (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">., where Section 702 of the US Foreign Intelligence Surveillance Act applies). Further, the UK Information Commissioner&#x2019;s Office (&#x201c;ICO&#x201d;) has provided for separate international data transfer mechanisms for restricted transfers of data from the UK: an international data transfer agreement (the UK equivalent of the EU Standard Contractual Clauses) (&#x201c;IDTA&#x201d;) and an international data transfer addendum (which amends the EU Standard Contractual Clauses for purposes of international data transfers from the UK to countries without an essentially equivalent data protection framework) (the &#x201c;Addendum&#x201d;). Both the IDTA and the Addendum came into force in March 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to implement a valid solution to transfer personal data from the EEA to the United States or other countries that have not been deemed to provide an essentially equivalent level of data protection, we may face increased exposure to regulatory action, substantial fines, or injunction orders to stop processing personal data from EEA, Swiss, or UK residents.  Any inability to import personal data to the United States may also restrict our clinical trials activities in the EU&#x37e; limit our ability to collaborate with contract research organizations as well as other service</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">providers, contractors and other companies subject to EU data privacy and security laws&#x37e; and require us to increase our data processing capabilities in the EU and the UK at significant expense. Additionally, other countries outside of the EU have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. The types of challenges we face in the EEA, Switzerland, and the UK will likely also arise in other jurisdictions that adopt laws similar to the GDPR or regulatory frameworks of equivalent complexity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions or criminal prosecution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section28">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees and Human Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had approximately 90 full-time employees, including five employees who have M.D.s or Ph.D.s. Within our workforce, seven employees were primarily engaged in research and development, 70 were primarily engaged in sales and marketing and 13 were primarily engaged in general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relationships with our employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We focus on identifying, attracting, incentivizing, developing and retaining an exceptional team of highly talented and motivated employees to support our current product pipeline and future business goals. In order to drive innovation, we continuously improve our human capital management strategies and find ways to foster engagement and growth within our company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We regularly benchmark total rewards we provide against our industry peers to ensure we offer competitive compensation and benefits packages to our employees and potential new hires. The principal purposes of our equity and cash incentive plans are to attract, retain and reward selected personnel through the granting of stock-based and cash-based compensation awards, as well as provide our employees with the opportunity to participate in our employee stock purchase plan, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We strive to build a diverse environment where our employees can thrive and one that inspires exceptional contributions and professional and personal development in order to achieve our vision to become the leading pain management company that can have a transformative impact on patients&#x2019; lives. The success of our business is fundamentally connected to the well-being, health and safety of our employees. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the COVID-19 outbreak, which included implementing social distancing policies at our facilities, facilitating remote working arrangements, requiring proof of vaccination or acceptable exemption, and imposing employee travel restrictions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We plan to continue to develop our efforts related to attracting, retaining and motivating our workforce as we grow and develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time we may become involved in various legal proceedings, including those that may arise in the ordinary course of business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 23, 2021, we filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the &#x201c;Sanofi-Aventis &amp; Hisamitsu Litigation&#x201d;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to begin on July 24, 2023. We cannot make any predictions about the outcome in this matter or the timing thereof.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Former Employee Litigation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 12, 2021, we filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#x201c;Virpax&#x201d;), a company now headed by Mr. Mack, alleging, among other things, breach by Mr. Mack of his non-compete agreement with us, breach of fiduciary duty, and tortious interference by Virpax with that non-compete agreement (the &#x201c;Former Employee Litigation&#x201d;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr. Mack from further violating his non-compete agreement and enjoining Virpax from tortiously interfering with Mr. Mack&#x2019;s non-compete agreement. The case was tried from September 12, 2022 to September 14, 2022. Post-trial briefing and closing arguments have been concluded and the case is under submission to the Court. We cannot make any predictions about the outcome in this matter or the timing thereof.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZTlido Patent Litigation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section29"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#x201c;Apotex&#x201d;) in the U.S. District Court for the Southern District of Florida (the &#x201c;ZTlido Patent Litigation&#x201d;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#x201c;ZTlido Patents&#x201d;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Apotex&#x2019;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. We are seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#x2019;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May 10, 2031, and such further and other relief as the court may deem appropriate. Apotex is subject to a 30-month stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November 11, 2024. Trial in the ZTlido Patent Litigation has not yet been scheduled. We cannot make any predictions about the final outcome of this matter or the timing thereof.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Corporate History</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legacy Scilex was incorporated in Delaware in February 2019 for the purpose of effecting a corporate reorganization. On March 18, 2019, Legacy Scilex entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharma pursuant to which Legacy Scilex acquired 100% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of Legacy Scilex Common Stock (such transaction, the &#x201c;Contribution&#x201d;). Pursuant to the Contribution and Loan Agreement, Sorrento provided Legacy Scilex with a loan with an initial principal amount of $16.5 million in the form of a note payable, which loan was used to fund the acquisition of Semnur. Concurrently therewith, Legacy Scilex entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., Legacy Scilex&#x2019;s prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, and Sorrento, for limited purposes (as amended, the &#x201c;Semnur Merger Agreement&#x201d;). Pursuant to the Semnur Merger Agreement, Sigma Merger Sub, Inc. merged with and into Semnur (such transaction, the &#x201c;Semnur Merger&#x201d;), with Semnur surviving the Semnur Merger as Legacy Scilex&#x2019;s wholly owned subsidiary. As a result of the Contribution and the Semnur Merger, Scilex Pharma and Semnur became Legacy Scilex&#x2019;s wholly owned subsidiaries. Prior to the Contribution and the Semnur Merger, operations of Legacy Scilex were conducted through Scilex Pharma, which was formed in September 2012. Semnur was formed in June 2013.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). As an emerging growth company, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Website Access to SEC Filings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We file annual, quarterly and special reports, proxy statements and other information with the SEC. The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including Scilex. We maintain an Internet website at www.scilexholding.com. The information contained on our website or that can be accessed through our website does not constitute a part of this report. We make available, free of charge through our Internet website, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), as soon as reasonably practicable after we electronically file or furnish this information to the SEC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Risk</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described below before deciding whether to invest in our common stock. Before you make a decision to buy our securities, in addition to the risks and uncertainties discussed above under &#x201c;Cautionary Note Regarding Forward-Looking Statements&#x201d;, you should carefully consider the specific risks set forth herein. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described below are not the only risks and uncertainties that we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may become material and adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factor Summary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC before making an investment decision regarding our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently a single commercial product company that is heavily dependent on the commercial success of ZTlido and we may be unable to generate sufficient revenue to support our operations. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to our Commercial Operations and Product Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interim &#x201c;top-line&#x201d; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to our Business and Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are substantially dependent on the intellectual property we in-license from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize SP-103 would be harmed. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recently entered into the Romeg Agreement for the in-licensing of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to Government Regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to our Relationship with Sorrento</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are controlled by Sorrento, whose interests may differ from those of our public shareholders. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sorrento has recently filed for bankruptcy protection, which may impair our relationship with Sorrento.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks Related to Ownership of our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a controlled company within the meaning of the rules and listing standards of Nasdaq (the &#x201c;Nasdaq Listing Rules&#x201d;) and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are currently a single commercial product company that is heavily dependent on the commercial success of ZTlido and we may be unable to generate sufficient revenue to support our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido is our only product approved for commercial sale and we are entirely dependent upon its sales to generate revenue. In February 2018, we obtained regulatory approval for ZTlido for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and we began commercializing ZTlido in the United States in October 2018. As a result, it is difficult to evaluate our current business and predict our future prospects. We cannot assure that ZTlido will gain market acceptance among physicians, health care payors, patients and the medical community, which is critical to our commercial success. We have limited experience engaging in commercial activities and limited relationships with physicians, hospitals and payors. Market acceptance of ZTlido depends on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance by physicians, major operators of clinics and patients of the drug as a safe and effective treatment for the relief of neuropathic pain associated with PHN; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability, cost and potential advantages of alternative treatments, including less expensive generic products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effectiveness of our sales and marketing efforts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of coverage, adequacy of reimbursement and favorability of pricing policies by third-party payors and government authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of other competitive products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product labeling or any product inserts required by the FDA; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of adverse side effects. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to successfully commercialize ZTlido, we will need to expand our marketing efforts to develop new relationships and expand existing relationships. Physicians may decide not to prescribe ZTlido for a variety of reasons, including changes in available offerings, adverse publicity, perceived safety issues, inadequate coverage or reimbursement for ZTlido or the utilization of products developed by other parties, all of which are circumstances outside of our control. Demand for ZTlido may not increase as quickly as we predict, and we may be unable to increase our revenue to the level that we currently expect. Even if we succeed in increasing market acceptance of ZTlido, maintaining and creating relationships with physicians, we may be unable to reach or sustain a level of profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to effectively promote ZTlido will also depend on pricing and cost-effectiveness, including our ability to produce at a competitive price. In addition, our efforts to educate the medical community and third-party payors on the benefits of ZTlido may require significant resources, may be constrained by FDA rules and policies on product promotion and may never be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a limited operating history. Prior to March 2019, our operations were conducted through Scilex Pharma, which was formed in September 2012 and is now our wholly owned subsidiary. In March 2019, we effected a corporate reorganization and acquired Semnur, which was formed in June 2013. Since our inception, we have focused on organizing and staffing our company, business planning, raising capital, identifying potential non-opioid pain therapy candidates, undertaking preclinical studies and clinical trials of our product candidates and establishing research and development and manufacturing collaborations. All of our revenue to date is attributable to sales of ZTlido, and we expect that sales of ZTlido will account for all of our revenue for at least the near term. Our relatively short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. Our ability to execute on our business model and generate revenues depends on a number of factors including our ability to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successfully complete ongoing pre-clinical studies and clinical trials and obtain regulatory approvals for our current and future product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identify new acquisition or in-licensing opportunities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successfully identify new product candidates and advance those product candidates into pre-clinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">raise additional funds when needed and on terms acceptable to us; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">attract and retain experienced management and advisory teams; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support clinical, pre-clinical manufacturing and planned future commercialization efforts and operations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launch commercial sales of our product candidates, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA, and other regulatory requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party payors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">achieve market acceptance of product candidates in the medical community and with third-party payors and consumers; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we cannot successfully execute any one of the foregoing, our business may not succeed or become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have incurred significant net losses, with net losses of $23.4 million, $88.4 million, and $47.5 million for the years ended December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022, we had an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accumulated deficit of approximately $375.9 million. For the foreseeable future, we expect to continue to incur significant expenses related to the commercialization of ZTlido and GLOPERBA and the research and development of our product candidates, SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (&#x201c;SEMDEXA&#x201d;), SP-103 (lidocaine topical system) 5.4% (&#x201c;SP-103&#x201d;), and SP-104 (4.5mg, low-dose naltrexone hydrochloride delayed-release capsules) (&#x201c;SP-104&#x201d;). We anticipate that our expenses will increase substantially due to the completion of the pivotal Phase 3 trial for SEMDEXA, commencement of the Phase 2 clinical trial for SP-103 and multiple Phase 1 trials for SP-104. Consequently, we expect to incur substantial losses for the foreseeable future and may never become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to risks incidental to the development of new biopharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as Vickers was a shell company prior to the completion of the Business Combination, we are currently ineligible to use short form registration statements on Form S-3 and will not be eligible to file such a registration statement until, among other things, at least 12 calendar months have lapsed since November 17, 2022, the date we filed a Current Report on Form 8-K disclosing that we ceased to be a shell company. Our inability to use Form S-3 may significantly impair our ability to raise necessary capital to run our operations and progress our product development programs. If we seek to access the capital markets through a registered offering during the period of time that we are unable to use Form S-3, we may be required to publicly disclose the proposed offering and the material terms thereof before the offering commences, we may experience delays in the offering process due to SEC review of a Form S-1 registration statement and we may incur increased offering and transaction costs and other considerations. Disclosing a public offering prior to the formal commencement of an offering may result in downward pressure on our stock price. If we are unable to raise capital through a registered offering, we would be required to conduct our equity financing transactions on a private placement basis, which may be subject to pricing, size and other limitations imposed under the Nasdaq Listing Rules, or seek other sources of capital.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be required to make milestone payments to the former stockholders of Semnur in connection with our development and commercialization of SEMDEXA, which could adversely affect the overall profitability of SEMDEXA, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Agreement and Plan of Merger we entered into with Semnur, Sigma Merger Sub, Inc., our prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, or the Semnur Equityholders, and Sorrento, for limited purposes, we are obligated to pay the Semnur Equityholders up to an aggregate of $280.0 million in contingent cash consideration based on the achievement of certain milestones. A $40.0 million payment will be due upon obtaining the first approval of a NDA of any Semnur product, which includes SEMDEXA. Additional payments will be due upon the achievement of certain cumulative net sales of Semnur products, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $20.0 million payment upon the achievement of $100.0 million in cumulative net sales of a Semnur product; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $20.0 million payment upon the achievement of $250.0 million in cumulative net sales of a Semnur product; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $50.0 million payment upon the achievement of $500.0 million in cumulative net sales of a Semnur product; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $150.0 million payment upon the achievement of $750.0 million in cumulative net sales of a Semnur product. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These milestone obligations could impose substantial additional costs on us, divert resources from other aspects of our business, and adversely affect the overall profitability of SEMDEXA, if approved. We may need to obtain additional financing to satisfy these milestone payments, and cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations have consumed substantial amounts of cash since inception. We expect to significantly increase our spending to continue our commercialization efforts for ZTlido and GLOPERBA, advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we expect to incur additional costs associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our cash and cash equivalents were approximately $2.2 million and we had an accumulated deficit of approximately $375.9 million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the degree of success we experience in commercializing ZTlido and GLOPERBA; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the revenue generated by sales of ZTlido, GLOPERBA and other products that may be approved, if any; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, SP-103 and SP-104; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which ZTlido, GLOPERBA or any of our product candidates, if approved for commercialization, is adopted by the physician community; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our need to expand our research and development activities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of acquiring, licensing or investing in businesses, product candidates and technologies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of competing products and product candidates and other market developments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and types of future products we develop and commercialize; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any product liability or other lawsuits related to our products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs associated with being a public company; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent and scope of our general and administrative expenses. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until we are able to generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Furthermore, any additional equity or equity-related financing may be dilutive to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants and significant interest costs. If we raise additional funds through collaborations or strategic alliances with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that may not be favorable to us. If we are unsuccessful in our efforts to raise additional financing on acceptable terms, we may be required to significantly reduce or cease our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Note 2 titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; of our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we disclose that there is substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting firm included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended December 31, 2022, which stated that substantial doubt existed about our ability to continue as a going concern. We have negative working capital and have incurred significant operating losses and negative cash flows from operations and expect to continue incurring losses for the foreseeable future. Further, we had an accumulated deficit of approximately $375.9 million as of December 31, 2022 and approximately $352.6 million as of December 31, 2021. These conditions raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to become a profitable operating company is dependent upon our ability to generate revenue and obtain financing adequate to fulfill our development and commercialization activities, and achieving a level of revenue adequate to support our cost structure. We have plans to obtain additional resources to fund our currently planned operations and expenditures through additional debt and equity financing. Our plans are substantially dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of our marketing of ZTlido and our ability to secure additional payor contracts with terms that are consistent with our business plan. If we are unable to obtain sufficient funding, our financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. Future financial statements may disclose substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have identified a material weakness in our internal control over financial reporting. Any material weakness may cause us to fail to timely and accurately report our financial results or result in a material misstatement of our financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the audit of our consolidated financial statements for the years ended December 31, 2022 and 2021, we identified control deficiencies in the design and operation of our internal control over financial reporting that constituted a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021, the material weakness identified in our internal control over financial reporting related to ineffective control activities in the areas of revenue, business combination, debt and derivative liabilities caused by a lack of sufficient accounting resources with appropriate experience and technical expertise to effectively execute controls over certain judgmental and technical accounting areas. As a result of the material weakness, we hired additional accounting personnel and are implementing remediation measures including, but not limited to, performing a comprehensive assessment of accounting and finance resource requirements and hiring other personnel with sufficient accounting expertise at Scilex to improve the operating effectiveness of our review controls and monitoring activities, and utilizing external accounting experts as appropriate. Any potential material misstatements were identified and corrected as audit adjustments in the applicable periods and are properly reflected in our financial statements included in this Annual Report on Form 10-K. We hired a new Chief Financial Officer in May 2022 at Legacy Scilex and she became Chief Financial Officer of the Company in connection with the closing of the Business Combination. In addition, we expect to hire additional personnel with accounting expertise and utilize external accounting experts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the future, in order to properly manage our internal control over financial reporting, we may need to take additional measures to further augment our finance resources, and we cannot be certain that the measures we have taken, and expect to take, to improve our internal controls will be sufficient to ensure that our internal controls will remain effective and eliminate the possibility that other material weaknesses or deficiencies may develop or be identified in the future. If we experience future material weaknesses or deficiencies in internal controls and we are unable to correct them in a timely manner, our ability to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC, will be adversely affected. Any such failure could negatively affect the market price and trading liquidity of our Common Stock, lead to delisting, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act as, we may be unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations. Failure to comply with Section 404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are unable to remediate any such material weakness, our business, financial condition and results of operations could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Commercial Operations and Product Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on a number of sole or single source suppliers and manufacturers, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the manufacturer and supplier for the commercial supply of ZTlido; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the manufacturer and supplier for the clinical supply of SP-103; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the manufacturer and supplier for the clinical supply of SP-104; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the supplier of sodium hyaluronate, one of the excipients for SEMDEXA; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the manufacturer for the clinical supply of SEMDEXA. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Product Development Agreement and the Commercial Supply Agreement, we license the rights to ZTlido from and rely exclusively on Oishi and Itochu for the manufacturing and supply of ZTlido and SP-103 (collectively, the &#x201c;Products&#x201d;). Oishi and Itochu have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances, including, among other things: (1) if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2) if, at any time during the term of the Product Development Agreement and the Commercial Supply Agreement, the market conditions are such that (a) our total net profits for ZTlido and SP-103 are equal to or less than five percent of our net sales of ZTlido and SP-103 for a period of four or more consecutive quarters, or (b) the economic viability of ZTlido and SP-103 is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a) and (b) after 30 days of good-faith discussion; and (3) in the event of our bankruptcy or assignment for the benefit of creditors. As of the date of this Annual Report on Form 10-K, our net profits for ZTlido and SP-103 have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this Annual Report on Form 10-K, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement and the Commercial Supply Agreement are terminated, we would lose access to the intellectual property and proprietary manufacturing process upon which ZTlido and SP-103 depend.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Genzyme Supply Agreement, we depend on Genzyme to fulfill our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SEMDEXA. Genzyme has the right to terminate the Supply Agreement under certain circumstances, including, but not limited to: (1) if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice of such breach, (2) if our development of SEMDEXA is ceased or we do not file for regulatory approval for SEMDEXA by January 1, 2020, or (3) if Genzyme decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#x2019; notice. We did not file for regulatory approval for SEMDEXA by January 1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with the preceding clause (3), Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement, effective as of May 31, 2024. Although we are currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements for sodium hyaluronate we may not be able to find an alternative supplier of sodium hyaluronate on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Lifecore Master Services Agreement, we depend on Lifecore to manufacture clinical supplies of SEMDEXA. Lifecore has the right to terminate the Lifecore Master Services Agreement under certain circumstances, including, but not limited to: (1) if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice; (2) if we (a) become insolvent, (b) cease to function as a going concern, (c) become convicted of or plead guilty to a charge of violating any law relating to either party&#x2019;s business, or (d) engage in any act which materially impairs goodwill associated with SEMDEXA or materially impairs the terminating party&#x2019;s trademark or trade name; (3) if we fail to pay past due invoices upon 30 days&#x2019; written notice, or (4) if we reject or fail to respond to a major change proposed by Lifecore that does not change Semnur&#x2019;s written and approved acceptance criteria in its product specifications. In the event that Lifecore decides to terminate the Lifecore Master Services Agreement, finding an alternative manufacturer on commercially reasonable terms, or at all, may be difficult.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Tulex Master Services Agreement and the Tulex Statement of Work, we depend on Tulex to develop, test and manufacture clinical supplies of SP-104. Tulex has the right to terminate the Tulex Master Services Agreement under certain circumstances, including, but not limited to: (1) if we are in material breach of the agreement or a statement of work and fail to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable statement of work) or (2) in the event of our insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any statement of work (a) without cause upon 30 days prior written notice to Tulex or (b) immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. In the event that the Tulex Master Services Agreement or a statement of work is terminated, we may not be able to find an alternative manufacturer and supplier on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the manufacturing facilities used by our third-party suppliers and manufacturers must continue to comply with FDA regulations and are subject to periodic announced or unannounced inspections. We have limited control over the ability of our third-party suppliers and manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If our third-party suppliers and manufacturers fail to comply with FDA regulations, the FDA may not authorize the manufacture of our products and product candidates at these facilities, and we may be unable to find alternative manufacturing facilities in a timely manner or at all. The failure by such third parties to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, import detention, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of our product, operating restrictions and criminal prosecutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />In addition, our product candidates may compete with other product candidates and products for access to manufacturing facilities and other supplies. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Also, prior to the approval of our product candidates, we would need to identify a contract manufacturer that could produce our products at a commercial scale and that could successfully complete FDA pre-approval inspection and inspections by other health authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates are disrupted or delayed, there can be no assurance that alternative sources can serve as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adequate replacements or that supplies will be available on terms that are favorable to us, if at all. Any disruption in supply could affect the profitability of ZTlido and the development of SEMDEXA, SP-103 and SP-104.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on a single third-party logistics distribution provider, Cardinal Health 105, which until recently had also been our only customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely on Cardinal Health 105 as our third-party logistics distribution provider for ZTlido in the United States. Cardinal Health 105 also performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December 31, 2020, 2021 and first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such periods. As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. Beginning on April 1, 2022, we began selling ZTlido directly to three large distributors, McKesson, Cardinal Health 110 and AmerisourceBergen, as well as to numerous pharmacies. If we are unable to maintain a favorable relationship with Cardinal Health 105 (or with any of our three large distributors), we expect that our revenue would decline and our business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health 105, as our only third-party logistics provider, may negatively impact our sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We discontinued our use of &#x201c;title model&#x201d; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. Any disruption in the abovementioned distribution channel would adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to achieve certain milestones in our Product Development Agreement with Itochu and Oishi, we could lose rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain of our existing license and supply agreements impose various milestone and other obligations on us. For example, under our Product Development Agreement with Itochu and Oishi, if our total net profits for ZTlido and SP-103 are equal to or less than five percent of our net sales of ZTlido and SP-103 for a period of four or more consecutive quarters, Itochu and Oishi have the right to terminate the Product Development Agreement if the parties are unable to resolve the concerns after 30 days of good-faith negotiation. As of the date of this Annual Report on Form 10-K, our net profits for ZTlido and SP-103 have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this Annual Report on Form 10-K, neither Oishi nor Itochu has exercised its right of termination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to achieve the milestones under the Product Development Agreement, we may lose our exclusivity rights or the counterparty may have the right to terminate the agreement, any of which could adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently do not have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as GCP requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations (&#x201c;CROs&#x201d;), to conduct GCP-compliant clinical trials of our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GCP-compliant clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount and timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GCP-compliant clinical trials, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with our investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. For any violations of laws and regulations in the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement actions that may include civil penalties up to and including criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our intellectual property by CROs, which may reduce our trade secret and intellectual property protection and allow our potential competitors to access and exploit our proprietary technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If the third parties conducting our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval or successful commercialization in a timely fashion, or at all, for the applicable product candidate. Our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may in the future enter into collaborations, in-licensing arrangements, joint ventures, or strategic alliances with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. In the ordinary course of our business, we may enter into collaborations, additional in-licensing arrangements (such as, for example, the Romeg Agreement), joint ventures, or strategic alliances to develop proposed products and to pursue new markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proposing, negotiating and implementing collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all, and may not realize the anticipated benefits of any such transactions or arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, with respect to current and future collaborations, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with our current or future collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our collaborators&#x2019; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delays in clinical trials could result in increased costs to us and delay our ability to obtain commercial approval and generate additional revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before obtaining marketing approval for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates for their intended indications. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in obtaining regulatory authorizations to commence a clinical trial or reaching a consensus with regulatory authorities on trial design; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in identifying prospective clinical investigators or clinical trial sites that have necessary qualifications, interest and capacity to perform a requested protocol; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in obtaining approval from one or more IRBs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IRBs refusing to approve, suspending or terminating the trial at the investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes to the clinical trial protocol; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in recruiting suitable subjects to participate in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to perform in accordance with GCPs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in subjects completing participation in a trial or returning for post-treatment follow-up, including, for example, as a result of reluctance to visit medical facilities as a result of the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trial sites or subjects dropping out of a trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">key investigators departing their clinical sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lack of adequate funding to continue the trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subjects experiencing severe or unexpected drug-related adverse effects; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, after an inspection of our clinical trial operations, trial sites or manufacturing facilities, or for other reasons; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">occurrence of serious adverse events in our trials or in trials of the same class of agents conducted by other sponsors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in regulatory requirements or guidance that require amending or submitting new clinical protocols; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a facility manufacturing our product candidates or any of their components being ordered by the FDA to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any changes to our manufacturing process that may be necessary or desired; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third-party contractors not performing data collection or analysis in a timely or accurate manner; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by subcontractors in support of our marketing applications. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, participants being exposed to unacceptable health risks, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product development costs will increase if we experience delays in testing or marketing approvals. The FDA and other regulatory agencies may impose new or refined testing expectations based on experience and increased</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">knowledge over time. In addition, if we make manufacturing or other changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. We do not know whether any of our clinical trials, including our planned clinical trials of SP-103, SP-104 and SEMDEXA, will begin or continue as planned, will need to be restructured or will be completed on schedule, or at all. We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face potential business disruptions and related risks resulting from the COVID-19 pandemic, which could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, a novel strain of coronavirus, or SARS-CoV-2, was reported to have surfaced in Wuhan, China. SARS-CoV-2 is the virus that causes COVID-19. The COVID-19 outbreak has grown into a global pandemic that has impacted countries throughout the world. Financial markets have been experiencing extreme fluctuations that may cause a contraction in available liquidity globally as important segments of the credit markets react to the development. The pandemic may lead to a decline in business and consumer confidence. The global outbreak of COVID-19 continues to rapidly evolve. As a result, businesses have closed or limited operations and limits have been placed on travel. The extent to which COVID-19 may impact our business, clinical trials and sales of ZTlido will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease and variants, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />We are monitoring the potential impact of the COVID-19 outbreak, and if COVID-19 or variants of concern continue to spread globally, including in the United States, we may experience disruptions that could severely impact the development of our product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in enrolling patients in our clinical trials as patients may be reluctant, or unable, to visit clinical sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators, clinical site staff and potential closure of clinical facilities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreases in patients seeking treatment for chronic pain; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in local regulations as part of a response to the COVID-19 outbreak, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or cause us to discontinue the clinical trials altogether; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party suppliers in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. Any manufacturing supply interruption of materials could adversely affect our ability to conduct ongoing and future research and testing activities. For example, we obtain our commercial supply of ZTlido and our clinical supply of SP-103 exclusively from Oishi and Itochu in Japan. The COVID-19 pandemic may result in delays in the procurement and shipping of ZTlido, which may have an adverse impact on our operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 24, 2021, the Safer Federal Workforce Task Force issued written guidance to implement Executive Order 14042, which was signed by President Biden on September 9, 2021. A number of federal courts have issued orders enjoining enforcement of the Executive Order, including one on a nationwide basis. As a result, the government stated that it will take no action to enforce the requirements of the Executive Order at this time. As a federal contractor, we have mandated that all of our employees and, in addition, contractors that enter our U.S. buildings and certain other locations, be fully vaccinated against COVID-19, subject to disability and religious exemptions, by December 8, 2021. Despite the government&#x2019;s no-action position, we continue to comply with the Executive Order. We may experience workforce constraints due to shortages of vaccinated personnel, strains on the labor market, limitations on hiring new employees and difficulty retaining and securing employees who are vaccinated, all of which could negatively affect our business and operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The spread of COVID-19, which has caused a broad impact globally, may materially affect the Company economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our Common Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the continued spread of COVID-19 globally could materially and adversely impact our operations, including without limitation, our manufacturing and supply chain, sales and marketing efforts, sales of ZTlido, travel and employee health and availability, which may have a material and adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval for our product candidates and the approval may be for a more narrow indication than we seek.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. Even if our product candidates meet the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory committee, if convened, recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory authority policy or data requirements during the period of product development, clinical trials and the regulatory review process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we receive regulatory approval, the FDA may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS. The FDA may require labeling that includes precautions or contra-indications with respect to conditions of use, or may grant approval subject to the performance of costly post-marketing clinical trials. In addition, the FDA may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if the results of any clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be delayed or fail in obtaining marketing approval for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as we intended or desired; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to changes in the way the products are administered;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified REMS; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be sued and held liable for harm caused to patients; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experience damage to our reputation. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may find it difficult to enroll or maintain patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identifying and qualifying patients to participate in any clinical trials of our product candidates is critical to our success. The timing of any clinical trials depends on our ability to recruit patients and to complete required follow-up periods. If patients are unwilling to participate in our clinical trials due to negative publicity from adverse events, competitive clinical trials for similar patient populations, or for other reasons, the timeline for recruiting patients, conducting trials and potentially obtaining regulatory approval may be delayed. We may also experience delays if patients withdraw from a clinical trial or do not complete the required monitoring period. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of clinical trials altogether.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient enrollment is affected by many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and nature of the patient population; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity of patients to clinical sites; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the eligibility and exclusion criteria for the trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the design of the clinical trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competing clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that enrolled patients will not complete a clinical trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ability to monitor patients adequately during and after treatment; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential disruptions caused by the COVID-19 pandemic, including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented and other factors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate in relation to other available products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The conditions for which we currently plan to evaluate our product candidates are common, but the eligibility criteria of our clinical trials limit the pool of available trial participants. For example, we experienced a delay in the enrollment of our now completed SEMDEXA Phase 3 clinical trial in sciatica due to the selective eligibility criteria in place to reduce the placebo effect and the impacts of COVID-19, and may experience similar issues with enrollment of our other planned clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to it, because some patients who have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a competitor. We may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodically, we make estimates regarding the incidence and prevalence of target patient populations of our product candidates based on various third-party sources and internally generated analyses and use such estimates in making decisions regarding our product development strategy, including acquiring or in-licensing product candidates and determining indications on which to focus in preclinical studies or clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunities will depend on, among other things, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which may significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face significant competition and our competitors may discover, develop or commercialize products faster or more successfully than us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by intense competition and rapid technological advances. In addition, the competition in the pain management market, and other relevant markets, is intense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ZTlido and our product candidate, SP-103, face and will likely face competition from prescription and generic topical lidocaine patches, including Lidoderm</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (a branded, prescription 5% lidocaine patch product) (&#x201c;Lidoderm&#x201d;) and generic lidocaine patches manufactured by Mylan N.V., Teva and Par Pharmaceutical, Inc. Additionally, SP-103, if approved, will likely compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants and anticonvulsants particularly as we seek approval for the treatment of acute LBP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEMDEXA, if approved, has the potential to become the first FDA-approved epidural steroid product for the treatment of sciatica. While there are currently no FDA approved epidural steroid injections indicated for the treatment of sciatica, we are aware of certain non-steroid product candidates in development. SEMDEXA, if approved, also will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the off-label and unapproved use of branded and generic injectable steroids.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of certain non-opioid therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, SP-104, will likely face direct competition from these candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that the market will become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates, and launching, marketing and selling product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. Accordingly,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do, which would have a material adverse impact on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain coverage and adequate reimbursement for ZTlido, GLOPERBA or our product candidates, if approved, could decrease our ability to generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is significant uncertainty related to the third-party coverage and reimbursement of existing and newly approved products. Market acceptance and sales of ZTlido, GLOPERBA and our product candidates, if approved, in domestic markets will depend significantly on the availability of coverage and adequacy of reimbursement from third-party payors, including government programs (such as Medicare and Medicaid) and private payor healthcare and insurance programs. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Coverage and reimbursement for ZTlido can differ significantly from payor to payor, and we may not be able to maintain adequate coverage and reimbursement in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. Additionally, coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside of the United States. Assuming that coverage is obtained for a given product, the resulting reimbursement rates might not be adequate or may require co-payments or co-insurance that patients find unacceptably high. Patients, physicians, and other healthcare providers may be less likely to prescribe, dispense or use, as applicable, any approved product unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market for our products will depend significantly on access to third-party payors&#x2019; drug formularies for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded product in their formularies or otherwise restrict patient access to a branded product when a less costly generic equivalent or other alternative is available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, even if we obtain adequate levels of reimbursement, third-party payors carefully review and increasingly question the coverage of, and challenge the prices charged for, products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined discounts from list prices and are challenging the prices for products. We cannot be sure that coverage and reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, what the level of reimbursement will be. If coverage and reimbursement of our product candidates are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Furthermore, the requirements governing medical product pricing vary widely from country to country. In some foreign countries, the proposed pricing for a prescription device must be approved before it may be lawfully marketed. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidate SEMDEXA is expected to be a physician-administered injectable viscous gel and as such, separate reimbursement for the product itself may not be available. Instead, if SEMDEXA receives regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval, the administering physician may be reimbursed only for providing the treatment or procedure in which SEMDEXA is used. To the extent separate coverage and reimbursement should become available for SEMDEXA, we anticipate that it will be sold to physicians on a &#x201c;buy and bill&#x201d; basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, the codes used by providers to bill for SEMDEXA, if approved, could also affect reimbursement. J-Codes are codes maintained by the Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;), which are a component of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We do not have a specific J-Code for any of our product candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a J-Code will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific J-Code is not available, physicians would need to use a non-specific miscellaneous J-Code to bill third-party payors for these physician-administered drugs. Because miscellaneous J-Codes may be used for a wide variety of products, health plans may have more difficulties determining the actual product used and billed for the patient. These claims must often be submitted with additional information and manually processed, which can create delays in claims processing times as well as increasing the likelihood for claim denials and claim errors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Apart from our FDA-approved product, ZTlido, we currently have several product candidates that are at various stages of development. We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with potential target indications or product candidates that later prove to have greater commercial potential than our current and planned development programs and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We strive to progress product candidates that can address unmet or underserved medical needs and favor those candidates with large market opportunities. However, our resource allocation decisions may cause us to fail to capitalize on viable commercial product candidates or profitable market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may be required to relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we may pursue additional in-licenses or acquisitions of product candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a successful product candidate, potentially resulting in a diversion of our management&#x2019;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing is expensive, difficult to design and implement, and can take many years to complete, in part because it is subject to rigorous regulatory requirements. The FDA or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates. They may also not agree with the scope of our proposed investigational plan. In addition, the outcome of our clinical trials is risky and uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the pharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This product candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early and late stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve their intended objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A Phase 3 trial was completed for SEMDEXA for the treatment of sciatica, a Phase 2 trial commenced in the second quarter of 2022 for SP-103, and multiple Phase 1 trials were initiated in the first quarter of 2022 for SP-104. We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of such clinical trials in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Our clinical trials may produce negative or inconclusive results, and, in the future, we may decide, or regulators may require us, to conduct additional clinical trials and preclinical studies in addition to those we have planned.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, we announced final results from our Phase 3 trial for SEMDEXA, which results reflect achievement of primary and secondary endpoints, and we intend to use the results to support an NDA submission seeking approval for the treatment of sciatica. However, the FDA may disagree with our assumptions and require us to conduct an additional Phase 3 trial before submitting an NDA. Our failure to adequately demonstrate the safety and effectiveness of our product candidates would prevent receipt of regulatory clearance or approval and, ultimately, the commercialization of that product or indication for use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interim &#x201c;top-line&#x201d; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may publish interim &#x201c;top-line&#x201d; or preliminary data from our clinical trials, which are based on a preliminary analysis of then-available data. Preliminary or interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In some instances, there can be significant variability in safety or efficacy results between different clinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trials or clinical trial sites for the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial procedures and the rate of dropout among clinical trial participants. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. Data disclosures must be carefully managed to conform to limitations on preapproval promotion and laws related to clinical trial registration and posting of results. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and stockholders may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product, product candidate or our business. If the &#x201c;top-line&#x201d; data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive non-clinical studies, pre-clinical studies and clinical trials that the applicable product candidate is both safe and effective for use in each target indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable non-U.S. regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or comparable non-U.S. regulatory authorities for support of a marketing approval, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. In cases where data from United States clinical trials are intended to serve as the basis for marketing approval in the foreign countries, the standards for clinical trials and approval may be different.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials, which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be impeded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business may suffer reputational harm due to failures of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The failure of any of our product candidates could have a lasting negative impact on our reputation, which could, in turn, impact our ability to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our results of operations and financial condition would likely suffer materially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with ZTlido, GLOPERBA and our product candidates. In the event that ZTlido or GLOPERBA is identified to have undesirable side effects, a number of potentially significant negative consequences could occur. Regulatory authorities may withdraw their approval of the product or seize the product. Restrictions may be imposed on the manufacturing or marketing of ZTlido or GLOPERBA or any component thereof, including the imposition of a REMS plan that may require creation of a Medication Guide outlining the risks of such side effects for distribution to patients, as well as elements to assure safe use of the product, such as a patient registry and training and certification of prescribers. Any of these events could damage our reputation and prevent us from achieving or maintaining market acceptance of ZTlido or GLOPERBA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the clinical trials we conduct with our product candidates, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal outcome. Often, it is not possible to determine whether the product candidate being studied caused or was associated with these conditions. In addition, it is possible that as we test our clinical products in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that our product candidates reveal an unacceptable severity and prevalence of these or other side effects, the clinical trials could be suspended or terminated and the FDA could order us to cease further development of or deny approval of our product candidates, for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of operations significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZTlido, GLOPERBA and our product candidates are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or manufacturing problems that result in delays in our development or commercialization programs, limit the supply of our product candidates, or otherwise harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently depend on contract manufacturers to conduct the manufacturing and supply activities for ZTlido, GLOPERBA and our product candidates. Manufacturing these product candidates require facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If contaminations are discovered in our supply of ZTlido, GLOPERBA or our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We may not be successful in securing additional sources at all or on a timely basis, which could materially harm our development timelines. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with cGMP, lot consistency and timely availability of raw materials. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our manufacturers may encounter problems hiring and retaining the experienced scientific, quality assurance, quality-control and manufacturing personnel needed to operate our complex manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in our manufacturing process could restrict our ability to meet potential future market demand for products, which could harm our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Business and Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, retain and motivate key executives to accomplish our business objectives, we may experience constraints that will significantly impede our ability to raise additional capital and our ability to implement our overall business strategy. In particular, we are highly dependent upon our executive officers, including Jaisim Shah, our President and Chief Executive Officer, Henry Ji, Ph.D., our Executive Chairperson, and Elizabeth Czerepak, our Executive Vice President, Chief Financial Officer and Chief Business Officer. The loss of services of these executive officers could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials and the successful commercialization of ZTlido and GLOPERBA. We do not carry &#x201c;key person&#x201d; insurance on any of our executive officers or other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition for key executives in the biotechnology and pharmaceuticals field is intense, due to the limited number of individuals who possess the skills and experience required by our industry. Many of the pharmaceutical companies against which we compete for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to qualified candidates than what we have to offer. In addition, regulation or legislation impacting the workforce, such as the proposed rule published by the Federal Trade Commission which would, if issued, generally prevent employers from entering into non-compete agreements with employees and require employers to rescind existing non-compete agreements, may lead to increased uncertainty in hiring and competition for talent. Further, we may experience employee turnover as a result of the ongoing &#x201c;great resignation&#x201d; occurring throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. Moreover, we conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. As such, we could have difficulty attracting and retaining experienced executives and may be required to expend significant financial resources in our recruitment and retention efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may need to increase the size of our company and may not effectively manage our growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had approximately 90 full-time employees. We may need to continue to expand our managerial, operational, sales and marketing, finance and other resources in order to manage our operations, clinical trials, research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities, including co-promotion activities. Future growth would impose significant added responsibilities on members of management, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">managing our internal development efforts effectively, including the clinical, FDA and internal regulatory review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, if any, which may cause a significant strain on our management, and our operational, financial and other resources. Our ability to manage our growth effectively will require us to implement and improve our operational, financial and management systems and to expand, train, manage and motivate our employees. These demands may require the hiring of additional management personnel and the development of additional expertise by management. Any increase in resources devoted to research and product development without a corresponding increase in our operational, financial and management systems could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we endeavor to obtain appropriate insurance coverage for insurable risks that we identify, we do not carry insurance for all categories of risk that our business may encounter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Insurance coverage is becoming increasingly expensive. We have observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower coverage limits. We may not be able to maintain insurance coverage at a reasonable cost, or in sufficient amounts to protect us against losses due to liability. While we maintain property, casualty and general liability coverage, we do not carry specific biological or hazardous waste insurance coverage and our insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing and marketing of ZTlido and GLOPERBA and clinical testing of our product candidates may expose us to individual product liability claims, class action lawsuits or actions, and other individual or mass tort claims. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. In addition, physicians may misuse our products with their patients if they are not adequately trained, potentially leading to injury and increased risk of product liability. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of risks inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates, if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue from product sales; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for our product candidates or products that we develop; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on labeling, the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a diversion of management&#x2019;s time and our resources; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants or patients; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize our product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently carry product liability insurance covering use in our clinical trials in the amount of $10.0 million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our principal executive offices are in the San Francisco Bay Area, California. Our facilities may be affected by natural or man-made disasters. Earthquakes are of particular significance since our facilities are located in an earthquake-prone area. We are also vulnerable to damage from other types of disasters, including power loss, attacks from extremist organizations, fires, floods and similar events. If our facilities are affected by a natural or man-made disaster, we may be forced to curtail our operations and/or rely on third-parties to perform some or all of our research and development activities. Although we believe we possess adequate insurance for damage to our property and the disruption of our business from casualties, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. In the future, we may choose to expand our operations in either our existing facilities or in new facilities. If we expand our worldwide manufacturing locations, there can be no assurance that this expansion will occur without implementation difficulties, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek to grow our business through acquisitions and may fail to realize the anticipated benefits of any acquisition, and acquisitions can be costly and dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends on our ability to continually enhance and broaden our product offerings in response to changing customer demands, competitive pressures, technologies and market pressures. Accordingly, from time to time we may expand our business and intellectual property portfolio through the acquisition of new businesses and technologies. We cannot assure that we will achieve anticipated benefits from any acquisition to justify the transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition within our industry for acquisitions of businesses, technologies and assets may become intense. Even if we are able to identify an acquisition that we would like to consummate, we may not be able to complete the acquisition on commercially reasonable terms or the target may be acquired by another company. We may enter into negotiations for acquisitions that are not ultimately consummated. Those negotiations could result in diversion of management time and significant out-of-pocket costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of any acquisition depends on, among other things, our ability to combine our business with an acquired business in a manner that does not materially disrupt existing relationships and that allows us to achieve development and operational synergies. If we are unable to achieve these objectives, the anticipated benefits of an acquisition may not be realized fully, or at all, or may take longer to realize than expected. In particular, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses or acquire intangible assets that could result in significant future amortization expenses. As a result, an acquisition may not be accretive to our stock value or development pipeline in the near or long term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to incur higher development and regulatory costs, and additional costs integrating the operations and personnel of any companies we acquire, which cannot be estimated accurately at this time. If the total costs of the integration of our companies and advancement of acquired product candidates and technologies exceed the anticipated benefits of the acquisition, our business, financial condition and results of operations could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">International components of our business expose us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business outside of the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently collaborate with international manufacturing partners and may potentially expand our business internationally in the future. The purchase and shipment of components from international sources subjects us to U.S. and foreign governmental trade, import and export, and customs regulations and laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with these regulations and laws is costly and exposes us to penalties for non-compliance. Other laws and regulations that can significantly impact us include various anti-bribery laws, including the FCPA, as well as export controls laws. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conducting business internationally involves a number of risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">multiple, sometimes conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties in enforcing our intellectual property rights and in defending against third-party threats and intellectual property enforcement actions against us, our distributors or any of our third-party suppliers; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of our product candidates, if approved, in various countries; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties in managing foreign operations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost and availability of shipping and other means of product transportation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign currency exchange rate fluctuations; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in duties and tariffs, license obligations and other non-tariff barriers to trade; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the imposition of new trade restrictions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complexities associated with managing multiple payor-reimbursement regimes or self-pay systems; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to comply with the FCPA, including its books and records provisions and its anti-bribery provisions, and similar anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors&#x2019; activities. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, negatively impact our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The increasing use of social media platforms presents new risks and challenges.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Social media is increasingly being used to communicate about our research, product candidates, investigational medicines and the diseases our product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of non-compliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged adverse event. When such disclosures occur, there is a risk that we may fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#x2019;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their activities on social media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business and operations would suffer in the event of a system failure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we have implemented and maintain security measures, our computer systems and those of our CROs and other contractors and consultants are vulnerable to computer viruses, unauthorized access, cybersecurity attacks, and other security incidents, including as perpetrated by hackers, or as the result of natural disasters, terrorism, war, or telecommunications or electrical failures. While we have not experienced any such system failure or a security breach to date, if such an event were to occur, it could result in a material disruption of our product development programs or a loss of our trade secrets or other proprietary information. For example, the loss of clinical trial data from completed, ongoing, or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce such data. To the extent that any disruption or security breach were to result in the loss of or damage to our data or applications, or the unauthorized disclosure of confidential or proprietary information, including personal data, we could incur material legal liability or be the subject of legal claims, suffer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">damage to our reputation, lose or harm our intellectual property rights, and delay the continued research, development and commercial efforts of ZTlido, GLOPERBA and our product candidates, if approved. If we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of cybersecurity matters or some other matter, that claim could have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, a security incident or privacy violation that leads to the unauthorized acquisition, interruption, modification, loss, theft, corruption, interference, or other unauthorized disclosure of, or prevents access to, personal data, including patient data or other protected health information, could harm our reputation, compel us to comply with federal or state breach notification laws and foreign equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents, and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Our ability to effectively manage and maintain our internal business information, and to ship products to customers and invoice them on a timely basis, depends significantly on our enterprise resource planning system and other information systems. Portions of our information technology systems may experience interruptions, delays, or cessations of service or produce errors in connection with ongoing systems implementation work. Cybersecurity attacks in particular are continually evolving and include, but are not limited to, malicious software, ransomware, attempts to gain unauthorized access to data under our custody or control, and other electronic security breaches that could lead to disruptions in systems, misappropriation of confidential or otherwise protected information, and corruption of data. If we are unable to prevent such cybersecurity attacks or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, we may suffer loss of reputation, we may be the subject of governmental investigations, legal claims, or litigation, or we may incur financial loss or other regulatory penalties, each of which may not be covered by our insurance. In addition, these breaches and other unauthorized access to our systems can be difficult to detect, and any delay in identifying any such event may lead to increased harm of the type described above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As widely reported, global credit and financial markets have experienced volatility and disruptions in the past several years and especially in 2020 and 2021 due to the impacts of the COVID-19 pandemic, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment, underemployment or the repeal of certain provisions of the ACA, may decrease the demand for healthcare services and pharmaceuticals. If fewer patients seek medical care because they do not have insurance coverage, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurances that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and price of our Common Stock, and could require us to delay or abandon clinical development plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to the environmental, social and governance matters, including related social expectations and concerns, may impose unexpected costs or results in reputational or other harm that could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is an increasing focus from certain investors, employees, regulators, listing exchanges and other stakeholders concerning corporate responsibility and sustainability matters, specifically related to environmental, social and governance (&#x201c;ESG&#x201d;) factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases, investors may choose not to invest in us if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers, and major institutional investors have publicly emphasized the importance of ESG measures to their investment decisions. Topics taken into account in such assessments include, among others, companies&#x2019; efforts and impacts on climate change and human rights, ethics and compliance with law, diversity and the role of companies&#x2019; board of directors in supervising various sustainability issues. In light of investors&#x2019; increased focus on ESG matters, if we are perceived as lagging with respect to ESG initiatives, these investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or take other actions, to hold us and our Board accountable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, there are rapid and ongoing developments and changing expectations relating to ESG matters, and the criteria by which our corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to adequately recognize and respond to such developments and governmental, societal, investor and consumer expectations relating to such ESG matters, we may miss corporate opportunities, become subject to additional scrutiny or incur unexpected costs. We may face risk of litigation or reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also face reputational damage if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our Common Stock from consideration by certain investors who may elect to invest with our competitors instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, financial condition or results of operations, including the sustainability of our business over time, and could cause the market value of our Common Stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, our emphasis on ESG issues may not maximize short-term financial results and may yield financial results that conflict with the market&#x2019;s expectations. We may in the future make business decisions that may reduce our short-term financial results if we believe that the decisions are consistent with our ESG goals, which we believe will improve our financial results over the long-term. These decisions may not be consistent with the short-term expectations of our stockholders and may not produce the long-term benefits that we expect, in which case our business, financial condition and results of operations could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Scilex&#x2019;s Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are substantially dependent on the intellectual property we in-license from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize SP-103 would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. Pursuant to the Product Development Agreement, we have been granted an exclusive, worldwide license (except with respect to Japan) under current and future intellectual property rights relating to ZTlido and SP-103 lidocaine tape products and the lidocaine in such products, including, among other things: (1) any patent applications, continuation applications, any issued or issuing patents, as well as any foreign patent applications, (2) all know-how, work product, trade secrets, inventions, data, processes, techniques, procedures, compositions, devices, methods, formulas, protocols and information, whether patentable or not, (3) copyrightable works, copyrights and applications, registrations and renewals, (4) logos, trademarks, service marks, and all applications and registrations relating thereto, (5) other proprietary rights, (6) abbreviated new drug applications or other applications to market, and (7) any regulatory exclusivities or supplemental protection certificates. Our ability to commercialize ZTlido and develop SP-103 depends on the effectiveness and continuation of the Product Development Agreement. If we lose the right to license the intellectual property rights granted by the Product Development Agreement, our ability to develop ZTlido and SP-103 as well as new product candidates based on the licensed intellectual property would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Product Development Agreement imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Oishi and Itochu have the right to terminate the Product Development Agreement under certain circumstances, including, among other things: (1) if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2) if, at any time during the term of the Product Development Agreement, the market conditions are such that (a) our total net profits for ZTlido and SP-103 are equal to or less than five percent of our net sales of ZTlido and SP-103 for a period of four or more consecutive quarters, or (b) the economic viability of ZTlido and SP-103 is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a) and (b) after 30 days of good-faith discussion; and (3) in the event of our bankruptcy or assignment for the benefit of creditors. As of the date of this Annual Report on Form 10-K, Scilex&#x2019;s net profits for ZTlido and SP-103 have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this Annual Report on Form 10-K, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or lack of economic viability, we will be required to transfer all licensed intellectual property rights, including those relating to ZTlido and SP-103, to Oishi and Itochu or their designee, at our own cost and expense. The loss of such licenses could materially harm our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We recently entered into the Romeg Agreement for the in-licensing of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recently entered into the Romeg Agreement for the in-licensing of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA. Pursuant to the Romeg Agreement, we have been granted (1) the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2) an exclusive, transferable license to use the trademark &#x201c;GLOPERBA.&#x201d; Under the Romeg Agreement, among other things, Romeg granted us (1) a transferable license, with the right to sublicense, under the patents and know-how specified therein to (a) commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#x201c;Initial Licensed Product&#x201d;) in the United States (including its territories) (the &#x201c;Territory&#x201d;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#x201c;Licensed Products&#x201d;) and commercialize any such products and (c) manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory; and (2) an exclusive, transferable license, with right to sublicense, to use the trademark &#x201c;GLOPERBA&#x201d; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The license to know-how is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the royalty term, but is otherwise non-exclusive. The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July 1, 2027 and, thereafter, is co-exclusive with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i) expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii) the tenth anniversary of the date of the Romeg Agreement. Our ability to commercialize GLOPERBA and develop Licensed Products depends on the effectiveness and continuation of the Romeg Agreement. If we lose the right to license the intellectual property rights granted by the Romeg Agreement, our ability to develop GLOPERBA as well as new product candidates based on the licensed intellectual property would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Romeg Agreement imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Romeg has the right to terminate the Romeg Agreement under certain circumstances, including, among other things: (a) in the event we are in material breach of the Romeg Agreement, unless we have cured any such breach within 60 days after any notice thereof was provided; (b) upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we have made such payment in full or delivered such quarterly report within such 30 day period; (c) immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; (d) by written notice to us if sales of Licensed Products do not commence or continue within specified periods agreed to by the parties; or (e) in the event of our bankruptcy or assignment for the benefit of creditors. If the Romeg Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or our failure to timely pay milestone payments, we will be required upon Romeg&#x2019;s request to transfer all licensed intellectual property rights, including those relating to GLOPERBA and the Licensed Products, to Romeg or its designee, within thirty days after the termination of the Romeg Agreement at a price to be agreed upon by the parties. The loss of such licenses could materially harm our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Potential disputes over intellectual property rights that we have licensed may prevent or impair our ability to maintain our current licensing arrangements on acceptable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensing of intellectual property rights is of high importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our financial or other obligations under the license agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to sublicense intellectual property rights to third parties under collaborative development relationships; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, financial condition and results of operations may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates, if approved. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to ZTlido, GLOPERBA and our product candidates. Our success depends in part on our ability to obtain and maintain patent protection in the United States, for GLOPERBA, and in the United States and other countries with respect to ZTlido and our product candidates. We seek to protect our proprietary position by filing and/or in-licensing patent applications in the United States and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patents and patent applications that we own or in-license may fail to result in issued patents with claims that protect ZTlido, GLOPERBA and our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover ZTlido, GLOPERBA and our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. Patent and Trademark Office (&#x201c;PTO&#x201d;) and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the non-compliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patent applications may not result in any patents being issued;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an interference proceeding can be provoked by a third party or instituted by the PTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March 16, 2013. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the patent applications we hold or in-license with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for ZTlido, GLOPERBA and our product candidates, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to commercialize ZTlido, GLOPERBA and our product candidates. Any such outcome could have a materially adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to product components and processes and brands for our development pipeline through acquisitions and in-licenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Presently we have intellectual property rights, through licenses from third parties related to ZTlido, SP-103, and GLOPERBA. Because our programs for ZTlido, GLOPERBA, SP-103 and SP-104 may require the use of additional proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. It may also be commercially advantageous to use trademarks held by others. We may be unable to acquire or in-license proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for our product candidates. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Where we obtain licenses from or collaborate with third parties, we may not have the right to control the preparation, filing and prosecution of patent and trademark applications, or to maintain the patents covering technology that we license from third parties and associated trademark registrations, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents, trademarks and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents and trademarks, or any patents and trademark registrations that may issue from such applications. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, or loss of trademark rights, could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents or trademarks against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#x2019;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. We may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the third-party may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition and results of operations could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to claims that former employees (including former employees of our licensors), collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Claims that we infringe, misappropriate, or violate the intellectual property rights of third parties may give rise to costly and lengthy litigation, and we could be prevented from selling products, forced to pay damages, and defend against litigation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties may assert patent or other intellectual property infringement or misappropriation claims against us or our strategic partners, licensors or licensees with respect to ZTlido, GLOPERBA and our product candidates. If ZTlido, GLOPERBA or any of our product candidates, methods, processes and other technologies are alleged to infringe on or be improperly based on the proprietary rights of other parties, we could face adverse consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. We cannot assure that any of our current or future product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by one of our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our product candidates or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion of our valuable management and employee resources from our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual property infringement claims brought by third parties. Any claims of patent infringement asserted by third parties would be time-consuming and could:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">result in costly litigation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">divert the time and attention of our technical personnel and management; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cause development delays; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require us to pay the attorney&#x2019;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing; and/or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do either. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#x2019;s time and attention in pursuing these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">some patent applications in the United States may be maintained in secrecy until the patents are issued; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patent applications in the United States are typically not published until 18 months after the priority date; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">publications in the scientific literature often lag behind actual discoveries. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#x2019;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours, and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive position. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the PTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions. Other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">countries have similar laws that permit secrecy of patent applications, and may be entitled to priority over our applications in such jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we were to prevail, any litigation or administrative proceeding could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. Furthermore, as a result of a patent infringement suit brought against us or our strategic partners or licensees, we or our strategic partners or licensees may be forced to stop or delay developing, manufacturing or selling technologies, product candidates or potential products that are claimed to infringe a third party&#x2019;s intellectual property unless that party grants us or our strategic partners&#x2019; or licensees&#x2019; rights to use its intellectual property. Ultimately, we may be unable to develop some of our product candidates or may have to discontinue development of a product candidate or cease some of our business operations as a result of patent infringement claims, which could severely harm our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and key personnel. For example, on June 22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp. and Apotex, Inc. (together, &#x201c;Apotex&#x201d;) in the U.S. District Court for the Southern District of Florida alleging infringement of certain Orange Book patents covering ZTlido. See the section titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business &#x2014; Legal Proceedings</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; for additional information regarding such proceedings. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#x2019;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our business, financial condition and results of operations. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. Any of the foregoing may have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our intellectual property rights are invalidated or circumvented, our business, financial condition and results of operations will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our long-term success depends on our ability to continually discover, develop and commercialize innovative new pharmaceutical products. Without strong intellectual property protection, we would be unable to generate the returns necessary to support the enormous investments in research and development and capital as well as other expenditures required to bring new product candidates to the market and for commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual property protection varies throughout the world and is subject to change over time. In the United States, for small molecule drug products, such as ZTlido and GLOPERBA, the Hatch-Waxman Act provides generic companies powerful incentives to seek to invalidate our pharmaceutical patents. As a result, we expect that our U.S. patents on major pharmaceutical products will be routinely challenged, and there can be no assurance that our patents will be upheld. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a distraction to management and other employees. We face generic manufacturer challenges to our patents outside the United States as well. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay damages for past infringement or royalties on future sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business, financial condition and results of operations may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have registered trademarks with the PTO for the mark &#x201c;ZTlido,&#x201d; &#x201c;SCILEX&#x201d; and &#x201c;RESPONSIBLE BY DESIGN,&#x201d; and we have filed trademark applications for the marks &#x201c;SEMNUR PHARMACEUTICALS&#x201d; and &#x201c;SEMDEXA&#x201d; in the United States. We also have trademark registrations for ZTlido in the UK and Greece, we have a pending trademark application for ZTlido in China and we are appealing a decision refusing to register a trademark application for ZTlido in China. In China, we detected a third-party trademark registration for ZTlido and filed an invalidation proceeding &#x2014; Invalidation of TM Registration No. 36299669 &#x201c;ZTlido&#x201d; in Class 5 in the name of &#x79e6;&#x7687;&#x5cf6;&#x6046;&#x99ff;&#x5546;&#x8cbf;&#x6709;&#x9650;&#x516c;&#x53f8; (Qinhuangdao Hengjun Trading Co., Ltd.) (the &#x201c;China ZTlido Trademark Invalidation Proceeding&#x201d;). The China ZTlido Trademark Invalidation Proceeding is pending. Our trademarks or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement, dilution or tarnishment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involve both technological and legal complexity. Therefore, obtaining and enforcing biotechnology and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (the &#x201c;AIA&#x201d;), which was passed in September 2011, resulted in significant changes to the U.S. patent system. An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned from a &#x201c;first-to-invent&#x201d; to a &#x201c;first-to-file&#x201d; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a &#x201c;first-to-file&#x201d; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the PTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the PTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in PTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a PTO proceeding sufficient for the PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, a third party may attempt to use the PTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#x2019; patent applications and the enforcement or defense of our or our licensors&#x2019; issued patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may become involved in opposition, interference, derivation, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review or other proceedings challenging our or our licensors&#x2019; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or in-licensed patent rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the PTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, the Biden administration recently indicated its support for a proposal at the World Trade Organization to waive patent rights with respect to COVID-19 vaccines. Any waiver of our patent or other intellectual property protection by the U.S. and other foreign governments could have a material adverse effect on our competitive position, business, financial condition and results of operations. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. For example, in Europe, a new unitary patent system takes effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (&#x201c;UPC&#x201d;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The PTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. For example, periodic maintenance fees on any issued patent are due to be paid to the PTO and other foreign patent agencies in several stages over the lifetime of the patent. The PTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. If we or any of our licensors fail to maintain the patents or patent applications covering ZTlido, GLOPERBA and our product candidates, our competitors may be able to enter the market, which would have an adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Confidentiality agreements with employees may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, or prior to seeking patent protection, we rely on trade secret protection and confidentiality agreements. To this end, we require all our employees to enter into agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements typically limit the rights of the third parties to use or disclose our confidential information. We also typically obtain agreements from these parties that provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">However, current or former employees may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our competitive position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential know-how is expensive, time-consuming and unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer. Moreover, our third-party licensing partners may retain rights in some of our proprietary or joint trade secrets, know-how, patented inventions or other proprietary information, including rights to sublicense and rights of publication, which may adversely impact our ability to obtain patents and protect trade secrets, know-how or other proprietary information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. We may also be subject to claims that patents and applications that we may file to protect inventions of our employees or consultants are rightfully owned by their former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. An inability to incorporate such technologies or features would have a material adverse effect on our business, financial condition and results of operations and may prevent us from successfully commercializing ZTlido, GLOPERBA and our product candidates, if approved. Moreover, any such litigation or the threat of such litigation may adversely affect our ability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize ZTlido, GLOPERBA and our product candidates, if approved. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, individuals executing agreements with us may have preexisting or competing obligations to a third party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our position as a relatively small company may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against infringement claims by third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Litigation relating to the ownership and use of intellectual property is expensive, and our position as a relatively small company in an industry dominated by very large companies may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against claims that ZTlido, GLOPERBA or any of our product candidates infringes or misappropriates third-party intellectual property rights. However, we may seek to use various post-grant administrative proceedings, including new procedures created under the AIA, to invalidate potentially overly-broad third-party rights. Even if we can defend our position, the cost of doing so may adversely affect our ability to grow, generate revenue or become profitable. In the course of the ongoing litigation or any future additional litigation to which we may be subject, we may not be able to protect our intellectual property at a reasonable cost, or at all. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities or otherwise affect our legal, contractual or intellectual property rights, which could have a significant adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including PTO administrative proceedings, such as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reviews, and reexamination proceedings before the PTO or oppositions and revocations and other comparable proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that ZTlido, GLOPERBA or our product candidates may give rise to claims of infringement of the patent rights of others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite safe harbor provisions, third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents, of which we are currently unaware, with claims to materials, formulations, methods of doing research, methods of manufacture or methods for treatment related to the use or manufacture of ZTlido, GLOPERBA or our product candidates. Because patent applications can take many years to issue, there may be currently pending unpublished patent applications which may later result in issued patents that ZTlido, GLOPERBA or our product candidates may infringe. In addition, third parties may obtain patents in the future</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and claim that the use of our technologies infringes these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of ZTlido, GLOPERBA or any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license, limit our uses, or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further commercialize ZTlido and GLOPERBA, or develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, cease marketing ZTlido or GLOPERBA, or developing our product candidates, limit our uses, pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of ZTlido, GLOPERBA or our product candidates, if approved. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further commercialize ZTlido or GLOPERBA, or develop and commercialize one or more of our product candidates, which could harm our business, financial condition and results of operations significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The requirements for patentability and the patent enforcement differ in many countries. Filing, prosecuting and defending patents on ZTlido and all of our product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement in some countries is not as strong as that in the United States. These products may compete with ZTlido and our product candidates, if approved, in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ongoing conflict in Ukraine and related sanctions could significantly devalue our Ukrainian and Russian patent applications. Recent Russian decrees may significantly limit our ability to enforce Russian patents. We cannot predict when or how this situation will change.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals and methods of treatment of the human body, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, many countries have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. Furthermore, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents and limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, and inventions agreements with employees, consultants and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, in 2010, the FDA, as part of its Transparency Initiative, recommended steps that the FDA could take to increase transparency, including with respect to making additional information publicly available on a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">routine basis, which may include information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#x2019;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Competitors and other third parties could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our reliance on third parties may require us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we rely on third parties to help manufacture and supply our products and product candidates, and we expect to collaborate with third parties on the continuing development of future product candidates, we must, at times, share trade secrets with them. We also expect to conduct research and development programs that may require us to share trade secrets under the terms of our partnerships or agreements with CROs. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations, including, material transfer agreements, consulting agreements, confidentiality agreements or other similar agreements with our advisors, contractors, service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#x2019;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations. For example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Others may be able to make products that are similar to ZTlido, GLOPERBA or our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pending patent applications may not lead to issued patents;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not develop additional proprietary technologies that are patentable; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patents of others may have an adverse effect on our business. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope or requests for patent term adjustments. If we or our partners, collaborators, licensees or licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect ZTlido, GLOPERBA and our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. If these changes were to occur, they could have a material adverse effect on our ability to generate revenue. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system takes effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the PTO or become involved in opposition, derivation, reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and potentially licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of ZTlido, GLOPERBA or our product candidates. Generally, patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted and increased to recapture a portion of delay incurred by the PTO in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">examining the patent application. The scope of patent protection may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Government Regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The time required to obtain marketing approval from the FDA for a product candidate is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities, and its outcome is inherently uncertain. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions. For example, we believe that the data from our Phase 3 CLEAR trial will be sufficient to support a 505(b)(2) NDA submission for SEMDEXA. However, the FDA may disagree and may require us to conduct additional clinical studies before we are able to submit the NDA, even though we believe the data from the CLEAR trial are adequate. Our future success depends on our ability to develop, receive regulatory approval for, and introduce new products or product enhancements that will be accepted by the market in a timely manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA can delay, limit or deny approval of a product candidate for many reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate to such authorities&#x2019; satisfaction that a product candidate is safe and effective for its proposed indication; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negative or ambiguous results from our clinical trials may not meet the level of statistical significance required for approval by the FDA; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States, and such authorities may impose requirements for additional preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it may disagree regarding the formulation, labeling and/or the specifications of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">such authorities may decline to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the FDA regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition and results of operations. In addition, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other than an NDA submitted for ZTlido in the United States, which was approved by the FDA in February 2018, we have not previously submitted an NDA to the FDA for any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if our clinical trials are successful. If we do not receive regulatory approvals for our product candidates, our business, financial condition and results of operations will be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section 505(b)(2) are not as we expect, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For our product candidates SEMDEXA, SP-103 and SP-104, we may seek FDA approval through the Section 505(b)(2) regulatory pathway. The Hatch-Waxman Act added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act (the &#x201c;FDCA&#x201d;). Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2) allows an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#x2019;s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for our product candidates by potentially decreasing the amount of data that we would need to generate in order to obtain FDA approval. If the FDA does not agree that the Section 505(b)(2) regulatory pathway is acceptable as we anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if FDA accepts our plan to pursue the Section 505(b)(2) regulatory pathway, we cannot assure that our product candidates will receive the requisite approvals for commercialization. In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent and market exclusivity rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation against us and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. Further, a manufacturer of an approved product may file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. FDA imposes strict requirements on such petitions in part to dissuade companies from improperly using these petitions to delay approval of competing drug products. Nonetheless, if successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even after a product is approved, we will remain subject to ongoing FDA and other regulatory requirements governing the manufacturing, testing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, import, export, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report adverse events and, among other things, any failure of a distributed product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. In addition, the FDA may impose significant restrictions on the approved indicated uses for which the product may be marketed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These requirements include submissions of safety and other post-marketing information and reports, registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. The future discovery of previously unknown problems with a product, including adverse events of unanticipated type, severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investigation or additional study obligations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">communications to prescribers or patients about specific information or issues; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning or untitled letters or holds on clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. We may not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant expense, lost revenues and damage to our reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change, and additional laws or government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our ability to generate revenue and achieve or sustain profitability. Changes in law or government regulations may also alter the competitive landscape, potentially to our disadvantage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain manufacturers in the market in which we compete distribute certain products without completing the FDA approval process. For example, we believe certain lidocaine topical patches, plaster or poultice products marketed</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OTC and without FDA approval, require approval and compete inappropriately with ZTlido. In December 2018, we filed a citizen&#x2019;s petition asking the FDA to clarify its requirements and take enforcement action against such products. The FDA has not responded with a decision or action. The FDA has generally held the position that requests for enforcement action via citizen petition are not allowed, which may reduce the likelihood of the FDA taking action explicitly in response to our December 2018 petition. Furthermore, we believe the labeling and marketing of certain OTC lidocaine patches products are false and deceptive, which could cause significant damages to our business and a diminution of goodwill in our intellectual property. In February 2021, we filed a complaint against such manufacturers to seek an award of damages and the entry of injective relief enjoining further dissemination of such false and deceptive advertisement. In addition, on March 7, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was signed into law, which included statutory provisions reforming FDA&#x2019;s mechanisms for regulating OTC drugs. Under the CARES Act, the FDA considers a drug to be generally recognized as safe and effective (&#x201c;GRASE&#x201d;) if it meets certain requirements, including items such as the active ingredient, indication for use, dosage, route of administration, and labeling set forth in the OTC monograph and related rulemakings. Historically, the FDA was required to establish, revise, and amend an OTC monograph by notice-and-comment rulemaking, which was lengthy and resource-intensive. The CARES Act replaces the rulemaking process with a final administrative order process. Administrative orders may be initiated by the FDA or at the request of a drug manufacturer or any other person. After a period for public comment on the administrative order, the FDA is able to issue a final administrative order, rather than a regulation, permitting the drug to be marketed over the counter. As this process is much more streamlined and less burdensome, this may benefit the manufacturers of lidocaine topical patches to obtain GRASE status from the FDA and thereby legally market these products over-the-counter and compete with ZTlido.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, recent U.S. administrations have taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#x2019;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA&#x2019;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#x2019;s ability to engage in oversight and implementation activities in the normal course, our business, financial condition and results of operations may be negatively affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A fast track product designation, breakthrough therapy designation or other designation to facilitate product candidate development may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A product sponsor may apply for fast track designation from the FDA if a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition. The FDA has broad discretion whether or not to grant this designation. We have received fast track designation for SEMDEXA for the treatment of sciatica and SP-103 for the treatment of acute LBP. Even though SEMDEXA and SP-103 have received fast track designation, we may not experience a faster process, review or approval compared to conventional FDA procedures. A fast track designation does not expedite clinical trials, or mean that regulatory requirements are less stringent or provide assurance of ultimate marketing approval by the FDA. Instead, fast track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review of individual sections of an NDA submitted to the FDA as they become finalized. The FDA may rescind the fast track designation if it believes that the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designation is no longer supported by data from our clinical development program. The FDA may also withdraw any fast track designation at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have applied for breakthrough therapy designation and expect to seek priority review for SEMDEXA for the treatment of sciatica. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in potentially less efficacious control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to provide such designation. In any event, the receipt of a breakthrough therapy designation may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if SEMDEXA qualifies as a breakthrough therapy for sciatica, the FDA may later decide that SEMDEXA no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If approved, our products candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (the &#x201c;BPCIA&#x201d;), which created an abbreviated approval pathway under section 351(k) of the Public Health Service Act (the &#x201c;PHSA&#x201d;) for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, a section 351(k) application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar or interchangeable product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full Biologics License Application (&#x201c;BLA&#x201d;) for the competing product submitted under section 351(a) of the PHSA containing the competing sponsor&#x2019;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#x2019;s biological product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whether approval of a biological product qualifies for reference product exclusivity turns on whether FDA consider the approval a &#x201c;first licensure&#x201d;. Not every licensure of a biological product is considered a &#x201c;first licensure&#x201d; that gives rise to its own exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our product candidates in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, our product candidates may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in funding for the FDA could hinder its ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disruptions at the FDA and other regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business, financial condition and results of operations. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. Increased cases associated with a COVID-19 variant led the FDA to again pause inspections, although the FDA announced in February 2022 that it would resume routine domestic surveillance inspections and that it would proceed with certain foreign surveillance inspections where country conditions permit. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and our collaborators are subject to federal, state and foreign data protection laws and regulations. In the United States, such laws may include, but are not limited to, U.S. state personal data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, including Section 5 of the FTC Act, each of which govern the collection, use, disclosure and protection of health-related and other personal information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we are not subject to HIPAA, as we are neither a Covered Entity nor Business Associate (as such terms are defined in HIPAA), we may have access to very sensitive data regarding patients who participate in, or whose tissue samples or other biospecimens are used in, our clinical trials. The maintenance of this data imposes upon us administrative and financial burdens and litigation risks. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data that are subject to HIPAA and other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">privacy, data security and consumer protection laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information maintained by a Covered Entity in a manner that is not authorized by HIPAA, and we may be subject to other civil and/or criminal penalties if we obtain, use, or disclose information in a manner not permitted by other privacy and data security and consumer protection laws. Our ability to use or disclose information may be limited by the scope of an authorization signed by clinical trial subjects or the terms of the contract that we enter into with providers or other data sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, U.S. states are constantly adopting new laws or amending existing laws relating to data privacy and security and consumer protection, which requires our frequent attention. For example, the CCPA creates new individual privacy rights for California consumers and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#x2019; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with a private right of action in connection with certain types of security incidents. The CCPA has been amended by the CPRA, which largely took effect on January 1, 2023. The CPRA also created a new state agency (the CPPA) vested with authority to implement and enforce the CCPA. New implementing regulations are expected to be introduced by the CPPA. Virginia also recently enacted a similar state privacy law, the Virginia Consumer Data Privacy Act (the &#x201c;VDCPA&#x201d;), and Colorado, Connecticut and Utah also have similar laws in place. New legislation enacted in various other states will continue to shape the data privacy environment nationally. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international, or other state laws, and such laws may differ from each other, which may complicate compliance efforts. The effects on our business of the CCPA, VDCPA, and other similar state privacy laws and general consumer protection authorities are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to so comply. Privacy laws and regulations are constantly evolving and there are a number of legislative proposals at both the state and federal levels that could impose new obligations or limitations in areas affecting our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FTC also sets expectations for failing to take appropriate steps to keep consumers&#x2019; personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section 5(a) of the FTC Act. The FTC expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#x2019; personal information. Any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">International data protection laws, including the GDPR, may also apply to health-related and other personal information obtained outside of the United States. The GDPR imposes several data protection requirements in the EU, as well as fines for violations that can reach up to the greater of &#x20ac;20 million or 4% of annual global revenue. The regulation imposes numerous requirements for the collection, use, storage and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information, including the right to access, correct and delete their data. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries in the EEA. Further, the UK&#x2019;s departure from the EU (Brexit) has led and could also lead to further legislative and regulatory changes and may increase our compliance costs. Presently, the processing of personal data of UK data subjects is governed by the UK GDPR, which authorizes similar fines to the EEA GDPR and potentially divergent enforcement actions for certain violations. On June 28, 2021, the European Commission adopted an adequacy decision for the UK, allowing for the relatively free exchange of personal information between the EU and the UK, however the European Commission may suspend such adequacy decision if it considers that the UK no longer provides for an adequate level of data protection. Other jurisdictions outside the EEA are similarly introducing or enhancing privacy and data security laws, rules, and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, increase our compliance costs, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We cannot guarantee that we are or will be in compliance with all applicable international regulations as they are enforced now or as they evolve. Claims that we have violated individual privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend against and could result in adverse publicity that could harm our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our manufacturers&#x2019; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk of fraud, illegal activity or other misconduct by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by employees could include intentional, reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA, EMA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, comply with laws and regulations, including, but not limited to the FCPA and internal policies restricting payments to government agencies and representatives, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by employees, independent contractors, consultants, commercial partners and vendors could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or FDA debarment or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition and results of operations, including the imposition of significant fines or other sanctions and serious harm to our reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency and disclosure, or sunshine, laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current and future arrangements with healthcare professionals, clinical sites and clinical investigators, consultants, customers, patient organizations and third-party payors may subject us to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our current activities with clinical study investigators and research subjects, as well as our current and future sales, marketing, patient assistance and education programs. In addition, we may be subject to physician payment transparency laws and patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the furnishing, recommending, or arranging for an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs &#x2014; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or special intent to violate the law in order to have committed a violation; in addition, </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used a false statement material to a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. The False Claims Act has been used to assert liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, and improper promotion of off-label uses (i.e., uses not expressly approved by the FDA in a drug&#x2019;s label); </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, which imposes criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services &#x2014; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals and, beginning in 2022, certain other healthcare professionals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing metrics to government agencies, including CMS and Department of Veterans Affairs (&#x201c;VA&#x201d;), where such reported prices may be used in the calculation of reimbursement and/or discounts on marketed products paid by government healthcare programs. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal healthcare programs and increased infrastructure costs, and may potentially limit a drug manufacturer&#x2019;s ability to offer certain marketplace discounts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Prescription Drug Marketing Act, which restricts the manner in which manufacturers may disseminate complimentary drug samples to healthcare practitioners, requires physical and accounting controls, and establishes penalties for improper sample distribution; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">state law equivalents of each of the above federal laws, such as licensing, anti-kickback, false claims, consumer protection and unfair competition laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing information and marketing expenditures, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, any future research and development of our product candidates outside the United States, and any future sales of our product or product candidates once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business practices and arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition and results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are found to have improperly promoted off-label uses of ZTlido, GLOPERBA or our product candidates, if approved, or if we are found to have improperly engaged in pre-approval promotion prior to the approval of such product candidates, we may become subject to significant liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as ZTlido, GLOPERBA and our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#x2019;s approved labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may nevertheless use our product for their patients in a manner that is inconsistent with the approved label, if the physicians believe in their professional medical judgment it could be used in such manner. However, if we are found to have promoted our product for any off-label uses, the federal government could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA, Department of Justice or other regulatory authorities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of ZTlido, GLOPERBA or our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare reform measures could hinder or prevent our product candidates&#x2019; commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been, and we expect there will continue to be, a number of legislative and regulatory changes to health care systems in the United States and abroad that could impact our ability to sell our products profitably. The United States government and other governments have shown significant interest in pursuing healthcare reform. For example, in 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. Healthcare reform measures like the ACA may adversely impact the pricing of healthcare products and services in the United States or internationally and the amount of reimbursement available from governmental agencies or other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been ongoing efforts to modify the ACA and its implementing regulations. For example, tax legislation enacted at the end of 2017 includes provisions that, effective January 1, 2019, eliminated the tax penalty for individuals who do not maintain sufficient health insurance coverage, or the so-called &#x201c;individual mandate.&#x201d; It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or efforts, if any, to modify the ACA or its implementing regulations, or portions thereof, will impact our business. Litigation and legislation over the ACA and other healthcare reform measures are likely to continue, with unpredictable and uncertain results. Further, additional legislative changes to and regulatory changes under or related to the ACA remain possible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020, through May 31, 2022, due to the COVID-19 pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs, as addressed further in the risk factor below titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and future prospects</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d; While any proposed measures may require authorization through additional</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">legislation to become effective, Congress and the Biden administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal health care programs and commercial payers will pay for healthcare products and services, which could result in reduced demand for ZTlido, GLOPERBA and our product candidates, if approved, or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition and results of operations. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These or other reforms could reduce the ultimate demand for ZTlido, GLOPERBA and our product candidates, if approved, or put pressure on our product pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, ZTlido may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and future prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by manufacturers, governmental or regulatory agencies and the courts. Such interpretation can change and evolve over time. In the case of Medicaid pricing data, if a manufacturer becomes aware that its reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, the manufacturer is obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and could result in an overage or underage in rebate liability for past quarters. Price recalculations also may affect the ceiling price at which a manufacturer is required to offer its products under the 340B program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A failure to comply with reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively affect financial results. CMS issued a final regulation, which became effective on April 1, 2016, to implement the changes under the ACA to the Medicaid Drug Rebate Program. The final regulation has increased and will continue to increase costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on the results of operations, particularly if CMS challenges the approach a manufacturer has taken in the implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate Program may have a similar impact.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers have obligations to report the average sales price for certain of drugs to the Medicare program as a part of the agreement to participate in the Medicaid Drug Rebate program. For calendar quarters beginning January 1, 2022, manufacturers are required to report the average sales price for certain drugs under the Medicare program regardless of whether they participate in the Medicaid Drug Rebate program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for products and the resulting Medicare payment rate, and could negatively affect results of operations. Starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologics, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or single-use packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10% of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125 percent of the refund amount. Congress further could enact a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if the average sales price of a drug were to increase faster than the pace of inflation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Health Resources and Services Administration (&#x201c;HRSA&#x201d;) issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019. Implementation of this regulation has affected manufacturer obligations and potential liability under the 340B program. Manufacturers are also required to report the 340B ceiling prices for covered outpatient drugs to HRSA, which then publishes them to 340B covered entities. Any charge by HRSA that a manufacturer has violated the requirements of the program or the regulation could negatively affect financial results. Moreover, under a final regulation effective January 13, 2021, HRSA newly established an administrative dispute resolution (&#x201c;ADR&#x201d;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that can be appealed to a federal court. An ADR proceeding could subject a manufacturer to onerous procedural requirements and could result in additional liability. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the ACA or otherwise could affect our 340B ceiling price calculations and negatively affect results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Civil monetary penalties can be applied if a manufacturer (i) is found to have knowingly submitted any false price or product information to the government, (ii) is found to have made a misrepresentation in the reporting of its average sales price, (iii) fails to submit the required price data on a timely basis, or (iv) is found to have knowingly and intentionally charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate the Medicaid Drug Rebate Agreement, or HRSA, or to terminate the 340B program participation agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for the manufacturer&#x2019;s covered outpatient drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, manufacturers are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program. Under either program, civil monetary penalties could be applied if a manufacturer fails to provide these discounts in the amount of 125 percent of the discount that was due. Furthermore, Congress could enact a Medicare Part D inflation rebate, under which manufacturers would owe additional rebates if the average manufacturer price of a drug were to increase faster than the pace of inflation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Congress could also enact additional changes that affect our overall rebate liability and the information we report to the government as part of price reporting calculations. In addition, Congress could enact a drug price negotiation program under which the prices for certain high Medicare spend single source drugs would be capped by reference to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the non-federal average manufacturer price. This or any other legislative change could impact the market conditions for our products. We expect continued scrutiny on government price reporting and pricing more generally from Congress, agencies, and other bodies and are seeing an increase in state interest in price reporting, transparency and other policies to address drug pricing concerns.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to applicable law, knowing provision of false information in connection with price reporting or contract-based requirements under the VA Federal Supply Schedule and/or Tricare programs can subject a manufacturer to civil monetary penalties. These programs and contract-based obligations also contain extensive disclosure and certification requirements. If a manufacturer overcharges the government in connection with its arrangements with Federal Supply Schedule or Tricare, the manufacturer may be required to refund the difference to the government. Failure to make necessary disclosures or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and future prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need to obtain prior FDA authorization for any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any brand names we intend to use for our product candidates will require authorization from the FDA regardless of whether we have secured a formal trademark registration from the PTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner, or at all, which would limit our ability to successfully commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations are subject to certain anti-corruption laws, including the FCPA, and other anti-corruption laws that apply in countries where we conduct business, including performing clinical trials. The FCPA and other anti-corruption laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We, our commercial partners and our affiliates operate in a number of jurisdictions that pose a risk of potential FCPA violations and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, such as trade control laws. Any investigation of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential violations of the FCPA, other anti-corruption laws or trade control laws by U.S., European Union or other authorities could have an adverse impact on our reputation, our business, financial condition and results of operations. Furthermore, should we be found not to be in compliance with the FCPA, other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, as well as the accompanying legal expenses, any of which could have a material adverse effect on our reputation and liquidity, as well as on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Relationship with Sorrento</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mr. Jaisim Shah, Dr. Henry Ji, Mr. Dorman Followwill, Ms. Laura J. Hamill, Dr. Tien-Li Lee, Mr. David Lemus and Mr. Tommy Thompson serve on our Board. Mr. Jaisim Shah and Dr. Henry Ji, who are our executive officers, are also members of the board of directors of Sorrento (and in the case of Dr. Henry Ji, the positions of President, Chief Executive Officer and Chairman of the board of directors of Sorrento).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our Board has determined that Mr. Dorman Followwill, Ms. Laura J. Hamill, Dr. Tien-Li Lee, Mr. David Lemus and Mr. Tommy Thompson are &#x201c;independent directors&#x201d; within the meaning of applicable regulatory and stock exchange requirements in the United States, both Mr. David Lemus and Mr. Dorman Followwill have served, and continue to serve, as directors of Sorrento (and in the case of Mr. Dorman Followwill, the Lead Independent Director of Sorrento) and Tommy Thompson has served, and continues to serve, as special consultant to the Chief Executive Officer of Sorrento, Dr. Henry Ji. Further, Dr. Tien-Li Lee is the founder, the Chief Executive Officer and a director of Aardvark, which has been involved in an asset purchase transaction with Sorrento in connection with Sorrento&#x2019;s acquisition of Aardvark&#x2019;s delayed burst release low dose naltrexone formulation asset and intellectual property rights. As part of Sorrento&#x2019;s investment in Aardvark relating to such asset purchase transaction, Sorrento paid cash for shares of Aardvark&#x2019;s Series B Preferred Stock, resulting in Sorrento holding approximately 8% of Aardvark&#x2019;s ownership interest as of December 31, 2021. Also as part of such investment, Dr. Henry Ji joined the board of directors of Aardvark in May 2021. Sorrento and Aardvark may enter into more commercial arrangements in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, such directors and officers may own shares of Sorrento common stock, options to purchase shares of Sorrento common stock or other Sorrento equity awards. These individuals&#x2019; holdings of Sorrento common stock, options to purchase shares of Sorrento common stock or other equity awards of Sorrento may be significant for some of these persons compared to these persons&#x2019; total assets. Their position at Sorrento and the ownership of any Sorrento equity or equity awards creates, or may create the appearance of, conflicts of interest when these directors and officers are faced with decisions that could have different implications for Sorrento than the decisions have for us. For example, potential conflicts of interest could arise in connection with the resolution of any dispute that may arise between Sorrento and us regarding the terms of the agreements governing the transition services and the relationship thereafter between the companies. Potential conflicts of interest may also arise if we enter into commercial arrangements with Sorrento in the future. As a result of these actual or apparent conflicts, we may be precluded from pursuing certain growth initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sorrento currently performs or supports many of our important corporate functions. Our financial statements may not necessarily be indicative of the conditions that would have existed or our results of operations if we had been operated as an unaffiliated company of Sorrento, and we will incur incremental costs as a stand-alone public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are in the process of replicating and replacing certain functions, systems and infrastructure to which we no longer have the same access after the Business Combination. We are also making investments and hiring additional employees to operate without the same access to Sorrento&#x2019;s existing operational and administrative infrastructure. These initiatives are costly to implement. Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs is subject to change.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sorrento currently performs or supports many important corporate functions for our company. Our financial statements reflect charges for these services on an allocation basis. As a result, our consolidated financial statements may not be reflective of conditions that would have existed or what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento. Pursuant to agreements we expect to enter into with Sorrento, we expect that Sorrento will continue to provide us with some of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We are also incurring additional costs as a stand-alone public company. As a stand-alone public company, our total costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and an enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to replace these services or enter into appropriate third-party agreements on terms and conditions, including costs, comparable to those that we will receive from Sorrento under our agreements with Sorrento. Additionally, after the agreements terminate, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from Sorrento. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically received informal support from Sorrento, which may not be addressed in our agreements with Sorrento. The level of this informal support will diminish or cease following the Business Combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are controlled by Sorrento, whose interests may differ from those of our public shareholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of the date of this Annual Report on Form 10-K, Sorrento controls approximately 52.1% of our voting power, which means that, based on its percentage voting power, Sorrento controls the vote of all matters submitted to a vote of our stockholders. This control will enable Sorrento to control the election of the members of our Board and all other corporate decisions. In particular, for so long as Sorrento continues to own a majority of the outstanding shares of our capital stock entitled to vote generally in the election of directors, Sorrento will be able to cause or prevent a change of control of the Company or a change in the composition of our Board and could preclude any unsolicited acquisition of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Amended and Restated Registration Rights Agreement entered into in connection with the Business Combination (the &#x201c;Registration Rights Agreement&#x201d;) and our Restated Certificate of Incorporation (the &#x201c;Certificate of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporation&#x201d;), Sorrento has certain rights, and the ability to take certain actions, that are not otherwise available to all of our stockholders. For example, the Registration Rights Agreement provides Sorrento the right, subject to certain conditions, to demand that we file a registration statement or request that their shares of our Common Stock be covered by a registration statement that we are otherwise filing. Refer to the description of our securities in the form filed as an exhibit to this Annual Report on Form 10-K for additional information regarding these rights. We have filed a registration statement on Form S-1 (File No. 333-268603) which was declared effective by the SEC on December 27, 2022, in order to satisfy these obligations. In addition, until such time as Sorrento first ceases to own greater than 50% of the outstanding voting power of the outstanding shares of our capital stock entitled to vote generally in the election of directors, the Certificate of Incorporation effectively provides Sorrento with the ability to fill vacancies on our Board, remove directors (with or without cause), call a special meeting of our stockholders, amend the Certificate of Incorporation (subject to approval of our Board) and amend our Bylaws (the &#x201c;Bylaws&#x201d;). The directors so elected will have the authority, subject to the terms of our indebtedness and applicable rules and regulations, to issue additional stock, implement stock repurchase programs, declare dividends and make other decisions. Refer to the description of our securities in the form filed as an exhibit to this Annual Report on Form 10-K for additional information regarding Sorrento&#x2019;s ability to take such actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even when Sorrento ceases to control a majority of the total voting power of Scilex, for so long as Sorrento continues to own a significant percentage of our Common Stock and for so long as the Sorrento Group owns any shares of preferred stock, par value $0.0001 per share, of Scilex, designated as Series A Preferred Stock (the &#x201c;Series A Preferred Stock&#x201d;) pursuant to the Certificate of Designations of Scilex (the &#x201c;Certificate of Designations&#x201d;), Sorrento will still be able to significantly influence the composition of our Board and the approval of actions requiring stockholder approval. Accordingly, for such period of time, Sorrento will have significant influence with respect to our management, business plans and policies. Because of the significant ownership position held by Sorrento, our classified board structure and the rights granted to Sorrento under the Stockholder Agreement, dated as of September 12, 2022, between Vickers and Sorrento (the &#x201c;Stockholder Agreement&#x201d;), new investors may not be able to effect a change in our business or management. The concentration of ownership and availability of the foregoing rights could deprive our stockholders of an opportunity to receive a premium for their shares of common stock as part of a sale of the Company and ultimately might affect the market price of our Common Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, the interests of Sorrento may not be aligned with those of our other stockholders and this could lead to actions that may not be in the best interests of our other stockholders. For example, Sorrento may have different tax positions or strategic plans for the Company, which could influence its decisions regarding whether and when we should dispose of assets or incur new or refinance existing indebtedness. Additionally, Sorrento&#x2019;s significant ownership in the Company may discourage someone from making a significant equity investment in the Company, or could discourage transactions involving a change in control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, Sorrento and its affiliates engage in a broad spectrum of activities, including investments in our industry generally. In the ordinary course of their business activities, Sorrento and its affiliates may engage in activities where their interests conflict with our interests or those of our other stockholders, such as investing in or advising businesses that directly or indirectly compete with certain portions of our business or those businesses that are suppliers or customers of ours. The Certificate of Incorporation provides that, to the fullest extent permitted by law, none of Sorrento and its affiliates and any person or entity who, while a stockholder, director, officer or agent of us or any of our affiliates, is a director, officer, principal, partner, member, manager, employee, agent and/or other representative of Sorrento and its affiliates (each an &#x201c;Identified Person&#x201d;) will have any duty to refrain from (i) engaging in a corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii) otherwise investing in or providing services to any person that competes with us or our affiliates engaging, directly or indirectly, in the same or similar business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">activities or lines of business in which we operate. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates. This means that Sorrento may pursue acquisition opportunities that may be complementary to our business and, as a result, those acquisition opportunities may not be available to us. In addition, Sorrento may have an interest in pursuing acquisitions, divestitures and other transactions that, in its judgment, could enhance its investment, even though such transactions might involve risks to our stockholders or may not prove beneficial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, on December 30, 2022, Sorrento announced that its board of directors has authorized Sorrento to dividend to Sorrento equityholders of record as of January 9, 2023 an aggregate of 76,000,000 shares of our Common Stock that were held by Sorrento. Subsequent to such dividend Sorrento continues to hold approximately 53.3% of our voting power, including shares of our Series A Preferred Stock and shares issuable upon exercise of warrants to purchase shares of our Common Stock, which shares have the rights, preferences and privileges described below, and Sorrento would still have significant rights that are not otherwise available to holders of our Common Stock. See the risk factor below titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sorrento, as the holder of Series A Preferred Stock, has rights, preferences and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sorrento has recently filed for bankruptcy protection, which may impair our relationship with Sorrento</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the Company is not a debtor in Sorrento&#x2019;s voluntary Chapter 11 filing. As of December 31, 2022, the Company had a $1.8 million receivable from Sorrento, which is considered collectible. Sorrento&#x2019;s filing for bankruptcy protection may impair our relationship with Sorrento.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sorrento, as the holder of Series A Preferred Stock, has rights, preferences and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Series A Preferred Stock is issued only to Sorrento and is not convertible into shares of our Common Stock. The holders of Series A Preferred Stock have rights, preferences and privileges that are senior, or in addition, to the rights, preferences and privileges of the holders of our Common Stock, including the right to receive, in the event of a change of control, liquidation dissolution or winding up of the Company, a preference amount out of the assets available for distribution to stockholders before any distribution can be made to holders of our Common Stock. The preference amount is $10.00 per share (subject to adjustment as set forth in the Certificate of Designations). If our Board declares or pays a dividend on our Common Stock, the holders of Series A Preferred Stock will participate, on a deemed as-converted-to-common stock basis, in such dividend with the holders of our Common Stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of Series A Preferred Stock have certain voting rights over our corporate actions including, among others, any change to the shares of Series A Preferred Stock into cash or other property, the issuance of equity securities that rank on a parity with or senior to Series A Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or winding-up of the Company and the amendment of the Certificate of Incorporation in a manner that adversely affects the holders of shares of Series A Preferred Stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the terms of the Stockholder Agreement, for so long as the Sorrento Group beneficially owns any shares of Series A Preferred Stock, among other things, (i) Sorrento shall have the right, but not the obligation, to designate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each director to be nominated, elected or appointed to our Board (each, a &#x201c;Stockholder Designee&#x201d; and collectively, the &#x201c;Stockholder Designees&#x201d;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board, or the size of our Board and (ii) we are required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of our Board. Notwithstanding the foregoing, the parties have agreed to ensure that our Board complies with all applicable requirements of the stock exchange, including independence requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Stockholder Agreement also provides that we are prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of our Board, the incurrence of certain amounts of indebtedness and the payment of dividends on our Common Stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For more information on the terms of the Series A Preferred Stock, refer to the description of our securities in the form filed as an exhibit to this Annual Report on Form 10-K for additional information regarding the rights of the holders of Series A Preferred Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to recently enacted state laws in California that require gender and diversity quotas for boards of directors of public companies headquartered in California.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, California enacted Senator Bill 826 (&#x201c;SB 826&#x201d;), which generally requires public companies with principal executive offices in California to have at least two female directors on its board of directors if the company has at least five directors, and at least three female directors on its board of directors if the company has at least six directors. SB 826 has been challenged in legal proceedings and on May 13, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down SB 826, holding that the statute violates the Equal Protection Clause of the California Constitution. The California Secretary of State has appealed the order and such appeal is currently pending. On September 16, 2022, the appellate court ruled to temporarily stay enforcement of the trial court&#x2019;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to SB 826, pending a further order of the appellate court. On December 1, 2022, the appellate court vacated the temporary stay order and on February 3, 2023, a record on appeal was filed and such appeal is currently pending. To the extent that this ruling of the appellate court permits the Secretary of State of California to collect and report diversity data, we may be required to comply with additional disclosure requirements. However, ultimate enforceability of SB 826 remains uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, on September 30, 2020, California enacted Assembly Bill 979 (&#x201c;AB 979&#x201d;), which generally requires public companies with principal executive offices in California to include specified numbers of directors from &#x201c;underrepresented communities&#x201d;. A director from an &#x201c;underrepresented community&#x201d; means a director who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, Alaska Native, gay, lesbian, bisexual or transgender. By December 31, 2021, each public company with principal executive offices in California was required to have at least one director from an underrepresented community. By December 31, 2022, a public company with more than four but fewer than nine directors will be required to have a minimum of two directors from underrepresented communities, and a public company with nine or more directors will need to have a minimum of three directors from underrepresented communities. On April 1, 2022, the Superior</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Court of California for the County of Los Angeles entered an order striking down AB 979, holding that the statute violates the Equal Protection Clause of the California Constitution. On June 6, 2022, a notice of appeal was filed. On September 16, 2022, the appellate court ruled to temporarily stay enforcement of the trial court&#x2019;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to AB 979, pending a further order of the appellate court. On December 1, 2022, the appellate court vacated the temporary stay order and on February 3, 2023, a record on appeal was filed and such appeal is currently pending. To the extent that this ruling of the appellate court permits the Secretary of State of California to collect and report diversity data, we may be required to comply with additional disclosure requirements. Litigation regarding AB 979 will continue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot assure that we can recruit, attract and/or retain qualified members of our Board and meet gender and diversity quotas under Nasdaq Listing Rules or any California law that may become applicable to the Company, which may expose us to financial penalties and adversely affect our reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Ownership of our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of the factors listed below could have a negative impact on your investment in our securities, and our securities may trade at prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Factors affecting the trading price of our securities may include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to commercialize ZTlido, GLOPERBA or our product candidates, if approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the status and cost of our marketing commitments for ZTlido, GLOPERBA and our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements regarding results of any clinical trials relating to our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unanticipated serious safety concerns related to the use of ZTlido, GLOPERBA or any of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse regulatory decisions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in laws or regulations applicable to ZTlido, GLOPERBA or our product candidates, including but not limited to clinical trial requirements for approvals; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for ZTlido, GLOPERBA or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our dependence on third parties; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements of the introduction of new products by our competitors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market conditions and trends in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements concerning product development results or intellectual property rights of others; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future issuances of common stock or other securities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to meet or exceed any financial guidance or expectations regarding product development milestones that we may provide to the public; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated variations in quarterly operating results; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to meet or exceed the estimates and projections of the investment community; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in financial estimates by the Company or by any securities analysts who might cover our stock; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fluctuation of the market values of any of our potential strategic investments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issuances of debt or equity securities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with our contractual obligations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of our Common Stock by us or our stockholders in the future; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trading volume of our Common Stock; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ineffectiveness of our internal controls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">publication of research reports about the Company or its industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to effectively integrate the operations of Semnur; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our relationship with Sorrento;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general political and economic conditions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effects of natural or man-made catastrophic events; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effects of public health crises, pandemics and epidemics, such as the COVID-19 pandemic; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other events or factors, many of which are beyond our control. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, the equity markets in general have recently experienced extreme price and volume fluctuations. Continued market fluctuations could result in extreme volatility in the price of our Common Stock, which could cause a decline in the value of our Common Stock. Price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#x2019; stock. Such litigation, if instituted against the Company, could cause us to incur substantial costs and divert management&#x2019;s attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;, could have a dramatic and material adverse impact on the market price of our Common Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have not paid cash dividends in the past and we do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of our Common Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not paid cash dividends on our Common Stock and we do not anticipate paying cash dividends on our Common Stock in the foreseeable future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. In addition, our ability to pay dividends may be limited by covenants in future outstanding indebtedness that we or our subsidiaries may incur. Since we do not intend to pay dividends, a stockholder&#x2019;s ability to receive a return on such stockholder&#x2019;s investment will depend on any future appreciation in the market value of our Common Stock. There is no guarantee that our Common Stock will appreciate or even maintain the price at which our stockholders have purchased it.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future sales of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our Common Stock, the trading price of our Common Stock could decline and it could impair our ability to raise capital through the sale of additional equity securities. Except as described below and unless otherwise waived by the Company and the applicable parties to the Registration Rights Agreement, Sorrento and certain directors and equityholders of Vickers, including Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (collectively, the &#x201c;Sponsors&#x201d;), are currently subject to lock-up provisions that restrict their ability to transfer certain of their shares of our Common Stock or any security convertible into or exercisable or exchanged for our Common Stock until 180 days from the Effective Time, subject to certain exceptions. In connection with the closing of the Business Combination, the Company, the Sponsors and Sorrento agreed to waive compliance with the lock-up provisions under the Registration Rights Agreement and any other applicable agreement that restricted the transfer of our Common Stock solely with respect to 1.5 million shares of our Common Stock held by the Sponsors as of such closing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As described elsewhere in this Form 10-K, on December 30, 2022, Sorrento announced that its board of directors authorized Sorrento to dividend to Sorrento equityholders of record as of January 9, 2023 an aggregate of 76,000,000 shares of our Common Stock that were held by Sorrento. Such shares are subject to a lock-up restriction and may not be sold, pledged or otherwise transferred until May 11, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our operating results may fluctuate significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our operating results to be subject to quarterly, and possibly annual, fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">variations in the level of expenses related to our development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the addition or termination of clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any intellectual property infringement lawsuit in which we may become involved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory developments affecting ZTlido, GLOPERBA or our product candidates, regulatory approvals of our product candidates, and the level of underlying demand for such products and purchasing patterns; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">143</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our quarterly or annual operating results fall below the expectations of investors or securities analysts, the price of our Common Stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our Common Stock to fluctuate substantially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our stock, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our Common Stock will be influenced by the research and reports that industry or securities analysts publish about the Company or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. Since we became public through a merger, securities analysts of major brokerage firms may not provide coverage of the Company since there is no incentive to brokerage firms to recommend the purchase of our Common Stock. If no or few securities or industry analysts commence coverage of the Company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover it issues an adverse opinion regarding the Company, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of the Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to ZTlido or our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may issue additional equity securities to fund future expansion and pursuant to equity incentive or employee benefit plans. We may also issue additional equity for other purposes. These securities may have the same rights as our Common Stock or, alternatively, may have dividend, liquidation or other preferences to our Common Stock. The issuance of additional equity securities, whether pursuant to that certain standby equity purchase agreement (the &#x201c;B. Riley Purchase Agreement&#x201d;), dated as of January 8, 2023, with B. Riley Principal Capital II, LLC, a Delaware limited liability company (&#x201c;B. Riley&#x201d;), that certain amended and restated standby equity purchase agreement (the &#x201c;A&amp;R Yorkville Purchase Agreement&#x201d;), dated as of February 8, 2023, with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#x201c;Yorkville&#x201d;) (pursuant to each of which we may also sell up to $500 million of shares of our Common Stock, or an aggregate of $1.0 billion, as more fully described elsewhere in this Annual Report on Form 10-K) or otherwise, will dilute the holdings of existing stockholders and may reduce the share price of our Common Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Scilex Holding Company 2022 Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d;), which became effective on November 9, 2022, we are authorized to grant equity awards to our employees, directors and consultants. In addition, pursuant to the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on November 9, 2022, we are authorized to sell shares to our employees. Further, pursuant to the Inducement Plan, which was adopted on January 17, 2023, we are authorized to grant equity awards to individuals as a material inducement to join the Company. A total of 20,276,666, 2,875,759 and 1,400,000 shares of our Common Stock have been reserved for future issuance under the Equity Incentive Plan, the ESPP and the Inducement Plan, respectively. In addition, the Equity Incentive Plan and ESPP provide for annual automatic increases in the number of shares reserved thereunder, in each case, beginning on January 1, 2023. As a result of such annual increases, our stockholders may experience additional dilution, which could cause the price of our Common Stock to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Registration Rights Agreement entered into in connection with the Business Combination, certain stockholders of Vickers and Legacy Scilex can each demand that we register their registrable securities under certain circumstances and will each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) covering such securities and certain of our other securities. We have filed a registration statement on Form S-1 (File No. 333-268603) which was declared effective by the SEC on December 27, 2022, in order to satisfy these obligations. The registration of these securities will permit the public sale of such securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of our Common Stock trading in the public market may have an adverse effect on the market price of our securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise additional funds through collaboration, licensing or other similar arrangements, we may have to relinquish valuable rights to ZTlido or our product candidates, or grant licenses on terms unfavorable to the Company. If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our principal stockholders, directors and executive officers will own a significant percentage of our capital stock, and have significant influence over our management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our directors, executive officers, holders of 5% or more of our capital stock and their respective beneficially own, in the aggregate, approximately 56.7% of our outstanding voting stock (which percentage gives effect to the dividend of 76,000,000 shares of our Common Stock by Sorrento to certain of its equityholders). This concentration of voting power may make it less likely that any other holder of our Common Stock will be able to affect the way we are managed and could delay or prevent an acquisition of the Company on terms that other stockholders may desire. This could prevent transactions in which stockholders might otherwise recover a premium for their shares over current market prices. See </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;Risk Factors &#x2014; We are controlled by Sorrento, whose interests may differ from those of our public shareholders&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> above for additional information regarding Sorrento&#x2019;s influence and control in the Company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have in the past and may in the future be subject to short selling strategies that may drive down the market</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short sellers have in the past and may attempt in the future to drive down the market price of our common stock. Short selling is the practice of selling securities that the seller does not own but may have borrowed with the intention of buying identical securities back at a later date. The short seller hopes to profit from a decline in the value of the securities between the time the securities are borrowed and the time they are replaced. As it is in the short seller&#x2019;s best interests for the price of the stock to decline, many short sellers (sometime known as &#x201c;disclosed shorts&#x201d;) publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects to create negative market momentum. Although traditionally these disclosed shorts were limited in their ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping and publication by weblog (&#x201c;blogging&#x201d;) have allowed many disclosed shorts to publicly attack a company&#x2019;s credibility, strategy and veracity by means of so-called &#x201c;research reports&#x201d; that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, led to selling of shares in the market. Further, these short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the U.S. and they are not subject to certification requirements imposed by the SEC. Accordingly, the opinions they express may be based on distortions, omissions or fabrications. Companies that are subject to unfavorable allegations, even if untrue, may have to expend a significant amount of resources to investigate such allegations and/or defend themselves,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">including shareholder suits against the company that may be prompted by such allegations. We may in the future be the subject of shareholder suits that we believe were prompted by allegations made by short sellers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss and tax credit carryforwards may be subject to limitation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, a change of more than 50% in the ownership of a company&#x2019;s stock, by value, over a three-year period constitutes an ownership change for U.S. federal income tax purposes. An ownership change may limit our ability to use our net operating loss carryforwards attributable to the period prior to the change. We have experienced a corporate reorganization in the past, some ownership changes as a result of the Business Combination and may experience some subsequent changes in the future in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability for the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Tax Cuts and JOBS Act of 2017 (the &#x201c;TCJA&#x201d;), as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating loss (&#x201c;NOL&#x201d;) carryforwards. The TCJA, as modified by the CARES Act, limits a taxpayer&#x2019;s ability to utilize NOL carryforwards to 80% of taxable income (as calculated before taking the NOLs, and certain other tax attributes, into account) for taxable years beginning after December 31, 2020. In addition, NOLs arising in tax years ending after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. NOLs arising in tax years beginning after December 31, 2017 can be carried forward indefinitely. NOLs generated in tax years beginning before January 1, 2021 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January 1, 2018 will continue to have a two-year carryback and 20-year carryforward period. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward/carryback periods, as well as the new limitation on use of NOLs may significantly impact our ability to utilize our NOLs to offset taxable income in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in our combined consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti-takeover provisions in the Certificate of Incorporation and the Bylaws and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation and our Bylaws and the General Corporation Law of the State of Delaware, as amended (the &#x201c;DGCL&#x201d;) contains provisions that could make it more difficult for a third party to acquire the Company, even if doing so might be beneficial to our stockholders. Among other things, these provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">allow our Board to authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of other stockholders; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide for a classified board of directors with staggered three-year terms; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that, at any time after the Sorrento Group first ceases to beneficially own more than 50% in voting power of the then-outstanding shares of our stock entitled to vote generally in the election of directors (the &#x201c;Sorrento Trigger Event&#x201d;), directors may only be removed for cause, and only by the affirmative vote of holders of at least 66 2/3% in voting power of all the then-outstanding shares of our Common Stock entitled to vote thereon, voting together as a single class; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prohibit stockholder action by written consent from and after the Sorrento Trigger Event; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that, at any time after the Sorrento Trigger Event, special meetings may only be called by or at the direction of the Chairperson of the Board, the Board or the Chief Executive Officer; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that, at any time after the Sorrento Trigger Event, any alteration, amendment or repeal, in whole or in part, of any provision of the Bylaws by our stockholders will require the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our Common Stock entitled to vote thereon, voting together as a single class; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish advance notice requirements for nominations for elections to the Board and for proposing matters that can be acted upon by stockholders at stockholder meetings. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 203 of the DGCL generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder. We have expressly elected not to be governed by Section 203 of the DGCL until the occurrence of a Sorrento Trigger Event. At that time, such election shall be automatically withdrawn and we will thereafter be governed by Section 203 of the DGCL, except that the restrictions on business combinations of Section 203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of its percentage ownership of our Common Stock. These provisions could discourage, delay or prevent a transaction involving a change in control of the Company. These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing and cause us to take other corporate actions they desire, including actions that our stockholders may deem advantageous. In addition, because our Board is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These anti-takeover provisions and other provisions in the Certificate of Incorporation, the Bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of the Board or initiate actions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">147</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that are opposed by our then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving the Company. The existence of these provisions could negatively affect the price of our Common Stock and limit opportunities for a stockholder to realize value in a corporate transaction. For information regarding these and other provisions, refer to the description of our securities in the form filed as an exhibit to this Annual Report on Form 10-K for additional information. In addition, if prospective takeovers are not consummated for any reason, we may experience negative reactions from the financial markets, including negative impacts on the price of our Common Stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders and the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Certificate of Incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom, will, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders; (iii) any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws; (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws; (v) any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware and (vi) any action asserting an &#x201c;internal corporate claim,&#x201d; as that term is defined in Section 115 of the DGCL; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided that</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for the avoidance of doubt, the foregoing forum selection provision will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation also provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The Certificate of Incorporation further provides that any person or entity purchasing or otherwise acquiring any interest in shares of our Common Stock is deemed to have notice of and consented to the provisions of the Certificate of Incorporation described above. Refer to the description of our securities in the form filed as an exhibit to this Annual Report on Form 10-K for additional information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The forum selection provisions in the Certificate of Incorporation may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If the enforceability of our forum selection provisions were to be challenged, it may incur additional costs associated with resolving such challenge. While we currently have no basis to expect any such challenge would be successful, if a court were to find its forum selection provisions to be inapplicable or unenforceable with respect to one or more of these specified types of actions or proceedings, we may incur additional costs associated with having to litigate in other jurisdictions, which could result in a diversion of the time and resources of our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">employees, management and board of directors, and could have an adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of the initial public offering of 13,800,000 units of Vickers consummated on January 11, 2021 (the &#x201c;IPO&#x201d;), (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which requires the market value of our Common Stock that is held by non-affiliates to equal or exceed $700 million as of the last business day of the second fiscal quarter of such year, and (2) the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sorrento controls a majority of the voting power of our outstanding shares of Common Stock. As a result, we are a &#x201c;controlled company&#x201d; within the meaning of the corporate governance standards of Nasdaq. Under these corporate governance standards, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a &#x201c;controlled company&#x201d; and may elect not to comply with certain corporate governance requirements. For example, controlled companies, within one year of the date of the listing of their common stock:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are not required to have a board that is composed of a majority of &#x201c;independent directors&#x201d; as defined under the Nasdaq Listing Rules; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are not required to have a compensation committee that is composed entirely of independent directors or have a written charter addressing the committee&#x2019;s purpose and responsibilities; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are not required to have director nominations be made, or recommended to the full board of directors, by its independent directors or by a nominating and corporate governance committee that is composed entirely of independent directors, and to adopt a written charter or a board resolution addressing the nominations process. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we do not presently intend to rely on these exemptions, we may opt to utilize these exemptions in the future as long as we remain a controlled company. Accordingly, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we cease to be a &#x201c;controlled company&#x201d; in the future, we will be required to comply with the Nasdaq listing standards, which may require replacing a number of our directors and will require development of certain other governance-related policies and practices. These and any other actions necessary to achieve compliance with such rules may increase our legal and administrative costs, will make some activities more difficult, time-consuming and costly and may also place additional strain on our personnel, systems and resources. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to related compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We incur significant legal, accounting and other expenses that Legacy Scilex did not incur as a private company, and these expenses may increase even more after we are no longer an &#x201c;emerging growth company.&#x201d; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#x201c;Dodd-Frank Act&#x201d;), as well as rules and regulations adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, we expect these rules and regulations to make it more difficult and more expensive for the Company to obtain directors&#x2019; and officers&#x2019; liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on the Board, our board committees or as executive officers. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we expect that we will need to implement an enterprise resource planning (&#x201c;ERP&#x201d;) system. An ERP system is intended to combine and streamline the management of our financial, accounting, human resources, sales and marketing and other functions, enabling it to manage operations and track performance more effectively. However, an ERP system would likely require us to complete many processes and procedures for the effective use of the system or to run our business using the system, which may result in substantial costs. Any disruptions or difficulties in implementing or using an ERP system could adversely affect our controls and harm our business, financial condition and results of operations, including our ability to forecast or make sales and collect our receivables. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we will be required to include an attestation report on internal control over financial reporting issued by our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaging in a process to document and evaluate its internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of our testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. See &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk Factors &#x2014; We have identified a material weakness in our internal control over financial reporting. Any material weakness may cause us to fail to timely and accurately report our financial results or result in a material misstatement of our financial statements.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; above for additional information regarding a previously identified material weakness. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management&#x2019;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and there could be a material adverse effect on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our failure to meet Nasdaq&#x2019;s continued listing requirements could result in a delisting of our Common Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to satisfy Nasdaq&#x2019;s continued listing requirements, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our Common Stock. Such a delisting would likely have a negative effect on the price of our Common Stock and would impair a stockholder&#x2019;s ability to sell or purchase our Common Stock when a stockholder wishes to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our Common Stock to become listed again, stabilize the market price or improve the liquidity of our Common Stock, prevent our Common Stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#x2019;s listing requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive U.S. federal income tax reform could adversely affect the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes to tax laws, which changes may have retroactive application, could adversely affect the Company or holders of our Common Stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The TCJA, which was enacted in 2017, included changes to U.S. federal tax rates, imposed significant additional limitations on the deductibility of interest, allowed for the expensing of capital expenditures, and put into effect the migration from a &#x201c;worldwide&#x201d; system of taxation to a modified territorial system. On March 27, 2020, President Trump signed into law the CARES Act, which included certain changes in tax law (including to the TCJA) intended to stimulate the U.S. economy in light of the COVID-19 pandemic, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which contained certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations, an excise tax of 1% on certain corporate stock buy-backs, and an excise tax with respect to certain drug sales for failing to offer a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law or for taking price increases that exceed inflation. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. The impact of these tax reforms on holders of our Common Stock is uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our Common Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Warrants are exercisable for our Common Stock, which would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding warrants to purchase an aggregate of 11,003,988 shares of our Common Stock (the &#x201c;Warrants&#x201d;) are exercisable in accordance with the terms of the Warrant Agreement, dated January 6, 2021, between Vickers and Continental Stock Transfer &amp; Trust Company (&#x201c;Continental&#x201d;) governing those securities. The exercise price of these Warrants is $11.50 per share. To the extent such Warrants are exercised, additional shares of our Common Stock will be issued, which will result in dilution to the holders of our Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market, or the fact that such Warrants may be exercised, could adversely affect the prevailing market prices of our Common Stock. However, there is no guarantee that the Warrants will ever be in the money prior to their expiration, and as such, the Warrants may expire worthless. See below risk factor, &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Warrants may never be in the money, they may expire worthless and the terms of the Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Warrants may never be in the money, they may expire worthless and the terms of the Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Warrants were issued in registered form under the Warrant Agreement between Continental, as warrant agent, and Vickers. The Warrant Agreement provides that the terms of the Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, but requires the approval by the holders of a majority of the then-outstanding Warrants to make any change that adversely affects the interests of the registered holders of Warrants. Accordingly, we may amend the terms of the Warrants in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment. Although our ability to amend the terms of the Warrants with the consent of majority of the then-outstanding Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the Warrants, convert the Warrants into cash, shorten the exercise period, or decrease the number of shares of our Common Stock purchasable upon exercise of a Warrant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may redeem any unexpired Warrants prior to their exercise at a time that is disadvantageous to you, thereby making the Warrants worthless.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have the ability to redeem outstanding Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per Warrant, provided that the closing price of our Common Stock equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) on each of the 20 trading days within any 30-trading-day period commencing after the Warrants become exercisable and ending on the third trading day prior to the date on which notice of redemption is given. If and when the Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding Warrants could force the holders thereof to: (i) exercise such Warrants and pay the exercise price therefor at a time when it may be disadvantageous for a holder to do so; (ii) sell such Warrants at the then-current market price when a holder might otherwise wish to hold such Warrants; or (iii) accept the nominal redemption price that, at the time the outstanding Warrants are called for redemption, is likely to be substantially less than the market value of such Warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may redeem the Warrants at any time after they become exercisable and prior to their expiration for a number of shares of our Common Stock determined based on the fair market value of our Common Stock. The value received upon exercise of the Warrants (1) may be less than the value the holders would have received if they had exercised their Warrants at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the Warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section39"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolv</span><span id="unresolved_staff_comments"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ed Staff Comments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section40"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. P</span><span id="properties"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">roperties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our principal executive office is currently located in Palo Alto, California, and consists of approximately 6,000 square feet of leased office space. The lease term expires in October 2024. We also sublease office space in San Diego, California. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate additional or alternative space will be available on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section42"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Lega</span><span id="legal_proceedings"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">l Proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information set forth under the section titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business &#x2014; Legal Proceedings</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; in Item 1, &#x201c;Business&#x201d; is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section43"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Safe</span><span id="mine_safety_disclosures"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ty Disclosures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section44"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span id="part_ii"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section45"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Reg</span><span id="market_for_registrant"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">istrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span><span id="section46"></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Common Stock and Warrants are currently listed on Nasdaq under the symbols &#x201c;SCLX&#x201d; and &#x201c;SCLXW,&#x201d; respectively. Prior to the consummation of the Business Combination, Vickers&#x2019;s ordinary shares, units and warrants were each listed on Nasdaq under the symbols &#x201c;VCKA,&#x201d; &#x201c;VCKAU&#x201d; and &#x201c;VCKAW,&#x201d; respectively. At the effective time of the Business Combination, without any action on the part of the holder, each unit of Vickers then outstanding separated automatically into its component securities, comprised of one share of Common Stock and one-half of one warrant to purchase one share of Common Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of March 3, 2023, there were 313 holders of record of our Common Stock and 2 holders of record of our Warrants, which amount does not include participants of The Depository Trust Company or beneficial owners holding shares through nominee names.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section47"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid any dividends on shares of our common stock. We anticipate that we will retain all of our future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our Board. It is the present intention of our board of directors to retain all earnings, if any, for use in our business operations and, accordingly, our board of directors does not anticipate declaring any dividends in the foreseeable future. Further, if we incur any indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith. The Stockholder Agreement also provides that we will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, the payment of dividends on shares of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Item 12. of Part III for information regarding securities authorized for issuance under our equity compensation plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unregistered Sales of Equity Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance Graph</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following information shall not be deemed to be &#x201c;filed&#x201d; with the SEC nor shall such information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, except to the extent that we specifically incorporate it by reference into such future filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following graph compares the cumulative total stockholder return on our common stock from March 3, 2021 to December 31, 2022 with the cumulative total return of (i) the Nasdaq Market Index and (ii) the Nasdaq Biotechnology Index. This graph assumes the investment of $100.00 after the market closed on March 3, 2021 (the date on which the Vickers ordinary shares and redeemable warrants comprising the units of Vickers sold in the IPO of Vickers, our predecessor, began separate trading) in our common stock, and in the Nasdaq Market Index and the Nasdaq Biotechnology Index, and it assumes any dividends are reinvested. The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img248422670_15.jpg" alt="img248422670_15.jpg" style="width:624px;height:361px;" />&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section49"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. [R</span><span id="selected_financial_data"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section50"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tem 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span><span id="mda"></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read together with the consolidated financial statements and related notes thereto included elsewhere in this annual report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this annual report, including those set forth in the sections of this annual report titled &#x201c;Risk Factors&#x201d; and &#x201c;Cautionary Note Regarding Forward-Looking Statements.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section51">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid management products for the treatment of acute and chronic pain. We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#x2019; lives. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are developing our late-stage pipeline.  Our commercial product, ZTlido is a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. We market ZTlido through a dedicated sales force of 60-70 sales representatives, targeting 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. We are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our development pipeline consists of three product candidates, (i) SP-102 (&#x201c;SEMDEXA&#x201d;) (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, (ii) SP-103 (lidocaine topical system) 5.4%, a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of acute LBP, and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2023.  SEMDEXA has been granted fast track designation by the FDA and, if approved, could become the first FDA-approved alternative to off-label ESIs, which are administered over 12 million times annually in the United States.  Top-line results from the completed Phase 3 study have been received in November 2021 and reflected achievement of primary and secondary endpoints. SP-103 has also been granted fast track designation by the FDA and, if approved, could become the first FDA-approved lidocaine topical product for the treatment of acute LBP. SP-103 is a triple-strength lidocaine topical system designed to deliver a dose of lidocaine threefold higher than any lidocaine topical product that we are aware of, either approved or in development.  We are examining SP-103 as a treatment for acute LBP, a condition with high unmet need which, as of 2019, affected over 22 million patients in the United States. According to the CDC in 2020, LBP was the most common type of pain reported by patients, with 25% of U.S. adults reporting LBP in the prior 3 months. We initiated a Phase 2 trial of SP-103 in acute LBP in the second quarter of our fiscal year 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. Prior to April 2022, we relied on a single third-party logistics distribution provider, Cardinal Health, for ZTlido distribution in the United States. Cardinal Health purchased and shipped ZTlido to customer wholesale distribution centers. Cardinal Health also performed order management services on our behalf. On April 2, 2022, we announced the expansion of our direct distribution network to national and regional wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for Scilex.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have invested substantial efforts and financial resources on acquiring product and technology rights while building our intellectual property portfolio and infrastructure.  We acquired Semnur and its lead product candidate, SEMDEXA, in the first quarter of 2019, and we intend to continue to explore and evaluate additional opportunities such as these to grow our business.  We have incurred significant operating losses as a result of such investment efforts, including the development of SEMDEXA, conducting of Phase 3 trials for SEMDEXA, and the development of SP-103.  Our ability to generate revenue sufficient to achieve profitability will depend on the successful commercialization of our product, ZTlido, and the development of our product candidates. For the years ended December 31, 2022, 2021, and 2020, we had a net loss of $23.4 million and $88.4 million, and $47.5 million respectively. As of December 31, 2022, we had an accumulated deficit of approximately</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $375.9 million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, we had cash and cash equivalents of approximately $2.2 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to make investments in our sales and marketing organization and expand digital marketing efforts to broaden awareness of ZTlido and GLOPERBA and in research and development, clinical trials and regulatory affairs to develop our product candidates, SEMDEXA, SP-103, and SP-104 (acquired from Sorrento in May 2022). As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, or at all.  If adequate funds on acceptable terms are not available when needed, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business Combination</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 10, 2022, we consummated the previously announced Business Combination pursuant to the Agreement and Plan of Merger, dated as of March 17, 2022 (as amended by Amendment No. 1 to Agreement and Plan of Merger, dated September 12, 2022, together, the &#x201c;Merger Agreement&#x201d;), by and among Vickers, Vantage Merger Sub Inc. (&#x201c;Merger Sub&#x201d;), a wholly owned subsidiary of Vickers and Legacy Scilex. Pursuant to the terms of the Merger Agreement, a business combination (herein referred to as the &#34;Business Combination&#34; or &#34;reverse recapitalization&#34; for accounting purposes) between Vickers and Legacy Scilex was effected through the merger of Merger Sub with and into Legacy Scilex with Legacy Scilex surviving the merger as Vickers's wholly owned subsidiary. In connection with the Business Combination, Vickers changed its name from Vickers Vantage Corp. I to Scilex Holding Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the Business Combination, New Scilex (as defined below) received net proceeds of approximately $3.4 million. Additionally, all existing related party indebtedness and payables between Legacy Scilex, Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;), and Sorrento, totaling $290.6 million, was converted into equity interests in New Scilex in connection with the consummation of the Business Combination and pursuant to the terms of the Contribution and Satisfaction of Indebtedness Agreement, dated as of September 12, 2022, by and among Sorrento,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legacy Scilex and Scilex Pharma (the &#x201c;Debt Exchange Agreement&#x201d;) (see Note 12 titled &#x201c;Related Party Transactions&#x201d; to our consolidated financial statements included elsewhere in this annual report for additional information). The Company operates as &#x201c;Scilex Holding Company&#x201d; and was listed on the Nasdaq Capital Market under the new ticker symbol &#x201c;SCLX&#x201d; on November 11, 2022. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#x201c;New Scilex&#x201d;.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers was treated as the &#x201c;acquired&#x201d; company for accounting purposes and the Business Combination was treated as the equivalent of Legacy Scilex issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with no goodwill or other intangible assets recorded.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section52">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Developments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">February 2023 Preliminary Unaudited Financial Results</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 1, 2023, we filed a Current Report on Form 8-K providing certain preliminary unaudited financial results for the one month ended February 28, 2023, and as of February 28, 2023, based on then currently available information. Our independent auditor has not reviewed or audited these preliminary estimated financial results. Our actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. We have not fully completed our review of these preliminary financial results for the one month ended February 28, 2023, and as of February 28, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In such Current Report on Form 8-K, we estimated that: ZTlido gross sales for February 2023 were in the range of $8.6 million to $8.8 million, compared to $5.1 million in February 2022, representing growth in the range of 68% to 72%; year-to-date February 2023 gross sales were in the range of $16.7 million to $17.3 million, compared to $10.3 million for year-to-date February 2022, representing growth in the range of 62% to 68%; net sales for February 2023 were in the range of $3.3 million to $3.5 million, compared to net sales of $2.0 million in February 2022, representing growth in the range of 65% to 75%; year-to-date February 2023 net sales were in the range of $6.6 million to $7.0 million, compared to $4.1 million for year-to-date February 2022, representing growth in the range of 61% to 70%. Historically, sales for ZTlido are low during the first quarter of the year due to deductibles with managed healthcare plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Elyxyb License</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 12, 2023, we acquired from BioDelivery Sciences International, Inc. (&#x201c;BSDI&#x201d;) and Collegium Pharmaceutical, Inc. (&#x201c;Collegium&#x201d;, and together with BDSI, the &#x201c;Collegium Sellers&#x201d;) the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (celecoxib oral solution) (the &#x201c;Product&#x201d;) and its commercialization in the United States and Canada (the &#x201c;Territory&#x201d;).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the acquisition, the Company assumed various rights and obligations under that certain asset purchase agreement, dated August 3, 2021 (the &#x201c;DRL APA&#x201d;), between BDSI and Dr. Reddy&#x2019;s Laboratories Limited, a company incorporated under the laws of India (&#x201c;DRL&#x201d;), including a license from DRL including an irrevocable, royalty-free, exclusive license to know-how and patents of DRL related to the Product and necessary or used to exploit the Product in the Territory. Additionally, under the Purchase Agreement, the Collegium Sellers granted the Company an irrevocable, royalty-free, exclusive license to know-how related to the Product and necessary or used to exploit the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product in the Territory. No cash consideration was or will be payable to the Collegium Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties to DRL for sales of the Product in the Territory for all indications and additional amounts if certain milestones are achieved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">B. Riley Purchase Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 8, 2023, we entered into the B. Riley Purchase Agreement with a wholly-owned subsidiary of B. Riley Principal Investments, LLC (&#x201c;B. Riley&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the B. Riley Purchase Agreement, we have the right, but not the obligation, to sell to B. Riley up to $500,000,000 of shares of Common Stock, from time to time at our sole and absolute discretion (each such sale, a &#x201c;B. Riley Advance&#x201d;) at any time during the 36 months following the date on which this registration statement has been declared effective by the SEC, subject to the terms of the B. Riley Purchase Agreement. To request a B. Riley Advance, we would submit an advance notice to B. Riley (each, a &#x201c;B. Riley Advance Notice&#x201d;) specifying the number of shares we intend to sell to B. Riley. The registration statement on Form S-1 (File No. 333-269205) related to the B. Riley Purchase Agreement was filed with the SEC on January 12, 2023 and was declared effective by the SEC on January 20, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The shares of Common Stock, if any, that we elect to sell to B. Riley pursuant to a B. Riley Advance will be purchased at a price equal to 98% of the VWAP (as defined below) during the period (such period, the &#x201c;Pricing Period&#x201d;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of shares of Common Stock (the &#x201c;Advance Shares&#x201d;) or such later time publicly announced as the official open of the primary (or &#x201c;regular&#x201d;) trading session on Nasdaq on such purchase date (the &#x201c;Purchase Commencement Time&#x201d;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier time publicly announced as the official close of the primary (or &#x201c;regular&#x201d;) trading session on Nasdaq on such purchase date, (ii) immediately at such time following the Purchase Commencement Time for such purchase that the total number (or volume) of shares of Common Stock traded on Nasdaq during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii) if we so elect in the applicable B. Riley Advance Notice for such B. Riley Advance (such election, a &#x201c;Limit Order Discontinue Election&#x201d;), such time the sale price of the shares of Common Stock traded on the Nasdaq Capital Market during such Pricing Period is less than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. &#x201c;VWAP&#x201d; means, for the Common Stock for a specified period, the dollar volume-weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its &#x201c;AOR&#x201d; function, subject to certain exceptions, qualifications and limitations. &#x201c;Advance Share Volume Maximum&#x201d; means, with respect to a B. Riley Advance, if such B. Riley Advance is designated in the B. Riley Advance Notice as a (i) purchase-Type A, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a) the Advance Share amount to be purchased by B. Riley, by (b) 0.10, or (ii) purchase-Type B, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a) the Advance Share amount to be purchased by B. Riley, by (b) 0.25 (in each case, subject to certain adjustments). We may also specify a certain minimum acceptable price per share in each B. Riley Advance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While there is no mandatory minimum amount for any B. Riley Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, a B. Riley Advance may be for a number of shares of Common Stock not to exceed (i) with respect to a B. Riley Advance, purchase-Type A, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000, and (b) the product of (1) 0.10, multiplied by (2) the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type A, and (ii) with respect to a B. Riley Advance, purchase-Type B, such number of shares of Common Stock that is equal to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lesser of: (a) 1,000,000 and (b) the product of (1) 0.25, multiplied by (2) the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type B.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The B. Riley Purchase Agreement also provides that we have the right, but not the obligation, to sell to B. Riley, from time to time subject to certain limitations, at our sole and absolute discretion an additional B. Riley Advance Notice (each, a &#x201c;B. Riley Additional Advance&#x201d;). To request an additional purchase, we would submit an additional B. Riley Advance Notice to B. Riley specifying the number of shares we intend to sell to B. Riley. The purpose of the B. Riley Additional Advance is to allow us to execute more than one advance request on a purchase date with B. Riley as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each B. Riley Additional Advance is generally subject to terms and conditions consistent with those of a B. Riley Advance, except for, among other things, the time period of the pricing period for such B. Riley Additional Advance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also specify a certain minimum acceptable price per share in each B. Riley Advance or B. Riley Additional Advance. In no event is B. Riley obligated to purchase any shares that would result in it owning more than 4.99% of the then-outstanding voting power or number of shares of Common Stock. Moreover, under the applicable Nasdaq Listing Rules, in no event will we issue to B. Riley shares that, in the aggregate, would exceed the 19.9% Exchange Cap, unless we have received stockholder approval for such issuance or such issuance is otherwise permitted by applicable Nasdaq Listing Rules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">B. Riley&#x2019;s obligation to purchase shares of Common Stock pursuant to the B. Riley Purchase Agreement is subject to a number of conditions, including that a registration statement be filed with the SEC registering the resale of the Commitment Shares and the shares to be issued pursuant to any B. Riley Advance or B. Riley Additional Advance under the Securities Act, and that the registration statement is declared effective by the SEC. As consideration for B. Riley&#x2019;s commitment to purchase shares of Common Stock at our direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, we issued to B. Riley 250,000 shares of Common Stock. Subsequent to the execution of the B. Riley Purchase Agreement on January 8, 2023 and through March 3, 2023, the Company sold an aggregate of 127,241 shares of Common Stock pursuant to the B. Riley Purchase Agreement for aggregate net proceeds to the Company of approximately $1 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Yorkville Purchase Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 17, 2022, we entered into that certain Standby Equity Purchase Agreement (the &#x201c;Original Purchase Agreement&#x201d;) with YA II PN, Ltd., a Cayman Islands exempted limited partnership (&#x201c;Yorkville&#x201d;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. On February 8, 2023, we entered into an Amended and Restated Standby Equity Purchase Agreement with Yorkville (the &#x201c;A&amp;R Yorkville Purchase Agreement&#x201d;), amending, restating and superseding the Original Purchase Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the A&amp;R Yorkville Purchase Agreement, we have the right, but not the obligation, to sell to Yorkville  up to $500,000,000 of shares of Common Stock, from time to time at our sole and absolute discretion (each such sale, a &#x201c;Yorkville Advance&#x201d;) by delivering written notice to Yorkville (each, a &#x201c;Yorkville Advance Notice&#x201d;) until the first day of the month following the 36-month anniversary of the date on which the Yorkville Registration Statement (as defined below) has been declared effective by the SEC.  Pursuant to the terms of the Original Purchase Agreement, we filed a registration statement on Form S-1 (File No. 333-268607) (the &#x201c;Yorkville Registration Statement&#x201d;) related to the Original Purchase Agreement with the SEC on November 30, 2022 (following the execution of the Original Purchase Agreement). The Yorkville Registration Statement was initially declared effective by the SEC on December 9, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The shares of Common Stock purchased pursuant to Yorkville Advance will be purchased at a price equal to 98% of the VWAP (as defined below) during the applicable pricing period (each, a &#x201c;Pricing Period&#x201d;) for such Yorkville Advance, which shall be the period commencing upon receipt by Yorkville of the Yorkville Advance Notice (or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. &#x201c;VWAP&#x201d; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg L.P. through its &#x201c;AQR&#x201d; function.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Yorkville Advance may be for a number of shares of Common Stock not to exceed 200% of the average of the daily trading volume of the Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five trading days immediately preceding the date of the Yorkville Advance Notice.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yorkville&#x2019;s purchase of shares of Common Stock under the A&amp;R Yorkville Purchase Agreement would be subject to certain limitations, including that Yorkville may not purchase shares that would result in it (together with its affiliates) owning more than 4.99% of the outstanding voting power or number of shares of Common Stock after such purchase or that would result in it owning more than 19.9% of the Company&#x2019;s aggregate amount of Common Stock issued and outstanding as of the date of the Original Yorkville Purchase Agreement (the &#x201c;Exchange Cap&#x201d;). The Exchange Cap will not apply under certain circumstances, including if the average price of all applicable sales of Common Stock under the A&amp;R Yorkville Purchase Agreement equals or exceeds a certain minimum price.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We previously paid Yorkville a structuring fee of $10,000 and issued 250,000 shares of Common Stock to Yorkville as a commitment fee pursuant to the Original Purchase Agreement (the &#x201c;Yorkville Commitment Shares&#x201d;).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yorkville&#x2019;s obligation to purchase shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement is subject to a number of conditions, including that a registration statement be filed with the SEC registering the resale of the Yorkville Commitment Shares and the shares to be issued pursuant to any Yorkville Advance under the Securities Act, and that such registration statement is declared effective by the SEC. Pursuant to the terms of the Original Purchase Agreement, the Company previously filed the Yorkville Registration Statement with the SEC on November 30, 2022, which was declared effective by the SEC on December 9, 2022. During the year ended December 31, 2022, no Yorkville Advances were requested or completed under the A&amp;R Yorkville Purchase Agreement. Subsequent to December 31, 2022 and through March 3, 2023, the Company sold an aggregate of  85,000 shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds to the Company of approximately $0.6 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section53">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impact of COVID-19 on Our Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are closely monitoring the COVID-19 pandemic and its potential impact on our business. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the outbreak, including implementing social distancing policies at our facilities, facilitating remote working arrangements and imposing employee travel restrictions. The extent to which COVID-19 may impact our business, clinical trials and sales of ZTlido will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section54">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comparability of Our Results and Our Relationship with Sorrento</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently operate as a majority-owned subsidiary of Sorrento. As a result, our consolidated financial statements may not be reflective of what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento.  In particular, certain legal, finance, human resources and other functions have historically been provided to us by Sorrento at cost plus an agreed-upon markup.  We expect that Sorrento may continue to provide us with some of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We will also incur additional costs as a stand-alone public company. As a stand-alone public company, our total costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento.  In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and an enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sorrento Chapter 11 filing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the Company is not a debtor in Sorrento&#x2019;s voluntary Chapter 11 filing. As of December 31, 2022, the Company had a $1.8 million receivable from Sorrento, which is considered collectible. The Company will evaluate the collectability of this receivable on a quarterly basis going forward.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section55">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Our Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net revenue consists solely of product sales of ZTlido in the United States. For product sales of ZTlido, we record gross-to-net sales adjustments for government and commercial rebates, chargebacks, wholesaler and distributor fees, sales returns, special marketing programs, and prompt payment discounts. We expect that any net revenue we generate will fluctuate from year to year as a result of the unpredictability of the demand for our product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Costs and Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of revenue consists of the cost of purchasing ZTlido from our manufacturing partners, inventory write-downs related to expiration dates for on-hand inventory, cost of shipments, and royalty payments to our manufacturers. We expect the cost of revenue to fluctuate with related sales revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">162</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are expensed when incurred and consist primarily of costs incurred for our research activities, including the development of our product candidates, and include:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to clinical trials;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">salaries, benefits and other related costs, including stock-based compensation expense for personnel engaged in research and development functions; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to outside consultants.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our research and development expenses to increase, as we will incur incremental expenses associated with our product candidates that are currently under development and in clinical trials. Product candidates in later stages of clinical development generally have higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, we expect to incur significant research and development expenses in connection with our Phase 3 clinical trial for SEMDEXA, our ongoing Phase 2 clinical trials for SP-103, and initiation of Phase 2 trials for SP-104.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Selling, General and Administrative</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative expenses consist primarily of costs related to our contract sales force, salaries and other related costs, including stock-based compensation, for personnel in our executive, marketing, finance, corporate and business development and administrative functions. Selling, general and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses from Sorrento for rent and maintenance of facilities and other operating costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our selling, general and administrative expenses will vary year over year in the future as we adapt our commercial strategies to changes in the business environment. We also expect to incur increased expenses as a result of the Business Combination and operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and listing standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services.  We also expect to adjust the size of our administrative, finance and legal functions to adapt to the changes above and the anticipated growth of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intangible Amortization Expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible amortization expense consists of the amortization expense of intangible assets recognized on a straight-line basis over the estimated useful lives of the assets. Our intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Gain) Loss on Derivative Liability</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on derivative liability consists of the changes to fair value of derivative liabilities between reporting periods relating to certain embedded derivative features within the Scilex Pharma Notes, and is recorded as other income or expense. See Note 7 titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and Note 12 titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Related Party Transactions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; to our consolidated financial statements appearing elsewhere in this annual report for a description of the Scilex Pharma Notes. Gain on derivative liability also included the remeasurement of the warrant derivative liability. See Note 4 titled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;Fair Value Measurements&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to our consolidated financial statements appearing elsewhere in the annual report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Gain) Loss on Debt Extinguishment, Net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on debt extinguishment, net consists of gains earned or losses incurred as a result of exercising our optional prepayment rights, which are treated as partial extinguishments, and the Early Paydown Provision, which is treated as a debt extinguishment, under the Scilex Pharma Notes, offset, for the year ended December 31, 2021, by a gain on debt extinguishment as a result of the forgiveness of the loan in the amount of $1.6 million received from Bank of America in May 2020 pursuant to the Paycheck Protection Program of the CARES Act (the &#x201c;PPP Loan&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense consists of interest related to the Scilex Pharma Notes and related party note payables to Sorrento.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Loss (gain) on Foreign Currency Exchange</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss (gain) on foreign currency exchange relates to foreign exchange losses on payments made to our foreign supplier, Itochu Chemical Frontier Corporation (&#x201c;Itochu&#x201d;), a manufacturer and supplier of lidocaine tape products, including ZTlido and SP-103.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section56">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize our results of operations for the years ended December 31, 2022 and 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.599%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.049%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.123%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except for per share amounts)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations Data:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,034</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,317</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating costs and expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,797</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,634</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,054</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,201</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,895</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,582</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible amortization</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,922</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,738</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating costs and expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,668</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,155</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(50,634</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(35,838</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other (income) expense:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(8,310</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on debt extinguishment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(28,634</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,463</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Pharma Notes principal increase</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,604</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,764</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Loss) gain on foreign currency exchange</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other (income) expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(27,274</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,581</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(23,360</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(88,419</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense (benefit)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(23,364</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(88,424</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share &#x2013; basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(0.17</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(0.67</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average number of shares during the period&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,226</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,858</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For financial information and discussions pertaining to the year ended December 31, 2020, refer to the registration statement on Form S-1 (File No. 333-269205) which was declared effective by the SEC on January 20, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section57">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comparison of Years Ending December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net revenue for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $38.0 million and $31.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The increase of $6.7 million was driven by the increased volume of gross product sales of ZTlido by approximately 50% offset by increase in rebates.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of revenue for the years ended December 31, 2022 and 2021 was $10.8 million and $3.6 million, respectively, and relates to product sales. The increase of $7.2 million was primarily due to an approximately 50% increase in gross revenue for the years ended December 31, 2022 compared to the year ended December 31, 2021, royalty expense of $4.5 million beginning in the second quarter of 2022, and the sale of $0.5 million of fully reserved inventory in May 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes research and development expenses by project for the years ended December 31, 2022 and 2021 (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:57.108%;"></td>
    <td style="width:1.385%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.819%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.385%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.819%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.385%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.096%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase <br />(Decrease)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-102</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contracted R&amp;D</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,488</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,952</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,464</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">555</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(305</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total SP-102</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,820</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,507</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,687</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-103</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contracted R&amp;D</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,739</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,816</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,923</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">596</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">878</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(282</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,147</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,147</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total SP-103</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,482</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,694</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,788</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SP-104</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contracted R&amp;D</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">388</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">388</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total SP-104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">551</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">388</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GLOPERBA</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contracted R&amp;D</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total GLOPERBA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">201</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">201</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Research and Development Expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,054</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,201</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(310</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses for the years ended December 31, 2022 and 2021 were $9.1 million and $9.2 million, respectively. The $0.1 million decrease was primarily attributed to the phasing out of the Phase 3 SP-102 trial in 2022, and was partially offset by the clinical trial costs of Phase 2 SP-103 in 2022, the Phase 1 SP-104 study in the first two quarters of 2022, and the development costs for GLOPERBA in the last quarter of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Selling, General and Administrative Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative expenses for the years ended December 31, 2022 and 2021 were $64.9 million and $50.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million, respectively. The increase of approximately $14.3 million was primarily due to a $7.5 million increase in legal expenses related to the ZTlido patent infringement in which the Company was the plaintiff, $1.1 million increase in travel and entertainment expenses, $3.1 million increase in consulting expenses, $2.1 million increase in insurance expense related to a directors and officers (D&amp;O) insurance policy incurred after the Business Combination, $0.6 million increase in personnel expense, and a $1.8 million increase related to a related party receivable reserve,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">166</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">offset by a $0.4 </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> decrease in contracted services, $1.2 million decrease in marketing expense, and a $0.3 million decrease in other expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intangible Amortization Expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible amortization expense for each of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $3.9 million and $3.7 million, respectively. The increase of $0.2 million is related to the amortization of acquired licenses for the exclusive license of GLOPERBA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Gain) Loss on Derivative Liability</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on derivative liability for the years ended December 31, 2022 and 2021 was $(8.3) million and $0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million, respectively. The gain and loss recognized during the years ended December 31, 2022 and 2021, respectively, was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to revised sales forecasts and the derivative warrant liability associated with the Private Warrants assumed in the Business Combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Gain) Loss on Debt Extinguishment, Net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on debt extinguishment, net for the years ended December 31, 2022 and 2021 was $(28.6) million and $12.5 million, respectively. The gain and loss incurred during the years ended December 31, 2022 and 2021, respectively, was attributed to Scilex Pharma&#x2019;s repurchase of the Scilex Pharma Notes of $20.0 million and $41.4 million in February 2022 and June 2022, respectively, as well as the Early Paydown Provision of $39.7 million in September 2022 (see Note 7 titled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;Debt&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to our consolidated financial statements included elsewhere in this annual report for additional information) and $20.0 million in each of February 2021 and April 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense for the years ended December 31, 2022 and 2021 was $9.6 million and $11.8 million, respectively. The decrease recognized during the years ended December 31, 2022 and 2021, respectively, was attributed to the payment of Scilex Pharma Notes in September 2022 and the conversion of related party notes payable with Sorrento that was outstanding as of the closing of the Business Combination into shares of Preferred Stock and Common Stock pursuant to the Debt Exchange Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Tax Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense for the years ended December 31, 2022 and 2021 was $4 thousand and $5 thousand, respectively. The lower income tax expense during the year ended December 31, 2022 was primarily due to an increase in share-based compensation tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section59"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had cash and cash equivalents of approximately $2.2 million. In connection with the completion of the Business Combination, we received approximately $3.4 million from the balance of the Vickers's Trust Account (the &#x201c;Trust Account&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have funded our operations primarily through the issuance of the Scilex Pharma Notes, related party notes with Sorrento, and the 2020 revolving credit facility. We also have deferred consideration related to the GLOPERBA license acquired in 2022. The following table summarizes the aggregate indebtedness of these issuances as of December 31, 2022 and December 31, 2021 (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.229%;"></td>
    <td style="width:1.602%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.290000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.589%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.290000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Pharma Notes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101,172</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Notes with Sorrento</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,111</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Revolving Credit Facility</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,815</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred Consideration with Romeg</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,650</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total indebtedness</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,650</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153,098</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scilex Pharma Notes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective February 14, 2022, Scilex Pharma issued to Sorrento a draw notice under the irrevocable standby letter of credit, issued by Sorrento to Scilex Pharma (the &#x201c;Letter of Credit&#x201d;), as required under the terms of the Indenture (as defined below) as a result of actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes (as defined below) through December 31, 2021 being less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $35.0 million in a single lump-sum amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $10.0 million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $20.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 2, 2022, Sorrento and the Company entered into a Consent Under and Amendment No. 4 with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the &#x201c;Trustee&#x201d;) and collateral agent (the &#x201c;Agent&#x201d;), and the beneficial owners of those certain senior secured notes due 2026 issued by Scilex Pharma in September 2018 (the &#x201c;Scilex Pharma Notes&#x201d;) listed on the signature pages thereto (the &#x201c;Holders&#x201d;), which amended that certain Indenture, dated September 7, 2018, by and among Scilex Pharma, Sorrento, the Trustee and the Agent, as amended (the &#x201c;Indenture&#x201d;).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the amendment to the Indenture (1) on June 3, 2022, Scilex Pharma repurchased $41.4 million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2) the Holders agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September 30, 2022 for $41.4 million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Holders will forgive and discharge $28.0 million of the aggregate principal amount of the Scilex Pharma Notes, (3) the minimum cash requirement under the Indenture was reduced to $5.0 million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4) the maximum aggregate principal amount of that certain intercompany promissory note issued by Scilex Pharma to Sorrento on October 5, 2018 was increased from up to $25.0 million to up to $50.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $1.7 million. On September 28, 2022, Scilex Pharma repurchased all of the outstanding aggregate principal amount of the Scilex Pharma Notes. As of immediately prior to the repurchase, the aggregate principal amount of the Scilex Pharma Notes was approximately $67.7 million, and Scilex Pharma repurchased the Scilex Pharma Notes for an aggregate cash payment of $39.7 million as the holders of the Scilex Pharma Notes forgave and discharged an aggregate of $28.0 million of principal amount of the Scilex Pharma Notes in connection with the repurchase. See Note 7 titled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;Debt&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to our consolidated financial statements elsewhere in this annual report for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quarterly principal payments, based on a percentage of projected net sales of ZTlido, optional and contingently accelerated repurchases, and the Early Paydown Provision under the Scilex Pharma Notes since January 1, 2021 are as follows (in thousands):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:79.118%;"></td>
    <td style="width:1.913%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:16.97%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Payments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2021*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,267</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2021*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,174</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,748</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,686</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,585</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2022*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,970</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30, 2022*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,444</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total payments since January 1, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151,874</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*Includes repurchase or Early Paydown Provision during the period (see Note 7 titled &#x201c;Debt&#x201d; to our consolidated financial statements elsewhere in this annual report).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Consideration</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have $3.7 million of deferred consideration related to minimum royalty payments that were included in the initial measurement of consideration transferred for the GLOPERBA license (see Note 3 titled &#x201c;Acquisitions&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to our consolidated financial statements included elsewhere in this annual report for additional information). Deferred consideration minimum royalty payments begin the first full quarter following June 14, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other contractual obligations include the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZTlido Royalties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Pharma is a party to the Product Development Agreement with the Developers, pursuant to which the Developers will manufacture and supply lidocaine tape products, including the Products, for Scilex Pharma.  Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. During the year ended December 31, 2022, Scilex Pharma made royalty payments in the amount of $2.3 million. As of December 31, 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.2 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that Scilex Pharma is in a net profit position, as defined in the Product Development Agreement, Scilex Pharma will first attempt to make aggregate royalty payments with cash generated from its operations. If these sources are insufficient, Scilex Pharma may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have $280.0 million, $13.0 million, and $23.0 million in aggregate contingent consideration obligations in connection with the SEMDEXA, GLOPERBA, and SP-104 acquisitions (see Note 3 titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisitions&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to our consolidated financial statements included elsewhere in this annual report for additional information), respectively, that are contingent upon achieving certain specified milestones or the occurrence of certain events. Contingent consideration obligations are comprised of regulatory milestones and additional payments that will be due upon the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">achievement of certain amounts of net sales (see Note 3 titled &#x201c;Acquisitions&#x201d; to our consolidated financial statements included elsewhere in this annual report for additional information).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Standby Equity Purchase Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 8, 2023, we entered into the A&amp;R Yorkville Purchase Agreement with Yorkville, whereby we have the right, but not the obligation, to sell to Yorkville up to $500.0 million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto has been declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the Original Purchase Agreement was declared effective by the SEC on December 9, 2022 and we are now able to offer and sell shares of our Common Stock under that agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 8, 2023, we entered into the B. Riley Purchase Agreement with B. Riley, whereby we have the right, but not the obligation, to sell to B. Riley up to $500.0 million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto has been declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the B. Riley Purchase Agreement was declared effective by the SEC on January 20, 2023 and we are now able to offer and sell shares of our Common Stock under that agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future Liquidity Needs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect.  The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the degree of success we experience in commercializing ZTlido and GLOPERBA;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the revenue generated by sales of ZTlido, GLOPERBA, and other products that may be approved, if any;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, SP-103, and SP-104;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of manufacturing ZTlido, GLOPERBA and our product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which ZTlido, GLOPERBA, or any of our product candidates, if approved for commercialization, is adopted by the physician community;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our need to expand our research and development activities;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">170</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of competing products and product candidates and other market developments;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and types of future products we develop and commercialize;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any product liability or other lawsuits related to our products;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expenses needed to attract, hire and retain skilled personnel;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our need to implement additional internal systems and infrastructure, including financial and reporting systems;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent and scope of our general and administrative expenses.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should our sales of ZTlido, GLOPERBA and other product candidates not materialize at the anticipated rate contemplated in our business plan, we will need to raise additional capital in order to continue to fund our research and development, including our plans for clinical and preclinical trials and new product development, as well as to fund operations generally. We will seek to raise additional funds through various potential sources, such as equity and debt financings and license agreements. As discussed above, following the completion of the Business Combination, we entered into the A&amp;R Yorkville Purchase Agreement and the B. Riley Purchase Agreement. The registration statement filed with the SEC in connection with the Original Purchase Agreement and the B. Riley Purchase Agreement were declared effective by the SEC on December 9, 2022 and January 20, 2023, respectively,  and we are now able to offer and sell shares of our Common Stock under both agreements, which will provide us with an additional source of liquidity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the liquidity provided by revenue generating products, Yorkville Advances under the A&amp;R Yorkville Purchase Agreement and B. Riley Advances and B. Riley Additional Advances under the B. Riley Purchase Agreement, we will receive up to an aggregate of approximately $126.5 million from the exercise of the Warrants (at an exercise price of $11.50 per share of Common Stock), assuming the exercise in full of all of the Warrants for cash, but will not receive any proceeds from the sale of the shares of our Common Stock issuable upon such exercise. However, our ability to generate proceeds will depend on the market price of our Common Stock. If the price of our Common Stock falls and remains below $11.50 per share, we believe warrant holders will be unlikely to cash exercise their Warrants, resulting in little or no cash proceeds to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The securities held by Sorrento and the Sponsors that were previously registered for resale on a registration statement on Form S-1 (File No. 333-268603) filed with the SEC on November 30, 2022, which was declared effective by the SEC on December 27, 2022 represent a substantial percentage of our outstanding Common Stock. After the restrictions on resale end, the Sponsors and Sorrento will be able to sell all of the shares of our Common Stock and any Warrants registered for resale thereunder for so long as such registration statement is available for use. The sale, or indication of an intention to sell, substantial amounts of our Common Stock or Warrants could result in a significant decline in the public trading price of our securities and impair our ability to raise capital through the sale of additional equity securities. Even if the current trading price of our Common Stock is at or significantly below the price at which the units were issued in Vickers&#x2019;s IPO, the Sponsors and Sorrento may have an incentive to sell because they will still profit on sales due to the lower price at which they purchased their shares compared to the public stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We can give no assurances that we will be able to secure additional sources of funds to support our operations on acceptable terms, or at all, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. These conditions, among others, raise substantial doubt about our ability to continue as a going concern. If</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">171</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we raise additional funds by issuing equity or convertible debt securities, including pursuant to the A&amp;R Yorkville Purchase Agreement and the B. Riley Purchase Agreement, it could result in dilution to our existing stockholders or increased fixed payment obligations. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur additional indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but we may have to relinquish valuable rights to ZTlido, GLOPERBA, or our product candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and results of operations. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also need to take certain other actions to allow us to maintain our projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for SP-102, SP-103, and SP-104 and other discretionary costs. Although we believe such plans, if executed and coupled with the above described sources of liquidity, should provide us with financing to meet our needs, successful completion of such plans is dependent on factors outside of our control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that we will continue to incur net losses into the foreseeable future as we support our clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our corporate infrastructure. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. See Note 2 titled &#x201c;Liquidity and Going Concern&#x201d; to our consolidated financial statements included elsewhere in this annual report for additional information. Net proceeds from the Trust Account in connection with the Business Combination, together with our existing cash and cash equivalents and proceeds from any Yorkville Advances made under the A&amp;R Yorkville Purchase Agreement or any B. Riley Advances or B. Riley Additional Advances made under the B. Riley Purchase Agreement, may be insufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. If these sources are insufficient to satisfy our liquidity requirements, we may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our cash flows for each of the periods presented:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.596%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.051%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.125%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash Flow Data:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used for operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(21,258</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(28,664</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used for investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,067</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used for) financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,171</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,163</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,154</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(501</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For financial information and discussions pertaining to the year ended December 31, 2020, refer to the registration statement on Form S-1 (File No. 333-269205) which was declared effective by the SEC on January 20, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">172</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Operating Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022, net cash used for operating activities was approximately $21.3 million, primarily from our net loss of $23.4 million, other non-cash reconciling items of $43.6 million related to depreciation and amortization, stock-based compensation, non-cash operating lease cost, non-cash interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net gain on debt extinguishment, and a gain on derivative liabilities and offset by changes in operating assets and liabilities that provided $45.7 million of cash.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021, net cash used for operating activities was approximately $28.7 million, primarily from our net loss of $88.4 million offset by other non-cash reconciling items of $46.1 million related to depreciation and amortization, principal increase to the Scilex Pharma Notes, stock-based compensation, non-cash operating lease cost, non-cash interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net loss on debt extinguishment, and a loss on derivative liabilities, and by changes in operating assets and liabilities that provided $13.6 million of cash.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Investing Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, net cash used for investing activities was approximately $2.1 million attributed to cash paid for the acquisition of GLOPERBA licenses from Romeg and $7.0 thousand attributed to cash paid for property and equipment purchases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2021, no cash was used for investing activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Financing Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, net cash provided by financing activities was approximately</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $21.2 million</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and is primarily related to $51.9 million in proceeds from related party payables, $62.5 million in proceeds from related party note payables, $9.9 million  in proceeds from the CNH Revolving loan, $96.0 thousand in proceeds from the exercise of stock options, and $3.4 million in proceeds from the Business Combination, offset by $18.8 million repayment on CNH Revolving Loan, $84.8 million repayment of the Scilex Pharma Notes, and $2.9 million on transaction costs payment related to the Business Combination.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2021, net cash provided by financing activities was approximately</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $28.2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million and was primarily related to $47.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million in proceeds from related party payables, $47.8 million in proceeds from the CNH Revolving Loan, $14.7 million in proceeds from related party note payable with Sorrento, and offset by $48.8 million repayment of the CNH Revolving Loan and $33.4 million repayment of the Scilex Pharma Notes.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section60">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Estimates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This management&#x2019;s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements which are prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the reporting period. We continually evaluate our estimates and judgments and base them on historical experience and other factors that we believe to be reasonable under the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">173</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">circumstances. Materially different results can occur as circumstances change and additional information becomes known.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the following accounting policies and estimates are most critical to aid in understanding and evaluating our reported financial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our revenue to date has been generated from product sales of ZTlido. We do not have significant costs associated with obtaining contracts with our customers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize revenue when control of the products is transferred to the customers in an amount that reflects the consideration we expect to receive from the customers in exchange for those products. In accordance with FASB ASC Topic 606 &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">this process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our performance obligations with respect to sales of ZTlido are satisfied at a certain point in time, and we consider control to have transferred upon delivery to the customer. We consider control to have transferred upon delivery to the customer because, upon delivery, the customer has legal title to the asset, physical possession of the asset has been transferred to the customer, the customer has significant risks and rewards in connection with ownership of the asset, and we have a present right to payment from the customer at that time.  Invoicing typically occurs upon shipment and the length of time between invoicing and the date on which payment is due is not significant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees, and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in our customer contracts, customary industry practices and current government regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rebates and Chargebacks</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rebates are discounts that we pay under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which we pay rebates and fees for access to and position on that provider&#x2019;s patient drug formulary.  Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated with commercial healthcare providers. Both types of rebates vary over time.  We record a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. We monitor the sales trends and adjust for these rebates on a regular basis to reflect the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">174</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are recorded as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheet.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prompt Payment Discounts</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We provide our customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Service Fees</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We compensate our customers and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received are not distinct from our sale of products to the customers, and therefore, these payments have been recorded as a reduction of revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Returns</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are obligated to accept the return of products sold that are damaged or do not meet certain specifications. We currently estimate our product returns using historical trends and product return rates typically experienced in the industry and record this estimate as a reduction of revenue in the period the related product revenue is recognized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Co-payment Assistance</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive co- payment assistance. We accrue for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative Liability</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities are recorded on our consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities included embedded derivatives that were identified and required bifurcation from the Scilex Pharma Notes and separate accounting as a single compound derivative. Certain of these embedded features include default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Scilex Pharma Notes were fully extinguished in September 2022 and, as such, there were no remaining derivative liabilities associated with the Scilex Pharma Notes as of December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At closing of the Business Combination, the Company assumed a derivative warrant liability of $2.5 million related to Private Warrants (See Note 8 titled &#x201c;Stockholder's Equity&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to our consolidated financial statements included elsewhere in this annual report for additional information). </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The warrant liability associated with the Private Warrants was valued using the Black-Scholes option pricing model, which is considered to be Level 3 fair value meas</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">urement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for stock-based compensation in accordance with FASB ASC Topic 718 &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation &#x2013; Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line-method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or non-employee&#x2019;s vesting period. We account for forfeitures as incurred.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. We use these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legacy Scilex Common Stock Valuation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the closing of the Business Combination, the estimated fair value of the Legacy Scilex Common Stock was determined by the board of directors of Legacy Scilex (the &#x201c;Legacy Scilex Board&#x201d;), considering our most recently available third-party valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#x2019;s assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the stock option grant. Prior to the Business Combination, given the absence of a public trading market for the Legacy Scilex Common Stock, the valuations of the Legacy Scilex Common Stock were determined in accordance with the &#x201c;American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation.&#x201d; The Legacy Scilex Board exercised its reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of fair value of the Legacy Scilex Common Stock, including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Independent valuations of the Legacy Scilex Common Stock performed at periodic intervals by an independent third-party valuation firm;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The likelihood of achieving a liquidity event, such as an initial public offering or sale of the company and the potential value of a strategic merger or sale at different time points, given prevailing market conditions;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our historical operating and financial performance as well as our estimates of future financial performance, including the regulatory status of ZTlido and GLOPERBA and the timing and probability of continuing growth since commercialization of ZTlido and GLOPERBA under different operational scenarios;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The status of research and development efforts;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stage of development and commercialization and our business strategy;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Industry information such as market trends and macro-economic events;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuations of comparable companies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">176</span></p>
  <hr style="page-break-after:always;" />
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to recognize a relative lack of marketability of the Legacy Scilex Common Stock; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional objective and subjective factors relating to our business.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The dates of our valuations did not always coincide with the dates of our stock option grants. In determining the exercise prices of the stock options at each grant date, the Legacy Scilex Board considered, among other things, the most recent valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#x2019;s assessment of additional objective and subjective factors we believed were relevant as of the grant date. The additional factors considered when determining any changes in fair value between the most recent valuation and the grant dates included our operating and financial performance and current business conditions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions underlying the valuations represented management&#x2019;s best estimate, which involved inherent uncertainties and the application of management&#x2019;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of the Legacy Scilex Common Stock and Legacy Scilex&#x2019;s stock-based compensation expense could have been materially different.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since a public trading market for our Common Stock has been established in connection with the closing of the Business Combination, it is no longer necessary for our Board to estimate the fair value of our Common Stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our Common Stock will be determined based on the quoted market price of our Common Stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section62">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 1 titled &#x201c;Nature of Operations and Basis of Presentation&#x201d; of the notes to our consolidated financial statements included elsewhere in this annual report for a discussion of recent accounting pronouncements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section63">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Off-Balance Sheet Arrangements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section64">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a description of our related party transactions, see Note 12 titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Related Party Transactions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; to our consolidated financial statements included elsewhere in this annual report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section65">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An &#x201c;emerging growth company&#x201d; as defined in the JOBS Act is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in New Scilex&#x2019;s business could significantly affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an emerging growth company we may take advantage of certain exemptions from various reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but are not limited to:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an exemption from compliance with the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex qualifies and will remain as an emerging growth company until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the closing of the IPO, (b) in which New Scilex has total annual gross revenue of at least $1.235 billion, or (c) in which New Scilex is deemed to be a large accelerated filer, which means the market value of the common equity of New Scilex that is held by non-affiliates equals or exceeds $700 million as of the last business day of its most recently completed second fiscal quarter; and (ii) the date on which New Scilex has issued more than $1.00 billion in non-convertible debt securities during the prior three-year period. References herein to &#x201c;emerging growth company&#x201d; have the meaning associated with it in the JOBS Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">178</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section67"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualita</span><span id="quantitative_and_qualitative"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tive Disclosures About Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section68">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our exposure to market risk is confined to our cash and cash equivalents. We have cash and cash equivalents and invest primarily in high-quality money market funds, which we believe are subject to limited credit risk. Due to the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section69">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to April 2, 2022, sales to our sole customer and third-party logistics distribution provider, Cardinal Health, represented 100% of our net revenue. On April 2, 2022, we announced the expansion of our direct distribution network to national and regional wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us. Additionally, during the year ended December 31, 2022, we purchased inventory from our sole supplier, Itochu. This exposes us to concentration of customer and supplier risk. We monitor the financial condition of our customers, limit our credit exposure by setting credit limits, and have not experienced any credit losses for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section70"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial State</span><span id="financial_statements_and_supplementary"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ments and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our consolidated financial statements and supplementary data required by this item are set forth at the pages indicated in Item 15(a)(1) and (a)(2), respectively, of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section71">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements With </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section72">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s regulations, rules and forms and that such information is accumulated and communicated to our management, including our principal officers, as appropriate, to allow for timely decisions regarding required disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As required by Rule 13a-15(b) promulgated by the SEC under the Exchange Act,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">179</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on the foregoing, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this Annual Report on Form 10-K as a result of the material weakness described below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Management Assessment Regarding Internal Control Over Financial Reporting or Attestation Report of Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K does not include a report of management&#x2019;s assessment regarding internal control over financial reporting (&#x201c;ICFR&#x201d;) as allowed by the SEC for reverse acquisitions between an issuer and a private operating company when it is not possible to conduct an assessment of the private operating company&#x2019;s ICFR in the period between the consummation date of the reverse acquisition and the date of management&#x2019;s assessment of ICFR (see Section 215.02 of the SEC Division of Corporation Finance&#x2019;s Regulation S-K Compliance &amp; Disclosure Interpretations). We completed the Business Combination on November 10, 2022, pursuant to which we acquired Legacy Scilex and its subsidiaries. Prior to the Business Combination, we were a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination involving one or more businesses. As a result, previously existing internal controls are no longer applicable or comprehensive enough as of the assessment date as our operations prior to the Business Combination were insignificant compared to those of the consolidated entity post-Business Combination. The design of ICFR for the Company post-Business Combination has required and will continue to require significant time and resources from management and other personnel. As a result, management was unable, without incurring unreasonable effort or expense, to conduct an assessment of our ICFR as of December 31, 2022. The Company intends to conduct a management assessment regarding ICFR as of December 31, 2023. This Annual Report also does not contain an attestation report of our registered public accounting firm regarding ICFR since the Company, as an &#x201c;emerging growth company,&#x201d; is not required to provide such report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate ICFR as defined in Rules 13a-15(f) under the Exchange Act. Our ICFR is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Because of its inherent limitations, ICFR may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite not conducting a formal assessment regarding ICFR, management concluded that we did not employ sufficient accounting resources with appropriate experience and technical expertise to effectively execute controls over certain judgmental and technical accounting areas. As a result, we identified that certain of our control activities in the areas of revenue, debt, business combination and derivative liabilities did not operate effectively and therefore, were deficient and the combination of the aforementioned deficiencies were deemed to represent a material weakness in our internal control over financial reporting as of December 31, 2022. While we have taken actions to remediate this material weakness, including (i) recruiting and employing personnel with appropriate experience and technical expertise to enhance management&#x2019;s assessment of judgmental and technical accounting areas, (ii) conducting additional training for staff involved in judgmental and technical accounting areas, and (iii) engaging additional independent third-party technical consultants to assist in performing accounting analyses of complex transactions, completion of our remediation efforts is ongoing. As such management has concluded the aforementioned material weakness has not been remediated as of December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">180</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a company with limited accounting resources, a significant amount of management&#x2019;s time and attention has been and will be diverted from our business to ensure compliance with these regulatory requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other than in connection with the closing of the Business Combination, there were no changes in our internal control over financial reporting (as defined by Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section78"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other Inf</span><span id="other_information"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ormation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section79"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosure Regarding F</span><span id="disclosure_regarding_foreign"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">oreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section80"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span id="part_iii"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section81">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fficers and Corporate Governance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference from the information contained in the 2023 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2023 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 10.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section94">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executive</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference from the information contained in the 2023 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2023 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 11.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section106"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of C</span><span id="security_ownership_of_certain"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ertain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference from the information contained in the 2023 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2023 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 12.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section110"><span id="section107">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section125"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Rel</span><span id="certain_relationships_and_related"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ated Transactions, and Director Independence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference from the information contained in the 2023 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2023 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 13.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section129"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accounting</span><span id="principal_accounting_fees"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Fees and Services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference from the information contained in the 2023 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2023 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 14.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">182</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section133"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART </span><span id="part_iv"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="item15"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, F</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inancial Statement Schedules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)(1) Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference is made to the Index to Consolidated Financial Statements of Scilex Holding Company appearing on page F-1 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)(2) All other schedules not listed above have been omitted because of the absence of conditions under which they are required, or because the required information is included in the consolidated financial statements or the notes thereto.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)(3) Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:13.002%;"></td>
    <td style="width:86.998%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;2.1#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement and Plan of Merger, dated as of March  18, 2019, by and among Scilex Holding Company, Sigma Merger Sub, Inc., Semnur Pharmaceuticals, Inc., Fortis Advisors LLC, solely as the representative of the Equityholders and, solely with respect to Section 1.8(a), Section  3.11 and Article X, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No.  333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;2.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to Agreement and Plan of Merger, dated as of August  7, 2019, by and among Semnur Pharmaceuticals, Inc., Scilex Holding Company, Sigma Merger Sub, Inc., Fortis Advisors, LLC, solely as the representative of the Equityholders and, solely with respect to Section  1.8(a), 3.11 and Article X of the Agreement and Plan of Merger, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.2 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on October June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;2.3#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bill of Sale and Assignment and Assumption Agreement, dated May  12, 2022, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.3 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;2.4&#94;#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Purchase Agreement, dated April  23, 2021, between Sorrento Therapeutics, Inc. and Aardvark Therapeutics, Inc., as assumed by Scilex Holding Company on May  12, 2022, pursuant to the Bill of Sale and Assignment and Assumption Agreement, dated as of such date, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.4 of Amendment No.  1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;2.5#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex2-1_vickers1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement and Plan of Merger, dated as of March 17, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#x2019;s Current Report on Form 8-K (File No. 001-39852), filed with the SEC on March 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;2.6#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex2-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to Agreement and Plan of Merger, dated as of September  12, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#x2019;s Current Report on Form 8-K (File No. 001-39852), filed with the SEC on September 14, 2022).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restated Certificate of Incorporation of Scilex Holding Company (incorporated by reference to Exhibit 3.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">183</span></p>
  <hr style="page-break-after:always;" />
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:13.002%;"></td>
    <td style="width:86.998%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificate of Designations of Scilex Holding Company (incorporated by reference to Exhibit 3.2 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;3.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex33.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bylaws of Scilex Holding Company (incorporated by reference to Exhibit 3.3 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000121390021001411/ea133037ex4-1_vickers1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant Agreement, dated as of January 6, 2021, by and between Vickers Vantage Corp. I and Continental Stock Transfer  &amp; Trust Company (incorporated by reference to Exhibit 4.1 of Vickers&#x2019;s Current Report on Form 8-K (File No. 001-39852), filed with the SEC on January  11, 2021).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.2+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sclx-ex4_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Securities of Scilex Holding Company.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Registration Rights Agreement, dated as of November  10, 2022, by and among Scilex Holding Company, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Sorrento Therapeutics, Inc. and certain security holders set forth on the signature pages thereto (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement of Scilex Holding Company (incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.3*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d7.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.4*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d8.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Option Agreement and Stock Option Grant Notice under the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.5*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d9.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.9 of Amendment No.  1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.6*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d10.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Option Agreement and Stock Option Grant Notice under the Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.10 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.7*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.8*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.9*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.10*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Holding Company 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex10-1_vickers1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sponsor Support Agreement, dated as of March 17, 2022, by and among Vickers Vantage Corp. I and certain stockholders (incorporated by reference to Exhibit 10.1 of Vickers&#x2019;s Current Report on Form 8-K (File No.  001-39852), filed with the SEC on March 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex10-2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to Sponsor Support Agreement, dated as of September  12, 2022, by and among Vickers Vantage Corp. I and certain stockholders (incorporated by reference to Exhibit  10.2 of</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184</span></p>
  <hr style="page-break-after:always;" />
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:13.002%;"></td>
    <td style="width:86.998%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex10-2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vickers&#x2019;s Current Report on Form 8-K (File No. 001-39852), filed with the SEC on September 14, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex10-2_vickers1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company Stockholder Support Agreement, dated as of March  17, 2022, by and among Vickers Vantage Corp. I, Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 of Vickers&#x2019;s Current Report on Form 8-K (File No. 001-39852), filed with the SEC on March 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.14*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d17.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter, dated as of April  19, 2019, between Scilex Pharmaceuticals Inc. and Jaisim Shah (incorporated by reference to Exhibit 10.17 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No.  333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.15*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d21.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter, dated as of April  27, 2022, by and between Scilex Holding Company and Elizabeth Czerepak (incorporated by reference to Exhibit 10.21 of Amendment No. 1 of Vickers&#x2019;s Form  S-4 (File No. 333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.16&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-22.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial Supply Agreement, dated as of February  16, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.22 of Amendment No.  2 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.17&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-23.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Addendum to Commercial Supply Agreement, dated as of August  31, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.23 of Amendment No.  2 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.18&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-24.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Addendum to Commercial Supply Agreement, dated as of May  9, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.24 of Amendment No.  2 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-25.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Addendum to Commercial Supply Agreement, dated as of August  30, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.25 of Amendment No.  2 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.20#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d26.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exclusive Distribution Agreement, dated as of August  6, 2015, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.26 of Amendment No. 4 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on September 13, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d27.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment to Exclusive Distribution Agreement, dated as of May  24, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.27 of Amendment No. 4 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on September 13, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.22#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d28.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Exclusive Distribution Agreement, dated as of September  19, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.28 of Amendment No. 4 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on September 13, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.23</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d29.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Exclusive Distribution Agreement, dated as of October  1, 2021, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, LLC (f/k/a Cardinal Health 105, Inc.). (incorporated by reference to Exhibit 10.29 of Amendment No. 4 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on September 13, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.24&#94;#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-33.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supply Agreement, dated as of December  17, 2015, by and between Genzyme Corporation and Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.33 of Amendment No.  2 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></p>
  <hr style="page-break-after:always;" />
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:13.002%;"></td>
    <td style="width:86.998%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.25&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-34.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product Development Agreement, dated as of May  11, 2011, by and between Scilex Pharmaceuticals, Inc. (as successor to Stason Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation. (incorporated by reference to Exhibit 10.34 of Amendment No.  2 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.26</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-35.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Product Development Agreement, dated as of April  2, 2013, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.35 of Amendment No.  2 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.27&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-36.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Product Development Agreement, dated as of February  20, 2017, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.36 of Amendment No. 2 of Vickers&#x2019;s Form  S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.28&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-37.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Product Development Agreement, dated as of August  29, 2018, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.37 of Amendment No. 2 of Vickers&#x2019;s Form  S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.29</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-38.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fourth Amendment to Product Development Agreement, dated as of December  13, 2019, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.38 of Amendment No. 2 of Vickers&#x2019;s Form  S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.30</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-39.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amendment to Product Development Agreement, dated as of April  30, 2021, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.39 of Amendment No. 2 of Vickers&#x2019;s Form  S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.31&#94;#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d40.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Master Services Agreement &#x2014; SP-102, dated as of January  27, 2017, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.40 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.32</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to Master Services Agreement, dated as of April  26, 2018, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.41 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.33</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Novation Agreement re Master Services Agreement, dated as of June  15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit 10.42 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.34#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d43.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Master Services Agreement, dated as of November  23, 2020, by and between Aardvark Therapeutics Inc. and Tulex Pharmaceuticals Inc. as assumed by Scilex Holding Company on May  12, 2022, as novated to Scilex Holding Company, pursuant to the Novation Agreement re Master Services Agreement, dated as of June  15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit 10.43 of Amendment No.  1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.35&#94;#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d44.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License and Commercialization Agreement, dated as of June  14, 2022, by and between Scilex Holding Company and RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC (incorporated by reference to Exhibit 10.44 of Amendment No. 1 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">186</span></p>
  <hr style="page-break-after:always;" />
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:13.002%;"></td>
    <td style="width:86.998%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.36&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d57.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assignment Agreement, dated August  6, 2013, between Semnur Pharmaceuticals, Inc. and Shah Investor LP (incorporated by reference to Exhibit 10.57 of Amendment No. 1 of Vickers&#x2019;s Form  S-4 (File No. 333-264941), filed with the SEC on June 27, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.37&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-59.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Office Lease, dated as of August 8, 2019, by and between Scilex Pharmaceuticals Inc. and 960 San  Antonio LLC (incorporated by reference to Exhibit 10.59 of Amendment No. 2 of Vickers&#x2019;s Form S-4 (File No.  333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.38&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-60.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Office Lease, dated as of September  15, 2019, by and between Scilex Pharmaceuticals Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.60 of Amendment No.  2 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.38&#94;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-61.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sublease Agreement, dated as of May  18, 2022, by and between Scilex Holding Company and Live Action, Inc. (incorporated by reference to Exhibit 10.61 of Amendment No. 2 of Vickers&#x2019;s Form  S-4 (File No. 333-264941), filed with the SEC on July 21, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.40</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d59.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholder Agreement, dated as of September  12, 2022, between Vickers Vantage Corp. I and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.59 of Amendment No.  4 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on September 13, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.41#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d60.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contribution and Satisfaction of Indebtedness Agreement, dated as of September  12, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Scilex Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.60 of Amendment No. 4 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on September 13, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.42</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-61.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter Agreement, dated October  17, 2022, between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.61 of Amendment No.  5 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on October 18, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.43#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-62.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant Transfer Agreement, dated October  17, 2022, by and among Sorrento Therapeutics, Inc., Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd and for the limited purposes set forth therein, Vickers Vantage Corp. I and Maxim Group LLC. (incorporated by reference to Exhibit 10.62 of Amendment No. 5 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on October 18, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.44#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-63.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt Contribution Agreement, dated October  17, 2022, by and among Vickers Vantage Corp. I, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (incorporated by reference to Exhibit 10.63 of Amendment No.  5 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on October 18, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.45</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-64.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter Agreement, dated October  17, 2022, by and among Sorrento Therapeutics, Inc., Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Vickers Vantage Corp. I and Maxim Group LLC. (incorporated by reference to Exhibit 10.64 of Amendment No.  5 of Vickers&#x2019;s Form S-4 (File No. 333-264941), filed with the SEC on October 18, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.46</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287974/d401087dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Standby Equity Purchase Agreement, dated as of November  17, 2022, by and between Scilex Holding Company and YA II PN, LTD. (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.  001-39852), filed with the SEC on November 18, 2022) .</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.47</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312523004041/d371589dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Standby Equity Purchase Agreement, dated as of January  8, 2023, by and between Scilex Holding Company and B. Riley Principal Capital II, LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No.  001-39852), filed with the SEC on January 9, 2023).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.48</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312523030002/d802493dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Standby Equity Purchase Agreement, dated as of February 8, 2023, by and between Scilex Holding Company and YA II PN, LTD. (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on February 9, 2023).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.49*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on January 17, 2023).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">187</span></p>
  <hr style="page-break-after:always;" />
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:13.002%;"></td>
    <td style="width:86.998%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	 &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.50*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhbit 10.2 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on January 17, 2023).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.51*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Unit Award Grant Notice and Award Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.3 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on January 17, 2023).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of our Current Report on Form 8-K (File No. 001-39852), filed with the SEC on November 17, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;23.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sclx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm of Scilex Holding Company.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#powerofatty"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (included on the signature page hereto)</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;31.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sclx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Jaisim Shah, Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;31.2+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sclx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Elizabeth Czerepak, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;32.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sclx-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Jaisim Shah, Principal Executive Officer, and Elizabeth Czerepak, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document.</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document.</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Indicates management contract or compensatory plan or arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ Filed herewith.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#94; Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) information that the Registrant treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"># Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item16"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K Summary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">188</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:middle;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Holding Company</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jaisim Shah</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jaisim Shah</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and President</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="powerofatty"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> OF ATTORNEY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, jointly and severally, each of Jaisim Shah and Elizabeth Czerepak, acting alone or together with another attorney-in-fact, as his or her attorney-in-fact, with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or his or her substitute, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.592%;"></td>
    <td style="width:1.135%;"></td>
    <td style="width:42.82%;"></td>
    <td style="width:2.034%;"></td>
    <td style="width:23.418%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jaisim Shah</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer, President and Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:top;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jaisim Shah</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Elizabeth A. Czerepak</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Vice President, Chief Financial Officer and Chief Business Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principal Financial Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Elizabeth A. Czerepak</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Henry Ji, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Chairperson and Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Henry Ji, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Dorman Followwill</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dorman Followwill</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Laura J. Hamill</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laura J. Hamill</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Tien-Li Lee, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tien-Li Lee, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David Lemus</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David Lemus</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Tommy Thompson</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.037in;vertical-align:bottom;padding-right:0.037in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tommy Thompson</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">189</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section139"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:91.004%;"></td>
    <td style="width:8.996%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_41b118ab-eeb6-4c7c-872d-d6cb4874012b" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets as of  December 31, 2022 and  2021</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations for the Years ended December 31, 2022, 2021, and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#stockholders_deficit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Stockholders&#x2019; Equity / (Deficit) for the Years ended December 31, 2022, 2021, and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years ended December 31, 2022, 2021, and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_unaudited"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section140"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of </span><span id="report_of_independent"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the stockholders and the Board of Directors of</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Holding Company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, stockholders' equity/(deficit) and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's Ability to Continue as a Going Concern</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has negative working capital, has suffered losses from operations, has recurring negative cash flows from operations, and has stated that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#x2019;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_564ba3ed-e6ec-448c-8760-eb779f77c1ab" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f685c75b-70fd-4b0c-8016-584f3ebec208" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Diego, California</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section141"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCILEX HOLDING COMPANY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED BALANC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">E SHEETS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS OF DECEMBER 31, 2022 AND 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except for par value and share amounts)</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.229%;"></td>
    <td style="width:1.602%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.290000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.589%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.290000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd977d72-c5ca-4510-a073-e1aca7661350" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f48e538-9699-4e3a-80f6-7a657fadb4e3" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_944ce2fc-bfa8-4a85-941d-99f6eeaaa145" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,236</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa503851-e1e4-42ac-bbcb-1164fcc1a9b1" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9592fb08-2127-4351-accb-b8b74682bb94" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,378</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b6eb4a6-f732-4b4c-aaf8-cc646244d8a8" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,562</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb90574e-81a2-4bce-ad2c-8797b8404624" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,810</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e4fcd4d-25c2-49e8-af17-21a6534e1250" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,835</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52e4aa5f-0cc1-464c-8a7a-3e6cdd518e0d" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,608</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69f5404a-9b6b-442b-b84b-f857c971375a" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,003</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b34ef29-4d75-4648-abbb-8be11ba6ea78" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">772</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8d1ac34-1501-4689-8484-83b665c8d12b" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">805</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_489fb0b9-0d0e-4e4d-b171-384b92a2b933" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,131</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f82bc666-602e-4221-a044-4a9b226485e5" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,303</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangibles, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_942d4f9c-2f6f-45ca-b0c4-149de63991f6" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,591</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fd49d2f-46fa-460a-b88b-138100939b3e" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,802</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f707d6e2-47d2-4a8e-832e-aac60fd856ea" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,481</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6b8de08-e503-4113-a256-9b62be38b77d" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,481</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ca17d8d-a7c4-421b-97e2-012c461ac1ee" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34d9036b-2a14-4421-a58a-3c72cb61302b" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">538</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_960b96eb-7504-49a9-8416-01f04dde52af" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,527</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8fa843e-6313-4b45-a36c-7dba82a2cb55" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,932</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY/(DEFICIT)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6ed55d5-bba2-47aa-9761-031fc5a46326" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,450</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4f70355-49ea-4690-a13f-944228337fbf" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,284</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued payroll</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f90baee-19ec-4a84-a0d1-5b7943a365f8" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,354</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c16f779-9933-4753-80c4-ce9cf17c93de" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued rebates and fees</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b549e711-b3f7-411d-8f90-716df1dbcbc0" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,893</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_092a3816-aab2-485f-9441-d8c16d8ab7ff" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,362</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_416c2030-59a3-43df-bb83-46cbde7edd7f" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="sclx:AccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,136</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8e934db-b0c5-4eb6-bffa-1b7ca5204f54" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="sclx:AccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of deferred consideration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a7b3168-71c9-4ae8-844b-73b2f7e1ea92" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="sclx:CurrentPortionOfDeferredConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">264</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33304c7d-6a61-403e-af1b-3457c5d24f7a" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="sclx:CurrentPortionOfDeferredConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of debt</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0246775-3337-4fad-906d-d5c10282a4ac" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:ShortTermBorrowings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0a8b43d-cfd2-41b2-b1a4-1c044e35f1fd" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:ShortTermBorrowings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,950</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related party payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_945f3617-ab97-48d5-9d80-5d089563c905" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="sclx:RelatedPartyPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eaed037a-1bba-4726-9a0f-85f8a782bac3" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="sclx:RelatedPartyPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,724</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related party note payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e50602e-1776-443a-9c83-cbd94eb78509" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ae398de-0479-4042-9a12-36e7adb3d024" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,608</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec61d1b7-adc6-491a-83e2-bfae8cbc08df" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">745</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acf02e1f-f765-4045-8058-d13c52cf864d" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0130324e-94c2-48a6-82aa-6bc0b045ae9c" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,842</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c50b9549-426a-493c-895f-8204419e45b4" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169,420</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of deferred consideration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cad9be4-db23-4e5c-bbe2-8ca1c2c5a6bc" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="sclx:LongTermPortionOfDeferredConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d7b0140-383d-416a-bc14-c3d4206d04f2" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="sclx:LongTermPortionOfDeferredConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term debt, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1004c63e-8828-47a2-86a9-10aa174a4497" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00b6ec92-36c5-4eac-b8b7-f3cc8e09c3f4" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related party note payable, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52e02b35-a289-4d3c-a9d8-236c767354ee" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8e8363b-84ac-442e-9d03-7f3f0be3152d" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0a7dfbd-1052-4371-8b2d-b57027c74a68" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c982953-be54-4e6f-a45c-9927384c2d1c" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8af56a58-0371-4e37-a6fd-77bd88da8aef" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b9094ef-2626-4622-8a75-60368653941a" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95865d95-99e3-431d-940f-7bb4fd5e691c" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5dc0759e-d02f-4ff3-bd5b-0d1d99028938" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39d3fa70-0955-4114-b191-ba5fde4be884" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0edbd4d5-d0ea-4aac-8549-2d7335c6caf6" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">301,808</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (See Note 10)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; equity/(deficit):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7736a45-43b2-4443-888c-b59dd08026b0" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal"><ix:nonFraction id="F_2164153d-3860-461b-a961-13ab002bc5a4" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_648bc0fa-c29a-4613-8e66-7a7175ccd380" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab98a179-57d0-4336-bc71-1093dc109cb7" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_d445e552-d371-417e-9136-062155233643" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,057,097</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2f3cb92-b265-48e3-9c17-5847532b737b" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_5e4e466c-8cb7-41c9-8263-c9b5171adcdd" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;issued and outstanding at December 31, 2022 and December 31, 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62f3d483-bb25-4d82-bfd7-b1e7967677e7" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ea66942-092f-4399-bdd3-cbed0741a953" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec743b83-ed54-405a-ab74-8b4f6d6604cf" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal"><ix:nonFraction id="F_866cc1d3-84e1-4c61-9abc-30a7d4f1c828" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ea7929d-4e7d-40c0-8713-0254582b836a" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">740,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7a2b3ea-f220-4af0-b2a6-ed95fb541fa7" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_97837da3-bca1-42e7-a9b0-a0b2de163db9" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">141,348,856</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5015b459-abce-4a82-bab5-7489f55bce6e" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_dd4104de-d0a4-47aa-9822-5050ae9beffd" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">132,858,484</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3c0accd-0e62-4546-af75-c98eb1b69f0e" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac26890c-871c-4f2f-b54e-240fabb1d0f9" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b0e0b30-5912-4424-99cf-2202eb2f76ed" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">412,136</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b18c7546-3414-4aa7-9900-33bfd81db78a" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,661</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3074711-2564-4b64-b503-04b0fea12797" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">375,914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c0319e6-b70a-4ab5-b757-65216a6c43de" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">352,550</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders&#x2019; equity/(deficit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88c18b19-a4c2-42f0-8cc1-8eb126bde65d" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,239</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e3431b8-d308-4838-bf8a-c7a68ea3a8b1" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">223,876</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity/(deficit)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62e977b2-229d-4993-aae5-5d864db0daa8" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,527</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95a3cce3-ab36-49b0-9a85-ec6412501b44" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,932</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to audited consolidated financial statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section142"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCILEX HOLDING COMPANY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OPERATIONS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOR THE YEARS ENDED DECEMBER 31, 2022, 2021, AND 2020</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except for net loss per share amounts)</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:56.996%;"></td>
    <td style="width:1.388%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.923%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.388%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.923%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.388%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.997%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2adb314-a93a-4a86-8da9-b42a53c7483e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,034</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d6f6a8f-32e5-46e5-a4c7-0fc96d14e5e6" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3816b7ac-8c68-4055-9cb3-32505a20cb1d" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,560</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating costs and expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e10a6d44-e9bb-4b2b-9c00-29764ae29b84" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c19657b2-b026-4837-b227-f047cc96b8cb" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,634</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_caa187bb-3a6e-4533-ae5f-49735bdcf0ce" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,149</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e00ec4a9-7d39-4f13-89b0-cc05187b3932" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abdf5d95-f881-4b67-b4e6-608d74d19cb3" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98f9503e-f9ea-4894-ad29-99a4718eda57" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,961</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6f1cdd1-175d-435e-af09-b32ed2234228" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,895</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4041e3f7-511c-4942-88ba-5d616197fb54" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a30b919f-baf6-48f6-834f-bdd95a2d8492" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3432708-14ad-40ac-adcb-b58ecce9fa91" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,922</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe2eebf1-1732-469d-ba9b-3818dd633590" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,738</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6680ef2-2840-4b96-a93a-bcf08b26433c" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,738</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating costs and expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a57551d5-62c4-47dd-a428-27bfd178bffa" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,668</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f49fff63-06a5-4df2-b598-3bd1da67e9fd" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18f435b8-9716-4344-838c-b1db288b9786" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,818</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_717c0511-c113-4aeb-8f01-104e1f01b1bc" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,634</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9944d982-e3b7-4805-aa5e-d98591064fdf" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,838</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e5f831d-4848-45ff-b66a-84d65d1a7d91" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other (income) expense:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on derivative liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e702b4cf-a9c8-48e8-8abd-049328dfd68f" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,310</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8aa52d6-7939-45a8-b73f-f9f13212e846" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_394c96cb-adaa-42a5-9d27-6bedecce029c" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on debt extinguishment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cca10bf6-ac23-4a00-99ce-36b4b4efdbbf" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,634</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce971922-88ab-4f53-be47-71bca290fb14" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,463</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef405865-68da-49a3-b5f7-81e7e57fcba9" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Pharma Notes principal increase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48262941-f162-4536-a36b-c285fb5d73d8" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:NotesPrincipalIncrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a42ed0c-fe2f-4bb9-ae8e-c7b322b9cc9b" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:NotesPrincipalIncrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6d06419-7212-4f58-bd9b-333a7cc114e1" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:NotesPrincipalIncrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05bca2e8-184b-4bfa-9048-afd52c89ba98" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf5ece8d-9007-43fa-97ac-8d36a532543d" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3133146-e487-4b7e-ada0-6682fce510eb" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss (gain) on foreign currency exchange</span></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7432b555-7c1b-442e-b8d1-962ab3fe9bdf" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28e58ac3-d856-46e7-8d6e-320889a80e1f" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb2ec820-69ae-43af-9f0f-dd15a5bd50ef" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other (income) expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd3fa9d1-7368-4683-9b3a-1a6596778c7e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f405d5d-0542-44d7-b144-77a0aa99f58d" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">52,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebf6c934-5727-4e14-bfaa-4dbc8b71d70f" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ba3c528-9a9b-4195-96d6-38572657243d" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dbb7286-f0e8-40b8-a1fe-39b23c2c4479" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">88,419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a140c53d-5a80-4175-8872-530cb5430bf7" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,572</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense (benefit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f4bb9a9-d0e1-4c51-a534-9f9d34f29543" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55fbd937-4ce4-4bff-9e9d-7666b7858080" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34483d69-d03b-4d40-99ec-0681b2750521" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cce7a311-9a49-44a4-a08b-9ed1ed376afa" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,364</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_081aa542-d940-4a44-a50a-c2e08c86df6b" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">88,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_735eec9e-1aa6-4749-af1f-40f6f5e3481b" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share attributable to common stockholders&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74025af5-b38e-4b25-aa81-d331bacd8b2a" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_9f7e80a9-3bcf-4836-a2e3-e7b38d01b9b7" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.17</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d52f999-97fd-4c0d-91ff-6b7745f65670" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_5c653416-456c-4c28-9b78-85bf0f0e12c5" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.67</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83cd5c51-fc6a-4cad-a63b-1fbdb4e6eb1a" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_2a49fd1d-e473-4e9c-9eb3-8b87d52fb8e8" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.36</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average number of shares during the period&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5aec110-6be3-4bef-9ea7-dc6085615853" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_d59bc7f9-dbe5-48ac-8259-762626a850ae" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">134,226</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb953708-87be-4210-b167-972207a7569c" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_272a3d3d-25e2-463a-8fee-df68ecf05140" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">132,858</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e1a2321-8809-47ff-a90c-82f006c08289" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_ff9bf13b-6990-43f8-9e5a-4b5404e741f6" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">132,891</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to audited consolidated financial statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section143"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCILEX HOLDING COMPANY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="stockholders_deficit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOCK</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HOLDERS&#x2019; EQUITY / (DEFICIT)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOR THE YEARS ENDED DECEMBER 31, 2022, 2021, AND 2020</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31.194%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.872999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.9%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.172%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.3389999999999995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.88%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.141%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.617%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.082%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.616%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.616%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legacy Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paid-in Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0b91674-79ec-4900-9bad-a828dc685bda" contextRef="C_8b6804ad-db9d-442b-8365-1912fdf47899" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">197,310</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4629ca07-e574-41a1-a2e0-8465af02ff72" contextRef="C_8b6804ad-db9d-442b-8365-1912fdf47899" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ff70a1d-50b7-4545-8156-244ac6d2ee9b" contextRef="C_b620909f-073f-4a76-8775-805e21b71726" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b54e17bc-61af-4171-b620-195b9f60d357;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30da95f8-ea1a-4890-91a9-39668458eb00" contextRef="C_6647079d-3f50-46e5-afdd-7cb5fff7d6ba" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_0bf5a962-5b24-48b1-9002-e5c81894ca56;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7e23235-e85c-4b8b-a032-0650d7f6cdf8" contextRef="C_2416c551-e9fc-44d6-b78f-4b72a1263fbd" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,578</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e33dd43-dcf3-461b-8e85-4d6b86c1aa13" contextRef="C_ed6ebbfe-7582-45c9-a505-88a5349d8983" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">216,607</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36194509-e803-4cd0-b492-7d522b977be1" contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">90,029</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Retroactive application of the recapitalization due to the Business Combination</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05f8a844-3ebd-4c34-8b7e-b63dcb489326" contextRef="C_4d25b0fa-f232-49d1-bb07-eac65211d5f0" name="sclx:RecapitalizationDuetotheBusinessCombinationShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">197,310</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a255f8e-cd62-4b46-ac30-6b111e97029f" contextRef="C_4d25b0fa-f232-49d1-bb07-eac65211d5f0" name="sclx:RecapitalizationDueToTheBusinessCombinationValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_461610d7-983a-4931-b72e-11cd72ebdd4f" contextRef="C_a3faac18-7970-4d6f-9b9f-ebaa1c4bc17f" name="sclx:RecapitalizationDuetotheBusinessCombinationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">132,888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcd171a8-2d8e-45dc-b156-fa5d97b22ed2" contextRef="C_a3faac18-7970-4d6f-9b9f-ebaa1c4bc17f" name="sclx:RecapitalizationDueToTheBusinessCombinationValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_728917e1-629e-4287-882c-0bb9e7bb1bc9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19b9cc1a-85ad-42d3-a20e-de0a20f98573" contextRef="C_ccca58d1-1a9c-4f4b-8d50-efc7509df65b" name="sclx:RecapitalizationDueToTheBusinessCombinationValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_61c0eef7-6384-452f-89b2-2406931de476;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d33d6a8-bb4e-41d1-aea0-99a920d89b29" contextRef="C_bef67e9a-4b76-4019-893d-8f19c877187f" name="sclx:RecapitalizationDueToTheBusinessCombinationValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2019, after the effect of Business Combination</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c625cfe-a3b6-497c-9adc-71812ccb9624" contextRef="C_a3faac18-7970-4d6f-9b9f-ebaa1c4bc17f" name="sclx:EffectOfBusinessCombinationInShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">132,888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b4c48a2-1da5-4f5d-94c8-e690b4a805f7" contextRef="C_a3faac18-7970-4d6f-9b9f-ebaa1c4bc17f" name="sclx:EffectOfBusinessCombinationInValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_14d9603c-d453-4443-95d8-8db6986dc87a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70415cb0-9140-4e86-9592-6538a4a723f8" contextRef="C_ccca58d1-1a9c-4f4b-8d50-efc7509df65b" name="sclx:EffectOfBusinessCombinationInValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,585</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6c4975f-64b6-492d-999b-246beab59ac1" contextRef="C_6bf9409a-d416-4d1d-a445-b90863d1d1c6" name="sclx:EffectOfBusinessCombinationInValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">216,607</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5867b50-65b7-402c-9201-f059de3fd166" contextRef="C_bef67e9a-4b76-4019-893d-8f19c877187f" name="sclx:EffectOfBusinessCombinationInValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">90,009</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options exercised</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57675bf2-e9fa-4a83-afad-2e7e61baa3ce" contextRef="C_3a251053-d0ea-4cdf-85a7-8504f3883048" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f317343f-8e67-4c6d-86ea-188b9d3b4b26" contextRef="C_0a7981fc-b448-47e6-bbe7-0f3aa97fb3c3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_0271b23c-aafd-4698-bd7b-106ba0477b32;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0958a5bc-2906-4b1b-8599-ab160d0952d3" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_499c8f70-8374-45f5-b8ae-da6a4a6253ed" contextRef="C_0a7981fc-b448-47e6-bbe7-0f3aa97fb3c3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,395</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_a0f75d3a-9e10-4019-b021-87432668c6ac;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c85fd78-ef5b-4ff6-a52c-925c683f435e" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,395</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Distribution to Sorrento</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7dac5043-921f-4752-b356-57be6d34bc6d" contextRef="C_4216d375-5857-4658-937f-eb7e215cb19f" name="sclx:DistributionToSorrentos" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_c168d39c-2871-42e8-b79d-b3ce199f3e7b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97e07aed-79f5-4d8c-8294-5d7aeb59149e" contextRef="C_7cfc2da8-8fde-41ac-99ad-52a0a1ee5813" name="sclx:DistributionToSorrentos" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancellation of shares held in escrow related to Semnur Acquisition</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3edbcf3b-15c6-4197-975b-bccbe53c9ace" contextRef="C_3a251053-d0ea-4cdf-85a7-8504f3883048" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">68</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64bc9980-b01b-4aca-824e-00b2f3348bb9" contextRef="C_8c37c057-4848-462d-ada1-a24a6cad00dd" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b06c520-7d4c-4eae-a5ac-ebbe14a9faec" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7635e97-e3ba-481f-907b-7e2bdd1889e1" contextRef="C_43387abc-3f9a-4d01-8539-0e8a069d288c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">132,858</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d64aab93-827b-4002-a6d5-1fe5232534d8" contextRef="C_43387abc-3f9a-4d01-8539-0e8a069d288c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c390b36a-ed8b-4489-833a-0bc7914603cb" contextRef="C_935d8df9-59c4-47da-a78c-46dc24743107" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,430</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ede3d78-9432-4d3f-8808-0bf299afabac" contextRef="C_1a7ce1a3-b831-4b91-8f43-85fae241ba37" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">264,126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96efa67b-6dae-48d3-bf8a-bdbad5c0f0f1" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">141,683</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1201c7ab-8eea-4c78-b231-af05b124a390" contextRef="C_7eb481bd-4d9b-4545-b52a-3d1554edfd5f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,822</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b1071206-0591-4a2e-8730-fb93dbb2b787;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92b2c83b-a956-45f7-a40e-3624bfef91af" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,822</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustment to shares issued in Semnur Acquisition</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f5fe878-8258-488a-b620-2a1955a5c98f" contextRef="C_7eb481bd-4d9b-4545-b52a-3d1554edfd5f" name="sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">409</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_3ae621a8-3f3f-4d53-a551-5225faec3ab9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e8c0a04-a90f-446b-b1ed-0da09102e1dc" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">409</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1251cd6-831b-4ba9-bad0-23dd63a99bc1" contextRef="C_9b930bf6-320d-4b6c-af8c-5aa608240d49" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">88,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79c0f569-050e-4a34-828e-781b2673f396" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">88,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1f24d70-211b-4b44-a5e0-88ac29fbbd04" contextRef="C_c8f61138-8d7f-420c-9c8d-08f6643abad5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">132,858</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90944053-88b6-4b57-a6e0-82cd2dc5c02f" contextRef="C_c8f61138-8d7f-420c-9c8d-08f6643abad5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_aefe8b43-5bdf-4327-b2fa-26db087baf25;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37805e6e-1022-4a23-b0d3-7ce5469c4731" contextRef="C_a34d7e4b-75b0-46b3-9b67-fb0bd31b0200" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,661</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d58da65d-a6b3-4f63-b533-af99851944c5" contextRef="C_edcc144e-d7f7-43da-bd1b-72d518cd963f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">352,550</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17660544-99a1-4312-b543-0746aa3bf321" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">223,876</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options exercised</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2b4018e-d4fa-4343-bf2f-c9e22c865235" contextRef="C_a7a078e2-6aea-4910-9389-223a17cbe1d4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">202</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4919129e-3643-47d9-b76c-f227c5887897" contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_11cebda7-8f87-4267-ac10-7be6b1acda18;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed46fb75-0353-4a8b-be87-24560aae6ffe" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aardvark SP-104 license transfer from Sorrento, net of discount</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1be57a39-ce5f-4a02-b966-da3c748abb2c" contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4" name="sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,127</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_54523a10-c706-4fd9-8164-2c0bfdbbf91a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_beaf1b8d-c2ca-447b-83c5-b86ad904127e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,127</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aardvark SP-104 discount amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5acca56-b5a0-44e9-bff4-73ac8d75c45d" contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4" name="sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_adf58944-3511-4a6c-9e5d-eeee7d745bfb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f874043-e8d7-44bd-ab65-9a4e84be64c4" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issued pursuant to the terms of the Debt Exchange Agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d09fc92a-d8b9-45a2-824c-af98e85a715c" contextRef="C_a7a078e2-6aea-4910-9389-223a17cbe1d4" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,906</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3aa0b864-65a2-4ce4-b542-06a427eccded" contextRef="C_0eb4f5f3-217e-4d32-9df0-0de97d9de853" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,057</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3009439e-efa6-40a5-8b62-f35fcf89d448" contextRef="C_0eb4f5f3-217e-4d32-9df0-0de97d9de853" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a2fef0d-d070-430b-9381-4c274d07579a" contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">289,730</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9210ffe7-39a4-4a0e-a307-01b932158bee;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ed64812-8a98-468d-9449-d8f841118973" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">289,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issued as a result of the Business Combination, net of transaction activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0236e0f5-934c-463c-87ed-9748d0e66919" contextRef="C_a7a078e2-6aea-4910-9389-223a17cbe1d4" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">5,133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4f3acd3-bb50-4acb-b27d-103481b3f2e6" contextRef="C_a7a078e2-6aea-4910-9389-223a17cbe1d4" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6463cc28-8d65-4f96-95bf-abffbc67ff81;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e4a5c6db-30ef-462c-82dd-288b64103342;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60b6df35-db74-4edc-8c19-2ac6def83695" contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,707</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_a4cda2f0-ffce-4c0e-ae35-a6cbdae92144;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1d57699-b778-4fd4-80ee-3b9e1ab2ecf5" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,706</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15a91f96-a8a4-43ea-a3b0-7c73f4cb4fb8" contextRef="C_a7a078e2-6aea-4910-9389-223a17cbe1d4" name="sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34a35d10-fde8-49d6-b6cb-70eb189c76b3" contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4" name="sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_d7125064-9b76-4c9c-9019-5e82b70b444a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37a8ddd2-3609-4512-9a18-5f5f64b6fbc6" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b87113f8-2b0e-4157-895a-e9777e5bd5dc" contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b5b86b27-0532-49c1-b76c-6f887f0a63fc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42646fb1-4db6-4e20-a1e3-eafde2ccfb5e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9d24379-c237-4c36-88f9-e7a7eb61a1d2" contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,364</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6527c118-654f-4517-a5a6-4159b85cbaa0" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,364</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance, December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4de2966c-7753-4481-9790-d822dabef9fc" contextRef="C_dbd5dc57-1898-456c-9638-93bc81132559" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">141,349</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_904bd5ed-5041-4243-970a-bf499c1e7ed2" contextRef="C_dbd5dc57-1898-456c-9638-93bc81132559" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0aa2d74b-d43c-460c-b95f-a02e3178197e" contextRef="C_0b6f23f6-2673-4fcb-bf14-d6a9163b7497" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,057</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc00b7e9-9054-45f2-bbb6-1d21412868fc" contextRef="C_0b6f23f6-2673-4fcb-bf14-d6a9163b7497" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c5bb50b-ff41-47c0-8e61-d3995c05d1d8" contextRef="C_b97057d7-7304-4fd2-8467-c5db2179660a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">412,136</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_823832f9-be73-4a49-b77b-ab1fc1252f1c" contextRef="C_47fbaa34-ba91-4f95-8043-9f86ce21361b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">375,914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1bb2a4b-97db-49ee-9bb1-a436fc343a90" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,239</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to audited consolidated financial statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section144"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCILEX HOLDING COMPANY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF CASH FL</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OWS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOR THE YEARS ENDED DECEMBER 31, 2022, 2021, AND 2020</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:58.285%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.974%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.263%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.974%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.263%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.241%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_087a4672-4086-4957-bf8f-df7f5931ce15" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,364</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4857313c-3f35-40a8-b59a-8d2fd1697d5b" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">88,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea0da0ec-810a-461a-9f94-cd0409c56505" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used for operating activities:</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93b524a0-06ce-43a4-bbbf-2680bc298b10" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,961</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23f493de-2da1-4623-899d-a547514f3d28" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,779</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa0e3f38-996a-4910-9b8e-29a073e623fc" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,777</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt issuance costs and debt discount</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fbeb1d1-9027-4fcc-af1d-1d11e5725a8b" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed8ac29e-fe66-4df2-8460-f2ca2037e56d" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9e5eb39-d19a-4927-9d4f-aa5359c517b4" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Pharma Notes principal increase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbfe7f9f-bf9e-4f51-8500-3fa69a1e7b1e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:NotesPrincipalIncrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8850997e-2eaa-43ac-9a5c-6dca163fd39c" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:NotesPrincipalIncrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b3c5908-c01d-4cbc-9a75-c0e45a58ab85" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:NotesPrincipalIncrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2020b43f-9ddc-4101-b75a-206dcaa4d987" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,190</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc5b7bcc-0323-4a7f-a9ee-c366f6bc14ff" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f51eb59a-d458-4f92-8aeb-aaf9fa435f61" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,866</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on debt extinguishment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2922d69c-8d7c-43b9-9f71-a6d7d7f0f680" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,634</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e680e30e-904a-4970-8de7-d921f5f47ccb" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,463</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5e65ac6-b743-4aba-9e9b-c6500cb200b4" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash operating lease cost</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62b387a2-280e-4b5b-b719-6fe432631955" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:NonCashOperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">492</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7eadeb3-89a4-4923-b720-fe007b929a2b" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:NonCashOperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">372</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_111b5d20-4553-4b47-afb6-136bbcff9e1c" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:NonCashOperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">825</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f3a04da-2e46-4f59-a59c-98908d566f1c" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4be6a76-5ba1-4fe4-adb0-a6777e01259b" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,822</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5f950f6-7b00-4777-bae8-b05d6951e954" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,395</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Gain) loss on derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9777b81e-c3c0-4884-8c4e-7780f6d07e9f" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,310</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a939a02d-4d5f-47c5-8d30-281a89bad577" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e7b2005-0ddb-43a0-885d-0ef36fd0d870" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeitures of Private Warrants</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ef55f2f-dc9a-4f62-93b6-db24d16392ac" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:ForfeituresOfPrivateWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,697</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94fcaecf-2511-4daa-a6de-a97406139a36" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:ForfeituresOfPrivateWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c503c40-5933-4246-8fd4-604abeaf599e" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:ForfeituresOfPrivateWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivables, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_772616be-751c-4f89-82e2-90a9e44fb223" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,968</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a022617-b1ed-419f-b778-fbdff3b86c5d" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7289920-75e1-4509-875e-8e3f7a043330" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">598</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_110049cc-9ffa-49a4-82a6-920b5568fce9" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b15b037b-fb18-43ca-b009-e19d502bca6b" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,417</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ca89a1d-9d4f-496b-9e6c-bb68bedb2e2d" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c048eee8-240c-4cd6-b196-b8f07512e9ee" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30b196b0-a000-4358-a39e-fa33dea88eb5" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e069136e-284f-4eb7-8ac4-f54b13cd39b5" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,035</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c60e4cc2-ea9a-4c3a-9678-a1a2fc88575c" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5c5a478-6d20-456d-b711-6b2c6a9410ce" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_406957f4-89af-431c-b471-18a93dfb4623" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,580</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2aecdccb-0ad0-4f00-8d04-9901eb660034" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,806</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e328769e-0e2a-4f96-abe8-118e104385ea" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,836</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cfbea42-c903-4a09-987d-e7fff3a9528a" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,062</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued payroll</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ecedb34-0272-4b77-ac19-3b28d8be1d4d" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:IncreaseDecreaseInAccruedPayroll" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99a54eeb-58b6-4e64-bfc2-c9d19c595535" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:IncreaseDecreaseInAccruedPayroll" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d674c18-9fda-4de4-b464-4b7e9486f7d5" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:IncreaseDecreaseInAccruedPayroll" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,247</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_918d6073-7f50-49d4-816c-76fb1fd26959" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">123</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f074a56-83ba-4a9c-b70e-f02ecb911d97" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_174901c2-d61b-4705-9f44-3be6a3fcd57c" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,066</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued rebates and fees</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb217f75-29af-4923-81b9-aa186144afb6" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:IncreaseDecreaseInAccruedRebatesAndFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,531</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5ae7dd2-2ea6-46d9-8acd-5e534150e951" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:IncreaseDecreaseInAccruedRebatesAndFees" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">255</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4e57b92-667d-4299-a3b3-4e9a43e62f73" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:IncreaseDecreaseInAccruedRebatesAndFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,117</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c3d3a8e-4802-453d-94b5-731daaf52a51" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1da4abf8-991a-4e90-99de-f5fcf93dfdbb" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3a18840-dad0-4e6e-bd92-84f22055d472" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related party payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f7ceddd-c27c-45e8-bbda-917c7b8a6b78" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19f7b6b2-dcf0-4678-aff2-1ae3d0a698a3" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,210</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91389548-5f21-4378-ab68-ef33aea34518" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,105</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_877bc249-036c-43ee-b935-590853240dee" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:OtherLongTermLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_557d651b-062c-47e0-8442-4e8146558b5a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_a2bc1cc5-c1e7-43cf-a6f8-b4f4facf181d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used for operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b5b8789-9fc3-426b-9c89-afa0aa9b6235" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">21,258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52384e0a-c5d2-4854-ada6-5042a188217b" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5822abf-0451-4a14-9bd9-3e11149cc36b" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisition consideration paid in cash for Romeg intangible asset acquisition</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ff64327-9b70-4185-bcdf-b5d8b8159143" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,060</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_747ead30-1bcb-4f08-99a9-7d3e9299809f" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5badaa74-93db-46e1-853a-6cc8c61e66f0" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19f408f9-6de6-4276-8fca-ea80d21faa7c" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7507b6d0-0aad-405f-aa00-91f9bd77ffba" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_242a8582-dcd1-4570-9a96-14915971d528" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used for investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55e63fed-edd7-4c83-bf60-4522b29b23e7" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,067</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f5bd135-39b2-4549-89e3-90afcfa2753a" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b7cf5e8-f1ec-4fab-9089-7bc7ff1dd192" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the Business Combination</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d0a954c-b038-4df1-ad3f-5b422466f7ed" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:ProceedsFromTheBusinessCombination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,375</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_caa3da7b-49c1-426d-8fe9-80ba1cf51c12" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:ProceedsFromTheBusinessCombination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9f2e336-aba5-4e9c-ac80-5494849a332b" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:ProceedsFromTheBusinessCombination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction costs paid related to the Business Combination</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc37241f-c77d-46bb-9b1e-853041d92215" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,949</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa419f5a-d140-4a3b-bd83-f04114fea818" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dde92be-24b0-4526-99cf-12bcb970ea0c" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repayment of principal on the Scilex Pharma Notes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fce4245-1e63-4049-afff-e463dce6d6e3" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">84,808</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de1370dc-77fd-4ecc-ae65-1b3756cfcd6c" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">33,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a290157-77ac-4342-847c-a5432beac6a9" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,927</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repayment on other loans</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7bf7b5f-3778-499d-9192-f0e59cee383c" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:ProceedsFromRepaymentOfLoansToPurchase" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">18,800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b75dae5a-f203-49d6-8638-11ef7b9fb1d2" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:ProceedsFromRepaymentOfLoansToPurchase" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">48,832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1ba986c-1f53-480e-835f-c1331c499271" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:ProceedsFromRepaymentOfLoansToPurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from other loans</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4b6c59a-7688-421c-b9c1-56e643fe79c9" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ProceedsFromOtherShortTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47841743-bc90-4bc6-8a95-562f11f044c0" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ProceedsFromOtherShortTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_612a0552-acce-4b88-a70e-41521b557e44" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ProceedsFromOtherShortTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from stock options exercised</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f0c20bd-6408-4880-a608-29e938a7adce" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_095f2d65-a86b-4b67-9bb7-e47c53fc3f19" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1eea942-aed0-4d88-900e-e37cb582416b" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from related party payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f0b945e-073e-485c-bf06-1ec181c5abf4" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ProceedsFromRelatedPartyDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,900</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd63ffb3-7852-484c-a728-115c150cd175" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ProceedsFromRelatedPartyDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_297575be-853a-4a5f-a967-5402ef36b154" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ProceedsFromRelatedPartyDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from related party note payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86af4f65-0868-4bbb-9ba9-5d9872e76004" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ProceedsFromSecuredNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d3e6e41-a198-48c3-971d-4fb4e8ffbdae" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ProceedsFromSecuredNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67e0da55-d8e4-4dc2-a775-a1ddb0690693" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ProceedsFromSecuredNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f50a3ff8-9090-441a-9763-ef389b26ad47" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae73e193-2107-4959-b4e1-4cb95595e715" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,163</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a193776-a784-4d09-b473-2aa879fb21d8" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77b74d8f-db2f-4314-a248-baf717de66c8" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,154</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa22ae6d-de1a-483b-989e-4fac04fc7cec" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">501</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_219ae017-0b5f-4d78-a44c-ab5ba090dc14" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,656</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f986b1b7-e253-4b7b-848e-8c1c8a3d63ed" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9770ef6-de42-493a-ab86-8656782bd6bf" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,839</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85966506-6bec-40a9-986f-39c061ebd783" contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,495</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d38ed802-b182-47a9-8cfc-fdbdb976e481" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad638411-f550-41ba-8c8c-3a5f587f609f" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0622b0c6-9199-498d-85f8-b746d54bf5bf" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,839</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures:</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures of non-cash investing and financing activities</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related party debt converted to equity pursuant to Debt Exchange Agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66c8d198-ab13-4191-84f6-0d564a5a7bf2" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">289,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred consideration for Romeg intangible asset acquisition</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b72fa42-fb58-4fa9-b997-bd4479d96544" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f9b20d0-c962-4071-a53f-0482f6faec3d" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_491f980b-a22b-4dbb-bbf6-96f1d8f36797" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash consideration in Semnur acquisition</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2d6a127-c984-4276-88dd-37e5f8f8626c" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:NonCashConsiderationInSemnurAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ac7d1ee-ad7f-486c-8876-dad19cbdd761" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:NonCashConsiderationInSemnurAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">409</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2925058c-e1a3-4f89-91c9-1b7bbf76f6ff" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:NonCashConsiderationInSemnurAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other loan forgiveness</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0426930-426e-4959-9423-6c3661fac775" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:OtherLoanForgiveness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afcd7357-3127-4bc5-94f9-4dd74558f1cd" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:OtherLoanForgiveness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a413bfd-d62a-45a6-9067-0271a027292a" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:OtherLoanForgiveness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b0dc563-fe52-4242-aeb5-4a8d42f0765a" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,162</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_553b73e8-b430-4f67-8db5-d6c7675d0445" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b4432a1-4dca-4b7b-9e1e-04d358b0fd21" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value adjustment to derivative liability in troubled debt restructuring</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1da2859-0206-4883-b281-f5e328d892fd" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b5188a0-6df1-48e4-b154-534366f0e15a" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7177e79e-4ae2-45ec-9330-342c49fa4ac6" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisition of right-of-use asset</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab7fb929-e19e-4072-9e21-bac1dbf0fd95" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:AcquisitionOfRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">320</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4531b770-f75c-45d7-8409-4aeda7c5ce5e" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:AcquisitionOfRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_158b111e-1e03-4a01-9939-7746255cd04f" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:AcquisitionOfRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of shares to Yorkville pursuant to Yorkville Purchase Agreement</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cb272e0-6f92-443b-a16e-77d31975e56a" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash distribution to Sorrento</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c0cf2e9-b349-45dd-b520-494f321e28f9" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:NonCashDistributionToSorrento" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_684d2d31-73ad-465d-a40d-3e7d53ac8685" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:NonCashDistributionToSorrento" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eae0b477-823e-48f6-8af0-f555f2345603" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:NonCashDistributionToSorrento" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Pharma Notes principal increase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ebe23cb-073a-4c8f-a684-c66e00759b7f" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:NotesPrincipalIncrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5f5f05c-d263-4143-a553-ab1a0f2bdd3a" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:NotesPrincipalIncrease" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7712c969-cdf4-4ba7-8eae-9b19b87526a8" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:NotesPrincipalIncrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrual for transaction costs related to the Business Combination</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c12c391f-41b0-4eae-b20a-ad2464fa5bf9" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:AccrualForTransactionCostsRelatedToTheBusinessCombination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,372</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6ef1b2d1-d409-4de2-8c2d-7363847d2a82;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_29c766bb-4fce-4dbc-b8e4-92a68d84c25f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transaction costs obligation assumed by Sorrento</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_267d29e3-20c4-498a-b50d-4f184624a8d5" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:TransactionCostsObligationAssumedBySorrento" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_53016aa0-3b61-4375-bbc0-41251f062de2;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_ac4101a1-c5ee-4706-a1b3-9f3fcddd0896;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to audited consolidated financial statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="section145"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCILEX HOLDING COMPANY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_unaudited"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_44aaa6e3-e1b0-4872-8b26-d6307e9fb083" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section146"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Nature of Operations and Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Organization and Principal Activities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Holding Company (&#x201c;Scilex&#x201d; and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) is the successor entity to Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;). Vickers was formed on February 21, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Scilex was originally formed in 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (&#x201c;Sorrento&#x201d;). Scilex has two wholly owned subsidiaries, Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;)</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Semnur Pharmaceuticals, Inc. (&#x201c;Semnur&#x201d;). The Company is a commercial biopharmaceutical company focused on acquiring, developing and commercializing non-opioid management products for the treatment of acute and chronic pain. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#x201c;ZTlido&#x201d;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. The Company in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The Company is currently developing three product candidates, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica (&#x201c;SP-102&#x201d; or &#x201c;SEMDEXA&#x201d;), SP-103 (lidocaine topical system) 5.4% (&#x201c;SP-103&#x201d;), for the treatment of acute low back pain, and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (&#x201c;SP-104&#x201d;), a novel formulation for the treatment of fibromyalgia. Since inception, the Company has devoted substantially all of its efforts to the development of SP-102, SP-103, SP-104, and the commercialization of ZTlido.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Business Combination</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 17, 2022, Scilex entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) with Vickers and Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#x201c;Vickers Merger Sub&#x201d;). Pursuant to the terms of the Merger Agreement, Vickers Merger Sub merged with and into Scilex, Inc. (f/k/a Scilex Holding Company and now a wholly owned subsidiary of Scilex) (&#x201c;Legacy Scilex&#34;), with Legacy Scilex surviving the merger and becoming a wholly-owned subsidiary of Vickers (collectively, the &#x201c;Business Combination&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 10, 2022, Vickers consummated the Business Combination pursuant to the terms of the Merger Agreement. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, Scilex received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c793792e-9af4-431c-999d-5b93fc0cce42" contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21" name="sclx:TransactionCostsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Additionally, all existing related party indebtedness between Legacy Scilex and Sorrento totaling </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_610cc26e-f2c7-4309-a0b4-b4f10512b50e" contextRef="C_6c47f53f-c811-4186-9ff5-419aa14184c5" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">290.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 12). The Company, as the successor entity of Vickers, will operate as &#x201c;Scilex Holding Company&#x201d; and was listed on the Nasdaq Capital Market under the new ticker symbol &#x201c;SCLX&#x201d; on November 11, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the closing of the Business Combination, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5673b9d3-ca04-4eaf-8c4c-3789bc313848" contextRef="C_8af3e27b-97dd-4b7e-8523-2366035accc5" name="sclx:ConversionOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">197,566,338</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a200450-f4f1-4830-be03-c7480cec06b8" contextRef="C_98ba01df-597b-4318-aca4-8f7bf10d4909" name="sclx:ConversionOfCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">25,151,428</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Legacy Scilex Common Stock (&#x201c;Legacy Scilex Common Stock&#x201d;) and Legacy Scilex stock options, respectively, were converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67bbf83d-ab64-47d4-9d86-9c1d9eaf7bca" contextRef="C_21eb1f4e-32ad-4b44-99ff-e9ffd99b9aa5" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">133,060,534</ix:nonFraction></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Common Stock (&#x201c;Common Stock&#x201d;) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_93ed3e11-0b64-4813-adb6-8515edc61158" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:CommonStockExchangeRatioDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as part of the consideration using the 0.673498:1 ratio of the Company Common Stock to Legacy Scilex Common Stock</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;Common Stock Exchange Ratio&#x201d;) and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0717f3a-5aed-4158-a47a-25e3051117ac" contextRef="C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,939,436</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock were reserved for Legacy Scilex optionholders. Pursuant to the terms of the Debt Exchange Agreement (see Note 12), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6815febb-e5f1-43f3-a5d6-75ba6e0b913a" contextRef="C_6c47f53f-c811-4186-9ff5-419aa14184c5" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">290.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed12828a-b386-4b7f-8254-ce57a226e70c" contextRef="C_de43cc1f-2fdb-4769-8c7b-6c7cef7cb9b0" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,057,097</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Preferred Stock (&#x201c;Preferred Stock&#x201d;) and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfe8e9d3-d78c-40e8-b2fa-cb2813769a01" contextRef="C_3377c481-f9db-4160-b872-f87f6e365001" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,905,710</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock. In addition, pursuant to the terms of the debt agreement entered between the Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd (&#x201c;Sponsors&#x201d;) and Vickers (&#x201c;Vickers Debt Agreement&#x201d;), the aggregate amount of loans that the Sponsors funded Vickers to finance the transaction costs (&#x201c;Working Capital Loans&#x201d;) at the closing of the Business Combination of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b9af90f-8e51-4f93-84a5-617f396b70af" contextRef="C_3ca96e60-bf56-4765-9420-632b08ad825f" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,330,557</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b15e484-fdd0-4136-a040-4ed2ac97bf1b" contextRef="C_3ca96e60-bf56-4765-9420-632b08ad825f" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">533,057</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers was treated as the &#x201c;acquired&#x201d; company for accounting purposes and the Business Combination was treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. Upon the closing of the Business Combination, the net assets of Vickers were recorded at historical cost, with no goodwill or other intangible assets recorded.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s legal, accounting and other fees directly attributable to the Business Combination were initially capitalized within prepaid expenses and other current assets on the consolidated balance sheets, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f25a4dea-0752-41e5-b629-b122a13c03dd" contextRef="C_42dde953-1de3-4888-9e2a-9a55861296bd" name="us-gaap:ProceedsFromOtherEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million has been offset against the equity proceeds in the Business Combination and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_255175b3-f273-482a-a6de-9fb4e067d3ab" contextRef="C_cb4e9c2d-4697-4133-b0c7-df08bcc87742" name="sclx:LiabilityClassifiedPrivateWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was attributed to the liability-classified Private Warrants and, as such, were expensed upon the closing of the Business Combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section147">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_017149be-bf07-46c9-9252-0705b6b8af10" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d9a67dab-0612-4e6a-9c6d-f371174d7768" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f63b0fb9-8dcb-4529-894d-cf9647a77626" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution.  Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a3be322a-6ed9-4fce-80ee-addfb38a00ab" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values.  Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and  2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices.  Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_34356861-5e61-4624-9a6e-aa95efff9103" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounts Receivable, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c5251be-2e3d-4b4c-96d1-3f6e581a0fd7" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines inventory cost on a first-in, first-out basis.  The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for on-hand inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. As of December 31, 2022 and  2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company&#x2019;s inventory was primarily comprised of finished goods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_907c7984-2316-46b8-98d6-5ace338821aa" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section153"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are carried at cost less accumulated depreciation.  Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.  The cost of repairs and maintenance is expensed as incurred.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c2a5f43a-f386-4dcc-9589-44822f70c17f" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:BusinessCombinationsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section154"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisitions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;D&#x201d;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, up-front payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations unless there is an alternative future use.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7c1d8511-7aa1-489e-94b7-f3ebb8f399dc" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section157"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill and Other Long-Lived Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired.  Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill.  The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company.  If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_762cdbe7-599f-4ada-96dd-041a06fc4d9d" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ContingentLiabilityReserveEstimatePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_41ce7ff0-3563-40d3-9f67-6decd19c349f" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Public Warrants and Private Placement Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon completion of the Business Combination, the Company assumed public and private placement warrants (&#x201c;Public Warrants&#x201d; and &#x201c;Private Warrants&#x201d;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on January 11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic No. 815-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contracts on an Entity&#x2019;s Own Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic 815-40. The Private Warrants are not considered indexed to the Company&#x2019;s stock per ASC Subtopic 815-40 as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a fixed-for-fixed option contract. Therefore, Private Warrants are recognized as derivative liabilities </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at their estimated fair value on November 10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet date, with fair value changes recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_71e98dbc-c45a-48ba-8054-df4e6d34bb5c" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DebtPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section159"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates.  This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6833883c-b8d4-497f-a17d-90b519f62d36" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DerivativesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section160"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative Liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c8ae21a0-de91-464f-acbb-e163ac789eb5" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section161"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses the cost of research and development as incurred.  Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.  Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e6856073-761b-4640-aeaa-b8862d05095e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section162"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provisions of the FASB ASC Topic 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Subtopic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.  The Company has determined that it has uncertain tax positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized.  As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company maintained a full valuation allowance against its deferred tax assets.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_53658874-2b67-48c5-a383-2768a6f51f12" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section163"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.  As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.  The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives.  The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_88a4faf4-4a24-4304-8d88-f3fcc3b3d97b" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section164"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#x2019;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
       <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.  Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December 31, 2022 and 2021 were not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rebates and Chargebacks</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rebates are discounts which the Company pays under either government or private health care programs.  Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers.  Both types of rebates vary over time.  The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prompt Payment Discounts</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Service Fees</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services.  The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Returns</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
       <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Co-Payment Assistance</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive co- payment assistance.  The Company accrues for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section165">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5d89da1c-6638-452d-9559-7ec1331c5edb" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Concentration Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to April 2, 2022, sales to the Company's sole distributor represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_604f9349-da55-4bfb-9254-11f86362f11e" contextRef="C_5732eb05-268c-4927-ab42-4931ac50cee6" name="sclx:PercentageOfNetRevenueSoleDistributors" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of net revenue. On April 2, 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The distributor continued to provide traditional third-party logistics functions for the Company. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had four customers during the year ended December 31, 2022, which individually generated 10% or more of the Company&#x2019;s total revenue. These customers accounted for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03c74761-df82-4681-8e72-f0b3ed3c0772" contextRef="C_5350c734-a3ef-4fd1-88d3-af11b48f40cf" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">83</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Company&#x2019;s revenue for the year ended December 31, 2022, individually ranging between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b71485b-3e25-401d-8ecb-8e1d0ce82847" contextRef="C_461cdc24-bee6-49eb-825f-a615ecb35d40" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">19</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ebfaf0c-16d6-44de-a36a-1ec54c15c924" contextRef="C_0cfa11ab-3c88-4cef-9e78-7b5083e4ce05" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">24</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, these customers represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2d097bd-5e4e-49e7-a07e-736f9770ae50" contextRef="C_0205795c-8a73-4b30-885d-bfc720c71093" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Company&#x2019;s outstanding accounts receivable, individually ranging between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bb905dd-7dd1-4d46-83cf-7fb9e759e8a8" contextRef="C_2e6b294a-07c5-4bc3-b0f8-28ef1bba9112" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">24</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3e19341-2ba9-46ed-9e0a-2bdfe4a55aa5" contextRef="C_27408945-d0d7-44d3-b555-007ee69f44da" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">36</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Additionally, during the fiscal years ended December 31, 2022 and 2021, the Company purchased inventory from its sole supplier, Itochu. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fb6e372d-a92b-4c33-ab6a-c7682a10ec64" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section166"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation &#x2013; Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or non-employee&#x2019;s vesting period. The Company accounts for forfeitures as incurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section167">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe61f762-faa6-42f3-85df-56959b5c0aa1" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of non-opioid products focused on pain management based on its platform technologies and all sales are based in the United States.  Accordingly, the Company has determined that it operates its business as a single reportable segment.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section168">&#160;</p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_848452a5-6edb-4a1f-bf4e-7a222f22a1a6" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section169">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f5ced228-9b16-4e21-b5e9-2c2769db660e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the FASB issued ASU 2021-08, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1f842410-70f3-4ec0-bd75-5f50f418b7b3" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section170"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.  Management has assessed the Company&#x2019;s ability to continue as a going concern for at least one year after the date the financial statements are issued.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 18, 2019, Scilex acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note 3). The Company anticipates the cash needed for the development of Semnur&#x2019;s primary product candidate in development, SP-102, as well in the development of SP-103, will be in excess of the Company&#x2019;s cash available within one year after the date these consolidated financial statements are issued.  Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the SP-104 Assets (see Note 3). SP-104 has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be responsible for funding all development and commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 14, 2022, the Company entered into a license and commercialization agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs related to the commercial launch and marketing of GLOPERBA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 12, 2022, Scilex and Scilex Pharma entered into a Debt Exchange Agreement (see Note 12) with Sorrento, pursuant to which all related party indebtedness that remained outstanding as of immediately prior to the closing of the Business Combination was converted into equity interests in the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, the Company exercised the Early Paydown Provision (see Note 7) to fully extinguish the Scilex Pharma Notes (see Note 7). In August 2022 and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a0835e0-6774-48ec-9f0f-f926e3b0853c" contextRef="C_456895c8-fe6d-4068-beff-13288c8937f7" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">41.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Pursuant to Amendment No. 4 (see Note 7), a principal balance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df5d4313-5494-412f-834c-bb12cadb0430" contextRef="C_3829a111-1d2a-42cf-8ef3-8eee8d13b455" name="us-gaap:DebtInstrumentDecreaseForgiveness" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was forgiven by the Scilex Pharma Note Purchasers (see Note 7) upon the Company&#x2019;s exercise of the Early Paydown Provision. The Company funded the principal payments with cash-on hand and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fcb443c-a59c-4c54-b8e3-a59e0b101149" contextRef="C_5afaea6d-9fb4-41dc-9415-7c291b048f12" name="us-gaap:ProceedsFromRelatedPartyDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> received from Sorrento on September 28, 2022 (see Note 7).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company&#x2019;s negative working capital was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ae7a50d-8d20-4214-a183-92b8acd57ecd" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="sclx:WorkingCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including cash and cash equivalents of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bc9c5a8-baef-47d2-8ecd-c76ca615cd75" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the year ended December 31, 2022, the Company had operating losses of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94748aa5-219c-4425-afa1-7520feda77e8" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">50.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and cash flows used for operations o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">f $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_470d59d2-635f-4bbb-91d1-2672382511b4" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company had an accumulated deficit of approximate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ly $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44c1e724-a1f4-485e-a168-c978a691e6fa" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">375.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. (&#x201c;Yorkville&#x201d;) on November 17, 2022 (as amended and restated on February 8, 2023), and a Standby Equity Purchase Agreement with B. Riley Principal Capital II, LLC (&#x201c;B. Riley&#x201d;) on January 8, 2023 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whereby the Company has the right, but not the obligation, to sell to Yorkville and B. Riley up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebaeca6c-d9b2-419d-b105-9ac0659e65e3" contextRef="C_10bd7df9-bc0a-460b-b471-0b07966dbf8a" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">500.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million each of shares of its Common Stock at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement has been declared effected by the SEC, subject to certain conditions (see Note 8 and Note 14). The Company&#x2019;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#x2019;s marketing of ZTlido. Should the Company&#x2019;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#x2019;s business plan, due to the COVID-19 pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for SP-102, SP-103, and SP-104, and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#x2019;s control.  As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year after the date the financial statements are issued.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c425966b-a5d1-42c7-a97c-4ff9dd56b5c3" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Acquisitions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-104 Acquisition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 12, 2022, the Company entered into a bill of sale and assignment and assumption agreement (the &#x201c;Bill of Sale&#x201d;), with Sorrento. Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#x2019;s Delayed Burst Release Low Dose Naltrexone (&#x201c;DBR-LDN&#x201d;) asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the &#x201c;SP-104 Assets&#x201d;). These assets had previously been acquired by Sorrento from Aardvark</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Therapeutics, Inc. (&#x201c;Aardvark&#x201d;) in April 2021 pursuant to an asset purchase agreement (the &#x201c;Aardvark Asset Purchase Agreement&#x201d;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#x2019;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the &#x201c;SP-104 Acquisition&#x201d;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the SP-104 Acquisition, the Company issued a promissory note in the aggregate principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82ec03eb-acd4-454b-ada5-73bf54e695f0" contextRef="C_49abe51e-8cd0-4386-b0ec-79317162d36d" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to Sorrento (the &#x201c;2022 Promissory Note&#x201d;). Upon issuance of the note, the Company recorded a related party note payable of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9279e4b-0a3b-46ec-9dec-9adc1af7309f" contextRef="C_49abe51e-8cd0-4386-b0ec-79317162d36d" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The 2022 Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b0f0299-5650-4092-9240-86a9968ef374" contextRef="C_6e6757a4-23e1-4b86-9c56-e99208d69c95" name="us-gaap:SubordinatedBorrowingInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.66</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% simple interest per annum and (b) the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company&#x2019;s common stock or any combination thereof, at the Company&#x2019;s sole discretion, and may be prepaid in whole or in part at any time without penalty. On November 10, 2022,  the 2022 Promissory Note was converted to equity, pursuant to the terms of the Debt Exchange Agreement (See Note 12).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c0ccb43-d7f3-499d-941a-a75ce53fb423" contextRef="C_ea7b3fbf-8dd6-49a4-a28c-adc88beeb0ae" name="sclx:AmountDueForNewDrugApplication" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, upon initial approval by the FDA of a new drug application for the SP-104 Assets (which amount may be paid in shares of the Company&#x2019;s common stock or cash, in the Company&#x2019;s sole discretion) (the &#x201c;Development Milestone</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Payment&#x201d;) and (ii) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bfe303e-664f-4540-8392-82180721c1c9" contextRef="C_ea7b3fbf-8dd6-49a4-a28c-adc88beeb0ae" name="sclx:PaymentUponTheAchievementOfNetSales" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the SP-104 Assets (the &#x201c;Sales Milestone Payment&#x201d;).  The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the SP-104 Assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, SP-104 Assets. The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and will not be recognized until the contingencies are realized in accordance with the Company&#x2019;s accounting policy for contingent consideration in an asset acquisition. The Development Milestone Payment represents a liability within the scope of ASC Topic 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which will be measured at fair value each reporting period. As of December 31, 2022, the contingent consideration of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae4a1c2f-0847-4f12-8521-82be2598e0f4" contextRef="C_64b784b2-80c2-40ef-8826-8180d2f928c8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> associated with Development Milestones Payment was recognized under other long-term liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GLOPERBA License Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 14, 2022, the Company entered into a license agreement (the &#x201c;Romeg License Agreement&#x201d;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#x201c;Romeg&#x201d;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (1) a transferable license, with the right to sublicense, under the patents and know-how specified therein (with such license to know-how being exclusive for the limited purposes specified therein) to (i) commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#x201c;Initial Licensed Product&#x201d; or &#x201c;GLOPERBA&#x201d;) in the United States of America (including its territories) (the &#x201c;Territory&#x201d;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#x201c;Licensed Products&#x201d;) and commercialize any such products and (iii) manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory; and (2) an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the license under the Romeg License Agreement, the Company paid Romeg an up-front license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33235d51-9558-4848-a109-d124052f4576" contextRef="C_9a36dab1-2630-4e69-8371-8793ba9072bb" name="sclx:Upfrontlicensefee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and has agreed to pay Romeg (a) upon the Company&#x2019;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8eae7160-4d0a-4589-a9cd-1476563aa54f" contextRef="C_9a36dab1-2630-4e69-8371-8793ba9072bb" name="sclx:PaymentUponTheAchievementOfNetSales" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, (b) certain royalties in the mid-single digit to low-double digit percentages based on annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c) minimum quarterly royalty payments totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e799b2c-7c58-4066-a2a2-ea64556a2cb6" contextRef="C_9a36dab1-2630-4e69-8371-8793ba9072bb" name="us-gaap:PaymentsForRoyalties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i) expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii) the tenth anniversary of the effective date of the Romeg License Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1c68ec0-e287-4707-a5af-ff4ae583dc13" contextRef="C_cb7297d5-c3c9-4562-83bf-bfeaeab23e3a" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is comprised of the upfront license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_182aeda3-9ce5-41d9-a8c6-d0d80ea8557a" contextRef="C_9a36dab1-2630-4e69-8371-8793ba9072bb" name="sclx:Upfrontlicensefee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and a deferred consideration of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7aa4686-7370-4192-b2cf-9de9caefa0fc" contextRef="C_646df392-6d69-4b69-80f2-861bf594ef6a" name="sclx:Deferredconsiderationliabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent sales milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, and will not be recognized until the contingencies are realized. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2f4d390-0a1d-46c7-b2ca-09a24ba3163d" contextRef="C_646df392-6d69-4b69-80f2-861bf594ef6a" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> contingent consideration was recognized as a liability or included in the fair value of the assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022. The Company determined the useful life of the intangible asset to be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4e3e3bf2-9097-451f-936b-4bda93ae1f8d" contextRef="C_9a36dab1-2630-4e69-8371-8793ba9072bb" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, which approximates the life of the licensed patents covering the Initial Licensed Product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_1693e1d0-d454-4062-b2e2-091f170336c4" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section172"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_af68513a-e196-4390-8205-10efaf40f1a0" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.662%;"></td>
        <td style="width:1.237%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.138%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.223%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.123%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.223%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.578999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.223%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.594%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br />in Active<br />Markets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Other<br />Observable<br />Inputs (Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24fe7873-8fb8-4032-9d68-f2926f583cab" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9db4067c-9f64-465f-b4af-44e28e487371" contextRef="C_a527389d-306f-4919-bfea-9e278fdd7f82" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45d9bf69-7146-4ba3-adcc-43b5611ff42a" contextRef="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e576b092-8c6b-4c3b-b12d-e91caaf14c91" contextRef="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c51528a-4212-4ecc-a9cb-655308c7d35a" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6eca079d-4777-44b7-bbe4-789224588eac" contextRef="C_a527389d-306f-4919-bfea-9e278fdd7f82" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5e9d170-35b6-4d98-8852-8b49f4db1105" contextRef="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ac5a283-ac7b-44a2-bcf1-00ed5c7198e1" contextRef="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_1b42e5e5-376a-4619-9690-cb8f5630cc07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a25b415-1268-4313-80be-87be6233c64f" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,231</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7258fcef-b573-4bbe-b3ec-8d65c5bef3f5" contextRef="C_a527389d-306f-4919-bfea-9e278fdd7f82" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1228804c-6341-4c21-8610-b31223f513ef" contextRef="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_396cc7f9-0e21-46cf-b27a-14e19c2967ca" contextRef="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,231</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ef68670-b90f-4ffb-8198-eaebd7611b6a" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_708be5d4-a9d0-4908-bbbe-b2da444eaa07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_174a237b-3e62-4fa6-915e-8a53d0d37000;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d1efa72-3953-40c8-87e8-e37e4709c65b" contextRef="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7588a4b7-21c3-424a-b1ad-0736ffde990c" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,394</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7007300f-cce2-4eac-b01e-4bc535dd2b7e" contextRef="C_a527389d-306f-4919-bfea-9e278fdd7f82" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e616a7c6-d537-4644-b4d1-52659c82336b" contextRef="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad6d8c9a-362a-4b60-a600-e3c93ef8eb30" contextRef="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,394</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.297%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.901%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.901%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.369%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.521%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br />in Active<br />Markets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Other<br />Observable<br />Inputs (Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Unobservable<br />Inputs (Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a08742c-22da-4cef-bf4c-16e62036ab9b" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,338</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e775dca3-1b4c-45d9-957b-701f5e597214" contextRef="C_a476f78c-ccf8-4bfe-b276-63e339cbc4fd" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,338</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc0fa511-9fcb-41ce-aafc-2124b7572544" contextRef="C_305b4be4-c15c-4501-b464-80c28ee532ec" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_208c3065-8b5f-40e6-ad17-b6f1c75482ca" contextRef="C_8a1e9628-d82e-4638-abce-1a2d0888da09" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f18bfe2a-6dbf-4bf3-a675-e2c28c80e518" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,338</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56c43b4d-bb75-4691-a0ba-f272000b53bb" contextRef="C_a476f78c-ccf8-4bfe-b276-63e339cbc4fd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,338</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84244b52-addb-4bf4-ab40-b0f643020260" contextRef="C_305b4be4-c15c-4501-b464-80c28ee532ec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_679ec885-84fc-4211-8e78-ed02e7c92f61" contextRef="C_8a1e9628-d82e-4638-abce-1a2d0888da09" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2e14ac05-2d70-479b-834b-0da0a2e27285;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2111b4f-f219-4e47-bcf0-8bba135b1e0a" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cff1c66f-c820-4f64-acb0-8bc30ac895db" contextRef="C_a476f78c-ccf8-4bfe-b276-63e339cbc4fd" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0a4d6ff-9762-419c-be82-4ac17650da1c" contextRef="C_305b4be4-c15c-4501-b464-80c28ee532ec" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ede16437-bf41-4922-886f-8b8028edf624" contextRef="C_8a1e9628-d82e-4638-abce-1a2d0888da09" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba998113-20bf-4cd7-b1d0-84255ff5d110" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e83a1cc1-1fff-486f-b2f9-67d0b079bae1" contextRef="C_a476f78c-ccf8-4bfe-b276-63e339cbc4fd" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d748ef1b-34af-4ab1-b735-a1ba985580f0" contextRef="C_305b4be4-c15c-4501-b464-80c28ee532ec" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7034ab48-cd8c-4df7-a487-771fa7c77266" contextRef="C_8a1e9628-d82e-4638-abce-1a2d0888da09" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and cash equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s financial assets carried at fair value are comprised of cash and cash equivalents.  Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable.  These assets are valued using inputs observable in active markets for identical securities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded a gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a09da2d-077b-403b-8925-c036043aee4b" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50a9810f-417c-4f14-acf5-6f406c39ccc8" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1862d57-dbcb-46c8-b152-0e5c020865af" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on derivative liabilities for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note 7) and Private Warrants. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19c0b59c-9f0b-4c75-8f34-ff95d9bf1e85" contextRef="C_e9f1e9c3-d961-4504-8da6-3bd4eb3c8fbc" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> immediately after </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entry into Amendment No. 4 (see Note 7) associated with the Scilex Pharma Notes on June 2, 2022. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No. 4. Significant Level 3 assumptions used in the measurement included a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7190e34c-f364-4687-87fa-3de395759151" contextRef="C_8af8c6e1-609d-44ef-9f26-2b6bd7056a94" name="sclx:RiskAdjustedNetSalesForecast" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% risk adjusted net sales forecast and an effective debt yield of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1925e3d-73e7-4293-948e-5b17535a89df" contextRef="C_8af8c6e1-609d-44ef-9f26-2b6bd7056a94" name="us-gaap:DebtSecuritiesAvailableForSaleWeightedAverageYield" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 7) and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022. At the closing of the Business Combination, the Company assumed a derivative warrant liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_41f57cde-2f51-43b9-9298-50e67016606a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to Private Warrants (See Note 8). The fair value of derivative warrant liability related to Private Warrants was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64066aeb-4a33-4e53-ad1c-3d965d2a5178" contextRef="C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7" name="sclx:DerivativeWarrantLiabilityPrivateWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7e4940ee-662a-4b4e-97d1-ea159075b3dc" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.153%;"></td>
        <td style="width:1.916%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.93%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending Balance at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_398bced8-5877-4a83-85a7-b5c06dec1ce2" contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan derivative liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6784ab27-3fe5-45df-8490-ea8f0e4592aa" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:LoanDerivativeLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,800</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Re-measurement of fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_488ff1ce-aeb3-4cb8-8f52-56daa17b9d9f" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:ReMeasurementOfFairValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">800</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_922fa547-a1fb-4353-b600-59a94ded62b5" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Re-measurement of fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04809ef4-bf52-4f6e-b523-070c0d211ff1" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:ReMeasurementOfFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77199c4a-af6f-4586-bb79-2f6c5b78a463" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Private Warrant liability acquired as part of the Business Combination</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06e2457b-770a-4ddf-948b-38f5e66e1a18" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:PrivatePlacementWarrantLiabilityAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,545</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeiture of Private Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be56dff0-1082-4ddb-86f2-a9e437754a9e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:ForfeitureOfPrivateWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,696</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value measurement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09d2296b-0c04-4dcb-9778-4b71b1272d40" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:ChangeInValuationInputsOrOtherAssumptions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">38,710</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96677002-d18e-400b-8cc8-2e097e7639de" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,231</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrant Liability Measurement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level 3 fair value measurement. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f6019b4f-1a08-4242-bc7d-8174ad0fbf53" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:FairValueConcentrationOfRiskTextBlock" escape="true" continuedAt="F_f6019b4f-1a08-4242-bc7d-8174ad0fbf53_1"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants. A summary of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inputs used in valuing the derivative warrant liabilities is as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_f6019b4f-1a08-4242-bc7d-8174ad0fbf53_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
       <hr style="page-break-after:always;" /></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.537%;"></td>
        <td style="width:1.624%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.107%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.624%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.107%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 10, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83505706-62e4-40f2-a9f8-6462e83e5163" contextRef="C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7" name="sclx:EquityValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.99</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24532bdb-1d65-4f49-b35d-a9b4ddabd4c2" contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21" name="sclx:EquityValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">9.01</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53d980c2-b37b-482c-a053-359627014b12" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25363114-e257-4689-9790-b78543bffe17" contextRef="C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_14a6e055-6ed7-42d9-8cea-a7eee1ae4151" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.86</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0e11d5e4-3ca2-4823-961c-9b17e9946696" contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15bd4454-04e2-4229-8524-61daf3ebe2e2" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">35.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2d45e1c-03f9-4e5e-8573-7533ccc74e7c" contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e901e6b2-7a46-4e0d-97c7-385165d4e2ad" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">3.94</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_272fe525-dfc8-4c08-899c-653a4f2185e5" contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">3.91</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d0fc8b5-ccfb-416e-84dd-45bc4a1d85b8" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15ba696c-7181-4254-942d-9d0d9abf918f" contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Call option value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebb5899b-6e77-4c51-b811-dc6b2074cf5e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:CallOptionValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ae06e58-a9a0-4c4a-b8f7-9f9582740d19" contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21" name="sclx:CallOptionValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Development Milestone Payment represents a liability under the scope of ASC Topic 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as it pertains to a potential contractual obligation to settle a fixed value in a variable number of shares of Common Stock. Upon the achievement of FDA approval for a new drug application for SP-104, the Company will transfer $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecafb5c4-e34d-47bb-ac2d-bad9f7ca6b20" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant Level 3 assumptions included the likelihood of receiving FDA approval for SP-104, expected timing for receipt of FDA approval for SP-104, and a discount rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5210986d-2487-4bea-8a77-c3b9598b0ed9" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:ProductLiabilityContingencyAccrualDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a341f1c-180b-4888-ab43-6e2c59cebd03" contextRef="C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7" name="sclx:FairValueOfContingentConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no transfers between fair value measurement levels during the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a189371a-a404-4b9a-8cf1-809515ef1cac" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section173"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Property and Equipment, Net</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_50f6ee9b-5be0-4383-86ed-4bae9b99e817" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.32%;"></td>
        <td style="width:1.583%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.772%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.583%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.742%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers &amp; equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2980b08-e787-4c22-ae1d-bf441cc1b4b2" contextRef="C_1c394325-8608-4ec1-8f78-11dd10ae9413" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ad0a502-929b-4ddb-a8c5-2e2065d65b0f" contextRef="C_76b68a36-8bf6-4b4f-ba40-ee105d4ec879" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57a54435-f89c-4c04-9c2f-94d874c570dc" contextRef="C_bd06b1ee-3d7a-4324-8584-ffe7cba561aa" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">118</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e059e7c-aee8-44bc-9a68-bf0df8ff3805" contextRef="C_7a25c562-96ff-46d5-bbd4-d140bf78fd97" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">118</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84436108-0866-40e7-bb10-3ea3c19dcdc3" contextRef="C_5ecb841e-8811-42ee-b52f-1ff866488d24" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4629ead8-3d00-4b71-ba55-aa0ff6556288" contextRef="C_e23bb04d-0ba8-4323-a7aa-cc2b64211427" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80ba3894-cd54-4802-ac3d-5f206f2b2ddc" contextRef="C_dbf37b66-c5d5-46d3-bd3a-c9a534d9acd9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">689</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6ecbe3f-e236-4ae1-8f4b-6735f03eac46" contextRef="C_6e8d69bd-8277-4214-b3a2-0f8215199def" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">689</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49b542d6-b77c-4c8a-b1f3-e76758084865" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c28ef217-5061-4567-8801-f8e6c41d5174" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab805bc3-9c6e-4be6-b0ba-1156410a1c8b" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">167</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b61142e1-a3b4-4039-a3d5-dac31555fe85" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1290a6e1-6201-49df-b1b5-d82bd493a240" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">772</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_502b508a-163d-453a-aee7-1c9e72ca3196" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">805</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense for each of the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0315d384-2c61-48c0-9c80-e745e8db114a" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8d8dc05-c043-4f17-89e7-3dee17faf357" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46090e20-fa47-4fdc-a88c-f198103057aa" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand, respectively.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_f1823a9f-2285-4942-85b5-d50635e5ce9f" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section174"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Goodwill and Intangible Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and December 31, 2021, the Company had recorded goodwill of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4134b950-640a-4a20-8d00-80848a5d4792" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_bc5f16f5-9b7e-41ab-8af0-588bcf427c0b" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.5</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company performed a qualitative test for goodwill impairment during the fourth quarter of 2022. Based upon the results of the qualitative testing, the Company concluded that it is more-likely-than-not that the fair value of the Company&#x2019;s goodwill was in excess of the carrying value and therefore performing the first step of the two-step</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impairment test was unnecessary. The conclusion has not changed as of December 31, 2022 and no goodwill impairment was recognized for the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_72d17f94-f79b-4347-8ecb-746e104e8a7c" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" escape="true" continuedAt="F_72d17f94-f79b-4347-8ecb-746e104e8a7c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the Company&#x2019;s identifiable intangible assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and December 31, 2021 is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_72d17f94-f79b-4347-8ecb-746e104e8a7c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:40.216%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.583000000000002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.293%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.827%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.293%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.787%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangibles, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent rights</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_389e0b5f-5e18-419b-82e5-37c8dc776158" contextRef="C_7a74f725-b9ea-4b81-818b-1b7c312abf01" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,630</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_274ed6b3-74f5-4bc2-995f-15d4a92f258d" contextRef="C_7a74f725-b9ea-4b81-818b-1b7c312abf01" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13,415</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6430d90a-86b4-40f8-b872-70ab783560ee" contextRef="C_7a74f725-b9ea-4b81-818b-1b7c312abf01" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,215</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired technology</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f3b9d58-9c13-49ed-be3b-eaf2a85c5bdd" contextRef="C_c1803839-1bed-4d8d-a474-a5546b31743c" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,940</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de1eef6c-f170-4093-ab5f-699fa2382ed6" contextRef="C_c1803839-1bed-4d8d-a474-a5546b31743c" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,216</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_793670ab-9f0f-48a9-9541-0a798f60a67c" contextRef="C_c1803839-1bed-4d8d-a474-a5546b31743c" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired licenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77d95468-471a-4189-8195-bc07620cc854" contextRef="C_fb34a34f-10db-4900-ac2a-b95cc1252ca0" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,711</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ccbd553-79ca-45ff-9b93-080e72b0c3a2" contextRef="C_fb34a34f-10db-4900-ac2a-b95cc1252ca0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c4edaa5-c170-4dfc-9302-63896c7f2f79" contextRef="C_fb34a34f-10db-4900-ac2a-b95cc1252ca0" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,527</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assembled workforce</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f67d6aa7-df46-49f2-9472-a46fe816300d" contextRef="C_ef14117d-6b86-46ed-956e-d73420b1a933" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6404738-2edb-4108-9f46-ff56cdf887d4" contextRef="C_ef14117d-6b86-46ed-956e-d73420b1a933" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23d57470-d488-4924-be01-10456e46c656" contextRef="C_ef14117d-6b86-46ed-956e-d73420b1a933" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6f2fcaa-08a1-47c3-bb1b-7abead35a25d" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,781</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a55333e6-6404-465d-ad97-fd741a0eb0b5" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">20,190</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_108e1664-3e8c-4774-9ecd-4b69a9e84838" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:39.894%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.459%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.28%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.447%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.268%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.651%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangibles, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent rights</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc3ee6fd-20de-4b92-8e0c-debcde883668" contextRef="C_d38defbd-6d26-448d-a459-d2d7ff5e7a40" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,630</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0f54ba7-e75b-4414-9a93-4b6bd5af45bd" contextRef="C_d38defbd-6d26-448d-a459-d2d7ff5e7a40" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,239</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ea37416-eb84-4624-98a6-37ade40dba3b" contextRef="C_d38defbd-6d26-448d-a459-d2d7ff5e7a40" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,391</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired technology</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7d56678-07dc-48de-a1ea-e64288fd2673" contextRef="C_3313f304-eb89-4d42-83ee-725fd81202b7" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,940</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4131c4fb-be17-4b3c-88f8-bb4bcc18b436" contextRef="C_3313f304-eb89-4d42-83ee-725fd81202b7" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,754</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5174e2e-1619-472a-99bb-aaf48c0de52c" contextRef="C_3313f304-eb89-4d42-83ee-725fd81202b7" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assembled workforce</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_147ad2af-86b0-43f4-8c18-860256310fad" contextRef="C_509f938b-6ead-4be2-8bdc-b00905b87017" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d12c1cb0-4bb5-4970-a16d-49a0b873646d" contextRef="C_509f938b-6ead-4be2-8bdc-b00905b87017" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a52897a-2a08-44d4-aabd-e6f6ab14a159" contextRef="C_509f938b-6ead-4be2-8bdc-b00905b87017" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b5d6c54-e577-4b83-92a3-981e4520a3df" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,070</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbef0e43-ba45-481b-bf96-107650a6b718" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16,268</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08c6967c-c743-4027-9567-59413afbde1b" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,802</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f2b20b5-f84b-43ef-afa9-2968e52cb4cf" contextRef="C_1bf41c40-384d-4879-a540-39666147391f" name="us-gaap:AssetAcquisitionConsiderationTransferred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was assigned to acquired licenses with an amortization period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_061eeed1-f368-475a-b1c2-9179a645ec4d" contextRef="C_1bf41c40-384d-4879-a540-39666147391f" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the weighted average remaining life for identifiable intangible assets was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_14b392b9-4493-4d1c-8101-5b6725527ddb" contextRef="C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years. Aggregate amortization expense was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eeeb7ad1-f77f-48cc-be73-bfa67649434b" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d561d068-a972-4ccc-bde0-cce79c7b7314" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a7ae762-8abb-4b1b-b4d1-b5431501d218" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the years ended December 31, 2022, 2021, and 2020, respectively. Patent rights and acquired technology are amortized over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6d9d1432-62cc-4c78-ba38-5d9b98b8746d" contextRef="C_e1a7d0f1-3664-4a42-9233-282dd426f358" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-year period.  Assembled workforce is amortized over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d85b3cf2-16e6-47f7-a094-3c96dbd3e362" contextRef="C_51878a55-90f9-402f-b4db-e8e5f31208c1" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-year period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8a79a1c9-cf44-4f11-81b1-7e879010028b" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated future amortization expense related to intangible assets at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:85.378%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.621%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13b2e8bc-89e1-4a55-9cff-2a2519c48bbe" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_047aada0-9c1d-42a8-8660-d2f89815da22" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b418617-6488-4fc0-bafe-216aa9d726e7" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,006</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e15aee65-ba69-422b-af52-3bb831d91e9a" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,006</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf76778e-daf4-4ec1-bdde-5aa7428d3062" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,006</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c24b37f-fd74-4529-abb6-aaac1cc3d108" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,436</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bab974ce-0d2d-4a52-baf1-ed1265db92b4" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="sclx:EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_36d24d6f-ba60-45a5-9a36-b0a892a7e914" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section175"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2018 Purchase Agreements and Indenture</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#x201c;2018 Purchase Agreements&#x201d;) with certain investors (collectively, the &#x201c;Scilex Pharma Note Purchasers&#x201d;). Pursuant to the 2018 Purchase Agreements, on September 7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due 2026 in an aggregate principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ab79eaf-27bc-42d7-995b-da7d17893401" contextRef="C_e39da0e0-163c-455f-965a-58ab13bf9d84" name="sclx:AggregatePrincipalAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">224.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the &#x201c;Scilex Pharma Notes&#x201d;) for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c8fe73b-2519-48f3-a3e7-17e67ee5f517" contextRef="C_e39da0e0-163c-455f-965a-58ab13bf9d84" name="sclx:DebtInstrumentPurcahsePrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">140.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the &#x201c;Offering&#x201d;). The Scilex Pharma Notes were governed by an indenture (as amended, the &#x201c;Indenture&#x201d;) with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as trustee (the &#x201c;Trustee&#x201d;) and collateral agent (the &#x201c;Collateral Agent&#x201d;), and Sorrento, as guarantor.  Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#x201c;Guarantee&#x201d;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The principal amount of the Scilex Pharma Notes increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58362889-8117-4bd3-89c2-3a39c000767b" contextRef="C_a8bd7dfd-bf6a-41eb-a0d6-21c0c0e518ef" name="sclx:IncreaseOfPrincipalBalance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on February 15, 2022 as a result of actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December 31, 2021 not equal or exceeding $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a1408db-8f2b-438f-97af-9abe5db788e4" contextRef="C_c64fc25e-92ac-443f-a2c8-1c627ddec5c4" name="sclx:ActualCumulativeNetSales" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">481.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. As a result, the Company recorded the increase of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07b6d6a2-706e-4f7a-85ca-9a43fa40e533" contextRef="C_c64fc25e-92ac-443f-a2c8-1c627ddec5c4" name="sclx:IncreaseOfPrincipalBalance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in principal and non-operating expense at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective February 14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December 31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78ded11a-7bd2-4345-bba0-687fcb74f574" contextRef="C_cce805c3-34ca-4d41-82ac-e95225784312" name="us-gaap:SubordinatedDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in a single lump-sum amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38723842-bbfa-4350-ab1d-cf6bb7adc09a" contextRef="C_fbd32b12-fb83-432d-9c2d-e70a0b209ce4" name="sclx:CashRequirement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_156b8511-5b1d-486d-b982-932afdc3e12e" contextRef="C_d26ddb1f-b0fe-4faf-b8a1-857c9dd18019" name="sclx:NotePrincipalReductionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No. 4 to Indenture (the &#x201c;Amendment No. 4&#x201d;) with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment No. 4, (1) on June 3, 2022, Scilex Pharma repurchased approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c458236f-b12e-4a5d-8a16-147ef5b3a023" contextRef="C_42d227b9-ddaf-4601-acc3-2ee568156933" name="sclx:NotePrincipalReductionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">41.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the aggregate principal amount of the outstanding Scilex Pharma Notes at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1409461-8ea1-49ef-b877-8f55b73ecad6" contextRef="C_60091fdd-6400-442e-a7a0-8a096195f3d1" name="sclx:RepurchasePrincipalInPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the principal amount thereof, (2) the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September 30, 2022 for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b564652-b542-4968-977b-d12001ebe41c" contextRef="C_6adfa385-28e2-4bb5-b8a7-8b66dc48c7de" name="sclx:NotePrincipalReductionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">41.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6f2b5b7-8efa-4dd4-bc31-2239fbc0094b" contextRef="C_6e32c9b3-9d19-4265-8164-574e03766785" name="sclx:ForgivenAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the aggregate principal amount of the Scilex Pharma Notes (the &#x201c;Early Paydown Provision&#x201d;), (3) the minimum cash requirement under the Indenture was reduced to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a854f1dc-d5c3-46d2-ba5b-97e72aeb90f2" contextRef="C_6e32c9b3-9d19-4265-8164-574e03766785" name="sclx:MinimumCashRequirement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4) the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to Sorrento on October 5, 2018 was increased from up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3b7924b-8657-473d-ae24-3079780a886e" contextRef="C_8b8c6875-5daf-4b8b-bbe3-c55418e62301" name="sclx:AggregatePrincipalAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_964fb9ef-2724-4630-96a5-09807bf7ef54" contextRef="C_478baeaf-44cf-43d3-a89f-f421fb630ec5" name="sclx:AggregatePrincipalAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company funded the repurchase with cash-on-hand and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a01f4e1-68a4-4abe-ad49-ed9e82c21f3b" contextRef="C_9c4a15ab-7f26-41bf-ba84-63b74afb22cb" name="sclx:CashReceivedFromParentCompany" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million received from Sorrento on June 2, 2022. The Company concluded that the Amendment No. 4 was a troubled debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No. 4, and accordingly, no gain was recognized in the quarter ended June 30, 2022. Due to a decrease of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eddf42ad-e9ec-458e-98ad-77dc5a22cbaa" contextRef="C_5c97eb44-901a-46bb-99e9-b42a24cc2386" name="sclx:FairValueDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the fair value of the Scilex Notes Derivative caused by the Amendment No. 4, the carrying value of the Scilex Notes was increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1db7d1d1-4f34-4ca6-bf5a-3adae832ace2" contextRef="C_5c97eb44-901a-46bb-99e9-b42a24cc2386" name="sclx:CarryingValueIncreased" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dbed207-01fd-4e83-95df-2314b35873ea" contextRef="C_7ca01e5c-64ba-4811-8dd0-2596f60a100f" name="us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_788276cb-9a4d-40b4-9078-c990da87567a" contextRef="C_6e32c9b3-9d19-4265-8164-574e03766785" name="us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">39.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,  respectively. Pursuant to Amendment No. 4, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83874e42-ad15-4c8e-98ca-98b5bbd8f0b8" contextRef="C_ae30ee0d-8ccb-47a5-834c-471e858d4c23" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The Company funded the repurchase with cash-on-hand and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8a61ac7-f425-4e56-8dda-106fe0ebe356" contextRef="C_4a8702ad-037a-48f2-8a73-f2f31cbe072b" name="sclx:CashReceivedFromParentCompany" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> received from Sorrento on September 28, 2022. The Company recorded a gain on debt extinguishment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43501855-c64d-4e80-8228-0615ffe71ceb" contextRef="C_99d36902-bfd3-4b3d-847f-f4e34de66d2f" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as a result of the extinguishment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_77560baa-a595-4733-a8e2-433a9aa026e5" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Borrowings of the Scilex Notes consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.099%;"></td>
        <td style="width:1.781%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.12%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bf6cbdf-e65b-4443-ab22-ec7c9dffd723" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,997</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt discount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_306bb4f4-68fe-4d89-91a1-0738e544ebdd" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,597</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_105c7d60-5c21-4c6d-88d9-168919682625" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af4aed04-b87b-46fa-8930-6945cc882d66" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:CommercialPaperAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">101,172</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6190b642-735f-416f-ab03-7bd2980660bc" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,135</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long term portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eec2de3e-0416-4d5f-82a1-a6d16af4bef8" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:OtherLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,037</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64562c2a-ea56-4b1e-ac5e-ee7f1ee71390" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company made principal payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79e3a818-a695-4c7c-a3f6-24cf9ab3b973" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">106.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ed76b38-56d2-423d-a656-17726635f9cf" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">45.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c871266-36f6-49ad-96e5-6de63e7de780" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">69.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, respectively. The amount of debt discount and debt issuance costs included in interest expense for the years ended December 31, 2022, 2021, and 2020 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77be56c3-8e1d-48a7-b847-db8fb7f3e8a7" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28ed062e-4bb5-4648-86cc-9838447854c3" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6b7c109-18f9-4e8b-a020-0a97a9471d63" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The Company recorded a gain on debt extinguishment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db9279db-254e-4427-89bf-7829d19882bc" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a loss on debt extinguishment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05101b7c-7703-478f-a33b-2e608e1b59f4" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3468bb23-124c-4acd-bbf4-9594df2e7f10" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gain/loss on debt extinguishment in connection with its repayments of principal made during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Related Party Notes Payable</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 12).  On March 18, 2019, the Company entered into a note payable with Sorrento (see Note 12). On February 14, 2022, Sorrento paid to Scilex Pharma </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05dfd139-53f8-44ba-a09f-bd56ba01569a" contextRef="C_f1bc45ab-d342-4c18-b196-5098efc938e5" name="sclx:PromissoryNote" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in a single lump-sum amount as a subordinated loan (see Note 12). On May 12, 2022, the Company issued Sorrento a promissory note of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_825d7aa3-9600-4ae5-bd5c-742de7222e4b" contextRef="C_46761a2f-b18a-4aaa-8269-68342d732dc9" name="sclx:PromissoryNote" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in exchange for the SP-104 Assets (see Note 3). On November 10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 12).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Revolving Credit Facility</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#x201c;Credit Agreement&#x201d;) with CNH Finance Fund I, L.P. (&#x201c;CNH&#x201d;) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f7b5ddc-4f9f-4da3-bba6-52837fc10e3f" contextRef="C_c80b9c46-2554-4fc5-8b0f-919a277a3868" name="us-gaap:FinancingReceivableRevolvingConvertedToTermLoan" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_addc9c6f-a839-4c2b-8a93-56e0cf129c3f" contextRef="C_01d3fa20-46b6-4e6b-9289-84ca49a349a9" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. All indebtedness incurred and outstanding will be due and payable in full on January 1, 2024; unless the Credit Agreement is earlier terminated. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the outstanding balance was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50d02eac-b227-4e1b-b18c-9a3214ae28b7" contextRef="C_422ae92b-12d6-4a4a-b618-0c2fa63c8e57" name="us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. On February 16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective March 18, 2022. Upon termination, all principal balances and interest accrued were settled.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_09e4e99a-cfd0-4670-908b-4f6a33b2a9f6" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section176"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Stockholders&#x2019; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated statement of stockholders&#x2019; equity has been retroactively adjusted for all periods to reflect the Business Combination and reverse recapitalization described in Note 1. The balances as of December 31, 2022 and 2021 from the consolidated financial statements of the Company as of that date, share activity (Preferred Stock, Common Stock, and additional paid-in-capital) and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the closing of the Business Combination, pursuant to the terms of the Amended and Restated Certificate of Incorporation, the Company authorized </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72461589-286a-42df-b50c-b057327bb396" contextRef="C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">740,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3eaafb72-dba5-43a0-98bf-cf1f00741d84" contextRef="C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e8f96e8-06cd-4beb-9dd8-83bab75e5d18" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">141,348,856</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares issued and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e05ca47f-5778-47fb-9788-3d289058274b" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">132,858,484</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Common Stock outstanding, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the closing of the Business Combination, all previously issued and outstanding shares of Legacy Scilex Common Stock and Legacy Scilex stock options were converted into shares of Common Stock pursuant to the Common Stock Exchange Ratio. The Company has retroactively adjusted shares issued and outstanding prior to November 10, 2022 to give effect to the Common Stock Exchange Ratio to determine the number of shares of Common Stock into which they were converted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of the Common Stock are entitled to one vote for each share of the Common Stock held at all meetings of stockholders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividends</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stockholders are entitled to receive dividends whenever funds are legally available and when declared by the Company's board of directors. No dividends have been declared as of December 31, 2022.The Stockholder Agreement, dated as of September 12, 2022, between Vickers and Sorrento (the &#x201c;Stockholder Agreement&#x201d;), provides that the Company will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, the payment of dividends on shares of the Common Stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidation Rights</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to the rights of the holders of Preferred Stock, in the event of our liquidation, dissolution or winding-up, holders of Common Stock are entitled to share equally in the assets available for distribution after payment of all creditors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the closing of the Business Combination, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0eaebd9-2ca0-474e-b7ba-7ff7e6f44b30" contextRef="C_cea31b52-db39-4e74-9ef9-00fbadd09e8a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">290.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento were cancelled in exchange for the issuance of preferred shares of Scilex (&#x201c;Series A Preferred Shares&#x201d; or &#x201c;Series A Preferred Stock&#x201d;). In connection with the closing of the Business Combination, all issued Scilex Series A Preferred Shares were cancelled and converted into the right to receive 1) one share of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">domesticated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">parent preferred shares (&#x201c;New Scilex Preferred Stock&#x201d; or &#x201c;Preferred Stock&#x201d;) par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3047dbb-2ab1-4293-9e7b-3132022322ef" contextRef="C_5033dffd-d662-4f5b-9fe3-88e68279b972" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and 2) one-tenth of one domesticated parent common stock (&#x201c;New Scilex Common Stock&#x201d; or &#x201c;Common Stock&#x201d; and such transaction including cancellation of all the existing related party indebtedness in exchange for Preferred Stock and Common Stock, the &#x201c;Conversion&#x201d; or &#x201c;Contribution&#x201d;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the Conversion, Legacy Scilex filed a Second Amended Certificate of Incorporation (defined below) to increase the authorized number of shares to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc89a4f0-e412-4369-a217-42cc46675b54" contextRef="C_5033dffd-d662-4f5b-9fe3-88e68279b972" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and a Certificate of Designation (&#x201c;Certificate of Designation&#x201d;) to designate the rights, preferences, and privileges of Scilex Series A Preferred Shares. In connection with the closing of the Business Combination, the Company filed the Certificate of Designation and issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a515655-c80a-4541-bfcd-f7c830d6eb59" contextRef="C_52b44a02-592f-4ce7-8c2c-3d786b8c7f58" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,057,097</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Series A Preferred Stock to Sorrento. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0521dd38-2dc5-4f75-8a05-dee6abf675f6" contextRef="C_5033dffd-d662-4f5b-9fe3-88e68279b972" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,057,097</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Preferred Stock outstanding. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3260da15-3aab-4797-b0aa-ebaa42150192" contextRef="C_9b7ed203-c059-4dea-8727-86670689b7cc" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Preferred Stock outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s Board of Directors have authority to issue such shares of Preferred Stock in one or more series, to establish, from time to time the number of shares to be included in each such series, and to fix the dividend, voting, and other rights, preferences, and privileges of the shares. Other than the Series A Preferred Stock issued to Sorrento in connection with the closing of the Business Combination, there are no other Preferred Stock outstanding and the Company has no current plans to issue any other shares of preferred stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of shares of Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Preferred Stock will be entitled to one vote for each share of Common Stock that such share of Preferred Stock would otherwise be convertible into pursuant to a deemed conversion on the record date for the determination of the stockholders entitled to vote.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Stockholder Agreement, holders of Series A Preferred Stock have the right to designate each director to be nominated, elected or appointed to the Board of Directors of the Company. The Series A Preferred Stock also has certain protective provisions, such as requiring a written consent of the holders of Series A Preferred Stock to change or amend their rights, powers, privileges, limitations and restrictions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividends</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of the Preferred Stock are not entitled to dividends unless the Company pays dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of the Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidation Rights</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to the rights of the holders of parity shares (if any), in the event of our liquidation, dissolution or winding-up, holders of Preferred Stock rank senior to the Common Stock and are entitled to share equally in the assets available for distribution after payment of all creditors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assumed Public Warrants and Private Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following the consummation of the Business Combination, holders of the Public Warrants and Private Warrants are entitled to acquire Common Stock of the Company. The warrants are exercisable on the later of (a) the completion of a Business Combination and (b) 12 months from the closing of Vickers's Initial Public Offering. The warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each warrant entitles the holder to purchase one share of Common Stock for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b07ccefb-f175-44c7-8f66-4a571607392e" contextRef="C_464851d6-2036-40d8-94d5-168fe9bff9ac" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the reported last sale price of the Common Stock equals or exceeds $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35d8b462-83d0-4bf3-9b98-16d51f3313dd" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">18.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5628f8a5-ed1d-4f84-b9a9-2419f59cf790" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per warrant upon not less than 30 days&#x2019; prior written notice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the warrants. As of December 31, 2022, there are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2aa4935e-5421-4a3c-9981-b69549f89583" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,899,988</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Public Warrants outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the closing of the Business Combination, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7371d4a6-3d4b-47c5-8c3c-cc68018c7fc5" contextRef="C_b50d45e3-e036-46e1-88f2-6346a47e412b" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,104,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Private Warrants were transferred to Sorrento pursuant to the Warrant Transfer Agreement between Vickers, the Sponsors, Sorrento and Maxim Group, LLC where Sorrento acquired all rights, title and interests to such Private Warrants (&#x201c;Warrant Transfer Agreement&#x201d;). As of December 31, 2022, there are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49c98ead-d2ed-40fe-9288-ed6ce0ebb5a6" contextRef="C_3a917c50-4370-49ab-9afd-58aaa9a10804" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,104,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Private Warrants outstanding, of which </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f396d0d-db94-424d-9621-4ca373352561" contextRef="C_d8ba7d57-830b-450b-b045-491a8e4913bd" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,104,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Private Warrants are held by Sorrento and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04d22306-ce38-44ab-92a7-1b4a409185e3" contextRef="C_05185b29-2199-41ac-97f8-a22476c305be" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Private Warrants are held by Sponsors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legacy Scilex Common Stock and Preferred Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the Business Combination, Legacy Scilex had the authority to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cdb1c18-737e-4c66-99f5-e3c8025cf56d" contextRef="C_5202eaa2-94ce-4852-a791-98e95950e6e6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6342b948-684d-48d6-9986-138925b06041" contextRef="C_5202eaa2-94ce-4852-a791-98e95950e6e6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f18a165-cf48-4922-81de-11c6c191e858" contextRef="C_5202eaa2-94ce-4852-a791-98e95950e6e6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff1610c8-e605-4099-ab88-2373dd090841" contextRef="C_5202eaa2-94ce-4852-a791-98e95950e6e6" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share per the Certificate of Incorporation dated February 27, 2019. The Certificate of Incorporation was amended and restated on March 4, 2019 (&#x201c;First Amended Certificate of Incorporation&#x201d;), in which Legacy Scilex had the authority to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f288548-d159-4595-9340-eddae6b90af1" contextRef="C_7cbfb5ab-baf8-419e-afef-9b3373e009f4" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">350,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10db7de5-c55a-468c-93de-fafc68b256fa" contextRef="C_7cbfb5ab-baf8-419e-afef-9b3373e009f4" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50dca872-d817-4762-b1a4-73d3e4dbaf35" contextRef="C_7cbfb5ab-baf8-419e-afef-9b3373e009f4" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f775979-c34e-4ee0-9f88-40bc378b7779" contextRef="C_7cbfb5ab-baf8-419e-afef-9b3373e009f4" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The First Amended and Restated Certificate of Incorporation was amended and restated on November 10, 2022 (&#x201c;Second Amended Certificate of Incorporation&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the Second Amended Certificate of Incorporation, Legacy Scilex had the authority to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d4cc429-16e2-46c6-ac39-e38987f5be63" contextRef="C_d23acd9a-b5cb-47a5-b3c3-5c16f3f1a346" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">785,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, consisting of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1af596d0-02f0-4318-8079-8d284fb42090" contextRef="C_c0de8b1c-7d16-427b-aa57-833ab07979da" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">740,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a074ad6d-5dbb-4173-b851-e17065ff1d14" contextRef="C_c0de8b1c-7d16-427b-aa57-833ab07979da" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock. Immediately prior to the Conversion, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e895af1-e6b5-4a27-a66f-a5cd35f627cb" contextRef="C_c0de8b1c-7d16-427b-aa57-833ab07979da" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">197,566,338</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Legacy Scilex Common Stock outstanding and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_221324fe-8eba-4ba6-91ad-24fed78b5893" contextRef="C_44ed269a-dde2-4886-8ee5-2f9c77ffdde5" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,057,097</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A Preferred Stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab8927ca-961d-4dee-a824-87baef65ac94" contextRef="C_44ed269a-dde2-4886-8ee5-2f9c77ffdde5" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, of Legacy Scilex outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Yorkville Standby Equity Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 17, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#x201c;Yorkville Purchase Agreement&#x201d;) with Yorkville, whereby the Company has the right, but not the obligation, to sell to Yorkville up to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_044ecaba-c20b-4d73-af3c-ea72c18d7111" contextRef="C_635fb103-c71a-477c-8c47-7047957e404b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">500.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of shares of its Common Stock at its request any time during the 36 months following the execution of the Yorkville Purchase Agreement, subject to certain conditions. Pursuant to the Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a sale of Common Stock (each such sale, a &#x201c;Yorkville Advance&#x201d;) will be purchased at a price equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5ecfdbe-655f-4f71-87d0-3b34cec1bcfd" contextRef="C_9da5d773-9803-4cb9-b88b-b575366eed3d" name="sclx:PurchaseOfStockPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">98</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the lowest daily volume weighted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">average </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">price of the Common Stock for any trading day (&#x201c;VWAP&#x201d;) during the two consecutive trading days commencing on the date of delivery of a written purchase notice to Yorkville (each, a &#x201c;Yorkville Advance Notice&#x201d;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for Yorkville's commitment to purchase shares of Common Stock at the Company&#x2019;s direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, upon execution of the Yorkville Purchase Agreement, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d40d138b-4e44-43c2-9709-f28184da87f0" contextRef="C_0acf01dd-c0f8-474b-86b7-9a4ee39ecb2c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock to Yorkville and paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6cafcf1-3407-4768-8259-e51458f13804" contextRef="C_fb1d9fe2-1ba9-49c8-9a85-dcf2896bdf52" name="sclx:StructuringFees" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in structuring fees. The registration statement on Form S-1 (File No. 333-268607) related to the Yorkville Purchase Agreement was filed with the SEC on November 30, 2022 and was declared effective by the SEC on December 9, 2022. As of December 31, 2022, there were no shares sold to Yorkville under the Yorkville Purchase Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Note 14 &#x201c;Subsequent Event&#x201d; below for a subsequent event related to the Yorkville Purchase Agreement.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_62df364c-b0de-436a-8d29-b2eebf967c4d" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="section177"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Stock Incentive and Employee Benefit Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated statements of stockholders&#x2019; equity / (deficit) have been retroactively adjusted for all periods to reflect the Business Combination and reverse recapitalization described in Note 1. The balances as of December 31, 2022, 2021, 2020 from the consolidated financial statements of the Company as of that date, share activity (stock options) and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2017 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#x201c;Scilex Pharma 2017 Plan&#x201d;).  The Scilex Pharma 2017 Plan reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45ad3504-c5c5-44e0-86b4-1723e8b7cf6e" contextRef="C_e2cce05e-1a26-43e6-8f1f-e439a7aa2acd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="INF" format="ixt:numdotdecimal">24.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million shares of Scilex Pharma common stock.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_960c0f34-f380-421a-9ff1-4138fe07dc72" contextRef="C_4a5c0b06-915d-455f-9fc7-0f9a23843003" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Scilex Pharma 2017 Plan was amended and restated on July 5, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#x2019;s common stock outstanding and unexercised immediately prior to reorganization was cancelled and substituted for that number of options to acquire Legacy Scilex Common Stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scilex Holding Company 2019 Stock Option Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#x201c;2019 Stock Option Plan&#x201d; or &#x201c;Prior Plan&#x201d;) on May 28, 2019. The 2019 Stock Option Plan was approved by the Company&#x2019;s stockholders on June 7, 2019. As of December 31, 2019, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_141b839f-3e2c-477e-98a6-369630fdb6c3" contextRef="C_58cd7445-cfd3-4b6c-9853-77975484a3f9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="INF" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million shares of Scilex Common Stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b9e5013e-21de-4ee9-9c4f-8b1b8a7947fc" contextRef="C_ffce1a83-cdb6-4f8b-8ce0-60c88047dbe7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the consummation of the Business Combination, the 2019 Stock Option Plan was terminated and no further awards were granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted under the terms of the Equity Incentive Plan (defined below).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scilex Holding Company 2022 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d;) on October 17, 2022. The 2022 Equity Incentive Plan was approved by the stockholders and became effective on November 9, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total number of common shares for which incentive stock options (&#x201c;ISOs&#x201d;) may be granted under the Equity Incentive Plan is not to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02847acf-91e4-465d-a21e-8b82b6c4a469" contextRef="C_43ab2205-1c3d-4a4c-81af-b8effc0a8d3f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,622,712</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares plus a  number of shares of Common Stock equal to the number of shares subject to outstanding stock awards granted under the Prior Plan (&#x201c;Returning Shares&#x201d;), </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_79a0348c-3323-49ee-a828-5e9bc1627dc3" contextRef="C_55510dfd-6682-410d-b6b4-4d16606f2bde" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if any, as such shares become available from time to time, which the amount will be increased commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7aa7de2d-291d-4857-a11c-38194645fb1c" contextRef="C_55510dfd-6682-410d-b6b4-4d16606f2bde" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of Common Stock outstanding on December 31 of the preceding year, (ii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6c9fda5-d380-425c-b820-aa91d40e2a45" contextRef="C_777530a8-90c5-459f-8a78-9891fb3b3069" name="sclx:CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,311,356</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock, and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there were no options to purchase shares of Common Stock outstanding under the Equity Incentive Plan and options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb98739b-eb33-450c-b6fc-297ffca9d2e5" contextRef="C_777530a8-90c5-459f-8a78-9891fb3b3069" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,939,436</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Common Stock were outstanding under previous plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation recorded within operating expenses was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ad6b72f-f2d1-447d-8a23-ed404e767c72" contextRef="C_55510dfd-6682-410d-b6b4-4d16606f2bde" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93674ebe-f66f-4f32-92e1-38035a2e3548" contextRef="C_67497c23-14fc-4051-a630-4c59813052eb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e482881-2f22-481d-af56-32a214426b9b" contextRef="C_fd0b590c-8ba4-42a9-a808-760e195081f7" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the years ended December 31, 2022, 2021, and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total unrecognized compensation costs related to unvested employee and non-employee stock option grants as of December 31, 2022 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6246554-cd6f-4d9f-b190-d8d891cb46a0" contextRef="C_777530a8-90c5-459f-8a78-9891fb3b3069" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the weighted average period over which these grants are expected to vest is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d8e87fb5-b1a9-446c-b5c7-d5ddac672e5a" contextRef="C_9b5ecdb8-3bc8-4088-bf74-05a8fbd7c323" name="sclx:WeightedAveragePeriodOverGrant" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scilex Holding Company 2022 Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 17, 2022, the Board adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP was approved by the stockholders and became effective on November 9, 2022. The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward the success of the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase the Common Stock in a manner that may qualify for favorable tax treatment under Section 423 of the Internal Revenue Code of 1986 (&#x201c;Code&#x201d;) (the &#x201c;423 Component&#x201d;) and accordingly, it will be construed in a manner that is consistent with the requirements of Section 423 of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the &#x201c;Non-423 Component&#x201d;) in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by the Board, it will operate and be administered in the same manner as the 423 Component.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Board administers the ESPP and will have the authority to determine how and when purchase rights are granted and the provisions of each offering. Initially, the total number of shares of the Common Stock that may be issued under the ESPP will not exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_318c6cd2-0d72-496f-8888-c389723373ae" contextRef="C_7bd18d66-7285-40d4-8961-714fd8c2eb8d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,462,271</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Common Stock. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_846f9e71-ebfc-40e5-a47c-b4bea273c47f" contextRef="C_4e69aafa-547e-45e9-bdf7-d87792ef197d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" continuedAt="F_846f9e71-ebfc-40e5-a47c-b4bea273c47f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">number of shares of the Common Stock that will be reserved for issuance will automatically increase on January 1 of each year for a period of up to ten years, commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_846f9e71-ebfc-40e5-a47c-b4bea273c47f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_275858fc-656d-48a9-8e58-d7f1b7b100ca" contextRef="C_4e69aafa-547e-45e9-bdf7-d87792ef197d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of the Common Stock outstanding on December 31 of the immediately preceding calendar year; (ii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b07a19f4-cfba-48f0-8a6f-dc483a7e00be" contextRef="C_b13cd8e3-7db7-4217-8072-5fe48b25740e" name="sclx:CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,827,839</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Common Stock; and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year, provided however, that the Board may act prior to January 1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i) to (iii) above.</span></ix:continuation></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba99dbfc-9d82-4aca-84bd-40f5a408dd2d" contextRef="C_b13cd8e3-7db7-4217-8072-5fe48b25740e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares outstanding under the ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option Valuation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52104eb0-0c4d-47c9-bb23-a831b0b6fa81" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_52104eb0-0c4d-47c9-bb23-a831b0b6fa81_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the year ended 2020 is set forth below:</span></ix:nonNumeric></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_52104eb0-0c4d-47c9-bb23-a831b0b6fa81_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.208%;"></td>
        <td style="width:0.344%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:24.32%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.127%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted &#x2013;average grant date fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42127bac-bf5e-41c8-ad43-08e0cf6ecbaf" contextRef="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9549f50c-fa33-4917-87fa-a92dc99a1a4a" contextRef="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock-price volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33030936-f1b8-42ee-ad6f-688e6b53dc17" contextRef="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">90.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52f97603-77c5-427c-a53c-405878f71425" contextRef="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term of options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9e7e52e6-e67f-4b8a-95fa-284cfaa7e6b1" contextRef="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value per share of common stock on date of grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8c066a1-e48b-4521-a82b-0344b8b409c9" contextRef="C_dc7d0f2d-5bbb-46cf-929e-8eb3fbe1169a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.72</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e643be7-e023-4731-9842-4afc618ea08b" contextRef="C_dc7d0f2d-5bbb-46cf-929e-8eb3fbe1169a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.72</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company bases the expected dividend yield assumption on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends on the Company&#x2019;s common stock.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected stock-price volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available.  The peer group was developed based on companies in the transdermal patch industry. In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches.  Management further considered the development stage of the peer group companies.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company bases the risk-free interest rate assumption on the U.S. Treasury&#x2019;s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected term of options</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The expected term of options represents the period of time when options are expected to be outstanding.  Because the Company does not have historic exercise behavior, the Company determines the expected term assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7ab7f156-a61f-46d9-bcc9-93eb7d7400c6" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following represents a summary of the options outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 and changes during the years then ended (in thousands, other than weighted-average exercise price):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.598%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.419%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.51%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.991%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.228000000000002%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average exercise price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33a345dd-7141-474c-92ba-66b5d6a104b6" contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">17,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c042995a-c75c-413f-a28c-fd770f65736f" contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.59</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ec6eebd-8bba-4542-8839-2a6671ae85d0" contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,183</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb9d9629-d6ae-4901-980a-39d123e13fae" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">4,172</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a050fbfb-25ad-4eee-ae9d-e3e32c13af39" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.72</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37d8bd63-18ff-4102-9196-92736b79d51b" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">38</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06a46a95-bf3f-4e0e-9ffb-ae3e325cc7bb" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af1f5f24-9419-45f4-9bd6-198bd5b24a05" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7abeaa7-b936-4451-9131-1d158e8df068" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8aa2e447-de17-4790-ae72-303b396f0dd0" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">20,746</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19acaf93-9d57-48a2-9c47-46d84f1bcefb" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7bc46f2-9de3-45e3-ae02-92f3d71bdded" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,172</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c8f542b-3217-44da-bffc-1dea9d239c25" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e89c275-3d2a-4fb6-ba3a-3b643e39b894" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91b5708e-8764-4340-8b52-9923931a1922" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0cbae00-6aef-4a3f-b6ef-ec7ab676512a" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_277a2079-bf58-4913-81f8-f5e04bf623d8" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">1,778</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74b2e001-22cf-4943-9cf4-da01a4f1e20e" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.01</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0cfb768-9e5f-41a8-8600-cf0a9dd83739" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">18,968</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fd3bff9-ce8d-4ee0-b5ec-7f8e66f04d15" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee3acf38-3e47-4c15-a981-bcc5e8a899ce" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">915</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1316335-27a0-474d-ad4d-4cad3d4a8cdb" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b70c52e-ca02-42a0-af9a-6a7ebc132252" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6840508f-0005-406b-9786-d7de5509e658" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">202</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6f52f8e-1d7e-444c-aa8f-db27d64acfa3" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.47</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0399c1ab-0d48-4b37-ad14-06e0b0ed8bcb" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">1,827</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a2d1374-2765-4154-8f9a-2f638c8eaab8" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.72</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e9a2923-f2c2-4db5-aad8-e007a5332d06" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">16,939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e65c5312-8aa2-40ea-89a1-edb1fd1e47ba" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1158bb6-dae8-4163-853c-8d0627953e82" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,942</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4a1c2b5-e3d5-425d-9800-6be7129f9961" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">14,487</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c6a1bb0-e045-486a-ad21-0dafca853b53" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Benefit Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16ce57a0-f980-407c-9f86-e95b0316252e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_8d8c37cc-655a-45dd-8128-11b67d67738e" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_473183fb-28d3-46c3-8e7e-02bf29d17edb" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for each of the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_4fc95f5d-1f1e-4f47-a722-822e4c25854b" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section178"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Development Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#x201c;Product Development Agreement&#x201d;) with two parties (the &#x201c;Developers&#x201d;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#x201c;Itochu&#x201d;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and SP-103 (the &#x201c;Products&#x201d;), for Scilex Pharma.  The Developers initially developed, and have intellectual property rights relating to, the Products.  Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc3387ab-ceeb-4250-9164-a326d755e938" contextRef="C_9922975f-1d41-4752-92b7-f2ec2c047e71" name="sclx:RoyaltyPaymentPercentageRelatedToFutureYears" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a073d50-de81-4653-a432-d707685c349e" contextRef="C_40562d01-6462-499f-a04a-47153823c26b" name="sclx:RoyaltyPaymentPercentageRelatedToFutureYears" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to the Developers based on net profits. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, Scilex Pharma made royalty payments in the amount of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4207bda-99ec-4c14-a92c-501cfd4b546a" contextRef="C_8c1f3d78-c5e0-4b4b-93a7-3c1f21841465" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, Scilex Pharma had ending balances of accrued royalty payables of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_289da7b4-4e5d-403d-bed1-56496ab2948b" contextRef="C_0a56b9b5-0e8c-4c4c-a42e-683ebcaf8d04" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Net </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">profits </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are defined as net sales, less cost of goods and marketing expenses.  Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ddead549-42fd-4a84-a9fa-ce4c0f5a0c16" contextRef="C_02f580e6-c788-4eef-9f36-799127c833b3" name="sclx:AgreementMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> October 2, 2028</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the date that is ten years from the date of the first commercial sale of ZTlido. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_106c02b8-a311-4439-b048-2e1f04ed5841" contextRef="C_02f580e6-c788-4eef-9f36-799127c833b3" name="sclx:MaturityRenewalDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon 6-month written notice.  </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#x201c;Supply Agreement&#x201d;) with the two Developers to provide commercial supply of ZTlido and SP-103 to Scilex Pharma.  The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive Distribution Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#x201c;Distribution Agreement&#x201d;) to appoint an exclusive third-party logistics distribution provider (the &#x201c;Distributor&#x201d;) and as an authorized distributor of record of ZTlido in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f583350-9fe2-448d-9c51-5602adede9e2" contextRef="C_8e55c840-7ba5-4068-b9ac-a6ab3b619797" name="sclx:AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% annual adjustment. The Distribution Agreement has an initial term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_711331d3-d399-4d1c-b7d7-57eb4ea44bbf" contextRef="C_8e55c840-7ba5-4068-b9ac-a6ab3b619797" name="sclx:AgreementInitialTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">following the first shipment of FDA-approved Product to a commercial customer and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_31d5983a-80ee-445e-88c6-fca5f6f3a824" contextRef="C_8e55c840-7ba5-4068-b9ac-a6ab3b619797" name="sclx:MaturityRenewalDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#x2019;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#x2019;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76cbb352-b104-464f-afdd-5e5b42f65515" contextRef="C_560e4782-7a8f-459f-9609-b04f9e8ab33f" name="sclx:DistributionFeesPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a1b0ff9-5a42-4631-8e3e-273c45afd9e2" contextRef="C_a708aae3-4854-410d-ab82-fbfc4a130c97" name="sclx:DistributionFeesPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% which was recorded as a gross-to-net sales adjustment. As the Company continues to expand the commercialization of ZTlido, it has expanded its direct distribution network to national and regional distributors and pharmacies since the beginning of April 2022. The Company currently holds all necessary wholesaler licenses and commenced selling directly to the main distributor customers as well as pharmacies in April 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales Operations Services</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#x201c;Project Agreement&#x201d;).  In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor.  In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor continued to provide sales operations services, fleet management services and sample accountability services. The work order was in effect until </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0c3af17-78d8-44bc-bd29-4fe6f436c27e" contextRef="C_3cf5091c-7b41-4d84-af4b-27015818f063" name="sclx:AgreementMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0dfb6ce3-5d7e-455b-92ec-dadea331494d" contextRef="C_3cf5091c-7b41-4d84-af4b-27015818f063" name="sclx:MaturityRenewalDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with 90 days&#x2019; notice</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Pharma paid</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implementation fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf56466f-1a55-434c-adac-ae30c5d51e1a" contextRef="C_3cf5091c-7b41-4d84-af4b-27015818f063" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.0 thousand and will pay fixed monthly fees of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33cf1281-8a51-4414-93b9-1dd7ae1cff3f" contextRef="C_2d79b6ca-f817-4000-9690-57cda2cd8b96" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">63.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f43428c-3ecf-43d7-9b0b-a0d5113ef67a" contextRef="C_4ffc6a81-2d13-4ca4-89ec-8c611943a526" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">65.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand for ongoing services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized an expense of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdd7ae46-0326-4481-ae6a-0b09c9aa450a" contextRef="C_3710aa11-fcfc-4dcd-aacb-4c89272492cc" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac826de1-c0e8-43e5-9922-fbf57bbfc03c" contextRef="C_85fddfc8-ede1-4821-8070-f8272993162e" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f9d2dd8-4d2b-40f4-84ac-bb16ec566d67" contextRef="C_2648accc-f3dc-426e-92a2-db64ebe17309" name="us-gaap:ProfessionalFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within selling, general and administrative expenses for services performed for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, respectively, including implementation fees, fixed monthly fees and pass-through costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Litigation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#x2019;s financial condition or results of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the &#x201c;Sanofi-Aventis &amp; Hisamitsu Litigation&#x201d;).  This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly the Company's claims, but which motions the court has largely rejected.  Discovery is proceeding.  The case is currently scheduled for trial to begin on July 24, 2023.  The Company cannot make any predictions about the outcome in this matter or the timing thereof.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Former Employee Litigation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#x201c;Virpax&#x201d;), a company now headed by Mr. Mack, alleging, among other things, breach by Mr. Mack of his non-compete agreement with the Company, breach of fiduciary duty, and tortious interference by Virpax with that non-compete agreement (the &#x201c;Former Employee Litigation&#x201d;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr. Mack from further violating his non-compete agreement and enjoining Virpax from tortiously interfering with Mr. Mack&#x2019;s non-compete agreement. The case was tried from September 12, 2022 to September 14, 2022. Post-trial briefing and closing arguments have been concluded and the case is under submission to the Court. The Company cannot make any predictions about the outcome in this matter or the timing thereof.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZTlido Patent Litigation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#x201c;Apotex&#x201d;) in the U.S. District Court for the Southern District of Florida (the &#x201c;ZTlido Patent Litigation&#x201d;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#x201c;ZTlido Patents&#x201d;).  The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the Hatch-Waxman Act, of an ANDA.  Apotex&#x2019;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed.  The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#x2019;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May 10, 2031, and such further and other relief as the court may deem appropriate. Apotex is subject to a 30-month stay preventing it from selling a generic version of ZTlido during that time.  The stay should expire no earlier than November 11, 2024.  Trial in the ZTlido Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases administrative and research and development facilities under various non-cancelable lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend.  As of December 31, 2022, the Company&#x2019;s leases have remaining lease terms of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_04b45e45-c258-4270-b25f-fb8fffbc65d1" contextRef="C_efd6a36c-f68c-4a10-8867-54bd97146b01" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_31aa322d-3609-4e86-a3e2-698c7f78befd" contextRef="C_81a151cb-066d-45a5-8264-1e0d16707f77" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The term of the Company&#x2019;s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7143fe0a-1e1e-4061-988f-ef1d211d3148" contextRef="C_efd6a36c-f68c-4a10-8867-54bd97146b01" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c5fc895d-82d7-491d-ba4b-191bc1d25971" contextRef="C_81a151cb-066d-45a5-8264-1e0d16707f77" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. Many of the Company&#x2019;s leases are subject to variable lease payments.  Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the right-of-use assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.  The Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease.  As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8f1c76c-e53e-4daa-ace6-6103317f69ca" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4a367a12-e012-4165-b149-5a78dbe3c071;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">finance leases</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c24e2c24-fa28-4e92-a1de-071fdf029b22" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.455%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.094%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.094%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.225%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost*</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8363f8e6-c596-4813-8080-7a4e38ce8500" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e396fbfd-ad00-4ecb-8915-41727ec1c12c" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">623</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60575421-3d34-4ea0-8e1b-127053a2b249" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">904</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Inclusive of variable lease costs, sublease income, and impairment, which were immaterial</span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the periods presented.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c1d6354-3efe-4dae-a739-65add9a14f92" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental quantitative information related to leases includes the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.253%;"></td>
        <td style="width:1.964%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.925%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.954%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.904%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdbc4d66-d21d-4623-909b-19498a6db065" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">746</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_162e43a5-7308-4959-9e86-3582368f8085" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">654</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets obtained in exchange for new operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d8e0ee2-072a-402c-b3a1-eb76336fad9a" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">320</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8554078a-7e95-41e3-aa0c-b9447207a346" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term in years &#x2014; operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a78bddc8-382d-48ba-981a-123e7e4f9c94" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7adbaa8f-1ed1-461c-8a42-95823f6b0298" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate &#x2014; operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1df51d7d-0f95-4347-b542-8e6905c11f5a" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">11.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b86025fc-cefc-4978-9c0c-2013c0a0ea97" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">12.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, the Company entered into a new non-cancelable lease agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ab48de88-65cb-4366-a6a5-cbcb858f2593" contextRef="C_906ba0ae-005a-42a4-a051-5cdede4e78db" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months and the Company does not expect to exercise the extension option at the end of the lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approximate future minimum lease payments under operating leases</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bcec32a4-ff06-4072-a745-9089be89f853" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_bcec32a4-ff06-4072-a745-9089be89f853_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_bcec32a4-ff06-4072-a745-9089be89f853_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.856%;"></td>
        <td style="width:1.475%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.67%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f2d235c-c0bb-41c3-9387-7b475890071a" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">872</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5555aaa3-01b1-4245-a724-a39454bc5ca0" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">703</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12de5d1a-7679-4a35-92b0-08ba39186759" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f556b964-ea33-46d7-9099-53f4a013ded6" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d08f73c-f612-43c2-9c4c-54bb8b5f6e97" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac169680-c433-4a1e-ba65-9311c654c18e" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,575</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2768206-f7d8-43b1-8ffc-65bd0e08cca9" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de9a035b-f425-44ef-88f3-41c431523c3d" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,410</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less current portion of lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4debaea4-8f83-4281-975f-c1e3884d3a4c" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">745</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability, net of current portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7e8f2a2-c11b-4622-834e-a7023fbcf468" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="sclx:LeaseLiabilityNetOfCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8d3e3b69-5190-4f1f-a2de-6075d7a294d6" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section179"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total loss before income taxes for the years ended December 31, 2022, 2021 and 2020 did not include a foreign component.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_bf237ff8-ece3-4527-bb8c-4fa67534fb13" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the provision expense (benefit) were as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.996%;"></td>
        <td style="width:1.388%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.923%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.388%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.923%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.388%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.997%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current income tax expense (benefit):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3afe8796-d7fd-4e94-855e-152419ab2a29" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8225e7b1-16ab-4e5e-8e15-051318ceff02" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0752542d-d6d4-4c28-a8a9-b5fcb59d8628" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2de0b638-956d-4e3e-b6a5-ba0853f6719f" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2464ba79-1a24-42aa-b100-3ef30bc85279" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af469633-bb96-4cb0-a938-e6417e14636a" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c52eeb02-8e2d-4873-9f6c-17c355327fea" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a74c3d79-aa39-448f-8fe7-7799c997362c" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cf1b137-da9e-459c-a148-39a142fe776b" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax expense (benefit):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7358790f-4115-46a3-b5d7-38dba3893548" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6388f081-e2cf-4d25-96b7-5bfea063d867" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,981</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ebed7a4-c756-4d03-93f9-e40b5cf0f500" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,970</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b91ac7d-6db3-45d1-8d12-da2c7908d4bd" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,851</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90aaebd2-2324-4a3d-9ac8-3d3368f57def" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,472</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a556af84-19c1-4e60-8940-98919fcabfa9" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">130</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c39c285f-b292-488e-a810-fd1465181e7f" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,247</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11ccbcd6-fa17-4ca1-a99c-4874533e5fa2" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_951ab722-4f47-493b-b09f-ea8dca697849" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_571f252b-f86c-4030-b704-aab6d5e522c3" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,347</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d2487d5-76a8-4163-810a-c0e26a99a2e3" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0208af14-c4f2-4421-a8e6-f9b863ebfba0" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b29c3bee-1835-4338-b155-d34e9e5a02b5" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85c0fa4d-d9dd-4c23-a7f8-09194dd11b36" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa6b7240-3052-40dd-9d0d-0870bb9dd0e4" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax benefit from continuing operations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_def36f5f-ce6c-4bea-b77a-2074349fab6b" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e82fdf2a-40ac-49cd-871e-e964add51978" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27aba563-fb91-4ac6-ab4d-a29862440898" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_72f5d1a9-d777-493b-98cb-024eeb3921f6" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows as of  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.049%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.123%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c3c9a21-bf88-44ef-a81a-d243e0c1bd07" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16351436-fc93-430d-986c-b643142e5718" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,714</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt related interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a705e4ba-69d4-4811-82cd-c5276a560969" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="sclx:DeferredTaxAssetsDebtRelatedInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c1106ba-b48b-466c-9e5a-64bcf22d1369" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="sclx:DeferredTaxAssetsDebtRelatedInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,205</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b190dd6d-7e16-4905-b209-d2741cae548a" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_990664db-56b3-4fcb-8029-b8d2b78c1336" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c852afc7-bbd6-4420-ba42-2bb4e0fcdf43" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,630</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11debf6f-7c4f-4d73-b172-66bc144a07aa" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,630</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50ef2941-94ff-492b-a017-42bfe4f8e45c" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,602</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a62e83af-1b3a-4d40-9991-c2a6f77342a8" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,233</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expense and reserves</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24ebf0ad-2350-41d7-a34d-dcca3f4e20fb" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="sclx:DeferredTaxAssetsAccruedExpenseAndReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">568</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cb4ce89-de16-4898-969f-b6c2860245a9" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="sclx:DeferredTaxAssetsAccruedExpenseAndReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,517</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ec8a86a-d954-429c-bcde-2bb3d3ca5cac" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="sclx:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">315</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee3ee9a5-b22b-4edb-bde4-b1ffd4f77539" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="sclx:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">404</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0eebaf4-9ad8-451c-85ca-dd6aa807626b" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b81a62fa-eac4-4785-9302-1fea926cb8ef" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">236</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bd86618-f527-4596-a643-8a2418c6c3bf" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,462</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67fbed58-1e34-44c0-bef2-1ee9cafc466d" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b49262a-f36a-436e-9a49-4d509b6b87b7" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,543</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3337b954-e83f-46dc-a65e-67a059088bbc" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,643</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_712c6116-945b-4c7a-b142-2680ee5a64c2" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d09566c2-3d30-45a3-9652-5d6d8dcb26ed" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,296</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81802297-583b-432f-8bb5-7bf91a865b39" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,666</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3857ffd0-e4cf-4f06-8c63-2ce53f1cd192" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f923495f-a262-4f55-8e80-70463d7117ce" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">253</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4697d5df-f505-414f-91d4-89ebbdb9c8ec" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">319</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70dd2c83-b54b-4466-b494-b4d154c81dd8" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cb49de2-1b70-483a-a28c-c5eea850c846" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78ab93b0-518f-436d-a61f-3a784744f7f9" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_209662b1-1c56-49ec-86e8-d622cbccc9ee" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,296</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f3326fc-f846-4a9d-99ed-b544efd28c02" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fafabe6b-ec98-435f-a564-c1e1da778437" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_25cc9aca-a3b2-4b92-8780-6f79ca30831a" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s provision for income taxes are as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020  (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.996%;"></td>
        <td style="width:1.388%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.923%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.388%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.923%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.388%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.997%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69b8f766-2bba-4ddb-9fea-5b3f02df92d5" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,905</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6993f06c-a6f0-451e-b38b-9c86d00c6618" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,150</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f907e5d2-62b1-4b85-9b52-d66483ec00b7" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33462846-5bb5-4230-8571-aaa8c43f6cec" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6498934b-0ffe-448a-b725-96cd7346331c" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f70c1995-33bf-437f-be11-bb2a377668c4" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discount and interest limitation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18fecd52-05a6-4123-8b88-65e2c3410a9f" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,293</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb7834f4-561c-4ad7-9f9d-e0f3e509e8ba" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,954</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57a36485-4757-4d55-bca1-8ab8171f12fe" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12423601-44ab-40fa-a2ce-06888a8a6eaf" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_986b2968-9d98-47da-9ffc-2ff829a590fd" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">224</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48b5b28e-e351-43d6-97c1-2c36fe0d430e" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">166</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisition related charges</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26c9aaf5-a37f-4dc4-8cad-08e6dbcff53f" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:IncomeTaxReconciliationAcquisitionRelatedCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">992</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6f119f2-8625-423a-a0f1-8932d5bb4003" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:IncomeTaxReconciliationAcquisitionRelatedCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c51c4f1-008d-456c-8570-9d0b193c7bfe" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:IncomeTaxReconciliationAcquisitionRelatedCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior year true-up and carryback</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da8acfa1-8877-418b-b9fe-315bc195e880" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">713</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46ed5968-e0fe-4934-81a6-7e474ff8d97f" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,968</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bf73033-9389-43d4-a334-8b53be328a21" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,955</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State, net of federal tax benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_915df701-0e64-443e-8ccf-c02ab9e8d50e" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a83d8bae-878b-44bf-a32a-c2ec5a809ba8" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,545</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f10fcfa-852b-41a4-bbc9-5735c88ec352" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,164</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax credits and incentives</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d6025b9-b7f9-4372-804b-8f8aab94bee4" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdf5eb59-8cda-4bb1-8aca-4b409c063186" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3443ea3f-2f37-426b-95a4-124a05020f64" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">101</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c9dadd7-9e04-400a-803d-ad173536b74d" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">728</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee52be55-37c6-4bd5-b72d-bccc8abf8108" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">993</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89612e1a-197a-49cd-a2cc-6c6016d0b83d" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">235</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f1dbb5c-ce63-4514-a587-d5d96b60f790" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0164be9-e827-4eba-88d7-2c8f531284b5" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c46faba-b5ad-4008-a918-33af2a2cd4c0" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fc6793b-1dc2-4a48-a5d7-3c565fd82d01" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">67.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> against its deferred tax assets as of December 31, 2022. Realization of the deferred tax assets will be primarily dependent upon the Company's ability to generate sufficient taxable income prior to the expiration of its net operating losses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e22bbe04-2b4e-48cf-a1f6-da7e9ff5260b" contextRef="C_34aca91d-0225-49d8-82d3-b112cf786117" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">205.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05164e44-3e9e-4fb8-ae81-93c966ae2895" contextRef="C_5024e079-7880-4bc6-b897-722b2e854e4c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">106.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of federal and state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_353d294a-fdb7-42a7-888f-95ce41fbb4b0" contextRef="C_7de5b4e3-ff7d-4a25-8702-760a6461c79b" name="sclx:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_130ece2e-3521-4003-bc99-3630152a4c64" contextRef="C_cc227406-9649-405a-abe9-80c403455490" name="sclx:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">state, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">respectively. The Company also had federal research and development income tax credits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b2859f0-892a-47e0-a70a-2ae0a5385975" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c5548447-407f-46d8-928d-ddbef1e6c9cb" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:TaxCreditCarryForwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal Revenue Code Section 382 rules apply to limit a corporation's ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section 382. For the years ended December 31, 2022 and 2021, there was no impact of such limitations on the Company&#x2019;s income tax provision.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#x2019;s tax years will remain open for three years for examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_61fa772a-81bf-47cd-a52f-86e040b77ae2" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.899%;"></td>
        <td style="width:1.376%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.985000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.386%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.985000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.386%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.985000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2935cf5-c84f-4730-a097-74a35ac070b0" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8e65196-fe2a-4f43-8513-2222d473a5c6" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">406</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6ea0903-7170-4315-8593-c70627d2b106" contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">385</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a48c71da-f79c-4940-b593-450d4d671293" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c1b73a4-791e-43bb-9f50-771c8c088d6c" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f6f36d4-4f30-4f45-8ff9-21eaf94b7265" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d54b8554-91e2-470b-b850-4ede43be29e3" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59563255-1ad9-4602-a368-eaa6f8a0b300" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e81bd80-1d68-416f-b1ee-f127bb7cc16e" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96c5b6cf-b269-4256-9b5d-d535be7e7c9b" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06618ac8-49f1-4b5a-a84e-511127e1bef5" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ec9a880-74b5-406f-bf0d-adaf5f69652f" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_123466bf-9096-4b48-84aa-abdfef505440" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_932b3fc9-0301-4c2b-ab85-4dfd3a47d8a9" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_737743d6-951a-4158-9781-6782ecfd8410" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">406</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, 2021, and 2020, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be3ad41f-81d5-46e1-b925-ca08e4c10ddd" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edc31180-0c55-442b-8fb6-c7adfa0990a0" contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_838d042f-e3f6-459c-b1a7-cd5cdec26c2b" contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, of the Company&#x2019;s total unrecognized tax benefits, if recognized, would impact the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe8805b9-d7f2-4990-a185-66e073809545" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_37f52ac7-8bcf-488b-93c2-3d27f49ade59" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c633d1d7-b060-46e3-93bc-9135d4ecc7d0" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> interest or penalties have been recognized as of and for the periods ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company believes that </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0244a4b-a715-4f35-a39f-ab7e2a6c8f8d" contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> material amount of the liabilities for uncertain tax positions are expected to reverse within 12 months of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4df1965d-4d2a-4e3d-99c0-8465dcf065ec" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section183"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Related Party Transactions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2020, approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7effeba-9eb6-4829-bf01-6518e56030a5" contextRef="C_c1cafa60-e7b5-445c-b9e8-7dc034751dc5" name="sclx:OutstandingCapitalStockPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">14.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding capital stock of the Company was held by Itochu. On January 13, 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_250c242c-aed8-4713-87d4-d9a945c8ece7" contextRef="C_52e1afd8-0dd3-4e45-8542-1b0396bc18c6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">34,889,868</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Legacy Scilex representing all outstanding capital stock of Legacy Scilex held by Itochu were acquired by non-related minority shareholders. Thus, Itochu is not a shareholder subsequent to January 13, 2021. During the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 the Company purchased approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28c3d990-e05e-4c6c-9bbf-d5bb127b46c5" contextRef="C_17686498-39e6-4eca-a9d9-732664349cdb" name="us-gaap:OtherInventoryPurchasedGoods" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9396583f-881b-401f-bb91-73b1777199db" contextRef="C_e0720b69-b850-4e33-b843-ca514f86a042" name="us-gaap:OtherInventoryPurchasedGoods" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91438b73-b15a-4223-85ab-1f90971683de" contextRef="C_c1cafa60-e7b5-445c-b9e8-7dc034751dc5" name="us-gaap:OtherInventoryPurchasedGoods" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#x2019;s statement of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Semnur is party to an Assignment Agreement, dated August 6, 2013 (the &#x201c;Assignment Agreement&#x201d;), with Shah Investor LP (&#x201c;Shah Investor&#x201d;). Mahendra Shah, Ph.D., who has served on the Company&#x2019;s board of directors since March 2019, is the managing partner of Shah Investor.  Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the low-single digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injection developed using such intellectual property, which would include SP-102. Through December 31, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2017, a Transition Services Agreement (&#x201c;TSA&#x201d;) was executed between Scilex Pharma and Sorrento.  Pursuant to the TSA, Sorrento agreed, at the Company&#x2019;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company.  During the years ended December 31, 2022, 2021, and 2020 the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3ffe697-3e1e-4960-b4b1-6f25b0aa0cff" contextRef="C_d408965d-1291-4b37-9b62-a779f1f46c23" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4085ad7-a3f5-496a-8c6e-eb43ac3e8ef0" contextRef="C_f6afef57-8906-4dde-a3a5-2e46d3fa8a04" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a98d8b1b-3841-4d49-a8e7-c66c5057a63e" contextRef="C_26f9a78f-d20f-4189-8bc1-b3bfc1c9e6c0" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aafbc466-686a-494e-94fa-164aea138216" contextRef="C_a481e148-6651-4f1b-8127-50bb57bdbf62" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the acquisition of Semnur.  The note is interest bearing at the lesser of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10e77e7f-79e5-406a-a9cf-72f736f26692" contextRef="C_a481e148-6651-4f1b-8127-50bb57bdbf62" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% simple interest per annum, and (b) the maximum interest rate permitted under law.  Interest is due and payable annually.  The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium.  During the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 Sorrento made advances to the Company in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0d818a9-9b1a-4885-afea-07cc0ed040eb" contextRef="C_33d1eca1-5b22-4cf6-bc73-83bb4af8df1a" name="us-gaap:NotesAndLoansPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">27.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_591f54d8-820c-449c-88b9-5bbb68238f36" contextRef="C_218d96e4-ea4f-4f86-8b2f-c64a6bcff94a" name="us-gaap:NotesAndLoansPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f982f10-de25-4bca-ad6f-62b33c41c3e2" contextRef="C_5d2870e1-119e-419e-9885-26f2174d6332" name="us-gaap:NotesAndLoansPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million respectively, under the note payable. All outstanding related party indebtedness immediately prior to the closing of the Business Combination was converted to equity pursuant to the Debt Exchange Agreement (defined below) and therefore the last day the debt outstanding was November 10, 2022 (see Note 12). The outstanding principal balance of the note on November 10, 2022 and December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26246c9f-079e-4561-9a9b-92e1b2698b9d" contextRef="C_fe20fc93-e090-4257-8aea-e4facd17edbf" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">47.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8818d468-20b3-421e-a0b8-7547c49bb579" contextRef="C_218d96e4-ea4f-4f86-8b2f-c64a6bcff94a" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, which was recorded under the current related party note payable in the Company&#x2019;s consolidated balance sheets. As of November 10, 2022 and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01890bd7-bb77-4048-9885-c3e8b94d7866" contextRef="C_fe20fc93-e090-4257-8aea-e4facd17edbf" name="us-gaap:DepositLiabilitiesAccruedInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_221c51e2-f7ee-462f-b982-8288f1f8d10e" contextRef="C_218d96e4-ea4f-4f86-8b2f-c64a6bcff94a" name="us-gaap:DepositLiabilitiesAccruedInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. The proceeds from the note payable were used to finance the operations of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87b8a74e-affa-4fe9-a0b7-62a8a68b7821" contextRef="C_0ee0f0fb-af92-4b7b-b642-acfabbcf105e" name="us-gaap:NotesIssued1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#x201c;Intercompany Note&#x201d;). Scilex Pharma may borrow up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc4b3c34-bbb8-441a-826e-e240855bd3e0" contextRef="C_97b73263-30f4-4653-9e9d-edde5c0042df" name="us-gaap:NotesAndLoansPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edfc525d-975b-4ba8-84a7-8e64e0b91b47" contextRef="C_97b73263-30f4-4653-9e9d-edde5c0042df" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% simple interest per annum, and (b) the maximum interest rate permitted under law. All outstanding principal amounts and accrued interest was due upon maturity on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_310e1957-7092-428c-96d0-8edcda3e5b13" contextRef="C_0ee0f0fb-af92-4b7b-b642-acfabbcf105e" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 31, 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. On October 22, 2018, Sorrento purchased from the Legacy Scilex 24,117,608 shares of the Legacy Scilex Common Stock in exchange for the repayment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32e8c060-31f4-41e9-8c97-6325245c4802" contextRef="C_b4cbb81e-b3d2-4016-bb84-fc0e80fe9230" name="us-gaap:RepaymentOfNotesReceivableFromRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of indebtedness under this promissory note.  During the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, Sorrento made advances to Scilex Pharma in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bf8c095-5a1a-484c-b029-9ab22be7b352" contextRef="C_ffc67561-e990-47ce-8a93-35879897d05b" name="us-gaap:NotesAndLoansPayable" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a2dd6d1-3c7e-467d-91e3-2ee47abc7f08" contextRef="C_e325ed31-26e8-4093-8e73-8b5f019c9102" name="us-gaap:NotesAndLoansPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df614dd6-6531-48f3-9ba9-2180fa72b2cc" contextRef="C_32ab59f7-6a30-49d8-81a3-b2690ed7e60b" name="us-gaap:NotesAndLoansPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million respectively, under the promissory note. As of November 10, 2022 and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22e555ed-51a4-4409-bf80-88a61960ed11" contextRef="C_01b3c958-391f-4745-a694-8e6d618b12d1" name="us-gaap:DepositLiabilitiesAccruedInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ad7b40c-bc88-4686-926c-d167cb428dc6" contextRef="C_e325ed31-26e8-4093-8e73-8b5f019c9102" name="us-gaap:DepositLiabilitiesAccruedInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. As of November 10, 2022 and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021, Scilex Pharma&#x2019;s outstanding principal balance under the promissory note was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3bae763-980f-4d94-82a3-12ac069b7ed4" contextRef="C_fe20fc93-e090-4257-8aea-e4facd17edbf" name="us-gaap:AccountsPayableRelatedPartiesNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_24cdcefb-778f-4a99-aa7f-907b672c48bc" contextRef="C_218d96e4-ea4f-4f86-8b2f-c64a6bcff94a" name="us-gaap:AccountsPayableRelatedPartiesNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">23.5</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was recorded under the non-current related party note payable in the Company&#x2019;s consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d03ce038-fd38-417c-9ec2-f65849659cfb" contextRef="C_16948957-8702-4576-aa50-3b0b402e4d82" name="us-gaap:ProceedsFromSaleOfNotesReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in February 2022 to fund the payment of Scilex Pharma Notes as described in Note 7. The $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8db80ccc-8130-45f7-846a-05aaa345140c" contextRef="C_e39411dd-ee32-4564-9103-dfccf71f4ba3" name="us-gaap:AccountsPayableRelatedPartiesNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> received in February 2022 was due no earlier than February 2030 and was recorded under the non-current related party note payable in the Company&#x2019;s consolidated balance sheets as of November 10, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional funding received from Sorrento was due on demand and recorded under the related party payable in the Company&#x2019;s consolidated balance sheets. As of November 10, 2022, related party payables due to Sorrento included</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75ee9de8-0f7e-4f66-aa6e-ae936e098d51" contextRef="C_e229956a-eca3-48a8-a9c3-297169d09bc5" name="sclx:WorkingCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">61.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to cover working capital requirements, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_670338f2-1b81-4140-9cd4-701d0f22d1ce" contextRef="C_6337de38-c2dc-48a8-b488-04cc48d9be24" name="sclx:RepurchasesOfNotes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for repurchases of Scilex Pharma Notes, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd823617-f184-4c4c-a2d6-bc8e30f68da1" contextRef="C_6337de38-c2dc-48a8-b488-04cc48d9be24" name="sclx:LitigationFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for litigation fees (see Note 7). As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, related party payables due to Sorrento consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd861f5f-0d74-4c38-b401-4999943cda0c" contextRef="C_a447a6e2-4ac3-4afb-95ec-8bfbc792b678" name="sclx:WorkingCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to cover working capital requirements, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6461b279-621b-44b8-bb79-c521c4c79aac" contextRef="C_8219a545-34c9-4750-80f1-f7f2e16e64f8" name="sclx:RepurchasesOfNotes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">51.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for repurchases of Scilex Pharma Notes, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4fb7408-7600-407a-ae69-67df1719f636" contextRef="C_8219a545-34c9-4750-80f1-f7f2e16e64f8" name="sclx:LitigationFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to pay litigation fees. As of December 31, 2022, the Company had a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_927b8867-9178-45d5-9044-d1c0e6d27064" contextRef="C_33d1eca1-5b22-4cf6-bc73-83bb4af8df1a" name="sclx:RelatedPartyReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related party receivable from Sorrento related to certain invoices paid on behalf of Sorrento, which was fully reserved (see Note 14).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#x2019;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e4155b2-9f38-4585-b528-e2d657ede476" contextRef="C_6202898d-9295-4896-a66a-61c32e1f4b3c" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.66</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% simple interest per annum and (b) the maximum interest rate permitted under law. As of November 10, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5b00070-bb69-433a-99e4-ba37aac197e5" contextRef="C_9bed26af-6062-4ef5-8277-06de00c7bdeb" name="us-gaap:AccountsPayableRelatedPartiesNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was recorded under the non-current related party note payable in the Company&#x2019;s consolidated balance sheets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt Exchange Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#x201c;Debt Exchange Agreement&#x201d;) with Sorrento, pursuant to which (i) Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company that remain outstanding as of immediately prior to the closing of the Business Combination (the &#x201c;Aggregate Outstanding Amount&#x201d; or &#x201c;Outstanding Indebtedness&#x201d;), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84fb1a46-b173-4553-91f7-2cd0f341c7c2" contextRef="C_3354e157-13ff-4e9f-bfd3-3f7a68647739" name="us-gaap:NotesIssued1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">27.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 7), in exchange for the issuance by the Company to Sorrento of Preferred Stock of the Company, (ii) the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii) upon the occurrence of the events described in clauses (i) and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to, and contingent upon, the closing of the Business Combination, Sorrento elected to contribute the Outstanding Indebtedness to the Company in exchange for the issuance by the Company to Sorrento of that number of shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6e9f390-1570-40e5-b2ed-237949beeba7" contextRef="C_6462068b-60b7-499d-ac23-4f81f11e97d2" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#x201c;Exchange Shares&#x201d; and such transaction, the &#x201c;Debt Contribution&#x201d;) that is equal to (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_927883ba-1d30-4fa1-876b-c91e3180ad87" contextRef="C_3a4759f2-8d65-4ebd-9e91-79f879ffa0f4" name="sclx:DebtExchangeDescriptions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Aggregate Outstanding Amount plus the amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ed6226f-b435-4079-a27c-a36fd3dcc96d" contextRef="C_36afe8fd-cd95-4f09-aed3-b9387cac7efb" name="srt:FinancingReceivableNonaccrualToOutstandingPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the Aggregate Outstanding Amount divided by (ii) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a4dd53c-f6ba-43b0-b345-94f3c11dfa73" contextRef="C_36afe8fd-cd95-4f09-aed3-b9387cac7efb" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (rounded up to the nearest whole share); provided, that in no event would the Aggregate Outstanding Amount exceed $ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d2dcdcc-272b-4eb3-9eb3-e0bfd98633a5" contextRef="C_3a4759f2-8d65-4ebd-9e91-79f879ffa0f4" name="us-gaap:LongTermDebtAverageAmountOutstanding" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">310,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5215525-9936-4467-ad4a-012212d524b3" contextRef="C_4b0d5c8f-c285-4b81-adfe-90ae2f642ce4" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">290.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement. This amount was converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93a1ebdb-029f-4fae-a3a3-f37d664136d4" contextRef="C_4b0d5c8f-c285-4b81-adfe-90ae2f642ce4" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">29,057,097</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Scilex Preferred Stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa38e573-8792-4f35-9594-5573e2c85271" contextRef="C_4b0d5c8f-c285-4b81-adfe-90ae2f642ce4" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,905,710</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's Common Stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_018e30a2-9df3-453a-a0b9-ff9346913ec1" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section184"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Loss Per Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Earnings Per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has two classes of shares, which are referred to as Common Stock and Preferred Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. The retroactive adjustment is based on the same number of weighted average shares outstanding in each historical period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022, 2021, and 2020, basic loss per share is computed using the two-class method. The two-class method is an earnings allocation formula that determines earnings per share for each class of common stock and participating securities according to dividends or dividend equivalents and participation rights in undistributed earnings. Preferred Stock is not contractually required to share in net losses of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c6c24190-1497-4994-b83c-88347f5c91b7" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020  (in thousands except per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.878%;"></td>
        <td style="width:1.579%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.763%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.589%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.763%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.589%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.837%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to Scilex</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46a51479-682a-4686-a065-356ded4a4a8a" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,364</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa4bc40c-6678-4d9f-a5bd-4e70b1f76fdb" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">88,424</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abef098f-2ed7-4bc2-9aa2-9a649f901366" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,519</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to participating securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82de177b-d633-4d95-9f82-71b429f05639" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1ddd558-ec08-42d8-9741-982a130e0498" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acf8b033-2384-4fe6-8626-cc65fbf7d2ca" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8d8b365-c8fb-4247-9431-c9da71b6ad6d" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,364</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_016a98ef-f62e-4675-ad67-ffbb548cd9cb" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">88,424</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b80bb23-b361-4b57-a2ef-e8388a641433" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,519</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common shares outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_163523b9-a1b0-4577-bc73-bb16fe21d950" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">134,226</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3d4303f-ddfd-46ee-94af-e8aa0a6ad2eb" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">132,858</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16264c2b-fe64-4d12-8d13-097bbebabb5e" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">132,891</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of Dilutive Securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbacad2e-5a9b-4cff-b1dc-6f3602841602" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="sclx:EffectOfDilutiveSecurities" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb98f62b-bd5e-445e-b032-8498e8e5429b" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="sclx:EffectOfDilutiveSecurities" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ee62080-3744-4388-af33-e6e58e375beb" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="sclx:EffectOfDilutiveSecurities" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator for Diluted Loss per Share - Adjusted for Dilutive Securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3551e538-34d5-4a46-bb69-17f038d898e7" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:DilutiveSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,226</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecc26d2f-6140-450c-9bb2-3a47ff30ddd0" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:DilutiveSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">132,858</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7b61027-903a-417f-810b-bb1afe515e9e" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:DilutiveSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">132,891</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and Diluted Loss Per Share</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f193b9d-5d7d-4176-b5a5-07343a9c6871" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_7ab27c7d-bb06-473e-88a0-6fcf1a866dbf" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" sign="-" format="ixt:numdotdecimal">0.17</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_751fe6da-7c53-47dd-bdb3-9e9a48bb296a" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_dec7770c-ca1c-4ff6-a544-3c42c65ab2a6" contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" sign="-" format="ixt:numdotdecimal">0.67</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e899a042-ca28-4672-9db3-8a979ad2ddef" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_fc5aa415-aad8-4ff7-9d90-46d616b7bae4" contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" sign="-" format="ixt:numdotdecimal">0.36</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9bbd8290-486d-4fcd-86c7-85efe4620916" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:55.176%;"></td>
        <td style="width:1.15%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.671%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.161%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.682%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.161%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.997%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1777473e-dfe4-4f10-826f-e735411d21f4" contextRef="C_5f187651-0980-4146-8085-29b42623f970" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">16,939,093</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_665c99a8-0659-4d56-9d81-60901c92d254" contextRef="C_c1e465a4-3408-4232-a9fe-97ae297cdf9c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">18,967,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5131f65-6cdf-4aed-89f2-9c653aa8a2db" contextRef="C_c57207b1-14a7-41a8-8d5b-1a183f1fb11b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">20,746,432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ecf922d-d51b-4564-97b1-e69886ac7d3f" contextRef="C_7fac449c-067b-401a-bdcc-4e3e9932dff4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,899,988</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_3ea715ce-1b17-4fc1-b25f-7f625140097e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_bdcbe9bc-f5de-47ee-9b21-0cb6f9049bc6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Private Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03f73104-965b-4a20-a35e-ca2c70b720ff" contextRef="C_d3d7eb79-4633-4e48-bbe1-9c972c6e1a38" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,104,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_7653d5f4-622c-4e12-b949-15400631d4f1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_13bda9ef-a43d-4945-8aa9-0cae0d8d0725;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c7eee81-e5ea-44d4-86ec-90df8914dc34" contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="section185"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has evaluated subsequent events for recognition and disclosure purposes in the audited consolidated financial statements as of December 31, 2022. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">B. Riley Standby Equity Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 8, 2023, the Company entered into a Standby Equity Purchase Agreement (the &#34;B. Riley Purchase Agreement&#34;) with B. Riley, whereby the Company shall have the right, but not the obligation, to sell to B. Riley up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fc4fd94-bee7-440c-bf37-256e010d964e" contextRef="C_2fac2033-f8b3-4b66-9e60-cd16541fd776" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">500.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of its shares of the Company&#x2019;s Common Stock at the Company's request any time during the 36 months following the execution of the B. Riley Purchase Agreement, subject to certain conditions. The Company expects to use the net proceeds received from this for working capital and general corporate purposes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for B. Riley&#x2019;s commitment to purchase shares of Common Stock at the Company&#x2019;s direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0fc57c3-a2bb-4b18-b294-2251bdbb5910" contextRef="C_a0ff95ef-24d5-464a-957b-98f6e31fc5f1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock to B. Riley in connection with the execution of the B. Riley Purchase Agreement on January 12, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to the execution of the B. Riley Purchase Agreement, the Company sold an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15a89247-2264-42f5-a10c-a6d8682bfb94" contextRef="C_5431b419-860c-45a2-bb9a-fd5a0ef55758" name="sclx:CommonStockSold" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">127,241</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock pursuant to the B. Riley Purchase Agreement for aggregate net proceeds to the Company of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_770eb7c4-b8e2-446f-b39f-1b832325c982" contextRef="C_5431b419-860c-45a2-bb9a-fd5a0ef55758" name="sclx:ProceedsFromSaleOfCommonStock" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scilex Holding Company 2023 Inducement Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 17, 2023, the Compensation Committee of the Board of Directors (the &#x201c;Compensation Committee&#x201d;) of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#x201c;Plan&#x201d;). The Plan will serve to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company as employees by affording such individuals an opportunity to acquire a proprietary interest in the Company. The Plan provides for the grant of equity-based awards in the form of non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards (as set forth under the Plan) solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initial maximum number of shares available for grant under the Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de29c2f1-d564-4d89-a1dd-d9b2fe2daeca" contextRef="C_4eac9786-7af1-498b-ade8-18ab32ec037e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,400,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendment to the Yorkville Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 8, 2023, the Company entered into an Amended and Restated Standby Equity Purchase Agreement with Yorkville (the &#x201c;A&amp;R Yorkville Purchase Agreement&#x201d;), amending, restating and superseding the Yorkville Purchase Agreement dated November 17, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the A&amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the lowest daily volume weighted average price of the Common Stock for any trading day on the date of delivery of a written purchase notice to Yorkville.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to December 31, 2022, the Company sold an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98d3b64c-b765-4526-a94b-1a971d94e137" contextRef="C_dc5b8987-1bb7-4130-9b7a-6a3c9e569fde" name="sclx:CommonStockSold" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">85,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds to the Company of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6169a2a-7abe-4732-9223-458dd7f2c3dd" contextRef="C_dc5b8987-1bb7-4130-9b7a-6a3c9e569fde" name="sclx:ProceedsFromSaleOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Elyxyb License</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 12, 2023, the Company acquired from BioDelivery Sciences International, Inc. (&#x201c;BSDI&#x201d;) and Collegium Pharmaceutical, Inc. (&#x201c;Collegium&#x201d;, and together with BDSI, the &#x201c;Collegium Sellers&#x201d;) the rights to certain patents,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
     <hr style="page-break-after:always;" /></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB (celecoxib oral solution) (the &#x201c;Product&#x201d;) and its commercialization in the United States and Canada (the &#x201c;Territory&#x201d;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the acquisition, the Company assumed various rights and obligations under that certain asset purchase agreement, dated August 3, 2021 (the &#x201c;DRL APA&#x201d;), between BDSI and Dr. Reddy&#x2019;s Laboratories Limited, a company incorporated under the laws of India (&#x201c;DRL&#x201d;), including a license from DRL including an irrevocable, royalty-free, exclusive license to know-how and patents of DRL related to the Product and necessary or used to exploit the Product in the Territory. Additionally, under the Purchase Agreement, the Seller granted the Company an irrevocable, royalty-free, exclusive license to know-how related to the Product and necessary or used to exploit the Product in the Territory. No cash consideration was or will be payable to Collegium Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties for sales of the Product in the Territory for all indications and additional amounts if certain milestones are achieved.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sorrento Chapter 11 filing</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the Company is not a debtor in Sorrento&#x2019;s voluntary Chapter 11 filing and management does not expect this will impact the Company and will continue to operate its business as usual. As of December 31, 2022, the Company had a $1.8 million receivable from Sorrento, which was fully reserved.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>2
<FILENAME>sclx-ex4_2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<html>
 <head>
  <title>EX-4</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 4.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DESCRIPTION OF OUR SECURITIES</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following description summarizes the most important terms of the securities of Scilex Holding Company (the &#x201c;Company&#x201d;). The following summary does not purport to be complete and is subject to the Restated Certificate of Incorporation of the Company (the &#x201c;Certificate of Incorporation&#x201d;), the Bylaws of the Company (the &#x201c;Bylaws&#x201d;) and the provisions of applicable law. A copy of the Certificate of Incorporation and a copy of the Bylaws are attached as exhibits to the registration statement of which this prospectus forms a part. The stockholders are encouraged to read the applicable provisions of the General Corporation Law of the State of Delaware, as amended (&#x201c;DGCL&#x201d;), the Certificate of Incorporation and the Bylaws in their entirety for a complete description of the rights and preferences of our securities.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Authorized and Outstanding Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation authorizes the issuance of (i) 740,000,000 shares of common stock, $0.0001 par value per share (the &#x201c;Common Stock&#x201d;) and (ii) 45,000,000 shares of preferred stock, $0.0001 par value per share (the &#x201c;Preferred Stock&#x201d;), of which 29,057,097 shares have been designated as Series A Preferred Stock (the &#x201c;Series A Preferred Stock&#x201d;). As of March 3, 2023, there were 145,800,574 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock issued and outstanding.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Common Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation provides the following with respect to the rights, powers, preferences and privileges of our Common Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividend Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of our Common Stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our Board of Directors (the &#x201c;Board&#x201d;) upon the shares of our capital stock, which dividends may be paid either in cash, in property or in shares of our capital stock, subject to preferences that may be applicable to preferred stock, if any, then outstanding. Subject to applicable law and the Certificate of Incorporation, our Board will have full power to determine whether any dividends shall be declared and paid to stockholders.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each holder of our Common Stock will be entitled to one vote for each share of our Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote, except for any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding classes or series of our Preferred Stock if the holders of such affected classes or series are entitled, either separately or together with the holders of one or more other such classes or series, to vote thereon pursuant to the Certificate of Incorporation or the DGCL. Any action or matter presented to the stockholders at a duly called or convened meeting, at which a quorum is present, will be decided by the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon, except that our directors will be elected by a plurality of the votes cast.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Right to Receive Liquidation Distributions</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of a liquidation, dissolution or winding up of the Company, the holders of our Common Stock will be entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of our Preferred Stock, if any, then outstanding.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Preemptive or Similar Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Common Stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our Common Stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fully Paid and Non-Assessable</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The outstanding shares of our Common Stock are fully paid and non-assessable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Preferred Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation authorizes our Board, subject to limitations prescribed by Delaware law, to issue up to 45,000,000 shares of preferred stock in one or more series, to determine and fix from time to time the number of shares to be included in each such series and to fix the designations, powers, rights and preferences of the shares of each such series, and the qualifications, limitations and restrictions thereof, including voting rights (if any), dividend rights, dissolution rights, conversion rights, exchange rights and redemption rights, in each case without further vote or action by our stockholders. The number of authorized shares of our Common Stock and our Preferred Stock may be increased or decreased (but not below the number of the shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of our outstanding stock entitled to vote thereon.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control and may adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. Other than the Series A Preferred Stock issued to Sorrento Therapeutics, Inc. (&#x201c;Sorrento&#x201d;) in connection with the closing of the Business Combination, there are no other Preferred Stock outstanding and we have no current plans to issue any other shares of preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Number and Designation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We filed the Certificate of Designations of the Company, designating 29,057,097 shares of our preferred stock as &#x201c;Series A Preferred Stock&#x201d; (the &#x201c;Certificate of Designations&#x201d;). As of the date of this Annual Report on Form 10-K, 29,057,097 shares of the Series A Preferred Stock have been issued to Sorrento pursuant to the terms of the Merger Agreement and such shares have all of the rights, preferences and privileges set forth in the Certificate of Designations as more fully described below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rank</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Series A Preferred Stock shall rank (i) senior to all of our Common Stock, and to all other classes or series of our capital stock, except for any such other class or series, the terms of which expressly provide that it ranks on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or winding-up of the Company (&#x201c;Junior Securities&#x201d;); and (ii) on parity with each class or series of our capital stock, created specifically ranking by its terms on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or winding-up of the Company (&#x201c;Parity Securities&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividend Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of the Series A Preferred Stock shall not be entitled to dividends unless we pay dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of our Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Series A Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidation Preference</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of a change of control, liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, before any payment or distribution of our property or assets (whether capital or surplus) shall be made to or set apart for the holders of Junior Securities, the holders of Series A Preferred Stock shall be entitled to receive an amount per share of Series A Preferred Stock equal to the greater of (i) the sum of $10.00 (which amount shall be appropriately adjusted in the event of any stock split, stock combination or other similar recapitalization of the Series A Preferred Stock) and all accrued and unpaid dividends and (ii) the amount such share of Series A Preferred Stock would be entitled to receive pursuant to the change of control, liquidation, dissolution or winding-up of the Company assuming that such share had been converted into shares of Common Stock in a Deemed Conversion (as defined below).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conversion and Redemption Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The shares of Series A Preferred Stock will not be convertible into Common Stock or any of our other securities and will not be redeemable by the Company; provided, however, a number of the rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designations will be determined based on an as-converted-to- Common Stock basis or otherwise assume that the shares of Series A Preferred Stock are converted into shares of Common Stock. Accordingly, the number of shares of Common Stock that each share of Series A Preferred Stock is deemed to be (or otherwise being treated as) converted into for the purpose of affecting the various rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designation (a &#x201c;Deemed Conversion&#x201d;), whether in connection with a change of control or otherwise, shall be equal to the result obtained by dividing (i) stated value by (ii) $10.00 (subject to anti-dilution adjustments).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting and Other Preferred Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Except as otherwise required by law or as set forth in the Certificate of Designations, the holders of shares of Series A Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Series A Preferred Stock will be entitled to one vote for each share of Common Stock that such share of Series A Preferred Stock would otherwise be convertible into pursuant to a Deemed Conversion on the record date for the determination of the stockholders entitled to vote.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of at least a majority of the outstanding shares of Series A Preferred Stock (a) change the Series A Preferred Stock (whether by merger, consolidation, reclassification or otherwise) into cash, securities or other property except in accordance with the terms of the Certificate of Designations; (b) create, authorize or issue any Parity Security or other equity security the terms of which provide that it ranks senior to the Series A Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or winding-up of the Company, or increase the authorized amount of any such other class or series; or (c) amend the Certificate of Incorporation or the Certificate of Designations in any manner that adversely affects the holders of Series A Preferred Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stockholder Agreement with Sorrento</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the terms of the Stockholder Agreement, dated as of September 12, 2022, between Vickers Vantage Corp. I (the Company&#x2019;s predecessor) and Sorrento (the &#x201c;Stockholder Agreement&#x201d;), from and after the time in which the Business Combination became effective  (the &#x201c;Effective Time&#x201d;), and for so long as Sorrento, together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries) (the &#x201c;Sorrento Group&#x201d;), beneficially owns any shares of Series A Preferred Stock, among other things, (i) Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#x201c;Stockholder Designee&#x201d; and collectively, the &#x201c;Stockholder Designees&#x201d;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the Board, or the size of the Board and (ii) we will be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholder Designee to be so nominated, elected or appointed to the Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. Notwithstanding the foregoing, the parties have agreed to ensure that the Board complies with all applicable requirements of the stock exchange, including independence requirements.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Stockholder Agreement also provides that we will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of the Board, the incurrence of certain amounts of indebtedness and the payment of dividends on our Common Stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Registration Rights Agreement entered into in connection with the closing of the Business Combination, certain of our stockholders are able to demand that we register their registrable securities under certain circumstances and each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) covering the resale of all such registrable securities. We have filed the registration statement of which this prospectus forms a part in order to satisfy the foregoing obligations. The registration of these securities will enable the public sale of such securities, subject to certain contractual restrictions imposed by the Amended and Restated Registration Rights Agreement dated November 10, 2022, entered into in connection with the closing of the Business Combination (the &#x201c;Registration Rights Agreement&#x201d;) and the Merger Agreement. The presence of these additional shares of common stock trading in the public market may have an adverse effect on the market price of our securities.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-Takeover Matters in our Governing Documents and Under Delaware Law</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain provisions of Delaware law, along with the Certificate of Incorporation and the Bylaws, all of which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of the Company. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of the Company to first negotiate with our Board. However, these provisions could have the effect of delaying, discouraging or preventing attempts to acquire the Company, which could deprive our stockholders of opportunities to sell their shares of our Common Stock at prices higher than prevailing market prices.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Authorized but Unissued Capital Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The authorized but unissued shares of our Common Stock and our Preferred Stock are available for future issuance without stockholder approval, subject to any limitations imposed by the rules and listing standards (the &#x201c;Nasdaq Listing Rules&#x201d;) of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;). These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and Preferred Stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Classified Board of Directors</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation provides that our Board are divided into three classes, with the classes as nearly equal in number as practical and each class serving three-year staggered terms. The directors in each class serve for a three-year term (except that the term of our current Class I directors shall expire at the first annual meeting of stockholders following the closing of the Business Combination and the term of our current Class II directors shall expire at the second annual meeting of stockholders following the closing of the Business Combination), with one class being elected each year by the stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of the Company, because it generally makes it more difficult for stockholders to replace a majority of the directors. See the section of this prospectus titled &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Management</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; for more information on the classified board.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation also provides that the total number of directors shall be determined from time to time exclusively by our Board; provided that, at any time prior to a time that the Sorrento Group first ceases to beneficially own more than 50% in voting power of the then-outstanding shares of our stock entitled to vote generally in the election of directors (&#x201c;Sorrento Trigger Event&#x201d;), the stockholders may also fix the number of directors by resolution adopted by the stockholders.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Removal of Directors; Vacancies</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation provides that, except as otherwise required by law or the Certificate of Incorporation, directors may be removed with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our stock entitled to vote generally in the election of such directors; provided, however, that, from and after the Sorrento Trigger Event, any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our stock entitled to vote thereon, voting together as a single class, in each case subject to the rights of holders of any series of Preferred Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Certificate of Incorporation provides that, except as otherwise provided therein or by law, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, may be filled by a majority of the directors then in office, although less than a quorum, or by our stockholders; provided, however, that from and after the Sorrento Trigger Event, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, shall be filled only by a majority of the directors then in office, although less than a quorum, and shall not be filled by our stockholders, in each case subject to the rights of the holders of any series of Preferred Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of the Company or changes in our management.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delaware Anti-Takeover Law</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation provides that we will opt out of Section 203 of the DGCL until the occurrence of a Sorrento Trigger Event, at which time we shall immediately and automatically become governed by Section 203 of the DGCL.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 203 of the DGCL prohibits persons deemed to be &#x201c;interested stockholders&#x201d; from engaging in a &#x201c;business combination&#x201d; with a publicly held Delaware corporation for three years following the date such persons become interested stockholders, unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our Board, including discouraging attempts that might result in a premium over the market price for the shares of Common Stock held by stockholders.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation provides that the restrictions on business combination of Section 203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of the percentage of ownership of the total voting power of all the then-outstanding shares of our capital stock entitled to vote generally in the election of directors beneficially owned by them.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Cumulative Voting</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. The Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Special Stockholder Meetings</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation provides that special meetings of stockholders may only be called by order of the Chairperson of our Board, our Board or the Chief Executive Officer; provided, however, that at any time prior to the Sorrento Trigger Event, special meetings of our stockholders shall also be called by or at the direction of our Board or the Chairperson of our Board at the request of Sorrento, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. The Bylaws prohibits the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Director Nominations and Stockholder Proposals</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Bylaws establishes advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our Board or a committee of our Board. In order for any matter to be &#x201c;properly brought&#x201d; before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, to be timely, a stockholder&#x2019;s notice must be delivered to our secretary at our principal executive offices not earlier than the close of business on the 120th day nor later than the close of business on the 90th day prior to the first anniversary of the preceding year&#x2019;s annual meeting (in the case of the first annual meeting of stockholders held after January 1, 2023, the date of the preceding year&#x2019;s annual meeting of the stockholders shall be deemed to be June 30, 2022); provided, however, that, if the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 60 days after the anniversary of the preceding year&#x2019;s annual meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting and the 10th day following the day on which public announcement of the date of such meeting is first made by us. The Bylaws also specifies requirements as to the form and content of a stockholder&#x2019;s notice. The Bylaws allows any previously scheduled stockholders meeting to be postponed, adjourned or canceled by resolution of our Board; provided, however, that with respect to any special meeting of stockholders scheduled at the request of Sorrento, our Board is not allowed to postpone, reschedule or cancel without the prior written consent of Sorrento. In addition, the Bylaws allows the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to influence or obtain control.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stockholder Action by Written Consent</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 228 of the DGCL and the terms of the Certificate of Incorporation , any action required or permitted to be taken by our stockholders must be effected by a duly called annual or special meeting of such stockholders; provided, however, that prior to the Sorrento Trigger Event, any action required or permitted to be taken at any annual or special meeting of our stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents, setting forth the action so taken, is signed by or on behalf of the holders of record of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted, is delivered to us in accordance with the DGCL, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendment of Certificate of Incorporation or Bylaws</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#x2019;s certificate of incorporation or bylaws, unless a corporation&#x2019;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation provides that, upon the occurrence of the Sorrento Trigger Event, the affirmative vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the following provisions of the Certificate of Incorporation: Article V (Board of Directors), Article VI (Consent of Stockholders in Lieu of Meeting; Special Meetings of Stockholders), Article VII (Limitation of Liability), Article VIII (Corporate Opportunities and Competition), Article IX (Exclusive Forum), Article X (Section 203 of the DGCL) and Article XI (Amendment of Certificate of Incorporation and Bylaws), and no other provision may be adopted, amended or repealed that would have the effect of modifying or permitting the circumvention of the provisions set forth in any of such Articles.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation and the Bylaws provide that, our Board is authorized to make, alter and repeal the Bylaws, without the consent or vote of the stockholders, by an approval of a majority of the total authorized number of directors. Upon the occurrence of the Sorrento Trigger Event, the affirmative vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the Bylaws.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provisions of the DGCL, the Certificate of Incorporation and the Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our Board and our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive Forum</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders, (iii) any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL or of the Certificate of Incorporation or the Bylaws, (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws, (v) any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi) any action asserting an &#x201c;internal corporate claim,&#x201d; as that term is defined in Section 115 of the DGCL. The foregoing exclusive forum provisions will not apply to claims arising under the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we believe these provisions benefit us by providing increased consistency in the application of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in the Certificate of Incorporation to be inapplicable or unenforceable in such action. We may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. Any person or entity</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in the Certificate of Incorporation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Limitation of Liability and Indemnification of Directors and Officers</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; any breach of their duty of loyalty to us or our stockholders;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; any transaction from which the director derived an improper personal benefit.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#x201c;Covered Person&#x201d;) and who is or was a party to, is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#x2019;s actions in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#x2019; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i) advance costs, fees or expenses (including attorneys&#x2019; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final disposition of such proceeding, subject to certain exceptions, and (ii) purchase and maintain insurance, at our expense, to protect us and any person who is or was a director, officer, employee or agent of the Company or is or was a director, officer, employee or agent of the Company serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into indemnification agreements with each of our directors, executive officers and certain other employees as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. Our Board believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain of our non-employee directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The limitation of liability and indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#x2019;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conflicts of Interest</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. The Certificate of Incorporation provides that, to the fullest extent permitted by law, no Identified Person (as defined therein) will have any duty to refrain from (i) engaging in a corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii) otherwise investing in or providing services to any person that is engaged in the same or similar business activities as we or our affiliates or competes with us or our affiliates. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer to us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates. Subject to the preceding sentences and to the fullest extent permitted by applicable law, neither we nor any of our subsidiaries shall have any rights in any business interests, activities or ventures of any Identified Person, and we waive and renounce any interest or expectancy therein, except with respect to opportunities offered solely and expressly to our officers in their capacity as such.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rights of Appraisal and Payment</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of the Company. Pursuant to Section 262 of the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. However, appraisal rights are not available in all circumstances.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; Derivative Actions</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the DGCL, any of our stockholders may bring an action in the Company&#x2019;s name to procure a judgment in its favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of our capital stock at the time of the transaction to which the action relates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the effective time of the Domestication, each warrant to purchase Vickers Ordinary Shares that was issued and outstanding immediately prior to the effective time of the Domestication and not terminated pursuant to its terms was converted into a warrant to purchase shares of our Common Stock on the same terms and conditions as are in effect with respect to such warrant immediately prior to the effective time of the Domestication. As of the date of this Annual Report on Form 10-K, there are 6,899,988 outstanding redeemable warrants that were included in the units of Vickers, each of which consisted of one Vickers Ordinary Share and one-half of one redeemable warrant upon the consummation of an initial business combination (&#x201c;Units&#x201d;), that entitle the holder of each whole warrant to purchase one Vickers Ordinary Share at a price of $11.50 per share (&#x201c;Public Warrants&#x201d;) and 4,104,000 outstanding warrants sold in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (&#x201c;Private Placement Warrants&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Public Warrants</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Public Warrant entitles the registered holder thereof to purchase one share of our Common Stock at a price of $11.50 per share, subject to adjustment as described in this prospectus. We may, in our sole discretion, lower the warrant exercise price at any time prior to the expiration date for a period of not less than 20 business days</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and any such reduction will be applied consistently to all of the warrants, provided that we will provide at least 20 days&#x2019; prior written notice to registered holders of the warrants.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">However, no Public Warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance of the Common Stock issuable upon exercise of the warrants and a current prospectus relating to such Common Stock. Notwithstanding the foregoing, if a registration statement covering the issuance of the Common Stock issuable upon exercise of the Public Warrants is not effective within 90 days from the consummation of the Business Combination, warrantholders may, from the 91st day after the consummation of the Business Combination until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The warrants will expire five years from the consummation of the Business Combination (i.e., November 10, 2027) at 5:00 p.m., New York City time or earlier upon redemption or liquidation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may call the warrants for redemption (excluding the Private Placement Warrants), in whole and not in part, at a price of $0.01 per warrant:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; at any time while the warrants are exercisable,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; upon not less than 30 days&#x2019; prior written notice of redemption to each warrantholder,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; if, and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for share sub-divisions, share dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third trading day prior to the date on which notice of redemption is given, and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149; if, and only if, there is an effective registration statement covering the Common Stock issuable upon exercise of the Public Warrants, and a current prospectus relating thereto, available throughout the 30-day redemption.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not exercise such redemption right if the issuance of the Common Stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. The right to exercise will be forfeited unless the warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such holder&#x2019;s warrant upon surrender of such warrant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The redemption criteria for our warrants have been established at a price which is intended to provide warrantholders a reasonable premium to the initial exercise price and provide a sufficient differential between the then-prevailing per share price of our Common Stock and the warrant exercise price so that if the per share price of our Common Stock declines as a result of our redemption call, the redemption will not cause the per share price of our Common Stock to drop below the exercise price of the warrants.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we call the warrants for redemption as described above, our management will have the option to require all holders of warrants to exercise their warrants on a &#x201c;cashless basis.&#x201d; In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the fair market value by (y) the fair market value. The &#x201c;fair market value&#x201d; for this purpose shall mean the average reported closing price of the shares of our Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. For example, if a holder held 150 warrants to purchase 150 shares of our Common Stock and the fair market value on the trading date prior to exercise was $15.00, that holder would receive 35 shares of our Common Stock without the payment of any additional cash consideration. Whether we will exercise our option to require all holders to exercise their warrants on a &#x201c;cashless basis&#x201d; will depend on a variety of factors including the price of our Common Stock at the time the warrants are called for redemption, our cash needs at such time and concerns regarding dilutive share issuances. Requiring a cashless exercise in this manner will reduce the number of shares of our Common Stock to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to use if we do not need the cash from the exercise of the Public Warrants.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The warrants are issued in registered form under a warrant agreement (the &#x201c;Warrant Agreement&#x201d;) between Continental Stock Transfer &amp; Trust Company (&#x201c;Continental&#x201d;), as warrant agent, and us. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the registered holders of a majority of the then-outstanding warrants (including the Private Placement Warrants) in order to make any change that adversely affects the interests of the registered holders.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of (i) a stock dividend or split up, (ii) a consolidation, combination, reverse stock split or reclassification of the Common Stock, (iii) extraordinary dividend or (iv) reclassification or reorganization of the outstanding Common Stock or an merger or consolidation of us with or into another corporation. However, the warrants will not be adjusted for issuances of shares of Common Stock at a price below the par value per share issuable upon exercise of the warrants. Whenever the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, the warrant exercise price will be adjusted by multiplying such warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y) the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified check or bank draft payable to the order of the warrant agent or wire transfer, for the number of warrants being exercised. The warrantholders do not have the rights or privileges of holders of shares of Common Stock and any voting rights until they exercise their warrants and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to one vote for each share of Common Stock held of record on all matters to be voted on by stockholders.</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Except as described above, no Public Warrants will be exercisable for cash and we will not be obligated to issue shares of Common Stock upon exercise of a warrant unless the shares of Common Stock issuable upon such warrant exercise have been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. Under the terms of the Warrant Agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants until the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants, holders will be unable to exercise their warrants and we will not be required to settle any such warrant exercise. If the prospectus relating to the Common Stock issuable upon the exercise of the warrants is not current or if the Common Stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, we will not be required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and the warrants may expire worthless.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrantholders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrantholder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder (together with such holder&#x2019;s affiliates) would beneficially own in excess of 9.8% of the Common Stock outstanding immediately after giving effect to such exercise.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number of shares of Common Stock to be issued to the warrantholder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Private Placement Warrants</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Private Placement Warrants are identical to the Public Warrants except that such Private Placement Warrants are exercisable for cash (even if a registration statement covering the issuance of the Common Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#x2019;s option, and will not be redeemable by us, in each case so long as they are still held by the initial purchasers or their affiliates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing summary of the terms and conditions of the warrants does not purport to be complete and is qualified in its entirety by reference to the copy of the Warrant Agreement that is filed as an exhibit to the registration statement of which this prospectus forms a part.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer Agent and Registrar</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transfer agent and registrar for our Common Stock is Continental. The transfer agent&#x2019;s address is 1 State Street, 30th Floor, New York, New York 10004.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Listing</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares of our Common Stock and Public Warrants are listed on Nasdaq under the symbols &#x201c;SCLX&#x201d; and &#x201c;SCLXW&#x201d; respectively.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>sclx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-269256) pertaining to the 2022 Equity Incentive Plan, the 2022 Employee Stock Purchase Plan, and the 2023 Inducement Plan of Scilex Holding Company, and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-269257) pertaining to the Scilex Pharmaceuticals Inc. Amended and Restated 2017 Equity Incentive Plan and the Scilex Holding Company 2019 Stock Option Plan, as amended;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our report dated March 7, 2023, with respect to the consolidated financial statements of Scilex Holding Company included in this Annual Report (Form 10-K) for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Diego, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 7, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>sclx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Rule 13a-14(a) adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Jaisim Shah, certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Scilex Holding Company;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/ Jaisim Shah</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:1pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jaisim Shah</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Executive Officer and President</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dated: March 7, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>sclx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Rule 13a-14(a) adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I,</font><font style="background-color:rgba(0,0,0,0);color:rgba(38,38,38,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Elizabeth Czerepak, certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Scilex Holding Company;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Elizabeth Czerepak</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:1pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Elizabeth Czerepak</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Executive Vice President, Chief Financial Officer and Chief Business Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dated: March 7, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>sclx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of the undersigned, in his or her capacity as the principal executive officer and principal financial officer of Scilex Holding Company (the &#x201c;Company&#x201d;), as the case may be, hereby certifies, pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), that, to the best of their knowledge:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. This Annual Report on Form 10-K for the period ended December 31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. The information contained in this Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by this Annual Report.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission (&#x201c;SEC&#x201d;) or its staff upon request.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of this Annual Report), irrespective of any general incorporation language contained in such filing.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> day of March 2023.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-bottom:0.02in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jaisim Shah</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:1pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.02in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-bottom:0.02in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jaisim Shah</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Executive Officer and President</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:45.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Elizabeth Czerepak</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:1pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Elizabeth Czerepak</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Executive Vice President, Chief Executive Officer and Chief Business Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial Officer)</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img248422670_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $W G # 2(  A$! Q$!_\0
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MB^B1/,+*-DJ2?,IPP)4G!&1^=)^U2N[FT/J,Y*,>5M^A+_PE/B'_ *#VJ?\
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MC5DT3G+F>H8;#470@W!;+HNQK?\ "4^(?^@]JG_@9)_C1_PE/B'_ *#VJ?\
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M_P C=:?]>"?^C)*UA.7LIZ]OU.+$X>BLPH)05K3Z+^Z<E_PE/B'_ *#VJ?\
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M^13_ .$I\0_]![5/_ R3_&C_ (2GQ#_T'M4_\#)/\:E7PS=QZ]::5>/' ]R
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M7WK(ARB_=D(+CIWP/IVQ4%_JU]J847D_F;9'E'R*/F<@L>!WP*Z#_A6?B_\
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MKF! 2>.6POS]!][/ZFH]3U6[UB[-W>M$\[?>=(4CW>YV@9/N>:Z#_A6?B_\
MZ!'_ ),Q?_%T?\*S\7_] C_R9B_^+I.E6>\7^)4<;EL+.-2"MMK'3T#P)_S,
MO_8!NO\ V6N2KT[PGX&\1Z9_;GVS3O+^TZ3/;0_OXSND;;M7AN,X/)XKGO\
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M?_%T?\*S\7_] C_R9B_^+I3A4DK*%OD7A\1A*4DY8I2MWDO\S(\+?\C?HO\
MU_P?^C%H\5?\C?K7_7_/_P"C&KI] ^'GBFR\1Z7=W&E[((+N*21OM$1VJK@D
MX#9Z"EU_X>>*;WQ'JEW;Z7O@GNY9(V^T1#<K.2#@MGH:/8U/9VY7OV'_ &C@
M_KG-[6-N7^9=_4X&MF+Q7K<&?+OB 9DGP8T(WJNT'!'IQ[]ZU/\ A6?B_P#Z
M!'_DS%_\71_PK/Q?_P! C_R9B_\ BZA4JRV3_$Z:F.RVII.I!^KB_P!3*/BG
M6AO\J_> ,JIBV180JJ20%" ;1EB<#&2><UFW=U-?7<UU<,&FF<N[!0N6/).
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ME[E7C6)Q)$CAU7=@'<#G[QZ_T%59=9OIK&2R:2-;>67SG2.%$W/D\DJ >,G
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M^Q1]@L_^?2#_ +]BCVS[!]0A_,_N_P"">@_:8/\ GO'_ -]BC[3!_P ]X_\
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M^D'_ '[%'V"S_P"?2#_OV*/;/L'U"'\S^[_@GH/VF#_GO'_WV*/M,'_/>/\
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M*I_VK8?\_<7_ 'U1_:MA_P _<7_?5%T'LY]BY15/^U;#_G[B_P"^J/[5L/\
MG[B_[ZHN@]G/L7**I_VK8?\ /W%_WU1_:MA_S]Q?]]470>SGV+E%4_[5L/\
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MHHH **** "BBB@ HHHH **** "L#6_\ C]3_ *YC^9K?K(U6*WDNE,MUY3;
M-OEEN,GFIEL;X=VG<Q:*N?9K+_G_ /\ R"U'V:R_Y_\ _P @M46/0]HO/[F4
MZF@@$V[+$ 8' ')/U(J;[-9?\_\ _P"06IR16L;934F4^JQ,*$B7/32_W/\
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M6WDD'<,-\H_PJ=KBW9E!1M@4C[HZ^N,TYKNW9O\ 5G;TP$'')_/M3(O_ '2
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M&6)"LBMC/N13)I?-9<# 50H&?2D[6+2=R.BBBD6%%%% !1110 4444 %%%%
M!1110 4444 %%%% !112,RHI9B H&23VH ;(WE;9UE,4D1W)*.JG_/;O75PW
M]U>>&9+R.,I=F!V14&[+@'! /KP<?A7.Z3I+ZU.MQ.I2RC.54\&0^I]J[&:2
M.QL99=N(X8RY ] ,UO2BUJSS<96C-J*Z=?T.)TO5?%RI)9:A:2%Q9&07!B9V
M9S&6!#K&B AOE\LKGOD]*9IWB;Q8]E-)-I3,EK;A_,?3YTDN"-N0$/.1EN@.
M[;D#!XZK3O$FF:K*T%I,SSK'YC1F-AZ9 )&"1N&<$XR/6LM_B!HT,$,ESYML
M\T9>.&8QJ[$2^45 W\MN[#/%;'"9;>+O$TD[K;Z%.1LDV>;ITR#(?"'=NYRN
M,J0"#5XZ_JK-K]K=03K_ &9$O[_3;<O+,[C<OE(=_.W&00>3Z"K4GC2VB%XD
MFF7XN+:Z6U^S@Q%I'*>8-I$FW[N3R01Z=*JS>/\ 3K6WN[I].O$BBM8KTNSP
M()(WR%(S(,'Y<;6P3V!H S'U+Q5%'HRO-J+DV\33R0:<3YC;R)=X:(%"J %>
M%W'H#TI-,U3Q))-H9:;5I%FO'^T)<:>8V6 [MHD_<*H8#&2&7&. _?T""9;B
MWCF4,JR(' 88(!&>1ZU)0!SWB*YU6XT>V;06N8;B:Z2,MY6QE3)#$B2-MHXZ
ME3^M<_%KOBW36CM+BQGOKCS9!+*+%S&P"\%74@ 9!."O(/!%>@T4 <>VK^)G
MT:.9K98+I-0@CEV6,CAH&V%B$W;N-Q!;)^Z3@=HXM<\0ZAI.J$Z?/;SP^7Y.
MVTDC8,7(9!OSYF% .]?E.[CI7:44 <$_C#Q$@N&&A73()'2$G39E8G82@*@M
MQD8+9Q]*GLO$?B9]0M8+W2_(@F(9ITL)W"#+#RR 3@G;G>< 9&1R#7;44 <5
M8ZEXF_L*^6ZMI6NHUC>W=;=E=MTC J0<[B%4'( X8<=RK:UXIET#5YA9+!>P
MP+-:[;*1LG<P*;"V7;"@\8^\./7M** . FU_Q;8SW 33WNH)9W\J4V$I,*@K
M@E0<LIR<#@C!.3@UH:YJ^NVWEBVM[H275@/)%O:M*J7)9>&.T[1@]7P.#G&*
MZ^B@#D]5UJ^M_$&ES0+J4FFR*RS6\-A+E3DC>Q\IN./N[D/0C<#76444 %%%
M5K[4;'2[8W.H7EO:6X(4RW$JQJ">@R2!0!9KBI?B+;6FN7.F7=A)&T=PT4++
M(&,Z@=5! YWX4@G W*2<&NO-U;^5#+YT9CF($;!@0^>F#WS5#4K+0(XQ)JEK
MIBQR.8PUU'& SR84C+=2W QWH S['QOIU]?_ &-;:\B<,T;O(B[8Y%#$H<,2
M3A&Y (XZ\C-&\\?"QF%Q+IV_2GNGM(YHIB9VD52V3$5 "G!&=V>AQS6_I]IH
M23/#IUOIRRV3!'2W1 T#;> 0OW3M8^G!]Z;?^&-$U-KE[K2[1YKE/+FG$*B1
MUX^4MC)' X]J ,S_ (3>U,T*+973/,K*D "B7S5D9&3E@O&QCG=CC@GBJL'Q
M!MKTP"RM)9O-N8H]_"JD;N%#-DYR<G@ ].<5T,GA[1);-;.31]/>U5 BPM;(
M4"@[@ N,8SSCUIQT'1C/#.=)L#- =T4GV9-T9XY4XX/ Z>@H T***;'(DJ;X
MW5U)(W*<C@X- #JQM31)-3C20,08OX3CN?:MFN<\0:K;V-^D4MCY[&(-N\TK
M@9/&,>U3)V1T8:,I3M%:C%LU<95R/E#8VYQGI_\ KIWV#"_,SAB 0-H]<>O2
MLK_A(;+_ *!/_DRW^%'_  D-E_T"?_)EO\*SYHGH>QK]G^'^9K#3PV2LI('7
MY.>_3GV--ALEDQND(Y(P%]\5E_\ "0V7_0)_\F6_PH_X2&R_Z!/_ ),M_A1S
M1#V-?L_P_P S12TS$)&9@N['W??&/K[5*MI%(90K,-LA SZ#K^G\JR?^$ALO
M^@3_ .3+?X4?\)#9?] G_P F6_PHYHC=&OV?X?YFN]@AW%&8*H)Z9-)%IX=W
M&]B$')V\=,^M9B>);5 0NED9ZXN6_P *9_PD-E_T"?\ R9;_  HYHD^QK]G^
M'^9J1V/F(K"0] 2-O//ISSTJ!K"*\A:WF&5>58F]"#G_  JE_P )#9?] G_R
M9;_"K%EKUK->V\*Z84WRJ WV@G!)QG&.:+Q8W3KI-V?X?YDG_""6O_/U/_WT
M:/\ A!+7_GZG_P"^C76T5IR1['F_6*W\S^]G)?\ ""6O_/U/_P!]&C_A!+7_
M )^I_P#OHUUM%')'L'UBM_,_O9R7_""6O_/U/_WT:/\ A!+7_GZG_P"^C76T
M4<D>P?6*W\S^]G)?\():_P#/U/\ ]]&C_A!+7_GZG_[Z-=;11R1[!]8K?S/[
MV<E_P@EK_P _4_\ WT:/^$$M?^?J?_OHUUM%')'L'UBM_,_O9R7_  @EK_S]
M3_\ ?1H_X02U_P"?J?\ [Z-=;11R1[!]8K?S/[V<E_P@EK_S]3_]]&C_ (02
MU_Y^I_\ OHUUM%')'L'UBM_,_O9R7_""6O\ S]3_ /?1H_X02U_Y^I_^^C76
MT4<D>P?6*W\S^]G)?\():_\ /U/_ -]&C_A!+7_GZG_[Z-=;11R1[!]8K?S/
M[V<E_P ():_\_4__ 'T:/^$$M?\ GZG_ .^C76T4<D>P?6*W\S^]G)?\():_
M\_4__?1H_P"$$M?^?J?_ +Z-=;11R1[!]8K?S/[V<E_P@EK_ ,_4_P#WT:/^
M$$M?^?J?_OHUUM%')'L'UBM_,_O9R7_""6O_ #]3_P#?1H_X02U_Y^I_^^C7
M6T4<D>P?6*W\S^]G)?\ ""6O_/U/_P!]&C_A!+7_ )^I_P#OHUUM%')'L'UB
MM_,_O9R7_""6O_/U/_WT:/\ A!+7_GZG_P"^C76T4<D>P?6*W\S^]G)?\():
M_P#/U/\ ]]&C_A!+7_GZG_[Z-=;11R1[!]8K?S/[V<E_P@EK_P _4_\ WT:/
M^$$M?^?J?_OHUUM%')'L'UBM_,_O9R7_  @EK_S]3_\ ?1J2'P/9QS*[SRNH
M.=K,2#74T4<D>PG7JM6<G]XR.-(8UCC4*JC  I)X8[B"2"5=T<BE'7.,@C!J
M2BJ,C,L_#VEZ?+YEK;&)PCH&$KY ;;N[_P"ROY56MO"&B6ELUO';2M&RE#YM
MU+(<%]Y&68G[W/6MRB@#"'A#1EL9;+R;HP23&<AKZ<L)"22RL7RI.YLX(SGF
MFIX,T2**YBABO(8KG ECBU"X12 H4  . !M &!C@5OT4 1P016UO'!"@2*)0
MB(.BJ!@"I*** "BBB@ HHHH **** "BBB@ HHHH **** "LS7-&36[>W@DGD
MA2*X2<F,E6;;G@$$$9SU%:=% '"ZO\.3J.LV-W;:I'9VED@CBMTM 6V",H%,
MFX%AD[N<\U;/@.!M!;2&NQ]G:Y6?"PX Q&$( SU)!;/J>_6NOHH X@^ )O[%
MO+'^UT>:]>.2XGGLED#L VX[2W!+-D8.1@"H+7X;26?AI](BU>)FDBA2:66Q
M#B5DWY<J6/S'<O.<C8.:[ZB@#S'0/AMJ5OIL$&IW]L9X9A(TJPDF<[ NXX8$
M.""0^=WS,2,FMBW^'<=K<BXAU$Q388-+%#M<EDE4D-NX)\Q#_P!LU]L=M10!
MQ-C\/5M);25KZ(R6S(R>7;% "'#':"YV[@"#C^\3W.>@\.Z''X>THV$1A,8G
MEE7RH?*&'<M@C)R1G&>,XZ"M:B@ KA_&7_(7B_ZX#_T)J[BN'\9?\A>+_K@/
M_0FK.I\)W9=_'^1D6]A)<P-,C( '"8.2<GZ#@?6I9-)GCNTMR\>7&0^& SSQ
MR,YX]*KP74\".(2 .K-L!(Y'?&0,XHBO)X9_.1QOR6^90PSZX/%8Z'MM5+NS
M)8].>2U%P98D0C.&W9QG;G@'OQ3X]*E>[GM_,C#Q$*3DX)STZ9]>U,BU*[B4
M+$Z@*V\#RU..<^G3/..E,2]D0S';&3+C.8Q@$'KMQC].]&@FJNNI;BT*YF0L
MLD8Y90&#C)!QC[N ?8XJ'^RI0(R\L2!XC+EMWR@>N!UY%-.JWA# R+SGGRUR
M,G)P<9'X4?VC>22F0N';#9S&K#!//&,4:"2K=6B5M&G01[I(AYDGEJ?FP3VY
MQ@9^M,DTJ>.*21GB"QN$?D\'C/;L2 ?>F'4[MB"9%+*Q96,:Y!/H<9%+)J=\
M\?EO.VPIM*X&&'J1W/OUHT!*MU:%.G$9VW5O(=C,!&^?NC)^G /Y50>[DL4^
MUP[?-AQ(FX9&1R,U8MY'B,C1IN/ELI./N@C!/Z_K5#4/^0?/_N&ID[*Z-J<6
MY6EJC<_X2W7O^>]I_P" Y_\ BJ/^$MU[_GO:?^ Y_P#BJQZ*RYY=R/JU'^1?
M<C8_X2W7O^>]I_X#G_XJC_A+=>_Y[VG_ (#G_P"*K'')J_/IRB[>VMI6EDB9
MED,BK&H(.."6.>?I3YIOJ2Z-"+LXK[BS_P );KW_ #WM/_ <_P#Q5'_"6Z]_
MSWM/_ <__%5G?8Y]A=D" -L^=@ISG'0G/'?TJ;[ L.I&SNIMIW;=T($@SG'J
M/\?:A2F^HG2PZ^RON1;_ .$MU[_GO:?^ Y_^*H_X2W7O^>]I_P" Y_\ BJJS
M::X):W+20AS&'<*A+ X( W'/45%]@N?.,6Q<A=V[>NS'KNSMQGCKUXHYI]V"
MI89_97W(O_\ "6Z]_P ][3_P'/\ \51_PENO?\][3_P'/_Q549K&6&%9,';L
M#/D8VDL5Q[GC^?I0-/NF,06+)E(50&!Y/0'G@_7%'-/NP]EA]^5?<B]_PENO
M?\][3_P'/_Q5'_"6Z]_SWM/_  '/_P 55'^S;L2;#%@[=V2PQC..N<=>,>O'
M6I/[/"ZE):22LHC5F9@F3A5+'C/7CUHYI]P]GA_Y5]R+7_"6Z]_SWM/_  '/
M_P 51_PENO?\][3_ ,!S_P#%55;2K@_- /-B(4JV0I.[.!@GKQT&>>F:K36\
MENX60#D9!5@P(]B.#1S3[L%2P\MHK[D:?_"6Z]_SWM/_  '/_P 51_PENO?\
M][3_ ,!S_P#%4QM$9=1:U,X*AE59 O#9<*?R.?RJI-:*L*SV\IEA+[/F3:RM
MZ$9(Y[8)_"CFGW%&&&EM%?<7O^$MU[_GO:?^ Y_^*H_X2W7O^>]I_P" Y_\
MBJHWUF;*94\P2 KG<!CG)!'X$$55I.<UU+C0H25U%?<;'_"6Z]_SWM/_  '/
M_P 51_PENO?\][3_ ,!S_P#%5CT4<\NX_JU'^1?<C8_X2W7O^>]I_P" Y_\
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M3[<PJP56S(SY"YQRQ/J: -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$ AFC5E$V\@-ORC\#RY1LY7G&1R:B'Q$NA=2K)IEG%'':M-M>^VLS#RR "4
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MXZ3_ -^I/_CE<OMJ??\  ^C^I8W_ )]K_P "_P" =!17/_\ "[/$G_/CI/\
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MCPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J)[>&6>*=XU:6'/EN1RN1@
MX^M2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'4''!KLJ "BBB@ HHHH **** "BBB@ HHHH **** "O!OC9_R.=G_P!@]/\
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M5 + D/A2 03NQCO3M=6U_K_AC)24)*5HW7F^GS^9U3:EKSZE:79\$ZR/LX?
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MU9@NZ"S)0G80KC:IZ)@, 5';.3QU-6[Y?"$D>H7"W=J\DJ$PQ1Q3HT9$6%"
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M:#2YVO6@GDMI5>,0L'0$L1EB"N ><YXY XSEMHFH+;M/Y*-&K%<I,C$@-MW
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M]=+M+.[U&)&OX8!$@QGRUW,WYY8UV5%%=T8J*LCYVM6E6GSR"BBBJ,@HHHH
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M50^%Y5E:<8.X, =P)"DA3QGNK&=KK3[:X8 -+$KD $ $@'H>?SJQ10 4444
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4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img248422670_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 3-"?P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML?8UL:!XILO$*R&WRA3LQZTW3FE=HF->G)\J>INU%<RF"!Y ,[1G%2U6O_\
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MA1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M UY?X8?S?%T$@Z-)FIIRE*#YBJ\*<*L5 W_B. ;SIWKI/AW_ ,@-O]ZN<^)
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M=V>K3C&,;1V"BBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXR\+:IK$P:T52 <\ULZ!H5S:^%FT^[4>:<\"NHHJW5DX\IBL/!3<^K/(?^$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *@N[J.RM)+B4X2-2QJ>N)\?S21&R^=E@+
M?O,=,4 %K\3M'NI_*6*=3G&6'%=<UW$MG]J)Q'MW9/I7E-]-I6K11Z;I C>5
M6#%E'-=%J5^^I)8Z%I[%XG01W$@ZH: -_2O%-EJ^I2V5NDFZ,9+$<&MVLW1M
M%MM%L8[: !BHYD(^8UI4 %%9VL:Q:Z/9M-<2JK$'RU/\1]*X(>.?%3Q-.FB
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6$3^/=%2(AG'=?X:S=&B\6Z3I_DZ1:K+;$G!:NA\*>'+M+AM0UA"+O=E1Z4
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M>XOF2*2<J2VULDUQ,$'CBSBFL(;13:L<*W?%=%I/A 0Z>\]R\AO)$.Y2> :
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M&$O&6;PU/(X/W@IJO!J_A4W"!?"TZL3P=IXKU<V\!.3#&3[J*!;0 Y$$>?\
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M%=)XIO7M-*<(P'F J:D\/Z%!HEELC!\R3#2$^M9OC73=1U*UMH[!-Q$F7^E
M$7P\MQ;Z'* ,;I2U'CFX6*&WC/WI#@5O:+8?V?8)"1AL GZUQ6H32>+/$T=O
M;#*Z?+\_IUH ZSPO"\.C1JZD'.<&MJD484 #&!2T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %74+:2[M&ABE\LL,$UF>&?#_\ PC]M/%YOF>:^\FMVB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_Q%X=?
M7)K9UN/*$1Y'K7044 5K&U^QVB09SM[U9HHH **** "BBB@ HHHH **** .:
M\3>%O[=7=#-Y$^,"3N*YZ+X?:R981=:Z\T"'F,YP17HU% %:PL8=/M%MX$"H
MO859HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112
M @]#0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%!('6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHZ4
M %%&<T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %% (/2B@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHR
M/6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HH)QUHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** <]*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BB@$'I0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %4K*1GGF!Z U=K/L/^/B?ZT :
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %5-0=HX 5ZYJW5+4_P#CV'^]0!:B.8E)]*?3(?\
M4I]*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4-RQ6W<CJ!4U0W?_'K)]* &V3%[96/6K%5K#_C
MT2K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %(W"'Z4M(_W&^E %2PD:1'W=FJY5'3?N2?[U7J "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** *5M(S7DJGH*NUGVO_ !_S5H4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5KYREL6'7-2VY+0(3U(J'4?^/1OK4MM_Q[1_2@"6BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** (YR5A<CL*BL7,EN"W7-2W'_'N_P!*@T[_ (]1]: +=%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 (>AJG8R,[R@]C5P]#5'3OOS?[U %^BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS/\ A(=+_P"?M*/^$ATO_G[2CDEV#VM/^9&G169_PD.E_P#/VE'_  D.E_\
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M')+L'M:?\R-.BLS_ (2'2_\ G[2C_A(=+_Y^THY)=@]K3_F1IT5F?\)#I?\
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MG_,C3HK,_P"$ATO_ )^TH_X2'2_^?M*.278/:T_YD:=%9G_"0Z7_ ,_:4?\
M"0Z7_P _:4<DNP>UI_S(TZ*S/^$ATO\ Y^TH_P"$ATO_ )^THY)=@]K3_F0^
MU_X_YJT*P+?7-,6\E8W*@'H:N?\ "0Z7_P _:4<DNP>UI_S(TZ*S/^$ATO\
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M*/\ A(=+_P"?M*.278/:T_YD:=%9G_"0Z7_S]I1_PD.E_P#/VE')+L'M:?\
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M*/\ A(=+_P"?M*.278/:T_YD:=%9G_"0Z7_S]I1_PD.E_P#/VE')+L'M:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7G/C4 W*9]:]&KSKQI_P ?*?6M\-_%1R8[_=Y'*[![_G1L
M'O\ G3J*],^<&[![_G1L'O\ G3J* &[![_G1L'O^=.HH ;L'O^=&P>_YTZB@
M!NP>_P"=&P>_YTZB@!NP>_YT;![_ )TZB@!NP>_YT;![_G3J* &[![_G1L'O
M^=.HH ;L'O\ G1L'O^=.HH ;L'O^=&P>_P"=.HH ;L'O^=&P>_YTZB@!NP>_
MYT;![_G3J* &[![_ )T;![_G3J* &[![_G1L'O\ G3J* &[![_G1L'O^=.HH
M ;L'O^=&P>].HH ;L'O^=&P>_P"=.HH ;L'O^=&P>_YTZB@!NP>_YT;![_G3
MJ* &[![_ )T;![_G3J* &[![_G1L'O\ G3J* &[![_G1L'O^=.HH ;L'O^=&
MP>_YTZB@!NP>_P"=&P>_YTZB@!NP>_YT;![_ )TZB@!NP>_YT;![_G3J* &[
M![_G1L'O^=.HH ;L'O\ G1L'O^=.HH ;L'O^=&P>_P"=.HH ;L'O^=&P>_YT
MZB@!NP>_YT;![_G3J* &[![_ )T;![_G3J* &[![T;![_G3J* &[![_G1L'O
M^=.HH ;L'O\ G1L'O^=.HH ;L'O^=&P>_P"=.HH ;L'O^=&P>_YTZB@!NP>_
MYT;![_G3J* &[![_ )T;![_G3J* &[![_G1L'O\ G3J* &[![_G1L'O^=.HH
M ;L'O^=&P>_YTZB@!NP>_P"=&P>_YTZB@!NP>_YT;![_ )TZB@!NP>_YT;![
M_G3J* &[![_G1L'O^=.HH ;L'O\ G1L'O^=.HH ;L'O^=&P>_P"=.HH ;L'O
M1L'O^=.HH ;L'O\ G1L'O^=.HH ;L'O^=&P>_P"=.HH ;L'O^=&P>_YTZB@!
MNP>_YT;![_G3J* &[![_ )T;![_G3J* &[![_G1L'O\ G3J* &[![_G1L'O^
M=.HH ;L'O^=&P>_YTZB@!NP>_P"=&P>_YTZB@!NP>_YT;![_ )TZB@!NP>_Y
MT;![_G3J* &[![_G1L'O^=.HH ;L'O\ G1L'O^=.HH ;L'O^=&P>_P"=.HH
M;L'O^=&P>_YTZB@!NP>]&P>_YTZB@!NP>_YT;![_ )TZB@!NP>_YT;![_G3J
M* &[![_G1L'O^=.HH ;L'O\ G1L'O^=.HH ;L'O^=&P>_P"=.HH ;L'O^=&P
M>_YTZB@!NP>_YT;![_G3J* &[![_ )T;![_G3J* &[![_G1L'O\ G3J* &[!
M[_G1L'O^=.HH ;L'O^=&P>_YTZB@!NP>_P"=&P>_YTZB@!NP>_YT;![_ )TZ
MB@!NP>_YT;![_G3J* &[![_G1L'O^=.HH ;L'O1L'O\ G3J* &[![_G1L'O^
M=.HH ;L'O^=&P>_YTZB@!NP>_P"=&P>_YTZB@!NP>_YT;![_ )TZB@!NP>_Y
MT;![_G3J* &[![_G1L'O^=.HH ;L'O\ G1L'O^=.HH ;L'O^=&P>_P"=.HH
M;L'O^=&P>_YTZB@!NP>_YT;![_G3J* &[![_ )T;![_G3J* &[![_G1L'O\
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M &[![_G71^!U UQO]VN>KHO!'_(<;_=K.K_#9T87^-'U/2Z***\D^F"BBB@
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M+Y:)N% '4445EZ]J@TO3VE!PY!"?6@#4HKAO!_BN\U&=K74\"=F.P 8XKN:
M"BFEUP<,,X]:\[?QAJBKJ9!7_1R0E 'HU%8?A35)M5\/P7ETR^:^=V*VP01D
M$8H 6BF[U_O#\Z=G/2@ HI"ZCJP_.L;73K!@7^QVBW[AG<>U &U14-L9!:Q?
M:"/-VC?]:E#J>C#\Z %HH) ZFF[T_O+^= #J* 0>AS5'6;J2RT>ZN8?]9'&6
M7/K0!>HKF/!NMW6LZ6+B\*AR372[U_O#\Z '44A( R2!2;U/\0_.@!U%)N'J
M*"0.IQ0 M%)N [B@.IZ,/SH 6BBB@ KSKQI_Q\I]:]%KSKQI_P ?*?6M\/\
MQ4<F._W>1R]%%%>F?.A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\)K%>IJL]V&?!1C1JEK+H<^DZDL;- B!I%49-&M>,H?$L4-GI]M<))O&2ZT
M:OB37)Y/"SW4!*2*H'![UBV?@_4;W05U<ZY<+(T9D\O/%:7B73I;'PB\>TNS
M '"C-;VD!AX$C!4AOLYXQS0!3^'^HSW6DF*Y9G=7(W$UN^(_^1=OO^N1KF_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO7#YWQ'TSS(L;1@9KJ+KQ-;6DZQ/#*2Q R!7+^-DN;+7K'Q BL]M @+*HY-
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MA4^H0"K%% #'BCD7:Z*R^A&:41HJ; H"]-H'%.HH 8D4<8PB*OT&*<RAE*L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M )3C:*[+_A7[?\_5'_"OV_Y^J/K%/N'U&O\ RG&T5V7_  K]O^?JC_A7[?\
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MIQ@XJ;_A7[?\_5'UBGW#ZC7_ )3C:*[+_A7[?\_5'_"OV_Y^J/K%/N'U&O\
MRG&T5V7_  K]O^?JC_A7[?\ /U1]8I]P^HU_Y3C:*[+_ (5^W_/U1_PK]O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !6?8?\ 'Q/]:T*S[#_CXG^M &A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !5+4_^/8?6KM4M3_X]A_O4 6H?]2GTI],A_P!2GTI] !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %0W?_'K)]*FJ&[_X]9/I0 RP_P"/1*LU6L/^/1*LT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4C_ '&^E+2/]QOI0!2TW[DG^]5ZJ.F_<D_WJO4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 9]K_ ,?\U:%9]K_Q_P U:% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %74?^/1OK
M4MM_Q[1_2HM1_P"/1OK4MM_Q[1_2@"6BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ([C_CW?Z5!
MIW_'J/K4]Q_Q[O\ 2H-._P"/4?6@"W1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'H:HZ=]^;_
M 'JO'H:HZ=]^;_>H OT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "L^P_P"/B?ZUH5GV'_'Q/]: -"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "J6I_\ 'L/]ZKM4M3_X]A]: +4/^I3Z4^F0_P"I3Z4^@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"H;O_CUD^E35#=_\>LGTH 98?\>B59JM8?\ 'HE6: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1_
MN-]*6D?[C?2@"EIOW)/]ZKU4=-^Y)_O5>H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S[7_C
M_FK0K/M?^/\ FK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH JZC_P >C?6I;;_CVC^E1:C_
M ,>C?6I;;_CVC^E $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]>K_ ,QVW_"?_P#3K^M'_"?_ /3K^M<311]7I]@^O5_YCMO^$_\ ^G7]:/\
MA/\ _IU_6N)HH^KT^P?7J_\ ,=M_PG__ $Z_K1_PG_\ TZ_K7$T4?5Z?8/KU
M?^8[;_A/_P#IU_6C_A/_ /IU_6N)HH^KT^P?7J_\QVW_  G_ /TZ_K4-SXX\
M^+8+;'.:X^BCZO3[!]>K_P QVJ^/=J ?9>@I?^$__P"G7]:XFBCZO3[!]>K_
M ,QVW_"?_P#3K^M'_"?_ /3K^M<311]7I]@^O5_YCMO^$_\ ^G7]:/\ A/\
M_IU_6N)HH^KT^P?7J_\ ,=M_PG__ $Z_K1_PG_\ TZ_K7$T4?5Z?8/KU?^8[
M;_A/_P#IU_6C_A/_ /IU_6N)HH^KT^P?7J_\QVW_  G_ /TZ_K1_PG__ $Z_
MK7$T4?5Z?8/KU?\ F.V_X3__ *=?UH_X3_\ Z=?UKB:*/J]/L'UZO_,=M_PG
M_P#TZ_K1_P )_P#].OZUQ-%'U>GV#Z]7_F.V_P"$_P#^G7]:/^$__P"G7]:X
MFBCZO3[!]>K_ ,QVW_"?_P#3K^M'_"?_ /3K^M<311]7I]@^O5_YCMO^$_\
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M )CMO^$__P"G7]:/^$__ .G7]:XFBCZO3[!]>K_S';?\)_\ ].OZT?\ "?\
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M /3K^M<311]7I]@^O5_YCMO^$_\ ^G7]:/\ A/\ _IU_6N)HH^KT^P?7J_\
M,=M_PG__ $Z_K1_PG_\ TZ_K7$T4?5Z?8/KU?^8Z^+QN8YWD-OG=VJ?_ (3_
M /Z=?UKB:*/J]/L'UZO_ #';?\)__P!.OZT?\)__ -.OZUQ-%'U>GV#Z]7_F
M.V_X3_\ Z=?UH_X3_P#Z=?UKB:*/J]/L'UZO_,=M_P )_P#].OZT?\)__P!.
MOZUQ-%'U>GV#Z]7_ )CMO^$__P"G7]:/^$__ .G7]:XFBCZO3[!]>K_S';?\
M)_\ ].OZT?\ "?\ _3K^M<311]7I]@^O5_YCMO\ A/\ _IU_6C_A/_\ IU_6
MN)HH^KT^P?7J_P#,=M_PG_\ TZ_K1_PG_P#TZ_K7$T4?5Z?8/KU?^8[;_A/_
M /IU_6C_ (3_ /Z=?UKB:*/J]/L'UZO_ #';?\)__P!.OZT?\)__ -.OZUQ-
M%'U>GV#Z]7_F.V_X3_\ Z=?UH_X3_P#Z=?UKB:*/J]/L'UZO_,=M_P )_P#]
M.OZT?\)__P!.OZUQ-%'U>GV#Z]7_ )CMO^$__P"G7]:/^$__ .G7]:XFBCZO
M3[!]>K_S';?\)_\ ].OZT?\ "?\ _3K^M<311]7I]@^O5_YCMO\ A/\ _IU_
M6C_A/_\ IU_6N)HH^KT^P?7J_P#,=M_PG_\ TZ_K1_PG_P#TZ_K7$T4?5Z?8
M/KU?^8[&X\=>="4%MC-.C\>;(U7[+G KC**/J]/L'UZO_,=M_P )_P#].OZT
M?\)__P!.OZUQ-%'U>GV#Z]7_ )CMO^$__P"G7]:/^$__ .G7]:XFBCZO3[!]
M>K_S';?\)_\ ].OZT?\ "?\ _3K^M<311]7I]@^O5_YCMO\ A/\ _IU_6C_A
M/_\ IU_6N)HH^KT^P?7J_P#,=M_PG_\ TZ_K1_PG_P#TZ_K7$T4?5Z?8/KU?
M^8[;_A/_ /IU_6C_ (3_ /Z=?UKB:*/J]/L'UZO_ #';?\)__P!.OZT?\)__
M -.OZUQ-%'U>GV#Z]7_F.V_X3_\ Z=?UH_X3_P#Z=?UKB:*/J]/L'UZO_,=M
M_P )_P#].OZT?\)__P!.OZUQ-%'U>GV#Z]7_ )CMO^$__P"G7]:/^$__ .G7
M]:XFBCZO3[!]>K_S';?\)_\ ].OZT?\ "?\ _3K^M<311]7I]@^O5_YCMO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NK\!?\
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M/WJW_%US/;:#YD$A1\CD4 =%17E%YXDNG-MIYO#"9Q@S$_=IEU!<^'_*N?\
MA*1>!F&8P^: /6J*SM&U)-3L4E3L ":T: "O.O&G_'RGUKT6O.O&G_'RGUK?
M#_Q4<F._W>1R]%%%>F?.A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%N!)#<_\?$@Z9]Z[6PU#2+6)+&"^@9HQC:&&: ->B@'(R.E% !1110 4444
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M#G<5YH FDC6> HPR&%>;YN_ VKR3.NZRN'W/M&>*],J&>UM[I=L\*2#T89H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKA;Z[A\*>,/M^I)(T>P_=&>M>FBSMEF,H@02'JV.:;<Z?9WG_'S;12_[ZYH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCS__ (0"Y_Y^11_P@%S_ ,_(KT"BCZS4[A_9]#L>?_\ " 7/_/R*/^$ N?\
MGY%>@44?6:G</[/H=CS_ /X0"Y_Y^11_P@%S_P _(KT"BCZS4[A_9]#L>?\
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M?6:G</[/H=CS_P#X0"Y_Y^11_P (!<_\_(KT"BCZS4[A_9]#L>?_ /" 7/\
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M'G__  @%S_S\BC_A +G_ )^17H%%'UFIW#^SZ'8\_P#^$ N?^?D4?\(!<_\
M/R*] HH^LU.X?V?0['G_ /P@%S_S\BC_ (0"Y_Y^17H%%'UFIW#^SZ'8\_\
M^$ N?^?D4?\ " 7/_/R*] HH^LU.X?V?0['G_P#P@%S_ ,_(H_X0"Y_Y^17H
M%%'UFIW#^SZ'8\__ .$ N?\ GY%'_" 7/_/R*] HH^LU.X?V?0['G_\ P@%S
M_P _(H_X0"Y_Y^17H%%'UFIW#^SZ'8\__P"$ N?^?D4?\(!<_P#/R*] HH^L
MU.X?V?0['G__  @%S_S\BC_A +G_ )^17H%%'UFIW#^SZ'8\_P#^$ N?^?D4
M?\(!<_\ /R*] HH^LU.X?V?0['G_ /P@%S_S\BC_ (0"Y_Y^17H%%'UFIW#^
MSZ'8\_\ ^$ N?^?D4?\ " 7/_/R*] HH^LU.X?V?0['G<_@:X@B+FX!Q3H_
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M[/H=CS__ (0"Y_Y^11_P@%S_ ,_(KT"BCZS4[A_9]#L>?_\ " 7/_/R*/^$
MN?\ GY%>@44?6:G</[/H=CS_ /X0"Y_Y^11_P@%S_P _(KT"BCZS4[A_9]#L
M>?\ _" 7/_/R*/\ A +G_GY%>@44?6:G</[/H=CS_P#X0"Y_Y^11_P (!<_\
M_(KT"BCZS4[A_9]#L>?_ /" 7/\ S\BC_A +G_GY%>@44?6:G</[/H=CS_\
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M_'K)]* &6'_'HE6:K6'_ !Z)5F@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ.F_<D_WJO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 9]K_ ,?\U:%9]K_Q_P U:% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% %74?^/1OK4MM_Q[1_2HM1_P"/1OK4MM_Q[1_2@"6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ([C_CW?Z5!IW_'J/K4]Q_Q[O\ 2H-._P"/4?6@"W1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% "'H:HZ=]^;_ 'JO'H:HZ=]^;_>H OT444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^$^@_P"?8_G1_P )]!_S['\Z/J]3L'UVA_,=E17&_P#"?0?\^Q_.C_A/H/\
MGV/YT?5ZG8/KM#^8[*D?[C?2N-/C^ #/V8_G72Z=?KJ6G"Y5=H8'BIE2G!7D
MC2GB*=1V@[AIOW)/]ZKU4=-^Y)_O5>K,V"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^U_P"/
M^:M"L^U_X_YJT* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** *NH_\>C?6I;;_ (]H_I46H_\
M'HWUJ6V_X]H_I0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% $=Q_Q[O\ 2H-._P"/4?6I[C_C
MW?Z5!IW_ !ZCZT 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]#5'3OOS?[U7CT-4=.^_-_O
M4 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O.?&G_'RGUKT:O.O&G_ !\I]:WP_P#%1R8[_=Y'+T445Z9\Z%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #7^X:]3\+_ /(O1?0UY8_W#7J?A?\ Y%Z+Z&N7%_ CT<L_BOT+VF_<D_WJ
MO51TW[DG^]5ZO//<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,^U_X_YJT*S[7_C_ )JT* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** *NH_\ 'HWUJ6V_X]H_I46H_P#'HWUJ6V_X]H_I0!+1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% $=Q_Q[O]*@T[_CU'UJ>X_X]W^E0:=_QZCZT 6Z***
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M!L$&HM0\7:SI]H%ELE%XPRL?K0!W=%8/AK4=6U*V,NI6@@R,KCO6]0 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]KTJ[X<O[O4]%ANKZ$0SMG*#M0!K4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9]K_P ?\U:%9]K_ ,?\U:% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %74?^/1OK4MM_P >T?TJ+4?^/1OK4MM_Q[1_2@"6BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** ([C_CW?Z5!IW_ !ZCZU/<?\>[_2H-._X]1]: +=%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M (>AJCIWWYO]ZKQZ&J.G??F_WJ +]%%% !1110 4444 %%%% !1110 4444
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MKT:>R#/FN< U5:76=#OHXI]?CN@W]ULU@G1[--<>\UIY8=.(^5TX.:U+2T\
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MU/<?\>[_ $J#3O\ CU'UH MT444 %%%% !1110 4444 %%%% !1110 4444
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MVM:B@"FNE6"P&%;6,1D8*XXJ"'P[I%N^^+3X$;KD+6G10!5NM.L[Y0+FWCE
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MK?3[2U(,%ND9']T59HH @N+.WNMOGPK)MZ;ATI);"UFMQ!) C1 Y"$<58HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$=Q_Q[O]*@T[_CU'UJ>X_P"/=_I4&G?\>H^M %NBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/
M0U1T[[\W^]5X]#5'3OOS?[U %^BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KSKQI_P ?*?6O1:XW6]"GURX/D.%V
M'G-:T)*-1-G-C(2G1<8J[.$HKJ/^$$O_ /GLM'_""7__ #V6O0]M3[GA_5*_
M\IR]%=1_P@E__P ]EH_X02__ .>RT>VI]P^J5_Y3EZ*ZC_A!+_\ Y[+1_P (
M)?\ _/9:/;4^X?5*_P#*<O174?\ ""7_ /SV6C_A!+__ )[+1[:GW#ZI7_E.
M7HKJ/^$$O_\ GLM'_""7_P#SV6CVU/N'U2O_ "G+T5U'_""7_P#SV6C_ (02
M_P#^>RT>VI]P^J5_Y3EZ*ZC_ (02_P#^>RT?\()?_P#/9:/;4^X?5*_\IR]%
M=1_P@E__ ,]EH_X02_\ ^>RT>VI]P^J5_P"4Y>BNH_X02_\ ^>RT?\()?_\
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M/^$$O_\ GLM'MJ?</JE?^4Y>BNH_X02__P">RT?\()?_ //9:/;4^X?5*_\
M*<O174?\()?_ //9:/\ A!+_ /Y[+1[:GW#ZI7_E.7HKJ/\ A!+_ /Y[+1_P
M@E__ ,]EH]M3[A]4K_RG+T5U'_""7_\ SV6C_A!+_P#Y[+1[:GW#ZI7_ )3E
MZ*ZC_A!+_P#Y[+1_P@E__P ]EH]M3[A]4K_RG+T5U'_""7__ #V6C_A!+_\
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M/_'HWUJ6V_X]H_I0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $=Q_P >[_2H-._X]1]:GN/^
M/=_I4&G?\>H^M %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** $/0U1T[[\W^]5X]#5'3OOS?[U
M %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K/L/^/B?ZUH5GV'_ !\3_6@#0HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEJ7_'L
M/K5VJ6I_\>P_WJ +4/\ J4^E/ID/^I3Z4^@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;O\ X]9/
MI4U0W?\ QZR?2@!EA_QZ)5FJUA_QZ)5F@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D?[C?2EI'^X
MWTH I:;]R3_>J]5'3?N2?[U7J "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^U_X_YJT*S[7_
M (_YJT* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** *NH_\>C?6I;;_CVC^E1:C_QZ-]:EMO\
MCVC^E $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 1W'_'N_TJ#3O^/4?6I[C_ (]W^E0:=_QZ
MCZT 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 0]#5'3OOS?[U7CT-4=.^_-_O4 7Z*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L^
MP_X^)_K6A6?8?\?$_P!: -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6I_\>P_WJNU2U/\
MX]A_O4 6H?\ 4I]*?3(?]2GTI] !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?\ QZR?2IJAN_\
MCUD^E #+#_CT2K-5K#_CT2K- !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %(_W&^E+2/\ <;Z4 4M-
M^Y)_O5>JCIOW)/\ >J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!GVO_'_-6A6?:_\ '_-6
MA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!5U'_CT;ZU+;?\>T?TJ+4?^/1OK4MM_P >T?TH
M EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@".X_P"/=_I4&G?\>H^M3W'_ ![O]*@T[_CU'UH
MMT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 AZ&J.G??F_WJO'H:HZ=]^;_ 'J +]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?8?\
M?$_UK0K/L/\ CXG^M &A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+4_^/8?[U7:I:G_ ,>P
M_P!Z@"U#_J4^E/ID/^I3Z4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;O_ (]9/I4U0W?_ !ZR
M?2@!EA_QZ)5FJUA_QZ)5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFKS7H-#N'\Y
M"V\\8KI:\Y\:?\?*?6M:,5*:3.?%5)4Z3G'<V?\ A.[+_GB_YTO_  G=E_SQ
M?\Z\^HKM^K4SQ_[0K]ST'_A.[+_GB_YT?\)W9?\ /%_SKSZBCZM3#^T*_<]!
M_P"$[LO^>+_G1_PG=E_SQ?\ .O/J*/JU,/[0K]ST'_A.[+_GB_YT?\)W9?\
M/%_SKSZBCZM3#^T*_<]!_P"$[LO^>+_G1_PG=E_SQ?\ .O/J*/JU,/[0K]ST
M'_A.[+_GB_YT?\)W9?\ /%_SKSZBCZM3#^T*_<]!_P"$[LO^>+_G1_PG=E_S
MQ?\ .O/J*/JU,/[0K]ST'_A.[+_GB_YT?\)W9?\ /%_SKSZBCZM3#^T*_<]!
M_P"$[LO^>+_G1_PG=E_SQ?\ .O/J*/JU,/[0K]ST'_A.[+_GB_YT?\)W9?\
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M4 ,L/^/1*LU6L/\ CT2K- !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %(_W&^E+2/]QOI0!2TW[DG^
M]5ZJ.F_<D_WJO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 9]K_Q_P U:%9]K_Q_S5H4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 5=1_P"/1OK4MM_Q[1_2HM1_X]&^M2VW_'M']* ):***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH CN/^/=_I4&G?\>H^M3W'_'N_TJ#3O^/4?6@"W1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% "'H:HZ=]^;_>J\>AJCIWWYO]Z@"_1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YUXT_X^4^M>BUY
MUXT_X^4^M;X?^*CDQW^[R.7HHHKTSYT**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#<\'_\ (P)]*]1KR[P?_P C GTKU&O/Q?QGN9;_  7ZA1117*>B%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#=_\>LGT
MJ:H;O_CUD^E #+#_ (]$JS5:P_X]$JS0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2/\ <;Z4M(_W
M&^E %+3?N2?[U7JHZ;]R3_>J]0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!GVO\ Q_S5H5GV
MO_'_ #5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 5=1_X]&^M2VW_'M']*BU'_ (]&^M2V
MW_'M']* ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH CN/^/=_I4&G?\>H^M3W'_'N_P!*@T[_
M (]1]: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 (>AJCIWWYO\ >J\>AJCIWWYO]Z@"_111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<#H#72US7A:VBTK32EU<0^:[%AN8 @5T@(8 @@@]"* %HHHH **** "BBB@
MHHHH **** "BBB@ J&[_ ./63Z5-4-W_ ,>LGTH 98?\>B59JM8?\>B59H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ I'^XWTI:1_N-]* *6F_<D_WJO51TW[DG^]5Z@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#/M?^/^:M"L^U_P"/^:M"@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ/_'H
MWUJ6V_X]H_I46H_\>C?6I;;_ (]H_I0!+1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $=Q_Q[O]
M*@T[_CU'UJ>X_P"/=_I4&G?\>H^M %NBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/0U1T[[\W
M^]5X]#5'3OOS?[U %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)_O5>JCIOW)/]ZKU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &?:_P#'_-6A6?:_\?\ -6A0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!5U'_CT;ZU+;?\>T?TJ+4?\ CT;ZU+;?\>T?TH E
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@".X_X]W^E0:=_QZCZU/<?\>[_ $J#3O\ CU'UH MT
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 AZ&J.G??F_P!ZKQZ&J.G??F_WJ +]%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C*K##
M$>XIHBC!R(T!_P!VGT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7G7C3_ (^4^M>BUYUXT_X^4^M;X?\ BHY,=_N\CEZ***],
M^="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH W/!_P#R,"?2O4:\N\'_ /(P)]*]
M1KS\7\9[F6_P7ZA1117*>B%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5#=_P#'K)]*FJ&[_P"/63Z4 ,L/^/1*LU6L/^/1
M*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4C_<;Z4M(_P!QOI0!2TW[DG^]5ZJ.F_<D_P!ZKU !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% &?:_\?\U:%9]K_P ?\U:% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M %74?^/1OK4MM_Q[1_2HM1_X]&^M2VW_ ![1_2@"6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M([C_ (]W^E0:=_QZCZU/<?\ 'N_TJ#3O^/4?6@"W1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
M'H:HZ=]^;_>J\>AJCIWWYO\ >H OT444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN_\ CUD^E35#=_\
M'K)]* &6'_'HE6:K6'_'HE6: "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1_N-]*6D?[C?2@"EIOW
M)/\ >J]5'3?N2?[U7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^U_X_P":M"L^U_X_YJT*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L^P_X^)_K
M6A6?8?\ 'Q/]: -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "J6I_\>P_WJNU2U/_ (]A_O4
M6H?]2GTI],A_U*?2GT %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5#=_\ 'K)]*FJ&[_X]9/I0 RP_
MX]$JS5:P_P"/1*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4C_<;Z4M(_W&^E %+3?N2?[U7JHZ
M;]R3_>J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!GVO_'_ #5H5GVO_'_-6A0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!5U'_ (]&^M2VW_'M']*BU'_CT;ZU+;?\>T?TH EHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@".X_X]W^E0:=_QZCZU/<?\>[_2H-._X]1]: +=%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (>AJCIWWYO]ZKQZ&J.G??F_WJ +]%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?8?\?$_UK0K/L/^/B?Z
MT :%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %4M3_ ./8?[U7:I:G_P >P_WJ +4/^I3Z4^F0
M_P"I3Z4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "H;O_CUD^E35#=_\>LGTH 98?\>B59JM8?\
M'HE6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:BY.R)G.,%S2>AT=%<Q_PG&F_P!UZ/\ A.--_NO6GL:G8Q^MT?YD=/17,?\
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M **** "H;O\ X]9/I4U0W?\ QZR?2@!EA_QZ)5FJUA_QZ)5F@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "D?[C?2EI'^XWTH I:;]R3_>J]5'3?N2?[U7J "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,^U_X_YJT*S[7_ (_YJT* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NH_\>C?6I;;_CVC
M^E1:C_QZ-]:EMO\ CVC^E $M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 1W'_'N_TJ#3O^/4?6
MI[C_ (]W^E0:=_QZCZT 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]#5'3OOS?[U7CT-4=.
M^_-_O4 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!IW_ !ZCZT 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 0]#5'3OOS?[U7CT-4=.^_-_O4 7Z
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **I:I?_V=8R7&S?L4G'K6
M#X7\:P>(G:+RA#*"1L)YH ZNBL?7=<&BPK(8O,R*L:+J8U?3DNPFS<>E &A1
M110 445R&M>.(])U2"S6W\WS'VLP/W: .OHID,T<\:R1L&4C.0:?0 45@6OB
M07/BJXT3R,&%=V_UK?H **** "BBB@ HHHH **** "BHKB;R(6DQG SBO/F^
M)=Y)>SV]IHLD_E-@E<T >C45YVOQ#U<NJ_\ ".38)QG!XKN[&Y>ZM4FDB,;,
M,E3VH LT444 %%%% !1161K^NQZ'!%(Z[S(X4"@#7HID3^;"DF,;E!Q]:?0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;Z4M(_W&^E %+3?N2?[U7JHZ;]R3_>J]0 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>=>-/^/E
M/K7HM<1XBT>[U>Y_T0 [#SFMJ#2J)LY<9%RH245=G$T5N_\ "':O_<%'_"':
MO_<%>A[6'<\+ZO6_E9A45N_\(=J_]P4?\(=J_P#<%'M8=P^KUOY685%;O_"'
M:O\ W!1_PAVK_P!P4>UAW#ZO6_E9A45N_P#"':O_ '!1_P (=J_]P4>UAW#Z
MO6_E9A45N_\ "':O_<%'_"':O_<%'M8=P^KUOY685%;O_"':O_<%'_"':O\
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M HHHH **** "BBB@ HHHH **** $/0U1T[[\W^]5X]#5'3OOS?[U %^BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK/L/^/B?ZUH5GV'_ !\3_6@#0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEJ?_'L/]ZKM4M3
M_P"/8?[U %J'_4I]*?3(?]2GTI] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?_ !ZR?2IJAN_^
M/63Z4 ,L/^/1*LU6L/\ CT2K- !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %(_W&^E+2/]QOI0!2TW
M[DG^]5ZJ.F_<D_WJO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 9]K_Q_P U:%9]K_Q_S5H4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 5=1_P"/1OK4MM_Q[1_2HM1_X]&^M2VW_'M']* )
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH CN/^/=_I4&G?\>H^M3W'_'N_TJ#3O^/4?6@"W111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "'H:HZ=]^;_>J\>AJCIWWYO]Z@"_1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5GV'_'Q/]:T
M*S[#_CXG^M &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *NH_\ 'HWUJ6V_X]H_I46H_P#'HWUJ6V_X]H_I0!+1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $=Q_Q[O]*@T[_CU'UJ>X_X]W^E0:=_QZCZT 6Z*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH 0]#5'3OOS?[U7CT-4=.^_-_O4 7Z*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "L^P_X^)_K6A6?8?\?$_U
MH T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *I:G_ ,>P_P!ZKM4M3_X]A_O4 6H?]2GTI],A
M_P!2GTI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %0W?_'K)]*FJ&[_X]9/I0 RP_P"/1*LU6L/^
M/1*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4C_ '&^E+2/]QOI0!2TW[DG^]5ZJ.F_<D_WJO4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 9]K_ ,?\U:%9]K_Q_P U:% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %74?^/1OK4MM_Q[1_2HM1_P"/1OK4MM_Q[1_2@"6BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ([C_CW?Z5!IW_'J/K4]Q_Q[O\ 2H-._P"/4?6@"W1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "'H:HZ=]^;_ 'JO'H:HZ=]^;_>H OT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEJ?\
MQ[#_ 'JNU2U/_CV'^]0!:A_U*?2GTR'_ %*?2GT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#=_\
M>LGTJ:H;O_CUD^E #+#_ (]$JS5:P_X]$JS0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2/\ <;Z4
MM(_W&^E %+3?N2?[U7JHZ;]R3_>J]0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!GVO\ Q_S5
MH5GVO_'_ #5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 5=1_X]&^M2VW_'M']*BU'_ (]&
M^M2VW_'M']* ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH CN/^/=_I4&G?\>H^M3W'_'N_P!*
M@T[_ (]1]: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (>AJCIWWYO\ >J\>AJCIWWYO]Z@"
M_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5YUXT_X^4^M>BUYUXT_P"/E/K6^'_BHY,=_N\CEZ***],^="BBB@ H
MHHH *5/]?%_OBDI4_P!?%_OB@$>RV7_'C!_N"IZ@LO\ CQ@_W!4]>,]SZN/P
MH****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52U/_
M (]A_O5=JEJ?_'L/]Z@"U#_J4^E/ID/^I3Z4^@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;O_CU
MD^E35#=_\>LGTH 98?\ 'HE6:K6'_'HE6: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1_N-]*6D?
M[C?2@"EIOW)/]ZKU4=-^Y)_O5>H **** "BBB@ HHHH **** "BBB@ HHHH
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MO#7V\33_ &D(&'S<5U/@N[FETB*"7D1K@'O0!T]>;^,-?OWOXCIDS1QVQ_?
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?\
MQZR?2IJAN_\ CUD^E #+#_CT2K-5K#_CT2K- !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(_W&^E+
M2/\ <;Z4 4M-^Y)_O5>JCIOW)/\ >J]0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!GVO_'_-
M6A6?:_\ '_-6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!5U'_CT;ZU+;?\>T?TJ+4?^/1O
MK4MM_P >T?TH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@".X_P"/=_I4&G?\>H^M3W'_ ![O
M]*@T[_CU'UH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 AZ&J.G??F_WJO'H:HZ=]^;_ 'J
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M#F]N?M-[:/=M>Q1MA9B<Y]Z]&K)T3P[IWA^)H]/B**W7)S6M0 4444 %%%%
M!1110 4444 %%%% !5+4_P#CV'^]5VJ6I_\ 'L/]Z@"U#_J4^E/ID/\ J4^E
M/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ J&[_X]9/I4U0W?_'K)]* &6'_'HE6:K6'_ !Z)5F@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D?[C?2EI'^XWTH I:;]R3_>J]5'3?N2?[U7J "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,^U_X_YJT*S[7_C_ )JT* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NH_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5#=_\>LGTJ:H;O_CUD^E #+#_ (]$JS5:P_X]$JS0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !2/\ <;Z4M(_W&^E %+3?N2?[U7JHZ;]R3_>J]0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!GVO\ Q_S5H5GVO_'_ #5H4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5=1_X]&^M2
MVW_'M']*BU'_ (]&^M2VW_'M']* ):*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CN/^/=_I4&G
M?\>H^M3W'_'N_P!*@T[_ (]1]: +=%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>AJCIWWYO\
M>J\>AJCIWWYO]Z@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_<;Z4 4M-^Y)_O5>JCIOW)/]ZKU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?:_\?\ -6A6
M?:_\?\U:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %74?\ CT;ZU+;?\>T?TJ+4?^/1OK4M
MM_Q[1_2@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ([C_CW?Z5!IW_'J/K4]Q_Q[O]*@T[_C
MU'UH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 AZ&J.G??F_WJO'H:HZ=]^;_>H OT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9
M]A_Q\3_6M"L^P_X^)_K0!H4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52U/\ X]A_O5=JEJ?_
M ![#_>H M0_ZE/I3Z9#_ *E/I3Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN_^/63Z5-4-W_QZ
MR?2@!EA_QZ)5FJUA_P >B59H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I'^XWTI:1_N-]* *6F_<
MD_WJO51TW[DG^]5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/M?^/^:M"L^U_X_P":M"@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"KJ/_ !Z-]:EMO^/:/Z5%J/\ QZ-]:EMO^/:/Z4 2
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!'<?\>[_2H-._X]1]:GN/^/=_I4&G?\>H^M %NBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $/0U1T[[\W^]5X]#5'3OOS?[U %^BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/L/^/B?ZUH
M5GV'_'Q/]: -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J6I_P#'L/\ >J[5+4_^/8?[U %J
M'_4I]*?3(?\ 4I]*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !4-W_QZR?2IJAN_^/63Z4 ,L/\
MCT2K-5K#_CT2K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %(_P!QOI2TC_<;Z4 4M-^Y)_O5>JCI
MOW)/]ZKU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &?:_P#'_-6A6?:_\?\ -6A0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!5U'_CT;ZU+;?\>T?TJ+4?\ CT;ZU+;?\>T?TH EHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@".X_X]W^E0:=_QZCZU/<?\>[_ $J#3O\ CU'UH MT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 AZ&J.G??F_P!ZKQZ&J.G??F_WJ +]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?8?\?$_P!:T*PF
MU:TTNXE^U/MWGBFDV[(4I**O)Z&[16'_ ,);I/\ SW/Y4?\ "6Z3_P ]S^55
M[*?8R^L4OYD;E%8?_"6Z3_SW/Y4?\);I/_/<_E1[*?8/K%+^9&Y16+'XJTN6
M58UF)9C@<5L@Y (Z&E*+CNBX5(S^%W%HHHJ2PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "J6I_\>P_WJNU2U/_ (]A_O4
M6H?]2GTI],A_U*?2GT %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5#=_\ 'K)]*FJ&[_X]9/I0 RP_
MX]$JS5:P_P"/1*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4C_<;Z4M(_W&^E %+3?N2?[U7JHZ
M;]R3_>J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!GVO_'_ #5H5GVO_'_-6A0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!5U'_ (]&^M2VW_'M']*BU'_CT;ZU+;?\>T?TH EHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@".X_X]W^E0:=_QZCZU/<?\>[_2H-._X]1]: +=%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (>AJCIWWYO]ZKQZ&J.G??F_WJ +]%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G/C0?Z2GUKT:O.O&G_'
MRGUK?#_Q4<F._P!WD<M@48%+17IGSHF!1@4M% $U@!_:=M_OBO98_P#5)_NB
MO&[#_D)VW^^*]DC_ -4G^Z*X<9NCU\KVD.HHHKC/6"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:G_P >P_WJNU2U/_CV
M'^]0!:A_U*?2GTR'_4I]*?0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !4-W_QZR?2IJAN_P#CUD^E
M #+#_CT2K-5K#_CT2K- !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %(_W&^E+2/]QOI0!2TW[DG^]5
MZJ.F_<D_WJO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 9]K_P ?\U:%9]K_ ,?\U:% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %74?^/1OK4MM_P >T?TJ+4?^/1OK4MM_Q[1_2@"6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ([C_CW?Z5!IW_ !ZCZU/<?\>[_2H-._X]1]: +=%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 (>AJCIWWYO]ZKQZ&J.G??F_WJ +]%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN>&5F-POVEB1R>10!T]%8GA^VU&U2X.HWR7.7RA4_='I6H;ZT5MIN80?0N*
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M:;S7" )R1[UKPR":%)0" ZAL'WH ?1110 4444 %%%% !1110 4444 %%%%
M!1110 52U/\ X]A_O5=JEJ?_ ![#_>H M0_ZE/I3Z9#_ *E/I3Z "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *AN_^/63Z5-4-W_QZR?2@!EA_QZ)5FJUA_P >B59H **** "BBB@
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MDW)<R%AGM5.UTB;Q'XPOK.>XE2&/GY6K8\5>'XM+OH+_ $NR""(998QUKEM
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MAM=5>^N1<M"9,;^,UGW.C7\_AVXNGA<RL^X)CFO0=/BE'@=(VC(D^SD;>^:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2/]QOI2TC_ '&^E %+3?N2?[U7JHZ;]R3_ 'JO4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 9]K_Q_S5H5GVO_ !_S5H4 %%%% !1110 4444 %%%% !1110 4444
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M17#C-T>OE>TAU%%%<9ZQDW_AVQU+4H;Z=6,T/W2#5ZXLHKFU-N^=A&.*L44
M9FE:'::18O:6X8Q.22'.:YNX^%N@7.H/>/YXD<Y(#\5V]% %/3=-M]*LUM;9
M<1KTS5>_T&SU'4;:^G#&6W^Y@\5J44 8?B+PKIWB:W6&^5MH_N'!I/#OA/3?
M#,!AL5;:3G+G)K=HH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6I_
M\>P_WJNU2U/_ (]A_O4 6H?]2GTI],A_U*?2GT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#=_\
M'K)]*FJ&[_X]9/I0 RP_X]$JS5:P_P"/1*LT %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C_<;Z4M
M(_W&^E %+3?N2?[U7JHZ;]R3_>J]0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!GVO_'_ #5H
M5GVO_'_-6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!5U'_ (]&^M2VW_'M']*BU'_CT;ZU
M+;?\>T?TH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@".X_X]W^E0:=_QZCZU/<?\>[_2H-._
MX]1]: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 (>AJCIWWYO]ZKQZ&J.G??F_WJ +]%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7G7C3_CY3ZUZ+7!^*-.N]0N1]EB+[3S6V':51-G+C4W0DD<=16E_PCNK?\^Q
MH_X1W5O^?8UZ7/'N>![&I_*S-HK2_P"$=U;_ )]C1_PCNK?\^QHYX]P]C4_E
M94L/^0G;?[XKV2/_ %2?[HKRRS\/ZJFH0.UL0JL"37J:#$:@]0!7%BY)M6/5
MRV$HJ7,K#J***Y#U HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "J6I_\>P_WJNU2U/_ (]A_O4 6H?]2GTI],A_U*?2GT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5#=_\ 'K)]*FJ&[_X]9/I0 RP_X]$JS5:P_P"/1*LT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4C_<;Z4M(_W&^E %+3?N2?[U7JHZ;]R3_>J]0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!GVO_'_ #5H5GVO_'_-6A0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5U'_ (]&
M^M2VW_'M']*BU'_CT;ZU+;?\>T?TH EHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".X_X]W^E0
M:=_QZCZU/<?\>[_2H-._X]1]: +=%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>AJCIWWYO]ZK
MQZ&J.G??F_WJ +]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !6?8?\?$_UK0K/L/^/B?ZT :%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %4M3_ ./8?[U7:I:G_P >P_WJ +4/^I3Z4^F0_P"I3Z4^@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "H;O_CUD^E35#=_\>LGTH 98?\>B59JM8?\ 'HE6: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *1_N-]*6D?[C?2@"EIOW)/]ZKU4=-^Y)_O5>H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S
M[7_C_FK0K/M?^/\ FK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZC_P >C?6I;;_CVC^E
M1:C_ ,>C?6I;;_CVC^E $M%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 1W'_'N_TJ#3O^/4?6I[
MC_CW?Z5!IW_'J/K0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T-4=.^_-_O5>/0U1T[[\W
M^]0!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *S[#_CXG^M:%9]A_Q\3_6@#0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEJ?\
MQ[#_ 'JNU2U/_CV'^]0!:A_U*?2GTR'_ %*?2GT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#=_\
M>LGTJ:H;O_CUD^E #+#_ (]$JS5:P_X]$JS0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2/\ <;Z4
MM(_W&^E %+3?N2?[U7JHZ;]R3_>J]0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!GVO\ Q_S5
MH5GVO_'_ #5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 5=1_X]&^M2VW_'M']*BU'_ (]&
M^M2VW_'M']* ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH CN/^/=_I4&G?\>H^M3W'_'N_P!*
M@T[_ (]1]: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (>AJCIWWYO\ >J\>AJCIWWYO]Z@"
M_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 1W'_'N_P!*@T[_ (]1]:GN/^/=_I4&G?\
M'J/K0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!#T-4=.^_-_O5>/0U1T[[\W^]0!?HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8'A<$!@O'WOI1::/<W7PSMQ%&T=PDVX@CDC->J".,9PBC=UXZT"-%7:$4+Z
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M5MH@WW@@!_*A;>!#E88U/J% J2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *I:G_Q[#_>J[5+4_P#CV'^]0!:A_P!2GTI],A_U*?2GT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5#=_P#'K)]*FJ&[_P"/63Z4 ,L/^/1*LU6L/^/1*LT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4C_<;Z4M(_P!QOI0!2TW[DG^]5ZJ.F_<D_P!ZKU !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &?:_\?\U:%9]K_P ?\U:% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %74?^/1OK4MM_Q[
M1_2HM1_X]&^M2VW_ ![1_2@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ([C_ (]W^E0:=_QZ
MCZU/<?\ 'N_TJ#3O^/4?6@"W1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'H:HZ=]^;_>J\>AJ
MCIWWYO\ >H OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %>=>-/^/E/K7HM>=>-/^/E/K6^'_BHY,=_N\CEZ***]
M,^="BBB@#K_ '_'S<?2N^K@? '_'S<?2N^KS,3_$9]!E_P# 04445@=H4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+4_^
M/8?[U7:I:G_Q[#_>H M0_P"I3Z4^F0_ZE/I3Z "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@!#T-4=.^_-_O5>/0U1T[[\W^]0!?HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "H;O\ X]9/I4U0W?\ QZR?2@!EA_QZ)5FJUA_QZ)5F@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "D?[C?2EI'^XWTH I:;]R3_>J]5'3?N2?[U7J "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,^U_X_YJT*S[7_ (_YJT* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NH_\>C?6I;;_CVC
M^E1:C_QZ-]:EMO\ CVC^E $M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 1W'_'N_TJ#3O^/4?6
MI[C_ (]W^E0:=_QZCZT 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]#5'3OOS?[U7CT-4=.
M^_-_O4 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img248422670_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_2.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &1 F # 2(  A$! Q$!_\0
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MUBPEUOQ;I44NG7VE:!J/V6,2)J5I=K%::W8Z4\T6_P"O+#X6_!76_%FI^/\
M3O!O@S4O&6FZU<66I>(;.QMY;Z#7].B6.Z2Y=!Y)UBSCG6":=E:ZC+&&20,K
MI7COP_\ A?\ LG?'SP2VM:%\(_"^J^$[7QGXSL3I^N^%Y-.-CXLTZ^U'PUXO
M:/2KK8+2:6[AO+"YE@18KB$R[=\4K$^PJN43C.K6P&+Y:5/#**HJC3I89U*:
M24Y05.OBXU'",Z=>O7A4JWJ.:<I1F?#SPG&&'J4<-@\_RA5<36Q\W];^NU\7
MF"H58RE4I>W>)P>6*@ZLJ>)P."RZIAJ%J"I5%&+IG :K_P %'_@G9?\ ";/I
M?AKXC^)HO ?A+0?%VJ7&@Z1H;VUS;:XOAF8Z7:W&J^(M+ABU;3=/\5:=J%Y;
MZC)8PW5LEXNBSZO=VDML(;?]N/2M-\;>*= UWP+\77U^\\3^#O"O@OX7GPIX
M'M_$8NM7\,^)?$=W?:?J^G>/]0L-9M+S1O#EWKABU:;2M1B!M=,T.TUJZODM
MZ^E&_9B^ 3:?J>CGX2>"?[)UK2M+T35M-72D6SU/2M$EM)](L;VV4B*YATR:
MPM'M1,&,?DPJ'V1JAO7O[.GP1U#4+[5KWX7>$+O5=1U'0=6N]1FTR-[RXU+P
MQ#/:^';Y[DGS5NM$M;B:VL9497C@EDB#%)9$,K$</1<5#!8RSBE*=2K"<V_:
MX.=U:I",(N-/%1G&*]MRU(PAB:49RE3U6 \0II3KYWDKJ0FY0IX;"UJ%#EE0
MS"'+)5,/B*M2I"=7 .E5J2EAH2I5*U3 UW3A1K>PV=P+NVM;H0S6_P!JMX;@
M07">7<0^;&L@BGCRWES1ABDB9.UPR\[=U?&O[9GQ>^(GP0TCX=>/O!NI >'=
M*\812_$OP^^D:=J(UCP)'$)==N[>YN+2?4]/O=#M ^HQ2Z;+"&CCF%S'(FP#
M[/15C1(XU$:1J$15&%55 "*!V&%4 >@YSDU\U_M!:Y\&M&U3X;VGQ8\ :AXT
MO/%FN7O@SP<]KX5N_$MO!J6OV+VM]I]TUOF&QCU73C<12M>*8I;6.XR=L<@K
M@RYP_M+"R>&^M4U6O]4Y8U/;I1=J-G+E:FK1E+24%^\IWJ0BG]%Q%&L\@S"$
M<P665GAX169.K.@L'4<Z4?K*G2C*5Z<WSQIV]G6E:A5:HU)L^?A^UOK^C_$/
M]HWQ7J-GK_C+X.?"+P-\/_$^B^'/ 6F>%YM6ET7Q"NMRZSXXO=0\1WOAR[O;
M.WATAK]+6PU*2)-&=+N"SO&\YQ;O_P!KW6="^+7BF;4-!\37?PSM?A+I?BOP
M_P"%+.S\%76O:MJE_P"/!X2T[7])URVU]=,30?$=M/!JEK)XBUVRM[336COM
M0326#PU[+JGP'^"TOB'7/"_ASPQJ?PY\7>,/"VF7&O>*_ 6C0:;/J_A'0[BU
MTM/">IZU?Z7K6@36-U9H=(N-#N;<S-I$MS]A^R92\I/ /A?]F_X_:-+XYT?X
M=:)K-M8&;X837'B3PW)9ZE:P?#3Q#! GAZ2VOU\]+/P[XCT&">Q'"+<6T-S
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ML:D*ZP4?84OK%7)X25&C&M2H87%U:=:>)G3YL[X(_'[0/CJNO7GA;PWXPL-
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M'$TFC^((-/T:TBUG2I)8UE>PU)9K5I0&,190U8^C?LD?LM^'M4TK7="_9J^
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MW+)#<Q)-%(C87<K1NK*W'4'@\5Y/\7?@#\)?CK::?8_%3P3I_B^WTH72Z?\
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MX.SVT:_/_D\N/P!Y_P#K;J^2 "21SUP3N/S8[CID_C@#/^S7UK^V(3_;_@[
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MX*>?8.K7S)XFG&%-7R]5\/\ 5K>W]J\-"<J=5-PC.I"\9<KC+\8QF5</U/I
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M0KJAA[RC5^HUJ-..(K8"E2H?I]\/['XF6&BWT?Q.\6^!?%^O-JU]/8:C\/?
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M<E7FU#$1J59J6CG26)I^Q<DE^[YYU8RI4%&$*N&IX)N$*"PI]F?M(VGC^_\
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MNZD#* ,!(I&R1@&L:Z\4?M0+=72VW@K16MEGE%NY32B6B$C"(MG7T+%H\')
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M@CPYX=F\3Z9H]I+8:1I_B"?2--L)-9LM)L)I;*PM]1,T5K;2206RQ1.4KCO
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M: ^#]W<:CXZ?X9V$-OX^\-227WQ"C@:Y?P19QKJ1:Z\4QVR&=]&A#7ZQ N8
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MJUAXJDT[J4;\ZDY-GX>^!O\ @CYJ/@2#XGK8_'7P=K?B'X@>(8=>TSQSXO\
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M1ZQXCNO#WC^]\4Z3J#3>"/$NC>(=+72?%%FDBV":PT%U+I\,EVDJGR5^AO\
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M)RN[MDKRK5\1)MUL2IJO47NRG&I-SJ1O%KEC.4I.48*,6IRC91;3_(GX,_\
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M-X>-22TE5C0=.-6:TG44I+1V"BBBD,**** "BBB@#X%_;$_Y&#P=SMQHM_\
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M]W$_3(>/OC =#:^_X5&@UD:PEFNE'6;<@Z:UI)+)J7G!]N5NU6U\K.X[BX!
M-:/A;QM\4=3;6!KWPQ70A::+>WNF,NJPS_VEJD$1>STW:CL8?M4F(Q*V N=Q
MQ7MU%?)-7/V^ST]YZ._KY/O\K??J?.5A\1?C3/?6<-W\&DM+.:ZMXKFZ_MJV
M<VUN\J)/<;!(2_DQN9 H&6"D8R5!EU;XA_&:UU+4[?3_ (.IJ&G6]]=P65\=
M:MT-[:17$D=M=F-G!3[1 B3;& *EMIQCCZ(HI@DU]IW[V7Y'B'BCQM\4],30
MCH7PP37'OM'AO-65M5@@&E:F\TJ3:8I=U\_RHHTE\U/E._&<@U0'C[XO'0'U
M!OA(G]M+K45DND?VS;8;3'LYII=3\_?M!CO(X[7RLY)D+\ 9KWZB@7*_YG]W
MDE^E_)GAWA;QM\4]2;5QKWPP30OL>C7U[IK+JT$_]HZG#"SVFFG8[>6+N4",
M2M@(<,2:P;+XC?&N:[M(KKX,QV]M+<01SS#7+9C;0O(HFN-N\[Q%&3)M4;CC
M'4<_1]%)*W]/_-_H/E?\S_JW^1\\:K\0OC):ZCJ5O8?!Y+_3[>^NH+&].M6T
M9O;2*>2.VNC&7!C-Q"BS;",KNVD<9K8\3^-?BGIL/A]]#^&"ZY+J&C0WFL1G
M5H(#H^IO)(LFG NR^>(XT5Q(N02V,Y&:]OHHWMY/^O\ A^G0.72S;?\ PR_)
MJZ/ 5\>_%XZ#<7Q^$T8UJ/6+:SATC^V(,2Z7)8W<]QJ1GW[1]GO;>"T\K.3Y
MX<?*A(_,[]MKX%?$+]HGXL_LN>.O$'@#QYH6H?!7Q7+K^C67@W14\5Z5J]Q+
MXB\'ZU]F\2ZI#<1KX:LQ+X5MXTGEWYM;BZNN%M#7[7U^ G_!7GQ5XE\/?M/?
M\$Z+#1/$>O:'8ZS\4[V'5;32=6OM/M=4B'COX3P>3J-O:7,,5]%Y5U-$([H2
M1A)IHP"DLH/S'&5?"8?A_%5<=A%CL-'%95&>&=65'FG4S3!PHSYX-27LJTJ=
M6R?O."B[IL_;OHZY7Q#F_BSD>7\,<0RX9SBKDG&]2CG$<)1QKHT,+P1Q!B<?
M0^K5X3I5/K^ HXG .3CS4UB?:PM.$6OUMM/B+\:Y;BWBN/@PEM;RSPQS3_VW
M;OY,+R*LLQ4/EO*0L^WJ>G4X-G5_B%\9+/5-4MM.^#ZZCIUMJ-[;:??G6K:(
MW]C%<21VEYY3.&C-W B3^6P!3?M8#%>X66K:7J,MS#I^IV%_-8RF"]AL[NWN
M9;2<%P8KJ.*222VEW(RF.8*V58$9#U8-Y:FZ^Q&YM_MOD_:?L?G1_:O(R$^T
M& .)?)WD1B7;MW$+NW<'Z;FVTWV?1KEYKK372[7DKGXA9Z^]+1V=[66JT^;=
MM?2USQWQ-XV^*FG1>'WT/X7IK4NH:1'=ZO&VJP0_V1J32R(^G!F=1,$C5)?-
M4D$-@9(J@GC[XOMHEQ?/\)436$U>UM(M*_MFWQ-ILME=2W&H^=OV@P7D,%KY
M6=S";?RJYKW*>[M;5[:.XNK>WDO)OLUI'/+'%)=S[&D\BV21E:>;RHV?RXPS
M[$9L$*QHN;JWLH7N;RY@M+>( R7%S+'##&"0H+RRM'&@+$*"Y&2P"C+$DYOD
MMKO:]HNU[;VEMOMW"SV<K:+_ "O\W==+OTL>.>$O&WQ3U6YU&+Q%\,$\/6]O
MI5[=64ZZK!<&\U&%-UI8%$9R@NW^3S6^5.K$5S]I\1OC7+<VL5S\%TM[>2>*
M.><:Y;-]GB>0+),%WY;RT)?:.3C'6OHK(8!E(=7 *N""",9#!AD$$<@J<$=>
M:@6\M'N9+)+FW:]ACCGFM%FC:YAAD++%/) &:5(I71E21U"N58*20U"=NEM7
MIZ+M]]]%:SNM&T6LE[[26O2W1+Y=E?5OUOX-K7Q"^,EGJNK6NF_!]=2TVTU&
M\MM.OSK5M&=0L8KF6.UO3$\BF(75O&EP8V&4WA2 1SK>(_&_Q4TZU\.RZ+\+
MTUFXU#21>:S VJP0C1M1,K(; ,[KYP$860RKD<A<Y(->WT50TFOM/[O3N_ZO
MZ'@">/OB^=#N;]OA(BZU%J]E9P:5_;-OB;39K.^FN]1\_?M7[-=VUM:B,G<P
MN=XRJ,:?H_CSXO7::N=2^$L>G-::3<W6G(-8MY/[1U&,K]GT\X<^6)PQ/F'A
M=O)^85[Y10'*]/>>GIY?Y?UU^?="\?\ QBOM7TVTU;X1)I>E7-U'%?:B-9MY
M396['$DXB60F38.=H!/UKS']H"^^*_C3X<?&WX<I\*[Z;PYXN\$?$+P*NNZ3
M=P7^KR:+KFB:OH2ZQINC"17O]0:QOC?V.FC#W%PJ66X&0FOL,7MHUR]BMU;M
M>QPK<R68GC-U';NY1)WMPWG+"[J425E"LRE5<G(KP+]K*[NK']EG]I:]L;JY
MLKVQ_9_^+UW9WEK+)!=6ES!\/_$4UO<VUQ$R36]Q;S1K+%-$ZRQ2*LB,CH#7
M'CY067XR52"J4XX:O*=.]O:0C1JN<;K5<T8RCTM=[-6/<X6HXFOQ/PYA\)BG
MA,56SO**6'Q7)&H\+7J9AA%0Q'LVG&?LJDJ=51DFI<J3O&3/G#]D[1/BG\"O
MV>?A+\*/#OPQUO7M(\(>';RRBU3Q2T/ACQ%(]UKVLZE*FI:++-(VG2QM?%$1
MBQ>W"2Y/F5]4W'C7XIQ>%=-U2+X8+-XEN-3N[6^\/_VM HLM/C3-M?"Y,FR7
MSVRIC#%EZG P*^;O^"8.K:EK?[!W[.VJ:OJ5_J^I7?A+6GN]0U.[N+Z^N63Q
MGXCB5[B[NI9;B=D2-(E:9W9414&T*!7Z US9%.C5R3**N'HK#T*F6X&=&@I.
M?L:4\)AY4Z2FVW)4X.,+N[?+=NY[7B;A,PP7B5XA8+-<P>:9IA.-.)\+F.:.
MC##O,<?A\^S&EC,>Z%-1A1>,Q$*E?V4$H4_:\L$E%'@&D^/_ (P75OKDFH?"
M1+">RTHW6DPC6+>0:IJ'VVTA%@6#GR,V=Q-=^8^!^Y\O.Z0"I/#'COXN:GK>
MEV.N_">/0](NKE8[_5!J]O.;& H29A"CL9,. NT9/(&,9->]T5ZI\39WOS/=
M:6WM;\['SKJ7Q#^-%O?7T-G\'([VSM[N>*TN_P"V[93=6Z2LL4^QG!0S1*)=
MIQMS@].;FN^/?B_97%G'I7PFCU2"72=+NKJ4ZQ;Q&WU"XLXYM0L K."PL+MG
MMQ)T?R]ZDJP9O?J*35U;^MQ<K_F>VNGE:^_EZGB-SXV^*<7A73M4@^&"S^);
MC5+FTO?#_P#:L 6STZ)"T-\+DNJ/Y\GR>6K$KU(K-TGQ_P#&"[AUEK_X2KI\
MMGI$EYI<?]LV\G]I:DM[90QZ<Q5SY6^SN;F[\UOE_P!&,9):0*WT!10U>WE_
MFG^@<KT]YZ=DM=EK]W]6/ ?#7CWXOZCK6E6>M_":/1M(N[R.&_U-=8MYOL%L
M<^9<"%'9I2G!VJ#Q575?B%\9[;4+ZWT_X.I?V,%W/%:79UJW0W=NDK+%/L9Q
ML\V,!]I&1NQ@GY:^B**8W%[\S_JWX:;>>MSY_P!;\?\ Q@LI;%-+^$B:I%/H
M^DW=W*=9MXA:ZE=64,VI:< S@N-.O9)+02CY7$>\$[J6Z\??%^/1]+N[?X2+
M/JMS<W\5_IAUBW7[#;P^3]CF6;S LGVL22':#N41\C)S7O\ 11_7]?<'*_YG
M_5K_ )=K^9X%H_CWXNW<.M/J/PF33I;+1Y;S2XQK%O)_:FII>64,>FY60B+S
M+.XN+H2N0H-N(\Y<4>&_'OQ=U'6M*LM:^$RZ-I-W=QQ7VIC6+>8V%LV?,N?)
M5V:4IM^ZHR<CGY37OM% N5_S/==%Y=[ZZ+T['SQJWQ#^,]KJ-_;Z?\'DO]/@
MN[B&SO#K5O&UW;I(ZP7!C,@V>;& Y4C*[BN..9]9\??&&SDL!IOPC34HY](T
MR\O'_MBWB-IJ5S:1RZAIX#.-_P!ANF:V\T9$FW<I((S] 44#L[6YGZV1X!<^
M/?C!'H^G7</PD275KF\O8+S3?[9MP+.VB6W-K=>:7 <W32R*5!8IY62 '&=+
M0?&OQ2OM(\4WFK?#%-)U32[2UFT#3_[5@E&O7,DLJ3VQE1V%M]GCB23>Y ;>
M ,D5[;122M^'X)+] Y7I[ST_$^?="^('QBO=5T^TU7X0II>F7%S'%>7XUJVD
M-G;L2))_+#DOL'.T D]!DUG2_$?XWI+,L?P422-9)%CD_MVU&] S!'.9.-RC
M<1[@$C-?2=%,%%_S/IIMM;SZVZ]V>(^,?&WQ2TG5!:^'/A@GB/3C8V4YOVU6
M"V(NY80]W:^5(ZG_ $64F+?T?J,U0F\>_%Z/1-.O8_A*DVL7%]>P7NF#6+=1
M9VL20M:70F,F'^TM)(I0'<GEY( ->^T4 TW?5J[OI;R\O+_ASP_0O&WQ3O=*
M\47.K?#!-+U+3+&WGT&P758)1KEW),Z36ID#L+?R(E6;<Y ;=@<CG,T7X@?&
M2\U33;;5/A FF:;<W<$-]?\ ]M6\ILK=W42W(C5V,GE*2VT#)QQFOH.B@.5_
MS/3\?7^NWG?YNF^)'QN269(_@LDL22NL4O\ ;MJ/-C5B$DQOXW* ^.H]/3I/
M&?C7XI:1JD=MX9^&*>)--:PLKE[]M5AMBEW*C-=6?ELZDFU<!-^,/G*YXKVV
MB@$FNKW7X?YG@$_C[XP)HEA>Q?"1)-7GU*^M[S3#K-N!:V<,-J]I>";?AS=R
MS31^6N2ODY/WP2ECX^^,,NF:W=7GPD2TU&R%B=*L1K5N_P#:9FG>.[!<2;8C
M:0*DO)R^=HR1Q] 44G\OFK_JO\^S74L^C:^2WTU^=M;[W/"O"'CGXL:KKMC8
M^(OA8GA[1YX[QKO5EU>"X-J\-A<SVJ>0CLTGVJ]ABLRP!"F;S#PA)Q+CXC_&
MV.>>.'X+I-"DLBQ3?VY;+YL:NRI)M+Y7>BAL=L[>U?2%%,'%O[37I\ORL[>I
MX%XA\??%[3]3GMM'^$R:OIZ);M%>G6+>(RM)!'),AC=U*F*=FBS@@E<\CYC>
MU/QK\5+;PYX<U&Q^%Z7NOZB^H+K6BG5H%&BI!>3PV+"X+JMQ]MM(H[HA&/E^
M;L/*$U[?10'*_P"9_P!6_P G]YX!I_CWXOSZ;KEQ>?"9+74+);+^R;,:Q XU
M-IIVCNU:0.1";6 +-EC\Q;"Y((-SP?XY^*VK:]86/B/X6IX>T:=;PWFJIJT%
MPUH8;"YFM1Y".S/]JO88;/@'9YWF'Y4)KW.BDE;\._:W<$G_ #?@NENWZ6/F
MZX^(_P ;HYITA^"\<T232)#+_;ELOFQ*Y6.3:9,@O& Y!Q@'':M+7O'_ ,7[
M#4)H-)^$B:M9+';-'>'6;>+S7>WCDN$V,X(\BX=X<D<[0PW [J]_HIBY7_,_
MNMY=&M/Z5CP"_P#'WQ?@T[0KFT^$:75_?6]Y)JUD=9MT_LJ:'4+BWM81(S@3
M?:K&**]#+D+YOEG#+SV_P[\0^,_$%MJ<OC/P:/!UQ:W$$=C M]'>_;87CD,T
MK-&[>7Y,BA-IP3G/:O2**35_Z\T_TM_PPU%IKWF[=_2W]6UZ7/@7]L//]O\
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M;=M_-=8KOV_K5BUY=M8Z/=]5VT5ULM-M=$?)'[?./^&9_B.,_P#+SX/'U/\
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M>);+Q;IOC3P]X<\-^*]&UJ[T>W6'4[*ZTKPOJ6GZA<^(E^P?^"?_ ,:?CO\
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M[0M%N_"MAIWP$U>[ET7PGXWTFW^(6FZ;KES?7HNIFTRYU>_NH5UQ_LO]G?\
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M$RI+FJJI**A":C2M#3GKT\(Z=!WLXQ]VA"I.G'EG5A1K/VOM:DJT/QE\&_\
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M\@T378[[6[?1]'M[NXDL]:D\:N/^"O7QKNO@_KGQ:\%?"WX1_$*SLO'OPO\
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M?T?XC?%/3=*U[P+/97NF_P#".>);2Q\:VT7B?3[32[^XTK3G\0#4+G3-+?\
ML[2YK&QCBMZ^EI*M]5C[24'BGAZ,H3A_!JU9Y?7O4BGK##SQE3!UZ:7M9SP\
M*DN=1K1H+\&O2>+;CS?4HXF<90NI8B-"&,PZ=-S=X?6H8>EBZ55VA#V]>"C3
MI?5G4K<;XC_X*&> M-TGQ;>6WPL_:'2V\*^"[_Q5XC\26GPNT_6M$\#R1>'S
MXIT_2?%<D/B^VBTG6=2\,"/Q'IMIJMS9Z9<136FB7>KV?B?4+3P[)S/Q,_X*
MH?LT_!/0?%.M_$ZX\8^'K+P=<^$]+EU/6M+\)>%X?%VI>*[.YGT]O#5OXE\;
M:.UI:SC3]1G%]XA?2-,O/L<]MX?U#7VDM'G^C_$/[&7[.OB?^W/[6\"7K+XG
M\"VGPV\3PZ=X\^(FBVWBGPA8Z<=(L-/\46NB>+=+MO$MW9:21IUKKFNI>Z]!
M:XBAU-%5 >+\9_LN_L>:;J/A/1_'FG:59>(?%\^D^!_AO_PF/Q>\<0>+)M0\
M-Q/KNEZ!\(]3UGQROB7P_K=C;Z7)JDT/PVN=.U2YM[)[K4C=6]F7%U.=U9*C
M*"I5)X6$5.+E/_>\7[6R4N5U:F'J8*CAJ=/V?[V515I8B6'HSQ&,'*-)3KVE
M5A2JRG[.7LJ*E[/ ZM3C.2I4YT\=4J3FY2<?8JFZ$:U5T/J/X=^/O#GQ1\#^
M#_B)X.O1J7A7QQX>TSQ1X?O\*OVK2=6M8;RRE9%>5%9H9E+*CLJL"JNPPY^0
M/V@O^"AGP:_9M\?>(/AUX_\ #7Q'O?$.B> W^(\"^%++P7K;:]X:M+C3+759
M]&T8>.+3Q2ATB34X'O)-:T+2K&XV2PZ->ZK=A;5_J+X=?#&R^&T_BUM.UWQ/
MJUIXHU;3M0MM/\1^(M?\0Q>'[?3=$TW0H-/TF?Q'J^O7T4,T6F_;KZ3SXQ>W
MTTEY<QO>27-U+\O>./V9_P!ACX_ZE\2OB7XCT[P/XTNM2\27'@?XG>*="^*G
MB/3],3QAX=M]*\"W_AGQ1)X/\::1HVE^*]-M;/2O"6K6%RMMK!$6G:7JJS/%
M:VZNK[V(B\.N2DX5JLJ-1J=6$94XTZ*YHQ2E'#XK$8=5JRY(U>54H*+Q4)4R
MDJBP_+7DOK+=*C"K"/[J==3C4J.,'+FO7PU'$SI4KRG"[;4E1E?P_P"-W_!2
M;2[3PAX:/P;\-^-[3XC/\5_!/A;QMH'C+P!8WL7P]T&Z^,WA;X5>)XOB"MIX
MRLQX>GU:7Q%(OA?4]&N_$;?:HHI[RP2S%T%_2OXA>-+?X=>"O$WC>_TO5-:L
MO">CWNN7FEZ+/HMOJ=Y;6<1EEALKCQ-K7AG0(90BL_FZOK.G64:!FFO(E5B?
MC#P[^PU^PE\3-(3Q%X8\%Z%\0-'D\5:WJ3>*]"^+?Q"\2_:_%>G>*[2_UU;O
MQ39^/K^ZU&_T/QUX8BOI;"\O9ET7Q/8/<6]O8ZE%<LWV3\1OAGX+^+/@C7OA
MQ\0M!B\4>"?$]A'INN:)>76HVJWUK!/!=0 W^GWEEJMM/;W=I!=6]Y9W<5Y%
M<1QSQ3I*@D$OVBR]TX.*S"<JE7VLD_JZE5PN"IT8TXRYJBH4Z]*M6C%\W-[:
M4^9RJ2MK3D_:I5:<72IUYQM"4E-T(UI-4ZFR=91YJ<Y)IQ:47=12C^9'@_\
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MVQ_=[Y_6D&!C&>NTD=.?X>?O?=Y[^^&6G*!P1GC@=N^??J#UST;C'&YO)W
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M?A3XK^*:_"CP!^TOJ>E>+?CGJWC";4+3XN?LO1Z)XGT2T\0_#&./Q=/:Z_\
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M\:#3-3UA_#T?V.:Y\C4(].TB]GD2[:+RW1()"EQ<VT3?FUXC_P""17P]U_\
M:4U;XZ)\0K33?"VM?$R3X@ZA\(;?X6^'#HMS;ZG8^&-2\1Z!<:VVK)+=_P!M
M_$_P=HGQ0&KW.E2SV&J+J&F0VLPU2ZU6N0_9^_X(X^'/@3>_"B_;XM:1X\U+
MX5?';1?C-;:IXM^&_BC6M2\66VD^#O&'@Z31_$1\6?&SQ?I6G>*I[?Q=_:J^
M./!6E^%[!=>TFPU"]\%ZEY,4,2PKE..'>*2H59+"_680E[94Y5*^$6(A":47
M+ZO0GB9\[A>K.BE3IRYX1G53EA+$<C=:"IU7A9)NFZD_JV/E0C64XM4YO$TL
M#"I&+E3<,6TL2G3JU:7[7D@#(R2,G ZGV&2!D]!NQZDJ.:^<_ '[3?@3XA>&
M]?URQL=9T#6]"\0^/?"J?#_Q1J/@FP\;Z]J_P^U&\TO5H_#EE:>,=1T74[>\
MNK"0Z7=-K4$7E31MJSZ0_P!HCC^C#G!VD!L';N#, <<$KE"0",$ @D<$@<U^
M0#_\$R/B#JOQ+\#^./$W[1_@Z^T_P+\7?%'Q=TC1-&_9ZO-$U*&_\4^,=3U_
M4]*C\6R?&W5M3DM+O0M8N?#5Y#JD>JZ0\UK8>(M,T+2KR.]MKS*I]8<U3II1
MC4I2A+$2:MAJLIX=4ZSIZSK<M-UVZ2A)3<81<H7<@TC3E4LIU(3C*.'3DIXB
M"A4YJ<9MQITTZGLN>;E&487E!5&G"7Z&_"O]H;X:?%?X;>&/BCI.O6'A[1/$
MVG:7=_V=XKUKPS8ZUX=OM5BCFM_#WB5=+U_6](L->'F+$]E;:I=I*^#97%U$
M\<S><:IXD^!7[4NC_$/X?_$GPW>Z=IGPY^,T_P -+O2_&VNZ?X9N-7\:^']*
MT?7=(U[P3K'@WQE<W\]IJ>C>*K*_T62&_P!.UTQ7$MIJVCZ;=17=D/S2\;_\
M$0=&\=:%;:5??'RWTN?2[_PQ9VNG^'_A;KOA/P7XD\*^$[+QO8Z>/B=H7@/X
MR^"O$'C;XCWEKX\OH]2^)&G>,_# =M'T!;'PQ86VG_8G[+Q]_P $@=2^)7B'
M3]<\4?M$:?<1:+\7IOB;I/AZS^&WQ(TC1H;&70/AYX>L]+O[K0OVD]&\2ZQX
MGTJ/X9Z/=Z9XUN_$*P&YNM5_M3PKJD-PJ+NE3J5Y^TII89\JA"34E2:QV35*
M>(N^>4I4,-+-'&DXV=6C"7M>>-"6(QJ3Q%*E1=%^UKJ,Y5I+]TY-8/,(NC&[
M4>2OB/J<954U)0JV=-1EB(T/TB^&?Q.^&&D_$C7?V9_ NA7^F7/PV\#Z7XOE
MO+.\\/ZGX8DL]8UB_P!-N=/-W:^*-;\6Q^*;?4[::[UU?%VE:==7GVN._AU'
M5I)KJ1>V\,_'GX/>+;WQ)IVA?$CPE>7_ (3\;WGPZUNU?6;&UFMO&EC';S77
MAV-+N:V:\U*)+F(&&S$Q9P47=)'*I^._V1_V#M?_ &7OBMXO\?S_ !=\,^/=
M$\2^%+WPH-/A^#K>$O'6I>;XUUCQE9^(OB#\1D^)/B./X@>*(3X@N]&OM8N_
M"VF2:A9VEB\:6313Q2>"^-_^"0NF^*?'7Q/\7:5\6_".AV?Q5\;^/O$FK:==
M_ BRUG5/#MC\0-1\*:M=:GX)\00_$C17\._%GPW?^%4/A3XI1Z;<+I]AJ-Q9
MW_A#5IH(+^BG.=1X.>(4E*MA*]7&5)3YIT<<L=#V-&6LU453!RJ.=2DYQA.,
M9RG*?-0G:2A'%*$4G3Q>'I82,;1ISPCPR]O6MHU*G74>6G+V3FG*$8Q@XU8?
MKUKOBSPSX8-H/$?B70/#IOS,+)==U>PTPWK6XC:<6HO[FU-P8!)&91!OV*Z>
M9C>M<OXV^+_PR^'FD^)=9\8^/?"V@V/A'0)?%'B(7VLV(N]+T&)-_P#:MQIZ
M3M?"SE&%MY5A83R.D<'G22*E?''[;7[#%[^UO:?!&#3_ (@^!O"+_!FZ\;WB
M3_$;X.W?Q??Q WB[X=:G\/H\MI_Q0^%#Z2VEIK$WB.5UEOAJ&N6&D3!+$6 ,
MOS1XO_X) GQ[-KS>+_CMH6LKK>F:K-)J4GP0B?Q5<^)-9^'&D?#VXTS7?$^I
M_%#5[KQ!\&+"31K?Q;H?PGO8%NM,\12O./'4\$4,:Y3E6:KJ%--PA6]A.37[
M^:4O90Y$U[/GY8MRJ3BO>46X+GJPK6V';M>I!2KJ+;]A4YI*4+N/OKEY'&5-
M27O3E+6"I5?U];QQX1A\.:=XPN?%&@V'A75;*SU&Q\0:EJEE8:3<6>H0QW%G
M.FH7D]M:[;J&1)(LR9;.,;B<>8>,/BS\!/AW9>)_B]XE\>>!M-@T/P9%J>N^
M)?\ A(;*_GM_!T%P9K::WM[:[O)I=/NKZ58[<Z9;L=0O7M[=#<SFVBKXK_;^
M_9;\>_%_]EWX8?!CP'X TOX@OX5U_P &0Z]HVB:+X>TK2ET30-'GT^ZN]&\,
MZK\<?@#%IUD\Q5H-)TCXGZ?>6-HXMXYM7CA>"7Y4M_\ @B;I?B:#QKKNN^/?
M!G@W4?B/\&?#?P\3P+I_PY\8Z]X1^$FIZ'X6\$^'K:S\):,_QWA\*:IX(BE\
M$:=JT_A77-&UO68-5N=3?3?B3-//%X@JV^:MC7"/+1PV)J4L'5E=5,3#ZE&M
M&:IR]FX*K*JL*JB_=1:KJI*#C8R<JBH8;FC^_K855<13^Q1K1Q6&I^RYXN<)
M<D/;XIJ4HR?L:2HQK*?/#]S]5\<>#M#MM.O-9\7>&=&L]6@DNM+NM6UW3-/M
MM3MXH/M<MQ83W5U!'>0Q6A%W)+;/(BV_[YF$9+FI_P +'^'^(&_X3OP<$NKR
M/3[=O^$DT;%Q?RVZW4-E WVW]]>36A6ZCMH]TTENRS+&8B'/RE^UY^Q-X5_:
MQ^&OP[\"ZIJOAWP5K'PZ\2:/JVB>)=/^'NFZU::?HLFC7_A#QYX5T+P]J.K1
M0Z'I?C7P1K6L^&[79J5XN@/-IFJO;:]-H5K;/\+:C_P1/\&7&C?L]V%I\8O]
M+^"6J>)KG6/[4\"^)8-*^(%AK&K^#[OP_+?6OPY^+OPOUBQ\6>"M#\$:-X7T
M+Q-JVO\ B>QGTN74%U3PU=B\\A'%MU:L9)0@L4J5"K?GY\.J5.;Q,H1Y7",I
M26'A25ZKJ4Z]2I"E05"6*MR:IT^6,YU9815:B?LXTX8IU:L/JJE[24GRTZ<*
MTZJA[/\ ?0IPE*2JNE^Q_P .?B9X'^+'AT>+/A[XHTGQ=X<;4M5TA=7T6Y2Y
MLCJ.BW\^F:I:B5./,M+ZUE@;LV/,1FCDB=N0^(?QO\.?#;QW\*/ WB'2/$)F
M^+NH^)-)T3Q-9C0%\,:#>^&O#=YXIO%\4W&HZ[IFLV4%UI6FWALKG2]*U6V6
M>(QZE-IRO!/)QO[)?[-]G^RQ\(K/X3:;J^A:[:6'B3Q=KT&K:'X-3P4UU%XF
M\0:AKL2:O8)K_B1=2UFQ34!I]WK2W=M_::6T4Z:?IZL;9>7_ &I/V;O&WQYU
M?X6ZOX/^*_AWX82?#9_']\W]M_"T_$B;5KWQAX%UKP19SP1S^/?!VCV4.B#7
M9=3EL]5TKQ!;:M)#'8LEC%++<%5'.,*;IQ]M+DA*4?=I\U3ZNI3BN:7N06(]
MU6E*T;/FE&\GO0C3E.M"O4=.FOKL:-1*4F^7VRP,VE%O]XU0=1.*LI34E3>L
M>_'[2_PU/Q7\/?"@:BIO/%?@NZ\:^%_&,6L>#Y_ WB.'3]<MM O_  YI.H6_
MB:XUFX\36U]?6C-8_P!BQVDL4F+._N[B&YM([WQ$_: \$_#V[\#6TD6H^+5\
M<_%KP[\&Y+GP7>^%M3A\%>)_%/VY-,N_&D5_XET>_L-*6YLC9W8TFUUC6+:6
M>"3^QS:)<WD7YCZ'_P $?CI^D>%=#U/XY^&=3M-&\5>*-:U*X@^!9M-1M-,\
M6^,O!_Q!U&+X7WNJ?%GQ!)\+O$EKXJ\*.VF>)K0>((=-T#5)-'L= MK^RM/$
M @\ _P#!'_5/AGH_B?0_"G[1\2_\)5\9O#GQ1U;Q+XB^''CWQ'XOU#2] U'Q
M/?)H=Y=7/[1%OX9M?%!3Q/<6MIXZ\.^%]!BA6TMIK_PKJK?*N<W6A#!NG3A6
MEST)XR/M.7W'F673JX92Y(I<N6U\=1^L4XS?M,#[:-.=2M2IU>6I.<H8SV<)
M4Y^QK1P*;C*]983,(4:\ES<L5+%8?+\1*A.HU;'SHRJPIT:DJ7VGX]N/V6_V
M:-*^)O[65GX:M=<UBWN+[5O$5SX'\6:=JNK:QJS1I8:_+X:T+Q9X[T'P+'XG
M@TF:X?58M*EL-=N=+@N[&U349Y(=)D^EO$_Q@^'G@M/AZ?%_BK2O"T_Q3UW3
M_#/@:SUNYAM;GQ!KVI:=<:M;Z39Q[Y%>[6PM;FYFVNT,443%Y?F5C^*6B_\
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M^(KOQ;X1L([T_$4W=@VD^([Z[U$WFGRP7NH_:KNVU:YU"RO;RTD_.1_V<_\
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MNR@;J\U7]G3X;KHC>'Q:ZI_9K:JNLE#JD_FF]2UDLE;S=N?+^SR,-F,;\-U
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M&&4>7*8V(60?,IY'W:P;3]F3X765S:W<%KK FL[B&ZAW:O,R"6"198RRE#N
M=02"?FZ'O0G?U_JPO?MLOO\ 3_@[[KM<].N?B1X LYY[6Z\=^#[:YMII+>YM
MY_$6D136T\+M%+#/$]VLD4L4BM')'(H='4JP!!%6+_QSX,TM;1M2\7>&-/34
M+5;VR:^US3;5;^S=BJ7=H9;J,7-LS*RK-#OC9@P#$AJ\OU3]FKX9:OJ.HZK>
M6NKM>:I?76H73QZM/&IN+R:2XG*(%*HADD.U1G:O / QL>)/@/X!\4PZ%!JM
MOJ;Q^'=(BT33?)U*:$I8Q222(LI53YLFZ5LR,"2..,9(U??I_75/L/W[[+_/
M;S_I7[G9CXA^!#9MJ(\;>%#IZ7<=B]\-?TLV:WDL4L\5HUR+LP+<RP02S) 6
M$C11R2*I6-R?R!_X*,_%+Q;#\=?V+4^%_@GP+\5O##^/+@_$#Q--\-_#GQ/?
MX?Z>WBOX>8U2/Q1/I&NR_#O=8?VC?KJ44UDS?V8-3,H.C1R)^GJ?L[_#B/0Y
M_#JVNJ?V9<:Q;ZY(AU28S&_M;.[L86\[;N$8M[V96C PS;6;E>?S'_;A\>?#
MW]F'XN?LL?#JS\!:]XCA^/7BZ?PU/?1>-+O3%T:.'Q+X.T#[0]K]AO!J.1XT
M>7R_,BP(/+W9G+CY[BMX19)B'C<;6R_#_6<NYL5AX.I5A-YCA52IJ"C*\:U7
MDHU/=TA.4FTDV?KO@3#B"IXF91'ASAG+>+<U_LCB]T<DS7%+"8+$45PAG;QN
M(G7E5I*%7+L"L3F.&7M%[3$X2E!*4IJ,OURC^)OP\E>../Q[X-EEE=8XHX_$
M>D,TCNP5$15O&9W9B%54R68J "34EU\1_ %E<W%I=^.O"-I=6L\MK<VMSXAT
MF*XM[B&1HIK>XADNTDBGAE0QRQR*'1U96 8$5YA:?LQ?"VSN;:ZAL]7$MK/%
M<19U>X91+"ZR1DJ5Y 91D=QD=^+&K_LV?#/6M3U35[VUU9KW5M0N]2NVCU6>
M-#=7UQ+<SM&@'[M#+,[*@) 4[?F %?1'Y$N?MZ:_\%W_ *9ZA?>._!FFI9R:
MCXP\,:?'J%L+RP>\US3+=+ZT9FC6ZM&FN8Q<VS.I19H2\98;0S$,*@7XA^!#
M9OJ \;^%&L$N8[-[T:_I1M8[N6*2>*V>X^U>4MQ+!!+*D+-YC1QR.@*QNQXW
MQ%\!O 'B>'08-4MM3DC\.Z4FBZ;Y6I2PE+&.668+*57]])OF?+MR1@8XS5!?
MV=?ANNBS>'_LNJ_V9/JUOK,D?]J3>;]NM;6[LH667;N5!;WLP*#AFVL>5&0/
M?[)_\,MKL]'T[QUX,U=YXM+\7^&=3EM[26\N(M/UO3KI[>T@7=/=3);W4ICM
MX5!,DS[4C7EW JG%\3/A[-(D47CWP;+)(XCCCC\1Z0[22.=J1HJWC,SLY"A0
M,DX !)KDO"OP'\ ^#[F_N]'M]32;4M+O-'N3/J4TX:RO4\JX5%8*(Y"I^20?
M<SGBL*U_9C^%UI<V]W#::N)K6>*XB+:O.RB2%UD0E2N"-R+N'0@8.:2M^5]+
M= ]_LM.SZ:;W=[W3^1Z==?$?P#97-Q9WGCGPA:7=I-+;75K=>(=*@GMKB%VB
MG@GAENTDBGAE1HY8I%5XW#(X5@5IUS\1/ EFT2W?C?PG:M/!%=0+<Z_I4)FM
MI@3#<1"2Z4RP3 $Q2IE'&2C,!FO-]8_9M^&>MZIJ>L7MIJIOM7U"[U*]:/59
MXXVN;ZXDNK@QQA2(D,TKE$4_(, &IM5_9V^&^M/9/?6NJE]/TRUTFW,>J3)B
MSLU=( V!\S@,<N<EC\QS0W]_1=P?-T5OG_PW],]"_P"%B>!/L@O_ /A-_"7V
M$W368O?[?TK[+]J6(3M:BX-UY)N$@99VBW^8(B'*A"&*VWQ#\"W:74MKXV\)
MW45E;BZO)+?7]*E2SMC)'"+BZ>.Z=;>$S21Q"64A/,=4W;G11YY_PSG\-O[$
M7P_]DU3^S5U5]9"?VI-YWVZ2T2Q9O.VAO+-M&J^7TW9;J:=IG[.WPXTFVUJS
ML[755@U[3O[,OP^J3.S6OVJVO-L3%<PN)[2)MZY.W<O1FRP]_M?SOZ>?]?.Q
MWMO\2?A_<SP6UOXZ\'W%Q<2QP000>(M(DFGFE<)%%#&EVSR32N0B1H"78@*"
M2 ?'/VC_ (CZ!I_P.^/%GH.M>#]=\967PH^)EOHW@Z\FT?Q!-K?B6'PEK<.G
M>&;KPI.UR-?DU+5HXM)G\/3V-Q_:$D[:7+:3M<20-MZ9^S3\,=*OK#4K6TU<
M76G7EM?VS2:M/(JW%I,D\)=&7$BK)&I*G@C(Z$UYM^T%\*_ASX1^&/QN^+]Q
MHVL:IJOA7P+\1/B=-90:[<62ZA?Z'H.K^*);2&812BQ6ZN+!H4D6-Q!O#A)/
M+5#RX[D^I8OVE25*G]7K*=2*YI4X^RGS3C'6\HJ\HZ/5;:GL<.+%/B'(5AL+
M2QN)_MC+%A\'6FH4<76>.PRI8>K)N/+2KU7&E4DW'EA.3=EJN3_83^)EL_[)
MWP4'Q+?P5\-?',WAO4I-<\$)IVA_#E-#E_X2771;V\7@F*#2(= 2YLXH;T6T
M5A"LQF:\"N;EI&^QY/'?@R+3X-7D\8>&(])N;B2TM]3DUO35L;BZB&9;:"\:
MY6VEGB'S20H[2(/F8 <U\,?LE>%/AQ^T;^SC\)/C-?\ AK6M"N/&7AZ]NQI+
M^);G4'L4LO$.L:6L+WQMK9KIG.G^?YA@4@.(P"(R:^K9_@/X NO#&F^$9;;4
MO[%TO4KK5K2,:E-YXO+M=DI><+EXROW4(P*Y\G='^R,K^KUIXF@\!@_98FI'
MDJ5Z7U6A[.M4C96G6BXSFK)J4FFM#UO$!9A'C_CB.:99ALFS*/%G$*S#*,%6
M5?"95C5G6/6+R["UN::J8; U_:8:A-3FITZ49*4E)2?:6WQ#\"7:W<EMXV\*
M7"65O]KO'@U_2Y4M+42Q0&YN66Z<00"XGA@,LA6/S9(H]V^6-:=8_$'P-J=W
M!I^G>-?"E_?W4@CMK*RU[2[BYN9#DB.""&ZDFF<@9"QJ6(!('&:\ZTS]G?X<
M:1!K-M:6FJK%KNF'2+\-JL[EK,WEE?[8F9<Q/]HL+=MZ\[=R\ L1+X<_9Z^'
M7A?6-,U[2[75$U+2;D75H\VIRS1+*%9!OB( =<,?E)KT5*_]?UYKY'R*Y]-%
MYZ^G;Y]/0[J?XD_#ZVEF@G\=^$+>>"1X9X9_$6DQRP2QL4DCEC>[#Q2(P*LD
MF&5LA@",4^\^(/@6P>*.^\;>$[)YK>WO(DNO$.F0-+:74:S6MS&LMVA>"ZA=
M)8)4!26-E>-F5@U>8ZA^S3\,-3O;O4+JUU@W-_=3W<Y75IT0S7$CS2E4"$(#
M(YPHXQ@#I5[6OV>/AQKTUI<7]KJC26>EZ=H\/DZK/&HL]+M(;&S5AM(:1;>%
M%D?J[98@DG,Z2MKMO^%]6O\ *_EJ*\[+1>:NW;9=_P"NO<](?QWX+BT^#5Y/
M%_AA-)NKB2TM]3?7--6PGNHANDMH+PW(MY9XE^:2))&D09+  5!;?$/P)>+=
MO:^-O"EREC;M>7;V_B#2I5M;-98H&NKDQW;B"W6>>&!II=L8FEBC9@\L8KC;
MCX$^ ;KPSIWA&6UU(Z)INIW.KVD8U&87"WETA25I+@+OD0J?EC. &YYK,TK]
MG7X;Z/%K$-G:ZJL>N:3)HM\'U6:4M8RWEC?,(SM!CD^T:=;L)1R$WQ@8=LM2
MVTW_ .!^CO\ AN/W^RZ=?O\ +3T5^EKGHUC\0? VIW5O8Z?XU\)ZA>W4JPVU
MG9:_I=Q=7,K?=B@MX;J2::1OX4B5F/857E^)OP[B=HY/'W@R-T9D=)/$FCJZ
M.IPRLK7@*E2"&!&1@@\BN%\/_L\?#CPUK.F:]I=KJJ:AI5W'>6C3:I/-$L\8
M)0O$P <#/*L<&LRX_9@^%ES--/+::R9)II)G(UB<#?*[2.0NW RS' '0''89
M:=]@7/I=+[WY>?Z-];='ZO>^/_!&G&U%_P",_"UB;VSM]1M!>:]IEN;NPNT\
MRTOK837*&:TNHOWD$\6Z*5?FB=P":'\?>"([*VU*3QGX6CTZ[GGMK6_?7M+6
MSN;BW"-/!!<-<K#+- LL1FCC9FC$D9D"B1*X'7_V??AWXC;26U*VU1CHVA:9
MX<LO)U.:+;INDPFWLED 4^;,L1Q),_S2').,FDN?V?OAY=:#IOAN6VU0Z3I&
MH7^IVD8U.99A=:BEM%=&28+NDC*VD6Q&.$(SGDY&]4N__ _37Y![^NB_'?W?
M^#MI?U.\MOB#X%NUNWM?&WA.Z2PM6OKU[?Q!I4RV=FDD<#W=R8[MQ;VRSW$,
M#3R[8Q++%&6#RQ@EC\0O NIW<%CI_C;PG?WEU*L%M9V6OZ5<75S*WW8H((;I
MY9I'_A2-2Q["O/=)_9V^'&C1ZU%96NJJFOZ1+HFH"35)I-UC-=V-](L60/*E
M-QIML?, +;=Z\B1C2^'OV=_AQX:UG3==TRUU5=1TF[CO;-YM5GFB6>/[IDA*
MA77U#=?6AO5+O_P/TU^0DY?R[J^_731W;Z7^X[VY^)'@"SFEMKKQUX0MKB"1
MX9X+CQ#I,,T,T;%9(I8Y+M'BDC8%&210RL,-@AA4MW\0_ EDT*WGC;PG9M<6
MT%[ MUK^E0F>TN4$MK=0B2Z0RV]S$RR0S(3')&P>-G4ACYEJG[-7PRU>_OM2
MO+75C=ZA=37ERT>K3QH\T\C22%45,*N]LJHX7.!WS8UC]G3X;ZV]C)?6FIL^
MGZ3I^BVQCU2:/;8Z7:QV=H&PIWR+!&H>0\NV6.2:=Q^_;9;KJ_+K?[_^#<]$
M?XA^!([:"]D\;^$X[*YEF@M[M_$&E"VGFA"--%#.;H1RR0K)&9$1F*!DW@;A
MF:S\=>#=0M]0O;'Q?X9O;/2HHY]2NK36]-GM].AF9TAEOYHKF2.TBE>-UCDN
M"BNRE4+,&%>:3?LZ?#:XTFPT22UU8V&FWEY>VRC59A()[Y;=+@R2XW.I2UBV
M@\*<@=36GHGP)\!:!I7B?1M.M]22R\6VEK8ZNLFHS2R/!9R32P""1@3;LKS/
MN9<EA@=LE)W0+G_X>_EY_P">M^C9V%I\1? =]<PV=EXX\(WEW<2"*"VM?$&D
MSSS2G[L<4,5TTDCGLJ L>WJ(6^)WP[0E7\?^#%96*LK>)='!#*<,I!O-P(((
M(/(/6N!T3]G#X::!J5AJUA:ZL+W3KE;JV:759Y8Q,ARI>,J ZC^Z>#5"7]E_
MX63222/9ZN6ED:1\:O< ;G)9B!MXR6/X <TP]]=$]5;5^7G_ )];Z,];U/QW
MX,T:=;/5O%WAG2[LQ13BVU'6].M)S!,GF0S"&XN8I?*GC^>*0C:Z_,I(^:H7
M^(7@6.UAOY/&WA..QN)9;>"\?Q!I2VTT\.TS0Q7#78ADEA$B-*D;%D#(7 #+
MGC/%GP'\ ^,]375];M]3>]6SM+ -;:G-;Q_9[&(06X,:JP+",#>W5CR?6J-Q
M^SO\.;G1[#0I+;5?[.TV\N[^V5=4F647%ZD$=P7E"[G4K;Q[5/"G)'))H!\_
M9;]'Y_UI\CTBT\=^"[^WU"\LO%_AB]M-+@6XU*ZM-<TV>WTZ"1BD<U]-%<R1
MVD4CJ522X959@50D@U6M/B-X"OKB"UM/'/A&\NKF58;>VM?$&DS33RN=J10Q
M1W;222.Q"HB!F9C@!B.>-T3X#> - TSQ-I&GVVI+9>*[*#3]6674II9)+>VF
M>>(0R,NZ!Q)(VYUR6  /OFZ/^S?\--#U+3]6L;355O-,NHKRU:359Y$6:!Q)
M&71EQ( P&5;@C@Y[@>]VNO77I?J^GGON=])\3?AW&S(_C_P:CHS(ZOXDT=65
MD.&5E-X"K*<A@<$'@].+^I^.O!NC3K::MXN\,Z3=M!%<K;:EK>FV=PUO,-T-
MP(;FYAD,,J M'(J[7'*DBO(Y?V8?A9/--,]GK.^:1Y9,:Q< %Y'9V.-O'S,<
MKT P.^:Z3Q;\"O 7C34H]6UJWU%[V*PM=.1K?49K>,6MFAC@4QJ"I<*3N?JQ
MY-)._IT?<7O]E;3KY>M]]-]=_([%_B'X$2UBOW\;>%$L9YY;:"\?7]+6VFN(
M%C>>"*<W8BDG@CFC>2)"717C9U D0TD7Q"\!SPW5S%XV\)RVMBL7VVYC\0:4
MT%HL[F.#[3,MVT=OY\BLD7G,ID<;$RP*UYY-^SM\-Y]'L="DM=4.GZ?J%YJ5
MN@U6<2_:KV&TM[@O*%W.K1V,2JA& =Q4DLV5L_V=/AO8Z;K&DP6NJ+9ZV+,7
MRG5)FD86$[W%OY<I7='B61B^ =XP#P,5.DK;_P#DO6S\^FOR:'[_ &6_?_@_
MA^!Z-IGC[P3K%Y%I^E>,O"^J7\XE,-EIVNZ9=W4P@ADN)S';V]U+,ZPV\4D\
MA52$B1Y'PD;M51_B;\.XF>.3Q_X,21&9'1_$FD*Z.I*LC*;L%75@058 @Y!&
M>G'>%?@!\/?!^M67B#1K;5(M2L4O$@:;4IIX M[976GS[X6 5S]FO)@A/W7V
MR#E16+/^S#\+;F:6XDM-8\V:62:0KJ\Z@R2N78@!/E!8G@=N.>M6-\VEE^/I
MY_YZ>MCU.\^(?@33[A[2_P#&WA.QNH]ADMKS7]+MYXQ(BR(7AENHY$#HP="P
M&4*L-RNK5/<>.O!EK96.J7/C#PS;Z9J1F73[^?6]-CL[]K>5X;@6=T]RL%T8
M)XWAE$#,8Y%='VLI%>:Z]^SQ\./$6H7&JZC;:LUY<+"DC0ZI-$A2WACMXR$5
M6"CRXEW$#+-\QR>3?U'X#> -4\/^'O#%U;:F=)\,O?/I:)J4R3(=1NY[ZY\V
M<*7F#7%Q(5#<*F%'"K23O?R_KR\Q+GZI?U\SM(?B'X$N(;NZ@\;>$Y[6Q$37
MMS%K^E/!9K.Q2 W4R71BMQ,ZLD1E*B1@53<P(J72_'G@O6KR#3M)\8>%]5U"
MZ,GV>QTS7=,O;NX\F.2>7R+:VNIIY?*MX9)I/+4[(D>1\)&[5YS8_L\?#C3]
M.UG2X+34Q9:['9QWZOJ<SNZ6,KSV_E2%<PA9');;C</E.0:M^$O@'\/_  7K
MVG^)-$MM3CU33/M7V5[C4IKB$?:[*YT^8O"P57)M;J55SC:Q##E0:$[_ -/]
M4@7-?5:??^O];ZG92_$CP!#/);2>.O"$=S%,T$EO)XATE)XYT<QO \378=)4
MD!B:-EWK("K ,K"K.I^/?!.CW3V.J^,/#&EWL:12/::CKFFVEPD<T:S02/!<
M7,4JI/ Z2Q,5"O$RNA965J\ONOV;/AE>:A<:I/::N;RYOI-1E9=6G"?:IKAK
MEV5=I"AIF)"*,!?DZ')U/%7P#^'_ (QU:;6]9M=3>_N+>TMI'M]3F@C\NQM(
M+*WVQJI 98+>-2QY9LL<EF)$[^3ZKL%YK[*>O1MZ:*^NW_ ;U.^D\=>#(M/@
MU>3Q?X:CTFYNGL[;4WUK35L+B[C5GDM8+UKD6TMQ&JEFB1S(J@E@ ":OZ+XC
MT#Q''/+H.NZ1KD5LZQW$FC:C:Z@EL[@M&D[6<UPL;NJED61E+*"5! W5YM<_
M ?P#=>&--\(2V^IG1-+U6?6;6,:E,+@7MS')%*TEQMWR1E)& 0\ X(Y!STO@
M+X;>&?AQ;ZC;>&X;R&'5)X;BZ%U=/=,TD$<B1E&D * (S9 ZG!SW+O\ U]W]
M?=W#WN972MJWOI:W2]GT]&[H^2/VQ,#7_!Q)/_(&O^!Z?;E!/0XZ]1SU'>OD
M?/).!Z],A??'&,'OU[XXKZV_;$_Y&#P;[:/?G^+&!>J3C'<=>../PKY*X'&>
M@/.3U /*X(SCICD^^"Q,_%KM;ROND_+T]")?$]V_^&\M^W7\11C!P<DD9QGC
M/3GLN"?O9^C9Y83S@$X7@M_>&<^O0>H]>>O+P.ISD?*>F-^,C"XY].F2,G<#
M2 \$'G&3R0><=R3M;J>!T[D;L&OZ_%/]/UWL3'375_@T[>:_);O>^@I/3&X'
MC@'@] ,\J<D<8Y_3-,SGG))7GZJ/3@@>^1CT_B6EY&&*@_U)R?T(YXY_4KAB
M<8Y/4Y]3W'W2HZ$=.O\ O5'\K;79);=M/3Y]EN/1:=DE]G?LMWU7GLO0+-SG
M&!SG'OC./F'+8/'_ ,4*0]",$Y)*@=ORS@]><D8/Y&#SGD#C)YQZC&<_=YPI
MX_'=1R"<8Y)V_P"]R"5_E]<<'[U&JLM.O2VUDGZ_=O8/)=+/1.U_==D];/;2
M^WJ*RD^Y)ZYSM'UP#Q^?/0T#KR,X &.AY)/0]><9Y''=AFFD^AS_ -]!\XP>
MWT]N,<[20'A@3M'0YSG!]^A]>.W;I3WM=VWTO\_1Z>76XK7T_I+1>NFEK+3H
M2 @=@,8SCD].[>F>_/OC%-SM)4'V[#'0'TZ!>N<]O]JDP&_BQ_ .I_B_D%QQ
MSC/S&E!&3E=K=#W'..-N[O\ RX!HMYZZ-]NG^5O)=+WN)7[WLG;T:U\];_#>
MVB>Q\D_M]$_\,T_$;)/_ !\^$.HQ_P SIH&#D!N0.F#S[\BOIO\ X()D']E?
MXKD#&?V@-;S]?^$ ^'>1^%8/Q)^!$7[2GAM_@Y-XGE\'1^/=9\-Z<_B&/2!K
M+Z8+?Q!INIB9-*?4=#%Z[_V<(-AO+< ,)=[[%B/JVF?!?QW_ ,$J_P!C#XK7
MOPK^)GA_XAZ['\3M*\?W&H^-O@OXB\30?V3KT?@[P1J6AZ9X%\"?%GPCK>LZ
MO;P:2NKZ=/9^(-\\S-IG]DS,5OJ^ICG.6T. \9E57$...J9S1Q,:/LJEOJ\H
MX&BZTJ\DL/&-.49.:E54^2#:C+W4_P 9QW!W$6(\?<EXXI9>GPS@>!\7E6)S
M'ZSA$Z>/^LYSB(X:.!59YC4<J6(H.-2EA)T;U%%U4XU+?LG17Y2?#K_@IE\/
M?"WPO^!NN_M6>*?!_@SQG^T%XM\5Z3\*Y/!6AZWI^D>,?"&E^*+#PWX?\=:C
MX3O_ !#X[UKX:_VD=:TD:SX;\1^(=7O_  [JUT-,O[YYH9D6V/\ @IAX%A_:
M%F\'/#J^K?!;4]"TW3/"OB_1_A3XZ?4-8^(MSX]?P.'T7Q2FIW_AOQCX!U#4
ME?2K76]$T.QM]/UNU:VFUC4?MMI'7RLYPA5I4N>/-7J5Z5.5W&+JX;#K$5J,
MN9*4,134H49X><8UJ>)J0PU2$*_-3C^U.K"-&I7F^2G2C&I)MIITIXF6%C7A
M*+E"IAG.%2I'$PE+#U*%*=>E4G2Y92_5"BOSYMO^"F'[*T_AVW\:MK_C2V\%
MGX<WOQ1UGQ==_#KQ;!X;\&^'K+2=:ULV/CK63IILO"'B.[TS0-0GL="UR6VU
M"[>..&%'ENK6-O'_ !M_P5,^%'B7P5\,O$?[-FMV_CO5O%_Q9^%'A37;/5_
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MIN)+U[C5/.5 NG+\'^/O^"3/Q=\,>!?'%[X/^('PJ^).OZ[8?$S3YO 7@[X
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MBK12LGA?2[:>[U#Q!;HE\\EUI%E:VTTT][:K);(D;%I.":_':]_8$^)WA_\
M8WT;P'X8^$/PZNOBFGB/X91Z!X(T_0-$M_#'@'1/#GQA_P"%D^(_$7B6T\>?
M&OXCP^*O$&OB:2\\86UE\4M5N=9O+=;72-;@CNI'/3WG_!(2?4;GP);WWQ^T
MV?P[X5TOXG0W?A@_!.WAT\7GQ>M?B);^-=/\,'3OB-8V^B>!XC\19!X4\%^(
MK3QFGAJQT"SM;35+EM2U>[FG$*O##XI850JXBE6Q='#WDE"M;!K%82NTYPE[
M*=6M0PM:SC&-2G6A&I4E&I4H.C)3G2]JI0C*-"=114VXQ>)E1Q$(R<$E4A"E
M*K3C-+GHU859*FO94\3^@7Q*_; ^#GPX^#.K?'2UUH_$CPKIG@C1_B:NC?#[
M5/"5QXOU#P!J<^EQR>*]/T7Q;XG\&(VDZ99:HNKZF+VZMKU+2VN[:QM;_6_L
MNB2_1_ASQ'HOBO1[#7O#NK:=K6CZC"LUM?Z7>VNH6K\?/%]JL9[JV>2!\PS)
M%,WER!T))0Y_(N^_X)17K_#SQO\ #W3?BO\ "2'_ (3?X2:)\,?^$IUG]FBY
MU;Q1X+-MX<T+PIXBD\":CIGQR\-OI7@_Q3I&A)+=>!=1&L166L7-QJ4>N7%N
MYTT_<O[)?[/&N_LU_#OQ#X&U?QIX4\9#5_'_ (F\:Z=+X*^'6H?#/0M M?$M
MQ#=OX>L?#>H_$+XH'R+&[2>2.Y@U:V21)E5K!)4>XDZ)*DZV)4'+V"C*>&G.
MTIRDL6Z,:#C&,='A/9XKVLH0O-5:;C%SITZ>-*>)EA\'*M1A#$2J3ABX0E=0
M@\)AJL*L=90<5BOK.&<(3G-)QG>5.'M9?5]%%%,Z3X/^,'[?/PT^#GC'XO\
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MOJUM>0ZK_8-J/*T^.SNH;C3C 6*G[1=3PW7F_>7R3&!B1C7+?##]L/\ 9_\
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MV9J+7MG-'J056Q.8[6VN+3R6^4_:3)G,:8]\HICY?-K;OTMKVO9=NQX-X=\
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M9U>]\1Z=IWA2Z:]D:WT,^&M.TN6]U>0BVC<ZRL=@H-WG46Q9G]:?VQ2?[?\
M!P'\6C7X_P#)Y<#^>/?\:_*QM;^(%U\;/$GAJW\8^)+;P;H5KX>UJ3R;3X?C
M2--6_MM1NI]+U-KWPXWBF\M-3DTJ.PM)=/OX)[22>2:?4)&%G;UZF3RQ-&O7
MK86KAJ52CA?;RJ8I5'%1H8K"5H.DJ<9J5=8BG0G3A.+C5<73:J.:IR^,XSH9
M=BL)E^$S/#9GBZ6,S58.E0RMX=5)SQF69CA*ZQ<Z]6E*E@:F KXVEB*U"K"M
MAHU%B(U*"I/$4<F\_9^\67%KXYN8-3TZWUW4?&]OKOA<MXJ\2M9+X:BNM*N;
MC1]6QID?]FW<_P#9,T8;3[;4(T6XEB60I<W"G@C\*_'FC^)OA%9>(-(U[Q5'
MX7TVTAO9_"_BS7QH<UT/$VKW:RW%Q=>#KN"[-IIDUG/J%MK6H>'%D18[*&[U
MQ(D!R-7^-WQHO)EELM4DT6R\1>,_'NDV:6F@^$-2G\-Z7\/=.U*\GCL?[0U"
MV75QKBPQR7?]L.MS"]A<#2[N--3L[>O6[S]HHR>$-<DTG3O$M]J'AKP;I6KZ
MUXJM],T$+I>H:GI4&L6XFT:[U*"U>>XLKC[0BV[-IIG$EC%<M)"R5]'".>X>
M-!2^I8F,Y4Y^SIU:L9X;GPSRV$JE9<BIP]I[2E*,:DI5<3&<J7-&K3G/\XG/
M@7,9XSE6=Y54HQJ0=;%8/"SHYC[+,Z?$4Z6'P4U6>(J^QA0Q$*E7#PI8;+JE
M.&*<)X?%4:,WQ6^#/C[QOXO\7WFD2>#+#PYXP^'<7PWGU#5=8UF36],AGOC?
MWVKP:#;>''TZ_EB5GM+.S;6K=7.V]FNH"&TX\IXK_9K^(6H'QW9:;XU@U+1-
M<\):-X5\,V.MZ_=6%CIUMIT6DV[0:WIMMX3\03W3PC1Y+^TU*SU-9&FN9;>?
M3]LC7Y[;4/VJO#6G7'B2RC\->+-9/A/4=(T6^O[:SMX;"[U+4;G3+&>WBN9Y
MH+.*:RN=<B:2&6022QB5[)9EB\P[F@_M$Z7XG?0;?PYX/\1ZQJ6L6>J7UUI\
M+:9!)HR:7JEYH4@O9+F^@MYTFU?3S9B:P>:.%98KJX:.-C)7%1J<1X.CAJE/
M"4X4*,8QISG"BXRM2HXV%2<JU3FIR]C2C*,U[)<LITN52J2C+V<5A?#C.,;F
M,*V;8C$9ACJTZM>G0KXJ,Z;GB,3DU3#T:>$PZHUZ?US$5J4Z,HXN3JT:5>4Y
M4L-"I3Y;0_@+XH77(-7UN]T:.(^.?$VJ7UA::_XBU2"?P5KUC*R:5%]HT[04
MAU:PUFWMI[?Y&M8K:>],,^_R;4\_?_L]?$FXN?%;R^-(M;CUOQUX>U^VBO/%
M6J:99KX?TW4[F\NK(6&G>$[B]TO5/[,NCH2M%JFH65Y;LLDR:<UG;QGZ%^&W
MQ#'Q%TV35X/#VI:#;QR/:LFIW&GR3QZA;RSV^H:;/#975XT%UIMQ;&&X$FU"
MS Q-("U>A XVX[<XXX).-O1CDC/'WA[_ 'CPU,WS7!XAPJK#JK1C2I^R<*=6
M,%2KT\3%*<9R=W5@G+EG+FNU+:'+[^&X/X7S3+J57"/'SP^+J8K%+$*O7PL\
M1+%X.MEU2=2E.C23C["K*-%2H15-QC.FES5/:^$?#WX:6NC>./%VJVEIKMCH
M-I+81:3I^O27LNW78;6YL=6U?1KN>_O%O=&U/3'LRB2JH&H?;)2J2JR5[PJ\
M<]/J1D]CC@Y &,>HX/WJ-O &!DL>"<<XZ@]3GMV!SZ;2,?JV<<%L;2,CM@ ^
MHZ9YY KR<3BJV+J1JUI.4HTZ5)7;;Y:=.G%>\]W*SD[N[;>KO<^KRW+,+E="
M>&PE*%*G/$XG%24(QA'GQ%>=>2C%>ZHQY^2"344H>[%)I)./7MD'&#P?4C/T
M/MCCABXG(7!8D#.U>O;J1GVXP._^RM-4$D<'V;OQGU[''KGTIQ QVYPN>P''
M'&T<%<Y[_P# N,%KKK>_^3TMZ+?T\ST'HTNFEK>=D]+=/739WW/'OV@/@SK7
MQ]^'.L?"OPYK?AOP[KOC35?"]A8ZOXSO+O3_  ]8R6WB72=0:35+NPL=:O((
MY([%HHS!:3,TS1JP57:6O3/@)X-^*7_!*_\ 8J^*_B*^A^"GQOU.'XR6GBV^
MAL/BMXR\$>$M.\-^(]-\$>"Y;B]\4VWP=^*&MKK&E7NF'4I])C\*W,$^G2H\
M.I17!%C7S'^WA=W-G^SA\1+BSN)[2YBNO"!CFMII(9HF_P"$ST %HY(C'(A(
M)7*L!R5/5A7;?\$J/A!>?M(_L.?%KP%JWQ:^)_PY2X_:5&L2>*?AU)X OO%"
M_P#"/>%OAIK=CIJ/\6?!?QA\.II[ZG:PW%P(=(:Z(C,<-W;I/=Q-];&EF+\/
ML96H8N-/!K/\)&IA%A:<ZDJE\N=2K]8J58VI^P=ITH1C4E&$O9SC5E!Q_$,?
MB\AC](C),#5R6M5XBEX?XZKA<\>:U:>%HX18C/(PP<\JAA:L9U7B(3G'%NJU
M'VL(SHSITVI_H'^SG_P43\"_&W0;?4?%<OPN^&FJ6?B_XI^']9MXOBQJ_B/P
M_J^E?"O1M'U'7?%_PSUK7?AA\.M1\6^'K>77;2+5QXO\/?#O4])$5]=VVGZS
M%#;-/]!Z;^V?^R_JUAX1U33OC9X)N]/\<^)I?!OAB\AN;HP:GXI@>WA?P^SF
MU4:=JK27=LL-GJAM)9_/MS;+,+F%F^3KK_@E!\(]6OM0U'Q-\;?VA?%6L>*O
M$GQ)\6?$K5]8U;X2V=S\3O$7Q,\'>&? 6HZGK\'AOX0^';#PU)X>\,^$-)L_
M#-I\,;7P-9PSQOJ.N6NN74KRM/>?\$K?AEJ=QH-[JGQ\_:3U/7K'XDZ5\6O%
M&LWFM?"9A\0/'&@MX*C\,:[XJT"'X0P^$K*^\-Z/\/M$\,Z9<^"=!\+7\FBS
M:J=6N=2U/5[[59OD8OGGAHU5&E#V&70Q52'/4MBG5H0S2I3C-QE.@J/MZV&E
MRT)3JJBG0HPQ,Z&!_;W[>,,1R7G+VV/EA55Y$_8\N(GEU.MR6C"7/]7I5W"5
M6U)M\\ZBE6E],I^W+^RC+X=;Q;%\</!]QX;CM;Z]EU:V&JSV\%KINNW'A?49
M[D0:=++;)IWB*WGT>]\]$-M>0S1S;/)E<<#J?[<'A(_%#X;^%_"3_#SQ[X!\
M;>--;\%:]XX\,_$?5+C7? ESI_P;\1?&?3M3UCP6/ !L;^SUG1?"]Y!;BR\7
M>8EE=V&LVS7K3S:/%5\:?\$^?AQXPT+XO^%[?XG?&OPCH_QG^),?Q$\1V?A?
MQ'X1:PTV"YAE/B?X?Z-HOBCP3XGT7_A7?C?4[G4/$'BG0=9TW5KJZ\0ZC=:M
MI^IZ7=0V36_C_A;_ ()2^#O!VM^&M6T7]JK]JRW3PK/87.DZ?'??L^V<<-QI
M?PAU7X'6%PFJ:7\ -/\ $=M<V_@36KZ..XL=:M)DUMHM721)(((4RA*JX593
MIJ%94,.\/3YXSISQ52E">*A6DN62HX:;EAJ4Z;A+$3A.LZ=.E[.%32JFIKV4
MHN@ZF)YW/G]K&A&HXX3DTE3EB*U.,:E534:5)U(0C*7+4DO3[G_@HO\  BV^
M+7@#PP_C#P"?A-\1_ ?B[Q#H/Q>/C+4HFC\<^"?&_@KP7JGP[U?PA<^$+6/2
MI+AO'VEWEKK]WXE,BW-G=:;J&@V4<EEJTE?6OV_O!^D>/+;1VD^%5Q\/+[PM
M\7-<MOBI%\6=<.B:+K_PH\=>!_ ]WX1\9Z;_ ,*MWZ#?7UWX^TPWE[97NN#2
M=3MY](%GJMJT&NOP&D_\$F_@QI6DZ1HLWQ@^/VJ06MWXUB\33ZAK7POAO/B/
MX:^(6I>!O$'C+P=XO?1?A3H\<&CZYXE^'N@^([C4?"<7AOQA'?+?P0>)X='U
M*^TF3/UC_@DWX%UFY\6,W[47[4.G67BQ_BSNTO3S^SF;/1H_C-XG\(^+_%\.
MD2WO[/-_J C37?!&B7.D'5KS5'LXDN+6:6\@N9E>X7C#"QDW.<*.;/%35HPJ
MUZCQ$\JC>RER898FA1]K&G3YY8!O$T*L7.MC](N$WB;J4(3K8989<OOTL/##
M.G6E*U24'5KXFC3Q%6E-SC3I8EQPV(4FJ& ]S\$_\%)/V//&M_XNTB'XS^&M
M&UKP1KWC7P_K.GZP-1L_M,_P\N#9>+=1T22XL8?[7TG3+X2P+<QI%=SQQ&X-
ME'%<VK/]RV=U!?6UM>VDJS6E[!%=6\RA@LL$\:S0S*&".%DC=7&X!\'D [@?
MS=@_X)Z^&])N_AYX8MM?UWQEX#\._M!>(_VE-5UOQYK^C)XRTSQCK]X-8UKP
M?X>TGP+\._!FC:MX'\:^))KO7_$D/BG5;F33Y"-/TVSNM(BL=+MOTK50   0
M   !P  < ?4'G_&M(QC[&BV[UN2C&K9.*G4CAL.Z]6,6N:DI8QXFC"DW)*&'
M]O3G*CBJ,:62Y_:U;/\ <^UQ,J/,TZBHRQ==82%1Q2A[18&&'J5N7FM4KNE?
MGH3J5I****9J%?AE_P %5_@S\3/B9^T?^P#XA\$>"-9\4:)X$^)=W?\ BG4-
M,AC>WT*T?QM\+[_[1?&2>(I%]ETF[G_=ACMM9#U !_<VOY]?^"PFJ:C8?M2?
M\$WX;+4;^RAN_BO>QW4%K=S6\=TG_">_"1-EQ'%(BSKMD9=LH92K,HRKN#\=
MQZZ*X7QCKPJ3I_7,FO&E4A2FW_;&!Y+2J4ZT4E/EE*]-WBG%.+:DOZ'^BO',
M9^-O#T<JKX/#8W_5[Q$<*V/PM?&X:-->'G%#Q$98?#8S UI3J8?VL*,XXF,:
M5:5.K.%:$)4I_I]XV_9*\0>,8O&ME#^U3^TCX>T?QW_;+ZOH=AKW@36M-M)=
M7G<F+04\8> _$LNAZ19V,LFDVWAVPEAT&2S?S;[3KN^ NU_-\_\ !+7]HC2M
M*^&.F:=\6OAUXKOO ?QK^*7Q%T;Q;XF\WPUK'P^A\:_&*+X@:5X@TK1_ OPN
MTWPY\46D\.VHTKQ+\(_&%GX8\'C6M0GU#0/&&GV6C:/:1?37QT_X*)^,OAQX
M\T/X>^"_V:/&/BKQ)??'*Q^%HL=>\1^!_"]YXF\-W%AXNG/C#PC::YXGT>:'
M3]2OO"-W%H]_K[65E-:I'=S1E;[35F\PO?\ @K'X1^)7POU./X;?#KXL>&?B
M/XS^'6E^(?A^D-]\)/[:TV+Q3\,?$GQ#D\3PW?B?4?$7P_ANOA]I7AZ]O=3T
MKQ9;7D6J7MK!9Z9I.OPW8A?Z-U*.&P[S:$9SI99"C-N+O4<*2I8^C#]].$XV
MA2Y8R=6F\*H3C*KAO8.5'^?*M"==2RNJXPCB:LJM5NZC1J5EB<IE.K.$9)^V
M]O52I.-6.+C)2C3KTZDXU.Y^,W[ WQ+7^VO$?[)'B?X>_LZ>-M1^)UKXA+^'
MIM>T/3M1\+W]G<CQ?K&IZK8^']>O[;QAK?BB?3_%6I:39::^C^(-!\.6_P ,
MY]:T6P\2^(O%I_5G3XKJ&QLXKRY6\O8;2WAN[I8Q"+JYCB19[E8@2(EFF#2B
M+G:&"9;&3^,&B_\ !5WP[\._ 7@RZ^)/@GXT?$;XD^*KCP)X=3P[X5T'P3?_
M -MZG+\'O#7Q'\3>*?!FG^%K2PO5TNYL=7?49=$UUIM9EU(S6.A65I9BTLF]
M_P#%/[:7B*\:3Q+X;\.:_P"!+/X9_$KX>:'XQ\!?$33=#BU;XF_#SXH^(7\'
M6'BG1M.L[R[\9>#[K2+K;KNAW.HV]O:ZE/:W^A:KITXEM[RW[&EA>? QE"4*
M&*HTY-7Y*7M*>78.FJ<JD82CAH1J4*SIP2DG+$M1?U:I2P_#[>E6C1QS3A[7
M#5JD%91G52J8C$U9UYQDXU:ZJQG1]MB*LE&U"FJJ5:#J_I?1115'4?'7[4W@
M7Q7K&L? +XB>&_#^H^.+;X.?%<^*/$?@O2Y(_P"TM1T+7O"^N^#+G7=+LY!G
M4=2\(R^((M;%C;.M]+IJ:HVE6]_J4=CIUQ^6-M_P3D_;;L?$W@WQ)97WP,@O
M_!&MV%]H=\O[4'QZ273K6R_:4D^+>(].E_9XO-/U.:Y^$UU>_!IH=5$D$%G.
MUVSWFGXT\?T)T5%"'L,30Q<'>KA\7]<I<RNE6]E1HJ_>,51YHI^]&56H^?\
MAJFW)NE5HOE]G7CAHU8N*ES_ %6M7KP;YW)6FZ_)6I)*A5ITX1J4I<U;VOXW
M?M,_L1?M1_$+XN>"?B%X'\<>"?B+<^$?!']A:/XT^+7Q1U7X4>,O"6N77Q=\
M&^/;I])T'X+_ +.E_P"$_$NA:?X5\)W7AFP7Q)-'?:G)JKG6MXBDOG\4N/\
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M_P $?#WX5_"SXI6GQ.O_ !'J%[;ZQ!\2/$7Q'\,?V3K'AR+PQ:_\(Q)HE_\
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M.BBBMCI/@3]L08\0>#N__$FU =.1_IJ#(R>QY'X]0:^#KWX4?#B_UB7Q%=^
M?"=WK]Q<0W4^L7&AV$FI3W$&##-+>/ ]Q++ 1^[=G+(0-I S7WA^V*/^)_X.
M.>1H]^.>/^7T$8]QM('7.?4BODKMC P,L3CJ#_L@Y& .^#P.5/6J-6M1;E1J
MU*,I1Y9.E.<'*#Y;Q;C)-KW5H[JZV=KOAQF"P>-488W"8?%PIU(U:<<31HUX
M4ZJCRQJPA6A-1J)2<8SBN9*32=G(X*3X2_#B:.%)/A]X1D2VN=3O($?0=-98
MKK6D$>L74:FW8)-J\2+'?2(0]TJ[;@RX%/D^$_PZDMI+-_ 'A)[6328?#\EJ
M^@Z:T3Z-:.9+;2'0VX#:=;NQD@M2/)C)+(@+,*[M3NP!G@YR!R%[ ?W1CZ\9
M&3GYCGYL;@3]?7(Z9 9NAS^9SS7US&67^U8C2S7[ZKH[J2:]_1IR;NM;N3WD
MSE>3Y/>3_LK+[R3C+_8\+[T7"$.67[C5.%.G&SWC"$?ABD<)>_"GX=:DMZM_
MX \)7HU,6:WXN]!TZ87R:>(UT\78>!Q<&Q%O&+8RAC$(X_*QM1:6S^%W@33(
MK6/2?!OA_0)-,74#I=WHFDV-A=Z)+JB,+^[TB>"W1K"[N6(F>:VVL\BK)()&
M7)[K)R!W7CYC[#/(Z8]<\].:"<$8!(YYSG=GT+#GVP<_C5+%XMQY'B<1R;\G
MMJMM8<CTY[?P[T]O@]WX78/[(RA55665Y?[9+2JL)A5425=8J*514E-6Q"]N
MO>O[=^UTJKG,3PUH%MX:TJSTFVGO+Q;6,^=?ZD\<U_J=RS;I]1U&XABM$N;Z
M[D!GN9UB3S)6+;$SMK;P3P#TX_7)QWXZ\Y(Z?-GYDVD 9?;D''7'KU[=NG/'
MMPH^\HX]U7D<DYSGH,  X]_[U8N<ZDYSFW*4G>4FFKM[NUDE?LE9>ECKHTJ5
M"E3HT(J%*E&,*<5=I1@E&*O*[>BLVVY2ZN]VS!X&/]K!R.>3C/H.O)&[Z\T+
M@J>, 8Z<]^=I)X_'L<MG.2B_=7)X[Y!X],?YQT_ &2"<#(ZG_@70G!S@+C(.
M![U*7WK>^NMH_P"7GW-6]EMMKM9W5NWHWKO?5#^>Q!SUR<G S],8! +9SGWI
M!T(W8S\P/4 ;NG/LO3I[TT\@#LV<=_F (/)!X].^<-\M* #@X'7!STZ_PD#'
M]>I/]XE^EG=/H[Z:?GZ=]M1:;=.Z\K?+2WZ'R1^WR?\ C&GXCD '%SX/ZC@D
M>-/#_4]\XSWSG=GC!^G/^"">/^&5OBMC_HX#7,]>O_" ?#O/7FLCX@_&_2?V
M=M _X6YKGAJX\7:3X'UOPUJ%UH%C/;6]SJ<5SX@TW35CAN+R*ZMD:-]06?,R
M%<1D##'<?KK]E+]L+QE^V9X*U[XB?!;X>:%\/O"_AKQ7<^!]1TGQO>Q7VI7.
MN6>E:+KLVHVCZ+'8VZ6$MAXCL;9(Y$:?[1;SN7*2Q)7UE'$XZ/!&+P<,NE/
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MG7YGT#17@&LO^T(-5U<:+#\/3HHU*^_LDWIO1=G3/M$OV W@20)]J-IL\_8
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M8SC/% <VVCU_S2_7J>^T5\Z3O^TCYLOD1?#;R?-?R-_V_?Y.X^7OQ*!OV_>
MXSG%='XP;XV#4XAX.B\$MI'V"U\PZR;L7?\ :&P_; HB=%^S^;CRL\[ <Y-
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M[OPYK>B>$O%FH64)+3Z7X2\7:GIFIWLSQ30Z6TD.OW/V>VT:>]@_.BW\+?\
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M<M4I_>[:?=\K:K:UEW%JWJGK;>S73R3=_/\ $C_O9W'!]>G!/)RW\6"#T/\
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MK+X=?&K0?B-XO^'6E^(OAU:+#\'GURUC\5?#3Q!\05\413>(?&6J^ HC\/\
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MOXK+6-"\%ZWJFE7<NGZE;76FW\<%_8PS-::C:W-C<JAM[JWN;>6>(\69<O\
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MURY+:O'=W*R:A/*X2411R>6D$3?4]YXF^.R>"-(OK7PAI<GC.;6+V#4]-:&
MV]OI4<8-G<HIUE(Q)+)\K$7#D@<Q1]:X?]@OP1H'PZ_9(^"W@SPK\1] ^*_A
M[0/#NJ6FE_$'PO#-;Z#XGAE\3ZW>R7NFPW,\]Q'%;3W,M@XEE9C-:R-E=P6O
ML:N?)_:2R?*I5:=&A4> P;G1PWL_JU*;PM'GIX=492HJA3E>-!4I2IJ"BX2E
M"S/6\0Z6'I>(/'%/ X[-,PP5/BWB*&$Q^=RQM3.<=AH9WCU0QF;RS*G0S"6:
M8JDH5LQGCJ%'&3Q52L\32I5W4A'Y=T3Q9^T/<6WB1M6\$Z3;W5KHIGT!(X8
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MQJHXFL\WPDOJF#]MF">,<(J<Z\E0H9?-8:FN=U,;.#E&&'E4._\ &_Q'\.>
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MZGKE@(RC+*TMK=S0A657D5]\-;L4T=Q&DT$T<T4P#)+"ZNDJL/E>-U)212.
MRL<YZ\YKY^\>_L^_\)@-8BM_%"Z$-6\&IX2:]M-'$NL#R);"2WDEU)=0M_,T
M]O[)\J\T^VBMI+A)707T"@)7J7PY\&IX"\):+X62\-^-)@,372+>)'([R-,_
MD17]_K5U;0AY6\J"2[G$2@)&^Q42N/$4\O5#V]#%MXB55+ZI[&HE3I2C)MJM
M4<K\DE&$8OGE)2<Y23NCV,!BL^>8?4L;E7)E]/"RE'.98["3J8G$0GAX1A+
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M&G^)?$>AZCK+_8O#M_+]G\.P7MWF!8'B:XNK&.3]G:_GY_X+!ZWK&E?M0_\
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M^A_N@'ITSTRX\C ')S]>.>,;<].!U_I^A0_9)^&J\?VKXPSV/]I:6/U.B_\
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M'O<YK?5FDL5H^71?O4E](*4986K_ ,2S9 WPNI0]C_8M)KBSVU+^RO:8E?\
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MP))):VCS,UO!)*WPVD:5X("L3.[R,Q!9G=CO/KOQ_P#A!^W]XJ\8VNI? O\
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img248422670_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_3.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $7 F # 2(  A$! Q$!_\0
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MTA_.FDTG[/\ 8]5Q-+;O!F6V C$RL"<?0_P]_;+\&>(KOXA2>,M:\'^$M)\
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MI)5I4^:56'LZ52=5U;U*5)4%+CP6.X\PN2Y!.IEE7,,\Q-?+:'%4,:\+3PF
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M'_"5:)_S_)_WXNO_ (S0!T=%<Y_PE6B?\_R?]^+K_P",T?\ "5:)_P _R?\
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MF]6MD6<X?+\)FE7+ZRP6-4I4*L5[2\8ZJ52,$YTHU(^_2E4C%5()RBVM3XO
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M#*3\L13D^9_8SE_#S3)JG_<_&CV_Z"84+:.^O9]=#Z]\=QIJ^)X2XWPUM_\
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MP[CZC:M'+,\E%5LIE=\M/"9W&MAUSZYU[J@_H!_VCDADO(;OX(_M!V<MJ]T
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MHK>2ZFUBVCM[:REDE66-+.))1^G][^S=XDU"TNK.[^,>J3Q7L.JP727'P_\
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M\!(>43R M;PQ^TDB%XOBE\-YKA+=U2&Z\!7JVLMT;N1D:X>WUQ;A(%L&2 I
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M_P '[_(^=F^*OQ:#R*O[./B5E2/6F5_^$X\& 2OI][:P:9$H^T$@Z]:7$U_
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M=ZBFLW5A/-)X>:26SNM9C35[BVD9H9M31+Z5&NU$])_PR9^S.K7+0_ 'X1V
MN[K4KVZCTGP-X?TJ"YOM81$U>^GMM-L;&WEOM7$2?VC=.AGO' >ZDF?+E_7,
MF=^;(*:[<F98^-O/WYU-?P[IZWG_ %=XTBUR^(F)GK=JOPOD$[K2T;T*.'TW
MN]&ULX[KY!MO^"IW@0"XEU;]F?\ :^TNUMXC(]U_PI74IHDV_,3<-/>V26\2
MQ!I'FDDVHHR1@Y'Y@:%_P6J^..M?M;6.CV/PYEU#X3ZUXNM/ 6F_"B#1V'CJ
M:"\U1;&TU6VN ?M9\8W+W"2+IC[M/)\K2S'M5[X?OY_PRC^SVC"2V^$WA73)
M!<K>,^B176C/-=1Z/<^'HIYWTBZTUKF2'0[N;3(&N#(8+9BL/ELD;UR_@C]B
MC]FSX>?%J3XU^$?A-X3T?X@'P_!H,.M)9SW=W9M#-<M)J]I-J-U?+;ZQ<V=P
MNF2:E!&E_P#88VMQ=>3=7<)]'+LVX9POUSZUPVZ[KX6I2H^TS"I65.J[).//
M1BZ3>[KQDZE-+]VM97^4XGX,\5,UED3RGQ0CE\<!F^&QF/\ 8<-X?!2Q6$@_
MWM.K*CCJT,3&,;QC@:U&.&KRG>O)J$91^G],O9=0L;:]DL+_ $N2XC+M8:DM
MNM];89U$=RMI<WULCD() (9Y5VD996RM9^G?\ASQ!_URTK_TGGKHZYS3O^0Y
MX@_ZY:5_Z3SU\KU=M%T2OIY:M_Y][G[-!.,4I2<Y)*\FDG)I).34;13=KV22
M6R0I_P"1EC_[ ,W_ *7QUP/QYUWQ5X;^$/Q#UWP/>Z78>+=(\,WU_HMYK$EO
M%86]W H8LSWC"S\]H@ZV2W6;=[TP13!XW=#WQ_Y&6/\ [ ,W_I?'61\0O .@
M?$WP=K_@;Q/'>/H?B.S-C??8+V6POH@LD=Q!<V5Y"1);W=I<P175O)AHQ+&G
MFQS1%XFRK*<J<HP;C*46DUNG=;7<4W:]DY1OMS15VM:<HQJ4Y22<8S@Y)JZ:
M4DVFK.Z=K/1Z=]C\X/AC^T!\3?&FD:5X=L?B1KO_ !<#XX:?\/M*USQ5H/AN
MS^*_P\TBS\%1:YXLT[Q/H=OH&G:!8ZO<ZY97T/A.6]TB99]%N+:^=-2\Z&9O
ML_\ 9E^(&O\ Q!^'=Y<^*KL:EX@\)>.?'?P\OM8%O%:MKI\%>)]0T&#6YK6V
MCBM+>YU&ULHKB[CM8TMUN3-Y,<4;)$.=M_V2_ T6G:Z;CQ1X_P!3\9Z]XGT'
MQG<?$V]U'PZGC>SU_P +Z7%H?ARYTTZ?X9L/"MNNE:+'_9B0/X<FBOH'EEUE
M=3NIWN6]N^'7P\\/?##PKI_@_P ,Q70TS3Y+VYDN+^X%WJ>J:EJ=Y<:CJNLZ
MO=E(_MFJ:MJ5W<7U[.$C1YY6$4<,2I N_/"TK))N&'BE%:2G##8"FYIR7-%0
MJ4L8I0T]M+%1KSE4FKQY8QFE23E)N,ZCE)ZOE=;'2<)).TO:1K8)QJ6_=K"2
MIJG2A-1?PAH_QQ\ ?%W_ (*!_ ZP\#W/BF>\\%_LC?MHV>O+XE^'/Q#\"PQ7
M&H?&?]AB"W.EW?C[PKX1MO$T37'A^]\Z?PO)J=I:QK:S7[01:IH\[_I97QAX
MW_Y/Y_9?_P"S/OVW?_5N_L!5]GUG#1?=^*3-PHHHJ@"BBB@#Q'XQ?L_?"SXZ
M:4FG_$#PQ::A=VT;)I?B"UQ8>)-$8Y99-+UF!5NH@LI\W[/(9K*20!Y;>1E!
MKY2N[3]I3]DRSGOK/5Y/VB/@?I$<D]S:>(KJ&S^(_@O1[< MY.KS.T6N6=I;
M!Y";QI9<*%A-M&8[<_HW7B'QY^$VJ?&GP#J'@*P\>ZAX!M=:$EKK5_INEVVJ
MRZEI,UK<02Z6\5Q>6?DQ222QS-+#.)0T(0':[Y^"XJX3HXBGCN(,APV+P?%]
M+#2>#QN38G"Y?B\PK0C_ +/A,R>+<<KS'!RJ<JG3S>GB(T:?,\,Z=509]YPI
MQ76P]3 </<08K"8W@ZMBH_7<#G6%Q68X/+J-2<?K.,RM8-2S3+,9R<SA4R>K
MAY5:CC'$1JTG,^1?V;_^"AGPO^)Z>,X?B3K5C\.=0L/$T\GAN+Q%<1);7_AK
M4I9SI]M%>V]I%;)=Z0+=K6]%R0SK+:SB>=GF*_=_AOXD?#_Q=Y?_  B_CKPA
MXD:4(8X]#\0:5J,IW9" PVMW/,C$C:%= ^05Y((K\[OA!_P3%\'?"[QIIGB?
M5/B"OQ#TFVCN;;5?"/BKX>Z'>Z+KEE=0F)[:Y34M4UB.!D?9<PW,=JT\$\:-
M"8V7)^A_$?["7[+?B/=(?A?8^'KH[O+N_"6L:]X<:%F .Z*RTS4K;3"01E/-
MLW$>"$51(X;Y/@JMXWT,BHPXHR?AK$YEA:U>E.&.SFK@\9CJ+DJU*O\ 7,GP
MV>Y?=*H\-&$\/AI?[.ISC)3]H_K>-Z'@76S^M/A7..*,+EF+HT:L9X#)J6,P
M6!K<OL:F'^IYUB<@S%Q<J2Q,IQQ6*@WB'"$HN'LH_8E%?!!_8:3P]D_"_P#:
M,_: ^'JKS'90^,Y=9T:$YPB?V9C2X;B%$+*D=T\Y#$/OW+BIU^$?[:/A3!\-
M_M+^%?'EM;']U8_$GP)86\LT:\*DU[X?@2\DD8*&9Y[R1B2W[T\$?7_ZS\3X
M7_D9^'^;I=:N29QD.;T5W?)B<=E&825M5RY?*3T2C=GR/^K'"^+_ .17XA9-
MS=*.>Y/Q!D]9WM9<^%P&<X",FW;WL?&*ZS1]X45\)'XC?MN^%/\ D/\ P-^&
MGQ#@ PT_@7Q;=:+<-@?>2QU+^V7_ (,A'E7+,HW@*358_MG^)O#Y$7Q$_9B^
M-GA=HS_I-UI^E6WB:QC7[S.IT=YIV1$R[,8E 4'G-"\1.':.F:4\]R-_:_M?
MAO/<+1AL_?QG]GSP%K._-'%2C9-\UM0_XASQ'6URNID&>1?P_P!C\3Y!BZT]
MOAP3S"GF">MN66$C-/3E/O:BOBO1OV^/V:M3N([/5/%U_P""[QQAK7QIX?U?
M0YHG+%=CK- Y4AEQDC:00V=I!KK/'?[7WP,\(>!=1\;6'Q!\*>)(K-[&*WT[
M2M5BN;^ZEO;F*%0MA )K]5CB=IG<VVQ0FV1XRX)[:?'O!-7"XC&4N*LBJX?"
M4:E?$RIYG@ISHTJ,'4J2G15?VT>6";Y73YG:R3=D<,^ >.*.+PV"K<)9_1KX
MRO2P^&53*\;"%:M6G&G3A3K2PZH2YI224E4Y;:MI:KZHHK"\/Z]IOB?1=(\0
MZ+>6^H:5KFGVNJ:=?6DBRV]U:7D*3P30R+@/')$X.01[@'*UNU]52JTZU.%6
ME*-2G4C&I3J0:E"<)Q4X3A)74HRBTXR3::::;5F?*U(5*52=*K"5.I2G*G4I
MSBXSA.#<9PG%I.,XR3C*+5TTT]= HHHJR HHHH _,'Q%^W_J_A_XM^(+,^ O
M#TWP$\(?M&V7[*GBCQI_PDEVOCG3_B;>>'=+U@:ROAD:>VF_\(;#?ZM!H#R2
MWZ:I)/%)J,$$FGM&]>1WO_!4WQ'H_@V#XH:C\%K*;P%\5/AG\2?B?^S@^D>)
M+NZU[Q'H_P .M8BT^<?$:R_LPPZ"FO:+./'=C/H4FIK8^&H)XM3,6H*8V]NU
M?_@G_P"&O'7[3FM?''QGH7A;P]X=B\66/C.#PUX%\8_$V:/XJ^,=+T$>'=$\
M?_%CP5J.K:1\+-.\6^'=+DFL+34/#GAG4=>U&T@T[^TO%3V-HFBC,_9P_85\
M8_";QG\(!XV\9^$/$OPU_9:\+?$7P-^S[INCV>J_\)+J>A>/M4,EO>?$J34+
M:+3;34?!GA?;X)TZS\/2:A9:U%&/$%[)I\[-HR\-%5I8:C3JS=/%RPR<JW+"
M=-7ROEQ56I%.-3ZS+-XT\3EE"G&,J.'Q4\+C%*.&G**J34<3.=.#GAE7HKV3
M]V<I1Q\I1A!VDEAUE[AA\;B)-^VK47B,*J;KQIFY^RC^W-K/[3/@CX6ZA8>!
M]#C\;^-/%7CBT\0P^'=;U#5? EA\._ 'B>]\-W?Q5\.Z_/IUO=:KX8\8W=JD
M'@9IX(#K%Y+<+!)-9:3J=]']V?$/QSI/PV\%>*_'6NF3^R?".A7^O7R0;?M%
MQ#86\DXM;;>RHUS=R(+>W5S@S2(&X;=7YB?M;_\ !.WQK^T)X(TL:+XZ\*6'
MQ,U+XE-XT\:S^(DUT>#9]-M_#FL^%_!FA^&H=%M?[4TRR^#O]LCQA\/K/[-%
M9W'CJ'4/$^J_9=;\1:KK-?3GQ]_9_P#B9\4/A1\*O@KI/BJPOO"$.J^#[#XY
M:]K'C/Q_X%\=>+?!/AJ/3YM3M?!OBGP#&^OZ1XB\3WM@#?:@FKZ5>P6C2K8Z
MM;7DYO(]ZCK5</6]E%8;%3Q-##T7*4:M*G'%4<-&>*?+!QCA\OJ3E+$1Y*WM
MI0KUL+*=.<,%A53_ '5:G[1O$4%1Q%>KRVA-2H5ZSAA([NI4Q=&,/J]7FA:$
MJ,*].%=5:U;>^!?[8WPQ^-'[.>G_ +2FHRK\*/![6^KGQ/8?$O5]%\.W7@?5
M-$U&YTC4]!\5:CJ-[8:/I.I6VHVIM&6[NH8_.DCC+AI 3\Y? '_@JG\#/CCX
MH\-Z)J>CWWP>T?Q9X-U[Q?X?\9_%'Q7X)T7PMK4ND?$=/AG:>&]%U4:W);:K
MX@UK67$^G6MG+(MS"T4-BU]-/'GP6R_X)L_'3P'<^//"OPQ\;_#23X/Z=^U'
MX=_:G^#_ (.^*WC#XM_%#4K_ %Z#2K_2/&7@OXR^(O'5KXMU_7]%\0WFK7GQ
M T[6AK6O:IH_C2STR1TOHXY;VOGN;_@D/^U1;^$_%?A8>-/V5?%'_"2?!OXH
M?"S2=2U/1O'WAN3P)<?$SXN0?$^35] MHO#_ (OCGD\/I;+I=C-'+H\UQ*(+
MAHK;R%)*<Y5,71KNG.E@Y0<IX1V]HI2R18F,'6O.49QSJI/ PDW[.G]1CB:[
MJ4,="#BK"HJ4J,*D'B(XK#QCBTE*G[&6;U:5:3I34%*-/*:>'Q=3D?-.ICIX
M7#VK8*=4_>N7XX?!J"^\;Z9-\7_AA#J?PVT[^U_B'I\WCOPO'>_#_2?+,IU/
MQO9R:H+CPGI_E?OOMFOI96WEKO\ ,V+DT[/XV> ]1U,MIOC'X?:EX/C\%7'C
MFZ\96/Q$\+7-I:Z1:WDEM+?RV,-[+,- CCBEN)O$QF&DPR1O;2S"5'8?D!\-
MO^"2OB3PK_PLZ?Q?_P (#XW\3^,'UFYTGQSK'QK_ &I;F[MX/%WC;P[XZU_P
MS9^"+;Q;HO@/X=IHFJZ,'\)^-OA]I=KK:ZC8Z'K%[I$4D=]:3PM_P2Z_:&U+
M4=4U#5/'?P(L=1U3X8:+X=O_ !%I>CZNVL>(O%/A/XTP_&;PUI?C^UTKP;X-
MT[QSX.D:V7P9XCU?4!:>)=<L9[[Q!=V4FHW]U;,X.5L/&H^24J,98J<(.I1H
M5)8?&RGR0YH8C%*E4AA5&G!T)RJJ=.,ZE.MAIU-ER.G6G>6F)]GAZ3:C5J8=
M8C 1]K4;<J5&4Z53$SUE6]SEC*%*K3Q#H_KG)^TS^SI#X<TGQG+^T#\$XO!^
MO)=/H7BN7XH>"4\.:W'97$=G>/I&NMK@TO4DL[N:*UNFL9YA;W$B0SM'+(J'
MVN">&ZA@N;>:&YM[B%)H)X)$EAGAF42130RQLR2Q2(RNDB%E=6#H3N#-_/W\
M6_\ @DS\9_B#X[\8_%/3;']DW3?&'Q1\'?&W0O%FFSV'C&+0_"NJ_%CP/H/@
M:VD\&W\?@>\U+4K/3ET/_A+M2FU*VT>?4-?N6@2SADC_ +8;]OO@QX9\3>#?
MA/\ #/PEXT?09O%OA/P+X9\,^()?"UQ?W6@3ZGHFCVFEW5QI%QJMEINI26-P
M]D9X#?VD-P%?;)'N7>;II2H2J5$Z-:+P\G0YXU%SU98V->G"JE%5%A5A\+-X
MA4X4ZZQ\%3@E1E*64VXU*$87J0G];=2IRRIN"I/ /"MTY7L\3'$XJ+ASSE2E
M@9RE+]_&,/4:YKPG_P B]HG_ &#K;_T4*Z6N<\)C'AS1!Z:;;K^2+_C5F@NL
M_P#'_P"$_P#L/3?^HUX@K=(P"V<<-R>W^U^/Z9SFL+6?^/\ \)_]AZ;_ -1K
MQ!6\/GZ]NF/U_I4RZ+JT^]NE]O(#\6M:^,GQ+\#>.OC%X@C\>^,;RZT;PU^T
M%K'@W5[K7]>UGX>?%*?P_I37.C>&O#?A.[N[CPUX2UOX326<]QJ<EC96T^J1
M03'[1J227>[[._9WU#7- ^)WB7X>GQCXI\<^&Y?A3\/?B(-3\6Z_J7B6\MO$
MFOBZM]7FM-0U.YOKFRT_73$NJ6^CVTD6DV.2FDV=I:X@KV32OV;_ (-:1XDU
M#Q99^"(!JNI'77FMKO6?$.H^'K2X\4P_9_$UUHW@[4M7O?"'AZ\\20,\&MWV
MA:18W>I1/(E]-<?:)U;I?AQ\'_A]\)K;4+;P+X>.CC4C;?;+BYU;6]>OYK>R
MC,&FZ:NJ>(M3UK4K?2-)MO\ 1=*T>WNH])TNWQ;Z99V=N%BHH-1I4H2U<,)2
MH2M9J4Z;QW/=NUH.6)P];G24JE7#04Z5E"I#.K%SJ5)P]U3Q5:LDW\,:D\#*
M$M+^_"GAL30C%N:A3QE14ZD8\U.7P9_P4 ^-]Y;^"3\+C\%/C;+;W7Q[_92T
MRW^)B>&O#P^&,\C?M%_![77N(=;/BZ/7)K:&*"73YC%H N!J$4Z"$6L+WX_4
M6OP?_P""H7QZU-/B3X-^&_AG5;BQ'PUDTOQOJ$MO(=B^,#-!J6@3O!(OV>6?
M08;:#4;?[0LL<<\RRQX99 ?T9_9?_;!\ ?M!^'M$M)KN+P]\17TNW?4_"^H2
M);G4+NVB2+4;WP[*Y"ZEI_VL2E$1OM4",$FBW*6K\NR;Q7X9S3COB+@1XBGA
M<?DM;#8?!UZ]>$:6;XGDY,PP^%YN51Q&!Q-L.Z3FY8A\TJ*:A-1_6,X\(^*<
MIX!X<X_6&JXO+\[HXC$XS#T*$Y5,GPW-&678G%./,YX?,,+?$*M&FH89*,*S
M7M(-_8]%%%?J9^5A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<IXT\5Z;X%\)>*O&>L^;_ &/X0\.ZOXFU3R4::<V&BV-Q
MJ5V(8D!:24P6KA$&6=B!@L:ZNL77+)]0T;5K%++3=1>^TV^M%T_6"PTF_-Q;
MRPBSU1HX+N06%R9!!>;+>=_L[2;8IF(C//BO;?5Z_P!7DH5_8U?8SE!U(PJ^
MSE[*3@DW-*IRMQ2?-:UG>STI<GM:7M8N5+VE/VD5)0DX<\>9*;TBW&_O/2.]
MF?DC%_P4]U_P?H\VM_%OX4^'M-@\?_ >R_:$^ ,7@7Q;<ZZ_B[P_J/BKP_X/
MB\%^,)=2TO3XM%\7V6J>,/#-Y=W&FF]TF>UU"Y6TFEN-.NXSQGQK_P""J_C_
M .!WAWQ)H?BSX/>"K?XQ> OC!H/PZ\<V\GC/6(_AG9Z7XI^%5_\ %OPCJEAX
MA;0_[5.K>,;&P?P-X>TB]L;=KKQXT=@DDD%U:E^K\.?\$J?#T?@CXL0ZE>Z5
MX1\=>-_"^E^#OAEI7A'Q/\2/&7P_^ /A_0/%0^(>GZ/X"F^*FNZ]KMGIVK^.
MDAU/6M.\-VGA/PQ8Z=9Z7HWACPGH[6UWJMW]-?!C]F+XG>"+7]H[QWXR\4^!
M+KX[_M'ZWX5U#5[_ ,/Z?J=YX'\%6G@CP=I_@7PI#H0UFRM-6U:[T_3[2Z\0
M2W6HVEL\VNWS6Y'V*UCF=S4FJJIITZT*"J\K<:L)-9S1Q&%PM*HK>TQBRAU<
MOQV(JKZJYTGBHJ52=)U>:%U*/M6ITI.I352$)P4*DLKIT)XFK2:YX82&8^UQ
MN&H4I3KMRCA^?V"LO8_@S\=;SXTZS<2:)X6FTSP=HOA/0Y_$.L:I/)'?VOQ%
MUJVL=5N_ EI8+!Y4Q\(Z5<F/Q->RSQO;ZS<0:1%$US8ZKY?TG7Y*:O\ \$Z/
M$EI^U;\!OC+X+^(FG:=X#^%$'A/^T5U1]9?XAQ/X?3X@2>+- T">Q:'0KC0_
MCCJOCJUU?XGMJK1375YX=TMOLNJQV.F06WZUUO%QG3]KR>QD\1BZ?L>9S_=4
MZS='$1J.TO8UE.4*%*K"G7I4J$5555.GB:ZIJK"I*G-^TBJ&#FL0K14JLZ"C
M6HNFKVJTG3C.M4A*5&K4KR]E[+EGAZ)7/:?_ ,ASQ#Z;-)]?^?>XZ_Q>F>V/
M?=70USFG?\ASQ!_URTK_ -)YZ#84_P#(RQ_]@&;_ -+XZZ*N=/\ R,R?]@&7
M_P!+8:Z*@ HHHH ^,/&W_)_/[+__ &9_^V]_ZMW]@+Z_Y].E?9]?&'C;_D_G
M]E__ +,__;>]?^BN_L!>O^?3BOL^ICU79V^Y) %%%%4 4444 %%%% !1110
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MX>O_ #'G26#^S8;*.[MFN6\^>TF"!G)>WEM;K%U6)^WY_P FYS?]EL_95_\
M6I/@[7VE7SV.X2X7S.GBZ>.R#*<0L<I?6IO X:%>JYS51U)8FG2AB56]JHU5
M7A6C6C6C&K"<:D8S7T&7\6\4Y94P=7 \0YOAW@)Q^J4UCL5.A1C3IQIQIQPU
M6K4PSH>R;HO#SHRHRHRE2E!TY.#_ #OT+]H/XF_LZ:I8?#_]J6Q.M>%9)8]/
M\*?'WP[:RRZ3J<.\1VUOXXLXXR^EZFD6U9K_  LA9 ]Y%?1RS:^_WWI&KZ;K
MVG6>KZ/J%IJNEZA ES9:CI]Q'<VEU!(,I+!/"SQR(?5&.""&P0PJMXA\-Z)X
MKTF^T'Q'I&GZYHVI0M;WNG:G;QW5K<1."K+)%,K*3@Y5@-RG!4@C<?@74_@I
M\6OV5]0O?&7[.5S<^/?A=),U]XD^ GB&]FEETR($O=WGP_U69IIH)EC =-/D
M1IP5*K_:Z-%IP^7Y^)>"E:J\?Q9PG2LE5M+$\49#15OXL8IU>),NI*-G5@I9
MW0IZSAFCYJD?J>3AKCC^%]1X1XOJ-7HMQPO"O$-9M?P9R<:7#.95I/\ A5''
M(J\W:$\J]V$_T8HKY_\ @?\ M&?#SX\:9<2^&;J?2_$FEE8O$G@?7U73_%/A
MV[ =9+?4-/=M\B++'(([RV,EK+M/SJZL@^@*^ZRS-,NSK T,RRK&4,?@<3'F
MHXG#SC4IS2TE&Z=XSA*\*E.:C4I3C*%2,9QE%?"YGE>99+CL1EF;8+$9?C\+
M)0KX7$TY4ZL&US1E9JTZ<X.,Z56#E3JPE&I3E*$HRD4445WG %%%% !1110
M4444 %%%% !1110 4444 %%%59XA<030,TB+-%)"SPR/#*BNI0M%/&ZR0R@-
MF.2-@\;A71@P5JF3:6BN[.R;M=]-;/=V6S?9,.JOI_EU=C\@O&7_  4"U7PW
M_P %&OAE\$X?&?AN3X$>*;W7_@+K?A>/11)X@M/CC-X<M_'_ (8\=W'BQ[4I
M;^')!I^J?"E="2[B3_A)+K[9/#=3R::%\:_;?_X*(?'3P_XY\.:9^S5=S^!/
M >F0?M/^'];\?^-/AUX7\7>&?'?CWX._!WQ)XRAT_P /1R>.+#Q596_A;7]
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MZK'73?$3_@G#^S1\4D\0Q^-+#XDZJ/%/A+7_  3JS#XP?$>UE.A^*[/3M/\
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MIVQ]K&\-_?<%JFG%U8XBI14HO5>UI86M5B_A]FJ<N9^UBCS_ ,;?\G\_LO\
M_9G_ .V]_P"K=_8"_P ^W2OM"OS1T?XV>$_BS_P4"^!UEX6T;XKZ5=^#?V1?
MVS[/5Y/B=\!?C9\&K*\N;_XT?L,002^$]2^,7P_^&]A\0;5)]!N);V^^'T^N
MZ=IUO)I5SJTEK!XA\,74OZ75E#2_R_%7V_K\#0****L HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\<^(OP&^$/Q4@:'QS\/_#.
MO2')6]N-/AAU&-R,>9'J-LL%V)%'W6,K%3R"#7L=%<>.R_ 9GAYX3,L%A<?A
M:BM4PV,P]'$T)_XJ5>%2#\KQTW.O YAF&68FGC,MQN+R_%TG>GB<%B*V%Q$/
M\%:A.G4CYVEKU/@27]B_7_ DDNH?L^?'OX@?#24#,/AS79_^$T\&R!#N6VDL
MM0FCO(87(12ZW%RL8 9;9\;6:_Q<_;!^$**OQ*^"6B_&G0+=D6?Q=\$M39=9
M$ Y>YN/">HVT5U=3*@\UHK6RL;5?NM>X D;[]HKX]\ X' MU.%LUSGA*I=M4
M,KQGUO*&[IJ,LBS>&8933IO526"PV#JM/W:T&DU]FO$#'X]*GQ7E62<7T]%*
MOFN"^J9NDDDY1S_)ZF7YO4J:)Q>-Q6-IIK6C)-I_'W@7]M[]G_QI>)H^H>([
M[X<>)F(CE\-?$[2Y?".H17(;RS;"\NGDT:YG\P>6(;74YY"Q *@D5]8V&HV.
MIVZ7>G7UK?VLJAX[BRGBN(&5@"&66%WC(*D-]X\'GGD\/X[^$_PV^)5J]GXY
M\$>&_%,4L;1-)JVG6\MTD9R"L5^%6\B&.@BF7!^;.:^4;W]AO3O#,LFH? 7X
MN?$7X,7Y=I8=/TW4Y->\*>87W;9M"U&956$X *6UQ =A(+?,-L?6/$3*?]YP
M&3<886G=?6,KK2X=S=QTU>7YE5Q>4XBK+[4HYM@(.7PTHIQ2/JWASF[OA<QS
MK@W%3M^XS6A#B3)^=M:1S'+*.#S;#TH\WNQGD^85%%ZUI--O[VHK\_[OQS^V
ME\&8)KCQ=X"\%?M >$-,AFN+WQ#X&U2'POXJMK"UC9Y+N]TC5MEN[I#&TLJ:
M?;Z@S;2[S)EFK$_9$_;<L?VB?B3\2?"&I::_AYS<_P!N^ ;.YNUN9'T"RMK7
M3[[3I&"Q@WXDMVUN58E\I1>W:"1A'%OFCXE<._VQE'#V8T\VR+.\ZQ%7#8++
MLZRO%X.52I1P\ZTG2QG)4RS%TW.,,/&>!Q^*B\15I4[ISC?2MX9\1_V-G'$6
M6U,GS[(LDP]+$XW,\DS;"XV%.G5Q%.@HU<%S4\TP=2,)RQ,J>/P&%:P]&M4U
MY&E^C=<YX4_Y%[1O^P=;_P#H"UT=<YX4_P"1=T3_ +!UOQ_=^05^@GYZ+K/_
M !_^$_\ L/3?^HUX@KHJY#Q3<26AT"ZAC$LMMJE_-'$1.XD>/PQXB=4V6MO>
MW3C(&5MH)IF'RQ12.52OG#X>_%[Q=XD^*5WX1M]8C\56,.E1:YJ%W;>#7TCP
ME96+/%%-IV@^(DUG4->&M6$MW&LT/BW1K>SU*2VN]-LKZTO;&_V3&7//V:6O
M+*5]U:,93ULKJ\83=VE%<MI2C<4GRQYWM=)=W=QCULKWFO=OS-7:3Y96^KI=
M1L8+J"SFOK.&]NE?[-:2W$275R(U+2&W@=Q-,$4%W,:,% )?&,E;/4+'4//%
ME>VE[]FF:WF^R7$5Q]GF7AX9O*>3RI5XW1R;74]0.M?C=+XE^)1\4^+?'&EW
MFF^.?B=X]N_VBO!Z^&+[2-.G\3?!QO!/A?6)/!>H^%M1,LFKZ/83O9V-I?1!
M4CU";5[:2$LTJH?H7]DY-#L_B1H]M\.98I_!FH?LX?#O6/%DEDS-#<>.;NX<
M_P!I:WEB6\4:C;M<RZE+<,VH2[3]L=F$9IT5[2,974;T*-6V]G7H9ABH1DTT
MN54<N<?:1YH2JUZ=.*]R:)JR]E*2MSJ-6K335]51Q.!P<W;>$G7QG/&G-1G[
M'#5:LDE*FY>D_M^?\FYS?]EL_95_]:D^#M?:5?E[_P % ?$O[02^!YM$'P?^
M%\WP7_X7M^R?$WQ%D^-^OIX[%DW[2'P9N);U?A3_ ,*4N-&-W'KA;2(K%OB/
M)')IVW7&OO.8^':_4*F7T^=_PBOT"BBB@#Y+^.'[*/AGXHZE#X]\&:O>?"OX
MPZ5NFTCQ_P"&!]GDO)DVO':>)K*%HH]:L)&14E\X?:1&6(D928F\[\!_M2^)
MOAWXBL/A3^U?H,7@CQ-<%+3PU\3]/WR_#KQZ4<PQRM?F.*/0-3G4(SK=^7:&
M02I=)H\K06;_ 'Q7#^/_ (>>$/B=X=OO"?C?0-.\1:%J$1CFL]0A27R9"K*M
MS:2G]]9W<0),5Q;LDJY8!MKNI^$S/A*OAL=7S_@[%4LDSJO+VN882I3G4R'/
MY)*RS;!4FG0Q;Y5&&<8!4L=#W?K"QU"/U:7W66<74,3@</D'&6$JY[DF'C[+
M+\92J1I\0</1;U>3XZJI*M@T_>GDN8>VR^I9_5G@<1+ZU'KH+B&ZABN+:>*X
MMIXUFAGAD66*:-\.DD4D;.KHX(*LIP5^;)P<VJ_-Z;PM\;_V-I)-3\#)K'QQ
M_9Y@9I]6\#W4OG^/OAOIH?,MUX:GD9I-:TRS3]Z;=4D:.W#BZM;9(YM;K[$^
M$7QL^'7QN\.1>)?A]K]MJUL547^G2*;36]#NMN9-/UO2I<75A=Q,2A\U6@F
M\RUFNH&65NS(N+*&/Q;R3-\-4R#B:G!U*F38VI&?UFC"RGC<GQJY:&;Y=S/^
M/A?WV';]GC\-@ZW[LX\\X2Q&782.=91BJ?$'"]6I&E2SO!4YQ^JUIJ\,#G>!
MDYXC)LQ2_P"7&+_<XA?O,!BL91_>'KM%%%?7GR(4444 %%%% !1110 4444
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MW_JW?V OY]:^SZ47=?U_P"@HHHI@%%%% !1110 4444 %%%% !1110 4444
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M<:]2OAJE:<71E*FHNI:,92Y.5MME<WX3!_X1W0S_ -0ZW_\ 1>*Z2N;\)?\
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M&97F-/?VN S/"3K8#&0LKMX?$5'%:3C"2Y36HHHKWSP HHHH **** "BBB@
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MMV4^CV[Z1/;:\4,VJ2W'VS5+C5F^\?V4?%VO^+/AE?IXDU6^UV]\)?$+XC>
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MBBB@ HHHH **** "N;\)_P#(NZ'Q_P PZW_']W_D5TE<YX4_Y%[1O^P=;_\
MH"T +K/_ !_^$_\ L/3?^HUX@KHJYW6?^/\ \)_]AZ;_ -1KQ!714 %%%% '
MQ;^WY_R;G-_V6S]E7_UJ3X.U]I5\6_M^?\FYS?\ 9;/V5?\ UJ3X.U]I4 MG
M_B?_ *3 *^)_VX/B_P#M)?!WX>^$];_9C^#]E\9O&6I^-(M(UW0=0T#7_$$>
ME^&GT;6+R36$MO#OB'PY=P.NIV=A9+<37<MMBY,1@\R6*1?MBBNC"5J>'Q5#
M$5<-2Q=.E)REAJ_.J59--<M1PE&?+K?W9)W2U/+SK+\1FN5XS+\+F>+R;$8J
MFJ=+,\ J+QF#DIQG[7#K$0JT>>T7#]Y3G'ED]+V:_G\'[=G_  5J/_-B.@#D
M<GX;?$\<GW_X6+QCGGZ8KS+X8_\ !0G_ (*L:[%XN_LG]EJQ^((T_P 7:I9W
M<M_\+_&41\+W.89'\)VQT;Q-X95[/3 X^SOJJ7^I8E87&I7(6)!_2A4"HB;M
MB*NYB[%%"[V)RQ? &YV/+,1N)^8G%?2KB3*8PG!\(Y*W-PY7SXNT>62O\564
M]5HN2=/^_P Z22_*JGA=Q;/$86M#QDXYA3H>W]K2]CD_[WVM.,(:PPE.FO9N
M/-^]HUWK[GLY7D_Q)^#7[9G_  4Y\6?%'X9^&OB)^QGHGA+X?>(O'/AC1?&O
MB>#P#\1;";PWX7U'6;2TUW6X[R]\=ZEI]H^EZ7/->"XOK:XMX?+$D\,JJ\5?
M27CR^^#VM?M$W%W?%;+7/ 6OZ5+ \UCKFH>(?&_Q*U+[-IGAG2]/M[7[,9/
MO@TWL6J:C;PW$-C>7S-->2Q6^D2W5?I717A9EC,-CL3AZ^'RW"Y7&A3J0=/
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MBOD_P[^VM^S'XE>.&U^+/A[2;B0#%OXH34/#$X<[L1M%K]KI3K)E"NS&[<0
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MG_']'_E??=2>)M(_MS0]3THZM?:''?VY@GU/39DM[NVM]X>Y$%Q(,6SRVZO
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M2Y7S6@TIOE%S+5]FUU^S+ED]M4G?5732YD^5IGIE%99U;3 H8ZE8!2"P8W<
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MF 50O+^SL(UDOKVULHW<1I)>3Q6\;N0S!%:=T5G*H2%Y( )[,:OUX?\ '+X
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M$O!O_!//]FWP)XI\,>,M TGQ/'KGA+7M,\1Z--<>*=0N;=-3TB]M]0LGGMI
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M-.,U3BE&*"BBBI- HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YS3O\
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MZO=^8]?Z7_!]?Z6OQC_PEO[?'_1O7['_ /XEQ\7/_H*Z7_A+?V^/^C>OV/\
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M15TKR>R5VM79;'BG_"6_M[_]&\_L??\ B7/Q=_\ H+*/^$M_;W_Z-Y_8^_\
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M74<8N348IRE)J,4KMMMI))=6W9)=?F?G5\#_ -A.YMO <2_&;XP?M<S^/?\
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M"_PR_P"BM?MB_P#B;7[5G_SVZ^T:* MZ_>_ZZ?U=GQ=_PPO\,O\ HK7[8O\
MXFU^U9_\]NO)?C[^PG/<_!7XN#X&?%_]KR#XU3?#KQ>GPIGOOVV_VE&L8?B
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M75MFI+5)IJ4;QE%IIQE%N,D[IV",E)7CM=K5----J2::34DTTTTFFK-7$/\
MR,L?_8!F_P#2^.NBKG3_ ,C+'_V 9O\ TOCKHJ0PHHHH _*W7=(U,_$'Q1X
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M$?;_ *#NO?\ @9%_\C444 '_  C[?]!W7O\ P,B_^1J/^$?;_H.Z]_X&1?\
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-56<8QDGDG@9** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img248422670_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_4.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $6 F(# 2(  A$! Q$!_\0
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MX/\ @I<?%+XC_"OQ->V-S9^'=4\1>/\ 1[M/ NEZ-J-Q#'8377@F]\2^)]\
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M_A'M/O+JZT[0/M@EE%Q_8]K8&:*1XG&R21*]>K+_ +6T_P#Z"-C_ .!5O_\
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M8K>VMXHX+:W@1(H8(8D$<<4,:!5CBCC1%C15545-@%5O[6T__H(V/_@5;_\
MQ=']K:?_ -!&Q_\  JW_ /BZ25E9/2_-RK2-W=MV75MMWWU=]Y75DY<SUE9*
M[U=DHI*[ULE"*2O]E=E;4HK+_M;3_P#H(V/_ (%6_P#\71_:VG_]!&Q_\"K?
M_P"+IC-2N5U7P?X:UO7?#7B75-'M-0UWP?)J;^&=2N!(TVBR:O;0VFI260#B
M)9;VTMX[>21D:18@51XPTF_6_M;3_P#H(V/_ (%6_P#\71_:VG_]!&Q_\"K?
M_P"+I-:IIV:V:WVMONODT#U37=-/T>C7HUHT]&M'H:E%9?\ :VG_ /01L?\
MP*M__BZ/[6T__H(V/_@5;_\ Q=,#4HK+_M;3_P#H(V/_ (%6_P#\71_:VG_]
M!&Q_\"K?_P"+H U**R_[6T__ *"-C_X%6_\ \71_:VG_ /01L?\ P*M__BZ
M-2BLO^UM/_Z"-C_X%6__ ,71_:VG_P#01L?_  *M_P#XN@#4HK+_ +6T_P#Z
M"-C_ .!5O_\ %T?VMI__ $$;'_P*M_\ XN@#4HK+_M;3_P#H(V/_ (%6_P#\
M71_:VG_]!&Q_\"K?_P"+H U**R_[6T__ *"-C_X%6_\ \71_:VG_ /01L?\
MP*M__BZ //\ QA\&_AMX\U./6_%/A2SU/6$TZ31VU&.ZU+3KNZT>5O-DTC49
MM*O-/;5-+E<_/I^H&ZM6WL&A_>/7H6F:;8:-866E:596NG:9IMK#96%A9PQP
M6ME:6R+%!;6T,2K'###$B1Q(J*B*H%-_M;3_ /H(V/\ X%6__P 71_:VG_\
M01L?_ JW_P#BZ23BN5.T;W<5HG+5\UMN9N4FW9_%+K)MIJ[YG=M*R;U=O=5K
MO6UH15KVLDMDK:E%9?\ :VG_ /01L?\ P*M__BZ/[6T__H(V/_@5;_\ Q=,9
MJ45F?VOIW_00L/\ P+@_^.U)%J%E,ZQQ7MI-(Q*K''<Q.[8&>$5R6./F]-M
M%^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BJ%_>VNFV5YJ-]/':V-A:S
MWMY<RG;%;VUK&\\]Q(W\*111M*S?PJOY^9?#KXQ^&OB;-*GA[2?&-M;#3X=4
MMM3U_P +:IH>F:C93E#;3Z==ZC% MTL\;I/&BJK>4V\JE2FY2<8I2<4I2L_A
M4E)Q;TT4N2?+WY)6^%V3:23>BD[1;^TURIV[V<X)]G.-[<T;[?Q'\ Z=\2?"
MUUX8U*]U/2EEO=*U2RU;2#9KJ>D:QH>IVFM:/JED-0LM1L'N+'5-/M+A8[S3
MKJVF\LQ30R1R.C>:P?  V/AS5/#]A\3/&%O_ &[>7&KZ]>W.C_#S6#J_B'4-
M4N=4U?7KG3==\&ZKI4=YJ37*VQM[2RMK&TM[2U-A;6MVLEU-]%T4<JY7'>,O
MB6MGHD[IMKWN6',K6FJ=)24O94^5ZZ>337DT]&NSCJHM?#S3M95)J7$?#_P1
MI?PY\'^'O!>BS7T^E^&M.BTZTFU&6.:]GC1F9YKEX8;:W,LLCLY6WMK>"/=L
M@A2)$C7J9;"RG<R365M+(Q^:26"*1FP HRS(7;"J%'^S5ZBKDY2E*<G>4Y.4
MGW;W?;7RLNUE9)1BHI16R5M;M_-O5OS9G?V5IW_0/L?]G_1H?E^G[NF_V5IW
M_0,L/_ 6#_XFM.BD.UME;Y&9_96G?] RP_\  6#_ .)H_LK3O^@98?\ @+!_
M\36G10!F?V5IW_0,L/\ P%@_^)IW]E:=_P! ZP_\!8?P_P"6?;_/K6C10!G?
MV5I__0/L/_ 6+_XBF_V5IW_0,L/_  %@_P#B:TZ* ,[^R].S_P @VQQ_U[0_
M_&_Z4W^RM._Z!EA_X"P?_$UIT4!:VRM\C._LK3_^@?8?^ L7_P 11_96G_\
M0/L/_ 6+_P"(K1HH$DELC/\ [+T[_H'6/_@-#_\ &J9_96G?] RP_P# 6#_X
MFM.B@=K;*WR,S^RM._Z!EA_X"P?_ !-._LO3L_\ (.L?_ 6'UQ_<_N_Y[5HT
M4!:^ZO\ (SO[,T__ *!ME_X#P?C_  =_\YH_LK3_ /H'V'_@+%_\16C10+E7
M9?<9W]E:?_T#[#_P%B_^(IO]E:=_T#+#_P !8/\ XFM.B@9F?V5IW_0,L/\
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M<?\ !)?QGX@_X)W?MR^&[KP5\.XOB3K#>"?COIEYK-OX6\+^(=;GE:^TWQU
M]U'9V6@:O<6UMJ>F:Q;(LMC%>S7%_#=V$DM[;53P>,KT<5BJ-!SPN"5)XJI%
M*7U>%:7LZ=2HE>2I2K6I.IR^SC4G2A.<9UJ<)JKB<'1>&H5:W)B\6ZJH4Y22
MC5E1M*=*FG%<U2-#]];F<I0C4<:?+2G4C_:Y17'Z59>'-=TW3]8T;59=7T?5
M;2#4--U32_$VJ7NGZE97,2S6U[9WEMJDUO=VUS#(DT-Q#*T<D;(Z/(AYT?\
MA&]-_OZG_P"#S7/_ )95([R_E_'_ (']>IOT5@?\(WIO]_4__!YKG_RRH_X1
MO3?[^I_^#S7/_EE0%Y?R_BC?HK _X1O3?[^I_P#@\US_ .65'_"-Z;_?U/\
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M_O:I_P"#W6__ )84!>7\OX_\ WJ*P/\ A&]-_OZG_P"#S7/_ )94?\(WIO\
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MNQ@OY(?IVN7TKP?X5T74M3UO2/#6AZ5K.M'.K:K8:99VM_J6UM^;Z[AACGN
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M" PR#_%S^-3T44[6VOKWU_K]>I2T7?\ X:VBZ>@4444#"BBB@ HHHH ****
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M+>*ZMKF!UDAN+:=%F@FA=2RO#-$ZO$ZLRNC!_>OQB_X*%?\ !*"+XX>+]/\
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M_H+:#_X3][_\TE'V;Q%_T%M#_P#!#??_ #25T%% &#Y'B'_H*Z'_ ."&\_\
MFBH\CQ#_ -!70_\ P0WG_P T5;U% N7SE][_ *_X?TMS_P!F\1?]!;0__!#?
M?_-)2_9O$>?^0MHF<_\ 0!OLY_\ "DZUOT4 U?O_ %;_ ".?^S^)/^@MH/\
MX3][_P#-)2_9O$7_ $%=#]_^)#>__-'Q6_10#5^_R=CG_LWB,_\ ,7T+\- O
M1_/Q&:=Y'B'_ *"NA_\ @AO/_FBK>HH"WF_DVETZ?UN<_P#9O$7_ $%M#_\
M!#??_-)1]G\2?]!;0?\ PG[W_P":2N@HH&<[Y'B+_H*:+_X(+[_YI*D\CQ#_
M -!70_\ P0WG_P T5;U%)*WX?@DOT)Y?-_>_+_+^M+<_]F\1?]!?0S_W ;T?
MR\1@4?9O$7_06T/_ ,$-]_\ -)7044Q\OG+[W_7_  _I; ^S>(O^@KH?O_Q(
M;W_YH^*3[/XD_P"@MH/_ (3][_\ -)7044 E;N_5W,#R?$/_ $%=$_\ !!??
M_-#2^1XA_P"@KH?_ ((;S_YHJWJ*!<OF_O?EY^OW^A@?9O$7;5M$_P#!%?9_
M]2,4GV?Q)_T%M!_\)^]_^:2N@HH&E;O\]3G_ +/XD_Z"V@_^$_>__-)4UO#K
M:RH;K4-*GMP3YD=MH]U;S,"IQLGEUR^2/Y\?>MY25&P=G3:HH&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115>@"Q1110 4444
M %%%% !1110 4444 %%%% !1110!S7BRV6[\+^);5[&ZU%+G0=6MVTZQF\B\
MOUEL9XFLK2<,I@NKD/Y,,NY?+ED1\_)D_!O[)FA>!M.\=I>^!1KDOVKX9Z<_
MBG3IO#\NB6'@?Q1)_8UEJ7AW5+BX\,^&[K4=2NYM*::*TF>Y72Y;34)K>SL8
M-10R?:'Q.T3Q9KOAL1>"=:@T;Q!8:QHNL6YO)[VUT_58=*U."]N="U*ZTYEO
MK>PU:WMY;*Z>WW;T<)+'-;O/!)YG\*OA+XQ\$^*?^$GU_P =7_B*\\2Z'J5Q
MXV@GUG6[O1[[Q1>ZLEYIW_",:!J%[>:9X;T3PSI9FTJR338;::\MY8Y+_P ^
M93)4T'R5*T[\OM(*DV[WM3P^)=+6-^>%6>)J1<7:4:U&C\-.M+FSKKGA3@H\
MSA4A45K.W/B<,ZC2=N6=..'IR;6DZ5:?QSI+V?TG117SG\??B)K'A7P+\1SI
MTVK^ 9-!\%WNMZ;\3]2C\)MX6;5(H\VVA60U'7SJ?]N7MPRVML+OPZ;-IF_<
M374_DV\ZG/D5WT3>Z6BU>KLMKNU[NW+%.32>T(N<HQ6\I1C?MS244WUM>2O9
M.RNWHFU]&45YU\*O%$'C'X=^"?$D.M67B'^V?#6DWD^KV$]I=6MY>O91+?2K
M-8$VC.MZEQ%-'#L6&97@*QLA2NLNM4G@E>&/1M5NE3;B>U&G^3+E%+!!<:A;
M3?*6V-NA'S*VWY-DAUG%TZE2G*W-3DX.VJO%M.UTG;31]48PJ1G"$UHIQ4DM
MW[R3MI?75&S16!_;5SU_X1W6_KC2O_EKG^O;%)_:]S_T+FN?EI7_ ,M:DT.@
MHK!_MF[_ .A<US\M)_\ EK1_;-W_ -"YKGY:3_\ +6@2=]OR9O5Y!\<_@QX0
M^/\ \+/&GPG\;V@NO#_C/1Y],FDVYN=,O,"33=:L')#17VDW\=O?6Y5D5V@,
M,H>":=)/0?[9N_\ H7-<_+2?_EK1_;-W_P!"YKGY:3_\M:UP]>OA,10Q>%JS
MH8C#585J%:FW&=*K2G&I3J0DFG&4)Q4HM;-&5>C1Q5"MAJ].-:A7ISHUJ4X\
MT*E*I%QG"49*THSBVI+JF?EM_P $U_C#XK\-R>/_ -AWXSW3CXI_LU7(T7PE
M?W6Y3XU^%,$GD>&]6TN25O,O[32K Z?!;RKEH=,NK*TD\N6RE0?K/7Y$?\%(
M/A3XUT:^^'_[:7P6\.ZM:?%C]G6Y&I^*+>SBL<>.?A>CK+KVCZJ;&^GN;^UT
MNR:^>2)X+@PZ=?7US"89K&-Z^_\ X&_'OPW\>_AEX-^*7@G3-6O- \9:3!J,
M&R32)&TZ\YAU#2;QCJ43K=:7?PW%E,9(XBYB$JIY;HQ^MXIH4,RP^%XSRZE"
MGA\YJ2HYQA:24899Q#2A&>*IJ*TAALSA+^TL%I9>TQ.'6N&<5\QPY7JY?6Q'
M"^-J2J5LKIPJY7B:CO+'Y)4DXX:<F_BQ&7RM@,5K>3A0KNWUF*/D7_@HS_P3
M)^#O[?W@_1M0U"ZN_A=^T/\ #:1]8^"?[0/@]I].\9^!?$-N\-W9PW=S82VL
MNN^')+ZUM)I]+OWE:RDB-YHTNG7CS2S_  5^RA_P4T^.?[/_ ,1!^P;_ ,%,
M;;0O!'[1;VBP?L__ +1'B*233_A-^T?ID4BZ=I\^LZ_IEK]ETKQ-+,+>&\F@
MA43W=W!;:E;:=JLZ1W/]!/\ ;-W_ -"YKGY:3_\ +6OS]_X*;?L;>'?V[_V3
M_B=\&M2^'6F:WX_?P_J>I_!WQ)XCMM&>3P-\1X+*6/1M>T?4UU07NE7$JRR:
M=>2VSHEQ9W<T5W'<VGF1U\3*Z?,G_6FG]>?8^L3OHG9>CTO;7;L?4?P2\=?$
M;Q[;Z[JWB_2? NEZ3I?B7QQX0M%\*:GKVH7MQJ?@GQGJW@Z\O)O[4TVPMH]-
MOY/#UW?6@BDEN4CGMDE4,)#7OM?PY_\ !)[]D_\ X+J?L::3\4=>^$_@CP'J
MO@:Z\;:UX9U[X._';XFV5_8^(_$7A+5K_0O$/BGP&VAZWKUGX>U&/6]%NM!O
MM2N;S3FUM+833VU]:VNG7Q_5Y_\ @L)^WE\#!8VW[6W_  2#_:"TNU,\T.J>
M,OV>KZ/XM>%["&.25EOF@\+V7BE+6WEME20+JNNZ9^]+(9%(V@B]+VY;Z[=-
M/+STTWZC2=[74O/;LM.^_P#2/Z+J*_"_X7?\'$'_  3;^(-[::+XG\>>._@7
MXDN;R;39-$^./@#5?!WV+4+8NMQ;:CK-I)K/AW2Q&\,T9EU?5].19$\F;R;A
MTAK]0_A9^U9\!_C;I\>I_"#XI_#WXJ64HR+CX>_$#P#XJ5.FZ.=-#\5ZA);3
M*3M>&X6&6)ODD1'XJT[ZH3=MTUY_UJ?1M%<\-;N' 8>'=;*D9##^R2&4CJ"-
M6Y&/Z4O]LW'/_%.ZU_WSI7/T_P")IS3&=!16#_;-W_T+FN?EI/\ \M:H'Q;
M)3 =-OUN!((C";G0_-\S=M\OR_[7W[]WR[-H;=QCO0)NW^75^AUM%8/]LW?_
M $+FN?EI/_RUH_MF[_Z%S7/RTG_Y:T#-ZBL'^V;O_H7-<_+2?_EK1_;-W_T+
MFN?EI/\ \M:!)WV_)F]17/\ ]L7')_X1S7./;2N?_*K@_C3O[9N_^A<US\M)
M_P#EK0":>WZF]17B'Q'^,Q^&T.G7FH?##XD>(+#4]5T#05O_  Q!X+N(+?6?
M%/B/2O"7AO3;E=8\:Z#=K/J_B'Q!I=A!-#;SV<'VKS[RXM88YI8_1[7Q!>7-
MK:SR>%/$=E)/;PS/:78T3[3:/+&KM;7/V76KNV\^W+^7-]GN+F'S%;R)ITV/
M(D_+]?R!-/;4ZBBL'^V;O_H7-<_+2?\ Y:T?VS=_]"YKGY:3_P#+6F,WJ*P?
M[9N_^A<US\M)_P#EK2?VS<_]"YK?Y:3V_P"XKV_2@2=]OR9OT5@_VS=_]"YK
MGY:3_P#+6N2\<^*?%&E>%==U/PQX<9];TRPEU"U7Q"+;^R7CL\7%Y'<_V;JZ
MWB%[2*98&A+[9VB9TD0.A ;LK_U^IZ717SUX'^+.O_\ "K$^)OQ.T:RTC3)/
M"<'CZYG\+V\]S9:3X9DT"VUZZ:\CN=3NM2O;JRA>Z9_L-H6N88U\FT\]_+/$
M?#3]MKX$?%B7P_9>#=7\3OJOB?4[G2M'T;Q1X'\5^ =?GGM_#DWB];JY\/?$
M#2O".O:9I.H>%[6YUK1M=U33K+1M=LK::31+[47AD0*+YG)15W!*4TM7",FU
M&4K7Y8R:DHRE9.47'=.QJHQDXM1G*48RL^64H04YQC)I)RA!J<XIWC#WG96/
MKRBN+'C.Q\B"Y%G<M:W$ODP7 O= ^SRS;BODQ2_VQL>8-E=D;LV[ ]JYCQE\
M9/!7P\TZ/6/&UY-X:TEO$7AKPK+J-ZMM>1VVN^+M;T[PUX9T^[M]$N=7U&W?
M5M>UG3-.BN)+(6T!NTN+V6VL4GND$VY1A%-SG.%.$5K*=6I*$*=.*M=SG.I"
M,(I.4I2BE&\HIB=TWT2<GIM&*<I-]E&,92D]E&+;T5SUNBLLZOIBI:RG4].$
M5ZVRR<W<'EW;DX5+9S+LG;/:%G_3G4H3OT[??9.WXK_+:[N%%%%,#\9_$'[1
MFJ:1\<OC]IOBKXRGP5=_""_MT^&/[.UE'X&37/C_ .&/^%7Z5XVG\3Z5!KFF
M7GC_ ,0W6K^*[WQ+X8TS_A#-7T^PTNX\'RPZC#=73W4:>'#_ (*2?%#4EFL?
M"?A#X,^-[R+P=JGQ$F\2>%O'.MZMX*@T[3/ %W\0+WP0^J6&F7DO_">Z3%IH
MTS4[+;%%9MJ%I<S>0)/(?[<\??M5_#;P3X]UGP[J/ASQ=J]MX/UO0O"GCGXD
MZ+H&FWW@CX6>(/%L6E77A[P[XRUJ;5;/7+*]U6U\4^'KJ1=(T+7+/2K;Q!IE
MSKMQI5K=)(>VU+XW? ?PQI%IJ^J?%7X3^'M#U.T_MJSU"^\6^&--T[4++4+N
M6Q.I6D\M_!!=07NH07%LT\>\7-S%+$[R2(Y3R4I>P3YE>="G1HU;:?6*=-RG
MB9J3E*K+$\]'$5*?-"DXQMA52PE7D7UR]G[:\H:1;E5IIR3=*I[*,(QFFH0]
MCR5J<9*#FY592KRJ5Z4)GP)XR_X**?$'P7/X>TCQ%HGP3\'ZQKT?BC68=4\9
M^/=6T;PN^F:9\/O#_P 2-#T"RO+NPMKB]\7ZS:>([C1?L<:M#)>VB36?VI Z
M5CZE_P %1/$D_BOQ+X3\-^ _"]UK4'P[/BS1M(U[6M0TO5?#_B.V\2_"_P -
M7_AOQ[IH6;6;&"&;XSMMU"UTF"WFF\/3K8/J2.\D7Z#QZW\ ?B'\0=(2U\4_
M#3QC\3OAMH-WKFG:=IOB72=3UWPQX>\66U@)]<N-#L;^=X]*UNQL-,:SU.^L
M98)(HXIK&:,R%Y.9T#]IWX1^)_!?Q6^)VBV.LW_AOX4:_J_ASQ1J47AE%N]4
M;06@-YJNA)*\<FNZ%Y<D=U9ZCNBANK:V>YMDD1('EVO2YY7@U'V56HH*;C[.
MFG/"QJ\\DW-0Q%;#.3Y8I5Z/)]NM*7.HU/8X:"KQE6YO8SJ^RA;$8B=1XRE%
M4XNT7]4I3C&*?OTG*<E_#<?E9OVY?B%X$^)<_@3QKIGA/5@WQ'\7>#K^'2M?
MBO?$)U71?"W@_5=)\/?#SP?9Z?HGB[5=$U:\U_65_M_4K#7ETNZ@MX=7OK6U
MNDDL^-C_ ."DGQ3US5-/\.>#_"/P?\6ZIKFDZ;XGBUK1/&FN:CX5\+PWWA#Q
M[XKN_AYXON]/T^\N;/XF^&X_AA#_ &WHD>%M;+Q3IEY,D/GQI-]H67[6/P0U
M;Q'XPT?3]0?4M>^'OQ(\+?"W57@TNV=HO$/C;28-5L-1TR\DGB670H=,6^;6
M=9$D"68\.:S%,K_V5)780?M!?L[0:$/$<'QE^#5OX;F\2S>'!K<'C?PC'I,O
MBF>&.>XTC^T$U!+637)K6XCNIK/S&O&M+E+QD^S3H[Y1A4^KPBVI5E1P]-5X
MQLO:2IX:K"<Z3O=U5B<-*W,I.G4HT^9SJUJF(UIRIPJ592M.$I8B4(.:3I)U
M*\6HS6C^KNC6A:2Y;TZLTHQHTHTO.4^/>M^/O@;\0/&WAOQ?\.?AOKT/PN\,
M>+=#U;Q!XAM;BR^'VJ>+?!EGXDM)_B1%?QP6.@6EG<ZG%)93:ANMKK3#%J5R
MOD;X:^,?AI^TE^T/\7/$7@+PU\)O&_BSQ7<:!81/XSU77#\'-8\)ZQ?Z/\1=
M&TKQA?:EXM\)^&M TSQ;X7@\*7.LV?A[4/AK'H,TVK6WV:\_XF-C=)7Z Z#^
MT]\"]6T?Q7JM[X_\)>#],\*^)_%G@O7$\;:WX=T';/X-\5W?@&_U 176I.DW
MA^]U[3FL]&O9FC744FMD\J">3[*GH_BGQOX3^'OA&/Q==B$^&8V\.V-I/X>M
MX+J.2#Q)K6G:)H\E@+>2*WDLIK[7K*3S(9'B-M(\R>9L-;J=+ZQ+$PH/ZO5]
MC/#T6^:$7.-25!2E*+]I3J1K1YJ;4)57&#<XNFS)4ZD:$<)6JIXJC[6AB*W(
MH3E.G.E#$.-):0J0J4Y133DJ7/**4E-,^3OCU^TEKG@7X@_LNI+XVL_@_I'C
MSXL>(/!'B7X<_$3_ (0RSUWQQI,/PX^(6JZ9JUKJ-SK6K7.GZ4_BWP[X8BM&
MTL6EW<7]S;V%Q<)]N_L^?Y%;]M/7=*\%?$#Q)XS_ &O(_#>E-\/=#UR^UNUM
M_A!83?"#XTZOXWU_PUHOP-M+K7?#DVA::==L=.MKB]L_B''KFN:;9:)J.MOJ
M>G:=?)/:_IM8?&CPCXF^+VN_"*T\(>(M:U[P38VE]KGBA]-T!_"_AR]O[)-4
MT[29;B[UE/%']H7]DRW$%U8^&I]*\S]R^K)>YAKRG4_VT_V=[+P?\:_%^HM?
M)H_P1\?P?#[QYI<WA0OK-YXNNKNTT[2DT+1]IF\2KJ]SJ<<>F:C;[Q<K!=G>
MB6,^WG27LH)O5QJ5[W]Z6'J2H8-23?--6Q%>G4HU.9Q]O/"QA2GA9SP]?234
MJBE%Q2C&CAN73E^LTZM;'2<FK)MX:+PM:$4I^PI5I5*BQ485*7+^-?VLO%'P
M@^#'[/\ X\UM?"_Q8;XEZ3:^$M1\4^!-5@U#1-4^)NMZ-%-X&30[KP[_ &EI
M%_H7B[Q%:W^BW6HZ;-+;6]S<V3V:/:SR&+I_V<OVMT^*'B?XB^"/'MY\/O"O
MC/PGXRA\+:/HGA;Q;!XABUA+F'6KFTAAUJVFGTJ^UZ2R\+WMY>>'(9(-=T18
M)?[4TRUM9-.OK[V#_AH+X$P?VCI]W\6OA?I5UX4TFR\0ZYH>J>+O#%AJ'A'3
M9TLI[.]UW3)]0CGT-83K6FJ6NHX/)DU"T4LAO;7S)K?X]? 6/5?"^DV_Q?\
MA''KWQ$M]/\ $'@[3+?QGX474_&UIK4MY8:7K7ARTBU 7/B&+6)]%OK.RO[*
M.\%]+I]S;0S3O"Z)T.SK5I>QTK5:BITXW2IQG.E4HTZ:2LZJ]AC87^"5/EA3
MHPEAZE2KG!)4:2]JG["E!U*C][VDXQM.I5<FY^SE[;"-1YHRC-RE.K-5X4X?
MGM\6?C3^U)8R?M8^*O#7BO5M,^'7PI\3^-/"UK>ZC8>!A8:.MAIG@:?PU'X,
M^QZ6/%=WJ\6H^(=7_MJZ\47>I6<EM.B6T23I"YN67_!3JZU/Q%\1/#=EIOP\
MBMO#_C'PYX9TOQSK'B6?2O!GA73]>\8>(O!TFL?%6:=Y]5\)1:;=^$6@D.I6
MND--J>H6EFD4=K/#=3_8OQ1_:M^'?PTUS6?"=YX?\6^+?$MCJGA#07T/PGIN
MARMJ^O>,[75]0TC1K:\\1:[X3T)M172/"MYJ=W'J.IZ>HMFM4MGOKN^MK5Z6
MM_M-_#G1KCXNVMY\.O&USI'PI\.WGBCXC:U:^'_#,VF6L%IX=M/%]]I\]C+X
MBA\0:OJEOH6HPW%Q#'H5Q TD4T27;S(B28P2<<*M'3HX2C0J2D^5XBI0I82>
M(Q-2H]5*LN>?->\(8B"=2I+EG-\DO:XBU24JM?$3JTZ<8>T]C"O6K^PP]*FG
M/FY/:TZ2C;WY8=VC",73A\(_%#_@HQ\3M5\._M(:)X3LOA]X:O/AQ\,/%>M:
M-X[T3Q[H5W=+JNA^']&UJS\>Z3H6IW<^KZQ\-/$$VM20Z1K\.@7-M]D^SW\T
MTD,\FWK&_P""EGBN!KRQ&E_!W59?#L-[>IKVG>.KR7P]\<1:>(-'T ^&/V?K
MU+5SXU\7VO\ ;K2:KI\?GQV5RVG0IYB7OF0_JO:6VC:A%%J=I:Z9<Q:AI\'D
MW4$$)-YI\L:RVT:R^7NFLYHY(Y(X]SIM9#M]7C2=-5+8+IMB%L)C-:#[);@6
M4[JX:6S7R_W$KAY,R0[6^=Q_RTK2\85*2E3:A2@XUJ3]V56JI3;G*7+>FXW@
M_9J"A[G)RM:L2YESQDI*4N>DU9P5*2PZ5)-2]^,E2FHU6Y2BZ[E%J2N6[6ZD
MG@M[@I- ;B"*9H91^\A+J',4H/W73++)Z,O?J=>:1QI=@=S#_3-1[C.#%I^,
M#'3:?X>YK,W' . .<'D GCY>!\V6!^8?=^YUXK1E#?V;9DE?+-U?[<G#;S%8
MEMVXC@!5V_Q??R"=E)[NRLG:RUT7/#35O_/NV4U;V,7)2:E9RM%-OV<DY62:
M3>NB75+S,_S'#9WOD \LQR" 5  SZ?\ ?//XA9SRI;'4@,Q ]<\C Z[: =VX
MYVG[QY.>",G^(G@_]]$FF\$$# (R>>I]@>G _,TS7E\__)5_EZ_TM7JS'DN<
M9.?WA7IDCN,#<#[TF]]P 9P,?+G);ISDCK_LY^E,&,$DXQS@D $< 9W$;BV?
MN_EFO*?!'QK\)^//%_Q2\$Z1;^(;+6OA#>Z18^)Y/$.A7VA64[:WI\FIV5WH
M<VII:W&K::;>UD7[?';QVDS*[VDUU!_I$BNKM::0E-W=K0BX1E+T3G%-]+J^
MY+5K><E%>['63U45IJVHS:7E]_K(=PV-[9Q_>(QP.>O.V@N^<[F#')/S'N<=
MSQ_GZU\1ZA_P4'^$&G65_>S^'_B/'YL>GWO@>WET30;1OB[H^I:W_P (U:^(
MOA_>:EXFT[21HHU\+I\]QXTU'P-/;M<VDTUHEEJ6GW5UZ^_[4'PSC^'_ ,-/
MB7<7>JVGA/XJ6;:GH,MYIZP76GZ7%H-_XGU/4]>LIKA6L;'1=%T6\N-1FMVU
M%HA$GV=+J%T<CNJ;JRBXTHSC3E4>D8U).25.3=DJB=.I&I!OFISISIS49Q:$
MK2J>Q33J6E)P44Y<L>1\UDG=2C.,Z;^&I&494W*#YG[]N<<ERI/(7+$=L9R3
MC/\ G%(9)&).YF!^4#<QYQ\NWG S_LX_Q\(^$_[17A7XJ6GBV:S\.^._!^H^
M"['3]=U+P[XR\/I%XBNO#6LV5UJ?AKQ5I&D^'K[Q?+J.F^)K#2[R;3+2%O[>
M\Z![&^T?3M5_T&N'OOVR_!5K\+H/C)9> OBKK7@07OB72]5NK+PYI%IJOABZ
M\,>(;OPEJ5MKN@Z[XC\.ZU'>W6NZ=):Z=IEA9:GJE],T-FNG)J,Z65-J<9.,
MH2C)<CDFFG#VFE/GNER.4KQM/EM.,H/WDT*+C*,9QE&4)2<82234Y**G:&GO
MWI^_'EOS0E&4;Q]Y_5WF.,?,XY()W=.HP>^>GRTNZ3Y1YCX;[IRPX'3IP,_*
MW7[M<!\/?B3H'Q'@\2OHT>IVEQX0\37G@[7;#6+);._T[5[*"UNY$>%9;M3!
M/;:C:302>9F2.3[J.DB5WI_H!USWP0,<@8/^]^M&JM=6O&,EUO&<(SA)6Z2C
M)23V:::T94;2O;HW%^ZMXNTEMNFFGV?I=OW,1_K&/IN9N.N<<C/\/\/YXKNO
MAZ7^V:@"6(6U4 DD])1UR>M<)D<9 SP!D 8[YYPW4M_CUKNOA[_Q^:CRIQ:(
M/E(/ E4#."><#\L55/\ B0^?Z'-C8VPM9^4>B7VX=CUFBH^/0?B!G\?FZT5W
M'SASGB]87\+>)DNM1DTBV?0-76XU5$=GTV!K"<3:BB(&=FL8]UPJH&D9HQLY
MK\L/V<OAI\;O$7C/X<ZQ=:YXO'@#P</#^MZ+K'BVV\=Z.MUH*1Q'4/[&77M1
MOI-:;QO8I#]IL]?&-)L[V22S6WGM$6OTK^+'B5/"/@3Q!XBN;W2+#3-)M#<Z
MS<ZU9ZA?6G]CEO*U"&&VTRZL[N2^N8)&AM#]H6)9I4:;]V'KXT_8SU+0I=8%
MMX:U;PWK&EZEX$L=4MHO!^E_$^UL/#-KYUDUIHVK'QMXZ\6Z)IUV8+I8[;3]
M(MXV*VEQLNS!#Y4LX6\<37JKXH0PLEU7-1CCJ\7435K:/V=N2,DJ].K&I%TH
MQSQ&M"E"2TJ2KTW?W;PJRP5*JH35GS+FBYW<GK1E2<'[1S_1:BBBJ- HHHH
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MJ86_\/ 9[RNIB*"U]VCFT(/$4HWY5CX8B,5S8I(_6#_A)-'_ .@A'_W[E_\
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M (U7044!:7\WX(P?^$ET7_G_ (_^_4W_ ,13?^$FT;_G^C_[]7'_ ,:KH**
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M_+"C_A&]-]=0_P#!QK/_ ,L*WJ* Y(]OS_S,'_A&]-]=0_\ !QK/_P L*/\
MA&]-]=0_\'&L_P#RPK>HH#DCV_/_ #,'_A&]-]=0_P#!QK/_ ,L*/^$;TWUU
M#_P<:S_\L*WJ* Y(]OS_ ,S!_P"$;TWUU#_P<:S_ /+"C_A&]-]=0_\ !QK/
M_P L*WJ* Y(]OS_S,'_A&]-]=0_\'&L__+"C_A&]-]=0_P#!QK/_ ,L*WJ*
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MQ222;;<L.E:SZV:TNM3IAGN05&E#.,KG)VM&.8863=[)62K-O5[;OI<^D_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*A_%>ST]3^YM[_X:6>H7$?RC?YMU'\0[".4LWS#%K& K%-I/SGSGXX_L/_\
M!0'5?A7XYT^+]ON]\<P-X?NC<>%KWP4?!3>(+"U03WEC+XFL==UN[TV:ZLH9
ML$6TD=Q(?LTUQ;PSRW4?[1?V5?\ _0SZO_WXT+_Y45SGBWP7JWBGP_JNA0_$
M'Q7X:.K6S64FJ:'9>#)M0MK>4A;J.V3Q!X4U_2_]+M_-M9&GTZ:2.*=WMF@N
MD@N(=Z'B!Q'1K4*[605I8>I"I%5.%.&US2A*,ES5*.64JZ;Y5><*L:J?O0J0
MFE)85>"<CJTJ])?VS35>$X3]GQ)GS5IQ<;*G4S*I1<4I.T)TI4VDE*$HMH^+
MO^"8GPB^+GP=_9;\,:-\7_%O_"3ZKKTX\5>&[3^T9M7_ .$7\(ZUI]C<:-H3
M:C*2972,R7Y@1WAL?MWV.*3;#D^"_$F;58+KXZ>%O"4GB/XF:GXIU)==O_$;
MZIX_\*WOA8R_$GPY:6WPN\<Z=]FUK3XH#97NI_\ "-^+?"UI:W:^&K'4(KG0
M)T1-0U'],_AU\-=4^'WAK3O# ^)WC7Q98:+:66EZ/-XDL/ 45UINDZ;8VNG6
M.FQ2>&?!?AJ"YB@ALT;[1?07=]))(_G74D?EHF7\5?B/HGP?T.S\0>+O$?B]
M[/4-4BT>RMO#_ARPUW4KB]D@NKLA;+3]"FN!##:6-S<7%PRK#;Q12-+(G-<-
M'B'&8S/\;FM3!4\7C<VQ<*\L)@DL'0==8B&(C&%.E3J5?9JI&+5.%6#E*"E7
MG7CSQGVSR3#87),-E=/$5:.%R[#NE#$XE_6JT:4</4P[J3G.=.FZOLZDUSSA
M.,(M^QA3G&G.EY[\.?"7Q ^%?@*X\-^,Y?"R^!V7QGK^NZ[IWQ(\9G5OAEH^
MJ7M]?Z9X/\(->^"9-2\4:5X8TZ6*WA\4:IXD\)ZF'\QK70[6VAM;6/X<TCQ5
MHNK_  9^%-KXLU[QSJ'@;3M)^/FE27.GWGBW^U1X_A\2:Q/\-K6]O+9H];N-
M9E\/W4%QX9^V32P74DUM_K/D0_H1_P +O\#3)>1V/C3Q;J.I67AE?%K:7;^$
M7BGETA](M]<C:*^N_"UKHC3-IMW;S21_VK^Z9F2;RY+>=$\]TO\ :N\/'Q'\
M.M+U;2/'>AV/CSX<:=\39M6\7IX0T;1?#^DZKH<^N#1K^<?9+G5-=T^SA+WN
MG>')-5N+>0H7\R+S#71A,1F<I8NI4RC$RQ$ZU/'U:M'$2P52*A@<U@L136(I
M5YO$.CB:M:CBJ4M:N$IS<*]><IU,*M/ Q>%=/,<.Z,85,-"C4HQQ<*CEC<HG
M.A*.&JT8K#O$1P]'$X1QY?98Z5"F\-AX0A3\X^!NJZ=K7QL\)B[\4ZMI/Q(\
M.?#6/2OBSHVJ:CX@E'CWQUJ.@>';FZ@TO3+Z=M)M-)\#'2[^X-W8V\<=Q?ZU
M+;6WF?9;HO\ HI7E7PB^*6G_ !=\+3>+-+T37-!L$U[7-"M[?7X;:"^NAHE_
M+ITFH);VUS=?9K>ZG@E,4%VT-["8WANK>*>-T'JM>+G&)GB,9RU,+/!U,-2A
MAYT)UH5E3G&52K.-.4*5/V=&,ZLE1H2=5X>ERT8U7"$(Q]7*,/'#X67)B(XJ
M%6JYQK*E*E*:A3IT%*JG4J*K7DJ//7Q$526(K2G6]FG.[****\L]4**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /#/VAO%,O@SX2^+/$,>K>.M'FT^"V*77PW\,:3XO\
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M*B3HE>A7-QJR3.MMI=I<P+M\N:74V@D;(4MNB%A="/:Y*K^\8%5W_+OV+K*
M,@< ?* .PS^/)_S[/K6;4JE2HHJ"G.4E!;03;:BMM%>RT6B2M8SA%PA"+DY.
M*BG)[RLDKOS=KOK<P/M6O?\ 0$L?3_D,2?\ RKZ^_6D^V:[_ - 73_\ P</_
M /*NN@HJ04?[S^Y>7^7^=];\_P#;-=_Z NG_ /@X?_Y5T?;-=_Z NG_^#A__
M )5UT%% ^7S?W>G^7]:WY[[7KO\ T!K#_P ',G_RKI?MFN_] 73_ /P</_\
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M (.9/_E71]KUW_H#6'_@YD_^5==#10'+YO[O3_+^M;\]]KUW_H#6'_@YD_\
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MJ4444%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK6&B:6M[I>GF_P!1G2VMA?:QJ5KH^E6GG2D*9]2U;4;&PLXP=TUS=00H/,D
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MY.6G2C&4ZM1QIQBY22/E7Q__ ,$WK+QNZ:]!XSTSPW\2;+0_A#X:\-_$_1M
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M?_!,+XG_  ]\)_$_QEH_B'PKXD\;W>LZS\3/ O@+X2>!?"O@73]%^*C>#X]
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M70?%<&GP:597EAIEI$EO/:K#:0=E^R!^V%\5_C+^T)>?#SQSKLID30?BA?\
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MXB_$;]J7X9_!3]F2VT+3_B5;:IJ/@;5Y/'VOZ'\'M=^-?CF'QKINC:1+\./
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M+K$?B%I?@QK7B+P9-+>_#[Q1J?AKQ/X:\::5X*U72=6GTWQ[:>&]$UCP[?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img248422670_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_5.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %= D0# 2(  A$! Q$!_\0
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M3_\ FTKTNBCE\W][\O/U^_R#E7;^OZ7]79YI_P *K\-_]!3XB_\ AV_BG_\
M-I1_PJOPW_T%/B+_ .';^*?_ ,VE>ET4<OF_O?EY^OW^0<J[?U_2_J[/-/\
MA5?AO_H*?$7_ ,.W\4__ )M*/^%5^&_^@I\1?_#M_%/_ .;2O2Z*.7S?WOR\
M_7[_ "#E7;^OZ7]79YI_PJOPW_T%/B+_ .';^*?_ ,VE'_"J_#?_ $%/B+_X
M=OXI_P#S:5Z711R^;^]^7GZ_?Y!RKM_7]+^KL\T_X57X;_Z"GQ%_\.W\4_\
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M\_7[_(.5=OZ_I?U=GFG_  JOPW_T%/B+_P"';^*?_P VE'_"J_#?_04^(O\
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MR\_7[_(.5=OZ_I?U=GFG_"J_#?\ T%/B+_X=OXI__-I1_P *K\-_]!3XB_\
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M1?\ P[?Q3_\ FTKTNBCE\W][\O/U^_R#E7;^OZ7]79YI_P *K\-_]!3XB_\
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M_!MG/;W.GZ=+IWAKQ-K7B'6H)-'T/1[VYCF:+E/'W[5OBS]GCQ1\,M._:3\
M>&?#7PZ^+7C"P^'&@_&'X<>,=3\3>&?"/Q!UF.9_#WA[XFZ)XG\*^"]5\)Z/
MX@:UN;/1O&>EWGB;2QJ$1A\267A2T>"^G^6-"LKGPA_P6I\9ZEXQ+P6GQ?\
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M1W4)BTW0[E=7CU-;7['?26\-L^H0^9=)]V?#[P1I/PX\%>$O FA-=R:3X/\
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M>_9#U3XV>//A+\:_A9\:-=_9[^//P=BU_1O#WC[2?#&E^.=$U_P7XI%J=?\
M!/CCP1J]]HUIXCT6XGL8+S3S_:EC)I-Y)<WMMOO39W5ES'Q;_86G^-OPML]!
M^(/Q\\>W?QQT+XB>$_BWX.^/^CZ/H.A:GX \?^!(]0M_"4O@SP)IWE^'M+\)
MZ5::[KT$OAJYN=0N]5D\0:KJ6K^(+W6)K?4K8373SOY/[MO/;[Q-2^2M;;TZ
M]?\ @V\^%M[O]JRRTW]L/0OBUHWB[5?@%=? 7Q/X@^%?C+XJW/P/@^)6C^*A
MX1U:T\6^!-:L/@=JMQH6L>';CS3K?AO6I]%L-1L(;>[TK4[O4FDT^8>*_P#!
M,'XL:A\=_@7\!OAWX"^*6N_#.Q_9F^#7PMT#XH^#X?#_ (5;QA\1=7\3^ =(
MUGPYJ<-GX[\)^(KC0?A7;V4LHTKQ7H<ZW_CO6H=3MM.DT30?#MGJWC'[7T?]
MF_XOWW@7QYI/Q5_:7N?BM\0/%G@#7?AMI'BN[^%VA>#_  7X.T7Q-;K:Z_J=
MA\-/"/B2P;5_%.KQPVOVK6=>\9WJ6!T^WM_#MCH.FWWB73O$'BG@O_@G?JWP
MUD_94\2?#KXX6_A'XF?LR?#X_!V]\:VGPS:>V^-OP?@M[%-.^'WQ2\.#X@V\
M-_8Z;>6<VKVNH6.I6]Y9:O=-J&B#1)X$)(M)?KTO_7>P)236FVGROK^>VNJ/
MM3X]?&OPA^SS\*O%_P 6_'%Y:67A[PE:V =[Z_M-*M+O5]<U;3O#?AK2;G6-
M0>'2]%AUCQ-KNC:7)K.JW%MI>D1WKZGJUQ:Z9:W5U'^+VJ_M0?LNZ?\ MH?L
M+^.)_P!J/X)>-M4;P_\ M7ZK\:_B'H?CC0IO#MEXQ\<>$OA=I/A70DN/MSC0
MO#D<'AYO!WP]TF_E%[/I'A=9;R75?$MSKVJ:C^^[V<=W:+:ZE#:7X=(EN4DM
M5-K/+'L<NMI.]XJ1^<GF1QR23F':G[V1T\ROFWQS^S#X9\;?'G]GWXX&^M=)
ME^ VC_%S1X?"UOX?L)K#Q;_PM32O"6F-<WU]Y\#V$GAH^$4N+)5LK_[6VH2H
M39B$22O1-;[/KZ);^>_?U*:??JFM-O/_ (<^HJ***904444 %%%% !1110 4
M444 %%%% !1110!YG\)_^18U?_LI7QB_]6UXUHH^$_\ R+&K_P#92OC%_P"K
M:\:T4"6R]%^0SX3?\BUJW_92?B__ .K6\:UZ?7F'PF_Y%K5O^RD_%_\ ]6MX
MUKT^IC]K_$P6R]%^044450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@""2..6-XI422&5&C>.15>.2-P5='1@5='0
M[65^&7\367HOA[0_#MN]GH&B:1H5I)*T\EIHNGVFFV\D[Y#S/#90VT32N!\T
MK)N;OSQ6W10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!YG\)_P#D6-7_ .RE?&+_ -6UXUHH^$__ "+&K_\ 92OC%_ZMKQK10);+
MT7Y#/A-_R+6K?]E)^+__ *M;QK7I]>8?";_D6M6_[*3\7_\ U:WC6O3ZF/VO
M\3!;+T7Y!7P3HW[6>N:@/ /CV72M"/PJ^(G[5_CC]EO2+.*UU)/%FGGPWXF\
M??"[2O'EQK+:Q)I6HV^N_%7X7:A;?\(^GAS2I+/PMXNTVZ;5)-4\-WMKXB^]
MJ^/=,_9.TK3=0\+:5_PE)D^&O@S]H;QA^TSX<\'+H1BU*#QOXMO_ !AXJFT:
M]\3?VQ+:S^$](^)'Q%\4^.M*L;7P[IVH)<KX=T=]1;2]"U%/$3>OZ.VP-7MY
M?U]W='FG@_\ :X\6^,_#'@3Q@+[X6>%=.^(R6/B%M/\ $B:E$WP?\'RZQ)>7
MJ_$_7YO%6FZ<_BRP\");R^(])>R\(1^!_B%KOA/P-JQU;_A+M$U>?[ZTO5=.
MUJPL]4T?4;#5M,U"%;JRU'2[N&]L;VW?E)[2[MI)K>XA?^&6&5HV_O\ K\Y?
M%']G8?$WQ;H'C*_\51Q:OX-^('@KQGX0L-0\/RZIX;T_2_!MIJ5W'X?U;28=
M>T>?5)]4\<ZT?'D^L66IZ&QUOPA\,_MECJ*_#^)]6^@/#>AP^'-(L]*BN)KU
MH3<W%W?W C%SJ>J:A=3ZCJ^KW*0)%;1W.JZK?7NH7$=K#!:QS7;I;0P6J0PQ
MB5OZ_K5]_0F+=[._?6_Y?J/U[Q%HOAFQ.IZ]JEII&GB:. W=[)Y47G2[C''O
M(/S2!&VY_NFN-_X7-\,/^AX\/?\ @8/\*]/HHY5O;7RVZ=->W3N6>8?\+F^&
M'_0\>'O_  ,'^%'_  N;X8?]#QX>_P# P?X5Z?13LO/\/+R\OZL@/,/^%S?#
M#_H>/#W_ (&#_"C_ (7-\,/^AX\/?^!@_P *]/HHLO/\/+R\OZL@/,/^%S?#
M#_H>/#W_ (&#_"C_ (7-\,/^AX\/?^!@_P *]/HHLO/\/+R\OZL@/,/^%S?#
M#_H>/#W_ (&#_"C_ (7-\,/^AX\/?^!@_P *]/HHLO/\/+R\OZL@/,/^%S?#
M#_H>/#W_ (&#_"C_ (7-\,/^AX\/?^!@_P *]/HHLO/\/+R\OZL@/,/^%S?#
M#_H>/#W_ (&#_"C_ (7-\,/^AX\/?^!@_P *]/HHLO/\/+R\OZL@/,/^%S?#
M#_H>/#W_ (&#_"C_ (7-\,/^AX\/?^!@_P *]/HHLO/\/+R\OZL@/F_4_P!K
MK]F+2+VZTW5OV@/A'I.I6,S07EAJ7C?0K.]LYEP6AN[6XO89[>0 J6CFC5E&
M,YYJI_PV7^RA_P!'(_!;_P .#X:_^6%?QV_\%)/^3S_VG/\ LI>I?^DUG7QI
M7]&Y5X#8+,<KRW,9<1XBD\?@<+BW266TYJD\30I5W34WC(N?(ZCCS.,>9).R
MV/R/%^)6(PN,Q>%654IK"XBM04WC)IS5*K*"DX^P:3DH7:N]6];'][O_  V7
M^RA_T<C\%O\ PX/AK_Y84?\ #9?[*'_1R/P6_P##@^&O_EA7\$5%=_\ Q+S@
M?^BGQ/\ X:Z7E_U'>7]:WP_XBCB?^A12_P#"R?E_U#^3^\_O=_X;+_90_P"C
MD?@M_P"'!\-?_+"C_ALO]E#_ *.1^"W_ (<'PU_\L*_@BHH_XEYP/_13XG_P
MUTO+_J.\OZUN?\11Q/\ T**7_A9/R_ZA_)_>?WN_\-E_LH?]'(_!;_PX/AK_
M .6%'_#9?[*'_1R/P6_\.#X:_P#EA7\$5%'_ !+S@?\ HI\3_P"&NEY?]1WE
M_6MS_B*.)_Z%%+_PLGY?]0_D_O/[W?\ ALO]E#_HY'X+?^'!\-?_ "PH_P"&
MR_V4/^CD?@M_X<'PU_\ +"OX(J*/^)><#_T4^)_\-=+R_P"H[R_K6Y_Q%'$_
M]"BE_P"%D_+_ *A_)_>?WN_\-E_LH?\ 1R/P6_\ #@^&O_EA1_PV7^RA_P!'
M(_!;_P .#X:_^6%?P144?\2\X'_HI\3_ .&NEY?]1WE_6MS_ (BCB?\ H44O
M_"R?E_U#^3^\_O=_X;+_ &4/^CD?@M_X<'PU_P#+"C_ALO\ 90_Z.1^"W_AP
M?#7_ ,L*_@BHH_XEYP/_ $4^)_\ #72\O^H[R_K6Y_Q%'$_]"BE_X63\O^H?
MR?WG]_?A[]I_]GKQ9-<VWACXU_#7Q-<VD0N+J#P]XKTK5IK:!G\M9KB+3[FZ
MDAC:3Y%DE54+G:.:Z[_A<WPP_P"AX\/?^!@_PK^;'_@WX_Y*Y\>_^R;:%_ZE
M,5?U.U^'<;<,T^$>),;D-/%SQT,+2P=58F=*-"4_K-"G7Y?9*=51Y+\B:FW*
MW,[.R7Z+PUG$\]RC#YG.@L/*M.M%THU'54?8U94D^=Q@WS<G,_=5FV>8?\+F
M^&'_ $/'A[_P,'^%'_"YOAA_T/'A[_P,'^%>GT5\I9>?X>7EY?U9'O'S1JO[
M87[+6B7UWI6K_M$?!S1]4L)VM[[3M4\>^'[&^LKA3\\%Y:76H0W%M,FY=T<\
M<;KW[52_X;6_9'_Z.;^!O_AQO"W_ ,M*_B._X*=?\GQ_M7?]E9UW_P!!MZ^)
M*_'\=XH5\'C,7A%E%.:PN)KT%-XV2<U1J2IJ3C]5=G)13:N[-[['^J_!W[-[
M(^*.$.%N)ZGBMFN#GQ%P_DV=SP<.$\+6AA99IEN$Q\L/&N\_I2K1HO$.E&I*
MG!S4>=PBVT?Z)G_#:_[(_P#T<S\#?_#D>%O_ )8T?\-K_LC_ /1S/P-_\.1X
M6_\ EC7^=G17)_Q%C$?]"6E_X72_^9#Z/_BF%D/_ $=_-_\ Q#\+Y?\ 51>O
MW^1_HF?\-K_LC_\ 1S/P-_\ #D>%O_EC1_PVO^R/_P!',_ W_P .1X6_^6-?
MYV=%'_$6,1_T):7_ (72_P#F0/\ BF%D/_1W\W_\0_"^7_51>OW^1_HF?\-K
M_LC_ /1S/P-_\.1X6_\ EC1_PVO^R/\ ]',_ W_PY'A;_P"6-?YV=%'_ !%C
M$?\ 0EI?^%TO_F0/^*860_\ 1W\W_P#$/POE_P!5%Z_?Y'^B9_PVO^R/_P!'
M,_ W_P .1X6_^6-'_#:_[(__ $<S\#?_  Y'A;_Y8U_G9T4?\18Q'_0EI?\
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M/^%S?##_ *'CP]_X&#_"O3Z*++S_  \O+R_JR \P_P"%S?##_H>/#W_@8/\
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M_)7?VC?^R9^%?_4J:OZY*_D;_P"#<;_DKO[1O_9,_"O_ *E35_7)7](>'/\
MR2.7_P#7['?^I50_P!^GW_RE%QQ_V*>#O_6:P 4445]P?QJ%%%% !1110 44
M44 %%%% !1110 4444 %%%% 'F?PG_Y%C5_^RE?&+_U;7C6BCX3_ /(L:O\
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MZ/\ A3_@/_H%:C_X5'BG_P"7='-Y/\/+S\T'-+^5_?\ \#S_ *LSU&BO+O\
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M $"M1_\ "H\4_P#R[K[;F\G^'EY^:/XUYI?RO[_^!Y_U9GJ-%>7?\*?\!_\
M0*U'_P *CQ3_ /+NC_A3_@/_ *!6H_\ A4>*?_EW1S>3_#R\_-!S2_E?W_\
M \_ZLSU&BO+O^%/^ _\ H%:C_P"%1XI_^7='_"G_  '_ - K4?\ PJ/%/_R[
MHYO)_AY>?F@YI?RO[_\ @>?]69ZC17EW_"G_  '_ - K4?\ PJ/%/_R[H_X4
M_P" _P#H%:C_ .%1XI_^7='-Y/\ #R\_-!S2_E?W_P# \_ZLSU&BO+O^%/\
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MG_)Y_P"TY_V4O4O_ $FLZ^-*^R_^"DG_ ">?^TY_V4O4O_2:SKXTK_0SA?\
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M110 4444 %%%% !1110!_09_P;C?\E<_:-_[)IX6_/\ X2D_TQ7]<E?R-_\
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M?.,_\+7Y?].?ZOZ!_P 5$/I*_P#0SX1_\1:GY?\ 4P\G_3T_D1_XAYOVP_\
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M-*=O[R5$MX(U=][*L$2](TJU110 4444 %%%% !1110 4444 %%%% !1110
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MXA?]$M;_ ,+#0_\ XS1=]O\ R:/EY^?]:V.;^M?+R\_R[GIU%>8_\)3\0O\
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MT2UO_"PT/_XS1=]O_)H^7GY_UK8YOZU\O+S_ "[GIU%>8_\ "4_$+_HEK?\
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M2N!_Z^XS_P!2JH4445^6GVX4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >9_"?_D6-7_[
M*5\8O_5M>-:*/A/_ ,BQJ_\ V4KXQ?\ JVO&M% ELO1?D,^$W_(M:M_V4GXO
M_P#JUO&M>GUYA\)O^1:U;_LI/Q?_ /5K>-:]/J8_:_Q,%LO1?D%%?)WQT^+G
MQ@^%>M>&/$&C^ _!^O\ PMN/B=\*OAGKEG<Z]JD/Q'UI/BEXM\+^!D\5>"+&
MSL+K04M/!VM^,[2?4]$UV6*^UO3- \1W<5YH=M;:9<ZGR.D?M8S:A=>"O%TF
MBZ</A5X^_:;\:_LM:!=Q/<_\)'!K?A?6_''@*U\=W<K3?V==:'X@^*?PTUOP
MC::##I]O>6ND:QHGB=]:FECU'P\CN^BOZ/T%S+3?5V_+_,^WZ*^$O"/[67B;
MQKH'@'Q7I7A7P=I6D?%JTTKQ5X:M_$'B?4++4O!7PZU2\U'4[3QAX^_XE1TK
M[1/\+]$U/X@WNBG5?#$'AW4XK/X?WFM:EJVM:%K.J?;UC?V6J6=IJ&G7EIJ.
MG7]O#>65[8SQW5I>VMQ&LMO=6MS \L-Q;SQ.DD,L,CQR(R.C;#R)[]UN--/;
M4OT5A:]XATOPU8C4=8N7M;/SH[;S([2\O6\V0,4'DV%O>W&"(W^;RMJ_QL*X
MS_A<7@#_ *#%U_X3WB7_ .5-";=FHO7_ ('9/NM[ Y);L]0HKR__ (7%X _Z
M#%U_X3WB7_Y4T?\ "XO '_08NO\ PGO$O_RIH][^7\_+^[YH7-'O^?\ D>H4
M5Y?_ ,+B\ ?]!BZ_\)[Q+_\ *FC_ (7%X _Z#%U_X3WB7_Y4T>]_+^?E_=\T
M'-'O^?\ D>H45Y?_ ,+B\ ?]!BZ_\)[Q+_\ *FC_ (7%X _Z#%U_X3WB7_Y4
MT>]_+^?E_=\T'-'O^?\ D>H45Y?_ ,+B\ ?]!BZ_\)[Q+_\ *FC_ (7%X _Z
M#%U_X3WB7_Y4T>]_+^?E_=\T'-'O^?\ D>H45Y?_ ,+B\ ?]!BZ_\)[Q+_\
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M/_4'#G\KYK_R-\U_[&&+_P#4BJ%%%%>X<(4444 %%%% !1110 4444 %%%%
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M6W&C7ESH^F:KXA.KWL-M)J$EW?W$WBCQ#Y_):1^R=_9UQX,\*2:[9_\ "K/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^:7WOR\_+\?)!R1[?G_F>7?\*:^&7_0G:5^5W_\ 'Z/^%-?#+_H3M*_*[_\
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M_1KWQ:_\)FY_QK^[ZBNO_B/_ !)_T)\G^_&__-!A_P 0NRC_ *&&8?\ EO\
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M^$,\:_\ 16O$'_A.^"?_ )GZ]0HHMZ=/LK^[_D'*O/[W_GY+[CR__A#/&O\
MT5KQ!_X3O@G_ .9^C_A#/&O_ $5KQ!_X3O@G_P"9^O4**+>G3[*_N_Y!RKS^
M]_Y^2^X\O_X0SQK_ -%:\0?^$[X)_P#F?H_X0SQK_P!%:\0?^$[X)_\ F?KU
M"BBWIT^RO[O^0<J\_O?^?DON/+_^$,\:_P#16O$'_A.^"?\ YGZ/^$,\:_\
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M4>,_ ^L:;!JE]J-KXI\/>,];ETZ^:.&;19?[*N)])U;5K22*Z/K)MZV7W_\
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M "BBB@ HHHH **** "BBB@ HHHH \S^$_P#R+&K_ /92OC%_ZMKQK11\)_\
MD6-7_P"RE?&+_P!6UXUHH$MEZ+\AGPF_Y%K5O^RD_%__ -6MXUKT^O,/A-_R
M+6K?]E)^+_\ ZM;QK7I]3'[7^)@MEZ+\@HHHJAA1110 4444 %%%% !1110
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M &4KXQ?^K:\:T4?"?_D6-7_[*5\8O_5M>-:*!+9>B_(9\)O^1:U;_LI/Q?\
M_5K>-:]/KR/3_AMJ.FG48=(^*'Q!TFPU#Q!XCU\:;;6WPWN;:QNO$^M7_B;4
M;>SFU3X>:AJ)M$U+5KL6JWM]>7$5MY<<ES,ZM*]__A"?$O\ T6#XC_\ @!\*
M?_G8U":6M])-M;WZ7Z?J"T25MK?I_7](]-HKS+_A"?$O_18/B/\ ^ 'PI_\
MG8T?\(3XE_Z+!\1__ #X4_\ SL:?,N_Y_P"7K_3T?R?]?/\ JWH>FT5YE_PA
M/B7_ *+!\1__   ^%/\ \[&C_A"?$O\ T6#XC_\ @!\*?_G8T<R[_G_EZ_T]
M#Y/^OG_5O0]-HKS+_A"?$O\ T6#XC_\ @!\*?_G8T?\ "$^)?^BP?$?_ , /
MA3_\[&CF7?\ /_+U_IZ'R?\ 7S_JWH>FT5YE_P (3XE_Z+!\1_\ P ^%/_SL
M:/\ A"?$O_18/B/_ . 'PI_^=C1S+O\ G_EZ_P!/0^3_ *^?]6]#TVBO,O\
MA"?$O_18/B/_ . 'PI_^=C1_PA/B7_HL'Q'_ / #X4__ #L:.9=_S_R]?Z>A
M\G_7S_JWH>FT5YE_PA/B7_HL'Q'_ / #X4__ #L:/^$)\2_]%@^(_P#X ?"G
M_P"=C1S+O^?^7K_3T/D_Z^?]6]#TVBO,O^$)\2_]%@^(_P#X ?"G_P"=C1_P
MA/B7_HL'Q'_\ /A3_P#.QHYEW_/_ "]?Z>A\G_7S_JWH>FT5YE_PA/B7_HL'
MQ'_\ /A3_P#.QH_X0GQ+_P!%@^(__@!\*?\ YV-',N_Y_P"7K_3T/D_Z^?\
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M1_\ P ^%/_SL:.9=_P _\O7^GH?)_P!?/^K>AZ;17F7_  A/B7_HL'Q'_P#
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M%/\ \[&CF7?\_P#+U_IZ'R?]?/\ JWH>FT5YE_PA/B7_ *+!\1__   ^%/\
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IT33M%TJ-!J.LW26T=GIEJD5JD$;B659)Y2ESK^K^7EYO[A+9>B_(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img248422670_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_6.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &H AX# 2(  A$! Q$!_\0
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M^A]0RNI1IXNOB)X:.*EBG&:=-TX^RS"C0A&GA5255Q>'J3J/EE:FZ=V[>X_
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MHFM7?@[Q'X7BUE-27PWJ+:OH]O)XJ^U7$>BVMU?$V%W:V\,JRZ?J8XCX>?\
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MZ+#X!_:5UWPGJG@Z6SU_3=4U33;?PBFNPM%XFTI3%]D?6$UB.ZMAI<VHI!+
M8KPQD)<E5<)DM*6*<<16Q$:%&%2@H8C"T_K3GB*$6H/V5:4)>PG5DZ=2FJE.
M=/533Y7>%S;C#%4\LC/+\)E];&XRM0QOM<NS/$QRN%/ 8N:G67UC!T\13^OT
M<)1AB:&)EA\11Q+<)4W'G73?#']K33Y_C/\ MDVOQ ^/7PLN?A=\!+#PSK/_
M  CEOX%^(?@[Q;\)-(_LV]?6K[X@:_XNT72="\20:Q-:&[T;_A$;O7CJ$317
M-@=.AU'3M)KZ \$_M7? WQ[XW\.?#30O&<\/CKQGX$M?B?X+T#Q%X:\5^%Y_
M&W@&]CFEM/%'@^Z\3:)HEAXDT][>VGN9(-(N+C4+:V@GNKZRMK>*6>OSIF_8
M_P#VG=(^*W_!2KXF>#O#'PLFNOVIO"WAS3/A+:?$.YT?Q3H4L_AQ4TC4K3QU
MX5OK'5M$E_MO19KN\T*VU.WUG0O[02R@\5VPLWO8!C?!S]C']IO0/VI/V*_C
MSXS\*^'K?3OA'\"M3^%OQ1BE^+3^(KZQ\17'AWQ1H]SK7A[0HO#FD^&/"OAR
M[N?$YD\.>!?AK;GPYI-A9I8-)I)DDEK2K@\JG"K5CBZ<>7"4W2C&MA8N6(IY
M91K.$Z:I14N;%J="4U[TZGQ>^^>6&%SCBG#U<)AY93B*L*N;5XXFI5P>93C#
M+ZW$F)PD:U/$5,16]FZ65RHXZ%&<?9TZ"_=VI6HTOJ;_ (*<?M@>+/V-OV>4
M\=?#_2K6_P#'7B?Q=H?@KP]>ZWH6LZQX;T(:F\MSJFLZDVGB#3?MT&GVDL6B
M:9JVHVHU"^F:[MK36;71M9TUNV^'?[1-WX(U;5? _P <O'NE>*_&?BO4_%OC
MKX.>&?!7PZ^(LOQ8D^ VD+!%:>(_BY\/[?P+HFH>&?$-I>V^H6-W-'X>TK1=
M1G6TTG0'U;5-\+>;_P#!4O\ 9D^*7[67[/F@_"KX2:9H=YXB@^)OAGQG=W7B
M77(-#TBTTOPY9:S;S0F<V][>37U[-K,*6L5M9O"(XKF2ZN('BLUD34/V;OB5
MX5_;AG_;.\-:#+XPTCQY^SW=?"#Q-\,[K7=#T[Q5X+\26E]X?U31]0TF]U"_
MB\)ZCX8O_P#A%K>RU=8-4AU'3[J]NM6L[+6UNIK"L:$,MGEE"%25*.*;S"I/
MWZ:K3G3^J?5*7M)QE["$_P!^XW]V?+.'QU82CU8RMQ%2XEQU7#PQ57+:?]@8
M>A%T<3+"4J.)>9+-<3&C1J06-KT&\%&2BG4I^TI5-:>%K0G[GXG_ &Y/V6_"
M'P_^&?Q9USXPZ+#\,?B]K,?AGP%XYL-&\5:WX<U7Q%+]J_XD^H:GH>AZK;^%
M=2A:PODN;3Q>='FM'T_5$NUMVT75TB]$^"G[1OPD_:$C\=M\*/%$_B-_AMXN
MN/ _C."\\->*?#-YH?B2V@2YDL)[+Q9HGAZ[N%:"1)(KRT@GLI5RL<[.CBOQ
M:OO^"6/QU\+?L>_LZ_ KP[>>$_&OC[P;^U9:?M.?$2XG\0MI/A'18;71K[1I
M/!7A2YU&R.IZE))!>6DJ7,]A:6<E_'K5Q.;>.;2U;^@JQ)>VBN7L)-,N+V.&
M[N[.;[*US!<R01"2"\EL9;JTGNK<(MK-+;W-Q"QC"P7$T0AE...H970I1^IU
MIXN<ZV)@I^TIJ-.E1K0C2G.@J#JOVU)RM)U*:YH\Z3BU [LAQ_$V.Q+_ +6P
M6'RO#TL%EM:=!X7$SJUL3B\).>+HT<:\9]7C]4Q2IJ4/J]:2A-T)R]K!U3\:
M?&_[<?Q^\9?M0_M3_!/X/:AX9\!V7[.'A;P1K&A7/CSX5?$[Q%HOB*XDCTCQ
M-\2-4^)"^%/"'B3Q=I6BVOAJ;5=.\"1:#;>&X?$5ZFE:GI^NZU%K>FVAXGXH
M_P#!0+XR_#K]C3]F7X_>&_BW\)/BYX@^(G[1\?P=\9^*/"OPZ\5Z9X(UOP]J
M-QX[NYKG1M$\8VO@KQ=8:YX>A\#+I;W(L+2RNVN[UTT^_P!FG:M7O/@[]EOX
MU^&/VOOV[/CC=>$-,N_!7[27PYT[P?X"ALO%6C_VU;:IX;\&:7X:@G\26-S<
M6EOIVFZY=:2\UO/97.J7-K%/:?;K")VOY5^6[/\ X)H_M#W?["'[.'[-L\?@
M'3/B-\&OVI9/C3K=S>^*+B3PSJGAJRL_B1JT,.F:II^CZI?_ -HWU_XQL?#R
M6]WI\2PW'VB_GD^Q1"]?V:?]B+ZHI?5%3IRRWVJ;H3=3VF75?KKJ3</:OV>*
M5-22E95)\W+I#D^,Q/\ KG)9G*E_:\J^(AQ)'#2C''T8X=T.(L)_8RP]+VT<
M*OK&5SK2IR]GSO#TN251-UG6_6[P?^UM\#O&WBCXE>!M%\4ZU;^//A+H1\3^
M-_ ?B+X?_$+PMXXTWPV]O;W4/B/3_!OB?POHOB7Q-H\T%W:M#=>&=.U-':]T
M^'B;5=+@E\W\#?\ !1;]CSXC:M\.](\'?&:RU>?XHS^)[?P=<OX0\>:3H][<
M^#;&YU'Q+8ZCKVM^%]*TCPU?:3IML^JSVGB6[TR<Z9)::C#')8ZQI%S-Y#:?
MLK?$?Q3^V;\5/VOM=T./PII<?[/TOP4^''P[;6M&N?%GBW5;F!Y=0\1>+KK2
M;[4_".AZ5'-++I>C65OJVJ7=U&+36-3.BMI\>C'EOV,_V(?B'\.OV"_B'^R1
M\71IOA+Q1XMTOXK^'8O%OA+5+;Q%I]O9?$O3]2L;?5M/:,:7J#76DQZ@\&I:
M=>PVL-W;JMM!?2PW=\P\N6%R:%%U)8BJYVP*]E&O1;I2Q%&J\3+W:$W7CA:D
M:$G&ERN4)RI.:FG47T]/,^+ZN+IT(Y?A84>;.Y+$U<!C8K$TL!B\$LMA[V.I
MQP%7,\-/&TXRQ+K*-2A#%JG*C..'G]D>$?VQ?V>?&VH?#NPT'XBP2Q_%O4/$
M&E_"S6M2\/\ BC0_"_Q*U'PM=M8:[8>!?%FN:)I7ASQ+>6MVAAM(=-OY6UM5
M>?P\-7MH9[@>=ZU_P49_9)T&U^)][??$77W@^#'B5/"?Q7^P_"3XPW\GPXUF
M34;C2 OC..T\!32:#IXU6UFTT:O?K%I4NH!;&WO)KVZM+9_B;1O^"?'QI\2^
M /\ @GK\&_%O]@>#M+_8M^)L_P 0?''CW2-=BU*U\;1>'M?34O"FG_#.TM0G
MB%+KQ#$BMX@N_&MAX:C\.L9)K*/Q/-#!$_/R_L%_M$7'@C_@J9H'_"->&(M1
M_;8^(%IXL^%X?QAIS0Z7I_\ PE_B'6)H/&\R))_95]!INM0RK'HRZS#+<I/:
MI=!4AO7WC@,CYGS8V;BJD8J,<107N2S-8=5/:2HN,KX%_6G!13IN/[S2I&,>
M*>>\:^RINGDM)2EAZE6526 QU1?6(<-K,?J_L(XR%2"CG:_LR-64Y0Q$:EJ2
M=2A4J3_3/PU^V=^SGXL^)/@CX3Z)\1#=>,OB3X=G\5_#E+CPMXQT_P .?$;0
M[:QEU&[O? /CG4_#UAX*\9)9V5O-<7">&]9OI(GAN+8K]ML-0LXX?#'[;'[.
M7C&'XU2^'?&^L:B_[/4AA^,5D/AK\4;;5? MRMWJ-B;/4=%OO!MKJU_?+<Z1
MJ"FRT:TO[H16EU.8A;VL]ROPCI?[%OQV@^*O_!+GQC-X:\/Q:/\ L:_!NS^&
M_P 4?^*KT][RZU8>"+/P'+>>$X$)35M-MY=+37M]]+IMT^G7,4$=J;^.YTYM
M#P7\(/ /QN_;KM/VD_V??BIH'BGX&_$SX9+J7[0.B^$[B.ZT_P 3>//A9XYT
M*V^&5U?H(T_LV36_$?A,:I#,T<4NIVOP_P#&%L[7FG>,M2=LY8#*[2<:U>4(
M8:=652%2G4ITZ]/%UH^PJSA0<8RQ>"H^TPW,XVK22<IQO;>GGG%'-2IU<%@J
M=:KFE+#4\/5P^(H5Z^ Q.58&?UZA3K8V,ZE/*\XQ?U?,W"-2^$A*<(8>JH\_
MWAXW_;!^ 7P]O/'NF^)/&E['J/PK\*Z!XV^)]EI7@[QKK]Y\-O"WB>W>\T75
M_'=GH/AW5+KPU'=6*&_EL]3BAU+3].*:CJEE8V,B79^6OVBOVR?%G@O]HC_@
MGEX<^$?B7P?XH^#G[8.L>(K;5M0.F1ZK]NT#2H?!5]I.N>$==M[NUDMFUFS\
M<JL_VN*YC1+&S:"&WE;4=_DW[37[*?[6'QB^)W[8%KI_AKX:2?#+XO\ P.3P
M+\+]9T'Q;#\--6N-?A\/V]H)?C%<^'/#5WXV^*5U%<?;M*T/0_%^JWGP_P!,
ML);=8K73S)=WHY'3_P!A[]HDS_\ !)^XO?"?A:T7]B:QU:#XI0IXVTZYFNAJ
M\O@W3XHO"^RUMH=2O+2S\%'6+N*XF@M%&H65C9ZE>S+J4@UPV$RFE"A6J8FC
M.<Z%=5*4Z]"I",JF4U:M)VY(3A5IX_DI^\KPGR*[MSSY<QS7BK$5,7A*&78R
MA2HXW O#8O#X/&T*TX8?BK!X?%0E)U*U*MA\1DCJXASB[5:2JU$HI^QI?H1X
MM_;N_9?\$IX_O-?^)I&C?"[QC:?#WXA>)=&\'>.O$?A3P;XXOFD2V\*:UXG\
M-^&M;T.+7/.3[%=6D-W.=-U-[?3-6:QU*_T^QDX;3/VFI]8_;&TWX96WQ?\
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MMX8?]!.=?^&J7_R_S_JS#_5G-/Y*/_@Y?Y?U;TO]145\N_\ "YO%/_/#1_\
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M8^O**^0_^%F^,_\ H.R?^ >F?_(E'_"S?&?_ $'9/_ /3/\ Y$I?\32\ ?\
M0IXK_P#"3)^MO^IY_>0?ZJYC_P _<)_X,K?_ #/Y_P!69]>45\A_\+-\9_\
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M_!+W]JGXE?MH_LJ^ OVB_B7I?@3PUJ7Q&U;QS9:?X6^'VE:]:6/A^W\$^/\
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M&-&524>6UNM65UM91M:SYOR$_P"$B\4_$\&?]I2/]N#Q[IUR,S?"KX)?L_\
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M%?77P\_Y$_0?^O-__2F:OD6OKKX>?\B?H/\ UYO_ .E,U?TK]%[_ )+;._\
MLF*W_JVRD^5XL_W+#?\ 84O_ $U4.VHHHK^ZSX$**** "BBB@ HHHH ****
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M%7_TW(^U****_P!:3\>"BBB@ HHHH **** "BBB@ HHHH **** "N?\ $_\
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M/CA_R#M _P"OV\_]$15X%7OOQP_Y!V@?]?MY_P"B(J\"K_.3Z0'_ "=CB/\
M[!LB_P#5+@C]+X;_ .13A_\ '7_]/3"ORX_X*0_!'X_^,O&O[,?QO^"/P^\
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MT^^22.-[&[66?>8HFMY1)*(P#(8T*AI!&&4N4!VY!<@$&I?[)U+_ *!>H?\
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M_P"$"\5_]"[J'_?G_P"RH_U1XP_Z)7B#_P ,^:?_ #%Z_P!/0^OX+_H+P_\
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M_P#F+U_IZ'U_!?\ 07A__!]+_P"3_JWI?EZ*ZC_A O%?_0NZA_WY_P#LJ/\
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M^*X5_P"1YXC?]ECE_P#Z[S@0[<5_ RW_ + JG_JQQX4445]J<04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!F:K_R#M3_Z\+K_ -$-7/\ P^_Y$;P5_P!BIH'_ *:K:N@U7_D'
M:G_UX77_ *(:N?\ A]_R(W@K_L5- _\ 35;5\/B?^3BY7_V1N>_^K[A<[H_\
MBVK_ -AU#_U'Q!V=%%%?<'"%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <!K__ "/'P^_ZX>+/
M_2+3:[^N U__ )'CX??]</%G_I%IM=_7Q7"O_(\\1O\ LL<O_P#7><"';BOX
M&6_]@53_ -6./"BBBOM3B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,S5?^0=J?\ UX77_HAJ
MY_X??\B-X*_[%30/_35;5T&J_P#(.U/_ *\+K_T0U<_\/O\ D1O!7_8J:!_Z
M:K:OA\3_ ,G%RO\ [(W/?_5]PN=T?^1;5_[#J'_J/B#LZ***^X.$**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH XOQ-X:U#5[_0M4TK74T2^T(:DL<DNEIJD=Q'J<5O#*K1->6(
M1D6U!5@S#YLX&T&J?]@^._\ H?M/_P#"-MO_ )=UZ!17R&*X'R'%YAF&:2EG
M^&Q>:5Z&)Q[ROB_B_)L/B,1A\#@\MI5Y8'*<]P6!A56!P&#P\JE+#4Y5(T(3
MJ.<^:3[(8_$0ITZ5L/.%&,HT_;8+!UY1C*I.JXJI6P]2HU[2<Y6<FES-*RT/
M/_[!\=_]#]I__A&VW_R[H_L'QW_T/VG_ /A&VW_R[KT"BLO]0LC_ .@SC#_Q
M8GB#Y?\ 54>7Y=BO[0K_ //O!?\ ALR[_P"9/+^KL\__ +!\=_\ 0_:?_P"$
M;;?_ "[H_L'QW_T/VG_^$;;?_+NO0**/]0LC_P"@SC#_ ,6)X@^7_54>7Y=@
M_M"O_P ^\%_X;,N_^9/+^KL\_P#[!\=_]#]I_P#X1MM_\NZ/[!\=_P#0_:?_
M .$;;?\ R[KT"BC_ %"R/_H,XP_\6)X@^7_54>7Y=@_M"O\ \^\%_P"&S+O_
M )D\OZNSS_\ L'QW_P!#]I__ (1MM_\ +NC^P?'?_0_:?_X1MM_\NZ] HH_U
M"R/_ *#.,/\ Q8GB#Y?]51Y?EV#^T*__ #[P7_ALR[_YD\OZNSS_ /L'QW_T
M/VG_ /A&VW_R[H_L'QW_ -#]I_\ X1MM_P#+NO0**/\ 4+(_^@SC#_Q8GB#Y
M?]51Y?EV#^T*_P#S[P7_ (;,N_\ F3R_J[//_P"P?'?_ $/VG_\ A&VW_P N
MZ/[!\=_]#]I__A&VW_R[KT"BC_4+(_\ H,XP_P#%B>(/E_U5'E^78/[0K_\
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M_P#PC;;_ .7=']@^._\ H?M/_P#"-MO_ )=UZ!11_J%D?_09QA_XL3Q!\O\
MJJ/+\NP?VA7_ .?>"_\ #9EW_P R>7]79Y__ &#X[_Z'[3__  C;;_Y=T?V#
MX[_Z'[3_ /PC;;_Y=UZ!11_J%D?_ $&<8?\ BQ/$'R_ZJCR_+L']H5_^?>"_
M\-F7?_,GE_5V>?\ ]@^._P#H?M/_ /"-MO\ Y=T?V#X[_P"A^T__ ,(VV_\
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M$X3_ /#7F7E_U._+\?6Y_J=E7_/W'?\ @ZE_\H\OZNSZV_X7#X'_ .@A<?\
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M_G[CO_!U+_Y1Y?U=GUM_PN'P/_T$+C_P77G_ ,;H_P"%P^!_^@A<?^"Z\_\
MC=?)-%'_ !--XE?] G"?_AKS+R_ZG?E^/K<_U.RK_G[CO_!U+_Y1Y?U=GUM_
MPN'P/_T$+C_P77G_ ,;H_P"%P^!_^@A<?^"Z\_\ C=?)-%'_ !--XE?] G"?
M_AKS+R_ZG?E^/K<_U.RK_G[CO_!U+_Y1Y?U=GUM_PN'P/_T$+C_P77G_ ,;H
M_P"%P^!_^@A<?^"Z\_\ C=?)-%'_ !--XE?] G"?_AKS+R_ZG?E^/K<_U.RK
M_G[CO_!U+_Y1Y?U=GUM_PN'P/_T$+C_P77G_ ,;H_P"%P^!_^@A<?^"Z\_\
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M95_S]QW_ (.I?_*/+^KL^MO^%P^!_P#H(7'_ (+KS_XW1_PN'P/_ -!"X_\
M!=>?_&Z^2:XRT^(W@2^\7WGP]L_'7A&]^(6F:3)XAU#P/:>(](G\7Z?H<5S:
M6<FN7OAF*\DUVTTF.]U>SLY-2N+5+1;B\M+=IA+>6<9J/TH_$^:DZ>7\+5.2
M+G4Y,HS27)"+BG.;CG+48)M)RE:*NKO5WE\'Y2FDZV-5W97KTE=Z:+]QJWT7
M77S/NG_A</@?_H(7'_@NO/\ XW1_PN'P/_T$+C_P77G_ ,;KY)HJ?^)IO$K_
M *!.$_\ PUYEY?\ 4[\OQ];U_J=E7_/W'?\ @ZE_\H\OZNSZV_X7#X'_ .@A
M<?\ @NO/_C='_"X? _\ T$+C_P %UY_\;KY)HH_XFF\2O^@3A/\ \->9>7_4
M[\OQ];G^IV5?\_<=_P"#J7_RCR_J[/K;_A</@?\ Z"%Q_P""Z\_^-T?\+A\#
M_P#00N/_  77G_QNOA#XA?$_X>_";0SXH^)OQ"\%?#+PNES%9/XB^(7BC1/"
M>A+=S;F@M&U?Q#?:3IRW,RP,T4!E\UPCE%<)(:W_  ]XCT+Q;HVE^(_#.NZ1
MXG\.:Y:1:AI&O>'=1L]6T;6+&8;H+[2]3TV:\L=0M9E^>*YM)9(G )1R.:O_
M (F@\4E1AB7EG#"P]2;IPKO)\U5&52"C*5.-5YQ[*52,7S."FY)-.2U][-<)
M90Y<JK8QRM=Q^L47)+2SY?87L_3773<^T/\ A</@?_H(7'_@NO/_ (W1_P +
MA\#_ /00N/\ P77G_P ;KY)HJ/\ B:;Q*_Z!.$__  UYEY?]3OR_'UOI_J=E
M7_/W'?\ @ZE_\H\OZNSZV_X7#X'_ .@A<?\ @NO/_C='_"X? _\ T$+C_P %
MUY_\;KY)HH_XFF\2O^@3A/\ \->9>7_4[\OQ];G^IV5?\_<=_P"#J7_RCR_J
M[/K;_A</@?\ Z"%Q_P""Z\_^-T?\+A\#_P#00N/_  77G_QNODFN0/Q!\$CQ
M<GP^/C7PH/B!)I$_B./P0?$&E#Q=)H5M+;P7&N)X:^U_VXVD6TVI6T$^I+;&
MTCDN;:.65&N;<&H_2B\3Y\WL\!PM4Y(2J3Y,HS27+"%G*<N7.9<L(K64Y6C&
M^KU=Y?"&4QM>KC5=I*]>BKMV22O05V_QVW>OW+_PN'P/_P!!"X_\%UY_\;H_
MX7#X'_Z"%Q_X+KS_ .-U\DT5/_$TWB5_T"<)_P#AKS+R_P"IWY?CZWK_ %.R
MK_G[CO\ P=2_^4>7]79];?\ "X? _P#T$+C_ ,%UY_\ &Z/^%P^!_P#H(7'_
M (+KS_XW7R311_Q--XE?] G"?_AKS+R_ZG?E^/K<_P!3LJ_Y^X[_ ,'4O_E'
ME_5V?6W_  N'P/\ ]!"X_P#!=>?_ !NGK\7_  ,S '5)D!)&Y]-O]OU.R!VQ
M] :^1J*:^E-XE)IO!\)-)IN+RO,[.UM';.T[.S6C3UWOJU_J=E7_ #]QWK[:
ME^N'?];GW=I&O:1KD+3Z5J-KJ$:XW_9I0SQ$]IXCB6 GLLRHQ'S 'J-JO@32
MM5O]%O(;_3;J6SN[=LI+$V,@G)BD0[DEB?&V2*4-&Z\,I!K[%\!^+8O&&B1W
MX18KV!_LVI6ZD[8KE5#>9$&+-Y%PA66+)^4EH2TC0NY_HWP>\=<!XCUIY'FF
M$I9/Q/2H3Q-.A1JRJ8',\/2Y?;SP3JMUJ-?#\RE5P5:=:?L']8HUZT(5UA_E
ML[X>JY5%5Z4Y5\)*7(YN-JE*3^%5%'W7&?2I%1BI>Y*,6X\W;4445_0)\X%%
M%% !1110 4444 %%%% !1110 4444 %%%% 'PSXWO);[Q5XCN)22QU>\@7)R
M5AM9WM8%[?<@MT7ZC\^=KN?BCHDFC>+=59D(M]4F?5[9\';(+MVDG&>1F*\,
ML14$,%V-QO2N&K_(7C;"X_ \:<5X7-(U%CZ6?9I]:=2_/4J5,=B:OMKOXXUX
MSC7IU%>-2G4C.+<6I/\ :\MG3J8#!SHV]F\/1Y$OLI4XKE\N5WC;=-6:3N%%
M%%?,G:%%%% 'YF?MM_ G]H/7/CC\#_VF?V4O$OPP\7?&?]FOP;XT\.ZY^S[\
M8[V6S\/?$'P!\5;FR%W?>'?$&GM<7WPQ\=ZC=?#"YT;P]XFU"U71]6^QSZ7J
MVI6VF:#XIT&O.?V;_C]>_&GX5?MMZU^RO\&+;]FC]N;PGXM_M;XT?L^_&[1(
MM3\.VGQY@\&VMIH]QJ%UX3U;P18Z_HWQ=\/^";/2+/XAZ-?6/]HR6,/C+4=*
ME7[2Y^_?&?[.?ASQ3\38_C+IWC#XC?#[XGQ>!;+X9)XA\"^)(K:RN/"NGZUK
M'B*UL-9\&^(-.\6?#OQ5/;:KXJO9[&]\9:#JUWI(GN?^$:FT9]2\02UYW%\)
M8?V2_!/Q=\=_ ?X+>*_VB_C-\3O&&D^./B#;ZCX^\,:+\1?C+KTLVF^'9M7U
M3QKX]O/"W@G2;;P9X2C:30?"]A_8?AFPT^Q;0_"NEZ5/J4['[_"9[E]?(\%E
M%2-#&YGA899A<EJUXT\MHQ7]MPS3'97Q!4KXVED^8</2JUL3B*&)QBI8[#XN
M<(U:]#+:,U+RI8:K&O.M[T*4G4G6C%NK*_L%2IU<,HTW7IXA*,8RA!RA**?+
M&=1H\V_9B_:^\0?M6Z5^SAK'PYO]$L8-=^$NO?$/]H>RU[PS>/JOPZ\5V6I/
M\/--^&$FG)KVE7'A?Q))\6?#7C.RD74O[12?1/A[XDM5-G/JWA?Q*?C75/\
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MN?"/X%?$/1/!_A;5?#NI>"=?^-4#6W@_QO\ #'5YO%'BG^VO"N@>(3#I^O\
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M1_86L_\ 0%U7_P  +K_XW7WO11_Q*)E'_1:X_P#\,F%\O^H[R_JRL?ZZ5_\
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MH_L+6?\ H"ZK_P" %U_\;K[WHH_XE$RC_HM<?_X9,+Y?]1WE_5E8_P!=*_\
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MUTK_ /0!2_\ !]3R_N?U]]_@C^PM9_Z NJ_^ %U_\;H_L+6?^@+JO_@!=?\
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MBI-,HHHK],/*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*3$_^&+//_F /]5\Z_Z!8_\ A1A__EO]6]#Z8HKYG_X7WJ'_ $+UG_X&S?\
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M **3$_\ ABSS_P"8 _U7SK_H%C_X48?_ .6_U;T/IBBOF?\ X7WJ'_0O6?\
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MZYAT+QU\%K;Q5I<EK>IX.F,RZ/J-Y\4->\):GJL^D?$BN1\%^-M2^+?[._\
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M6*JX:KBZ+H5\?CJV'E4P\*D</4J4L-AJ=2K*+K2K5W0JT:=-_*<1\14,91>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:W/JN'_Y\TO_  53\O[GDC4_X2+7?^@[K'_@QO/_ ([1_P )%KO_ $'=8_\
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MHJ_+:[;BH_S:6O=7]B_X2+7?^@[K'_@QO/\ X[1_PD6N_P#0=UC_ ,&-Y_\
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MV;M*^T*&$J+FA3HR5[75.DU=6TNHO565UNK>>NI_PD6N_P#0=UC_ ,&-Y_\
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MF\ Z5<_%'X*_M9>$_C?XKAM_&7AO_A'9_"'AK]H_Q!\<K@:)K4E[#+?:M?\
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M1V_VQFO_ $,<9_X45/\ Y(\J_P"%.>"?^?.[_P#!A<?XT?\ "G/!/_/G=_\
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M_AEP/_RG^K^@?VQFO_0QQG_A14_^2/*O^%.>"?\ GSN__!A<?XT?\*<\$_\
M/G=_^#"X_P :]5HH_P"(3>&7_1!\+?\ AEP/_P I_J_H']L9K_T,<9_X45/_
M )(\J_X4YX)_Y\[O_P &%Q_C1_PISP3_ ,^=W_X,+C_&O5:*/^(3>&7_ $0?
M"W_AEP/_ ,I_J_H']L9K_P!#'&?^%%3_ .2/*O\ A3G@G_GSN_\ P87'^-'_
M  ISP3_SYW?_ (,+C_&O5:*/^(3>&7_1!\+?^&7 _P#RG^K^@?VQFO\ T,<9
M_P"%%3_Y(\J_X4YX)_Y\[O\ \&%Q_C1_PISP3_SYW?\ X,+C_&O5:*/^(3>&
M7_1!\+?^&7 __*?ZOZ!_;&:_]#'&?^%%3_Y(\J_X4YX)_P"?.[_\&%Q_C1_P
MISP3_P ^=W_X,+C_ !KU6BC_ (A-X9?]$'PM_P"&7 __ "G^K^@?VQFO_0QQ
MG_A14_\ DCRK_A3G@G_GSN__  87'^-'_"G/!/\ SYW?_@PN/\:]5HH_XA-X
M9?\ 1!\+?^&7 _\ RG^K^@?VQFO_ $,<9_X45/\ Y(\J_P"%.>"?^?.[_P#!
MA<?XT?\ "G/!/_/G=_\ @PN/\:]5HH_XA-X9?]$'PM_X9<#_ /*?ZOZ!_;&:
M_P#0QQG_ (45/_DCRK_A3G@G_GSN_P#P87'^-'_"G/!/_/G=_P#@PN/\:]5H
MH_XA-X9?]$'PM_X9<#_\I_J_H']L9K_T,<9_X45/_DCRK_A3G@G_ )\[O_P8
M7'^-'_"G/!/_ #YW?_@PN/\ &O5:*/\ B$WAE_T0?"W_ (9<#_\ *?ZOZ!_;
M&:_]#'&?^%%3_P"2/*O^%.>"?^?.[_\ !A<?XT?\*<\$_P#/G=_^#"X_QKU6
MBC_B$WAE_P!$'PM_X9<#_P#*?ZOZ!_;&:_\ 0QQG_A14_P#DCRK_ (4YX)_Y
M\[O_ ,&%Q_C1_P *<\$_\^=W_P"#"X_QKU6BC_B$WAE_T0?"W_AEP/\ \I_J
M_H']L9K_ -#'&?\ A14_^2/*O^%.>"?^?.[_ /!A<?XT?\*<\$_\^=W_ .#"
MX_QKU6BC_B$WAE_T0?"W_AEP/_RG^K^@?VQFO_0QQG_A14_^2/*O^%.>"?\
MGSN__!A<?XT?\*<\$_\ /G=_^#"X_P :]5HH_P"(3>&7_1!\+?\ AEP/_P I
M_J_H']L9K_T,<9_X45/_ )(\J_X4YX)_Y\[O_P &%Q_C1_PISP3_ ,^=W_X,
M+C_&O5:*/^(3>&7_ $0?"W_AEP/_ ,I_J_H']L9K_P!#'&?^%%3_ .2/*O\
MA3G@G_GSN_\ P87'^-'_  ISP3_SYW?_ (,+C_&O5:*/^(3>&7_1!\+?^&7
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MXFEEF/JU%5DYTZV8T*.)O'#TCR_]H7]I3XS?L^VGP.?Q?:?"'1V^*O[4>D?
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M54ZY[WX:_:[^!WBWQ%X-\(Z)XGO;OQ1XY\4_$/P/HNACPYX@6[C\:?"O0O\
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MQX4TJPN6M5M[&YTR;5H+:"PNM0MM0MDN_P#@F]X;O-$^.&DK\4=4TB;XVS_
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MXS_X4]\*-6\57GA#6=<\->.-#\1> ?B+X>\2^'=0'B?PUXMT?2=+U+PLD?\
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M,33HMZ?55%?EEH/BWP/XS_X*1P>/O"WB'PSXF^&FG?L(^(=>U#Q9HVI:=?\
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M'O(/[?U!&]P_8,\7_$?XRP?%?7/CO-JUK\1/ MK\)?A!-X:N;F\TB\\)M/\
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M?M;>TC"E).4E[6/LW&*5W>4>:/+'E^U97YG?&LLLE[?"5UAO]WG5KTY*$/\
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MZ$%^T1:1/:ZDS>5.@.=\0/B9X:^'/ART\5:R]U?66I^*/!_@W2;;0HH=0O\
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7?&U94XJ:4%&G%*RES?;5%%%<!].?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img248422670_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_7.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $5 D(# 2(  A$! Q$!_\0
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M5=OZ_I?U=G._\(QIW_/UX@_\*KQ+_P#+:C_A&-._Y^O$'_A5>)?_ );5T5%
M<J[?U_2_J[.=_P"$8T[_ )^O$'_A5>)?_EM1_P (QIW_ #]>(/\ PJO$O_RV
MKHJ* Y5V_K^E_5V<[_PC&G?\_7B#_P *KQ+_ /+:C_A&-._Y^O$'_A5>)?\
MY;5T5% <J[?U_2_J[.=_X1C3O^?KQ!_X57B7_P"6U'_",:=_S]>(/_"J\2__
M "VKHJ* Y5V_K^E_5V<[_P (QIW_ #]>(/\ PJO$O_RVH_X1C3O^?KQ!_P"%
M5XE_^6U=%10'*NW]?TOZNSG?^$8T[_GZ\0?^%5XE_P#EM1_PC&G?\_7B#_PJ
MO$O_ ,MJZ*B@.5=OZ_I?U=G._P#",:=_S]>(/_"J\2__ "VH_P"$8T[_ )^O
M$'_A5>)?_EM7144!RKM_7]+^KLYW_A&-._Y^O$'_ (57B7_Y;4?\(QIW_/UX
M@_\ "J\2_P#RVKHJ* Y5V_K^E_5V<[_PC&G?\_7B#_PJO$O_ ,MJ/^$8T[_G
MZ\0?^%5XE_\ EM7144!RKM_7]+^KLYW_ (1C3O\ GZ\0?^%5XE_^6U'_  C&
MG?\ /UX@_P#"J\2__+:NBHH#E7;^OZ7]79SO_",:=_S]>(/_  JO$O\ \MJ/
M^$8T[_GZ\0?^%5XE_P#EM7144!RKM_7]+^KLYW_A&-._Y^O$'_A5>)?_ );4
M?\(QIW_/UX@_\*KQ+_\ +:NBHH#E7;^OZ7]79SO_  C&G?\ /UX@_P#"J\2_
M_+:C_A&-._Y^O$'_ (57B7_Y;5T5% <J[?U_2_J[.=_X1C3O^?KQ!_X57B7_
M .6U'_",:=_S]>(/_"J\2_\ RVKHJ* Y5V_K^E_5V<[_ ,(QIW_/UX@_\*KQ
M+_\ +:C_ (1C3O\ GZ\0?^%5XE_^6U=%10'*NW]?TOZNSG?^$8T[_GZ\0?\
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M*6)Q)'+%(H:.6)U+(\;H5965V5E;=C'6S7P";UT:_KSL_P #ZI.^OY!1113
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M<Y^P4445^;GV(4444 %%%% !1110 4444 %%%% !1110 4444 5+S_CWN?\
MKVE_]!-9WAW_ ) 6A?\ 8'T[_P!(XJT;S_CWN?\ KVE_]!-9WAW_ ) 6A?\
M8'T[_P!(XJ"7NOZ^U$W****"@HHHH **** "BBB@ HHHH **** "BBB@ KG?
M#'_(+7_K^UG_ -/-_715SOAC_D%K_P!?VL_^GF_H(EO'U_5'14444%A1110
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M[*_PE_:Q^'UU\/\ XJ:"E[&JW$WAKQ-9>3;^*/!.KRQ"-=9\-:HT4C6LVZ.
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MTFOI,#6I8'AV>-C@<OQ.(GG"P[J8W"4\4XT5A(U.2'M/@]]\VGFG>[/Q_/\
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M/_@VFT'0_$G[-O[>-EKFFV6KVMG_ ,%5OC?XELH;R))UM=9T#P_\%-;T#58
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M<ZIX%745O/\ A#M3N9]2\-'3+Z>:=_>*I*U]ODK$WOTM]_9?K?7_ ""BBBF
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M3LDVEMH^M[O>_P#P_GU*C>VN]^UC+U;_ )!^H_\ 7C=?^D[U\.?\$T_^31_
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M;]\+?_40TFO<7_))/_L?/_U!@?F*_P"3R2_[-NO_ %I3Z[J(G'3TZ\=FX/\
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MF?B_QMXF^!WPX\(_L[Z,WQ7^)'[1_P"TQ^R3\0- \5_&&ZT3P]\+/C!^S=X
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M<^#=7O+M3\KP:79^)6U9@-Q233TG3,B(Y_NWK_..!(*XR#G@CJ",XP>H/?\
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M^'U]%!-I7A)O GP_^(.G6_A@^(-,\1)\2O&6EZOX=E;X?Z)'IWB_5.A\8?\
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M_OB/_P!C5\-O_4VTFO>X4_Y*GA[_ +&V!_\ 4N@?FOC+_P FD\2?^R+XB_\
M55BC];****\$_2C\^?V&?^1P_;3_ .SLOB1_Z<;BOT&K\^?V&?\ D</VT_\
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MSJWA76[<8$AT_6;*>PFGM9&5_(O+99_M-E=*IDM;N&&YB(DA1J_@:^.GP?\
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M<0VO=O2E!X>F[IINI7Y+P?Q4XU']D_5*BBBOXD/Z,"BBB@ HHHH ^/?V^O\
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M 5_/'_P7*_9#?Q5X7T']J[P9IAEU3PA;6?A#XKV]G!NEN_#-S=-'X7\7RI$
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MH6>RU.*.Z9M \%2' 1Y/&&I6$T5W"7A;_A'M-U^YBE%W:P))_;$JJJA5PJ*
MJJHP%5> H S@*!E,<#K7QS^PU^R3X<_8[^!6@?#BP-I?>+]1V>(OB5XFMDY\
M0^,;VWA6]\B65(Y3HVAQ1PZ+H4+11$:?9)?3P)J>HZE+/]EU_#GB;QD^,N)*
M];#5)2R?+E+!Y5%IJ-2FI)U\:XNS4\94@I*_*_J]/#QG!3A*_P#1O!O#ZR#*
M80JP4<?B^6OC7HW&5OW>'YDM8X>+:W:=65649.,E8HHHK\]/K0HHHH ****
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M%02]U_7VHFY11104%%%% !1110 4444 %%%% !1110 4444 %<[X8_Y!:_\
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MX;_^9ZBB@+>OWO\ KI_5V']E:A_T-&N_]^/#?_S/4?V5J'_0T:[_ -^/#?\
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M .9ZBB@+>OWO^NG]78?V5J'_ $-&N_\ ?CPW_P#,]1_96H?]#1KO_?CPW_\
M,]110%O7[W_73^KL/[*U#_H:-=_[\>&__F>H_LK4/^AHUW_OQX;_ /F>HHH"
MWK][_KI_5V']E:A_T-&N_P#?CPW_ /,]1_96H?\ 0T:[_P!^/#?_ ,SU%% 6
M]?O?]=/ZNP_LK4/^AHUW_OQX;_\ F>H_LK4/^AHUW_OQX;_^9ZBB@+>OWO\
MKI_5V']E:A_T-&N_]^/#?_S/4?V5J'_0T:[_ -^/#?\ \SU%% 6]?O?]=/ZN
MP_LK4/\ H:-=_P"_'AO_ .9ZC^RM0_Z&C7?^_'AO_P"9ZBB@+>OWO^NG]78Q
M]%O7C9&\3Z]MD4HP$/ASE6#*P_Y%_N*VK&V2RM+2RB9VBL[6&VB:0J9&2!%A
M1I"JHI<J@+%44;B<!0=M%%1#;Y_HA=5Z/_VTN44458PHHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img248422670_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_8.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %W B\# 2(  A$! Q$!_\0
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M/M7BO_H!^'?_  IK_P#^96NFHH YG[5XK_Z ?AW_ ,*:_P#_ )E:7[5XJ_Z
MOAS_ ,*;4/\ YE*Z6B@#F?M7BO\ Z ?AW_PIK_\ ^96C[5XK_P"@'X=_\*:_
M_P#F5KIJ* .:-SXJ'31?#F??Q-J _P#=4-'VKQ5_T!?#G_A3:A_\RE=+10!S
M/VKQ7_T _#O_ (4U_P#_ #*T?:O%?_0#\._^%-?_ /S*UTU% '-?:O%6?^0+
MX<QZ_P#"3:AG\O\ A%/ZTGVKQ7_T _#O_A37_P#\RM=-10!S?VGQ5_T!?#O7
M_H9=0Z?^$IU]OUI/M/BKOHOAS_PI=0_^905TM% ',_:O%?\ T _#O_A37_\
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M]J\5?] 7PY_X4VH?_,I2?:O%?_0#\._^%-?_ /S*UTU% '-?:O%7_0%\.?\
MA3:A_P#,I2?:O%?_ $ _#O\ X4U__P#,K7344 <U]J\5?] 7PY_X4VH?_,I2
M?:O%?_0#\._^%-?_ /S*UTU% ',_:O%?_0#\._\ A37_ /\ ,K1]J\5_] /P
M[_X4U_\ _,K7344 <S]J\5_] /P[_P"%-?\ _P RM N?%7_0$\._CXGU _\
MNJFNFHH YK[5XJ_Z OAS_P *;4/_ )E*/M7BK_H"^'/_  IM0_\ F4KI:* .
M9^U>*_\ H!^'?_"FO_\ YE:/M7BO_H!^'?\ PIK_ /\ F5KIJ* .:^U>*O\
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M_P#^96E^U>*_^@'X>_\ "EO_ /YEOK^7Y=+10!S/VKQ7_P! /P[_ .%-?_\
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M%MY&D6(PKCS?,'01H(@J(JHB*$55 5550 JJH*@!0  !Q@8%<;\0/^0#8_\
M8Y_#[_U/?#M=<G"OBY35-4J=6O*2I1TC3C.JI*G%I1TC&2@FE%V5TEI;GPU*
M5*C0I3G*I*G3I4YU);U)0A"$IN[;O-Q;>KUD]9:-ZOVGQ3_T!?#O_A2ZA_\
M,K2?:O%7_0$\/?\ A2WW_P RU=+161L<S]I\4_\ 0$\/_P#A3:A_\R].^T^*
M?^@+X=_\*74/_F5KI** .;^U>)_^@-X?_P#"BU#_ .9:D^U>*O\ H">'O_"E
MOO\ YEJZ6B@#F_M/BG_H"^'?_"EU#_YE:;]I\4_] 3P__P"%-J'_ ,R]1>*_
M%_ASP-I,FO>*M8M=#TA+FVM'O;PR^6+F\F6"WB BCGE<N[;G*(1#"DMU,T5M
M!<3#I1A\,I!5@#D'(P1D'/<$<@^OO7+#&86IB:V#IXBA/&8:G0K8C"QK4Y8B
MA1Q4JT,-6JT5)U*=+$2PV(C0G4C&-9T*RIN3I5%'25&O"C2Q$J%6.'K5*M*E
M7=.:HU*E!4I5Z=.JXJ%2=%5Z+JPC)RIQK4Y324XWP?M/BG_H"^'?_"EU#_YE
M:3[7XI_Z GA_U_Y&2_\ _F6Z^W6MYW2-))))%B2)6>1W8*BHH+,[LQ"JBJ"Q
M8D  %F.,FO/]:^+'PQ\/;UUCX@^#M/FC!+6TVOZ8UW\J[CML8KB2[D^7&%CC
M;+%54,SH#ECLTRW*Z7M\SQ^"RZC_ ,_<;B\/A:?G[^(J4HZ:[2>W;4UPN"QN
M-J>RP6#Q.,J?\^\-0JUYZV2]RC"<M6[+17>QT?VGQ3_T!?#O_A2ZA_\ ,K1]
MJ\3_ /0&\/\ _A1:A_\ ,M7@7C?]J?X<>'_#&M:OX?GU?Q)=VEC(MA-9^&?$
M":(VISPL-,6[US4-.L=*6VGN63S'@NKAS&L@ACFG'D'Y.^%/[7OB'P]\/_%.
MG:W8W/C#Q'H\M_K5MK6L>(8;5DL=6N[&UACDANX[N^UB6RUW4DQ8Z<"JZ=/@
MK9VFGW=\/RO/?'?PWX?SW Y)B<]H8N.+RO,\SJYAE3_M;"82.7J,Z="J\N6*
ME4J8NG#'3C*ES0PZP-1XF5)5(R7W65>%W&6;97BLRH955P\L/CL#@883'VR^
MO7EC'RRJ0^NN@HPH3GA8R4^657ZU#V*FXN+_ $GBU#Q)/YODZ7X9F$,K02^5
MXIO9/)F3!>&0IX6.R5 REXV^<9!."0:I6?B/5+^]U33K*'PA>:GH;VT6KZ?;
M>,+F:\TJ2[A^T6B:C:Q^&7GLFN[;]_;BX1/.BR\6]49J_)#X2?M/^*_AE;>,
M1=:KH]U;Z[=7?BN[U#QC'J-\O]MB*1KMD>QO](Q=:]B"*2>\G2W-S:V7FRV\
M?VJXK@O /[3\_A/QSXG\:S?$;2M(E\7+JESX@OHH-*\1*'FDDU&%K;0[[6-'
MMI9(+N..RLVDO(!96LL@C,D2SV-?G>7_ $G\ES:CPG4RWAK.<74SC,\7@L\P
MN&I_6)Y/"FITL%&A7YJ6%Q.)Q6(K9?5:Q%3"T*6%JUKU?:137T^/\&<7E53/
MX9EQ!E&"AEN!P^+RROBJ\</','+V=3$SJT9<^(H8:A2I8VGS4X5ZLZ]*GRT^
M5Z_LQ:^.Y+[Q1J?@VU'A:?Q1HVGVNK:EHR>)-5^T6FGW;A(+EV/A,0N&:6(O
M''(\T0FM7G2%+VU9^E-WXH#!/['\/;B"P4^)K\,54@,P4^%B6"EP"1D9*@_>
M&?P!\,?MG^%]'^)LGQ'3XS?#^7Q%JFH71U)Y?$?A_45NH-0'V:6T?28M4TE+
MV&V@V"ST^&6U1)+>U6WEM##;RU]*:A^U;XQ/Q<T[X@B;2=7M?#UK<^&;?3],
M@U+2M%UW0YY9!>7:VMY/?:C8R:I,L>K0->,]Q;/;:8MW;RFP>Q.\?I'X?)L!
M'%\<<(<1\,U,7Q1/+<NACLLQN!IU>'I8BG..;/Z[!5\1B\OP$XSS+"X.C5IR
MQ'L8T:E*.*IPARX;PKP^?XNIA^#.+N'>)HX/(J>-S"669K@,QGA\W=*4?J#>
M!JU*6'P^-Q=*<<!7Q52G/V,:KJ4YO#SD_P!9GU#Q'%)!"^E^&DFN-_D1OXHO
MEEF\M0TODH?"RO+Y2?._E@[5P[8R#4_VGQ3_ - 7P[_X4NH?_,K7Y$_%#]IO
MQ3XI^(WA;Q;IS6FE+\/KN4:3#H6HW]QI]^\MUNU.Z-U=VVESW%EKEG;QZ=-%
M):0++IR^3/ 5GN(S]B^%/VZ?@EKFH+H>MZNGASQ#';6]Q?Z:FI:/XFDTU;B"
M&ZA&I6WA6_U;6M'=[:Y@N#%KFCZ9*MO)'.\:*VY?L^#_ !XX)XMSGBC*J.)J
M8&CD&)H+#YCBZ.)IX/'9?*E3I5\QQ%>6'C0RJGA\R]M@W_:%:C"K3>%K4YN=
M>I0H>'Q)X9\0<-9=P_CL1"C6J9Y"</J=*OAOK-+'*4ZE' X:E[?VV95JV!5/
M$J."I5)QY<1"4%"C&I4^L/M7BK_H">'O_"EOO_F6I?M/BG_H"^'?_"EU#_YE
M:^7?BI^V?\,O  T6U\,9^)6L:U:S:D+;P[=&'2-(TZVF2WEDU[71:7UMI>H7
M,TI_LW1GA?5+Q(Y;J2VM=/AEU >X_"/XN^!_CCX-T_QY\/M9_M31+B[OM,O;
M>6/[+JN@Z[I4[6FL>'/$%@[--IFM:1=HUO=6TA>*9&@U'3KC4-)U#2]4F_4<
MMXDR+.<9C,!E&:X+,L3E^%R[&XR."KPQ,*&%S:6+CEU9UZ+GAYQQ3P.*<(TZ
MLIQA"%2I&$*]!U?A,9@L9E\<++'X6M@OKM?'X;"PQ4)4*E>OE<<%/,(0HUE"
MJWA%F&$59\G*I5>1-SIU8P[#[7XI_P"@)X?Q_P!C)?Y_+_A%OZ_XTGVGQ3_T
M!/#_ /X4VH?_ #+UTU%>X<QS/VGQ3_T!/#__ (4VH?\ S+T?:?%/_0$\/_\
MA3:A_P#,O7344 <U]K\4_P#0$\/^O_(R7_\ \RW7VZTOVGQ3_P! 7P[_ .%+
MJ'_S*UTE% '-_:?%/_0%\._^%+J'_P RM'VGQ3_T!?#O_A2ZA_\ ,K7244 <
MU]K\4_\ 0$\/^O\ R,E__P#,MU]NM+]I\4_] 7P[_P"%+J'_ ,RM=)10!S/V
MGQ3_ - 3P_\ ^%-J'_S+T[[3XI_Z OAW_P *74/_ )E:Z2B@#F?M/BG_ * G
MA_\ \*;4/_F7IWVGQ3_T!?#O_A2ZA_\ ,K7244 <U]J\5?\ 0$\/?^%+??\
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M !S]?:@!;G_D:M$_[%WQ+_Z</"G?M_GTKI*YFZ_Y&O0_^Q=\3?\ I?X5KIJ
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MM2J1=XU*56$:E.<7UC.$E*+ZIW04444C4**** "BBB@ HHHH **** "BBB@
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M3]Y2C"4?UHHHHJS4**** "BBB@ KAOB!_P @&Q_['/X??^I[X=KN:X;X@?\
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MA@AD:*T\->/;NSUF>><DB**U^)UEXE>5CY,7C'P[ SS"[\-OV_+%?%</PO\
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M2@DY2CB:57E3YHKVCP\(RBH*7[Z-&=9.3LZ-*6)A*455JP?ZCT445184444
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MT6N6&)PF&S;#RJ."JTI_9M%%%?2DA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7F'Q5^#GPS^-GAR7PC\4_ WAWQU
MX?F+.EEX@L4N'T^Y*E!?Z1?J8]1T34HT)$.IZ/<6FH0D[H;B(Y:O3Z*J%2I2
MJ0JT:DZ56FU*%2G*4)PDFFI1E%J49*VC3370PQ6%PV-P]7"8S#T<5A:\'3KX
M?$TJ=>A6IR^*G5HU8SIU(26DHSBXM;H_*;Q#^QY\<O@?J5UXJ_9Q\=:C\2]
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MYK6G4C>%2/O0;BTV4445WG*%%%% !1110 4444 %%%% !1110 4444 %%%%
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MB_[_ /AKKZ_\C%^OWO:C^W-0_P"A/\1?]_?#'_S1UTU% ',?V[J/_0G>(?\
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M?XB_[^^&/_FCH_MS4/\ H3_$7_?WPQ_\T==-10!S']NZC_T)WB'_ +_^&/\
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M^(_%7G>!KV*RCTF?Q2HTW5EU*72;#5+C5VUZXE$X73$5.;W:?LJC<[.7M)+
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M4$KZVC2I0BK]%W"BBBOJ3R HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7^<DQJI)?YB<%N2U7JHV0"V=H!)#.!;0 2VRA8)E\I1YD"AW"PO]Z-0S (5
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M).Z>D)\-QFK<K4HQ:DFD?I$/%.F@ &VU_@#IX6\3'_W$T?\ "5:=_P ^NO\
M_A+>)_\ Y3UTM%>TE;\/P5OQL=9S7_"5:=_SZZ__ .$MXG_^4]'_  E6G?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N:T+_ )"?C#_L8[?_
M -1;PU72US6A?\A/QA_V,=O_ .HMX:H 2Z_Y&O0_^Q=\3?\ I?X5KIJYNY_Y
M&G1?^Q=\2_\ I?X5KI* "BBB@#R#XXIXOE^%WC&+P)=:O9>));"&**]\/P17
M'B6RTM[ZU3Q#>^%[:X2>"Y\4V?AYM1G\.PS02I-K"62&&X+"!_C3]F/6_!+?
M$JQT3X#Z_P#M+>,O#4=OK<OQAUGXW#XDR^&]/O8[(C28[:3XKZ5I&H6OQ!N?
M$9@\^T\(6\6F2:.-9FUV)S!X<DK[6^,7CZ\^&GPZ\4>,M,T*?Q1K&DVMK'H7
MAJU'^D^(];U&_M-*T70[5QA8KC5=4O[>QMY)FCMHI)EENIH;=99Q\LWO[8'B
MZ3Q#\/\ P-%\&M0\$?$GQ*_CG4O$7@_XC^(-+0Z3H'@CP?%XM6?3-9\%2^*]
M+U"3Q0EW:Z;IMZTT<>FSI>G5++S($MWSISC2E7JMVBJ+51W]G:$:%2<W*<[^
MUHX:ESXNK0I+VD.2%>I+E<$YJ0=6-&G%-SE7O32]Y2FI4FX**MRU9\L:5.K4
M;BO:.G%<TF??5?C)\0?#VM?$7Q)XG\8^'OV0?C1XZ^%'A_QIXHU%/#VM_M*>
M&_#OPIUOQ/X2\17T.J^*=3^!M_XBEU&.&+Q1H=QK1T.&"%-1E5KUM(-WJ=TA
M_6_P5XMTSQWX2\+>,]&:5M'\7^'M*\2Z89D\N;[!K-C!J%JLR9.R58;E$D3)
M"N&"EL;J_(+7_P!GSP#KVL_$;XIW7[*]_)\&(]?\<>(=<^(U]^TCX[T7Q]J-
MO;:SJ\_B'QSX8^%VG:A_PA*Z)IDMM=3:)X=UN6WN]0T>TAEN;:>6?^Q3K",J
M.9X>-:+I2P\I\_-I[.K3Q.%TD_W5G"4&U;%T)1J0A52?LO;X:7.%?!R]DG56
M(E1Y(1C)SJ4ZM&O?DBE4E=J4$_\ 9:W-"<J6]14:_P"SMHQ:UM7,:Q;[>)C$
MHVK&6C&8P,C 3.T#M@*#W-RJ-B8&LK0VSF2V>UMS;R'.7A,:F%SD*<M'ACD
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M/2;JZC\P-&/[4^*^^RF>+#36\J1RKMD23W'X CS_  =KVM'D>)/B1\2=<&<
M8G\9ZS9?*@R8A_H.-LC.VX%MVUUQ\_Q!>>?>'&!B[QIX+B_B"2Z<]*5+(>:U
M[)J./I1YOY9I;,X>%?>EXIYA*RDLTX0X:C*VKHTLHP_$48WTNO;8C$^[9VE"
M3LG<]SHHHKW3M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ&;P]_X-['_X_72T4 <S_P )?X6_Z&CP_P#^#?3_ /X]1_PE_A;_ *&CP_\
M^#?3_P#X]7344 <S_P )?X6_Z&CP_P#^#?3_ /X]1_PE_A;_ *&CP_\ ^#?3
M_P#X]7344 <S_P )?X6_Z&CP_P#^#?3_ /X]3O\ A+O"W_0SZ#_X-=/_ /C]
M=)10!S7_  E_A;_H9_#_ /X-[#MU_P"6_P")H_X2_P +_P#0SZ!UQ_R%[#KZ
M?Z[K72T4 <U_PE_A;_H9] _\&UA^'_+?O_\ JS2?\)?X6_Z&CP__ .#?3_\
MX]7344 <U_PE_A;/_(S^'_I_:]A_\?S2?\)?X6_Z&CP__P"#?3__ (]7344
M<U_PE_A?K_PD^@8]?[7L/_CU)_PE_A;_ *&CP_\ ^#?3_P#X]7344 <S_P )
M?X6_Z&CP_P#^#?3_ /X]1_PE_A8=?$_A_P#\&]A_\>KIJ* .9_X2_P +?]#1
MX?\ _!OI_P#\>H_X2_PM_P!#1X?_ /!OI_\ \>KIJ* .9_X2_P +?]#1X?\
M_!OI_P#\>IW_  EWA;_H9]!_\&NG_P#Q^NDHH YG_A+_  M_T-'A_P#\&^G_
M /QZC_A+_"W_ $-'A_\ \&^G_P#QZNFHH YG_A+_  M_T-'A_P#\&^G_ /QZ
MC_A+_"W_ $-'A_\ \&^G_P#QZNFHH YG_A+_  M_T-'A_P#\&^G_ /QZE_X2
M_P +'IXG\/\ X:O8?_'S72T4 <U_PF'A7_H9O#W_ (-['_X_2?\ "7^%O^AH
M\/\ _@WT_P#^/5TU% ',_P#"7^%O^AH\/_\ @WT__P"/4?\ "7^%O^AH\/\
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M#JRG#*P-RB@ KFM!_P"0GXQ]_$=N?_+6\-K_ .RUTM<UH1_XF?C >GB*W_\
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M **** "BBB@ HHHH *YK0O\ D)^,/^QCM_\ U%O#5=+7-:%_R$_&'_8QV_\
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M[]15H2ITVE*/+*>68FKB(Q=[/#TW2I-R5%N=>,J4\1*BE2_6FBBBJ-0HHHH
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MI_X0,^'5\=GPYK0\&'Q@-0/A4>*O[-N?^$=/B@:/_P 3@^'AK7V7^V!I!_M
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MZMJ[Z?I]IXFO?"<VAS:7#;'4N/V@=2^,?[&7Q9^(/A/08O!%YH^A^*O#,/\
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MJ5WT&?8?FG^%&?8?FG^%<]_PB'A7_H5O#O\ X)M._P#C%'_"(>%?^A6\._\
M@FT[_P",5^UGYN=#GV'YI_A1GV'YI_A7/?\ "(>%?^A6\._^";3O_C%'_"(>
M%?\ H5O#O_@FT[_XQ0!T.?8?FG^%&?8?FG^%<]_PB'A7_H5O#O\ X)M._P#C
M%'_"(>%?^A6\._\ @FT[_P",4 =#GV'YI_A1GV'YI_A7/?\ "(>%?^A6\._^
M";3O_C%'_"(>%?\ H5O#O_@FT[_XQ0!T.?8?FG^%&?8?FG^%<]_PB'A7_H5O
M#O\ X)M._P#C%'_"(>%?^A6\._\ @FT[_P",4 =#GV'YI_A1GV'YI_A7/?\
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M";3O_C%+_P (?X5_Z%?PY_X)M/\ _D:@#H,^P_-/\*,^P_-/\*Y__A$?"_\
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M;CP+IFBZG\+_ !_I,/CB*'P_HOB:*2[\30_&C71X4NKJTUT:4DJ>'O$,$-Y
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MUIRJCC98FA"-DHTZ4+734I%%%% PHHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YK0O^0GXP_[&
M.W_]1;PU72US.@_\A3QC_P!C%;?^HMX;H 2\_P"1JT/_ +%[Q+_Z</"E=/7,
M7G_(U:'_ -B]XE_].'A2NGH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^(__  '\+?\ S-444 ']A:G_ -#AXB_\!_"__P S?3]?>C^PM3_Z'#Q%_P"
M_A;Z_P#0M_A]/?YJ** #^PM3_P"AQ\1_^ _A;_YFJ/["U/\ Z''Q'_X#^%O_
M )FJ** #^PM3_P"AQ\1_^ _A;_YFJ/["U/\ Z''Q'_X#^%O_ )FJ** #^PM3
M_P"AQ\1_^ _A;_YFJ/["U/\ Z''Q'_X#^%O_ )FJ** #^PM3_P"AQ\1_^ _A
M;_YFJ/["U/\ Z''Q'_X#^%O_ )FJ** #^PM3_P"AQ\1_^ _A;_YFJ/["U/\
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M/_H<?$?_ (#^%O\ YFJ** #^PM3_ .AQ\1_^ _A;_P"9JC^PM3_Z''Q'_P"
M_A;_ .9JBB@ _L+4_P#H<?$?_@/X6_\ F:H_L+4_^AQ\1_\ @/X6_P#F:HHH
M /["U/\ Z''Q'_X#^%O_ )FJ/["U/_H<?$?_ (#^%O\ YFJ** #^PM3_ .AQ
M\1_^ _A;_P"9JC^PM3_Z''Q'_P" _A;_ .9JBB@ _L+4_P#H<?$?_@/X6_\
MF:H_L+4_^AP\1?\ @/X7_P#F;Z?K[T44 ']A:G_T./B/_P !_"W_ ,S5']A:
MG_T./B/_ ,!_"W_S-444 ']A:G_T./B/_P !_"W_ ,S56M)TD:6-0/V^]U*X
GU&]%_=7-^+(2M,+.STY L>GV>FVR1I;:; BA8=Y8.[NY:BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img248422670_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_9.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %% F # 2(  A$! Q$!_\0
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MB00P>'1J%X;M/%OEV[.VM'239K =)#6OVP79D=8?(8Z=U!\83J=\;.\^'?\
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MBN\W$7B2.RM%.P12N-S'WNB@#Y\U";]I[^Q/%)TW3?@"WB5?%L2^#$U#6OB
MFB3>!_G^T7'BF6WT*74+;Q:#L\FUT>.XTD@OONU.P&]?R_M%#5_B'_9UA\$V
MT!-!B?X6M?ZQXX35KGQ-]GL!/%\1(H-%ELK#P^)SJ)AF\,2WU^T8L"\"O)>A
M?=:* /#-*E_:(-_X+&LZ?\%(]+?P[=-\0&TG5_&[W\'BP"X%C#X+CN]%AM[O
MPX<6QNY]>>UU%3]I,-N^R"L^RF_:=_LGP6;_ $WX!KKC>+G7Q\EGK?C]])@\
M"?:H1%/X,DFT*.\NO%YL?/:2VUV.UT@77D(MV83-(/H.B@#Y^UF7]ID6_P 0
MSH6F_ 9[M-8TT?"T:SK7CZ*VN-!-U(-8E^(;66A7$MCK"6'E-ID7AE;VS>Z,
MJW<L4(24Z,DW[0W]HZN(M/\ @J=''@VT?0WDU;QL-1?Q^;2,WUOK$:Z.;6/P
M:NH>8MK=64DFLM;;))K-)B\=>X44 >(6$G[0?VKX:C4K#X,+8R6MT?BW]@U;
MQJ]S:WPA;[$OPU6?1HH;^U:?;]K;Q4UA,L>YH$D<!:PGG_:J_L.T:/2OV>#X
MG_X3:5+V-]=^(@T,?#SR<03VLP\/G4&\;&?*RVLT*Z((1E+PON6OHRB@#PK4
M)?VC!%\2/[,T_P""+3)<VH^$XU#5_'"175IYJ+>?\+(^SZ+*UA<+;>8]LOA8
M7T;7'EK,R1[WJY'+\??[;MA-I_P;'AG_ (0.5[MX]5\9'6A\2OLKF*VM8VT<
M:>? 9OBBRWDTJZZ+7>Z6+R[(S[310!\_:9)^TUCX9?VOIWP&4R7FHCXO#3=9
M\?2"VT_^T$&D/\,OM6A0_P!H7K:/YLFHKXL^P0QZB(HK1Y;;S+@UGF_:G.EZ
MZ5TS]GLZZ/&-NGAI&USXAC2Y/ ?F2_:I]>D&@&\A\8B(0_9[73HYM':3SO-N
MT58\_15?D1\1_P#@I5J_PU\>>-=;UGPUX)?X%?#WXV:C\ /$\"7VHQ?%K3_%
M-AX/O?&$?C!XI[Y-"_X1>]M[&>TMM)_L[^T&C,6J1ZI)$3:")5(QERR=K4Y5
MI/I"G&K0P_,]W[V)Q6%P\5%-NI7A=*/-*.D*-6JKTX.H^=048VYY3=.K6<8Q
M=KN-##XBM+5>Y1G:\W",OT&U*;]H@7'Q"_LK3_@K):)IFGGX7G4M7\;QW%QK
M7[L:M'\0A;:++#9:6B>:VGR>&FOKIW\O[5'"#(3-%)\?_P"T_"0FL/@T-$;P
MC*WC=XM5\9G4XO'7V%S!;^$8VT@6ESX1.J")9+G6I+;5Q9&25+0SA(#^7'B?
M_@HO^TGX:T#1$?X*>$-<\8?%CX>^ _C;\-%\%:'\1/'J> _A1XB\8V/AKQA=
M?$3P-X1O-4\<?$?6?AY:ZOH6I7S?#!; :M%JTDT.E:?;:'J3U]__ +//QQ^(
M7QET3X;WNO\ PU3X?:Q/\-/#GBCXS:'JLUX;[P'X_P#$NA:=JEO\,["W*1R?
MVOI27SZAKIU1EN=+L&TZUGMGN-6AO$V5*HXUI\J4:%:6'G><4_;4_K,:R2;]
M^G0KX/$X2KB*;GA_KE)X:G5J57&+Y_:PYU!2C*3IPK+D?,O958X:K0DI6LYU
MJ&+H8F-%/V]/#U(5:]*E"<6^PT>;]ITZ9X+.N:;\ DUM_$5TOQ!32-:\?R:9
M!X4#*+*;P7)>:##>7?B-D\S[7;Z\EIIJL$$-RX+DSWTW[2HT+QPVGZ=\"6\4
M)X@@7X=1WVL^/$T*X\+%P+F7QQ-#H;ZC:>(%AW-;P>'X;O3VDVB2X5<FOGC]
MJ/\ ;-\0?L^?&G]GWP+8> K'Q#\._B!XUTGPK\7?'MW?7-L?AJ/&4ESI7@22
MVA@!M9KG5O$%N+:[7472.&UGMY8@[2JQY7]L;]O^P_9_\9_"3X8?"_3/"_Q)
M^)/CGXZ_"_X3>+]#U>Z\9:=I?@NS^(UU'%9B[\6Z%X4UWPE8^,+JTN+34M/\
M+Z]K5CK*Z!<-XIAT/6M,MC;RX*HI0H3C>2Q.,6 HQ@G4G+%.OAL.X>S@I5$H
MSQ>'<I<ME3G[3X%=ZS4J?MG)<L</@GF%63:4(854Z]7VDINT4W'#54H7YG-1
MA\4DCZR\0V7QTU'4O%,5MH'P+U+PZO@L?\(:OB*\\7RZC-X^>&V$]KXJMX]"
MN[&W\%-,+E1<Z1)<ZR\7V9I+,,9D'GR_!OQ7XAOO R>/O@O^R9K&D-I-S-\2
M?+\/:EJU[!XDCDF33/\ A!X]:\)&UOM(^RM#]JF\0M9W\<K3+;QO&L1/SO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:RFDF:"_U6WL!B:[M-'2\U4VXEDL;&^F46S?$W[,'[1?QT^,?QK^(^EZ_P"
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MDY4J;A<ISE2=!R?L9<W-!:*7,Z;]YJSERNE"5-MMTI)RI.$I2<OC[]N+X<>
M/&/[,G[1.L^*O 7@WQ5K.A_L]_&%]$U;Q'X:T;6=1T9H_ GB"[C;2K_4;&\N
M].:.YA6Z4V31%;A$F&)5#U[Q\'_^24?"[_LGG@W_ -1W3Z\X_:__ .34OVH?
M^S>?C%_ZKSQ)7HWP?_Y)5\+?^R=^#O\ U'=.ID-7MY?YI_H>E4444#"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >>?$WQ,WA;P;KNH6>F7&NZR=-NXM
M"\/V<"WFH:YJS02?9=/LK%B&O92P,TD2\+!%+*Y5$=QXW^SQHGC'X5Z-XA\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1PO9/_GSTT^[OH'_ !-UQCM_JSPXK6_Y>9IKI%;?6^Z7?4_N3_X>(?L3]/\
MAI?X5$GH/[:.1U_Z88H_X>(_L3?]'+_"D]_^0T1^'^J/^/2OX;B1S@C/4,>F
M<\@9X_AW*<^@)Q365B<C)&<CN.<'MW^OR\\&A>%>4O;,,?I_<PRTLO\ ISZ:
M>7>R%_Q-SQBM7PUP[IJ_?S6]KI;/&+K96Z:7L?W)?\/$?V)O^CE_A5_X._\
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M#7+76]'\52&/0]2TN]TBXOK2]CO6C>-%@D+K,C0RA73!^G/VE/V#;[P%XO\
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M\17I:-Y'-?\ =1BKW4>OU)^6]^O0/^)/L4]9<?T/1<,U5V=],]>JU6_EW/\
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MU4YJU2K;CG%149U:&/PU92@N#U3A%4LVS-\KC&G3JYABL1%1Q%:=5\7\//\
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M">^M>(=*BT;2_P!N+X7Z%IT7[)'A?]DI?MOP9LM8NA8>'M5TS5G\9+-%\?\
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MVE)!-J2W'QX\,1-IT5SJ$FDVTM\)"IM([C58)-+A>X"I+?1/8HSSH\!Z(_\
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M<=BU.519)1C4JXR.)JXV,HU(9HI0G0Q&*KUJ?)."P_MFH\D&D]/[9\8W&;?
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MI]/L20UJL1BGFMI70Q/]G?"SPQ>77[1OP^\=^-/'/AB70OV9/V<=8_9[\/\
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M*5"K/D5Y2Y9**;T?[W?\+#\"?]#QX1_\*+2/_DJC_A8?@3_H>/"/_A1:1_\
M)5?BYIW_  2S_P"">GB#5-"'A/Q!>^+_  ?J&D^,-5U3QAHG[07AB[MM%;PG
M<Z-:3PQV-I;WDFK6WGZU)!K.HVMQ';:!/;V]OK6R75M/%8?C?_@FM_P3K\,^
M#M8\?:)<>._B5X8\):IIUCXZN_A[\6])\07'@BQOA#(^KZK::7;7LOEV-G>1
M:E<V0V7HT]S?Q121JK4OJO"2M?/,TU4):Y+07+&=6-&%2I?-/W=*533VL^6F
ME>;DH/F#^UO&+2W /",K\RBH\=XV4I3IJ\Z<8KA)N55*$K4HIU)-\L8.3BI?
MM_\ \+#\"?\ 0\>$?_"BTC_Y*H_X6'X$_P"AX\(_^%%I'_R57Y76G_!%3]AK
M4+2UO[./XEW-G?6\%[:W-OX]9H;BWN(A-!<0NNEX:.:&19(V'WE8-SD5/_PY
M(_8B_P"?3XG\?]3W)[?]0O\ V1^0_%_5.$DVGG>;)Q=FGDE"Z::5FGFET[JS
M5MVT0LZ\7Y*,H\!\(2BTFI+CS&V<6HM-?\8GJFE^+WZ_J5_PL/P)_P!#QX1_
M\*+2/_DJC_A8?@3_ *'CPC_X46D?_)5?EK_PY(_8B_Y]/BA_X7DI_P#<92_\
M.2OV(N/]$^)_'IXZD'3Z:72^J\)+;/,T>V^2T/+_ *FC[?GWLG_;'C!I_P 8
M%PC_ .)WCO)?]$FNS?S?4_4G_A8?@3_H>/"/_A1:1_\ )5'_  L/P)_T/'A'
M_P *+2/_ )*K\MO^')7[$?\ SZ_%#KGGQW*?_<92_P##DG]B/I]E^)^.F/\
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M25?"[K_R3SP=UZ_\B[IW7WIF?W[O^O3L_P ;W/BS_@DVN/V /V?O^P=\0/\
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MH)88];\*>);RVL;6QAEUC0;QD:WEFMM/M(;N]\.WFC:K/#;0QF_V+\WYC_\
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M&\(VL6@>)+?QKKOB/1?&.LZ4- UO4=#@T[4TL-9?5[^)+C1Y+'_#K?\ :?\
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M.7P38W6D33Z=JDH^ ,TMKKTB>&XHXK>&*YL6;6)G:[ M#&W3?\.M_P!I[/\
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M_P!F\?&/KT_Y)YXCZ_YZ9KTCX0?\DJ^%W_9//!W3I_R+NG=*H#XL_P""3?\
MR8!^SY_V"_'W_JU/'%;'@G5_A[#^VMXPT_0/VC/$'B/Q=>^#KF/Q5\'+W7;[
M5M(TZ\@DBFM;K2=+$*:-X=BT>S5VN5@E:\FFG5;G(*@^#_\ !,/]HGX">#OV
M'O@7X5\:?'/X0^%?$NE6'CE=3\.>)_B5X.T+7=->Y^)7C&_M4O\ 2M6U>RU"
MS:YLKNWO8%NH%\ZUN(+B,/#/%(?MNW_:2_8^M-1GUFT^/7[,]KK-UO\ M&JV
MWQ+^&4.HW/F8\SS[Z/6ENYO, &_?(V=HW9Q7U.9T<72XBXBJ_4L=.%?$YS0I
MNC1;C/ZSB:RIRDZN&K1G05U4:IJG4<HPG2K4Y14S\;X0QV48OP\\,Z*SS(</
M5R[)>#<9B(XW&1]K36"R? ^VI4(X?,\%.AC=Z7-B77P\82K4L1@Z\9R@?+/A
M(Z>G[;7_  4!?4_&-UX!L4^'7[+<LOBNRO[/3[C2I(]&\0/;E+G4(KBU<7UR
MD6F2VK(TUY%<OIUJ$GNH):^K/@K\1OB#XKUN[TC4[$^+? -OHC7NE?%[^P[S
MP6==U-;RWB&E?\(GJC-=RLT$MRQO[,1V\/\ 9W^D([:E:N?SPT'XO_!?Q/\
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M;'#P;>%HRP]5UH4)^RM'%8ATI3J8F"LG\<8RIXB#J25>A4PZEQ)PY*4>?/\
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M_$%KK&BZ2^@Z9J6O:]I'C6UU/Q)=V6D3SV4,VLS7+".ZO=V3>7!?PH_LD_\
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M?A_P8XJAF*P]>/#&0I3K4,HEB,*^6>7JSJ9BX4*<:G+2JJ#C[7GG[)?5TO\
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MAM?^']/\0PR^+IOB3%87>L@^-;*[&GZ0;QK:QFMKW538PZAHLLGA_@S]A/\
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M]BW]I7Q+X.US4O#O@O\ 9;TOXF?%#]K'X._M'>/? 4GQ*\>Z7\+O!5A\)8O
M22V?@_Q58_ B_P#$'C?Q=\1G^'45UXCUG6_ W@BSM9=4\IK?7'T2'4)^;-HJ
MKC</&I4="/U'A>$JBI\\H8>I@\@I8BK%-2]H_JM?,:BC"/-A99=&5:%2.885
M0];@%4(Y1C9R]]OC#Q'E.D^91?LN+>)9T8-P<91<Z\:"=Y05:%:5.E5A5I5&
M>L?LI?\ !22+]JOXFZI\//"WPO\ ",$7@2.\L?C%JGAW]HOX6_$#4/AMK]M
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MR2U/T9HHHKRS[<**** "BBB@ HHHH **** "BBB@ HHHH **** .6\9?9?\
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M5G"K_P ;#XN4?8T<NS/-*U52EG=G*&%RQR]FM>>K]7YOK5*IAX_9&J?LP_\
M!3/0[*?4M9_X*/>#]&TVU"M<ZAJO@S0K*QM@S;%,]W=^'K>"(,[A5,CJ"Q 7
MYL*+J?LG_P#!4*6-)(O^"AWAR2.1%ECDC\ Z2\<BOAD=''AME9&4AU93\P.0
M2"*\"_X+,?':]BT+XF_ _P 1_$2Q^%_A?1/A?X-^)?A3PW>>$(-?U?\ :$\1
M/XXMK34_#WA.\DM+K6A=>"+6U6_N[+P4CZWONX[F[,MF&BJ/PE^VG^UM\2/C
MQ\0?AMX6\:?"7X8>!O#'AGQ'X:T7X=^*]?TS3_CU<>'[7X;&]\(_&3P!\)M;
M^&S^.=?DN/$!M)FN-6UZ;P>EI-)9ZAIMCJ*0P'BCQ=CWA\3B%@\F<:%+&5HQ
MCD64VG2P%.?M^:?U3EA5G6I.E1I+FFT_:U?94E*4='X09 IX>']M\<IU:M*C
M/F\0N,$X2K0P5:C*,/[;<YTXX?&*K5J**C!PE1I^TK?NW]!C]DO_ (*B_P#2
M0KP_N[C_ (0#2NO\/_,LYXX[C^IJ:A^RW_P4VTJSNM1U+_@HQX4TS3K*)[F[
MO=0\$:):V=I;Q@LTUU=7/AV&&"&, [Y9G50,EF&,U^?GP[_X*)?&7X8_#+]@
MG1--_:8T[X@7DOPJ_9O\0?&;2/'?A[P'I-YXNT?XL_%F7X=^(KO_ (2V_MKC
MQ'XKN?A^$3PK>3>!(=+/AS4[-M9^(_BC4=5U&+PN/I+XD_M.Q_&[]FO]MZ?X
MQ_M(_"NTMM&\#_&7PSXD_9>UG1_#WA[Q1\%;OPOKM]IG@CQ)JFLK>Z5XR&F>
M*-*L[#7HK_Q='+IFK7>JVJ^%[L*HM3V8SB+,L)'&5/JV1U(X/$YIAYM9'E*Y
MWE,J4*]2G%8.4ITJSK4U0K4^>DI3C#$5,.I1E*:/A'P]4K4*<LYX]4:\\MBI
M?Z_<872S)5)TE-/.TJ52E3HSG6I57"IRN/L8UG))^[6W[*G_  4]O8(;JT_X
M*)^&KNTN8XY[>XMO NCS6\\,JAXIX)HO#DD<L4B$-'(C,K!@RD]:J:Q^S)_P
M4P\/Z?>:OKG_  4@\&Z'I%A&9[W5-9\':#I^GV40(7S;N]O/#UM;6R!B 7GD
M"<@9R:^$8O\ @II\7? GPSNOAM\+?VB?@;\3[K1]>^ 7AQ_B<WB#X=^&]#^
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M6!(92/#1!!!!##.<@C^\?@CXX?M<ZC\;?V/_ -K:T^*/QM^&WQQ^%-G^S1\
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M4T;0=*_X*E?"K4]<\0Z,/$>A:-IVD>#;O5=>T'"'^WM'TZWTB>\U+1B)$/\
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M7[>T4?7>%_\ HFL5O?\ Y']7=:I_\B_=/42X;\5E_P W4RK_ ,5UA5>ZL_\
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MTY1C&%.I5J3F^6$*-"G*M6J2W]V%.G*323=DU&,FU%W_ .R?V^/^B@_L=_\
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5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img248422670_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_10.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &7 F # 2(  A$! Q$!_\0
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M@[6G*^T)=)/W7=V=SL_^*A_Z@O\ Y-4?\5#_ -07_P FJWJ\F^)_QO\ A/\
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M ":H_P"*A_Z@O_DU6]10'+YO\7V?5OM_5M<'_BH?^H+_ .35'_%0_P#4%_\
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M%F#_ ,5#_P!07_R:H_XJ'_J"_P#DU6]10)1:ZOI^%O\ *WS^_!_XJ'_J"_\
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MO@SQ=X9UE95$KIOMXXIKB8HRJ&42HCG)8JJ8->8?LLG]NS_A#(I=(N)X]/\
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MX"U'2;N>:'_EV11-<!96)7EB BLK.1G;7Y;:3_P6^^)Z_'C_ (2C5O#6ES_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%9?\AG7?\
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MLS7.DZ5\0/"UQYCM'-X<^(.L6TL"O&T;0Q2:@-3=8GW%F!9G8\%RC.C0Q_\
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M\:%R!E]B(C,3L1!\M._X4!^T5_T>OXY_\-9\,O\ Y"K[+HJ5&VWZ^7GZ_?\
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MC_A5?[9W_1W_ ,+?_$5#_P#/]K[,HH"R[+[CXS_X57^V=_T=_P#"W_Q%0_\
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MY;@<;.K+#QG"C:IBJ%2<(PC5J6A&7)><I<MVV_DC3_V-/@%=^%]"TKQK\+?
M.N:_8:186.L>(M(T"/PM=:O?VT,27&I/-X=?2;I)[F:/S9)C.TTK,SRL6GF!
MXR[_ .">O[.XF-SX:@\>>!+H$>3<^#_'NO6T\"AHWQ%+K4^NR!2T:Y!<GG<"
M'577[JHKNK>'G F(A3C7X2R&M.E"%.&(GEN#^N6IQ48REC516+E4LDY5)5G.
M<KSE)S;D^&AXB<>X:=66'XOS^C"M4G4GAH9EC/J5ZDG*<8X%UW@X0NVHTXT%
M3C#W(Q4-#X.7]D+XC^'P6\#?M=?'#1XX^+>R\1:A'XQT]!E2$$&L7+01JH3)
M\NUPW*E0COO7_A7/[<GAP!]*^/WP[\=)$RF.U\8^!;/3YY5&,I-<>'X-)7E0
M%9MX=@S$G<<C[PHKF?AYP_2_Y%U?B+)^T<LXJXCP]%/2S6$EF=3!:=%]6<=6
MG%IM/I_XB)Q#5?\ PI4.&\Y[RS7A+AK$UVM+IXR.5T\==VUDL2I?WKI,^#?^
M%A?MR>%L'6O@I\,O'T2[ \GA#Q5<:7.Z[E5WC@U!9U1]H)6*23;TR^!DUC^V
M!\4/#V8_'7[)?Q?TUDQYMQX<2Q\3VR $;RD>E_:)9, [E"@D\@X;FOONBE_J
MGQ!AO^1;X@\14DOAIYE@>'\WI+;XI5<JH8R6V[QBE_>OJ4N+.'L1_P C/P\X
M:K-_%4RS&\1Y/5;TUC&CG&(P<-ME@N6[ORVT/@^U_P""A7P%B>.W\5V_CWP%
M>,RI+!XM\':E8+"[#.UY%W$[5^9L1Y !)'KZYX<_:W_9N\4>4-*^,/@M7FV
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MS/R8TO\ X*530^(_"_C#Q5X,\(Z?^S_X\^-WQ$_9Z\-ZYI7BB^O/B?X?\=^
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M_DV[Q?\ ]C1\(?\ U<?@*OKBOD?]N/\ Y-N\7_\ 8T?"'_U<?@*@.J_Q1_\
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M@*7_ -+UKH:Y[_F8T_[ 4O\ Z7K70T"CM]W_ *2@KXH^)?Q/\2^"]"U+PO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\!5]<5\C_MQ_\FW>+_\ L:/A#_ZN/P%0'5?XH_\ I2/KBBBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L&Q_Y#&N?]<=+_ /15U6]6
M%9?\AG7?^N6E_P#HJZH$]X^K_)D?_,QI_P!@*7_TO6NAKGO^9C3_ + 4O_I>
MM=#0"=_P_)/]0HHHH&%%%% !1110 5\C_MQ_\FW>+_\ L:/A#_ZN/P%7UQ7R
M/^W'_P FW>+_ /L:/A#_ .KC\!4!U7^*/_I2/KBBBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1?\ PRW[/O\ \PU'_"@?VF?^C\/B+_X9;]GW_P"8:OL^BF!\8?\ "@?VF?\
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MK'AKQ'IMMJ^@Z]I]QIFJZ;>)OM[VRN8VCEAE7((!4Y5T(='"NC*Z*YXOX?\
MPA\*?#B6[O-(DUS5=3NK*UTLZQXHUJ\\0:M;Z+8;C8:):WU^\L]OI-EDB"T3
MY<_-*TSY>II>Y.I*5K333?6=-T*D84ULZ7L\7*GB9SB_W\5[&I%*G!RBJG.-
M-1T<)\RUM&,O:T)2FU9^T<L/"M0C&27L95/:PE><E#U2BBBJ+"BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%9?\AG7?^N6E_\
MHJZK=K"LO^0SKO\ URTO_P!%75 NJ]'^:(_^9C3_ + 4O_I>M=#7/?\ ,QI_
MV I?_2]:Z&@4=ON_])04444%!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %85E_R&==_P"N6E_^BKJMVL*R_P"0
MSKO_ %RTO_T5=4">\?5_DR/_ )F-/^P%+_Z7K70USW_,QI_V I?_ $O6NAH%
M';[O_24%%%%!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !6%9?\AG7?^N6E_\ HJZK=K"LO^0SKO\ URTO_P!%
M75 GNOFOU_0EO-(CN[F.\%W>V<\5NUMOM)DCWPM(LI1UDCG!PZ!@PY'O4/\
M8;_]!K6O_ FW_P#D6BB@++>W;\+6_)"_V++C']MZW_X$V^?S^RY_6D_L-_\
MH-:U_P"!-O\ _(M%% <J[?B_\_)"_P!B2?\ 0;UO_P "H/\ Y%I/[#?_ *#6
MM?\ @3;_ /R+110'*NWXO_/38/[#?_H-:U_X$V__ ,BT?V&__0:UK_P)M_\
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M_H-:U_X$V_\ \BT44!R1[?G_ )_UN+_8DG_0;UO_ ,"H/_D6C^Q)/^@UK/\
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M;_\  FW_ /D6BB@.5>?WO_/\!/[#?_H-:U_X$V__ ,BT?V&__0:UK_P)M_\
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$Z(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img248422670_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_11.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'X F # 2(  A$! Q$!_\0
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M-=/L8K':+ 7TDEXT_5IW@$:)".GR;R['G. #DT[_ (J'_J"_^35,7_D99?\
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M_%0_]07_ ,FJ/^*A_P"H+_Y-5O44 8/_ !4/_4%_\FJ/^*A_Z@O_ )-5O44
M8/\ Q4/_ %!?_)JC_BH?^H+_ .35;U% &#_Q4/\ U!?_ ":H_P"*A_Z@O_DU
M6]10!@_\5#_U!?\ R:H_XJ'_ *@O_DU6]10!@_\ %0_]07_R:H_XJ'_J"_\
MDU6]10!@_P#%0_\ 4%_\FJ/^*A_Z@O\ Y-5O44 8/_%0_P#4%_\ )JC_ (J'
M_J"_^35;U% &#_Q4/_4%_P#)JC_BH?\ J"_^35;U% &#_P 5#_U!?_)JC_BH
M?^H+_P"35;U% &#_ ,5#_P!07_R:H_XJ'_J"_P#DU6]10!@_\5#_ -07_P F
MJ/\ BH?^H+_Y-5O44 8/_%0_]07_ ,FJ/^*A_P"H+_Y-5O44 8/_ !4/_4%_
M\FJ/^*A_Z@O_ )-5O44 8/\ Q4/_ %!?_)JC_BH?^H+_ .35;U% &#_Q4/\
MU!?_ ":H_P"*A_Z@O_DU6]10!@_\5#_U!?\ R:H_XJ'_ *@O_DU6]10!@_\
M%0_]07_R:H_XJ'_J"_\ DU6]10!@_P#%0_\ 4%_\FJ/^*A_Z@O\ Y-5O44 8
M/_%0_P#4%_\ )JC_ (J'_J"_^35;U% &#_Q4/_4%_P#)JC3+Z\FO-1LKZ.U6
M2Q2RD62S,I25;M9SM99@6#H;;J"00<\8R=ZN>L?^0]X@_P"O;1__ $#4* $'
M_(S/_P!@&+_TMFKHJYY?^1EE_P"P!%_Z725T- !1110!$6 4DD!0"222 !G)
M))RH !R2<D?6ORJT&XTKXMO_ ,%(?A_\/O%^A:OXM\47]Q'HECH>MV%[?W4<
M/@*QT.6XMH;.ZEFFM(M80Z!<W<.88-0S8RR1W0\D?JU16,J*G[52E[M7"5L*
M^5)->UG0FJEY<R?(Z$;P<;23:O%ZEPG*FZ4H6YJ6)H8B-[V:HJHG!J+C+WE4
M?OJ2<;+1GXM_&;1[[]I;2/AWIGP>%Y?W'PB_9P\>:?X^L=+AG4Z1X@UBU\):
M98_"[6$<1-;>*;J;PI?2S^'YB+^WM;>*ZN;6)+O3[AOI/X5ZYIWQ@_:/^%/C
MGP!/)?>#OA7^SMJWA+QEJ4$,T5CI_B[Q9K'AYK+P%=R.D:KXDT*/PG=7^M:4
MV;O1P]FNI06DE]9QG]$:*Z8SM555KF<98NHELO:XV.;0K-[MTXPS>NJ<-)1E
M2I2E4FG5C4YG1BZ?L[NUL-!-WO[/"U,KJP6C2=253*Z;G.W*XUJL%32C2]G\
MQ_M;?";XA?&CX)^,? WPS^(-Y\//$VKZ1J5O'=VD-NZ:[#-IUW;_ /".W=Y+
M_I.E6NHSS1J^H:>\=U#M4!O*>93_ #K_ +%/[(/[8]A\8[[Q1\*_"6F_!CQ3
M\ [J]\#^+-3^(5S/#X?UW7Y[&UU&;P9-:Z>M_>>(;#4=$\16/B1M1ABDM19:
MAINH1WNZ[T5C_6)7Q?\ LO332_&C_@H?#)+(\%G^V%X3M[6%W=HK2*7]AC]C
M+498K>,G9;QS7M_=7TJ1!4DNKNXNWS<7$SO])D_%F/R3*<RRC#T,'6H9FH*<
ML1AH5)1<9)33T3JQG3<HJ$W+D>L=+Q?YOQ;X7Y1Q=Q#D_$.*S#-,%B<LM&<<
M#B53E4C0J1Q.#GA:U2G5J9;7H8VG2K5*N EAWBJ:E3Q"J/DG#Q.;XG_\%.O"
M*B+5?V</@)\44C&6N? /Q%O-(N9U&"5CC\6_\(]:QLP. '  <'YBNQC5;]NC
M]I?PIB+XA_\ !.KX_0M'@7%W\.;S2?B/"6#&-A;67A.TU:64!XG962\D!B,+
MKE)$D;]1J*X?[2P-3_>,ARR=]Y4*N986?2[7L\<Z2V_Y\V6FFFOHOA#/:#<L
MO\0^**+V5+'X3AK-:"6ED_K&1PQDO-_75)K>5]3\MU_X*S? #295MOB3\-_V
MB/A%<@HMP?B#\(]7TZU@9BAY>TN;RZ=4BDCE<FRC8AUV(X*LWJ_AC_@I;^Q!
MXL6,67[0O@O29G"[H?%MKK_A!H9"@=HI)?%.DZ#:EHLE'>*:2$R K'+( &/W
M4Z*59'17212K1N RLK##*RG*LK E2#P02#QG/F/B7X(_![Q?YG_"3_"CX<^(
MFFW%Y=8\'>'K^8EF+LPN;G3Y9U=FR6='#$LV2<G,>WX=GI/*\QPTM-</FE"M
M!/3:GB,N<[+1I?6.CUV8++O$?"M^QXJX8S."_P"7>8\*8_!U]U_S%9;Q(J5V
ME9R_L^U]5'2Q2\)_'_X&^._*7P9\:?A1XR:? B3PMX_\*ZW)(S':%6+3-6O)
M"X;Y3'C?O!4C*E:]7BN;>;!BN8Y<]!%*CY^FQVKXK\5?\$Y_V+?%ZS-JG[/_
M (&@N)B3]ITF._TF>(D $Q"PO;:!3M &#&0.HY^:O([G_@E)^SG:!G\!>*?C
M3\+IQM\D^!_BEXCTNUM]@Q'Y-FDZ1KL  7G   '%"H\/5+.&99EAFTO=KY;0
MKPTLTW4P^80D[7Z4/D'U_P 2,,K5>&>%\T2_Y>8'BC,<!-K3;#X_AVM34GO:
M6/E;;F/T[HK\NA^P!\9O"P:7X:_MZ?M"Z&X/[FT\4'0O%UDBALB-WU2"2[F!
M3*-OF9F R&!)S;A^"/\ P4B\);CX=_:V^$GCZ-2/+M?B)\,;NPEF0+GRY;_2
M;C53&SN@0SQ6PVHSN$RB)5_V=E]2[H9]E\G>RCB*&8X:3VZO!U*2WZU;=+C7
M%?$5#3,/#SB.FEO4RW,>&LTIVTUC%9SA<5+5[?55+^[T/TZHK\SW\9?\%/\
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M)U'AWBJD<SP6)P^=8I5WA,.XT<=F.(HX=JHJ4%!T(X?Q$?L>_MH6-N\>G?\
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MHK$YC7MLM7=]$TM#QJ3P[_P5;AN5%OX\_8MOK2-HVS>Q_$FRDN54J9$FAM?
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M>B2=;(.#YO9)M^QR+#IMV?115](V6OD$W_!13Q/8SK;:G^PI^V593@1-/&?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *YZQ_P"0]X@_Z]M'_P#0-0KH:YZQ
M_P"0]X@_Z]M'_P#0-0H 0?\ (S/_ -@&+_TMFKHJYY?^1EE_[ $7_I=)70T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7/6/_(>\0?]>VC_ /H&H5T-<]8_\A[Q!_U[:/\ ^@:A0 +_ ,C++_V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$AD<EO)OY;HHH(%Q*017VAX3\9^%_'&DV^N^$/$.D>)='NT5X-0T>\AO("&
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MD[]WN^?#.]"BTK+V5*RLDDG3BTDE&*5K[**79):(HHHJ#8*^*/V6_P#DMO\
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M'XI\%_$ZUU*"TT#Q2L.H>+?"FBZ9+:)+#:^*BSZF-*OS=+IENDK(3'!<)8B
M171?VK]E3_@HA\/KOX:^&?#'QHU'6=(\4>'XUT"_\83:5>7^AZE% T@T>ZU&
M[L?M5Q9ZC+IZP177GP,+J>VN+M3&C>6/G,)XT\.0XOQ?!?$E"?"F:X'!4J^(
MK9ICL!4R_P"N3E3G]2IXW"UJE#EEA*]#&T,37GAW.G.I3K4,-7I>SG]-B_!/
MB6IP=A.-N&:T.+<JQV-JT<-1RK 9C2S!X*$9P^NU<%BL/3KJ4,91Q&!Q&&H0
MQ*IU84ZM&OB:%7VD/UJHKAO!?Q&\"_$*P74?!/C'PYXLLV4,TN@ZM9WY@R0
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MBB@ KGK'_D/>(/\ KVT?_P! U"NAKGK'_D/>(/\ KVT?_P! U"@ 7_D99?\
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M+*4%%SC&5N63@IPYDFW'FBVES*[Z***LD**** "BBB@ HHHH **** "BBB@
MHHHH **** "N>L?^0]X@_P"O;1__ $#4*Z&N>L?^0]X@_P"O;1__ $#4* %7
M_D9)/^P!'_>_Y_I/7Y?RY]>U=!7/+_R,LO\ V (O_2Z2NAH **** "BBB@ H
MHHH *^*OV6O^2V_\%&?^SQ?!W_K!W[%5?:M?%7[+7_);?^"C/_9XO@[_ -8.
M_8JH&MGZ?JC[5HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 96J:3INMV<VGZOIEAJVGW"[9[+4[6"^M)E_NRV]Q'-!*/9T:OE
M#QA^P_\  3Q->3:SH.B:A\,O$SAFC\0_#;6+_P +WD4S,3YQM[25+&0@8 B>
MW\D@ %"!\WV)17BYMPWD&?0C3SO*,!FBA_#EB\+1JU*+_FH5I0=:A-;J=*I"
M:>JE?4]G*.(^(.'ZCJY)G.8Y6Y_Q8X/%5J-*NM/=Q%",U1Q%-VM*G7IU(25E
M*+1_-E^W%XQ\:^$/$T7P7'QS\6?%'PKX9EM]:<^(+>WL=1T37;.[U#2QHVH:
MC:)9OK<VE/I_VV.[9%A1YH'@!F@>Z/W#^SE_P40BU#X<:!#\4/AU\0[R/P]!
M9^&]:^)OA/16\3:%/?VL>R.ZU^SMX[2ZTB\EL$M[FY2V74S>2_:+BVAB'^BQ
M_>OC7]FOX%?$+6)O$7C3X7^%/$VN3Q^5+J6J6DDUS)%Y]Q<[&<2H"OVBYFFQ
MC[\CGJ0#W'@'X9> _AEHMQX;\!>%-(\+:#=7MQJ%SI>E0F.SFOKF*"WN+B2*
M1I SSP6\,<F20R( 1]XG\0R+PM\1,AXYSOB++^-,%@<GS2G["G@:E#,L]G]4
MPT^?*\+B*6<5N?V>%YIQ4Z.:PK4H5*E*A4A2JR@OW//O%7PXX@X#R/AO,>!\
M?F&<Y75CB*F/I5\LR"F\7B8*&:XRA5R:@H^UQ?+3?+7RJ5"K.G2J8BE.K2C-
M\=\/?VB?@G\484;P3\3/"FLW+C<=,:_33=9MSD+LNM"U=;#6+)]QVE+JSC<L
MI7[RL#[6"",@C! ((/WAU!!'RL",X/\ ^NOG#XB_LF_ /XG.]WX@^'NBV>KN
MXD37O#JMX=UF"0$L)8K[238R++O^=GP79CN8DLS'Q9/V6_CC\,V\[X&_M*>(
M%T^-VDA\(?%RU_X2[0<,W_'NFKHDFIVT*QA8E=K2^G )(<,JD?IBS7CS*Y<N
M:\-8+B##1WQW"^/CAL4TN5.<\CSVKAXPTUY,/G6-J=%%MI/\O64<!9JKY3Q/
MC>'L3+X<!Q7E\L3A.9VM&.?9!1Q#DV[1Y\3D>!I+1RE%7M]^T5\%3_M$_M%_
M"M"/C-^S=J/B72;=CY_C+X&ZE!XELS#'UO)O#>IS6VHVZR;3([W=YIH7(1(,
MD*/3_AY^V-^S[\1YH-.T[QU9^'M?E80GPUXU@G\*ZXETW6V6UU=;2.\E7&"U
MC-<0CM*:[,'Q[PMBL3# U\QEE&95/@RS/\+B<BQLY72Y*%+-:6$CBW=JTL%/
M$TY+53:U.3&< \5X7#5,?0RU9QEM-<T\SX>Q6%S_  ,(;\^(K935Q<L&K7O'
M'4\-4BU:4$?4U%5+:XM[N%+BUGAN8)%W1SVTRS0R+SAEDC9E<9[HQ'/X5;KZ
M^,E)*47=.S36J=TGH^JUWZGQUFFTTTT[-.Z::W332::>EF%%%%4 4444 %%%
M% !1110 4444 %<]8_\ (>\0?]>VC_\ H&H5T-<]8_\ (>\0?]>VC_\ H&H4
M "_\C++_ -@"+_TNDKH:YY?^1EE_[ $7_I=)70T %%%% !1110 4444 %?%7
M[+7_ "6W_@HS_P!GB^#O_6#OV*J^U:^*/V6_^2V_\%&/^SQO!O\ ZP=^Q3[?
MX?TI-V^[_)?J-;/T_5'VO1113$%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %>1^/_ (&_"3XFP31^-_A[X5\0
MR3AP]Y>:3:C4 T@PTR:C"B7JRYY63S2ZL P*L"3ZY17)C<!@<RP\\)F.#PN.
MPM16J8?%X>EB:,UU4J5:%2F]--8LZ\%C\=EN(AB\NQF*P&*IN]/$X.O6PU>#
MNFG&K1G"I'5=)(^"KO\ 8INO"4IO_@)\=OB=\))HSN@T*XU&7QGX.8("8[9]
M'U6\MYXX&; 8)?21*IRMLP4(R+\0/VU/A2$C\:?"GP=\?_#\"XD\1?"G5CH'
MBDQY!\Z?P_JMJD-W<J@+&STS34B+CRS?H")3][45\>^ ,LP<G4X9S'.>$JE[
MJED^.=7*VU;EC+(<UAF.21@G>ZP^ P\VFTJD=&OL%X@9GC8QI<3Y=DO%]))1
M=3.< J6:6M:36?Y54R[/9S:2:>(S#$4U))NE+5/XN\-?MT_ W5+F+2?&<_B;
MX/>(7.R30_BGX>NO#CI,"$9(M7@.HZ)*N_*QG^T!(X^=XHR&0?66A>)-!\36
M<6H>'];TO7;*5 \=UI-[;WL.&&5+/;R2A<CLYSZBL[Q;X$\'>.+*73O%WA;0
M?$ME-&(I(-:TZUO08LL=BO/&\D8R2W[ME[X[U\CZW^P?\-K>\DUGX1^+?'OP
M+UW<\D5SX UVX72!*[!@9M U"2:S,*D*##:26)8# G7))CG\1<KE[U#(N,<+
M#KAY5>&<XY;J]J6(EF.3XJJ[7;^LY12;3:4+Z4J?AOFOPU\_X,Q4[NV(C1XI
MR7F_Z^T(99G.$HK9)8;.*L4[MS>_W117P:UA^VY\)HB;'5/ '[3/ANW5@+;5
MHW\"^._(B!<[9HGN])FN&";5>2?5)96)46ZDQT:7^W;X2T>ZCTGXW?#;XB_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5DZKHVEZW:O8ZQI=AJ]E)D26FIVD%Y;/D%23#<
MQRQDE21G;]TX/?.M145*<*L7"I&,X23C*,HJ49)[J49)II[----73*A.=.49
MTY2A.#4HSA)QE&2U3C*+337=,^/_ !G^Q'\!?%5S+JVBZ#J'PQ\2N?,C\2?"
M_5KGPC?1S [A-):6>=)NY-XW$W>GW&"6V[&D<GAX_@_^U]\*/G^&OQUT3XP:
M#&P9?"OQPTJ5=52)=P6"W\5:1+)=W3A!MCDFFTRW7/-NWDQD_?%%?&XGP_X8
MJ5Y8S+\)7X>Q\GS/'<-XS$Y'5G.]W/$4,!4HX#&MOXEC\'BHR5DXZ'V>&\0>
M**="&#S+&4.(\O@E&. XFP6&SRC""22AAZ^84ZV88&*M[KR_&82<=;2U/@O_
M (;#\7^ 2MI\?/V>/B'X%$<GE2^)_!RQ^/?"$@7"M=":SBL]0LXB23Y7D7WE
M+C-RY8$?0'PY_:-^"GQ4BC;P;\1/#>HW,A"G39KV/3M6BE(SY,NFW_V6Z68
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M-!'%I5NUT'+/%'(? /BG^S%\'OA?^R+\8K0:7X5\6?$GP/X#\0ZUK_B!]*L
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MNIQAA/K<ZB76#IJ3IN+FY1Y)3C3E4C _4^N>L?\ D/>(/^O;1_\ T#4*^%/
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MU_3M]HT5\7_\._OV7O\ H4?&_3;_ ,ES^._W?3_DI- _X)_?LNC[OA#QN/\
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M_P##OS]ES_H4/&W_ (?/X[__ #R:!W\G_5OZ^\^TJ*^+?^'?G[+G_0H>-O\
MP^?QW_\ GDTO_#O[]EW_ *%'QO\ ^'T^/'_SR: 3]5\O3_/^MS[1HKXM_P"'
M?G[+G_0H>-O_  ^?QW_^>31_P[\_9<_Z%#QM_P"'S^.__P \F@5_)_=Z?Y_@
MS[2HKXN_X=_?LN_]"CXW_P##Z?'C_P">31_P[^_9=_Z%'QO_ .'T^/'_ ,\F
M@>GG]WI_7].WVC17P!I_[(.B_"G]H']GSQS\%=!\8:7X3T8?%'3_ (LS7_Q?
M\=^(],;2]5\%F#P@E]X:\>^.O$":FY\3I&;:;1=/N+K3YV-U<RVUNSW%??\
M0 5SUC_R'O$'_7MH_P#Z!J%=#7/6/_(>\0?]>VC_ /H&H4 "_P#(RR_]@"+_
M -+I*Z&N>7_D99?^P!%_Z725T- !1110 4444 %%%% &?J-_9Z78WVI:C<QV
MECIUK-?7ES,VV*WM;:)IIYI6/ 2**-G8]@#DFO OAK^TGX/^)7B'2_#5MX?\
M9>%;OQ-X>N_%_@&[\8:?I5A8_$?PE87:65YXB\*-I6NZY=1VUO)/;73Z=XDM
MM"UY=/O++4?[*-E<K<UWWQE\+ZEXR^%7Q'\+:-QJWB/P9X@T?3N0FZ\O--N(
M+:/>2 GFS.L>XX W9SBOA_X1VMQX_P#B/^R-_8^F:M8GX ?"'Q7IOQ+:YTV[
MLX_#?B+4M%T/PC;>"K^>XMH8'UF6^T>ZU*2S@=GCT^S@U*5##>Z?+4TO?Q%2
M$OAC"#C:\7)3PN:5IS4K:>QJX/"0>ZE'$.DU[:MAY1FK[L*;3LY.LY2U:C*G
M5P$:-)Q6_P!:6(Q$4[IP=)5;^RI5HS_2^BBBJ*"BBB@ HHHH **** "BBB@
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M?*]&DI.$:D8MM+WITW*48J[M3J<W*X,]=HHHIE!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SUC_P A[Q!_
MU[:/_P"@:A70USUC_P A[Q!_U[:/_P"@:A0 +_R,LO\ V (O_2Z2NAKGE_Y&
M67_L 1?^ETE=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %*\@EN;2YMX;J>Q
MEG@E@CO;9+=Y[5WC9%N84NX;NUDEA)$L:W4$T!90)HI$WQGY0B_9'TE/@UXB
M^"DWQ7^)]YH?B/Q1)XHFUZ<> E\1V,MUK$>OWFFV3VO@:WT?^SKO5HGN9/M>
ME75Y$L[V]K>6UO' B?7E%3&/*Y.[O+V:;ZVI5(5H+R7M(1<DOB2497C=-W>G
M]UN2[IN$J=[[WY9R2_ENW&SU/BN^_8RT^_U_6?$$OQL^+@N];^)7A?XJWD*0
M?"_[,OBCPEHRZ#I)B5OAP\J6"Z;#;QSVK2LLTENDQ;S7G::3P1^QIH?P]U71
M->\,?%SXM:=K^E6&NZ%?:Q'<^!%NO$/A77O$=]XMD\+ZU;KX)%B;'3/$&J:G
MJ&D:EIUM8^(+$ZA<0PZN(8K5(OM"BG"\.3E=O9I*"LK12P]/"Z+^]AJ4</);
M2H7I2O"4HRAP4E*+ORRMS+FDD[59UU>SWC7J2KQ?V:[596J1C)>#?%OX<:WX
M@U'X:>-_"?V:]\6?"O7;G4+'3]3NOLJZ[I&LZ<=$U_3GU&1+A+:]DLI%O;*X
MN8W@>\M8X[IEAEDD'F=W^R/::GX&^(G@.\^,/Q5%A\3_ !^/B3KUZ(?AHNJ6
M&NRWNGZE=VFERQ?#X6D6G7-WI=BTL4UK=2QK:>797-O%<W:S?8M%**<;M-W;
M6NMU'VN&Q#A%W]V$J^$H5G%:.<+M-.2;:YN5/:-N6-E:\88BFI_XU3Q>(IJ>
MZA4:^S%KY13]DGP6WBN[\1W?BOQOJ&FZMXHT/Q[X@\%W-WH">%-?^(.A:/9Z
M+;>-[VWM?#]KJ=IJUS;6%K<7UEI&I:?H-Q?PK>'21+O)\OU7_@GYX'U33;#2
MA\7?C/I]GI'AR7P=HL5EJW@[R=,\(CQ/9>+;/0%M+WP7=VM[;:;JNGVJVEYJ
ML%]JC6L20W=_=2*)3]_44XIQ<'%\KIN+ARKE47"G[&FTE97IT;T*7_/K#/ZM
M3Y:*4$G%.][OF45)R;FVHS56S<FV^:JO;3U_>5_W\^:K[Y\O>+?@01XOL?BY
MINI^*/&OCCPE:R/X3\-:M?\ AC1=%EU6;2+30"U[K5IX;M]>M-*>*.35;[2X
M-0ETG[5+=W=IHL]S]@M5]%^"GPS7X2_#O0O!C:A'JNIV[:GJWB#5H8'MX=5\
M2>(=4OM>\1:A;6\DTK6UK<:OJERUK"[F2.V$*2$N&8^N44*Z3C>\7TLE9<\J
MDDK6LISE>:=[J%*.BI02.5>Z[?#;>[NXPC3@W=O6$%)1>]ZM63;E4DV4444R
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *YZQ_Y#WB#_KVT?_T#4*Z&N>L?^0]X@_Z]M'_] U"@ 7_D99?^
MP!%_Z725T-<\O_(RR_\ 8 B_]+I*Z&@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGK'_D/>(/\ KVT?
M_P! U"NAKGK'_D/>(/\ KVT?_P! U"@ 7_D99?\ L 1?^ETE=#7/+_R,LO\
MV (O_2Z2NAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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&Y** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img248422670_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_12.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '+ F # 2(  A$! Q$!_\0
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M+)"8#-:W,3++;7,:GS(9X65XI0)$*LH8_ ?P*\!ZA\&OVN_B'\,]/^+7QO\
MB#X,O?V;/AW\0(](^,WQ9\9?% :3XGO?B5\1/#MWJ6BW'C'4M5N-(%[I.AV5
MM>1631PRBVC>1&=0Q_0VOC/3/^3^?&W_ &9S\-,''7_B\?Q4SS^7%/7J[_+^
MMQI6LEV_))?DC[,HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY$^SG[2'(OM\RY;W/4**^?=(^/WAOQ-\1/ 7A/PA+H7C+PK\0O!7BGQ=HOQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV=R%NH(I69%N%60#<HKYS_8_^(&L>-M2\>)J'Q;^(?Q1BT^TT0V[?$'X6_\
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M]+:6\]@HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?\,<_#3\_P#A<?Q4[X_KCVK[(/S].,=<_I_6OC?3!_QGSXV/?_ACGX: ]?\
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M\[6?SNK_ #04445Q&84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0NN6>VLJ5DI=XZWOMK_$C?[<%JNLHZ*_9N.B[^KN?8-%%%<)D%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6:1D"*J9;G@$\5\3_P##7NO?]"=H_P#X'7U=&'PF)Q492H4U)1LFW.,=7?\
MF:OL]MNMMBX4YU+\JO:V^F_K^/8^]J*\%_X:,^%7_0:N?_!==?GT_0<^U)_P
MT9\*C_S&KC\-.NO_ &91_G\*7U3&?] M;_P7/K_V[Y^KZ#]E4_Y]S_\  7_7
M7^K,][HKYYU+]I/X;0:??RZ?J4MUJ$-E<RV%K+974<5S>)"[VUO)(%_=+-,J
MQ-)U0$OGBO'-._:TUR]O[&S;PEI*+=7=O:LZW]Z619IDC+J",94,2 ?E)&"!
M6L,OQM12DL.XJ._/)4^E[I3Y6U;M_D$:526T79=7I^?]?,^Z:***XS,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MYW3/^0QXG_Z^M._]-5O715SNF?\ (8\3_P#7UIW_ *:K>@!DO_(U6?OX<O\
M_P =U'3C_6NEKFG_ .1IM/\ L7M1_P#3CI]=+0 5\R_M1WEM;>!]$CU;1_A]
M?^'KCQGH \2:S\3=,O-8\)^$-)MGFU!O$-W86%Q8W1NTGLXM/TRX%U!;6=]>
MP75](UI%<1O]-5\U?M0^%M0\6_#J/3QHGB[Q5X7CUJTN_'?@_P !W<5GXN\6
M>%8K:[6XT71II=1TE7D>\DLKJZM#J%LU_96]S9I*'N%1LJLI0]G./+>%;#S3
MG?D7)B*,KSY;R5-)7G**;C&\K:%12ESQ=TI4:Z]WX[NC42]G=QBZMVO91E)0
ME4Y8S:@Y,\C_ &0]:^'&K^/OV@)_A/X5\+MX)G\1Z+?V?Q/\)Z7<V6G>-M0O
MK*>?5-+6X::;3=2'AV[,D,=UH:VVG,+@[XGO#<3/]XU\3_L>Z)#H5CXLL_"/
MPK\;_!GX5VXTR+PIX'^(EW"/$B7^+B74]6&A)JNLR^'-/NU>)8K&YO&>>6.2
M\1$28+7VQ71-**I0CS\M/#T*:]HX^T_=THP7-&#<(723C!/FC!Q51*HIG/1Y
MFJDI**E*M4F^3FY7S2YKJ4O>DW>\I?"Y\WL[4^1'R'\;_P!F35?BMXEU_P 0
MZ/\ $:U\-P^-/AE-\)_%VB^)/!$?CG3W\.3WUY?IJ?A)/^$G\*_\(UXH22_N
M8SJ%V->TV?%I)=:-/+90$X>K_L<6=Q)>:/HOQ#U33/ 'BG2O NF?$?POJ&C)
MK.K>+G^'XM(]+O+'Q*-9TQ?#]SJ]M9PV?B1GT;61?VT:K8?V5*6N&^V**R@G
M345!I<LE.-XJ6JK5L0E+FOSTXU\17JQI3YJ<9U')1NHVUDE._-=WCRO5Q_Y=
MX>ES+EMRU/987#T_:1M4Y*2CS6<DZR01) ML$4P)"(!$PRAB1!'L93N5EV *
M0000,$<YKXI\,:)I&B?MZ>.HM'T?3-'AF_8]^&LDT.EV-M8QS2CXQ?%11)(E
MK'"DD@0!0[*6"@+NP,#[?KXSTPG_ (;Z\;#M_P ,<_#0]<_\UC^*GY_6GK=M
MN]_+YOUU?4$DK)622T5NUEIZ+3T9]F4444QA1110 4444 %%%% !1110 444
M4 %>)?M :M_9/PJ\3NKXEOH;32HU!*M)_:%Y#!.@(9>EL\[D$[2$(((;!]MK
MY4_:MU$Q>#O#>CH=CZMXGA=QT\R"PLKE'4CKCSKV!\@?*4[Y..C!PY\;A8_]
M/8R^4&IN_P HLNFN:I!6O[R=O1W_ $/3/@=I/]D?"[PI"5(DN+&2^ER>KW=S
M+(I''0Q-$>3GC.>3GH/B=\0=$^%G@#QI\1/$ES#::)X)\-ZKXDU&>>3RHQ;Z
M99RW1C+X(7SFC$"G&<N, FNET#3QI6BZ+INT+_9VEV-E@# !MK6*!L=^63)S
MR6.3R<U^*G_!:_XX:IH_PT^&?[+?@B=Y?&_[1'B:WLK^RLW+7B>$M.U"SMXH
MI(H<SI#K^OW5MIR%E$=S:66KQKN\N0#NRC+Y9WGN&P:TCB\3.=>?_/K#TVZV
M(J7Z<E",Y+6R:2OJ?$>(O%E+@O@SB#B>=I5L#A']0H6;>+S3&3CA,KPL4O>D
M\1CZ^&IR2NU"4I;19X'_ ,$T8'\8Z[^UC_P4$^+5@;^7QQJ6N^#/ EAJP+)J
M$&JW#OJ6G6DI5\J$M=,\,230!3#;6FHR[72:15^V_AK^RCK'Q0\%7_Q'NM8/
MAW7=;N[Z_P##VF_8D33[UUN6D^VR%/+FT^UN)Q+;V4<*N(O+6[4_9S'".6^'
MWP>C@L/@C^R-X1^7PM\)-&LI_B#J5B0(;SQ \45UXNU*26$;9ITOKJ72;*=O
M,9IY@\F!YQ'Z_P"G:?9:18V6FZ?;QV=AIUK#96=K H6*WMK=%BAAB4<!8XT5
M/7JQ)+,Q_G/B_+\E^D)XJ<2YEFV$6-\.N Z=?A'AJ%*=7#?VCG;C3IYEF%#%
M4)1K?5\FI8>AAL,E-T'CJE6M#GC[>$OU3PERS-O +P>X3R.CB'1\0N+;<7<7
MXBK"G7G1^OU)8Y4,12JQ<'7Q^)Q5=U)2BJL<%0H4GR-4I+XG^"/[1&J:9K*_
M"3XV1OH'BFP>+3=(UO4 88=59/W$%KJ$@7R([F157[+J*L+6\P(G9)WB63[C
M5E90RD,K*'5E.593T(/0@CD$=1\PYYKPOXW? ?PQ\9M%\N[5-+\4649.B>(X
M(_\ 2;:5 S1VUULV/=:?)(1YT3G?'Q)"T<J CYN^%OQO\3_!_7H_A)\<EGAM
M;=TL] \6W!D>W^SAEBMV>]E2+[9I94J@O3^\M& 2[$961ZPRGB;/O"W,<'PG
MXB8ZIFG"N+JQP?"OB'7C9TY2:C0R3BZSY,-C814:>&S:3CA\9!1=>2JQKRI?
M98[)<KXXPF)S[A##0P6?4(.OGW"-)MJ:2O4S/A^]Y5L+-MSKY?'FJX:3:I1=
M.5)3_0JBJT$T5Q%'/!+'/!,BRQ30LKQRHXW))&Z,5='7!5D)!X8'N;-?O<9*
M24HM-.S333332:::;333T:9^6NZT:::T::::?9IZI^1\_?M'_LU?"S]J/X=Z
ME\./BKH$.K:5=JTNF:E$!!K?AK51&\=KK6A7^TRV=[;,^XJ#Y%R@:WNXI[>2
M2-OP?\'?$3]H7_@CC\2X/AK\4TUGXO\ ['/C#5Y#X;\5VT$GVCPX;@1AK[06
M^T7,.D:C9$+_ &]X-O98['45#ZCHDL#W)N&_IAKS7XK_  F\!?&OP1KOP[^)
M7AG3?%?A+Q#;"WO]+U.(2(KHPDM[VTF!$UE?V<RK-:W=LR3PNORN4>1#]%DV
M>K TYY9F='^T,BQ3OB<%)VG1EHOK6!J-WH8JG?FBXRC"I\,[74X?EG'?AT\^
MQ6'XKX6QJX:\0<IIM97GU*FI4<=16LLGS_#*,HYCE&)MR2C4A4K85M5L.VHS
MHU;?PV^)?@CXM^$-%\>?#SQ+IGBWPGX@M$O-+UC29A-!-&P^:*5>);6YA;,=
MQ:W*QSPR!HY8U92!W]?S*Z]X:_:%_P""-'Q-;Q5X1EUSXN_L;>--9']JZ-*T
MS-X<>>5XX;.^=TN(=#UVVA9$T_6HPMEK2(+>] F4&OW&_9T_;!^ ?[4%F&^$
MWQ!TG7-?MO#^E^(=<\'R&2S\3>';35&DB$>I:==10-*]C>0O97TNGF[M[69[
M9YY88M4TLRUF_#U3!4XYEEDY9GD>(7/0Q]*#O1LTI4,=",;X;$4I2C":G&$)
MNSAK)PC' _B;A\\Q53A;BG#TN%O$'+I1HYCPYBZ\(K&MQE*GF/#]:I.V:Y;B
MX4YUJ3P\JM:A",XUXVC&M5^I*\7^(OP1\'_$)9+R6$Z+K^P^5K.EQI'+))QL
M.H0@+'J"J=HW2%;A5RL<\8YKVBBO IU*M*:G2J2IS76/7R?1I]4[I]M$?JZD
MXN\6TUU1\60^)OBO\")$L/$ME+XV\$1R&.#4XWD>:TMQPOV>^)FDM-B?.;'5
M$>([/)@FMHR]P>F@_:T\#2SPQR:!XGMTDDCA>::+33' KR!6ED6/4))&CC4E
MV"*[[5(56; /T_=VT-Y:W%M/##/#/&\<D-PB2PR!PP"R1R*Z2+G!(92,#IW/
MP+I?[*WCB#4]-DU"X\+S6$-]:R7T*ZC?LTMHDZ-<1HO]F)N:2 ,H7<N2<;E)
MW5Z6'J9?BU.>,C"C6C;WH3</;-K67)\*FG%7:TES*]M4;0=.:;J)1:MK%V37
M=):7ZO:_GN>OZS^U'H"2M9^#_#6M>*KS.V.0(]C:.2612 (;J\.2,[3:QAE(
M/F UD#6/VCO'^5L=.M/ 6E3C N'B2RG$3G"NT]ZU[J;.H.[S-.A@X&=BG&?I
M"QT/P;X(TZXO+6PT+PUIEA ]S=7\BVME;V=M"N9I[K4+@H(88XT+22SRJB*&
M9V W-7YF?M)?\%A_V3_@,UYHWA76)_CEXQ@:2!=(^',]O/H-M<J2%BO_ !=,
M9-+D#,  VC)K !#)(86P*VR[!XG,:JH9+DT\95TYIS4JW)?EUJ-J.'I)VNI5
M)*-]+W/E^)N-.$^#,$\PXFSG+LEPUFZ<\?B(^VKN-N:.%PD7+$XNHO\ GWAL
M/5GUY5N_J>W_ &8'U(2WWCWX@ZYK%\\;M(ULY,<;JK,));W5GO)YXD;$DBF&
MV)&0LBDF8_G]X4^-W[)WBWXS>)?@A9?M(VECXE\/.+.WUS5_#D5AX5\2:K')
M-#J.B>']<N-?CM;[4=,DMQYJ'9%<ARVERWHM[UCX*_CW_@J5_P %!_-@\&>&
MV_93^"6MQ-#_ &QK<-UX>N-4TYSY<A2ZO+-_&&N+?VLF]7TZSM-%N!O^S7T*
ML%.U\'_^""O@SPYXVU'5_C!\6KSQOX:.C6CZ78>&+*\\,ZHOBN68OJ&H7EW/
M<WK&SLS''+I@BE\V66Y<W2;K:!Z^JH8++<MHXM<2\0TJ..=&/U; 95"EC9X6
MJI*\:SA1GAW53:@\.JT%R^TE*I=1:_&\?XI^)_$^/R:?A1P-BL3P]]>:S3/>
M+J7]A8/,L(Z;=)Y70KUJ694L&[3J?VA]0JMU%AX1PSC*I&?Z\?\ "2_LE_\
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MBL'/'X.CA\.L2YTXPYZCGBN92YE&2E*A%4W.?,I1C*/S7$O&WTA,@IY9FD.
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MK:7EO-+);R*'23R4D:95*]=Z9'0X*E3D?$'P'H/Q#\-:AX=\0:=!J%M=0/\
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MDLY;875Y<6D%S=Q0J]>1ZG\5]4\<^&/BY\7]&\3>+O"G_"IM#^#=Y\+/"_\
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M**_0#R@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5F]FGR7U]GR7UN<M"#IPE%Q4;U)RLFVO>DY::+>]Y62CSN5M HKYM^._QO\
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M4Y!9XC<P !F9XAM0_E%\5?\ @AOHBZA+XH_9Z^+.J_#WQ#;L\^G(TNH6"Q3
M J$O-.ED:%,@ 16HT^/.2[%&(KPW6M0_X*B?LEP"Q^(W@2;]J#X6Z2)HR^I:
M9+XMGM=-M@/+,6OZ3'_PE.CRO &>V@M+FYVNA,RR^7@_88;,>%\YY*=3&8G)
M<;)6^H\5X:EE=>#M'EITN(<#5QG"^,JU/AHT7F5*M-_%3A-M&-3BSQ#X9O'C
M?@3^WLNI64N+/#/&5.(</*#M?$8GA7&4L'Q?@J-&/O8FK_9F-H45SN-6I%*;
M_ICT37='U^TCOM%U.SU2RE7<D]G,DR8/9@I9HVZ_(X5NO%;5?S1?"G_@J/\
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M0/&WA[6_"GBG2+#7O#OB+3KC2M8TC4[:.ZL;^PNHVBGM[B"97CDC='/WE.&
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M[.[N9TT^Z^=^Z\^_Z+J&O]7[Q\^U_P"KL^</^'GG_!-__I(3^Q!_XE+\#_\
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M3?\ ^DA/[$'_ (E+\#__ )NZ^[:*>O\ 2_X(6_K7R\_+\?6_PC_P\[_X)O\
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MLK"201J))%&U9)%7#R! QVAFR0I/ ."3@M5BA:773HUL_-7UVMO<(O1>BW]
MKY.^.?[1FH_#;QA\,O"'A/0+'Q%+XI^(WACPAXRU>^EF%AX2L?$;W(MH8DMI
M[=[K7[Y;626UMVD,5G;QBZNX)5F@C;ZQKXL^,W[%GP]^)VM>'O$FDK>>'-9M
MOBAH?Q#\67"^*/'(M_$2:8&2]M8--L_$UKIFE:E>1B**+4["UMI;=(]J.J.P
MI)VQ&$Y_X"Q6&>(MO['ZWAU633<?W?L'6E4<9>T2BE"%3F<0J7]AB.32L\/B
M%1TVJO#U?9N+V]I[7V:IJ2Y+R<I2ARIGVG15>.,11QQ(I"1HJ(&9G(" !07<
ML['"\LS%FZL<DL;%5>_?Y^E_U'KU_P _T05\*?&']K;_ (1+XHGX9^';G1?#
M%AX?O/#EK\0OBKXZ\*>-/$?@;P[JOBFXM#H?@Q'\(OIUEI?B#4K*>.Z?5O&O
MB3PYHNGI>6(@37KF:335^ZZ^(?B/^RIKWC#7OBW8:5XTTBP^'/QYU'POJ_Q$
MT?4]'N;WQ#IVH^'K?2K"[G\(:A#<16< UO2=$L;:4ZG#,;"X$M[9,'VH%'_>
M*'-_"3YI+51G)5:*4*DDI2A2]DZU3FC&=ZU.C3J4JM&I5I34]:51)M2=H\T5
MS3A%I\TZ<&XQJ5$^2/)*4%[.56<*M.M"E-?:Z'*JVY6RJG<O"MG'S*-S_*>&
M!);C'+?>J>JT$,=M##;Q B*WBCAC!)++'&@1 2<$D*@))R6//4YJS1IK:[5]
MVMUT?;5=$W;:]D@C?E7-:]E>SNKV5[.ROKL^JU"O@'XE?M9>*O!_B_XH7%A!
MX#M_!/P8\4^#?"OBGPQK\6K+\1_%B^*[71[J7Q%X0U"/7;'1+#3;(ZY;6EG:
MZAHVI'5+BROP^H:83"K??U?)WQ1_9IM_C+\1=#U_QQ%X('@[PQJ6E:Q8VFD^
M%H1XW\17.DJ+FST_Q/XNO!-=0Z'::J6O(M+T?R8KGRXENF<-*K*/^\8=RM[)
M27M+K2,?:T92DU?]XW1A6HQHZ7E6555*<Z,)HG_!JI7Y^1\B5U*4K.,81E_R
M[?M)0J.H](QIRC)2C.47]3V\R74$-Q'N"7$231[^&"2QK(H8 D!MK#<,GD$$
MG.:M5"%"J%4!550%4#"X'0*HR,*O QTZ_2:FK7?*FE?2^KMT3=M;*WZ:;J/-
MRKFLW97:32;LKNSVN[Z=-C$UR?5+71]4N=&M[&\U:WL+J;3[75;NXLM.GNTA
M>2"*^O+2RU2YMK9W 62:"SN)47)2%R0*^+_#/[3_ (XUOX&^ /&5SX<\)Q?%
M/XE_$5?A9H6EV3:U/X-TW7IM:U'3Y-8OQ-<P:YJ.CZ-IVEWFKW444^G7>HK$
MEI'+I!NEG7[7U:*\GTW4(-.:UCOYK.>&T>^65K5;AXF2)KE8&69H0Y!D$3;B
MOW2IYKXM\)?LM>,M&^#?AGP)J?C#PS_PG'@#XE_\+/\ !/B/2-*U--&35XM7
MO=4^P:WI]]=RW<]E=V^IWND7OV2>*1;25+B K.J@9Q_B3]I=T>;+W+=-TECJ
M?UU4W&T_:2P?M$WI-6A[)QGN5.:T/9Z5+8Q1=DXJH\'4>$=533A[-8M4KJS3
M7-[12AM[7\$OB5XA\<CXA>&_&-MH\/CCX4>-[CP1XGO/#4%W9>&M=W:;I^OZ
M-KVA:;J6J:YJNF6^I:)K%I)<:9J5_>RV-^MU:Q:CJ=LD&H2^]UX?\%OA7?\
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MMI923HBW,]I87<\46]XK>9P$/QGX<_:^U&W_ &9/"OQK\9>%(-6\<>*]9O\
MPOHW@?P##J=S#KGB?_A(=6T73M-TA)EUG6I[=8=-:]O[B*VO+U[6&XN+32Y;
MB2WTMOM;7+?4+O1M6M=*>SCU2ZTZ[@L'U$2O8QW4L$D=N]XELZ7#6RRLIE6
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M;U!J,E_Y&JS_ .Q=O_UU#3O\*Z6N;E_Y&FS]/^$>O_K_ ,A#3<5TE !1110
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M>Z2,:MJ-KX?C@TG4M=U?_A(=5-OIEK)%++-9VTGEQ1S-ZEJG[4WQ>\*^+5\
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M[\67_P GT?V_+_T+^O?]^++_ .3ZZ*B@#G?[?E_Z%_7O^_%E_P#)]']OR_\
M0OZ]_P!^++_Y/KHJ* .=_M^7_H7]>_[\67_R?1_;\O\ T+^O?]^++_Y/KHJ*
M .=_M^7_ *%_7O\ OQ9?_)]']OR_]"_KW_?BR_\ D^NBHH YW^WY?^A?U[_O
MQ9?_ "?1_;\O_0OZ]_WXLO\ Y/KHJ* .=_M^7_H7]>_[\67_ ,GT?V_+_P!"
M_KW_ 'XLO_D^NBHH YW^WY?^A?U[_OQ9?_)]']OR_P#0OZ]_WXLO_D^NBHH
MYW^WY?\ H7]>_P"_%E_\GT?V_+_T+^O?]^++_P"3ZZ*B@#G?[?E_Z%_7O^_%
ME_\ )]']OR_]"_KW_?BR_P#D^NBHH YW^WY?^A?U[_OQ9?\ R?1_;\O_ $+^
MO?\ ?BR_^3ZZ*B@#G?[?E_Z%_7O^_%E_\GT?V_+_ -"_KW_?BR_^3ZZ*B@#G
M?[?E_P"A?U[_ +\67_R?1_;\O_0OZ]_WXLO_ )/KHJ* .=_M^7_H7]>_[\67
M_P GT?V_+_T+^O?]^++_ .3ZZ*B@#G?[?E_Z%_7O^_%E_P#)]']OR_\ 0OZ]
M_P!^++_Y/KHJ* .=_M^7_H7]>_[\67_R?1_;\O\ T+^O?]^++_Y/KHJ* .=_
MM^7_ *%_7O\ OQ9?_)]']OR_]"_KW_?BR_\ D^NBHH YW^WY?^A?U[_OQ9?_
M "?1_;\O_0OZ]_WXLO\ Y/KHJ* .=_M^7_H7]>_[\67_ ,GT?V_+_P!"_KW_
M 'XLO_D^NBHH YW^WY?^A?U[_OQ9?_)]']OR_P#0OZ]_WXLO_D^NBHH YW^W
MY?\ H7]>_P"_%E_\GT?V_+_T+^O?]^++_P"3ZZ*B@#G?[?E_Z%_7O^_%E_\
M)]']OR_]"_KW_?BR_P#D^NBHH YW^WY?^A?U[_OQ9?\ R?1_;\O_ $+^O?\
M?BR_^3ZZ*B@#G?[?E_Z%_7O^_%E_\GT?V_+_ -"_KW_?BR_^3ZZ*B@#G?[?E
M_P"A?U[_ +\67_R?3-%^T2WNN7DMC=V,=W=6C0)>B-)9!#8P6[OMAFN%"^9&
-5!+9;&<8S72T4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img248422670_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_13.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $+ F8# 2(  A$! Q$!_\0
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M\_M-?]$B^!O^J\__ )!7Q$_U.-WF_P#)0/\ 5XYW_=QSG%5_Q#CBO_H%P?\
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MY)TX8'&5)>_[N%Q,O:>RJU/Z0**^5?VT?COK_P"S9^S3\5/C5X4TG1-;\1>
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M@9T,?QECZ+>6Y;)\]+!4IW@LSS10DI0PT6G]6P_-"KCJL7"#A0AB*]'^G?\
MX)=?M@_$/]LRW_:+^)'C9(=.TVP^)&A:-X)\':?)YNE^"O#":#-<6^EQ7#Q0
MRZGJ-S)*UYK.M7*K/J%Z[[+?2],AT?2K7]8J_CI_X)G_ /!1_P"&W[%W@;XE
M^$_'7@+QQXONO&_BS3?$EC<^$&T(06=O9:4=-DM[Q=9U#3G,TDF)$,"NFS.X
MACBOT@_XB /V>_\ HA_QF_\  CP9_P#+RN_B/@O/)9YC_P"R,CJ/+>:A'">Q
MG0C3]G##4*;MSU%-OVBES2FN>4U*<G*4G)_,^%GCUP'1X!X>CQKQYAEQ1.GC
MJV<?7:&/GB/K-?-,977.Z&$J48KV-:C[.G1DJ5&ER4J<*<(1IQ_?:BOP)_XB
M /V>_P#HA_QF_P# CP9_\O*/^(@#]GO_ *(?\9O_  (\&?\ R\KQ?]2N+O\
MH18G_P '8;K;_I[_ 'D?H'_$P'@U_P!%[EG_ (39GUM_U _WD?OM17X$_P#$
M0!^SW_T0_P",W_@1X,_^7E'_ !$ ?L]_]$/^,W_@1X,_^7E'^I7%W_0BQ/\
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MJ*_ G_B( _9[_P"B'_&;_P "/!G_ ,O*/^(@#]GO_HA_QF_\"/!G_P O*/\
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ML_\ ";,^MO\ J!_O(_?:BOP)_P"(@#]GO_HA_P 9O_ CP9_\O*/^(@#]GO\
MZ(?\9O\ P(\&?_+RC_4KB[_H18G_ ,'8;K;_ *>_WD'_ !,!X-?]%[EG_A-F
M?6W_ % _WD?OM17X$_\ $0!^SW_T0_XS?^!'@S_Y>4?\1 '[/?\ T0_XS?\
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M0I>PQ<%0QT\!C*<*D\-4C5C4C4P]>OA\1_H]T5^&_P#P2W_X*CZ?^T3I^C_
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M72;70;Y/"-V^@76@:/:Q?99+32=6>QDM3#I][;5T?B3_ (*-:?J]U\2KC2_
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M_8-_;$^'OPL_:G\7_'?XD2ZSH'@KPY\%/$V@^'?#UQJ-OXF\03+9G0+'PCX
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M)-$\#:'-(K?9K;<L/]I:WJ7D17'B#Q#<1I=ZI=I&JQV6G6/A[P]7RQ6YXO\
M"'B/P'XCUWPAXOT'4O#'BKPQJ5SHVNZ%K-L]IJ.DZA:.8KBTO+>4!T=&&589
MCDC*30L\<D<U8=>U@</A,)A*&'P-*G1PE*G&.'A1LZ:IV3BXM-J7.GSN=VYR
MDYRE*4FW\/G69YQG.<9EFG$&*Q6,SG&8JI4S"OC%*.)>)BW"I3J4Y*+H^Q<?
M8QPZITX8>%.-"G3ITZ<:<"BBBNL\P**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ]@^&?P&\3_%#PE\1O&NC:GH.GZ'\+9O!L'B;^UCKLNH
M;O'?B!?"OAL:1IN@:'XFO=7:XUN5+.6&SC:YC#+,L$JEFJ;PG^SSX^\9^,7\
M':):V<SRV_Q O-(\3S?VA#X-\4VOPYT'Q'XG\0W'AGQ$^G&UU6&?1O 6I7&E
MR(J+=/%%!*;625@>D^"?[2FM?!/X>_&WP9X<T_48-:^,,'@2&+Q;I?B$Z5<^
M%/\ A!_$;>)K=8].72M176[77)9&TG5[.[N;>VN-+DGLI$E2YF8^Y>!_^"@^
ML^$=$T/1Y?AAHVI_8/ _ACP!J5Q#K36"WUCX+^$/Q:^"GAK4-*MSHVI#0M0?
MP]^T'?:WXDF,EZ^M:QIUK+ ^BVM_KFG'P<35SV$\=]5PM*M%24<#S5:-.\7A
M,.W4FI-7Y<4\1&TIIRC",>6$7&N?<Y1A/#VO1X?6<9MC,!4=*57B#V6"QF)B
MJJSC'PCAL/*G%I>TR>GE]5SI4*D:-6M4J>VQ%6$\!'Y9^(7P(^(/PY\1ZKX;
MU/0KG6;C1=(\$:[J.I>%;34M7T:TLO'_ (5T/QIX7%QJ"6-O]FN;_1/%]BIM
MKU(I!>O)81K*T>^N1UGX>^-O#UO+=Z[X)\6:':027<4UUK/A_5M/MX9;"^@T
MJ^CFN+VTMX8Y+#5;^#2KM)"&@OKB"QG"3W-O"?M7Q/\ \%"M9U[2]?TVW^&.
MCV']H^%->\):7/<:V]\-/C\5?L_> _V:_$=]JT?]CZ?_ &_*/"?PDL_$GAR/
M=8KHWB&]O9[F37;);#23QGQ._;N^(WQ,L?",&J^%_A_+>^$_%3^-Q>Z[X2T#
MQ?;:[KFI>"/"?A/Q;-XAT+Q;I>O>'M=M/&_B3P._Q0UK3M=LKVT_X2F\BOK6
M*&31M)NB8>OGS^KJOE^'C>"^LU'BXJU14H_!"FJJ:G433>OLXMV51PC*H9EE
M_AU!YG4R_B7,ZJC7_P"$K#1R:K)3P\L3/^-6Q-3"RYZ&%<;1<8O$S4'.6&]K
M4IX;YCL_AKX^OX["6R\!>,KZ#5(]*ETV6S\-:S/'J,6N3WEGHDU@\-E(MY'K
MEYI-U::4]J76]GL[R"Q,\EG>)72^ _@=X[\=?$_P1\((]'E\*>-_B#J^D:)X
M?LO'%IJF@Q37>O%4T1[KSM/N+VWLM6DECCM;W[,ULWFQW$DB6XGO#]O_  5_
M;_T;3]8^!.C^._ ]IX?TGP7XJ^ R>+?&.A7:IIUOX6^$'QQ\:?&5+G0OAUHG
MA>&*QO+R+XLZGX?;2]+O?[+6.RTDZ19Z- MY8'QR_P#VO8=.^.OP!^)VD>#%
MU+0OV8AI^F>$-+G\0SF_\80:-XZ\4_$&'5-<\077AVSFMX]3\0^.;EH;*/1H
M#8Z(EIH^TWR7_B(S];SR<\5166PI.%&M+#5G7A.%2<:57ZN]9*%YUX0C*E)P
ME&%15*KI124]EDWA_2P^3XZ7%5?%QK8W 4\TP2P%?#XC#4)8K O,HN$:<JRA
M1R^OB*L,73C5I5,3AGAL+'%2E*=#QOXB?LW_ !*^'-EX:UB^T7_A(O#GB[P_
M?^*=&\0^$(M0U32GTO2M<UOPQJDFH>98:?J.B/IVN>#M2LI1K=K:I*MI+?6$
MEY:;;^LMO@-\2K7P]KGB+5/"&N^'DT;5/#FBP:1X@T#Q#INM^(KWQ-J&KZ38
MQ^&K*?25AU,VFI^&KG3[^,S0S)=-%9VL5W.;JW/L6F?MD^*H/"'Q8\(:M;>(
MM<7X@>)+?Q+X:\0W/B]9O$G@:*+P[X\\%S>$WU76/#OB1]7\&ZEX.^,>MZ#?
M:/HH\-SF.ZN_L%_86FK>(]%7UO3?^"DGB;3/B)\4?B!%\/8]0D^(WCOX7^.+
M/0M>\7WFIZ7X.C^'T6LVUWHNCJ^BVN4\1Q>*[JXAO;=;.31]0CLM3C@U66TD
MB*E7XAA!QC@<-6G!IQJ+$4Z?MHNKA7[/EE)J$E1J5XSJNZE/#3E"G#VM&(Z6
M \,ZU:%6IQ!F> I5XRA4PTLNQ&+>!J?4\TB\0ZE.E"6)A]=PF75*.$4E*G1S
M6E2K8JK]3QTSY+^&W[/7Q+^)^NZ[X=T/POJ-A?>&_#OB#Q/K-QX@TW5].T_2
M;/P]X0UCQ]/:ZG??V=<PZ7J.J^%_"5]?:%;:K]F34Y(D@M)G>> UX_7Z&Z-_
MP43O-/\ #OA?PQ=?":QNM-\ ^&;[PEX1GL/%7]G:E]AU7]GJ[_9PU.?QG=_\
M(U?+XMO%T.[3Q3H\MO%I$>EWZ2Z4L5Y874<=?GE7?@:F95*F(>.PL,+34*'L
M(QJPK2E.]95G*<)-VY5AVDXQY7*<8RJI<[\/.\+PMA<)E\>'LUKYKBI5\?\
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MIR#BFEQACL;4R+,:&80P<\FPU"&(E0G&2I2K0QTY4U+ELY1IR:OHM+'Y-?\
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MPF_\+JY_^4-?V)T4?\1.XH_FR_\ \))__-']7] _XE(\)?Y>)/\ P[T?+_J
M\D?QV?\ #C#]LK^Y\)O_  NKG_Y0T?\ #C#]LK^Y\)O_  NKG_Y0U_8G11_Q
M$[BC^;+_ /PDG_\ -']7] _XE(\)?Y>)/_#O1\O^H#R1_'9_PXP_;*_N?";_
M ,+JY_\ E#1_PXP_;*_N?";_ ,+JY_\ E#7]B=%'_$3N*/YLO_\ "2?_ ,T?
MU?T#_B4CPE_EXD_\.]'R_P"H#R1_'9_PXP_;*_N?";_PNKG_ .4-'_#C#]LK
M^Y\)O_"ZN?\ Y0U_8G11_P 1.XH_FR__ ,))_P#S1_5_0/\ B4CPE_EXD_\
M#O1\O^H#R1_'9_PXP_;*_N?";_PNKG_Y0T?\.,/VRO[GPF_\+JY_^4-?V)T4
M?\1.XH_FR_\ \))__-']7] _XE(\)?Y>)/\ P[T?+_J \D?QV?\ #C#]LK^Y
M\)O_  NKG_Y0T?\ #C#]LK^Y\)O_  NKG_Y0U_8G11_Q$[BC^;+_ /PDG_\
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M_-']7] _XE(\)?Y>)/\ P[T?+_J \D?QV?\ #C#]LK^Y\)O_  NKG_Y0T?\
M#C#]LK^Y\)O_  NKG_Y0U_8G11_Q$[BC^;+_ /PDG_\ -']7] _XE(\)?Y>)
M/_#O1\O^H#R1_'9_PXP_;*_N?";_ ,+JY_\ E#1_PXP_;*_N?";_ ,+JY_\
ME#7]B=%'_$3N*/YLO_\ "2?_ ,T?U?T#_B4CPE_EXD_\.]'R_P"H#R1_'9_P
MXP_;*_N?";_PNKG_ .4-'_#C#]LK^Y\)O_"ZN?\ Y0U_8G11_P 1.XH_FR__
M ,))_P#S1_5_0/\ B4CPE_EXD_\ #O1\O^H#R1_'9_PXP_;*_N?";_PNKG_Y
M0T?\.,/VRO[GPF_\+JY_^4-?V)T4?\1.XH_FR_\ \))__-']7] _XE(\)?Y>
M)/\ P[T?+_J \D?QV?\ #C#]LK^Y\)O_  NKG_Y0T?\ #C#]LK^Y\)O_  NK
MG_Y0U_8G11_Q$[BC^;+_ /PDG_\ -']7] _XE(\)?Y>)/_#O1\O^H#R1_'9_
MPXP_;*_N?";_ ,+JY_\ E#1_PXP_;*_N?";_ ,+JY_\ E#7]B=%'_$3N*/YL
MO_\ "2?_ ,T?U?T#_B4CPE_EXD_\.]'R_P"H#R1_'9_PXP_;*_N?";_PNKG_
M .4-'_#C#]LK^Y\)O_"ZN?\ Y0U_8G11_P 1.XH_FR__ ,))_P#S1_5_0/\
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M,5%.=2<JE2;44DY5*DI5)RM><Y2G*\I-LHHHH+"BBB@ HHHH **** "BBB@
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M9\TTVFVK?X?FMK7TULWOZ'ZS?\/!/@__ -"K\1O_  6>'?\ YJ*/^'@GP?\
M^A5^(W_@L\.__-17Y,T57U:EVE]_]?T_2SYI?S/[E_E_5_2WZS?\/!/@_P#]
M"K\1O_!9X=_^:BC_ (>"?!__ *%7XC?^"SP[_P#-17Y,U\R_M3_'3Q!\ -%^
M&/C&ST71]2\$ZU\8/ /PY^)FJZLUXC^ _"WCG6(O#=OX[@-K-;PS0:/XAU"P
MTR]MKTA#'J:7T4V_3WTRIE0I15VI-==?-+^O*[Z(7-.Z5]_\*[>77\W9>7]
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MLU_Q)=^'[CP9H1N/$7AJTAM_$'B&ZDMHM32L^2@VDE)MM+XNKMO^/GY?RO\
M>*Z[)M[=++^7OI\[KI;^E7_AX)\'_P#H5?B-_P""SP[_ /-11_P\$^#_ /T*
MOQ&_\%GAW_YJ*_)FBMOJU+M+[_Z_I^ECFE_,_N7^7]7]+?K-_P /!/@__P!"
MK\1O_!9X=_\ FHH_X>"?!_\ Z%7XC?\ @L\._P#S45^3-%'U:EVE]_\ 7]/T
ML<TOYG]R_P OZOZ6_6;_ (>"?!__ *%7XC?^"SP[_P#-11_P\$^#_P#T*OQ&
M_P#!9X=_^:BOR5.<' Y[;N1GT/*[O;GMPU?F"_\ P4 \::%JFGZ/XO\ "'A+
M2-0\.?M=7G[,OQ8CMEUD1>"_!]Y<^&[+P1\8H+BZU".,:#XMN?B)X<A']J^6
MMM_PD<<L)OD\->(&,3HT86YE+7S[6W^^[?37RL)S>S;^4?\ +R_&V]C^JC_A
MX)\'_P#H5?B-_P""SP[_ /-11_P\$^#_ /T*OQ&_\%GAW_YJ*_G>U#]H_P 5
MZ'X^_9%\%:AX3\/WUE^T[J'Q%,WB"UU'4M.N_#&F>%O /B#XC^'TB\-3VFK)
M/?:QI&FZ;;:K+/K(2PO7U*VMK2]C%EJ)Z+X1?%WXH^*?B_\ &?X9^/OA]X9T
M+2_ &D>!_$WASQ3X+\0ZGKMC-#XR.OD>"/%LFIZ/X?AM/'>@V/AJV\0:C;:"
M;JP&DZWI%V6ABO\ 1-0*5*BVE:5WYOLGKHFM-=MK^0N:I:]^E]XZ^\H_R][Z
M;[Z;6_?_ /X>"?!__H5?B-_X+/#O_P U%'_#P3X/_P#0J_$;_P %GAW_ .:B
MOR9HK3ZM2[2^_P#K^GZ6?-+^9_<O\OZOZ6_6;_AX)\'_ /H5?B-_X+/#O_S4
M4?\ #P3X/_\ 0J_$;_P6>'?_ )J*_)FBCZM2[2^_^OZ?I8YI?S/[E_E_5_2W
MZS?\/!/@_P#]"K\1O_!9X=_^:BC_ (>"?!__ *%7XC?^"SP[_P#-17X _M>?
M'+Q%^SM\+D^*NC:)I&N:!X:\9>#++XAG5OMQE\.^ /$'B/3_  YK_C+3(K&:
MV:^N_"0UN#6Y["Y:."XT^&\>:[L%MVNZ\X^#_P"U7XH^)?Q:^+/PDGTCPSIV
MN?#/XJZ=HMH]M!JDT?B?X/:KX4USQ#I'Q/M'?4<HFL:YX:D\%QW5JEUH]MJ"
MV\XFU/\ MFQLJS]E1O:TF_7T\O7IOIII9*52U[Z+?X=+<M^G][\?N_I%_P"'
M@GP?_P"A5^(W_@L\._\ S44?\/!/@_\ ]"K\1O\ P6>'?_FHK^8I_P#@H FD
M>#?%^M>(_A]%!XNMOVL?&_[)7@WPMX>U76-=L]8U+P;)+)JGC76M4L?#,NO6
MV@:;H6AZMXOU<:)X>O\ 48;*UM]'TS3M5O[NWFK[A\!>*]*\<^$/"_B[0O$.
MC>+=$\4Z)IVNZ7XB\-*XT77+&_MTNK;4=+2:YU&6.TN891)''//+,G*3E9%D
MBH5*B[)*5]&]?3YZ^G76V@<U1)-W5W_==]GT7:[^]+I;]E/^'@GP?_Z%7XC?
M^"SP[_\ -11_P\$^#_\ T*OQ&_\ !9X=_P#FHK\F:*T^K4NTOO\ Z_I^EGS2
M_F?W+_+^K^EOUF_X>"?!_P#Z%7XC?^"SP[_\U%'_  \$^#__ $*OQ&_\%GAW
M_P":BOR9HH^K4NTOO_K^GZ6.:7\S^Y?Y?U?TM^LW_#P3X/\ _0J_$;_P6>'?
M_FHH_P"'@GP?_P"A5^(W_@L\._\ S45^!?[7?QE\5_ #X)>,_B[X2\-Z=XME
M^'O]E:[XCT?41>[F\&#4[6T\6:OIXL)[:22^\,:)>S>*_)G=8;JSTV[L#);2
MW=OJ->1_#O\ :YU[Q]\:/BG\(K33_"PE\,>(_AY>_#C6(;?4VM?B?\,O$]IX
MJO/%/BVQ:XU6W%M<>%KSX7>(_!L4T22Z;<Z_IMC*6%EXFLI:R=*BG9J5[)[^
MGSOOTZVTNK"<W'FOIU^'^[IMO[VWG?;X?Z4/^'@GP?\ ^A5^(W_@L\.__-11
M_P /!/@__P!"K\1O_!9X=_\ FHK^8K4?VR?B?X/\:^)/AY\0/AAX1TO6;SX\
M_ KX'> /$OA'Q!K/B+PE<7WQDTW6?$U_8>(WO])\)7TOBCX7^#_#!UW6=.TS
M[-;:LVM>&HH)M!MM5_M<_3G[,7QPM/VBO@I\.OB]9Z0^@#QKI5U->:,UP;M=
M)UC1]5U#PYK]A;7C16;7UE:Z[H%W#8WDL,$ES9K#=2P6TDDEK35*A)V2E?S;
M6S2?3^N9=U9.51*[VT[.][/I'M>_7?3:W[L_\/!/@_\ ]"K\1O\ P6>'?_FH
MH_X>"?!__H5?B-_X+/#O_P U%?DS16GU:EVE]_\ 7]/TL^:7\S^Y?Y?U?TM^
MLW_#P3X/_P#0J_$;_P %GAW_ .:BC_AX)\'_ /H5?B-_X+/#O_S45^3-%'U:
MEVE]_P#7]/TL<TOYG]R_R_J_I;]9O^'@GP?_ .A5^(W_ (+/#O\ \U%?'W[5
MOQY\)_&^^\&7/A;3/$&FQ>'+368;Q?$-MIUL\LFHS6$L1M5TS4=85U1;!Q*9
MC$063R@ZES7Y?_M._'3Q!\!8O@WXAM=%T;4/ WC'XS>"_A3\1-9U,WBS^!=(
M\=7W]BZ/XRA-O<6EHUC:>))+/0-1&H$)"=7M-25F33[RPKS']GS]J[QM\:KW
MQYX>C\,^%K3QO\._B'\0_#NH^'6;5M+@U[P3HOASP[KOPX\;V&I7EUJEQHL'
MQ-B^)GAK6+9=0TZ[^RZ1>ZRJP7-[X;>*HC"G"<;*7,K];K6R[:W3;V[]M$W-
MQOO'2][:6<;].CWVLVO)'[-_LL?M+7'PHU-/"WBBXGNOAUK-T&D)WS2>$[Z=
M@&U:RC 9Y+"=F!U:QA!<I_Q,K)'N8[JP;]FK.[M;^UM;ZQNH+RRO((;JTN[6
M5)K:[MYXUF@N+::-GCFAFB=9HY(F9'0JR$A@U?Q/:[^VO\1? 7P!_:.^(OC?
MX6>')?B'\#?%/Q-\,:#I?@_7]5O?!'Q#T_P!I6D:AJ'CBQU;5=,TK6;'P[H&
MJ^('\#^)#);/L\6Z;+X7M;N'4=5M+"OWC_8R_:K?PQ:Z%X)\?7A7P9KUO:W&
MC:E/(S1^#=0OXXYFM9I9"63P]=3SD.[';IT[?;6VP2:C,%**E>4%K9.2U5_/
MUU>RVLT.FY124MK\J=T]K:*W35>GWV_8JBF*00""I!7<",D$$Y!![@T5D;#Z
M**^'_P!M:SU'71^R]X,M_&'CSP;I?C_]J/PSX1\3W?PZ\9^)? >O:IH$WPO^
M+6N2Z.WB'PIJFC:S'83:AH6G7DUO%=&"2:RMY7C+V\)7HPE#ZUB:=!S]FIJK
M*53EY^6-&E.M-J%X\SY8-17-&[M=I:GDYYF<LGRROCX8;ZW4ISPM&EAO:K#J
MK6QF,P^"I1E7=.JJ4%5Q$)3G[.HXP4FH2>A]P45\8_\ ##WP]_Z*Y^UA_P")
M6_';_P";>C_AA[X>_P#17/VL/_$K?CM_\V];^SRK_H8XG_PW+_YM/,_M#B[_
M *)G*O\ Q)ZG_P X#[.HKXQ_X8>^'O\ T5S]K#_Q*WX[?_-O1_PP]\/?^BN?
MM8?^)6_';_YMZ/9Y5_T,<3_X;E_\VA_:'%W_ $3.5?\ B3U/_G ?9U?Q,?\
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MSY_T3?3O_!OXD_\ EQ7UBQ$5T[=8Z:)=_P"K/?0\)0GJ]'?^]Y)?R_?Z??\
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M]._\&_B3_P"7%'_#)/[/G_1-]._\&_B3_P"7%7]9CV?WQ_S_ *MZ7?)/LO\
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M\/\ 3_#[3ZA<ZI;?%:34-/FTW5-3U+4[^TM=)M-'ADF,C5?"/[6^I>,?VKO
M7P M_AS>:#X3\>?L;3_M:Z7XG\52:WX?\?6#R^/_  1X+B\!>+/AIKWAW1[[
MP1JVFP>,'N]7AU;4KC5[:_@?1]0TO1KK3]05@%JMN[ZZZ).R\K6MJ]#[>KXQ
M_; _Y#/[('_9XGPU_P#4.^)%?9U?&/[8'_(9_9 _[/$^&O\ ZAWQ(KORO_D8
M8?\ P8K_ -1:Q\MQI_R3N,_["<I_]7& /LZBBBN ^I"BBB@#^<.]_P"/J\_Z
M^)/_ $8U1U)>_P#'U>?]?$G_ *,:HZ_PQJ?QJW_7R?\ Z<F?ZAT?X4/\$/\
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M_?I5%%048RC%QBN56^,O^%(?M7?]'O7O_B/GPO\ _DRC_A2'[5W_ $>]>_\
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M:SI,^M:C>W7BSXDZ5XNL73Z<T']G#_@H9:?&6.ZUSXI_$FZ_9RU/QU\9-?\
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MV6C6GB6?4KC_ (2CPS:W'B'03;P.-5T2WGUC3#=6,4UV?G*P_84^,C_L-_\
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M$O\ XFG&7E_U/O+^M;_&7_"D/VKO^CWKW_Q'SX7_ /R91_PI#]J[_H]Z]_\
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M (CY\+__ ),H_P"%(?M7?]'O7O\ XCY\+_\ Y,K[-HH_M/%?R9?_ .&?*/\
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M0/G_ %=7_92BOQK_ .&X/C1_S\^&?_!#'_\ )%'_  W!\:/^?GPS_P""&/\
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MX^KS_KXD_P#1C5'4E[_Q]7G_ %\2?^C&J.O\,:G\:M_U\G_Z<F?ZAT?X4/\
M!#_TB)^E'_!/C_D7OB9_V&O#G_I'JU?HQ7YS_P#!/C_D7OB9_P!AKPY_Z1ZM
M7Z,5_J_]&_\ Y,EP+_V#9Q_ZT.;'\#^,7_)S.*O^O^7?^J?+PHHHK]O/S0**
M** "BBB@ HHHH **** "BBB@ KS#XS_\DC^*_P#V3;QK_P"HUJ=>GUYO\7[>
M>Z^%7Q0M;:":YN;GX>>,8+>W@C>6:>:;P[J,<4,,4:M)-++(RQQQQJ79R%52
MS '2B_\ :</_ -?J=WM9*I!W_ X,U3>69@DFV\%BDDDVV_85+));MNR7FS@O
MV3O^37OV:_\ L@GPD_\ 4!\/U]"U^5'[/7_!0W]E#P9\"O@CX*\5?$+Q'I7B
M;PE\)?AQX6\2:6_P=^--RVF:]H/A#2-(U6QDNK#X?7EE=/9:C8SVIGLKB>UF
MVF2WFN(7CE/N&D_\%&_V2=:,\>C^.?&FL/;A7G32O@1\?+YH5D+!&E6U^&<S
M1*Y1A&7 !((#$K71B(3Q.98J&&ISQ$ZN*Q#IPHKVLJB56I.\(T^:4_<O+W4U
MRIN]M3YC(^)N&\)P_D\<5G^389T<JRVE66(S/!472J0P6'ISA552O%TY1FG"
M49V:E[N^A]ST5\8?\-^?LT?]![XE_P#B/'[0_P#\ZZC_ (;\_9H_Z#WQ+_\
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M-T;_ ,3IX2O$^#*W7AM/$]](U[KRZ(]LNJW+O=:G]ID9I17]DYO_ -"K,?\
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M_P"SIXNTO4/V@OAIX@U.?P]K+WMMXV^#OB30M8\#R:V\ A\5SW^@VETEQ?\
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MPU^%'_!3#X-^-?C_ &7PG\/Z_H/P]^)OQJ_:J^*VHZ9=R?"JYTFU7QK^WO\
M"[Q=I/B;X;B26[\5V7B_QI^Q]XC^,FK^'K+Q'/<VUOXC@T;2]>L]%\1V/@G1
M*%B\$U?^R,*O^YG,?+_J,\M/*S#^P\\_Z+3.-KJ^6\,ZZI?]"/\ K7R/UO\
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MV]O&\TT\]Y^S_##!$@+R2RR2?'!4BC15+O([*J@$L5 )$%M^UQ\0KY)I+/\
M8J_:8NTMF"SO;:E^SU.D#&-9@)FB^.3B%C"ZS /@F-E<95E8_FU^T%IW_!1'
MQ?XCUSX<>"/ _P </'/P"\6?#SXD^"_$UU\3I?V>AJ'BWPO\1OV;_P!I.70/
M#EUIOAO5-"U31-6\'?&.7X1^$;K6M5:\\47L#VK>(-1T[39?'%P_H7["/P"^
M*7P+^%G[:Q^+/[-WB'Q9#XTT?]G+4?#OPD6Z^']]>?&E? ?["'[/'P8\;>!8
M8]4\4VWA)%OOB3\+?$G@74[?QW?Z7H6IV<+ZEJ5S?^%=8COISZU@O^A3A?\
MPIS'R_ZC/+\NPUD>>6UXTSA:7M_9O#-]TK/_ (1%K^GRM]R6G[6WQ$U"S@U"
MP_8H_:9O=/NH1<P7]GJ/[/=S93V[#<MQ#=0_'%X)H67YQ*CLA7Y@2*DM?VL?
MB1?6\=W8_L2?M.7EK."T5S:WW[/MQ;S %E+1S1?'!XY '4J2K'# @\@@?%/P
M@^&/[0OP=_8;\#>#/V>_@?\ $?\ 9U\1S_M9Z7XR^(WPLU"7X+_\)UX1^"'Q
M(_:&'Q%_: L_@GX8\+^,/BO\(/!7AW1/#GC/Q)X6^&7@_3O$>H:UIWP[TE+G
M3V3Q]=:=#7RO^S;X:_X*"?LT^#_V5?AUJ'P\\??"3X)_#2?3-3^/WB'7?$?[
M/L_ACPU\.?$WC_\ :WUSXNZ]=SV.NZI>Z7J/A_0/$/P<\?ZQJ\;ZFVEQ6.DP
M>"M,\/VR_''1BGB\$K?\)&%_\*<Q[Q7_ $&?U9=@_L///^BTSC>S_P"$WAG_
M .<=OQZ^A^PO_#4OQ1_Z,:_:D_[_ /P _P#GWT?\-2_%'_HQK]J3_O\ _ #_
M .??7P7\(=1_X*&ZGX&_9+\6#QW:_&?=\5]<\-_%_4]'D\'VOAKXQ_!KPW\5
M? W@#PI\>/#?CC0[*;3O#&J^/?AMH?B_]HE/"L/AV_\ A]XI\$>*]?\ !NF:
MS\.OB#I/[.MTFA^UKXC_ ."EK?'7XP:=^SYX-^(T?PIMOAW\7M(\">(X+SX)
MWNC:MXOU']DF^USX/7_A*QUJ_LM:T670/VJ])M-&O+WQI:WTM[?:GJEGXDNK
M7X>CP18._K6"_P"A3A?_  IS'R_ZC/+\NP?V'GFO_&:9QI_U+>&==O\ J2=?
MU]#[<N_VL_B/I]O)=W_[$W[3=C:0[3+=7=_^SY;6\0=TC1I)IOCBD<>^1UC7
M<PW.RJ,LX%6!^U/\4B,C]AS]J0@\@BX^ ."#W_Y+?7XF_M._"C_@JQ\;/@1^
MT3\#?%6@?$?XA>"?B-X._:7\+>&M/,O[/VF^+_%>M^*OV:?V>O\ A36B^*+Y
M7\*Z5I?PUC^.-_\ M#:==W-D=.URSO;+PLM]=1:)#\-M0K])/VP?$G[<FF?$
M;X"6?[,W@/QY>>$+%_A;JWQ&O-.U#X3W/AVWL(_VA?@YH_Q.\):YI'B34[+7
M[G69_@!J'Q&NTU#3-1U'2+.&WDF\+12>+O[&\66)]:P7_0IPO_A3F/E_U&>7
MY=@_L//-/^,USC_PV\,]D]?^$3^M?*WT1=?M8_$FQ@ENKW]B3]IVTM8%WS7-
MU??L^V]O$A(4-+--\<4CC4L0N6;&2!GD92W_ &LOB1=^?]E_8E_:<NOLT[6M
MQ]GO_P!GV;R+E%BD:WG\OXXMY4ZQS1R-$^'"/&Q&V1"?A?\ X*(_##]LGXZ:
M'^WA\'?#7A;QUKGPQ\=_LEZSX;_9XT?X?R?"9?!OQ&\6>*?A)\9?!GCSX??%
MR[\9WVG^-O#_ (F_X67XH^&GBWPWK&BSV6BQZ7H.@0Z1KUII,W[1FF3_ #AX
M]^'W_!4;P58?')?V=O"7C+X>W6O>._VTOB'X3@\(:!^SGI@\;^)7^'/[.J_L
MIW_BZ36;"XDUJ77?&GAOXCZ!J>K^()4\176C6:Z;\3M7325^'<E'UK!?]"G"
M_P#A3F/E_P!1GE^78/[#SO3_ (S3./\ PV\,^5O^9)UU_'R/UWM_VL?B1=B8
MVO[$G[3MR+:>6TG-O??L^S"&Z@;9/;2F+XXMY4\+866%]LD;<2*A%+<?M7_$
MNSMKB[N_V(OVGK6TM(9+BYN;B]_9^@M[>WA1I9IYYI/C@L<,,,2M)++(RI&@
M9W954L/A7X$^$/VW_#?[0?B;3-:\%^+?AO\ L[^.?VD?VCOB+9:_\*/#WP"T
MWQ#>ZC<_&SX2>+OAUJGQAL+N.WO]6\!_$WX':/\ $CP!?^)4@U'XB1:AJNKZ
MCXNDM?&>G_ 3QF/5?VSOA-^V/XNO?VQ]%^'>H_\ ">?!?XH?L4^.(_A9X!OK
M+X;7PT[]I*Q\"_$[X>V_P?N?#GBW2&T+Q7\//C,WC_P9X]UN7XEW.H^'['6O
M >H^&=11_!_C37],!]:P7_0IPO\ X4YCY?\ 49Y?EV%_8>>?]%IF_3_F6\,[
MNVG_ "(_ZN_(^DI?VL_B- +8S?L2_M-PB]F2WM#+?_L^1BZGE1Y(H+8O\<0+
MB:6*)Y(XHMSNB,R@JI(FF_:L^)MO%+//^Q!^U!!!!&\LTTUW^S_'%%%&I>22
M61_C@J1QH@+N[L%5<LQ !-?FC>?#K_@H5XG\8?!S0_%7@A/$7P[\'?M)? OQ
MIH^J-X>^$^BWGPG\#VFA?$SPGXQTX^#]6MO%6@Z3K/PZ4>%]6\(_%3X(:O9:
M])X;\0:=IMUX5\,>*+?XLVIZ;Q]^SK^TCX__ ."*'A+X">-/AIX]\>?M:#X1
M_"/0?$?A?QMKW@[7_&5[\3/#_C+PMJ?C/6;CQA-XFO/"TJHFDZQJ%CKM[KB7
MEWII@AFDFU#4!:,?6L%_T*<+_P"%.8^7_49Y?EV'_8>=V3_UTSAZI?\ (MX9
MZV_ZDEO^#V5FOT$?]K#XD1W$%I)^Q)^TZEW<QS36UJ][^SZMQ<1VQA%S+!"W
MQP$DL=N;F(3O&K"(S1"3;YT>Y!^UG\1VNVL!^Q-^TV;Z. 73V0U#]GPW:6Q8
MQK<-;CXX^:L#2YB$Q0(7^4$MQ7S(/@W^UQJO_!43X/\ QX\2^"O E]^SIX;^
M!/[1_P /-/\ &.C>/M=_MKPOH_CK6O@+K7@_PYKWPWU/PGH$&D>,+_6?AO?Z
MA+<Z!>>([.]M'\2S>*O%^A#P[\'?AJ?C>#X?_P#!1K2_V@/%?QY\1_"?XF^+
M?B)%X"\>?!:XUGPEKWP+TCP[!X1U7_@HKX.\3^%/#?PSCO=6L?$#^"9OV+-&
MCU76-2O;5O&\%R-<BT_7_#'Q.NEUBCZU@O\ H4X7_P *<Q\O^HSR_+L']AYY
M_P!%IG'_ (;>&/+K_8G7]?0_6O\ X:E^*/\ T8U^U)_W_P#@!_\ /OH_X:E^
M*/\ T8U^U)_W_P#@!_\ /OK\V_@AXE_X*#^++O3_  EXM^,=S#\6-+_8W\?7
MWQE\&:=:_!37?B#\"/VFO!=]KVF_!K5[CP9HUS9^%M:D_:0\)?$_PA\1-.T/
MQ=X@LO"=\_PDU58M4\+1>*_$B'Z%\9ZW^WU;_L@?#>UTWP5XCU']IS4?B[XE
M\+^,6^&WB7P>UO;>!3J_Q0L_"GQ(6X^*4'@_5K#P3=VUKX'\2Z3X.N[C_A9^
ME07NB>$/B9XGU2&U^,'C<GUK!?\ 0IPO_A3F/E_U&>7Y=A?V)GG_ $6><=/^
M9;PREK:^KR1;?+KY'TFO[7'Q">_ETI/V*OVEWU6&TCOY=,74OV>VU"*QFDE@
MAO9+,?'$W"6LLT,D,5PT8BDE22-'9HW N?\ #4OQ1_Z,:_:D_P"__P  /_GW
MU^,_PX_98_;5UOXM>&?VCOB3\-/B59_%_7_VDOV%/%7Q/U?2-<^&.C:M=_"^
MT_8_^'NC?M-^']/BL?$%I86/@2V_:S^%_AV^\4>![6ZMM-U"7PMX8\::3HFJ
MVN@Z#XFKZ)^$GAG_ (*C>,Q^R_IOQC^)?Q>^&EQXH\<?$*P_:EU#X<^$OV>=
M/7X;Q:9\&_%-CI%_X#US7]0^/-EXN\"^+OC?IGA77?"MY%X6T[4-)T75+VPO
M["WTH:\@/K6"_P"A3A?_  IS'R_ZC/+\NP_[#SSIQIG#V_YEO#/E_P!2/U^_
MS5L;XD^"_P!H_P 9^.?&OBBP_8]^-,-CXE\2:OK=I#>ZO\'%NH;?4+Z>YBCN
MH[?XI74*3I'*%E2&61 X81R2##UZ#^SA%^T%\'?'C>*M>_8U^.MY8G0M1TH0
MZ+JOP5ENQ-=S6;H_EW_Q7TV#R5%JRR$R[U++L1MQ:N[_ &Q-=_;Q\-?%OQSX
MA^$^I6.B_!#0/#GPHUK1=6M3X3&B:7X,TWPY^T5??M4ZMXX?6HI_$$7C33?L
MOP:O/A[]@0V+7\>A?\(Y'/HP_:8@/Q%^SQ\1?^"L7QH^&_[/WQ$\.>-/%^H?
M!OXR> O@3XHO/B5-X0^!GB?XDZ7XP\9?L?P:QXE\>:3X*B\3_!G0M8^"D7[2
MNJZ-?/HFK:GIVNKJ"W<>HV+_  Y7Q+I"_B.7> WA+E/%>'XSP?"]>&=X;-99
MS2JU.(,[J4%CIXF6)E)X>6,Y)4W5J2?LVN6S4=C]-QGB#XI8_(*W#>)X_P 4
M\KK8"&6SA'ASA"%7ZK&E"@H1K+(U-3Y(17.O>;7,?L3_ ,-2_%'_ *,:_:D_
M[_\ P _^??5>V_:R^)%XDDEI^Q+^TY=1Q32V\KVU_P#L^3I'/"Q2>"1HOCBR
MI+"X*RQL0\; JX5N*^+_ (*_\/2(/C;\5#JL\=]X!U0?M3?\*_@^/L7@=?AM
MHD.F_M;Z#_PS-&TOPGM8OBDD^K_LBZEXCN&EU*2_GDU2UTBV^(=Q8Z[:VMD?
MG?2?"'_!1OX->*OB-IGP6^$/CK3M&\:?MP?%[XY:OJ6CZI\'+OPAXB\#^,OV
MO/@7-K,MSHVOZ]#XI+>+?V;;[XGWU@;V:W;2X;>]6'0(O',?A3QF/V[ZU@O^
MA3A?_"G,?+_J,\OR['YC_8F>?]%IG%_^Q=PS;IU_L3\>SOVM^K-I^UC\2+Z"
M.ZL?V)?VG+RUF!,-S:WW[/MQ;RA69&,<T/QP>-PKHR$JQPRLIY4BDM_VLOB/
M=M<+;?L2_M-W#6D[6MTL%_\ L^S-;7**KO;W(C^.+&"=$D5C%)MD"LI*@,"?
MQ^^#7P:_X*C?L]_#WP5\/_AKH_B/0?A9I&KZ7<?$GPO+!\*?$/BOPL?&?[7'
MQO\ %WC*_P#@)&-;\*?VS'%\"O%_@7Q-XWT[4_$:#RI1H/P]O;3X@:?\2?#Y
M_2?_ ()]_!_XS?"_Q?\ ML:S\9=)U&/6/BS^T+\/OB-I/C#4M,\*:&?B:NG?
MLG_LY_"[Q=XVC\,>$?%7C32_!SZG\2?A?XNCG\.Q:E<)8^0LVE7VMZ'<Z'KM
MT?6L%_T*<+_X4YCY?]1GE^78:R///^BTSCR_X3>&==5_U)/G\W\O8O\ AJ7X
MH_\ 1C7[4G_?_P" '_S[Z/\ AJ7XH_\ 1C7[4G_?_P" '_S[Z^SJ*/K6"_Z%
M.%_\*<Q\O^HSR_+L']AYY_T6><_^&WAG_P"<G]7]#X(\5?''Q?XT31(?$G[!
M?[3FK6OA_7;7Q+86=U<?L_M:'5;&TO;*UENH#\;C'=QVZ:G-<+;3 Q&>.*21
M'$+Q&WXA_;0\0^"K2PUOQW^R+^TAX)\+W/B/PGX9O?%.NM\%)],T:[\9>*-$
M\&Z)<:C#X?\ B]K>J/:RZ_XCTZT=K'3[R:-97F\HQJY7[LKXR_;Y_P"3;M6_
M[*K^S;_ZT?\ "FC+L-DU3-8N&18"A7S;$X*AC<51J8V.)K0A*&&H^TJO%2=1
MX>E.2H1J<].G>7+#WY\WG<11XHRKAW,\PCQIF^*_L+*LSS#!83$Y?P\\(JE#
M#U,7*G*%+**<X4\15HQ6(="I2JSCM44HQDOLVBBBO//N0HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#^<.]_X^KS_KXD_]&-4=27O_ !]7
MG_7Q)_Z,:HZ_PQJ?QJW_ %\G_P"G)G^H='^%#_!#_P!(B?I1_P $^/\ D7OB
M9_V&O#G_ *1ZM7Z,5^<__!/C_D7OB9_V&O#G_I'JU?HQ7^K_ -&__DR7 O\
MV#9Q_P"M#FQ_ _C%_P G,XJ_Z_Y=_P"J?+PHHHK]O/S0**** "BBB@ HHHH
M**** "BBB@ KS#XS_P#)(_BO_P!DV\:_^HUJ=>GUYU\6;&\U/X8?$K3M.M+F
M_P!0U#P#XNL;&RM(9+F[O+NYT#4(+:UM+>%7FN+FYGE6""&)#))*RHBNS '2
MB[8C#W_Y_4_DE4@V_DE^IP9HI2RS,(Q3E*6"Q222;;;H5+))7;;=DDNYY_\
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M4?\ #:OAG_H@/[87_B+OQ7_^45']E9I_T UO_)?+S\T'^NO"G_0\P7_@4_\
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M8G#XE.-.:4).3H*#NU92;6J04445_3Y^(A1110 4444 %%%% !1110 4444
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M&S4HMIIW3M8_:O\ X:U_9]_Z*%;?^$_XL_\ E+1_PUK^S[_T4*V_\)_Q9_\
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M!N&,RB24Z<N2I"7+E#M.$X.$XO6,DXNTHVC^U?\ PUK^S[_T4*V_\)_Q9_\
M*6C_ (:U_9]_Z*%;?^$_XL_^4M?BI14?\3A>)?\ T)>"O_"#/O+_ *J/R_%]
MS3_B7/@K_H9\2_\ A5E7E_U)_+^K*W[5_P##6O[/O_10K;_PG_%G_P I:/\
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MNHSC*#:G'E7[3?\ #6O[/O\ T4*V_P#"?\6?_*6C_AK7]GW_ **%;?\ A/\
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M3>I__(]'_"A/B_\ ]$H\=?\ A-ZG_P#(]<G^J/&'_1*<0_\ AFS7R_Z@O/\
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M*]0_X4)\7_\ HE'CK_PF]3_^1Z/^%"?%_P#Z)1XZ_P#";U/_ .1Z/]4>,/\
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M?5(RIJ=3+<KQ7N[8O+<#7TE0C;PL9_J9C\SPN;ULZRU8W"_5O95*>;X*,?\
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M#JTN$LQSJAF=/-\%/,I.A2HQPV9X&7/4IT,9AZ=L/SU(UZM18^+E&=.JJM3
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B7X=M2]G3O;VE:I:$L1B)14ZTXK2-*-*E2****_2#Y$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img248422670_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_14.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 EH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BJ5]<&T
MM+RY10[6UK/.%;(5FAC>158CD E .Y(/')R;M9.L_P#(*U;_ +!MY_Z3/0!F
MVK^);FWMK@3:$@G@BF"FTOR5\U%?:&%X <;B,K@GVJ?9XE_Y^= _\ [[_P"3
M:T-*_P"0?I__ %X6O_HI*T: .>\OQ'_S\Z%_X"W_ /\ )E&SQ+_S\Z!_X!WW
M_P FUT-% '/;/$O_ #\Z!_X!WW_R;1L\2_\ /SH'_@'??_)M=#10!SVSQ+_S
M\Z!_X!WW_P FT;/$O_/SH'_@'??_ ";70T4 <]L\2_\ /SH'_@'??_)M&SQ+
M_P _.@?^ =]_\FUT-% '/;/$O_/SH'_@'??_ ";1L\2_\_.@?^ =]_\ )M=#
M10!SVSQ+_P _.@?^ =]_\FT;/$O_ #\Z!_X!WW_R;70T4 <]L\2_\_.@?^ =
M]_\ )M&SQ+_S\Z!_X!WW_P FUT-% '/;/$O_ #\Z!_X!WW_R;1L\2_\ /SH'
M_@'??_)M=#10!SVSQ+_S\Z!_X!WW_P FT;/$O_/SH'_@'??_ ";70T4 <]L\
M2_\ /SH'_@'??_)M&SQ+_P _.@?^ =]_\FUT-% '/;/$O_/SH'_@'??_ ";1
ML\2_\_.@?^ =]_\ )M=#10!SVSQ+_P _.@?^ =]_\FT;/$O_ #\Z!_X!WW_R
M;70T4 <]L\2_\_.@?^ =]_\ )M'E^)?^?G0?_ 6__+_C\Z_[77VKH:* .>V>
M)?\ GYT#_P  [[_Y-HV>)?\ GYT#_P  [[_Y-KH:* .>V>)?^?G0/_ .^_\
MDVC9XE_Y^= _\ [[_P"3:Z&B@#GMGB7_ )^= _\  .^_^3:-GB7_ )^= _\
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M?^@%IW_@[?\ ^5-='10!SGV[Q#_T M._\';_ /RIH^W>(?\ H!:=_P"#M_\
MY4UT=% '.?;O$/\ T M._P#!V_\ \J:/MWB'_H!:=_X.W_\ E371T4 <Y]N\
M0_\ 0"T[_P ';_\ RIH^W>(?^@%IW_@[?_Y4UT=% '.?;O$/_0"T[_P=O_\
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M?:U[/56>W4T3;2;5FUL^GEI=:>3L%%%% PHHHH **** "BBB@ HHHH ****
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MC)'X<L=<:ZU"&T:*;5)+>W<7CXWQ@_X)JZ1\3O'/[77CS3OC7XJ\(ZA^V/\
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M[_\ 1$M #=-BB>QTV1X8VD6PMU5V1695:!-ZJQ!(5NA"MCUS69J/_(P^&_\
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M)('S5/\ V[_U"-:_\ ?_ +90!O45@?V]_P!0C6__   /_P <H_M[_J$:W_X
M'_XY0!OT5@?V]_U"-;_\ #_\<J&X\20VT?FSZ9K4,>^*,.VGMC=/*D$*G$C'
M,DTJHO'WB,D [J .EHK _M[_ *A&M_\ @ ?_ (Y1_;W_ %"-;_\   __ !R@
M#?HK _M[_J$:W_X '_XY1_;W_4(UO_P /_QR@#?HKFY_$D-M#+<3Z7K4<,*-
M++(U@VU$499SAS@ >F?:I?[>_P"H1K?_ ( '_P".4 ;]%8']O?\ 4(UO_P
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M"_Z#NC_^#&S_ /CM &Y16'_PD6A?]!W1_P#P8V?_ ,=H_P"$BT+_ *#NC_\
M@QL__CM &Y16'_PD6A?]!W1__!C9_P#QVC_A(M"_Z#NC_P#@QL__ ([0!N45
MB?\ "0:)_P!!S2/_  86G_QRD_X2+0O^@[H__@QL_P#X[0!N45A_\)%H7_0=
MT?\ \&-G_P#':/\ A(M"_P"@[H__ (,;/_X[0!N45A_\)%H7_0=T?_P8V?\
M\=H_X2+0O^@[H_\ X,;/_P".T ;E%8?_  D6A?\ 0=T?_P &-G_\=H_X2+0O
M^@[H_P#X,;/_ ..T ;E%8G_"0Z'U_MW2,>O]H6?_ ,=Q^M)_PD6A?]!W1_\
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M&)CUQ=3MF;Q#HMEJ.CZ=(/0_^"F7P'T'XX_!/0T\6GXJMX3^'_C33/'>M?\
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M* "BBB@#GM4_Y"OA?_K_ +[_ -,U_70USVJ?\A7PO_U_WW_IFOZZ&@#\P_\
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MKQ%;GY6U"5+-,EII<R3Y7*->5DY1349:MI1E]7T445N(**** "BBB@ HHHH
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M****Z!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!SVJ?\A7PO_U_WW_IFOZZ&N>U3_D*^%_^O^^_],U_70T
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M*K8BHX6BJ5.I1E0A[2;_ (KG.C*]&,?W:E1JN;]K:G^K.E?\@_3_ /KPM?\
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M^OM1)ELO\4/_ $N)U-%%%44%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SVI?\
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ML%%>$_\ "*_'_P#Z+/\ #G_PR6I_C_S6+_/O1_PBOQ__ .BS_#G_ ,,EJ?\
M\^&M?8T?^@W#?^ XWK;_ *A'WN<7]I8O_H19I_X.R7K;_J;OO_6Q[M17A/\
MPBOQ_P#^BS_#G_PR6I__ #X:WM3UWQ+\/?ASKVO>+]3C\;Z_HMEJ%\DG@OP1
MKMF^I-M8:9IUEX4T[4OB!K4LYF:*"6:WEN-X9KAH;>))365:-.E3<XXBE6:^
MQ3CB%.UG*Z]KAZ<.RMS<S;22>MNC"8K$8FLJ53+,9@U):5<35RZ5/FO&T+87
M'XFK=J5[^SY$HN\D[7]8HK\U/ACXE^,G@2U^*WAJR\'^(M%\7^(M*TCXV^%4
M\5:)X@\=Z%J5]?63P^/O#XUG2XO#6F:+K&J_\(\=5T?0-3U6+4H-2U28363I
M):Z>+?B[]HG]IO2/$GP_.F_#FV/@GQRHU\ZIJ?PZ\<S:KH6@7VL-;V^B:UIO
MAZ^\0W6B^*-'\/[-?N4UB"TCU&[<:&8])D@N+NHE>+@FE>7+%V:Y8U.2;G'F
MV48U:&)HQG/V?-+#RYXTY2A!]JDG&4OLQ<FM'S."]FXRY4KN3IUJ$Y1ASJ/M
M;1E.-.I./Z045^:MC^U!\>;:Q^"U]JW@NZU!_&/]AWGQ!M;?X,_$K1K?PQI>
MHZW/H6IW!OKW4-0DTB\\/F"/6KRTUBV)?3;CS]WV&VN-7K@8_P!KO]IR^T3Q
M#K&A>%?#.OW$6NZ79Z5I-K\+?B9;WVE>&KHZR)?&-Y!+?FX\6Z-)J6G:?H,)
M\)PW#6K:A-K-\8X/L=FP^97TT4Y4WKKS0E2C+W;<SC>K%\\8N%HU&VE2J<C>
MGSA">ZMRS4VES7Y5/]VUR.2FW*G&,92JTU+]:**^!/BAK>EWGB?]DKQ[\0O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWF^)?^?'0/\ P9WW_P JJ/-\2_\ /CH'_@SOO_E570T4 <]YOB7_ )\= _\
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AT.[NYYI&FLKFS5 DUE9HJC[3YA;>3A<!3NYZ>BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img248422670_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248422670_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %J G$# 2(  A$! Q$!_\0
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M_P"_9_QJ6B@"+;/_ ,](_P#OV?\ &C;/_P ](_\ OV?\:EHH BVS_P#/2/\
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MMG_YZ1_]^S_C1MG_ .>D?_?L_P"-2T4 1;9_^>D?_?L_XT;9_P#GI'_W[/\
MC4M% $6V?_GI'_W[/^-&V?\ YZ1_]^S_ (U+10!%MG_YZ1_]^S_C1MG_ .>D
M?_?L_P"-2T4 1;9_^>D?_?L_XTFZ5)(PS(P9L<*1V)]?:IJBE_UD'^^?_030
M!+1110!%%_K)_P#?'_H(J6HHO]9/_OC_ -!%2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <YXLMKF4Z3<QP27%M:7J37$,:EF*] P4<
MM@G.!537HVO8]+U"UTZY:S@U%9[F'[.5DD &T2>7C<<'U&>,XQS7744 <)>V
M=W?GQ7?VUG<I;W=DL,2/"R//(JGD(1N[@#(Y[5A7>AZNVG76D"QG:PMX'OH<
M1-\\KQ@",#'569SBO4[BY@M(&GN9HX84^])(P55^I/%,GU"RM;5;JXN[>&W;
M&V620*ASTP2<<T <9=Z-J%_K-A!$#;Q2:&UM--+;-(J[L KU #?7TZ&J^N:%
MJ5]+/:6%HS6VE6,<%I)<.R,9 5??'\A#G"*O;OSS7=RZA90- LUW;QFX(6$/
M(!YI.,!<GGJ.GK4=WJVFZ?(L=[J%I;2,,JLTRH2/4 F@#CM8L]5UW5--NK6*
MZLY9=*E#,8.$D8#]VVX8&3D=CZ58LK65[SP7+%IUS;0P07"RQO&W[@F,##$\
MC)!QGK772WMK!<0V\US#'--D11O( SX_N@\G\*5;NV:*:5;B(QPEEE<.,(5^
M\&/;'?/2@#C]$MKRRUQK73X[K^SW29S]ML]C6<A/1),8<,W89X Y-9\%C=R>
M%=+T*/3KN+5+>^1Y)'@940JY9I?-QM/'H23GI7>6>I6.HJ[6-[;700@,8)5?
M;]<'BEN=1LK.6**ZO+>"28XB2655+GI@ GGJ.E ' :_H^J+K?B#6+"UG>7"0
M&,(<7,+P*K;?[Q5@#QW%=KIT$X\+6ENNZ&Y^Q(@W @H^P#GTP:LW6I6%C)&E
MY>VUN\O^K6:54+_3)YZBGM>VB2RQ-=0K)"GF2H9 "B_WB.P]S0!P=O9W4WAW
M0-&ATV[@U"SO$>9Y(&5(MC$NXDQM;/)&TG.:V=&L]2C\7Z_.-L-I+/$?WMNQ
M,H$>/D?< ,?0UT4E]9PV0O9;J!+0J&$[2 )@XP=W3!R,?6HXM7TR>%)HM1M)
M(GE$*.DZE6D/1 <\M[=: ,GQ?:W$]KITL4$ES!;7T4]Q!&NYGC&<X7^+!(..
M]5O$ ;4-/M+VQL+DK;ZI!<S+]G9))%3 +!" Q(&!R,_+QQBNFBN;>>26.&>*
M1XFVR*C@E#Z$#H:8]_9Q_:-]W OV8 S[I /*!&1NY^7(YYH XZZM+J]@\97T
M-I=>5>VT<5NKPLCR%(V!PA&[JP XYK N]#U=M.NM(%C.UA;P/?0XB;YY7C $
M8&.JLSG%>G7.IV%E!'/=7UM!%)]R26555N,\$GGBG?;[/R(9_M<'E3LJ0R>8
M-LC'H%.>2>V* .5$4^G>(=&U&>TNFMETO[,[0P/*R29!PRJ"PZ=<5GQZ;>V'
MA7PYYUG<EXM76ZFBCA:1XHR9#DJH)Z$9]SBNXO=3T_3MGVZ^MK7S,[//E5-V
M.N,GGJ/SIS7UHD$,[74"PS%1%(9 %<M]W:>ASVQUH Y?Q';W?B.]L;*ULFDL
MA!)<2FZ$D",S QJN2A(899L$>E5FCU*\\,^&X[BSN?M=IJENDX,39"QL07Z?
M=Q@[NG-=@=0LA//";RW$MNN^9/-7=&N,Y89X&.<FB?4;*UM4NKB\MXK9\;9I
M)55&SR,$G!S0!B7-I-)\0;:=K=WM?[,DC>0H2F2X^4GIG':L?PYI>H+KL%A=
MVTRV.B&?[--(AVS;VPA!/!VKGZ5V]O<P7<"SVTT<T+_=DC8,K?0CBHI-2L(K
MU+*2]MDNGQM@:50[?1<Y- '+^#XY[2\U"&X;4HFDOKAT@>T(A*DY#^9Y??']
M_'M6CXXMI[OP??P6T,DTS>7MCC4LQQ(I. /:M6?5]-MKM;2?4+2*Y; 6&295
M<YZ84G/-227UG%=QVDEW ES*,QPM( [CU"]3T/Y4 8.M136_B[2-4DMYY[&&
M*:(F")I3#(PX8JH+8(!&0#[XS5"TT^\_X1CQ5(+2:-+\W,MK;,A#D-'@?)U!
M8]NM=:+^S:ZEM1=P&XA7?)$)!O1>#DC.0.1U]:CL]5T[479+'4+6Y9!EA!,K
MD#WP: .5O[*_U"Q\.Z0FGM)#';K/="<M$F50*J%]K8.XYQC/RU4,>I+X8T&"
M\LKLSZ9JT23;(7D)CCW?.H RR[<<@5W5M>6MX)#:W,,XC8H_E2!MK#J#CH?:
MHXM4T^>&.:&^M9(I)/*1TF4JS_W00>3[4 3V\Z7,"31B0*PR!)&T;?BK $?B
M*\^\(Z7?Z?<>'9;VVNI(_LT\:J\14V<FXGG 'RLO][//>N[.IV"QO(U];!$E
M\AF,JX63^X3GAO;K5J@#C? T<]G!+;7)U**0S3,+>:T98E!?(8/L')'^T>O2
MK&C6-T)O%*/!)']ING\DR*5#@H "">HSWK??5=.CMGN)+^U6!',;RM,H57'5
M2<X!]JF6Y@><P+/&TP0.8PX+!3T..N/>@#A-*LKR>/PK8FRNHIM,D=[LS0,B
M(%!'#D;6R2,;2?7I42:9J$6IR7DMM=2V:^(FE:U\D]"H"SJ0-Q )YY*D#IUK
MN[74K"]EDBM+VVN)(O\ 6)%*KE/J >*M4 >8:UHNJQWGB+5;"TN'EED>U:$1
MM^_ADB"[E'\6UL'CW]*]%TQ&CTFS1U*NL"!E88(.T<&K5% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !44O^L@_WS_Z":EJ*7_60?[Y_
M]!- $M%%% $47^LG_P!\?^@BI:BB_P!9/_OC_P!!%2T %%%% !1110 4444
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M.\8PPVLWF7%TCQ J5\Y!M+;2>N0".*U(E;5/%NE7UE8W-M;6=K(D[SV[0<.
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MRT0PFPESM7A,@@_=/(SQT%% !5>*%65B2^2[='(_B/O5BHH/]6?]]_\ T(T
M'D)_>D_[^-_C1Y"?WI/^_C?XU+10!%Y"?WI/^_C?XT>0G]Z3_OXW^-2T4 1>
M0G]Z3_OXW^-'D)_>D_[^-_C4M% $7D)_>D_[^-_C1Y"?WI/^_C?XU+10!%Y"
M?WI/^_C?XT>0G]Z3_OXW^-2T4 1>0G]Z3_OXW^-'D)_>D_[^-_C4M% $7D)_
M>D_[^-_C1Y"?WI/^_C?XU+10!%Y"?WI/^_C?XT>0G]Z3_OXW^-2T4 1>0G]Z
M3_OXW^-'D)_>D_[^-_C4M% $7D)_>D_[^-_C1Y"?WI/^_C?XU+10!%Y"?WI/
M^_C?XT>0G]Z3_OXW^-2T4 1>0G]Z3_OXW^-'D)_>D_[^-_C4A(49)  [FJ4^
MLZ;;?ZV^MU([>8"?R%3*48ZR=BHPE+2*N6?(3^])_P!_&_QH\A/[TG_?QO\
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M/_OD5+10!%]F@_YXQ_\ ?(H^S0?\\8_^^14M% $7V:#_ )XQ_P#?(H^S0?\
M/&/_ +Y%2T4 1?9H/^>,?_?(H^S0?\\8_P#OD5+10!%]F@_YXQ_]\BC[-!_S
MQC_[Y%2T4 8NL^'H]5,!25;<Q;ONQYW9Q[CTJ.S\)V$,)2Z47,F<A\LG'I@-
M6]12L.[9D_\ ",Z/_P ^?_D5_P#&C_A&='_Y\_\ R*_^-:U%,1D_\(SH_P#S
MY_\ D5_\:/\ A&='_P"?/_R*_P#C6M10!D_\(SH__/G_ .17_P :/^$9T?\
MY\__ "*_^-:U% &3_P (SH__ #Y_^17_ ,:/^$9T?_GS_P#(K_XUK44 9/\
MPC.C_P#/G_Y%?_&C_A&='_Y\_P#R*_\ C6M10!D_\(SH_P#SY_\ D1_\:/\
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M&/\ [Y%'V:#_ )XQ_P#?(K&M_%=I<Y\NUNVQU*(& _(U/_PDFG+_ *UY8O\
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M47VF#_GM'_WT*/M,'_/:/_OH4 4;OP_IMVWF-;".7J)(3L8'UXJM_9VLV/\
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M +Z%602T5%]I@_Y[1_\ ?0H^TP?\]H_^^A0!+147VF#_ )[1_P#?0H^TP?\
M/:/_ +Z% $M%1?:8/^>T?_?0H^TP?\]H_P#OH4 2T5%]I@_Y[1_]]"E6>%F
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M?ZR?_?'_ *"*EJ*+_63_ .^/_014M !17(RZ]J]HT\$T:-?RSJD%L+? 1"2
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M;?X4>>G]V3_OVW^% $M%1>>G]V3_ +]M_A1YZ?W9/^_;?X4 2T5%YZ?W9/\
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M;?X4>>G]V3_OVW^% $M%1>>G]V3_ +]M_A1YZ?W9/^_;?X4 2T5%YZ?W9/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT[3_ !!>7=WI^;]A,XMU^Q-$JF=&CS)+@KNX.[D$+\G3F@#M:B@_U9_WW_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M *R#_?/_ *":EJ*7_60?[Y_]!- $M%%% $47^LG_ -\?^@BI:BB_UD_^^/\
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M>D?_ '[/^- $M%1;9_\ GI'_ -^S_C1MG_YZ1_\ ?L_XT 2T5%MG_P">D?\
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M-&V?_GI'_P!^S_C0!+146V?_ )Z1_P#?L_XT;9_^>D?_ '[/^- $M%1;9_\
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MY_\ 034M12_ZR#_?/_H)H EHHHH BB_UD_\ OC_T$5+447^LG_WQ_P"@BI:
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M8:7-;S*UNP!?8J *2,/D@D;<\#W%6Q8ZB][86\UO*;?2;I(X7VDB52W#_P#
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MP"7!$>UMQ8$@]3SGEHT_4D2^L8[6?[+J=S<2RL5.$"S2%A])$\L#U&37=T4
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0DDD>A'8^]3T4 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>sclx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-07T13:28:20.9565+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sclx-20221231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="sclx-20221231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals" xlink:href="sclx-20221231.xsd#vcka_r_ConsolidatedBalanceSheet_Parentheticals" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement" xlink:href="sclx-20221231.xsd#vcka_r_ConsolidatedIncomeStatement" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3" xlink:href="sclx-20221231.xsd#vcka_r_ShareholdersEquityType2or3" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow" xlink:href="sclx-20221231.xsd#vcka_r_ConsolidatedCashFlow" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentation" xlink:href="sclx-20221231.xsd#DisclosureNatureOfOperationsAndBasisOfPresentation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcern" xlink:href="sclx-20221231.xsd#DisclosureLiquidityAndGoingConcern" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="sclx-20221231.xsd#DisclosurePropertyAndEquipment" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPolicies" xlink:href="sclx-20221231.xsd#vcka_r_SummaryofSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOffering" xlink:href="sclx-20221231.xsd#vcka_r_PublicOffering" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacement" xlink:href="sclx-20221231.xsd#vcka_r_PrivatePlacement" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactions" xlink:href="sclx-20221231.xsd#vcka_r_RelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingencies" xlink:href="sclx-20221231.xsd#vcka_r_CommitmentsandContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquity" xlink:href="sclx-20221231.xsd#vcka_r_ShareholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_Warrants" xlink:href="sclx-20221231.xsd#vcka_r_Warrants" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitions" xlink:href="sclx-20221231.xsd#DisclosureAcquisitions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurements" xlink:href="sclx-20221231.xsd#vcka_r_FairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" xlink:href="sclx-20221231.xsd#DisclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebt" xlink:href="sclx-20221231.xsd#DisclosureDebt" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlans" xlink:href="sclx-20221231.xsd#DisclosureStockIncentiveAndEmployeeBenefitPlans" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatements" xlink:href="sclx-20221231.xsd#vcka_r_RestatementofPreviouslyIssuedFinancialStatements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShare" xlink:href="sclx-20221231.xsd#DisclosureLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SubsequentEvents" xlink:href="sclx-20221231.xsd#vcka_r_SubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies" xlink:href="sclx-20221231.xsd#DisclosureNatureOfOperationsAndBasisOfPresentationPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesTables" xlink:href="sclx-20221231.xsd#vcka_r_SummaryofSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables" xlink:href="sclx-20221231.xsd#vcka_r_FairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="sclx-20221231.xsd#DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="sclx-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtTables" xlink:href="sclx-20221231.xsd#DisclosureDebtTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansTables" xlink:href="sclx-20221231.xsd#DisclosureStockIncentiveAndEmployeeBenefitPlansTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="sclx-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareTables" xlink:href="sclx-20221231.xsd#DisclosureLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatementsTables" xlink:href="sclx-20221231.xsd#vcka_r_RestatementofPreviouslyIssuedFinancialStatementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails" xlink:href="sclx-20221231.xsd#vcka_r_SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofcondensedbalancesheetsTable" xlink:href="sclx-20221231.xsd#vcka_r_ScheduleofcondensedbalancesheetsTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable" xlink:href="sclx-20221231.xsd#vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureAcquisitionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails" xlink:href="sclx-20221231.xsd#vcka_r_PublicOfferingDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails" xlink:href="sclx-20221231.xsd#vcka_r_PrivatePlacementDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails" xlink:href="sclx-20221231.xsd#vcka_r_RelatedPartyTransactionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingenciesDetails" xlink:href="sclx-20221231.xsd#vcka_r_CommitmentsandContingenciesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails" xlink:href="sclx-20221231.xsd#vcka_r_WarrantsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable" xlink:href="sclx-20221231.xsd#vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable" xlink:href="sclx-20221231.xsd#vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3" xlink:href="sclx-20221231.xsd#DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable" xlink:href="sclx-20221231.xsd#vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable" xlink:href="sclx-20221231.xsd#vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="sclx-20221231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" xlink:href="sclx-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xlink:href="sclx-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails" xlink:href="sclx-20221231.xsd#DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails" xlink:href="sclx-20221231.xsd#vcka_r_ShareholdersEquityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatementsDetails" xlink:href="sclx-20221231.xsd#vcka_r_RestatementofPreviouslyIssuedFinancialStatementsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable" xlink:href="sclx-20221231.xsd#vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails" xlink:href="sclx-20221231.xsd#DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" xlink:href="sclx-20221231.xsd#DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetails" xlink:href="sclx-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" xlink:href="sclx-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails" xlink:href="sclx-20221231.xsd#DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" xlink:href="sclx-20221231.xsd#DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LongTermPortionOfDeferredConsideration" xlink:label="sclx_LongTermPortionOfDeferredConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AccruedExpenses" xlink:label="sclx_AccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CurrentPortionOfDeferredConsideration" xlink:label="sclx_CurrentPortionOfDeferredConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyPayable" xlink:label="sclx_RelatedPartyPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="sclx_LongTermPortionOfDeferredConsideration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sclx_AccruedExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sclx_CurrentPortionOfDeferredConsideration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sclx_RelatedPartyPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NotesPrincipalIncrease" xlink:label="sclx_NotesPrincipalIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="sclx_NotesPrincipalIncrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoMember" xlink:label="sclx_SorrentoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LegacyCommonStockMember" xlink:label="sclx_LegacyCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectOfBusinessCombinationInValue" xlink:label="sclx_EffectOfBusinessCombinationInValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectOfBusinessCombinationInShares" xlink:label="sclx_EffectOfBusinessCombinationInShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RecapitalizationDuetotheBusinessCombinationShares" xlink:label="sclx_RecapitalizationDuetotheBusinessCombinationShares"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RecapitalizationDueToTheBusinessCombinationValue" xlink:label="sclx_RecapitalizationDueToTheBusinessCombinationValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DistributionToSorrentos" xlink:label="sclx_DistributionToSorrentos"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xlink:label="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xlink:label="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xlink:label="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_21"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_22"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_SorrentoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sclx_LegacyCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_EffectOfBusinessCombinationInValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_EffectOfBusinessCombinationInShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_RecapitalizationDuetotheBusinessCombinationShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_RecapitalizationDueToTheBusinessCombinationValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_DistributionToSorrentos" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsFromTheBusinessCombination" xlink:label="sclx_ProceedsFromTheBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:label="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" xlink:label="sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:label="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" xlink:label="sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" xlink:label="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NonCashConsiderationInSemnurAcquisition" xlink:label="sclx_NonCashConsiderationInSemnurAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsFromRepaymentOfLoansToPurchase" xlink:label="sclx_ProceedsFromRepaymentOfLoansToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NotesPrincipalIncrease" xlink:label="sclx_NotesPrincipalIncrease"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OtherLoanForgiveness" xlink:label="sclx_OtherLoanForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xlink:label="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" xlink:label="sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" xlink:label="sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseDecreaseInLongTermDeposits" xlink:label="sclx_IncreaseDecreaseInLongTermDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NonCashOperatingLeaseCost" xlink:label="sclx_NonCashOperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquisitionOfRightOfUseAsset" xlink:label="sclx_AcquisitionOfRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiveActionRightOfUseAssetInPaloAlto" xlink:label="sclx_LiveActionRightOfUseAssetInPaloAlto"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseDecreaseInAccruedPayroll" xlink:label="sclx_IncreaseDecreaseInAccruedPayroll"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NonCashDistributionToSorrento" xlink:label="sclx_NonCashDistributionToSorrento"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ForfeituresOfPrivateWarrants" xlink:label="sclx_ForfeituresOfPrivateWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:label="sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:label="sclx_IncreaseDecreaseInAccruedRebatesAndFees"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="sclx_ScilexPharmaNotesPrincipalIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NotesPrincipalIncrease" xlink:label="sclx_NotesPrincipalIncrease_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination" xlink:label="sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OtherLongTermLiabilities" xlink:label="sclx_OtherLongTermLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TransactionCostsObligationAssumedBySorrento" xlink:label="sclx_TransactionCostsObligationAssumedBySorrento"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredUnderwritingFeePayable" xlink:label="sclx_DeferredUnderwritingFeePayable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:label="sclx_OfferingCostIncludedInAccruedOfferingCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sclx_ProceedsFromTheBusinessCombination" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_NonCashConsiderationInSemnurAcquisition" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sclx_ProceedsFromRepaymentOfLoansToPurchase" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sclx_NotesPrincipalIncrease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_OtherLoanForgiveness" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sclx_IncreaseDecreaseInLongTermDeposits" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sclx_NonCashOperatingLeaseCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_AcquisitionOfRightOfUseAsset" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_LiveActionRightOfUseAssetInPaloAlto" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sclx_IncreaseDecreaseInAccruedPayroll" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_NonCashDistributionToSorrento" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sclx_ForfeituresOfPrivateWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sclx_IncreaseDecreaseInAccruedRebatesAndFees" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_ScilexPharmaNotesPrincipalIncrease" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_NotesPrincipalIncrease_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sclx_OtherLongTermLiabilities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_TransactionCostsObligationAssumedBySorrento" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_DeferredUnderwritingFeePayable" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sclx_OfferingCostIncludedInAccruedOfferingCost" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NotesIssued1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcern" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOffering" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProposedPublicOfferingAbstract" xlink:label="sclx_ProposedPublicOfferingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProposedPublicOfferingTextBlock" xlink:label="sclx_ProposedPublicOfferingTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ProposedPublicOfferingAbstract" xlink:to="sclx_ProposedPublicOfferingTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDisclosureTextblockAbstract" xlink:label="sclx_PrivatePlacementDisclosureTextblockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDisclosureTextblock" xlink:label="sclx_PrivatePlacementDisclosureTextblock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PrivatePlacementDisclosureTextblockAbstract" xlink:to="sclx_PrivatePlacementDisclosureTextblock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_Warrants" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlans" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock" xlink:label="sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SpacTransactionsPolicyTextBlock" xlink:label="sclx_SpacTransactionsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xlink:label="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sclx_SpacTransactionsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueConcentrationOfRiskTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumberOfShares" xlink:label="sclx_NumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SpacTransactionMember" xlink:label="sclx_SpacTransactionMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_VickersDebtAgreementMember" xlink:label="sclx_VickersDebtAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FourCustomerMember" xlink:label="sclx_FourCustomerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtExchangeAgreementMember" xlink:label="sclx_DebtExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementWarrantMember" xlink:label="sclx_PrivatePlacementWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregateGrossProceeds" xlink:label="sclx_AggregateGrossProceeds"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LegacyScilexCommonStockMember" xlink:label="sclx_LegacyScilexCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LegacyScilexStockOptionsMember" xlink:label="sclx_LegacyScilexStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CapitalizedCost" xlink:label="sclx_CapitalizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PercentageOfNetRevenueSoleDistributor" xlink:label="sclx_PercentageOfNetRevenueSoleDistributor"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PercentageOfNetRevenueSoleDistributors" xlink:label="sclx_PercentageOfNetRevenueSoleDistributors"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsOfInitialPublicOffering" xlink:label="sclx_ProceedsOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SaleOfWarrants" xlink:label="sclx_SaleOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_GrossProceedsOfWarrants" xlink:label="sclx_GrossProceedsOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TransactionCostsAmount" xlink:label="sclx_TransactionCostsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="us-gaap_OtherUnderwritingExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredUnderwritingFees" xlink:label="sclx_DeferredUnderwritingFees"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OtherOfferingCosts" xlink:label="sclx_OtherOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SaleOfStockDescriptionOfTransactions" xlink:label="sclx_SaleOfStockDescriptionOfTransactions"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumberOfBusinessDays" xlink:label="sclx_NumberOfBusinessDays"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PricePerPublicShare" xlink:label="sclx_PricePerPublicShare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NetTangibleAssets" xlink:label="sclx_NetTangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PercentageOfPublicShares" xlink:label="sclx_PercentageOfPublicShares"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_BusinessCombinationRedeemPercentage" xlink:label="sclx_BusinessCombinationRedeemPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DepositIntoTrustAccount" xlink:label="sclx_DepositIntoTrustAccount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InterestExpenses" xlink:label="sclx_InterestExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:label="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ConversionOfCommonStock" xlink:label="sclx_ConversionOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockExchangeRatioDescription" xlink:label="sclx_CommonStockExchangeRatioDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiabilityClassifiedPrivateWarrants" xlink:label="sclx_LiabilityClassifiedPrivateWarrants"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_NumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="sclx_SpacTransactionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_VickersDebtAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sclx_FourCustomerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_DebtExchangeAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sclx_PrivatePlacementWarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_AggregateGrossProceeds" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sclx_LegacyScilexCommonStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_TransactionTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sclx_LegacyScilexStockOptionsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_CapitalizedCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_PercentageOfNetRevenueSoleDistributor" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="srt_RangeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_PercentageOfNetRevenueSoleDistributors" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_ProceedsOfInitialPublicOffering" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_SaleOfWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_GrossProceedsOfWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_TransactionCostsAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_DeferredUnderwritingFees" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_OtherOfferingCosts" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_SaleOfStockDescriptionOfTransactions" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_NumberOfBusinessDays" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_PricePerPublicShare" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_NetTangibleAssets" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_PercentageOfPublicShares" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_BusinessCombinationRedeemPercentage" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_DepositIntoTrustAccount" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_InterestExpenses" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_Cash" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_ConversionOfCommonStock" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_CommonStockExchangeRatioDescription" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_LiabilityClassifiedPrivateWarrants" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="sclx_LiquidityAndGoingConcernLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WorkingCapital" xlink:label="sclx_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="sclx_LiquidityAndGoingConcernTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoMember" xlink:label="sclx_SorrentoMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FundingCommitmentLetterMember" xlink:label="sclx_FundingCommitmentLetterMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScilexPharmaNotesMember" xlink:label="sclx_ScilexPharmaNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" xlink:label="us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="sclx_WorkingCapital" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_SorrentoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_FundingCommitmentLetterMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sclx_LiquidityAndGoingConcernTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sclx_ScilexPharmaNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernTable" xlink:to="sclx_LiquidityAndGoingConcernLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_LoansPayable" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="sclx_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="us-gaap_OtherDeferredCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="us-gaap_ExcessStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FounderShares" xlink:label="sclx_FounderShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherDeferredCostsNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sclx_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="sclx_FounderShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofcondensedbalancesheetsTable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScheduleOfCondensedBalanceSheetsAbstract" xlink:label="sclx_ScheduleOfCondensedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_GrossProceeds" xlink:label="sclx_GrossProceeds"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PlusAbstract" xlink:label="sclx_PlusAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LessAbstract" xlink:label="sclx_LessAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OrdinarySharesIssuanceCost" xlink:label="sclx_OrdinarySharesIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesSubjectToPossibleRedemption" xlink:label="sclx_SharesSubjectToPossibleRedemption"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfCondensedBalanceSheetsAbstract" xlink:to="sclx_GrossProceeds" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PlusAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_LessAbstract" xlink:to="sclx_OrdinarySharesIssuanceCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="sclx_SharesSubjectToPossibleRedemption" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfCondensedBalanceSheetsAbstract" xlink:to="sclx_LessAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfCondensedBalanceSheetsAbstract" xlink:to="sclx_PlusAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DenominatorAbstract" xlink:label="sclx_DenominatorAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract" xlink:label="sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumeratorAbstract" xlink:label="sclx_NumeratorAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DenominatorAbstract0" xlink:label="sclx_DenominatorAbstract0"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome" xlink:label="us-gaap_TemporaryEquityNetIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract" xlink:to="sclx_NumeratorAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DenominatorAbstract0" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_NumeratorAbstract" xlink:to="us-gaap_TemporaryEquityNetIncome" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DenominatorAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract" xlink:to="sclx_DenominatorAbstract0" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_DenominatorAbstract0" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract" xlink:to="sclx_DenominatorAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="sclx_TwoThousandTwentyTwoPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LicenseAgreementMember" xlink:label="sclx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MergerAgreementMember" xlink:label="sclx_MergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IssuedAndOutstandingCapitalStockMember" xlink:label="sclx_IssuedAndOutstandingCapitalStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurMember" xlink:label="sclx_SemnurMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UpfrontConsiderationForCommonStock" xlink:label="sclx_UpfrontConsiderationForCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoMember" xlink:label="sclx_SorrentoMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RomegLicenseAgreementMember" xlink:label="sclx_RomegLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductOneMember" xlink:label="sclx_SemnurProductOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ExchangeAgreementMember" xlink:label="sclx_ExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CashPayment" xlink:label="sclx_CashPayment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurCashExchangePaymentMember" xlink:label="sclx_SemnurCashExchangePaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductTwoMember" xlink:label="sclx_SemnurProductTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurPharmaceuticalsIncMember" xlink:label="sclx_SemnurPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductThreeMember" xlink:label="sclx_SemnurProductThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductFourMember" xlink:label="sclx_SemnurProductFourMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockToBeIssued" xlink:label="sclx_CommonStockToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregateContingentCashConsideration" xlink:label="sclx_AggregateContingentCashConsideration"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AmountDueForNewDrugApplication" xlink:label="sclx_AmountDueForNewDrugApplication"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PaymentUponTheAchievementOfNetSales" xlink:label="sclx_PaymentUponTheAchievementOfNetSales"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CumulativeNetSales" xlink:label="sclx_CumulativeNetSales"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregateGrossProceeds" xlink:label="sclx_AggregateGrossProceeds"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesToBeIssued" xlink:label="sclx_SharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ReclassificationAmountFromAdditionalPaidInCapital" xlink:label="sclx_ReclassificationAmountFromAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare" xlink:label="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice" xlink:label="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Percentageofoutstandingcommonstockheld" xlink:label="sclx_Percentageofoutstandingcommonstockheld"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Upfrontlicensefee" xlink:label="sclx_Upfrontlicensefee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Deferredconsiderationliabilities" xlink:label="sclx_Deferredconsiderationliabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="sclx_TwoThousandTwentyTwoPromissoryNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sclx_LicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sclx_MergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="sclx_IssuedAndOutstandingCapitalStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="sclx_SemnurMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_UpfrontConsiderationForCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sclx_SorrentoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="sclx_RomegLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sclx_SemnurProductOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sclx_ExchangeAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_CashPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="sclx_SemnurCashExchangePaymentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sclx_SemnurProductTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sclx_SemnurPharmaceuticalsIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sclx_SemnurProductThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sclx_SemnurProductFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_CommonStockToBeIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_OwnershipAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_AggregateContingentCashConsideration" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_AmountDueForNewDrugApplication" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_PaymentUponTheAchievementOfNetSales" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_CumulativeNetSales" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_AggregateGrossProceeds" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_SharesToBeIssued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_ReclassificationAmountFromAdditionalPaidInCapital" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Percentageofoutstandingcommonstockheld" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Upfrontlicensefee" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Deferredconsiderationliabilities" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicOfferingDetailsTable" xlink:label="sclx_PublicOfferingDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="sclx_PublicOfferingDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumberOfSaleUnits" xlink:label="sclx_NumberOfSaleUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProposedPublicOfferingAbstract" xlink:label="sclx_ProposedPublicOfferingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchasePricePerShare" xlink:label="sclx_PurchasePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PublicOfferingDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PublicOfferingDetailsLineItems" xlink:to="sclx_NumberOfSaleUnits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ProposedPublicOfferingAbstract" xlink:to="sclx_PublicOfferingDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PublicOfferingDetailsTable" xlink:to="sclx_PublicOfferingDetailsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PublicOfferingDetailsLineItems" xlink:to="sclx_PurchasePricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PublicOfferingDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="sclx_PrivatePlacementDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDisclosureTextblockAbstract" xlink:label="sclx_PrivatePlacementDisclosureTextblockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="sclx_PrivatePlacementDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PrivatePlacementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PrivatePlacementDisclosureTextblockAbstract" xlink:to="sclx_PrivatePlacementDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PrivatePlacementDetailsTable" xlink:to="sclx_PrivatePlacementDetailsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="sclx_RelatedPartyTransactionsDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="sclx_RelatedPartyTransactionsDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FounderSharesMember" xlink:label="sclx_FounderSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_aggregatePurchasePrice" xlink:label="sclx_aggregatePurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PromissoryNoteRelatedPartyMember" xlink:label="sclx_PromissoryNoteRelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CapitalizationOfShareOutstanding" xlink:label="sclx_CapitalizationOfShareOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OrdinarySharesIssuedAndOutstanding" xlink:label="sclx_OrdinarySharesIssuedAndOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FundExpenses" xlink:label="sclx_FundExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="us-gaap_DueToAffiliateCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepaidAmount" xlink:label="sclx_RepaidAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="us-gaap_BusinessCombinationControlObtainedDescription"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregatePrincipalAmount" xlink:label="sclx_AggregatePrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:label="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PricePerWarrants" xlink:label="sclx_PricePerWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="sclx_RelatedPartyTransactionsDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="sclx_FounderSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_aggregatePurchasePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="sclx_PromissoryNoteRelatedPartyMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_CapitalizationOfShareOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsTable" xlink:to="sclx_RelatedPartyTransactionsDetailsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_OrdinarySharesIssuedAndOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_FundExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueToAffiliateCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_RepaidAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_BusinessCombinationControlObtainedDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_AggregatePrincipalAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_PricePerWarrants" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AssetsHeldInTrust" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingenciesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="us-gaap_OtherCommitmentsDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsDetailsTable" xlink:label="sclx_WarrantsDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsDetailsLineItems" xlink:label="sclx_WarrantsDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsOutstandingShares" xlink:label="sclx_WarrantsOutstandingShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicWarrantsRedemptionDescription" xlink:label="sclx_PublicWarrantsRedemptionDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CapitalRaisingDescription" xlink:label="sclx_CapitalRaisingDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="sclx_WarrantsDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_WarrantsDetailsLineItems" xlink:to="sclx_WarrantsOutstandingShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_WarrantsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_WarrantsDetailsLineItems" xlink:to="sclx_PublicWarrantsRedemptionDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_WarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_WarrantsDetailsLineItems" xlink:to="sclx_CapitalRaisingDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_WarrantsDetailsTable" xlink:to="sclx_WarrantsDetailsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueMeasurementsValuationProcessesDescription1" xlink:label="sclx_FairValueMeasurementsValuationProcessesDescription1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RiskAdjustedNetSalesForecast" xlink:label="sclx_RiskAdjustedNetSalesForecast"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:label="us-gaap_ProductLiabilityContingencyAccrualDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MilestonePayment" xlink:label="sclx_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueOfContingentConsideration" xlink:label="sclx_FairValueOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DerivativeWarrantLiabilityPrivateWarrants" xlink:label="sclx_DerivativeWarrantLiabilityPrivateWarrants"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AssetsHeldInTrust" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="sclx_FairValueMeasurementsValuationProcessesDescription1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="sclx_RiskAdjustedNetSalesForecast" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProductLiabilityContingencyAccrualDiscountRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="sclx_MilestonePayment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="sclx_FairValueOfContingentConsideration" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="sclx_DerivativeWarrantLiabilityPrivateWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_6"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InterestIncomeSecuritiesUSTreasury" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueMeasurementStrikePrice" xlink:label="sclx_FairValueMeasurementStrikePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:label="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueOfWarrantsinDollars" xlink:label="sclx_FairValueOfWarrantsinDollars"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_FairValueMeasurementStrikePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_FairValueOfWarrantsinDollars" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementWarrantLiabilityAcquired" xlink:label="sclx_PrivatePlacementWarrantLiabilityAcquired"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LoanDerivativeLiability" xlink:label="sclx_LoanDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ReMeasurementOfFairValue" xlink:label="sclx_ReMeasurementOfFairValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ForfeitureOfPrivateWarrants" xlink:label="sclx_ForfeitureOfPrivateWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="sclx_ChangeInValuationInputsOrOtherAssumptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_6"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_PrivatePlacementWarrantLiabilityAcquired" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_LoanDerivativeLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_ReMeasurementOfFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_ForfeitureOfPrivateWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_ChangeInValuationInputsOrOtherAssumptions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DerivativeLiabilities_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:label="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UnderlyingWarrantValue" xlink:label="sclx_UnderlyingWarrantValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EquityValue" xlink:label="sclx_EquityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_HoldingPeriod" xlink:label="sclx_HoldingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CallOptionValue" xlink:label="sclx_CallOptionValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="sclx_UnderlyingWarrantValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="sclx_EquityValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="sclx_HoldingPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="sclx_CallOptionValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Derivativeliabilityatfairvalueadditions" xlink:label="sclx_Derivativeliabilityatfairvalueadditions"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ReMeasurementOfFairValue" xlink:label="sclx_ReMeasurementOfFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability_6"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueNetAssetLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_Derivativeliabilityatfairvalueadditions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="sclx_ReMeasurementOfFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueNetAssetLiability_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PatentRightsMember" xlink:label="sclx_PatentRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AssembledWorkforceMember" xlink:label="sclx_AssembledWorkforceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquiredLicensesMember" xlink:label="sclx_AcquiredLicensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_PatentRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_AssembledWorkforceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_AcquiredLicensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PatentRightsMember" xlink:label="sclx_PatentRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquiredTechnologyMember" xlink:label="sclx_AcquiredTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquiredLicensesMember" xlink:label="sclx_AcquiredLicensesMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AssembledWorkforceMember" xlink:label="sclx_AssembledWorkforceMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_PatentRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_AcquiredTechnologyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_AcquiredLicensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_AssembledWorkforceMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" xlink:label="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyNotesPayableMember" xlink:label="sclx_RelatedPartyNotesPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember" xlink:label="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_WSAG" xlink:label="exch_WSAG"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtInstrumentPurcahsePrice" xlink:label="sclx_DebtInstrumentPurcahsePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfLoansNet" xlink:label="us-gaap_GainLossOnSalesOfLoansNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AmendmentNumberFourMember" xlink:label="sclx_AmendmentNumberFourMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ActualCumulativeNetSales" xlink:label="sclx_ActualCumulativeNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrincipalAndNonOperatingExpense" xlink:label="sclx_PrincipalAndNonOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseOfPrincipalBalance" xlink:label="sclx_IncreaseOfPrincipalBalance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebt" xlink:label="us-gaap_SubordinatedDebt"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CashRequirement" xlink:label="sclx_CashRequirement"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ForgivenAmount" xlink:label="sclx_ForgivenAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NotePrincipalReductionAmount" xlink:label="sclx_NotePrincipalReductionAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepurchasePrincipalInPercentage" xlink:label="sclx_RepurchasePrincipalInPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepurchaseWithCashOnHand" xlink:label="sclx_RepurchaseWithCashOnHand"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CashReceivedFromParentCompany" xlink:label="sclx_CashReceivedFromParentCompany"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregatePrincipalAmount" xlink:label="sclx_AggregatePrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UnrestrictedCash" xlink:label="sclx_UnrestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MinimumCashRequirement" xlink:label="sclx_MinimumCashRequirement"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PromissoryNote" xlink:label="sclx_PromissoryNote"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OutstandingPrincipalAmountPeriod" xlink:label="sclx_OutstandingPrincipalAmountPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueDecrease" xlink:label="sclx_FairValueDecrease"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CarryingValueIncreased" xlink:label="sclx_CarryingValueIncreased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:label="us-gaap_FinancingReceivableRevolvingConvertedToTermLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_RelatedPartyNotesPayableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EquityUnitPurchaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="exch_WSAG" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_DebtInstrumentPurcahsePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_PledgingPurposeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainLossOnSalesOfLoansNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sclx_AmendmentNumberFourMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_ActualCumulativeNetSales" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_PrincipalAndNonOperatingExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_IncreaseOfPrincipalBalance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SubordinatedDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_CashRequirement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_ForgivenAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowings" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_NotePrincipalReductionAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_RepurchasePrincipalInPercentage" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_RepurchaseWithCashOnHand" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_CashReceivedFromParentCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_AggregatePrincipalAmount" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_UnrestrictedCash" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_MinimumCashRequirement" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_PromissoryNote" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_OutstandingPrincipalAmountPeriod" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_FairValueDecrease" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_CarryingValueIncreased" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:label="us-gaap_CommercialPaperAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="us-gaap_ShorttermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_CommercialPaperAtCarryingValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_OtherLongTermDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShorttermDebtFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ShareholdersEquityDetailsLineItems" xlink:label="sclx_ShareholdersEquityDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ShareholdersEquityDetailsTable" xlink:label="sclx_ShareholdersEquityDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantTransferAgreementMember" xlink:label="sclx_WarrantTransferAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsMember" xlink:label="sclx_WarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoTherapeuticsIncMember" xlink:label="sclx_SorrentoTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SponsorMember" xlink:label="sclx_SponsorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FirstAmendedCertificateOfIncorporationMember" xlink:label="sclx_FirstAmendedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SecondAmendedCertificateOfIncorporationMember" xlink:label="sclx_SecondAmendedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EquityPurchaseAgreementMember" xlink:label="sclx_EquityPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="sclx_OrdinarySharesSubjectToPossibleRedemption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseOfStockPercentage" xlink:label="sclx_PurchaseOfStockPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_StructuringFees" xlink:label="sclx_StructuringFees"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="sclx_ShareholdersEquityDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_WarrantTransferAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sclx_WarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="sclx_SorrentoTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sclx_SponsorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_FirstAmendedCertificateOfIncorporationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_SecondAmendedCertificateOfIncorporationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_EquityPurchaseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="dei_LegalEntityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="sclx_OrdinarySharesSubjectToPossibleRedemption" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="sclx_ShareholdersEquityDetailsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="sclx_PurchaseOfStockPercentage" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="sclx_StructuringFees" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatementsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract" xlink:label="sclx_ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdjustmentsRestatement2Member" xlink:label="sclx_AdjustmentsRestatement2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AsRestatedMember" xlink:label="sclx_AsRestatedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_RestatementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_Liabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="sclx_AdjustmentsRestatement2Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="sclx_AsRestatedMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_BlackScholesOptionPricingMethodMember" xlink:label="sclx_BlackScholesOptionPricingMethodMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="sclx_BlackScholesOptionPricingMethodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="sclx_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScilexPharmaMember" xlink:label="sclx_ScilexPharmaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember" xlink:label="sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandNineteenStockOptionPlanMember" xlink:label="sclx_TwoThousandNineteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear" xlink:label="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WeightedAveragePeriodOverGrant" xlink:label="sclx_WeightedAveragePeriodOverGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_TwoThousandSeventeenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_ScilexPharmaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_TwoThousandNineteenStockOptionPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sclx_WeightedAveragePeriodOverGrant" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LeaseLiabilityNetOfCurrentPortion" xlink:label="sclx_LeaseLiabilityNetOfCurrentPortion"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sclx_LeaseLiabilityNetOfCurrentPortion" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommitmentsAndContingenciesLineItems" xlink:label="sclx_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:label="sclx_RoyaltyPaymentPercentageRelatedToFutureYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FrequencyOfPaymentsDomain" xlink:label="sclx_FrequencyOfPaymentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MonthlyMember" xlink:label="sclx_MonthlyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DevelopersMember" xlink:label="sclx_DevelopersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="sclx_ProductDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommitmentsAndContingenciesTable" xlink:label="sclx_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FrequencyOfPaymentsAxis" xlink:label="sclx_FrequencyOfPaymentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ResearchAndDevelopmentFacilitiesMember" xlink:label="sclx_ResearchAndDevelopmentFacilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_VendorMember" xlink:label="sclx_VendorMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ExclusiveDistributionAgreementMember" xlink:label="sclx_ExclusiveDistributionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdministrativeFacilityMember" xlink:label="sclx_AdministrativeFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AccruedRoyaltyPayables" xlink:label="sclx_AccruedRoyaltyPayables"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProjectAgreementMember" xlink:label="sclx_ProjectAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NonCancelableLeaseAgreementsMember" xlink:label="sclx_NonCancelableLeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AgreementMaturityDate" xlink:label="sclx_AgreementMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MaturityRenewalDescription" xlink:label="sclx_MaturityRenewalDescription"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProfitPercentageNet" xlink:label="sclx_ProfitPercentageNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DistributionFeesPercentage" xlink:label="sclx_DistributionFeesPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears" xlink:label="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AgreementInitialTerm" xlink:label="sclx_AgreementInitialTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_RoyaltyPaymentPercentageRelatedToFutureYears" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_FrequencyOfPaymentsDomain" xlink:to="sclx_MonthlyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_DevelopersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_ProductDevelopmentAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sclx_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_FrequencyOfPaymentsAxis" xlink:to="sclx_FrequencyOfPaymentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sclx_ResearchAndDevelopmentFacilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_VendorMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_ExclusiveDistributionAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sclx_AdministrativeFacilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_AccruedRoyaltyPayables" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_ProjectAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_NonCancelableLeaseAgreementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="sclx_FrequencyOfPaymentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_AgreementMaturityDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_MaturityRenewalDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_ProfitPercentageNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="sclx_CommitmentsAndContingenciesLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_DistributionFeesPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_AgreementInitialTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ProfessionalFees" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles" xlink:label="sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:label="sclx_DeferredTaxAssetsDebtRelatedInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:label="sclx_DeferredTaxAssetsInterestExpenseLimitations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:label="sclx_DeferredTaxAssetsAccruedExpenseAndReserves"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="sclx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="sclx_DeferredTaxAssetsDebtRelatedInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="sclx_DeferredTaxAssetsInterestExpenseLimitations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="sclx_DeferredTaxAssetsAccruedExpenseAndReserves" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="sclx_DeferredTaxAssetsOperatingLeaseLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xlink:label="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:label="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="sclx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncomeTaxDisclosureTable" xlink:label="sclx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IndefiniteCarryforwardPeriodMember" xlink:label="sclx_IndefiniteCarryforwardPeriodMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember" xlink:label="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="sclx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TaxCreditCarryForwardsExpirationYear" xlink:label="sclx_TaxCreditCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sclx_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sclx_IndefiniteCarryforwardPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureTable" xlink:to="sclx_IncomeTaxDisclosureLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="sclx_OperatingLossCarryforwardsExpirationYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="sclx_TaxCreditCarryForwardsExpirationYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AardvarkAssetPurchaseAgreementMember" xlink:label="sclx_AardvarkAssetPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IssuedAndOutstandingCapitalStockMember" xlink:label="sclx_IssuedAndOutstandingCapitalStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScilexPharmaMember" xlink:label="sclx_ScilexPharmaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoMember" xlink:label="sclx_SorrentoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtExchangeAgreementMember" xlink:label="sclx_DebtExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ItochuMember" xlink:label="sclx_ItochuMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensationCash" xlink:label="us-gaap_DividendsShareBasedCompensationCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesAcquired" xlink:label="sclx_SharesAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryPurchasedGoods" xlink:label="us-gaap_OtherInventoryPurchasedGoods"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OutstandingCapitalStockPercent" xlink:label="sclx_OutstandingCapitalStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansPayable" xlink:label="us-gaap_NotesAndLoansPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyPayable" xlink:label="sclx_RelatedPartyPayable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WorkingCapital" xlink:label="sclx_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepurchasesOfNotes" xlink:label="sclx_RepurchasesOfNotes"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LitigationFees" xlink:label="sclx_LitigationFees"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyReceivable" xlink:label="sclx_RelatedPartyReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtExchangeDescriptions" xlink:label="sclx_DebtExchangeDescriptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAverageAmountOutstanding" xlink:label="us-gaap_LongTermDebtAverageAmountOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_FinancingReceivableNonaccrualToOutstandingPercent" xlink:label="srt_FinancingReceivableNonaccrualToOutstandingPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_AardvarkAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="sclx_IssuedAndOutstandingCapitalStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_ScilexPharmaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sclx_SorrentoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_DebtExchangeAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sclx_ItochuMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DividendsShareBasedCompensationCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_SharesAcquired" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherInventoryPurchasedGoods" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_OutstandingCapitalStockPercent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NotesAndLoansPayable" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NotesIssued1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesNoncurrent" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_RelatedPartyPayable" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_WorkingCapital" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_RepurchasesOfNotes" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_LitigationFees" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_RelatedPartyReceivable" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_DebtExchangeDescriptions" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermDebtAverageAmountOutstanding" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="srt_FinancingReceivableNonaccrualToOutstandingPercent" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectOfDilutiveSecurities" xlink:label="sclx_EffectOfDilutiveSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="sclx_EffectOfDilutiveSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_DilutiveSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicWarrantsMember" xlink:label="sclx_PublicWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_StockOptionsMember" xlink:label="sclx_StockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivateWarrantsMember" xlink:label="sclx_PrivateWarrantsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sclx_PublicWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sclx_StockOptionsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sclx_PrivateWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:label="us-gaap_NetIncomeLossAttributableToParentDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToParentDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseAgreementDomain" xlink:label="sclx_PurchaseAgreementDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseAgreementMember" xlink:label="sclx_PurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScintillaPharmaceuticalsMember" xlink:label="sclx_ScintillaPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InducementPlanDomain" xlink:label="sclx_InducementPlanDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InducementPlanMember" xlink:label="sclx_InducementPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InducementPlanAxis" xlink:label="sclx_InducementPlanAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseAgreementAxis" xlink:label="sclx_PurchaseAgreementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_BRileyPurchaseAgreementMember" xlink:label="sclx_BRileyPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="sclx_ARYorkvillePurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockSold" xlink:label="sclx_CommonStockSold"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="sclx_ProceedsFromSaleOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SponsorLoan" xlink:label="sclx_SponsorLoan"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ReceivableBasisOfGoingForward" xlink:label="sclx_ReceivableBasisOfGoingForward"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantExercisePrice" xlink:label="sclx_WarrantExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdditionalPrincipalAmount" xlink:label="sclx_AdditionalPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ConvertiblePromissoryNote" xlink:label="sclx_ConvertiblePromissoryNote"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PurchaseAgreementDomain" xlink:to="sclx_PurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sclx_ScintillaPharmaceuticalsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_InducementPlanDomain" xlink:to="sclx_InducementPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_InducementPlanAxis" xlink:to="sclx_InducementPlanDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PurchaseAgreementAxis" xlink:to="sclx_PurchaseAgreementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PurchaseAgreementDomain" xlink:to="sclx_BRileyPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="sclx_PurchaseAgreementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sclx_PurchaseAgreementDomain" xlink:to="sclx_ARYorkvillePurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="sclx_InducementPlanAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_CommonStockSold" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_ProceedsFromSaleOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_SponsorLoan" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_ReceivableBasisOfGoingForward" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_WarrantExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_AdditionalPrincipalAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_ConvertiblePromissoryNote" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>sclx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-07T13:28:24.4275+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IssuedAndOutstandingCapitalStockMember" xlink:label="sclx_IssuedAndOutstandingCapitalStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:label="sclx_OfferingCostIncludedInAccruedOfferingCost"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_aggregatePurchasePrice" xlink:label="sclx_aggregatePurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Deferredconsiderationliabilities" xlink:label="sclx_Deferredconsiderationliabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_StockOptionsMember" xlink:label="sclx_StockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ShareholdersEquityDetailsLineItems" xlink:label="sclx_ShareholdersEquityDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FundExpenses" xlink:label="sclx_FundExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommitmentsAndContingenciesLineItems" xlink:label="sclx_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockSold" xlink:label="sclx_CommonStockSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AccruedRoyaltyPayables" xlink:label="sclx_AccruedRoyaltyPayables"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" xlink:label="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicOfferingDetailsTable" xlink:label="sclx_PublicOfferingDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PricePerPublicShare" xlink:label="sclx_PricePerPublicShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RecapitalizationDueToTheBusinessCombinationValue" xlink:label="sclx_RecapitalizationDueToTheBusinessCombinationValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScheduleOfCondensedBalanceSheetsAbstract" xlink:label="sclx_ScheduleOfCondensedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:label="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CurrentPortionOfDeferredConsideration" xlink:label="sclx_CurrentPortionOfDeferredConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueOfWarrantsinDollars" xlink:label="sclx_FairValueOfWarrantsinDollars"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare" xlink:label="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" xlink:label="sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="us-gaap_OtherDeferredCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PlusAbstract" xlink:label="sclx_PlusAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdditionalPrincipalAmount" xlink:label="sclx_AdditionalPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:label="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoMember" xlink:label="sclx_SorrentoMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OtherOfferingCosts" xlink:label="sclx_OtherOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseAgreementDomain" xlink:label="sclx_PurchaseAgreementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementWarrantMember" xlink:label="sclx_PrivatePlacementWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CumulativeNetSales" xlink:label="sclx_CumulativeNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDisclosureTextblock" xlink:label="sclx_PrivatePlacementDisclosureTextblock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurMember" xlink:label="sclx_SemnurMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurPharmaceuticalsIncMember" xlink:label="sclx_SemnurPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice" xlink:label="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensationCash" xlink:label="us-gaap_DividendsShareBasedCompensationCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="us-gaap_BusinessCombinationControlObtainedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="sclx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueMeasurementStrikePrice" xlink:label="sclx_FairValueMeasurementStrikePrice"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScilexPharmaNotesMember" xlink:label="sclx_ScilexPharmaNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregatePrincipalAmount" xlink:label="sclx_AggregatePrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregateGrossProceeds" xlink:label="sclx_AggregateGrossProceeds"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepurchasePrincipalInPercentage" xlink:label="sclx_RepurchasePrincipalInPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_GrossProceeds" xlink:label="sclx_GrossProceeds"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="sclx_PrivatePlacementDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InducementPlanDomain" xlink:label="sclx_InducementPlanDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xlink:label="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TaxCreditCarryForwardsExpirationYear" xlink:label="sclx_TaxCreditCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UnrestrictedCash" xlink:label="sclx_UnrestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NetTangibleAssets" xlink:label="sclx_NetTangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xlink:label="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="us-gaap_OtherCommitmentsDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregateContingentCashConsideration" xlink:label="sclx_AggregateContingentCashConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:label="sclx_DeferredTaxAssetsDebtRelatedInterest"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InducementPlanAxis" xlink:label="sclx_InducementPlanAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredUnderwritingFeePayable" xlink:label="sclx_DeferredUnderwritingFeePayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScilexPharmaMember" xlink:label="sclx_ScilexPharmaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DenominatorAbstract" xlink:label="sclx_DenominatorAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="sclx_PublicOfferingDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PercentageOfNetRevenueSoleDistributor" xlink:label="sclx_PercentageOfNetRevenueSoleDistributor"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AsRestatedMember" xlink:label="sclx_AsRestatedMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LessAbstract" xlink:label="sclx_LessAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LoanDerivativeLiability" xlink:label="sclx_LoanDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquiredTechnologyMember" xlink:label="sclx_AcquiredTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears" xlink:label="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepaidAmount" xlink:label="sclx_RepaidAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="us-gaap_IntangibleAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="sclx_RelatedPartyTransactionsDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ExchangeAgreementMember" xlink:label="sclx_ExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoTherapeuticsIncMember" xlink:label="sclx_SorrentoTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectOfDilutiveSecurities" xlink:label="sclx_EffectOfDilutiveSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MergerAgreementMember" xlink:label="sclx_MergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FrequencyOfPaymentsDomain" xlink:label="sclx_FrequencyOfPaymentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProjectAgreementMember" xlink:label="sclx_ProjectAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OutstandingCapitalStockPercent" xlink:label="sclx_OutstandingCapitalStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CallOptionValue" xlink:label="sclx_CallOptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AmountDueForNewDrugApplication" xlink:label="sclx_AmountDueForNewDrugApplication"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" xlink:label="sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicWarrantsRedemptionDescription" xlink:label="sclx_PublicWarrantsRedemptionDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiabilityClassifiedPrivateWarrants" xlink:label="sclx_LiabilityClassifiedPrivateWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" xlink:label="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PaymentUponTheAchievementOfNetSales" xlink:label="sclx_PaymentUponTheAchievementOfNetSales"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchasePricePerShare" xlink:label="sclx_PurchasePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_FinancingReceivableNonaccrualToOutstandingPercent" xlink:label="srt_FinancingReceivableNonaccrualToOutstandingPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="sclx_LiquidityAndGoingConcernLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdjustmentsRestatement2Member" xlink:label="sclx_AdjustmentsRestatement2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:label="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FounderShares" xlink:label="sclx_FounderShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_VendorMember" xlink:label="sclx_VendorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract" xlink:label="sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CapitalRaisingDescription" xlink:label="sclx_CapitalRaisingDescription"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ForfeituresOfPrivateWarrants" xlink:label="sclx_ForfeituresOfPrivateWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredUnderwritingFees" xlink:label="sclx_DeferredUnderwritingFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantTransferAgreementMember" xlink:label="sclx_WarrantTransferAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MonthlyMember" xlink:label="sclx_MonthlyMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_StructuringFees" xlink:label="sclx_StructuringFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NonCashDistributionToSorrento" xlink:label="sclx_NonCashDistributionToSorrento"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MinimumCashRequirement" xlink:label="sclx_MinimumCashRequirement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="sclx_LiquidityAndGoingConcernTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_HoldingPeriod" xlink:label="sclx_HoldingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NonCashOperatingLeaseCost" xlink:label="sclx_NonCashOperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesToBeIssued" xlink:label="sclx_SharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CashReceivedFromParentCompany" xlink:label="sclx_CashReceivedFromParentCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:label="us-gaap_NetIncomeLossAttributableToParentDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear" xlink:label="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MilestonePayment" xlink:label="sclx_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_WSAG" xlink:label="exch_WSAG"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AmendmentNumberFourMember" xlink:label="sclx_AmendmentNumberFourMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AgreementMaturityDate" xlink:label="sclx_AgreementMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RomegLicenseAgreementMember" xlink:label="sclx_RomegLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseOfPrincipalBalance" xlink:label="sclx_IncreaseOfPrincipalBalance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Upfrontlicensefee" xlink:label="sclx_Upfrontlicensefee"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:label="sclx_DeferredTaxAssetsAccruedExpenseAndReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RiskAdjustedNetSalesForecast" xlink:label="sclx_RiskAdjustedNetSalesForecast"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FourCustomerMember" xlink:label="sclx_FourCustomerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Percentageofoutstandingcommonstockheld" xlink:label="sclx_Percentageofoutstandingcommonstockheld"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesAcquired" xlink:label="sclx_SharesAcquired"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Derivativeliabilityatfairvalueadditions" xlink:label="sclx_Derivativeliabilityatfairvalueadditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtInstrumentPurcahsePrice" xlink:label="sclx_DebtInstrumentPurcahsePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAverageAmountOutstanding" xlink:label="us-gaap_LongTermDebtAverageAmountOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtExchangeAgreementMember" xlink:label="sclx_DebtExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="sclx_ARYorkvillePurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_BRileyPurchaseAgreementMember" xlink:label="sclx_BRileyPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PricePerWarrants" xlink:label="sclx_PricePerWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LegacyScilexStockOptionsMember" xlink:label="sclx_LegacyScilexStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LongTermPortionOfDeferredConsideration" xlink:label="sclx_LongTermPortionOfDeferredConsideration"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PromissoryNoteRelatedPartyMember" xlink:label="sclx_PromissoryNoteRelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsOutstandingShares" xlink:label="sclx_WarrantsOutstandingShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScintillaPharmaceuticalsMember" xlink:label="sclx_ScintillaPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CarryingValueIncreased" xlink:label="sclx_CarryingValueIncreased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseDecreaseInLongTermDeposits" xlink:label="sclx_IncreaseDecreaseInLongTermDeposits"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OrdinarySharesIssuedAndOutstanding" xlink:label="sclx_OrdinarySharesIssuedAndOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantExercisePrice" xlink:label="sclx_WarrantExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TransactionCostsObligationAssumedBySorrento" xlink:label="sclx_TransactionCostsObligationAssumedBySorrento"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OutstandingPrincipalAmountPeriod" xlink:label="sclx_OutstandingPrincipalAmountPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyNotesPayableMember" xlink:label="sclx_RelatedPartyNotesPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepurchaseWithCashOnHand" xlink:label="sclx_RepurchaseWithCashOnHand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProposedPublicOfferingAbstract" xlink:label="sclx_ProposedPublicOfferingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectOfBusinessCombinationInValue" xlink:label="sclx_EffectOfBusinessCombinationInValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AccruedExpenses" xlink:label="sclx_AccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LicenseAgreementMember" xlink:label="sclx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="sclx_TwoThousandTwentyTwoPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="sclx_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PatentRightsMember" xlink:label="sclx_PatentRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SaleOfStockDescriptionOfTransactions" xlink:label="sclx_SaleOfStockDescriptionOfTransactions"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsFromTheBusinessCombination" xlink:label="sclx_ProceedsFromTheBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="sclx_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProposedPublicOfferingTextBlock" xlink:label="sclx_ProposedPublicOfferingTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NonCashConsiderationInSemnurAcquisition" xlink:label="sclx_NonCashConsiderationInSemnurAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsDetailsLineItems" xlink:label="sclx_WarrantsDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="us-gaap_ExcessStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="sclx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivateWarrantsMember" xlink:label="sclx_PrivateWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ActualCumulativeNetSales" xlink:label="sclx_ActualCumulativeNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WorkingCapital" xlink:label="sclx_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:label="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles" xlink:label="sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DevelopersMember" xlink:label="sclx_DevelopersMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurCashExchangePaymentMember" xlink:label="sclx_SemnurCashExchangePaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xlink:label="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="us-gaap_ShorttermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination" xlink:label="sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract" xlink:label="sclx_ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDisclosureTextblockAbstract" xlink:label="sclx_PrivatePlacementDisclosureTextblockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyReceivable" xlink:label="sclx_RelatedPartyReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UpfrontConsiderationForCommonStock" xlink:label="sclx_UpfrontConsiderationForCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WeightedAveragePeriodOverGrant" xlink:label="sclx_WeightedAveragePeriodOverGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryPurchasedGoods" xlink:label="us-gaap_OtherInventoryPurchasedGoods"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumberOfBusinessDays" xlink:label="sclx_NumberOfBusinessDays"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ResearchAndDevelopmentFacilitiesMember" xlink:label="sclx_ResearchAndDevelopmentFacilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsFromRepaymentOfLoansToPurchase" xlink:label="sclx_ProceedsFromRepaymentOfLoansToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LegacyCommonStockMember" xlink:label="sclx_LegacyCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OrdinarySharesIssuanceCost" xlink:label="sclx_OrdinarySharesIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PercentageOfNetRevenueSoleDistributors" xlink:label="sclx_PercentageOfNetRevenueSoleDistributors"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock" xlink:label="sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ConversionOfCommonStock" xlink:label="sclx_ConversionOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncomeTaxDisclosureTable" xlink:label="sclx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FounderSharesMember" xlink:label="sclx_FounderSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LegacyScilexCommonStockMember" xlink:label="sclx_LegacyScilexCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsMember" xlink:label="sclx_WarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FirstAmendedCertificateOfIncorporationMember" xlink:label="sclx_FirstAmendedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandNineteenStockOptionPlanMember" xlink:label="sclx_TwoThousandNineteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProfitPercentageNet" xlink:label="sclx_ProfitPercentageNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:label="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OtherLongTermLiabilities" xlink:label="sclx_OtherLongTermLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesSubjectToPossibleRedemption" xlink:label="sclx_SharesSubjectToPossibleRedemption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InterestExpenses" xlink:label="sclx_InterestExpenses"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ItochuMember" xlink:label="sclx_ItochuMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InducementPlanMember" xlink:label="sclx_InducementPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="sclx_PrivatePlacementDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseAgreementAxis" xlink:label="sclx_PurchaseAgreementAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SpacTransactionMember" xlink:label="sclx_SpacTransactionMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DistributionFeesPercentage" xlink:label="sclx_DistributionFeesPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DistributionToSorrentos" xlink:label="sclx_DistributionToSorrentos"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdministrativeFacilityMember" xlink:label="sclx_AdministrativeFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductThreeMember" xlink:label="sclx_SemnurProductThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UnderlyingWarrantValue" xlink:label="sclx_UnderlyingWarrantValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LitigationFees" xlink:label="sclx_LitigationFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember" xlink:label="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyPayable" xlink:label="sclx_RelatedPartyPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="sclx_ProductDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IndefiniteCarryforwardPeriodMember" xlink:label="sclx_IndefiniteCarryforwardPeriodMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:label="us-gaap_FinancingReceivableRevolvingConvertedToTermLoan"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" xlink:label="sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiveActionRightOfUseAssetInPaloAlto" xlink:label="sclx_LiveActionRightOfUseAssetInPaloAlto"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumberOfSaleUnits" xlink:label="sclx_NumberOfSaleUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AssembledWorkforceMember" xlink:label="sclx_AssembledWorkforceMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicWarrantsMember" xlink:label="sclx_PublicWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AardvarkAssetPurchaseAgreementMember" xlink:label="sclx_AardvarkAssetPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquiredLicensesMember" xlink:label="sclx_AcquiredLicensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:label="sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:label="sclx_RoyaltyPaymentPercentageRelatedToFutureYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EquityPurchaseAgreementMember" xlink:label="sclx_EquityPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SponsorLoan" xlink:label="sclx_SponsorLoan"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ShareholdersEquityDetailsTable" xlink:label="sclx_ShareholdersEquityDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_VickersDebtAgreementMember" xlink:label="sclx_VickersDebtAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:label="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_BlackScholesOptionPricingMethodMember" xlink:label="sclx_BlackScholesOptionPricingMethodMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PercentageOfPublicShares" xlink:label="sclx_PercentageOfPublicShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SpacTransactionsPolicyTextBlock" xlink:label="sclx_SpacTransactionsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember" xlink:label="sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockToBeIssued" xlink:label="sclx_CommonStockToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ReMeasurementOfFairValue" xlink:label="sclx_ReMeasurementOfFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SaleOfWarrants" xlink:label="sclx_SaleOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseOfStockPercentage" xlink:label="sclx_PurchaseOfStockPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommitmentsAndContingenciesTable" xlink:label="sclx_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DerivativeWarrantLiabilityPrivateWarrants" xlink:label="sclx_DerivativeWarrantLiabilityPrivateWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="us-gaap_OtherUnderwritingExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquisitionOfRightOfUseAsset" xlink:label="sclx_AcquisitionOfRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrincipalAndNonOperatingExpense" xlink:label="sclx_PrincipalAndNonOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FrequencyOfPaymentsAxis" xlink:label="sclx_FrequencyOfPaymentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NotesPrincipalIncrease" xlink:label="sclx_NotesPrincipalIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductOneMember" xlink:label="sclx_SemnurProductOneMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" xlink:label="sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OtherLoanForgiveness" xlink:label="sclx_OtherLoanForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductFourMember" xlink:label="sclx_SemnurProductFourMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectOfBusinessCombinationInShares" xlink:label="sclx_EffectOfBusinessCombinationInShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:label="us-gaap_CommercialPaperAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_BusinessCombinationRedeemPercentage" xlink:label="sclx_BusinessCombinationRedeemPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ConvertiblePromissoryNote" xlink:label="sclx_ConvertiblePromissoryNote"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="sclx_ScilexPharmaNotesPrincipalIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TransactionCostsAmount" xlink:label="sclx_TransactionCostsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfLoansNet" xlink:label="us-gaap_GainLossOnSalesOfLoansNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockExchangeRatioDescription" xlink:label="sclx_CommonStockExchangeRatioDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xlink:label="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementWarrantLiabilityAcquired" xlink:label="sclx_PrivatePlacementWarrantLiabilityAcquired"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RecapitalizationDuetotheBusinessCombinationShares" xlink:label="sclx_RecapitalizationDuetotheBusinessCombinationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ReceivableBasisOfGoingForward" xlink:label="sclx_ReceivableBasisOfGoingForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EquityValue" xlink:label="sclx_EquityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AgreementInitialTerm" xlink:label="sclx_AgreementInitialTerm"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DenominatorAbstract0" xlink:label="sclx_DenominatorAbstract0"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseAgreementMember" xlink:label="sclx_PurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductTwoMember" xlink:label="sclx_SemnurProductTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ForfeitureOfPrivateWarrants" xlink:label="sclx_ForfeitureOfPrivateWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtExchangeDescriptions" xlink:label="sclx_DebtExchangeDescriptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueMeasurementsValuationProcessesDescription1" xlink:label="sclx_FairValueMeasurementsValuationProcessesDescription1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LeaseLiabilityNetOfCurrentPortion" xlink:label="sclx_LeaseLiabilityNetOfCurrentPortion"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CapitalizationOfShareOutstanding" xlink:label="sclx_CapitalizationOfShareOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseDecreaseInAccruedPayroll" xlink:label="sclx_IncreaseDecreaseInAccruedPayroll"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:label="us-gaap_ProductLiabilityContingencyAccrualDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepurchasesOfNotes" xlink:label="sclx_RepurchasesOfNotes"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CapitalizedCost" xlink:label="sclx_CapitalizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome" xlink:label="us-gaap_TemporaryEquityNetIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ReclassificationAmountFromAdditionalPaidInCapital" xlink:label="sclx_ReclassificationAmountFromAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:label="sclx_DeferredTaxAssetsInterestExpenseLimitations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PromissoryNote" xlink:label="sclx_PromissoryNote"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:label="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="sclx_ProceedsFromSaleOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NotePrincipalReductionAmount" xlink:label="sclx_NotePrincipalReductionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsDetailsTable" xlink:label="sclx_WarrantsDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xlink:label="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueOfContingentConsideration" xlink:label="sclx_FairValueOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:label="sclx_IncreaseDecreaseInAccruedRebatesAndFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_GrossProceedsOfWarrants" xlink:label="sclx_GrossProceedsOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SecondAmendedCertificateOfIncorporationMember" xlink:label="sclx_SecondAmendedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DepositIntoTrustAccount" xlink:label="sclx_DepositIntoTrustAccount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsOfInitialPublicOffering" xlink:label="sclx_ProceedsOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NonCancelableLeaseAgreementsMember" xlink:label="sclx_NonCancelableLeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CashPayment" xlink:label="sclx_CashPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember" xlink:label="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueDecrease" xlink:label="sclx_FairValueDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ExclusiveDistributionAgreementMember" xlink:label="sclx_ExclusiveDistributionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ForgivenAmount" xlink:label="sclx_ForgivenAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="sclx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SponsorMember" xlink:label="sclx_SponsorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebt" xlink:label="us-gaap_SubordinatedDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="sclx_OrdinarySharesSubjectToPossibleRedemption"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MaturityRenewalDescription" xlink:label="sclx_MaturityRenewalDescription"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FundingCommitmentLetterMember" xlink:label="sclx_FundingCommitmentLetterMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" xlink:label="us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumberOfShares" xlink:label="sclx_NumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumeratorAbstract" xlink:label="sclx_NumeratorAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CashRequirement" xlink:label="sclx_CashRequirement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="us-gaap_DueToAffiliateCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="sclx_ChangeInValuationInputsOrOtherAssumptions"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="sclx_RelatedPartyTransactionsDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansPayable" xlink:label="us-gaap_NotesAndLoansPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xlink:label="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IssuedAndOutstandingCapitalStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued and outstanding capital stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IssuedAndOutstandingCapitalStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issued And Outstanding Capital Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IssuedAndOutstandingCapitalStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issued And Outstanding Capital Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OfferingCostIncludedInAccruedOfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs included in accrued offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OfferingCostIncludedInAccruedOfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering cost included in accrued offering cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OfferingCostIncludedInAccruedOfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OfferingCostIncludedInAccruedOfferingCost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_aggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase price value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_aggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">aggregate purchase price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_aggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">aggregatePurchasePrice</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from related party payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Related Party Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Deferredconsiderationliabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Deferredconsiderationliabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DeferredConsiderationLiabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Deferredconsiderationliabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">DeferredConsiderationLiabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Net Asset (Liability), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value, beginning blance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value, ending blance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Asset (Liability)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability &#8211; Private Placement Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ShareholdersEquityDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity (Details) [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FundExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fund expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FundExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fund expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FundExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FundExpenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows from Financing Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommonStockSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommonStockSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock sold.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Year Ended December 31,</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Romeg License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AccruedRoyaltyPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Royalty Payables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AccruedRoyaltyPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalty Payables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AccruedRoyaltyPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Royalty Payables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated future amortization expense related to intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated future amortization expense related to intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated future amortization expense related to intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PublicOfferingDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PricePerPublicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per public share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PricePerPublicShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PricePerPublicShare</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RecapitalizationDueToTheBusinessCombinationValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recapitalization Due to the Business Combination Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RecapitalizationDueToTheBusinessCombinationValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recapitalization Due to the Business Combination Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party note payable, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Related Parties, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized under the plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScheduleOfCondensedBalanceSheetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of condensed balance sheets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of quantitative information regarding Level 3 fair value measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Concentration of Risk [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line Of Credit FacilityI nterest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal depository insurance coverage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, FDIC Insured Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CurrentPortionOfDeferredConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CurrentPortionOfDeferredConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current portion of deferred consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CurrentPortionOfDeferredConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of deferred consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueOfWarrantsinDollars_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueOfWarrantsinDollars_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FairValueOfWarrantsinDollars</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instruments and Hedges, Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Instruments and Hedges, Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Eligible percentage of equity interest acquired by third party to exchange share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AssetAcquisitionEligiblePercentageOfEquityInterestAcquiredByRelatedPartyToExchangeShare</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AssetAcquisitionEligiblePercentageOfEquityInterestAcquiredByRelatedPartyToExchangeShare</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Redemption Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating cash flows from operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock upon conversation of cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preference shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of condensed balance sheets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Balance Sheet [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Options Outstanding, Forfeited/Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Consideration for Romeg Intangible Asset Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Consideration for Romeg Intangible Asset Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherDeferredCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Deferred Costs, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherDeferredCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherDeferredCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Deferred Costs, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities for uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PlusAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plus:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PlusAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PlusAbstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdditionalPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdditionalPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdditionalPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AdditionalPrincipalAmount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition related charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Acquisition Related Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation acquisition related charges.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SorrentoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sorrento</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SorrentoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sorrento [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SorrentoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sorrento [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OtherOfferingCosts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchaseAgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchaseAgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase Agreement Domain</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities and stockholders' equity/(deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private Placement Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Warrant [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PrivatePlacementWarrantMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CumulativeNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CumulativeNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">cumulative net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Convertible Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementDisclosureTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PRIVATE PLACEMENT</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementDisclosureTextblock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PrivatePlacementDisclosureTextblock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Operations and Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Semnur [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Semnur [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Milestones Payment was recognized under other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value, Beginning</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value, Ending</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Semnur Pharmaceuticals Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Semnur Pharmaceuticals Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loans receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans and Leases Receivable, Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loans and Leases Receivable, Related Parties, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loans and Leases Receivable, Related Parties, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trailing volume weighted average share price, term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trailing volume</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfDaysTrailingVolumeWeightedAverageSharePrice</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfDaysTrailingVolumeWeightedAverageSharePrice</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income, Securities, US Treasury</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsShareBasedCompensationCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsShareBasedCompensationCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend, Share-Based Payment Arrangement, Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationControlObtainedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationControlObtainedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Control Obtained Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueMeasurementStrikePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strike price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueMeasurementStrikePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Strike price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueMeasurementStrikePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FairValueMeasurementStrikePrice</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScilexPharmaNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scilex Pharma Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScilexPharmaNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scilex Pharma Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party note payable, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Related Parties, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AggregatePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AggregatePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of aggregate principal amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AggregatePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AggregatePrincipalAmount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preference shares, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total Deferred Tax Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AggregateGrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross Proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AggregateGrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AggregateGrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Gross Proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepurchasePrincipalInPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Principal In Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepurchasePrincipalInPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase Principal In Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Benefit for Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate - operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_GrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_GrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GrossProceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_InducementPlanDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Plan [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_InducementPlanDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement Plan Domain</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount and interest limitation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Debt Discount Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation debt discount amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TaxCreditCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TaxCreditCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TaxCreditCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carry forwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_UnrestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrestricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_UnrestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrestricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NetTangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net tangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NetTangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NetTangibleAssets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, subject to forfeiture (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-based Payment Arrangement, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of shares during the period-basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aardvark SP-104 license transfer from Sorrento, net of discount value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting agreement, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AggregateContingentCashConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate contingent cash consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AggregateContingentCashConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate contingent cash consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsDebtRelatedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt related interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsDebtRelatedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Debt Related Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsDebtRelatedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, debt related interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_InducementPlanAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Plan [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_InducementPlanAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement Plan Axis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private Placement Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued royalty payables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Guarantees, Commitments, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredUnderwritingFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred underwriting fee payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredUnderwritingFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred underwriting fee payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredUnderwritingFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DeferredUnderwritingFeePayable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of total number of shares of common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares Subject to Possible Redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScilexPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scilex Pharmaceuticals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScilexPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scilex Pharma [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScilexPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scilex Pharma</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DenominatorAbstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PublicOfferingDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering (Details) [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PercentageOfNetRevenueSoleDistributor_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net revenue, sole distributor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PercentageOfNetRevenueSoleDistributor_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Net Revenue, Sole Distributor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PercentageOfNetRevenueSoleDistributor_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of Net Revenue, Sole Distributor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired In-Process Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party indebtedness converted into shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AsRestatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">As Restated [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AsRestatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AsRestatedMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock consideration value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AssetAcquisitionEquityInterestIssuedOrIssuableValueAssigned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AssetAcquisitionEquityInterestIssuedOrIssuableValueAssigned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of identifiable intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, limitations on use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Limitations on Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Related party receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Notes Receivable, Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">LessAbstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LoanDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LoanDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LoanDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquiredTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired technology</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquiredTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired technology [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquiredTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired technology [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual adjustment distribution fee percentage related to future years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Adjustment Distribution Fee Percentage Related To Future Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual Adjustment Distribution Fee Percentage Related To Future Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepaidAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repaid amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepaidAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repaid Amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepaidAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">RepaidAmount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net tangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyTransactionsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">As Previously Reported [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Previously Reported [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SorrentoTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sorrento Therapeutics, Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SorrentoTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sorrento Therapeutics, Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SorrentoTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sorrento Therapeutics, Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator for Diluted Loss per Share - Adjusted for Dilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive Securities, Effect on Basic Earnings Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dilutive Securities, Effect on Basic Earnings Per Share, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders - diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EffectOfDilutiveSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Dilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EffectOfDilutiveSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effect of Dilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merger Agreement[ Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger Agreement[ Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FrequencyOfPaymentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Frequency of Payments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FrequencyOfPaymentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Frequency of Payments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProjectAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Project Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProjectAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Project Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OutstandingCapitalStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding capital stock, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OutstandingCapitalStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding capital stock, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OutstandingCapitalStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding capital stock, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CallOptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Call option value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CallOptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Call option value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CallOptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Call option value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AmountDueForNewDrugApplication_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount due for New Drug Application</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AmountDueForNewDrugApplication_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount due for New Drug Application</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair value adjustment to derivative liability in troubled debt restructuring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value adjustment to derivative liability in troubled debt restructuring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivables, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivables, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Revolving Credit Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Credit Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value, 45,000,000 shares authorized; 29,057,097 and 0 issued and outstanding at December 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PublicWarrantsRedemptionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public warrants redemption, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PublicWarrantsRedemptionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PublicWarrantsRedemptionDescription</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liabilities as of December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LiabilityClassifiedPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability-classified Private Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LiabilityClassifiedPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability classified private warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LiabilityClassifiedPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liability classified private warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchased aggregate amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Borrowings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Borrowings, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment of principal on the Scilex Pharma Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayment of principal on the Scilex Pharma Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PaymentUponTheAchievementOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment upon the achievement of net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PaymentUponTheAchievementOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">payment upon the achievement of net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchasePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per unit (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchasePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PurchasePricePerShare</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_FinancingReceivableNonaccrualToOutstandingPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate outstanding amount equal percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_FinancingReceivableNonaccrualToOutstandingPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, Nonaccrual to Outstanding, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued pursuant to the terms of the Debt Exchange Agreement, (In shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LiquidityAndGoingConcernLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity and Going Concern [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LiquidityAndGoingConcernLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and Going Concern [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdjustmentsRestatement2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments Restatement 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdjustmentsRestatement2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AdjustmentsRestatement2Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant to transfer shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Tax Expense, Due to Affiliates, Deferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FounderShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder shares (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FounderShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of founder shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FounderShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FounderShares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_VendorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vendor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_VendorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vendor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase of private placement warrants (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of the calculation of basic and diluted net income per ordinary share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CapitalRaisingDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital raising, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CapitalRaisingDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CapitalRaisingDescription</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ForfeituresOfPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forfeitures of Private Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ForfeituresOfPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Forfeitures of Private Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred underwriting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred underwriting fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DeferredUnderwritingFees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate outstanding amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loans Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Notes Payable, Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Transfer Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Transfer Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Transfer Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MonthlyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monthly [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MonthlyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monthly [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_StructuringFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Structuring fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_StructuringFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Structuring Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_StructuringFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Structuring Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NonCashDistributionToSorrento_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash distribution to Sorrento</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NonCashDistributionToSorrento_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-Cash Distribution to Sorrento</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NonCashDistributionToSorrento_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-Cash Distribution to Sorrento</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MinimumCashRequirement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Cash Requirement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MinimumCashRequirement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum Cash Requirement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LiquidityAndGoingConcernTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity and Going Concern [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LiquidityAndGoingConcernTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and Going Concern [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Converted into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ownership of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_HoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Holding period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_HoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">HoldingPeriod</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Organization and Business Operations (Details) [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE MEASUREMENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued as a result of the Business Combination, net of transaction activities (In Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from other loans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Other Short-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NonCashOperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NonCashOperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Operating Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NonCashOperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash operating lease cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares to be issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares to be issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Principal Amount Outstanding of Loans Held-in-portfolio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Principal Amount Outstanding of Loans Held-in-portfolio, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CashReceivedFromParentCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CashReceivedFromParentCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received From Parent company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CashReceivedFromParentCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Received From Parent company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToParentDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Attributable to Parent, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToParentDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToParentDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Parent, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development income tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock capital incremental shares reserved for future issuance each year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Incremental Shares Reserved For Future Issuance Each Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Capital Incremental Shares Reserved For Future Issuance Each Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Scilex Pharma Notes principal increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Notes Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLossOnDerivative_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLossOnDerivative_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Loss on Derivative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="exch_WSAG_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WALL STREET ACCESS [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of impact of these adjustments to the financial statement, as previously reported</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Statements [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AmendmentNumberFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Number Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AmendmentNumberFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amendment Number Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AgreementMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AgreementMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AgreementMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUBSEQUENT EVENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of shares during the period -diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted weighted average ordinary shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RomegLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Romeg License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RomegLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Romeg License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseOfPrincipalBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase of Principal Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseOfPrincipalBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase of Principal Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State, net of federal tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers &amp; equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Leases Supplemental Quantitative Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Converted into Preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation cost related to unvested stock option grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Text Block [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Upfrontlicensefee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front license fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Upfrontlicensefee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UpFrontLicenseFee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Upfrontlicensefee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">UpFrontLicenseFee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsAccruedExpenseAndReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expense and reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsAccruedExpenseAndReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Accrued Expense and Reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsAccruedExpenseAndReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, accrued expense and reserves.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from related party note payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Secured Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RiskAdjustedNetSalesForecast_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risk Adjusted Net Sales Forecast</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RiskAdjustedNetSalesForecast_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risk adjusted net sales forecast</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FourCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Four Customer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FourCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Four Customer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FourCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Four Customer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PledgingPurposeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pledging Purpose [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Percentageofoutstandingcommonstockheld_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of outstanding common stock held</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Percentageofoutstandingcommonstockheld_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Percentageofoutstandingcommonstockheld_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PercentageOfOutstandingCommonStockHeld</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Percentageofoutstandingcommonstockheld_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PercentageOfOutstandingCommonStockHeld</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Derivativeliabilityatfairvalueadditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Derivativeliabilityatfairvalueadditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DerivativeLiabilityAtFairValueAdditions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Derivativeliabilityatfairvalueadditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">DerivativeLiabilityAtFairValueAdditions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DebtInstrumentPurcahsePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purcahse price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DebtInstrumentPurcahsePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Purcahse Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DebtInstrumentPurcahsePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument purcahse price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax expense (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax (benefit) expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAverageAmountOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Outstanding Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAverageAmountOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Average Amount Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DebtExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Exchange Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DebtExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Exchange Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DebtExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Exchange Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ARYorkvillePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A&amp;R Yorkville Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ARYorkvillePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A R Yorkville Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ARYorkvillePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">A R Yorkville Purchase Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited/Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Changes in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_BRileyPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">B. Riley Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_BRileyPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B Riley Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_BRileyPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">B Riley Purchase Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Servicing Liability, Fair Value, Change in Fair Value, Other, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preference shares issue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PricePerWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per warrant (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PricePerWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Price per warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PricePerWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PricePerWarrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued rebates and fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued rebates and fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LegacyScilexStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legacy Scilex Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LegacyScilexStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legacy Scilex Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LegacyScilexStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legacy Scilex Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial measurement on December 20, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property, plant, and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of property, plant, and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LongTermPortionOfDeferredConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of deferred consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LongTermPortionOfDeferredConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term portion of deferred consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LongTermPortionOfDeferredConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term portion of deferred consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PromissoryNoteRelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory Note - Related Party [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PromissoryNoteRelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PromissoryNoteRelatedPartyMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantsOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantsOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants outstanding shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantsOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WarrantsOutstandingShares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares to Sponsor (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScintillaPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scintilla Pharmaceuticals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScintillaPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scintilla Pharmaceuticals [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScintillaPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scintilla Pharmaceuticals [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CarryingValueIncreased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carrying value increased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CarryingValueIncreased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value increased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityUnitPurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Purchase Agreements and Indenture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityUnitPurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Unit Purchase Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Return to provision adjustments and carryback</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseDecreaseInLongTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseDecreaseInLongTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Long-term deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseDecreaseInLongTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease In Long-term deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrdinarySharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued and outstanding (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrdinarySharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ordinary shares issued and outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrdinarySharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OrdinarySharesIssuedAndOutstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WarrantExercisePrice</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TransactionCostsObligationAssumedBySorrento_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs obligation assumed by Sorrento</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TransactionCostsObligationAssumedBySorrento_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction costs obligation assumed by Sorrento</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TransactionCostsObligationAssumedBySorrento_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs obligation assumed by Sorrento</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OutstandingPrincipalAmountPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount outstanding, rate per annum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OutstandingPrincipalAmountPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding principal amount period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OutstandingPrincipalAmountPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding principal amount period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Notes Payable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Notes Payable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyNotesPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Notes Payable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepurchaseWithCashOnHand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase with cash-on-hand</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepurchaseWithCashOnHand_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase with cash-on-hand</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProposedPublicOfferingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proposed Public Offering [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares subject to possible redemption 13,800,000 as of December 31, 2021 and no shares as of December 31, 2020 at redemption value of $10.10</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary Shares Subject to Possible Redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EffectOfBusinessCombinationInValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Business Combination In Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EffectOfBusinessCombinationInValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effect Of Business Combination In Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandTwentyTwoPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandTwentyTwoPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandTwentyTwoPromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Two Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2017 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PatentRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PatentRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent rights [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PatentRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent rights [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Asset Impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill and Intangible Asset Impairment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SaleOfStockDescriptionOfTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SaleOfStockDescriptionOfTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock description of transaction.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SaleOfStockDescriptionOfTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SaleOfStockDescriptionOfTransactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsFromTheBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsFromTheBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from the Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsFromTheBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from the Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Description of Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProposedPublicOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PUBLIC OFFERING</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProposedPublicOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ProposedPublicOfferingTextBlock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Parent, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Shareholders&#8217; Equity (Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NonCashConsiderationInSemnurAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-cash Consideration in Semnur Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NonCashConsiderationInSemnurAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash Consideration in Semnur Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantsDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants (Details) [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Excess Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 740,000,000 shares authorized; 141,348,856 and 132,858,484 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of indebtedness</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment of Notes Receivable from Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Gain) loss on derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">(Gain) loss on derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative, Gain (Loss) on Derivative, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivateWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivateWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivateWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ActualCumulativeNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Actual cumulative net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ActualCumulativeNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Actual cumulative net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense, interest and penalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Negative working capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Working Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Transaction costs paid related to the Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs paid related to recapitalization transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction costs paid related to the recapitalization transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs paid related to the recapitalization transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Asset Acquired Other than through Business Combination, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of intangibles</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Amortization of Intangibles</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities, Amortization of Intangibles</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating costs and expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuance, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principle amount of issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Issued, Principal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DevelopersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developers [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DevelopersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Developers [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurCashExchangePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Semnur Cash Exchange Payment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurCashExchangePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Semnur Cash Exchange Payment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to shares issued in Semnur Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to shares issued in Semnur Acquisition value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment to shares issued in Semnur Acquisition value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments Restatement 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares issued as a result of the Business Combination, net of transaction activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued as a result of the Business Combination, net of transaction activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Purchase of Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Notes Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShorttermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShorttermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Term of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual for transaction costs related to the Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrual for transaction costs related to the Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrual for transaction costs related to the Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of impact of these adjustments to the financial statement, as previously reported [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock-price volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementDisclosureTextblockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Disclosure Textblock [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related party receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_UpfrontConsiderationForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront consideration for common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_UpfrontConsiderationForCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">upfront consideration for common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total other (income) expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other (income) expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WeightedAveragePeriodOverGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average period over grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WeightedAveragePeriodOverGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average period over grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventoryPurchasedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventoryPurchasedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Inventory, Purchased Goods, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant price per share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NumberOfBusinessDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of business days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NumberOfBusinessDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of business days.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NumberOfBusinessDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NumberOfBusinessDays</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ResearchAndDevelopmentFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Facilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ResearchAndDevelopmentFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development Facilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income taxes, foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsFromRepaymentOfLoansToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment on other loans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsFromRepaymentOfLoansToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Repayment Of Loans To Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsFromRepaymentOfLoansToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Repayment Of Loans To Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LegacyCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legacy Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LegacyCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legacy Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LegacyCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legacy Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to Scilex</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining Amortization Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less current portion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrdinarySharesIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Ordinary shares issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrdinarySharesIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow from the additional capital contribution to the entity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrdinarySharesIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OrdinarySharesIssuanceCost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PercentageOfNetRevenueSoleDistributors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net revenue, sole distributor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PercentageOfNetRevenueSoleDistributors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of net revenue, sole distributors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PercentageOfNetRevenueSoleDistributors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net revenue, sole distributors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash &#8211; Beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash &#8211; End of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Principal Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organisation and Principal Activities [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organisation and Principal Activities [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Valuation Assumption Used</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assumptions Used in the Black-Scholes Option-Pricing Method Related To Options Issued to Employees and Nonemployees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Amounts of Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ConversionOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ConversionOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ConversionOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founder Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FounderSharesMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of units amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LegacyScilexCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legacy Scilex Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LegacyScilexCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legacy Scilex Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LegacyScilexCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legacy Scilex Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows from Operating Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FirstAmendedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Amended Certificate of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FirstAmendedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Amended Certificate of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FirstAmendedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Amended Certificate of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandNineteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandNineteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandNineteenStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProfitPercentageNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net profit percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProfitPercentageNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Percentage Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProfitPercentageNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit Percentage, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Change in Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposit interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income, Deposit with Financial Institution, Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares subject to possible redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ordinary shares subject to possible redemption.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SharesSubjectToPossibleRedemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_InterestExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_InterestExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_InterestExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">InterestExpenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ItochuMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Itochu [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ItochuMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Itochu [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Servicing Liability at Fair Value, Other Changes in Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement (Details) [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchaseAgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchaseAgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase Agreement Axis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SpacTransactionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SPAC Transaction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SpacTransactionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SPAC Transaction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DistributionFeesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distribution fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DistributionFeesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Distribution Fees Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DistributionFeesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Distribution Fees Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Other Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DistributionToSorrentos_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distribution to sorrentos</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DistributionToSorrentos_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Distribution to Sorrento's</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DistributionToSorrentos_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Distribution to Sorrento's</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposit Liabilities, Accrued Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdministrativeFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Administrative Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AdministrativeFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Administrative Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PledgingPurposeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pledging Purpose [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to aggregate amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash consideration to equity holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies (Details) [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost*</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Maturities of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Semnur Product 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Semnur Product Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Semnur Product Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_UnderlyingWarrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underlying warrant value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_UnderlyingWarrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underlying warrant value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_UnderlyingWarrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UnderlyingWarrantValue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LitigationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LitigationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax credits and incentives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Outstanding Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain on debt extinguishment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Gain) loss on debt extinguishment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Gain) loss on debt extinguishment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior secured notes due 2026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Secured Notes Due Two Thousand Twenty six [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Senior secured notes due two thousand twenty six member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows from Investing Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related party payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated future amortization expense related to intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProductDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProductDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IndefiniteCarryforwardPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite Carryforward Period [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IndefiniteCarryforwardPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Carryforward Period [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IndefiniteCarryforwardPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indefinite Carryforward Period [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to current year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (See Note 10)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable revolving loan facility in an aggregate amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, Revolving, Converted to Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party debt converted to equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related party debt converted to equity pursuant to Debt Exchange Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party debt converted to equity pursuant to Debt Exchange Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WARRANTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LiveActionRightOfUseAssetInPaloAlto_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Live Action right-of-use asset in Palo Alto</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LiveActionRightOfUseAssetInPaloAlto_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Live Action right-of-use asset in Palo Alto</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NumberOfSaleUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of sale units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NumberOfSaleUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Sale units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NumberOfSaleUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NumberOfSaleUnits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current expense:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of related party extension loans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Description of Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AssembledWorkforceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assembled workforce</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AssembledWorkforceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assembled workforce [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AssembledWorkforceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Assembled workforce [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AardvarkAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aardvark Asset Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AardvarkAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aardvark Asset Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquiredLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired licenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquiredLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired licenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquiredLicensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired licenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares to Yorkville</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of shares to Yorkville pursuant to Yorkville Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of shares to Yorkville pursuant to Yorkville Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RoyaltyPaymentPercentageRelatedToFutureYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment percentage related to future years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RoyaltyPaymentPercentageRelatedToFutureYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payment Percentage Related To Future Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RoyaltyPaymentPercentageRelatedToFutureYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Payment Percentage Related To Future Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EquityPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EquityPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share exchange period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period commencing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AssetAcquisitionEquityInterestIssuedOrIssuablePeriodOfShareExchange</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AssetAcquisitionEquityInterestIssuedOrIssuablePeriodOfShareExchange</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Deficit:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss (gain) on foreign currency exchange</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss (gain) on foreign currency exchange</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offset against the equity proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Other Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SponsorLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsor loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SponsorLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsor loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SponsorLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SponsorLoan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ShareholdersEquityDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_VickersDebtAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vickers Debt Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_VickersDebtAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vickers Debt Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_VickersDebtAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vickers Debt Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of derivative component of the obligation is initially valued and classified as a derivative liability [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_BlackScholesOptionPricingMethodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Black-Scholes Option Pricing Method [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_BlackScholesOptionPricingMethodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Black-Scholes Option Pricing Method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PercentageOfPublicShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of public shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PercentageOfPublicShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of public shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PercentageOfPublicShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PercentageOfPublicShares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SpacTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SPAC Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SpacTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SPAC Transactions [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SpacTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SPAC Transactions [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Employee and Non-employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Employee and Non-employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommonStockToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock to be issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommonStockToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock to be issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to participating securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Equity Incentive Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Two Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt, Maximum Amount During Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Current Maturities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (income) expense:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liabilities as of December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ReMeasurementOfFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Re-measurement of fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ReMeasurementOfFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Re-measurement of fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease related to prior year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease related to prior year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SaleOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of warrants (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SaleOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SaleOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SaleOfWarrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchaseOfStockPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of stock, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchaseOfStockPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of stock, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchaseOfStockPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of stock, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DerivativeWarrantLiabilityPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative warrant liability private warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DerivativeWarrantLiabilityPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Warrant Liability Private Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DerivativeWarrantLiabilityPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative warrant liability private warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash underwriting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Underwriting Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquisitionOfRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquisitionOfRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition of right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AcquisitionOfRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition of right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrincipalAndNonOperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Principal and non-operating expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrincipalAndNonOperatingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">principal and non-operating expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock consideration value per share (usd per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AssetAcquisitionEquityInterestIssuedOrIssuableValueAssignedPerShare</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AssetAcquisitionEquityInterestIssuedOrIssuableValueAssignedPerShare</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FrequencyOfPaymentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Frequency of Payments [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FrequencyOfPaymentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Frequency of Payments [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior year true-up and carryback</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NotesPrincipalIncrease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Scilex Pharma Notes principal increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NotesPrincipalIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scilex Pharma Notes principal increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NotesPrincipalIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes principal increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NotesPrincipalIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes principal increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating costs and expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating and formation costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Semnur Product 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Semnur Product One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Semnur Product One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted -average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OtherLoanForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Loan Forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OtherLoanForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Loan Forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Semnur Product 4 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Semnur Product Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Semnur Product Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EffectOfBusinessCombinationInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Business Combination In Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EffectOfBusinessCombinationInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effect of Business Combination In Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_BusinessCombinationRedeemPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination redeem percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_BusinessCombinationRedeemPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination redeem percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_BusinessCombinationRedeemPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BusinessCombinationRedeemPercentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ConvertiblePromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ConvertiblePromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ConvertiblePromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ConvertiblePromissoryNote</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldInTrust_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets Held-in-trust, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldInTrust_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trust account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldInTrust_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assets held in the trust account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldInTrust_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Held-in-trust</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScilexPharmaNotesPrincipalIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scilex Pharma Notes principal increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ScilexPharmaNotesPrincipalIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scilex Pharma Notes principal increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TransactionCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TransactionCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction costs amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TransactionCostsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TransactionCostsAmount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs and debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSalesOfLoansNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Actual cumulative net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSalesOfLoansNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Sales of Loans, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSalesOfLoansNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Sales of Loans, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Notes Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommonStockExchangeRatioDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock exchange ratio, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommonStockExchangeRatioDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Exchange Ratio, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CommonStockExchangeRatioDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Exchange Ratio, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Warrants and Private Placement Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Warrant And Private Placement Warrants [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Warrant And Private Placement Warrants [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementWarrantLiabilityAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Warrant liability acquired as part of the Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementWarrantLiabilityAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private placement warrant liability acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PrivatePlacementWarrantLiabilityAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private placement warrant liability acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RecapitalizationDuetotheBusinessCombinationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recapitalization DueToThe Business Combination Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RecapitalizationDuetotheBusinessCombinationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recapitalization DueToThe Business Combination Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROU assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ReceivableBasisOfGoingForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable basis going forward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ReceivableBasisOfGoingForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable basis of going forward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ReceivableBasisOfGoingForward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Receivable basis of going forward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EquityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EquityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_EquityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AgreementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement initial term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AgreementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Initial Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_AgreementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Initial Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DenominatorAbstract0_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DenominatorAbstract0_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DenominatorAbstract0</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock consideration common stock value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt principal forgive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Decrease, Forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Additional amount borrowed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RELATED PARTY TRANSACTIONS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Cash investing and financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Semnur Product 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Semnur Product Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SemnurProductTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Semnur Product Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ForfeitureOfPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture of Private Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ForfeitureOfPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forfeiture of Private Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ForfeitureOfPrivateWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Forfeiture of Private Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of Private Placement Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate purchase price (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory federal income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition consideration transferred amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Acquisition, Consideration Transferred, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of fair value assets measured on a recurring basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of the reconciliation of basic and diluted loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DebtExchangeDescriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Exchange Descriptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DebtExchangeDescriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Exchange Descriptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued pursuant to the terms of the Debt Exchange Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueMeasurementsValuationProcessesDescription1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial measurement , description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueMeasurementsValuationProcessesDescription1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Valuation Processes Description 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LeaseLiabilityNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LeaseLiabilityNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease liability, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_LeaseLiabilityNetOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liability, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CapitalizationOfShareOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalization of share outstanding (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CapitalizationOfShareOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalization of share outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CapitalizationOfShareOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CapitalizationOfShareOutstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of carrying value to redemption value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion Option Liability (see Note 5)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expenses, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseDecreaseInAccruedPayroll_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Payroll</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseDecreaseInAccruedPayroll_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued payroll</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseDecreaseInAccruedPayroll_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease In Accrued payroll</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductLiabilityContingencyAccrualDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate of FDA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductLiabilityContingencyAccrualDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Liability Contingency, Accrual, Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepurchasesOfNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchases of Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RepurchasesOfNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchases of Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CapitalizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CapitalizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CapitalizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityNetIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of net income (loss), as adjusted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityNetIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Net Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of option outstanding to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options per share fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Net (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ReclassificationAmountFromAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification amount from additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ReclassificationAmountFromAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification amount from additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsInterestExpenseLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense limitations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsInterestExpenseLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Interest Expense Limitations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DeferredTaxAssetsInterestExpenseLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Interest Expense Limitations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedBorrowingInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinated Borrowing, Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options vesting description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders - basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basic Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net income (loss) per ordinary share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Incentive and Employee Benefit Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Promissory note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Promissory note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Annual Principal Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from sale of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from sale of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NotePrincipalReductionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note Principal Reduction Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NotePrincipalReductionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Note Principal Reduction Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NotePrincipalReductionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Note Principal Reduction Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock-price volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Organization and Business Operations (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of borrowings of the scilex notes consisted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_WarrantsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aardvark SP-104 discount amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AdjustmentToAdditionalPaidInCapitalDiscountAmortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AdjustmentToAdditionalPaidInCapitalDiscountAmortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary share, per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2022 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Two Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseDecreaseInAccruedRebatesAndFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued rebates and fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseDecreaseInAccruedRebatesAndFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Rebates and Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_IncreaseDecreaseInAccruedRebatesAndFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (Decrease) in Accrued Rebates and Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancellation of ordinary shares (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_GrossProceedsOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds of amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_GrossProceedsOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_GrossProceedsOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GrossProceedsOfWarrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SecondAmendedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amended Certificate of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SecondAmendedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amended Certificate of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SecondAmendedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second Amended Certificate of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DepositIntoTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposit into trust account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DepositIntoTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deposit into Trust Account.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_DepositIntoTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DepositIntoTrustAccount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds of initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ProceedsOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ProceedsOfInitialPublicOffering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NonCancelableLeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-cancelable Lease Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NonCancelableLeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cancelable Lease Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Liabilities and Related Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research &amp; Development and Orphan Drug Credits [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development and Orphan Drug Credits [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development and Orphan Drug Credits [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to prior year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair value decrease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FairValueDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value decrease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ExclusiveDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive Distribution Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ExclusiveDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive Distribution Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee benefit plan contributions by employer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining life for identifiable intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration, term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ForgivenAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forgiven amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ForgivenAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Forgiven amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used for investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options exercised (In Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Options Outstanding, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Promissory note issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs paid through promissory note &#8211; related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash Transfer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsor [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SponsorMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subordinated loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinated Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Subordinated Debt, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Subordinated Debt, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubordinatedDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Subordinated Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Long-Term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrdinarySharesSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subject to possible redemption shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrdinarySharesSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary shares subject to possible redemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_OrdinarySharesSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OrdinarySharesSubjectToPossibleRedemption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MaturityRenewalDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement maturity renewal description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MaturityRenewalDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity Renewal Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_MaturityRenewalDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturity Renewal Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding principal balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary shares, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FundingCommitmentLetterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Commitment Letter [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_FundingCommitmentLetterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding Commitment Letter [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in the principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt, Maximum Amount Outstanding During Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Maximum Amount Outstanding During Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NumberOfShares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Others</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Others</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NumeratorAbstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales operation implementation fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit at federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CashRequirement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Requirement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_CashRequirement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Requirement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToAffiliateCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advances outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToAffiliateCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due to Affiliate, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value per share of common stock on date of grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain income tax position, likelihood</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Likelihood of Unfavorable Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Weighted Average Yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ChangeInValuationInputsOrOtherAssumptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ChangeInValuationInputsOrOtherAssumptions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in valuation inputs or other assumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ChangeInValuationInputsOrOtherAssumptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in valuation inputs or other assumptions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_ChangeInValuationInputsOrOtherAssumptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ChangeInValuationInputsOrOtherAssumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_RelatedPartyTransactionsDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions (Details) [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advances in note payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes and Loans Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesAndLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes and Loans Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party note payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_IssuedAndOutstandingCapitalStockMember" xlink:to="sclx_IssuedAndOutstandingCapitalStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:to="sclx_OfferingCostIncludedInAccruedOfferingCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_aggregatePurchasePrice" xlink:to="sclx_aggregatePurchasePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_Deferredconsiderationliabilities" xlink:to="sclx_Deferredconsiderationliabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_StockOptionsMember" xlink:to="sclx_StockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="sclx_ShareholdersEquityDetailsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FundExpenses" xlink:to="sclx_FundExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_CommitmentsAndContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CommonStockSold" xlink:to="sclx_CommonStockSold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AccruedRoyaltyPayables" xlink:to="sclx_AccruedRoyaltyPayables_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" xlink:to="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PublicOfferingDetailsTable" xlink:to="sclx_PublicOfferingDetailsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PricePerPublicShare" xlink:to="sclx_PricePerPublicShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RecapitalizationDueToTheBusinessCombinationValue" xlink:to="sclx_RecapitalizationDueToTheBusinessCombinationValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ScheduleOfCondensedBalanceSheetsAbstract" xlink:to="sclx_ScheduleOfCondensedBalanceSheetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:to="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:to="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CurrentPortionOfDeferredConsideration" xlink:to="sclx_CurrentPortionOfDeferredConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xlink:to="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FairValueOfWarrantsinDollars" xlink:to="sclx_FairValueOfWarrantsinDollars_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare" xlink:to="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" xlink:to="sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCostsNet" xlink:to="us-gaap_OtherDeferredCostsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PlusAbstract" xlink:to="sclx_PlusAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AdditionalPrincipalAmount" xlink:to="sclx_AdditionalPrincipalAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:to="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SorrentoMember" xlink:to="sclx_SorrentoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OtherOfferingCosts" xlink:to="sclx_OtherOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PurchaseAgreementDomain" xlink:to="sclx_PurchaseAgreementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PrivatePlacementWarrantMember" xlink:to="sclx_PrivatePlacementWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CumulativeNetSales" xlink:to="sclx_CumulativeNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PrivatePlacementDisclosureTextblock" xlink:to="sclx_PrivatePlacementDisclosureTextblock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SemnurMember" xlink:to="sclx_SemnurMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SemnurPharmaceuticalsIncMember" xlink:to="sclx_SemnurPharmaceuticalsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice" xlink:to="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:to="us-gaap_InterestIncomeSecuritiesUSTreasury_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsShareBasedCompensationCash" xlink:to="us-gaap_DividendsShareBasedCompensationCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationControlObtainedDescription" xlink:to="us-gaap_BusinessCombinationControlObtainedDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="sclx_IncomeTaxDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FairValueMeasurementStrikePrice" xlink:to="sclx_FairValueMeasurementStrikePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ScilexPharmaNotesMember" xlink:to="sclx_ScilexPharmaNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AggregatePrincipalAmount" xlink:to="sclx_AggregatePrincipalAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AggregateGrossProceeds" xlink:to="sclx_AggregateGrossProceeds_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RepurchasePrincipalInPercentage" xlink:to="sclx_RepurchasePrincipalInPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_GrossProceeds" xlink:to="sclx_GrossProceeds_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PrivatePlacementDetailsTable" xlink:to="sclx_PrivatePlacementDetailsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_InducementPlanDomain" xlink:to="sclx_InducementPlanDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xlink:to="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_TaxCreditCarryForwardsExpirationYear" xlink:to="sclx_TaxCreditCarryForwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_UnrestrictedCash" xlink:to="sclx_UnrestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NetTangibleAssets" xlink:to="sclx_NetTangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xlink:to="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AggregateContingentCashConsideration" xlink:to="sclx_AggregateContingentCashConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:to="sclx_DeferredTaxAssetsDebtRelatedInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_InducementPlanAxis" xlink:to="sclx_InducementPlanAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DeferredUnderwritingFeePayable" xlink:to="sclx_DeferredUnderwritingFeePayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ScilexPharmaMember" xlink:to="sclx_ScilexPharmaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DenominatorAbstract" xlink:to="sclx_DenominatorAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PublicOfferingDetailsLineItems" xlink:to="sclx_PublicOfferingDetailsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PercentageOfNetRevenueSoleDistributor" xlink:to="sclx_PercentageOfNetRevenueSoleDistributor_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AsRestatedMember" xlink:to="sclx_AsRestatedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned" xlink:to="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LessAbstract" xlink:to="sclx_LessAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LoanDerivativeLiability" xlink:to="sclx_LoanDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AcquiredTechnologyMember" xlink:to="sclx_AcquiredTechnologyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears" xlink:to="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RepaidAmount" xlink:to="sclx_RepaidAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsCurrent" xlink:to="us-gaap_IntangibleAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RelatedPartyTransactionsDetailsTable" xlink:to="sclx_RelatedPartyTransactionsDetailsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ExchangeAgreementMember" xlink:to="sclx_ExchangeAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SorrentoTherapeuticsIncMember" xlink:to="sclx_SorrentoTherapeuticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_EffectOfDilutiveSecurities" xlink:to="sclx_EffectOfDilutiveSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_MergerAgreementMember" xlink:to="sclx_MergerAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FrequencyOfPaymentsDomain" xlink:to="sclx_FrequencyOfPaymentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ProjectAgreementMember" xlink:to="sclx_ProjectAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OutstandingCapitalStockPercent" xlink:to="sclx_OutstandingCapitalStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CallOptionValue" xlink:to="sclx_CallOptionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AmountDueForNewDrugApplication" xlink:to="sclx_AmountDueForNewDrugApplication_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" xlink:to="sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PublicWarrantsRedemptionDescription" xlink:to="sclx_PublicWarrantsRedemptionDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LiabilityClassifiedPrivateWarrants" xlink:to="sclx_LiabilityClassifiedPrivateWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" xlink:to="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PaymentUponTheAchievementOfNetSales" xlink:to="sclx_PaymentUponTheAchievementOfNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PurchasePricePerShare" xlink:to="sclx_PurchasePricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_FinancingReceivableNonaccrualToOutstandingPercent" xlink:to="srt_FinancingReceivableNonaccrualToOutstandingPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="sclx_LiquidityAndGoingConcernLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AdjustmentsRestatement2Member" xlink:to="sclx_AdjustmentsRestatement2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:to="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FounderShares" xlink:to="sclx_FounderShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_VendorMember" xlink:to="sclx_VendorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract" xlink:to="sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CapitalRaisingDescription" xlink:to="sclx_CapitalRaisingDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ForfeituresOfPrivateWarrants" xlink:to="sclx_ForfeituresOfPrivateWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DeferredUnderwritingFees" xlink:to="sclx_DeferredUnderwritingFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_WarrantTransferAgreementMember" xlink:to="sclx_WarrantTransferAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_MonthlyMember" xlink:to="sclx_MonthlyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_StructuringFees" xlink:to="sclx_StructuringFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NonCashDistributionToSorrento" xlink:to="sclx_NonCashDistributionToSorrento_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_MinimumCashRequirement" xlink:to="sclx_MinimumCashRequirement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LiquidityAndGoingConcernTable" xlink:to="sclx_LiquidityAndGoingConcernTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_HoldingPeriod" xlink:to="sclx_HoldingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NonCashOperatingLeaseCost" xlink:to="sclx_NonCashOperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SharesToBeIssued" xlink:to="sclx_SharesToBeIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:to="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CashReceivedFromParentCompany" xlink:to="sclx_CashReceivedFromParentCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:to="us-gaap_NetIncomeLossAttributableToParentDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear" xlink:to="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_MilestonePayment" xlink:to="sclx_MilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="exch_WSAG" xlink:to="exch_WSAG_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AmendmentNumberFourMember" xlink:to="sclx_AmendmentNumberFourMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AgreementMaturityDate" xlink:to="sclx_AgreementMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RomegLicenseAgreementMember" xlink:to="sclx_RomegLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_IncreaseOfPrincipalBalance" xlink:to="sclx_IncreaseOfPrincipalBalance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_Upfrontlicensefee" xlink:to="sclx_Upfrontlicensefee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:to="sclx_DeferredTaxAssetsAccruedExpenseAndReserves_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSecuredNotesPayable" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RiskAdjustedNetSalesForecast" xlink:to="sclx_RiskAdjustedNetSalesForecast_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FourCustomerMember" xlink:to="sclx_FourCustomerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_Percentageofoutstandingcommonstockheld" xlink:to="sclx_Percentageofoutstandingcommonstockheld_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SharesAcquired" xlink:to="sclx_SharesAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_Derivativeliabilityatfairvalueadditions" xlink:to="sclx_Derivativeliabilityatfairvalueadditions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DebtInstrumentPurcahsePrice" xlink:to="sclx_DebtInstrumentPurcahsePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAverageAmountOutstanding" xlink:to="us-gaap_LongTermDebtAverageAmountOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DebtExchangeAgreementMember" xlink:to="sclx_DebtExchangeAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ARYorkvillePurchaseAgreementMember" xlink:to="sclx_ARYorkvillePurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_BRileyPurchaseAgreementMember" xlink:to="sclx_BRileyPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PricePerWarrants" xlink:to="sclx_PricePerWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LegacyScilexStockOptionsMember" xlink:to="sclx_LegacyScilexStockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LongTermPortionOfDeferredConsideration" xlink:to="sclx_LongTermPortionOfDeferredConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PromissoryNoteRelatedPartyMember" xlink:to="sclx_PromissoryNoteRelatedPartyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_WarrantsOutstandingShares" xlink:to="sclx_WarrantsOutstandingShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ScintillaPharmaceuticalsMember" xlink:to="sclx_ScintillaPharmaceuticalsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CarryingValueIncreased" xlink:to="sclx_CarryingValueIncreased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityUnitPurchaseAgreementsMember" xlink:to="us-gaap_EquityUnitPurchaseAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_IncreaseDecreaseInLongTermDeposits" xlink:to="sclx_IncreaseDecreaseInLongTermDeposits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OrdinarySharesIssuedAndOutstanding" xlink:to="sclx_OrdinarySharesIssuedAndOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_WarrantExercisePrice" xlink:to="sclx_WarrantExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_TransactionCostsObligationAssumedBySorrento" xlink:to="sclx_TransactionCostsObligationAssumedBySorrento_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OutstandingPrincipalAmountPeriod" xlink:to="sclx_OutstandingPrincipalAmountPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RelatedPartyNotesPayableMember" xlink:to="sclx_RelatedPartyNotesPayableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RepurchaseWithCashOnHand" xlink:to="sclx_RepurchaseWithCashOnHand_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ProposedPublicOfferingAbstract" xlink:to="sclx_ProposedPublicOfferingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_EffectOfBusinessCombinationInValue" xlink:to="sclx_EffectOfBusinessCombinationInValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AccruedExpenses" xlink:to="sclx_AccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LicenseAgreementMember" xlink:to="sclx_LicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:to="sclx_TwoThousandTwentyTwoPromissoryNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="sclx_TwoThousandSeventeenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PatentRightsMember" xlink:to="sclx_PatentRightsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SaleOfStockDescriptionOfTransactions" xlink:to="sclx_SaleOfStockDescriptionOfTransactions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ProceedsFromTheBusinessCombination" xlink:to="sclx_ProceedsFromTheBusinessCombination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="sclx_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ProposedPublicOfferingTextBlock" xlink:to="sclx_ProposedPublicOfferingTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NonCashConsiderationInSemnurAcquisition" xlink:to="sclx_NonCashConsiderationInSemnurAcquisition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_WarrantsDetailsLineItems" xlink:to="sclx_WarrantsDetailsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="sclx_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PrivateWarrantsMember" xlink:to="sclx_PrivateWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ActualCumulativeNetSales" xlink:to="sclx_ActualCumulativeNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_WorkingCapital" xlink:to="sclx_WorkingCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:to="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles" xlink:to="sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DevelopersMember" xlink:to="sclx_DevelopersMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SemnurCashExchangePaymentMember" xlink:to="sclx_SemnurCashExchangePaymentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xlink:to="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtFairValue" xlink:to="us-gaap_ShorttermDebtFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination" xlink:to="sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract" xlink:to="sclx_ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PrivatePlacementDisclosureTextblockAbstract" xlink:to="sclx_PrivatePlacementDisclosureTextblockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RelatedPartyReceivable" xlink:to="sclx_RelatedPartyReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_UpfrontConsiderationForCommonStock" xlink:to="sclx_UpfrontConsiderationForCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_WeightedAveragePeriodOverGrant" xlink:to="sclx_WeightedAveragePeriodOverGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventoryPurchasedGoods" xlink:to="us-gaap_OtherInventoryPurchasedGoods_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NumberOfBusinessDays" xlink:to="sclx_NumberOfBusinessDays_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ResearchAndDevelopmentFacilitiesMember" xlink:to="sclx_ResearchAndDevelopmentFacilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ProceedsFromRepaymentOfLoansToPurchase" xlink:to="sclx_ProceedsFromRepaymentOfLoansToPurchase_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LegacyCommonStockMember" xlink:to="sclx_LegacyCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OrdinarySharesIssuanceCost" xlink:to="sclx_OrdinarySharesIssuanceCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PercentageOfNetRevenueSoleDistributors" xlink:to="sclx_PercentageOfNetRevenueSoleDistributors_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock" xlink:to="sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ConversionOfCommonStock" xlink:to="sclx_ConversionOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_IncomeTaxDisclosureTable" xlink:to="sclx_IncomeTaxDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FounderSharesMember" xlink:to="sclx_FounderSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:to="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LegacyScilexCommonStockMember" xlink:to="sclx_LegacyScilexCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_WarrantsMember" xlink:to="sclx_WarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FirstAmendedCertificateOfIncorporationMember" xlink:to="sclx_FirstAmendedCertificateOfIncorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_TwoThousandNineteenStockOptionPlanMember" xlink:to="sclx_TwoThousandNineteenStockOptionPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ProfitPercentageNet" xlink:to="sclx_ProfitPercentageNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:to="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OtherLongTermLiabilities" xlink:to="sclx_OtherLongTermLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SharesSubjectToPossibleRedemption" xlink:to="sclx_SharesSubjectToPossibleRedemption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_InterestExpenses" xlink:to="sclx_InterestExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ItochuMember" xlink:to="sclx_ItochuMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:to="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_InducementPlanMember" xlink:to="sclx_InducementPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PrivatePlacementDetailsLineItems" xlink:to="sclx_PrivatePlacementDetailsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PurchaseAgreementAxis" xlink:to="sclx_PurchaseAgreementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SpacTransactionMember" xlink:to="sclx_SpacTransactionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DistributionFeesPercentage" xlink:to="sclx_DistributionFeesPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DistributionToSorrentos" xlink:to="sclx_DistributionToSorrentos_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AdministrativeFacilityMember" xlink:to="sclx_AdministrativeFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_PledgingPurposeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SemnurProductThreeMember" xlink:to="sclx_SemnurProductThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_UnderlyingWarrantValue" xlink:to="sclx_UnderlyingWarrantValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LitigationFees" xlink:to="sclx_LitigationFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember" xlink:to="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RelatedPartyPayable" xlink:to="sclx_RelatedPartyPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ProductDevelopmentAgreementMember" xlink:to="sclx_ProductDevelopmentAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_IndefiniteCarryforwardPeriodMember" xlink:to="sclx_IndefiniteCarryforwardPeriodMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:to="us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" xlink:to="sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LiveActionRightOfUseAssetInPaloAlto" xlink:to="sclx_LiveActionRightOfUseAssetInPaloAlto_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NumberOfSaleUnits" xlink:to="sclx_NumberOfSaleUnits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AssembledWorkforceMember" xlink:to="sclx_AssembledWorkforceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PublicWarrantsMember" xlink:to="sclx_PublicWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AardvarkAssetPurchaseAgreementMember" xlink:to="sclx_AardvarkAssetPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AcquiredLicensesMember" xlink:to="sclx_AcquiredLicensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:to="sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:to="sclx_RoyaltyPaymentPercentageRelatedToFutureYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_EquityPurchaseAgreementMember" xlink:to="sclx_EquityPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange" xlink:to="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SponsorLoan" xlink:to="sclx_SponsorLoan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="sclx_ShareholdersEquityDetailsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_VickersDebtAgreementMember" xlink:to="sclx_VickersDebtAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_BlackScholesOptionPricingMethodMember" xlink:to="sclx_BlackScholesOptionPricingMethodMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PercentageOfPublicShares" xlink:to="sclx_PercentageOfPublicShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SpacTransactionsPolicyTextBlock" xlink:to="sclx_SpacTransactionsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember" xlink:to="sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CommonStockToBeIssued" xlink:to="sclx_CommonStockToBeIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:to="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ReMeasurementOfFairValue" xlink:to="sclx_ReMeasurementOfFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SaleOfWarrants" xlink:to="sclx_SaleOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PurchaseOfStockPercentage" xlink:to="sclx_PurchaseOfStockPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="sclx_CommitmentsAndContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DerivativeWarrantLiabilityPrivateWarrants" xlink:to="sclx_DerivativeWarrantLiabilityPrivateWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AcquisitionOfRightOfUseAsset" xlink:to="sclx_AcquisitionOfRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PrincipalAndNonOperatingExpense" xlink:to="sclx_PrincipalAndNonOperatingExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare" xlink:to="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FrequencyOfPaymentsAxis" xlink:to="sclx_FrequencyOfPaymentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NotesPrincipalIncrease" xlink:to="sclx_NotesPrincipalIncrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SemnurProductOneMember" xlink:to="sclx_SemnurProductOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" xlink:to="sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OtherLoanForgiveness" xlink:to="sclx_OtherLoanForgiveness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SemnurProductFourMember" xlink:to="sclx_SemnurProductFourMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_EffectOfBusinessCombinationInShares" xlink:to="sclx_EffectOfBusinessCombinationInShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperAtCarryingValue" xlink:to="us-gaap_CommercialPaperAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_BusinessCombinationRedeemPercentage" xlink:to="sclx_BusinessCombinationRedeemPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ConvertiblePromissoryNote" xlink:to="sclx_ConvertiblePromissoryNote_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrust" xlink:to="us-gaap_AssetsHeldInTrust_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ScilexPharmaNotesPrincipalIncrease" xlink:to="sclx_ScilexPharmaNotesPrincipalIncrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_TransactionCostsAmount" xlink:to="sclx_TransactionCostsAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfLoansNet" xlink:to="us-gaap_GainLossOnSalesOfLoansNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CommonStockExchangeRatioDescription" xlink:to="sclx_CommonStockExchangeRatioDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xlink:to="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PrivatePlacementWarrantLiabilityAcquired" xlink:to="sclx_PrivatePlacementWarrantLiabilityAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RecapitalizationDuetotheBusinessCombinationShares" xlink:to="sclx_RecapitalizationDuetotheBusinessCombinationShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ReceivableBasisOfGoingForward" xlink:to="sclx_ReceivableBasisOfGoingForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_EquityValue" xlink:to="sclx_EquityValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_AgreementInitialTerm" xlink:to="sclx_AgreementInitialTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DenominatorAbstract0" xlink:to="sclx_DenominatorAbstract0_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PurchaseAgreementMember" xlink:to="sclx_PurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SemnurProductTwoMember" xlink:to="sclx_SemnurProductTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ForfeitureOfPrivateWarrants" xlink:to="sclx_ForfeitureOfPrivateWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DebtExchangeDescriptions" xlink:to="sclx_DebtExchangeDescriptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FairValueMeasurementsValuationProcessesDescription1" xlink:to="sclx_FairValueMeasurementsValuationProcessesDescription1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_LeaseLiabilityNetOfCurrentPortion" xlink:to="sclx_LeaseLiabilityNetOfCurrentPortion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CapitalizationOfShareOutstanding" xlink:to="sclx_CapitalizationOfShareOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_IncreaseDecreaseInAccruedPayroll" xlink:to="sclx_IncreaseDecreaseInAccruedPayroll_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:to="us-gaap_ProductLiabilityContingencyAccrualDiscountRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RepurchasesOfNotes" xlink:to="sclx_RepurchasesOfNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CapitalizedCost" xlink:to="sclx_CapitalizedCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityNetIncome" xlink:to="us-gaap_TemporaryEquityNetIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ReclassificationAmountFromAdditionalPaidInCapital" xlink:to="sclx_ReclassificationAmountFromAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:to="sclx_DeferredTaxAssetsInterestExpenseLimitations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedBorrowingInterestRate" xlink:to="us-gaap_SubordinatedBorrowingInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PromissoryNote" xlink:to="sclx_PromissoryNote_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:to="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ProceedsFromSaleOfCommonStock" xlink:to="sclx_ProceedsFromSaleOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NotePrincipalReductionAmount" xlink:to="sclx_NotePrincipalReductionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_WarrantsDetailsTable" xlink:to="sclx_WarrantsDetailsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xlink:to="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FairValueOfContingentConsideration" xlink:to="sclx_FairValueOfContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:to="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:to="sclx_IncreaseDecreaseInAccruedRebatesAndFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_GrossProceedsOfWarrants" xlink:to="sclx_GrossProceedsOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SecondAmendedCertificateOfIncorporationMember" xlink:to="sclx_SecondAmendedCertificateOfIncorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_DepositIntoTrustAccount" xlink:to="sclx_DepositIntoTrustAccount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ProceedsOfInitialPublicOffering" xlink:to="sclx_ProceedsOfInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NonCancelableLeaseAgreementsMember" xlink:to="sclx_NonCancelableLeaseAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CashPayment" xlink:to="sclx_CashPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember" xlink:to="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FairValueDecrease" xlink:to="sclx_FairValueDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ExclusiveDistributionAgreementMember" xlink:to="sclx_ExclusiveDistributionAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ForgivenAmount" xlink:to="sclx_ForgivenAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OperatingLossCarryforwardsExpirationYear" xlink:to="sclx_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SponsorMember" xlink:to="sclx_SponsorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedDebt" xlink:to="us-gaap_SubordinatedDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:to="sclx_OrdinarySharesSubjectToPossibleRedemption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_MaturityRenewalDescription" xlink:to="sclx_MaturityRenewalDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:to="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_FundingCommitmentLetterMember" xlink:to="sclx_FundingCommitmentLetterMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:to="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" xlink:to="us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NumberOfShares" xlink:to="sclx_NumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_NumeratorAbstract" xlink:to="sclx_NumeratorAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_CashRequirement" xlink:to="sclx_CashRequirement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToAffiliateCurrent" xlink:to="us-gaap_DueToAffiliateCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:to="sclx_ChangeInValuationInputsOrOtherAssumptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayable" xlink:to="us-gaap_NotesAndLoansPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xlink:to="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>sclx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-07T13:28:21.1350+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="sclx-20221231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="sclx-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2" xlink:href="sclx-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement" xlink:href="sclx-20221231.xsd#vcka_r_ConsolidatedIncomeStatement" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow" xlink:href="sclx-20221231.xsd#vcka_r_ConsolidatedCashFlow" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="sclx-20221231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" xlink:href="sclx-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebt" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="sclx_LongTermPortionOfDeferredConsideration" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sclx_AccruedExpenses" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sclx_CurrentPortionOfDeferredConsideration" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBorrowings" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sclx_RelatedPartyPayable" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="16" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LongTermPortionOfDeferredConsideration" xlink:label="sclx_LongTermPortionOfDeferredConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AccruedExpenses" xlink:label="sclx_AccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CurrentPortionOfDeferredConsideration" xlink:label="sclx_CurrentPortionOfDeferredConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyPayable" xlink:label="sclx_RelatedPartyPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" xlink:label="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_CostOfRevenue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingCostsAndExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="sclx_NotesPrincipalIncrease" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="5" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NotesPrincipalIncrease" xlink:label="sclx_NotesPrincipalIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sclx_ProceedsFromTheBusinessCombination" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sclx_IncreaseDecreaseInAccruedPayroll" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sclx_ProceedsFromRepaymentOfLoansToPurchase" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sclx_ForfeituresOfPrivateWarrants" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sclx_NonCashOperatingLeaseCost" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sclx_IncreaseDecreaseInLongTermDeposits" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="11" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent" order="12" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="13" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="15" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="16" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="17" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sclx_OtherLongTermLiabilities" order="18" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="19" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sclx_IncreaseDecreaseInAccruedRebatesAndFees" order="20" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="21" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" order="22" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="23" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="24" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="25" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsFromTheBusinessCombination" xlink:label="sclx_ProceedsFromTheBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:label="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseDecreaseInAccruedPayroll" xlink:label="sclx_IncreaseDecreaseInAccruedPayroll"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:label="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsFromRepaymentOfLoansToPurchase" xlink:label="sclx_ProceedsFromRepaymentOfLoansToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ForfeituresOfPrivateWarrants" xlink:label="sclx_ForfeituresOfPrivateWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" xlink:label="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NonCashOperatingLeaseCost" xlink:label="sclx_NonCashOperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseDecreaseInLongTermDeposits" xlink:label="sclx_IncreaseDecreaseInLongTermDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OtherLongTermLiabilities" xlink:label="sclx_OtherLongTermLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:label="sclx_IncreaseDecreaseInAccruedRebatesAndFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xlink:label="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sclx_DeferredTaxAssetsAccruedExpenseAndReserves" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sclx_DeferredTaxAssetsDebtRelatedInterest" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sclx_DeferredTaxAssetsOperatingLeaseLiabilities" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:label="sclx_DeferredTaxAssetsAccruedExpenseAndReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:label="sclx_DeferredTaxAssetsDebtRelatedInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="sclx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="8" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xlink:label="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:label="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>sclx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-07T13:28:20.9517+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3" xlink:href="sclx-20221231.xsd#vcka_r_ShareholdersEquityType2or3" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails" xlink:href="sclx-20221231.xsd#vcka_r_SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureAcquisitionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails" xlink:href="sclx-20221231.xsd#vcka_r_PublicOfferingDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails" xlink:href="sclx-20221231.xsd#vcka_r_PrivatePlacementDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails" xlink:href="sclx-20221231.xsd#vcka_r_RelatedPartyTransactionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails" xlink:href="sclx-20221231.xsd#vcka_r_WarrantsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable" xlink:href="sclx-20221231.xsd#vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="sclx-20221231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" xlink:href="sclx-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails" xlink:href="sclx-20221231.xsd#vcka_r_ShareholdersEquityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable" xlink:href="sclx-20221231.xsd#vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails" xlink:href="sclx-20221231.xsd#DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" xlink:href="sclx-20221231.xsd#DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="sclx-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoMember" xlink:label="sclx_SorrentoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LegacyCommonStockMember" xlink:label="sclx_LegacyCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectOfBusinessCombinationInValue" xlink:label="sclx_EffectOfBusinessCombinationInValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EffectOfBusinessCombinationInShares" xlink:label="sclx_EffectOfBusinessCombinationInShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RecapitalizationDuetotheBusinessCombinationShares" xlink:label="sclx_RecapitalizationDuetotheBusinessCombinationShares"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RecapitalizationDueToTheBusinessCombinationValue" xlink:label="sclx_RecapitalizationDueToTheBusinessCombinationValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DistributionToSorrentos" xlink:label="sclx_DistributionToSorrentos"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xlink:label="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xlink:label="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xlink:label="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:label="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_SorrentoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sclx_LegacyCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_EffectOfBusinessCombinationInValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_EffectOfBusinessCombinationInShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_RecapitalizationDuetotheBusinessCombinationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_RecapitalizationDueToTheBusinessCombinationValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_DistributionToSorrentos" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumberOfShares" xlink:label="sclx_NumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SpacTransactionMember" xlink:label="sclx_SpacTransactionMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_VickersDebtAgreementMember" xlink:label="sclx_VickersDebtAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FourCustomerMember" xlink:label="sclx_FourCustomerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtExchangeAgreementMember" xlink:label="sclx_DebtExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementWarrantMember" xlink:label="sclx_PrivatePlacementWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregateGrossProceeds" xlink:label="sclx_AggregateGrossProceeds"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LegacyScilexCommonStockMember" xlink:label="sclx_LegacyScilexCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LegacyScilexStockOptionsMember" xlink:label="sclx_LegacyScilexStockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CapitalizedCost" xlink:label="sclx_CapitalizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PercentageOfNetRevenueSoleDistributor" xlink:label="sclx_PercentageOfNetRevenueSoleDistributor"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PercentageOfNetRevenueSoleDistributors" xlink:label="sclx_PercentageOfNetRevenueSoleDistributors"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsOfInitialPublicOffering" xlink:label="sclx_ProceedsOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SaleOfWarrants" xlink:label="sclx_SaleOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_GrossProceedsOfWarrants" xlink:label="sclx_GrossProceedsOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TransactionCostsAmount" xlink:label="sclx_TransactionCostsAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="us-gaap_OtherUnderwritingExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DeferredUnderwritingFees" xlink:label="sclx_DeferredUnderwritingFees"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OtherOfferingCosts" xlink:label="sclx_OtherOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SaleOfStockDescriptionOfTransactions" xlink:label="sclx_SaleOfStockDescriptionOfTransactions"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumberOfBusinessDays" xlink:label="sclx_NumberOfBusinessDays"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PricePerPublicShare" xlink:label="sclx_PricePerPublicShare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NetTangibleAssets" xlink:label="sclx_NetTangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PercentageOfPublicShares" xlink:label="sclx_PercentageOfPublicShares"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_BusinessCombinationRedeemPercentage" xlink:label="sclx_BusinessCombinationRedeemPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DepositIntoTrustAccount" xlink:label="sclx_DepositIntoTrustAccount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InterestExpenses" xlink:label="sclx_InterestExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:label="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ConversionOfCommonStock" xlink:label="sclx_ConversionOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockExchangeRatioDescription" xlink:label="sclx_CommonStockExchangeRatioDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiabilityClassifiedPrivateWarrants" xlink:label="sclx_LiabilityClassifiedPrivateWarrants"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_NumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="sclx_SpacTransactionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_VickersDebtAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sclx_FourCustomerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_DebtExchangeAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sclx_PrivatePlacementWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_AggregateGrossProceeds" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sclx_LegacyScilexCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sclx_LegacyScilexStockOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_CapitalizedCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_PercentageOfNetRevenueSoleDistributor" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_PercentageOfNetRevenueSoleDistributors" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_ProceedsOfInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_SaleOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_GrossProceedsOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_TransactionCostsAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_DeferredUnderwritingFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_OtherOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_SaleOfStockDescriptionOfTransactions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_NumberOfBusinessDays" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_PricePerPublicShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_NetTangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_PercentageOfPublicShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_BusinessCombinationRedeemPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_DepositIntoTrustAccount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_InterestExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_ConversionOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_CommonStockExchangeRatioDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="sclx_LiabilityClassifiedPrivateWarrants" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="sclx_LiquidityAndGoingConcernLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="sclx_LiquidityAndGoingConcernTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WorkingCapital" xlink:label="sclx_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoMember" xlink:label="sclx_SorrentoMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FundingCommitmentLetterMember" xlink:label="sclx_FundingCommitmentLetterMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScilexPharmaNotesMember" xlink:label="sclx_ScilexPharmaNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" xlink:label="us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="sclx_LiquidityAndGoingConcernTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="sclx_WorkingCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_LiquidityAndGoingConcernTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_SorrentoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_FundingCommitmentLetterMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sclx_ScilexPharmaNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_LiquidityAndGoingConcernTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_LiquidityAndGoingConcernTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_LiquidityAndGoingConcernTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_LiquidityAndGoingConcernLineItems" xlink:to="us-gaap_LoansPayable" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="sclx_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="us-gaap_OtherDeferredCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="us-gaap_ExcessStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FounderShares" xlink:label="sclx_FounderShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="sclx_SummaryofSignificantAccountingPoliciesDetailsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherDeferredCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="sclx_FounderShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="sclx_TwoThousandTwentyTwoPromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LicenseAgreementMember" xlink:label="sclx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MergerAgreementMember" xlink:label="sclx_MergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IssuedAndOutstandingCapitalStockMember" xlink:label="sclx_IssuedAndOutstandingCapitalStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurMember" xlink:label="sclx_SemnurMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UpfrontConsiderationForCommonStock" xlink:label="sclx_UpfrontConsiderationForCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoMember" xlink:label="sclx_SorrentoMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RomegLicenseAgreementMember" xlink:label="sclx_RomegLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductOneMember" xlink:label="sclx_SemnurProductOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ExchangeAgreementMember" xlink:label="sclx_ExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CashPayment" xlink:label="sclx_CashPayment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurCashExchangePaymentMember" xlink:label="sclx_SemnurCashExchangePaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductTwoMember" xlink:label="sclx_SemnurProductTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurPharmaceuticalsIncMember" xlink:label="sclx_SemnurPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductThreeMember" xlink:label="sclx_SemnurProductThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SemnurProductFourMember" xlink:label="sclx_SemnurProductFourMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockToBeIssued" xlink:label="sclx_CommonStockToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregateContingentCashConsideration" xlink:label="sclx_AggregateContingentCashConsideration"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AmountDueForNewDrugApplication" xlink:label="sclx_AmountDueForNewDrugApplication"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PaymentUponTheAchievementOfNetSales" xlink:label="sclx_PaymentUponTheAchievementOfNetSales"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CumulativeNetSales" xlink:label="sclx_CumulativeNetSales"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregateGrossProceeds" xlink:label="sclx_AggregateGrossProceeds"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesToBeIssued" xlink:label="sclx_SharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ReclassificationAmountFromAdditionalPaidInCapital" xlink:label="sclx_ReclassificationAmountFromAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare" xlink:label="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange" xlink:label="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice" xlink:label="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Percentageofoutstandingcommonstockheld" xlink:label="sclx_Percentageofoutstandingcommonstockheld"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate" xlink:label="us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Upfrontlicensefee" xlink:label="sclx_Upfrontlicensefee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_Deferredconsiderationliabilities" xlink:label="sclx_Deferredconsiderationliabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="sclx_TwoThousandTwentyTwoPromissoryNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sclx_LicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sclx_MergerAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="sclx_IssuedAndOutstandingCapitalStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="sclx_SemnurMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_UpfrontConsiderationForCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sclx_SorrentoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="sclx_RomegLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sclx_SemnurProductOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sclx_ExchangeAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_CashPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="sclx_SemnurCashExchangePaymentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sclx_SemnurProductTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sclx_SemnurPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sclx_SemnurProductThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sclx_SemnurProductFourMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_CommonStockToBeIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_AggregateContingentCashConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_AmountDueForNewDrugApplication" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_PaymentUponTheAchievementOfNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_CumulativeNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_AggregateGrossProceeds" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_SharesToBeIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_ReclassificationAmountFromAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Percentageofoutstandingcommonstockheld" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SubordinatedBorrowingInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Upfrontlicensefee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsForRoyalties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sclx_Deferredconsiderationliabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="sclx_PublicOfferingDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicOfferingDetailsTable" xlink:label="sclx_PublicOfferingDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NumberOfSaleUnits" xlink:label="sclx_NumberOfSaleUnits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchasePricePerShare" xlink:label="sclx_PurchasePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclx_PublicOfferingDetailsLineItems" xlink:to="sclx_PublicOfferingDetailsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_PublicOfferingDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_PublicOfferingDetailsLineItems" xlink:to="sclx_NumberOfSaleUnits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_PublicOfferingDetailsLineItems" xlink:to="sclx_PurchasePricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_PublicOfferingDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="sclx_PrivatePlacementDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="sclx_PrivatePlacementDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclx_PrivatePlacementDetailsLineItems" xlink:to="sclx_PrivatePlacementDetailsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_PrivatePlacementDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_PrivatePlacementDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="sclx_RelatedPartyTransactionsDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="sclx_RelatedPartyTransactionsDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FounderSharesMember" xlink:label="sclx_FounderSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_aggregatePurchasePrice" xlink:label="sclx_aggregatePurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PromissoryNoteRelatedPartyMember" xlink:label="sclx_PromissoryNoteRelatedPartyMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CapitalizationOfShareOutstanding" xlink:label="sclx_CapitalizationOfShareOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OrdinarySharesIssuedAndOutstanding" xlink:label="sclx_OrdinarySharesIssuedAndOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FundExpenses" xlink:label="sclx_FundExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="us-gaap_DueToAffiliateCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepaidAmount" xlink:label="sclx_RepaidAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="us-gaap_BusinessCombinationControlObtainedDescription"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregatePrincipalAmount" xlink:label="sclx_AggregatePrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:label="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PricePerWarrants" xlink:label="sclx_PricePerWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_RelatedPartyTransactionsDetailsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="sclx_FounderSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_aggregatePurchasePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="sclx_PromissoryNoteRelatedPartyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_CapitalizationOfShareOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_OrdinarySharesIssuedAndOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_FundExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueToAffiliateCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_RepaidAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_BusinessCombinationControlObtainedDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_AggregatePrincipalAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="sclx_PricePerWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AssetsHeldInTrust" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsDetailsLineItems" xlink:label="sclx_WarrantsDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsDetailsTable" xlink:label="sclx_WarrantsDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsOutstandingShares" xlink:label="sclx_WarrantsOutstandingShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicWarrantsRedemptionDescription" xlink:label="sclx_PublicWarrantsRedemptionDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CapitalRaisingDescription" xlink:label="sclx_CapitalRaisingDescription"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclx_WarrantsDetailsLineItems" xlink:to="sclx_WarrantsDetailsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_WarrantsDetailsLineItems" xlink:to="sclx_WarrantsOutstandingShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_WarrantsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_WarrantsDetailsLineItems" xlink:to="sclx_PublicWarrantsRedemptionDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_WarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_WarrantsDetailsLineItems" xlink:to="sclx_CapitalRaisingDescription" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueMeasurementsValuationProcessesDescription1" xlink:label="sclx_FairValueMeasurementsValuationProcessesDescription1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RiskAdjustedNetSalesForecast" xlink:label="sclx_RiskAdjustedNetSalesForecast"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:label="us-gaap_ProductLiabilityContingencyAccrualDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MilestonePayment" xlink:label="sclx_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueOfContingentConsideration" xlink:label="sclx_FairValueOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DerivativeWarrantLiabilityPrivateWarrants" xlink:label="sclx_DerivativeWarrantLiabilityPrivateWarrants"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AssetsHeldInTrust" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="sclx_FairValueMeasurementsValuationProcessesDescription1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="sclx_RiskAdjustedNetSalesForecast" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProductLiabilityContingencyAccrualDiscountRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="sclx_MilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="sclx_FairValueOfContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="sclx_DerivativeWarrantLiabilityPrivateWarrants" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InterestIncomeSecuritiesUSTreasury" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_LiabilitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PatentRightsMember" xlink:label="sclx_PatentRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AssembledWorkforceMember" xlink:label="sclx_AssembledWorkforceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquiredLicensesMember" xlink:label="sclx_AcquiredLicensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_PatentRightsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_AssembledWorkforceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_AcquiredLicensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PatentRightsMember" xlink:label="sclx_PatentRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquiredTechnologyMember" xlink:label="sclx_AcquiredTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AcquiredLicensesMember" xlink:label="sclx_AcquiredLicensesMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AssembledWorkforceMember" xlink:label="sclx_AssembledWorkforceMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_PatentRightsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_AcquiredTechnologyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_AcquiredLicensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sclx_AssembledWorkforceMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="us-gaap_PledgingPurposeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyNotesPayableMember" xlink:label="sclx_RelatedPartyNotesPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="us-gaap_EquityUnitPurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember" xlink:label="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_WSAG" xlink:label="exch_WSAG"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtInstrumentPurcahsePrice" xlink:label="sclx_DebtInstrumentPurcahsePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfLoansNet" xlink:label="us-gaap_GainLossOnSalesOfLoansNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AmendmentNumberFourMember" xlink:label="sclx_AmendmentNumberFourMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ActualCumulativeNetSales" xlink:label="sclx_ActualCumulativeNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" xlink:label="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrincipalAndNonOperatingExpense" xlink:label="sclx_PrincipalAndNonOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncreaseOfPrincipalBalance" xlink:label="sclx_IncreaseOfPrincipalBalance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebt" xlink:label="us-gaap_SubordinatedDebt"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CashRequirement" xlink:label="sclx_CashRequirement"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ForgivenAmount" xlink:label="sclx_ForgivenAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NotePrincipalReductionAmount" xlink:label="sclx_NotePrincipalReductionAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepurchasePrincipalInPercentage" xlink:label="sclx_RepurchasePrincipalInPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepurchaseWithCashOnHand" xlink:label="sclx_RepurchaseWithCashOnHand"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CashReceivedFromParentCompany" xlink:label="sclx_CashReceivedFromParentCompany"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AggregatePrincipalAmount" xlink:label="sclx_AggregatePrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UnrestrictedCash" xlink:label="sclx_UnrestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MinimumCashRequirement" xlink:label="sclx_MinimumCashRequirement"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PromissoryNote" xlink:label="sclx_PromissoryNote"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OutstandingPrincipalAmountPeriod" xlink:label="sclx_OutstandingPrincipalAmountPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FairValueDecrease" xlink:label="sclx_FairValueDecrease"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CarryingValueIncreased" xlink:label="sclx_CarryingValueIncreased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:label="us-gaap_FinancingReceivableRevolvingConvertedToTermLoan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_RelatedPartyNotesPayableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EquityUnitPurchaseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="exch_WSAG" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_DebtInstrumentPurcahsePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_PledgingPurposeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainLossOnSalesOfLoansNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="sclx_AmendmentNumberFourMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_ActualCumulativeNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_PrincipalAndNonOperatingExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_IncreaseOfPrincipalBalance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SubordinatedDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_CashRequirement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_ForgivenAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_NotePrincipalReductionAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_RepurchasePrincipalInPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_RepurchaseWithCashOnHand" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_CashReceivedFromParentCompany" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_AggregatePrincipalAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_UnrestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_MinimumCashRequirement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_PromissoryNote" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_OutstandingPrincipalAmountPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_FairValueDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sclx_CarryingValueIncreased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ShareholdersEquityDetailsLineItems" xlink:label="sclx_ShareholdersEquityDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ShareholdersEquityDetailsTable" xlink:label="sclx_ShareholdersEquityDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantTransferAgreementMember" xlink:label="sclx_WarrantTransferAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantsMember" xlink:label="sclx_WarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoTherapeuticsIncMember" xlink:label="sclx_SorrentoTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SponsorMember" xlink:label="sclx_SponsorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FirstAmendedCertificateOfIncorporationMember" xlink:label="sclx_FirstAmendedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SecondAmendedCertificateOfIncorporationMember" xlink:label="sclx_SecondAmendedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_EquityPurchaseAgreementMember" xlink:label="sclx_EquityPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="sclx_OrdinarySharesSubjectToPossibleRedemption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseOfStockPercentage" xlink:label="sclx_PurchaseOfStockPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_StructuringFees" xlink:label="sclx_StructuringFees"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="sclx_ShareholdersEquityDetailsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_WarrantTransferAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sclx_WarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="sclx_SorrentoTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sclx_SponsorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_FirstAmendedCertificateOfIncorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_SecondAmendedCertificateOfIncorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_EquityPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="sclx_OrdinarySharesSubjectToPossibleRedemption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="sclx_PurchaseOfStockPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_ShareholdersEquityDetailsLineItems" xlink:to="sclx_StructuringFees" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdjustmentsRestatement2Member" xlink:label="sclx_AdjustmentsRestatement2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AsRestatedMember" xlink:label="sclx_AsRestatedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="sclx_AdjustmentsRestatement2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="sclx_AsRestatedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_BlackScholesOptionPricingMethodMember" xlink:label="sclx_BlackScholesOptionPricingMethodMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="sclx_BlackScholesOptionPricingMethodMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="sclx_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScilexPharmaMember" xlink:label="sclx_ScilexPharmaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember" xlink:label="sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandNineteenStockOptionPlanMember" xlink:label="sclx_TwoThousandNineteenStockOptionPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear" xlink:label="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WeightedAveragePeriodOverGrant" xlink:label="sclx_WeightedAveragePeriodOverGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_TwoThousandSeventeenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_ScilexPharmaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_TwoThousandNineteenStockOptionPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sclx_WeightedAveragePeriodOverGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommitmentsAndContingenciesLineItems" xlink:label="sclx_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommitmentsAndContingenciesTable" xlink:label="sclx_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:label="sclx_RoyaltyPaymentPercentageRelatedToFutureYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FrequencyOfPaymentsDomain" xlink:label="sclx_FrequencyOfPaymentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MonthlyMember" xlink:label="sclx_MonthlyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DevelopersMember" xlink:label="sclx_DevelopersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="sclx_ProductDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FrequencyOfPaymentsAxis" xlink:label="sclx_FrequencyOfPaymentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_FrequencyOfPaymentsDomain" xlink:label="sclx_FrequencyOfPaymentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ResearchAndDevelopmentFacilitiesMember" xlink:label="sclx_ResearchAndDevelopmentFacilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_VendorMember" xlink:label="sclx_VendorMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ExclusiveDistributionAgreementMember" xlink:label="sclx_ExclusiveDistributionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdministrativeFacilityMember" xlink:label="sclx_AdministrativeFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AccruedRoyaltyPayables" xlink:label="sclx_AccruedRoyaltyPayables"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProjectAgreementMember" xlink:label="sclx_ProjectAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_NonCancelableLeaseAgreementsMember" xlink:label="sclx_NonCancelableLeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AgreementMaturityDate" xlink:label="sclx_AgreementMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_MaturityRenewalDescription" xlink:label="sclx_MaturityRenewalDescription"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProfitPercentageNet" xlink:label="sclx_ProfitPercentageNet"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DistributionFeesPercentage" xlink:label="sclx_DistributionFeesPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears" xlink:label="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AgreementInitialTerm" xlink:label="sclx_AgreementInitialTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_RoyaltyPaymentPercentageRelatedToFutureYears" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_FrequencyOfPaymentsDomain" xlink:to="sclx_MonthlyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_DevelopersMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_ProductDevelopmentAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sclx_FrequencyOfPaymentsAxis" xlink:to="sclx_FrequencyOfPaymentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sclx_FrequencyOfPaymentsAxis" xlink:to="sclx_FrequencyOfPaymentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sclx_ResearchAndDevelopmentFacilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_VendorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_ExclusiveDistributionAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sclx_AdministrativeFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_AccruedRoyaltyPayables" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_ProjectAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sclx_NonCancelableLeaseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="sclx_FrequencyOfPaymentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_AgreementMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_MaturityRenewalDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_ProfitPercentageNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_DistributionFeesPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="sclx_AgreementInitialTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ProfessionalFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="sclx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IncomeTaxDisclosureTable" xlink:label="sclx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IndefiniteCarryforwardPeriodMember" xlink:label="sclx_IndefiniteCarryforwardPeriodMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember" xlink:label="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="sclx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_TaxCreditCarryForwardsExpirationYear" xlink:label="sclx_TaxCreditCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="sclx_IncomeTaxDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sclx_IndefiniteCarryforwardPeriodMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sclx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="sclx_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="sclx_TaxCreditCarryForwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AardvarkAssetPurchaseAgreementMember" xlink:label="sclx_AardvarkAssetPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_IssuedAndOutstandingCapitalStockMember" xlink:label="sclx_IssuedAndOutstandingCapitalStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScilexPharmaMember" xlink:label="sclx_ScilexPharmaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SorrentoMember" xlink:label="sclx_SorrentoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtExchangeAgreementMember" xlink:label="sclx_DebtExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ItochuMember" xlink:label="sclx_ItochuMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsShareBasedCompensationCash" xlink:label="us-gaap_DividendsShareBasedCompensationCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SharesAcquired" xlink:label="sclx_SharesAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryPurchasedGoods" xlink:label="us-gaap_OtherInventoryPurchasedGoods"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_OutstandingCapitalStockPercent" xlink:label="sclx_OutstandingCapitalStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansPayable" xlink:label="us-gaap_NotesAndLoansPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfNotesReceivable" xlink:label="us-gaap_ProceedsFromSaleOfNotesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyPayable" xlink:label="sclx_RelatedPartyPayable"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WorkingCapital" xlink:label="sclx_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RepurchasesOfNotes" xlink:label="sclx_RepurchasesOfNotes"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_LitigationFees" xlink:label="sclx_LitigationFees"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_RelatedPartyReceivable" xlink:label="sclx_RelatedPartyReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_DebtExchangeDescriptions" xlink:label="sclx_DebtExchangeDescriptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAverageAmountOutstanding" xlink:label="us-gaap_LongTermDebtAverageAmountOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_FinancingReceivableNonaccrualToOutstandingPercent" xlink:label="srt_FinancingReceivableNonaccrualToOutstandingPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_AardvarkAssetPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="sclx_IssuedAndOutstandingCapitalStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sclx_ScilexPharmaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sclx_SorrentoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sclx_DebtExchangeAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sclx_ItochuMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DividendsShareBasedCompensationCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_SharesAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherInventoryPurchasedGoods" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_OutstandingCapitalStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NotesAndLoansPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NotesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromSaleOfNotesReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_RelatedPartyPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_WorkingCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_RepurchasesOfNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_LitigationFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_RelatedPartyReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="sclx_DebtExchangeDescriptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermDebtAverageAmountOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="srt_FinancingReceivableNonaccrualToOutstandingPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PublicWarrantsMember" xlink:label="sclx_PublicWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_StockOptionsMember" xlink:label="sclx_StockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PrivateWarrantsMember" xlink:label="sclx_PrivateWarrantsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sclx_PublicWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sclx_StockOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sclx_PrivateWarrantsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseAgreementDomain" xlink:label="sclx_PurchaseAgreementDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseAgreementMember" xlink:label="sclx_PurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ScintillaPharmaceuticalsMember" xlink:label="sclx_ScintillaPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InducementPlanDomain" xlink:label="sclx_InducementPlanDomain"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InducementPlanMember" xlink:label="sclx_InducementPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InducementPlanAxis" xlink:label="sclx_InducementPlanAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_InducementPlanDomain" xlink:label="sclx_InducementPlanDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseAgreementAxis" xlink:label="sclx_PurchaseAgreementAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_PurchaseAgreementDomain" xlink:label="sclx_PurchaseAgreementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_BRileyPurchaseAgreementMember" xlink:label="sclx_BRileyPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="sclx_ARYorkvillePurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_CommonStockSold" xlink:label="sclx_CommonStockSold"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="sclx_ProceedsFromSaleOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_SponsorLoan" xlink:label="sclx_SponsorLoan"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ReceivableBasisOfGoingForward" xlink:label="sclx_ReceivableBasisOfGoingForward"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_WarrantExercisePrice" xlink:label="sclx_WarrantExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_AdditionalPrincipalAmount" xlink:label="sclx_AdditionalPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="sclx-20221231.xsd#sclx_ConvertiblePromissoryNote" xlink:label="sclx_ConvertiblePromissoryNote"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_PurchaseAgreementDomain" xlink:to="sclx_PurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sclx_ScintillaPharmaceuticalsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_InducementPlanDomain" xlink:to="sclx_InducementPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sclx_InducementPlanAxis" xlink:to="sclx_InducementPlanDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sclx_InducementPlanAxis" xlink:to="sclx_InducementPlanDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sclx_PurchaseAgreementAxis" xlink:to="sclx_PurchaseAgreementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sclx_PurchaseAgreementAxis" xlink:to="sclx_PurchaseAgreementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_PurchaseAgreementDomain" xlink:to="sclx_BRileyPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="sclx_PurchaseAgreementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sclx_PurchaseAgreementDomain" xlink:to="sclx_ARYorkvillePurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="sclx_InducementPlanAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_CommonStockSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_ProceedsFromSaleOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_SponsorLoan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_ReceivableBasisOfGoingForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_WarrantExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_AdditionalPrincipalAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sclx_ConvertiblePromissoryNote" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>27
<FILENAME>sclx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-07T13:28:22.2124+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.scilexholding.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:sclx="http://www.scilexholding.com/20221231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" namespace="http://xbrl.sec.gov/exch/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" namespace="http://fasb.org/us-gaap-sup/2022q3"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sclx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sclx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sclx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sclx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails2" id="DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2" id="DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2">
        <link:definition>100030 - Disclosure - Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals" id="vcka_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>100040 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement" id="vcka_r_ConsolidatedIncomeStatement">
        <link:definition>100050 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3" id="vcka_r_ShareholdersEquityType2or3">
        <link:definition>100060 - Statement - Statements of Changes in Shareholders' (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow" id="vcka_r_ConsolidatedCashFlow">
        <link:definition>100070 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentation" id="DisclosureNatureOfOperationsAndBasisOfPresentation">
        <link:definition>100080 - Disclosure - Nature of Operations and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcern" id="DisclosureLiquidityAndGoingConcern">
        <link:definition>100090 - Disclosure - Liquidity and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>100100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPolicies" id="vcka_r_SummaryofSignificantAccountingPolicies">
        <link:definition>100110 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOffering" id="vcka_r_PublicOffering">
        <link:definition>100120 - Disclosure - Public Offering</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacement" id="vcka_r_PrivatePlacement">
        <link:definition>100130 - Disclosure - Private Placement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactions" id="vcka_r_RelatedPartyTransactions">
        <link:definition>100140 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingencies" id="vcka_r_CommitmentsandContingencies">
        <link:definition>100150 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquity" id="vcka_r_ShareholdersEquity">
        <link:definition>100170 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_Warrants" id="vcka_r_Warrants">
        <link:definition>100180 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitions" id="DisclosureAcquisitions">
        <link:definition>100190 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurements" id="vcka_r_FairValueMeasurements">
        <link:definition>100200 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" id="DisclosureGoodwillAndIntangibleAssets">
        <link:definition>100210 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>100220 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlans" id="DisclosureStockIncentiveAndEmployeeBenefitPlans">
        <link:definition>100230 - Disclosure - Stock Incentive and Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatements" id="vcka_r_RestatementofPreviouslyIssuedFinancialStatements">
        <link:definition>100240 - Disclosure - Restatement of Previously Issued Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShare" id="DisclosureLossPerShare">
        <link:definition>100250 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SubsequentEvents" id="vcka_r_SubsequentEvents">
        <link:definition>100260 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies" id="DisclosureNatureOfOperationsAndBasisOfPresentationPolicies">
        <link:definition>100270 - Disclosure - Nature of Operations and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesTables" id="vcka_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables" id="vcka_r_FairValueMeasurementsTables">
        <link:definition>100290 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>100300 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" id="DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>100310 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>100320 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansTables" id="DisclosureStockIncentiveAndEmployeeBenefitPlansTables">
        <link:definition>100330 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100340 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100350 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareTables" id="DisclosureLossPerShareTables">
        <link:definition>100360 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatementsTables" id="vcka_r_RestatementofPreviouslyIssuedFinancialStatementsTables">
        <link:definition>100370 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" id="DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Nature of Operations and Basis of Presentation (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" id="DisclosureLiquidityAndGoingConcernAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Liquidity and Going Concern (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails" id="vcka_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofcondensedbalancesheetsTable" id="vcka_r_ScheduleofcondensedbalancesheetsTable">
        <link:definition>100410 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of condensed balance sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable" id="vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable">
        <link:definition>100420 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of the calculation of basic and diluted net income per ordinary share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails" id="DisclosureAcquisitionsAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Acquisitions (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails" id="vcka_r_PublicOfferingDetails">
        <link:definition>100440 - Disclosure - Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails" id="vcka_r_PrivatePlacementDetails">
        <link:definition>100450 - Disclosure - Private Placement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails" id="vcka_r_RelatedPartyTransactionsDetails">
        <link:definition>100460 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingenciesDetails" id="vcka_r_CommitmentsandContingenciesDetails">
        <link:definition>100470 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails" id="vcka_r_WarrantsDetails">
        <link:definition>100480 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Fair Value Measurements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable" id="vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable">
        <link:definition>100500 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable" id="vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable">
        <link:definition>100510 - Disclosure - Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3" id="DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3">
        <link:definition>100520 - Disclosure - Fair Value Measurements (Details) - Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable" id="vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable">
        <link:definition>100530 - Disclosure - Fair Value Measurements  (Details) - Schedule of derivative component of the obligation is initially valued and classified as a derivative liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable" id="vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable">
        <link:definition>100540 - Disclosure - Fair Value Measurements  (Details) - Schedule of change in the fair value of conversion option liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100550 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Property and Equipment (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" id="DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails">
        <link:definition>100580 - Disclosure - Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" id="DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails">
        <link:definition>100590 - Disclosure - Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="DisclosureDebtAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Debt (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails" id="DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails">
        <link:definition>100610 - Disclosure - Debt - Summary of borrowings of the scilex notes consisted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails" id="vcka_r_ShareholdersEquityDetails">
        <link:definition>100620 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatementsDetails" id="vcka_r_RestatementofPreviouslyIssuedFinancialStatementsDetails">
        <link:definition>100630 - Disclosure - Restatement of Previously Issued Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable" id="vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable">
        <link:definition>100640 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails" id="DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails">
        <link:definition>100650 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Valuation Assumption Used (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" id="DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails">
        <link:definition>100660 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" id="DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>100670 - Disclosure - Stock Incentive and Employee Benefit Plans (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetails">
        <link:definition>100680 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails">
        <link:definition>100690 - Disclosure - Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>100700 - Disclosure - Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails">
        <link:definition>100720 - Disclosure - Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails">
        <link:definition>100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100740 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" id="DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>100750 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100760 - Disclosure - Income Taxes (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100770 - Disclosure - Related Party Transactions (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails" id="DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails">
        <link:definition>100780 - Disclosure - Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" id="DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails">
        <link:definition>100790 - Disclosure - Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails" id="DisclosureLossPerShareAdditionalInformationDetails">
        <link:definition>100800 - Disclosure - Loss Per Share (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100810 - Disclosure - Subsequent Events (Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sclx_DenominatorAbstract" name="DenominatorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_LessAbstract" name="LessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_NumeratorAbstract" name="NumeratorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PlusAbstract" name="PlusAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PrivatePlacementDisclosureTextblockAbstract" name="PrivatePlacementDisclosureTextblockAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ProposedPublicOfferingAbstract" name="ProposedPublicOfferingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ScheduleOfCondensedBalanceSheetsAbstract" name="ScheduleOfCondensedBalanceSheetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" name="ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract" name="ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract" name="ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_FrequencyOfPaymentsAxis" name="FrequencyOfPaymentsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_InducementPlanAxis" name="InducementPlanAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PurchaseAgreementAxis" name="PurchaseAgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination" name="AccrualForTransactionCostsRelatedToTheBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_AccruedExpenses" name="AccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_AccruedRoyaltyPayables" name="AccruedRoyaltyPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" name="AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_AcquisitionOfRightOfUseAsset" name="AcquisitionOfRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_ActualCumulativeNetSales" name="ActualCumulativeNetSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_AdditionalPrincipalAmount" name="AdditionalPrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" name="Adjustmenttoadditionalpaidincapitaldiscountamortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" name="AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" name="AdjustmentToSharesIssuedInSemnurAcquisitionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_AggregateContingentCashConsideration" name="AggregateContingentCashConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_AggregateGrossProceeds" name="AggregateGrossProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_AggregatePrincipalAmount" name="AggregatePrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_aggregatePurchasePrice" name="aggregatePurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_AgreementInitialTerm" name="AgreementInitialTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_AgreementMaturityDate" name="AgreementMaturityDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_AmountDueForNewDrugApplication" name="AmountDueForNewDrugApplication" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears" name="AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare" name="Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange" name="Assetacquisitionequityinterestissuedorissuableperiodofshareexchange" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned" name="Assetacquisitionequityinterestissuedorissuablevalueassigned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare" name="Assetacquisitionequityinterestissuedorissuablevalueassignedpershare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice" name="Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_BusinessCombinationRedeemPercentage" name="BusinessCombinationRedeemPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_CallOptionValue" name="CallOptionValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_CapitalizationOfShareOutstanding" name="CapitalizationOfShareOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_CapitalizedCost" name="CapitalizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_CapitalRaisingDescription" name="CapitalRaisingDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_CarryingValueIncreased" name="CarryingValueIncreased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_CashPayment" name="CashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_CashReceivedFromParentCompany" name="CashReceivedFromParentCompany" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_CashRequirement" name="CashRequirement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_ChangeInValuationInputsOrOtherAssumptions" name="ChangeInValuationInputsOrOtherAssumptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear" name="CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_CommonStockExchangeRatioDescription" name="CommonStockExchangeRatioDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_CommonStockSold" name="CommonStockSold" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_CommonStockToBeIssued" name="CommonStockToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_ConversionOfCommonStock" name="ConversionOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_ConvertiblePromissoryNote" name="ConvertiblePromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_CumulativeNetSales" name="CumulativeNetSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_CurrentPortionOfDeferredConsideration" name="CurrentPortionOfDeferredConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_DebtExchangeDescriptions" name="DebtExchangeDescriptions" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_DebtInstrumentPurcahsePrice" name="DebtInstrumentPurcahsePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" name="DeferredConsiderationForRomegIntangibleAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_Deferredconsiderationliabilities" name="Deferredconsiderationliabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_DeferredTaxAssetsAccruedExpenseAndReserves" name="DeferredTaxAssetsAccruedExpenseAndReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_DeferredTaxAssetsDebtRelatedInterest" name="DeferredTaxAssetsDebtRelatedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_DeferredTaxAssetsInterestExpenseLimitations" name="DeferredTaxAssetsInterestExpenseLimitations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles" name="DeferredTaxLiabilitiesAmortizationOfIntangibles" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_DeferredUnderwritingFeePayable" name="DeferredUnderwritingFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_DeferredUnderwritingFees" name="DeferredUnderwritingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_DenominatorAbstract0" name="DenominatorAbstract0" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_DepositIntoTrustAccount" name="DepositIntoTrustAccount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_Derivativeliabilityatfairvalueadditions" name="Derivativeliabilityatfairvalueadditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_DerivativeWarrantLiabilityPrivateWarrants" name="DerivativeWarrantLiabilityPrivateWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_DistributionFeesPercentage" name="DistributionFeesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_DistributionToSorrentos" name="DistributionToSorrentos" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" name="EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_EffectOfBusinessCombinationInShares" name="EffectOfBusinessCombinationInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_EffectOfBusinessCombinationInValue" name="EffectOfBusinessCombinationInValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_EffectOfDilutiveSecurities" name="EffectOfDilutiveSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_EquityValue" name="EquityValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" name="EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" name="FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_FairValueDecrease" name="FairValueDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_FairValueMeasurementStrikePrice" name="FairValueMeasurementStrikePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_FairValueMeasurementsValuationProcessesDescription1" name="FairValueMeasurementsValuationProcessesDescription1" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_FairValueOfContingentConsideration" name="FairValueOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_FairValueOfWarrantsinDollars" name="FairValueOfWarrantsinDollars" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_ForfeitureOfPrivateWarrants" name="ForfeitureOfPrivateWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_ForfeituresOfPrivateWarrants" name="ForfeituresOfPrivateWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_ForgivenAmount" name="ForgivenAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_FounderShares" name="FounderShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_FundExpenses" name="FundExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_GrossProceeds" name="GrossProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_GrossProceedsOfWarrants" name="GrossProceedsOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_HoldingPeriod" name="HoldingPeriod" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" name="IncomeTaxReconciliationAcquisitionRelatedCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_IncreaseDecreaseInAccruedPayroll" name="IncreaseDecreaseInAccruedPayroll" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_IncreaseDecreaseInAccruedRebatesAndFees" name="IncreaseDecreaseInAccruedRebatesAndFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_IncreaseDecreaseInLongTermDeposits" name="IncreaseDecreaseInLongTermDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_IncreaseOfPrincipalBalance" name="IncreaseOfPrincipalBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_InterestExpenses" name="InterestExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement" name="IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_LeaseLiabilityNetOfCurrentPortion" name="LeaseLiabilityNetOfCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_LiabilityClassifiedPrivateWarrants" name="LiabilityClassifiedPrivateWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_LitigationFees" name="LitigationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_LiveActionRightOfUseAssetInPaloAlto" name="LiveActionRightOfUseAssetInPaloAlto" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_LoanDerivativeLiability" name="LoanDerivativeLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_LongTermPortionOfDeferredConsideration" name="LongTermPortionOfDeferredConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_MaturityRenewalDescription" name="MaturityRenewalDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_MinimumCashRequirement" name="MinimumCashRequirement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_NetTangibleAssets" name="NetTangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_NonCashConsiderationInSemnurAcquisition" name="NonCashConsiderationInSemnurAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_NonCashDistributionToSorrento" name="NonCashDistributionToSorrento" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_NonCashOperatingLeaseCost" name="NonCashOperatingLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_NotePrincipalReductionAmount" name="NotePrincipalReductionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_NotesPrincipalIncrease" name="NotesPrincipalIncrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_NumberOfBusinessDays" name="NumberOfBusinessDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_NumberOfSaleUnits" name="NumberOfSaleUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_NumberOfShares" name="NumberOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_OfferingCostIncludedInAccruedOfferingCost" name="OfferingCostIncludedInAccruedOfferingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_OrdinarySharesIssuanceCost" name="OrdinarySharesIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_OrdinarySharesIssuedAndOutstanding" name="OrdinarySharesIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_OrdinarySharesSubjectToPossibleRedemption" name="OrdinarySharesSubjectToPossibleRedemption" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_OtherLoanForgiveness" name="OtherLoanForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_OtherLongTermLiabilities" name="OtherLongTermLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_OtherOfferingCosts" name="OtherOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_OutstandingCapitalStockPercent" name="OutstandingCapitalStockPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_OutstandingPrincipalAmountPeriod" name="OutstandingPrincipalAmountPeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" name="PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_PaymentUponTheAchievementOfNetSales" name="PaymentUponTheAchievementOfNetSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_PercentageOfNetRevenueSoleDistributor" name="PercentageOfNetRevenueSoleDistributor" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PercentageOfNetRevenueSoleDistributors" name="PercentageOfNetRevenueSoleDistributors" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_Percentageofoutstandingcommonstockheld" name="Percentageofoutstandingcommonstockheld" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PercentageOfPublicShares" name="PercentageOfPublicShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PricePerPublicShare" name="PricePerPublicShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PricePerWarrants" name="PricePerWarrants" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PrincipalAndNonOperatingExpense" name="PrincipalAndNonOperatingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_PrivatePlacementWarrantLiabilityAcquired" name="PrivatePlacementWarrantLiabilityAcquired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_ProceedsFromRepaymentOfLoansToPurchase" name="ProceedsFromRepaymentOfLoansToPurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_ProceedsFromSaleOfCommonStock" name="ProceedsFromSaleOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_ProceedsFromTheBusinessCombination" name="ProceedsFromTheBusinessCombination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_ProceedsOfInitialPublicOffering" name="ProceedsOfInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_ProfitPercentageNet" name="ProfitPercentageNet" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PromissoryNote" name="PromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" name="PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_PublicWarrantsRedemptionDescription" name="PublicWarrantsRedemptionDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PurchaseOfStockPercentage" name="PurchaseOfStockPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PurchasePricePerShare" name="PurchasePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_RecapitalizationDuetotheBusinessCombinationShares" name="RecapitalizationDuetotheBusinessCombinationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_RecapitalizationDueToTheBusinessCombinationValue" name="RecapitalizationDueToTheBusinessCombinationValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_ReceivableBasisOfGoingForward" name="ReceivableBasisOfGoingForward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_ReclassificationAmountFromAdditionalPaidInCapital" name="ReclassificationAmountFromAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" name="RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_RelatedPartyPayable" name="RelatedPartyPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_RelatedPartyReceivable" name="RelatedPartyReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_ReMeasurementOfFairValue" name="ReMeasurementOfFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_RepaidAmount" name="RepaidAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" name="RepaymentOfPrincipalOnTheScilexPharmaNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_RepurchasePrincipalInPercentage" name="RepurchasePrincipalInPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_RepurchasesOfNotes" name="RepurchasesOfNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_RepurchaseWithCashOnHand" name="RepurchaseWithCashOnHand" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_RiskAdjustedNetSalesForecast" name="RiskAdjustedNetSalesForecast" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_RoyaltyPaymentPercentageRelatedToFutureYears" name="RoyaltyPaymentPercentageRelatedToFutureYears" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_SaleOfStockDescriptionOfTransactions" name="SaleOfStockDescriptionOfTransactions" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_SaleOfWarrants" name="SaleOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_ScilexPharmaNotesPrincipalIncrease" name="ScilexPharmaNotesPrincipalIncrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_SharesAcquired" name="SharesAcquired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" name="SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" name="SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_SharesSubjectToPossibleRedemption" name="SharesSubjectToPossibleRedemption" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_SharesToBeIssued" name="SharesToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_SponsorLoan" name="SponsorLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_StructuringFees" name="StructuringFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_TaxCreditCarryForwardsExpirationYear" name="TaxCreditCarryForwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_TransactionCostsAmount" name="TransactionCostsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_TransactionCostsObligationAssumedBySorrento" name="TransactionCostsObligationAssumedBySorrento" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" name="TransactionCostsPaidRelatedToTheRecapitalizationTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_UnderlyingWarrantValue" name="UnderlyingWarrantValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_UnrestrictedCash" name="UnrestrictedCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_UpfrontConsiderationForCommonStock" name="UpfrontConsiderationForCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sclx_Upfrontlicensefee" name="Upfrontlicensefee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_WarrantExercisePrice" name="WarrantExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_WarrantsOutstandingShares" name="WarrantsOutstandingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sclx_WeightedAveragePeriodOverGrant" name="WeightedAveragePeriodOverGrant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_WorkingCapital" name="WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sclx_FrequencyOfPaymentsDomain" name="FrequencyOfPaymentsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_InducementPlanDomain" name="InducementPlanDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PurchaseAgreementDomain" name="PurchaseAgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" name="DescriptionofOrganizationandBusinessOperationsDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_LiquidityAndGoingConcernLineItems" name="LiquidityAndGoingConcernLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PrivatePlacementDetailsLineItems" name="PrivatePlacementDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PublicOfferingDetailsLineItems" name="PublicOfferingDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_RelatedPartyTransactionsDetailsLineItems" name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ShareholdersEquityDetailsLineItems" name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_WarrantsDetailsLineItems" name="WarrantsDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_AardvarkAssetPurchaseAgreementMember" name="AardvarkAssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_AcquiredLicensesMember" name="AcquiredLicensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_AcquiredTechnologyMember" name="AcquiredTechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_AdjustmentsRestatement2Member" name="AdjustmentsRestatement2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_AdministrativeFacilityMember" name="AdministrativeFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_AmendmentNumberFourMember" name="AmendmentNumberFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ARYorkvillePurchaseAgreementMember" name="ARYorkvillePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_AsRestatedMember" name="AsRestatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_AssembledWorkforceMember" name="AssembledWorkforceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_BlackScholesOptionPricingMethodMember" name="BlackScholesOptionPricingMethodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_BRileyPurchaseAgreementMember" name="BRileyPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_DebtExchangeAgreementMember" name="DebtExchangeAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_DevelopersMember" name="DevelopersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_EquityPurchaseAgreementMember" name="EquityPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ExchangeAgreementMember" name="ExchangeAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ExclusiveDistributionAgreementMember" name="ExclusiveDistributionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_FirstAmendedCertificateOfIncorporationMember" name="FirstAmendedCertificateOfIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_FounderSharesMember" name="FounderSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_FourCustomerMember" name="FourCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_FundingCommitmentLetterMember" name="FundingCommitmentLetterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_IndefiniteCarryforwardPeriodMember" name="IndefiniteCarryforwardPeriodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_InducementPlanMember" name="InducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_IssuedAndOutstandingCapitalStockMember" name="IssuedAndOutstandingCapitalStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ItochuMember" name="ItochuMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_LegacyCommonStockMember" name="LegacyCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_LegacyScilexCommonStockMember" name="LegacyScilexCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_LegacyScilexStockOptionsMember" name="LegacyScilexStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_MergerAgreementMember" name="MergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_MonthlyMember" name="MonthlyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_NonCancelableLeaseAgreementsMember" name="NonCancelableLeaseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PatentRightsMember" name="PatentRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PrivatePlacementWarrantMember" name="PrivatePlacementWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PrivateWarrantsMember" name="PrivateWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ProductDevelopmentAgreementMember" name="ProductDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ProjectAgreementMember" name="ProjectAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PromissoryNoteRelatedPartyMember" name="PromissoryNoteRelatedPartyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PublicWarrantsMember" name="PublicWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PurchaseAgreementMember" name="PurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_RelatedPartyNotesPayableMember" name="RelatedPartyNotesPayableMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember" name="ResearchAndDevelopmentAndOrphanDrugCreditsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ResearchAndDevelopmentFacilitiesMember" name="ResearchAndDevelopmentFacilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_RomegLicenseAgreementMember" name="RomegLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ScilexPharmaMember" name="ScilexPharmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ScilexPharmaNotesMember" name="ScilexPharmaNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ScintillaPharmaceuticalsMember" name="ScintillaPharmaceuticalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SecondAmendedCertificateOfIncorporationMember" name="SecondAmendedCertificateOfIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SemnurCashExchangePaymentMember" name="SemnurCashExchangePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SemnurMember" name="SemnurMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SemnurPharmaceuticalsIncMember" name="SemnurPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SemnurProductFourMember" name="SemnurProductFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SemnurProductOneMember" name="SemnurProductOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SemnurProductThreeMember" name="SemnurProductThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SemnurProductTwoMember" name="SemnurProductTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember" name="SeniorSecuredNotesDueTwoThousandTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SorrentoMember" name="SorrentoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SorrentoTherapeuticsIncMember" name="SorrentoTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SpacTransactionMember" name="SpacTransactionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SponsorMember" name="SponsorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_StockOptionsMember" name="StockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_TwoThousandNineteenStockOptionPlanMember" name="TwoThousandNineteenStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_TwoThousandSeventeenEquityIncentivePlanMember" name="TwoThousandSeventeenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" name="TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" name="TwoThousandTwentyTwoEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_TwoThousandTwentyTwoPromissoryNoteMember" name="TwoThousandTwentyTwoPromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember" name="UnvestedEmployeeAndNonEmployeeStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_VendorMember" name="VendorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_VickersDebtAgreementMember" name="VickersDebtAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_WarrantsMember" name="WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_WarrantTransferAgreementMember" name="WarrantTransferAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" name="DescriptionofOrganizationandBusinessOperationsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_LiquidityAndGoingConcernTable" name="LiquidityAndGoingConcernTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PrivatePlacementDetailsTable" name="PrivatePlacementDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_PublicOfferingDetailsTable" name="PublicOfferingDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_RelatedPartyTransactionsDetailsTable" name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_ShareholdersEquityDetailsTable" name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_SummaryofSignificantAccountingPoliciesDetailsTable" name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_WarrantsDetailsTable" name="WarrantsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock" name="OrganisationAndPrincipalActivitiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PrivatePlacementDisclosureTextblock" name="PrivatePlacementDisclosureTextblock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_ProposedPublicOfferingTextBlock" name="ProposedPublicOfferingTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" name="PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sclx_SpacTransactionsPolicyTextBlock" name="SpacTransactionsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659325998976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 03, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Scilex Holding Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">92-1062542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">960 San Antonio Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">516-4310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SCLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,800,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001820190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant&#8217;s fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659325083552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,184<span></span>
</td>
<td class="nump">$ 4,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">21,236<span></span>
</td>
<td class="nump">14,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">2,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">4,810<span></span>
</td>
<td class="nump">1,835<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">29,608<span></span>
</td>
<td class="nump">23,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">772<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">1,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">40,591<span></span>
</td>
<td class="nump">38,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,481<span></span>
</td>
<td class="nump">13,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment', window );">Other long term assets</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">86,527<span></span>
</td>
<td class="nump">77,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,450<span></span>
</td>
<td class="nump">4,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">3,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued rebates and fees</a></td>
<td class="nump">30,893<span></span>
</td>
<td class="nump">7,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">3,136<span></span>
</td>
<td class="nump">3,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CurrentPortionOfDeferredConsideration', window );">Current portion of deferred consideration</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current portion of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyPayable', window );">Related party payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">92,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related party note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">44,842<span></span>
</td>
<td class="nump">169,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongTermPortionOfDeferredConsideration', window );">Long-term portion of deferred consideration</a></td>
<td class="nump">3,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Related party note payable, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">35,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">665<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">50,288<span></span>
</td>
<td class="nump">301,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 45,000,000 shares authorized; 29,057,097 and 0 issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 740,000,000 shares authorized; 141,348,856 and 132,858,484 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">412,136<span></span>
</td>
<td class="nump">128,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(375,914)<span></span>
</td>
<td class="num">(352,550)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="nump">36,239<span></span>
</td>
<td class="num">(223,876)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 86,527<span></span>
</td>
<td class="nump">$ 77,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CurrentPortionOfDeferredConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of deferred consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CurrentPortionOfDeferredConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongTermPortionOfDeferredConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term portion of deferred consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongTermPortionOfDeferredConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659325892720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">740,000,000<span></span>
</td>
<td class="nump">740,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">141,348,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,858,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">141,348,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,858,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659318703584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="nump">$ 38,034<span></span>
</td>
<td class="nump">$ 31,317<span></span>
</td>
<td class="nump">$ 23,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">10,797<span></span>
</td>
<td class="nump">3,634<span></span>
</td>
<td class="nump">2,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,054<span></span>
</td>
<td class="nump">9,201<span></span>
</td>
<td class="nump">9,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">64,895<span></span>
</td>
<td class="nump">50,582<span></span>
</td>
<td class="nump">42,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization</a></td>
<td class="nump">3,922<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">88,668<span></span>
</td>
<td class="nump">67,155<span></span>
</td>
<td class="nump">58,818<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(50,634)<span></span>
</td>
<td class="num">(35,838)<span></span>
</td>
<td class="num">(35,258)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on derivative liability</a></td>
<td class="num">(8,310)<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on debt extinguishment, net</a></td>
<td class="num">(28,634)<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NotesPrincipalIncrease', window );">Scilex Pharma Notes principal increase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">9,604<span></span>
</td>
<td class="nump">11,764<span></span>
</td>
<td class="nump">13,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Loss (gain) on foreign currency exchange</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expense</a></td>
<td class="num">(27,274)<span></span>
</td>
<td class="nump">52,581<span></span>
</td>
<td class="nump">12,314<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(23,360)<span></span>
</td>
<td class="num">(88,419)<span></span>
</td>
<td class="num">(47,572)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,364)<span></span>
</td>
<td class="num">$ (88,424)<span></span>
</td>
<td class="num">$ (47,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - basic</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted Average Number of Shares Outstanding, Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares during the period-basic</a></td>
<td class="nump">134,226<span></span>
</td>
<td class="nump">132,858<span></span>
</td>
<td class="nump">132,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares during the period -diluted</a></td>
<td class="nump">134,226<span></span>
</td>
<td class="nump">132,858<span></span>
</td>
<td class="nump">132,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NotesPrincipalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes principal increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NotesPrincipalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659316696896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Shareholders' (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Sorrento</div></th>
<th class="th"><div>Legacy Common Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Preferred Stock Member</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Sorrento</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Sorrento</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">$ (90,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 126,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (216,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,310<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (In Shares)</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised value</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">5,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DistributionToSorrentos', window );">Distribution to sorrentos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Cancellation of ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(47,519)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,519)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">$ (141,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (In Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 5,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue', window );">Adjustment to shares issued in Semnur Acquisition</a></td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(88,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">$ (223,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">128,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(352,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (In Shares)</a></td>
<td class="nump">202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised value</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">5,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Shares issued pursuant to the terms of the Debt Exchange Agreement, (In shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,906<span></span>
</td>
<td class="nump">29,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Shares issued pursuant to the terms of the Debt Exchange Agreement</a></td>
<td class="nump">289,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">289,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued as a result of the Business Combination, net of transaction activities (In Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Shares issued as a result of the Business Combination, net of transaction activities</a></td>
<td class="num">(8,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue', window );">Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value</a></td>
<td class="num">(4,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization', window );">Aardvark SP-104 discount amortization</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares', window );">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement', window );">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(23,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 36,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 412,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (375,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,349<span></span>
</td>
<td class="nump">29,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to shares issued in Semnur Acquisition value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>AdjustmentToAdditionalPaidInCapitalDiscountAmortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DistributionToSorrentos">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distribution to Sorrento's</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DistributionToSorrentos</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659324527136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Scilex</a></td>
<td class="num">$ (23,364)<span></span>
</td>
<td class="num">$ (88,424)<span></span>
</td>
<td class="num">$ (47,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,961<span></span>
</td>
<td class="nump">3,779<span></span>
</td>
<td class="nump">3,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">3,142<span></span>
</td>
<td class="nump">7,909<span></span>
</td>
<td class="nump">10,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NotesPrincipalIncrease', window );">Scilex Pharma Notes principal increase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount', window );">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</a></td>
<td class="num">(21,190)<span></span>
</td>
<td class="num">(12,487)<span></span>
</td>
<td class="num">(10,866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on debt extinguishment, net</a></td>
<td class="num">(28,634)<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashOperatingLeaseCost', window );">Non-cash operating lease cost</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="nump">5,280<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
<td class="nump">5,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on derivative liability</a></td>
<td class="num">(8,310)<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ForfeituresOfPrivateWarrants', window );">Forfeitures of Private Warrants</a></td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivables, net</a></td>
<td class="num">(6,968)<span></span>
</td>
<td class="num">(1,142)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
<td class="nump">2,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other</a></td>
<td class="num">(2,629)<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="num">(1,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long term assets</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">2,806<span></span>
</td>
<td class="num">(3,836)<span></span>
</td>
<td class="num">(4,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncreaseDecreaseInAccruedPayroll', window );">Accrued Payroll</a></td>
<td class="num">(2,379)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(123)<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="num">(1,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncreaseDecreaseInAccruedRebatesAndFees', window );">Accrued rebates and fees</a></td>
<td class="nump">23,531<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="nump">3,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="num">(392)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="nump">30,125<span></span>
</td>
<td class="nump">18,210<span></span>
</td>
<td class="nump">5,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OtherLongTermLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">163<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,258)<span></span>
</td>
<td class="num">(28,664)<span></span>
</td>
<td class="num">(31,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition', window );">Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</a></td>
<td class="num">(2,060)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant, and equipment</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,067)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromTheBusinessCombination', window );">Proceeds from the Business Combination</a></td>
<td class="nump">3,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction', window );">Transaction costs paid related to the Business Combination</a></td>
<td class="num">(2,949)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes', window );">Repayment of principal on the Scilex Pharma Notes</a></td>
<td class="num">(84,808)<span></span>
</td>
<td class="num">(33,387)<span></span>
</td>
<td class="num">(58,927)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromRepaymentOfLoansToPurchase', window );">Repayment on other loans</a></td>
<td class="num">(18,800)<span></span>
</td>
<td class="num">(48,832)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherShortTermDebt', window );">Proceeds from other loans</a></td>
<td class="nump">9,857<span></span>
</td>
<td class="nump">47,832<span></span>
</td>
<td class="nump">11,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party payable</a></td>
<td class="nump">51,900<span></span>
</td>
<td class="nump">47,850<span></span>
</td>
<td class="nump">18,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSecuredNotesPayable', window );">Proceeds from related party note payable</a></td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
<td class="nump">10,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">21,171<span></span>
</td>
<td class="nump">28,163<span></span>
</td>
<td class="num">(19,170)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Change in Cash</a></td>
<td class="num">(2,154)<span></span>
</td>
<td class="num">(501)<span></span>
</td>
<td class="num">(50,656)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,338<span></span>
</td>
<td class="nump">4,839<span></span>
</td>
<td class="nump">55,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">4,338<span></span>
</td>
<td class="nump">4,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-Cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement', window );">Related party debt converted to equity</a></td>
<td class="nump">289,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition', window );">Deferred Consideration for Romeg Intangible Asset Acquisition</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashConsiderationInSemnurAcquisition', window );">Non-cash Consideration in Semnur Acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OtherLoanForgiveness', window );">Other Loan Forgiveness</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,536<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount', window );">Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount</a></td>
<td class="nump">4,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring', window );">Fair value adjustment to derivative liability in troubled debt restructuring</a></td>
<td class="nump">30,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AcquisitionOfRightOfUseAsset', window );">Acquisition of right-of-use asset</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashDistributionToSorrento', window );">Non-cash distribution to Sorrento</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement', window );">Issuance of shares to Yorkville</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NotesPrincipalIncrease', window );">Scilex Pharma Notes principal increase</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(28,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination', window );">Accrual for transaction costs related to the Business Combination</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionCostsObligationAssumedBySorrento', window );">Transaction costs obligation assumed by Sorrento</a></td>
<td class="nump">$ 5,148<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual for transaction costs related to the Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AcquisitionOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition of right-of-use asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AcquisitionOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Consideration for Romeg Intangible Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment to derivative liability in troubled debt restructuring</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ForfeituresOfPrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forfeitures of Private Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ForfeituresOfPrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncreaseDecreaseInAccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accrued payroll</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncreaseDecreaseInAccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncreaseDecreaseInAccruedRebatesAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Rebates and Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncreaseDecreaseInAccruedRebatesAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares to Yorkville pursuant to Yorkville Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashConsiderationInSemnurAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Consideration in Semnur Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashConsiderationInSemnurAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashDistributionToSorrento">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Distribution to Sorrento</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashDistributionToSorrento</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NotesPrincipalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes principal increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NotesPrincipalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OtherLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Loan Forgiveness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OtherLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OtherLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other long-term liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OtherLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromRepaymentOfLoansToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Repayment Of Loans To Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromRepaymentOfLoansToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromTheBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromTheBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party debt converted to equity pursuant to Debt Exchange Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of principal on the Scilex Pharma Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionCostsObligationAssumedBySorrento">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs obligation assumed by Sorrento</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionCostsObligationAssumedBySorrento</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs paid related to the recapitalization transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the current portion (due within one year or one business cycle, whichever is longer) of the amount owed by the reporting entity in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from short-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSecuredNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSecuredNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659325861744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Operations and Basis of Presentation</a></td>
<td class="text"><p id="section146" style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Nature of Operations and Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Organization and Principal Activities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Holding Company (&#8220;Scilex&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is the successor entity to Vickers Vantage Corp. I (&#8220;Vickers&#8221;). Vickers was formed on February 21, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Scilex was originally formed in 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;). Scilex has two wholly owned subsidiaries, Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;)</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;). The Company is a commercial biopharmaceutical company focused on acquiring, developing and commercializing non-opioid management products for the treatment of acute and chronic pain. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. The Company in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The Company is currently developing three product candidates, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica (&#8220;SP-102&#8221; or &#8220;SEMDEXA&#8221;), SP-103 (lidocaine topical system) 5.4% (&#8220;SP-103&#8221;), for the treatment of acute low back pain, and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (&#8220;SP-104&#8221;), a novel formulation for the treatment of fibromyalgia. Since inception, the Company has devoted substantially all of its efforts to the development of SP-102, SP-103, SP-104, and the commercialization of ZTlido.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Business Combination</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 17, 2022, Scilex entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Vickers and Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#8220;Vickers Merger Sub&#8221;). Pursuant to the terms of the Merger Agreement, Vickers Merger Sub merged with and into Scilex, Inc. (f/k/a Scilex Holding Company and now a wholly owned subsidiary of Scilex) (&#8220;Legacy Scilex"), with Legacy Scilex surviving the merger and becoming a wholly-owned subsidiary of Vickers (collectively, the &#8220;Business Combination&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 10, 2022, Vickers consummated the Business Combination pursuant to the terms of the Merger Agreement. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, Scilex received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Additionally, all existing related party indebtedness between Legacy Scilex and Sorrento totaling </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">290.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 12). The Company, as the successor entity of Vickers, will operate as &#8220;Scilex Holding Company&#8221; and was listed on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221; on November 11, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the closing of the Business Combination, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197,566,338</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,151,428</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Legacy Scilex Common Stock (&#8220;Legacy Scilex Common Stock&#8221;) and Legacy Scilex stock options, respectively, were converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,060,534</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Common Stock (&#8220;Common Stock&#8221;) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as part of the consideration using the 0.673498:1 ratio of the Company Common Stock to Legacy Scilex Common Stock</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#8220;Common Stock Exchange Ratio&#8221;) and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,939,436</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock were reserved for Legacy Scilex optionholders. Pursuant to the terms of the Debt Exchange Agreement (see Note 12), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">290.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,057,097</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Preferred Stock (&#8220;Preferred Stock&#8221;) and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,905,710</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock. In addition, pursuant to the terms of the debt agreement entered between the Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd (&#8220;Sponsors&#8221;) and Vickers (&#8220;Vickers Debt Agreement&#8221;), the aggregate amount of loans that the Sponsors funded Vickers to finance the transaction costs (&#8220;Working Capital Loans&#8221;) at the closing of the Business Combination of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,330,557</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">533,057</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers was treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination was treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. Upon the closing of the Business Combination, the net assets of Vickers were recorded at historical cost, with no goodwill or other intangible assets recorded.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s legal, accounting and other fees directly attributable to the Business Combination were initially capitalized within prepaid expenses and other current assets on the consolidated balance sheets, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million has been offset against the equity proceeds in the Business Combination and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was attributed to the liability-classified Private Warrants and, as such, were expensed upon the closing of the Business Combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p id="section147" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution.  Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values.  Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and  2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices.  Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounts Receivable, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines inventory cost on a first-in, first-out basis.  The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for on-hand inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. As of December 31, 2022 and  2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company&#8217;s inventory was primarily comprised of finished goods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="section153" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are carried at cost less accumulated depreciation.  Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.  The cost of repairs and maintenance is expensed as incurred.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="section154" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisitions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, up-front payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations unless there is an alternative future use.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="section157" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill and Other Long-Lived Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired.  Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill.  The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company.  If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Public Warrants and Private Placement Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon completion of the Business Combination, the Company assumed public and private placement warrants (&#8220;Public Warrants&#8221; and &#8220;Private Warrants&#8221;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on January 11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic No. 815-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contracts on an Entity&#8217;s Own Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic 815-40. The Private Warrants are not considered indexed to the Company&#8217;s stock per ASC Subtopic 815-40 as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a fixed-for-fixed option contract. Therefore, Private Warrants are recognized as derivative liabilities </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at their estimated fair value on November 10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet date, with fair value changes recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="section159" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates.  This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="section160" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative Liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="section161" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses the cost of research and development as incurred.  Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.  Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="section162" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provisions of the FASB ASC Topic 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Subtopic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.  The Company has determined that it has uncertain tax positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized.  As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company maintained a full valuation allowance against its deferred tax assets.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="section163" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.  As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.  The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives.  The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="section164" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#8217;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.  Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December 31, 2022 and 2021 were not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rebates and Chargebacks</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rebates are discounts which the Company pays under either government or private health care programs.  Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers.  Both types of rebates vary over time.  The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prompt Payment Discounts</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Service Fees</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services.  The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Returns</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Co-Payment Assistance</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive co- payment assistance.  The Company accrues for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></p></div><p id="section165" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Concentration Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to April 2, 2022, sales to the Company's sole distributor represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of net revenue. On April 2, 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The distributor continued to provide traditional third-party logistics functions for the Company. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had four customers during the year ended December 31, 2022, which individually generated 10% or more of the Company&#8217;s total revenue. These customers accounted for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Company&#8217;s revenue for the year ended December 31, 2022, individually ranging between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, these customers represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Company&#8217;s outstanding accounts receivable, individually ranging between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Additionally, during the fiscal years ended December 31, 2022 and 2021, the Company purchased inventory from its sole supplier, Itochu. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p id="section166" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation &#8211; Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or non-employee&#8217;s vesting period. The Company accounts for forfeitures as incurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p id="section167" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of non-opioid products focused on pain management based on its platform technologies and all sales are based in the United States.  Accordingly, the Company has determined that it operates its business as a single reportable segment.</span></p></div><p id="section168" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.</span></p></div><p id="section169" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the FASB issued ASU 2021-08, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659327885968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p id="section170" style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.  Management has assessed the Company&#8217;s ability to continue as a going concern for at least one year after the date the financial statements are issued.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 18, 2019, Scilex acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note 3). The Company anticipates the cash needed for the development of Semnur&#8217;s primary product candidate in development, SP-102, as well in the development of SP-103, will be in excess of the Company&#8217;s cash available within one year after the date these consolidated financial statements are issued.  Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the SP-104 Assets (see Note 3). SP-104 has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be responsible for funding all development and commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 14, 2022, the Company entered into a license and commercialization agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs related to the commercial launch and marketing of GLOPERBA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 12, 2022, Scilex and Scilex Pharma entered into a Debt Exchange Agreement (see Note 12) with Sorrento, pursuant to which all related party indebtedness that remained outstanding as of immediately prior to the closing of the Business Combination was converted into equity interests in the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, the Company exercised the Early Paydown Provision (see Note 7) to fully extinguish the Scilex Pharma Notes (see Note 7). In August 2022 and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Pursuant to Amendment No. 4 (see Note 7), a principal balance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was forgiven by the Scilex Pharma Note Purchasers (see Note 7) upon the Company&#8217;s exercise of the Early Paydown Provision. The Company funded the principal payments with cash-on hand and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> received from Sorrento on September 28, 2022 (see Note 7).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company&#8217;s negative working capital was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including cash and cash equivalents of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the year ended December 31, 2022, the Company had operating losses of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and cash flows used for operations o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">f $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company had an accumulated deficit of approximate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ly $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">375.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. (&#8220;Yorkville&#8221;) on November 17, 2022 (as amended and restated on February 8, 2023), and a Standby Equity Purchase Agreement with B. Riley Principal Capital II, LLC (&#8220;B. Riley&#8221;) on January 8, 2023 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whereby the Company has the right, but not the obligation, to sell to Yorkville and B. Riley up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million each of shares of its Common Stock at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement has been declared effected by the SEC, subject to certain conditions (see Note 8 and Note 14). The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#8217;s marketing of ZTlido. Should the Company&#8217;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#8217;s business plan, due to the COVID-19 pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for SP-102, SP-103, and SP-104, and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control.  As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements are issued.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320148016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="section173" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Property and Equipment, Net</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.32%;"/>
        <td style="width:1.583%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.583%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.742%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers &amp; equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">689</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">689</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">932</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">772</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense for each of the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320054976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="section183" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Related Party Transactions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2020, approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding capital stock of the Company was held by Itochu. On January 13, 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,889,868</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Legacy Scilex representing all outstanding capital stock of Legacy Scilex held by Itochu were acquired by non-related minority shareholders. Thus, Itochu is not a shareholder subsequent to January 13, 2021. During the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 the Company purchased approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#8217;s statement of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Semnur is party to an Assignment Agreement, dated August 6, 2013 (the &#8220;Assignment Agreement&#8221;), with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who has served on the Company&#8217;s board of directors since March 2019, is the managing partner of Shah Investor.  Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the low-single digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injection developed using such intellectual property, which would include SP-102. Through December 31, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2017, a Transition Services Agreement (&#8220;TSA&#8221;) was executed between Scilex Pharma and Sorrento.  Pursuant to the TSA, Sorrento agreed, at the Company&#8217;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company.  During the years ended December 31, 2022, 2021, and 2020 the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the acquisition of Semnur.  The note is interest bearing at the lesser of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% simple interest per annum, and (b) the maximum interest rate permitted under law.  Interest is due and payable annually.  The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium.  During the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 Sorrento made advances to the Company in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million respectively, under the note payable. All outstanding related party indebtedness immediately prior to the closing of the Business Combination was converted to equity pursuant to the Debt Exchange Agreement (defined below) and therefore the last day the debt outstanding was November 10, 2022 (see Note 12). The outstanding principal balance of the note on November 10, 2022 and December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, which was recorded under the current related party note payable in the Company&#8217;s consolidated balance sheets. As of November 10, 2022 and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. The proceeds from the note payable were used to finance the operations of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#8220;Intercompany Note&#8221;). Scilex Pharma may borrow up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% simple interest per annum, and (b) the maximum interest rate permitted under law. All outstanding principal amounts and accrued interest was due upon maturity on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 31, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. On October 22, 2018, Sorrento purchased from the Legacy Scilex 24,117,608 shares of the Legacy Scilex Common Stock in exchange for the repayment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of indebtedness under this promissory note.  During the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, Sorrento made advances to Scilex Pharma in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million respectively, under the promissory note. As of November 10, 2022 and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. As of November 10, 2022 and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021, Scilex Pharma&#8217;s outstanding principal balance under the promissory note was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was recorded under the non-current related party note payable in the Company&#8217;s consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in February 2022 to fund the payment of Scilex Pharma Notes as described in Note 7. The $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> received in February 2022 was due no earlier than February 2030 and was recorded under the non-current related party note payable in the Company&#8217;s consolidated balance sheets as of November 10, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional funding received from Sorrento was due on demand and recorded under the related party payable in the Company&#8217;s consolidated balance sheets. As of November 10, 2022, related party payables due to Sorrento included</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to cover working capital requirements, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for repurchases of Scilex Pharma Notes, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for litigation fees (see Note 7). As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, related party payables due to Sorrento consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to cover working capital requirements, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for repurchases of Scilex Pharma Notes, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to pay litigation fees. As of December 31, 2022, the Company had a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related party receivable from Sorrento related to certain invoices paid on behalf of Sorrento, which was fully reserved (see Note 14).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% simple interest per annum and (b) the maximum interest rate permitted under law. As of November 10, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was recorded under the non-current related party note payable in the Company&#8217;s consolidated balance sheets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt Exchange Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#8220;Debt Exchange Agreement&#8221;) with Sorrento, pursuant to which (i) Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company that remain outstanding as of immediately prior to the closing of the Business Combination (the &#8220;Aggregate Outstanding Amount&#8221; or &#8220;Outstanding Indebtedness&#8221;), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 7), in exchange for the issuance by the Company to Sorrento of Preferred Stock of the Company, (ii) the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii) upon the occurrence of the events described in clauses (i) and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to, and contingent upon, the closing of the Business Combination, Sorrento elected to contribute the Outstanding Indebtedness to the Company in exchange for the issuance by the Company to Sorrento of that number of shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#8220;Exchange Shares&#8221; and such transaction, the &#8220;Debt Contribution&#8221;) that is equal to (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Aggregate Outstanding Amount plus the amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the Aggregate Outstanding Amount divided by (ii) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (rounded up to the nearest whole share); provided, that in no event would the Aggregate Outstanding Amount exceed $ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">290.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement. This amount was converted to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,057,097</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Scilex Preferred Stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,905,710</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's Common Stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320037424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="section178" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Development Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with two parties (the &#8220;Developers&#8221;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#8220;Itochu&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and SP-103 (the &#8220;Products&#8221;), for Scilex Pharma.  The Developers initially developed, and have intellectual property rights relating to, the Products.  Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to the Developers based on net profits. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, Scilex Pharma made royalty payments in the amount of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, Scilex Pharma had ending balances of accrued royalty payables of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Net </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">profits </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are defined as net sales, less cost of goods and marketing expenses.  Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> October 2, 2028</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the date that is ten years from the date of the first commercial sale of ZTlido. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon 6-month written notice.  </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the two Developers to provide commercial supply of ZTlido and SP-103 to Scilex Pharma.  The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive Distribution Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#8220;Distribution Agreement&#8221;) to appoint an exclusive third-party logistics distribution provider (the &#8220;Distributor&#8221;) and as an authorized distributor of record of ZTlido in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% annual adjustment. The Distribution Agreement has an initial term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">following the first shipment of FDA-approved Product to a commercial customer and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#8217;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#8217;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% which was recorded as a gross-to-net sales adjustment. As the Company continues to expand the commercialization of ZTlido, it has expanded its direct distribution network to national and regional distributors and pharmacies since the beginning of April 2022. The Company currently holds all necessary wholesaler licenses and commenced selling directly to the main distributor customers as well as pharmacies in April 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales Operations Services</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#8220;Project Agreement&#8221;).  In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor.  In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor continued to provide sales operations services, fleet management services and sample accountability services. The work order was in effect until </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with 90 days&#8217; notice</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Pharma paid</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implementation fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.0 thousand and will pay fixed monthly fees of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand for ongoing services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized an expense of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within selling, general and administrative expenses for services performed for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, respectively, including implementation fees, fixed monthly fees and pass-through costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Litigation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the &#8220;Sanofi-Aventis &amp; Hisamitsu Litigation&#8221;).  This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly the Company's claims, but which motions the court has largely rejected.  Discovery is proceeding.  The case is currently scheduled for trial to begin on July 24, 2023.  The Company cannot make any predictions about the outcome in this matter or the timing thereof.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Former Employee Litigation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;), a company now headed by Mr. Mack, alleging, among other things, breach by Mr. Mack of his non-compete agreement with the Company, breach of fiduciary duty, and tortious interference by Virpax with that non-compete agreement (the &#8220;Former Employee Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr. Mack from further violating his non-compete agreement and enjoining Virpax from tortiously interfering with Mr. Mack&#8217;s non-compete agreement. The case was tried from September 12, 2022 to September 14, 2022. Post-trial briefing and closing arguments have been concluded and the case is under submission to the Court. The Company cannot make any predictions about the outcome in this matter or the timing thereof.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ZTlido Patent Litigation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#8220;Apotex&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;ZTlido Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;).  The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the Hatch-Waxman Act, of an ANDA.  Apotex&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed.  The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May 10, 2031, and such further and other relief as the court may deem appropriate. Apotex is subject to a 30-month stay preventing it from selling a generic version of ZTlido during that time.  The stay should expire no earlier than November 11, 2024.  Trial in the ZTlido Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases administrative and research and development facilities under various non-cancelable lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend.  As of December 31, 2022, the Company&#8217;s leases have remaining lease terms of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. The term of the Company&#8217;s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. Many of the Company&#8217;s leases are subject to variable lease payments.  Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the right-of-use assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.  The Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease.  As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_4a367a12-e012-4165-b149-5a78dbe3c071;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">finance leases</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.455%;"/>
        <td style="width:1.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.094%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.094%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.225%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost*</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">623</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">904</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Inclusive of variable lease costs, sublease income, and impairment, which were immaterial</span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the periods presented.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental quantitative information related to leases includes the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.253%;"/>
        <td style="width:1.964%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.925%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.954%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.904%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">746</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">654</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets obtained in exchange for new operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term in years &#8212; operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate &#8212; operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2022, the Company entered into a new non-cancelable lease agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months and the Company does not expect to exercise the extension option at the end of the lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approximate future minimum lease payments under operating leases</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were as follows (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.856%;"/>
        <td style="width:1.475%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.67%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">872</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">703</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,575</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,410</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less current portion of lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">745</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability, net of current portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320245072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="section179" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total loss before income taxes for the years ended December 31, 2022, 2021 and 2020 did not include a foreign component.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the provision expense (benefit) were as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.996%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current income tax expense (benefit):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax expense (benefit):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,396</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,981</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,970</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,851</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,472</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,247</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,453</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,347</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,900</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,422</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,007</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax benefit from continuing operations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows as of  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.049%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.123%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,984</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,714</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt related interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,205</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,630</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,630</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,602</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,233</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expense and reserves</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">568</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,517</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">315</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">404</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">236</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,462</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,939</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,543</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,643</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,919</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,296</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,666</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,975</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">319</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,296</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s provision for income taxes are as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020  (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.996%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,905</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,150</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,900</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,422</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,007</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discount and interest limitation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,293</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,954</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">806</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,469</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">224</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">166</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisition related charges</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">992</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior year true-up and carryback</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">713</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,968</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,955</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State, net of federal tax benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,545</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,164</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax credits and incentives</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">728</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">993</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">235</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> against its deferred tax assets as of December 31, 2022. Realization of the deferred tax assets will be primarily dependent upon the Company's ability to generate sufficient taxable income prior to the expiration of its net operating losses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">205.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of federal and state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">state, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">respectively. The Company also had federal research and development income tax credits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal Revenue Code Section 382 rules apply to limit a corporation's ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section 382. For the years ended December 31, 2022 and 2021, there was no impact of such limitations on the Company&#8217;s income tax provision.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#8217;s tax years will remain open for three years for examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.899%;"/>
        <td style="width:1.376%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.985000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.386%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.985000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.386%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.985000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">406</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">385</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">406</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, 2021, and 2020, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, of the Company&#8217;s total unrecognized tax benefits, if recognized, would impact the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> interest or penalties have been recognized as of and for the periods ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company believes that </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> material amount of the liabilities for uncertain tax positions are expected to reverse within 12 months of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320287664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="section176" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Stockholders&#8217; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated statement of stockholders&#8217; equity has been retroactively adjusted for all periods to reflect the Business Combination and reverse recapitalization described in Note 1. The balances as of December 31, 2022 and 2021 from the consolidated financial statements of the Company as of that date, share activity (Preferred Stock, Common Stock, and additional paid-in-capital) and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the closing of the Business Combination, pursuant to the terms of the Amended and Restated Certificate of Incorporation, the Company authorized </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">740,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock with a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141,348,856</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares issued and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,858,484</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Common Stock outstanding, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the closing of the Business Combination, all previously issued and outstanding shares of Legacy Scilex Common Stock and Legacy Scilex stock options were converted into shares of Common Stock pursuant to the Common Stock Exchange Ratio. The Company has retroactively adjusted shares issued and outstanding prior to November 10, 2022 to give effect to the Common Stock Exchange Ratio to determine the number of shares of Common Stock into which they were converted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of the Common Stock are entitled to one vote for each share of the Common Stock held at all meetings of stockholders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividends</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stockholders are entitled to receive dividends whenever funds are legally available and when declared by the Company's board of directors. No dividends have been declared as of December 31, 2022.The Stockholder Agreement, dated as of September 12, 2022, between Vickers and Sorrento (the &#8220;Stockholder Agreement&#8221;), provides that the Company will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, the payment of dividends on shares of the Common Stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidation Rights</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to the rights of the holders of Preferred Stock, in the event of our liquidation, dissolution or winding-up, holders of Common Stock are entitled to share equally in the assets available for distribution after payment of all creditors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the closing of the Business Combination, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">290.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento were cancelled in exchange for the issuance of preferred shares of Scilex (&#8220;Series A Preferred Shares&#8221; or &#8220;Series A Preferred Stock&#8221;). In connection with the closing of the Business Combination, all issued Scilex Series A Preferred Shares were cancelled and converted into the right to receive 1) one share of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">domesticated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">parent preferred shares (&#8220;New Scilex Preferred Stock&#8221; or &#8220;Preferred Stock&#8221;) par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, and 2) one-tenth of one domesticated parent common stock (&#8220;New Scilex Common Stock&#8221; or &#8220;Common Stock&#8221; and such transaction including cancellation of all the existing related party indebtedness in exchange for Preferred Stock and Common Stock, the &#8220;Conversion&#8221; or &#8220;Contribution&#8221;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the Conversion, Legacy Scilex filed a Second Amended Certificate of Incorporation (defined below) to increase the authorized number of shares to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and a Certificate of Designation (&#8220;Certificate of Designation&#8221;) to designate the rights, preferences, and privileges of Scilex Series A Preferred Shares. In connection with the closing of the Business Combination, the Company filed the Certificate of Designation and issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,057,097</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Series A Preferred Stock to Sorrento. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,057,097</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Preferred Stock outstanding. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Preferred Stock outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s Board of Directors have authority to issue such shares of Preferred Stock in one or more series, to establish, from time to time the number of shares to be included in each such series, and to fix the dividend, voting, and other rights, preferences, and privileges of the shares. Other than the Series A Preferred Stock issued to Sorrento in connection with the closing of the Business Combination, there are no other Preferred Stock outstanding and the Company has no current plans to issue any other shares of preferred stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of shares of Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Preferred Stock will be entitled to one vote for each share of Common Stock that such share of Preferred Stock would otherwise be convertible into pursuant to a deemed conversion on the record date for the determination of the stockholders entitled to vote.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Stockholder Agreement, holders of Series A Preferred Stock have the right to designate each director to be nominated, elected or appointed to the Board of Directors of the Company. The Series A Preferred Stock also has certain protective provisions, such as requiring a written consent of the holders of Series A Preferred Stock to change or amend their rights, powers, privileges, limitations and restrictions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividends</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of the Preferred Stock are not entitled to dividends unless the Company pays dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of the Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidation Rights</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to the rights of the holders of parity shares (if any), in the event of our liquidation, dissolution or winding-up, holders of Preferred Stock rank senior to the Common Stock and are entitled to share equally in the assets available for distribution after payment of all creditors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assumed Public Warrants and Private Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following the consummation of the Business Combination, holders of the Public Warrants and Private Warrants are entitled to acquire Common Stock of the Company. The warrants are exercisable on the later of (a) the completion of a Business Combination and (b) 12 months from the closing of Vickers's Initial Public Offering. The warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each warrant entitles the holder to purchase one share of Common Stock for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the reported last sale price of the Common Stock equals or exceeds $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per warrant upon not less than 30 days&#8217; prior written notice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the warrants. As of December 31, 2022, there are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,899,988</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Public Warrants outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the closing of the Business Combination, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,104,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Private Warrants were transferred to Sorrento pursuant to the Warrant Transfer Agreement between Vickers, the Sponsors, Sorrento and Maxim Group, LLC where Sorrento acquired all rights, title and interests to such Private Warrants (&#8220;Warrant Transfer Agreement&#8221;). As of December 31, 2022, there are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,104,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Private Warrants outstanding, of which </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,104,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Private Warrants are held by Sorrento and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Private Warrants are held by Sponsors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legacy Scilex Common Stock and Preferred Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the Business Combination, Legacy Scilex had the authority to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share per the Certificate of Incorporation dated February 27, 2019. The Certificate of Incorporation was amended and restated on March 4, 2019 (&#8220;First Amended Certificate of Incorporation&#8221;), in which Legacy Scilex had the authority to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">350,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The First Amended and Restated Certificate of Incorporation was amended and restated on November 10, 2022 (&#8220;Second Amended Certificate of Incorporation&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the Second Amended Certificate of Incorporation, Legacy Scilex had the authority to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">785,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, consisting of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">740,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock. Immediately prior to the Conversion, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197,566,338</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Legacy Scilex Common Stock outstanding and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,057,097</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A Preferred Stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, of Legacy Scilex outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Yorkville Standby Equity Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 17, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with Yorkville, whereby the Company has the right, but not the obligation, to sell to Yorkville up to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of shares of its Common Stock at its request any time during the 36 months following the execution of the Yorkville Purchase Agreement, subject to certain conditions. Pursuant to the Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a sale of Common Stock (each such sale, a &#8220;Yorkville Advance&#8221;) will be purchased at a price equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the lowest daily volume weighted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">average </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">price of the Common Stock for any trading day (&#8220;VWAP&#8221;) during the two consecutive trading days commencing on the date of delivery of a written purchase notice to Yorkville (each, a &#8220;Yorkville Advance Notice&#8221;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for Yorkville's commitment to purchase shares of Common Stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, upon execution of the Yorkville Purchase Agreement, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock to Yorkville and paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in structuring fees. The registration statement on Form S-1 (File No. 333-268607) related to the Yorkville Purchase Agreement was filed with the SEC on November 30, 2022 and was declared effective by the SEC on December 9, 2022. As of December 31, 2022, there were no shares sold to Yorkville under the Yorkville Purchase Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Note 14 &#8220;Subsequent Event&#8221; below for a subsequent event related to the Yorkville Purchase Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320112736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Acquisitions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SP-104 Acquisition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 12, 2022, the Company entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), with Sorrento. Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#8217;s Delayed Burst Release Low Dose Naltrexone (&#8220;DBR-LDN&#8221;) asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the &#8220;SP-104 Assets&#8221;). These assets had previously been acquired by Sorrento from Aardvark</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Therapeutics, Inc. (&#8220;Aardvark&#8221;) in April 2021 pursuant to an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the &#8220;SP-104 Acquisition&#8221;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the SP-104 Acquisition, the Company issued a promissory note in the aggregate principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to Sorrento (the &#8220;2022 Promissory Note&#8221;). Upon issuance of the note, the Company recorded a related party note payable of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The 2022 Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% simple interest per annum and (b) the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company&#8217;s common stock or any combination thereof, at the Company&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. On November 10, 2022,  the 2022 Promissory Note was converted to equity, pursuant to the terms of the Debt Exchange Agreement (See Note 12).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, upon initial approval by the FDA of a new drug application for the SP-104 Assets (which amount may be paid in shares of the Company&#8217;s common stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Payment&#8221;) and (ii) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the SP-104 Assets (the &#8220;Sales Milestone Payment&#8221;).  The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the SP-104 Assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, SP-104 Assets. The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and will not be recognized until the contingencies are realized in accordance with the Company&#8217;s accounting policy for contingent consideration in an asset acquisition. The Development Milestone Payment represents a liability within the scope of ASC Topic 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which will be measured at fair value each reporting period. As of December 31, 2022, the contingent consideration of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> associated with Development Milestones Payment was recognized under other long-term liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GLOPERBA License Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 14, 2022, the Company entered into a license agreement (the &#8220;Romeg License Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (1) a transferable license, with the right to sublicense, under the patents and know-how specified therein (with such license to know-how being exclusive for the limited purposes specified therein) to (i) commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221; or &#8220;GLOPERBA&#8221;) in the United States of America (including its territories) (the &#8220;Territory&#8221;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#8220;Licensed Products&#8221;) and commercialize any such products and (iii) manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory; and (2) an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the license under the Romeg License Agreement, the Company paid Romeg an up-front license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and has agreed to pay Romeg (a) upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, (b) certain royalties in the mid-single digit to low-double digit percentages based on annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c) minimum quarterly royalty payments totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i) expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii) the tenth anniversary of the effective date of the Romeg License Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is comprised of the upfront license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and a deferred consideration of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent sales milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, and will not be recognized until the contingencies are realized. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> contingent consideration was recognized as a liability or included in the fair value of the assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022. The Company determined the useful life of the intangible asset to be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, which approximates the life of the licensed patents covering the Initial Licensed Product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320305632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="section172" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.662%;"/>
        <td style="width:1.237%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.138%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.223%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.123%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.223%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.578999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.223%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.594%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs (Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,184</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,184</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_1b42e5e5-376a-4619-9690-cb8f5630cc07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,231</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,231</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_708be5d4-a9d0-4908-bbbe-b2da444eaa07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_174a237b-3e62-4fa6-915e-8a53d0d37000;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,394</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,394</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.297%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.901%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.901%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.521%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs (Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs (Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,338</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,338</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,338</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,338</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2e14ac05-2d70-479b-834b-0da0a2e27285;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,700</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,700</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and cash equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial assets carried at fair value are comprised of cash and cash equivalents.  Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable.  These assets are valued using inputs observable in active markets for identical securities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded a gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on derivative liabilities for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note 7) and Private Warrants. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> immediately after </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entry into Amendment No. 4 (see Note 7) associated with the Scilex Pharma Notes on June 2, 2022. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No. 4. Significant Level 3 assumptions used in the measurement included a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% risk adjusted net sales forecast and an effective debt yield of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 7) and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022. At the closing of the Business Combination, the Company assumed a derivative warrant liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_41f57cde-2f51-43b9-9298-50e67016606a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> related to Private Warrants (See Note 8). The fair value of derivative warrant liability related to Private Warrants was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.153%;"/>
        <td style="width:1.916%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.93%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending Balance at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan derivative liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,800</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Re-measurement of fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">800</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,400</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Re-measurement of fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,700</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Private Warrant liability acquired as part of the Business Combination</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,545</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeiture of Private Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,696</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value measurement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,710</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,231</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrant Liability Measurement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level 3 fair value measurement. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants. A summary of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inputs used in valuing the derivative warrant liabilities is as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.537%;"/>
        <td style="width:1.624%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.624%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.107%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 10, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.99</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.50</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.50</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.86</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.94</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Call option value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Development Milestone Payment represents a liability under the scope of ASC Topic 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as it pertains to a potential contractual obligation to settle a fixed value in a variable number of shares of Common Stock. Upon the achievement of FDA approval for a new drug application for SP-104, the Company will transfer $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant Level 3 assumptions included the likelihood of receiving FDA approval for SP-104, expected timing for receipt of FDA approval for SP-104, and a discount rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no transfers between fair value measurement levels during the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320305632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p id="section174" style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Goodwill and Intangible Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and December 31, 2021, the Company had recorded goodwill of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company performed a qualitative test for goodwill impairment during the fourth quarter of 2022. Based upon the results of the qualitative testing, the Company concluded that it is more-likely-than-not that the fair value of the Company&#8217;s goodwill was in excess of the carrying value and therefore performing the first step of the two-step</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impairment test was unnecessary. The conclusion has not changed as of December 31, 2022 and no goodwill impairment was recognized for the years ended December 31, 2022 and 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the Company&#8217;s identifiable intangible assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and December 31, 2021 is as follows (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:40.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.583000000000002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.293%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.827%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.293%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.787%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangibles, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent rights</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,630</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,215</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired technology</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,940</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,216</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,724</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired licenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,711</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,527</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assembled workforce</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">375</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,781</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,190</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:39.894%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.459%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.28%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.447%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.268%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.651%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangibles, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent rights</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,630</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,239</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,391</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired technology</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,940</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,754</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,186</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assembled workforce</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,070</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,268</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,802</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was assigned to acquired licenses with an amortization period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the weighted average remaining life for identifiable intangible assets was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years. Aggregate amortization expense was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the years ended December 31, 2022, 2021, and 2020, respectively. Patent rights and acquired technology are amortized over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-year period.  Assembled workforce is amortized over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-year period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated future amortization expense related to intangible assets at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:85.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.621%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,006</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,006</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,006</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,436</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320066992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p id="section175" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2018 Purchase Agreements and Indenture</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#8220;2018 Purchase Agreements&#8221;) with certain investors (collectively, the &#8220;Scilex Pharma Note Purchasers&#8221;). Pursuant to the 2018 Purchase Agreements, on September 7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due 2026 in an aggregate principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">224.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the &#8220;Scilex Pharma Notes&#8221;) for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (the &#8220;Offering&#8221;). The Scilex Pharma Notes were governed by an indenture (as amended, the &#8220;Indenture&#8221;) with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Collateral Agent&#8221;), and Sorrento, as guarantor.  Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#8220;Guarantee&#8221;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The principal amount of the Scilex Pharma Notes increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on February 15, 2022 as a result of actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December 31, 2021 not equal or exceeding $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">481.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. As a result, the Company recorded the increase of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in principal and non-operating expense at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective February 14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December 31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in a single lump-sum amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No. 4 to Indenture (the &#8220;Amendment No. 4&#8221;) with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment No. 4, (1) on June 3, 2022, Scilex Pharma repurchased approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the aggregate principal amount of the outstanding Scilex Pharma Notes at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the principal amount thereof, (2) the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September 30, 2022 for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the aggregate principal amount of the Scilex Pharma Notes (the &#8220;Early Paydown Provision&#8221;), (3) the minimum cash requirement under the Indenture was reduced to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4) the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to Sorrento on October 5, 2018 was increased from up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company funded the repurchase with cash-on-hand and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million received from Sorrento on June 2, 2022. The Company concluded that the Amendment No. 4 was a troubled debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No. 4, and accordingly, no gain was recognized in the quarter ended June 30, 2022. Due to a decrease of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the fair value of the Scilex Notes Derivative caused by the Amendment No. 4, the carrying value of the Scilex Notes was increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,  respectively. Pursuant to Amendment No. 4, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The Company funded the repurchase with cash-on-hand and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> received from Sorrento on September 28, 2022. The Company recorded a gain on debt extinguishment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as a result of the extinguishment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Borrowings of the Scilex Notes consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.099%;"/>
        <td style="width:1.781%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.12%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,997</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt discount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,597</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101,172</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long term portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,037</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company made principal payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, respectively. The amount of debt discount and debt issuance costs included in interest expense for the years ended December 31, 2022, 2021, and 2020 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The Company recorded a gain on debt extinguishment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a loss on debt extinguishment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gain/loss on debt extinguishment in connection with its repayments of principal made during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Related Party Notes Payable</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 12).  On March 18, 2019, the Company entered into a note payable with Sorrento (see Note 12). On February 14, 2022, Sorrento paid to Scilex Pharma </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in a single lump-sum amount as a subordinated loan (see Note 12). On May 12, 2022, the Company issued Sorrento a promissory note of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in exchange for the SP-104 Assets (see Note 3). On November 10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 12).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Revolving Credit Facility</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#8220;Credit Agreement&#8221;) with CNH Finance Fund I, L.P. (&#8220;CNH&#8221;) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. All indebtedness incurred and outstanding will be due and payable in full on January 1, 2024; unless the Credit Agreement is earlier terminated. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the outstanding balance was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. On February 16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective March 18, 2022. Upon termination, all principal balances and interest accrued were settled.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320112736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Stock Incentive and Employee Benefit Plans</a></td>
<td class="text"><p id="section177" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Stock Incentive and Employee Benefit Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated statements of stockholders&#8217; equity / (deficit) have been retroactively adjusted for all periods to reflect the Business Combination and reverse recapitalization described in Note 1. The balances as of December 31, 2022, 2021, 2020 from the consolidated financial statements of the Company as of that date, share activity (stock options) and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2017 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;).  The Scilex Pharma 2017 Plan reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million shares of Scilex Pharma common stock.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Scilex Pharma 2017 Plan was amended and restated on July 5, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#8217;s common stock outstanding and unexercised immediately prior to reorganization was cancelled and substituted for that number of options to acquire Legacy Scilex Common Stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scilex Holding Company 2019 Stock Option Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221; or &#8220;Prior Plan&#8221;) on May 28, 2019. The 2019 Stock Option Plan was approved by the Company&#8217;s stockholders on June 7, 2019. As of December 31, 2019, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million shares of Scilex Common Stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the consummation of the Business Combination, the 2019 Stock Option Plan was terminated and no further awards were granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted under the terms of the Equity Incentive Plan (defined below).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scilex Holding Company 2022 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;) on October 17, 2022. The 2022 Equity Incentive Plan was approved by the stockholders and became effective on November 9, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total number of common shares for which incentive stock options (&#8220;ISOs&#8221;) may be granted under the Equity Incentive Plan is not to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,622,712</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares plus a  number of shares of Common Stock equal to the number of shares subject to outstanding stock awards granted under the Prior Plan (&#8220;Returning Shares&#8221;), </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if any, as such shares become available from time to time, which the amount will be increased commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of Common Stock outstanding on December 31 of the preceding year, (ii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,311,356</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock, and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there were no options to purchase shares of Common Stock outstanding under the Equity Incentive Plan and options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,939,436</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Common Stock were outstanding under previous plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation recorded within operating expenses was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the years ended December 31, 2022, 2021, and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total unrecognized compensation costs related to unvested employee and non-employee stock option grants as of December 31, 2022 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the weighted average period over which these grants are expected to vest is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scilex Holding Company 2022 Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 17, 2022, the Board adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP was approved by the stockholders and became effective on November 9, 2022. The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward the success of the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase the Common Stock in a manner that may qualify for favorable tax treatment under Section 423 of the Internal Revenue Code of 1986 (&#8220;Code&#8221;) (the &#8220;423 Component&#8221;) and accordingly, it will be construed in a manner that is consistent with the requirements of Section 423 of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the &#8220;Non-423 Component&#8221;) in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by the Board, it will operate and be administered in the same manner as the 423 Component.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Board administers the ESPP and will have the authority to determine how and when purchase rights are granted and the provisions of each offering. Initially, the total number of shares of the Common Stock that may be issued under the ESPP will not exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,462,271</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Common Stock. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">number of shares of the Common Stock that will be reserved for issuance will automatically increase on January 1 of each year for a period of up to ten years, commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of </span></span><span style=""/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of the Common Stock outstanding on December 31 of the immediately preceding calendar year; (ii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,827,839</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Common Stock; and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year, provided however, that the Board may act prior to January 1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i) to (iii) above.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares outstanding under the ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option Valuation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the year ended 2020 is set forth below:</span></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.208%;"/>
        <td style="width:0.344%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.32%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.127%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted &#8211;average grant date fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock-price volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.53</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term of options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value per share of common stock on date of grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.72</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.72</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company bases the expected dividend yield assumption on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends on the Company&#8217;s common stock.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected stock-price volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available.  The peer group was developed based on companies in the transdermal patch industry. In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches.  Management further considered the development stage of the peer group companies.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company bases the risk-free interest rate assumption on the U.S. Treasury&#8217;s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected term of options</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The expected term of options represents the period of time when options are expected to be outstanding.  Because the Company does not have historic exercise behavior, the Company determines the expected term assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following represents a summary of the options outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 and changes during the years then ended (in thousands, other than weighted-average exercise price):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.598%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.255%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.419%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.51%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.991%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.228000000000002%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average exercise price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,183</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,172</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.72</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">502</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.40</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,746</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,172</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,778</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.01</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,968</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.68</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">915</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">202</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.47</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,827</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.72</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.68</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,942</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,487</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.70</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Benefit Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for each of the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320147200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><p id="section184" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Loss Per Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Earnings Per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has two classes of shares, which are referred to as Common Stock and Preferred Stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. The retroactive adjustment is based on the same number of weighted average shares outstanding in each historical period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022, 2021, and 2020, basic loss per share is computed using the two-class method. The two-class method is an earnings allocation formula that determines earnings per share for each class of common stock and participating securities according to dividends or dividend equivalents and participation rights in undistributed earnings. Preferred Stock is not contractually required to share in net losses of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020  (in thousands except per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.878%;"/>
        <td style="width:1.579%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.763%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.589%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.763%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.589%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.837%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to Scilex</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,364</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,519</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to participating securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,364</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,519</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common shares outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,226</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of Dilutive Securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator for Diluted Loss per Share - Adjusted for Dilutive Securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,226</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and Diluted Loss Per Share</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.67</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:55.176%;"/>
        <td style="width:1.15%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.671%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.161%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.682%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.161%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,939,093</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,967,724</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,746,432</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,899,988</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_3ea715ce-1b17-4fc1-b25f-7f625140097e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_bdcbe9bc-f5de-47ee-9b21-0cb6f9049bc6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Private Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,104,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_7653d5f4-622c-4e12-b949-15400631d4f1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_13bda9ef-a43d-4945-8aa9-0cae0d8d0725;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659319910640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="section185" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has evaluated subsequent events for recognition and disclosure purposes in the audited consolidated financial statements as of December 31, 2022. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">B. Riley Standby Equity Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 8, 2023, the Company entered into a Standby Equity Purchase Agreement (the "B. Riley Purchase Agreement") with B. Riley, whereby the Company shall have the right, but not the obligation, to sell to B. Riley up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of its shares of the Company&#8217;s Common Stock at the Company's request any time during the 36 months following the execution of the B. Riley Purchase Agreement, subject to certain conditions. The Company expects to use the net proceeds received from this for working capital and general corporate purposes.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for B. Riley&#8217;s commitment to purchase shares of Common Stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock to B. Riley in connection with the execution of the B. Riley Purchase Agreement on January 12, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to the execution of the B. Riley Purchase Agreement, the Company sold an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,241</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock pursuant to the B. Riley Purchase Agreement for aggregate net proceeds to the Company of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scilex Holding Company 2023 Inducement Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 17, 2023, the Compensation Committee of the Board of Directors (the &#8220;Compensation Committee&#8221;) of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#8220;Plan&#8221;). The Plan will serve to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company as employees by affording such individuals an opportunity to acquire a proprietary interest in the Company. The Plan provides for the grant of equity-based awards in the form of non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards (as set forth under the Plan) solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initial maximum number of shares available for grant under the Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,400,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendment to the Yorkville Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 8, 2023, the Company entered into an Amended and Restated Standby Equity Purchase Agreement with Yorkville (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;), amending, restating and superseding the Yorkville Purchase Agreement dated November 17, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the A&amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the lowest daily volume weighted average price of the Common Stock for any trading day on the date of delivery of a written purchase notice to Yorkville.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to December 31, 2022, the Company sold an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds to the Company of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Elyxyb License</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 12, 2023, the Company acquired from BioDelivery Sciences International, Inc. (&#8220;BSDI&#8221;) and Collegium Pharmaceutical, Inc. (&#8220;Collegium&#8221;, and together with BDSI, the &#8220;Collegium Sellers&#8221;) the rights to certain patents,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB (celecoxib oral solution) (the &#8220;Product&#8221;) and its commercialization in the United States and Canada (the &#8220;Territory&#8221;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the acquisition, the Company assumed various rights and obligations under that certain asset purchase agreement, dated August 3, 2021 (the &#8220;DRL APA&#8221;), between BDSI and Dr. Reddy&#8217;s Laboratories Limited, a company incorporated under the laws of India (&#8220;DRL&#8221;), including a license from DRL including an irrevocable, royalty-free, exclusive license to know-how and patents of DRL related to the Product and necessary or used to exploit the Product in the Territory. Additionally, under the Purchase Agreement, the Seller granted the Company an irrevocable, royalty-free, exclusive license to know-how related to the Product and necessary or used to exploit the Product in the Territory. No cash consideration was or will be payable to Collegium Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties for sales of the Product in the Territory for all indications and additional amounts if certain milestones are achieved.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sorrento Chapter 11 filing</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the Company is not a debtor in Sorrento&#8217;s voluntary Chapter 11 filing and management does not expect this will impact the Company and will continue to operate its business as usual. As of December 31, 2022, the Company had a $1.8 million receivable from Sorrento, which was fully reserved.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659317635648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution.  Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values.  Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and  2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices.  Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounts Receivable, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines inventory cost on a first-in, first-out basis.  The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for on-hand inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. As of December 31, 2022 and  2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company&#8217;s inventory was primarily comprised of finished goods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="section153" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are carried at cost less accumulated depreciation.  Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.  The cost of repairs and maintenance is expensed as incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><p id="section154" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisitions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, up-front payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations unless there is an alternative future use.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent Consideration</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Topic 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Other Long-Lived Assets</a></td>
<td class="text"><p id="section157" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill and Other Long-Lived Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired.  Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill.  The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company.  If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock', window );">Public Warrants and Private Placement Warrants</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Public Warrants and Private Placement Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon completion of the Business Combination, the Company assumed public and private placement warrants (&#8220;Public Warrants&#8221; and &#8220;Private Warrants&#8221;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on January 11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic No. 815-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contracts on an Entity&#8217;s Own Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic 815-40. The Private Warrants are not considered indexed to the Company&#8217;s stock per ASC Subtopic 815-40 as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a fixed-for-fixed option contract. Therefore, Private Warrants are recognized as derivative liabilities </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">at their estimated fair value on November 10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet date, with fair value changes recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt</a></td>
<td class="text"><p id="section159" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates.  This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><p id="section160" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Derivative Liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="section161" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses the cost of research and development as incurred.  Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.  Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="section162" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provisions of the FASB ASC Topic 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Subtopic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.  The Company has determined that it has uncertain tax positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized.  As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company maintained a full valuation allowance against its deferred tax assets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="section163" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.  As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.  The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives.  The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="section164" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#8217;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.  Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December 31, 2022 and 2021 were not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rebates and Chargebacks</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rebates are discounts which the Company pays under either government or private health care programs.  Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers.  Both types of rebates vary over time.  The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prompt Payment Discounts</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Service Fees</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services.  The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product Returns</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Co-Payment Assistance</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive co- payment assistance.  The Company accrues for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Concentration Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to April 2, 2022, sales to the Company's sole distributor represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of net revenue. On April 2, 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The distributor continued to provide traditional third-party logistics functions for the Company. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company had four customers during the year ended December 31, 2022, which individually generated 10% or more of the Company&#8217;s total revenue. These customers accounted for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Company&#8217;s revenue for the year ended December 31, 2022, individually ranging between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As of December 31, 2022, these customers represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Company&#8217;s outstanding accounts receivable, individually ranging between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Additionally, during the fiscal years ended December 31, 2022 and 2021, the Company purchased inventory from its sole supplier, Itochu. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="section166" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation &#8211; Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or non-employee&#8217;s vesting period. The Company accounts for forfeitures as incurred.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of non-opioid products focused on pain management based on its platform technologies and all sales are based in the United States.  Accordingly, the Company has determined that it operates its business as a single reportable segment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the FASB issued ASU 2021-08, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Warrant And Private Placement Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320029248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the reconciliation of basic and diluted loss per share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020  (in thousands except per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.878%;"/>
        <td style="width:1.579%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.763%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.589%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.763%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.589%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.837%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to Scilex</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,364</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,519</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to participating securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,364</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,519</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common shares outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,226</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of Dilutive Securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator for Diluted Loss per Share - Adjusted for Dilutive Securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,226</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and Diluted Loss Per Share</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.67</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659324477040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value assets measured on a recurring basis</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.662%;"/>
        <td style="width:1.237%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.138%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.223%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.123%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.223%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.578999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.223%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.594%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs (Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs (Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,184</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,184</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_1b42e5e5-376a-4619-9690-cb8f5630cc07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,231</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,231</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_708be5d4-a9d0-4908-bbbe-b2da444eaa07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_174a237b-3e62-4fa6-915e-8a53d0d37000;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,394</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,394</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.297%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.901%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.901%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.521%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value measurements at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs (Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs (Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,338</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,338</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,338</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,338</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2e14ac05-2d70-479b-834b-0da0a2e27285;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derivative liabilities</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,700</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,700</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.153%;"/>
        <td style="width:1.916%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.93%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending Balance at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loan derivative liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,800</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Re-measurement of fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">800</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,400</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Re-measurement of fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,700</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Private Warrant liability acquired as part of the Business Combination</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,545</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeiture of Private Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,696</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value measurement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,710</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,231</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskTextBlock', window );">Schedule of quantitative information regarding Level 3 fair value measurements</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants. A summary of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inputs used in valuing the derivative warrant liabilities is as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.537%;"/>
        <td style="width:1.624%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.624%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.107%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 10, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.99</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.50</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.50</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.86</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.94</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Call option value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13572-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13587-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659325988016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment consisted of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.32%;"/>
        <td style="width:1.583%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.583%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.742%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers &amp; equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">689</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">689</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">932</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">772</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320049712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Summary of identifiable intangible assets</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the Company&#8217;s identifiable intangible assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and December 31, 2021 is as follows (in thousands):</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:40.216%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.583000000000002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.293%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.827%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.293%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.787%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangibles, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent rights</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,630</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,215</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired technology</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,940</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,216</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,724</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired licenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,711</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,527</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assembled workforce</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">375</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,781</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,190</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:39.894%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.459%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.28%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.447%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.268%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.651%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangibles, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent rights</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,630</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,239</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,391</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired technology</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,940</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,754</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,186</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assembled workforce</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,070</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,268</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,802</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization expense related to intangible assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated future amortization expense related to intangible assets at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:85.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.621%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,006</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,006</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,006</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,436</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320245072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of borrowings of the scilex notes consisted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Borrowings of the Scilex Notes consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.099%;"/>
        <td style="width:1.781%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.12%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,997</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt discount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,597</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carrying value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101,172</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long term portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,037</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company made principal payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, respectively. The amount of debt discount and debt issuance costs included in interest expense for the years ended December 31, 2022, 2021, and 2020 was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The Company recorded a gain on debt extinguishment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a loss on debt extinguishment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gain/loss on debt extinguishment in connection with its repayments of principal made during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659318686992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options Valuation Assumption Used</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the year ended 2020 is set forth below:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.208%;"/>
        <td style="width:0.344%;"/>
        <td style="width:1.0%;"/>
        <td style="width:24.32%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.127%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted &#8211;average grant date fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock-price volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.53</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term of options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value per share of common stock on date of grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.72</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.72</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Outstanding Activity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following represents a summary of the options outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 and changes during the years then ended (in thousands, other than weighted-average exercise price):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.598%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.255%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.419%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.51%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.991%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.228000000000002%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average exercise price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,183</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,172</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.72</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">502</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.40</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,746</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,172</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,778</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.01</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,968</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.68</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">915</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">202</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.47</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,827</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.72</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.68</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,942</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,487</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.70</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659323234720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.455%;"/>
        <td style="width:1.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.094%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.094%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.225%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost*</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">623</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">904</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Inclusive of variable lease costs, sublease income, and impairment, which were immaterial</span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for the periods presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Leases Supplemental Quantitative Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental quantitative information related to leases includes the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:58.253%;"/>
        <td style="width:1.964%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.925%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.954%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.904%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">746</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">654</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets obtained in exchange for new operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term in years &#8212; operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate &#8212; operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Maturities of Lease Liabilities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were as follows (in thousands):</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.856%;"/>
        <td style="width:1.475%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.67%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">872</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">703</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,575</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,410</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less current portion of lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">745</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability, net of current portion</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659323482944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Benefit for Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the provision expense (benefit) were as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.996%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current income tax expense (benefit):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax expense (benefit):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,396</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,981</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,970</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,851</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,472</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,247</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,453</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,347</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,900</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,422</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,007</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax benefit from continuing operations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Liabilities and Related Valuation Allowance</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows as of  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.599%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.049%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.123%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,984</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,714</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt related interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,205</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,630</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,630</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,602</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,233</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expense and reserves</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">568</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,517</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">315</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">404</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">236</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,462</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,939</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,543</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,643</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,919</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,296</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,666</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,975</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">319</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,296</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s provision for income taxes are as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020  (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.996%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.388%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,905</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,150</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,900</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,422</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,007</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discount and interest limitation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,293</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,954</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">806</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,469</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">224</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">166</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisition related charges</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">992</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior year true-up and carryback</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">713</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,968</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,955</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State, net of federal tax benefit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,545</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,164</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax credits and incentives</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">728</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">993</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">235</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.899%;"/>
        <td style="width:1.376%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.985000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.386%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.985000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.386%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.985000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">406</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">385</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ending balance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">406</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659318528544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the reconciliation of basic and diluted loss per share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020  (in thousands except per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.878%;"/>
        <td style="width:1.579%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.763%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.589%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.763%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.589%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.837%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to Scilex</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,364</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,519</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to participating securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,364</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,519</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average common shares outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,226</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of Dilutive Securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator for Diluted Loss per Share - Adjusted for Dilutive Securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,226</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,891</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and Diluted Loss Per Share</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.67</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:55.176%;"/>
        <td style="width:1.15%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.671%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.161%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.682%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.161%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,939,093</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,967,724</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,746,432</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,899,988</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_3ea715ce-1b17-4fc1-b25f-7f625140097e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_bdcbe9bc-f5de-47ee-9b21-0cb6f9049bc6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Private Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,104,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_7653d5f4-622c-4e12-b949-15400631d4f1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_13bda9ef-a43d-4945-8aa9-0cae0d8d0725;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659318216176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionCostsAmount', window );">Transaction costs amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockExchangeRatioDescription', window );">Common stock exchange ratio, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">as part of the consideration using the 0.673498:1 ratio of the Company Common Stock to Legacy Scilex Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,939,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">$ 4,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,835,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_VickersDebtAgreementMember', window );">Vickers Debt Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Offset against the equity proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiabilityClassifiedPrivateWarrants', window );">Liability classified private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_DebtExchangeAgreementMember', window );">Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of stock, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfNetRevenueSoleDistributors', window );">Percentage of net revenue, sole distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Four Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Minimum [Member] | Four Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Maximum [Member] | Four Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Four Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Minimum [Member] | Four Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Maximum [Member] | Four Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,060,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Vickers Debt Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of stock, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,330,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,905,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sclx_LegacyScilexCommonStockMember', window );">Legacy Scilex Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfCommonStock', window );">Conversion of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,566,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sclx_LegacyScilexStockOptionsMember', window );">Legacy Scilex Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfCommonStock', window );">Conversion of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,151,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockExchangeRatioDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Exchange Ratio, Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockExchangeRatioDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LiabilityClassifiedPrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability classified private warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LiabilityClassifiedPrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfNetRevenueSoleDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net revenue, sole distributors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfNetRevenueSoleDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_VickersDebtAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_VickersDebtAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_DebtExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_DebtExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sclx_FourCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sclx_FourCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_LegacyScilexCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_LegacyScilexCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_LegacyScilexStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_LegacyScilexStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659317669328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 28, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkingCapital', window );">Negative working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">$ 4,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,634)<span></span>
</td>
<td class="num">(35,838)<span></span>
</td>
<td class="num">$ (35,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(375,914)<span></span>
</td>
<td class="num">(352,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,900<span></span>
</td>
<td class="nump">$ 47,850<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_FundingCommitmentLetterMember', window );">Funding Commitment Letter [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Debt, Maximum Amount During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party</a></td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember', window );">Scilex Pharma Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Debt principal forgive</a></td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LiquidityAndGoingConcernLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LiquidityAndGoingConcernLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_FundingCommitmentLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_FundingCommitmentLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659318715488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of the calculation of basic and diluted net income per ordinary share - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average ordinary shares outstanding</a></td>
<td class="nump">134,226<span></span>
</td>
<td class="nump">132,858<span></span>
</td>
<td class="nump">132,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding</a></td>
<td class="nump">134,226<span></span>
</td>
<td class="nump">132,858<span></span>
</td>
<td class="nump">132,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per ordinary share</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659324606944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 14, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 18, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
<td class="nump">132,858,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AmountDueForNewDrugApplication', window );">Amount due for New Drug Application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentUponTheAchievementOfNetSales', window );">Payment upon the achievement of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Development Milestones Payment was recognized under other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_RomegLicenseAgreementMember', window );">Romeg License Agreement [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentUponTheAchievementOfNetSales', window );">Payment upon the achievement of net sales</a></td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Upfrontlicensefee', window );">Up-front license fee</a></td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible asset</a></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for Royalties</a></td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Deferredconsiderationliabilities', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=sclx_TwoThousandTwentyTwoPromissoryNoteMember', window );">2022 Promissory Note [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes Payable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Subordinated Borrowing, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AmountDueForNewDrugApplication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due for New Drug Application</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AmountDueForNewDrugApplication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Deferredconsiderationliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>DeferredConsiderationLiabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Deferredconsiderationliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentUponTheAchievementOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>payment upon the achievement of net sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentUponTheAchievementOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Upfrontlicensefee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>UpFrontLicenseFee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Upfrontlicensefee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_RomegLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_RomegLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=sclx_TwoThousandTwentyTwoPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=sclx_TwoThousandTwentyTwoPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320222768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Private Placement (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementDetailsLineItems', window );"><strong>Private Placement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrivatePlacementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrivatePlacementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659326220720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional amount borrowed</a></td>
<td class="nump">$ 412,136<span></span>
</td>
<td class="nump">$ 128,661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659317640752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Jun. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,310)<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="num">$ (800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Liabilities, Fair Value Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RiskAdjustedNetSalesForecast', window );">Risk Adjusted Net Sales Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield', window );">Debt Securities, Available-for-Sale, Weighted Average Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Common stock upon conversation of cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyAccrualDiscountRate', window );">Discount rate of FDA</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfContingentConsideration', window );">Development Milestone Payment</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DerivativeWarrantLiabilityPrivateWarrants', window );">Derivative warrant liability private warrants</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DerivativeWarrantLiabilityPrivateWarrants', window );">Derivative warrant liability private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DerivativeWarrantLiabilityPrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative warrant liability private warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DerivativeWarrantLiabilityPrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RiskAdjustedNetSalesForecast">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk adjusted net sales forecast</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RiskAdjustedNetSalesForecast</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average yield of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyAccrualDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate applied to the undiscounted amount of estimated damages for product liability to arrive at the present value recorded as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyAccrualDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659325154560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,184<span></span>
</td>
<td class="nump">$ 4,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,184<span></span>
</td>
<td class="nump">$ 4,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Warrant Liability &#8211; Private Placement Warrants</a></td>
<td class="nump">$ 30,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="nump">$ 33,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">35,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Conversion Option Liability (see Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">4,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">4,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Conversion Option Liability (see Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Conversion Option Liability (see Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">35,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Conversion Option Liability (see Note 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659320213840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Options per share fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 10 months 9 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659326084192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, Beginning</a></td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="nump">$ 33,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementWarrantLiabilityAcquired', window );">Private Warrant liability acquired as part of the Business Combination</a></td>
<td class="nump">2,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LoanDerivativeLiability', window );">Loan derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ReMeasurementOfFairValue', window );">Re-measurement of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ForfeitureOfPrivateWarrants', window );">Forfeiture of Private Warrants</a></td>
<td class="nump">1,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInValuationInputsOrOtherAssumptions', window );">Change in fair value measurement</a></td>
<td class="num">(38,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, Ending</a></td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInValuationInputsOrOtherAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in valuation inputs or other assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInValuationInputsOrOtherAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ForfeitureOfPrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forfeiture of Private Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ForfeitureOfPrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LoanDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan derivative liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LoanDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrivatePlacementWarrantLiabilityAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private placement warrant liability acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrivatePlacementWarrantLiabilityAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ReMeasurementOfFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Re-measurement of fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ReMeasurementOfFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659316768176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of derivative component of the obligation is initially valued and classified as a derivative liability - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract', window );"><strong>Schedule of derivative component of the obligation is initially valued and classified as a derivative liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EquityValue', window );">Equity Value</a></td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="nump">$ 9.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.91%<span></span>
</td>
<td class="nump">3.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CallOptionValue', window );">Call option value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CallOptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Call option value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CallOptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659319396352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of change in the fair value of conversion option liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ReMeasurementOfFairValue', window );">Re-measurement of fair value</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="num">$ (800)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ReMeasurementOfFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Re-measurement of fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ReMeasurementOfFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659326170144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 939<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">772<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers &amp; equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659324675952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659317059840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 13,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,481<span></span>
</td>
<td class="nump">$ 13,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life for identifiable intangible assets</a></td>
<td class="text">10 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,922<span></span>
</td>
<td class="nump">$ 3,738<span></span>
</td>
<td class="nump">$ 3,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Romeg License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition consideration transferred amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember', window );">Patent rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember', window );">Assembled workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659316935344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 60,781<span></span>
</td>
<td class="nump">$ 55,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">20,190<span></span>
</td>
<td class="nump">16,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">40,591<span></span>
</td>
<td class="nump">38,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember', window );">Patent rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">32,630<span></span>
</td>
<td class="nump">32,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">13,415<span></span>
</td>
<td class="nump">11,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">19,215<span></span>
</td>
<td class="nump">21,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredTechnologyMember', window );">Acquired technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">21,940<span></span>
</td>
<td class="nump">21,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">6,216<span></span>
</td>
<td class="nump">4,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">15,724<span></span>
</td>
<td class="nump">17,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredLicensesMember', window );">Acquired licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">5,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">5,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember', window );">Assembled workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659323134976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract', window );"><strong>Year Ended December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2023</a></td>
<td class="nump">$ 4,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2024</a></td>
<td class="nump">4,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2025</a></td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2026</a></td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2027</a></td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">20,436<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets', window );">Total</a></td>
<td class="nump">$ 40,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated future amortization expense related to intangible assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659313115488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 03, 2022</div></th>
<th class="th"><div>Jun. 02, 2022</div></th>
<th class="th"><div>Feb. 15, 2022</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
<th class="th"><div>Sep. 07, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 28, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Feb. 16, 2022</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Dec. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,000,000.0<span></span>
</td>
<td class="nump">$ 45,900,000<span></span>
</td>
<td class="nump">$ 69,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on debt extinguishment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,634,000)<span></span>
</td>
<td class="nump">12,463,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember', window );">2018 Purchase Agreements and Indenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentPurcahsePrice', window );">Purcahse price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ActualCumulativeNetSales', window );">Actual cumulative net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncreaseOfPrincipalBalance', window );">Increase of Principal Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubordinatedDebt', window );">Subordinated loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NotePrincipalReductionAmount', window );">Note Principal Reduction Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregatePrincipalAmount', window );">AggregatePrincipalAmount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_RelatedPartyNotesPayableMember', window );">Related Party Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PromissoryNote', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2018 Purchase Agreements and Indenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CashRequirement', window );">Cash Requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">2020 Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan', window );">Accounts receivable revolving loan facility in an aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Line Of Credit FacilityI nterest Rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_AmendmentNumberFourMember', window );">Amendment Number Four [Member] | 2018 Purchase Agreements and Indenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ForgivenAmount', window );">Forgiven amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NotePrincipalReductionAmount', window );">Note Principal Reduction Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepurchasePrincipalInPercentage', window );">Repurchase Principal In Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CashReceivedFromParentCompany', window );">Cash Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumCashRequirement', window );">Minimum Cash Requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on debt extinguishment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueDecrease', window );">Fair value decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CarryingValueIncreased', window );">Carrying value increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_AmendmentNumberFourMember', window );">Amendment Number Four [Member] | Maximum [Member] | 2018 Purchase Agreements and Indenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregatePrincipalAmount', window );">AggregatePrincipalAmount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ActualCumulativeNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actual cumulative net sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ActualCumulativeNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CarryingValueIncreased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value increased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CarryingValueIncreased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CashReceivedFromParentCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Received From Parent company</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CashReceivedFromParentCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CashRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Requirement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CashRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentPurcahsePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument purcahse price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentPurcahsePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value decrease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ForgivenAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forgiven amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ForgivenAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncreaseOfPrincipalBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase of Principal Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncreaseOfPrincipalBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumCashRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Cash Requirement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumCashRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NotePrincipalReductionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note Principal Reduction Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NotePrincipalReductionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory note</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepurchasePrincipalInPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase Principal In Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepurchasePrincipalInPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of revolving financing receivable converted to term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI https://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120270059-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRevolvingConvertedToTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=d3e107314-111719<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of subordinated debt (with initial maturities beyond one year or beyond the operating cycle if longer). Subordinated debt places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_RelatedPartyNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_RelatedPartyNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_AmendmentNumberFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_AmendmentNumberFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659323238944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of borrowings of the scilex notes consisted (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal</a></td>
<td class="nump">$ 133,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(30,597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(2,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaperAtCarryingValue', window );">Carrying value</a></td>
<td class="nump">101,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion</a></td>
<td class="num">(29,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Long term portion</a></td>
<td class="nump">72,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 115,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaperAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaperAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659312813600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 04, 2019</div></th>
<th class="th"><div>Feb. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,000,000<span></span>
</td>
<td class="nump">740,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
<td class="nump">132,858,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
<td class="nump">132,858,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,899,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_FirstAmendedCertificateOfIncorporationMember', window );">First Amended Certificate of Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecondAmendedCertificateOfIncorporationMember', window );">Second Amended Certificate of Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,566,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecondAmendedCertificateOfIncorporationMember', window );">Second Amended Certificate of Incorporation [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_EquityPurchaseAgreementMember', window );">Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value</a></td>
<td class="nump">$ 500,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfStockPercentage', window );">Purchase of stock, percentage</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_EquityPurchaseAgreementMember', window );">Equity Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_StructuringFees', window );">Structuring fees</a></td>
<td class="nump">$ 10,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants [Member] | Warrant Transfer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to transfer shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants [Member] | Warrant Transfer Agreement [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants [Member] | Warrant Transfer Agreement [Member] | Sorrento Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseOfStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of stock, percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseOfStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StructuringFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Structuring Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StructuringFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_FirstAmendedCertificateOfIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_FirstAmendedCertificateOfIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_SecondAmendedCertificateOfIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_SecondAmendedCertificateOfIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_EquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_EquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sclx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_WarrantTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_WarrantTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sclx_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sclx_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_SorrentoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_SorrentoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659316772176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant Liability</a></td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="nump">$ 33,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">50,288<span></span>
</td>
<td class="nump">301,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="nump">412,136<span></span>
</td>
<td class="nump">128,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(375,914)<span></span>
</td>
<td class="num">(352,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Equity (Deficit)</a></td>
<td class="nump">$ 36,239<span></span>
</td>
<td class="num">$ (223,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659316878224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Valuation Assumption Used (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Fair value per share of common stock on date of grant</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember', window );">Black-Scholes Option Pricing Method [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted -average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock-price volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Fair value per share of common stock on date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659317153648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning Balance</a></td>
<td class="nump">18,968,000<span></span>
</td>
<td class="nump">20,746,000<span></span>
</td>
<td class="nump">17,114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Outstanding, Exercised</a></td>
<td class="num">(202,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(38,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options Outstanding, Forfeited/Cancelled</a></td>
<td class="num">(1,827,000)<span></span>
</td>
<td class="num">(1,778,000)<span></span>
</td>
<td class="num">(502,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending Balance</a></td>
<td class="nump">16,939,000<span></span>
</td>
<td class="nump">18,968,000<span></span>
</td>
<td class="nump">20,746,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Exercisable</a></td>
<td class="nump">14,487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning Balance</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0.47<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="nump">1.72<span></span>
</td>
<td class="nump">1.01<span></span>
</td>
<td class="nump">1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending Balance</a></td>
<td class="nump">1.68<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 38,942<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 2,172<span></span>
</td>
<td class="nump">$ 2,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659317028160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Nov. 09, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,939,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of option outstanding to purchase common stock</a></td>
<td class="nump">16,939,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,939,000<span></span>
</td>
<td class="nump">18,968,000<span></span>
</td>
<td class="nump">20,746,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,114,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,280<span></span>
</td>
<td class="nump">$ 5,822<span></span>
</td>
<td class="nump">$ 5,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employee benefit plan contributions by employer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">14,622,712<span></span>
</td>
<td class="nump">24,000,000.0<span></span>
</td>
<td class="nump">14,622,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options vesting description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandNineteenStockOptionPlanMember', window );">2019 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock options vesting description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember', window );">2022 Equity Incentive Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription', window );">Shares of common stock reserved for future issuance, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">if any, as such shares become available from time to time, which the amount will be increased commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of (i) 4% of the total number of shares of Common Stock outstanding on December 31 of the preceding year, (ii) 7,311,356 shares of Common Stock, and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of total number of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear', window );">Common stock capital incremental shares reserved for future issuance each year</a></td>
<td class="nump">7,311,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,311,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of option outstanding to purchase common stock</a></td>
<td class="nump">16,939,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,939,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation cost related to unvested stock option grants</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WeightedAveragePeriodOverGrant', window );">Weighted average period over grant</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember', window );">2022 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,462,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription', window );">Shares of common stock reserved for future issuance, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of shares of the Common Stock that will be reserved for issuance will automatically increase on January 1 of each year for a period of up to ten years, commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of (i) 1% of the total number of shares of the Common Stock outstanding on December 31 of the immediately preceding calendar year; (ii) 1,827,839 shares of the Common Stock; and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year, provided however, that the Board may act prior to January 1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i) to (iii) above.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of total number of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear', window );">Common stock capital incremental shares reserved for future issuance each year</a></td>
<td class="nump">1,827,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,827,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of option outstanding to purchase common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Incremental Shares Reserved For Future Issuance Each Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WeightedAveragePeriodOverGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WeightedAveragePeriodOverGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sets forth the nature of any other increase or decrease in the number of shares reserved for issuance under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659325871104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost*</a></td>
<td class="nump">$ 469<span></span>
</td>
<td class="nump">$ 623<span></span>
</td>
<td class="nump">$ 904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659323326704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="num">$ (746)<span></span>
</td>
<td class="num">$ (654)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases remaining lease term</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659317108768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities as of December 31, 2022</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liability</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LeaseLiabilityNetOfCurrentPortion', window );">Lease liability, net of current portion</a></td>
<td class="nump">$ 665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LeaseLiabilityNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liability, net of current portion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LeaseLiabilityNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659312635952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2020</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Feb. 28, 2013</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Developers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Accrued royalty payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementMaturityDate', window );">Agreement maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  02,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MaturityRenewalDescription', window );">Agreement maturity renewal description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon 6-month written notice.  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Developers [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageRelatedToFutureYears', window );">Royalty payment percentage related to future years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Developers [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageRelatedToFutureYears', window );">Royalty payment percentage related to future years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember', window );">Exclusive Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MaturityRenewalDescription', window );">Agreement maturity renewal description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears', window );">Annual adjustment distribution fee percentage related to future years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementInitialTerm', window );">Agreement initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember', window );">Exclusive Distribution Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DistributionFeesPercentage', window );">Distribution fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember', window );">Exclusive Distribution Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DistributionFeesPercentage', window );">Distribution fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember', window );">Project Agreement [Member] | Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementMaturityDate', window );">Agreement maturity date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MaturityRenewalDescription', window );">Agreement maturity renewal description</a></td>
<td class="text">extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with 90 days&#8217; notice<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Sales operation implementation fees</a></td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember', window );">Project Agreement [Member] | Vendor [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Sales operation implementation fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember', window );">Project Agreement [Member] | Vendor [Member] | Minimum [Member] | Monthly [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Sales operation implementation fees</a></td>
<td class="nump">63,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember', window );">Project Agreement [Member] | Vendor [Member] | Maximum [Member] | Monthly [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Sales operation implementation fees</a></td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember', window );">Non-cancelable Lease Agreements [Member] | Administrative Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">26 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember', window );">Non-cancelable Lease Agreements [Member] | Minimum [Member] | Research and Development Facilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember', window );">Non-cancelable Lease Agreements [Member] | Maximum [Member] | Research and Development Facilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Initial Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Maturity Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Adjustment Distribution Fee Percentage Related To Future Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DistributionFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distribution Fees Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DistributionFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MaturityRenewalDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity Renewal Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MaturityRenewalDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RoyaltyPaymentPercentageRelatedToFutureYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Percentage Related To Future Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RoyaltyPaymentPercentageRelatedToFutureYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_DevelopersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_DevelopersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_VendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_VendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FrequencyOfPaymentsAxis=sclx_MonthlyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FrequencyOfPaymentsAxis=sclx_MonthlyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_AdministrativeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_AdministrativeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_ResearchAndDevelopmentFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_ResearchAndDevelopmentFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659326173680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Benefit for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(10,396)<span></span>
</td>
<td class="num">(12,981)<span></span>
</td>
<td class="num">(3,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,851)<span></span>
</td>
<td class="num">(2,472)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(12,247)<span></span>
</td>
<td class="num">(15,453)<span></span>
</td>
<td class="num">(4,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Changes in tax rate</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">10,900<span></span>
</td>
<td class="nump">15,422<span></span>
</td>
<td class="nump">4,007<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659316733696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 48,984<span></span>
</td>
<td class="nump">$ 39,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsDebtRelatedInterest', window );">Debt related interest</a></td>
<td class="nump">15,272<span></span>
</td>
<td class="nump">12,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">1,630<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">1,602<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsAccruedExpenseAndReserves', window );">Accrued expense and reserves</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Others</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total Deferred Tax Assets</a></td>
<td class="nump">70,462<span></span>
</td>
<td class="nump">58,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(67,543)<span></span>
</td>
<td class="num">(56,643)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total Deferred Tax Assets</a></td>
<td class="nump">2,919<span></span>
</td>
<td class="nump">2,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(2,666)<span></span>
</td>
<td class="num">(1,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">(2,919)<span></span>
</td>
<td class="num">(2,296)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsAccruedExpenseAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, accrued expense and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsAccruedExpenseAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsDebtRelatedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, debt related interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsDebtRelatedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659324700192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate</a></td>
<td class="num">$ (4,905)<span></span>
</td>
<td class="num">$ (19,150)<span></span>
</td>
<td class="num">$ (9,408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">10,900<span></span>
</td>
<td class="nump">15,422<span></span>
</td>
<td class="nump">4,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount', window );">Debt discount and interest limitation</a></td>
<td class="num">(9,293)<span></span>
</td>
<td class="nump">8,954<span></span>
</td>
<td class="num">(806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Compensation expense</a></td>
<td class="nump">2,469<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges', window );">Acquisition related charges</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior year true-up and carryback</a></td>
<td class="num">(713)<span></span>
</td>
<td class="num">(3,968)<span></span>
</td>
<td class="nump">6,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal tax benefit</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(2,545)<span></span>
</td>
<td class="num">(1,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Income tax credits and incentives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation debt discount amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation acquisition related charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxReconciliationAcquisitionRelatedCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659323035328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease related to prior year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659317062048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">67,543<span></span>
</td>
<td class="nump">56,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development income tax credits</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TaxCreditCarryForwardsExpirationYear', window );">Tax credit carry forwards expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Total unrecognized tax benefits</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax expense, interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liabilities for uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 205,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards, expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 106,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards, expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TaxCreditCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TaxCreditCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659312256320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Sep. 12, 2022</div></th>
<th class="th"><div>Oct. 22, 2018</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Jan. 13, 2021</div></th>
<th class="th"><div>Mar. 18, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
<td class="nump">132,858,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
<td class="nump">132,858,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyPayable', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 92,724,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkingCapital', window );">Working Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayable', window );">Advances in note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="nump">13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal balance</a></td>
<td class="nump">$ 47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Promissory note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties', window );">Repayment of indebtedness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesNoncurrent', window );">Related party note payable, net</a></td>
<td class="nump">23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyReceivable', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayable', window );">Advances in note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="nump">10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sclx_ItochuMember', window );">Itochu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,889,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryPurchasedGoods', window );">Inventory purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OutstandingCapitalStockPercent', window );">Outstanding capital stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesNoncurrent', window );">Related party note payable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfNotesReceivable', window );">Proceeds from Sale of Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkingCapital', window );">Working Capital</a></td>
<td class="nump">61,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepurchasesOfNotes', window );">Repurchases of Notes</a></td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LitigationFees', window );">Litigation Fees</a></td>
<td class="nump">18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_AardvarkAssetPurchaseAgreementMember', window );">Aardvark Asset Purchase Agreement [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesNoncurrent', window );">Related party note payable, net</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_DebtExchangeAgreementMember', window );">Debt Exchange Agreement [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Promissory note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtExchangeDescriptions', window );">Debt Exchange Descriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Aggregate Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share); provided, that in no event would the Aggregate Outstanding Amount exceed $ 310,000,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Related party indebtedness converted into shares</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Converted into common stock</a></td>
<td class="nump">2,905,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of stock, amount</a></td>
<td class="nump">$ 290,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAverageAmountOutstanding', window );">Aggregate Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_FinancingReceivableNonaccrualToOutstandingPercent', window );">Aggregate outstanding amount equal percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtExchangeDescriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Exchange Descriptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtExchangeDescriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LitigationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LitigationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OutstandingCapitalStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding capital stock, percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OutstandingCapitalStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepurchasesOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchases of Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepurchasesOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_FinancingReceivableNonaccrualToOutstandingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of nonaccrual to total financing receivable outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_FinancingReceivableNonaccrualToOutstandingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued but unpaid interest on deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAverageAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average amount outstanding of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAverageAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryPurchasedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of components used by the entity which are bought from another entity rather than produced by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryPurchasedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_ItochuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_ItochuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_AardvarkAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_AardvarkAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_DebtExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_DebtExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659312223936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Scilex</a></td>
<td class="num">$ (23,364)<span></span>
</td>
<td class="num">$ (88,424)<span></span>
</td>
<td class="num">$ (47,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic', window );">Net loss attributable to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (23,364)<span></span>
</td>
<td class="num">$ (88,424)<span></span>
</td>
<td class="num">$ (47,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding</a></td>
<td class="nump">134,226<span></span>
</td>
<td class="nump">132,858<span></span>
</td>
<td class="nump">132,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectOfDilutiveSecurities', window );">Effect of Dilutive Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Denominator for Diluted Loss per Share - Adjusted for Dilutive Securities</a></td>
<td class="nump">$ 134,226<span></span>
</td>
<td class="nump">$ 132,858<span></span>
</td>
<td class="nump">$ 132,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">134,226<span></span>
</td>
<td class="nump">132,858<span></span>
</td>
<td class="nump">132,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Loss Per Share</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Loss Per Share</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectOfDilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of Dilutive Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectOfDilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2740-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659323202384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,899,988<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_StockOptionsMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">16,939,093<span></span>
</td>
<td class="nump">18,967,724<span></span>
</td>
<td class="nump">20,746,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_PrivateWarrantsMember', window );">Private Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">4,104,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659316991584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 08, 2023</div></th>
<th class="th"><div>Jan. 08, 2023</div></th>
<th class="th"><div>Jan. 17, 2023</div></th>
<th class="th"><div>Jan. 12, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
<td class="nump">132,858,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | B. Riley Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSaleOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | A&amp;R Yorkville Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSaleOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InducementPlanAxis=sclx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InducementPlanAxis=sclx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_BRileyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_BRileyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140659318573520">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectOfBusinessCombinationInValue', window );">Effect Of Business Combination In Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_EffectOfBusinessCombinationInValue</td>
<td class="num">$ (90,009,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RecapitalizationDueToTheBusinessCombinationValue', window );">Recapitalization Due to the Business Combination Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_RecapitalizationDueToTheBusinessCombinationValue</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectOfBusinessCombinationInValue', window );">Effect Of Business Combination In Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_EffectOfBusinessCombinationInValue</td>
<td class="nump">126,585,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RecapitalizationDueToTheBusinessCombinationValue', window );">Recapitalization Due to the Business Combination Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_RecapitalizationDueToTheBusinessCombinationValue</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectOfBusinessCombinationInValue', window );">Effect Of Business Combination In Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_EffectOfBusinessCombinationInValue</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RecapitalizationDueToTheBusinessCombinationValue', window );">Recapitalization Due to the Business Combination Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_RecapitalizationDueToTheBusinessCombinationValue</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectOfBusinessCombinationInValue', window );">Effect Of Business Combination In Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_EffectOfBusinessCombinationInValue</td>
<td class="num">(216,607,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RecapitalizationDueToTheBusinessCombinationValue', window );">Recapitalization Due to the Business Combination Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_RecapitalizationDueToTheBusinessCombinationValue</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectOfBusinessCombinationInValue', window );">Effect Of Business Combination In Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_EffectOfBusinessCombinationInValue</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RecapitalizationDueToTheBusinessCombinationValue', window );">Recapitalization Due to the Business Combination Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_RecapitalizationDueToTheBusinessCombinationValue</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RecapitalizationDuetotheBusinessCombinationShares', window );">Recapitalization DueToThe Business Combination Shares</a></td>
<td class="th" style="border-bottom: 0px;">sclx_RecapitalizationDuetotheBusinessCombinationShares</td>
<td class="nump">132,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectOfBusinessCombinationInShares', window );">Effect of Business Combination In Shares</a></td>
<td class="th" style="border-bottom: 0px;">sclx_EffectOfBusinessCombinationInShares</td>
<td class="nump">132,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sclx_LegacyCommonStockMember', window );">Legacy Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RecapitalizationDueToTheBusinessCombinationValue', window );">Recapitalization Due to the Business Combination Value</a></td>
<td class="th" style="border-bottom: 0px;">sclx_RecapitalizationDueToTheBusinessCombinationValue</td>
<td class="num">$ (20,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RecapitalizationDuetotheBusinessCombinationShares', window );">Recapitalization DueToThe Business Combination Shares</a></td>
<td class="th" style="border-bottom: 0px;">sclx_RecapitalizationDuetotheBusinessCombinationShares</td>
<td class="num">(197,310)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectOfBusinessCombinationInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of Business Combination In Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectOfBusinessCombinationInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectOfBusinessCombinationInValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect Of Business Combination In Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectOfBusinessCombinationInValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RecapitalizationDueToTheBusinessCombinationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recapitalization Due to the Business Combination Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RecapitalizationDueToTheBusinessCombinationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RecapitalizationDuetotheBusinessCombinationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recapitalization DueToThe Business Combination Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RecapitalizationDuetotheBusinessCombinationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_LegacyCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_LegacyCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>sclx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sclx="http://www.scilexholding.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sclx-20221231.xsd" xlink:type="simple"/>
    <context id="C_cea31b52-db39-4e74-9ef9-00fbadd09e8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7eb481bd-4d9b-4545-b52a-3d1554edfd5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8af3e27b-97dd-4b7e-8523-2366035accc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:LegacyScilexCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_4eac9786-7af1-498b-ade8-18ab32ec037e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InducementPlanAxis">sclx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-17</instant>
        </period>
    </context>
    <context id="C_0ee0f0fb-af92-4b7b-b642-acfabbcf105e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-05</startDate>
            <endDate>2018-10-05</endDate>
        </period>
    </context>
    <context id="C_36afe8fd-cd95-4f09-aed3-b9387cac7efb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e229956a-eca3-48a8-a9c3-297169d09bc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="C_ffc67561-e990-47ce-8a93-35879897d05b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_49abe51e-8cd0-4386-b0ec-79317162d36d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="C_c80b9c46-2554-4fc5-8b0f-919a277a3868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="C_27408945-d0d7-44d3-b555-007ee69f44da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_67497c23-14fc-4051-a630-4c59813052eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_305b4be4-c15c-4501-b464-80c28ee532ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9bed26af-6062-4ef5-8277-06de00c7bdeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:AardvarkAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="C_dbf37b66-c5d5-46d3-bd3a-c9a534d9acd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e325ed31-26e8-4093-8e73-8b5f019c9102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fb34a34f-10db-4900-ac2a-b95cc1252ca0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a527389d-306f-4919-bfea-9e278fdd7f82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5024e079-7880-4bc6-b897-722b2e854e4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_01d3fa20-46b6-4e6b-9289-84ca49a349a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_7a74f725-b9ea-4b81-818b-1b7c312abf01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_51878a55-90f9-402f-b4db-e8e5f31208c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d8ba7d57-830b-450b-b045-491a8e4913bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:SorrentoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_560e4782-7a8f-459f-9609-b04f9e8ab33f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_de43cc1f-2fdb-4769-8c7b-6c7cef7cb9b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_ea7b3fbf-8dd6-49a4-a28c-adc88beeb0ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="C_3a251053-d0ea-4cdf-85a7-8504f3883048">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5ecb841e-8811-42ee-b52f-1ff866488d24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8a1e9628-d82e-4638-abce-1a2d0888da09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_da474804-4de4-46da-8eb7-10fd79d64919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_83eae59f-9d4a-4170-b358-a33c0ee64291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d26ddb1f-b0fe-4faf-b8a1-857c9dd18019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2e6b294a-07c5-4bc3-b0f8-28ef1bba9112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_646df392-6d69-4b69-80f2-861bf594ef6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4a5560ce-e23e-4368-8572-860644a67abb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_906ba0ae-005a-42a4-a051-5cdede4e78db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:AdministrativeFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_9da5d773-9803-4cb9-b88b-b575366eed3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="C_60091fdd-6400-442e-a7a0-8a096195f3d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-03</startDate>
            <endDate>2022-06-03</endDate>
        </period>
    </context>
    <context id="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2fac2033-f8b3-4b66-9e60-cd16541fd776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-08</instant>
        </period>
    </context>
    <context id="C_d23acd9a-b5cb-47a5-b3c3-5c16f3f1a346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecondAmendedCertificateOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_0a7981fc-b448-47e6-bbe7-0f3aa97fb3c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_99d36902-bfd3-4b3d-847f-f4e34de66d2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7ca01e5c-64ba-4811-8dd0-2596f60a100f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_00732d84-d8e8-4024-abae-db67a18b5da3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4d25b0fa-f232-49d1-bb07-eac65211d5f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:LegacyCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_47fbaa34-ba91-4f95-8043-9f86ce21361b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2648accc-f3dc-426e-92a2-db64ebe17309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9b7ed203-c059-4dea-8727-86670689b7cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6c47f53f-c811-4186-9ff5-419aa14184c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_8e55c840-7ba5-4068-b9ac-a6ab3b619797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-01</startDate>
            <endDate>2015-08-31</endDate>
        </period>
    </context>
    <context id="C_3ca10b55-83d0-43b1-ba2e-ab5f1c28907e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2023-03-03</instant>
        </period>
    </context>
    <context id="C_ffce1a83-cdb6-4f8b-8ce0-60c88047dbe7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6647079d-3f50-46e5-afdd-7cb5fff7d6ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_dc5b8987-1bb7-4130-9b7a-6a3c9e569fde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-08</startDate>
            <endDate>2023-02-08</endDate>
        </period>
    </context>
    <context id="C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="C_b4cbb81e-b3d2-4016-bb84-fc0e80fe9230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-22</startDate>
            <endDate>2018-10-22</endDate>
        </period>
    </context>
    <context id="C_a481e148-6651-4f1b-8127-50bb57bdbf62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="C_4b0d5c8f-c285-4b81-adfe-90ae2f642ce4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_4ffc6a81-2d13-4ca4-89ec-8c611943a526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:FrequencyOfPaymentsAxis">sclx:MonthlyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="C_10bd7df9-bc0a-460b-b471-0b07966dbf8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:FundingCommitmentLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-08</instant>
        </period>
    </context>
    <context id="C_5f187651-0980-4146-8085-29b42623f970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c57207b1-14a7-41a8-8d5b-1a183f1fb11b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_43ab2205-1c3d-4a4c-81af-b8effc0a8d3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bd06b1ee-3d7a-4324-8584-ffe7cba561aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3ca96e60-bf56-4765-9420-632b08ad825f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:VickersDebtAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_0b6f23f6-2673-4fcb-bf14-d6a9163b7497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_509f938b-6ead-4be2-8bdc-b00905b87017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c64fc25e-92ac-443f-a2c8-1c627ddec5c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0205795c-8a73-4b30-885d-bfc720c71093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7cfc2da8-8fde-41ac-99ad-52a0a1ee5813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e9f1e9c3-d961-4504-8da6-3bd4eb3c8fbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="C_1b29efe1-913c-4907-b34e-894a0a2002b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_74765fdd-abd5-4a48-b447-771ee939f2e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fd0b590c-8ba4-42a9-a808-760e195081f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7bd18d66-7285-40d4-8961-714fd8c2eb8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="C_e5358be9-d8b5-4ee2-b332-0a8d62231dd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1bf41c40-384d-4879-a540-39666147391f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="C_d38defbd-6d26-448d-a459-d2d7ff5e7a40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6adfa385-28e2-4bb5-b8a7-8b66dc48c7de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_02f580e6-c788-4eef-9f36-799127c833b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <context id="C_b97057d7-7304-4fd2-8467-c5db2179660a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1c394325-8608-4ec1-8f78-11dd10ae9413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c1803839-1bed-4d8d-a474-a5546b31743c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dc7d0f2d-5bbb-46cf-929e-8eb3fbe1169a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4216d375-5857-4658-937f-eb7e215cb19f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_26f9a78f-d20f-4189-8bc1-b3bfc1c9e6c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4a8702ad-037a-48f2-8a73-f2f31cbe072b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-28</instant>
        </period>
    </context>
    <context id="C_8b6804ad-db9d-442b-8365-1912fdf47899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:LegacyCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_85fddfc8-ede1-4821-8070-f8272993162e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5732eb05-268c-4927-ab42-4931ac50cee6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-02</instant>
        </period>
    </context>
    <context id="C_7fac449c-067b-401a-bdcc-4e3e9932dff4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cb4e9c2d-4697-4133-b0c7-df08bcc87742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:VickersDebtAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="C_9b5ecdb8-3bc8-4088-bf74-05a8fbd7c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3377c481-f9db-4160-b872-f87f6e365001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_21eb1f4e-32ad-4b44-99ff-e9ffd99b9aa5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_6e32c9b3-9d19-4265-8164-574e03766785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_2416c551-e9fc-44d6-b78f-4b72a1263fbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0a56b9b5-0e8c-4c4c-a42e-683ebcaf8d04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a8bd7dfd-bf6a-41eb-a0d6-21c0c0e518ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="C_ed6ebbfe-7582-45c9-a505-88a5349d8983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_64b784b2-80c2-40ef-8826-8180d2f928c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1a7ce1a3-b831-4b91-8f43-85fae241ba37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_635fb103-c71a-477c-8c47-7047957e404b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="C_3cf5091c-7b41-4d84-af4b-27015818f063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="C_16948957-8702-4576-aa50-3b0b402e4d82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_3313f304-eb89-4d42-83ee-725fd81202b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6bf9409a-d416-4d1d-a445-b90863d1d1c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_44ed269a-dde2-4886-8ee5-2f9c77ffdde5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecondAmendedCertificateOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="C_42d227b9-ddaf-4601-acc3-2ee568156933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="C_bc2eaed7-a292-4f4d-8ddb-007ba59ac15f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c21a30a8-2bf8-4636-8fbe-e62375d50217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_42dde953-1de3-4888-9e2a-9a55861296bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:VickersDebtAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_b620909f-073f-4a76-8775-805e21b71726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ccca58d1-1a9c-4f4b-8d50-efc7509df65b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_f1bc45ab-d342-4c18-b196-5098efc938e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="C_fbd32b12-fb83-432d-9c2d-e70a0b209ce4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="C_a476f78c-ccf8-4bfe-b276-63e339cbc4fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_97b73263-30f4-4653-9e9d-edde5c0042df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3a917c50-4370-49ab-9afd-58aaa9a10804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_efd6a36c-f68c-4a10-8867-54bd97146b01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_46761a2f-b18a-4aaa-8269-68342d732dc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="C_4e69aafa-547e-45e9-bdf7-d87792ef197d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_52e1afd8-0dd3-4e45-8542-1b0396bc18c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ItochuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="C_a34d7e4b-75b0-46b3-9b67-fb0bd31b0200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e0720b69-b850-4e33-b843-ca514f86a042">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ItochuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e1a7d0f1-3664-4a42-9233-282dd426f358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8af8c6e1-609d-44ef-9f26-2b6bd7056a94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_bef67e9a-4b76-4019-893d-8f19c877187f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_5350c734-a3ef-4fd1-88d3-af11b48f40cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4a5c0b06-915d-455f-9fc7-0f9a23843003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="C_a708aae3-4854-410d-ab82-fbfc4a130c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0cfa11ab-3c88-4cef-9e78-7b5083e4ce05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7a25c562-96ff-46d5-bbd4-d140bf78fd97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_05185b29-2199-41ac-97f8-a22476c305be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sclx:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_01b3c958-391f-4745-a694-8e6d618b12d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="C_e30cd740-80d0-4ec4-bcbe-c140def0f039">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c0de8b1c-7d16-427b-aa57-833ab07979da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecondAmendedCertificateOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="C_e39da0e0-163c-455f-965a-58ab13bf9d84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-07</startDate>
            <endDate>2018-09-07</endDate>
        </period>
    </context>
    <context id="C_935d8df9-59c4-47da-a78c-46dc24743107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_464851d6-2036-40d8-94d5-168fe9bff9ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3a4759f2-8d65-4ebd-9e91-79f879ffa0f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dbd5dc57-1898-456c-9638-93bc81132559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5c97eb44-901a-46bb-99e9-b42a24cc2386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_3710aa11-fcfc-4dcd-aacb-4c89272492cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_32ab59f7-6a30-49d8-81a3-b2690ed7e60b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b50d45e3-e036-46e1-88f2-6346a47e412b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="C_cc227406-9649-405a-abe9-80c403455490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ef14117d-6b86-46ed-956e-d73420b1a933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3829a111-1d2a-42cf-8ef3-8eee8d13b455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-28</startDate>
            <endDate>2022-09-28</endDate>
        </period>
    </context>
    <context id="C_6337de38-c2dc-48a8-b488-04cc48d9be24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_a3faac18-7970-4d6f-9b9f-ebaa1c4bc17f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_f6afef57-8906-4dde-a3a5-2e46d3fa8a04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cb7297d5-c3c9-4562-83bf-bfeaeab23e3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-14</instant>
        </period>
    </context>
    <context id="C_3354e157-13ff-4e9f-bfd3-3f7a68647739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-12</startDate>
            <endDate>2022-09-12</endDate>
        </period>
    </context>
    <context id="C_0acf01dd-c0f8-474b-86b7-9a4ee39ecb2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="C_7de5b4e3-ff7d-4a25-8702-760a6461c79b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b13cd8e3-7db7-4217-8072-5fe48b25740e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ae30ee0d-8ccb-47a5-834c-471e858d4c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_e23bb04d-0ba8-4323-a7aa-cc2b64211427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5afaea6d-9fb4-41dc-9415-7c291b048f12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-28</startDate>
            <endDate>2022-09-28</endDate>
        </period>
    </context>
    <context id="C_6e8d69bd-8277-4214-b3a2-0f8215199def">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8b8c6875-5daf-4b8b-bbe3-c55418e62301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-05</startDate>
            <endDate>2018-10-05</endDate>
        </period>
    </context>
    <context id="C_c8f61138-8d7f-420c-9c8d-08f6643abad5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6462068b-60b7-499d-ac23-4f81f11e97d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="C_c1cafa60-e7b5-445c-b9e8-7dc034751dc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ItochuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d408965d-1291-4b37-9b62-a779f1f46c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_58cd7445-cfd3-4b6c-9853-77975484a3f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_52b44a02-592f-4ce7-8c2c-3d786b8c7f58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="C_9c4a15ab-7f26-41bf-ba84-63b74afb22cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-02</instant>
        </period>
    </context>
    <context id="C_8219a545-34c9-4750-80f1-f7f2e16e64f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_81a151cb-066d-45a5-8264-1e0d16707f77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_76b68a36-8bf6-4b4f-ba40-ee105d4ec879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8c37c057-4848-462d-ada1-a24a6cad00dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8c1f3d78-c5e0-4b4b-93a7-3c1f21841465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_456895c8-fe6d-4068-beff-13288c8937f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_43387abc-3f9a-4d01-8539-0e8a069d288c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_218d96e4-ea4f-4f86-8b2f-c64a6bcff94a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_40562d01-6462-499f-a04a-47153823c26b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <context id="C_461cdc24-bee6-49eb-825f-a615ecb35d40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:FourCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2d79b6ca-f817-4000-9690-57cda2cd8b96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:VendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:FrequencyOfPaymentsAxis">sclx:MonthlyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="C_34aca91d-0225-49d8-82d3-b112cf786117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a447a6e2-4ac3-4afb-95ec-8bfbc792b678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_422ae92b-12d6-4a4a-b618-0c2fa63c8e57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-16</instant>
        </period>
    </context>
    <context id="C_5202eaa2-94ce-4852-a791-98e95950e6e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:FirstAmendedCertificateOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-27</instant>
        </period>
    </context>
    <context id="C_5d2870e1-119e-419e-9885-26f2174d6332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a7a078e2-6aea-4910-9389-223a17cbe1d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5431b419-860c-45a2-bb9a-fd5a0ef55758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-08</startDate>
            <endDate>2023-01-08</endDate>
        </period>
    </context>
    <context id="C_cce805c3-34ca-4d41-82ac-e95225784312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_55510dfd-6682-410d-b6b4-4d16606f2bde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e2cce05e-1a26-43e6-8f1f-e439a7aa2acd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="C_d123794d-4e0e-4ed2-bb14-c7d85afb939f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_9b930bf6-320d-4b6c-af8c-5aa608240d49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_edcc144e-d7f7-43da-bd1b-72d518cd963f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7c048ae5-b63f-448b-ac5e-16d9e9290785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_170226e9-c00b-474c-bd4f-5a9963f10134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9a36dab1-2630-4e69-8371-8793ba9072bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="C_6202898d-9295-4896-a66a-61c32e1f4b3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:AardvarkAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="C_98ba01df-597b-4318-aca4-8f7bf10d4909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:LegacyScilexStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="C_fb1d9fe2-1ba9-49c8-9a85-dcf2896bdf52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:EquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="C_47ef1e97-f5b2-4965-919e-b1ad07eae683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_33d1eca1-5b22-4cf6-bc73-83bb4af8df1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_478baeaf-44cf-43d3-a89f-f421fb630ec5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:AmendmentNumberFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="C_777530a8-90c5-459f-8a78-9891fb3b3069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5033dffd-d662-4f5b-9fe3-88e68279b972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6e6757a4-23e1-4b86-9c56-e99208d69c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="C_0eb4f5f3-217e-4d32-9df0-0de97d9de853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a0ff95ef-24d5-464a-957b-98f6e31fc5f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-12</instant>
        </period>
    </context>
    <context id="C_17686498-39e6-4eca-a9d9-732664349cdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ItochuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c1e465a4-3408-4232-a9fe-97ae297cdf9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fe20fc93-e090-4257-8aea-e4facd17edbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="C_7cbfb5ab-baf8-419e-afef-9b3373e009f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:FirstAmendedCertificateOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-04</instant>
        </period>
    </context>
    <context id="C_e39411dd-ee32-4564-9103-dfccf71f4ba3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_a46bc651-8cf6-4139-83ff-4cec7e844fea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d3d7eb79-4633-4e48-bbe1-9c972c6e1a38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9922975f-1d41-4752-92b7-f2ec2c047e71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="C_0eb4f5f3-217e-4d32-9df0-0de97d9de853"
      id="F_6463cc28-8d65-4f96-95bf-abffbc67ff81"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683"
      id="F_9210ffe7-39a4-4a0e-a307-01b932158bee"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="C_0eb4f5f3-217e-4d32-9df0-0de97d9de853"
      id="F_e4a5c6db-30ef-462c-82dd-288b64103342"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6647079d-3f50-46e5-afdd-7cb5fff7d6ba"
      id="F_0bf5a962-5b24-48b1-9002-e5c81894ca56"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683"
      id="F_b5b86b27-0532-49c1-b76c-6f887f0a63fc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bc2eaed7-a292-4f4d-8ddb-007ba59ac15f"
      id="F_aefe8b43-5bdf-4327-b2fa-26db087baf25"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sclx:AccrualForTransactionCostsRelatedToTheBusinessCombination
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      id="F_29c766bb-4fce-4dbc-b8e4-92a68d84c25f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b620909f-073f-4a76-8775-805e21b71726"
      id="F_b54e17bc-61af-4171-b620-195b9f60d357"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization
      contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683"
      id="F_adf58944-3511-4a6c-9e5d-eeee7d745bfb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue
      contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683"
      id="F_54523a10-c706-4fd9-8164-2c0bfdbbf91a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_d7029d50-a9ef-4592-9ed0-d44a967cfa64">--12-31</dei:CurrentFiscalYearEndDate>
    <sclx:AccrualForTransactionCostsRelatedToTheBusinessCombination
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      id="F_6ef1b2d1-d409-4de2-8c2d-7363847d2a82"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_a527389d-306f-4919-bfea-9e278fdd7f82"
      id="F_708be5d4-a9d0-4908-bbbe-b2da444eaa07"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sclx:TransactionCostsObligationAssumedBySorrento
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      id="F_53016aa0-3b61-4375-bbc0-41251f062de2"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sclx:OtherLongTermLiabilities
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      id="F_557d651b-062c-47e0-8442-4e8146558b5a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7c048ae5-b63f-448b-ac5e-16d9e9290785"
      id="F_3ea715ce-1b17-4fc1-b25f-7f625140097e"
      unitRef="U_shares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9b930bf6-320d-4b6c-af8c-5aa608240d49"
      id="F_b1071206-0591-4a2e-8730-fb93dbb2b787"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      id="F_2e14ac05-2d70-479b-834b-0da0a2e27285">http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <sclx:TransactionCostsObligationAssumedBySorrento
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      id="F_ac4101a1-c5ee-4706-a1b3-9f3fcddd0896"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_caaad943-62b2-4ebc-80c9-006fe6443079">0001820190</dei:EntityCentralIndexKey>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456"
      id="F_174a237b-3e62-4fa6-915e-8a53d0d37000"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sclx:OtherLongTermLiabilities
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      id="F_a2bc1cc5-c1e7-43cf-a6f8-b4f4facf181d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      id="F_4a367a12-e012-4165-b149-5a78dbe3c071">http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <sclx:DerivativeWarrantLiabilityPrivateWarrants
      contextRef="C_da474804-4de4-46da-8eb7-10fd79d64919"
      decimals="-5"
      id="F_41f57cde-2f51-43b9-9298-50e67016606a"
      unitRef="U_USD">2500000</sclx:DerivativeWarrantLiabilityPrivateWarrants>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_170226e9-c00b-474c-bd4f-5a9963f10134"
      id="F_7653d5f4-622c-4e12-b949-15400631d4f1"
      unitRef="U_shares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8c37c057-4848-462d-ada1-a24a6cad00dd"
      id="F_a0f75d3a-9e10-4019-b021-87432668c6ac"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sclx:DistributionToSorrentos
      contextRef="C_1b29efe1-913c-4907-b34e-894a0a2002b7"
      id="F_c168d39c-2871-42e8-b79d-b3ce199f3e7b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue
      contextRef="C_9b930bf6-320d-4b6c-af8c-5aa608240d49"
      id="F_3ae621a8-3f3f-4d53-a551-5225faec3ab9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      id="F_1b42e5e5-376a-4619-9690-cb8f5630cc07">http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e5358be9-d8b5-4ee2-b332-0a8d62231dd7"
      id="F_bdcbe9bc-f5de-47ee-9b21-0cb6f9049bc6"
      unitRef="U_shares"
      xsi:nil="true"/>
    <sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement
      contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683"
      id="F_d7125064-9b76-4c9c-9019-5e82b70b444a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sclx:EffectOfBusinessCombinationInValue
      contextRef="C_d123794d-4e0e-4ed2-bb14-c7d85afb939f"
      id="F_14d9603c-d453-4443-95d8-8db6986dc87a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_29bd1289-b520-4e29-8ba1-ad024d26bcc3">false</dei:AmendmentFlag>
    <sclx:RecapitalizationDueToTheBusinessCombinationValue
      contextRef="C_d123794d-4e0e-4ed2-bb14-c7d85afb939f"
      id="F_728917e1-629e-4287-882c-0bb9e7bb1bc9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683"
      id="F_11cebda7-8f87-4267-ac10-7be6b1acda18"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_8c37c057-4848-462d-ada1-a24a6cad00dd"
      id="F_0271b23c-aafd-4698-bd7b-106ba0477b32"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sclx:RecapitalizationDueToTheBusinessCombinationValue
      contextRef="C_6bf9409a-d416-4d1d-a445-b90863d1d1c6"
      id="F_61c0eef7-6384-452f-89b2-2406931de476"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_00732d84-d8e8-4024-abae-db67a18b5da3"
      id="F_13bda9ef-a43d-4945-8aa9-0cae0d8d0725"
      unitRef="U_shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683"
      id="F_a4cda2f0-ffce-4c0e-ae35-a6cbdae92144"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_18bdd4e4-1c39-4997-8142-276300487882">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_efe1a9a6-58f4-4735-a3c3-cf9c01c9b525">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_5269e161-f1d0-44d3-a47d-581709f9f4f1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_d0e317b2-65f6-4ad5-8814-db0bff27a8b3">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_5c0d9927-878f-4b08-9d89-b9859313cddb">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_3e44c532-fc70-4029-a22b-51996ac39baa">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_3a7cfb6b-b0e6-49b0-9561-38dfb3b674d6">001-39852</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_6cdee382-bbf2-4606-a892-36366d7d4d33">Scilex Holding Company</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_b24830a1-e261-416d-846a-20ff83f31353">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_b4b7d034-878d-4867-80ce-db60af085964">92-1062542</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_d99b021f-8c31-45c1-a7b4-a591b8b0b8e8">960 San Antonio Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_f0f16efd-ee96-45f9-9116-d9c4f988d09c">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_e414a74c-2b71-4ed6-9788-06d5105a1397">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_4cbef0c2-a9df-4421-bdc5-f883c8f129c9">94303</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_22d1f716-d5c9-42d5-b4ec-42111a01a4bd">(650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_2a6d9990-bb60-4096-a549-b35dc26c8ea0">516-4310</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_b47a529d-625b-42b0-82e9-e2ef4fa4a7da">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_8414da00-804a-4be8-bf22-26941ca74d72">SCLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_cc35dcbd-01a7-460f-b4b8-21be601af1b4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_d0dcd4b4-ddbe-4bfb-aa7b-0056e575b8c5">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_e182a69c-1860-4476-ba3c-7eb4f96e0e21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_edaa7a10-87a4-4f67-a1a4-4ddd76ea54b0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_3fb2259a-3dea-49bc-b399-0331d4a60fc7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_e8e86531-519b-41c6-ab67-2218ffbd16a0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_cfd0e12d-dd68-4e8a-84bf-075699b69174">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_d4c36710-9dec-46c4-a12b-9e05a00103f4">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_e4bdf706-ed4f-428f-8fc1-59b7cb0f0015">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_66571ff9-5e67-4495-ab30-1b3e78bb4296">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_0fe5b75c-cd26-47f6-a5d2-cea7bb6fad9c">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_8af8c6e1-609d-44ef-9f26-2b6bd7056a94"
      decimals="-5"
      id="F_fa9d9e67-e8e8-4a71-a988-a9494f0efc97"
      unitRef="U_USD">99400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_3ca10b55-83d0-43b1-ba2e-ab5f1c28907e"
      decimals="INF"
      id="F_3c1386de-03ea-4c76-9d19-d099df31ebd9"
      unitRef="U_shares">145800574</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_7bd9bf5b-1927-49ac-bf66-3038ddc22733">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant&#x2019;s fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_41b118ab-eeb6-4c7c-872d-d6cb4874012b">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_564ba3ed-e6ec-448c-8760-eb779f77c1ab">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_f685c75b-70fd-4b0c-8016-584f3ebec208">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_dd977d72-c5ca-4510-a073-e1aca7661350"
      unitRef="U_USD">2184000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_3f48e538-9699-4e3a-80f6-7a657fadb4e3"
      unitRef="U_USD">4338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_944ce2fc-bfa8-4a85-941d-99f6eeaaa145"
      unitRef="U_USD">21236000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_fa503851-e1e4-42ac-bbcb-1164fcc1a9b1"
      unitRef="U_USD">14268000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_9592fb08-2127-4351-accb-b8b74682bb94"
      unitRef="U_USD">1378000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_8b6eb4a6-f732-4b4c-aaf8-cc646244d8a8"
      unitRef="U_USD">2562000</us-gaap:InventoryNet>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_eb90574e-81a2-4bce-ad2c-8797b8404624"
      unitRef="U_USD">4810000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_9e4fcd4d-25c2-49e8-af17-21a6534e1250"
      unitRef="U_USD">1835000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_52e4aa5f-0cc1-464c-8a7a-3e6cdd518e0d"
      unitRef="U_USD">29608000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_69f5404a-9b6b-442b-b84b-f857c971375a"
      unitRef="U_USD">23003000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_1b34ef29-4d75-4648-abbb-8be11ba6ea78"
      unitRef="U_USD">772000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_a8d1ac34-1501-4689-8484-83b665c8d12b"
      unitRef="U_USD">805000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_489fb0b9-0d0e-4e4d-b171-384b92a2b933"
      unitRef="U_USD">1131000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_f82bc666-602e-4221-a044-4a9b226485e5"
      unitRef="U_USD">1303000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_942d4f9c-2f6f-45ca-b0c4-149de63991f6"
      unitRef="U_USD">40591000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_5fd49d2f-46fa-460a-b88b-138100939b3e"
      unitRef="U_USD">38802000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_f707d6e2-47d2-4a8e-832e-aac60fd856ea"
      unitRef="U_USD">13481000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_f6b8de08-e503-4113-a256-9b62be38b77d"
      unitRef="U_USD">13481000</us-gaap:Goodwill>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_3ca17d8d-a7c4-421b-97e2-012c461ac1ee"
      unitRef="U_USD">944000</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_34d9036b-2a14-4421-a58a-3c72cb61302b"
      unitRef="U_USD">538000</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:Assets
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_960b96eb-7504-49a9-8416-01f04dde52af"
      unitRef="U_USD">86527000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_e8fa843e-6313-4b45-a36c-7dba82a2cb55"
      unitRef="U_USD">77932000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_d6ed55d5-bba2-47aa-9761-031fc5a46326"
      unitRef="U_USD">8450000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_b4f70355-49ea-4690-a13f-944228337fbf"
      unitRef="U_USD">4284000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_9f90baee-19ec-4a84-a0d1-5b7943a365f8"
      unitRef="U_USD">1354000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_3c16f779-9933-4753-80c4-ce9cf17c93de"
      unitRef="U_USD">3733000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_b549e711-b3f7-411d-8f90-716df1dbcbc0"
      unitRef="U_USD">30893000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_092a3816-aab2-485f-9441-d8c16d8ab7ff"
      unitRef="U_USD">7362000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <sclx:AccruedExpenses
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_416c2030-59a3-43df-bb83-46cbde7edd7f"
      unitRef="U_USD">3136000</sclx:AccruedExpenses>
    <sclx:AccruedExpenses
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_f8e934db-b0c5-4eb6-bffa-1b7ca5204f54"
      unitRef="U_USD">3259000</sclx:AccruedExpenses>
    <sclx:CurrentPortionOfDeferredConsideration
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_3a7b3168-71c9-4ae8-844b-73b2f7e1ea92"
      unitRef="U_USD">264000</sclx:CurrentPortionOfDeferredConsideration>
    <sclx:CurrentPortionOfDeferredConsideration
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_33304c7d-6a61-403e-af1b-3457c5d24f7a"
      unitRef="U_USD">0</sclx:CurrentPortionOfDeferredConsideration>
    <us-gaap:ShortTermBorrowings
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_c0246775-3337-4fad-906d-d5c10282a4ac"
      unitRef="U_USD">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_a0a8b43d-cfd2-41b2-b1a4-1c044e35f1fd"
      unitRef="U_USD">37950000</us-gaap:ShortTermBorrowings>
    <sclx:RelatedPartyPayable
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_945f3617-ab97-48d5-9d80-5d089563c905"
      unitRef="U_USD">0</sclx:RelatedPartyPayable>
    <sclx:RelatedPartyPayable
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_eaed037a-1bba-4726-9a0f-85f8a782bac3"
      unitRef="U_USD">92724000</sclx:RelatedPartyPayable>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_3e50602e-1776-443a-9c83-cbd94eb78509"
      unitRef="U_USD">0</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_1ae398de-0479-4042-9a12-36e7adb3d024"
      unitRef="U_USD">19608000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_ec61d1b7-adc6-491a-83e2-bfae8cbc08df"
      unitRef="U_USD">745000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_acf02e1f-f765-4045-8058-d13c52cf864d"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_0130324e-94c2-48a6-82aa-6bc0b045ae9c"
      unitRef="U_USD">44842000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_c50b9549-426a-493c-895f-8204419e45b4"
      unitRef="U_USD">169420000</us-gaap:LiabilitiesCurrent>
    <sclx:LongTermPortionOfDeferredConsideration
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_9cad9be4-db23-4e5c-bbe2-8ca1c2c5a6bc"
      unitRef="U_USD">3387000</sclx:LongTermPortionOfDeferredConsideration>
    <sclx:LongTermPortionOfDeferredConsideration
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_0d7b0140-383d-416a-bc14-c3d4206d04f2"
      unitRef="U_USD">0</sclx:LongTermPortionOfDeferredConsideration>
    <us-gaap:LongTermDebt
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_1004c63e-8828-47a2-86a9-10aa174a4497"
      unitRef="U_USD">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_00b6ec92-36c5-4eac-b8b7-f3cc8e09c3f4"
      unitRef="U_USD">72037000</us-gaap:LongTermDebt>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_52e02b35-a289-4d3c-a9d8-236c767354ee"
      unitRef="U_USD">0</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_c8e8363b-84ac-442e-9d03-7f3f0be3152d"
      unitRef="U_USD">23503000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_a0a7dfbd-1052-4371-8b2d-b57027c74a68"
      unitRef="U_USD">1231000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_8c982953-be54-4e6f-a45c-9927384c2d1c"
      unitRef="U_USD">35700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_8af56a58-0371-4e37-a6fd-77bd88da8aef"
      unitRef="U_USD">665000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_7b9094ef-2626-4622-8a75-60368653941a"
      unitRef="U_USD">1148000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_95865d95-99e3-431d-940f-7bb4fd5e691c"
      unitRef="U_USD">163000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_5dc0759e-d02f-4ff3-bd5b-0d1d99028938"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_39d3fa70-0955-4114-b191-ba5fde4be884"
      unitRef="U_USD">50288000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_0edbd4d5-d0ea-4aac-8549-2d7335c6caf6"
      unitRef="U_USD">301808000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="4"
      id="F_b7736a45-43b2-4443-888c-b59dd08026b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="4"
      id="F_2164153d-3860-461b-a961-13ab002bc5a4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="INF"
      id="F_648bc0fa-c29a-4613-8e66-7a7175ccd380"
      unitRef="U_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="INF"
      id="F_ab98a179-57d0-4336-bc71-1093dc109cb7"
      unitRef="U_shares">29057097</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="INF"
      id="F_d445e552-d371-417e-9136-062155233643"
      unitRef="U_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="INF"
      id="F_c2f3cb92-b265-48e3-9c17-5847532b737b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="INF"
      id="F_5e4e466c-8cb7-41c9-8263-c9b5171adcdd"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_62f3d483-bb25-4d82-bfd7-b1e7967677e7"
      unitRef="U_USD">3000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_1ea66942-092f-4399-bdd3-cbed0741a953"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="4"
      id="F_ec743b83-ed54-405a-ab74-8b4f6d6604cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="4"
      id="F_866cc1d3-84e1-4c61-9abc-30a7d4f1c828"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="INF"
      id="F_6ea7929d-4e7d-40c0-8713-0254582b836a"
      unitRef="U_shares">740000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="INF"
      id="F_b7a2b3ea-f220-4af0-b2a6-ed95fb541fa7"
      unitRef="U_shares">141348856</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="INF"
      id="F_97837da3-bca1-42e7-a9b0-a0b2de163db9"
      unitRef="U_shares">141348856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="INF"
      id="F_5015b459-abce-4a82-bab5-7489f55bce6e"
      unitRef="U_shares">132858484</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="INF"
      id="F_dd4104de-d0a4-47aa-9822-5050ae9beffd"
      unitRef="U_shares">132858484</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_c3c0accd-0e62-4546-af75-c98eb1b69f0e"
      unitRef="U_USD">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_ac26890c-871c-4f2f-b54e-240fabb1d0f9"
      unitRef="U_USD">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_7b0e0b30-5912-4424-99cf-2202eb2f76ed"
      unitRef="U_USD">412136000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_b18c7546-3414-4aa7-9900-33bfd81db78a"
      unitRef="U_USD">128661000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_e3074711-2564-4b64-b503-04b0fea12797"
      unitRef="U_USD">-375914000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_0c0319e6-b70a-4ab5-b757-65216a6c43de"
      unitRef="U_USD">-352550000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_88c18b19-a4c2-42f0-8cc1-8eb126bde65d"
      unitRef="U_USD">36239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_1e3431b8-d308-4838-bf8a-c7a68ea3a8b1"
      unitRef="U_USD">-223876000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_62e977b2-229d-4993-aae5-5d864db0daa8"
      unitRef="U_USD">86527000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_95a3cce3-ab36-49b0-9a85-ec6412501b44"
      unitRef="U_USD">77932000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_e2adb314-a93a-4a86-8da9-b42a53c7483e"
      unitRef="U_USD">38034000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_8d6f6a8f-32e5-46e5-a4c7-0fc96d14e5e6"
      unitRef="U_USD">31317000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_3816b7ac-8c68-4055-9cb3-32505a20cb1d"
      unitRef="U_USD">23560000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_e10a6d44-e9bb-4b2b-9c00-29764ae29b84"
      unitRef="U_USD">10797000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_c19657b2-b026-4837-b227-f047cc96b8cb"
      unitRef="U_USD">3634000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_caa187bb-3a6e-4533-ae5f-49735bdcf0ce"
      unitRef="U_USD">2149000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_e00ec4a9-7d39-4f13-89b0-cc05187b3932"
      unitRef="U_USD">9054000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_abdf5d95-f881-4b67-b4e6-608d74d19cb3"
      unitRef="U_USD">9201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_98f9503e-f9ea-4894-ad29-99a4718eda57"
      unitRef="U_USD">9961000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_c6f1cdd1-175d-435e-af09-b32ed2234228"
      unitRef="U_USD">64895000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_4041e3f7-511c-4942-88ba-5d616197fb54"
      unitRef="U_USD">50582000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_a30b919f-baf6-48f6-834f-bdd95a2d8492"
      unitRef="U_USD">42970000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_b3432708-14ad-40ac-adcb-b58ecce9fa91"
      unitRef="U_USD">3922000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_fe2eebf1-1732-469d-ba9b-3818dd633590"
      unitRef="U_USD">3738000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_c6680ef2-2840-4b96-a93a-bcf08b26433c"
      unitRef="U_USD">3738000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_a57551d5-62c4-47dd-a428-27bfd178bffa"
      unitRef="U_USD">88668000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_f49fff63-06a5-4df2-b598-3bd1da67e9fd"
      unitRef="U_USD">67155000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_18f435b8-9716-4344-838c-b1db288b9786"
      unitRef="U_USD">58818000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_717c0511-c113-4aeb-8f01-104e1f01b1bc"
      unitRef="U_USD">-50634000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_9944d982-e3b7-4805-aa5e-d98591064fdf"
      unitRef="U_USD">-35838000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_6e5f831d-4848-45ff-b66a-84d65d1a7d91"
      unitRef="U_USD">-35258000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_e702b4cf-a9c8-48e8-8abd-049328dfd68f"
      unitRef="U_USD">8310000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_c8aa52d6-7939-45a8-b73f-f9f13212e846"
      unitRef="U_USD">-300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_394c96cb-adaa-42a5-9d27-6bedecce029c"
      unitRef="U_USD">800000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_cca10bf6-ac23-4a00-99ce-36b4b4efdbbf"
      unitRef="U_USD">28634000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_ce971922-88ab-4f53-be47-71bca290fb14"
      unitRef="U_USD">-12463000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_ef405865-68da-49a3-b5f7-81e7e57fcba9"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <sclx:NotesPrincipalIncrease
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_48262941-f162-4536-a36b-c285fb5d73d8"
      unitRef="U_USD">0</sclx:NotesPrincipalIncrease>
    <sclx:NotesPrincipalIncrease
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_1a42ed0c-fe2f-4bb9-ae8e-c7b322b9cc9b"
      unitRef="U_USD">-28000000</sclx:NotesPrincipalIncrease>
    <sclx:NotesPrincipalIncrease
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_e6d06419-7212-4f58-bd9b-333a7cc114e1"
      unitRef="U_USD">0</sclx:NotesPrincipalIncrease>
    <us-gaap:InterestExpense
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_05bca2e8-184b-4bfa-9048-afd52c89ba98"
      unitRef="U_USD">9604000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_cf5ece8d-9007-43fa-97ac-8d36a532543d"
      unitRef="U_USD">11764000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_e3133146-e487-4b7e-ada0-6682fce510eb"
      unitRef="U_USD">13116000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_7432b555-7c1b-442e-b8d1-962ab3fe9bdf"
      unitRef="U_USD">-66000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_28e58ac3-d856-46e7-8d6e-320889a80e1f"
      unitRef="U_USD">-54000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_fb2ec820-69ae-43af-9f0f-dd15a5bd50ef"
      unitRef="U_USD">2000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_bd3fa9d1-7368-4683-9b3a-1a6596778c7e"
      unitRef="U_USD">27274000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_2f405d5d-0542-44d7-b144-77a0aa99f58d"
      unitRef="U_USD">-52581000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_ebf6c934-5727-4e14-bfaa-4dbc8b71d70f"
      unitRef="U_USD">-12314000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_3ba3c528-9a9b-4195-96d6-38572657243d"
      unitRef="U_USD">-23360000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_6dbb7286-f0e8-40b8-a1fe-39b23c2c4479"
      unitRef="U_USD">-88419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_a140c53d-5a80-4175-8872-530cb5430bf7"
      unitRef="U_USD">-47572000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_6f4bb9a9-d0e1-4c51-a534-9f9d34f29543"
      unitRef="U_USD">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_55fbd937-4ce4-4bff-9e9d-7666b7858080"
      unitRef="U_USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_34483d69-d03b-4d40-99ec-0681b2750521"
      unitRef="U_USD">-53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_cce7a311-9a49-44a4-a08b-9ed1ed376afa"
      unitRef="U_USD">-23364000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_081aa542-d940-4a44-a50a-c2e08c86df6b"
      unitRef="U_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_735eec9e-1aa6-4749-af1f-40f6f5e3481b"
      unitRef="U_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="2"
      id="F_74025af5-b38e-4b25-aa81-d331bacd8b2a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="2"
      id="F_9f7e80a9-3bcf-4836-a2e3-e7b38d01b9b7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="2"
      id="F_0d52f999-97fd-4c0d-91ff-6b7745f65670"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="2"
      id="F_5c653416-456c-4c28-9b78-85bf0f0e12c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="2"
      id="F_83cd5c51-fc6a-4cad-a63b-1fbdb4e6eb1a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="2"
      id="F_2a49fd1d-e473-4e9c-9eb3-8b87d52fb8e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="0"
      id="F_d5aec110-6be3-4bef-9ea7-dc6085615853"
      unitRef="U_shares">134226</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="0"
      id="F_d59bc7f9-dbe5-48ac-8259-762626a850ae"
      unitRef="U_shares">134226</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="0"
      id="F_cb953708-87be-4210-b167-972207a7569c"
      unitRef="U_shares">132858</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="0"
      id="F_272a3d3d-25e2-463a-8fee-df68ecf05140"
      unitRef="U_shares">132858</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="0"
      id="F_4e1a2321-8809-47ff-a90c-82f006c08289"
      unitRef="U_shares">132891</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="0"
      id="F_ff9bf13b-6990-43f8-9e5a-4b5404e741f6"
      unitRef="U_shares">132891</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_8b6804ad-db9d-442b-8365-1912fdf47899"
      decimals="INF"
      id="F_e0b91674-79ec-4900-9bad-a828dc685bda"
      unitRef="U_shares">197310</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8b6804ad-db9d-442b-8365-1912fdf47899"
      decimals="-3"
      id="F_4629ca07-e574-41a1-a2e0-8465af02ff72"
      unitRef="U_USD">20000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_b620909f-073f-4a76-8775-805e21b71726"
      decimals="0"
      id="F_2ff70a1d-50b7-4545-8156-244ac6d2ee9b"
      unitRef="U_shares">0</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_6647079d-3f50-46e5-afdd-7cb5fff7d6ba"
      decimals="0"
      id="F_30da95f8-ea1a-4890-91a9-39668458eb00"
      unitRef="U_shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2416c551-e9fc-44d6-b78f-4b72a1263fbd"
      decimals="-3"
      id="F_d7e23235-e85c-4b8b-a032-0650d7f6cdf8"
      unitRef="U_USD">126578000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ed6ebbfe-7582-45c9-a505-88a5349d8983"
      decimals="-3"
      id="F_3e33dd43-dcf3-461b-8e85-4d6b86c1aa13"
      unitRef="U_USD">-216607000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28"
      decimals="-3"
      id="F_36194509-e803-4cd0-b492-7d522b977be1"
      unitRef="U_USD">-90029000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <sclx:RecapitalizationDuetotheBusinessCombinationShares
      contextRef="C_4d25b0fa-f232-49d1-bb07-eac65211d5f0"
      decimals="INF"
      id="F_05f8a844-3ebd-4c34-8b7e-b63dcb489326"
      unitRef="U_shares">-197310</sclx:RecapitalizationDuetotheBusinessCombinationShares>
    <sclx:RecapitalizationDueToTheBusinessCombinationValue
      contextRef="C_4d25b0fa-f232-49d1-bb07-eac65211d5f0"
      decimals="-3"
      id="F_3a255f8e-cd62-4b46-ac30-6b111e97029f"
      unitRef="U_USD">-20000</sclx:RecapitalizationDueToTheBusinessCombinationValue>
    <sclx:RecapitalizationDuetotheBusinessCombinationShares
      contextRef="C_a3faac18-7970-4d6f-9b9f-ebaa1c4bc17f"
      decimals="INF"
      id="F_461610d7-983a-4931-b72e-11cd72ebdd4f"
      unitRef="U_shares">132888</sclx:RecapitalizationDuetotheBusinessCombinationShares>
    <sclx:RecapitalizationDueToTheBusinessCombinationValue
      contextRef="C_a3faac18-7970-4d6f-9b9f-ebaa1c4bc17f"
      decimals="-3"
      id="F_dcd171a8-2d8e-45dc-b156-fa5d97b22ed2"
      unitRef="U_USD">13000</sclx:RecapitalizationDueToTheBusinessCombinationValue>
    <sclx:RecapitalizationDueToTheBusinessCombinationValue
      contextRef="C_ccca58d1-1a9c-4f4b-8d50-efc7509df65b"
      decimals="-3"
      id="F_19b9cc1a-85ad-42d3-a20e-de0a20f98573"
      unitRef="U_USD">7000</sclx:RecapitalizationDueToTheBusinessCombinationValue>
    <sclx:RecapitalizationDueToTheBusinessCombinationValue
      contextRef="C_bef67e9a-4b76-4019-893d-8f19c877187f"
      decimals="-3"
      id="F_5d33d6a8-bb4e-41d1-aea0-99a920d89b29"
      unitRef="U_USD">20000</sclx:RecapitalizationDueToTheBusinessCombinationValue>
    <sclx:EffectOfBusinessCombinationInShares
      contextRef="C_a3faac18-7970-4d6f-9b9f-ebaa1c4bc17f"
      decimals="INF"
      id="F_8c625cfe-a3b6-497c-9adc-71812ccb9624"
      unitRef="U_shares">132888</sclx:EffectOfBusinessCombinationInShares>
    <sclx:EffectOfBusinessCombinationInValue
      contextRef="C_a3faac18-7970-4d6f-9b9f-ebaa1c4bc17f"
      decimals="-3"
      id="F_6b4c48a2-1da5-4f5d-94c8-e690b4a805f7"
      unitRef="U_USD">13000</sclx:EffectOfBusinessCombinationInValue>
    <sclx:EffectOfBusinessCombinationInValue
      contextRef="C_ccca58d1-1a9c-4f4b-8d50-efc7509df65b"
      decimals="-3"
      id="F_70415cb0-9140-4e86-9592-6538a4a723f8"
      unitRef="U_USD">126585000</sclx:EffectOfBusinessCombinationInValue>
    <sclx:EffectOfBusinessCombinationInValue
      contextRef="C_6bf9409a-d416-4d1d-a445-b90863d1d1c6"
      decimals="-3"
      id="F_d6c4975f-64b6-492d-999b-246beab59ac1"
      unitRef="U_USD">-216607000</sclx:EffectOfBusinessCombinationInValue>
    <sclx:EffectOfBusinessCombinationInValue
      contextRef="C_bef67e9a-4b76-4019-893d-8f19c877187f"
      decimals="-3"
      id="F_c5867b50-65b7-402c-9201-f059de3fd166"
      unitRef="U_USD">-90009000</sclx:EffectOfBusinessCombinationInValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3a251053-d0ea-4cdf-85a7-8504f3883048"
      decimals="INF"
      id="F_57675bf2-e9fa-4a83-afad-2e7e61baa3ce"
      unitRef="U_shares">38</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0a7981fc-b448-47e6-bbe7-0f3aa97fb3c3"
      decimals="-3"
      id="F_f317343f-8e67-4c6d-86ea-188b9d3b4b26"
      unitRef="U_USD">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_0958a5bc-2906-4b1b-8599-ab160d0952d3"
      unitRef="U_USD">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0a7981fc-b448-47e6-bbe7-0f3aa97fb3c3"
      decimals="-3"
      id="F_499c8f70-8374-45f5-b8ae-da6a4a6253ed"
      unitRef="U_USD">5395000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_1c85fd78-ef5b-4ff6-a52c-925c683f435e"
      unitRef="U_USD">5395000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sclx:DistributionToSorrentos
      contextRef="C_4216d375-5857-4658-937f-eb7e215cb19f"
      decimals="-3"
      id="F_7dac5043-921f-4752-b356-57be6d34bc6d"
      unitRef="U_USD">-9600000</sclx:DistributionToSorrentos>
    <sclx:DistributionToSorrentos
      contextRef="C_7cfc2da8-8fde-41ac-99ad-52a0a1ee5813"
      decimals="-3"
      id="F_97e07aed-79f5-4d8c-8294-5d7aeb59149e"
      unitRef="U_USD">-9600000</sclx:DistributionToSorrentos>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_3a251053-d0ea-4cdf-85a7-8504f3883048"
      decimals="INF"
      id="F_3edbcf3b-15c6-4197-975b-bccbe53c9ace"
      unitRef="U_shares">-68</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProfitLoss
      contextRef="C_8c37c057-4848-462d-ada1-a24a6cad00dd"
      decimals="-3"
      id="F_64bc9980-b01b-4aca-824e-00b2f3348bb9"
      unitRef="U_USD">-47519000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_3b06c520-7d4c-4eae-a5ac-ebbe14a9faec"
      unitRef="U_USD">-47519000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_43387abc-3f9a-4d01-8539-0e8a069d288c"
      decimals="INF"
      id="F_c7635e97-e3ba-481f-907b-7e2bdd1889e1"
      unitRef="U_shares">132858</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_43387abc-3f9a-4d01-8539-0e8a069d288c"
      decimals="-3"
      id="F_d64aab93-827b-4002-a6d5-1fe5232534d8"
      unitRef="U_USD">13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_935d8df9-59c4-47da-a78c-46dc24743107"
      decimals="-3"
      id="F_c390b36a-ed8b-4489-833a-0bc7914603cb"
      unitRef="U_USD">122430000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_1a7ce1a3-b831-4b91-8f43-85fae241ba37"
      decimals="-3"
      id="F_0ede3d78-9432-4d3f-8808-0bf299afabac"
      unitRef="U_USD">-264126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="-3"
      id="F_96efa67b-6dae-48d3-bf8a-bdbad5c0f0f1"
      unitRef="U_USD">-141683000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7eb481bd-4d9b-4545-b52a-3d1554edfd5f"
      decimals="-3"
      id="F_1201c7ab-8eea-4c78-b231-af05b124a390"
      unitRef="U_USD">5822000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_92b2c83b-a956-45f7-a40e-3624bfef91af"
      unitRef="U_USD">5822000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue
      contextRef="C_7eb481bd-4d9b-4545-b52a-3d1554edfd5f"
      decimals="-3"
      id="F_4f5fe878-8258-488a-b620-2a1955a5c98f"
      unitRef="U_USD">409000</sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue>
    <sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_4e8c0a04-a90f-446b-b1ed-0da09102e1dc"
      unitRef="U_USD">409000</sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_9b930bf6-320d-4b6c-af8c-5aa608240d49"
      decimals="-3"
      id="F_d1251cd6-831b-4ba9-bad0-23dd63a99bc1"
      unitRef="U_USD">-88424000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_79c0f569-050e-4a34-828e-781b2673f396"
      unitRef="U_USD">-88424000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_c8f61138-8d7f-420c-9c8d-08f6643abad5"
      decimals="INF"
      id="F_a1f24d70-211b-4b44-a5e0-88ac29fbbd04"
      unitRef="U_shares">132858</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c8f61138-8d7f-420c-9c8d-08f6643abad5"
      decimals="-3"
      id="F_90944053-88b6-4b57-a6e0-82cd2dc5c02f"
      unitRef="U_USD">13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a34d7e4b-75b0-46b3-9b67-fb0bd31b0200"
      decimals="-3"
      id="F_37805e6e-1022-4a23-b0d3-7ce5469c4731"
      unitRef="U_USD">128661000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_edcc144e-d7f7-43da-bd1b-72d518cd963f"
      decimals="-3"
      id="F_d58da65d-a6b3-4f63-b533-af99851944c5"
      unitRef="U_USD">-352550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_17660544-99a1-4312-b543-0746aa3bf321"
      unitRef="U_USD">-223876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a7a078e2-6aea-4910-9389-223a17cbe1d4"
      decimals="INF"
      id="F_a2b4018e-d4fa-4343-bf2f-c9e22c865235"
      unitRef="U_shares">202</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4"
      decimals="-3"
      id="F_4919129e-3643-47d9-b76c-f227c5887897"
      unitRef="U_USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_ed46fb75-0353-4a8b-be87-24560aae6ffe"
      unitRef="U_USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue
      contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4"
      decimals="-3"
      id="F_1be57a39-ce5f-4a02-b966-da3c748abb2c"
      unitRef="U_USD">-4127000</sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue>
    <sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_beaf1b8d-c2ca-447b-83c5-b86ad904127e"
      unitRef="U_USD">-4127000</sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue>
    <sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization
      contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4"
      decimals="-3"
      id="F_c5acca56-b5a0-44e9-bff4-73ac8d75c45d"
      unitRef="U_USD">-35000</sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization>
    <sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_3f874043-e8d7-44bd-ab65-9a4e84be64c4"
      unitRef="U_USD">-35000</sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="C_a7a078e2-6aea-4910-9389-223a17cbe1d4"
      decimals="INF"
      id="F_d09fc92a-d8b9-45a2-824c-af98e85a715c"
      unitRef="U_shares">2906</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="C_0eb4f5f3-217e-4d32-9df0-0de97d9de853"
      decimals="INF"
      id="F_3aa0b864-65a2-4ce4-b542-06a427eccded"
      unitRef="U_shares">29057</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="C_0eb4f5f3-217e-4d32-9df0-0de97d9de853"
      decimals="-3"
      id="F_3009439e-efa6-40a5-8b62-f35fcf89d448"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4"
      decimals="-3"
      id="F_3a2fef0d-d070-430b-9381-4c274d07579a"
      unitRef="U_USD">289730000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_5ed64812-8a98-468d-9449-d8f841118973"
      unitRef="U_USD">289733000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="C_a7a078e2-6aea-4910-9389-223a17cbe1d4"
      decimals="INF"
      id="F_0236e0f5-934c-463c-87ed-9748d0e66919"
      unitRef="U_shares">-5133</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="C_a7a078e2-6aea-4910-9389-223a17cbe1d4"
      decimals="-3"
      id="F_f4f3acd3-bb50-4acb-b27d-103481b3f2e6"
      unitRef="U_USD">-1000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4"
      decimals="-3"
      id="F_60b6df35-db74-4edc-8c19-2ac6def83695"
      unitRef="U_USD">8707000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_c1d57699-b778-4fd4-80ee-3b9e1ab2ecf5"
      unitRef="U_USD">8706000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares
      contextRef="C_a7a078e2-6aea-4910-9389-223a17cbe1d4"
      decimals="INF"
      id="F_15a91f96-a8a4-43ea-a3b0-7c73f4cb4fb8"
      unitRef="U_shares">250</sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares>
    <sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement
      contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4"
      decimals="-3"
      id="F_34a35d10-fde8-49d6-b6cb-70eb189c76b3"
      unitRef="U_USD">1238000</sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement>
    <sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_37a8ddd2-3609-4512-9a18-5f5f64b6fbc6"
      unitRef="U_USD">1238000</sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_74765fdd-abd5-4a48-b447-771ee939f2e4"
      decimals="-3"
      id="F_b87113f8-2b0e-4157-895a-e9777e5bd5dc"
      unitRef="U_USD">5280000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_42646fb1-4db6-4e20-a1e3-eafde2ccfb5e"
      unitRef="U_USD">5280000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProfitLoss
      contextRef="C_47ef1e97-f5b2-4965-919e-b1ad07eae683"
      decimals="-3"
      id="F_b9d24379-c237-4c36-88f9-e7a7eb61a1d2"
      unitRef="U_USD">-23364000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_6527c118-654f-4517-a5a6-4159b85cbaa0"
      unitRef="U_USD">-23364000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_dbd5dc57-1898-456c-9638-93bc81132559"
      decimals="INF"
      id="F_4de2966c-7753-4481-9790-d822dabef9fc"
      unitRef="U_shares">141349</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_dbd5dc57-1898-456c-9638-93bc81132559"
      decimals="-3"
      id="F_904bd5ed-5041-4243-970a-bf499c1e7ed2"
      unitRef="U_USD">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_0b6f23f6-2673-4fcb-bf14-d6a9163b7497"
      decimals="INF"
      id="F_0aa2d74b-d43c-460c-b95f-a02e3178197e"
      unitRef="U_shares">29057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0b6f23f6-2673-4fcb-bf14-d6a9163b7497"
      decimals="-3"
      id="F_fc00b7e9-9054-45f2-bbb6-1d21412868fc"
      unitRef="U_USD">3000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b97057d7-7304-4fd2-8467-c5db2179660a"
      decimals="-3"
      id="F_3c5bb50b-ff41-47c0-8e61-d3995c05d1d8"
      unitRef="U_USD">412136000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_47fbaa34-ba91-4f95-8043-9f86ce21361b"
      decimals="-3"
      id="F_823832f9-be73-4a49-b77b-ab1fc1252f1c"
      unitRef="U_USD">-375914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_a1bb2a4b-97db-49ee-9bb1-a436fc343a90"
      unitRef="U_USD">36239000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_087a4672-4086-4957-bf8f-df7f5931ce15"
      unitRef="U_USD">-23364000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_4857313c-3f35-40a8-b59a-8d2fd1697d5b"
      unitRef="U_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_ea0da0ec-810a-461a-9f94-cd0409c56505"
      unitRef="U_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_93b524a0-06ce-43a4-bbbf-2680bc298b10"
      unitRef="U_USD">3961000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_23f493de-2da1-4623-899d-a547514f3d28"
      unitRef="U_USD">3779000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_fa0e3f38-996a-4910-9b8e-29a073e623fc"
      unitRef="U_USD">3777000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_4fbeb1d1-9027-4fcc-af1d-1d11e5725a8b"
      unitRef="U_USD">3142000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_ed8ac29e-fe66-4df2-8460-f2ca2037e56d"
      unitRef="U_USD">7909000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_a9e5eb39-d19a-4927-9d4f-aa5359c517b4"
      unitRef="U_USD">10664000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <sclx:NotesPrincipalIncrease
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_dbfe7f9f-bf9e-4f51-8500-3fa69a1e7b1e"
      unitRef="U_USD">0</sclx:NotesPrincipalIncrease>
    <sclx:NotesPrincipalIncrease
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_8850997e-2eaa-43ac-9a5c-6dca163fd39c"
      unitRef="U_USD">-28000000</sclx:NotesPrincipalIncrease>
    <sclx:NotesPrincipalIncrease
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_4b3c5908-c01d-4cbc-9a75-c0e45a58ab85"
      unitRef="U_USD">0</sclx:NotesPrincipalIncrease>
    <sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_2020b43f-9ddc-4101-b75a-206dcaa4d987"
      unitRef="U_USD">21190000</sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount>
    <sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_fc5b7bcc-0323-4a7f-a9ee-c366f6bc14ff"
      unitRef="U_USD">12487000</sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount>
    <sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_f51eb59a-d458-4f92-8aeb-aaf9fa435f61"
      unitRef="U_USD">10866000</sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_2922d69c-8d7c-43b9-9f71-a6d7d7f0f680"
      unitRef="U_USD">28634000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_e680e30e-904a-4970-8de7-d921f5f47ccb"
      unitRef="U_USD">-12463000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_d5e65ac6-b743-4aba-9e9b-c6500cb200b4"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <sclx:NonCashOperatingLeaseCost
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_62b387a2-280e-4b5b-b719-6fe432631955"
      unitRef="U_USD">492000</sclx:NonCashOperatingLeaseCost>
    <sclx:NonCashOperatingLeaseCost
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_a7eadeb3-89a4-4923-b720-fe007b929a2b"
      unitRef="U_USD">372000</sclx:NonCashOperatingLeaseCost>
    <sclx:NonCashOperatingLeaseCost
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_111b5d20-4553-4b47-afb6-136bbcff9e1c"
      unitRef="U_USD">825000</sclx:NonCashOperatingLeaseCost>
    <us-gaap:ShareBasedCompensation
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_1f3a04da-2e46-4f59-a59c-98908d566f1c"
      unitRef="U_USD">5280000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_f4be6a76-5ba1-4fe4-adb0-a6777e01259b"
      unitRef="U_USD">5822000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_d5f950f6-7b00-4777-bae8-b05d6951e954"
      unitRef="U_USD">5395000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_9777b81e-c3c0-4884-8c4e-7780f6d07e9f"
      unitRef="U_USD">8310000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_a939a02d-4d5f-47c5-8d30-281a89bad577"
      unitRef="U_USD">-300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_3e7b2005-0ddb-43a0-885d-0ef36fd0d870"
      unitRef="U_USD">800000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <sclx:ForfeituresOfPrivateWarrants
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_7ef55f2f-dc9a-4f62-93b6-db24d16392ac"
      unitRef="U_USD">1697000</sclx:ForfeituresOfPrivateWarrants>
    <sclx:ForfeituresOfPrivateWarrants
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_94fcaecf-2511-4daa-a6de-a97406139a36"
      unitRef="U_USD">0</sclx:ForfeituresOfPrivateWarrants>
    <sclx:ForfeituresOfPrivateWarrants
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_5c503c40-5933-4246-8fd4-604abeaf599e"
      unitRef="U_USD">0</sclx:ForfeituresOfPrivateWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_772616be-751c-4f89-82e2-90a9e44fb223"
      unitRef="U_USD">6968000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_0a022617-b1ed-419f-b778-fbdff3b86c5d"
      unitRef="U_USD">1142000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_a7289920-75e1-4509-875e-8e3f7a043330"
      unitRef="U_USD">598000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_110049cc-9ffa-49a4-82a6-920b5568fce9"
      unitRef="U_USD">-1184000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_b15b037b-fb18-43ca-b009-e19d502bca6b"
      unitRef="U_USD">1417000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_9ca89a1d-9d4f-496b-9e6c-bb68bedb2e2d"
      unitRef="U_USD">-2379000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_c048eee8-240c-4cd6-b196-b8f07512e9ee"
      unitRef="U_USD">2629000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_30b196b0-a000-4358-a39e-fa33dea88eb5"
      unitRef="U_USD">-1479000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_e069136e-284f-4eb7-8ac4-f54b13cd39b5"
      unitRef="U_USD">1035000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_c60e4cc2-ea9a-4c3a-9678-a1a2fc88575c"
      unitRef="U_USD">-350000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_e5c5a478-6d20-456d-b711-6b2c6a9410ce"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_406957f4-89af-431c-b471-18a93dfb4623"
      unitRef="U_USD">-2580000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_2aecdccb-0ad0-4f00-8d04-9901eb660034"
      unitRef="U_USD">2806000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_e328769e-0e2a-4f96-abe8-118e104385ea"
      unitRef="U_USD">-3836000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_1cfbea42-c903-4a09-987d-e7fff3a9528a"
      unitRef="U_USD">-4062000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <sclx:IncreaseDecreaseInAccruedPayroll
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_3ecedb34-0272-4b77-ac19-3b28d8be1d4d"
      unitRef="U_USD">-2379000</sclx:IncreaseDecreaseInAccruedPayroll>
    <sclx:IncreaseDecreaseInAccruedPayroll
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_99a54eeb-58b6-4e64-bfc2-c9d19c595535"
      unitRef="U_USD">-21000</sclx:IncreaseDecreaseInAccruedPayroll>
    <sclx:IncreaseDecreaseInAccruedPayroll
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_9d674c18-9fda-4de4-b464-4b7e9486f7d5"
      unitRef="U_USD">1247000</sclx:IncreaseDecreaseInAccruedPayroll>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_918d6073-7f50-49d4-816c-76fb1fd26959"
      unitRef="U_USD">-123000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_8f074a56-83ba-4a9c-b70e-f02ecb911d97"
      unitRef="U_USD">664000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_174901c2-d61b-4705-9f44-3be6a3fcd57c"
      unitRef="U_USD">-1066000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <sclx:IncreaseDecreaseInAccruedRebatesAndFees
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_fb217f75-29af-4923-81b9-aa186144afb6"
      unitRef="U_USD">23531000</sclx:IncreaseDecreaseInAccruedRebatesAndFees>
    <sclx:IncreaseDecreaseInAccruedRebatesAndFees
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_d5ae7dd2-2ea6-46d9-8acd-5e534150e951"
      unitRef="U_USD">-255000</sclx:IncreaseDecreaseInAccruedRebatesAndFees>
    <sclx:IncreaseDecreaseInAccruedRebatesAndFees
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_c4e57b92-667d-4299-a3b3-4e9a43e62f73"
      unitRef="U_USD">3117000</sclx:IncreaseDecreaseInAccruedRebatesAndFees>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_5c3d3a8e-4802-453d-94b5-731daaf52a51"
      unitRef="U_USD">-392000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_1da4abf8-991a-4e90-99de-f5fcf93dfdbb"
      unitRef="U_USD">-80000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_d3a18840-dad0-4e6e-bd92-84f22055d472"
      unitRef="U_USD">-604000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_7f7ceddd-c27c-45e8-bbda-917c7b8a6b78"
      unitRef="U_USD">30125000</us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_19f7b6b2-dcf0-4678-aff2-1ae3d0a698a3"
      unitRef="U_USD">18210000</us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_91389548-5f21-4378-ab68-ef33aea34518"
      unitRef="U_USD">5105000</us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent>
    <sclx:OtherLongTermLiabilities
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_877bc249-036c-43ee-b935-590853240dee"
      unitRef="U_USD">163000</sclx:OtherLongTermLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_4b5b8789-9fc3-426b-9c89-afa0aa9b6235"
      unitRef="U_USD">-21258000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_52384e0a-c5d2-4854-ada6-5042a188217b"
      unitRef="U_USD">-28664000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_a5822abf-0451-4a14-9bd9-3e11149cc36b"
      unitRef="U_USD">-31461000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_8ff64327-9b70-4185-bcdf-b5d8b8159143"
      unitRef="U_USD">2060000</sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition>
    <sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_747ead30-1bcb-4f08-99a9-7d3e9299809f"
      unitRef="U_USD">0</sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition>
    <sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_5badaa74-93db-46e1-853a-6cc8c61e66f0"
      unitRef="U_USD">0</sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_19f408f9-6de6-4276-8fca-ea80d21faa7c"
      unitRef="U_USD">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_7507b6d0-0aad-405f-aa00-91f9bd77ffba"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_242a8582-dcd1-4570-9a96-14915971d528"
      unitRef="U_USD">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_55e63fed-edd7-4c83-bf60-4522b29b23e7"
      unitRef="U_USD">-2067000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_5f5bd135-39b2-4549-89e3-90afcfa2753a"
      unitRef="U_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_1b7cf5e8-f1ec-4fab-9089-7bc7ff1dd192"
      unitRef="U_USD">-25000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <sclx:ProceedsFromTheBusinessCombination
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_7d0a954c-b038-4df1-ad3f-5b422466f7ed"
      unitRef="U_USD">3375000</sclx:ProceedsFromTheBusinessCombination>
    <sclx:ProceedsFromTheBusinessCombination
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_caa3da7b-49c1-426d-8fe9-80ba1cf51c12"
      unitRef="U_USD">0</sclx:ProceedsFromTheBusinessCombination>
    <sclx:ProceedsFromTheBusinessCombination
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_a9f2e336-aba5-4e9c-ac80-5494849a332b"
      unitRef="U_USD">0</sclx:ProceedsFromTheBusinessCombination>
    <sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_cc37241f-c77d-46bb-9b1e-853041d92215"
      unitRef="U_USD">2949000</sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction>
    <sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_aa419f5a-d140-4a3b-bd83-f04114fea818"
      unitRef="U_USD">0</sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction>
    <sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_6dde92be-24b0-4526-99cf-12bcb970ea0c"
      unitRef="U_USD">0</sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction>
    <sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_2fce4245-1e63-4049-afff-e463dce6d6e3"
      unitRef="U_USD">-84808000</sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes>
    <sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_de1370dc-77fd-4ecc-ae65-1b3756cfcd6c"
      unitRef="U_USD">-33387000</sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes>
    <sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_7a290157-77ac-4342-847c-a5432beac6a9"
      unitRef="U_USD">-58927000</sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes>
    <sclx:ProceedsFromRepaymentOfLoansToPurchase
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_b7bf7b5f-3778-499d-9192-f0e59cee383c"
      unitRef="U_USD">-18800000</sclx:ProceedsFromRepaymentOfLoansToPurchase>
    <sclx:ProceedsFromRepaymentOfLoansToPurchase
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_b75dae5a-f203-49d6-8638-11ef7b9fb1d2"
      unitRef="U_USD">-48832000</sclx:ProceedsFromRepaymentOfLoansToPurchase>
    <sclx:ProceedsFromRepaymentOfLoansToPurchase
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_a1ba986c-1f53-480e-835f-c1331c499271"
      unitRef="U_USD">0</sclx:ProceedsFromRepaymentOfLoansToPurchase>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_e4b6c59a-7688-421c-b9c1-56e643fe79c9"
      unitRef="U_USD">9857000</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_47841743-bc90-4bc6-8a95-562f11f044c0"
      unitRef="U_USD">47832000</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_612a0552-acce-4b88-a70e-41521b557e44"
      unitRef="U_USD">11007000</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_9f0c20bd-6408-4880-a608-29e938a7adce"
      unitRef="U_USD">96000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_095f2d65-a86b-4b67-9bb7-e47c53fc3f19"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_d1eea942-aed0-4d88-900e-e37cb582416b"
      unitRef="U_USD">50000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_8f0b945e-073e-485c-bf06-1ec181c5abf4"
      unitRef="U_USD">51900000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_bd63ffb3-7852-484c-a728-115c150cd175"
      unitRef="U_USD">47850000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_297575be-853a-4a5f-a967-5402ef36b154"
      unitRef="U_USD">18400000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_86af4f65-0868-4bbb-9ba9-5d9872e76004"
      unitRef="U_USD">62500000</us-gaap:ProceedsFromSecuredNotesPayable>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_2d3e6e41-a198-48c3-971d-4fb4e8ffbdae"
      unitRef="U_USD">14700000</us-gaap:ProceedsFromSecuredNotesPayable>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_67e0da55-d8e4-4dc2-a775-a1ddb0690693"
      unitRef="U_USD">10300000</us-gaap:ProceedsFromSecuredNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_f50a3ff8-9090-441a-9763-ef389b26ad47"
      unitRef="U_USD">21171000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_ae73e193-2107-4959-b4e1-4cb95595e715"
      unitRef="U_USD">28163000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_5a193776-a784-4d09-b473-2aa879fb21d8"
      unitRef="U_USD">-19170000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_77b74d8f-db2f-4314-a248-baf717de66c8"
      unitRef="U_USD">-2154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_aa22ae6d-de1a-483b-989e-4fac04fc7cec"
      unitRef="U_USD">-501000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_219ae017-0b5f-4d78-a44c-ab5ba090dc14"
      unitRef="U_USD">-50656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_f986b1b7-e253-4b7b-848e-8c1c8a3d63ed"
      unitRef="U_USD">4338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="-3"
      id="F_b9770ef6-de42-493a-ab86-8656782bd6bf"
      unitRef="U_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28"
      decimals="-3"
      id="F_85966506-6bec-40a9-986f-39c061ebd783"
      unitRef="U_USD">55495000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_d38ed802-b182-47a9-8cfc-fdbdb976e481"
      unitRef="U_USD">2184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_ad638411-f550-41ba-8c8c-3a5f587f609f"
      unitRef="U_USD">4338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="-3"
      id="F_0622b0c6-9199-498d-85f8-b746d54bf5bf"
      unitRef="U_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_66c8d198-ab13-4191-84f6-0d564a5a7bf2"
      unitRef="U_USD">289733000</sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement>
    <sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_0b72fa42-fb58-4fa9-b997-bd4479d96544"
      unitRef="U_USD">3650000</sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition>
    <sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_8f9b20d0-c962-4071-a53f-0482f6faec3d"
      unitRef="U_USD">0</sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition>
    <sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_491f980b-a22b-4dbb-bbf6-96f1d8f36797"
      unitRef="U_USD">0</sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition>
    <sclx:NonCashConsiderationInSemnurAcquisition
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_f2d6a127-c984-4276-88dd-37e5f8f8626c"
      unitRef="U_USD">0</sclx:NonCashConsiderationInSemnurAcquisition>
    <sclx:NonCashConsiderationInSemnurAcquisition
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_6ac7d1ee-ad7f-486c-8876-dad19cbdd761"
      unitRef="U_USD">409000</sclx:NonCashConsiderationInSemnurAcquisition>
    <sclx:NonCashConsiderationInSemnurAcquisition
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_2925058c-e1a3-4f89-91c9-1b7bbf76f6ff"
      unitRef="U_USD">0</sclx:NonCashConsiderationInSemnurAcquisition>
    <sclx:OtherLoanForgiveness
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_b0426930-426e-4959-9423-6c3661fac775"
      unitRef="U_USD">0</sclx:OtherLoanForgiveness>
    <sclx:OtherLoanForgiveness
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_afcd7357-3127-4bc5-94f9-4dd74558f1cd"
      unitRef="U_USD">1536000</sclx:OtherLoanForgiveness>
    <sclx:OtherLoanForgiveness
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_5a413bfd-d62a-45a6-9067-0271a027292a"
      unitRef="U_USD">0</sclx:OtherLoanForgiveness>
    <sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_7b0dc563-fe52-4242-aeb5-4a8d42f0765a"
      unitRef="U_USD">4162000</sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount>
    <sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_553b73e8-b430-4f67-8db5-d6c7675d0445"
      unitRef="U_USD">0</sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount>
    <sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_9b4432a1-4dca-4b7b-9e1e-04d358b0fd21"
      unitRef="U_USD">0</sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount>
    <sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_b1da2859-0206-4883-b281-f5e328d892fd"
      unitRef="U_USD">30400000</sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring>
    <sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_2b5188a0-6df1-48e4-b154-534366f0e15a"
      unitRef="U_USD">0</sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring>
    <sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_7177e79e-4ae2-45ec-9330-342c49fa4ac6"
      unitRef="U_USD">0</sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring>
    <sclx:AcquisitionOfRightOfUseAsset
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_ab7fb929-e19e-4072-9e21-bac1dbf0fd95"
      unitRef="U_USD">320000</sclx:AcquisitionOfRightOfUseAsset>
    <sclx:AcquisitionOfRightOfUseAsset
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_4531b770-f75c-45d7-8409-4aeda7c5ce5e"
      unitRef="U_USD">0</sclx:AcquisitionOfRightOfUseAsset>
    <sclx:AcquisitionOfRightOfUseAsset
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_158b111e-1e03-4a01-9939-7746255cd04f"
      unitRef="U_USD">0</sclx:AcquisitionOfRightOfUseAsset>
    <sclx:IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_6cb272e0-6f92-443b-a16e-77d31975e56a"
      unitRef="U_USD">1238000</sclx:IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement>
    <sclx:NonCashDistributionToSorrento
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_8c0cf2e9-b349-45dd-b520-494f321e28f9"
      unitRef="U_USD">0</sclx:NonCashDistributionToSorrento>
    <sclx:NonCashDistributionToSorrento
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_684d2d31-73ad-465d-a40d-3e7d53ac8685"
      unitRef="U_USD">0</sclx:NonCashDistributionToSorrento>
    <sclx:NonCashDistributionToSorrento
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_eae0b477-823e-48f6-8af0-f555f2345603"
      unitRef="U_USD">9600000</sclx:NonCashDistributionToSorrento>
    <sclx:NotesPrincipalIncrease
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_9ebe23cb-073a-4c8f-a684-c66e00759b7f"
      unitRef="U_USD">0</sclx:NotesPrincipalIncrease>
    <sclx:NotesPrincipalIncrease
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_c5f5f05c-d263-4143-a553-ab1a0f2bdd3a"
      unitRef="U_USD">-28000000</sclx:NotesPrincipalIncrease>
    <sclx:NotesPrincipalIncrease
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_7712c969-cdf4-4ba7-8eae-9b19b87526a8"
      unitRef="U_USD">0</sclx:NotesPrincipalIncrease>
    <sclx:AccrualForTransactionCostsRelatedToTheBusinessCombination
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_c12c391f-41b0-4eae-b20a-ad2464fa5bf9"
      unitRef="U_USD">1372000</sclx:AccrualForTransactionCostsRelatedToTheBusinessCombination>
    <sclx:TransactionCostsObligationAssumedBySorrento
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_267d29e3-20c4-498a-b50d-4f184624a8d5"
      unitRef="U_USD">5148000</sclx:TransactionCostsObligationAssumedBySorrento>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_44aaa6e3-e1b0-4872-8b26-d6307e9fb083">&lt;p id="section146" style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Nature of Operations and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Organization and Principal Activities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Scilex Holding Company (&#x201c;Scilex&#x201d; and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) is the successor entity to Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;). Vickers was formed on February 21, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Scilex was originally formed in 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (&#x201c;Sorrento&#x201d;). Scilex has two wholly owned subsidiaries, Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Semnur Pharmaceuticals, Inc. (&#x201c;Semnur&#x201d;). The Company is a commercial biopharmaceutical company focused on acquiring, developing and commercializing non-opioid management products for the treatment of acute and chronic pain. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#x201c;ZTlido&#x201d;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. The Company in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The Company is currently developing three product candidates, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica (&#x201c;SP-102&#x201d; or &#x201c;SEMDEXA&#x201d;), SP-103 (lidocaine topical system) 5.4% (&#x201c;SP-103&#x201d;), for the treatment of acute low back pain, and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (&#x201c;SP-104&#x201d;), a novel formulation for the treatment of fibromyalgia. Since inception, the Company has devoted substantially all of its efforts to the development of SP-102, SP-103, SP-104, and the commercialization of ZTlido.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Business Combination&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 17, 2022, Scilex entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) with Vickers and Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#x201c;Vickers Merger Sub&#x201d;). Pursuant to the terms of the Merger Agreement, Vickers Merger Sub merged with and into Scilex, Inc. (f/k/a Scilex Holding Company and now a wholly owned subsidiary of Scilex) (&#x201c;Legacy Scilex"), with Legacy Scilex surviving the merger and becoming a wholly-owned subsidiary of Vickers (collectively, the &#x201c;Business Combination&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 10, 2022, Vickers consummated the Business Combination pursuant to the terms of the Merger Agreement. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, Scilex received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Additionally, all existing related party indebtedness between Legacy Scilex and Sorrento totaling &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;290.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 12). The Company, as the successor entity of Vickers, will operate as &#x201c;Scilex Holding Company&#x201d; and was listed on the Nasdaq Capital Market under the new ticker symbol &#x201c;SCLX&#x201d; on November 11, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At the closing of the Business Combination, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197,566,338&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,151,428&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Legacy Scilex Common Stock (&#x201c;Legacy Scilex Common Stock&#x201d;) and Legacy Scilex stock options, respectively, were converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,060,534&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of Common Stock (&#x201c;Common Stock&#x201d;) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as part of the consideration using the 0.673498:1 ratio of the Company Common Stock to Legacy Scilex Common Stock&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (the &#x201c;Common Stock Exchange Ratio&#x201d;) and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,939,436&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Common Stock were reserved for Legacy Scilex optionholders. Pursuant to the terms of the Debt Exchange Agreement (see Note 12), &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;290.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,057,097&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Preferred Stock (&#x201c;Preferred Stock&#x201d;) and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,905,710&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Common Stock. In addition, pursuant to the terms of the debt agreement entered between the Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd (&#x201c;Sponsors&#x201d;) and Vickers (&#x201c;Vickers Debt Agreement&#x201d;), the aggregate amount of loans that the Sponsors funded Vickers to finance the transaction costs (&#x201c;Working Capital Loans&#x201d;) at the closing of the Business Combination of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,330,557&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;533,057&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Common Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers was treated as the &#x201c;acquired&#x201d; company for accounting purposes and the Business Combination was treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. Upon the closing of the Business Combination, the net assets of Vickers were recorded at historical cost, with no goodwill or other intangible assets recorded.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s legal, accounting and other fees directly attributable to the Business Combination were initially capitalized within prepaid expenses and other current assets on the consolidated balance sheets, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million has been offset against the equity proceeds in the Business Combination and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was attributed to the liability-classified Private Warrants and, as such, were expensed upon the closing of the Business Combination.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p id="section147" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution.  Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values.  Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and  2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices.  Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines inventory cost on a first-in, first-out basis.  The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for on-hand inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. As of December 31, 2022 and  2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company&#x2019;s inventory was primarily comprised of finished goods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="section153" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are carried at cost less accumulated depreciation.  Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.  The cost of repairs and maintenance is expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="section154" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, up-front payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations unless there is an alternative future use.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;amp;D over its estimated useful life.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Capitalized IPR&amp;amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="section157" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Goodwill and Other Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired.  Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill.  The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company.  If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and Topic 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Public Warrants and Private Placement Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon completion of the Business Combination, the Company assumed public and private placement warrants (&#x201c;Public Warrants&#x201d; and &#x201c;Private Warrants&#x201d;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on January 11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic No. 815-40, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contracts on an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic 815-40. The Private Warrants are not considered indexed to the Company&#x2019;s stock per ASC Subtopic 815-40 as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a fixed-for-fixed option contract. Therefore, Private Warrants are recognized as derivative liabilities &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;at their estimated fair value on November 10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet date, with fair value changes recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="section159" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates.  This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="section160" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="section161" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company expenses the cost of research and development as incurred.  Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.  Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="section162" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The provisions of the FASB ASC Topic 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Subtopic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.  The Company has determined that it has uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized.  As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company maintained a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="section163" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.  As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.  The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives.  The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="section164" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue from product sales is fully comprised of sales of ZTlido. The Company&#x2019;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.  Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December 31, 2022 and 2021 were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Rebates are discounts which the Company pays under either government or private health care programs.  Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers.  Both types of rebates vary over time.  The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Prompt Payment Discounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Service Fees&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company compensates its customer and others in the distribution chain for wholesaler and distribution services.  The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Product Returns&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Co-Payment Assistance&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive co- payment assistance.  The Company accrues for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p id="section165" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Customer Concentration Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to April 2, 2022, sales to the Company's sole distributor represented &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of net revenue. On April 2, 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The distributor continued to provide traditional third-party logistics functions for the Company. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company had four customers during the year ended December 31, 2022, which individually generated 10% or more of the Company&#x2019;s total revenue. These customers accounted for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the Company&#x2019;s revenue for the year ended December 31, 2022, individually ranging between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2022, these customers represented &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the Company&#x2019;s outstanding accounts receivable, individually ranging between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Additionally, during the fiscal years ended December 31, 2022 and 2021, the Company purchased inventory from its sole supplier, Itochu. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the years ended December 31, 2022, 2021, and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p id="section166" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or non-employee&#x2019;s vesting period. The Company accounts for forfeitures as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p id="section167" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of non-opioid products focused on pain management based on its platform technologies and all sales are based in the United States.  Accordingly, the Company has determined that it operates its business as a single reportable segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p id="section168" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p id="section169" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <sclx:TransactionCostsAmount
      contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21"
      decimals="-5"
      id="F_c793792e-9af4-431c-999d-5b93fc0cce42"
      unitRef="U_USD">3400000</sclx:TransactionCostsAmount>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_6c47f53f-c811-4186-9ff5-419aa14184c5"
      decimals="-5"
      id="F_610cc26e-f2c7-4309-a0b4-b4f10512b50e"
      unitRef="U_USD">290600000</us-gaap:ConversionOfStockAmountConverted1>
    <sclx:ConversionOfCommonStock
      contextRef="C_8af3e27b-97dd-4b7e-8523-2366035accc5"
      decimals="INF"
      id="F_5673b9d3-ca04-4eaf-8c4c-3789bc313848"
      unitRef="U_shares">197566338</sclx:ConversionOfCommonStock>
    <sclx:ConversionOfCommonStock
      contextRef="C_98ba01df-597b-4318-aca4-8f7bf10d4909"
      decimals="INF"
      id="F_3a200450-f4f1-4830-be03-c7480cec06b8"
      unitRef="U_shares">25151428</sclx:ConversionOfCommonStock>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_21eb1f4e-32ad-4b44-99ff-e9ffd99b9aa5"
      decimals="INF"
      id="F_67bbf83d-ab64-47d4-9d86-9c1d9eaf7bca"
      unitRef="U_shares">133060534</us-gaap:ConversionOfStockSharesConverted1>
    <sclx:CommonStockExchangeRatioDescription
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_93ed3e11-0b64-4813-adb6-8515edc61158">as part of the consideration using the 0.673498:1 ratio of the Company Common Stock to Legacy Scilex Common Stock</sclx:CommonStockExchangeRatioDescription>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213"
      decimals="INF"
      id="F_b0717f3a-5aed-4158-a47a-25e3051117ac"
      unitRef="U_shares">16939436</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_6c47f53f-c811-4186-9ff5-419aa14184c5"
      decimals="-5"
      id="F_6815febb-e5f1-43f3-a5d6-75ba6e0b913a"
      unitRef="U_USD">290600000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_de43cc1f-2fdb-4769-8c7b-6c7cef7cb9b0"
      decimals="INF"
      id="F_ed12828a-b386-4b7f-8254-ce57a226e70c"
      unitRef="U_shares">29057097</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_3377c481-f9db-4160-b872-f87f6e365001"
      decimals="INF"
      id="F_cfe8e9d3-d78c-40e8-b2fa-cb2813769a01"
      unitRef="U_shares">2905710</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_3ca96e60-bf56-4765-9420-632b08ad825f"
      decimals="0"
      id="F_9b9af90f-8e51-4f93-84a5-617f396b70af"
      unitRef="U_USD">5330557</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_3ca96e60-bf56-4765-9420-632b08ad825f"
      decimals="INF"
      id="F_9b15e484-fdd0-4136-a040-4ed2ac97bf1b"
      unitRef="U_shares">533057</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_42dde953-1de3-4888-9e2a-9a55861296bd"
      decimals="-5"
      id="F_f25a4dea-0752-41e5-b629-b122a13c03dd"
      unitRef="U_USD">9100000</us-gaap:ProceedsFromOtherEquity>
    <sclx:LiabilityClassifiedPrivateWarrants
      contextRef="C_cb4e9c2d-4697-4133-b0c7-df08bcc87742"
      decimals="-5"
      id="F_255175b3-f273-482a-a6de-9fb4e067d3ab"
      unitRef="U_USD">400000</sclx:LiabilityClassifiedPrivateWarrants>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_017149be-bf07-46c9-9252-0705b6b8af10">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_d9a67dab-0612-4e6a-9c6d-f371174d7768">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_f63b0fb9-8dcb-4529-894d-cf9647a77626">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution.  Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_a3be322a-6ed9-4fce-80ee-addfb38a00ab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values.  Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and  2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices.  Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_34356861-5e61-4624-9a6e-aa95efff9103">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_1c5251be-2e3d-4b4c-96d1-3f6e581a0fd7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines inventory cost on a first-in, first-out basis.  The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for on-hand inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. As of December 31, 2022 and  2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company&#x2019;s inventory was primarily comprised of finished goods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_907c7984-2316-46b8-98d6-5ace338821aa">&lt;p id="section153" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are carried at cost less accumulated depreciation.  Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.  The cost of repairs and maintenance is expensed as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_c2a5f43a-f386-4dcc-9589-44822f70c17f">&lt;p id="section154" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, up-front payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations unless there is an alternative future use.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;amp;D over its estimated useful life.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Capitalized IPR&amp;amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_7c1d8511-7aa1-489e-94b7-f3ebb8f399dc">&lt;p id="section157" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Goodwill and Other Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired.  Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill.  The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company.  If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_762cdbe7-599f-4ada-96dd-041a06fc4d9d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and Topic 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved.&lt;/span&gt;&lt;/p&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <sclx:PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_41ce7ff0-3563-40d3-9f67-6decd19c349f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Public Warrants and Private Placement Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon completion of the Business Combination, the Company assumed public and private placement warrants (&#x201c;Public Warrants&#x201d; and &#x201c;Private Warrants&#x201d;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on January 11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic No. 815-40, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contracts on an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic 815-40. The Private Warrants are not considered indexed to the Company&#x2019;s stock per ASC Subtopic 815-40 as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a fixed-for-fixed option contract. Therefore, Private Warrants are recognized as derivative liabilities &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;at their estimated fair value on November 10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet date, with fair value changes recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</sclx:PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_71e98dbc-c45a-48ba-8054-df4e6d34bb5c">&lt;p id="section159" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates.  This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_6833883c-b8d4-497f-a17d-90b519f62d36">&lt;p id="section160" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_c8ae21a0-de91-464f-acbb-e163ac789eb5">&lt;p id="section161" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company expenses the cost of research and development as incurred.  Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.  Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_e6856073-761b-4640-aeaa-b8862d05095e">&lt;p id="section162" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The provisions of the FASB ASC Topic 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Subtopic 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.  The Company has determined that it has uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized.  As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company maintained a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_53658874-2b67-48c5-a383-2768a6f51f12">&lt;p id="section163" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.  As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.  The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives.  The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_88a4faf4-4a24-4304-8d88-f3fcc3b3d97b">&lt;p id="section164" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue from product sales is fully comprised of sales of ZTlido. The Company&#x2019;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.  Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December 31, 2022 and 2021 were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Rebates are discounts which the Company pays under either government or private health care programs.  Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers.  Both types of rebates vary over time.  The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Prompt Payment Discounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Service Fees&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company compensates its customer and others in the distribution chain for wholesaler and distribution services.  The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Product Returns&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Co-Payment Assistance&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive co- payment assistance.  The Company accrues for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_5d89da1c-6638-452d-9559-7ec1331c5edb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Customer Concentration Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to April 2, 2022, sales to the Company's sole distributor represented &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of net revenue. On April 2, 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The distributor continued to provide traditional third-party logistics functions for the Company. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company had four customers during the year ended December 31, 2022, which individually generated 10% or more of the Company&#x2019;s total revenue. These customers accounted for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the Company&#x2019;s revenue for the year ended December 31, 2022, individually ranging between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2022, these customers represented &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the Company&#x2019;s outstanding accounts receivable, individually ranging between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Additionally, during the fiscal years ended December 31, 2022 and 2021, the Company purchased inventory from its sole supplier, Itochu. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the years ended December 31, 2022, 2021, and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <sclx:PercentageOfNetRevenueSoleDistributors
      contextRef="C_5732eb05-268c-4927-ab42-4931ac50cee6"
      decimals="INF"
      id="F_604f9349-da55-4bfb-9254-11f86362f11e"
      unitRef="U_pure">1</sclx:PercentageOfNetRevenueSoleDistributors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_5350c734-a3ef-4fd1-88d3-af11b48f40cf"
      decimals="2"
      id="F_03c74761-df82-4681-8e72-f0b3ed3c0772"
      unitRef="U_pure">0.83</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_461cdc24-bee6-49eb-825f-a615ecb35d40"
      decimals="2"
      id="F_4b71485b-3e25-401d-8ecb-8e1d0ce82847"
      unitRef="U_pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0cfa11ab-3c88-4cef-9e78-7b5083e4ce05"
      decimals="2"
      id="F_5ebfaf0c-16d6-44de-a36a-1ec54c15c924"
      unitRef="U_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0205795c-8a73-4b30-885d-bfc720c71093"
      decimals="2"
      id="F_b2d097bd-5e4e-49e7-a07e-736f9770ae50"
      unitRef="U_pure">0.90</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2e6b294a-07c5-4bc3-b0f8-28ef1bba9112"
      decimals="2"
      id="F_3bb905dd-7dd1-4d46-83cf-7fb9e759e8a8"
      unitRef="U_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_27408945-d0d7-44d3-b555-007ee69f44da"
      decimals="2"
      id="F_c3e19341-2ba9-46ed-9e0a-2bdfe4a55aa5"
      unitRef="U_pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_fb6e372d-a92b-4c33-ab6a-c7682a10ec64">&lt;p id="section166" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or non-employee&#x2019;s vesting period. The Company accounts for forfeitures as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_fe61f762-faa6-42f3-85df-56959b5c0aa1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of non-opioid products focused on pain management based on its platform technologies and all sales are based in the United States.  Accordingly, the Company has determined that it operates its business as a single reportable segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_848452a5-6edb-4a1f-bf4e-7a222f22a1a6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_f5ced228-9b16-4e21-b5e9-2c2769db660e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_1f842410-70f3-4ec0-bd75-5f50f418b7b3">&lt;p id="section170" style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.  Management has assessed the Company&#x2019;s ability to continue as a going concern for at least one year after the date the financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 18, 2019, Scilex acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note 3). The Company anticipates the cash needed for the development of Semnur&#x2019;s primary product candidate in development, SP-102, as well in the development of SP-103, will be in excess of the Company&#x2019;s cash available within one year after the date these consolidated financial statements are issued.  Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the SP-104 Assets (see Note 3). SP-104 has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be responsible for funding all development and commercialization efforts.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 14, 2022, the Company entered into a license and commercialization agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs related to the commercial launch and marketing of GLOPERBA.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On September 12, 2022, Scilex and Scilex Pharma entered into a Debt Exchange Agreement (see Note 12) with Sorrento, pursuant to which all related party indebtedness that remained outstanding as of immediately prior to the closing of the Business Combination was converted into equity interests in the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2022, the Company exercised the Early Paydown Provision (see Note 7) to fully extinguish the Scilex Pharma Notes (see Note 7). In August 2022 and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Pursuant to Amendment No. 4 (see Note 7), a principal balance &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was forgiven by the Scilex Pharma Note Purchasers (see Note 7) upon the Company&#x2019;s exercise of the Early Paydown Provision. The Company funded the principal payments with cash-on hand and&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; received from Sorrento on September 28, 2022 (see Note 7).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company&#x2019;s negative working capital was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, including cash and cash equivalents of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During the year ended December 31, 2022, the Company had operating losses of&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and cash flows used for operations o&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;f $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company had an accumulated deficit of approximate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ly $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;375.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. (&#x201c;Yorkville&#x201d;) on November 17, 2022 (as amended and restated on February 8, 2023), and a Standby Equity Purchase Agreement with B. Riley Principal Capital II, LLC (&#x201c;B. Riley&#x201d;) on January 8, 2023 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;whereby the Company has the right, but not the obligation, to sell to Yorkville and B. Riley up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million each of shares of its Common Stock at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement has been declared effected by the SEC, subject to certain conditions (see Note 8 and Note 14). The Company&#x2019;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#x2019;s marketing of ZTlido. Should the Company&#x2019;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#x2019;s business plan, due to the COVID-19 pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for SP-102, SP-103, and SP-104, and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#x2019;s control.  As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year after the date the financial statements are issued.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_456895c8-fe6d-4068-beff-13288c8937f7"
      decimals="-5"
      id="F_6a0835e0-6774-48ec-9f0f-f926e3b0853c"
      unitRef="U_USD">41400000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="C_3829a111-1d2a-42cf-8ef3-8eee8d13b455"
      decimals="-5"
      id="F_df5d4313-5494-412f-834c-bb12cadb0430"
      unitRef="U_USD">28000000.0</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="C_5afaea6d-9fb4-41dc-9415-7c291b048f12"
      decimals="-5"
      id="F_5fcb443c-a59c-4c54-b8e3-a59e0b101149"
      unitRef="U_USD">34000000.0</us-gaap:ProceedsFromRelatedPartyDebt>
    <sclx:WorkingCapital
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-5"
      id="F_4ae7a50d-8d20-4214-a183-92b8acd57ecd"
      unitRef="U_USD">15200000</sclx:WorkingCapital>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-5"
      id="F_0bc9c5a8-baef-47d2-8ecd-c76ca615cd75"
      unitRef="U_USD">2200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-5"
      id="F_94748aa5-219c-4425-afa1-7520feda77e8"
      unitRef="U_USD">-50600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-5"
      id="F_470d59d2-635f-4bbb-91d1-2672382511b4"
      unitRef="U_USD">21300000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-5"
      id="F_44c1e724-a1f4-485e-a168-c978a691e6fa"
      unitRef="U_USD">-375900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_10bd7df9-bc0a-460b-b471-0b07966dbf8a"
      decimals="-5"
      id="F_ebaeca6c-d9b2-419d-b105-9ac0659e65e3"
      unitRef="U_USD">500000000.0</us-gaap:LongTermDebtCurrent>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_c425966b-a5d1-42c7-a97c-4ff9dd56b5c3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3. Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;SP-104 Acquisition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 12, 2022, the Company entered into a bill of sale and assignment and assumption agreement (the &#x201c;Bill of Sale&#x201d;), with Sorrento. Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#x2019;s Delayed Burst Release Low Dose Naltrexone (&#x201c;DBR-LDN&#x201d;) asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the &#x201c;SP-104 Assets&#x201d;). These assets had previously been acquired by Sorrento from Aardvark&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Therapeutics, Inc. (&#x201c;Aardvark&#x201d;) in April 2021 pursuant to an asset purchase agreement (the &#x201c;Aardvark Asset Purchase Agreement&#x201d;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#x2019;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the &#x201c;SP-104 Acquisition&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for the SP-104 Acquisition, the Company issued a promissory note in the aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to Sorrento (the &#x201c;2022 Promissory Note&#x201d;). Upon issuance of the note, the Company recorded a related party note payable of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The 2022 Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.66&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% simple interest per annum and (b) the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company&#x2019;s common stock or any combination thereof, at the Company&#x2019;s sole discretion, and may be prepaid in whole or in part at any time without penalty. On November 10, 2022,  the 2022 Promissory Note was converted to equity, pursuant to the terms of the Debt Exchange Agreement (See Note 12).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, upon initial approval by the FDA of a new drug application for the SP-104 Assets (which amount may be paid in shares of the Company&#x2019;s common stock or cash, in the Company&#x2019;s sole discretion) (the &#x201c;Development Milestone&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Payment&#x201d;) and (ii) $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the SP-104 Assets (the &#x201c;Sales Milestone Payment&#x201d;).  The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the SP-104 Assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, SP-104 Assets. The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and will not be recognized until the contingencies are realized in accordance with the Company&#x2019;s accounting policy for contingent consideration in an asset acquisition. The Development Milestone Payment represents a liability within the scope of ASC Topic 480, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which will be measured at fair value each reporting period. As of December 31, 2022, the contingent consideration of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; associated with Development Milestones Payment was recognized under other long-term liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;GLOPERBA License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 14, 2022, the Company entered into a license agreement (the &#x201c;Romeg License Agreement&#x201d;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#x201c;Romeg&#x201d;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (1) a transferable license, with the right to sublicense, under the patents and know-how specified therein (with such license to know-how being exclusive for the limited purposes specified therein) to (i) commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#x201c;Initial Licensed Product&#x201d; or &#x201c;GLOPERBA&#x201d;) in the United States of America (including its territories) (the &#x201c;Territory&#x201d;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#x201c;Licensed Products&#x201d;) and commercialize any such products and (iii) manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory; and (2) an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for the license under the Romeg License Agreement, the Company paid Romeg an up-front license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and has agreed to pay Romeg (a) upon the Company&#x2019;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, (b) certain royalties in the mid-single digit to low-double digit percentages based on annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c) minimum quarterly royalty payments totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i) expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii) the tenth anniversary of the effective date of the Romeg License Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which is comprised of the upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and a deferred consideration of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent sales milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, and will not be recognized until the contingencies are realized. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; contingent consideration was recognized as a liability or included in the fair value of the assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022. The Company determined the useful life of the intangible asset to be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years, which approximates the life of the licensed patents covering the Initial Licensed Product.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_49abe51e-8cd0-4386-b0ec-79317162d36d"
      decimals="-5"
      id="F_82ec03eb-acd4-454b-ada5-73bf54e695f0"
      unitRef="U_USD">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="C_49abe51e-8cd0-4386-b0ec-79317162d36d"
      decimals="-5"
      id="F_c9279e4b-0a3b-46ec-9dec-9adc1af7309f"
      unitRef="U_USD">4100000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="C_6e6757a4-23e1-4b86-9c56-e99208d69c95"
      decimals="4"
      id="F_3b0f0299-5650-4092-9240-86a9968ef374"
      unitRef="U_pure">0.0266</us-gaap:SubordinatedBorrowingInterestRate>
    <sclx:AmountDueForNewDrugApplication
      contextRef="C_ea7b3fbf-8dd6-49a4-a28c-adc88beeb0ae"
      decimals="0"
      id="F_4c0ccb43-d7f3-499d-941a-a75ce53fb423"
      unitRef="U_USD">3000000</sclx:AmountDueForNewDrugApplication>
    <sclx:PaymentUponTheAchievementOfNetSales
      contextRef="C_ea7b3fbf-8dd6-49a4-a28c-adc88beeb0ae"
      decimals="0"
      id="F_3bfe303e-664f-4540-8392-82180721c1c9"
      unitRef="U_USD">20000000</sclx:PaymentUponTheAchievementOfNetSales>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="C_64b784b2-80c2-40ef-8826-8180d2f928c8"
      decimals="-5"
      id="F_ae4a1c2f-0847-4f12-8521-82be2598e0f4"
      unitRef="U_USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <sclx:Upfrontlicensefee
      contextRef="C_9a36dab1-2630-4e69-8371-8793ba9072bb"
      decimals="-5"
      id="F_33235d51-9558-4848-a109-d124052f4576"
      unitRef="U_USD">2000000.0</sclx:Upfrontlicensefee>
    <sclx:PaymentUponTheAchievementOfNetSales
      contextRef="C_9a36dab1-2630-4e69-8371-8793ba9072bb"
      decimals="-5"
      id="F_8eae7160-4d0a-4589-a9cd-1476563aa54f"
      unitRef="U_USD">13000000.0</sclx:PaymentUponTheAchievementOfNetSales>
    <us-gaap:PaymentsForRoyalties
      contextRef="C_9a36dab1-2630-4e69-8371-8793ba9072bb"
      decimals="-5"
      id="F_2e799b2c-7c58-4066-a2a2-ea64556a2cb6"
      unitRef="U_USD">7100000</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="C_cb7297d5-c3c9-4562-83bf-bfeaeab23e3a"
      decimals="-5"
      id="F_f1c68ec0-e287-4707-a5af-ff4ae583dc13"
      unitRef="U_USD">5700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <sclx:Upfrontlicensefee
      contextRef="C_9a36dab1-2630-4e69-8371-8793ba9072bb"
      decimals="-5"
      id="F_182aeda3-9ce5-41d9-a8c6-d0d80ea8557a"
      unitRef="U_USD">2000000.0</sclx:Upfrontlicensefee>
    <sclx:Deferredconsiderationliabilities
      contextRef="C_646df392-6d69-4b69-80f2-861bf594ef6a"
      decimals="-5"
      id="F_c7aa4686-7370-4192-b2cf-9de9caefa0fc"
      unitRef="U_USD">3700000</sclx:Deferredconsiderationliabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_646df392-6d69-4b69-80f2-861bf594ef6a"
      decimals="0"
      id="F_e2f4d390-0a1d-46c7-b2ca-09a24ba3163d"
      unitRef="U_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_9a36dab1-2630-4e69-8371-8793ba9072bb"
      id="F_4e3e3bf2-9097-451f-936b-4bda93ae1f8d">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_1693e1d0-d454-4062-b2e2-091f170336c4">&lt;p id="section172" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.662%;"/&gt;
        &lt;td style="width:1.237%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.138%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.578999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.594%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value measurements at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_1b42e5e5-376a-4619-9690-cb8f5630cc07;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_708be5d4-a9d0-4908-bbbe-b2da444eaa07;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_174a237b-3e62-4fa6-915e-8a53d0d37000;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.297%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.901%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.901%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.521%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value measurements at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_2e14ac05-2d70-479b-834b-0da0a2e27285;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial assets carried at fair value are comprised of cash and cash equivalents.  Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable.  These assets are valued using inputs observable in active markets for identical securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recorded a gain of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and gain of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million on derivative liabilities for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note 7) and Private Warrants. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; immediately after &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;entry into Amendment No. 4 (see Note 7) associated with the Scilex Pharma Notes on June 2, 2022. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No. 4. Significant Level 3 assumptions used in the measurement included a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% risk adjusted net sales forecast and an effective debt yield of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 7) and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022. At the closing of the Business Combination, the Company assumed a derivative warrant liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_41f57cde-2f51-43b9-9298-50e67016606a;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; related to Private Warrants (See Note 8). The fair value of derivative warrant liability related to Private Warrants was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.153%;"/&gt;
        &lt;td style="width:1.916%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.93%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ending Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loan derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Re-measurement of fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ending Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Re-measurement of fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Private Warrant liability acquired as part of the Business Combination&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeiture of Private Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in fair value measurement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Warrant Liability Measurement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level 3 fair value measurement. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants. A summary of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;inputs used in valuing the derivative warrant liabilities is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.537%;"/&gt;
        &lt;td style="width:1.624%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.624%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;November 10, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.86&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Call option value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Development Milestone Payment represents a liability under the scope of ASC Topic 480, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, as it pertains to a potential contractual obligation to settle a fixed value in a variable number of shares of Common Stock. Upon the achievement of FDA approval for a new drug application for SP-104, the Company will transfer $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant Level 3 assumptions included the likelihood of receiving FDA approval for SP-104, expected timing for receipt of FDA approval for SP-104, and a discount rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were no transfers between fair value measurement levels during the years ended December 31, 2022, 2021, and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_af68513a-e196-4390-8205-10efaf40f1a0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.662%;"/&gt;
        &lt;td style="width:1.237%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.138%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.578999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.223%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.594%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value measurements at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_1b42e5e5-376a-4619-9690-cb8f5630cc07;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_708be5d4-a9d0-4908-bbbe-b2da444eaa07;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_174a237b-3e62-4fa6-915e-8a53d0d37000;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.297%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.901%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.901%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.521%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value measurements at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_2e14ac05-2d70-479b-834b-0da0a2e27285;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_24fe7873-8fb8-4032-9d68-f2926f583cab"
      unitRef="U_USD">2184000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a527389d-306f-4919-bfea-9e278fdd7f82"
      decimals="-3"
      id="F_9db4067c-9f64-465f-b4af-44e28e487371"
      unitRef="U_USD">2184000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456"
      decimals="-3"
      id="F_45d9bf69-7146-4ba3-adcc-43b5611ff42a"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc"
      decimals="-3"
      id="F_e576b092-8c6b-4c3b-b12d-e91caaf14c91"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_0c51528a-4212-4ecc-a9cb-655308c7d35a"
      unitRef="U_USD">2184000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a527389d-306f-4919-bfea-9e278fdd7f82"
      decimals="-3"
      id="F_6eca079d-4777-44b7-bbe4-789224588eac"
      unitRef="U_USD">2184000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456"
      decimals="-3"
      id="F_c5e9d170-35b6-4d98-8852-8b49f4db1105"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc"
      decimals="-3"
      id="F_9ac5a283-ac7b-44a2-bcf1-00ed5c7198e1"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_2a25b415-1268-4313-80be-87be6233c64f"
      unitRef="U_USD">1231000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_a527389d-306f-4919-bfea-9e278fdd7f82"
      decimals="-3"
      id="F_7258fcef-b573-4bbe-b3ec-8d65c5bef3f5"
      unitRef="U_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456"
      decimals="-3"
      id="F_1228804c-6341-4c21-8610-b31223f513ef"
      unitRef="U_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc"
      decimals="-3"
      id="F_396cc7f9-0e21-46cf-b27a-14e19c2967ca"
      unitRef="U_USD">1231000</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_5ef68670-b90f-4ffb-8198-eaebd7611b6a"
      unitRef="U_USD">163000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc"
      decimals="-3"
      id="F_2d1efa72-3953-40c8-87e8-e37e4709c65b"
      unitRef="U_USD">163000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_7588a4b7-21c3-424a-b1ad-0736ffde990c"
      unitRef="U_USD">1394000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_a527389d-306f-4919-bfea-9e278fdd7f82"
      decimals="-3"
      id="F_7007300f-cce2-4eac-b01e-4bc535dd2b7e"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_e75088c7-2c8c-4b46-a857-0ea6d5ab3456"
      decimals="-3"
      id="F_e616a7c6-d537-4644-b4d1-52659c82336b"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_e4458cda-f6dc-4b82-9ecd-4eafdfcd12fc"
      decimals="-3"
      id="F_ad6d8c9a-362a-4b60-a600-e3c93ef8eb30"
      unitRef="U_USD">1394000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_3a08742c-22da-4cef-bf4c-16e62036ab9b"
      unitRef="U_USD">4338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a476f78c-ccf8-4bfe-b276-63e339cbc4fd"
      decimals="-3"
      id="F_e775dca3-1b4c-45d9-957b-701f5e597214"
      unitRef="U_USD">4338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_305b4be4-c15c-4501-b464-80c28ee532ec"
      decimals="-3"
      id="F_fc0fa511-9fcb-41ce-aafc-2124b7572544"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_8a1e9628-d82e-4638-abce-1a2d0888da09"
      decimals="-3"
      id="F_208c3065-8b5f-40e6-ad17-b6f1c75482ca"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_f18bfe2a-6dbf-4bf3-a675-e2c28c80e518"
      unitRef="U_USD">4338000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a476f78c-ccf8-4bfe-b276-63e339cbc4fd"
      decimals="-3"
      id="F_56c43b4d-bb75-4691-a0ba-f272000b53bb"
      unitRef="U_USD">4338000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_305b4be4-c15c-4501-b464-80c28ee532ec"
      decimals="-3"
      id="F_84244b52-addb-4bf4-ab40-b0f643020260"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8a1e9628-d82e-4638-abce-1a2d0888da09"
      decimals="-3"
      id="F_679ec885-84fc-4211-8e78-ed02e7c92f61"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_b2111b4f-f219-4e47-bcf0-8bba135b1e0a"
      unitRef="U_USD">35700000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_a476f78c-ccf8-4bfe-b276-63e339cbc4fd"
      decimals="-3"
      id="F_cff1c66f-c820-4f64-acb0-8bc30ac895db"
      unitRef="U_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_305b4be4-c15c-4501-b464-80c28ee532ec"
      decimals="-3"
      id="F_e0a4d6ff-9762-419c-be82-4ac17650da1c"
      unitRef="U_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_8a1e9628-d82e-4638-abce-1a2d0888da09"
      decimals="-3"
      id="F_ede16437-bf41-4922-886f-8b8028edf624"
      unitRef="U_USD">35700000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_ba998113-20bf-4cd7-b1d0-84255ff5d110"
      unitRef="U_USD">35700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_a476f78c-ccf8-4bfe-b276-63e339cbc4fd"
      decimals="-3"
      id="F_e83a1cc1-1fff-486f-b2f9-67d0b079bae1"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_305b4be4-c15c-4501-b464-80c28ee532ec"
      decimals="-3"
      id="F_d748ef1b-34af-4ab1-b735-a1ba985580f0"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_8a1e9628-d82e-4638-abce-1a2d0888da09"
      decimals="-3"
      id="F_7034ab48-cd8c-4df7-a487-771fa7c77266"
      unitRef="U_USD">35700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-5"
      id="F_5a09da2d-077b-403b-8925-c036043aee4b"
      unitRef="U_USD">8300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-5"
      id="F_50a9810f-417c-4f14-acf5-6f406c39ccc8"
      unitRef="U_USD">-300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-5"
      id="F_a1862d57-dbcb-46c8-b152-0e5c020865af"
      unitRef="U_USD">800000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_e9f1e9c3-d961-4504-8da6-3bd4eb3c8fbc"
      decimals="-5"
      id="F_19c0b59c-9f0b-4c75-8f34-ff95d9bf1e85"
      unitRef="U_USD">30400000</us-gaap:LiabilitiesFairValueAdjustment>
    <sclx:RiskAdjustedNetSalesForecast
      contextRef="C_8af8c6e1-609d-44ef-9f26-2b6bd7056a94"
      decimals="3"
      id="F_7190e34c-f364-4687-87fa-3de395759151"
      unitRef="U_pure">0.061</sclx:RiskAdjustedNetSalesForecast>
    <us-gaap:DebtSecuritiesAvailableForSaleWeightedAverageYield
      contextRef="C_8af8c6e1-609d-44ef-9f26-2b6bd7056a94"
      decimals="3"
      id="F_b1925e3d-73e7-4293-948e-5b17535a89df"
      unitRef="U_pure">0.215</us-gaap:DebtSecuritiesAvailableForSaleWeightedAverageYield>
    <sclx:DerivativeWarrantLiabilityPrivateWarrants
      contextRef="C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7"
      decimals="-5"
      id="F_64066aeb-4a33-4e53-ad1c-3d965d2a5178"
      unitRef="U_USD">1200000</sclx:DerivativeWarrantLiabilityPrivateWarrants>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_7e4940ee-662a-4b4e-97d1-ea159075b3dc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.153%;"/&gt;
        &lt;td style="width:1.916%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.93%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ending Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loan derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Re-measurement of fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ending Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Re-measurement of fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Private Warrant liability acquired as part of the Business Combination&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeiture of Private Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in fair value measurement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28"
      decimals="-3"
      id="F_398bced8-5877-4a83-85a7-b5c06dec1ce2"
      unitRef="U_USD">33400000</us-gaap:DerivativeLiabilities>
    <sclx:LoanDerivativeLiability
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_6784ab27-3fe5-45df-8490-ea8f0e4592aa"
      unitRef="U_USD">2800000</sclx:LoanDerivativeLiability>
    <sclx:ReMeasurementOfFairValue
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_488ff1ce-aeb3-4cb8-8f52-56daa17b9d9f"
      unitRef="U_USD">-800000</sclx:ReMeasurementOfFairValue>
    <us-gaap:DerivativeLiabilities
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="-3"
      id="F_922fa547-a1fb-4353-b600-59a94ded62b5"
      unitRef="U_USD">35400000</us-gaap:DerivativeLiabilities>
    <sclx:ReMeasurementOfFairValue
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_04809ef4-bf52-4f6e-b523-070c0d211ff1"
      unitRef="U_USD">300000</sclx:ReMeasurementOfFairValue>
    <us-gaap:DerivativeLiabilities
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_77199c4a-af6f-4586-bb79-2f6c5b78a463"
      unitRef="U_USD">35700000</us-gaap:DerivativeLiabilities>
    <sclx:PrivatePlacementWarrantLiabilityAcquired
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_06e2457b-770a-4ddf-948b-38f5e66e1a18"
      unitRef="U_USD">2545000</sclx:PrivatePlacementWarrantLiabilityAcquired>
    <sclx:ForfeitureOfPrivateWarrants
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_be56dff0-1082-4ddb-86f2-a9e437754a9e"
      unitRef="U_USD">1696000</sclx:ForfeitureOfPrivateWarrants>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_09d2296b-0c04-4dcb-9778-4b71b1272d40"
      unitRef="U_USD">-38710000</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_96677002-d18e-400b-8cc8-2e097e7639de"
      unitRef="U_USD">1231000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueConcentrationOfRiskTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_f6019b4f-1a08-4242-bc7d-8174ad0fbf53">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants. A summary of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;inputs used in valuing the derivative warrant liabilities is as follows:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.537%;"/&gt;
        &lt;td style="width:1.624%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.624%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;November 10, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.86&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Call option value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <sclx:EquityValue
      contextRef="C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7"
      decimals="2"
      id="F_83505706-62e4-40f2-a9f8-6462e83e5163"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.99</sclx:EquityValue>
    <sclx:EquityValue
      contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21"
      decimals="2"
      id="F_24532bdb-1d65-4f49-b35d-a9b4ddabd4c2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.01</sclx:EquityValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="2"
      id="F_53d980c2-b37b-482c-a053-359627014b12"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213"
      decimals="2"
      id="F_25363114-e257-4689-9790-b78543bffe17"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_14a6e055-6ed7-42d9-8cea-a7eee1ae4151">P4Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21"
      id="F_0e11d5e4-3ca2-4823-961c-9b17e9946696">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="3"
      id="F_15bd4454-04e2-4229-8524-61daf3ebe2e2"
      unitRef="U_pure">0.350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21"
      decimals="3"
      id="F_a2d45e1c-03f9-4e5e-8573-7533ccc74e7c"
      unitRef="U_pure">0.100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="4"
      id="F_e901e6b2-7a46-4e0d-97c7-385165d4e2ad"
      unitRef="U_pure">0.0394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21"
      decimals="4"
      id="F_272fe525-dfc8-4c08-899c-653a4f2185e5"
      unitRef="U_pure">0.0391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="4"
      id="F_7d0fc8b5-ccfb-416e-84dd-45bc4a1d85b8"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21"
      decimals="4"
      id="F_15ba696c-7181-4254-942d-9d0d9abf918f"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <sclx:CallOptionValue
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="2"
      id="F_ebb5899b-6e77-4c51-b811-dc6b2074cf5e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.30</sclx:CallOptionValue>
    <sclx:CallOptionValue
      contextRef="C_86a3f7ce-707c-41fc-90d3-06bc58d03c21"
      decimals="2"
      id="F_7ae06e58-a9a0-4c4a-b8f7-9f9582740d19"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.62</sclx:CallOptionValue>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-5"
      id="F_ecafb5c4-e34d-47bb-ac2d-bad9f7ca6b20"
      unitRef="U_USD">3000000.0</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ProductLiabilityContingencyAccrualDiscountRate
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="3"
      id="F_5210986d-2487-4bea-8a77-c3b9598b0ed9"
      unitRef="U_pure">0.100</us-gaap:ProductLiabilityContingencyAccrualDiscountRate>
    <sclx:FairValueOfContingentConsideration
      contextRef="C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7"
      decimals="-5"
      id="F_1a341f1c-180b-4888-ab43-6e2c59cebd03"
      unitRef="U_USD">200000</sclx:FairValueOfContingentConsideration>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_a189371a-a404-4b9a-8cf1-809515ef1cac">&lt;p id="section173" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consisted of the following as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.32%;"/&gt;
        &lt;td style="width:1.583%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.583%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.742%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computers &amp;amp; equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense for each of the years ended December 31, 2022, 2021, and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_50f6ee9b-5be0-4383-86ed-4bae9b99e817">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment consisted of the following as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.32%;"/&gt;
        &lt;td style="width:1.583%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.583%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.742%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computers &amp;amp; equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1c394325-8608-4ec1-8f78-11dd10ae9413"
      decimals="-3"
      id="F_d2980b08-e787-4c22-ae1d-bf441cc1b4b2"
      unitRef="U_USD">77000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_76b68a36-8bf6-4b4f-ba40-ee105d4ec879"
      decimals="-3"
      id="F_9ad0a502-929b-4ddb-a8c5-2e2065d65b0f"
      unitRef="U_USD">77000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bd06b1ee-3d7a-4324-8584-ffe7cba561aa"
      decimals="-3"
      id="F_57a54435-f89c-4c04-9c2f-94d874c570dc"
      unitRef="U_USD">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7a25c562-96ff-46d5-bbd4-d140bf78fd97"
      decimals="-3"
      id="F_0e059e7c-aee8-44bc-9a68-bf0df8ff3805"
      unitRef="U_USD">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5ecb841e-8811-42ee-b52f-1ff866488d24"
      decimals="-3"
      id="F_84436108-0866-40e7-bb10-3ea3c19dcdc3"
      unitRef="U_USD">55000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e23bb04d-0ba8-4323-a7aa-cc2b64211427"
      decimals="-3"
      id="F_4629ead8-3d00-4b71-ba55-aa0ff6556288"
      unitRef="U_USD">48000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_dbf37b66-c5d5-46d3-bd3a-c9a534d9acd9"
      decimals="-3"
      id="F_80ba3894-cd54-4802-ac3d-5f206f2b2ddc"
      unitRef="U_USD">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6e8d69bd-8277-4214-b3a2-0f8215199def"
      decimals="-3"
      id="F_c6ecbe3f-e236-4ae1-8f4b-6735f03eac46"
      unitRef="U_USD">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_49b542d6-b77c-4c8a-b1f3-e76758084865"
      unitRef="U_USD">939000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_c28ef217-5061-4567-8801-f8e6c41d5174"
      unitRef="U_USD">932000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_ab805bc3-9c6e-4be6-b0ba-1156410a1c8b"
      unitRef="U_USD">167000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_b61142e1-a3b4-4039-a3d5-dac31555fe85"
      unitRef="U_USD">127000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_1290a6e1-6201-49df-b1b5-d82bd493a240"
      unitRef="U_USD">772000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_502b508a-163d-453a-aee7-1c9e72ca3196"
      unitRef="U_USD">805000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_0315d384-2c61-48c0-9c80-e745e8db114a"
      unitRef="U_USD">40000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_b8d8dc05-c043-4f17-89e7-3dee17faf357"
      unitRef="U_USD">39000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_46090e20-fa47-4fdc-a88c-f198103057aa"
      unitRef="U_USD">40000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_f1823a9f-2285-4942-85b5-d50635e5ce9f">&lt;p id="section174" style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. Goodwill and Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and December 31, 2021, the Company had recorded goodwill of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company performed a qualitative test for goodwill impairment during the fourth quarter of 2022. Based upon the results of the qualitative testing, the Company concluded that it is more-likely-than-not that the fair value of the Company&#x2019;s goodwill was in excess of the carrying value and therefore performing the first step of the two-step&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;impairment test was unnecessary. The conclusion has not changed as of December 31, 2022 and no goodwill impairment was recognized for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the Company&#x2019;s identifiable intangible assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and December 31, 2021 is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.583000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.293%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.827%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.293%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.787%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangibles, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Patent rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquired technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquired licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assembled workforce&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.894%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.459%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.28%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.447%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.268%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.651%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangibles, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Patent rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquired technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assembled workforce&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was assigned to acquired licenses with an amortization period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the weighted average remaining life for identifiable intangible assets was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;years. Aggregate amortization expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, an&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the years ended December 31, 2022, 2021, and 2020, respectively. Patent rights and acquired technology are amortized over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-year period.  Assembled workforce is amortized over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-year period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated future amortization expense related to intangible assets at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:85.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.621%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-5"
      id="F_4134b950-640a-4a20-8d00-80848a5d4792"
      unitRef="U_USD">13500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-5"
      id="F_bc5f16f5-9b7e-41ab-8af0-588bcf427c0b"
      unitRef="U_USD">13500000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_72d17f94-f79b-4347-8ecb-746e104e8a7c">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the Company&#x2019;s identifiable intangible assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and December 31, 2021 is as follows (in thousands):&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.216%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.583000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.293%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.827%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.293%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.787%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangibles, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Patent rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquired technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquired licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assembled workforce&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.894%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.459%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.28%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.447%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.268%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.651%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangibles, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Patent rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquired technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assembled workforce&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_7a74f725-b9ea-4b81-818b-1b7c312abf01"
      decimals="-3"
      id="F_389e0b5f-5e18-419b-82e5-37c8dc776158"
      unitRef="U_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_7a74f725-b9ea-4b81-818b-1b7c312abf01"
      decimals="-3"
      id="F_274ed6b3-74f5-4bc2-995f-15d4a92f258d"
      unitRef="U_USD">-13415000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_7a74f725-b9ea-4b81-818b-1b7c312abf01"
      decimals="-3"
      id="F_6430d90a-86b4-40f8-b872-70ab783560ee"
      unitRef="U_USD">19215000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_c1803839-1bed-4d8d-a474-a5546b31743c"
      decimals="-3"
      id="F_0f3b9d58-9c13-49ed-be3b-eaf2a85c5bdd"
      unitRef="U_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_c1803839-1bed-4d8d-a474-a5546b31743c"
      decimals="-3"
      id="F_de1eef6c-f170-4093-ab5f-699fa2382ed6"
      unitRef="U_USD">-6216000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_c1803839-1bed-4d8d-a474-a5546b31743c"
      decimals="-3"
      id="F_793670ab-9f0f-48a9-9541-0a798f60a67c"
      unitRef="U_USD">15724000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_fb34a34f-10db-4900-ac2a-b95cc1252ca0"
      decimals="-3"
      id="F_77d95468-471a-4189-8195-bc07620cc854"
      unitRef="U_USD">5711000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_fb34a34f-10db-4900-ac2a-b95cc1252ca0"
      decimals="-3"
      id="F_8ccbd553-79ca-45ff-9b93-080e72b0c3a2"
      unitRef="U_USD">-184000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_fb34a34f-10db-4900-ac2a-b95cc1252ca0"
      decimals="-3"
      id="F_4c4edaa5-c170-4dfc-9302-63896c7f2f79"
      unitRef="U_USD">5527000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_ef14117d-6b86-46ed-956e-d73420b1a933"
      decimals="-3"
      id="F_f67d6aa7-df46-49f2-9472-a46fe816300d"
      unitRef="U_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_ef14117d-6b86-46ed-956e-d73420b1a933"
      decimals="-3"
      id="F_f6404738-2edb-4108-9f46-ff56cdf887d4"
      unitRef="U_USD">-375000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_ef14117d-6b86-46ed-956e-d73420b1a933"
      decimals="-3"
      id="F_23d57470-d488-4924-be01-10456e46c656"
      unitRef="U_USD">125000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_e6f2fcaa-08a1-47c3-bb1b-7abead35a25d"
      unitRef="U_USD">60781000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_a55333e6-6404-465d-ad97-fd741a0eb0b5"
      unitRef="U_USD">-20190000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_108e1664-3e8c-4774-9ecd-4b69a9e84838"
      unitRef="U_USD">40591000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_d38defbd-6d26-448d-a459-d2d7ff5e7a40"
      decimals="-3"
      id="F_dc3ee6fd-20de-4b92-8e0c-debcde883668"
      unitRef="U_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_d38defbd-6d26-448d-a459-d2d7ff5e7a40"
      decimals="-3"
      id="F_c0f54ba7-e75b-4414-9a93-4b6bd5af45bd"
      unitRef="U_USD">-11239000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_d38defbd-6d26-448d-a459-d2d7ff5e7a40"
      decimals="-3"
      id="F_8ea37416-eb84-4624-98a6-37ade40dba3b"
      unitRef="U_USD">21391000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_3313f304-eb89-4d42-83ee-725fd81202b7"
      decimals="-3"
      id="F_c7d56678-07dc-48de-a1ea-e64288fd2673"
      unitRef="U_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_3313f304-eb89-4d42-83ee-725fd81202b7"
      decimals="-3"
      id="F_4131c4fb-be17-4b3c-88f8-bb4bcc18b436"
      unitRef="U_USD">-4754000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_3313f304-eb89-4d42-83ee-725fd81202b7"
      decimals="-3"
      id="F_b5174e2e-1619-472a-99bb-aaf48c0de52c"
      unitRef="U_USD">17186000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_509f938b-6ead-4be2-8bdc-b00905b87017"
      decimals="-3"
      id="F_147ad2af-86b0-43f4-8c18-860256310fad"
      unitRef="U_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_509f938b-6ead-4be2-8bdc-b00905b87017"
      decimals="-3"
      id="F_d12c1cb0-4bb5-4970-a16d-49a0b873646d"
      unitRef="U_USD">-275000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_509f938b-6ead-4be2-8bdc-b00905b87017"
      decimals="-3"
      id="F_6a52897a-2a08-44d4-aabd-e6f6ab14a159"
      unitRef="U_USD">225000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_9b5d6c54-e577-4b83-92a3-981e4520a3df"
      unitRef="U_USD">55070000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_dbef0e43-ba45-481b-bf96-107650a6b718"
      unitRef="U_USD">-16268000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_08c6967c-c743-4027-9567-59413afbde1b"
      unitRef="U_USD">38802000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_1bf41c40-384d-4879-a540-39666147391f"
      decimals="-5"
      id="F_8f2b20b5-f84b-43ef-afa9-2968e52cb4cf"
      unitRef="U_USD">5700000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_1bf41c40-384d-4879-a540-39666147391f"
      id="F_061eeed1-f368-475a-b1c2-9179a645ec4d">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7"
      id="F_14b392b9-4493-4d1c-8101-5b6725527ddb">P10Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-5"
      id="F_eeeb7ad1-f77f-48cc-be73-bfa67649434b"
      unitRef="U_USD">3900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-5"
      id="F_d561d068-a972-4ccc-bde0-cce79c7b7314"
      unitRef="U_USD">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-5"
      id="F_5a7ae762-8abb-4b1b-b4d1-b5431501d218"
      unitRef="U_USD">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_e1a7d0f1-3664-4a42-9233-282dd426f358"
      id="F_6d9d1432-62cc-4c78-ba38-5d9b98b8746d">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_51878a55-90f9-402f-b4db-e8e5f31208c1"
      id="F_d85b3cf2-16e6-47f7-a094-3c96dbd3e362">P5Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_8a79a1c9-cf44-4f11-81b1-7e879010028b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated future amortization expense related to intangible assets at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:85.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.621%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_13b2e8bc-89e1-4a55-9cff-2a2519c48bbe"
      unitRef="U_USD">4106000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_047aada0-9c1d-42a8-8660-d2f89815da22"
      unitRef="U_USD">4031000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_8b418617-6488-4fc0-bafe-216aa9d726e7"
      unitRef="U_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_e15aee65-ba69-422b-af52-3bb831d91e9a"
      unitRef="U_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_cf76778e-daf4-4ec1-bdde-5aa7428d3062"
      unitRef="U_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_5c24b37f-fd74-4529-abb6-aaac1cc3d108"
      unitRef="U_USD">20436000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <sclx:EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_bab974ce-0d2d-4a52-baf1-ed1265db92b4"
      unitRef="U_USD">40591000</sclx:EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_36d24d6f-ba60-45a5-9a36-b0a892a7e914">&lt;p id="section175" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7. Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2018 Purchase Agreements and Indenture&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On September 7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#x201c;2018 Purchase Agreements&#x201d;) with certain investors (collectively, the &#x201c;Scilex Pharma Note Purchasers&#x201d;). Pursuant to the 2018 Purchase Agreements, on September 7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due 2026 in an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;224.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (the &#x201c;Scilex Pharma Notes&#x201d;) for an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;140.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (the &#x201c;Offering&#x201d;). The Scilex Pharma Notes were governed by an indenture (as amended, the &#x201c;Indenture&#x201d;) with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as trustee (the &#x201c;Trustee&#x201d;) and collateral agent (the &#x201c;Collateral Agent&#x201d;), and Sorrento, as guarantor.  Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#x201c;Guarantee&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The principal amount of the Scilex Pharma Notes increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million on February 15, 2022 as a result of actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December 31, 2021 not equal or exceeding $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;481.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. As a result, the Company recorded the increase of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in principal and non-operating expense at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective February 14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December 31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in a single lump-sum amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No. 4 to Indenture (the &#x201c;Amendment No. 4&#x201d;) with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment No. 4, (1) on June 3, 2022, Scilex Pharma repurchased approximately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the aggregate principal amount of the outstanding Scilex Pharma Notes at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the principal amount thereof, (2) the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September 30, 2022 for &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the aggregate principal amount of the Scilex Pharma Notes (the &#x201c;Early Paydown Provision&#x201d;), (3) the minimum cash requirement under the Indenture was reduced to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4) the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to Sorrento on October 5, 2018 was increased from up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company funded the repurchase with cash-on-hand and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million received from Sorrento on June 2, 2022. The Company concluded that the Amendment No. 4 was a troubled debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No. 4, and accordingly, no gain was recognized in the quarter ended June 30, 2022. Due to a decrease of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the fair value of the Scilex Notes Derivative caused by the Amendment No. 4, the carrying value of the Scilex Notes was increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;,  respectively. Pursuant to Amendment No. 4, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The Company funded the repurchase with cash-on-hand and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; received from Sorrento on September 28, 2022. The Company recorded a gain on debt extinguishment of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as a result of the extinguishment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Borrowings of the Scilex Notes consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.099%;"/&gt;
        &lt;td style="width:1.781%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.12%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long term portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;115,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company made principal payments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020, respectively. The amount of debt discount and debt issuance costs included in interest expense for the years ended December 31, 2022, 2021, and 2020 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The Company recorded a gain on debt extinguishment of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, a loss on debt extinguishment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; gain/loss on debt extinguishment in connection with its repayments of principal made during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Related Party Notes Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 12).  On March 18, 2019, the Company entered into a note payable with Sorrento (see Note 12). On February 14, 2022, Sorrento paid to Scilex Pharma &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in a single lump-sum amount as a subordinated loan (see Note 12). On May 12, 2022, the Company issued Sorrento a promissory note of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in exchange for the SP-104 Assets (see Note 3). On November 10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 12).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2020 Revolving Credit Facility&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On December 14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#x201c;Credit Agreement&#x201d;) with CNH Finance Fund I, L.P. (&#x201c;CNH&#x201d;) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. All indebtedness incurred and outstanding will be due and payable in full on January 1, 2024; unless the Credit Agreement is earlier terminated. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the outstanding balance was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. On February 16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective March 18, 2022. Upon termination, all principal balances and interest accrued were settled.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <sclx:AggregatePrincipalAmount
      contextRef="C_e39da0e0-163c-455f-965a-58ab13bf9d84"
      decimals="-5"
      id="F_4ab79eaf-27bc-42d7-995b-da7d17893401"
      unitRef="U_USD">224000000.0</sclx:AggregatePrincipalAmount>
    <sclx:DebtInstrumentPurcahsePrice
      contextRef="C_e39da0e0-163c-455f-965a-58ab13bf9d84"
      decimals="-5"
      id="F_7c8fe73b-2519-48f3-a3e7-17e67ee5f517"
      unitRef="U_USD">140000000.0</sclx:DebtInstrumentPurcahsePrice>
    <sclx:IncreaseOfPrincipalBalance
      contextRef="C_a8bd7dfd-bf6a-41eb-a0d6-21c0c0e518ef"
      decimals="-5"
      id="F_58362889-8117-4bd3-89c2-3a39c000767b"
      unitRef="U_USD">28000000.0</sclx:IncreaseOfPrincipalBalance>
    <sclx:ActualCumulativeNetSales
      contextRef="C_c64fc25e-92ac-443f-a2c8-1c627ddec5c4"
      decimals="-5"
      id="F_6a1408db-8f2b-438f-97af-9abe5db788e4"
      unitRef="U_USD">481000000.0</sclx:ActualCumulativeNetSales>
    <sclx:IncreaseOfPrincipalBalance
      contextRef="C_c64fc25e-92ac-443f-a2c8-1c627ddec5c4"
      decimals="-5"
      id="F_07b6d6a2-706e-4f7a-85ca-9a43fa40e533"
      unitRef="U_USD">28000000.0</sclx:IncreaseOfPrincipalBalance>
    <us-gaap:SubordinatedDebt
      contextRef="C_cce805c3-34ca-4d41-82ac-e95225784312"
      decimals="-5"
      id="F_78ded11a-7bd2-4345-bba0-687fcb74f574"
      unitRef="U_USD">35000000.0</us-gaap:SubordinatedDebt>
    <sclx:CashRequirement
      contextRef="C_fbd32b12-fb83-432d-9c2d-e70a0b209ce4"
      decimals="-5"
      id="F_38723842-bbfa-4350-ab1d-cf6bb7adc09a"
      unitRef="U_USD">10000000.0</sclx:CashRequirement>
    <sclx:NotePrincipalReductionAmount
      contextRef="C_d26ddb1f-b0fe-4faf-b8a1-857c9dd18019"
      decimals="-5"
      id="F_156b8511-5b1d-486d-b982-932afdc3e12e"
      unitRef="U_USD">20000000.0</sclx:NotePrincipalReductionAmount>
    <sclx:NotePrincipalReductionAmount
      contextRef="C_42d227b9-ddaf-4601-acc3-2ee568156933"
      decimals="-5"
      id="F_c458236f-b12e-4a5d-8a16-147ef5b3a023"
      unitRef="U_USD">41400000</sclx:NotePrincipalReductionAmount>
    <sclx:RepurchasePrincipalInPercentage
      contextRef="C_60091fdd-6400-442e-a7a0-8a096195f3d1"
      decimals="2"
      id="F_d1409461-8ea1-49ef-b877-8f55b73ecad6"
      unitRef="U_pure">1</sclx:RepurchasePrincipalInPercentage>
    <sclx:NotePrincipalReductionAmount
      contextRef="C_6adfa385-28e2-4bb5-b8a7-8b66dc48c7de"
      decimals="-5"
      id="F_2b564652-b542-4968-977b-d12001ebe41c"
      unitRef="U_USD">41400000</sclx:NotePrincipalReductionAmount>
    <sclx:ForgivenAmount
      contextRef="C_6e32c9b3-9d19-4265-8164-574e03766785"
      decimals="-5"
      id="F_a6f2b5b7-8efa-4dd4-bc31-2239fbc0094b"
      unitRef="U_USD">28000000.0</sclx:ForgivenAmount>
    <sclx:MinimumCashRequirement
      contextRef="C_6e32c9b3-9d19-4265-8164-574e03766785"
      decimals="-5"
      id="F_a854f1dc-d5c3-46d2-ba5b-97e72aeb90f2"
      unitRef="U_USD">5000000.0</sclx:MinimumCashRequirement>
    <sclx:AggregatePrincipalAmount
      contextRef="C_8b8c6875-5daf-4b8b-bbe3-c55418e62301"
      decimals="-5"
      id="F_a3b7924b-8657-473d-ae24-3079780a886e"
      unitRef="U_USD">25000000.0</sclx:AggregatePrincipalAmount>
    <sclx:AggregatePrincipalAmount
      contextRef="C_478baeaf-44cf-43d3-a89f-f421fb630ec5"
      decimals="-5"
      id="F_964fb9ef-2724-4630-96a5-09807bf7ef54"
      unitRef="U_USD">50000000.0</sclx:AggregatePrincipalAmount>
    <sclx:CashReceivedFromParentCompany
      contextRef="C_9c4a15ab-7f26-41bf-ba84-63b74afb22cb"
      decimals="-5"
      id="F_0a01f4e1-68a4-4abe-ad49-ed9e82c21f3b"
      unitRef="U_USD">15000000.0</sclx:CashReceivedFromParentCompany>
    <sclx:FairValueDecrease
      contextRef="C_5c97eb44-901a-46bb-99e9-b42a24cc2386"
      decimals="-5"
      id="F_eddf42ad-e9ec-458e-98ad-77dc5a22cbaa"
      unitRef="U_USD">30400000</sclx:FairValueDecrease>
    <sclx:CarryingValueIncreased
      contextRef="C_5c97eb44-901a-46bb-99e9-b42a24cc2386"
      decimals="-5"
      id="F_1db7d1d1-4f34-4ca6-bf5a-3adae832ace2"
      unitRef="U_USD">30400000</sclx:CarryingValueIncreased>
    <us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio
      contextRef="C_7ca01e5c-64ba-4811-8dd0-2596f60a100f"
      decimals="-5"
      id="F_9dbed207-01fd-4e83-95df-2314b35873ea"
      unitRef="U_USD">1700000</us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio>
    <us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio
      contextRef="C_6e32c9b3-9d19-4265-8164-574e03766785"
      decimals="-5"
      id="F_788276cb-9a4d-40b4-9078-c990da87567a"
      unitRef="U_USD">39700000</us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="C_ae30ee0d-8ccb-47a5-834c-471e858d4c23"
      decimals="-5"
      id="F_83874e42-ad15-4c8e-98ca-98b5bbd8f0b8"
      unitRef="U_USD">28000000.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <sclx:CashReceivedFromParentCompany
      contextRef="C_4a8702ad-037a-48f2-8a73-f2f31cbe072b"
      decimals="-5"
      id="F_d8a61ac7-f425-4e56-8dda-106fe0ebe356"
      unitRef="U_USD">34000000.0</sclx:CashReceivedFromParentCompany>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_99d36902-bfd3-4b3d-847f-f4e34de66d2f"
      decimals="-5"
      id="F_43501855-c64d-4e80-8228-0615ffe71ceb"
      unitRef="U_USD">28600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_77560baa-a595-4733-a8e2-433a9aa026e5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Borrowings of the Scilex Notes consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.099%;"/&gt;
        &lt;td style="width:1.781%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.12%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long term portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;115,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company made principal payments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020, respectively. The amount of debt discount and debt issuance costs included in interest expense for the years ended December 31, 2022, 2021, and 2020 was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The Company recorded a gain on debt extinguishment of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, a loss on debt extinguishment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; gain/loss on debt extinguishment in connection with its repayments of principal made during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_3bf6cbdf-e65b-4443-ab22-ec7c9dffd723"
      unitRef="U_USD">133997000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_306bb4f4-68fe-4d89-91a1-0738e544ebdd"
      unitRef="U_USD">30597000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_105c7d60-5c21-4c6d-88d9-168919682625"
      unitRef="U_USD">2228000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:CommercialPaperAtCarryingValue
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_af4aed04-b87b-46fa-8930-6945cc882d66"
      unitRef="U_USD">101172000</us-gaap:CommercialPaperAtCarryingValue>
    <us-gaap:DebtCurrent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_6190b642-735f-416f-ab03-7bd2980660bc"
      unitRef="U_USD">29135000</us-gaap:DebtCurrent>
    <us-gaap:OtherLongTermDebt
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_eec2de3e-0416-4d5f-82a1-a6d16af4bef8"
      unitRef="U_USD">72037000</us-gaap:OtherLongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_64562c2a-ea56-4b1e-ac5e-ee7f1ee71390"
      unitRef="U_USD">115400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-5"
      id="F_79e3a818-a695-4c7c-a3f6-24cf9ab3b973"
      unitRef="U_USD">106000000.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-5"
      id="F_7ed76b38-56d2-423d-a656-17726635f9cf"
      unitRef="U_USD">45900000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-5"
      id="F_3c871266-36f6-49ad-96e5-6de63e7de780"
      unitRef="U_USD">69800000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-5"
      id="F_77be56c3-8e1d-48a7-b847-db8fb7f3e8a7"
      unitRef="U_USD">3100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-5"
      id="F_28ed062e-4bb5-4648-86cc-9838447854c3"
      unitRef="U_USD">7900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="-5"
      id="F_d6b7c109-18f9-4e8b-a020-0a97a9471d63"
      unitRef="U_USD">10700000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-5"
      id="F_db9279db-254e-4427-89bf-7829d19882bc"
      unitRef="U_USD">28600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-5"
      id="F_05101b7c-7703-478f-a33b-2e608e1b59f4"
      unitRef="U_USD">-12500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_3468bb23-124c-4acd-bbf4-9594df2e7f10"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <sclx:PromissoryNote
      contextRef="C_f1bc45ab-d342-4c18-b196-5098efc938e5"
      decimals="-5"
      id="F_05dfd139-53f8-44ba-a09f-bd56ba01569a"
      unitRef="U_USD">35000000.0</sclx:PromissoryNote>
    <sclx:PromissoryNote
      contextRef="C_46761a2f-b18a-4aaa-8269-68342d732dc9"
      decimals="-2"
      id="F_825d7aa3-9600-4ae5-bd5c-742de7222e4b"
      unitRef="U_USD">5000.0</sclx:PromissoryNote>
    <us-gaap:FinancingReceivableRevolvingConvertedToTermLoan
      contextRef="C_c80b9c46-2554-4fc5-8b0f-919a277a3868"
      decimals="-2"
      id="F_8f7b5ddc-4f9f-4da3-bba6-52837fc10e3f"
      unitRef="U_USD">10000.0</us-gaap:FinancingReceivableRevolvingConvertedToTermLoan>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_01d3fa20-46b6-4e6b-9289-84ca49a349a9"
      decimals="4"
      id="F_addc9c6f-a839-4c2b-8a93-56e0cf129c3f"
      unitRef="U_pure">0.0175</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio
      contextRef="C_422ae92b-12d6-4a4a-b618-0c2fa63c8e57"
      decimals="-5"
      id="F_50d02eac-b227-4e1b-b18c-9a3214ae28b7"
      unitRef="U_USD">8800000</us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_09e4e99a-cfd0-4670-908b-4f6a33b2a9f6">&lt;p id="section176" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8. Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated statement of stockholders&#x2019; equity has been retroactively adjusted for all periods to reflect the Business Combination and reverse recapitalization described in Note 1. The balances as of December 31, 2022 and 2021 from the consolidated financial statements of the Company as of that date, share activity (Preferred Stock, Common Stock, and additional paid-in-capital) and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon the closing of the Business Combination, pursuant to the terms of the Amended and Restated Certificate of Incorporation, the Company authorized &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;740,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Common Stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and December 31, 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141,348,856&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares issued and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,858,484&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of Common Stock outstanding, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the closing of the Business Combination, all previously issued and outstanding shares of Legacy Scilex Common Stock and Legacy Scilex stock options were converted into shares of Common Stock pursuant to the Common Stock Exchange Ratio. The Company has retroactively adjusted shares issued and outstanding prior to November 10, 2022 to give effect to the Common Stock Exchange Ratio to determine the number of shares of Common Stock into which they were converted.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Voting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The holders of the Common Stock are entitled to one vote for each share of the Common Stock held at all meetings of stockholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stockholders are entitled to receive dividends whenever funds are legally available and when declared by the Company's board of directors. No dividends have been declared as of December 31, 2022.The Stockholder Agreement, dated as of September 12, 2022, between Vickers and Sorrento (the &#x201c;Stockholder Agreement&#x201d;), provides that the Company will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, the payment of dividends on shares of the Common Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidation Rights&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subject to the rights of the holders of Preferred Stock, in the event of our liquidation, dissolution or winding-up, holders of Common Stock are entitled to share equally in the assets available for distribution after payment of all creditors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon the closing of the Business Combination, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;290.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento were cancelled in exchange for the issuance of preferred shares of Scilex (&#x201c;Series A Preferred Shares&#x201d; or &#x201c;Series A Preferred Stock&#x201d;). In connection with the closing of the Business Combination, all issued Scilex Series A Preferred Shares were cancelled and converted into the right to receive 1) one share of&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;domesticated &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;parent preferred shares (&#x201c;New Scilex Preferred Stock&#x201d; or &#x201c;Preferred Stock&#x201d;) par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, and 2) one-tenth of one domesticated parent common stock (&#x201c;New Scilex Common Stock&#x201d; or &#x201c;Common Stock&#x201d; and such transaction including cancellation of all the existing related party indebtedness in exchange for Preferred Stock and Common Stock, the &#x201c;Conversion&#x201d; or &#x201c;Contribution&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the Conversion, Legacy Scilex filed a Second Amended Certificate of Incorporation (defined below) to increase the authorized number of shares to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares and a Certificate of Designation (&#x201c;Certificate of Designation&#x201d;) to designate the rights, preferences, and privileges of Scilex Series A Preferred Shares. In connection with the closing of the Business Combination, the Company filed the Certificate of Designation and issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,057,097&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Series A Preferred Stock to Sorrento. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,057,097&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Preferred Stock outstanding. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Preferred Stock outstanding at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s Board of Directors have authority to issue such shares of Preferred Stock in one or more series, to establish, from time to time the number of shares to be included in each such series, and to fix the dividend, voting, and other rights, preferences, and privileges of the shares. Other than the Series A Preferred Stock issued to Sorrento in connection with the closing of the Business Combination, there are no other Preferred Stock outstanding and the Company has no current plans to issue any other shares of preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Voting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The holders of shares of Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Preferred Stock will be entitled to one vote for each share of Common Stock that such share of Preferred Stock would otherwise be convertible into pursuant to a deemed conversion on the record date for the determination of the stockholders entitled to vote.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the Stockholder Agreement, holders of Series A Preferred Stock have the right to designate each director to be nominated, elected or appointed to the Board of Directors of the Company. The Series A Preferred Stock also has certain protective provisions, such as requiring a written consent of the holders of Series A Preferred Stock to change or amend their rights, powers, privileges, limitations and restrictions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Holders of the Preferred Stock are not entitled to dividends unless the Company pays dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of the Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidation Rights&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subject to the rights of the holders of parity shares (if any), in the event of our liquidation, dissolution or winding-up, holders of Preferred Stock rank senior to the Common Stock and are entitled to share equally in the assets available for distribution after payment of all creditors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assumed Public Warrants and Private Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Following the consummation of the Business Combination, holders of the Public Warrants and Private Warrants are entitled to acquire Common Stock of the Company. The warrants are exercisable on the later of (a) the completion of a Business Combination and (b) 12 months from the closing of Vickers's Initial Public Offering. The warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Each warrant entitles the holder to purchase one share of Common Stock for &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If the reported last sale price of the Common Stock equals or exceeds $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per warrant upon not less than 30 days&#x2019; prior written notice.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the warrants. As of December 31, 2022, there are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,899,988&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Public Warrants outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the closing of the Business Combination, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,104,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Private Warrants were transferred to Sorrento pursuant to the Warrant Transfer Agreement between Vickers, the Sponsors, Sorrento and Maxim Group, LLC where Sorrento acquired all rights, title and interests to such Private Warrants (&#x201c;Warrant Transfer Agreement&#x201d;). As of December 31, 2022, there are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,104,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Private Warrants outstanding, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,104,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Private Warrants are held by Sorrento and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Private Warrants are held by Sponsors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Legacy Scilex Common Stock and Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the Business Combination, Legacy Scilex had the authority to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share per the Certificate of Incorporation dated February 27, 2019. The Certificate of Incorporation was amended and restated on March 4, 2019 (&#x201c;First Amended Certificate of Incorporation&#x201d;), in which Legacy Scilex had the authority to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;350,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The First Amended and Restated Certificate of Incorporation was amended and restated on November 10, 2022 (&#x201c;Second Amended Certificate of Incorporation&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of the Second Amended Certificate of Incorporation, Legacy Scilex had the authority to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;785,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, consisting of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;740,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock. Immediately prior to the Conversion, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197,566,338&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of Legacy Scilex Common Stock outstanding and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,057,097&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series A Preferred Stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, of Legacy Scilex outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Yorkville Standby Equity Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 17, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#x201c;Yorkville Purchase Agreement&#x201d;) with Yorkville, whereby the Company has the right, but not the obligation, to sell to Yorkville up to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of shares of its Common Stock at its request any time during the 36 months following the execution of the Yorkville Purchase Agreement, subject to certain conditions. Pursuant to the Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a sale of Common Stock (each such sale, a &#x201c;Yorkville Advance&#x201d;) will be purchased at a price equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of the lowest daily volume weighted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;average &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;price of the Common Stock for any trading day (&#x201c;VWAP&#x201d;) during the two consecutive trading days commencing on the date of delivery of a written purchase notice to Yorkville (each, a &#x201c;Yorkville Advance Notice&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for Yorkville's commitment to purchase shares of Common Stock at the Company&#x2019;s direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, upon execution of the Yorkville Purchase Agreement, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Common Stock to Yorkville and paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in structuring fees. The registration statement on Form S-1 (File No. 333-268607) related to the Yorkville Purchase Agreement was filed with the SEC on November 30, 2022 and was declared effective by the SEC on December 9, 2022. As of December 31, 2022, there were no shares sold to Yorkville under the Yorkville Purchase Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Refer to Note 14 &#x201c;Subsequent Event&#x201d; below for a subsequent event related to the Yorkville Purchase Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213"
      decimals="INF"
      id="F_72461589-286a-42df-b50c-b057327bb396"
      unitRef="U_shares">740000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213"
      decimals="4"
      id="F_3eaafb72-dba5-43a0-98bf-cf1f00741d84"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="INF"
      id="F_4e8f96e8-06cd-4beb-9dd8-83bab75e5d18"
      unitRef="U_shares">141348856</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="INF"
      id="F_e05ca47f-5778-47fb-9788-3d289058274b"
      unitRef="U_shares">132858484</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_cea31b52-db39-4e74-9ef9-00fbadd09e8a"
      decimals="-5"
      id="F_d0eaebd9-2ca0-474e-b7ba-7ff7e6f44b30"
      unitRef="U_USD">290600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_5033dffd-d662-4f5b-9fe3-88e68279b972"
      decimals="INF"
      id="F_a3047dbb-2ab1-4293-9e7b-3132022322ef"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_5033dffd-d662-4f5b-9fe3-88e68279b972"
      decimals="INF"
      id="F_dc89a4f0-e412-4369-a217-42cc46675b54"
      unitRef="U_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_52b44a02-592f-4ce7-8c2c-3d786b8c7f58"
      decimals="INF"
      id="F_6a515655-c80a-4541-bfcd-f7c830d6eb59"
      unitRef="U_shares">29057097</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_5033dffd-d662-4f5b-9fe3-88e68279b972"
      decimals="INF"
      id="F_0521dd38-2dc5-4f75-8a05-dee6abf675f6"
      unitRef="U_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9b7ed203-c059-4dea-8727-86670689b7cc"
      decimals="INF"
      id="F_3260da15-3aab-4797-b0aa-ebaa42150192"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SharePrice
      contextRef="C_464851d6-2036-40d8-94d5-168fe9bff9ac"
      decimals="2"
      id="F_b07ccefb-f175-44c7-8f66-4a571607392e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.50</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="2"
      id="F_35d8b462-83d0-4bf3-9b98-16d51f3313dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.00</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="2"
      id="F_5628f8a5-ed1d-4f84-b9a9-2419f59cf790"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="INF"
      id="F_2aa4935e-5421-4a3c-9981-b69549f89583"
      unitRef="U_shares">6899988</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_b50d45e3-e036-46e1-88f2-6346a47e412b"
      decimals="INF"
      id="F_7371d4a6-3d4b-47c5-8c3c-cc68018c7fc5"
      unitRef="U_shares">3104000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_3a917c50-4370-49ab-9afd-58aaa9a10804"
      decimals="INF"
      id="F_49c98ead-d2ed-40fe-9288-ed6ce0ebb5a6"
      unitRef="U_shares">4104000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_d8ba7d57-830b-450b-b045-491a8e4913bd"
      decimals="INF"
      id="F_6f396d0d-db94-424d-9621-4ca373352561"
      unitRef="U_shares">3104000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_05185b29-2199-41ac-97f8-a22476c305be"
      decimals="INF"
      id="F_04d22306-ce38-44ab-92a7-1b4a409185e3"
      unitRef="U_shares">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_5202eaa2-94ce-4852-a791-98e95950e6e6"
      decimals="INF"
      id="F_1cdb1c18-737e-4c66-99f5-e3c8025cf56d"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_5202eaa2-94ce-4852-a791-98e95950e6e6"
      decimals="INF"
      id="F_6342b948-684d-48d6-9986-138925b06041"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_5202eaa2-94ce-4852-a791-98e95950e6e6"
      decimals="INF"
      id="F_3f18a165-cf48-4922-81de-11c6c191e858"
      unitRef="U_shares">20000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_5202eaa2-94ce-4852-a791-98e95950e6e6"
      decimals="INF"
      id="F_ff1610c8-e605-4099-ab88-2373dd090841"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7cbfb5ab-baf8-419e-afef-9b3373e009f4"
      decimals="INF"
      id="F_0f288548-d159-4595-9340-eddae6b90af1"
      unitRef="U_shares">350000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_7cbfb5ab-baf8-419e-afef-9b3373e009f4"
      decimals="INF"
      id="F_10db7de5-c55a-468c-93de-fafc68b256fa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_7cbfb5ab-baf8-419e-afef-9b3373e009f4"
      decimals="INF"
      id="F_50dca872-d817-4762-b1a4-73d3e4dbaf35"
      unitRef="U_shares">20000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_7cbfb5ab-baf8-419e-afef-9b3373e009f4"
      decimals="INF"
      id="F_8f775979-c34e-4ee0-9f88-40bc378b7779"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d23acd9a-b5cb-47a5-b3c3-5c16f3f1a346"
      decimals="INF"
      id="F_8d4cc429-16e2-46c6-ac39-e38987f5be63"
      unitRef="U_shares">785000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c0de8b1c-7d16-427b-aa57-833ab07979da"
      decimals="INF"
      id="F_1af596d0-02f0-4318-8079-8d284fb42090"
      unitRef="U_shares">740000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c0de8b1c-7d16-427b-aa57-833ab07979da"
      decimals="INF"
      id="F_a074ad6d-5dbb-4173-b851-e17065ff1d14"
      unitRef="U_shares">45000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c0de8b1c-7d16-427b-aa57-833ab07979da"
      decimals="INF"
      id="F_6e895af1-e6b5-4a27-a66f-a5cd35f627cb"
      unitRef="U_shares">197566338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_44ed269a-dde2-4886-8ee5-2f9c77ffdde5"
      decimals="INF"
      id="F_221324fe-8eba-4ba6-91ad-24fed78b5893"
      unitRef="U_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_44ed269a-dde2-4886-8ee5-2f9c77ffdde5"
      decimals="INF"
      id="F_ab8927ca-961d-4dee-a824-87baef65ac94"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_635fb103-c71a-477c-8c47-7047957e404b"
      decimals="-5"
      id="F_044ecaba-c20b-4d73-af3c-ea72c18d7111"
      unitRef="U_USD">500000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sclx:PurchaseOfStockPercentage
      contextRef="C_9da5d773-9803-4cb9-b88b-b575366eed3d"
      decimals="2"
      id="F_c5ecfdbe-655f-4f71-87d0-3b34cec1bcfd"
      unitRef="U_pure">0.98</sclx:PurchaseOfStockPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0acf01dd-c0f8-474b-86b7-9a4ee39ecb2c"
      decimals="INF"
      id="F_d40d138b-4e44-43c2-9709-f28184da87f0"
      unitRef="U_shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sclx:StructuringFees
      contextRef="C_fb1d9fe2-1ba9-49c8-9a85-dcf2896bdf52"
      decimals="-2"
      id="F_a6cafcf1-3407-4768-8259-e51458f13804"
      unitRef="U_USD">10000.0</sclx:StructuringFees>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_62df364c-b0de-436a-8d29-b2eebf967c4d">&lt;p id="section177" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9. Stock Incentive and Employee Benefit Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated statements of stockholders&#x2019; equity / (deficit) have been retroactively adjusted for all periods to reflect the Business Combination and reverse recapitalization described in Note 1. The balances as of December 31, 2022, 2021, 2020 from the consolidated financial statements of the Company as of that date, share activity (stock options) and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#x201c;Scilex Pharma 2017 Plan&#x201d;).  The Scilex Pharma 2017 Plan reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million shares of Scilex Pharma common stock.  &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Scilex Pharma 2017 Plan was amended and restated on July 5, 2018.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#x2019;s common stock outstanding and unexercised immediately prior to reorganization was cancelled and substituted for that number of options to acquire Legacy Scilex Common Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Scilex Holding Company 2019 Stock Option Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#x201c;2019 Stock Option Plan&#x201d; or &#x201c;Prior Plan&#x201d;) on May 28, 2019. The 2019 Stock Option Plan was approved by the Company&#x2019;s stockholders on June 7, 2019. As of December 31, 2019, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million shares of Scilex Common Stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon the consummation of the Business Combination, the 2019 Stock Option Plan was terminated and no further awards were granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted under the terms of the Equity Incentive Plan (defined below).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Scilex Holding Company 2022 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d;) on October 17, 2022. The 2022 Equity Incentive Plan was approved by the stockholders and became effective on November 9, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The total number of common shares for which incentive stock options (&#x201c;ISOs&#x201d;) may be granted under the Equity Incentive Plan is not to exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,622,712&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares plus a  number of shares of Common Stock equal to the number of shares subject to outstanding stock awards granted under the Prior Plan (&#x201c;Returning Shares&#x201d;), &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;if any, as such shares become available from time to time, which the amount will be increased commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of shares of Common Stock outstanding on December 31 of the preceding year, (ii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,311,356&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Common Stock, and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there were no options to purchase shares of Common Stock outstanding under the Equity Incentive Plan and options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,939,436&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Common Stock were outstanding under previous plans.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation recorded within operating expenses was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the years ended December 31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The total unrecognized compensation costs related to unvested employee and non-employee stock option grants as of December 31, 2022 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the weighted average period over which these grants are expected to vest is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Scilex Holding Company 2022 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 17, 2022, the Board adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP was approved by the stockholders and became effective on November 9, 2022. The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward the success of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase the Common Stock in a manner that may qualify for favorable tax treatment under Section 423 of the Internal Revenue Code of 1986 (&#x201c;Code&#x201d;) (the &#x201c;423 Component&#x201d;) and accordingly, it will be construed in a manner that is consistent with the requirements of Section 423 of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the &#x201c;Non-423 Component&#x201d;) in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by the Board, it will operate and be administered in the same manner as the 423 Component.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Board administers the ESPP and will have the authority to determine how and when purchase rights are granted and the provisions of each offering. Initially, the total number of shares of the Common Stock that may be issued under the ESPP will not exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,462,271&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Common Stock. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;number of shares of the Common Stock that will be reserved for issuance will automatically increase on January 1 of each year for a period of up to ten years, commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of shares of the Common Stock outstanding on December 31 of the immediately preceding calendar year; (ii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,827,839&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Common Stock; and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year, provided however, that the Board may act prior to January 1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i) to (iii) above.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares outstanding under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Option Valuation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant.  &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the year ended 2020 is set forth below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.208%;"/&gt;
        &lt;td style="width:0.344%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.32%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.127%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted &#x2013;average grant date fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected stock-price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Term of options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value per share of common stock on date of grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.  The Company bases the expected dividend yield assumption on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends on the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected stock-price volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available.  The peer group was developed based on companies in the transdermal patch industry. In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches.  Management further considered the development stage of the peer group companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company bases the risk-free interest rate assumption on the U.S. Treasury&#x2019;s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected term of options&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The expected term of options represents the period of time when options are expected to be outstanding.  Because the Company does not have historic exercise behavior, the Company determines the expected term assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following represents a summary of the options outstanding at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 and changes during the years then ended (in thousands, other than weighted-average exercise price):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.598%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.255%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.419%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.51%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.228000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee Benefit Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for each of the years ended December 31, 2022, 2021, and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e2cce05e-1a26-43e6-8f1f-e439a7aa2acd"
      decimals="INF"
      id="F_45ad3504-c5c5-44e0-86b4-1723e8b7cf6e"
      unitRef="U_shares">24000000.0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_4a5c0b06-915d-455f-9fc7-0f9a23843003"
      id="F_960c0f34-f380-421a-9ff1-4138fe07dc72">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_58cd7445-cfd3-4b6c-9853-77975484a3f9"
      decimals="INF"
      id="F_141b839f-3e2c-477e-98a6-369630fdb6c3"
      unitRef="U_shares">30000000.0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_ffce1a83-cdb6-4f8b-8ce0-60c88047dbe7"
      id="F_b9e5013e-21de-4ee9-9c4f-8b1b8a7947fc">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_43ab2205-1c3d-4a4c-81af-b8effc0a8d3f"
      decimals="INF"
      id="F_02847acf-91e4-465d-a21e-8b82b6c4a469"
      unitRef="U_shares">14622712</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription
      contextRef="C_55510dfd-6682-410d-b6b4-4d16606f2bde"
      id="F_79a0348c-3323-49ee-a828-5e9bc1627dc3">if any, as such shares become available from time to time, which the amount will be increased commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of (i) 4% of the total number of shares of Common Stock outstanding on December 31 of the preceding year, (ii) 7,311,356 shares of Common Stock, and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_55510dfd-6682-410d-b6b4-4d16606f2bde"
      decimals="2"
      id="F_7aa7de2d-291d-4857-a11c-38194645fb1c"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <sclx:CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear
      contextRef="C_777530a8-90c5-459f-8a78-9891fb3b3069"
      decimals="INF"
      id="F_a6c9fda5-d380-425c-b820-aa91d40e2a45"
      unitRef="U_shares">7311356</sclx:CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_777530a8-90c5-459f-8a78-9891fb3b3069"
      decimals="INF"
      id="F_fb98739b-eb33-450c-b6fc-297ffca9d2e5"
      unitRef="U_shares">16939436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensation
      contextRef="C_55510dfd-6682-410d-b6b4-4d16606f2bde"
      decimals="-5"
      id="F_8ad6b72f-f2d1-447d-8a23-ed404e767c72"
      unitRef="U_USD">5300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_67497c23-14fc-4051-a630-4c59813052eb"
      decimals="-5"
      id="F_93674ebe-f66f-4f32-92e1-38035a2e3548"
      unitRef="U_USD">5800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_fd0b590c-8ba4-42a9-a808-760e195081f7"
      decimals="-5"
      id="F_4e482881-2f22-481d-af56-32a214426b9b"
      unitRef="U_USD">5400000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_777530a8-90c5-459f-8a78-9891fb3b3069"
      decimals="-5"
      id="F_e6246554-cd6f-4d9f-b190-d8d891cb46a0"
      unitRef="U_USD">2700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <sclx:WeightedAveragePeriodOverGrant
      contextRef="C_9b5ecdb8-3bc8-4088-bf74-05a8fbd7c323"
      id="F_d8e87fb5-b1a9-446c-b5c7-d5ddac672e5a">P1Y4M24D</sclx:WeightedAveragePeriodOverGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7bd18d66-7285-40d4-8961-714fd8c2eb8d"
      decimals="INF"
      id="F_318c6cd2-0d72-496f-8888-c389723373ae"
      unitRef="U_shares">1462271</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription
      contextRef="C_4e69aafa-547e-45e9-bdf7-d87792ef197d"
      id="F_846f9e71-ebfc-40e5-a47c-b4bea273c47f">The number of shares of the Common Stock that will be reserved for issuance will automatically increase on January 1 of each year for a period of up to ten years, commencing on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to the lesser of (i) 1% of the total number of shares of the Common Stock outstanding on December 31 of the immediately preceding calendar year; (ii) 1,827,839 shares of the Common Stock; and (iii) such number of shares of the Common Stock determined by the Board or the compensation committee of the Board prior to January 1 of a given year, provided however, that the Board may act prior to January 1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i) to (iii) above.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_4e69aafa-547e-45e9-bdf7-d87792ef197d"
      decimals="2"
      id="F_275858fc-656d-48a9-8e58-d7f1b7b100ca"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <sclx:CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear
      contextRef="C_b13cd8e3-7db7-4217-8072-5fe48b25740e"
      decimals="INF"
      id="F_b07a19f4-cfba-48f0-8a6f-dc483a7e00be"
      unitRef="U_shares">1827839</sclx:CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b13cd8e3-7db7-4217-8072-5fe48b25740e"
      decimals="INF"
      id="F_ba99dbfc-9d82-4aca-84bd-40f5a408dd2d"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_52104eb0-0c4d-47c9-bb23-a831b0b6fa81">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the year ended 2020 is set forth below:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.208%;"/&gt;
        &lt;td style="width:0.344%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:24.32%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.127%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted &#x2013;average grant date fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected stock-price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Term of options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value per share of common stock on date of grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4"
      decimals="2"
      id="F_42127bac-bf5e-41c8-ad43-08e0cf6ecbaf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.23</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4"
      decimals="4"
      id="F_9549f50c-fa33-4917-87fa-a92dc99a1a4a"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4"
      decimals="4"
      id="F_33030936-f1b8-42ee-ad6f-688e6b53dc17"
      unitRef="U_pure">0.9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4"
      decimals="4"
      id="F_52f97603-77c5-427c-a53c-405878f71425"
      unitRef="U_pure">0.0053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4"
      id="F_9e7e52e6-e67f-4b8a-95fa-284cfaa7e6b1">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_dc7d0f2d-5bbb-46cf-929e-8eb3fbe1169a"
      decimals="2"
      id="F_a8c066a1-e48b-4521-a82b-0344b8b409c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.72</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_dc7d0f2d-5bbb-46cf-929e-8eb3fbe1169a"
      decimals="2"
      id="F_1e643be7-e023-4731-9842-4afc618ea08b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_7ab7f156-a61f-46d9-bcc9-93eb7d7400c6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following represents a summary of the options outstanding at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 and changes during the years then ended (in thousands, other than weighted-average exercise price):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.598%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.255%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.419%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.51%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.228000000000002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28"
      decimals="INF"
      id="F_33a345dd-7141-474c-92ba-66b5d6a104b6"
      unitRef="U_shares">17114000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28"
      decimals="2"
      id="F_c042995a-c75c-413f-a28c-fd770f65736f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28"
      decimals="-3"
      id="F_8ec6eebd-8bba-4542-8839-2a6671ae85d0"
      unitRef="U_USD">2183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="INF"
      id="F_fb9d9629-d6ae-4901-980a-39d123e13fae"
      unitRef="U_shares">4172000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="2"
      id="F_a050fbfb-25ad-4eee-ae9d-e3e32c13af39"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="INF"
      id="F_37d8bd63-18ff-4102-9196-92736b79d51b"
      unitRef="U_shares">38000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="2"
      id="F_06a46a95-bf3f-4e0e-9ffb-ae3e325cc7bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="INF"
      id="F_af1f5f24-9419-45f4-9bd6-198bd5b24a05"
      unitRef="U_shares">502000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="2"
      id="F_d7abeaa7-b936-4451-9131-1d158e8df068"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="INF"
      id="F_8aa2e447-de17-4790-ae72-303b396f0dd0"
      unitRef="U_shares">20746000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="2"
      id="F_19acaf93-9d57-48a2-9c47-46d84f1bcefb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="-3"
      id="F_f7bc46f2-9de3-45e3-ae02-92f3d71bdded"
      unitRef="U_USD">2172000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="INF"
      id="F_4c8f542b-3217-44da-bffc-1dea9d239c25"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="0"
      id="F_8e89c275-3d2a-4fb6-ba3a-3b643e39b894"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="INF"
      id="F_91b5708e-8764-4340-8b52-9923931a1922"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="0"
      id="F_a0cbae00-6aef-4a3f-b6ef-ec7ab676512a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="INF"
      id="F_277a2079-bf58-4913-81f8-f5e04bf623d8"
      unitRef="U_shares">1778000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="2"
      id="F_74b2e001-22cf-4943-9cf4-da01a4f1e20e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="INF"
      id="F_d0cfb768-9e5f-41a8-8600-cf0a9dd83739"
      unitRef="U_shares">18968000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="2"
      id="F_1fd3bff9-ce8d-4ee0-b5ec-7f8e66f04d15"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_ee3acf38-3e47-4c15-a981-bcc5e8a899ce"
      unitRef="U_USD">915000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="INF"
      id="F_a1316335-27a0-474d-ad4d-4cad3d4a8cdb"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="0"
      id="F_4b70c52e-ca02-42a0-af9a-6a7ebc132252"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="INF"
      id="F_6840508f-0005-406b-9786-d7de5509e658"
      unitRef="U_shares">202000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="2"
      id="F_e6f52f8e-1d7e-444c-aa8f-db27d64acfa3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="INF"
      id="F_0399c1ab-0d48-4b37-ad14-06e0b0ed8bcb"
      unitRef="U_shares">1827000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="2"
      id="F_6a2d1374-2765-4154-8f9a-2f638c8eaab8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="INF"
      id="F_8e9a2923-f2c2-4db5-aad8-e007a5332d06"
      unitRef="U_shares">16939000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="2"
      id="F_e65c5312-8aa2-40ea-89a1-edb1fd1e47ba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_e1158bb6-dae8-4163-853c-8d0627953e82"
      unitRef="U_USD">38942000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="INF"
      id="F_f4a1c2b5-e3d5-425d-9800-6be7129f9961"
      unitRef="U_shares">14487000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="2"
      id="F_9c6a1bb0-e045-486a-ad21-0dafca853b53"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-5"
      id="F_16ce57a0-f980-407c-9f86-e95b0316252e"
      unitRef="U_USD">300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-5"
      id="F_8d8c37cc-655a-45dd-8128-11b67d67738e"
      unitRef="U_USD">300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-5"
      id="F_473183fb-28d3-46c3-8e7e-02bf29d17edb"
      unitRef="U_USD">300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_4fc95f5d-1f1e-4f47-a722-822e4c25854b">&lt;p id="section178" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Product Development Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#x201c;Product Development Agreement&#x201d;) with two parties (the &#x201c;Developers&#x201d;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#x201c;Itochu&#x201d;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and SP-103 (the &#x201c;Products&#x201d;), for Scilex Pharma.  The Developers initially developed, and have intellectual property rights relating to, the Products.  Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to the Developers based on net profits. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, Scilex Pharma made royalty payments in the amount of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As of December 31, 2022, Scilex Pharma had ending balances of accrued royalty payables of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Net &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;profits &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;are defined as net sales, less cost of goods and marketing expenses.  Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; October 2, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the date that is ten years from the date of the first commercial sale of ZTlido. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon 6-month written notice.  &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#x201c;Supply Agreement&#x201d;) with the two Developers to provide commercial supply of ZTlido and SP-103 to Scilex Pharma.  The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Exclusive Distribution Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#x201c;Distribution Agreement&#x201d;) to appoint an exclusive third-party logistics distribution provider (the &#x201c;Distributor&#x201d;) and as an authorized distributor of record of ZTlido in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% annual adjustment. The Distribution Agreement has an initial term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three years &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;following the first shipment of FDA-approved Product to a commercial customer and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#x2019;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#x2019;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% which was recorded as a gross-to-net sales adjustment. As the Company continues to expand the commercialization of ZTlido, it has expanded its direct distribution network to national and regional distributors and pharmacies since the beginning of April 2022. The Company currently holds all necessary wholesaler licenses and commenced selling directly to the main distributor customers as well as pharmacies in April 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sales Operations Services&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#x201c;Project Agreement&#x201d;).  In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor.  In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor continued to provide sales operations services, fleet management services and sample accountability services. The work order was in effect until &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;June 30, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with 90 days&#x2019; notice&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Scilex Pharma paid&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;an &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;implementation fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.0 thousand and will pay fixed monthly fees of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand for ongoing services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized an expense of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million within selling, general and administrative expenses for services performed for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020, respectively, including implementation fees, fixed monthly fees and pass-through costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#x2019;s financial condition or results of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the &#x201c;Sanofi-Aventis &amp;amp; Hisamitsu Litigation&#x201d;).  This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly the Company's claims, but which motions the court has largely rejected.  Discovery is proceeding.  The case is currently scheduled for trial to begin on July 24, 2023.  The Company cannot make any predictions about the outcome in this matter or the timing thereof.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Former Employee Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#x201c;Virpax&#x201d;), a company now headed by Mr. Mack, alleging, among other things, breach by Mr. Mack of his non-compete agreement with the Company, breach of fiduciary duty, and tortious interference by Virpax with that non-compete agreement (the &#x201c;Former Employee Litigation&#x201d;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr. Mack from further violating his non-compete agreement and enjoining Virpax from tortiously interfering with Mr. Mack&#x2019;s non-compete agreement. The case was tried from September 12, 2022 to September 14, 2022. Post-trial briefing and closing arguments have been concluded and the case is under submission to the Court. The Company cannot make any predictions about the outcome in this matter or the timing thereof.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;ZTlido Patent Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#x201c;Apotex&#x201d;) in the U.S. District Court for the Southern District of Florida (the &#x201c;ZTlido Patent Litigation&#x201d;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#x201c;ZTlido Patents&#x201d;).  The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in the Hatch-Waxman Act, of an ANDA.  Apotex&#x2019;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed.  The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#x2019;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May 10, 2031, and such further and other relief as the court may deem appropriate. Apotex is subject to a 30-month stay preventing it from selling a generic version of ZTlido during that time.  The stay should expire no earlier than November 11, 2024.  Trial in the ZTlido Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company leases administrative and research and development facilities under various non-cancelable lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend.  As of December 31, 2022, the Company&#x2019;s leases have remaining lease terms of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years. The term of the Company&#x2019;s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years. Many of the Company&#x2019;s leases are subject to variable lease payments.  Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the right-of-use assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.  The Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease.  As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_4a367a12-e012-4165-b149-5a78dbe3c071;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;finance leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.455%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.094%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.094%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.225%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;* Inclusive of variable lease costs, sublease income, and impairment, which were immaterial&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental quantitative information related to leases includes the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.253%;"/&gt;
        &lt;td style="width:1.964%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.925%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.954%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.904%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average remaining lease term in years &#x2014; operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average discount rate &#x2014; operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2022, the Company entered into a new non-cancelable lease agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; months and the Company does not expect to exercise the extension option at the end of the lease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Approximate future minimum lease payments under operating leases&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.856%;"/&gt;
        &lt;td style="width:1.475%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.67%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less current portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sclx:RoyaltyPaymentPercentageRelatedToFutureYears
      contextRef="C_9922975f-1d41-4752-92b7-f2ec2c047e71"
      decimals="2"
      id="F_dc3387ab-ceeb-4250-9164-a326d755e938"
      unitRef="U_pure">0.25</sclx:RoyaltyPaymentPercentageRelatedToFutureYears>
    <sclx:RoyaltyPaymentPercentageRelatedToFutureYears
      contextRef="C_40562d01-6462-499f-a04a-47153823c26b"
      decimals="2"
      id="F_6a073d50-de81-4653-a432-d707685c349e"
      unitRef="U_pure">0.35</sclx:RoyaltyPaymentPercentageRelatedToFutureYears>
    <us-gaap:RoyaltyExpense
      contextRef="C_8c1f3d78-c5e0-4b4b-93a7-3c1f21841465"
      decimals="-5"
      id="F_b4207bda-99ec-4c14-a92c-501cfd4b546a"
      unitRef="U_USD">2300000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="C_0a56b9b5-0e8c-4c4c-a42e-683ebcaf8d04"
      decimals="-5"
      id="F_289da7b4-4e5d-403d-bed1-56496ab2948b"
      unitRef="U_USD">2200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <sclx:AgreementMaturityDate
      contextRef="C_02f580e6-c788-4eef-9f36-799127c833b3"
      id="F_ddead549-42fd-4a84-a9fa-ce4c0f5a0c16">2028-10-02</sclx:AgreementMaturityDate>
    <sclx:MaturityRenewalDescription
      contextRef="C_02f580e6-c788-4eef-9f36-799127c833b3"
      id="F_106c02b8-a311-4439-b048-2e1f04ed5841">The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon 6-month written notice.  </sclx:MaturityRenewalDescription>
    <sclx:AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears
      contextRef="C_8e55c840-7ba5-4068-b9ac-a6ab3b619797"
      decimals="2"
      id="F_1f583350-9fe2-448d-9c51-5602adede9e2"
      unitRef="U_pure">0.03</sclx:AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears>
    <sclx:AgreementInitialTerm
      contextRef="C_8e55c840-7ba5-4068-b9ac-a6ab3b619797"
      id="F_711331d3-d399-4d1c-b7d7-57eb4ea44bbf">P3Y</sclx:AgreementInitialTerm>
    <sclx:MaturityRenewalDescription
      contextRef="C_8e55c840-7ba5-4068-b9ac-a6ab3b619797"
      id="F_31d5983a-80ee-445e-88c6-fca5f6f3a824">shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term</sclx:MaturityRenewalDescription>
    <sclx:DistributionFeesPercentage
      contextRef="C_560e4782-7a8f-459f-9609-b04f9e8ab33f"
      decimals="2"
      id="F_76cbb352-b104-464f-afdd-5e5b42f65515"
      unitRef="U_pure">0.01</sclx:DistributionFeesPercentage>
    <sclx:DistributionFeesPercentage
      contextRef="C_a708aae3-4854-410d-ab82-fbfc4a130c97"
      decimals="2"
      id="F_8a1b0ff9-5a42-4631-8e3e-273c45afd9e2"
      unitRef="U_pure">0.02</sclx:DistributionFeesPercentage>
    <sclx:AgreementMaturityDate
      contextRef="C_3cf5091c-7b41-4d84-af4b-27015818f063"
      id="F_d0c3af17-78d8-44bc-bd29-4fe6f436c27e">2022-06-30</sclx:AgreementMaturityDate>
    <sclx:MaturityRenewalDescription
      contextRef="C_3cf5091c-7b41-4d84-af4b-27015818f063"
      id="F_0dfb6ce3-5d7e-455b-92ec-dadea331494d">extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with 90 days&#x2019; notice</sclx:MaturityRenewalDescription>
    <us-gaap:ProfessionalFees
      contextRef="C_3cf5091c-7b41-4d84-af4b-27015818f063"
      decimals="-3"
      id="F_cf56466f-1a55-434c-adac-ae30c5d51e1a"
      unitRef="U_USD">59000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_2d79b6ca-f817-4000-9690-57cda2cd8b96"
      decimals="-2"
      id="F_33cf1281-8a51-4414-93b9-1dd7ae1cff3f"
      unitRef="U_USD">63700</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_4ffc6a81-2d13-4ca4-89ec-8c611943a526"
      decimals="-2"
      id="F_9f43428c-3ecf-43d7-9b0b-a0d5113ef67a"
      unitRef="U_USD">65800</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_3710aa11-fcfc-4dcd-aacb-4c89272492cc"
      decimals="-5"
      id="F_cdd7ae46-0326-4481-ae6a-0b09c9aa450a"
      unitRef="U_USD">900000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_85fddfc8-ede1-4821-8070-f8272993162e"
      decimals="-5"
      id="F_ac826de1-c0e8-43e5-9922-fbf57bbfc03c"
      unitRef="U_USD">1900000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_2648accc-f3dc-426e-92a2-db64ebe17309"
      decimals="-5"
      id="F_9f9d2dd8-4d2b-40f4-84ac-bb16ec566d67"
      unitRef="U_USD">10500000</us-gaap:ProfessionalFees>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_efd6a36c-f68c-4a10-8867-54bd97146b01"
      id="F_04b45e45-c258-4270-b25f-fb8fffbc65d1">P1Y7M6D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_81a151cb-066d-45a5-8264-1e0d16707f77"
      id="F_31aa322d-3609-4e86-a3e2-698c7f78befd">P1Y10M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_efd6a36c-f68c-4a10-8867-54bd97146b01"
      id="F_7143fe0a-1e1e-4061-988f-ef1d211d3148">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_81a151cb-066d-45a5-8264-1e0d16707f77"
      id="F_c5fc895d-82d7-491d-ba4b-191bc1d25971">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_d8f1c76c-e53e-4daa-ace6-6103317f69ca"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_c24e2c24-fa28-4e92-a1de-071fdf029b22">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.455%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.094%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.094%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.225%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;* Inclusive of variable lease costs, sublease income, and impairment, which were immaterial&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_8363f8e6-c596-4813-8080-7a4e38ce8500"
      unitRef="U_USD">469000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_e396fbfd-ad00-4ecb-8915-41727ec1c12c"
      unitRef="U_USD">623000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_60575421-3d34-4ea0-8e1b-127053a2b249"
      unitRef="U_USD">904000</us-gaap:OperatingLeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_8c1d6354-3efe-4dae-a739-65add9a14f92">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental quantitative information related to leases includes the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.253%;"/&gt;
        &lt;td style="width:1.964%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.925%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.954%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.904%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average remaining lease term in years &#x2014; operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average discount rate &#x2014; operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_fdbc4d66-d21d-4623-909b-19498a6db065"
      unitRef="U_USD">746000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_162e43a5-7308-4959-9e86-3582368f8085"
      unitRef="U_USD">654000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_4d8e0ee2-072a-402c-b3a1-eb76336fad9a"
      unitRef="U_USD">320000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_8554078a-7e95-41e3-aa0c-b9447207a346"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      id="F_a78bddc8-382d-48ba-981a-123e7e4f9c94">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      id="F_7adbaa8f-1ed1-461c-8a42-95823f6b0298">P2Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="3"
      id="F_1df51d7d-0f95-4347-b542-8e6905c11f5a"
      unitRef="U_pure">0.118</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="3"
      id="F_b86025fc-cefc-4978-9c0c-2013c0a0ea97"
      unitRef="U_pure">0.122</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_906ba0ae-005a-42a4-a051-5cdede4e78db"
      id="F_ab48de88-65cb-4366-a6a5-cbcb858f2593">P26M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_bcec32a4-ff06-4072-a745-9089be89f853">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; were as follows (in thousands):&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.856%;"/&gt;
        &lt;td style="width:1.475%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.67%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less current portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_9f2d235c-c0bb-41c3-9387-7b475890071a"
      unitRef="U_USD">872000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_5555aaa3-01b1-4245-a724-a39454bc5ca0"
      unitRef="U_USD">703000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_12de5d1a-7679-4a35-92b0-08ba39186759"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_f556b964-ea33-46d7-9099-53f4a013ded6"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_3d08f73c-f612-43c2-9c4c-54bb8b5f6e97"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_ac169680-c433-4a1e-ba65-9311c654c18e"
      unitRef="U_USD">1575000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_b2768206-f7d8-43b1-8ffc-65bd0e08cca9"
      unitRef="U_USD">165000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_de9a035b-f425-44ef-88f3-41c431523c3d"
      unitRef="U_USD">1410000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_4debaea4-8f83-4281-975f-c1e3884d3a4c"
      unitRef="U_USD">745000</us-gaap:OperatingLeaseLiabilityCurrent>
    <sclx:LeaseLiabilityNetOfCurrentPortion
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_a7e8f2a2-c11b-4622-834e-a7023fbcf468"
      unitRef="U_USD">665000</sclx:LeaseLiabilityNetOfCurrentPortion>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_8d3e3b69-5190-4f1f-a2de-6075d7a294d6">&lt;p id="section179" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total loss before income taxes for the years ended December 31, 2022, 2021 and 2020 did not include a foreign component.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the provision expense (benefit) were as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.996%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current income tax expense (benefit):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income tax expense (benefit):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total income tax benefit from continuing operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows as of  &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.599%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.049%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt related interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expense and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s provision for income taxes are as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020  (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.996%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax benefit at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt discount and interest limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquisition related charges&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior year true-up and carryback&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax credits and incentives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; against its deferred tax assets as of December 31, 2022. Realization of the deferred tax assets will be primarily dependent upon the Company's ability to generate sufficient taxable income prior to the expiration of its net operating losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;205.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of federal and state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;federal and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;state, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;respectively. The Company also had federal research and development income tax credits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; which will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Internal Revenue Code Section 382 rules apply to limit a corporation's ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section 382. For the years ended December 31, 2022 and 2021, there was no impact of such limitations on the Company&#x2019;s income tax provision.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#x2019;s tax years will remain open for three years for examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.899%;"/&gt;
        &lt;td style="width:1.376%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.985000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.386%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.985000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.386%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.985000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022, 2021, and 2020, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, of the Company&#x2019;s total unrecognized tax benefits, if recognized, would impact the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; interest or penalties have been recognized as of and for the periods ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company believes that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; material amount of the liabilities for uncertain tax positions are expected to reverse within 12 months of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_bf237ff8-ece3-4527-bb8c-4fa67534fb13">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the provision expense (benefit) were as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.996%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current income tax expense (benefit):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income tax expense (benefit):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total income tax benefit from continuing operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_3afe8796-d7fd-4e94-855e-152419ab2a29"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_8225e7b1-16ab-4e5e-8e15-051318ceff02"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_0752542d-d6d4-4c28-a8a9-b5fcb59d8628"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_2de0b638-956d-4e3e-b6a5-ba0853f6719f"
      unitRef="U_USD">4000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_2464ba79-1a24-42aa-b100-3ef30bc85279"
      unitRef="U_USD">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_af469633-bb96-4cb0-a938-e6417e14636a"
      unitRef="U_USD">-53000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_c52eeb02-8e2d-4873-9f6c-17c355327fea"
      unitRef="U_USD">4000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_a74c3d79-aa39-448f-8fe7-7799c997362c"
      unitRef="U_USD">5000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_1cf1b137-da9e-459c-a148-39a142fe776b"
      unitRef="U_USD">-53000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_7358790f-4115-46a3-b5d7-38dba3893548"
      unitRef="U_USD">-10396000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_6388f081-e2cf-4d25-96b7-5bfea063d867"
      unitRef="U_USD">-12981000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_9ebed7a4-c756-4d03-93f9-e40b5cf0f500"
      unitRef="U_USD">-3970000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_3b91ac7d-6db3-45d1-8d12-da2c7908d4bd"
      unitRef="U_USD">-1851000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_90aaebd2-2324-4a3d-9ac8-3d3368f57def"
      unitRef="U_USD">-2472000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_a556af84-19c1-4e60-8940-98919fcabfa9"
      unitRef="U_USD">-130000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_c39c285f-b292-488e-a810-fd1465181e7f"
      unitRef="U_USD">-12247000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_11ccbcd6-fa17-4ca1-a99c-4874533e5fa2"
      unitRef="U_USD">-15453000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_951ab722-4f47-493b-b09f-ea8dca697849"
      unitRef="U_USD">-4100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_571f252b-f86c-4030-b704-aab6d5e522c3"
      unitRef="U_USD">1347000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_4d2487d5-76a8-4163-810a-c0e26a99a2e3"
      unitRef="U_USD">31000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_0208af14-c4f2-4421-a8e6-f9b863ebfba0"
      unitRef="U_USD">93000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_b29c3bee-1835-4338-b155-d34e9e5a02b5"
      unitRef="U_USD">10900000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_85c0fa4d-d9dd-4c23-a7f8-09194dd11b36"
      unitRef="U_USD">15422000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_fa6b7240-3052-40dd-9d0d-0870bb9dd0e4"
      unitRef="U_USD">4007000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_def36f5f-ce6c-4bea-b77a-2074349fab6b"
      unitRef="U_USD">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_e82fdf2a-40ac-49cd-871e-e964add51978"
      unitRef="U_USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_27aba563-fb91-4ac6-ab4d-a29862440898"
      unitRef="U_USD">-53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_72f5d1a9-d777-493b-98cb-024eeb3921f6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows as of  &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.599%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.049%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt related interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expense and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_3c3c9a21-bf88-44ef-a81a-d243e0c1bd07"
      unitRef="U_USD">48984000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_16351436-fc93-430d-986c-b643142e5718"
      unitRef="U_USD">39714000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <sclx:DeferredTaxAssetsDebtRelatedInterest
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_a705e4ba-69d4-4811-82cd-c5276a560969"
      unitRef="U_USD">15272000</sclx:DeferredTaxAssetsDebtRelatedInterest>
    <sclx:DeferredTaxAssetsDebtRelatedInterest
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_2c1106ba-b48b-466c-9e5a-64bcf22d1369"
      unitRef="U_USD">12205000</sclx:DeferredTaxAssetsDebtRelatedInterest>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_b190dd6d-7e16-4905-b209-d2741cae548a"
      unitRef="U_USD">2014000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_990664db-56b3-4fcb-8029-b8d2b78c1336"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_c852afc7-bbd6-4420-ba42-2bb4e0fcdf43"
      unitRef="U_USD">1630000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_11debf6f-7c4f-4d73-b172-66bc144a07aa"
      unitRef="U_USD">1630000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_50ef2941-94ff-492b-a017-42bfe4f8e45c"
      unitRef="U_USD">1602000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_a62e83af-1b3a-4d40-9991-c2a6f77342a8"
      unitRef="U_USD">3233000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <sclx:DeferredTaxAssetsAccruedExpenseAndReserves
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_24ebf0ad-2350-41d7-a34d-dcca3f4e20fb"
      unitRef="U_USD">568000</sclx:DeferredTaxAssetsAccruedExpenseAndReserves>
    <sclx:DeferredTaxAssetsAccruedExpenseAndReserves
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_5cb4ce89-de16-4898-969f-b6c2860245a9"
      unitRef="U_USD">1517000</sclx:DeferredTaxAssetsAccruedExpenseAndReserves>
    <sclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_6ec8a86a-d954-429c-bcde-2bb3d3ca5cac"
      unitRef="U_USD">315000</sclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <sclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_ee3ee9a5-b22b-4edb-bde4-b1ffd4f77539"
      unitRef="U_USD">404000</sclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_a0eebaf4-9ad8-451c-85ca-dd6aa807626b"
      unitRef="U_USD">77000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_b81a62fa-eac4-4785-9302-1fea926cb8ef"
      unitRef="U_USD">236000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_1bd86618-f527-4596-a643-8a2418c6c3bf"
      unitRef="U_USD">70462000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_67fbed58-1e34-44c0-bef2-1ee9cafc466d"
      unitRef="U_USD">58939000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_3b49262a-f36a-436e-9a49-4d509b6b87b7"
      unitRef="U_USD">67543000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_3337b954-e83f-46dc-a65e-67a059088bbc"
      unitRef="U_USD">56643000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_712c6116-945b-4c7a-b142-2680ee5a64c2"
      unitRef="U_USD">2919000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_d09566c2-3d30-45a3-9652-5d6d8dcb26ed"
      unitRef="U_USD">2296000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_81802297-583b-432f-8bb5-7bf91a865b39"
      unitRef="U_USD">2666000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_3857ffd0-e4cf-4f06-8c63-2ce53f1cd192"
      unitRef="U_USD">1975000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_f923495f-a262-4f55-8e80-70463d7117ce"
      unitRef="U_USD">253000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_4697d5df-f505-414f-91d4-89ebbdb9c8ec"
      unitRef="U_USD">319000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_70dd2c83-b54b-4466-b494-b4d154c81dd8"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_4cb49de2-1b70-483a-a28c-c5eea850c846"
      unitRef="U_USD">2000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_78ab93b0-518f-436d-a61f-3a784744f7f9"
      unitRef="U_USD">2919000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_209662b1-1c56-49ec-86e8-d622cbccc9ee"
      unitRef="U_USD">2296000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_9f3326fc-f846-4a9d-99ed-b544efd28c02"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_fafabe6b-ec98-435f-a564-c1e1da778437"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_25cc9aca-a3b2-4b92-8780-6f79ca30831a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s provision for income taxes are as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020  (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.996%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.388%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax benefit at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,905&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt discount and interest limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquisition related charges&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior year true-up and carryback&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax credits and incentives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_69b8f766-2bba-4ddb-9fea-5b3f02df92d5"
      unitRef="U_USD">-4905000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_6993f06c-a6f0-451e-b38b-9c86d00c6618"
      unitRef="U_USD">-19150000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_f907e5d2-62b1-4b85-9b52-d66483ec00b7"
      unitRef="U_USD">-9408000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_33462846-5bb5-4230-8571-aaa8c43f6cec"
      unitRef="U_USD">10900000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_6498934b-0ffe-448a-b725-96cd7346331c"
      unitRef="U_USD">15422000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_f70c1995-33bf-437f-be11-bb2a377668c4"
      unitRef="U_USD">4007000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_18fecd52-05a6-4123-8b88-65e2c3410a9f"
      unitRef="U_USD">-9293000</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_bb7834f4-561c-4ad7-9f9d-e0f3e509e8ba"
      unitRef="U_USD">8954000</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_57a36485-4757-4d55-bca1-8ab8171f12fe"
      unitRef="U_USD">-806000</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_12423601-44ab-40fa-a2ce-06888a8a6eaf"
      unitRef="U_USD">2469000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_986b2968-9d98-47da-9ffc-2ff829a590fd"
      unitRef="U_USD">224000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_48b5b28e-e351-43d6-97c1-2c36fe0d430e"
      unitRef="U_USD">166000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sclx:IncomeTaxReconciliationAcquisitionRelatedCharges
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_26c9aaf5-a37f-4dc4-8cad-08e6dbcff53f"
      unitRef="U_USD">992000</sclx:IncomeTaxReconciliationAcquisitionRelatedCharges>
    <sclx:IncomeTaxReconciliationAcquisitionRelatedCharges
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_e6f119f2-8625-423a-a0f1-8932d5bb4003"
      unitRef="U_USD">75000</sclx:IncomeTaxReconciliationAcquisitionRelatedCharges>
    <sclx:IncomeTaxReconciliationAcquisitionRelatedCharges
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_4c51c4f1-008d-456c-8570-9d0b193c7bfe"
      unitRef="U_USD">63000</sclx:IncomeTaxReconciliationAcquisitionRelatedCharges>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_da8acfa1-8877-418b-b9fe-315bc195e880"
      unitRef="U_USD">-713000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_46ed5968-e0fe-4934-81a6-7e474ff8d97f"
      unitRef="U_USD">-3968000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_9bf73033-9389-43d4-a334-8b53be328a21"
      unitRef="U_USD">6955000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_915df701-0e64-443e-8ccf-c02ab9e8d50e"
      unitRef="U_USD">-174000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_a83d8bae-878b-44bf-a32a-c2ec5a809ba8"
      unitRef="U_USD">-2545000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_6f10fcfa-852b-41a4-bbc9-5735c88ec352"
      unitRef="U_USD">-1164000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_2d6025b9-b7f9-4372-804b-8f8aab94bee4"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_fdf5eb59-8cda-4bb1-8aca-4b409c063186"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_3443ea3f-2f37-426b-95a4-124a05020f64"
      unitRef="U_USD">101000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_1c9dadd7-9e04-400a-803d-ad173536b74d"
      unitRef="U_USD">728000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_ee52be55-37c6-4bd5-b72d-bccc8abf8108"
      unitRef="U_USD">993000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_89612e1a-197a-49cd-a2cc-6c6016d0b83d"
      unitRef="U_USD">235000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_0f1dbb5c-ce63-4514-a587-d5d96b60f790"
      unitRef="U_USD">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_c0164be9-e827-4eba-88d7-2c8f531284b5"
      unitRef="U_USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_9c46faba-b5ad-4008-a918-33af2a2cd4c0"
      unitRef="U_USD">-53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-5"
      id="F_1fc6793b-1dc2-4a48-a5d7-3c565fd82d01"
      unitRef="U_USD">67500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_34aca91d-0225-49d8-82d3-b112cf786117"
      decimals="-5"
      id="F_e22bbe04-2b4e-48cf-a1f6-da7e9ff5260b"
      unitRef="U_USD">205600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_5024e079-7880-4bc6-b897-722b2e854e4c"
      decimals="-5"
      id="F_05164e44-3e9e-4fb8-ae81-93c966ae2895"
      unitRef="U_USD">106900000</us-gaap:OperatingLossCarryforwards>
    <sclx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_7de5b4e3-ff7d-4a25-8702-760a6461c79b"
      id="F_353d294a-fdb7-42a7-888f-95ce41fbb4b0">2035</sclx:OperatingLossCarryforwardsExpirationYear>
    <sclx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_cc227406-9649-405a-abe9-80c403455490"
      id="F_130ece2e-3521-4003-bc99-3630152a4c64">2034</sclx:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-5"
      id="F_6b2859f0-892a-47e0-a70a-2ae0a5385975"
      unitRef="U_USD">2000000.0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <sclx:TaxCreditCarryForwardsExpirationYear
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_c5548447-407f-46d8-928d-ddbef1e6c9cb">2035</sclx:TaxCreditCarryForwardsExpirationYear>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_61fa772a-81bf-47cd-a52f-86e040b77ae2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.899%;"/&gt;
        &lt;td style="width:1.376%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.985000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.386%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.985000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.386%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.985000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_f2935cf5-c84f-4730-a097-74a35ac070b0"
      unitRef="U_USD">408000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="-3"
      id="F_a8e65196-fe2a-4f43-8513-2222d473a5c6"
      unitRef="U_USD">406000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28"
      decimals="-3"
      id="F_a6ea0903-7170-4315-8593-c70627d2b106"
      unitRef="U_USD">385000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_a48c71da-f79c-4940-b593-450d4d671293"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_5c1b73a4-791e-43bb-9f50-771c8c088d6c"
      unitRef="U_USD">2000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_9f6f36d4-4f30-4f45-8ff9-21eaf94b7265"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_d54b8554-91e2-470b-b850-4ede43be29e3"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_59563255-1ad9-4602-a368-eaa6f8a0b300"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_5e81bd80-1d68-416f-b1ee-f127bb7cc16e"
      unitRef="U_USD">4000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_96c5b6cf-b269-4256-9b5d-d535be7e7c9b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_06618ac8-49f1-4b5a-a84e-511127e1bef5"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_8ec9a880-74b5-406f-bf0d-adaf5f69652f"
      unitRef="U_USD">25000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_123466bf-9096-4b48-84aa-abdfef505440"
      unitRef="U_USD">408000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-3"
      id="F_932b3fc9-0301-4c2b-ab85-4dfd3a47d8a9"
      unitRef="U_USD">408000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="-3"
      id="F_737743d6-951a-4158-9781-6782ecfd8410"
      unitRef="U_USD">406000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-5"
      id="F_be3ad41f-81d5-46e1-b925-ca08e4c10ddd"
      unitRef="U_USD">400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_e30cd740-80d0-4ec4-bcbe-c140def0f039"
      decimals="-5"
      id="F_edc31180-0c55-442b-8fb6-c7adfa0990a0"
      unitRef="U_USD">400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_c21a30a8-2bf8-4636-8fbe-e62375d50217"
      decimals="-5"
      id="F_838d042f-e3f6-459c-b1a7-cd5cdec26c2b"
      unitRef="U_USD">400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_fe8805b9-d7f2-4990-a185-66e073809545"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_37f52ac7-8bcf-488b-93c2-3d27f49ade59"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_c633d1d7-b060-46e3-93bc-9135d4ecc7d0"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_4a5560ce-e23e-4368-8572-860644a67abb"
      decimals="-3"
      id="F_b0244a4b-a715-4f35-a39f-ab7e2a6c8f8d"
      unitRef="U_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_4df1965d-4d2a-4e3d-99c0-8465dcf065ec">&lt;p id="section183" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12. Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2020, approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the outstanding capital stock of the Company was held by Itochu. On January 13, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34,889,868&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Legacy Scilex representing all outstanding capital stock of Legacy Scilex held by Itochu were acquired by non-related minority shareholders. Thus, Itochu is not a shareholder subsequent to January 13, 2021. During the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 the Company purchased approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#x2019;s statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Semnur is party to an Assignment Agreement, dated August 6, 2013 (the &#x201c;Assignment Agreement&#x201d;), with Shah Investor LP (&#x201c;Shah Investor&#x201d;). Mahendra Shah, Ph.D., who has served on the Company&#x2019;s board of directors since March 2019, is the managing partner of Shah Investor.  Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the low-single digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;injection developed using such intellectual property, which would include SP-102. Through December 31, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 1, 2017, a Transition Services Agreement (&#x201c;TSA&#x201d;) was executed between Scilex Pharma and Sorrento.  Pursuant to the TSA, Sorrento agreed, at the Company&#x2019;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company.  During the years ended December 31, 2022, 2021, and 2020 the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the acquisition of Semnur.  The note is interest bearing at the lesser of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% simple interest per annum, and (b) the maximum interest rate permitted under law.  Interest is due and payable annually.  The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium.  During the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 Sorrento made advances to the Company in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, an&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;million respectively, under the note payable. All outstanding related party indebtedness immediately prior to the closing of the Business Combination was converted to equity pursuant to the Debt Exchange Agreement (defined below) and therefore the last day the debt outstanding was November 10, 2022 (see Note 12). The outstanding principal balance of the note on November 10, 2022 and December 31, 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, which was recorded under the current related party note payable in the Company&#x2019;s consolidated balance sheets. As of November 10, 2022 and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. The proceeds from the note payable were used to finance the operations of the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#x201c;Intercompany Note&#x201d;). Scilex Pharma may borrow up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% simple interest per annum, and (b) the maximum interest rate permitted under law. All outstanding principal amounts and accrued interest was due upon maturity on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. On October 22, 2018, Sorrento purchased from the Legacy Scilex 24,117,608 shares of the Legacy Scilex Common Stock in exchange for the repayment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of indebtedness under this promissory note.  During the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020, Sorrento made advances to Scilex Pharma in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million respectively, under the promissory note. As of November 10, 2022 and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. As of November 10, 2022 and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021, Scilex Pharma&#x2019;s outstanding principal balance under the promissory note was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which was recorded under the non-current related party note payable in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in February 2022 to fund the payment of Scilex Pharma Notes as described in Note 7. The $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; received in February 2022 was due no earlier than February 2030 and was recorded under the non-current related party note payable in the Company&#x2019;s consolidated balance sheets as of November 10, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional funding received from Sorrento was due on demand and recorded under the related party payable in the Company&#x2019;s consolidated balance sheets. As of November 10, 2022, related party payables due to Sorrento included&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to cover working capital requirements, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for repurchases of Scilex Pharma Notes, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for litigation fees (see Note 7). As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, related party payables due to Sorrento consisted of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to cover working capital requirements, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for repurchases of Scilex Pharma Notes, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to pay litigation fees. As of December 31, 2022, the Company had a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related party receivable from Sorrento related to certain invoices paid on behalf of Sorrento, which was fully reserved (see Note 14).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#x2019;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.66&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% simple interest per annum and (b) the maximum interest rate permitted under law. As of November 10, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which was recorded under the non-current related party note payable in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt Exchange Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On September 12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#x201c;Debt Exchange Agreement&#x201d;) with Sorrento, pursuant to which (i) Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company that remain outstanding as of immediately prior to the closing of the Business Combination (the &#x201c;Aggregate Outstanding Amount&#x201d; or &#x201c;Outstanding Indebtedness&#x201d;), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 7), in exchange for the issuance by the Company to Sorrento of Preferred Stock of the Company, (ii) the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii) upon the occurrence of the events described in clauses (i) and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to, and contingent upon, the closing of the Business Combination, Sorrento elected to contribute the Outstanding Indebtedness to the Company in exchange for the issuance by the Company to Sorrento of that number of shares of preferred stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#x201c;Exchange Shares&#x201d; and such transaction, the &#x201c;Debt Contribution&#x201d;) that is equal to (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the Aggregate Outstanding Amount plus the amount equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the Aggregate Outstanding Amount divided by (ii) $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (rounded up to the nearest whole share); provided, that in no event would the Aggregate Outstanding Amount exceed $ &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;310,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;290.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement. This amount was converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,057,097&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Scilex Preferred Stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,905,710&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's Common Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <sclx:OutstandingCapitalStockPercent
      contextRef="C_c1cafa60-e7b5-445c-b9e8-7dc034751dc5"
      decimals="3"
      id="F_e7effeba-9eb6-4829-bf01-6518e56030a5"
      unitRef="U_pure">0.147</sclx:OutstandingCapitalStockPercent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_52e1afd8-0dd3-4e45-8542-1b0396bc18c6"
      decimals="INF"
      id="F_250c242c-aed8-4713-87d4-d9a945c8ece7"
      unitRef="U_shares">34889868</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OtherInventoryPurchasedGoods
      contextRef="C_17686498-39e6-4eca-a9d9-732664349cdb"
      decimals="-5"
      id="F_28c3d990-e05e-4c6c-9bbf-d5bb127b46c5"
      unitRef="U_USD">6700000</us-gaap:OtherInventoryPurchasedGoods>
    <us-gaap:OtherInventoryPurchasedGoods
      contextRef="C_e0720b69-b850-4e33-b843-ca514f86a042"
      decimals="-5"
      id="F_9396583f-881b-401f-bb91-73b1777199db"
      unitRef="U_USD">5700000</us-gaap:OtherInventoryPurchasedGoods>
    <us-gaap:OtherInventoryPurchasedGoods
      contextRef="C_c1cafa60-e7b5-445c-b9e8-7dc034751dc5"
      decimals="-5"
      id="F_91438b73-b15a-4223-85ab-1f90971683de"
      unitRef="U_USD">1000000.0</us-gaap:OtherInventoryPurchasedGoods>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d408965d-1291-4b37-9b62-a779f1f46c23"
      decimals="-5"
      id="F_f3ffe697-3e1e-4960-b4b1-6f25b0aa0cff"
      unitRef="U_USD">3800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f6afef57-8906-4dde-a3a5-2e46d3fa8a04"
      decimals="-5"
      id="F_c4085ad7-a3f5-496a-8c6e-eb43ac3e8ef0"
      unitRef="U_USD">4000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_26f9a78f-d20f-4189-8bc1-b3bfc1c9e6c0"
      decimals="-5"
      id="F_a98d8b1b-3841-4d49-a8e7-c66c5057a63e"
      unitRef="U_USD">2300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_a481e148-6651-4f1b-8127-50bb57bdbf62"
      decimals="-5"
      id="F_aafbc466-686a-494e-94fa-164aea138216"
      unitRef="U_USD">16500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_a481e148-6651-4f1b-8127-50bb57bdbf62"
      decimals="2"
      id="F_10e77e7f-79e5-406a-a9cf-72f736f26692"
      unitRef="U_pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesAndLoansPayable
      contextRef="C_33d1eca1-5b22-4cf6-bc73-83bb4af8df1a"
      decimals="-5"
      id="F_e0d818a9-9b1a-4885-afea-07cc0ed040eb"
      unitRef="U_USD">27500000</us-gaap:NotesAndLoansPayable>
    <us-gaap:NotesAndLoansPayable
      contextRef="C_218d96e4-ea4f-4f86-8b2f-c64a6bcff94a"
      decimals="-5"
      id="F_591f54d8-820c-449c-88b9-5bbb68238f36"
      unitRef="U_USD">6600000</us-gaap:NotesAndLoansPayable>
    <us-gaap:NotesAndLoansPayable
      contextRef="C_5d2870e1-119e-419e-9885-26f2174d6332"
      decimals="-5"
      id="F_8f982f10-de25-4bca-ad6f-62b33c41c3e2"
      unitRef="U_USD">13700000</us-gaap:NotesAndLoansPayable>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_fe20fc93-e090-4257-8aea-e4facd17edbf"
      decimals="-5"
      id="F_26246c9f-079e-4561-9a9b-92e1b2698b9d"
      unitRef="U_USD">47100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_218d96e4-ea4f-4f86-8b2f-c64a6bcff94a"
      decimals="-5"
      id="F_8818d468-20b3-421e-a0b8-7547c49bb579"
      unitRef="U_USD">19600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="C_fe20fc93-e090-4257-8aea-e4facd17edbf"
      decimals="-5"
      id="F_01890bd7-bb77-4048-9885-c3e8b94d7866"
      unitRef="U_USD">7200000</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="C_218d96e4-ea4f-4f86-8b2f-c64a6bcff94a"
      decimals="-5"
      id="F_221c51e2-f7ee-462f-b982-8288f1f8d10e"
      unitRef="U_USD">3900000</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:NotesIssued1
      contextRef="C_0ee0f0fb-af92-4b7b-b642-acfabbcf105e"
      decimals="-5"
      id="F_87b8a74e-affa-4fe9-a0b7-62a8a68b7821"
      unitRef="U_USD">21700000</us-gaap:NotesIssued1>
    <us-gaap:NotesAndLoansPayable
      contextRef="C_97b73263-30f4-4653-9e9d-edde5c0042df"
      decimals="-5"
      id="F_fc4b3c34-bbb8-441a-826e-e240855bd3e0"
      unitRef="U_USD">25000000.0</us-gaap:NotesAndLoansPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_97b73263-30f4-4653-9e9d-edde5c0042df"
      decimals="2"
      id="F_edfc525d-975b-4ba8-84a7-8e64e0b91b47"
      unitRef="U_pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0ee0f0fb-af92-4b7b-b642-acfabbcf105e"
      id="F_310e1957-7092-428c-96d0-8edcda3e5b13">2026-08-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties
      contextRef="C_b4cbb81e-b3d2-4016-bb84-fc0e80fe9230"
      decimals="-5"
      id="F_32e8c060-31f4-41e9-8c97-6325245c4802"
      unitRef="U_USD">21700000</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:NotesAndLoansPayable
      contextRef="C_ffc67561-e990-47ce-8a93-35879897d05b"
      decimals="-6"
      id="F_6bf8c095-5a1a-484c-b029-9ab22be7b352"
      unitRef="U_USD">0</us-gaap:NotesAndLoansPayable>
    <us-gaap:NotesAndLoansPayable
      contextRef="C_e325ed31-26e8-4093-8e73-8b5f019c9102"
      decimals="-5"
      id="F_4a2dd6d1-3c7e-467d-91e3-2ee47abc7f08"
      unitRef="U_USD">8100000</us-gaap:NotesAndLoansPayable>
    <us-gaap:NotesAndLoansPayable
      contextRef="C_32ab59f7-6a30-49d8-81a3-b2690ed7e60b"
      decimals="-5"
      id="F_df614dd6-6531-48f3-9ba9-2180fa72b2cc"
      unitRef="U_USD">10300000</us-gaap:NotesAndLoansPayable>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="C_01b3c958-391f-4745-a694-8e6d618b12d1"
      decimals="-5"
      id="F_22e555ed-51a4-4409-bf80-88a61960ed11"
      unitRef="U_USD">5100000</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="C_e325ed31-26e8-4093-8e73-8b5f019c9102"
      decimals="-5"
      id="F_3ad7b40c-bc88-4686-926c-d167cb428dc6"
      unitRef="U_USD">3100000</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:AccountsPayableRelatedPartiesNoncurrent
      contextRef="C_fe20fc93-e090-4257-8aea-e4facd17edbf"
      decimals="-5"
      id="F_d3bae763-980f-4d94-82a3-12ac069b7ed4"
      unitRef="U_USD">23500000</us-gaap:AccountsPayableRelatedPartiesNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesNoncurrent
      contextRef="C_218d96e4-ea4f-4f86-8b2f-c64a6bcff94a"
      decimals="-5"
      id="F_24cdcefb-778f-4a99-aa7f-907b672c48bc"
      unitRef="U_USD">23500000</us-gaap:AccountsPayableRelatedPartiesNoncurrent>
    <us-gaap:ProceedsFromSaleOfNotesReceivable
      contextRef="C_16948957-8702-4576-aa50-3b0b402e4d82"
      decimals="-5"
      id="F_d03ce038-fd38-417c-9ec2-f65849659cfb"
      unitRef="U_USD">35000000.0</us-gaap:ProceedsFromSaleOfNotesReceivable>
    <us-gaap:AccountsPayableRelatedPartiesNoncurrent
      contextRef="C_e39411dd-ee32-4564-9103-dfccf71f4ba3"
      decimals="-5"
      id="F_8db80ccc-8130-45f7-846a-05aaa345140c"
      unitRef="U_USD">35000000.0</us-gaap:AccountsPayableRelatedPartiesNoncurrent>
    <sclx:WorkingCapital
      contextRef="C_e229956a-eca3-48a8-a9c3-297169d09bc5"
      decimals="-5"
      id="F_75ee9de8-0f7e-4f66-aa6e-ae936e098d51"
      unitRef="U_USD">61700000</sclx:WorkingCapital>
    <sclx:RepurchasesOfNotes
      contextRef="C_6337de38-c2dc-48a8-b488-04cc48d9be24"
      decimals="-5"
      id="F_670338f2-1b81-4140-9cd4-701d0f22d1ce"
      unitRef="U_USD">100000000.0</sclx:RepurchasesOfNotes>
    <sclx:LitigationFees
      contextRef="C_6337de38-c2dc-48a8-b488-04cc48d9be24"
      decimals="-5"
      id="F_cd823617-f184-4c4c-a2d6-bc8e30f68da1"
      unitRef="U_USD">18200000</sclx:LitigationFees>
    <sclx:WorkingCapital
      contextRef="C_a447a6e2-4ac3-4afb-95ec-8bfbc792b678"
      decimals="-5"
      id="F_fd861f5f-0d74-4c38-b401-4999943cda0c"
      unitRef="U_USD">35700000</sclx:WorkingCapital>
    <sclx:RepurchasesOfNotes
      contextRef="C_8219a545-34c9-4750-80f1-f7f2e16e64f8"
      decimals="-5"
      id="F_6461b279-621b-44b8-bb79-c521c4c79aac"
      unitRef="U_USD">51000000.0</sclx:RepurchasesOfNotes>
    <sclx:LitigationFees
      contextRef="C_8219a545-34c9-4750-80f1-f7f2e16e64f8"
      decimals="-5"
      id="F_f4fb7408-7600-407a-ae69-67df1719f636"
      unitRef="U_USD">6000000.0</sclx:LitigationFees>
    <sclx:RelatedPartyReceivable
      contextRef="C_33d1eca1-5b22-4cf6-bc73-83bb4af8df1a"
      decimals="-5"
      id="F_927b8867-9178-45d5-9044-d1c0e6d27064"
      unitRef="U_USD">1800000</sclx:RelatedPartyReceivable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_6202898d-9295-4896-a66a-61c32e1f4b3c"
      decimals="4"
      id="F_2e4155b2-9f38-4585-b528-e2d657ede476"
      unitRef="U_pure">0.0266</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AccountsPayableRelatedPartiesNoncurrent
      contextRef="C_9bed26af-6062-4ef5-8277-06de00c7bdeb"
      decimals="-5"
      id="F_e5b00070-bb69-433a-99e4-ba37aac197e5"
      unitRef="U_USD">4200000</us-gaap:AccountsPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesIssued1
      contextRef="C_3354e157-13ff-4e9f-bfd3-3f7a68647739"
      decimals="-5"
      id="F_84fb1a46-b173-4553-91f7-2cd0f341c7c2"
      unitRef="U_USD">27500000</us-gaap:NotesIssued1>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_6462068b-60b7-499d-ac23-4f81f11e97d2"
      decimals="4"
      id="F_e6e9f390-1570-40e5-b2ed-237949beeba7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <sclx:DebtExchangeDescriptions
      contextRef="C_3a4759f2-8d65-4ebd-9e91-79f879ffa0f4"
      id="F_927883ba-1d30-4fa1-876b-c91e3180ad87">the Aggregate Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share); provided, that in no event would the Aggregate Outstanding Amount exceed $ 310,000,000.</sclx:DebtExchangeDescriptions>
    <srt:FinancingReceivableNonaccrualToOutstandingPercent
      contextRef="C_36afe8fd-cd95-4f09-aed3-b9387cac7efb"
      decimals="2"
      id="F_8ed6226f-b435-4079-a27c-a36fd3dcc96d"
      unitRef="U_pure">0.10</srt:FinancingReceivableNonaccrualToOutstandingPercent>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_36afe8fd-cd95-4f09-aed3-b9387cac7efb"
      decimals="2"
      id="F_1a4dd53c-f6ba-43b0-b345-94f3c11dfa73"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:LongTermDebtAverageAmountOutstanding
      contextRef="C_3a4759f2-8d65-4ebd-9e91-79f879ffa0f4"
      decimals="0"
      id="F_2d2dcdcc-272b-4eb3-9eb3-e0bfd98633a5"
      unitRef="U_USD">310000000</us-gaap:LongTermDebtAverageAmountOutstanding>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_4b0d5c8f-c285-4b81-adfe-90ae2f642ce4"
      decimals="-5"
      id="F_d5215525-9936-4467-ad4a-012212d524b3"
      unitRef="U_USD">290600000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_4b0d5c8f-c285-4b81-adfe-90ae2f642ce4"
      decimals="INF"
      id="F_93a1ebdb-029f-4fae-a3a3-f37d664136d4"
      unitRef="U_shares">29057097</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_4b0d5c8f-c285-4b81-adfe-90ae2f642ce4"
      decimals="INF"
      id="F_fa38e573-8792-4f35-9594-5573e2c85271"
      unitRef="U_shares">2905710</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_018e30a2-9df3-453a-a0b9-ff9346913ec1">&lt;p id="section184" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13. Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company has two classes of shares, which are referred to as Common Stock and Preferred Stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. The retroactive adjustment is based on the same number of weighted average shares outstanding in each historical period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the years ended December 31, 2022, 2021, and 2020, basic loss per share is computed using the two-class method. The two-class method is an earnings allocation formula that determines earnings per share for each class of common stock and participating securities according to dividends or dividend equivalents and participation rights in undistributed earnings. Preferred Stock is not contractually required to share in net losses of the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020  (in thousands except per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.878%;"/&gt;
        &lt;td style="width:1.579%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.763%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.589%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.763%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.589%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.837%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to Scilex&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to participating securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effect of Dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator for Diluted Loss per Share - Adjusted for Dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and Diluted Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.176%;"/&gt;
        &lt;td style="width:1.15%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.671%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.161%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.682%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.161%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,939,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,967,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,746,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Public Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,899,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_3ea715ce-1b17-4fc1-b25f-7f625140097e;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_bdcbe9bc-f5de-47ee-9b21-0cb6f9049bc6;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Private Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,104,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_7653d5f4-622c-4e12-b949-15400631d4f1;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_13bda9ef-a43d-4945-8aa9-0cae0d8d0725;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_c6c24190-1497-4994-b83c-88347f5c91b7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020  (in thousands except per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.878%;"/&gt;
        &lt;td style="width:1.579%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.763%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.589%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.763%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.589%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.837%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to Scilex&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to participating securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effect of Dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator for Diluted Loss per Share - Adjusted for Dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and Diluted Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_46a51479-682a-4686-a065-356ded4a4a8a"
      unitRef="U_USD">-23364000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_fa4bc40c-6678-4d9f-a5bd-4e70b1f76fdb"
      unitRef="U_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_abef098f-2ed7-4bc2-9aa2-9a649f901366"
      unitRef="U_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_82de177b-d633-4d95-9f82-71b429f05639"
      unitRef="U_USD">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_f1ddd558-ec08-42d8-9741-982a130e0498"
      unitRef="U_USD">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_acf8b033-2384-4fe6-8626-cc65fbf7d2ca"
      unitRef="U_USD">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_e8d8b365-c8fb-4247-9431-c9da71b6ad6d"
      unitRef="U_USD">-23364000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_016a98ef-f62e-4675-ad67-ffbb548cd9cb"
      unitRef="U_USD">-88424000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_2b80bb23-b361-4b57-a2ef-e8388a641433"
      unitRef="U_USD">-47519000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="INF"
      id="F_163523b9-a1b0-4577-bc73-bb16fe21d950"
      unitRef="U_shares">134226</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="INF"
      id="F_b3d4303f-ddfd-46ee-94af-e8aa0a6ad2eb"
      unitRef="U_shares">132858</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="INF"
      id="F_16264c2b-fe64-4d12-8d13-097bbebabb5e"
      unitRef="U_shares">132891</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <sclx:EffectOfDilutiveSecurities
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="0"
      id="F_cbacad2e-5a9b-4cff-b1dc-6f3602841602"
      unitRef="U_shares">0</sclx:EffectOfDilutiveSecurities>
    <sclx:EffectOfDilutiveSecurities
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="0"
      id="F_fb98f62b-bd5e-445e-b032-8498e8e5429b"
      unitRef="U_shares">0</sclx:EffectOfDilutiveSecurities>
    <sclx:EffectOfDilutiveSecurities
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="0"
      id="F_5ee62080-3744-4388-af33-e6e58e375beb"
      unitRef="U_shares">0</sclx:EffectOfDilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="-3"
      id="F_3551e538-34d5-4a46-bb69-17f038d898e7"
      unitRef="U_USD">134226000</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="-3"
      id="F_ecc26d2f-6140-450c-9bb2-3a47ff30ddd0"
      unitRef="U_USD">132858000</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="-3"
      id="F_d7b61027-903a-417f-810b-bb1afe515e9e"
      unitRef="U_USD">132891000</us-gaap:DilutiveSecurities>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="INF"
      id="F_8f193b9d-5d7d-4176-b5a5-07343a9c6871"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      decimals="INF"
      id="F_7ab27c7d-bb06-473e-88a0-6fcf1a866dbf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="INF"
      id="F_751fe6da-7c53-47dd-bdb3-9e9a48bb296a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a46bc651-8cf6-4139-83ff-4cec7e844fea"
      decimals="INF"
      id="F_dec7770c-ca1c-4ff6-a544-3c42c65ab2a6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="INF"
      id="F_e899a042-ca28-4672-9db3-8a979ad2ddef"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_db7cfe09-6ef6-4dd8-9501-bdc6c3607b53"
      decimals="INF"
      id="F_fc5aa415-aad8-4ff7-9d90-46d616b7bae4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_9bbd8290-486d-4fcd-86c7-85efe4620916">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.176%;"/&gt;
        &lt;td style="width:1.15%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.671%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.161%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.682%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.161%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,939,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,967,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,746,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Public Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,899,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_3ea715ce-1b17-4fc1-b25f-7f625140097e;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_bdcbe9bc-f5de-47ee-9b21-0cb6f9049bc6;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Private Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,104,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_7653d5f4-622c-4e12-b949-15400631d4f1;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_13bda9ef-a43d-4945-8aa9-0cae0d8d0725;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5f187651-0980-4146-8085-29b42623f970"
      decimals="0"
      id="F_1777473e-dfe4-4f10-826f-e735411d21f4"
      unitRef="U_shares">16939093</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c1e465a4-3408-4232-a9fe-97ae297cdf9c"
      decimals="0"
      id="F_665c99a8-0659-4d56-9d81-60901c92d254"
      unitRef="U_shares">18967724</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c57207b1-14a7-41a8-8d5b-1a183f1fb11b"
      decimals="0"
      id="F_f5131f65-6cdf-4aed-89f2-9c653aa8a2db"
      unitRef="U_shares">20746432</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7fac449c-067b-401a-bdcc-4e3e9932dff4"
      decimals="0"
      id="F_8ecf922d-d51b-4564-97b1-e69886ac7d3f"
      unitRef="U_shares">6899988</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d3d7eb79-4633-4e48-bbe1-9c972c6e1a38"
      decimals="0"
      id="F_03f73104-965b-4a20-a35e-ca2c70b720ff"
      unitRef="U_shares">4104000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_83eae59f-9d4a-4170-b358-a33c0ee64291"
      id="F_1c7eee81-e5ea-44d4-86ec-90df8914dc34">&lt;p id="section185" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has evaluated subsequent events for recognition and disclosure purposes in the audited consolidated financial statements as of December 31, 2022. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;B. Riley Standby Equity Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 8, 2023, the Company entered into a Standby Equity Purchase Agreement (the "B. Riley Purchase Agreement") with B. Riley, whereby the Company shall have the right, but not the obligation, to sell to B. Riley up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of its shares of the Company&#x2019;s Common Stock at the Company's request any time during the 36 months following the execution of the B. Riley Purchase Agreement, subject to certain conditions. The Company expects to use the net proceeds received from this for working capital and general corporate purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for B. Riley&#x2019;s commitment to purchase shares of Common Stock at the Company&#x2019;s direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Common Stock to B. Riley in connection with the execution of the B. Riley Purchase Agreement on January 12, 2023.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subsequent to the execution of the B. Riley Purchase Agreement, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,241&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Common Stock pursuant to the B. Riley Purchase Agreement for aggregate net proceeds to the Company of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Scilex Holding Company 2023 Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 17, 2023, the Compensation Committee of the Board of Directors (the &#x201c;Compensation Committee&#x201d;) of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#x201c;Plan&#x201d;). The Plan will serve to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company as employees by affording such individuals an opportunity to acquire a proprietary interest in the Company. The Plan provides for the grant of equity-based awards in the form of non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards (as set forth under the Plan) solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The initial maximum number of shares available for grant under the Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,400,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Amendment to the Yorkville Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 8, 2023, the Company entered into an Amended and Restated Standby Equity Purchase Agreement with Yorkville (the &#x201c;A&amp;amp;R Yorkville Purchase Agreement&#x201d;), amending, restating and superseding the Yorkville Purchase Agreement dated November 17, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the A&amp;amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the lowest daily volume weighted average price of the Common Stock for any trading day on the date of delivery of a written purchase notice to Yorkville.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subsequent to December 31, 2022, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Common Stock pursuant to the A&amp;amp;R Yorkville Purchase Agreement for aggregate net proceeds to the Company of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Elyxyb License&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 12, 2023, the Company acquired from BioDelivery Sciences International, Inc. (&#x201c;BSDI&#x201d;) and Collegium Pharmaceutical, Inc. (&#x201c;Collegium&#x201d;, and together with BDSI, the &#x201c;Collegium Sellers&#x201d;) the rights to certain patents,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB (celecoxib oral solution) (the &#x201c;Product&#x201d;) and its commercialization in the United States and Canada (the &#x201c;Territory&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for the acquisition, the Company assumed various rights and obligations under that certain asset purchase agreement, dated August 3, 2021 (the &#x201c;DRL APA&#x201d;), between BDSI and Dr. Reddy&#x2019;s Laboratories Limited, a company incorporated under the laws of India (&#x201c;DRL&#x201d;), including a license from DRL including an irrevocable, royalty-free, exclusive license to know-how and patents of DRL related to the Product and necessary or used to exploit the Product in the Territory. Additionally, under the Purchase Agreement, the Seller granted the Company an irrevocable, royalty-free, exclusive license to know-how related to the Product and necessary or used to exploit the Product in the Territory. No cash consideration was or will be payable to Collegium Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties for sales of the Product in the Territory for all indications and additional amounts if certain milestones are achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sorrento Chapter 11 filing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the Company is not a debtor in Sorrento&#x2019;s voluntary Chapter 11 filing and management does not expect this will impact the Company and will continue to operate its business as usual. As of December 31, 2022, the Company had a $1.8 million receivable from Sorrento, which was fully reserved.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockValue
      contextRef="C_2fac2033-f8b3-4b66-9e60-cd16541fd776"
      decimals="-5"
      id="F_8fc4fd94-bee7-440c-bf37-256e010d964e"
      unitRef="U_USD">500000000.0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a0ff95ef-24d5-464a-957b-98f6e31fc5f1"
      decimals="INF"
      id="F_e0fc57c3-a2bb-4b18-b294-2251bdbb5910"
      unitRef="U_shares">250000</us-gaap:CommonStockSharesIssued>
    <sclx:CommonStockSold
      contextRef="C_5431b419-860c-45a2-bb9a-fd5a0ef55758"
      decimals="0"
      id="F_15a89247-2264-42f5-a10c-a6d8682bfb94"
      unitRef="U_shares">127241</sclx:CommonStockSold>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="C_5431b419-860c-45a2-bb9a-fd5a0ef55758"
      decimals="-6"
      id="F_770eb7c4-b8e2-446f-b39f-1b832325c982"
      unitRef="U_USD">1000000</sclx:ProceedsFromSaleOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_4eac9786-7af1-498b-ade8-18ab32ec037e"
      decimals="INF"
      id="F_de29c2f1-d564-4d89-a1dd-d9b2fe2daeca"
      unitRef="U_shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <sclx:CommonStockSold
      contextRef="C_dc5b8987-1bb7-4130-9b7a-6a3c9e569fde"
      decimals="0"
      id="F_98d3b64c-b765-4526-a94b-1a971d94e137"
      unitRef="U_shares">85000</sclx:CommonStockSold>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="C_dc5b8987-1bb7-4130-9b7a-6a3c9e569fde"
      decimals="-5"
      id="F_a6169a2a-7abe-4732-9223-458dd7f2c3dd"
      unitRef="U_USD">600000</sclx:ProceedsFromSaleOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>97
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &6)9U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !EB6=6$H3@4.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O305E=#U9<,G!<&!XEM(;EM8DX;DI-VW-ZU;A^@'$/*2NW]^
M]SM(HX/4?<27V >,9#'=C*[S2>JP8@>B( &2/J!3J<P)GYN[/CI%^1KW$)0^
MJCV"X/P.')(RBA1,P"(L1-8V1DL=45$?SWBC%WSXC-T,,QJP0X>>$E1E!:R=
M)H;3V#5P!4PPPNC2=P'-0IRK?V+G#K!S<DQV20W#4 [UG,L[5/#^_/0ZKUM8
MGTAYC?E5LI). 5?L,OFM7F^VCZP57-0%S^=^*X2LN+Q]^)A<?_A=A5UO[,[^
M8^.+8-O KW_1?@%02P,$%     @ 98EG5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M)=B.?[>BK?TZ5>'AZYWZ?39X&,P<)V3$HS]I*%?7K<L6"LD"IY%\YIN?R79
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M>9R]7!$,NXA: +Y?<"YW;]0*]D\GW?P/4$L#!!0    ( &6)9U;OS?Y*L@8
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M;PK7'Q1?M2_;IEPI7K672T:U:F.@_[_@NA3;?##O[W;O:\?_ E!+ P04
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M 39NDP*W].?V^+LKECQGJ,D$^N=F(96 &?&O+=B5,\_N3"\3EW)+E^QZ!.N
M9.*1C6:__H(#YS=;H$[I+#Z1LZ,@>DT0O2'OLP^P1 KVR(H=LP6M,@Y+8[T4
M/L[<R'&]J\GC830L*.SB\!@5FRCB^H'3H([&[S?C]P>+H)YYQ1HMN83)"%,-
ML6=8W263ES9&_BG+X)3.XA,Y.PICT(0Q&"R#.01/+V0#I5 Y" [2AYUPVDGR
MW$2Y0;=>8A-$L#>U%T+8, @'&7R"F%"QW)05D "-C&_UJF"C$AKOGSI^MZ@M
M(.+@#A,+:!I@.Y.H81(-,GF 9@X%_1:M60'%G96,: )-+-7+F^[W-E*1,93
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M0LE :$K]!2L FY T]0D!(@7CL6YQ^H/$]<<VW-VL#!()A<*$!KH70ODRLH!
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MA]8UMZ4;.WL)0VYM*SG@;@B@:?R5)H#QB4%FQJH=U DC>J!\X^>#:A<N\7Q
M(1V49 &Q$!80@RR-$7-:B9)7I8%/5<.;\B6;5U$-]NK=JV-:*XYE;>C3O?W
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M_9=6KKL7LFYEV\I5]W$IN)E:+<#\OI F4K=?[ UV+P%>_!]02P,$%     @
M98EG5GZ59IV;*0  S8   !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RU
M/6ESVT:6?P7E36;M*HK6Y3-'E2S;,]YR8JV59*9V:ZL6!)IDQR":00.2.+]^
MW]D'",K*UNZ'Q)((=+]^_>Z+W]^Z[HM?&],7=YNF]3\\6O?]]O73I[Y:FTWI
MYVYK6OADZ;I-V<.OW>JIWW:FK.FE3?/T]/CX^=--:=M'/WY/?[OJ?OS>#7UC
M6W/5%7[8;,IN]\8T[O:'1R>/] ^?[6K=XQ^>_OC]MER9:]/_NKWJX+>G897:
M;DSKK6N+SBQ_>'1Q\OK-.3Y/#_QFS:U/?B[P) OGON O'^H?'ATC0*8Q58\K
ME/#/C;DT38,+ 1A_R)J/PI;X8OJSKOZ>S@YG693>7+KF[[;NUS\\>OFHJ,VR
M')K^L[O]FY'S/,/U*M=X^G]QR\^>OWA45(/OW49>!@@VMN5_RSO!0_+"R^,#
M+YS*"Z<$-V]$4+XM^_+'[SMW6W3X-*R&/]!1Z6T SK9X*==]!Y]:>*__\>>R
M'SI3N&7Q:6NZ$C'EB[*MBS>EMQ[_?M49;]J>/OK^:0][XIM/*UG_#:]_>F#]
MD]/B)]?V:U^\:VM3YPL\!6 #Q*<*\9O3>U=\:ZIY<78R*TZ/3T_O6>\L8.",
MUCL[L-Y%5;FA[6V[*JY<8RMK?/&?%PO?=T Q_S5U8E[O?'H]Y*+7?EM6YH='
M6T1==V,>_?B7?SEY?OS=/=">!VC/[UO]_^"^[E__I)@7?VZ/XE.W*EO[3_X%
M'[OJ;%O9;=D4%\ASMD>47E>V,7?%WUQ3(ZHOW69;MKOB\5_^Y>7IZ?%W_#']
M<O(=K=*[E>G7I@.&Z->%[7UQNW9-LRO<;6MJD"(+;VM;=K#XK( '"UE)5I:E
MGA0 ,7[JAZHRWKNN ,!MOX/UB]]L]<5TOOBMA+.L# #5;>?%AP"4?*Y+S<,+
MMZ4O4" "''#F]V;1#2#1BE.FRN,"/BZ+RW*W*=OB@V_@.+XP=V:S[>&-2HX.
M"Q!DVZ';.D_X-LLE2BO 3UEL3+<RW:SPZQ(NP]Q5Z[)=F1FL[4%6E]4?@_46
M<:Z/P#KPC(='.N/2.X%]O-W8I@0!-GBX<.\1B(5M^7-"L&L-/KAQL)(^!=>F
M^ (LS_4.\?2NLRMX'^]#$&%;./O)*[H[B^??E+_#4_WN:'1A.SSIM>LZ6-@5
MO\ 5EULS]+:">_S0 G,'FI!G(OX% #AET=^Z^PA"GKP"S&R %W'YLO&C]=-G
M KT@_-=FTP[=^.TQ>/10! Y.$LB:$  XADNL+##"PKIMMEA"!2#EF8[H3H%W
M5C/0*S>@+[=$"6V=K&3_B7]K77L$GSI; Y9;(%U0DWVQ[5P]5+T/E-6#FN[I
M(\!X60V]X=76G6MM56Q!9^=@-^70@MJOB=V6MO-]>@A9'V_Z4]6[!? FW/C+
M6?$?OS2V=L5C_'\%B\+. !V>TN]\;S9/BI/YRV\#XOAQ11Q0=(&"LNKLELCQ
MT"IPI+)'S-;&VQ5>.1%NZP!516^J=>L:MR+&+NNZ0RI')#1 ^KT(,4!#-1!1
M'=R2R!$%UF*'![ZQ)*YP0[L$8-H>",YN\!, H*S7QJO8JQQJD<$-GC +7-A8
MLX05.S>LUF 0$3@GIT?P<P>O@C:WJ&4( A"TUM4C(FJ/0!^! 00[X:L@ QK@
MS!M3=&AKX$%3PC#%7S]^NGKW^<U%\1C,@FH-N@Q.].OUU1-@5T2C:P86&""6
MWK^]."JW<@[X9[O>-6@B50G5(!WA499#4ZSP $N0(8 :.%Q9@]D#' $_(FB_
MSJ^!,;PQQ<\.J.QTGQVV( 5;1.5AJ$F"G)[MO2I7!HA/V +0"KLI2<+%U+8N
M>V+]JZ.3X]/B\<EQL2%6NBLWH$E*CR+.N]H.FV*[=AX8$D"]L;["*UN9ADCQ
M"D5H<39CNIJEGY.D&QH1JL!1:*L9 (L8N'(=8,\!I7;(EX@[L[7U@)BW[>]L
MA7H\/B&X:(;-POFRPL^[LK;5@ (:T3TCB0WH04D1Q0T=2S4D/*%_?_?3VW?_
MN(CL1 ^>W<>-S^;GW^;KGL77[Q$>8,&#"5Q]$2A)4N+;Y\7C\_DSPC8\<E2C
M-@/= "O<(<[7N[ISU;H!;5 ;N(^FW)GZ"-C#(*JK<NN'QO@G.43GJ7Q@'D_1
M/PGETBXZM]F5S<J6H"S "C$%_F_+5-\G9(4J!*C)]:(Y>N!L2^H,_H=KH00$
M=0R7RG>V-DI]NAM?B.);_CUGM.#C*94'FF'9QR3^1I7Q9:*,/[7%3R4H\N+D
M!9NX09?!MJ8C18L2KBTN5L !! P97<!?N,%/9#84CQ.+2/X4G@^JCN2GVC2X
MB!I"\L;UL&"=AW? RG92F>L2([LI629JR:NA\P-LHTB%,VU(,.,O8TAGQ?Y2
M;!B)\"=C _'!.%(-O7SZY6EYR.3$=UJ@Y/* _<#V";T;:?*C69753O[\"(B2
MML_^"BMT-V#NDG R8K_1;@L#M,!6W4.P",*;G%:@MEUFVDX13,0L4,[/P"<;
MU,LGQTH\NBIH)W*\>U$FD\2W_3.7$\UA-EQ0'S+OX-.@+I"I"/,&/NY1GR$!
M^YY6S% W+R[08((/0:OH"E,0!F;H3&4LJJ[6D.%3&5/3NJ33[BP>%*[VF^)L
M?@Y^<]/@\6";NB:;&3E]1N":.U#"""3((T+.MNP(UMHLX%<"8&'Z6V/:T763
M^%,SMG<]\#DL\TUQ^NIX_CSLB<8RX/[&=+WR[AXZ0/$I*N%'>+J5F 41&<L2
MN3T1(P=O$(&Z]Q;?PK&*=^)-)#(D*N^3D?9&EV/:A8I$B_R =T_^HL$7<AM[
MQ(.IGX<(:N .V ;&?7XN?5W^ ?[3%@RW!L7A%[CD 6Z$97YK;HN>]@6-!DJT
M"9M=?OQ'4) I-TBT .Z?C;"J<1[!N9?23EZ]F#U[_GQV=O:2 #U]-CMY=C([
M/WW)#M<^&>/[&]CXNG>@)"=%1_9(YG.,9 DMX4AS>?3H_#:*A%N@FX2HX)I/
MSLYFQ\^/9\_.SA/@)L&9!L 3W2M"D-Q 5XMM.GB5:4#8+\[.7[U\?5+09_J\
MBM9L0P#K/NSD+GO\(-#F9]PA0]')\]FKLU>S\[/GAPY)F)&H"]M@.0B,4)#!
M<#C_%67T($Z9?87A8>'35[/C9R]FQZ]>)%!?=69I.I29^>V,_IX=_W3VZOC9
M[ 78M=.GGX/V0]='H@+WB@&4;D49SJ2VA4HZ?"1$1^!#C >]']!"^%!<P<D_
M]O7LX ./T19YHL]%LVX+5.5B.(4MC@.F R%_SV)A;5BNX.\KDC,;#-WAF1I7
MHG&-'B(^HGL52Q0;<1M Q1(8' U#MA[AK9)E+9KN$8Z_N^X+"2P10A]Q_0CY
M@\4(?O9-\0R$"##GLQ?[U/$,.??9BX-7>M!0Q)5*CET*J9>L0V%MCTQ0,>AJ
M?*+3!H]W-9V>- MY;7^]N+B:%[^*= 5W"YTE5[/5KZ'161;Z(J,;U;U/K1.U
M E0"IW&NN)*&NWRPDP^>;K0-JLV;LA'K.Q4[UON!O'1B)74-T#*@8)G/%!6"
M@J]9)/<=82S'%"!C*YKH07KBX%XJC1#I>(R^ /3VX 5Q_,?W,XU@@'?M:M:@
M7>$HZ@G6 <@=NVB,+JP+9<H9D7WRXCM0H< 1S2Q%-.*7UUH:0'<-=U.A$UWV
M?6<70U_BVB(;IN\ P;>M%<<H8$F,;R"H;6? %:S!B-IBF,(G>VJ<1;'2!L7B
M&O+4 ?ME0[1(V0NX&<#<[=J"Z_--\6I^$@0JNFH+%$INN:30YPJ\3]\'FNAW
MT0"4<,1!T^@;4&'GF:A6;# W<L"H7-@& Y=5 ]#;)5+*50>T!Q+G[V4',J.G
MDY)A!$;16C2R8*$NAC]!/_,#476\8R75':[!<@OC<&!7]R06/>#FQC!RZ"K8
M/=SC\Y3[.#8/_G:Q,BUH>')Y*_21^5V*YL"=DP;"@ I"=@'.3!J+"((CD^6P
M<C. AX]F=5G_/OB>@01K%@Z-7HZRYK*T'47@PG%SC@Y4'0\-,L-FGC]'S+PN
MHWR1X2PCMTD$*LR]O#JTO1^+EQ(Y&<_D[T]#@'G9-&S6J^P3$A=A%[5->G,&
M(Y1M*?B/(+,HXL3 ._!1-G0;>$:^ZQ1QWCSHK/@01E&09W(- -*%I+=/ \K
M$)OR"Q!VV!V/ 3PQ;+82S4*%6U+6@E &@#G2;*R9V2-C"8"O*FM96:JV'EE$
MLDT<0%TE4F/O'=X%S_AG#JZ:9@JZ(+KJH5,SEY\C=I&P[$\1*0L,Z]Z8:&SX
M#$$D\3'6B.+UNV+M;E$AHV#N!XSTD8N+6-[!Z0%Q()T[MQFO,P?#PW-X@WYX
M%W2?SZ*C:JA[8KJU7:V!,AL+3R,Q 93"@IH;DK")9F\ #+#<&+>$3XRI;CA?
M"VS64 S=P9%!^ ,440/[/$B+H>P-* 9FD K$D.V+SOHO>)$.(YFZ<Z7'&B](
M\7;"-JI'.(6!#X:RUSN11?\ )(KKB5N!.-N08 G7CJK!]@-SST4#ILRP8A]:
MU0W>FMT8O@-SAXH#-&3-LO (WA]0C%+:P.\'#5O7$\T P\-B0$J8-G&<*VM)
M&P0Y,B_>HYS[#<Y!Y/H^ /D!@.R&S=YU+D&RN%N?"NP57"6!C:(/E[NAY39
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MI%@MZ_[/)6;M#'O:9%9F/A4WYXD5B(5M"T)P%<(W(7@6>B+B*28 LIY$T*C
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MB6FU-8/A'H$4$J/ EIV+W\-3A FYE"EHFOV1]'$4%DG$R?'_OP8C8@PSF2R
MLO\]FL*\J05.&Y?OLB0IJTL^9"&1*[?T#=>F/E)5FHCJT#*2OI_Y+8FCH0;)
M6R$#L(S1I/BSY].@/"-I8I$0]TU&UQ'IH8#!OLVJW]<SE 66@O5Q00^10A@B
MGQCXDY?/WR\VN;E/FH'PM/! ^$S'8@8>/4@$!IO _3W<1 VZ%&%*ON.Z<QR:
M8#WU(?TN5W7KR#L0 ^OB^E?ZY.@87(0I"O;%8^EB.W[VY'6Z%6)&VW=TN@4E
M//5O>ZUQEWFUR&7PE/=&<.E@GXXUVJ$1*RZI\N1 &?D'P?Q+2\;"W])4R(3O
M%-VFY\?/YRF"2 V$QB^>RI[XU O0)OP=J#PD(;B!V/X7O&MXE&2+6$Q<0KS!
MKN/QU\/Z\8Q\H6EV2+AUD0N:R P2'?+5KTN83WU-^=/D*^;IFPTO0562E=7V
M_&WSX:^8_<+OG7]]P5]1'Q__\?LMR(V?R@[P@/4J2WCU>/[BV2,N]M!?>K>E
M+ZQ?N!ZNGWY<FQ)X'A^ SY<.>$I^P0TP;$;@_?@_4$L#!!0    ( &6)9U9'
M%#'L>0H  /8:   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK5E_;]LX
M$OTJA+=8; '7B9VT3=LD0)*V>UGT1]#T]K!WN#]H:6QQ*Y$J2<7)??I[,Y1D
MV7&S+>Z [<:6R.',FYDW,_3QRODOH2"*ZK8J;3@9%3'6+_?V0E90I</$U63Q
M9N%\I2.^^N5>J#WI7#95Y=YL?__97J6-'9T>R[,K?WKLFE@:2U=>A::JM+\[
MI]*M3D;34??@DUD6D1_LG1[7>DG7%/]>7WE\V^NEY*8B&XRSRM/B9'0V?7E^
MR.MEP>^&5F'P6;$E<^>^\)?+_&2TSPI125ED"1I_;NB"RI(%08VOK<Q1?R1O
M''[NI+\5VV'+7 >Z<.4_3!Z+D]'12.6TT$T9/[G5WZBUYRG+RUP9Y/]JU:[=
M'ZFL"=%5[69H4!F;_NK;%H?OV3!K-\Q$[W20:/E:1WUZ[-U*>5X-:?Q!3)7=
M4,Y8=LIU]'AKL"^>OC-?&Y.;>*>TS=6OSMBENG V(V^/]R(.X&5[62OL/ F;
M?4/8=*;>.QN+H-[8G/)- 7O0K%=OUJEW/GM0XFO*)NI@.E:S_=GL 7D'O;D'
M(N_@&_(^^J6VYC^:(V+,A@97FERG  $ 5YX"V9@>N(5Z:ZRVF=&ENL9#0C3&
MH/YU-@_1(Y[^O0NBI,#A;@4XQUZ&6F=T,JKY+']#H].??YH^VW_U@'F'O7F'
M#TG_46\^+&RF)NH!@>IS04BJS%6UMG?\(NOAI%PM>N3"&KE"WY":$UD%XVOM
ML4X'\ 'OCH6.^!]!ODA$(I0ERXS&-C@I**V6KCV'%1BK56&R0I9059<X)8@
MD%/9^IA]B!,(9[,! 0_#0F?=J]+HN2E---AIK&RVG.M\;N,#\9IY$P!,"!/U
M7EOP%%L"0X+(Q7_Y4.F??SJ:39^_PDN1>Z>B>\@$!595,+LD':)REM0=:3Q9
M1/(BEK&4#SOA!(#* #_*)^JCA7X><$R/.%NF+\;J.C,EW<)'\"%#?4V5;;P
M$<5W>!Z,8+%BW>#+QHKO6"M&+&&WL?*70*0^.*AU\'@B,=#Y2\/,S-2]&S(=
M"F6)\E:BV$,WJ .U8 ALDT8]:+4W7!GPU^5-%B'!YA).[)S!5IAV]62Z/QNS
MEBLP>N>\;?&\ZF"<(FDN4N@V@]/XY2ZOB<KZ1IM2STO"OEA@SP-^08C\==0/
MW=3Z@./'.E48$+PW&=9[J"Y!8O/[63#GH XU3C*L%Z.Y:( -(DGC]=!LWH^<
MK,BS&ET:T )[VB3(=&TB3NPDL(N O0LL'!%;>-<L"W;&#5N)L^IF7II,$:(
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M($Q?GA?@_<*!8=HO?$#_4]?I?P%02P,$%     @ 98EG5C_+HXKW @  PP8
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MTE#3<\N,_C*H+(#.5U*:G6 O:/Y;L]]02P,$%     @ 98EG5EU6U9^C#0
MMRL  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULS5KY;]PV%OY7"+?;
MM0%E/(?/Y@"<H]@LVL:(O;M8+/8'CD3/L)'$"2G9GO[U^[U'2J(T1]($;?>'
MQ".)?'SG]P[IV8.Q']Q2J4H\%GGIGA\LJVKU_?&Q2Y>JD&YD5JK$DSMC"UGA
MTBZ.W<HJF?&F(C^>CL=GQX74Y<&+9WSOVKYX9NHJUZ6ZML+512'M^J7*S</S
M@\E!<^.]7BPKNG'\XME*+M2-JOZQNK:X.FZI9+I0I=.F%%;=/3^XFGS_\H36
M\X)_:O7@HM^"))D;\X$NWF;/#\;$D,I56A$%B3_WZI7*<R($-CX&F@?MD;0Q
M_MU0_X%EARQSZ=0KD_]+9]7R^<'%@<C4G:SSZKUY^)L*\IP2O=3DCO\7#W[M
M#(O3VE6F")O!0:%+_U<^!CU$&R[&.S9,PX8I\^T/8BY?RTJ^>&;-@["T&M3H
M!XO*N\&<+LDH-Y7%4XU]U8OW*I>5RL2UM-5:W%I9.LGZ<L^.*]"G5<=IH/72
MTYKNH#69BI],62V=>%-F*NL3. 9C+7?3AKN7T[T47ZMT)&:31$S'T^D>>K-6
MVAG3F_UF:<5_KN:NLKCZ[S;!/=F3[60I<+YW*YFJYP>(#*?LO3IX\=TWD[/Q
MTSU,G[1,G^RC_N+]FQ^O;M^\%M=7[V__+6[?7_U\<_7J]NV[GV^V<;J7UG9.
M)].1V*.9*R?,G8 I5#%7MC''.!%RM;+F42,T5+X6DY/1N?@++:V62B#^727+
M3)<+D<J5KF0NX,SIAV;!*U.L9+D6#]*)I<HS,5^+MUBPK$?B72G^+LL:("$F
M,SX-9\Y.DHN+R^3B[$*XI03S1.E'M9#I6MRD.E>/  D6JJSH5)GG^[GH[^WS
M(!Z458",C[6VBN^7IGQB@Y(0A\9JZ(D969H\4]:-Q.VR=DE#0#MLJ82,UP#Z
MYDY]K,&AJ,R&C"/QNK;$*NEGK:1U0E$@;>A^VN@$HK$M>AI=U39= JBR@8&^
M%6>P4*'SG. PP?5I=^UI?2LFHW&[!+I<*4;-?)V0QG1Y#]8-6+ZSI@B28J>
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M* "V=:53,$DE5)U[?Z$+4*7;F<KA> @J['*@9'3F"'%T^4LH7;(0*YFHB0G
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M=(;GO2S0%A^\Q;7M%U8'8/)G]GA!1=DR$;<:#-=I< 6*J*YEZ!-@% 8%\P"
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MO?(?8W;+_2>M/TF[H!?ON;K#UO'H_/3 =T3-1656_&GFW%25*?CG4DED$5J
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M-=,4SZ%3M:5F5<P\":2X]B/VS%QO=L8A>3HH_71)F"EG:O@.)I9;.8=IM4E
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MM #S*ZUM^T('='_^N?DO4$L#!!0    ( &6)9U;O]:[Q[PX  ,DP   9
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M&7U<"PY*PP7P?*E (>X+'E#_WPL7_P%02P,$%     @ 98EG5C+GND97"P
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M8?Q\].H)?2^ROA=/2?^F/Y[<O5^W\Z'H2Q7WMZ?CT47_F?A<BX]R)<:3B/M
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M^98Z6@3L3&J70DDAV4D9ZZ+5\( MF9IQ,B;76"FZZ76PB?,V'MROC(:3W*\
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M'B?NFF]^_IQI?V9*0:05ZG\RJ,365?LG&6R(7_9RX7?QQ?H&CJH #)CK::=
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M?E34.LK:450<(#PVLRIX\$(T;=ZT!6(Y=PT;XP@846D'P*K-E*$$.ZF2::>
M&Z8TOXH44)^)"/!E_@;AAOD\E@%U^4<N8T?#J>K'A'6=E#+)8MDH_ZVCK8&4
MZ?,J4B1^V<W(3E4/WAT#)*YTE=W7*_.I]3+:OJE'/S/H%Y?>VIUJ<XUO72%K
M(/*/\G+0_4AEXF.W/VA=/0D= *O[&Q7%+YIAOWRV[NEF2-=PAQT/T+8GQ^RH
MBR3]L3'%"!-HPX,^/5IWZ,:'"XUBKRG3<-@8BWB@5;<NY2.!YK!HOJ @2O_
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M!<<);J)^E.^C,O4<R,"=/4> BY'NOAO 2+CS&X3#L+\\L?$P%X[;'Q /]VX
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MX*'.K/QHE;0Y'H _D5+BWD!QG:.*^P+;0'-TZU;_.*!A--'59S&WBN*!&@S
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M,"YX;6RU66ES&[D1_2LH[L:1JVA>DFRM=511Q]8ZY744T=Z-*Y4/X Q(PL(
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MTWHNK+SB3HXW4L%_S)%UIU@7M<\.-.0)*I*BI2#3*E@-I-2*73AX5MV/5?2
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MXZ<?=]: *L('X/.- U&77W""\#VI+_\/4$L#!!0    ( &6)9U9=QD6]7 ,
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M->K?7 >@FQ>CV5A5^2F]499FOA<+>F11NPOT/U?*'C;.0/MLSWX!4$L#!!0
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M($Y>]R7_ISY-56%)X6HT'?0(7#.@N_)E)6O7/0_O4^*IT^%EK@1'Y.&H.\"
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MEA$$%U7%\\NJ9HZ]ES'YNUJ4*X%?-4>MNW?5"7L?,;<0\EU]B?2.J)@<]?S
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MLR2=(G$43)Y5>AW827R-F=+.$08[:C+@]'-QX<&2B#4WA4M&FXMD&HS/CF5
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M0:\W5'8!_5]+DL%N8#?HWX/S?P%02P,$%     @ 98EG5L"P,8Z8"0  BVH
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MMQ:IB^*THF<++CC0_MY:/!FAE<8?0?$74$L#!!0    ( &6)9U8-E0=?*@(
M ",%   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;*U446O;,!#^*T(K
MHX6MLN74+9EM:!/&"AV$I-T>QAX4^Q*+RI8GR7'[[R?)CDE9.@K;BZ63[OON
MOI/ODDZJ1UT"&/14B5JGN#2FF1*B\Q(JIL]E [6]V4A5,6--M26Z4< *#ZH$
MH4$0DXKQ&F>)/UNH+)&M$;R&A4*ZK2JFGF] R"[%(=X?+/FV-.Z 9$G#MK "
M\] LE+7(R%+P"FK-98T4;%)\'4YGD?/W#M\X=/I@CYR2M92/SK@M4ARXA$!
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M185ZFA>R6&1_T:Y(:QHHW C)DB)8E2"A:?X??R\>Q%Z JFA]@%T$V*<&=(J
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MDPM=2$773'<3Q:NVO5QQI9O5=ICK#Q 4QD#OKSE7KQ-SP/!)$_\+4$L#!!0
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MUZR))HVNNP]F'T:X;2<"@S-#J_]^9X#2TB):0U]:!NX]G'OF#-RAOV#\1<P
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M]7BT7DBVK2:,=TQ*5E27&X(SPC5 /5\Q)A\7>FC9#JF7_P-02P,$%     @
M98EG5OM\P!F' @  W08  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
ME95=;YLP%(;_BL6JJ96V0B A24>0VJ;=>C&IZL>F73IP"%8-9K8)W7[]C@UE
MV4H2]09L[/=]WL/'(6J$?%(Y@";/!2_5PLFUKLY<5R4Y%%2=B@I*7,F$+*C&
MJ5R[JI) 4RLJN.M[7N@6E)5.'-EKMS*.1*TY*^%6$E47!96_+H"+9N&,G)<+
M=VR=:W/!C:.*KN$>]&-U*W'F]BXI*Z!43)1$0K9PSD=G%W.SWV[XQJ!16V-B
M*ED)\60F-^G"\4P@X)!HXT#QM(%+X-P888R?G:?3(XUP>_SB?FUKQUI65,&E
MX-]9JO.%,W-("AFMN;X3S1?HZID8OT1P98^DZ?9Z#DEJI471B3%!P<KV3)^[
M^[ E\/T= K\3^#9W"[(IEU33.)*B(=+L1C<SL*5:-89CI7DH]UKB*D.=CC\+
MD3:,<T++E-R4FI9KMN) SI4"K<A'<J4TP^(A)5FM:PF$%D)J]IO:FPK/^'8H
M("(C[*^8MN+C)6C*N#HA1[A*'G)1*\2HR-68W/#=I$MYT:;T=Z1<0G)*@M$'
MXGN^3Q[OE^3XZ.1?&Q<+[ZOW^^I]ZQOL\/T!5)*K,L7J$ '%"J3!# 5LC<;#
M1N;3.5,536#AX+>A0&[ B=^_&X7>ISTQ@SYFL,\]QJJ#H4RM:FI5YNO;Q..1
M%T;N9H U[EGC0ZSQ$*M5A=LL+Q@-LR8]:W*(-1EB3098N^H*>U9XB!4.L<(W
ML*8]:WJ(-1UB3=_ FO6LV5[60P[8C#,-<H@X>T7TO7&P SGOD?/]2*$I'Z+-
M7[^/WF3^_TOB;G4KT_B_4KEFI2(<,M1YIU-\_+)MINU$B\HVL)70V [M,,?_
M#TBS =<S(?3+Q/3$_H\6_P%02P,$%     @ 98EG5M&)F(M>#@  5.0  !D
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M4=3;.\T WXORS_73OOL/4$L#!!0    ( &6)9U8@(;(%P (  "D'   9
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M:W-H965T<R]S:&5E=#4P+GAM;+6=6V_C-AJ&_PKA7>RV0#;6T8=I$B 3'CI
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MFTA2U#(J+DBR*F>Y2O_</TULU&+%N:H%":,;V& -JSO]EYLH]M;_KOHONTI
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M0VD"13,5H'W5V.ZK;N]'MS,>:3XC/U8_BR>I.KHI]II<>Q8HC4)I#$KC4)I
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M\/I<-1/\A *A 3B^YESM.OH.W7Z4S?\#4$L#!!0    ( &6)9U9^.DJSQ@0
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M=>=2Y1R1U93K5<KUK,K]"3S368T5^:Q),3M!#VV!\,:\9@=V"Z!*1"@K\ML
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MM:7X48Q.QP_JM-S3M Q*L./Y=5J-T;2EM=]VP,9%\VE:9TZ]93,G<N/6;.;
M.CNCF8;N5^P'X'Y# )MW!.\K:J<GY+*Y6M!Z2?//*'RAV<JK$_P5&P2XWR'
MYBW"N4/UK7FYE#\.4ANJ%UKLEUPOJ19=2NV8_WXG INW(I/EDN$E$AC<$<$2
MPI,8?$?IYCAWC>0+X>" O-<?^-IPU\T&L%M/5=W(A?JL8K+J[Q.Z0& ?G-)E
MF"WSXU$.8KHAHCB9JIY61["3_."Q]GP*;\+B('4O4YSK?D%,+D\X2/%"2CJ=
M0/8A*XY*BQM!U_E9X",5@F;YY0JC.6;*0+Y?4"I>;U0#U8'U^']02P,$%
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M/#[RB.K,LQL8V3@[F4N#YN2Z%?YO0-D 7%](:38#N\'P!\O^ E!+ P04
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M8T7?%&C\ GJ_TMH]#?P&W5=*_A]02P,$%     @ 98EG5C.L#DX] P  5 P
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MS9V0^E49I4V]K6<XLGN&/9*3#AOGBSJ:L(CF]7E]<\WD)G.)=XP8L5>N=V>
M6H]0&H72 BB-06D<2A,HFMD]6J=S=,C9DR.H@PFE^5 :A=("*(U!:1Q*$RB:
M*>_6P1S99T^^RET*F8;J-/^RX>TL!FI>0FD^E$9WM*"S&OE^VER3R:0>I]XI
M:JAO":5QU$$*5+5,/;>6Y<AN6?;-Q:&S*Z$T'TJC.]KM[47: F@]&)3&WWU4
M E4/0Z?CUJD<VYW*/EGW:Y?R6[-N>^7ZRAY*\Z$T"J4%4!J#TCB4)E TLWNT
M#N;XD [F&.I@0FD^E$:AM !*8U :A]($BF;*NW4PQW8'\]U9MYW;6]E0JQ-*
MHSM:L$E(G>%+1NJ.WLR[H15C4!K'':9 5<S4=&MRCNTF9\_,VT[KK62H:0FE
MT1WM-GX[\X;6@T%I_-U')5#U6.GTI)Q+6?EA%5Y=I+*8R1N9)"6)\F56Z?QB
M8ZLZRS[H]X]\O'8')Z^VWS@??:=C.W4^LGK[28N_NEB$,_DY+&9Q5BJA/ZBB
MAL>GXP$IXME\_:7*%Y<#=:6YSZLJ3^N/<QE.9:%W4+]_R//JY8LN0,]YKP_G
MZO]02P,$%     @ 98EG5IT.V[60 P  O@T  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3DN>&ULK5?;CILZ%/T5BU95*YT.U]RF"5(36IT^5!HUT]-G#^P$
M5+!3VR3IWQ_;, P!0Z,J+PF&M9;7WKYM+T^4_>0I@$#G(B=\9:5"'.YMF\<I
M%)C?T0,0^65'68&%;+*]S0\,<*))16Y[CC.U"YP1*USJ=P\L7-)2Y!F!!X9X
M6128_5Y#3D\KR[6>7WS+]JE0+^QP><![V(+X?GA@LF4W*DE6 .$9)8C!;F5]
M=.\CUU<$C?@O@Q-O/2,5RA.E/U7C2[*R'.4(<HB%DL#R[P@;R'.E)'W\JD6M
MID]%;#\_JW_6P<M@GC"'#<U_9(E(5];<0@GL<)F+;_3T+]0!391>3'.N?]&I
MQCH6BDLN:%&3I8,B(]4_/M>):!'<Z0#!JPE>EQ ,$/R:X%]+"&I"H#-3A:+S
M$&&!PR6C)\046JJI!YU,S9;A9T2-^U8P^363/!%^(3$M #WB,W#T'FWEO$K*
M'!#=H0TM#I0 $5RUUD!@EPDDIQJZ(+V-0. LY^\D_?LV0F]?OT.O44;08TI+
MCDG"E[:03E5_=ER[6E>NO %7KH>^4B)2CCZ1!))+ 5N&V,3I/<>Y]D85(XCO
MD._^@SS'\PR&-M?370,]NI[NC$3C-Z/F:SU_0&]3,B8'!L%9KG\.]Z8,5PJ!
M64%M)_?\@&-867*_X,".8(5O7KE3YX,I.[<4BVXD=I&YH,E<,*8>?H8$&,Y-
M":N(,TU4V^4QE$-U;&?ACXAH#''A=]+XG8SZW0HLP.2VHDU;/04=MWW$I..V
MCW@_\<U^IXW?Z:C?1RIP+C<N/3]-OJ=_]-U'='WW$8.^9XWOV>B*BF 'TG-B
MLCR[Y4JZI5AT([&+C,V;C,W_=B7-^^/C.OYBVAEH$\Q;S-W.:!M@_F(VL*X6
MC?O%WZVKA<'4?-+QM#&@O&#F=9R;M/P!XZ[S<F([5RRQ9&3"U@*=S$J#G2B,
MN$G06DM5'"9<X#I#D;1J#W<TDDV*R5Z6$+)8$/B,V,"0U"KM[EV_'TP?Y7>G
MD@&S&-@X7.\E"N_:*(XX+W%5S^:RHL8D-@?D]0-R%D[WN#'!)H'7G64&6. X
MLX&P7DH,=_0<KJ:9T;W?.^2Z6[@!TMW##9#^)FZW"ML"V%Y?$#B*:4E$5?LU
M;YM+R$==>G?>K]7E1!?,+S+5S>8K9ON,<)3#3DHZ=S-Y*++JLE U!#WH\OF)
M"EF,Z\=47K" *8#\OJ-4/#=4!\V5+?P?4$L#!!0    ( &6)9U9;4X\#.@0
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MA,?R>[E\(.@JNWB:42%HG#TN <M&)A60[^>4BMT@7:"\'9W\!U!+ P04
M" !EB6=6CFO,%%P.  !VNP  &0   'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6RUW5MSHT8"!>"_TJ7-;LU4>2UNNDUL5WG,G9[$-=YL'E+[@*6V1 T"!9 \
MKMH?OR!AH1:MELB>>4C&%_IKR?@8!$=P\YIFW_(%8P7YOHR3_+:W*(K5IWX_
MGR[8,LROTQ5+RN^\I-DR+,I/LWD_7V4LG&T'+>.^IBC#_C*,DM[=S?9KC]G=
M3;HNXBAACQG)U\MEF+U]9G'Z>MM3>^]?^!K-%T7UA?[=S2J<LR=6_+9ZS,K/
M^GME%BU9DD=I0C+V<MN[5S_1@58-V"[Q[XB]Y@<?D^JI/*?IM^H3;W;;4ZI'
MQ&(V+2HB+/_9L <6QY54/HX_:[2WG[,:>/CQNVYOGWSY9)[#G#VD\>_1K%C<
M]L8],F,OX3HNOJ:O+JN?T*#RIFF<;_]/7G?+CK0>F:[S(EW6@\M'L(R2W;_A
M]_H'<3! -4X,T.H!VJ4#]'J ?ND HQY@' \8G!@PJ <,+ATPK <,CP:,E1,#
M1O6 T:7/85P/&%\Z8%(/F!P/T$^M..5]S2F7SJ'N5_;%:UM]7]WJ=GWW=[]8
MV]]*,RS"NYLL?259M7SI51]L?[6WX\M?QBBI4OA49.5WHW)<<?>5Q6'!9N0Q
MS(HW\J\L3/)PFX^<?+B?S:+JPS F7K(+?/G91_+!9$48Q?E'\D_RVY-)/OST
M\:9?E ^F(OO3>F)[-[%V8F*5?$F38I$3*YFQF6"\<V:\)@'ZY4]A_Z/0WG\4
MGS6I^$NZN2:J<D4T1=,$#^A!/OR)K<KAVLGAIGSXK]/BFFC;X>I8,-RZ8+@R
M.#G<E@^WV7,Y^_CD@W?DPTTVO2:Z>G*X>_EP53#<NWRX(ACNRX=_"=]DZRV0
MC_;#I%SM^LG'3L]-GI7#MS]X=2+Y)=;W>=:WGMXUS^0/6BY*O((M\_\('N?G
MG6N(W6IGX%.^"J?LME=N[7.6;5CO[A]_4X?*SZ*H(#$3B5E(S$9B#A)SD9B'
MQ'PD%B Q"L*XW!K[W!HR_>XA72[+D#X5Z?3;%7E:A.445\3+\[5PX_A9JG5-
M*Q(SD9B%Q&PDYNRPX1:K7NIL[E1#U8WQ>#"\Z6\.HRA84M?&@[$Q-O@E/>0#
M])%8@,0H".-R-MCG;/ 7<O;KNLB+,)E%R5P4-BG9-6Q(S$1B%A*SD9@SN#AL
M@B5/A WY 'TD%B Q"L*XL WW81M*P_:^,[K:[HRNPK?P.6:B@$F9K@%#8B82
MLY"8C<2<'38ZB(UR%*SV$A-MI!F*<K2@AWQ</A(+D!@%85RN1OM<C:2Y^CW-
MOI6;*O(0KJ(BC$6)D@)=$X7$3"1F(3$;B3FC5E[4@:8HK;RXR%D]).8CL0")
M41#&A6^\#]]8&K['C+VP+"LW:_EN)[+<NI%-&*^%6S:IU36'2,Q$8A82LY&8
ML\/&AUNVZS*$ZE$*+UO,0SXT'XD%2(R","Y?DWV^)M)\/:5EN)(B)7]\8<MG
ME@D/5DJ)KK%"8B82LY"8C<0<).8B,0^)^4@L0&(4A'$1597FK*'R@TXSU# H
MNE#-A&H65+.AF@/57*CF034?J@50C:(T/L0'I_Y5Z9;680G+PIB$R8R$LV64
M1'F1A54KAK#O*Y;D+!<F6*IV3C!2,Z&:!=5LJ.;4VN$+3'TL>GTI6-!0! MZ
M@@4U7;"@#WTB 52C*(V/E-9$2I-&RDNB(BHCM<JB9!JMJG MTW52"',DI3KG
M"*F94,V":C94<Z":"]4\J.9#M0"JT5KC#I<-!_P?'SZ232%&E9ZW+R-9L/(1
M%*3<M D/T<C'=\XAM/H"U:Q:JW8[#@YS'!WCL*%S.E#-A6H>5/.A6@#5Z+DU
MSV>K*:VH\M;*_6P3)E.6DR@A25HPV3D^.=4Y9M#."E2S:HW;D1J(=KELZ+R.
MVFZ::*.!<)^PO>1P*-PG%)571L*=0FC?!*I1E,:GI*F<J/+.R4&[Y&#'\#F,
MJ^P(HS)H[[*/5,%/_4$^<^<80.LD4,V&:@Y4<U5!ZV0BSA.T=0+5 JA&41J?
MN:9YHLJK)_?3:;9F,_*^]R>,V;"UVD:B4[0/\KDZIPS:*8%J-E1SH)HK6%WZ
M1!@R: 4%J@50C:(T/F1-#465]U >LW09Y7F:O>WV_J*3=64YU'GG#UI(@6J6
MVBY^:*IHC\F&SNM -1>J>5#-AVH!5*,HC0]D4TU1Y=T4DST7Y28O+[+UDB7%
M%?D2%NLL*MZ(>>K@![2@ M5,J&:=^='=K^>[-Y%5;^0:"K>-T%X*5'.AF@?5
M?*@60#6*TOB\-E475=YU^<I6X5N55)*^D"B9E?%ELX3EXO-NT-(+5#-K[?Q6
MSX+.:T,U!ZJY4,V#:CY4"Z :16G\F\";:HLF/>M^]*:%PZ.:5R1APA>2M<@=
M>--%!]X>Y'-W31U4LZ":#=4<J.9>O+X\Z+P^5 N@&D5I?.J:+HHF[Z+PJ<O8
ME$6;4V<2Y%37#2%4,Z&:!=5LJ.;4&G?04UA @4[K034?J@50C:(T/I%-E463
M5UE:/6SR7W)TP$<83FBK!:J94,V":C94<Z":"]4\J.9#M0"J493&)[AIOF@_
MZEHP&K02 ]5,J&9!-1NJ.5#-A6H>5/.A6@#5*$KC0]Q4;#1<Q49.=8XMM&(#
MU2RH9D,U1VMW9EJ[Q.U%QJ)^AR=84%6$I6SH<PB@&D5I?(2:_HTF[]]<T@70
MVA6.@;!Q(Y^K<RJ@C1NH9D,U!ZJY@M6EBP,$+=Q M0"J493&AZPIW&CRPHU7
MI-/%6OJF7;G0>?,$+>5 -0NJV5#-@6HN5/.@F@_5 JA&41J?UJ:YHXU^U$M#
M:),'JIE0S8)J-E1SH)H+U3RHYD.U *I1E,:'N&G[:/+*RE^ZEJ'<[)Q?:.$'
MJEE0S89J#E1SH9H'U7RH%M0:M]]OC,>3\7#,[_A3U+Q\-IMFCR9O]GC)ICIY
MDKV1U3J;+L)<W(N5*YW3".WT0#4+JME0S=':[:6AJ+SDU@MR1PE$"WH"416]
M \R'/I$ JE&4QE_(OBGBZ/(BSN';IJ:[*QWN+[G&LBD3OZM>CG9-%%0SH9H%
MU6RHYD U%ZIYM::JAP=HKU5C=!1-Z*P!5*,HC8]FT];1Y6V=IVD4L^_DL=SE
M7(:'!8&++MXFQSM'%-K?@6H65+.AF@/57*CF034?J@50C:(T/LA-R4?7?M!Q
M(!W:\X%J)E2SH)H-U1RHYD(U#ZKY4"V :A2E\2$^N.63_ HW?Z&Q+A<[IQ=[
MNR?L_9ZP-WS26Z_K=.&E/1SHO"Y4\Z":#]4"J$91&I_,IKRCR\L[CUDZ96R6
MDY<L79*G,&;5&[U^*1.:DZ_2CKL<[AQ0:)4'JEE0S:ZU2P**G->%:AY4\Z%:
M -4H2N,#VE2#='DUZ(([:>CMJLE0^-;&!_E<G5,&K09!-1NJ.5#-%:PO77R0
M%CJO#]4"J$91&I^RIANDG[L/U/M)D'R__1-&K7V%E_JH>3MKT/8/5+.@F@W5
M'*CF"E;80'B>PX/.ZT.U *I1E,9GK6GVZ/)K\M"HB.;;&W43FYV(V:@=L['P
MPE?RN3JG#%K/@6HV5'.@FJNW+RDT%(<,VKR!:@%4HRB-#UG3O-'/7"PFS&:;
M,/M&[O.<%>2QWKJ1^WG&V/9Z'IW/B4!K.5#-A&H65+.AF@/57*CF034?J@50
MC:(T/MQ-=4>?_*AS(M V#U0SH9H%U6RHYD U%ZIY4,V':@%4HRB-"['1E(<,
M>7GH[%7_Y>.[9A6JF5#-@FHV5'.@F@O5/*CF&\+6D:(-C^Y@'D"GI2B-CV%3
M%#*Z7-;GHE.3AN!^1<(7I_*I.V<.6OR!:C94<Z":"]4\J.9#M0"J493&![,I
M_ACRJ_MLKQ1K?2]?MB;S_^=UJWR:SIM1: T(JEE0S89J#E1SH9H'U7RH%D U
MBM+X2#<U(.-'7>['@+:!H)H)U2RH9D,U!ZJY4,V#:CY4"Z :16E\B)O&D'&V
M,73A+17D4.?0MGLSXGM'F=!Y+:AF0S4'JKE0S8-J/E0+H!I%:7P@FX:0(6\(
M/6;LA94[PK/]>\_"C&S">"T^JH2L;3S4VI@_9* HZG$DH54AJ&9#-0>JN5#-
M@VH^5 N@&D5I?"2;.I$AKQ/QKUU-ED^S:%7MZ K;#G*L<R2AO2.H9D$U&ZHY
M9U9IL:@.0LPS-B]?PAQ>PH+<;^^?35;Q.B?54KO[:1/VYSJ,29$25?E[U2D[
M"\RB330K_XH_OY$/4?21_*2JY9]2\B$KOUM]?;VJM(I)6+@]<_"Z2&-&\NJR
M&A]_)JLLW0)7Y3)AL;L:(V'5F_S):[J.9^<? ?M>=<')3T17E:ORKWCUW[7P
MSQ+TFDI0S8=J 52C*(W_L]0TKPQY\XH_UGUX-Q<R39,-RZIO1M4!M>WOE/B/
M5;N:I4V4P4B9C(Z/?D.K65#-@FHV5'.@F@O5/*CF0[4 JE&4QD>UZ6\9YZZ<
MQ.5QNKN0TG8'7YC*]E5GMJE46Z>DH+TKJ&9!-1NJ.5#-A6H>5/.A6@#5*$KC
M0]GTK@SY)9-VH<RK ];E#EW]:GNWNR<,I>"68Q-%=-?E!_G$G6,);5)!-1NJ
M.5#-A6H>5/.A6@#5*$KC8CEHFE0#>9-*]II&E$LYU_7U-E0SH9H%U6RHYM0:
M]SY85?A6*A<ZL0?5?*@60#6*TOA<-M6J@;Q:]9A%4U9="6WW<I)\B!)BIG$<
M9GGSU8_"A$*OOP353*AF034;JCF#=L]-58^C"2U7034?J@50C:(T/II-N6H@
M+U<UF\ST8)/)';FLKV 8SH6GD>1^YX1"6U50S8)J-E1S:DU5N/-OK8Q"VU)0
MS8=J 52C*&V7T7Z^8*PPPR*\NUFR;,X>6!Q7!U[+R-WVJN3NOTHR]E+=FOO3
MO=;KM[[NJ)\\M?IZOV'N;E9E4+^$V3Q*<A*SEY)4KD>#'LFB^6+_29&NRM^6
M'GE.BR)=;C]<L'#&LFJ!\OLO:5J\?U)-\)IFW[8/^^Y_4$L#!!0    ( &6)
M9U:!,=)V] ,  .0-   9    >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;*U7
M;6_;-A#^*X16#"V01B^693NS#=A1A@WH2U OZX=A'VB)MKA(I$I2=O;O>Z1D
M179HQ2CZQ:;(YQ[QN3L=C],]%X\R(T2AIR)G<N9D2I4WKBN3C!187O.2,%C9
M<%%@!8]BZ\I2$)P:HR)W \^+W )3YLRG9NY>S*>\4CEEY%X@614%%O\O2<[W
M,\=W#A-?Z#93>L*=3TN\)2NB'LI[ 4]NRY+2@C!).4.";&;.PK^)_4 ;&,3?
ME.QE9XRTE#7GC_KASW3F>'I')">)TA08_G;DEN2Y9H)]?&M(G?:=VK [/K#_
M;L2#F#66Y);G7VFJLIDS=E!*-KC*U1>^_X,T@H::+^&Y-+]HWV ]!R655+QH
MC&$'!67U/WYJ'-$Q\*,S!D%C$)P:A&<,!HW!X%*#L#$(C6=J*<8/,59X/A5\
MCX1& YL>&&<::Y!/F8[[2@E8I6"GYA^XE.B>"+3*L"#H/5I!9J553A#?()41
MB&W"64)SBDV<8!;<3!.$68I2FE>*I"C7)"602$/R-B8*TUR^ [J'58S>OGF'
MWB"W7I6(,O3 J))7, GCOS)>26"34U>!(+TM-VDVOZPW'YS9O!^@CYRI3*([
MEI+TF, %3[3N" [N6 :]C#%)KM' OT*!%P26#=U>;NY;S./+S;T>-8,VN /#
M-SC#=X<%HVS;#? _B[54 KZV?VWNKNE".YTN03>RQ F9.5!C)!$[XLQ__<6/
MO-]LKOJ99/%/(CMR8]BZ,>QCGW^"\FM2'"LEZ+I2> W?A^+PK="</-D<61..
M#*$NO;OY^V PB,*IN^NZR (;C\/@!!9;8.%HZ$]:V)&L82MK^&.R2BP436@)
M7SS;(DF22E!%B?4#K5\1=;;FG6A\%1'W(8Z41:VRZ,>4);PHH(A!54T>,YZG
M1%A%19=%SP*S1<\"ZXG>J-4XZM7XU9QH4'SQC@@XH5MM=9&%(UXJJ*H009O"
MT0N7^X,P"*(3A398,!Z.3Q3:81/?KG#<*ASW*KS;;* YT"=.K,\9: _0JC<7
MQZ_FXJN(N ]QI&+2JICTJH@)XW!N8\4%@C:MU@)A^W X,P\'[R+]#XY[6&E1
MKRN>O$@M:QAM,$L8[;!S8?2]YQ;#NRQ5%TVJ?JJ*-2B'R*[J;/W\G*U7!P]9
MVP'OLKRUXBR*S^#.2NYT57ZOY*7ID8Z;*ZN@FF;2+0[>M3\ZU6.%1:-3.5;8
M(#JC)GA6$_3G<#=G^_4$E^FQPE[JL<)>Z'$[[6]!Q-9<(R04Q(JINO5K9]NK
MRL(TZ"?S2WV%,6WU,TU]__F(Q98RB7*R 4KO>@1GEJBO%/6#XJ5ILM=<0<MN
MAAE<PXC0 %C?<*X.#_H%[<5N_AU02P,$%     @ 98EG5F:)IHTM P  '0P
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MYH%@#1--:A--L W#!.D6),Q&PAPDS$7"/!"LX1:K=HO5.>7\F:M9A/#U2[-
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MP%)U@OQ^S7GVLJ->9ZQ?P5W\#U!+ P04    " !EB6=64Q'@^[@#  ##%
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
M+AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*
M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC
M)8QQ8K3^-8+)#^Q^ %!+ P04    " !EB6=6)3Y6GWH%   >+0  #P   'AL
M+W=O<FMB;V]K+GAM;,6:2V_;.!" _PKARZ:'K&V]^D!3P(F=U$ V,>*TUP4M
MT3$1BG1)*D[ZZW<HQ2B5QV ODYQL2[3T::CA1X[T=6?L[<J86W9?*^V.!AOO
MMU^&0U=N1,W=WV8K-.Q9&UMS#S_MS=!MK>"5VPCA:S5,1J-B6'.I!]^^[H^U
ML,/XA_&B]-)HV!@V_)1BY_[L#S_9G71R)97T#T>#]KL2 U9++6OY6U1'@]&
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M .M&J1/8=JG/#:_VK_?N7TW^]A]02P,$%     @ 98EG5A;=:Q0F @  8R@
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:2T[C0!2%X:U$7@"5
MNJ] BS#J"5/$!JQ0>8@DCEQN ;OO* R28_6@)\AG9)4M7_^C3U;9CR]EWPZ[
M[EBWNU.=?1[VQ[ILML-P^I5276W+H:UWW:D<SU?677]HA_.RWZ13NWIO-R7)
M?!ZIOYW1/#W>SIR]?IW*_TSLUNO=JOSN5G\.Y3C\8W#ZZ/KWNBUE:&:O;;\I
MP[))G_OKZ9HNAWQWGMS,GM^63?_\EILT=9! D$P?I!"DTP<9!-GT00Y!/GU0
M0%!,'[2 H,7T0?<0=#]]T ,$/4P?E.<HXYP@:80U@=89N<X$7F<$.Q.(G9'L
M3&!V1K0S@=H9V<X$;F>$.Q/(G9'N3&!W1KPS@=Z">@N!WH)Z"X'>,GK9)M!;
M4&\AT%M0;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;4&\AT%M1;R706U%O)=!;
M46\ET%M'FR4$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z
M&^IM!'H;ZFT$>AOJ;01ZVVBSFT!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U
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M_YJW> %02P$"% ,4    " !EB6=6!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &6)9U82A.!0[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( &6)9U:97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 98EG5D^]L'>'"   J30  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( &6)9U;OS?Y*L@8  +L=   8              " @<L0  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !EB6=61U2SC" #   /
M#0  &               @(&S%P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ 98EG5IN..:U<!@  [!L  !@              ("!"1L
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &6)9U; ._1R
M>0D  !!;   8              " @9LA  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " !EB6=6>@WW6B$+   0.   &
M@(%**P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 98EG
M5GZ59IV;*0  S8   !@              ("!H38  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( &6)9U9'%#'L>0H  /8:   8
M      " @7)@  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" !EB6=6/\NCBO<"  ##!@  &               @($A:P  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 98EG5EU6U9^C#0  MRL  !D
M             ("!3FX  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " !EB6=6CLI)+784  #C.   &0              @($H?   >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &6)9U;YX.L#A@D
M  H:   9              " @=60  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ 98EG5N_UKO'O#@  R3   !D              ("!
MDIH  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !EB6=6
M,N>Z1E<+  #T'P  &0              @(&XJ0  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( &6)9U:W0,_U! D  (49   9
M      " @4:U  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ 98EG5H7=6)/Y!0  &0\  !D              ("!@;X  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !EB6=6Q'0YVM0+  #((@
M&0              @(&QQ   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( &6)9U8.&XG$! \  $ M   9              " @;S0  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 98EG5HH^6UM?
M!0  -PT  !D              ("!]]\  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " !EB6=6;$XK@SL*  #X&@  &0
M@(&-Y0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( &6)
M9U:^7L6'KR,  #-U   9              " @?_O  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ 98EG5EW&1;U< P  P@<  !D
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M=#(V+GAM;%!+ 0(4 Q0    ( &6)9U:82=:H: 0  %4*   9
M  " @<DG 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M98EG5O$GUL0M!   2@H  !D              ("!:"P! 'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " !EB6=6)XIN"5X&  !<$0  &0
M            @(',, $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( &6)9U;J)9ZZ P0  !L*   9              " @6$W 0!X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 98EG5L"P,8Z8"0
MBVH  !D              ("!FSL! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " !EB6=66: +VI$%   P*0  &0              @(%J
M10$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( &6)9U9>
M-)H91P,  . *   9              " @3)+ 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ 98EG5L;A\@F$!@  XS4  !D
M     ("!L$X! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &6)9U9_&M64HP(  -P&   9              "
M@9QF 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 98EG
M5B\W,YBS P  9PT  !D              ("!=FD! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " !EB6=6CNH>7X<#  #>#   &0
M        @(%@;0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( &6)9U9:9$-I@ (  /D%   9              " @1YQ 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ 98EG5CU5AYN, P  3!$
M !D              ("!U7,! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " !EB6=6ZDTP!'P"  "F!@  &0              @(&8=P$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( &6)9U;F:FQ[
MH 0  -\>   9              " @4MZ 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ 98EG5C-Q^KHV!   L!8  !D
M ("!(G\! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !E
MB6=6^WS &8<"  #=!@  &0              @(&/@P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( &6)9U;1B9B+7@X  %3D   9
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M970U,BYX;6Q02P$"% ,4    " !EB6=6 >ATT;($  "\%@  &0
M    @(%/JP$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M &6)9U8IT8^/M@H  &-=   9              " @3BP 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ 98EG5HMP#KB1 @  S08  !D
M             ("!);L! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " !EB6=6OD5XWCP#  "Q"   &0              @('MO0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( &6)9U8SK Y./0,
M %0,   9              " @6#! 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ 98EG5DGK)M"<#   1)D  !D              ("!
MU,0! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " !EB6=6
MG0[;M9 #  "^#0  &0              @(&GT0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( &6)9U9;4X\#.@0  /H/   9
M      " @6[5 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ 98EG5KP>(.H@!   [0T  !D              ("!W]D! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " !EB6=6^3])LQ,#  #P"0
M&0              @($VW@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( &6)9U:S2=2 _@0  "D=   9              " @8#A 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ 98EG5HYKS!1<
M#@  =KL  !D              ("!M>8! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " !EB6=6@3'2=O0#  #D#0  &0
M@(%(]0$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( &6)
M9U9FB::-+0,  !T,   9              " @7/Y 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ 98EG5MFPBT@!!0  CBL  !D
M         ("!U_P! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
M    " !EB6=64Q'@^[@#  ##%   &0              @($/ @( >&PO=V]R
M:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( &6)9U:BXTO9.@,  .X3
M   -              "  ?X% @!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !, $P RQ0  '84 @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>222</ContextCount>
  <ElementCount>437</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Changes in Shareholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Changes in Shareholders' (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Nature of Operations and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Stock Incentive and Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlans</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Nature of Operations and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies</Role>
      <ShortName>Nature of Operations and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansTables</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlans</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Nature of Operations and Basis of Presentation (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Operations and Basis of Presentation (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Liquidity and Going Concern (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails</Role>
      <ShortName>Liquidity and Going Concern (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcern</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of the calculation of basic and diluted net income per ordinary share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of the calculation of basic and diluted net income per ordinary share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Acquisitions (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Private Placement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails</Role>
      <ShortName>Private Placement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Fair Value Measurements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Fair Value Measurements (Details) - Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Fair Value Measurements  (Details) - Schedule of derivative component of the obligation is initially valued and classified as a derivative liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of derivative component of the obligation is initially valued and classified as a derivative liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Fair Value Measurements  (Details) - Schedule of change in the fair value of conversion option liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of change in the fair value of conversion option liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Property and Equipment (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Debt (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Debt - Summary of borrowings of the scilex notes consisted (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails</Role>
      <ShortName>Debt - Summary of borrowings of the scilex notes consisted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquity</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Valuation Assumption Used (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Valuation Assumption Used (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Stock Incentive and Employee Benefit Plans (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Income Taxes (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Related Party Transactions (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactions</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails</Role>
      <ShortName>Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Subsequent Events (Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events (Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SubsequentEvents</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="sclx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - sclx-20221231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - sclx-20221231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, sclx:DerivativeWarrantLiabilityPrivateWarrants -  sclx-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="sclx-20221231.htm">sclx-20221231.htm</File>
    <File>sclx-20221231.xsd</File>
    <File>sclx-20221231_cal.xml</File>
    <File>sclx-20221231_def.xml</File>
    <File>sclx-20221231_lab.xml</File>
    <File>sclx-20221231_pre.xml</File>
    <File>sclx-ex23_1.htm</File>
    <File>sclx-ex31_1.htm</File>
    <File>sclx-ex31_2.htm</File>
    <File>sclx-ex32_1.htm</File>
    <File>sclx-ex4_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img248422670_0.jpg</File>
    <File>img248422670_1.jpg</File>
    <File>img248422670_10.jpg</File>
    <File>img248422670_11.jpg</File>
    <File>img248422670_12.jpg</File>
    <File>img248422670_13.jpg</File>
    <File>img248422670_14.jpg</File>
    <File>img248422670_15.jpg</File>
    <File>img248422670_2.jpg</File>
    <File>img248422670_3.jpg</File>
    <File>img248422670_4.jpg</File>
    <File>img248422670_5.jpg</File>
    <File>img248422670_6.jpg</File>
    <File>img248422670_7.jpg</File>
    <File>img248422670_8.jpg</File>
    <File>img248422670_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="799">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>103
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sclx-20221231.htm": {
   "axisCustom": 3,
   "axisStandard": 27,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 799,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 222,
   "dts": {
    "calculationLink": {
     "local": [
      "sclx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sclx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sclx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sclx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sclx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sclx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd"
     ]
    }
   },
   "elementCount": 886,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 21,
    "http://www.scilexholding.com/20221231": 15,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 40
   },
   "keyCustom": 98,
   "keyStandard": 339,
   "memberCustom": 49,
   "memberStandard": 27,
   "nsprefix": "sclx",
   "nsuri": "http://www.scilexholding.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Acquisitions",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Stock Incentive and Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlans",
     "shortName": "Stock Incentive and Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Loss Per Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShare",
     "shortName": "Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Nature of Operations and Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies",
     "shortName": "Nature of Operations and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansTables",
     "shortName": "Stock Incentive and Employee Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareTables",
     "shortName": "Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_86a3f7ce-707c-41fc-90d3-06bc58d03c21",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sclx:TransactionCostsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Nature of Operations and Basis of Presentation (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of Operations and Basis of Presentation (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_86a3f7ce-707c-41fc-90d3-06bc58d03c21",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sclx:TransactionCostsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sclx:WorkingCapital",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Liquidity and Going Concern (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
     "shortName": "Liquidity and Going Concern (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of the calculation of basic and diluted net income per ordinary share",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of the calculation of basic and diluted net income per ordinary share",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Acquisitions (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
     "shortName": "Acquisitions (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_ea7b3fbf-8dd6-49a4-a28c-adc88beeb0ae",
      "decimals": "0",
      "lang": null,
      "name": "sclx:AmountDueForNewDrugApplication",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Private Placement (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails",
     "shortName": "Private Placement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdditionalPaidInCapital",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Fair Value Measurements (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_8af8c6e1-609d-44ef-9f26-2b6bd7056a94",
      "decimals": "3",
      "lang": null,
      "name": "sclx:RiskAdjustedNetSalesForecast",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable",
     "shortName": "Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable",
     "shortName": "Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_e30cd740-80d0-4ec4-bcbe-c140def0f039",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Fair Value Measurements (Details) - Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3",
     "shortName": "Fair Value Measurements (Details) - Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "lang": null,
      "name": "sclx:PrivatePlacementWarrantLiabilityAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "sclx:EquityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Fair Value Measurements  (Details) - Schedule of derivative component of the obligation is initially valued and classified as a derivative liability",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable",
     "shortName": "Fair Value Measurements  (Details) - Schedule of derivative component of the obligation is initially valued and classified as a derivative liability",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "sclx:EquityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_a46bc651-8cf6-4139-83ff-4cec7e844fea",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sclx:ReMeasurementOfFairValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Fair Value Measurements  (Details) - Schedule of change in the fair value of conversion option liability",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable",
     "shortName": "Fair Value Measurements  (Details) - Schedule of change in the fair value of conversion option liability",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Property and Equipment (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_57381cb7-a42d-4d36-b7f9-ce9622ae4ed7",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Debt (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_e30cd740-80d0-4ec4-bcbe-c140def0f039",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentAnnualPrincipalPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Debt - Summary of borrowings of the scilex notes consisted (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails",
     "shortName": "Debt - Summary of borrowings of the scilex notes consisted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_e30cd740-80d0-4ec4-bcbe-c140def0f039",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentAnnualPrincipalPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Changes in Shareholders' (Deficit) Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3",
     "shortName": "Statements of Changes in Shareholders' (Deficit) Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_6ff4e4eb-9cea-48a0-bd2b-5a71cde4fd28",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Shareholders' Equity (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable",
     "shortName": "Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_86a3f7ce-707c-41fc-90d3-06bc58d03c21",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Valuation Assumption Used (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails",
     "shortName": "Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Valuation Assumption Used (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_a6ec871e-fb58-4be0-9d47-39ad5d9c44c4",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_e30cd740-80d0-4ec4-bcbe-c140def0f039",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails",
     "shortName": "Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_bc2e1302-aaf4-4441-811c-cc9a8fc0f213",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Stock Incentive and Employee Benefit Plans (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
     "shortName": "Stock Incentive and Employee Benefit Plans (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetails",
     "shortName": "Commitments and Contingencies - Schedule of Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails",
     "shortName": "Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Commitments and Contingencies (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_8c1f3d78-c5e0-4b4b-93a7-3c1f21841465",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_e30cd740-80d0-4ec4-bcbe-c140def0f039",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Income Taxes (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Related Party Transactions (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_d408965d-1291-4b37-9b62-a779f1f46c23",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails",
     "shortName": "Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_7fac449c-067b-401a-bdcc-4e3e9932dff4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100790 - Disclosure - Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
     "shortName": "Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_7fac449c-067b-401a-bdcc-4e3e9932dff4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4a5560ce-e23e-4368-8572-860644a67abb",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100810 - Disclosure - Subsequent Events (Additional Information (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events (Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_4eac9786-7af1-498b-ade8-18ab32ec037e",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Nature of Operations and Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentation",
     "shortName": "Nature of Operations and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Liquidity and Going Concern",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcern",
     "shortName": "Liquidity and Going Concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_83eae59f-9d4a-4170-b358-a33c0ee64291",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sclx-20221231.htm",
      "contextRef": "C_bef67e9a-4b76-4019-893d-8f19c877187f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sclx:EffectOfBusinessCombinationInValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - sclx-20221231.htm",
     "menuCat": "Cover",
     "order": "68",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - sclx-20221231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 80,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_WSAG": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WALL STREET ACCESS [Member]"
       }
      }
     },
     "localname": "WSAG",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ARYorkvillePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A R Yorkville Purchase Agreement.",
        "label": "A R Yorkville Purchase Agreement [Member]",
        "terseLabel": "A&amp;R Yorkville Purchase Agreement [Member]"
       }
      }
     },
     "localname": "ARYorkvillePurchaseAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AardvarkAssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aardvark Asset Purchase Agreement",
        "label": "Aardvark Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AardvarkAssetPurchaseAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AccrualForTransactionCostsRelatedToTheBusinessCombination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual for transaction costs related to the Business Combination",
        "label": "Accrual for transaction costs related to the Business Combination",
        "terseLabel": "Accrual for transaction costs related to the Business Combination"
       }
      }
     },
     "localname": "AccrualForTransactionCostsRelatedToTheBusinessCombination",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses",
        "label": "Accrued expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedExpenses",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AccruedRoyaltyPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Royalty Payables",
        "label": "Accrued Royalty Payables",
        "terseLabel": "Accrued Royalty Payables"
       }
      }
     },
     "localname": "AccruedRoyaltyPayables",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AcquiredLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired licenses [Member]",
        "label": "Acquired licenses [Member]",
        "terseLabel": "Acquired licenses"
       }
      }
     },
     "localname": "AcquiredLicensesMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AcquiredTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired technology [Member]",
        "label": "Acquired technology [Member]",
        "terseLabel": "Acquired technology"
       }
      }
     },
     "localname": "AcquiredTechnologyMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition",
        "label": "Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition",
        "negatedLabel": "Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition",
        "terseLabel": "Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition"
       }
      }
     },
     "localname": "AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AcquisitionOfRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of right-of-use asset",
        "label": "Acquisition of right-of-use asset",
        "terseLabel": "Acquisition of right-of-use asset"
       }
      }
     },
     "localname": "AcquisitionOfRightOfUseAsset",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ActualCumulativeNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actual cumulative net sales",
        "label": "Actual cumulative net sales"
       }
      }
     },
     "localname": "ActualCumulativeNetSales",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdditionalPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional principal amount",
        "label": "AdditionalPrincipalAmount",
        "terseLabel": "Additional principal amount"
       }
      }
     },
     "localname": "AdditionalPrincipalAmount",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value",
        "label": "Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value",
        "terseLabel": "Aardvark SP-104 license transfer from Sorrento, net of discount value"
       }
      }
     },
     "localname": "AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to shares issued in Semnur Acquisition value",
        "label": "Adjustment to shares issued in Semnur Acquisition value",
        "terseLabel": "Adjustment to shares issued in Semnur Acquisition"
       }
      }
     },
     "localname": "AdjustmentToSharesIssuedInSemnurAcquisitionValue",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdjustmentsRestatement2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AdjustmentsRestatement2Member",
        "terseLabel": "Adjustments Restatement 2 [Member]"
       }
      }
     },
     "localname": "AdjustmentsRestatement2Member",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AdjustmentToAdditionalPaidInCapitalDiscountAmortization",
        "label": "AdjustmentToAdditionalPaidInCapitalDiscountAmortization",
        "terseLabel": "Aardvark SP-104 discount amortization"
       }
      }
     },
     "localname": "Adjustmenttoadditionalpaidincapitaldiscountamortization",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdministrativeFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Administrative Facility [Member]",
        "label": "Administrative Facility [Member]"
       }
      }
     },
     "localname": "AdministrativeFacilityMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AggregateContingentCashConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate contingent cash consideration",
        "label": "Aggregate contingent cash consideration"
       }
      }
     },
     "localname": "AggregateContingentCashConsideration",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AggregateGrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Proceeds",
        "label": "Aggregate Gross Proceeds",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "AggregateGrossProceeds",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of aggregate principal amount.",
        "label": "AggregatePrincipalAmount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "AggregatePrincipalAmount",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AgreementInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Initial Term",
        "label": "Agreement Initial Term",
        "terseLabel": "Agreement initial term"
       }
      }
     },
     "localname": "AgreementInitialTerm",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_AgreementMaturityDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Maturity Date",
        "label": "Agreement Maturity Date",
        "terseLabel": "Agreement maturity date"
       }
      }
     },
     "localname": "AgreementMaturityDate",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "sclx_AmendmentNumberFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment Number Four [Member]",
        "label": "Amendment Number Four [Member]"
       }
      }
     },
     "localname": "AmendmentNumberFourMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AmountDueForNewDrugApplication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due for New Drug Application",
        "label": "Amount due for New Drug Application"
       }
      }
     },
     "localname": "AmountDueForNewDrugApplication",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Adjustment Distribution Fee Percentage Related To Future Years",
        "label": "Annual Adjustment Distribution Fee Percentage Related To Future Years",
        "terseLabel": "Annual adjustment distribution fee percentage related to future years"
       }
      }
     },
     "localname": "AnnualAdjustmentDistributionFeePercentageRelatedToFutureYears",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_AsRestatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AsRestatedMember",
        "terseLabel": "As Restated [Member]"
       }
      }
     },
     "localname": "AsRestatedMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AssembledWorkforceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assembled workforce [Member]",
        "label": "Assembled workforce [Member]",
        "terseLabel": "Assembled workforce"
       }
      }
     },
     "localname": "AssembledWorkforceMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AssetAcquisitionEligiblePercentageOfEquityInterestAcquiredByRelatedPartyToExchangeShare",
        "label": "AssetAcquisitionEligiblePercentageOfEquityInterestAcquiredByRelatedPartyToExchangeShare",
        "terseLabel": "Outstanding equity",
        "verboseLabel": "Eligible percentage of equity interest acquired by third party to exchange share"
       }
      }
     },
     "localname": "Assetacquisitioneligiblepercentageofequityinterestacquiredbyrelatedpartytoexchangeshare",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_Assetacquisitionequityinterestissuedorissuableperiodofshareexchange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AssetAcquisitionEquityInterestIssuedOrIssuablePeriodOfShareExchange",
        "label": "AssetAcquisitionEquityInterestIssuedOrIssuablePeriodOfShareExchange",
        "terseLabel": "Period commencing",
        "verboseLabel": "Share exchange period"
       }
      }
     },
     "localname": "Assetacquisitionequityinterestissuedorissuableperiodofshareexchange",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_Assetacquisitionequityinterestissuedorissuablevalueassigned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AssetAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
        "label": "AssetAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
        "terseLabel": "Stock consideration value"
       }
      }
     },
     "localname": "Assetacquisitionequityinterestissuedorissuablevalueassigned",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Assetacquisitionequityinterestissuedorissuablevalueassignedpershare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AssetAcquisitionEquityInterestIssuedOrIssuableValueAssignedPerShare",
        "label": "AssetAcquisitionEquityInterestIssuedOrIssuableValueAssignedPerShare",
        "terseLabel": "Stock consideration value per share (usd per share)"
       }
      }
     },
     "localname": "Assetacquisitionequityinterestissuedorissuablevalueassignedpershare",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfDaysTrailingVolumeWeightedAverageSharePrice",
        "label": "AssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfDaysTrailingVolumeWeightedAverageSharePrice",
        "terseLabel": "Trailing volume",
        "verboseLabel": "Trailing volume weighted average share price, term"
       }
      }
     },
     "localname": "Assetacquisitionequityinterestsissuedorissuablenumberofdaystrailingvolumeweightedaverageshareprice",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_BRileyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "B Riley Purchase Agreement.",
        "label": "B Riley Purchase Agreement [Member]",
        "terseLabel": "B. Riley Purchase Agreement [Member]"
       }
      }
     },
     "localname": "BRileyPurchaseAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_BlackScholesOptionPricingMethodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black-Scholes Option Pricing Method",
        "label": "Black-Scholes Option Pricing Method [Member]"
       }
      }
     },
     "localname": "BlackScholesOptionPricingMethodMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_BusinessCombinationRedeemPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination redeem percentage.",
        "label": "BusinessCombinationRedeemPercentage",
        "terseLabel": "Business combination redeem percentage"
       }
      }
     },
     "localname": "BusinessCombinationRedeemPercentage",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_CallOptionValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Call option value",
        "label": "Call option value",
        "terseLabel": "Call option value"
       }
      }
     },
     "localname": "CallOptionValue",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_CapitalRaisingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CapitalRaisingDescription",
        "terseLabel": "Capital raising, description"
       }
      }
     },
     "localname": "CapitalRaisingDescription",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CapitalizationOfShareOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalization of share outstanding.",
        "label": "CapitalizationOfShareOutstanding",
        "terseLabel": "Capitalization of share outstanding (in Shares)"
       }
      }
     },
     "localname": "CapitalizationOfShareOutstanding",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_CapitalizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Cost",
        "label": "Capitalized Cost",
        "terseLabel": "Capitalized cost"
       }
      }
     },
     "localname": "CapitalizedCost",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CarryingValueIncreased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value increased",
        "label": "Carrying value increased"
       }
      }
     },
     "localname": "CarryingValueIncreased",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payment",
        "label": "Cash payment"
       }
      }
     },
     "localname": "CashPayment",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CashReceivedFromParentCompany": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Received From Parent company",
        "label": "Cash Received From Parent company",
        "terseLabel": "Cash Received"
       }
      }
     },
     "localname": "CashReceivedFromParentCompany",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CashRequirement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Requirement",
        "label": "Cash Requirement"
       }
      }
     },
     "localname": "CashRequirement",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ChangeInValuationInputsOrOtherAssumptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in valuation inputs or other assumptions.",
        "label": "ChangeInValuationInputsOrOtherAssumptions",
        "negatedLabel": "Change in valuation inputs or other assumptions",
        "terseLabel": "Change in fair value measurement"
       }
      }
     },
     "localname": "ChangeInValuationInputsOrOtherAssumptions",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies [Line Items]",
        "label": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies [Table]",
        "label": "Commitments and Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Capital Incremental Shares Reserved For Future Issuance Each Year",
        "label": "Common Stock Capital Incremental Shares Reserved For Future Issuance Each Year",
        "terseLabel": "Common stock capital incremental shares reserved for future issuance each year"
       }
      }
     },
     "localname": "CommonStockCapitalIncrementalSharesReservedForFutureIssuanceEachYear",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_CommonStockExchangeRatioDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Exchange Ratio, Description",
        "label": "Common Stock Exchange Ratio, Description",
        "terseLabel": "Common stock exchange ratio, description"
       }
      }
     },
     "localname": "CommonStockExchangeRatioDescription",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CommonStockSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock sold.",
        "label": "Common stock sold"
       }
      }
     },
     "localname": "CommonStockSold",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_CommonStockToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock to be issued",
        "label": "Common stock to be issued"
       }
      }
     },
     "localname": "CommonStockToBeIssued",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_ConversionOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of common stock.",
        "label": "Conversion of Common Stock",
        "terseLabel": "Conversion of common stock"
       }
      }
     },
     "localname": "ConversionOfCommonStock",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_ConvertiblePromissoryNote": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory note",
        "label": "ConvertiblePromissoryNote",
        "terseLabel": "Convertible promissory note"
       }
      }
     },
     "localname": "ConvertiblePromissoryNote",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CumulativeNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "cumulative net sales",
        "label": "Cumulative net sales"
       }
      }
     },
     "localname": "CumulativeNetSales",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CurrentPortionOfDeferredConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of deferred consideration",
        "label": "Current portion of deferred consideration",
        "terseLabel": "Current portion of deferred consideration"
       }
      }
     },
     "localname": "CurrentPortionOfDeferredConsideration",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DebtExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Exchange Agreement",
        "label": "Debt Exchange Agreement [Member]",
        "terseLabel": "Debt Exchange Agreement [Member]"
       }
      }
     },
     "localname": "DebtExchangeAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_DebtExchangeDescriptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Exchange Descriptions",
        "label": "Debt Exchange Descriptions"
       }
      }
     },
     "localname": "DebtExchangeDescriptions",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DebtInstrumentPurcahsePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument purcahse price.",
        "label": "Debt Instrument Purcahse Price",
        "terseLabel": "Purcahse price"
       }
      }
     },
     "localname": "DebtInstrumentPurcahsePrice",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Consideration for Romeg Intangible Asset Acquisition",
        "label": "Deferred Consideration for Romeg Intangible Asset Acquisition"
       }
      }
     },
     "localname": "DeferredConsiderationForRomegIntangibleAssetAcquisition",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredTaxAssetsAccruedExpenseAndReserves": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, accrued expense and reserves.",
        "label": "Deferred Tax Assets, Accrued Expense and Reserves",
        "terseLabel": "Accrued expense and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccruedExpenseAndReserves",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredTaxAssetsDebtRelatedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, debt related interest.",
        "label": "Deferred Tax Assets, Debt Related Interest",
        "terseLabel": "Debt related interest"
       }
      }
     },
     "localname": "DeferredTaxAssetsDebtRelatedInterest",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredTaxAssetsInterestExpenseLimitations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Interest Expense Limitations",
        "label": "Deferred Tax Assets Interest Expense Limitations",
        "terseLabel": "Interest expense limitations"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestExpenseLimitations",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredTaxLiabilitiesAmortizationOfIntangibles": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Amortization of Intangibles",
        "label": "Deferred Tax Liabilities, Amortization of Intangibles",
        "negatedLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAmortizationOfIntangibles",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredUnderwritingFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred underwriting fee payable.",
        "label": "DeferredUnderwritingFeePayable",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredUnderwritingFeePayable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredUnderwritingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred underwriting fees.",
        "label": "DeferredUnderwritingFees",
        "terseLabel": "Deferred underwriting fees"
       }
      }
     },
     "localname": "DeferredUnderwritingFees",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Deferredconsiderationliabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DeferredConsiderationLiabilities",
        "label": "DeferredConsiderationLiabilities",
        "terseLabel": "Deferred consideration"
       }
      }
     },
     "localname": "Deferredconsiderationliabilities",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DenominatorAbstract",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DenominatorAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DenominatorAbstract0",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract0",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DepositIntoTrustAccount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit into Trust Account.",
        "label": "DepositIntoTrustAccount",
        "terseLabel": "Deposit into trust account"
       }
      }
     },
     "localname": "DepositIntoTrustAccount",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DerivativeWarrantLiabilityPrivateWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative warrant liability private warrants.",
        "label": "Derivative Warrant Liability Private Warrants",
        "terseLabel": "Derivative warrant liability private warrants"
       }
      }
     },
     "localname": "DerivativeWarrantLiabilityPrivateWarrants",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Derivativeliabilityatfairvalueadditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DerivativeLiabilityAtFairValueAdditions",
        "label": "DerivativeLiabilityAtFairValueAdditions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "Derivativeliabilityatfairvalueadditions",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations (Details) [Line Items]"
       }
      }
     },
     "localname": "DescriptionofOrganizationandBusinessOperationsDetailsLineItems",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations (Details) [Table]"
       }
      }
     },
     "localname": "DescriptionofOrganizationandBusinessOperationsDetailsTable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DevelopersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developers [Member]",
        "label": "Developers [Member]"
       }
      }
     },
     "localname": "DevelopersMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_DistributionFeesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution Fees Percentage",
        "label": "Distribution Fees Percentage",
        "terseLabel": "Distribution fees"
       }
      }
     },
     "localname": "DistributionFeesPercentage",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_DistributionToSorrentos": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution to Sorrento's",
        "label": "Distribution to Sorrento's",
        "terseLabel": "Distribution to sorrentos"
       }
      }
     },
     "localname": "DistributionToSorrentos",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_EffectOfBusinessCombinationInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of Business Combination In Shares",
        "label": "Effect of Business Combination In Shares"
       }
      }
     },
     "localname": "EffectOfBusinessCombinationInShares",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_EffectOfBusinessCombinationInValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect Of Business Combination In Value",
        "label": "Effect Of Business Combination In Value"
       }
      }
     },
     "localname": "EffectOfBusinessCombinationInValue",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_EffectOfDilutiveSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of Dilutive Securities",
        "label": "Effect of Dilutive Securities"
       }
      }
     },
     "localname": "EffectOfDilutiveSecurities",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation debt discount amount.",
        "label": "Effective Income Tax Rate Reconciliation Debt Discount Amount",
        "terseLabel": "Debt discount and interest limitation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDebtDiscountAmount",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_EquityPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Purchase Agreement [Member]",
        "label": "Equity Purchase Agreement [Member]"
       }
      }
     },
     "localname": "EquityPurchaseAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_EquityValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Value",
        "label": "Equity Value",
        "terseLabel": "Equity Value"
       }
      }
     },
     "localname": "EquityValue",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated future amortization expense related to intangible assets",
        "label": "Estimated future amortization expense related to intangible assets",
        "terseLabel": "Estimated future amortization expense related to intangible assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement",
        "label": "Exchange Agreement [Member]"
       }
      }
     },
     "localname": "ExchangeAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ExclusiveDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive Distribution Agreement [Member]",
        "label": "Exclusive Distribution Agreement [Member]"
       }
      }
     },
     "localname": "ExclusiveDistributionAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustment to derivative liability in troubled debt restructuring",
        "label": "Fair value adjustment to derivative liability in troubled debt restructuring"
       }
      }
     },
     "localname": "FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_FairValueDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value decrease",
        "label": "Fair value decrease"
       }
      }
     },
     "localname": "FairValueDecrease",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_FairValueMeasurementStrikePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strike price.",
        "label": "FairValueMeasurementStrikePrice",
        "terseLabel": "Strike price"
       }
      }
     },
     "localname": "FairValueMeasurementStrikePrice",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_FairValueMeasurementsValuationProcessesDescription1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements Valuation Processes Description 1",
        "terseLabel": "Initial measurement , description"
       }
      }
     },
     "localname": "FairValueMeasurementsValuationProcessesDescription1",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_FairValueOfContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration.",
        "label": "Fair value of contingent consideration",
        "terseLabel": "Development Milestone Payment"
       }
      }
     },
     "localname": "FairValueOfContingentConsideration",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_FairValueOfWarrantsinDollars": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FairValueOfWarrantsinDollars",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueOfWarrantsinDollars",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_FirstAmendedCertificateOfIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Amended Certificate of Incorporation [Member]",
        "label": "First Amended Certificate of Incorporation [Member]",
        "terseLabel": "First Amended Certificate of Incorporation [Member]"
       }
      }
     },
     "localname": "FirstAmendedCertificateOfIncorporationMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ForfeitureOfPrivateWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forfeiture of Private Warrants",
        "label": "Forfeiture of Private Warrants",
        "terseLabel": "Forfeiture of Private Warrants"
       }
      }
     },
     "localname": "ForfeitureOfPrivateWarrants",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ForfeituresOfPrivateWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forfeitures of Private Warrants",
        "label": "Forfeitures of Private Warrants"
       }
      }
     },
     "localname": "ForfeituresOfPrivateWarrants",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ForgivenAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiven amount",
        "label": "Forgiven amount"
       }
      }
     },
     "localname": "ForgivenAmount",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_FounderShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of founder shares.",
        "label": "FounderShares",
        "terseLabel": "Founder shares (in Shares)"
       }
      }
     },
     "localname": "FounderShares",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_FounderSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FounderSharesMember",
        "terseLabel": "Founder Shares [Member]"
       }
      }
     },
     "localname": "FounderSharesMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_FourCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Customer [Member]",
        "label": "Four Customer [Member]",
        "terseLabel": "Four Customer [Member]"
       }
      }
     },
     "localname": "FourCustomerMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_FrequencyOfPaymentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequency of Payments [Axis]",
        "label": "Frequency of Payments [Axis]"
       }
      }
     },
     "localname": "FrequencyOfPaymentsAxis",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_FrequencyOfPaymentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequency of Payments [Domain]",
        "label": "Frequency of Payments [Domain]"
       }
      }
     },
     "localname": "FrequencyOfPaymentsDomain",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_FundExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund expenses.",
        "label": "FundExpenses",
        "terseLabel": "Fund expenses"
       }
      }
     },
     "localname": "FundExpenses",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_FundingCommitmentLetterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Commitment Letter [Member]",
        "label": "Funding Commitment Letter [Member]"
       }
      }
     },
     "localname": "FundingCommitmentLetterMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_GrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "GrossProceeds",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "GrossProceeds",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofcondensedbalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_GrossProceedsOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds of warrants.",
        "label": "GrossProceedsOfWarrants",
        "terseLabel": "Gross proceeds of amount"
       }
      }
     },
     "localname": "GrossProceedsOfWarrants",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_HoldingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HoldingPeriod",
        "terseLabel": "Holding period"
       }
      }
     },
     "localname": "HoldingPeriod",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure [Line Items]",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure [Table]",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_IncomeTaxReconciliationAcquisitionRelatedCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation acquisition related charges.",
        "label": "Income Tax Reconciliation Acquisition Related Charges",
        "terseLabel": "Acquisition related charges"
       }
      }
     },
     "localname": "IncomeTaxReconciliationAcquisitionRelatedCharges",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_IncreaseDecreaseInAccruedPayroll": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Accrued payroll",
        "label": "Increase Decrease In Accrued payroll",
        "terseLabel": "Accrued Payroll"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedPayroll",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_IncreaseDecreaseInAccruedRebatesAndFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Accrued Rebates and Fees",
        "label": "Increase (Decrease) in Accrued Rebates and Fees",
        "terseLabel": "Accrued rebates and fees"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedRebatesAndFees",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_IncreaseDecreaseInLongTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Long-term deposits",
        "label": "Increase Decrease In Long-term deposits",
        "terseLabel": "Long-term deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInLongTermDeposits",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_IncreaseOfPrincipalBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase of Principal Balance",
        "label": "Increase of Principal Balance"
       }
      }
     },
     "localname": "IncreaseOfPrincipalBalance",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_IndefiniteCarryforwardPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite Carryforward Period [Member]",
        "label": "Indefinite Carryforward Period [Member]",
        "terseLabel": "Indefinite Carryforward Period [Member]"
       }
      }
     },
     "localname": "IndefiniteCarryforwardPeriodMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_InducementPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Plan Axis",
        "label": "Inducement Plan [Axis]"
       }
      }
     },
     "localname": "InducementPlanAxis",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_InducementPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Plan Domain",
        "label": "Inducement Plan [Domain]"
       }
      }
     },
     "localname": "InducementPlanDomain",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Plan Member",
        "label": "Inducement Plan Member",
        "terseLabel": "Inducement Plan [Member]"
       }
      }
     },
     "localname": "InducementPlanMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_InterestExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense",
        "label": "InterestExpenses",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenses",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares to Yorkville pursuant to Yorkville Purchase Agreement",
        "label": "Issuance of shares to Yorkville pursuant to Yorkville Purchase Agreement",
        "terseLabel": "Issuance of shares to Yorkville"
       }
      }
     },
     "localname": "IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_IssuedAndOutstandingCapitalStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued And Outstanding Capital Stock",
        "label": "Issued And Outstanding Capital Stock [Member]",
        "terseLabel": "Issued and outstanding capital stock"
       }
      }
     },
     "localname": "IssuedAndOutstandingCapitalStockMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ItochuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Itochu [Member]",
        "label": "Itochu [Member]"
       }
      }
     },
     "localname": "ItochuMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_LeaseLiabilityNetOfCurrentPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liability, net of current portion",
        "label": "Lease liability, net of current portion",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "LeaseLiabilityNetOfCurrentPortion",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LegacyCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Common Stock [Member]",
        "label": "Legacy Common Stock [Member]",
        "terseLabel": "Legacy Common Stock"
       }
      }
     },
     "localname": "LegacyCommonStockMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_LegacyScilexCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Scilex Common Stock [Member]",
        "label": "Legacy Scilex Common Stock [Member]",
        "terseLabel": "Legacy Scilex Common Stock [Member]"
       }
      }
     },
     "localname": "LegacyScilexCommonStockMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_LegacyScilexStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Scilex Stock Options [Member]",
        "label": "Legacy Scilex Stock Options [Member]",
        "terseLabel": "Legacy Scilex Stock Options [Member]"
       }
      }
     },
     "localname": "LegacyScilexStockOptionsMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_LessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LessAbstract",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LessAbstract",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofcondensedbalancesheetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LiabilityClassifiedPrivateWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability classified private warrants.",
        "label": "Liability classified private warrants",
        "terseLabel": "Liability-classified Private Warrants"
       }
      }
     },
     "localname": "LiabilityClassifiedPrivateWarrants",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Member]",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_LiquidityAndGoingConcernLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and Going Concern [Line Items]",
        "label": "Liquidity and Going Concern [Line Items]"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernLineItems",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LiquidityAndGoingConcernTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and Going Concern [Table]",
        "label": "Liquidity and Going Concern [Table]"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernTable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LitigationFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Fees",
        "label": "Litigation Fees"
       }
      }
     },
     "localname": "LitigationFees",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LiveActionRightOfUseAssetInPaloAlto": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Live Action right-of-use asset in Palo Alto",
        "label": "Live Action right-of-use asset in Palo Alto"
       }
      }
     },
     "localname": "LiveActionRightOfUseAssetInPaloAlto",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LoanDerivativeLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan derivative liability",
        "label": "Loan derivative liability",
        "terseLabel": "Loan derivative liability"
       }
      }
     },
     "localname": "LoanDerivativeLiability",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongTermPortionOfDeferredConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term portion of deferred consideration",
        "label": "Long-term portion of deferred consideration",
        "terseLabel": "Long-term portion of deferred consideration"
       }
      }
     },
     "localname": "LongTermPortionOfDeferredConsideration",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MaturityRenewalDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity Renewal Description",
        "label": "Maturity Renewal Description",
        "terseLabel": "Agreement maturity renewal description"
       }
      }
     },
     "localname": "MaturityRenewalDescription",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_MergerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement[ Member]",
        "label": "Merger Agreement[ Member]"
       }
      }
     },
     "localname": "MergerAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment",
        "label": "Milestone Payment",
        "terseLabel": "Development Milestone Payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MinimumCashRequirement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Cash Requirement",
        "label": "Minimum Cash Requirement"
       }
      }
     },
     "localname": "MinimumCashRequirement",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MonthlyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly [Member]",
        "label": "Monthly [Member]"
       }
      }
     },
     "localname": "MonthlyMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_NetTangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NetTangibleAssets",
        "terseLabel": "Net tangible assets"
       }
      }
     },
     "localname": "NetTangibleAssets",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCancelableLeaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cancelable Lease Agreements [Member]",
        "label": "Non-cancelable Lease Agreements [Member]"
       }
      }
     },
     "localname": "NonCancelableLeaseAgreementsMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_NonCashConsiderationInSemnurAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash Consideration in Semnur Acquisition",
        "label": "Non-cash Consideration in Semnur Acquisition"
       }
      }
     },
     "localname": "NonCashConsiderationInSemnurAcquisition",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashDistributionToSorrento": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Distribution to Sorrento",
        "label": "Non-Cash Distribution to Sorrento",
        "terseLabel": "Non-cash distribution to Sorrento"
       }
      }
     },
     "localname": "NonCashDistributionToSorrento",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashOperatingLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash operating lease cost.",
        "label": "Non Cash Operating Lease Cost",
        "terseLabel": "Non-cash operating lease cost"
       }
      }
     },
     "localname": "NonCashOperatingLeaseCost",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NotePrincipalReductionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Principal Reduction Amount",
        "label": "Note Principal Reduction Amount",
        "terseLabel": "Note Principal Reduction Amount"
       }
      }
     },
     "localname": "NotePrincipalReductionAmount",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NotesPrincipalIncrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes principal increase",
        "label": "Notes principal increase",
        "negatedLabel": "Scilex Pharma Notes principal increase",
        "terseLabel": "Scilex Pharma Notes principal increase"
       }
      }
     },
     "localname": "NotesPrincipalIncrease",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NumberOfBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of business days.",
        "label": "NumberOfBusinessDays",
        "terseLabel": "Number of business days"
       }
      }
     },
     "localname": "NumberOfBusinessDays",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sclx_NumberOfSaleUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Sale units.",
        "label": "NumberOfSaleUnits",
        "terseLabel": "Number of sale units"
       }
      }
     },
     "localname": "NumberOfSaleUnits",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfShares",
        "terseLabel": "Number of shares (in Shares)"
       }
      }
     },
     "localname": "NumberOfShares",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumeratorAbstract",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_OfferingCostIncludedInAccruedOfferingCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering cost included in accrued offering cost.",
        "label": "OfferingCostIncludedInAccruedOfferingCost",
        "terseLabel": "Offering costs included in accrued offering costs"
       }
      }
     },
     "localname": "OfferingCostIncludedInAccruedOfferingCost",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Expiration Year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards, expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "sclx_OrdinarySharesIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "OrdinarySharesIssuanceCost",
        "negatedLabel": "Ordinary shares issuance costs"
       }
      }
     },
     "localname": "OrdinarySharesIssuanceCost",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofcondensedbalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OrdinarySharesIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares issued and outstanding.",
        "label": "OrdinarySharesIssuedAndOutstanding",
        "terseLabel": "Ordinary shares issued and outstanding (in Shares)"
       }
      }
     },
     "localname": "OrdinarySharesIssuedAndOutstanding",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_OrdinarySharesSubjectToPossibleRedemption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrdinarySharesSubjectToPossibleRedemption",
        "terseLabel": "Subject to possible redemption shares",
        "verboseLabel": "Ordinary shares subject to possible redemption"
       }
      }
     },
     "localname": "OrdinarySharesSubjectToPossibleRedemption",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_OrganisationAndPrincipalActivitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organisation and Principal Activities [Policy Text Block]",
        "label": "Organisation and Principal Activities [Policy Text Block]",
        "terseLabel": "Organization and Principal Activities"
       }
      }
     },
     "localname": "OrganisationAndPrincipalActivitiesPolicyTextBlock",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_OtherLoanForgiveness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Loan Forgiveness",
        "label": "Other Loan Forgiveness"
       }
      }
     },
     "localname": "OtherLoanForgiveness",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OtherLongTermLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other long-term liabilities",
        "label": "Other long-term liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermLiabilities",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OtherOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other offering costs.",
        "label": "OtherOfferingCosts",
        "terseLabel": "Other offering costs"
       }
      }
     },
     "localname": "OtherOfferingCosts",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OutstandingCapitalStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding capital stock, percent",
        "label": "Outstanding capital stock, percent",
        "terseLabel": "Outstanding capital stock, percent"
       }
      }
     },
     "localname": "OutstandingCapitalStockPercent",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_OutstandingPrincipalAmountPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding principal amount period",
        "label": "Outstanding principal amount period",
        "terseLabel": "Principal amount outstanding, rate per annum"
       }
      }
     },
     "localname": "OutstandingPrincipalAmountPeriod",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PatentRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent rights [Member]",
        "label": "Patent rights [Member]",
        "terseLabel": "Patent rights"
       }
      }
     },
     "localname": "PatentRightsMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount",
        "label": "Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount",
        "negatedLabel": "Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount",
        "terseLabel": "Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount"
       }
      }
     },
     "localname": "PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PaymentUponTheAchievementOfNetSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "payment upon the achievement of net sales",
        "label": "Payment upon the achievement of net sales"
       }
      }
     },
     "localname": "PaymentUponTheAchievementOfNetSales",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PercentageOfNetRevenueSoleDistributor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Net Revenue, Sole Distributor",
        "label": "Percentage of Net Revenue, Sole Distributor",
        "terseLabel": "Percentage of net revenue, sole distributor"
       }
      }
     },
     "localname": "PercentageOfNetRevenueSoleDistributor",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfNetRevenueSoleDistributors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net revenue, sole distributors",
        "label": "Percentage of net revenue, sole distributors",
        "terseLabel": "Percentage of net revenue, sole distributor"
       }
      }
     },
     "localname": "PercentageOfNetRevenueSoleDistributors",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfPublicShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of public shares.",
        "label": "PercentageOfPublicShares",
        "terseLabel": "Percentage of public shares"
       }
      }
     },
     "localname": "PercentageOfPublicShares",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_Percentageofoutstandingcommonstockheld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PercentageOfOutstandingCommonStockHeld",
        "label": "PercentageOfOutstandingCommonStockHeld",
        "terseLabel": "Contingent consideration, liability",
        "verboseLabel": "Percentage of outstanding common stock held"
       }
      }
     },
     "localname": "Percentageofoutstandingcommonstockheld",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PlusAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PlusAbstract",
        "terseLabel": "Plus:"
       }
      }
     },
     "localname": "PlusAbstract",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofcondensedbalancesheetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PricePerPublicShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PricePerPublicShare",
        "terseLabel": "Price per public share (in Dollars per share)"
       }
      }
     },
     "localname": "PricePerPublicShare",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PricePerWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per warrant.",
        "label": "PricePerWarrants",
        "terseLabel": "Price per warrant (in Dollars per share)"
       }
      }
     },
     "localname": "PricePerWarrants",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PrincipalAndNonOperatingExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "principal and non-operating expense",
        "label": "Principal and non-operating expense"
       }
      }
     },
     "localname": "PrincipalAndNonOperatingExpense",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PrivatePlacementDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement (Details) [Line Items]"
       }
      }
     },
     "localname": "PrivatePlacementDetailsLineItems",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PrivatePlacementDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement (Details) [Table]"
       }
      }
     },
     "localname": "PrivatePlacementDetailsTable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PrivatePlacementDisclosureTextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PrivatePlacementDisclosureTextblock",
        "terseLabel": "PRIVATE PLACEMENT"
       }
      }
     },
     "localname": "PrivatePlacementDisclosureTextblock",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_PrivatePlacementDisclosureTextblockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Disclosure Textblock [Abstract]"
       }
      }
     },
     "localname": "PrivatePlacementDisclosureTextblockAbstract",
     "nsuri": "http://www.scilexholding.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sclx_PrivatePlacementWarrantLiabilityAcquired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private placement warrant liability acquired",
        "label": "Private placement warrant liability acquired",
        "terseLabel": "Private Warrant liability acquired as part of the Business Combination"
       }
      }
     },
     "localname": "PrivatePlacementWarrantLiabilityAcquired",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PrivatePlacementWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Warrant [Member].",
        "label": "PrivatePlacementWarrantMember",
        "terseLabel": "Private Placement [Member]",
        "verboseLabel": "Private Placement Warrant [Member]"
       }
      }
     },
     "localname": "PrivatePlacementWarrantMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PrivateWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Warrants [Member]",
        "label": "Private Warrants [Member]",
        "terseLabel": "Private Warrants"
       }
      }
     },
     "localname": "PrivateWarrantsMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ProceedsFromRepaymentOfLoansToPurchase": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Repayment Of Loans To Purchase",
        "label": "Proceeds From Repayment Of Loans To Purchase",
        "terseLabel": "Repayment on other loans"
       }
      }
     },
     "localname": "ProceedsFromRepaymentOfLoansToPurchase",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of common stock.",
        "label": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromSaleOfCommonStock",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ProceedsFromTheBusinessCombination": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from the Business Combination",
        "label": "Proceeds from the Business Combination",
        "terseLabel": "Proceeds from the Business Combination"
       }
      }
     },
     "localname": "ProceedsFromTheBusinessCombination",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ProceedsOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds of initial public offering.",
        "label": "ProceedsOfInitialPublicOffering",
        "terseLabel": "Proceeds of initial public offering"
       }
      }
     },
     "localname": "ProceedsOfInitialPublicOffering",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ProductDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Development Agreement [Member]",
        "label": "Product Development Agreement [Member]"
       }
      }
     },
     "localname": "ProductDevelopmentAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ProfitPercentageNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Percentage, Net",
        "label": "Profit Percentage Net",
        "terseLabel": "Net profit percentage"
       }
      }
     },
     "localname": "ProfitPercentageNet",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_ProjectAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Project Agreement [Member]",
        "label": "Project Agreement [Member]"
       }
      }
     },
     "localname": "ProjectAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PromissoryNote": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note",
        "label": "Promissory note"
       }
      }
     },
     "localname": "PromissoryNote",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount",
        "label": "Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount"
       }
      }
     },
     "localname": "PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PromissoryNoteRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PromissoryNoteRelatedPartyMember",
        "terseLabel": "Promissory Note - Related Party [Member]"
       }
      }
     },
     "localname": "PromissoryNoteRelatedPartyMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ProposedPublicOfferingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proposed Public Offering [Abstract]"
       }
      }
     },
     "localname": "ProposedPublicOfferingAbstract",
     "nsuri": "http://www.scilexholding.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sclx_ProposedPublicOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProposedPublicOfferingTextBlock",
        "terseLabel": "PUBLIC OFFERING"
       }
      }
     },
     "localname": "ProposedPublicOfferingTextBlock",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOffering"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_PublicOfferingDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering (Details) [Line Items]"
       }
      }
     },
     "localname": "PublicOfferingDetailsLineItems",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PublicOfferingDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering (Details) [Table]"
       }
      }
     },
     "localname": "PublicOfferingDetailsTable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Warrant And Private Placement Warrants [Policy Text Block]",
        "label": "Public Warrant And Private Placement Warrants [Policy Text Block]",
        "terseLabel": "Public Warrants and Private Placement Warrants"
       }
      }
     },
     "localname": "PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_PublicWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Warrants [Member]",
        "label": "Public Warrants [Member]",
        "terseLabel": "Public Warrants"
       }
      }
     },
     "localname": "PublicWarrantsMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PublicWarrantsRedemptionDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PublicWarrantsRedemptionDescription",
        "terseLabel": "Public warrants redemption, description"
       }
      }
     },
     "localname": "PublicWarrantsRedemptionDescription",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PurchaseAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement Axis",
        "label": "Purchase Agreement [Axis]"
       }
      }
     },
     "localname": "PurchaseAgreementAxis",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PurchaseAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement Domain",
        "label": "Purchase Agreement [Domain]"
       }
      }
     },
     "localname": "PurchaseAgreementDomain",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement",
        "label": "Purchase Agreement Member",
        "terseLabel": "Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PurchaseOfStockPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of stock, percentage",
        "label": "Purchase of stock, percentage",
        "terseLabel": "Purchase of stock, percentage"
       }
      }
     },
     "localname": "PurchaseOfStockPercentage",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PurchasePricePerShare",
        "terseLabel": "Purchase price per unit (in Dollars per share)"
       }
      }
     },
     "localname": "PurchasePricePerShare",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_ReMeasurementOfFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Re-measurement of fair value",
        "label": "Re-measurement of fair value"
       }
      }
     },
     "localname": "ReMeasurementOfFairValue",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RecapitalizationDueToTheBusinessCombinationValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization Due to the Business Combination Value",
        "label": "Recapitalization Due to the Business Combination Value"
       }
      }
     },
     "localname": "RecapitalizationDueToTheBusinessCombinationValue",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RecapitalizationDuetotheBusinessCombinationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization DueToThe Business Combination Shares",
        "label": "Recapitalization DueToThe Business Combination Shares"
       }
      }
     },
     "localname": "RecapitalizationDuetotheBusinessCombinationShares",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_ReceivableBasisOfGoingForward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable basis of going forward",
        "label": "Receivable basis of going forward",
        "terseLabel": "Receivable basis going forward"
       }
      }
     },
     "localname": "ReceivableBasisOfGoingForward",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ReclassificationAmountFromAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification amount from additional paid-in capital",
        "label": "Reclassification amount from additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationAmountFromAdditionalPaidInCapital",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party debt converted to equity pursuant to Debt Exchange Agreement",
        "label": "Related party debt converted to equity pursuant to Debt Exchange Agreement",
        "terseLabel": "Related party debt converted to equity"
       }
      }
     },
     "localname": "RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RelatedPartyNotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Notes Payable [Member]",
        "label": "Related Party Notes Payable [Member]",
        "terseLabel": "Related Party Notes Payable [Member]"
       }
      }
     },
     "localname": "RelatedPartyNotesPayableMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_RelatedPartyPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party payable",
        "label": "Related party payable",
        "terseLabel": "Related party payable"
       }
      }
     },
     "localname": "RelatedPartyPayable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RelatedPartyReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party receivable",
        "label": "Related party receivable",
        "terseLabel": "Related party receivable"
       }
      }
     },
     "localname": "RelatedPartyReceivable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RelatedPartyTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_RelatedPartyTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsTable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_RepaidAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repaid Amount.",
        "label": "RepaidAmount",
        "terseLabel": "Repaid amount"
       }
      }
     },
     "localname": "RepaidAmount",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of principal on the Scilex Pharma Notes",
        "label": "Repayment of principal on the Scilex Pharma Notes"
       }
      }
     },
     "localname": "RepaymentOfPrincipalOnTheScilexPharmaNotes",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RepurchasePrincipalInPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase Principal In Percentage",
        "label": "Repurchase Principal In Percentage"
       }
      }
     },
     "localname": "RepurchasePrincipalInPercentage",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_RepurchaseWithCashOnHand": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase with cash-on-hand",
        "label": "Repurchase with cash-on-hand"
       }
      }
     },
     "localname": "RepurchaseWithCashOnHand",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RepurchasesOfNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchases of Notes",
        "label": "Repurchases of Notes"
       }
      }
     },
     "localname": "RepurchasesOfNotes",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ResearchAndDevelopmentAndOrphanDrugCreditsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development and Orphan Drug Credits [Member]",
        "label": "Research and Development and Orphan Drug Credits [Member]",
        "terseLabel": "Research &amp; Development and Orphan Drug Credits [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAndOrphanDrugCreditsMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ResearchAndDevelopmentFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Facilities [Member]",
        "label": "Research and Development Facilities [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentFacilitiesMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_RiskAdjustedNetSalesForecast": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk adjusted net sales forecast",
        "label": "Risk Adjusted Net Sales Forecast"
       }
      }
     },
     "localname": "RiskAdjustedNetSalesForecast",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_RomegLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Romeg License Agreement [Member]",
        "label": "Romeg License Agreement [Member]"
       }
      }
     },
     "localname": "RomegLicenseAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_RoyaltyPaymentPercentageRelatedToFutureYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payment Percentage Related To Future Years",
        "label": "Royalty Payment Percentage Related To Future Years",
        "terseLabel": "Royalty payment percentage related to future years"
       }
      }
     },
     "localname": "RoyaltyPaymentPercentageRelatedToFutureYears",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_SaleOfStockDescriptionOfTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock description of transaction.",
        "label": "SaleOfStockDescriptionOfTransactions",
        "terseLabel": "Sale of stock, description"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransactions",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_SaleOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of warrants.",
        "label": "SaleOfWarrants",
        "terseLabel": "Sale of warrants (in Shares)"
       }
      }
     },
     "localname": "SaleOfWarrants",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_ScheduleOfCondensedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of condensed balance sheets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetsAbstract",
     "nsuri": "http://www.scilexholding.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of derivative component of the obligation is initially valued and classified as a derivative liability [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract",
     "nsuri": "http://www.scilexholding.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of impact of these adjustments to the financial statement, as previously reported [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReportedAbstract",
     "nsuri": "http://www.scilexholding.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the calculation of basic and diluted net income per ordinary share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerOrdinaryShareAbstract",
     "nsuri": "http://www.scilexholding.com/20221231",
     "xbrltype": "stringItemType"
    },
    "sclx_ScilexPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex Pharma",
        "label": "Scilex Pharma [Member]",
        "terseLabel": "Scilex Pharmaceuticals"
       }
      }
     },
     "localname": "ScilexPharmaMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ScilexPharmaNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex Pharma Notes [Member]",
        "label": "Scilex Pharma Notes [Member]"
       }
      }
     },
     "localname": "ScilexPharmaNotesMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ScilexPharmaNotesPrincipalIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex Pharma Notes principal increase",
        "label": "Scilex Pharma Notes principal increase"
       }
      }
     },
     "localname": "ScilexPharmaNotesPrincipalIncrease",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ScintillaPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scintilla Pharmaceuticals [Member]",
        "label": "Scintilla Pharmaceuticals [Member]",
        "terseLabel": "Scintilla Pharmaceuticals"
       }
      }
     },
     "localname": "ScintillaPharmaceuticalsMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SecondAmendedCertificateOfIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Amended Certificate of Incorporation [Member]",
        "label": "Second Amended Certificate of Incorporation [Member]",
        "terseLabel": "Second Amended Certificate of Incorporation [Member]"
       }
      }
     },
     "localname": "SecondAmendedCertificateOfIncorporationMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SemnurCashExchangePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Semnur Cash Exchange Payment [Member]",
        "label": "Semnur Cash Exchange Payment [Member]"
       }
      }
     },
     "localname": "SemnurCashExchangePaymentMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SemnurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Semnur [Member]",
        "label": "Semnur [Member]"
       }
      }
     },
     "localname": "SemnurMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SemnurPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Semnur Pharmaceuticals Inc [Member]",
        "label": "Semnur Pharmaceuticals Inc [Member]"
       }
      }
     },
     "localname": "SemnurPharmaceuticalsIncMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SemnurProductFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Semnur Product Four [Member]",
        "label": "Semnur Product Four [Member]",
        "terseLabel": "Semnur Product 4 [Member]"
       }
      }
     },
     "localname": "SemnurProductFourMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SemnurProductOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Semnur Product One [Member]",
        "label": "Semnur Product One [Member]",
        "terseLabel": "Semnur Product 1 [Member]"
       }
      }
     },
     "localname": "SemnurProductOneMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SemnurProductThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Semnur Product Three [Member]",
        "label": "Semnur Product Three [Member]",
        "terseLabel": "Semnur Product 3 [Member]"
       }
      }
     },
     "localname": "SemnurProductThreeMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SemnurProductTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Semnur Product Two [Member]",
        "label": "Semnur Product Two [Member]",
        "terseLabel": "Semnur Product 2 [Member]"
       }
      }
     },
     "localname": "SemnurProductTwoMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SeniorSecuredNotesDueTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior secured notes due two thousand twenty six member.",
        "label": "Senior Secured Notes Due Two Thousand Twenty six [Member]",
        "terseLabel": "Senior secured notes due 2026 [Member]"
       }
      }
     },
     "localname": "SeniorSecuredNotesDueTwoThousandTwentySixMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_ShareholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsLineItems",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ShareholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsTable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_SharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares acquired",
        "label": "Shares acquired",
        "terseLabel": "Shares acquired"
       }
      }
     },
     "localname": "SharesAcquired",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement",
        "label": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement",
        "terseLabel": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement"
       }
      }
     },
     "localname": "SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)",
        "label": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)",
        "terseLabel": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)"
       }
      }
     },
     "localname": "SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_SharesSubjectToPossibleRedemption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares subject to possible redemption.",
        "label": "SharesSubjectToPossibleRedemption",
        "terseLabel": "Ordinary shares subject to possible redemption"
       }
      }
     },
     "localname": "SharesSubjectToPossibleRedemption",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofcondensedbalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SharesToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares to be issued",
        "label": "Shares to be issued"
       }
      }
     },
     "localname": "SharesToBeIssued",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_SorrentoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sorrento [Member]",
        "label": "Sorrento [Member]",
        "terseLabel": "Sorrento"
       }
      }
     },
     "localname": "SorrentoMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SorrentoTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sorrento Therapeutics, Inc. [Member]",
        "label": "Sorrento Therapeutics, Inc. [Member]",
        "terseLabel": "Sorrento Therapeutics, Inc. [Member]"
       }
      }
     },
     "localname": "SorrentoTherapeuticsIncMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SpacTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPAC Transaction [Member]",
        "label": "SPAC Transaction [Member]"
       }
      }
     },
     "localname": "SpacTransactionMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SpacTransactionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPAC Transactions [Policy Text Block]",
        "label": "SPAC Transactions [Policy Text Block]",
        "terseLabel": "SPAC Transaction"
       }
      }
     },
     "localname": "SpacTransactionsPolicyTextBlock",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_SponsorLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor loan",
        "label": "SponsorLoan",
        "terseLabel": "Sponsor loan"
       }
      }
     },
     "localname": "SponsorLoan",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SponsorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor [Member].",
        "label": "SponsorMember",
        "terseLabel": "Sponsor [Member]"
       }
      }
     },
     "localname": "SponsorMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options [Member]",
        "label": "Stock Options [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_StructuringFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structuring Fees",
        "label": "Structuring Fees",
        "terseLabel": "Structuring fees"
       }
      }
     },
     "localname": "StructuringFees",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_TaxCreditCarryForwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carry forwards expiration year.",
        "label": "Tax Credit Carry Forwards Expiration Year",
        "terseLabel": "Tax credit carry forwards expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryForwardsExpirationYear",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "sclx_TransactionCostsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs amount.",
        "label": "TransactionCostsAmount",
        "terseLabel": "Transaction costs amount"
       }
      }
     },
     "localname": "TransactionCostsAmount",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_TransactionCostsObligationAssumedBySorrento": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs obligation assumed by Sorrento",
        "label": "Transaction costs obligation assumed by Sorrento",
        "terseLabel": "Transaction costs obligation assumed by Sorrento"
       }
      }
     },
     "localname": "TransactionCostsObligationAssumedBySorrento",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs paid related to the recapitalization transaction",
        "label": "Transaction costs paid related to the recapitalization transaction",
        "negatedLabel": "Transaction costs paid related to the Business Combination",
        "terseLabel": "Transaction costs paid related to recapitalization transaction"
       }
      }
     },
     "localname": "TransactionCostsPaidRelatedToTheRecapitalizationTransaction",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_TwoThousandNineteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Stock Option Plan [Member]",
        "label": "Two Thousand Nineteen Stock Option Plan [Member]",
        "terseLabel": "2019 Stock Option Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenStockOptionPlanMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Equity Incentive Plan [Member]",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Two Employee Stock Purchase Plan [Member]",
        "label": "2022 Employee Stock Purchase Plan",
        "terseLabel": "2022 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandTwentyTwoEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Two Equity Incentive Plan [Member]",
        "label": "Two Thousand Twenty Two Equity Incentive Plan [Member]",
        "terseLabel": "2022 Equity Incentive Plan Member"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoEquityIncentivePlanMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandTwentyTwoPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Two Promissory Note [Member]",
        "label": "Two Thousand Twenty Two Promissory Note [Member]",
        "terseLabel": "2022 Promissory Note [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoPromissoryNoteMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_UnderlyingWarrantValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underlying warrant value",
        "label": "UnderlyingWarrantValue",
        "terseLabel": "Underlying warrant value"
       }
      }
     },
     "localname": "UnderlyingWarrantValue",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_UnrestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrestricted cash",
        "label": "Unrestricted cash"
       }
      }
     },
     "localname": "UnrestrictedCash",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_UnvestedEmployeeAndNonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Employee and Non-employee Stock Option [Member]",
        "label": "Unvested Employee and Non-employee Stock Option [Member]"
       }
      }
     },
     "localname": "UnvestedEmployeeAndNonEmployeeStockOptionMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_UpfrontConsiderationForCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "upfront consideration for common stock",
        "label": "Upfront consideration for common stock"
       }
      }
     },
     "localname": "UpfrontConsiderationForCommonStock",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Upfrontlicensefee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UpFrontLicenseFee",
        "label": "UpFrontLicenseFee",
        "terseLabel": "Up-front license fee"
       }
      }
     },
     "localname": "Upfrontlicensefee",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_VendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor [Member]",
        "label": "Vendor [Member]"
       }
      }
     },
     "localname": "VendorMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_VickersDebtAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vickers Debt Agreement [Member]",
        "label": "Vickers Debt Agreement [Member]",
        "terseLabel": "Vickers Debt Agreement [Member]"
       }
      }
     },
     "localname": "VickersDebtAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_WarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsequent Events",
        "label": "WarrantExercisePrice",
        "terseLabel": "Warrant exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePrice",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_WarrantTransferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Transfer Agreement [Member]",
        "label": "Warrant Transfer Agreement [Member]",
        "terseLabel": "Warrant Transfer Agreement [Member]"
       }
      }
     },
     "localname": "WarrantTransferAgreementMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_WarrantsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Line Items]"
       }
      }
     },
     "localname": "WarrantsDetailsLineItems",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Table]"
       }
      }
     },
     "localname": "WarrantsDetailsTable",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants [Member]",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_WarrantsOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants outstanding shares.",
        "label": "WarrantsOutstandingShares",
        "terseLabel": "Warrants outstanding shares"
       }
      }
     },
     "localname": "WarrantsOutstandingShares",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_WeightedAveragePeriodOverGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average period over grant",
        "label": "Weighted average period over grant"
       }
      }
     },
     "localname": "WeightedAveragePeriodOverGrant",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital",
        "label": "Working Capital",
        "terseLabel": "Negative working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_aggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "aggregate purchase price.",
        "label": "aggregatePurchasePrice",
        "terseLabel": "Aggregate purchase price value"
       }
      }
     },
     "localname": "aggregatePurchasePrice",
     "nsuri": "http://www.scilexholding.com/20221231",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Financial Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_FinancingReceivableNonaccrualToOutstandingPercent": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of nonaccrual to total financing receivable outstanding.",
        "label": "Financing Receivable, Nonaccrual to Outstanding, Percent",
        "terseLabel": "Aggregate outstanding amount equal percentage"
       }
      }
     },
     "localname": "FinancingReceivableNonaccrualToOutstandingPercent",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r333",
      "r646",
      "r728",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r360",
      "r361",
      "r363",
      "r364",
      "r431",
      "r572",
      "r596",
      "r615",
      "r616",
      "r644",
      "r653",
      "r664",
      "r725",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r360",
      "r361",
      "r363",
      "r364",
      "r431",
      "r572",
      "r596",
      "r615",
      "r616",
      "r644",
      "r653",
      "r664",
      "r725",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r333",
      "r646",
      "r728",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r331",
      "r574",
      "r645",
      "r663",
      "r720",
      "r721",
      "r728",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r331",
      "r574",
      "r645",
      "r663",
      "r720",
      "r721",
      "r728",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r360",
      "r361",
      "r363",
      "r364",
      "r422",
      "r431",
      "r459",
      "r460",
      "r461",
      "r568",
      "r572",
      "r596",
      "r615",
      "r616",
      "r644",
      "r653",
      "r664",
      "r719",
      "r725",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r360",
      "r361",
      "r363",
      "r364",
      "r422",
      "r431",
      "r459",
      "r460",
      "r461",
      "r568",
      "r572",
      "r596",
      "r615",
      "r616",
      "r644",
      "r653",
      "r664",
      "r719",
      "r725",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r278",
      "r279",
      "r300",
      "r517",
      "r518",
      "r699",
      "r700",
      "r701",
      "r702",
      "r704",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Adjustments Restatement 1 [Member]"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r224",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r300",
      "r342",
      "r343",
      "r490",
      "r516",
      "r517",
      "r518",
      "r519",
      "r539",
      "r554",
      "r555",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r224",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r300",
      "r342",
      "r343",
      "r490",
      "r516",
      "r517",
      "r518",
      "r519",
      "r539",
      "r554",
      "r555",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r224",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r282",
      "r300",
      "r490",
      "r516",
      "r517",
      "r518",
      "r539",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r714",
      "r715",
      "r774",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Previously Reported [Member]",
        "terseLabel": "As Previously Reported [Member]"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r695",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of condensed balance sheets"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r267",
      "r623",
      "r624",
      "r625",
      "r626",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Condensed Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "auth_ref": [
      "r695",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Condensed Financial Statements [Table Text Block]",
        "terseLabel": "Schedule of impact of these adjustments to the financial statement, as previously reported"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r712",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r18",
      "r661"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Accounts Payable, Related Parties, Noncurrent",
        "terseLabel": "Related party note payable, net"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r23",
      "r629"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r86",
      "r232"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average remaining life for identifiable intangible assets"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r12",
      "r661"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "netLabel": "Additional amount borrowed",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "verboseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r696",
      "r697",
      "r698",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r396",
      "r537",
      "r642",
      "r643",
      "r688"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount",
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r47",
      "r71",
      "r80"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Intangible amortization",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r656",
      "r767",
      "r768",
      "r769"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Asset acquisition consideration transferred amount",
        "totalLabel": "Asset Acquisition, Consideration Transferred, Total"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "auth_ref": [
      "r767",
      "r768",
      "r769"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Common stock upon conversation of cash"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r183",
      "r200",
      "r236",
      "r262",
      "r316",
      "r325",
      "r329",
      "r340",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r506",
      "r510",
      "r524",
      "r661",
      "r723",
      "r724",
      "r786"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r227",
      "r244",
      "r262",
      "r340",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r506",
      "r510",
      "r524",
      "r661",
      "r723",
      "r724",
      "r786"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Total current assets:",
        "totalLabel": "Total current assets:"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at fair value",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldInTrust": {
     "auth_ref": [
      "r689"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.",
        "label": "Assets Held-in-trust",
        "terseLabel": "Trust account",
        "totalLabel": "Assets Held-in-trust, Total",
        "verboseLabel": "Assets held in the trust account"
       }
      }
     },
     "localname": "AssetsHeldInTrust",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.",
        "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment",
        "terseLabel": "Other long term assets"
       }
      }
     },
     "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r502",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r502",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r143",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Stock consideration common stock value"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r142",
      "r145",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationControlObtainedDescription": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents a description of how the entity obtained control of the acquired entity.",
        "label": "Business Combination, Control Obtained Description",
        "terseLabel": "Business combination, description"
       }
      }
     },
     "localname": "BusinessCombinationControlObtainedDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible asset",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "terseLabel": "Development Milestones Payment was recognized under other long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r608",
      "r609",
      "r661",
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash Transfer"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r49",
      "r230",
      "r627"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash \u2013 End of period",
        "periodStartLabel": "Cash \u2013 Beginning of period",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r43",
      "r49",
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r43",
      "r171"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net Change in Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Federal depository insurance coverage"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-Cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r262",
      "r286",
      "r287",
      "r294",
      "r296",
      "r304",
      "r305",
      "r340",
      "r365",
      "r367",
      "r368",
      "r369",
      "r372",
      "r373",
      "r404",
      "r405",
      "r407",
      "r411",
      "r418",
      "r524",
      "r617",
      "r677",
      "r690",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Price per warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Warrant to transfer shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Aggregate purchase of private placement warrants (in Shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Commercial Paper, at Carrying Value",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "CommercialPaperAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Promissory note"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r29",
      "r188",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r358",
      "r359",
      "r611",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r696",
      "r697",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Fair value per share of common stock on date of grant"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Ordinary shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11",
      "r661"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 740,000,000 shares authorized; 141,348,856 and 132,858,484 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively",
        "totalLabel": "Common Stock Value",
        "verboseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r106",
      "r107",
      "r113",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Stock Incentive and Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers &amp; equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r166",
      "r167",
      "r333",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r61",
      "r62",
      "r166",
      "r167",
      "r333",
      "r607",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r61",
      "r62",
      "r166",
      "r167",
      "r333",
      "r610",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r197",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r61",
      "r62",
      "r166",
      "r167",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r166",
      "r167",
      "r333",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "auth_ref": [
      "r225",
      "r267",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "terseLabel": "RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.",
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of stock, amount"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock, shares"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Converted into common stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r8",
      "r185",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible promissory notes",
        "totalLabel": "Convertible Debt, Total"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r6",
      "r184",
      "r199",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Promissory Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r9",
      "r10",
      "r98",
      "r100",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Converted into Preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r34",
      "r262",
      "r340",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r524",
      "r723"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue",
        "totalLabel": "Cost of Revenue, Total"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in cumulative translation adjustment before transfers included in determining net income.",
        "label": "Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Increase in the principal amount",
        "totalLabel": "Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current expense:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r693",
      "r762",
      "r764"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r693",
      "r762"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r135",
      "r486",
      "r494",
      "r693"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r693",
      "r762",
      "r764"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r60",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r51",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Related party indebtedness converted into shares"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "negatedLabel": "Current portion",
        "terseLabel": "Current portion of debt",
        "totalLabel": "Debt, Current, Total",
        "verboseLabel": "Current portion"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r260",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r390",
      "r397",
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r184",
      "r185",
      "r199",
      "r267",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r538",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r8",
      "r185",
      "r199",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Outstanding principal balance"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r691"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt Instrument, Decrease, Forgiveness",
        "terseLabel": "Debt principal forgive"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r173",
      "r175",
      "r374",
      "r538",
      "r640",
      "r641"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Initial principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r388",
      "r523",
      "r640",
      "r641"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value",
        "totalLabel": "Debt Instrument, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r25",
      "r173",
      "r403",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r25",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Issued, Principal",
        "terseLabel": "Principle amount of issued"
       }
      }
     },
     "localname": "DebtInstrumentIssuedPrincipal",
     "nsuri": "http://fasb.org/us-gaap-sup/2022q3",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r245",
      "r639",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r26",
      "r267",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r538",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Principal payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r26",
      "r98",
      "r101",
      "r102",
      "r103",
      "r172",
      "r173",
      "r175",
      "r196",
      "r267",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r538",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r172",
      "r175",
      "r726"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized debt discount",
        "terseLabel": "Unamortized debt discount",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield": {
     "auth_ref": [
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average yield of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Weighted Average Yield"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleWeightedAverageYield",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r693",
      "r763",
      "r764"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r174",
      "r726"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs",
        "totalLabel": "Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r135",
      "r693",
      "r763"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r47",
      "r135",
      "r487",
      "r493",
      "r494",
      "r693"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r693",
      "r763",
      "r764"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r133",
      "r761"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r760"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r760"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r133",
      "r761"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r133",
      "r761"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r131",
      "r133",
      "r761"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r131",
      "r133",
      "r761"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development income tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r133",
      "r761"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r126",
      "r760"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total Deferred Tax Liabilities",
        "totalLabel": "Deferred Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r133",
      "r761"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r133",
      "r761"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred Tax Liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r133",
      "r761"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r421",
      "r423",
      "r430",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employee benefit plan contributions by employer"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepositLiabilitiesAccruedInterest": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued but unpaid interest on deposit liabilities.",
        "label": "Deposit Liabilities, Accrued Interest",
        "terseLabel": "Accrued Interest"
       }
      }
     },
     "localname": "DepositLiabilitiesAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r47",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r47",
      "r314"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r772"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "(Gain) loss on derivative liability",
        "terseLabel": "Gain on derivative liability",
        "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total",
        "verboseLabel": "(Gain) loss on derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgesLiabilities": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum as of the balance sheet date of the (a) fair values of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and (b) the carrying amounts of the liabilities arising from financial instruments or contracts used to mitigate a specified risk (hedge), and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.",
        "label": "Derivative Instruments and Hedges, Liabilities",
        "terseLabel": "Derivative liabilities",
        "totalLabel": "Derivative Instruments and Hedges, Liabilities, Total"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgesLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "WARRANTS"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r246",
      "r247",
      "r523",
      "r630"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "periodEndLabel": "Fair value, Ending",
        "periodStartLabel": "Fair value, Beginning",
        "terseLabel": "Warrant liability",
        "totalLabel": "Derivative Liability, Total",
        "verboseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputsLevel3",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative liability.",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Loss on Derivative",
        "terseLabel": "Derivative warrant liability"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DilutiveSecurities": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Denominator for Diluted Loss per Share - Adjusted for Dilutive Securities",
        "totalLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Total"
       }
      }
     },
     "localname": "DilutiveSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsShareBasedCompensationCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for award under share-based payment arrangement.",
        "label": "Dividend, Share-Based Payment Arrangement, Cash",
        "terseLabel": "Cash payment"
       }
      }
     },
     "localname": "DividendsShareBasedCompensationCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToAffiliateCurrent": {
     "auth_ref": [
      "r4",
      "r176",
      "r213",
      "r694"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "terseLabel": "Advances outstanding"
       }
      }
     },
     "localname": "DueToAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r256",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r284",
      "r286",
      "r294",
      "r295",
      "r296",
      "r300",
      "r518",
      "r519",
      "r591",
      "r594",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic Loss Per Share",
        "terseLabel": "Basic net income (loss) per ordinary share",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net loss per share attributable to common stockholders - basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r256",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r286",
      "r294",
      "r295",
      "r296",
      "r300",
      "r518",
      "r519",
      "r591",
      "r594",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted Loss Per Share",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net loss per share attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate",
        "totalLabel": "Income Tax Benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r264",
      "r474",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r756",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r496",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r756",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r756",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Return to provision adjustments and carryback"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r756",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r755"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to unvested stock option grants"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97",
      "r223",
      "r251",
      "r252",
      "r253",
      "r268",
      "r269",
      "r270",
      "r272",
      "r279",
      "r282",
      "r303",
      "r341",
      "r420",
      "r464",
      "r465",
      "r466",
      "r489",
      "r490",
      "r517",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r555",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Percentage of ownership of common stock"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityUnitPurchaseAgreementsMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts and securities that allow the holder to buy equity units from the entity.",
        "label": "Equity Unit Purchase Agreements [Member]",
        "terseLabel": "2018 Purchase Agreements and Indenture"
       }
      }
     },
     "localname": "EquityUnitPurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Ordinary shares issued (in Shares)"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value assets measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r388",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r520",
      "r565",
      "r566",
      "r567",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueConcentrationOfRiskTextBlock": {
     "auth_ref": [
      "r166",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.",
        "label": "Fair Value, Concentration of Risk [Table Text Block]",
        "terseLabel": "Schedule of quantitative information regarding Level 3 fair value measurements"
       }
      }
     },
     "localname": "FairValueConcentrationOfRiskTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r388",
      "r423",
      "r428",
      "r520",
      "r565",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r388",
      "r423",
      "r428",
      "r520",
      "r566",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r388",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r520",
      "r567",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Initial measurement on December 20, 2021"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r388",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r565",
      "r566",
      "r567",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "periodEndLabel": "Fair value, ending blance",
        "periodStartLabel": "Fair value, beginning blance",
        "totalLabel": "Fair Value, Net Asset (Liability), Total"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r541",
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease liabilities",
        "totalLabel": "Finance Lease, Liability, Total"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability.",
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinancingReceivableRevolvingConvertedToTermLoan": {
     "auth_ref": [
      "r344",
      "r637"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of revolving financing receivable converted to term loan.",
        "label": "Financing Receivable, Revolving, Converted to Term Loan",
        "terseLabel": "Accounts receivable revolving loan facility in an aggregate amount"
       }
      }
     },
     "localname": "FinancingReceivableRevolvingConvertedToTermLoan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r234",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2": {
       "order": 1.0,
       "parentTag": "sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2": {
       "order": 2.0,
       "parentTag": "sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2": {
       "order": 4.0,
       "parentTag": "sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2": {
       "order": 5.0,
       "parentTag": "sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2": {
       "order": 3.0,
       "parentTag": "sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails2": {
       "order": 0.0,
       "parentTag": "sclx_EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r349",
      "r352",
      "r353",
      "r355",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r79",
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r72",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r79",
      "r575"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "terseLabel": "Intangibles, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]",
        "terseLabel": "Year Ended December 31,"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Remaining Amortization Period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Loss (gain) on foreign currency exchange",
        "terseLabel": "Loss (gain) on foreign currency exchange",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSalesOfLoansNet": {
     "auth_ref": [
      "r47",
      "r192",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net gain (loss) resulting from a sale of loans, including adjustments to record loans classified as held-for-sale at the lower-of-cost-or-market and fair value adjustments to loan held for investment purposes.",
        "label": "Gain (Loss) on Sales of Loans, Net",
        "terseLabel": "Actual cumulative net sales",
        "totalLabel": "Gain (Loss) on Sales of Loans, Net, Total"
       }
      }
     },
     "localname": "GainLossOnSalesOfLoansNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r47",
      "r93",
      "r94"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "(Gain) loss on debt extinguishment, net",
        "terseLabel": "(Gain) loss on debt extinguishment, net",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "verboseLabel": "Gain on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r233",
      "r348",
      "r590",
      "r638",
      "r661",
      "r717",
      "r718"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill impairment charges",
        "totalLabel": "Goodwill and Intangible Asset Impairment, Total"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering [Member]",
        "verboseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development Expense"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r32",
      "r180",
      "r190",
      "r209",
      "r316",
      "r324",
      "r328",
      "r330",
      "r592",
      "r636"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedTotalLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r263",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Loss before income taxes, foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r264",
      "r475",
      "r480",
      "r485",
      "r491",
      "r497",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "auth_ref": [
      "r125",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.",
        "label": "Income Tax Examination, Likelihood of Unfavorable Settlement",
        "terseLabel": "Uncertain income tax position, likelihood"
       }
      }
     },
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r757"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax expense, interest and penalties",
        "totalLabel": "Income Tax Examination, Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r265",
      "r281",
      "r282",
      "r315",
      "r473",
      "r492",
      "r498",
      "r595"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense (benefit)",
        "negatedTotalLabel": "Total",
        "terseLabel": "Income tax (benefit) expense",
        "totalLabel": "Total",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r250",
      "r471",
      "r472",
      "r480",
      "r481",
      "r484",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r756"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      },
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance",
        "verboseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r470",
      "r474"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Changes in tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r756"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r756"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r756"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "terseLabel": "Prior year true-up and carryback"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r756"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State, net of federal tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r756"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Income tax credits and incentives",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivables, net",
        "terseLabel": "Accounts receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "terseLabel": "Inventory",
        "totalLabel": "Increase (Decrease) in Inventories, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the current portion (due within one year or one business cycle, whichever is longer) of the amount owed by the reporting entity in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Notes Payable, Related Parties, Current",
        "terseLabel": "Related party payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInNotesPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount owed to the reporting entry (during the current year or operating cycle) in the form of loans and obligations (generally evidenced by promissory notes) made to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Notes Receivable, Related Parties, Current",
        "negatedLabel": "Related party receivable",
        "terseLabel": "Related party receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInNotesReceivables": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note.",
        "label": "Increase (Decrease) in Notes Receivables",
        "negatedLabel": "Scilex Pharma Notes principal increase"
       }
      }
     },
     "localname": "IncreaseDecreaseInNotesReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r687"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r687"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long term assets",
        "terseLabel": "Other long term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaid expenses and other",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r350",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "auth_ref": [
      "r0"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.",
        "label": "Intangible Assets, Current",
        "terseLabel": "Net tangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r70",
      "r77"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangibles, net",
        "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r174",
      "r195",
      "r254",
      "r313",
      "r536"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseBorrowings": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of interest expense on all borrowings.",
        "label": "Interest Expense, Borrowings",
        "terseLabel": "Repurchased aggregate amount",
        "totalLabel": "Interest Expense, Borrowings, Total"
       }
      }
     },
     "localname": "InterestExpenseBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease": {
     "auth_ref": [
      "r617",
      "r619",
      "r620",
      "r621"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in interest income on deposit with financial institution.",
        "label": "Interest Income, Deposit with Financial Institution, Increase (Decrease)",
        "terseLabel": "Deposit interest income"
       }
      }
     },
     "localname": "InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeSecuritiesUSTreasury": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity.",
        "label": "Interest Income, Securities, US Treasury",
        "terseLabel": "Investments held in Trust Account \u2013 U.S. Treasury Securities Money Market Fund"
       }
      }
     },
     "localname": "InterestIncomeSecuritiesUSTreasury",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r243",
      "r628",
      "r661"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, Net, Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r229",
      "r242",
      "r302",
      "r345",
      "r346",
      "r347",
      "r573",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Lease Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease liabilities as of December 31, 2022",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r22",
      "r262",
      "r340",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r507",
      "r510",
      "r511",
      "r524",
      "r635",
      "r723",
      "r786",
      "r787"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r186",
      "r204",
      "r661",
      "r692",
      "r713",
      "r776"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "terseLabel": "Total liabilities and stockholders' equity/(deficit)",
        "totalLabel": "Total liabilities and stockholders' deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r228",
      "r262",
      "r340",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r507",
      "r510",
      "r511",
      "r524",
      "r661",
      "r723",
      "r786",
      "r787"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Total current liabilities:",
        "totalLabel": "Total current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "terseLabel": "Warrant Liability \u2013 Private Placement Warrants"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities measured at fair value",
        "totalLabel": "Total liabilities measured at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as current.",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Liabilities for uncertain tax positions"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Romeg License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Line Of Credit FacilityI nterest Rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LoansAndLeasesReceivableRelatedParties": {
     "auth_ref": [
      "r176",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.",
        "label": "Loans and Leases Receivable, Related Parties",
        "periodEndLabel": "Loans and Leases Receivable, Related Parties, Ending Balance",
        "periodStartLabel": "Loans and Leases Receivable, Related Parties, Beginning Balance",
        "terseLabel": "Loans receivables"
       }
      }
     },
     "localname": "LoansAndLeasesReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayable": {
     "auth_ref": [
      "r8",
      "r185",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Loans Payable",
        "terseLabel": "Aggregate outstanding amount",
        "totalLabel": "Loans Payable, Total"
       }
      }
     },
     "localname": "LoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r8",
      "r185",
      "r202",
      "r387",
      "r402",
      "r640",
      "r641"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt, net",
        "totalLabel": "Long-Term Debt, Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAverageAmountOutstanding": {
     "auth_ref": [
      "r617",
      "r618"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average amount outstanding of long-term debt.",
        "label": "Long-Term Debt, Average Amount Outstanding",
        "terseLabel": "Aggregate Outstanding Amount"
       }
      }
     },
     "localname": "LongTermDebtAverageAmountOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Debt, Maximum Amount During Period",
        "totalLabel": "Long-Term Debt, Current Maturities, Total"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r26",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "terseLabel": "Net cash used for investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r43",
      "r45",
      "r48"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r43",
      "r45",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r33",
      "r48",
      "r191",
      "r208",
      "r226",
      "r248",
      "r249",
      "r253",
      "r262",
      "r271",
      "r273",
      "r274",
      "r276",
      "r277",
      "r281",
      "r282",
      "r292",
      "r316",
      "r324",
      "r328",
      "r330",
      "r340",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r519",
      "r524",
      "r636",
      "r723"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Scilex",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToParentDiluted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.",
        "label": "Net Income (Loss) Attributable to Parent, Diluted",
        "terseLabel": "Net Income (Loss) Attributable to Parent, Diluted, Total",
        "totalLabel": "Net Income (Loss) Attributable to Parent, Diluted, Total"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToParentDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other (income) expense",
        "totalLabel": "Total other (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (income) expense:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansPayable": {
     "auth_ref": [
      "r8",
      "r185",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Notes and Loans Payable",
        "terseLabel": "Advances in note payable",
        "totalLabel": "Notes and Loans Payable, Total"
       }
      }
     },
     "localname": "NotesAndLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued",
        "terseLabel": "Offering costs paid through promissory note \u2013 related party",
        "verboseLabel": "Promissory note issued"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r17",
      "r177",
      "r694"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Notes Payable, Related Parties, Current",
        "terseLabel": "Related party note payable"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r176",
      "r207",
      "r694"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties.",
        "label": "Notes Payable, Related Parties"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r27",
      "r176",
      "r694"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).",
        "label": "Notes Payable, Related Parties, Noncurrent",
        "terseLabel": "Related party note payable, net"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "terseLabel": "Operating and formation costs",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r316",
      "r324",
      "r328",
      "r330",
      "r636"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r545",
      "r660"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost*"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities as of December 31, 2022",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Less current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r543",
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Operating cash flows from operating leases",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r549",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r548",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Operations and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55",
      "r56",
      "r66",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "negatedLabel": "Accrued rebates and fees",
        "terseLabel": "Accrued rebates and fees"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Other Commitments, Description",
        "terseLabel": "Underwriting agreement, description"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherDeferredCostsNet": {
     "auth_ref": [
      "r680"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.",
        "label": "Other Deferred Costs, Net",
        "terseLabel": "Offering costs amount",
        "totalLabel": "Other Deferred Costs, Net, Total"
       }
      }
     },
     "localname": "OtherDeferredCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryPurchasedGoods": {
     "auth_ref": [
      "r683"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of components used by the entity which are bought from another entity rather than produced by the entity.",
        "label": "Other Inventory, Purchased Goods, Gross",
        "terseLabel": "Inventory purchased"
       }
      }
     },
     "localname": "OtherInventoryPurchasedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "verboseLabel": "Conversion Option Liability (see Note 5)"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r8",
      "r185",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-Term Debt",
        "terseLabel": "Long term portion",
        "totalLabel": "Other Long-Term Debt, Total",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r684",
      "r716"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherUnderwritingExpense": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.",
        "label": "Other Underwriting Expense",
        "terseLabel": "Cash underwriting fees"
       }
      }
     },
     "localname": "OtherUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": {
     "auth_ref": [
      "r293",
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic",
        "terseLabel": "Net loss attributable to participating securities"
       }
      }
     },
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r39",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to aggregate amount",
        "verboseLabel": "Cash consideration to equity holders"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant, and equipment",
        "terseLabel": "Purchase of property, plant, and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PledgingPurposeAxis": {
     "auth_ref": [
      "r569",
      "r657",
      "r662",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by pledging purpose of pledged asset owned.",
        "label": "Pledging Purpose [Axis]"
       }
      }
     },
     "localname": "PledgingPurposeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PledgingPurposeDomain": {
     "auth_ref": [
      "r569",
      "r657",
      "r662",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledging purpose of pledged asset owned.",
        "label": "Pledging Purpose [Domain]"
       }
      }
     },
     "localname": "PledgingPurposeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock Member"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "auth_ref": [
      "r96",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.",
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Ordinary per share"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RestatementofPreviouslyIssuedFinancialStatementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preference shares, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r10",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Preference shares issue"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preference shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedBalanceSheet_Parentheticals",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r10",
      "r661"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 45,000,000 shares authorized; 29,057,097 and 0 issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.",
        "label": "Principal Amount Outstanding of Loans Held-in-portfolio",
        "terseLabel": "Outstanding principal amount",
        "totalLabel": "Principal Amount Outstanding of Loans Held-in-portfolio, Total"
       }
      }
     },
     "localname": "PrincipalAmountOutstandingOfLoansHeldInPortfolio",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]",
        "verboseLabel": "Private Placement Warrants [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from sale of Private Placement Warrants",
        "verboseLabel": "Aggregate purchase price (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "totalLabel": "Proceeds from Notes Payable, Total"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Offset against the equity proceeds"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherShortTermDebt": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from short-term debt classified as other.",
        "label": "Proceeds from Other Short-Term Debt",
        "terseLabel": "Proceeds from other loans"
       }
      }
     },
     "localname": "ProceedsFromOtherShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from related party",
        "verboseLabel": "Proceeds from related party payable"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfNotesReceivable": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Sale of Notes Receivable"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSecuredNotesPayable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from Secured Notes Payable",
        "terseLabel": "Proceeds from related party note payable"
       }
      }
     },
     "localname": "ProceedsFromSecuredNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r120"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Share options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductLiabilityContingencyAccrualDiscountRate": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate applied to the undiscounted amount of estimated damages for product liability to arrive at the present value recorded as of the balance sheet date.",
        "label": "Product Liability Contingency, Accrual, Discount Rate",
        "terseLabel": "Discount rate of FDA"
       }
      }
     },
     "localname": "ProductLiabilityContingencyAccrualDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Sales operation implementation fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r226",
      "r248",
      "r249",
      "r257",
      "r262",
      "r271",
      "r281",
      "r282",
      "r316",
      "r324",
      "r328",
      "r330",
      "r340",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r505",
      "r508",
      "r509",
      "r519",
      "r524",
      "r592",
      "r636",
      "r658",
      "r659",
      "r685",
      "r723"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r85",
      "r231"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r87",
      "r205",
      "r593",
      "r661"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r429",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred": {
     "auth_ref": [
      "r759"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of any deferred tax-related balances due to affiliates as of the date of each statement of financial position presented.",
        "label": "Related Party Tax Expense, Due to Affiliates, Deferred",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "RelatedPartyTaxExpenseDueToAffiliatesDeferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r178",
      "r558"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Debt discount amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r221",
      "r558",
      "r559",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "auth_ref": [
      "r222",
      "r238",
      "r551",
      "r552",
      "r553",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.",
        "label": "Related Party Transaction, Description of Transaction",
        "terseLabel": "Description of related party extension loans"
       }
      }
     },
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r429",
      "r558",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r556",
      "r557",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentOfNotesReceivableFromRelatedParties": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Repayment of Notes Receivable from Related Parties",
        "terseLabel": "Repayment of indebtedness"
       }
      }
     },
     "localname": "RepaymentOfNotesReceivableFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r686"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes writeoff for research and development asset acquired in transaction other than business combination.",
        "label": "Research and Development Asset Acquired Other than through Business Combination, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r122",
      "r217",
      "r794"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r13",
      "r104",
      "r203",
      "r601",
      "r606",
      "r661"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "verboseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r223",
      "r268",
      "r269",
      "r270",
      "r272",
      "r279",
      "r282",
      "r341",
      "r464",
      "r465",
      "r466",
      "r489",
      "r490",
      "r517",
      "r597",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r255",
      "r262",
      "r311",
      "r312",
      "r323",
      "r326",
      "r327",
      "r331",
      "r332",
      "r333",
      "r340",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r524",
      "r592",
      "r723"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net revenue",
        "totalLabel": "Revenues, Total"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "2020 Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r547",
      "r660"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Accrued royalty payables"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of units amount"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "auth_ref": [
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.",
        "label": "Sale of Stock, Description of Transaction",
        "terseLabel": "Sale of stock, description"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in Dollars per share)",
        "verboseLabel": "Warrant price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r333",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r138",
      "r139",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Leases Supplemental Quantitative Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Benefit for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r26",
      "r98",
      "r101",
      "r102",
      "r103",
      "r172",
      "r173",
      "r175",
      "r196",
      "r640",
      "r642",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of borrowings of the scilex notes consisted"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Liabilities and Related Valuation Allowance"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleoffairvalueassetsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of the reconciliation of basic and diluted loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareTables",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Summary of identifiable intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Outstanding Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Valuation Assumption Used",
        "verboseLabel": "Assumptions Used in the Black-Scholes Option-Pricing Method Related To Options Issued to Employees and Nonemployees"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r655",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization expense related to intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "totalLabel": "Selling, General and Administrative Expense, Total"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r681",
      "r682",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes increase (decrease) in fair value classified as other for contract to service financial asset under which estimated future revenue from contractually specified servicing fee, late fee, and other ancillary revenues are not expected to adequately compensate servicer.",
        "label": "Servicing Liability, Fair Value, Change in Fair Value, Other, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.",
        "label": "Servicing Liability at Fair Value, Other Changes in Fair Value",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "ServicingLiabilityAtFairValueOtherChangesInFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofchangeinthefairvalueofconversionoptionliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expenses",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "terseLabel": "Stock options vesting description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock-price volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock-price volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options Outstanding, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options Outstanding, Forfeited/Cancelled",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the nature of any other increase or decrease in the number of shares reserved for issuance under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period, Description",
        "terseLabel": "Shares of common stock reserved for future issuance, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Outstanding, Ending Balance",
        "periodStartLabel": "Options Outstanding, Beginning Balance",
        "terseLabel": "Number of option outstanding to purchase common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of total number of shares of common stock outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r437",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Options per share fair value",
        "verboseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Term (in years)",
        "verboseLabel": "Term of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofderivativecomponentoftheobligationisinitiallyvaluedandclassifiedasaderivativeliabilityTable",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofquantitativeinformationregardingLevel3fairvaluemeasurementsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted -average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Ordinary share, per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.",
        "label": "Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]",
        "terseLabel": "Ordinary Shares Subject to Possible Redemption"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r5",
      "r184",
      "r201",
      "r661"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Current portion of debt",
        "totalLabel": "Short-Term Debt, Total"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShorttermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.",
        "label": "Short-Term Debt, Fair Value",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "ShorttermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, the maximum amount borrowed at any time during the period.",
        "label": "Short-Term Debt, Maximum Amount Outstanding During Period",
        "terseLabel": "Debt, Maximum Amount Outstanding During Period"
       }
      }
     },
     "localname": "ShorttermDebtMaximumAmountOutstandingDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r262",
      "r286",
      "r287",
      "r294",
      "r296",
      "r304",
      "r305",
      "r340",
      "r365",
      "r367",
      "r368",
      "r369",
      "r372",
      "r373",
      "r404",
      "r405",
      "r407",
      "r411",
      "r418",
      "r524",
      "r617",
      "r677",
      "r690",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r31",
      "r97",
      "r223",
      "r251",
      "r252",
      "r253",
      "r268",
      "r269",
      "r270",
      "r272",
      "r279",
      "r282",
      "r303",
      "r341",
      "r420",
      "r464",
      "r465",
      "r466",
      "r489",
      "r490",
      "r517",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r555",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r303",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r10",
      "r11",
      "r97",
      "r98",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Shares issued pursuant to the terms of the Debt Exchange Agreement, (In shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r97",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of ordinary shares to Sponsor (in Shares)",
        "verboseLabel": "Shares issued, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Cancellation of ordinary shares (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Shares issued as a result of the Business Combination, net of transaction activities (In Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) forfeited during the period.",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited",
        "terseLabel": "Ordinary shares, subject to forfeiture (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r10",
      "r11",
      "r97",
      "r104",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options Outstanding, Exercised",
        "terseLabel": "Options Outstanding, Exercised",
        "verboseLabel": "Stock options exercised (In Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r31",
      "r97",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Shares issued pursuant to the terms of the Debt Exchange Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r97",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Shares issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "negatedLabel": "Shares issued as a result of the Business Combination, net of transaction activities",
        "terseLabel": "Shares issued as a result of the Business Combination, net of transaction activities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r97",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r14",
      "r15",
      "r67",
      "r661",
      "r692",
      "r713",
      "r776"
     ],
     "calculation": {
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance",
        "terseLabel": "Total Shareholders\u2019 Equity (Deficit)",
        "totalLabel": "Total stockholders' deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r147",
      "r148",
      "r152",
      "r223",
      "r224",
      "r252",
      "r268",
      "r269",
      "r270",
      "r272",
      "r279",
      "r341",
      "r420",
      "r464",
      "r465",
      "r466",
      "r489",
      "r490",
      "r517",
      "r529",
      "r530",
      "r534",
      "r555",
      "r598",
      "r599",
      "r692",
      "r713",
      "r776"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r261",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r420",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated interest rate of the subordinated debt.",
        "label": "Subordinated Borrowing, Interest Rate"
       }
      }
     },
     "localname": "SubordinatedBorrowingInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SubordinatedDebt": {
     "auth_ref": [
      "r6",
      "r8",
      "r185",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of subordinated debt (with initial maturities beyond one year or beyond the operating cycle if longer). Subordinated debt places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.",
        "label": "Subordinated Debt",
        "periodEndLabel": "Subordinated Debt, Ending Balance",
        "periodStartLabel": "Subordinated Debt, Beginning Balance",
        "terseLabel": "Subordinated loan",
        "totalLabel": "Subordinated Debt, Total"
       }
      }
     },
     "localname": "SubordinatedDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r535",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r535",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r535",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r535",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r562",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PrivatePlacementDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_PublicOfferingDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_RelatedPartyTransactionsDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_SummaryofSignificantAccountingPoliciesDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the limitation related to use of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Limitations on Use",
        "terseLabel": "Tax credit carryforward, limitations on use"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "terseLabel": "Accretion of carrying value to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofcondensedbalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r365",
      "r367",
      "r368",
      "r369",
      "r372",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Ordinary shares subject to possible redemption 13,800,000 as of December 31, 2021 and no shares as of December 31, 2020 at redemption value of $10.10",
        "verboseLabel": "Ordinary Shares Subject to Possible Redemption"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofimpactoftheseadjustmentstothefinancialstatementaspreviouslyreportedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of net income or loss attributable to temporary equity interest.",
        "label": "Temporary Equity, Net Income",
        "terseLabel": "Allocation of net income (loss), as adjusted"
       }
      }
     },
     "localname": "TemporaryEquityNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Unamortized debt issuance costs",
        "terseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureDebtSummaryOfBorrowingsOfTheScilexNotesConsistedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r469",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Total unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decrease related to prior year tax positions",
        "terseLabel": "Decrease related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r306",
      "r307",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureNatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureStockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsValuationAssumptionUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Public Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants expiration, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r285",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average ordinary shares outstanding",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted average number of shares during the period -diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r284",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted average number of shares during the period-basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.scilexholding.com/20221231/taxonomy/role/DisclosureLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ConsolidatedIncomeStatement",
      "http://www.scilexholding.com/20221231/taxonomy/role/vcka_r_ScheduleofthecalculationofbasicanddilutednetincomeperordinaryshareTable"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13572-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13587-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(b))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.7(e))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.13(h))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.2)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "720",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=35755714&loc=d3e28434-158551",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=126898705&loc=d3e5864-122674",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120270059-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918703-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919784-209982",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "5",
   "Subparagraph": "Schedule I",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "7",
   "Subparagraph": "Schedule II",
   "Subsection": "05",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "9",
   "Subsection": "06",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r666": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r667": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r668": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r669": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r671": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r672": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r673": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r674": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r675": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2740-109256",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(b))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>104
<FILENAME>0000950170-23-006493-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-006493-xbrl.zip
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MP&U*JBS&R((NZBE#2+YN3^3TVO?KH"@XU"B45F \THU7(A UGKHJQJC^0X<
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M=-M/[MVDX$#'5A)[@ 1TPNT.J(]0'IL0!Y1^?8TO'M1#9)[TG6G3Q?W-P;3
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MX"A%;=54 8@0EDLHCR3?HN/"=567K)J-9"84Q:)FC5.&Z<=R\IF3O#)ZZ'+
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M]:$%%/#9A )!F1"<!0^(QRQH&99^5@O(@_I2];MOJBC6#1QX1%=8IIHWO^9
MX-,@3.$_/U=HWU-PNMW+NC@[JQ$KDQ#[]%&AY7V^Y5C^S6W%1-L\UM#[#7PE
MM16P=&;S%0H([XL>D4*!8S50FVX):,A#$8PL"E8W\PKS"IBY!\R)N#QP3':B
M%W(]RVMJ*=V1&MRQSG%9&/:E'+3?$>V:#6!LRG JW=TKJ<.' K_@*;_"HAC%
MRF%4@K23K.WS8XS[\/9#RLI>?IN#'&_T A8:WNYU%>_M=[KM3@7QYRSX90>"
M3+VZFW_)HG)BI]8K;7:7/;1KPEEYO*ZZM>L;)>[;+QR(P70J>&*&[L)PF_[G
M':1C!]]F7EU^-W!@^^EQBJ/8W:73Q3$H #<$!?#40!4V[4EH6H*N)J6=7&%U
M72\Y=KMTHF^%6+-ILZ+*/TPDQ-,IX,F3<TV%Z_#GS NG4EQKS@<;_(Q$&DQ;
M?PF^K(0"+8Y0H$-=8[08<P X-:*2JY:(;N CI"\A0W+?3BQZTAA[@"_&3X2H
MQ4X]'88.8[%5Y5N?>4D=,>B7"%5)GIF.ZXP//@A4U[YW-&.7<\(/SL^:#"HM
MO#A)>,56L?&BL&A+2F:S&@56%J792Q%:6.-=$C3_RBZ\DZ][317991YLVA%N
MTF!?84FJ9VT^&:\=_DSKC'=)0O%+?C2$<1W[:B%%TC_^.U#XWW@O__=YD;^$
MS*,Z#JP@[3TET<Y$W@@U8M#R(.M"/BH48+B(/J /S#A;-[#?>>N2:9VO7310
M</"T%3GPZ3SV]$3]R5=!Y;K1$L2!/"(A61**6/$MT.?]:_^MFY=YM@4SP<$.
MTH+Z)(?4;XEWL]45I>M6C=EM_#?"REA')/'*VO[+,6N\B38=G1>.E$81G:/L
M+[/@HH-B,U,)#RBC4#2='!BE]=8H0XB!#>ZA#XE(V985E:,Z@?3D=IJ$+?QL
M1";PR0X+XF3B>)DPAWT9-4Q$G3)33: U2R!E&YF,QD[8FR<T_K3U!O'KG %M
M02L_P/W1D<D.EV&0$,/'6^B<>\X6T<UETOI(N[Z\@-&@2DYS PV%29>(:MJ,
M:+-$#G!)6B.C5W4*XW**%FJ2Z[P8-2E5-_8/P8,+U,T1=L=[.=55__CHV4E2
M@6NJ+ [ARU&-R#9^%8G\Z(D7^@8H6_E;;9//:;;M\BX27%!P&33F&HC@-&ML
M'5^DM;W%7>5+G9F(>$@4MB&SX/"]1T,#3>2UD/\2&5\ZTKS;V+>+P0)8>;$8
M(D=$%3EEH=_R72V\(?H,X8)[7[&C7BK&[F)L_J%# \B%^@UIB&\#B6-(LAD?
M\FBLP0-S190P>3SL/>QEN9U['_H-[4"U[=XB561#_I5)^SK6$B?\.>[W$$,&
M=XFM]=,#$.[9*=*8+?J0+[(/*_/>-6*'I)0)6A/V/ :6X7KH [H'.9GHC[]$
M1.FWOQCML65N<YWMSCTH:'CPW>4$D_14,:ZU'JU[:_)Y_FF/X+4K#MV&IRTR
M&F<./(/W2P%5^B/I]\7.LLZ,A?K%V50I36,,>FNDE-:9X>)B>.<&9!8W3[5I
M+FH4IEQV[9JTP[^CB0%^K1][*)QX!%*91J_Z)(F9=L;TY-&_2'0/V=(?A TO
MB?:=A&"YDF-(/_&J]'IBIX-(L;5DC% '!=3<YJ;.=]78A/!6;F_M$3N"/Z$W
MOJF+N2^H[AAC^/811 WN]5![_8OS=8W8R\=F,;P90JSO0LR0[0C_3R]?'53G
MMNSY$0B08(&@ 8)M@@4)[A:"A!#<W8*[NP0)9..P<0GN[JX;A^#N[NZRAW.G
MZMXS=\ZY[TU-U?NCJ_JK6M75W>MK^:VUJCFW3+:(UH@F\._-<MA"RUQ '!*X
M,8PQ-F5*>E_A;MRKS2\(B##G7]9D7<M_&BEN'LF99<5:]A4Y?667%(GR2IHJ
M:I#F>#."./L7=L3G$>UBAA2S/,TD.&^."EP9I"^8H>- QVH3RX$H@LFZ(4.Y
M14T4M:(39D@=%;$W2#&$3K-BTK!6G7F8B#9D$].[+<#UK>@'7^1<2W>:](56
MW9213.$#LH%3@PI]FZ']]0,<H\^_SP^PV,.D:Y@*GBL-@&]0DFP[;Q. W^G!
MU,#?T7^C#S&<GA=#L+/BY!)]FXF($+9WK1C8,%8=21$QWVP[0MVS2%B\-D=>
MGG><ZY*AA/J1"8&Z]YYO#WO84F','=KI6A0<" /$,"$:B"JOUHZ,P."3BC#]
M:VC-K:VZAG_U.^7W>FA8K^)Y[:9R)H,J?8@RPSCZSS %9U6\;?J)T)H\!*#)
M#S^>Q3I%/RM65(2C@J<@.NL>3:P+/'2JG9.26^1Y7IE,2<LL(4.8W'I.1=S$
M(I>=E]-)>;KLL!3A@W76PS7D?&N?#0-T"=XIAF3-=IZ6!;SDZZ5(M?KLN]B^
M4+1QEFE#'=V9*/V\K!M_ZRDI_S)E;OABJ[FS9/S^N.PG2I4('12#HD1 JXJR
M.B,G4__@%2^X# & @IF1D*A2*OE_E-&]>&<X=X8EGZ2?S3)UDJ_FGS[3^P8^
M4N'P-L#PP7'KY%=U0 S-=B+^.\6*N&>\.TF(@,YSH@<NSOL"#AD8$.X. P[?
M5(A-S\F0#Q)1?!71#1.4@)I2YI=-H0@M1,AJDMR3<:?>/\QZ2HG]DU.]H[ED
MNMTDN1D90D<S#3');$IPBYMUL/UB?$C8USN$N$$QEU:P=.RWZW5V97+#1O)/
MCNWE3P.1,GS5>SGMH'CV#*+?\W2"79OA]1!K)=YJ3]D:TDO>LQU9:>?(76TS
M\7C;55'AF]ZAK^A(.&5/..;K$TH2<$R-DOTSWRM?2GNM6-G"0FV*;.#75.L0
M:A2>QX760&1_>76K,&9:.C108MK^^E68*7>!=9=/CX;33G#+WPB3^25+I_*U
M&F=O\"9>?I?<#?_@#44YV5VY=@P7*"6Y#<KG4T RAYG?2E&A<)HI@?Q<]+,O
M#S7?792RU\J+)Z"V=3AV:BKP+]:]BN?%9#L?5^RJ85>N:+7>I#'!VJP0S;NQ
MY!FBY5$O$^9=.2VH/T%,C' +[>>8'OZ905,8T/[Z"2\.+^2LCWO]B[55V!>P
M\I]:5+N-=[S-+&-R@4N^WXA)$!W:?\9DMV]*-Y=9'Z/&.<LF&Y)9C/2;-I<D
MQOSO);']:,^SHZ&[[Y/=,_P&$?UN;>;#C08#[+90E7/<7_HPKOBDOU)G"@&=
MB4=*=<6A<[7BOXV[V*P2^$L;N4P=*97:&2M;7K_=?#@\&*$4602+VRL*?1_7
M ;C/$O+^\O>1VQD\9PVE0\,Q!-E%*XO]W=;NYTQ[:73  &ZN/KJGTNE']01T
M4QND>W/_S%_*[Y/\U:*\8^=W5T/:_(?SGU+CH)G5?!50KV$^ZJ?E& 2!VL9]
MHZQN(5I;!OKFDH_E<IS:5G8'6D'Z^E8Y:D5-]19"O50%)'(>)I>0<%5URJ9&
M70HM;\_,VU37A/J=41DMHZ"?77T-Y:-DG["5<O!E_W&(^2]24*9C4?M2O8'0
MA2_6&-Y0!K498MD9E)31TOC)0_@S.V3]%7046PABCKJ,H44-_[WB.#;8H&R"
MGDU]VT@]_'D%VN>53KH82L?RLQX0%V6 S6_%LA4OS&Y]-VS7=()OM:)*''(%
ME;3J+PW@K3EIAKGF?*U-R4[(FOMB26;H0.H?ZWSW)=IT,HSZSX@BVN:6YI@8
M.RO0DZ;&/NJSVLXW6M]P9.@J!I&8-B\E#ZT"K;UKB]X,\\Y675]CD1-F#!9(
MHHL<R%D8WPD.%80[Z9O IW4#$9(F*T>OU$TYIJZ4S:QA@%X"/D@]QX0@T40[
M/#]?WX1 ?A@I.(2?S"-_5/('_2OD;R&J(G,]:"W4]Q@,LA4Q6P1$"3_<1>KQ
MY H3#)-DNTW'+-P."@=XRP%*@,(\+>7!&H, L CT=Y?EB\Z1'?_!+-RL6*$M
M20N]$>X*DFW(2-+Q5H?W1M.H/%X*LK#"VKK3&1"5%&.;'_"+B=:WRO["'S<[
MW;8W.:V9]9ALX4+PG"K(0*X.BCQ, #SJ>-!V =8VSFY=[+<. Q6[H5>OYGHF
MRX1<6+XS'/00>J*@?SA[/762.>G.LX9RP",>W*$4NN@<R>+"HSE(6($[X/V\
M+P+L$Q$Q'7QDG(;^S@O5[$QCYR?EJ;29&5.$7VSDAO"0YE?V5-;HV18N?+KP
MKQ)9S<=/_:K1Q"9D24%E/V5M4.'./%V0QUXS#;T73)3<58KF6"F#A,GOLYHS
MIA? <]W5 _D(:IEE05L/B]1Z'=*82G5(=+&:N^3,T^7$7F3N8%\;8-PW$*7]
M)<-EX0Q,TP-O/-.>(K%NM_TDY;7'2@O6TJZ3WVZ+X=BF0VM54[(!\HMM;@I]
M$GMO*4MG.6(EXF>XDUE&XX;TH+0DO]X5L6R )-3,].^/3_YQA!)X$GOOOPH#
MBN%A@+#I(=W ([F[R,0]Y2KR^_?T^YG!DHIQ\2/]E@QK%>C\LJI*D6 KBM_]
M-.-Y/S8RB_=OI[,^/37^QPV\$C" GUOZX38*!H0^!35*16?JV5HF#%C*$[C>
ML+TS]8 !\-N/62%/P6H& YX]M?KVV,H"_[[0K.N$I)O%A<Q^ 9D@[4XX,/H=
MQ=JFQ1A:1LKU()L<QK?'5:. KHY5L/+#$PP$*CY]ZSV1A]J(>8 2M"+3H=*T
MRSCF&99S8)=XWA.HZ<[)5=C$!*'X"'Q]!2T!\&V6N16#A])[M\DC5Y'T[J&3
MFS.F/NP1L:4'DC0T7&/WNE+'J+38Z1'/*$A@J_O)GA8YKY,^@15'YZA'=_O4
MNPLJ&$"4=9!W=8_F^7_8@6/U^:FL-L4^.(4]N1"GSZM]_X3J_GI'X&I7^I%+
M^5S@YR/I^+U0]K244?9[9659X0WR<"8E:W3F!Y?L OEF&."#P^0\@3B/NS3X
M9-1E/G5Z0UC8_]<;JS]3T,$*Q#G'>2(KD%\]HF]=9VU/;N0_7'+^!W+F@ [?
M$.W#@/VWJ;?,GZ\2CJU"4D^Y9F# -)_ N4',X,]'@D/KH[O=<Z-$627[JP"^
MSQ.'PG&X!LR6&B%U!#U'70Z.Y<Z:;W?I"@HDA!I<TLAI(/29:&DK\'!3WMQK
M52YE_K>I5FH-V8^X#YA=4T)6:VBBPU\#^B;(_?5"UE3AQ34LX4%8ZXQ?5@0)
MJ(*G,9;[$Q,;?N9E#-2P<+M7Y!%$K:^(CN .U=Z<C:956J$(K1S(#-J8.TA@
M?:H1UTL%(,O/9I[;](#@]Z3>0<)RSD--8U9D*;GE',UR/)M_U@4WD]>S<T"F
M7G783XGGC@UH#\CD6+>APG%M@=Z,\?.-?PF0+IL)-(A0"6-%8F#:[_#$3T)'
MIFM=+4Z]%DJA^>P=26WPZ9T[4_O]3%N'D:- ('RX<WX"[J_T:N]+[M1I7%T*
M_%FSCSVMI+P1)?'@K5_#0E>VM(67FR(2HTDN35%+-9Y+-KTCFA=)GN@557BV
MO/KN40^I+C%9M*!V2YF7/J5)6TEKB[E=>'Y??]EMSL_1I\ZT>K]WHNS7.>WV
M)K))>>FJ8&OBEEAH:G$7.=8_U$VBQD]2+TF"9>(4&?!A;J&+SI\HO/A%=PMV
M_4-7T62-'5N$O.6<HX5FQJ&W<^M10LX3]B:Q\6JD=70E)NG,.:+3]#3ZK7U<
MS4IR<SGN=33ZCZ%(T[^]MN:>8KOE*3:ZID)DU3UL\Y:]=);O!!HOM:_5WV#<
MWYD*7.T(_#$'RMQ8X.S@J6XO/47VZAXT?R,EUL$+N[QC_<<J;?&9AM@KA"UX
MA@ZJ#3Z^)R2F7)H5L9Q>0I>UZSI\3Q^"].A117)WGOK'O*<_:>"PIG""'?+Z
M,R;85- (WONK]8NKMOO<VXTGC?ZW#HS_48>^T"!GUJ.:S:G]Z[LELY^.-DD6
M"PV<!^ [)0\,/%7CWE )G]@.IS.^V$=<Z/>G9#8;]G K_<<PI#\+/;ES,RE.
MGL2>EWTC2@#_,@-TMD]+RU^G4++_'N>@9-&-\3^J+W>[(?/8UG;IY;+?\E_X
M5FR*-O 2':/B;MB\XCIUY:ZA=EG7R9)H;2"!#9D_\T.7H_@>.5T&HA(!*KK0
MVZHS- <MG),N&!!(K&-K:7_JXA]&<QA8,Y9S5I2GKWD@LPI=Q]S8[.!SX\^I
M'U&]Y:_2+9ZAG_!;%1%P<64F$24.,59.2S#=OG%IEXD"QR3\]R::X*C+2&2.
M,41.ER;_LGD[.>NDLX94PPKW+?CLLORD,WV1*D$7=_\#UL<X7_^7K1=ZMC-#
MA]_#5/4"H>R+)'&9RN6[C#CE!;R7CSHZ@0-47!_/=!Q[N 8!)WOEYRO7]W;/
M=CZ86EBO2!+V4K(?JL1C:&82-WRHL2+=(@6_++9/Q3?5V]:4<+( C<WE>56^
M-\54D[KCC<>IUBEF_OCV@1I^Q+@8=TWZQ#'>B6):VL&#) :;BKD]^XN(4+2+
M]X'%]?*QK5U*^FNJSM?8^CV)=J*^HDI5B,P8/$(]WWBQOF(#@@1M:1B"Z76:
MPG/*M5.\O*N+U^\I!AKK:NI>X-J$T:>?"9)&U2:Q/_-F20+/%/+JS397^VZ>
M%!)T0DR' :5>Z1CQCEQX)R1B)*HD;Z=H90)L3[K$59#<L!6SLR<H$76L7:$:
M^/*\8_G4NG7Y*F<[W+D<37A:JP*%M,L 7"EU&F/7P%OM9$[LEL('\+RD&Z88
MN[>R5%I]<6A8]T,\KB'R610\UUQX2\=&N'.'XV61S"*]-@J%>:V'C,8SF8=D
MS8QN6G5*)(%.["3'(T%B!QRHX"/+XV!,L7[B,(=$C+?ZD4JSQ:*L?F58PU,9
M8^=PX.QT;#E.'+:@'=Q2%Q\31:F9"9(]NPG@-3"'#ECU&W&EH2\&K[ESX 5G
M34UN:04;KTDJ@[U/7'B"A-G]*(-:S2'$0MV(#;1_WV.T-;-[]6P9/07J.0P8
MB51NG/KN_@18(H:&']MV8$ &J-A<^WC8+M!K23F#=[:^Y5IHLSX93ZK%U\WN
M54RQ(1V1KLO\#.JT8O=@ X*!C4:6%?NO53,!_EV3JF?N?C[%(",K>A(LV@ !
M^R3XL"*7THT[\3MSL:JQ&0FJK5,& 1_+\7;?QZD!+]8> D/9-]E+B=&]2+9K
M\+5\S")*_"];FOU!D@W8C#1!LIEZ$F<(7NV9.G6R25=(V3:0^LWRT6?U13<>
M,_BU[NO>S4WB@ ?PE%(JJWA<7GI4'U*)@<+8H@LL%_;:YN%NP1<YSMKZ_%\4
MBX9*=G;5'[M"&CD>"G"6$IGY9XHFY*](J[&C6ISX^\-<IZ+:3'(632YODP=.
M^/91>](7 BA1$5M=%L!;O.C<WDY*K*/7/\6J:VI2I.2@B _KF T26*F7T43H
M6Q%[1PIK9EM5)A0N [C]I>'=F 7KF/OHTL2G)EIT]NAL6?D)54OWS[VHKA[=
MOK?_?#YXKCR%)0+9>Z6*(X-D9%%'&(>6@<XLSHOJT_/Z"3(2H-J:T3/\H@G\
M'"'B3U\7HX*5Y6ENQ#DL [<02<=QT$PQ=M"\1&&**>;XD\C)-I#0FR>@%^/W
M.=^+_*(\T\D:V7E))X?-.I8 %Y6C>2:5LZ&5M@LBQ1R$"^TI86P;YJ9\QMVI
MG;T=6V*E[CL6E:;2I9;]L4:>LJOJ,H('6CKIZ[N?#RMRIN3[IAQHGOB://&4
M\P"H9C"%<XMK;3(Y2UW"K6!F5A@.XC(*ZFV=[X2[38 .ZY?QR#>F2@VZTE7"
M '_=58S#-AC@]9SDN)!7Z&%:X&@Y_X\9O2E&EY#7CYZ,C:M[:ATR554CC*0)
MLX3QAK7^D32-K4P%I.]?,I]RH.>T?%[\&RD*IB7E(B?37 7</X_VV3VD)27Y
M^"R.UFH37JPYW.E$1%(B.Z$5X$]S6*Q(&GC;04VK-O->5$S26USD+1@Y&\BS
M1GY(1?Y8[ @^53#TW8(?+7IR=ND)TI7.4X[W#;M6>DOZN$]R=:S8QY;\,);
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M2E+?J1O$&]F*^@K0DL*+961[*MP2LNE+=-F/:^ CY7/)G-(I^[N>]DK(%>;
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M%5A3KU8TF<Q7VN+%,31_@&48U(9(J;00P*5GU[KUY"NLX'563?A.Q]A+)^Z
M@JWW*JKZ>'+<Y?LZSCIP/-5$*<Z\MQ?G?]TK#Z<2>ZT[E<. 4ENO[5ZZ;>Z;
ML[62^]!+[4MTZ0<"2MV@:PSE=S# 50M\]H8Z[^!]L=76*3VI2];L<!GB5VPL
M+R$MCV(/.Q.ZBJPQ7DR&@I7M"TFWWQJ%A9>K6 ._["K!1.$J%LL&6)Q<>6$=
M-[H5M9%[<KX$Y,KAQ)'8]BI7,,">B1>SYT 5Q6S5@LU )B$YKD84W:]1E)7S
MVQH8WEMZ-+^ZI;"QV6QWZH!*@*O.U@6?=^MWQ#F;!72RNIJ+RZRWAJ#@#8<6
M6G-E54.M6P-Y=9K5,]%^]H4N4054?](S\#I<5#A5PS%NGJ%QS6L-51\0/2\U
M\<_/P0'"8OT^I\\\]?BX3U2T9V<C0IUA0"5#M?1CG?MF9Y+^)L%6*%?>E/H4
M0P8[A<(X*'1YG\DCJZ\WZC=X>3UU,LQAL:=8;7<J\NRQI23BR7L8%R)!61R.
M;]6>$=Q#X;0!/RZM3":NN^9,92JUWMR]'?I.":]<.BC^0+H3 ISWS-:TT38?
MG<!^Q4/8@:?J*4**JF=;69*G=E]TX450%H/#O6@\FDH9# C;]EK"T:IDI1-M
M.4%,-BC$*;;4]_NPC<*D\5C%'U C.Y$LM11\Q%CULV$O-L5X4](OX(4E"C*N
MC"@>7X 8@+I6)<XKA9W 5P6&?./Z]>GG 2;^E"WB\.!=^58H$Q$Z$LZ<5WML
MU*.OY*/7,NN_6+;\'%5[WK B'?-8YK'Q+<J3@"@+M]RBZO"I5_,+3=V)K&5U
M] T!GYS%97V=26L$G/63JD_DO4SFM(HBOQ'N' Y8SGU_\7*#VQ%E:BG+\:G%
MS5I_*L"1,"#U&HWDSQ]OAZH3+!X\_;HQ?;3-SLYY]U0GR,</TR.10;Z<4\9!
M"7QI6P+4H:RR-YYLED==3K&S70L7_<.L=I3M'Q%JGONA4%.@I'10>"/:S#:4
M7,N=>OV6\!J^1PS[%QM;7C#=4JQ3^(<9ZY7#^',J'LF9(Z,F16M!6)HCAS<L
M"QEZ<$.><CGS$V:,KSOTK7+RIUG/9K^4N\0R%WXW1HL;6W^N<#B$PH249)!P
MT+(BV0L#A"AA@,#Q&X$_?[C'E+AA7B2A-U\^YJ3NOFE*?LPSXU$9O!0O?3LU
M& */NNY_NOI)X^K&[DAF+R&FN<#C,M'-9;GO@.9]/ZD,IZ),[B\%] ^#KASW
M-"X"VZ"6K4=XL7^Q<ML3II.LH1Q(N F0Q9Q4R>*;:KFYAT3"_?3*A9;L;K2&
M''=]G+*,ZU^(N2"I5QH+==XB'T55S 7C^D4[X<'W#>(7;.-/'<H_-W?BFF?E
M(C6 ^-#0L*Z!:L.64^C@2$TX1NGB=WLS!V)>@]E&2>P-F3OA\L7HP?O#"_R(
MDA5OD>\$IU-V'%L0MAG93TZBM+0]-[,366KNIR^ITW-[_M-]]9^)%F7&T!>Z
M:BQK .&<B< /Q_<)?P&LG>9MIZ%C#:\2U$LZAU25S!J6XR%\=&@,8(KGH+5
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M(DZ+44F$92Z\%JL<R0>V:D S'I64H25R@7%[,#-T0;O)C%%,PX=X<N:D@]1
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MGM_# A[NLQ7UKE-[%L-J27SU_8;D2O*2J) 0OW/65Y3Q4Q]DC\ES5.-!G6#
M5NUF@^/>!-56SS5>>P;&XO2E5A0JIE"=-+/LU#G]R]/W:LJ'"WUDH3WVN+B=
M&3&R=-(<EZ95+-*@[Z_J;S>1B(3:3<6:"+T\ ,@;Y)V&&R_$=.S&.R[L]+?L
M>)ZJ>>X$VXZ8(M'EBT$J.&W!*<1#Y-3QC)&9P_CHM6/UJ_MY14=L.GV2$O=9
M4YWR;E0\X+@Z!WL?]  M-+90K<!VG^OMFW90CZ2""V(0)7% $@IIB1KG%H53
M^"D:LNO?("Y]PUZ=HR<3/%T7I12XPDL<RTS@*+5D\7W[*.X]Z[BV$B_D*-9"
M.C //PW@!%PAL&74#6; E2+CHP'>3$5>;+7.E:*Q"+T0J1E*9>!UI5L:"A17
MTED_K"P-7*34*9>C*:A4&NK(^(6?>.FN50@(3"B=AB>U H^U4+*\NPH?1&C@
MN90BPK_PI6DO4A+[Q/?>NLIQM1H+V%S/LX836B J V:YV>6..Q_=C(_?:-P[
M%S$Z%'M&6U.6[&H&YVMXB6JFD_+9JZU7S]IF'#V'^M( 07*DE(1;@JV/N3?+
M!4VV7[7;WN+&K3,PDG#P-C#8CZ69!#L4(*XS:'_@SCN);3-MF.SD=<UEK_ 4
MG+Y$:/#LU/"I(F5Y0$_<-^DLLI#CY/HM9%6$6R95_CX>;G9Z (A%_&TH9S^N
M>J'%2]Z5&RMT:+RM#Y>\N'%%'O/0@-K#,\H8<_M?]PO$5@:IY\I>:J,!.J!B
M].#T\GTJF";3)3MBW*T1 IJ3(#R4QBG\PJ4C?)YW:;$%P/7%$WOBX)0A[H_8
MI[/WPK.+4ZW"&>WOGG8GO-1-@T/R<?3$*E0B!YUD0G:\?547"R_YWB NDP>N
M3D)U1SEL6_J";6D'E@>_V-\E&#Q7(*AQ&@(A*1X.9?0E'I3YB)([-CV'!9HL
MBDZLIJ/#($\L!>3\+:MJ)GCBE<?N#Z</)WL,'$MK+QE/8@%HY&WW@_I(LY/8
M_?9>[_].[/Z3_J_IM^Q,\M_G::PPYM.*@UNUW.GU,0O!]3;G6M)+=QFSB&EO
MY +DK^.A0,G%B,SN6A5KTP9#',&A 3O-%KZ7Q"UI5.%#^=RXPE5!D48<7(.Y
M6=$,6:K1"L6-X==XMC1.4QD:O7(F0VBFZLI>LL!A8+]P(LA"_NR]V A]*<>K
ML-!EWAG?-3")2)ZLJD%Z "4 !ZX0R/)8_P ;Q_XC_9[<B![RD79="FYM-(\'
M&UW3A-G-MKW63I]FZ9%)K[N,T5_! C(Z_J^;('O[Q5B@4'O5HTFSY#"'6=[-
M?+UD]-@O%PL$^4UL;BNB>'8I<H>/M2/^(UO&$LU!R" 8"_"T]YDF'()VL$!J
MOLRD>=7AD>8VU+=E40@+Q$Y;%W<=TQ[X]PRQ_2IVOTUZ<IL)"W0Z(?3O8P'B
MHZ:YQ:BO<GTM4AWW(_R_B(Z RK\U_U6N=)EZM:]"T\9+>]J/7YO_*M8@YY-T
MAOF>FC!TN>G7QK])/0'%]N?"E%LL26H_3;'S<A/ZVX]QM!]* @R?B8S4AO=C
M@1]!R[^BY?\ IKQR#%EZ:.J*6-MO7-+0)?@ZNRJE/V):B.NG_7X<3(&?\8%4
MI,L_"+S?]&ADTN HAT$TK^FGG7YH3/?,"&VX/!K[(AH6(3^FAG]%J_\A3*8R
MCXP(PXYR1',4/W-&"YW,A(*_P=K_\\+Z*W:5Q3'.O8BD%5-\6PE_7 0:<J#&
M_=O/#W7^DI#_])CD()^=Q9QV7MJ+_L[X]@\9 ]GGP7XL%W&\8OVK(D52!*\?
M*#:)</KN,;3)WQK\Q'1[))@:8=NN:NU*HRGOV5'[K]Y4]=]^MI5Z%PNPG3D"
MWZA8EIF>\B\"K+_G&:(NG_JQ5 BJ>.AO?P\&<6S9MGG^*65G$X=>;[?R\IF;
M,-LQ"[*DO]0 W2P0,FHYEJ(N[/W#=9Q*6,"I,181M<N\($N#F*CA.ACRREUH
M>JB^F[_]779],((%.@Z'T@QWFM!80,CZ>TI--?!,_[[*+.P?=OT&7/R.Q &N
M1!1FUS_K>HY_1^[^X.X_M^0L,GEW]I=B =;@W(4)/\AN+N[1OSI9_4?IP0?_
MCE8L8-3[SRG/5-$^L?#=XVW3?*/40V^*$\O\6NZ4+7><)1V[_X>+8"_].CI^
MJ\UD/!G;K*%ZMLB00Z^+AG^\BO*7HA >&[95D?X 'IM?!X?F@-],ZIKNXG<5
M[?8@3^RP5W"C8L5_^MBV]_O*/&NC#KU$4%F5)R*MC^/H,DZ@1VSGV3=-C\AD
M 2K?,?I.N__#N,A;E9D>.X[#3SYI(&-)EF[^.PP@USO$(K'6?;QM]E>JRS3<
M84.C95 !@M]S;UR*SSDQ<,O18IT.4@:SPV8$("GV8_>U%YYA@3SU+.D_KF?P
MVK'4O7V=H5^7%#B^@7]'NBZLZ->Q8OV'<["9_M43MXP4#R*VX,1&D$\Q1XL-
M.BZ_KBC?95>!7P='X8$Y!@O $-^5*,8M_H=A(7_B<G5D^-H:0S [40NRU'U_
M?.7'8>DX]&[JAP\T30_ZVGK_W;+2BU?['>@IMX04U0XV_1OTH^1T7-::1$Y\
M"K_O.JS@7T@UJNKFQZ^K(6.>2=VNKG/2OSZ@02$LL@03>\)>YO4]C/R"!3#J
M6&!A>#OC^ P6V'<] H>FUQV7J)=-'7DU;;)4'7)A@:VE_3XL0(0%CL2/D:U]
MBD,+.Q0E^L>6OYS(A@6.D_V-9"9EL$"..:H:QKW?(-V\O8@%WKE-K*=B@8&2
M)<6O,H;/R+/IYWR0;C#?BQS]VIKU;R*FK#,6MPX(A@NPP-51_]?^6$"MJ8CM
MJP@351I?L]0[^]O^LQ*0_ZQP5,' ,IM9R6&'_3<U$=\D. EJ;GOY!BX-88$7
M*TU?U8SZ*J*8$RI=HE[J^V=&BB3KB93$5)+8.<.FYW\7/%(2Y09GNS_/X_^C
M*?SOTS5_'.G 1?1<XAFNCT[/4=6=?X=&PV.I\\GYRO>7U'^:Z<^(-*3CXVG?
MA.WB2[]C\:V*E RZ8U\1 TO]::2_"E)Q3+V#9?*,\-[82,Y/,_UED+9/=YBY
M7,2K%%"+ZDABUSW@=P2%_] *__MTS7<@542O8C[Z=86':_,=.L^TE8Y:52_^
MM.\/A13I0G'&W]Y$TDRM.T.L1+"XY)7Y!F7J@N%0!F$S(F+]0^U  </;>2]:
M&DTSSY6G7DP9.;Y[3>,%'=]JHH&F[SM][U]'9J[3ZI@]]2(O/L_A")GI+]+(
M1C9,[DR'?]V;+_/IT*V>Y']Y(N8G_<]I\1 /"YPG.H[KU-?_?'F/4'VK\&0<
MD26+RDRW;EWB3J_/6#C]+4>G.]T[Q"))Q?&1K4V6_GO2?_]3 CU#-X5>WJ)%
M&A,.S;R<)@65E(AC4GFJ8E23]9W99[C79$FC]#&/>/TL;-97VKWT2H+J-7V=
M!4; ;YZ9TK7>(4?&0-!GM QH_4NY[$AQ<?+MR6:+,LV7G&_L.!M_>7:E&4ZA
MFUY?][I6K:'8L#GW;<&;Y_'O^[U0.5!7YJ[DASVRI=76(SK NYPT./D.=),D
MF=UD'?%L3*7@K2>C@\YL_)IA$]H* 7-]LF:5Y?E,@T!_RM=M3A$V=$?W+D]S
MM]W"+H6K572CB$B6IUE1EJT9RV"AUL[V-EYB*=$Q4__Z>)K'!*55!3A8^#7O
MT\U7<(K;Z=43M.-CQF ]&]*5LW;2=R2&I2ML&R\-S?6OE&0B*$D3%;V [4NS
M@FO4RK[%8P9DU4%E)I^,W)\BDK6DKHQUNYX-2T4X/S(P8@WS=YV6"&39O'DW
MYIH_4I:U+T7 Q*UAJNY)M;$JK1XX?/(1RU+F8):WK]A'@6I^4!C&][2SV:(^
M=< &D2@7$M!--46OP JKQ'UNG/.S(+ANZA_BHPPN'ED-Q0)>+T5WBT*G#.$>
M8W(@7$*AN5JAZOYZH_A>LK+.F5(:G/E!?8+)AAL;_D^9NA$#%<ULGVYXT HW
M^;I30-F#>3Y:?(Q.#Y"PM8NH%+X[B ON#&K# D_7<AZ;&B*R B8-DY@7[<]H
MU?1M[Q5F#LD@+*A27YR% I]Z)57SE^+%.^*H??,_=KYJB' QTME_U$=GKR44
MN<S#7]"KG^QA-6O@(S3E7>!VM9,%6KIBR@J]C"P)Z:T;*ZWF;LL\WN$^I=B2
M<C[&R//1:*4(R/2BAT+"W;R1CV:V;E7%!:29#(-'BUN)DC?.K8=?$TRLA?&2
M>^('B"_FY)LTI"0X.3/@3=]XQ=2ZSMUP_)ISWRI>^_SYI'XD$@OL >-88%A
MEE&:9G@5F>MN<B%O+LME>_JJN<G(_-6P!]:)J?C71Y!\".^XC57UL*&W..'&
M6.#623^" M!J&=[D(0](Z<D8K5K4R!X86^\*KR:PK2?PMG[>,YX_-<A=(HW.
M3O.^+QT0/WP[71'GC8Q7U:&ILU1EX.SU\XIO9C0(Y.4]Y>="^5^.VLRNOW[
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MR!$@%5-)9J=:-G%PIWHMH9*JYV=K^,XUWB-@MJAS*7N;+$?G4",VM?RW-JQ
M9#T"]K?TI1#2$YO*7_>7V=!1_ZU59N)$]1&0U*Q0DCDBG6WRY;8Q=.&WMOT+
ML4? ^J#55L]><"_G$7"EN=/HM\8CX#'Y$7#HS<TXE.RXFPZ9%O/BS/JMD6DU
MP.0(:#=/&]989M(LV,_DE7/]K>UGM[QM?&L7HH^ %]-S_V=?P^U42WW_S7N:
ME;FJM7&R,N..N/K/-TY(+7==Y=YC=Q#S3#\>PG_'GJI$O=ON;#!L>7WJMVN=
M!75 - $.&2&BKV2Q OAXB/]]>OIG'@*.,;QJ#H4$Q)!5'[EUN;*!XKNB1U&&
M.W'/7]A1N]]EU\Q4+\NU4LHX:)(9R^U54-F+A%3JY#[9K/F%*-3I'_@"SA_R
M_9<D2^Z? 0O4;7XGY=5.%/^"2:KP9SDR29.'4I_FU:P_81:DBW'L?Z'W?UX$
M\1L4!S#Y%U V_Q#]V,U'_^<F6%9XUW\%[YYM8X+Y+(UP^Y;]+3,&(U;[GKOQ
MZANT<^X/OV:6_1$PV:>:KJ(VBITM><G*P'<$84[?MRSC/ZY8?LW>2/^6R &D
M_SF/9/W*N!YKOO\YFN_W[*:^P)\@=>"7K-$?^UWE+/V$1,M2IWQ/WA#XELKQ
MQW,M?K)&W,_L?*"9;&=#^:U6GLQD)T?K'T^W^)J] ?J>R8$#^LX<.6'QVRQ?
MG7V_Y.<D\"W8A[1BUYX?V(M?R@C1ZH%,=E8AN)'[W@H;68C? S#8<?5_@?V8
M_XPQ5/],J@#(7^@^[D]/:0[F-^^I'^^OH#C^F?0CQ2G_YR98Q3B_%('YON75
MBM;0;TE/?MS?]X:[_VVCN#\NHWZP1[30#Z0Z.T[,-R&2^STM\ \O%%>^PJ%C
MOM5/P(WYP1Y:#"++2H>;QK\$4SY6M_YCU"VXS;KQHQNE$#%B!\E[Y?H_X<_Z
M_'?B;LW6:T:+WW8:&<2:!<O-AQ[5LUB]_^1H[#X&TE:Q"UW:15QM/.PH&-E@
MVKG]N7KVV=<< W?S(T#29+U .C4\5X-LZ=1!^[7?KE;89W,S6:\_ L37%]AW
M$7S'U_X3KG7%_Q1JQ_:$HV:PS1-.#97.OR53S+DML8'IC4L-9RW"ESBD0/%^
M01\!B9Z;E+[Z+R%6.LM>9+_=469"H@AK7/)^Z4]65^C-#MX*?#B;8?V0JZ27
M5Z[8J:AP&9Q2P+,*V0\YN5&@#K]UD_FD/EMV0+YX\9<,+$_>=?N;-,(?ZR&'
MS?=\:34\KF^*@_;W7%#!/RP9[LB,.*1S,Q\T[*KA<W]?#W/$O^/>?PEE>>Y'
MK%7[NQKQ2^(+1^?/HJRIOU<F8">M?F'!#?O=2HB0^AWRW0IW]!<Z_Q]5%NX?
MLZ.$B"33$<",Z\O9 VZN^.VPO7[?LBSF",#?#:14-\Q,_5MDWG':]'\33.%_
MBV@/+_49W.QF*=?=KWDD"A<8;AQCJ4#J+>U+MU.XF":!4S"S^\^VF99[DT\D
M[-QN/A@"FCLKK%V=?$K*$<^+(LH)X)VZXD$:S[W.&EJ&+5V@_F2/1\,.:,,?
MKM2)5XC;)SM82P]:UCQ:D67,EO-T2W-'MQ*<V#/?<;LGQA@]-#8VHC!!6!&*
M<;PP0C_F)\)>(*A*8T-C3(G4-9<9XMH#]1II0\Y9>1D8&WXZ21E:ZV #;.K7
M8VZ7C#%V3/60\_*EX-E)U&R_M9%F*"Y/1((N38?>WU<^ B*$)P^F8:3!BI7B
M,5%V'CK6K_"H-G(1#8C]70=_+C:D7=Y%@K(#(1\P7 ]BI6\#/L^2P.DJ"B.[
MDUKQ21Z3_[Z;=[SB0;\C><K! BU%/;+O"!@Z"W[.6OJEHFAD7(W0$[[P2*'K
M<A4'??.Y]W '>8Q;8=90NR=/Y#V$'%>DFZEA R)KH7P[D <>V'40B5>DV<YE
MX\MY&Z.^&OR2=Y+Z,KFV])X5'O8Z>'Z>,9J$'?%2]"KI*_CT2:N>-^^9(XRU
M5E<7AGQ#8M=N9RIIW[VW@NJ#TW\ZZP'=&I_7+]8N9':$CV;A=<W!\>0P0F/)
MV:#TA7Z0DZ35[4TQJFN7,>Y/&-&^/#LW3MO+:F.'/<I98'A8Z:J+W.4RL .5
MR0*=2[^V,*-[S)XC9T+\G7Y7^BO%30Q],R>D;1\[]K99N5==Z/I\.:EMCCOG
MPPW>;!B9;5&,WF=TC,=^F=Z#ICF;>L_1C,H\_=9[V]W+8?-^^AV8&*0O#DB*
MQRY6DI^YRT]"F;/=U83<9*3>W-SLP85R5UP%,__R'!5OM R)I X=O("D1T!4
M[<D(%-@8XN"TOKG5J4QZ(TLL^Q^U"P1]$AEV?OA+1R\(38_]=CB+/KPZT@P)
M.+B>8T,7#7]EWSUZJS U)-)FU/GP4D=UR3GM>R193.)>_5?FHB5%)BDQU 7.
M=B?NOC_S\8,,M%QB>-A.NG?9?D8W1;5BJ4,GR8.TC42FWBLT/6?)GV:::M!F
MB+_/7+C_L71"\WKC2!S0O)H9RHR1SX2<(*J2*_O"PE3'F5_ OV-G9I>Q$VN(
M*%9Y+C^@/G?5.,&#$N<16O4, _69-W67RYWV2JLKP+&%F.4RJH\\9:GQ1 PE
M>:$C?99A//"5"A4SAWO#/+7WV#YGP/IL]^4RG^GYZ'C$EEBHG67^W(,SXA%?
M3V&%N<FU5-7MQ&&O>& 3_+C"SCG?4)4@VX(KZ6)G3N.3"AG/W&']T?D[>2)7
MSJP-HD[K2&7,(<?.[]T<NY1H;X["9[XO1><GCL"PUAU>41$?&E"ZK\/M*(YG
MQ.UL3%WR3+E;V<CPQ@R*FOXE+KZ+7Q 00"1%!,/__UMLC_VJQW[57Z1I22^G
MB<4 "$I/FA(#?V0VT6S@N8*K_.CT:QU75TL'[Y-0-/\E1EB?S/[%AXPRZZ>#
MUV"D.@:]4?7Z(6Y>&IY]GZ4M\"K5>V![I"GI0Z5?TIZ?V@"3$*MTTPN[/3U[
M!%BD)RL7E25:Q(T:RXF=]K7">['C;]MX"P1W@U_5=.6ELUJ:("A&EGX2>WS1
MT$7HDY'>>V^< #0_B^6.BCGOHPTJEE!QKJ0*-<(X:[YVTXEAN]N:=5P'*BZ,
M5S Q$;X3GG9V;.0M'PCX.WK#Z>;?ZLX7'L0(Q[3J0M)@\X85ZP.+9S*2+2<&
MN2T=<5X6> $;X?@!DFQFI7<_YQT!3^_S/K(_>;C6]RDX+UFU8RG_OMA]0PH=
M7J[\36)G!U?RIK,+&7ZBS6B9"1-=QC$YJYWSX3LW^QD$>CN$$VVVGMET9 <2
M4$G@J):\#6@CNS3&%W$$N*@1A@Y9%RT0YS61)SZ]."+''?1JPO1>KG>!8:T(
MIH%V7*?@6OJ@@8*@X[NLM^<_$&*T79)(.U@?K&3>U-T4A9&2J75O<,H 8R7A
M/NN-J(2DC/+1BV]71\D.Q$76\CTJ1%[76O1%#,J_D>%*##4.:QOCY+>*R/+C
M&4TLE&7T'4=Y\AXR&5XC8@W)KW<6%I=_1C7Z<9$N;^L!P?A%9J'/)>*^\$2R
M*.M3]>?$AJH0\BLUNT(;&:!XVBGG)A8UPL0AJX?G8BQ]V31C%E9Y%,U:;79,
MZL4M0O'K2S)%D5&0<PS@-T6K;>&9M\P116%LS">@YNV!@J FD793"F0V)4Y;
M;?XHN'N!$S^51,KLLEC/782C<!PB;JY?6_[&[*LP&L;-I:URU_3H0B0RT.Q)
MB!UC=((D<\K)6X]N/_,48Z/$\<^Q;G6=\!78$L+RFR8IF**F2^1)A69_U_VZ
M,P52G-V'S62##UO?>$JX+2U!"\Q>ZUJG4<?,TT!B_"11]73G'1>=$/OM#K8&
M*YFFBB[))T!<IOO7G'AH[4[7K1MG^Z8/VEA1K^&_(/7/%?3@K5UX'Q1/>NT#
MVH]WGN^:P[VG#E<BN4A>[VKMAM&:!?"?5Z92 $Y%^IWZ6:J]$_R_FMZ.4_85
M&T]+,6^<9FSTI\.'O)-2+<@=WAX.SN2O^C1(4=8T0(#SQ8:J^*HSWJ2OFK=.
MFI:$+T];W_3R!?\[.GLMXG%ELHP.X]2$#8P7\-X> ?K+O$*YQ.=\<I^6\"]!
M(_M!146E,=X>U&+F8FY,]7)MT>:>;*^DRE%><<!XA?:S=(^H6ST]%BV):TH'
MG5J2>NAG3%2L^6%/+Y1%L)ZN9>#LLM]HEE@T=7#&;3I#.^3+$98\H4(!>MEJ
M;DHIP(16EZ43KB[O'E^7-BJ$0S@F>3.EK_18%JL'%DET,[2ZWX(V%X>$*^<[
M9.KKJ["\N9ZUYHN6Z" ,VH'I@CR8U'IF2U#7<>L>C_?#=Y3!V2X&3N(/E]2(
M1C9-[XSM@&[TV$ON54I?,3_$4.6?YA^N>5Z78G8M4'U [<2+8]ONV+;[AQ#1
MQSR^=V>7KZ2RO_\0BG,$N"7_#9Z&?Q!*%L_Y_1&PQL?652E?@?K3X;Y)@_<K
MAU63+'4YJH]>%_^6R70<ECP.2_X328>F8"Y6O[5]EQ_/=%9HZ$>4,N?Q"&M+
MR$)WJ*XHR,(Q>?6Q3?*8OLP$4:],!6+>11LK^;(>0"PZUR6[#\^$:NPU*^Q?
MI,O<CJGD@4HCU&3>6GU)PHIS(OGL@^FT[R<8Q\HQZ6<Q#1;[M&/Y]#&SYN%:
MYX\S"D"IX?F:9)^'I"WC(#5G<R">5C_.Z$_O5.C+(=RR8[K:^OWAQ=]/ '?-
MI2UJX>T)A[^:^9\OI[Z9XW\0K]"RKKIS74AUA9OI^^\;Y>R[O;*'K6DSGIG?
M7S;\^^]>1I2^-K!_D\X(.!#:J%V>,:_W<KW34STYX&OUHU..Q./Y*B_XS-^G
M_WS<Z^_1X/]G%]J8:\>HJ[M=S<L2LF4E=!SDJ$*5P^P_SZ==%S1K/I,*Y2 )
M.(X>'T>/_QWH[P[6^P;2RT6 -+!SVA0[,OK!!\J^5S8^0'HRNY+_N*YS'$@\
M#B3^<^BX)/EQ2?)_M<)R_V+TLR2YCI@SW, *2>X+HZC 0&UX;G]XU<9GV.7%
MP$#5 JEQRC@"7+_6&IU4.5SL2VK(-&/*[SR\[[*APW\$G&R(/^A/.Z0(%=DK
M4"C,'I!&*GR)Z.XT;-QGHW/8-@[?N2WX:;F2L2'S[NXHTXR"JIPSTVJ"=?6H
ME\R$:#>D?,.;+O'1H@OD%8/4__&HSL\V;F3_YD\*SMC):-9 47?D$DHCRM39
M2U%7=35#Y3Q0V,7HCN[7N:KUO7Q[[S%._CB>\Z\6S_FCQ-GF\R-#5/XOU&2I
M(DRG97SQK2Z+_[P\83I65O^=_Q)L/Y*9NFN2[N7K&?P(,B5=K;RQNUX(.;<\
M7?W^"Y;S#!MAWQQI/Y5=HQ](_"S<GF^ XHSO]N0?[C_'=S^QAJ8(!+/(UN5W
M[KLLMT%\8\ _OEY_-0FO6'^U#OVN_(]*RK_TO8X+*?\K%5+FB,F&'"2:L3:T
M[E$F>/61!>Z#"9\DIJX]%@B0K_&$D<*AC?VN[U-KBF@K6J"%J0MF.MV1GR^W
M-J8#5M^5GP=T_6',7:Z*7'V?6M>9P'PR;G[BNU>>MY['Y$6\,6<6(\#:<U3^
M8/0U9W1N*,6']X'N#IOY?V&V9\$OKUVTYD\XC:[X4L4ZIN0M59GQC.50XVYT
M*^ E1#4+QI#I\.0> 413 VSGWJ-1*/K8<H32ZR<-+0*:6S!BP=]L>CVZ0Q1C
M\(D[XBL"HFKL>,;0^ZHS-9%F]"_.^UIO #H_G-C&SWYB_QR"#SG$^#\MKXEY
ML:=67IV]_C?,/Y(5@B/@@^_#Z/G-&4:2(^#Y[@%G]V);O8\E*N8(()RAU#""
M-K00*)Z8[*M8.P+0C(5@M]7ZB;+I4XJG<6;*PF4W]#G;-IB>TGBUO>Y325.B
M?.(X/@O=$!)34SU'"?QF'SLG\6)R=UQ3PCY^^-1\\?U-&;><>>.K=NX'U#,?
MA@S)7C:,6N$AOYG0F[.'%W:>2C]99,B(V?8[?9779FX#0GXC>XXS2S'W=" Q
MK=(4DS(PFOJF@K] J6!(13 FXU/S<QAAZ6;^T/'J<[SZ_&.)?U_1*:T-,B T
M8\Q8&'N[FP5#"<0JG<(8OT*;A5)/'M3JFI!2L:W6/5E@.)W)(2\'7$,SW);2
MD0^X*5,Q&,,8?4+Z@AWO>PQK2GVG[:G9"@6J3T&;2O(U'48B'\GD&'NO#H/L
M4M]#BHOE&IP[U AR#3W0'\F6.,O0PLHB16&E\'[9WF[=[DNE&NM\,V5+!O5>
M0HU!+,B@+3$>N@NI%_NEH\'O^HH:7RL(/GWKN%>,TS5F+&=FLTUQ_M)F@5BW
M[84^GLWXX5=GLNYTF)=K?PH3TCW\,'2]A.<R'E[E/:Q&<MIGF'9:/+].Y=)T
MM H ]KBA#VV7O>+)<U]'M%$L[\.F"8U-?U1SAF) W^6YVJP\XJ7+JB1@B*G>
MF($O"HEP9:3&\+S*K!4W;GO.+\,N4R][OB_>-T\DA,?\NO00C0"YA YL[N%%
M<"OCPL)$T-Q)DDVX0:U[WVYFG9&\(M4MU;, M*W///Z:025SM#>2JQBGPYJ1
ML_JPLRKRP/_MD$^(5Z^B_;YEWDIIMP-WUPC_Q),VCI8XROSQ9F?R*)Z6LA7#
MDHBT^: AU1*/2(,K[DRC!/6 2]\8;[4P4JV)(SY7?3VB(\[>WW>2Q)*F6?#>
MAP3 *Z[>CD;NS=NR6)7>ULGR_?U^Y_'+3*O/ZL/\0P&SG7#COHQJQ-M.5MW7
M\U>B0N(4"R2U4E>2]<L#%!6_7#^;T%/%6;*ZE>UZ+EF7^JI"XP='%<>AOJ0G
M_BZ)-D9*;]<OWG-DQ\L)V&L0GYG?0*%< E45F(4J)Z2\%@X7)E6K(HP7/JU$
MSZEX'CY-FV_H#-U^DEX8>^@95._ZD+S#!03ZPM:]^=;UJN^AIR#.\ (39I:M
MJR*WEI'[S>IR9G:C^_G'%:_P:806D/MZ2H=+GL&/A1@(^C5Z:30]J%J2>>/*
M8*10WJ?E7$5Y8)(&W7&?:.^Z\J1T,TJ1$EO\C([VB%9^UT\$0?3F1:-)? $(
M(=&4ON)S*0B.A<7 85G*9<D;4SOZ4@J.Y(K5O'VEH6SU#]GZZ$!6;*$\Q R!
MI;0YXJ$MVU<(@SN2!4;?:&K82\HPE!2>,AZK?&S^X#XA+8PTB<2DSHLTS8ZT
MTOGT,\?W&LU"F9.\9XRM.CGU1;\4AC>4>51(3)1M$IW;O[--SFR.)^R9>R@8
M>@$!E;G:HE9[V@HGW'4R%TRVI 2_* Q%?0Q#@9/Z$20F>MW<#E..II[ M17C
MJ)RS6,%*^7ICCZ] JD):U5^P*7GZ61NA3"C@91E$H:ERF3]'O#A>OK7J97YY
M>V?!DBN)\$EN"SW-2P$*9E#L(OH3M;FA_Q-YXB.#46\*.P+<(YH[Y:CFD\7_
M%J>\@X?(X8W%C0+5 KY5A_W@_GGC9&,WSDFI$>2.#%_>DK/:85.7905@P=\
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MC(T]E5GF#!VO4)^@=R"YYN"<+A@X=$LTXFV]N?$B==>"XZ!-V/R]CR(O%N.
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M\MF(OA0D1AB186VFH')*ARB(GYV@4AX*8)H$5;3VKPA:#*F*38W0G._=4Z4
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M:9NGU67@YCJX5N6?'TKCH33^-Z5QO^]O4$L#!!0    ( &6)9U;Y*>-OY)
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MZT%YK!L-Z( %Y5?O/%!TY.[O^NF$>HN67)O_OA=0<Q2K&_8@5XC*G(G^)M2
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M-[6U*ZSTCE(F"H7+6\/R+J"';N7M5KY>"12IK#HLB4BK+NG)W7%M <MYTQN
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M(,GQ82=?0)4.MS=WM@I;D0KQ.4'9T_=38$7!0F\X,=#ZOWWD>CS$Z3 3,ZX
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M-L$T?OP YFNKXE=:Y/IDL1;5:^=7>S]L 83T'SK'#&E U'D7/?EB$44#]"?
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MKBA>J#D/K]\AW@/56U,$44D(W#1<@08L2Y)DX]+YO(X.@X\H- !6;TA&C="
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MMN.<UO///T0MVV%8V<P,T25O'L 0JN\;B,76D@4)&?-MCS+_5)<:QJN%L-$
M(3"KFD<=@O-N'5]/\#6K_6GYHK>/KOK,N[Q<:47)U&NS(FG RT@X4RRV$>^
M2H8SP89*I05E<$^+'WQJ/;,5S.VK:;WJJ?^*0?C9T:]H, 0QV]HK>&^\XRI1
MQM'KN6A)V)&BE/;5JKF>9YX>-S0O;L^^NNU7Y'O$O&$XL5,$VU$B27TI-DO1
M#X2<6;O"_[(JI4A*PO'J+&-(]BXK&W4$S "W1I$02XO=7GKN)WBWR&)%-T*3
MC$\4NT.@\'9]%FU5_X3G=Z5!L5E.:-<?$F^+JT55KPPKQ%6Z5>#5SORZ6OPT
MLVV:07C>0Z76=9HLWXO@NX39S(!N+:F%2PZOR51[JH!%!M?K\P9696:E1K8W
MQO?!%V'6/65\W0OBN.T.GJ!RM^R1_-)2H];:LXG#?=:0$S].+X7W^3LHP_7I
MR:-3FP:X4!RR[5B9UATYFA_=;L*AXMKT'X^!+5/X(%LZYK6- 6J/S]N]?_C\
M441J:R[XTQ3AY2FB/\F8^BV/)?'VU7E#S"&R4D-+@KGVN]U@H>T/O8B7-4.)
MNPGLPWL9=8CSGQKO=S!_K6-$$MZ(<75G&]BX1X_LP@NO9LP9<HN$JK<TU":?
MJ[&"&:L-[ZX22O)P"<W.$PL]R\$COA)R:DN8K;+XL'7241Q1&,Y%J6M3^JJE
M3#+_G2?5D)";@3BOQ5(<_>H,=KAC0KH*>4*F_G@'?O+\$(_-CQP(AG6^N]MC
M<4[P-%$$S[4@\UF U6H:KAZB45;#6+R<G6:W^.1$3V(0I\/SW+Y,OD=N-.#+
MX,NF0=G&7C47(C\F97OBBZ+T=$71+(EC;B:=G2C&:F=?E]@D)[]*O"P]"$JU
M#+%1[E%W-+^C..40\B1S3[GTCP,G#D%6^M./.B=E@(7.LO0/,MJU#>8SPL)O
MX86AG]1E&!5"H]8F6/*S.9\(,/BQ%X(:=[H=Q"/Q,]WYB2#6[]Y[PGBQY\A3
M7@_G+F:DK-B8#_*9[)RO9?NBZ4>OD6+2.]-HP&*=[>S=_-F1VK>_1!MF5O,@
MF4MK[ZM1U]H.F- EO/05Z_O5;76CZ,L>/%-S=0S\E,?X8<+'GWD_8O>1^]H'
MA1WL>'TR!XC@-P&_@#$Y3X3T62U<FJFO5+&I1S%3XLWJ)@,U_SP\F_L)DN.V
M=#MA)-GW4E:M[?MJWK8<TU;6[_2N) =)>:_-IU_I00.^MU@G!0S?W+N+/Q%>
M8K^E=_6U<EZ)LXNO[[5UFP7; 9XK^JD#37$!>PY/ZZ O\2PO][3^,'4WNYY?
MF4UR2?Z,43RCY:.6K=;"7A!5;IRVA%<2,TOP5?!/0T>E3;F;%]F67$DPASG#
M-;&>=9?[\(*NW<T9=AD/Y(GP5C:M,-X&]GK?B]GFY:<K5*[D:NQV]6<HK3\J
M,AI+M)UTWVL>^$@)T>6PGLWGXC#5!?[IXF2Y:OG(/^(,C.=K<M:2?VK2]5])
MP6JEI;D=)HZA"*>]HW&/M?VG[@X.$._LI]OA0^2L<?I&46RN@P&S$+M['<_@
MDO))8'K=%M1C,KO1_6PU'1._,1I+!>$7GRNQ\L(B=^!0M,T^,6!0YH)](S&T
MLAMZ(B?$MW2M,O#]#X_SIV1GHX4P<D2)F23XV:4U+7?,SDO>NUR+;&''826$
M"$K^YKX)NX?UA$?'!5QF;)O NXUGB%Z55/UD*EOKL*8A,9Q>^/ M./R&E,[)
M1?>5113WY?CT3P;*$<7 D1WBU#&-_GYH?-YYH@@Z)J#5B=N6J'^=J+J4(R/E
MA'>-:;,I\*"> W.&*9%O-(_5@\\3^WN/6,.1E?JW<2.)-?7MS%[F%I/GBLKM
ME4N3G0D^E 2J,%R3&(L;[$5PDGV71KG6P'69G4[<\.-$OA+8HU';J%"3;L>K
MTVWRP>6P:HR&Q]-7-C<PX,WD8\20;GGW(]Y%]P%^WJA":.[.0J^Z#[Y:0ZG(
MT:]$_:&DHX>DX[!TOGSBAGA32];7YA6M\@LWE>RO91P7./"87!L]G4QPL1YT
M]"LZ:1;ARS$1GA*Q;D@R/PO^T=#\,+PDW:+GH:]B.8]QE1B3-6<T= .F'19.
M>$)!(J%S4IT(EAVEY%-N*412W]%,K'$=]!U$-;NDFZ*)7GS99BC[H@)^;PRN
M3Q!NFH1K8H*QAG) K^\9;M[M(JTMUC<E1$2/ZC<*OA+"I7'B==G&L[0-KQ*W
MN<#5TE#?RPP/ZFM>&L8NB\0M29O*_QE1%T5)(2!T\AL346XFT<]$HG*PH&.&
M>&:3>#.X'GXU'\MRUC>,%S9HG-Q)E<*Y1NR?#J"(\@V;+0RB=6 IW7T+C/4J
M.QYP2*%N^2+?-=L#) GQKD,)#A#',-#9Y$Y0W5__D(&@$T/,O%0[PXX3:["@
MF+F=1+AZ.;$:O9KC[N6%345O03M]/+0OC;>Y8#8@BB5V'AM!7J+I I214DZL
MTZQ-D;NZ91[?A4TL[_WBV&[3;LG$.XDF%>B/$H_XT4R;5[.8"??S?UJE&QBR
MQ70U=_8S167[+E='1QJT? _^5FG;[N'K6VHPUC,B7U@ZM1P(P?C0@+:"8;.T
MAR#GZ(IT2^L+UIH$)4J#%\I]^ +6930!+@#JNA:TU)A87=\.T9]2-E?R6N*C
M2((X8$+],YG63PDWNR9ZJ.Q-C=/%29;W*PR:G@]?;GR]L92<Y(2S-!%<RU.E
M?$2@=3; )]L,</U+U9]1$8M<<#!&[@+,'W,BUU<2EH\IP($3O ,E IO(,M"*
M[XG\!J4PVS\Z[,0P E?\/8V#J1KYF5*/1=S='7ZB-5:LSQ#U4E UO'N1@0:X
M+<ZN0E_0@(L!J%@G7FUMN"WQ0V!3A;(#N!M\'BZ$ <5EE_2\J92%BY6LNW83
M-!@[1.HFO.L3#MT_#$*]6@>H5^C[IQ(-\(3&G"=VK>Y@@C9'W4MA^80G1&>2
MHN&'>3?P^:WZ\F$Y=$F/)H)[EOC5Z[JMH7^Q!W=+8)V=R;NYM>STTN:WG8*E
M9U1J'+^DMMN+6(X:YTHRLT=:5GHZ2'-!(W/A=Q]*Z%E(.?LT&RMPK#7I6=0]
M7OR4Q,*I%V$9>"U#-$UZW:HZJISY50KRC/+=;I'>R>YO::6EI6.=UL,XLU)3
MC7B2:H9IM?13P4#$/2\:X 6=19+YRF'H#O'O ^_=M&6@T4?(]L9HLI,_A@T+
MJQ"97,%MOUEJ4N)+YMG(W"J^H=T(? M(O,F7>^PT<MZ]2BE&=-)C(9/D&C;,
M^W,FPBL &M]R[A,\J,3]67)TU?XPV+%C/$\@Q,KAI&ZRU?36_IMZ!(L';UY=
MJTGMN)9Y</%ZJB$49C56-'[ XTP>)M+[1,8.XB#>N8^7!B3#@[DW*[$V%73/
M#/-AJR.IW# :T$T5QN]T)5]TWR4KIJ*#XK1 >+$[>-:(QR29(8T %.X54;_'
M5C:_U/!A93>OO3M&8<9R2Q6!,TGF_[UXOH.9.+-42I0AR<L]K];2!,5N@5V_
MDUUQ.]T:^2^5RDF53M9$ZS+RI0F9Y"ZGV [!&6^YJH <@9#>.='D:J*986F;
M#?K Z)9HTGL1,^/P4J93DSU+$C,)(,WN\?(,](8S1&RH&:LO7VF6X&)D66IX
M-J)']R&^J2Q+S9F#4EBBK+] ]ZSL>Q$K?.*=^IJI@NC"M- #JZH3N3RS'[NJ
MA+B-^I#,%KX0EGUJ#LDS;*1%KCL>%*NQL\6T1$_L1),>01F\=S2ZFIW(W2UX
M><IYD@:@^5O2D:&J!M_@$JR)@;E/02?F+IF<A^68/%]CNYE8ZC3PT#,H8QV,
MNS?Z?="HU9"+4JC%\/%'+KB+=WB4+#2^[B@2?6<,'AQ,R4%?@SJVX%;S*^U@
M$)VIG5D9Z_LSRS43GJ+9G%.RFV%3#-!(*@<]OC7![LF1W-J,>$(RUND%MQ,[
M_"R6=8XG.:IZOI_;Z2Q<9TEN[KAC=$_0JP&8ENJY]@)B=9=M<7&%%=3Y@\-W
M"*_?L'.@S*O,(:>K4XBE%!H@& ".1H#".,B:^)+/_;B=/M +Q_-$$]=*XANR
M_\/RM>R^7&RH81]5=.;#^/[B.8^CT*HWOH%5B]_=-'03-_.=D0V?[&(_N9Y5
M*C;//+>AL^#;3;+UR43=,>TV#A0GV?B7)?E%"4B;QUNL/W+1*^8WNJOL,>K>
M)UFQ-E&Z+:T+N]FVM'+:%$8TC1*:U2W53PDOM7QH;EPO0;H3Z(-/EV0].G$F
MJ>QW9_ISE\>7RB4.PR7L2_EN2WY^=6/8R'XGLE)9D_4<+&S4A@LTK_),]HU[
M656Z<L^1&ZJQ+DIJ])-)$%/QY#3"+9$Z+#+5=J'-3M"MZ'6>XIBU?6&1^OO)
ME+24E#HS V3 ])_%(\\XO[32+K-DX>)37^^%]!E+-+4CXR>6Z67)E:Y/%:AE
MQ2H:,",C1P-T':RV_OLW5MYEMH4A7H/(0^XTX($$8K\=4E 5\M]^.H1M?IL&
MC-\SU>7@^*O.@?^L#AL6/#?=IH_YZ1Y( WC7>/5[!/X'-^\=U?2VM0O';4<0
MI1<E*KU;"%VR00$! >F=J(B4"$B3("%1$5!:-GT;VJ:$T*/TF@BA" @(H4BH
M"0+2$VJ$$#[VOM^]XYSW['O>=Y_QEC'N'W,D8Z3\5IEK/<\SUUS3PF08<8DA
MK#]46=L(G/%RN?NJZTRHOEUU4S^(P[N%&A*JW#)F9LJ^I"ZF7J),+ROD^.Y1
ML\1 ;<-IA^Q!/[3,.(1J##8=D>S',9VF]V58PV,M(BJ#<%7YU)\)=% ,V6LX
M6WXXC3>C4G @4/ZZO!Z9W#OB&&;UJJ5+M6DQRLR$#1U=4^Y!(DW/WHNY4L9B
M\TSG%=!HCPH'/\I>ICP:@/<L]2&0RF-^S^REC:OGQ3V,J^?&GH1;Z105L!5E
M6P( 5LXOCOSR4S@9,'TV> YO_"<QF+(_/2+FJII80RYM-!P P@J&TXOW^L>8
M=W:I45+Y1_[WV?1?,:N\FH@G;^]'W8==N:W_B;7 +LQ$JE?H2B35&/Q00B-A
M3OEH+U"%/1 -KD$NE]*/SE35A%UFF%'6CMVN#YS+#:$ZI.&6)\Y8-]2]L]90
MO'&/#Q$X\1NG)NK(KU1*XQR[B7XGY#AR&@WA6=9TXF*:A^F2&B\-SZ_PBP#I
M25^@RC5G-"74-K&D4F_E25U ZB=^WT[W :^->KG(G;@H9J0&[=;+VLAHR79!
MC%Q7]0/S?*' J[YM#V:2>QX4D+*%S%L:+^1]'PS7\OQBE9AAT OO,J_?CQ2E
M=\<Q_%\7TIY9V<AEIPY@WV)-!>4DKMCEB<A4+G65^!H)"X1X^F7)"]8K)IQ_
M[27./<V['X]78$CN$$XCH9 HM.4UCNIZ293S2(>ZIE%B%2_( M0H<X+WM9#Y
M-;7[G2]D'A0B)IU_B@FMT&7HT\M;OL9N+/A/,&P<Z\V&7N''%*___!M5EO?K
MA%7S& 1N!M$] )S;D6TY5&C1(*KSQ:H?TK-UVP\@)T]BZOP:)\O<DMMDH0+3
MN7R5Y5I>C$@T]= /0I-H'5R2WL_?83E=-Z]5.%E6.&:FV* [\0F9RN;&4];P
M8X1J5!13>B\K&EP!;NL[67D[+>/6[0_1;6A-]]^ 2L;YV6G=LJE<FN[*H=0R
MMI%LF/[V]#X:[MSIP]]J!#P[U1#L9DQW+9T+#^;)F$GV?GBNY1/"FJOK:FCQ
MDD55<AA 6_52;'-D]DE4Q]C&--.)AJ/@XES.,_H.*?LKIFV#H32=/U(IPVKF
MY-//W,YD1V-OHJ\,[7I]@F%Y(MI(AG[T:-G)Z/7/U'3[:N$WJL^5BGO<!X(C
M;D5W%S:/F;@E6Q'6-SWF)D5F!FQ9'#W7/1,8'RYHM/H5ZW!LV06=NU\ADV@#
M.;E=)8S4>)XV":2[1<"M?+9Q'+!$'3IO]9=)1&21G:<OP !0,6KZ]-RW<\V?
M+K\\=C2Y+ $/I .9W#O;3X?+A/9^_K)U (@4RM;R] 1S,DV+OJ^Q_Q!_]*IW
MU\F\A>2AMKY<6CK3K I@;AU2*/:Z/1V&F"S\ZGY98Y!XXRTO?"Q=O6ND_9D!
MUPNNJ97=PB%O\PNN)T>]O(1.;9>P_RH O3F3?N(=]NC 9^GV\:]E E0Y/AES
MXR7QEWW?G^Z[5PVG7Q-X![E3)\OQR/'TK[*S\$ ;A4*-]0>UV,AKM7=TBT/*
M.VC["%&,V,2*.>R)>OGPM>= 9#_DF$KT <";\%.A4 <1&4X0D)/_9!9(D;=?
M(]HW#<)FR0-;:Y3K82DBCM?T$%:/(&C#AXAQ4TH=XI"!3)]L-XU<.W4 N#O(
MKW, >!VM]^;5K>N3"UH/WXP<6_4[>T0V7H<N'/ET+54=F_'TVW ":_Q3Q5T)
MH>M-)1LR,,]1"P>\^\RLL.SD<-VANTZ]H<NFB1?&T\5 'H_46#8QK9WNE=V>
M#]T?=S9@NN6.N2*#4M$+H5NZ<-PT84QE^PE])%'D'=V(2 X<Q][_0#_3G3TA
MZMM:6B#?5.[G^WE"N_=:WX"024,N='ANZ=:P4I/GR&S;9&(HM,!A]J7LWI*:
M&VH>D/PCXF?5WAL0XQ3?$[H9S9:=%3$U2ODC*LI'A</;Q$HRB\(]$Z(KA@QD
M[<9_Q) N]96KQZ4$)LR]L[K](]B?_:SLJ;&F2EB4Y6#9IHD\MC_M$#F>SR?\
M,_W\=UKZ[T\':J#_IKI(" Z]C]0!_^T]2L>=OX6PW\S^'K3^^--U\$K' 4!B
MXG!-[PEIG3L +,[0>$-](:*L<>2ZU^0A/'[(I7"RRL!'[EVT8>0> #"B2U%2
M.2_8_K/LU1US5VDY#SDW-0,S.]-\JW)AUC%URTUS:%IH?3XN< A.=,BO]VSR
M1B.*.GZ!=4SK-^-$4K6N,B#3/N=Z)/R#"MR%_"?;3?SZ/<\3>5<:?C'M8__.
MI$T2;GH2WO-_)&I,,836.J;8 LU/1VQ\U%(:EAL^[4LLL?^\V_NUF]G'T3C<
MW?LUQB@<5R>%0W^&*;[V?QY7[4H,UI,]-S&L8'M!Z=J'D V+]@&,J:")S0B:
M=T9V*22O#]NM.A*][ND99]=:U\O-GIS))<"\2S./RURF@3P'FP?C6"N&W-$F
M/: 0YEFD&XJ<VAPKR$#NV2VRKM2\\<UCVGZ1!S$F[K%6!4%O3Q06E9>_$'H4
M$GSVSJ4X=Y^WD.KYE[P$BA1#?!H<->Q[X<Q4).)RHCXA07RZ*V#">.OX]??'
MJP4O'YN^9+$^,L5CD\ XPQD.'^4_[^NL,T(TB0B"J+3H[WUH]KW2^_1+I+-A
MP$(>BZ^D=$GA9NO#DHI)8<J%?0W_05S\@W7XH]T:N2#V1A2W6M/-W8H"LG60
M_L?WB$FM"U^R/C$J:$CJ6LN\:8I#DPO1PO/YG:=:?O4IZ3AO%W9.F_&"6^4O
MB%I]TS@R:?L9G=JN!(Z:Y(ZCZO O/V]:_UXC->].7BK:C[C>$?,DOED2L,K.
MV7_#0=NO0>%21 "P65/G$'/PCJHX;CIN>8PF2CV5R.+J>\TZ-:0@]K '47\3
MGU'T:,;7V.4.JW?HRKA.XNP$^_MQA.LG5 $L_N7(Z59'<%:+[$1V^K?:DF)N
M<4S=QH54?AM.0?GTW 0'ZT&?#_O9E#+P_EJD*BIRT7 $%S\/<YPZ<U%^U;5N
MF"M.PJ@HNL]&M[<&AKQ \ 2&'P".5(+9EO#B@S:6D>U"9 \A32'V[9H-8W8O
MSNW,DM(+I3SH9[&\K5R3G^)L*X=I^GB'<-Y-^=B5:HR;&]+M>I]'B!?';$E_
M5H*[POG'$;K@5IQP\5F"<Q5S"#$,/A(X(3QS,HJI02-,][5J< (8"(<08RX-
M)XTVEM2'>K?*FH0="]*6T=!P'@QT)D8@URA2^IBO[F5.83W$T'Z"Q'X=R!30
MIQ!+=7#2,*8Y#=5$;$X=8SXY?(?=3DYZ%M_-3M:JXLB/I;I%D)4=U"*RG]T/
M3Q#U7!UPTH7\^G0MIE$_=N;S7D1%)M?G(LK[G@?E7Y^R1,J4E>B"D*H(WS>9
MBC<BC#4?<W.KJM?:L&O*MF?(!&1'%*L/I!,LJ>#CM3XG/SK>;!V5%'"M_&";
MO%4R -=]BWD9^'2TG#C82=NDO7/<*+C_X5=; [-V::I;9(9A1;&FE4S C GX
M0Z5-LP6K/ZNRYH6VZ5MP^7 NSO[G"Z9E3#'Z,:'9DI?!4R(HY'F\8X&<J$/A
MV_;QXO,9/IRL*<@1Q=6< 2;$E^H37M\=-G>X@YUK5"ERGU,^)@U1NG4)SG7D
M,J_VHLYTUE A ]6\6/*4P1P(%I$P%H^DRIT 1\Y]VYP-OSO#\8HX-/3]^W A
M_V/2AQ\W33D8G0,IHHI=V5D/<M+Q'XC!$9#6:[-5/S!&$JTSOCS)58C)<&E]
MHXZ:L4V;XQ3.MTC.QB N@S^$(J25JJOPP;V^)_P;Y>=OG1[L?8%\1SJY]4I.
M",3X.ZV$Q@GS1K2;Q\(EKL1)Q+"$:I^_+S5T"B4GS4H9Z67&?N^+;7WPP5:]
MG#AS=8A6-;VB+H"VDK(*6Y$)=#G=83G2Q+/Y0)?'>NY/V:^M=3!K= 2\%/>N
M86EV FF25>H]S(%B1H#Z=F?^5W[HZ9 .!"%U_JO;/Y$K(,S(8\)F$H\91 5N
MNE_(XF+*#$T1R4/S;T'[B(E?/(7 +QM%J9R"DPO'!]2X]YR4SG!H*^VXNQIH
M%F/M7M\M%VBI3U0P4.THP775-]AO.S1(!GG5HQQ4O/C6<K80(0IKNH6;L;QS
M! Z\+$R4VAZW._*J*KNP^:A8T+8-7XV]-R[/^$J*@Y>#_F#I"DA>_9F5JM&O
MO(_(DQ9W>-%-,H6%NE5BI/Y1;(6-*52)9*Q$]LC/0/,\RL/QH5<;*Z%#-X4F
M;@H<PA;[OU0$X#\*L/^J\78S(ILG>>E.>=4BXK3VEU0-P7*)BA&E8GE#\CWM
M8P8<W[C;#P#2HO.WFE5W%J5*BN_EOL'*6"U8E!IZM <LDF+OF"C"NKC-8W*&
MX^25AN>2BJV)@^&>O)YFQ<:%.J72O1EW#)0&<U5!4IU*:(_\S,^,[K:L]T'+
M)&IJ2 /PF/'TS7O5C"U(9/TDEA+L-<Z97+I9^SA-^VT\[7LW)OUZ7(&AB@"A
MG-"! [Q4;.$D]W6<)[?>J:8= -J$A8%""P;\-.)V-P.7>6KLB,#H@G59V/7;
MG9=Q7]AD9Z ,W^9DSS[N\,X'B2X2)-CDQ38757^>;U46&8YQ^*/DWIV&DB*)
M-/-H+1(G55]H(/>"@J)&9N"KJ%E;$;&6^[6IIW*Q=6QVV\!KV]?*RRTO2@++
MA^)ITHSPO:?PF^::9K3? ^SMQLI<]SPA9[<*-SD>4WA<\[V4F8O7&K^>/)6R
MW=]P+JS[OGW)&&MB\GR_<!>CBE9!'6E1LRSQFV"DM=38/%?,>EGG,K39FCG8
MJJ8QWMZL_SDZ)JO1,Z.GM.F;%^]0I8K9.?U47R[#2+635W0#9;0O9<YL=>_;
M4N$GZA1%'B-Z92=:Z"(.J6Z#7-8[SA))UTLFH<87'7M+=H8FT'@I"ASQ;@HP
MFSD $5&,J)#KB%QJJK*U)_6LPPR6 HUD,?Q![FU2&*HS^SX&?Y3!O(T78!1/
M-W2_?2]:63LL7[G4LC)P&5H(BBDW!,^G>ZYL]4+'<Q/4S-4>!J2H61I<B"^O
MK[\J+'C1+CDI[M:)2W':?:"-OEBDJ^+H%!608GJ>*4;S=^ZU[2S\/FQ,:;++
M>"GBLC@IG*8[*![XK3"%:M6G^BV,DH!HL<;S)4TPN1D[]#2*7';CU\TEGW.=
M5""G[$_@0(E47X5T[Y6N%YI-.HO[00]U\HHN1:+H0$42/_$=\'P_BHG_M('^
M8:)L+TM8'E\/:Y$86B;4E&0FE ^"*YC*GPGCC$0PI;ZWYU[?NKT:_K1&L>Y<
M\%EQ%_OH_NY]B)>^9=J7?4 ._H03<)O.>!;UA&E%P\W@4T]#QAEA=T5XZ3PI
MWZ]5.B[<TB/Q3>=$*(H%E7P+O-YP4X=0K=@*/E'>3 _;OL](I82?W*DGO#[F
M?+T_08ESSA%!%8:VO4Z6(]3]DI/>L+(_8T[GE&Y9R')-UR=>KV^L>)+(;W-2
M)+8;U,7GD=0BO5\X0RTMKKG%NCSG%=WPZ8:)$!6VFIWD5FMHVRE9'F>5WHA5
M2<I:)QZ1#/2RV]GG73<- WMEC3:T)Y2F \^5:&H45AP*DW*F@T\@96DHZ0.'
M,(;IJQ>#6O^0\+/JIW$"*%0M%[HK^48^?"Z\U,-^-IO<'9@'(2\J'P"4[VAY
MY=6<7]?Z/G[2>0:5UU4;?;G/HZA.P3]E[I>)QK,:9][Z'@ N2%D5JFHM^D8[
M/8$/0XF-VO&FH_/!$AY)O0OBJ(_4]T4V-<TRFQ[M'E/Z)\7VTBS-=$,DX_[8
M7,)<#EE_K#^K=N$/UE_\#ZQ?EM")R/L/%%/!16F),TWIBJ\VY8T.I3Z[)I>F
M*%VP41OI'^BB_)(SRF?+2RBDN[AX31!F_A&J=2&Z(S6(="<UJ+JO"+.5YGB7
MG)';U*"#&,'UHDXPP704BB7-*/<1@>MFM8IPE \WZE^<RPJE<XV6*2W,X)/<
MS\-</E8CN&C5#;1$6]K@&3;=XE'H#C]_?&M-RX83/WUQ*]$D,-O4"NBFGNAI
MHA(KD^36^1G-()O-$M:X?1W+9PO9$F?SYQ^1"T^U@9#/\SSU%A5V?&T2$J*?
M>ACLI=.R!@G'O!J-BV&FNO3(5A2[QRY_:W2QP[[*O?K* <)[G.)FX*"8U_5Y
MB_Y$B^$3R<&A7L?X:]0?[>SDMU F5<MX;G0XSSK;3%]$&L=.-9^9.0 P;,FK
MX<<2)SV71-)WMNM]:\][#$^*U?<?>WX+^E#BO(&,P]>^@C>/"*%:7(]_V<4\
M(2?.156*O"^?C:U?;Q/G7=OP7Q<_B_ VEDL)($7Y>M7E_UA=)0UT[79VI*;&
M]]3'7<#WUVT ,\#<+%6H/2J6);:HGHQK-5)\D?434QL#TV]'1Q)-SSG 0BP:
MZ;QM<>\*H>I3;T"RPBO@]DBB"'^D[?N:5%.:ZT1I:Z+\;&^A?$^E[&-W6"X5
M^R8PZRQK "(8D"4 RVP9FY:,68'?G#;F-AA>NT_;8L53)FX0ZR/J)-]L*E:6
M1K[-I_LOI5[M"*':KKF55T2US^NEFM0Z=$Y-,*WV;E17E# -4/KT!G?G(XP^
MY(-BICG-<O)"I&7#T):1K#'8I*&6UO<F[@/V -!RXP!PFB\UG_P5]DHC0]+9
M;D BRUC=>'F$/^X P(7XO(W&8ZC%'*)MHC\S?.C<][Y4H=YD'C?^:7)]QF%(
M4\,+8SN&CZ0>+;('<I"7U!%OL;:,J*'-4MM);??2?--<1\?)/N6 @'!>#3WG
M]O1@<@,VUO^CZ?FW&<E%]_8GU3/Y9#-Q0_3SQ&&,D*]A1J>>E;B"G6H(Y#F;
MX=!5WU@KP]<*.0M4\15I4V[)3E-ROS]&LG><E=0?>*1H0=TZ7_3: <##8]B&
M>B.F8[L8MJI9KOT@>0.@*N8[I0;.(-1DK8C24'=HG-$(=B=8HF4D]78FB"&.
ME7B3>8;^>5ABS8J109NQ?Q_#R =RC,-T^;P4ML]$O-M"5;0L#P<EZ >R;[ML
MOI+*K8D2>*#-<Z\]_G91@[5J_VWWL$Q>LY^/EIUT]H=((?ZMPK::4#-HLY?_
MGKG@G1@ZX(%HRD<GQ/!D?&M">Y.5Z[Q'BANT:G.BI.3^=TFD_PZ3D;2Z;_7"
M]?XM6?97G,?.P63TNVY= #Y/B3*&L 3!?5_ 9=@46/=T1PL*>/L+HYLR$M9H
M6-(0M%A_\?4&UJQ>-IYM_.>EA-OQ=Q)DN:R:>]?2JE!?^:=?UK+Z:<</ *W
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MUE28>9(2*D"A['*E-/M[)3^U*P2[MY\>Q/<9-R&! P1)ECRB)YYYC7X42CX
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M=*N.2RH84V<Z7T?ED0BK5VBJ=D7@DS?% ZBS_.8[F-ZQ^7+'G9VDI"53,O8
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M+PJTFHW5#1&VMW?2$PU94=C^>N)^<_8OR419F_F^E4-G.A[&N$8C?3S-N;R
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MO=54P3J?B?ZUOPV?EC.ZZ+LH:=Q?21?%5'H> #PR)AW2L!YB,EIM)!8/\_H
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M#6+QM$Z=?,(2A9TT'@6&5^Z!^>W@YRK*1W!*IFRP:$/Z\==:TFEWZ>WO)-^
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M#.1->QIM%I-'S:R\B:K)W@I7T;;"KNQG=2P'4Q<+/%,U7GFJ0">KR#;0Y@.
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MQD,("1BI3>LRJ1)\ZONP/\3^ZXD&.@(K/YF6-_IU*JLZ=<6*SKEMM9\"UZ5
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M=G=%4C3L(97@BK; OM[#X97C>>CNX2;&W^TOI J+;>_JV![)V_942_G\<V2
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MC;<S,KVF7R*RGCQ6X?9Z_^;>&,?@8FW0 /'!XG42 .X)) 'N?A>EH,8GCI$
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M!&QG#'JSI0%'P"1OO:**-,2M]XRN6NS=- K3'U^JJ+:S?:=IZ83[4F6WW^/
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M;1"> 0,G4F['G&XUT1+U\#!TJ$[;<?Q.><YTQN\=5C/O7<O\MR@S4QUM!RT
M19H^]9U7$BNGX"=CL^+J ?/+,5'A7ZJ3&@X@276?*N:P6X/\/'Q<"N8F0YG7
M;XV0 #'!85_ AQJ^8WAQD-\9M$]W '47,D@$1E<=GA^J37SHDOYS#_$+Y%_O
M"?$C 4:D@)@]Z"P=,7;T'0D099",/"UY[V\']2^#P5#;WDVN\ 0D:I$$:& G
M,.;+DB$WC!=ZH*N)5UTZ)G?$#[*E4)3)"ISHYDJYMQ $-P!#MH[/->)Q[43>
MO?,;T''.23"F DOVJEP3M*>3["V9,P$5%R*KF@H)L);U%Q*^L+F^1ES9Y9)
M[^'\D3M1),!#ET?D2"X;@. GQDF JR>$-\B-Q$T8SA1'3LL<*PK5$[NJR;&9
ML\ZN\0]=DF", 73V.H",JVFDGKD8<TFT ]EPOQ>W%KY'6UY_&Y"1D:I%J4C.
MI8[OT!X <01X*(XC5[BK(BG(T\+W%OO0[&U"T$;7Y+\L3?0% GD--DRQ0"*/
M 1]TGYB">R(S"R-&&9 I":H7NTX"R&R0\VY[G6#][7!O3O/8&^=WKA^BBL10
M]]YA&S:*R[).NFC>&JZ)Q/0WV ?4'.6+!P?GJK8'OXU J[>TQHPE^!HK3-H:
M=$/"R<D41H<'?^OB"F#NGE.(0WE>O<9L@&BZ=^7W^ZWHD\>=!QVG7D>\]_T.
M?GO]+LY"S;O+5==KVI$G0D]U3O;#MPHT&*]40(9BJP01_$V&'?):W8?'GI$
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MG3%['@!U,1ZOV*W21MOK5_GNMX::/WXF<NQ%\[V[+,:/):_&N*SI_WOOBO5
M<_/]?^7?<&##-!CU"OI9_8 <T G+/T.AJ BD0[4O'+&-ALVZ #'MT.4BX'%
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M"=-C;6WB3+_R1(8Y7^C+&N5T0"3T)RPL]*>#:CAQL\MCLYI]9P,Q^% 4F#I
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MN14S2&8)S/FG@#$'GVS5T<]WHW)U-FXZB6XFI<7?[37CGV<X5#@A)GU*&T-
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MC(%5T.^P\K73CE'V#B)VP'!$O!7RR529+M]D9L2[+L)-:EW=^C"[ I%_RL.
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M9GEGC:^'[BC*B Y.!0OIBS-_6-26]<A !$YZ?@U8>K)TXOV7@@Z': 3IWZA
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M3S+&$+P8L8/!@]P<HY1M-'-Z6)@'65GC@XP&Z]C)4BP$5X_#=N>#GICU\D%
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MG^L*[AG<Q3V'EK!BX::6-^+(&^R?@![T:>[)=F!HJ@(3#=V]I=ZC5W&IZCH
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M.03^EE;@W_4-_%_">.S>_.?\Y$EJ%@C<"UGT4G0A]_CV8[3WX"&NU%O4M1(
M8@J6#!*P5\.3Z\FB/ECK%2S6=_ZB_WT.19;%2,&?R\W#["N^18;+0)ZWDN9N
M! >J-N(,>B+XH/_K FU_]RII9!':N^0]U=<E^75(MFYPY>AHCH;V^ZIE>"$4
MF^N@_TV"\MA[-F@ZEZD>2VC 1/,4D7&6S.'F.*X7S96P#QG&Z.'MP+%B,25.
M3EPS9E8,V=D#F=B97 )KG7D7,O() @_:0L2K-JB&!G'Z5<TXRF-N50,(Z@&4
M>CFRG^;8C1;Q^>!+.<KT?J 9H?=S7HVZYO@#U2+*I5VSKQ?EIW[2\3Y3$\<3
M)W\0<)INM)2\G5KJ.Z(T*=0)EIHG2)#GK'#UJ5V11]XUN(MU:E.$"05T\GZP
M<S;'K/5=<?V]L2G2TN2[D@NB*QA5*W6TN*T$<..[,V16@%WG;!962P6ZY#O)
M_#F\W&SOO-9RQ;69 Q4KG7G6;ZSK,QM]3V,==\AJ/G+@@UR<DB[:M=X)RG+E
MG+ O,B)N*1>6/?ZSAUYY+)T'JGCU(@I,)V1T8]Y7_'HML:I]M-Q71N/7VG&G
M]^.;M<4Y.H+OO=[9*D&J<^Z?ZX'>P0MU$A+)GCTV4Y:N_J+(YHZ"HT $/9JF
M+@W8]6:WGM3M32MORKE6.7:IV>/@J+X];=NTWX:H!5,U?K5J/J*^M^>'V&4X
M-L4R:)YW&"!UM8.8I55TB+2GKTO(/>@AAZT87AK6EYR_G.[Y.ML\\)"L7#ZO
M9&^"ZWT$+N5#R2_?+H0>CCU^K.87HYMB>R@ PA%@22=6+_). I!*E'$M"]S%
MD$96GRT9U>J?@'6-.!J>^K2.>_XC@6484[H0:9I? M.I.*J>=K>X0_/MO-=K
MVP:LL\&-W?JEQ1D-L).F$J>2&OWTUWP=\@);L\J??[*08)/TRHCU%M;/K-7Z
M7N74U0PJMZ"LM>R_R91(3RP_'FAV:;O91-(^\\_^Y;C;?I8U&&MX".E_E85(
M7'?2=!<RC_?"X1YZ94U,!R=01D;(^V>>M[7A\XD4(G'DK)]2_HCRC70ST!S*
M@-4VFAJD4=T_B98%9$=<LU,O-[(FFN*Q"ZWM!>*R<K=4U2^-KG,FU-XLJDZ3
M@63-Y-LG9%J)DRF7;J)_,8)312VKY\'?^J]'Z%T9CI0%O.F\N"KNE3I2(>%A
M3E<%% &#ED]TE51X:L6F54"@$0B%@U8-=P_F'#GS,"><?;YAI$JS)M'0BM=2
MAE+)H/<^XX-VEK DMV(&YKB'S:R(Y+7W[C"%A0U=(:ZB:&7R'A@[XW6=2?H;
MY]L>$Q3EZN '_F96EFDZ*R76SKX(7V+PHCXLZ 93]XR;6V,Y>,+D%NVD5J.]
M6RCAH05,ENAND']F,J."O5VJ(MP0W0BI4RY,>-;Y)^\_BXD"1:Q^,^!&V4<*
M6'X?JZ9;3!KFXE%3XP) 7DB'*;*;P7%!.V,:DR,GD:F>S.K<;&E3Y'5QLS+S
M<LJ' ;G2AUCJQ \_(0ABW%#:8'R!&%,@8(<CMDMH-9+S=;ZM]M1LYJ\__MRJ
M[[CWDK0EK,)\*MRR AJ7M_.U;=?W$J;T=MOMTJ <)A_4K?XURI;IG9QG"31B
M <MNBL@0"J1_.'PJ!$@K@@6Z"E+WK0M8*)D:=VO(#ZX5'AYZE*4XP& ;%J20
M8'O[O?<IAO%!2P1FT15 E:E!8W0-^,V*Y*--B-4KZYOPAP4DCK_'L#KW0D77
M+:<FN*KZ>OSR]V3C7YZ8V<3.0A5/2"G96:25[^]Q5T2X'CR@;!Y>GW3G7:V]
M8J.%UL+P_:FEN0LY9UM,\=^WR^SQ8^2,7<L+WC?RJ."(/<U$87[TB=29OJLE
M+NH?=07Z\/9+=;].-*Q6X37<=%\M?F/[NN^;TQ^L%V5S5';OK<QPL^C0+OZA
MPOSHWK38ZSOJ[:?3#J>8E_R89IRJD#(0DRQN>?;6DI1,QML=C-SXIHQZFY P
MG'/P+.)C%:)F,PK(3EY\UD:I,"D:7N.*%1C*\8@442!KD@\Z"/1?9%)3EY:Y
M0E,1=K39HL>+!0>UY4\06-KIMX\6O(2\C1S7^@!1','N?'3!6?=FFI4DT=/,
M"WH 7X6)1<LU>,;+*[)J[I4PL4G<'5.,K\Q*W1<I8JR)ZI@]I9KY7HIP%3?B
MNI@P,KK74&ZXH8(D^?;D5F2=_ENW'M6VF3;\XK-VR^UL0U5 Z46[U'8UZEK-
M@N/7EXAH'T:"X>E=WJ74B079TNC*_NN:\ L724_NK03[-+ZL2Y<[;2F5?3#^
M2DRP?;K% L%++-E(S/ 4($@ 8HEKEU W(EAB/5NW,&CZKF#T5TALERSX)^[Q
MHLNWN>J39X(]I>8]Y"+\;1,YQHOV[QB:,%A_>)MQ^.CJ\NWOB3=\2Z1LK^9:
M6SO?$I)RT6VQJ_)4Z[JN!%-57)YYP'ZT.-:9=$@=(KZ4=7N!DE>9F7[E]2FG
M,%V5JR5F!QT2 N +^3LMQSYIV09[R^:4FY$YZF__Z:DH#Q__RUO%_^WF*#Y5
M)=.=RXB;):%4ID0(.Q96W>=?HZRP\V%J-1%>UW:N[5NXZ^P$)'0Y#8E.+-^W
M>]]E^.1:L&A#1D3%KVGTBT:[D$?IF&[T'J[RL.$IKBDP()C42",#QMU9GO<8
M:Q%"+] B>0XD]65\H#]M4!29898'8?K=@TK><1[W,*/OH)NVD:9EHCZ].GBL
MV6EWI]NG.T31@/%<=HY^>:>P_E/K]1/#R?O=U2-7W#))97I&(>15\Q[%\-(G
M)Y)QQ95/=O6-X90WH$9$"Y4I*SMV/[/I(3W?OW,(=0; EO?3& ]:_3OS!AQ$
ME;K8K1$ODQK;OA5%=[&SI^Q9TCFABDTM_H>C1FU<SRQ]_\CD6(E6+";4.T)'
M!\U!HTZ0II@68&&N"7X8[XD=K%B0ER,U1!SC@YR8'CEP>I5=1P %QAR'!9Y'
M"3W0=+>@Z*%%!JH_6/K#5)=.6?IS1N^B>(,YGK=ILNYG)RQ.=7>8SAO<^90<
MLNPSE'D"DJV1&$!.R,L:K4_"VEF6F6IYF:QJ!6&:DLIZ/%8K9*R%;1T,&87X
MK^G4;KBWQ3O#_<B#':/96X[Q[:J+.;(1*;CPF\W8KE;IM%+MYNH%UCSB&GQE
M7;+V:F-M%#>B0*\B*WN!/*NLT(1^H ]A,>C4./T=+(HD@&%9<WH-A8!IU$X:
M1KJ'F='17'"@EKE=W?P8VBEJYU@'A!3LXP0/$QX46,[7C'DGS)([JF(2^N_"
M+I[%ZEB9E)<,[&\[2^R>K,V8$60?MPBU6T3K'ZI^G='U$[6V$$^B=BE)!3^;
M?9)4(]+6]O%'F&)U,FEV)MGDZ'I8PJ:0XW8%5Y4F9SIUKH6YD8IRA='X('$H
M=8\61GZ>'2D=9Y)'A_?&0RO.TUQCG@]S]33#JDODEHN/\4B7HCM'R%EDIX&R
ML3Y)YLL^7TPSYJ>&9*$++#EJ%SHA&8M,I/4FLU3,M5O1L>JE.9='4.=OT%*7
M<+]4<NV-WFNI&CF\@U]OSUT;GY=W>\#.S1]2-(;D?BC8RGRR_\P$Q\PAB249
MNL\",GZEE"79]F[N/*E"DN:0\7,)MZ^C++#/8O2^_26;' VKG@#'LC((Q5>K
M2!>^:I>;.A'D^"J$(+\N)@?$N0+.CY'^/80]D4?&/K)'GWD@DR/!BR&4_>UM
MS^ 0:W?72T2\5Z7[HFQP3VMG,Z)5TVY^TJWOFG0-].GXKT<$*\\HSWTR]-&N
M*J'>@/<F);X93=AB9)Q%E+-2$Y%K19NP7CW'DHO)[ZXKSI&^ Y.U)Y.MCNQ2
M;/BA/B9@T@"N!',9#&:8O+H2F.@X>]];WMDJO'U;.\_^<&"!CGDPJL8T/>.^
MKZEJ0]L\*2#S>O6R-59')=H@)$&Y],J_4_WP_VF5BW^WV>*C7/,L\Y!^V+IL
MI&*4WOC-YM!E]ZF;KK_8KAS$.2O>3SL)"_[FK?258PD7J0<VC=7'P.:0:(\C
MP'&='G3\1B[X ==&*>'8*%;^*T_Q]_W!E68U%&@3!#8)BP!S=!D.\2LW.1Y9
MP:$2;]CLYNP1UHOX]1FI4ZDJ&3A\6ZY_5?G5&!]UQ>7#,@KM"IE>R D=!';#
M-7TE[WXYA4/-#K#<]/MP>]U0I7T[J8&SC79F?4,X:*@FTN9/=XSAG: 8_XQ2
MYYP&BCI=3G_4-8]WI76]RA8I[?(_Q*Y2.4ET+>[!C^:79G2 ZTKCF!OV0UJ,
MW2@WP:P&MF4?BWOB"1/_ (C[X2_0W,.[$135C,ZMX59 P2E/3J-;MA1;!I7-
MSH??H(OL*W.[L*?Z<,+P$<%*_ [^[%GWMEP+X5=#EF(0D4(>6S;SSB=7BYAY
M"V9FD?(=V\_']E6];BG.:'0>=:RG:"U8X#W'JH>]?-.2<J)1KL#=*B#:YO.>
MI%W;N1L]&.'U\7SCEY!W*^VO6E?2*N=?7AQ=FWMWT_)^4UOZ*Y.V9\];DB?#
M^YVF6KUBG17DO1&<HV3?R&^!^$F]P20C*9.X;CX(G!JON_XQCE:XD"V[U-P:
M68* EO3+=-&@TOF!B)+W#756L."3,.C,F-MX3V!(?42BB3+V8,/$N,MB,!@6
MVWW&A#IQOX*F['#7Y6SGLN9T'BPORZ#(SVG,A15[)!<##.M[',DM6)"2Y9R"
MS4ANIZ.D*2HX@60D</W+H*W-"9I&\D!T!T(G["NDG2<0_<2'':;:G,R +Z.,
M8.5DWU'M$>EFF1$7TQ+L1QT99A6->!'7]VG;D;=K<S+"SJJ6&-=#3=J**$BC
M]:'D"GN\*I!Z?23](_H0+_JXP0ZX.DH& 0N'ERZT1CPE>_C6>OHFPR0N(-#!
M1^(AU'=V"7?OW$55YR7&G9BQN8-=@C9D9<T/M0E[KB[NYE5!LA.NF/?H41@/
M3<S[6IJ*M!P&^IHVG]; #="AGANKLQ4,C#JR>?*\O'H=T")812FS:E+T%6%'
M 4B72R,?%*OI+NWN #]".J<:7N6"]*-Z-! +E*>'_1N>:^T*PC1:(A#0PL%
MMHC]FF<49O<H3;VK3:0CN<SLZ4+(<OD"Y?OA)_>6:<,H<[J<+<>#)?T$[J]
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M3#L*S+=\XH*N8_G\CO?=]^XU?UO F;?96#0EG1:"8J9>::4#%B3B08<\Y73
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M=LYY=@6H$3/O\M V&#*"Y\IOS0;^^?:O\+-U1X$WK=\LO]$?"%9^$-M:P_U
MSO.:=TK2@?TB6RIVS-APLZ9E,)JC>1.97S<Y[8K$Y96.6OGG!',4/',,N6@5
M?30VL\)M/&<&&=/&,'S#;% UI7G(M4U&-L7.M<,T 8V>>[]W_?\)^[<\U"BQ
M[#MT> 621VM%;9THV/Y@>$$'))8.T;JFM= G#^4WZ8#EW<JDA@9&JJ6B"Q;3
M^(:ZQZ1*E2P\)3K)9<T/-#7*W[)>:JHD+4)/)-6D'.QQ%M@6K2%(B9_O:#T_
MXB4<(5F(O6E_UV1,S8@8=_^EY]/Z)A7I6*#]QWK;0+] /S'/W; ,@P%)Q<7J
M:"_#PD514K<X*KMHGA^LH_0ZVUQM.LD>M)#>)=JT&.V5:F"%L@7I6/?3 ;4"
M73 ^ZI^DV;=[=,!Y&XK#YNP32B)!]B(EF<:JN<'M>7,$JH_ P#-\;8.OLYF#
M) <O!D]&/8^XTRS<3V20Q< $H/Y5;37#K2I4!9)SZDF9B@V8=INB10S1ZISA
MC'R<\PZ_<K293&12>DC6B9*]L%VA<-^K!)P'MJAKS3-)6AUPJCTVA-X@6W</
M783X8$*YR%Z14$&1F'G054KWYDZGQHW19EV^9:I@P K"YJ?M_2)*>L>&^_)T
M.\_4D-2!,EHJ44@NM9ZIS+*C;]4B[>Z%U?HFY+,;5OQ//@W(!L)J=M",[,KM
M71URL7.+G$OAKL<_\KY6] YP9"(D%-BY[T\4!R'$!ASN9 .38[\H"(B=%,+<
MX@P)Z3&Z;]4DG:62'Y).\F(U1*&&H] [Y9 F3-MEJCK"W@X(-G<+NAH9")^Q
M-T'H@WU>[3BX!?GG%3_1&4^_W@=4]4DD,N.]NLD@R&2WQHWTCL:$CM,=ZR!&
M4GJO9E$-MJZH@&RN==WYA2RAO,< LX-&GE!"^PTB.U7\IBM2IRO+O3X.7$FO
M.^8@-,&BVVHT/T!]B""NM58^2F0QQ6J2N(4I8X[(XY2?1%YNK>&'PU>6CK@4
M\LX;X+NR( 'V\?U/1GUW0RS<Q\YSHM/<+U9*=R[ST '[:A,(-Q7F2*@[?S(I
MH1./?*>PQ461F]=-.[8;]0.=L5WQ;PS8-XE*MD1%/JK">:#L%=7=+NXVK10I
M3I9O2CVJWK*0RM%TERXM#L'6*02;N//>ZV&^TBH7SJZS4V96C0#FJ.Q:ZI6B
M/1T&]_>-7E/E3%91=I;*TP[-Y*3250/DYHI9 ==(<K@U]TFIYQ=#\T"IJO:7
M7WD1(AEC8D_#!>502=\6S>[-QW(+!5[0?FSS#5 +Y2.M$67?AMX*G3[-AE[-
MC/-M%R";/28G'VG<$[,.$*7.(,VH\G7/!4H[V=BOMJE^&*EPP<,SE_.ZT-W&
MON=^WMP/N$Z62 ]_U#;UW*C;8'E+2.70*XSJ6429"6Y:QWW\-/%$KCJI_(*H
MYF7(];]IUTBZ&X3Y-1-&B";&@;FFY>1C*_?4-)YBJX655W5O"J=@R,;LN4M,
M,F/=DC%AT0H?G%(?O66[U?KW.04/.R\O56C==O#>;,6TSHK0#$*ZA7,U[S O
M<%B;K>^26/Z;_\CD:D/NRU?(6HPN (IRBNU!WR[^+>[B(8QYD<3)^URY/V -
M=!FJ1'J1*T@1)O,O]]]UF'4C;DY$"2_F/40;=@L*,MS:?VK#+/HG@H%]3[<[
MSOQ8E "+W0PX%XCZ(+]W@\,18<@>HW-&_5' (Y,' ,>?8\Q_,W%+A;)"0GFC
M=DXJ.. AKR/OO6AN;HC64(U$Q;.&_-Q;L_\9E,#\#F&CJO*I7,UL:]UQ(V\&
M;U+4F*ECAYJT;4P$5DR%;#59CI=R[D/)LE2AO"N[;R6W&H;5IEGG1:68TF9K
M[B9UIB=-$*&YQH$+.YM^V\SK9*%<'G);)S(R74VZ8KVQ-NG&QB38;U\R_=$;
M;N?HS;^_@%+*'V'\#9F195(OV>Y89ELWF'97*-9YE[$K>*[XR+>NK>1GHJ;K
M0K=WDQHGQV;_S(^6_/0F/UH,D-_<MS//W!%SN:R,=_:#P[F:EJKZS)'MD;7.
M(S4ECO3'>F03#Q^V=+#4=8R<VNLNB<AX2Z=7?'J5[@XG^;1+D-<#LEZA@A3G
M0W[32YC/,\@HS_ZOS[G+?85Q,@5A9V]6"L?]J=O1G*\O:+YS+U=^;IU=!>>=
M;8GY"83XB4;E0-<DX3P2THA@:S6[P!O &K,:LP./$.;GD5?)'"*^"$+UC9GF
M-1NS."DTK^GHDGZE]A75I<8 HY <?_6^:/*Q;/PIY7IM?&Y^3XQ\.Q^Q>E/(
M/1"YLL\I5G'P<-]ZQV8&WS^1WQ"AG$Y)=2\<UKA)4>W2H4VVTZ1(R!@%0TEQ
M+QZ,[GBYYX0C5[QHDR(SP@A\&CFZ#%,HUC#9!L>,H92@V]GFF'M'*>"GD$CA
M;ERGT"^S#N>&4!'X"\(&9U6Q[G655//PI9Q[?62[?J-'[@L-8QSL$L^K8_N9
MC&-JP<3;]QIO%X#%--U54,]X_)--H9N*:?'?M\20 ^I:M$OG$*Y6UT%K;8R[
MGSKQ)G$*(2+JUXG-0=\3&#$#H4,Z9 L>J@^$6;^!M+OBX>O'QPY'M]:,+D2M
MH-,S'VXL(W_6": $VOETCR5403%T %-Q_5@^S@GK02#G12ZF45S=MBICY TW
MQG6U+LR;WWZ_?SO6\Z'J163P^H.@UX,RI@' ;FF$83K1U/BNW:"X ^OXM/_V
M85(V8FW@XFM#(^4-SOZ!0KL*H?4LF&K!Q"]DWIXFWGP.I8B/&M&0AHJ.^MFJ
M<YJ,%Z!:*.$%X$S8OG^5MR.XP 'D5C<[R6""W;/-,>BX+%D%?NW)OXKS*/AD
MUVWR3+3;)-SJ*#W*UQ;YP>%LW;B:8"',$U*F#V/[13S !/WU,'7/R&UZ,[\!
MNXO39Z%-A+!=2W%*S- *+YPTV+ )/FH=Q:UJ&KC;;/7NEUM[*>975%8O+)C4
MY*$B;QU#^],.U!]$'Q[H44X(;=>A#TF<8=2;,N'SLI>H#TC6T5#[?.I?I*%H
M:;\0Z052?%D16"4M@Z\EKF*@@HC")XFUUN$^]7A[>8.]G1.X4DC[ BC.3G7#
M'H<[I(KTCK;S&JES2 '7&<91O\M#L8Y&8WM<M9:HYA"0%HE60-H?Z3ZR9>+8
MVW//X:/>]_#QWI?,DM8@'@6@7:Y[/HZQJT;PU$3G-6P.=^DRFIGY+,:R>;-:
MS*)>M1SB5HZ)2P9R>1.Q7SAPA4@5V6OEN,/TZEBX*&_)=I^<FW[GT6HT.41P
M/Y+"7HD)48PC9Q%"*ZYF/ M!K+*NM"J0]HA/P/@7B*OP$-\?;JP5+44Y\A_.
M+786ZGI)2AA_^\Z17WM2$/K'S RXT0/9G1<^#HRH><9?5FAC2YG%C$R[!;VH
MFNH_E8*>F3$#?DY"5@%FPM_/Y+O.Y;PG<O.D*\ZXG>I>T2!P!4ZE(F#?9XW[
MB8=D\;ZM&6W-.-/-/G,?M1720(!%*^WC)3O+:1I4R3&7'[P8T/50#G>\0^WY
M)K_]8Y,H%>6,=:KF'T.(Z5]U8XB2KHJ>(D&&,O2D5 'VJ:3:2+U3?*4--(0B
M7F(#<3>KH320-H.9N58/@IC#9=*[,L7>=^('XGHF9'8'SNLV:^.\GC9,7F]W
M7&J8YI6H'KB>OJ68GS^5%;U8T[(HH[?B?HPUOH.= 9=,%R6]UK='I68UN<VL
M+J4U!2?:C5@W)C3OUJA'1(L5/3:UT][JU/P#/*ZDJ$2[2^J*VR@<.H>K&*LM
MON_M)?^BK$M-;DJH2B_V@N2M",:(R^WE3+;S)AW3/&(OFLG=D?<R\/>ZD^4;
MYR4E-K]__97H5OWWIQ7ACAY>@<0GZ'XKA'5JBJM%<K!8A^>)[X$"UG2[=X-;
M=<,5'5)WZ+Z"6!VU3ET!<8=RKG%L^;C,QYWG&G%^FVS9J"*UB'-,S)%6*,3*
MP,,*^S@@!%<^W+P^\(E+7!"?4L_,!=SFQNZ);!>->Q2Y:3.&'\388"L]75[H
MIHYQW:I/LS'0B9.\@*O+K^%GRQ0V:)8=>%"Z.&8=-BYA.T.R.OS)DS0CYU %
M2_#*B1^,IJ!-3TJ:'9T*H88X:X)+!+R>$DAV8PX'/8-%HQ_WEO=+X=U@GCJZ
MF Q@'UL"\*OW\V<- 5YUNOM?I4?T0XA><6V77FH2Q-%CH2)4U9%:V3^>X!T@
M1]TPKE\+$'&9%[:0V4YF;^E8O'W-C-*$QV;M/:FP[0V0C/*-AW*Q*8B.?+00
MP;C<*=@AYY&& #OW!-ZN%</^X+4_2CT_3O<B0D=NT2VYD*;BX[N05I>)M&;J
MPV,S+7_AX%S3#7U,/9DRTD<X=J**R083Z;T]&1VIP?_+096TWT T8:>8F7!3
M0M4%+;ZVUN!09W.D1]:,F]\M/6S=R8C]"$_/=;BPF%U=^!*W@3/8-W/K;2C<
MJ_%=-4C5+@5V%(H:&ZX/RL74&/V1Y%&(!3\P$LDR+3-6 +>H&&<3[K7 N44J
M/YD^.1JK*:0$Z.&H]Y%NF:$?/O]2<=JOK5A3J9U25'%.+%Q)VYYU4RF"!_L)
M68TI\OCE-*/3 P)8A:[9%B8_6KGAN;R41_$4^#E_CPZ(*#O)O7M:85YV_)L.
M&#KVK/L2T46T@$=T$"5+ZA$J\FXXT]?Z<%%C5OV)65M[^\KBC/C![9>5OBM+
M@97VZ<;E=BM:?/$=SX3-6))BX<;W,D?A][J-!_5MU/D2RDI.4YPF1<QZW11^
M*GQ)"[.H@_;>K>;'"@+KQP-WNWFLRCY/P)SP60T]4<TF14,AA*V+(?G"DL6P
M#J,2<!L^X.G$2L3VOMZ&B>%I;NDZO@$;QM$&Z0"*?S,S'=#?^"O-.DLWM5^J
M1]O(YWZSC+"/;@8F(W1IP$=<9Z464ANRL82)@Z@4EG;<L,34I'*7^J7X-%<T
M6O*I^%E(",<<B*Q8%ING64&3PS;ZY8=.%_L):GAL1%%9)LC&T*2A+#CHY>/[
M8'[&AB2F(($ST+^P,AZ=:6EUZ?CX#*<R5T5^V>JLSH\K^/ <7.4'B!0'0<8C
MDTCKEHRJY%;C/-8#0I:M?U3*#W#J86G\JZ$,3>0B!'' J\L,G-D3OBG?W[N[
MX?C7>/,=I4BCVKBE.(3MD'O)D#=1S$I &,YR>S*76QR;8^#W=,4XN58/UZ*L
M=6!6.35OJF.:4!VV^'TD)FD??*RO(_OK-B56XRZS+GM8A2%[1.=]BR^@RU9<
MF0J.$C\^YZB@A,W8><O,+HKIHSG%X>L$9=V5(\GVRC;P[,1,O_&(7_!0_.Q%
M:?D*;X6+\O8Z\STS/-']UD82WNZ(WF*[7H24=4S1M-SDS">^KN9.7>6X;^Q>
MCTX*:&?<67_:@F$\-/;5 )XB>/$OO*\BOQ)I\7MC1$5IY8GLHYIX/AV=AK91
M[/F^L6LC4_$>8X_%#(PFM-&^Y:FS=Y/>Q:5;*WU+VP2>?K![</^1VLDFH%@E
M6*ER.+YZO?;G_JKD$C(*A!IZVRQ)0+*Z.S"-J0F35<U(+M%JJH0\+@H,,R.'
M'3<EC>(WFSP^U[BY%]M"WAFJ]JMFO:,#)M"GA8OW@A%+_=L?:3\ID>2D'0R_
M+,D: SM/,5+S(4OV\.C4$&.DKQX[@"Z[!G&&-:OA/8HJB+(LD'#Y!-8A%Z^3
M@HJ5(X<<EV(P3^KTR0:FM(LIM>*$:I:5\DRLJ]<B&X&MJWP=P<_5<*\PZU4\
M3WZG<?[)E%@W7-\D+567)T@Q)UTJ$.Z??FL_MWNDR:XFU=8LEJ]8)2E6D%.Y
MW7#6%<F!HF )TS(8;3H@'.'WA<I'%FFIM(<$ZY%F8Z&F!1C%IA+;[VGD!*;I
M*?VBRC:OT.V"E0&72U/Z;(F!^_L'(H;:;?E4'XH247)#U_!'JQ14=:Q6^M:0
M^:B"+9-DUQ'[WDR68_Z40B4R(,3+(T2^K@YOB:^M^Z+6A_"0.PQ@XGUWYCNZ
M$2U5["<T+G73N'#2;27XGD5LJ?LQ:EQ3NC-GH[4ZUL](== LC#TG;TOT8G=N
M[G',0DO&FH7U-X<+)T@- 4CKO%T@5(LTKC>"2N!=:^7^BENDY!1/XR$U#T@'
MD6T$P5&J(8$U4TK0/K=C@!BBJUOKS1?WL7%4P/K3_7VP"AT020?4<K8/?5"1
M:I4FS7:: 'H)O"87\1"T56L3.3[5JX+BW+>]^/E#L_67.Y*$_CN+BFL#AF;Q
M%HW6U6G#0O'Z8BTC(>HY*@,S4RFE(WZ(0? $UCS,I7^#+>27\57<3;&;J(IE
M,]\"C\!2\W+23BPLH[O4^\#+#US689I\I!)-5D7B9><48H/4T# >#4Z@-G+%
MU#V3#7T:Q.NF:RIJ!VN%7:7@V*/HBLT\F=+^(OAB%83G,.VGGHN7U+Z*0"<2
M $GO!&Z%^3+S0%QLR=81!>B\3GZ!$;\8R6EK[>A?#"^/X*G-(T-.^^%/AV/"
M'O3U_?TL!7M0MQAP@*N=23;(QQ\439>"-U7%@;_L^L9;4C]OP2O,IN)/BOV^
MC26M!)<=^/VG1XI]W++4.$5'&GQRY]"-Q\^W=N"4(P4M\TYB,A-HV?+X%5<
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MB17RP+E^<#7PI]:-YT[!ATM-#4T-V2>&Y.MSRS%^LE%M5S7N0!CL29LY\W3
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M8ZW]OHZN690YIS@&?8T3:P"*C\:NJKQZ#3[YHAWJ2)O61#D=A*'ZD9<@YCW
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M8800%^-Q5.!R*SI3,H-?VEJ_IKY^5D3F*WFP6ENJ)-#D6N@0Z K5:%Z!/(.
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M,%> 'L:(CBL W8 !T5 -SO[4P2YJ_OE$88%6'ZM6WGTI.HBT60A7:?;$0F]
M(6$A_#1#SI!.8-ZW[.5>6@"8WU#=8JWBJ+Z].Y:P2%=6GO_M6A%].]H]# Q1
M>F!$DO#_;QF(ZW^TQ!B\ O01N&5]"2&7_ZKGVF>,0F*S!*H#Q=^$L6OU>SX]
M\>:&)=G%BP5<L]O='4\<2,[,UQH.2=::@EH5X"C$O\A95T#>S3]+:Y[X(XUH
M^22OX-O8<L'0C@!''KK6];0@:FT\Y=273ZS$@Z;9[D-=,"NHE)Q'&*69W()E
MX1(P71E:4T4=.2L$E<D_,Y(26ZE/?;OC[LFU.#,&>M-DWU"7AK-<+$@P^PGG
MGWRCDPE%IO*I2='R+DN4-);T[/"[&AIPE*4J.!;ZF+-O;MQ.WH(;"A^E_AY(
MF<KB0CH5U^]('/&7WN-K89[='RV%OICUO@)$FQX6KK+1X,5PFB5.LHI0,4QZ
M[$'=Y;/NF6,E!W9(^IMDY<G#(R.E20DFC+"0H*L]J,LMA5]YE:U*8!TXE[DV
M4X$M,\<EI$4)(ZX#HLL-A< TQ)FI-T]8STH(J;R^4(GRRH35]=PVC6&D^\8X
M+_]R67K-3D'QK*;W=\-L*A*-ZJ=G-=/YEKK@X:[_+:5H R0SB'8=$/Y;U)H9
M-7S-@U,FW3(*"O[HZ+@L]? N"5MDN QK9\X''6=?4U)=9]K_R:3@O^+(DRL
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M048S(I-PR"Y81XEVX/G_X?I\YO5_K7MPAD=0R#:; @36K18X++#*49@^]2M
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M>9]^O$NO^V$OSB;)Q*!ABYZ>EOUN:. XHE4H8R'%6\AS#K\)"4O%MM'3:#T
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M[5K_7(+X\<N2=@?@!_^#PW:L_7D'5 .=+=6;(=>F,$[92WD?)X$ 6^%4)F:
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M&42H-K]0"-HQ4Z@+ITEF/3;,]G]2I:E.;5A<,H5D2I7239E*CLG7TU]\[#8
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M'L10MCMOJ-G"56/DNA);-=\9[:ZCN51<&.!FFTIPL=I:_Z]7Z1O1K\6S."H
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MPJL2JC?QWI3'$AW\%LJK(OV%6VG\H?4(DYNT!J9MQG7EAYA-&<'EWR6?GAN
M1G%NY858&SKC8FHQ)%@8V\%)'YV/80NB-C;K'Y)#)924;MW)24L^FZH\KM_'
MN\:<NZ!+5K0*289$;ZSXS3WN%]K6K$Z]:4JZ-$I&T6/XNZ\D;(7?5:4L&B6[
M(A=JUA8#.G$I?\IHFK&\FQEI 4F#K\)/O*]IYMD[KK@Q5K>;^#\(^ACNW'^K
MYE.']AJ8EMC\K'T"H5X(/6M,W9"R&*8Y+F*YSFPVSR--X\$83A5*T\81V33(
M^=9!T_0Y# M3^VZ#QOL1&LM(SR;]9%7^WC,A YD!2[5RJ@%0S[%#F=;)0F#K
MT96&>HNWG(FN+Q.[Q*/JQHO2-)1KKO<B]%,\XF]W*4H3%-)L$S=.39S>H+4A
M:O-W4MW*L/A:O:E<X>N:\G-&[V**H1"D5M*Z,OLHLQ)#WL:'A-NSQ6&>^2&]
M+S-(/E0LYC(E]-;#^ZR()PVQ G;E8,I"?K' @6?]Q(CS)^2OHR?@*SN&"'F\
MRC#KBDU[TM,'K4TO[Q4EZ"?:IIU+)&5Y.3_C"^=M":N_]^MGA$WMSS<D48_;
MC>M*P]V1W#QB_+E!ELTG;O.W;Q-@/+I\8ZR.UC_,S>,]WWO86*E3FWS3N"91
M^?!Q%*?^DWR>**;'Y?=+_S(V LC^NLJ9; +#'2;<K(.NEVXO>F?8=ZAC=41!
MN7*1"B;&;TM/+<S!MR=TA7H,#.+6QM7I()(@G3K7X:U:\KV7^KW30T0;BK U
MZLR"C5P.P2T_DI%)M'FXA_X%DL%@UF"S0C-+3V-R8E-)2=B"RJ]*! <_P+VP
M>K\ 07-UT F.#S+JBWB@+-]7O--6"^1=+(B^"+@3)]]_)SKV?HH]:S%KOX2.
M1*P]8Y(V;Y+.(!"PD/SZSP-OU6Y:"&A::(=W6@0T5_Q)JJ6/_M7H!238K/*_
M"1:=5SN9#O6!?(TM;HZ4)F)##**:WN1ZXJC\Z=>0WNZL\.?EIIF_*84'QPXY
MLZ(D%S7U\QQ;GLV*8JHAWY\Y"DP7"\,%RA[L3H?_VC=TK] QR5'HUY;J%AV5
MXLQCTWHX5)L1>T,RM 9,%U$FY,U<3D!4"3XV:5B3$="#"C1Z!;N'$W^>"X\]
MR_7%=(<E:C<,+7M5%<U7P&DE;@3F4!?4<COD!F=::K)-!BPTER)4+QJ"@7X+
MF#O.[/&)I<1GRVZZ*EH&[<TMM5 #N90^3UZ/GA/E\H=:K_?&F"Q@\C?WK3PU
MZPFW$RJ< V+M+&B<P.T3-?8\]W U+Y*6'7NN(;Y]T>)A(XU_#I [H"VQ<&&/
M;4,EU'!C6-CE3H*37<52'KY(<A$.Y)T9LV.U$6(2%I.+NNLJ?+HNO^;&VJ$R
M)OF,)30C<U&CQWA_K%HI@AC#EF['DZ096S!C$SKJ*912K^CO*A318&:&9H#X
MZ?R:<N)GCS*Z@(F-*RMA1[JE,!X7[/Y:]).H6[:>B#S:V((C0:-O6 (K-2?_
MVUS9,&NMR)32R;@  SCO.C_PZZ:C>W6&MSO;4P7J(G>CW]?N?#X+EL'_QL'^
MI,?3B]Q+ &Q)"*H,6_M.4ED/BTH'$:/6_$0;+@'T%D-&D6,?R>#D:HM"SHL\
M?7.IL#FA5P L[9M+0(,;FJ:.)$NL]<#JB2U%Q:C/N/+=B7R?9*\G; 8W?=9\
M](ARY462X#A DM&<JN"BG"Q$I']Z0!9! +OI'OOH5CA+6)E7A*V.W&N1FWGM
M!E0U.)N[=9H*4*CI_$Q<%V/&3%3T9\OU+7.N"TIW-Y2_0.5L@,"IVH9CA[35
MSU.%=V4BT5]10Q>;PR,([L#5&?/^TY?\PI_7Y6TPU!4L3..I,V6Z?V7,"6L6
M#AVY54P76P.9A#(@1U4@CRV4P- (J;#=;6&!3&'7/&]2>'T;)WXN&)H,UM.V
M/MP"4^\V>VB_XGGA--6H=FW8I?+;P$E-$]$=UVR4>55$T>-7S1MD$_*@D7 ^
MX',)H/9R8R .K,W&-N[3/%"[L4A2#]&+>43@CZFY*CH;$KR XJ&B:JE^;+YK
MZIO J5AYZ"^[#_=Z)=UV 9U .M>\46/QBAFG)H;#[_W"N2[.N5BS$LCI,+'T
M<O5[')75./'U]HEC 0<!MH(4;0HABFME-9]MYI7(%'VKG6I8\7A57O*7/$:O
MK#PV:"YO'2'AK2K=RL[3>XU35<<L4XU<')_G^Q:LG-NFIW-&*R7]/)].XZSX
M&^4@]A_$)M5;:I;\ OM^WFIIBV?;XG1$LU(O*%10<QMGOO!\1L.N4&TKIR,-
MM7.W7BJU-]H&NA1K1F?SRX@[ZALT'Z[0^SG^"L.[5,+\X"D$( ,>9*A6L]W!
MD;T*>VD>KYVR5C:=X^<PE^KB1?"N&WP>$LY "V:)Q.AC>B-X/1B%[,3/=_$#
MZZ+DQ#)@!)(Q\5>5:T_2T(!)IUB4WT*H#\%J]%W<=MF-Y4N >[3MH<Z7#:>]
MZ1=_WRV[_OK6\!56_*,?-,'BP5^ZF_\9A*XJ]\&A>:P-^S:AEX!&_I""='#F
MQ-Z]DCXLQ[FFGSC?5UR- TO4O<R_'I2M#<ZAFE(:S@([A"ILX'X<6&1D,-/>
M(/XG-G/LS.M5[4[N_=<_:BVRM1CUW-$7<J!5?T]Z5Y'O&2_%V=Z8@J#)V$\9
MF5/"MEU5\<508[2GIV&-'DD^FW.B$2)E?:C?V0C174)6XFN8\)< 3@<_Z[MK
MV5X2+2(Z266W34%=S)VJQA94T>BQ:?>6-@97ID_'A6Q]Q0*MD]G\XG6EY9_
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M[DHX3Y(^:JY(DHBV#%5WU^O**Y*F&U3I[*L]DSMY<I&%0V@7^@'5F4W9?7O
MH;(/=]JNQQ+X.I:%I^_;>I2Y*(;J=WS2+MW/3%:MQPJN^4:S\2?HO#-I>+=(
MFT1@B#L2HUI;%*=U+Q;R6V%6UH]#J#X*R^L$1Q!=0D^EQ/A'%=R.$5U2($:N
M)UW-0M8#M\M?V_'0CK9XAG]:%O>K,I7 4AA%A)!O8IW7B<ET'*\]U"(SAIZ7
MI>!GKBOU=R*RJ&1L[I0=!8'IK(*<$HW0VA>TYVHD\9E@?K\T9((-,T_@0'LK
M U%=LXT:GB0_?)'Y:W[$4LO>CI5&:/:MR,<5W2V&.VY?V2O<KLE^ZG-SHU>_
MW@&E?HAAX@D7F!+2C/PH5"[0^T8B(9UM3-0TYC."Z>WJJW@%5^ZJ9\&.,57*
M:-5Q"=,T->4Q"=E<86!,=C;JIU[+\X)M@:\?"Z]MBOF/G[@*8)_9,&RYL4&R
M'[8H,N:'#M4-*=K6=71%;^:'YC,YG]=J3Y<6LIA4I,SK>X3^T65=4Z>?_R>6
MQ__5N+K9'0^L[3[8/__[^^( @6'-)K3F^$-*!L+0J>11B5_FD&7URQ#(I&H/
M4CA5G\WB0W%HV?"]N_:G"1=E:JNY>7>Z;6DY>PC;C[\E8)#OR R$ZH@*:/HG
MJR4+:Z*/</MY3(Z*S$!C8. Q7-6"M=+4H.G^O%)[IUA@FH?["[<#@]9N)C_3
MOPG-$8W=E'ZHIY]F.Y2PHHKK.C/2<:!YI0J.<ZK2>4'<C[L?K!5XO#Q_IZR]
M<9SOT0L@J>1@B9XL;&LNQGZ4*<7J+*GG+HF?9PL5^HWY*2FMAVECFA7#)4/O
M&0L>3GM#-0QM,HAQ:VZT?B%A\3P,X>@7+7E7K5D/LJ*@J_AI#^*S8.ZLLR*/
MI#(=@Y'#:6MI(9/A6M=BEH.?6M^-4LK5TKOM;>;S>O,:5M"B0(RB9DEZ9H$9
M9K9TTP07ZQ=MZ\N,-3F;>;1A'1_W8&ZJ#E09W%>S"<,"0X)YD#UW+P%0#C=&
M/Z\]R,I!-T$*P_TRT<NAI47Q"MN39H@*Z>&G(QFNVVPCT-8GF5W1C)C^0[J'
MY!3R'80IOJ8_[Z\=;E5\>"&L=)<=%ROG/%//NT_5X8*C\^[??-'[U*'W])/T
M:UM=QNJ.2X!@8=B)0HG)$B)=$N0'65"482%\2ITISPF@=Y6,J8-Z/B:D@,:N
MK(MHW9GHW^AX%(Y*(0S0C.6R1-7Y#?W*+LF;EJJL-JC';+3VR5\X78=P+O<;
MY-+7&PLL!Q=K,)J.Y>7_'S.E9$$(0V?DGO743;*1- DI].^[9:K=AV)[0/#I
M+6AW#6K=B@_P#^+C/X+IW[( R16Y]R<))*#)+, ^G7^Y_:IMD!'PW7\YMDQ>
M DR!?6!;<B#EOUO]=A1B$_KT&-9RT[>7'W;,N'Z[!-1Y^5EI] UO)N,8[!]0
M/?%&CZRFNRUA^-SW'I)%$4Z3JEP+-%*@.!DD\W*I!9>8I /S\HO[2EF_$B1O
MG2XQ4IT/9@%PCQUJE(G^^/BMP%EB#B'X3"G'P%=/<P$\M6D&EZ[M?@@N.ZUB
MJK0V2+& 45-9.'Y_2:]P:%H=SYUMRPF2Q!?6U!?[E-MQ9VHYL?(30#/-O3_+
M6_IX47+.+A-S8TOM6AU-3?/?1_%R:+4["/WI?&((05-[+(O'?UXMPG$YL>%:
MQ>=G"E>6/Y>:T/VUM>0T\GZMUCKQ7!OAC4<=#.,-^[N92)IW0W3QKI$V>I.&
M0\WDB6E>XX:OOY18!^/5) \):TW1U_H9[EU9I22XQ:_@]<%SZJNB\>6Y]XG-
M:U8PS(EL\\O97FOF[@0,^_1R/C4([G5Z=V(4_XG%]Y&HQO1*.OPO>]X)7@\I
MVBWAD[*+%E5>\M(*RZ^?5\&.6 MPR&RP[&0Z6HV&).8F?DQ1!=\*Y-#S.9G%
M:5)=N 0)'<+*[.IEFYY_B+& ^X5_#!JI>##J&>L#I(L:+I]<(W&Z8.LYK;2.
M+66!?X67E$\5AN:8E6(]_,*80'0Q*!"=M_ LQB!.7A.%)0OXH='9_*EV=8OU
MBCWV?BL2*9+5W(,/0:QG#9[*7ETU$7U;[]$@M^MO>J8R*\RG8@GR4>5F"%GF
M[H8R134[9(^BFM,X1_!4-P/)__PI0DM.SWM]U.6G\91W15^:?LF.:?.PATI)
M*F_AL)QB9A]77/C7:^Q!W?-9%+Q-TQ>J?I[H3*TP:;@<^HPI5C$XN6B^N#BG
MDF?CZ?L[NLE)AT\QPR+5NH,\4JU\&;.Y)!JB\9I:R H-0GBU^^;NS:>37DL<
M8--XOQ'?(TL.>1-M[SM]V=8"5Q3L?>YS=3U?\SNA)"W<3!UGP_C_YG)B_$A,
MCW)\G%+()M1PJ!SR%Y,NWUIVFX].+L-?X;%"]GPZ#\U(,R7"'*J.BA*HL_';
MCBW!]*NYG*LBY0W[CN;7%8F5UI(>[C482[U,/2PQ).J(@WQ8+2XY8%3^::@!
M)<)L :9Z%Z*3LO@/XS#RX+]ZLO>_"V6W]>;/*W^1OUX":!"Z^&:L;"ISQ=H*
MW5P#QX?GRU"YO7B1QBHAIVOS+@%>U2^;,Y6=MJ-^:RA_0>8"Y]:QOI@\(I\:
MCL?_7(X$[^B84;U!'+MPP-O$///4*AI%65OUG\R?Y/!> OC:%G01=V<;CGW@
M4L^/GM);K(B.(I\;$\9Q%>=<1(:30:)NT*HXXP!71)1TK4<Y297P6KCJ9QA)
M1[0HGJTG*K'::^$@QLJD][%M2^-]#;,?555.8.3]T=T7G4WF'_JPDL\&TN2'
M!*W] A)UI&N)1BOM4?E>\WJ!+M#)U/FBM=-T;GRP;4+5V_7;=W(X6;C=-X20
M+Z?+EY0?^*<;)>7*A7NF<P1:=G,7(E2TRW3%!P)%K"@,&ZV1E0U5!@,6DY7>
M<,D?5!=*AHWO3H9^S&LD4669?W,,-RN*K5-4E/SDR/L"_QKD+7RZ\T>5OB+/
MJDH3F0BT^A>A2)<R5VGP'>?,AG\LF>A@"2>!_L\")R;_EOLM3+DTYU+;7T]T
MO8B2#+<0=$@R#8.=L50KKPA6):_S163G0\*>]G=1L>E"Y$=$]:"FQ7R%(%D#
M4T2]0<RTU<7-ZQ[A-OVM?,H+UT%-# PZ5<]NNZ78S3ZP3=SZ#E-G2]UBS"G^
MIS<)/]@O4:-IM#_9(?3@SZKM'S$3]I^$#+Z^!'R9=MJ_!-SZD3^K]NO.I"=Q
M5ON_H0L1# 3U]6V,E; 5<1*K1K6R.^\4HN:457/3'!9P?285ZB\7_Z-Q4+3:
M^WO)U-928.% "=3TO6SZ@[0[G=_?+P<5J"0".RLV:2/5ZI8BXA&F6"L(+;N+
MXLU0\CW=M9B$J%SJ$-WP0S7F1:(.P?77H&@C5!RW\74>1Z_$]8(OE=!5%RU?
M(.M*W6\\'4!#HMA;_A1SDF*1H^/C6B6C;1)24OA@6UXW[=M6E"C4R,153Y0Y
M.<5[*TQA2<@S>=,%7E10TIJ<I)H)-QCC$MAGF94]"\YASKDH\_4.4O8Y:3*!
MN9U4Q&2UEV4*B.)P<+2>\I'B */+X=.ATA$U8,-/HL#/@UMY30,Q'0:7@&;?
M Z]<^M:+5#+0+W@%DW"N3>*TH1W'*M%&K]![ZW8R<SD0,=!DF"SD)0I:NKB;
M")K]:F8-61I_E39K<CA[@) 0D1A@A#7)%YH5&BL+%?P_[7UW6)-9MV]FU'$4
M$4&*@H#2.Q:*4I)1I ^]28VB""$3(B42)! +18C 2%6J]!HB)90 R4@=0$!:
MD$ ("8+2$Z0$",EE;CG?=^_YSCWG._?^>?YXW^?)>O9>S]I[K;U^O_WNDFA;
M8E^AY*[DTI/P/@^"R1[8)2 CU*K%;1T\_O%&LWU*B[GG[J07-W1ST_3#!OJ#
M#6@V^X.<#JUQ?<6SW$.E[N:]8NXHZ-@6OPGW;FE?W6C]/DC"8P9,\R1.A;OK
M7__2U-ST^F)CHGFQ(Z[?RHC+-U!B/H>60 ;UTY]*B3:&Y^C^D2M?D^ZJG>-B
ME[B(O9OE4#>&@VVNZLT<H,-]U1)4*->-0H7?Z_5+;_JJ0;2"C%34:BR2+M0T
M32=)5,K%]UF?=S5W/G[QN>.6/DF]'LZ6/_Y'PA'&#B;RRN)>%+::7;)D^7D3
M0Q. A&:*Q6JN!<RL[>UW- 195)929W[\O5<O'7G&NB&&++'?$KHG)8GKJ)=/
MS#A#]_=.Z;#?BU(>+')I3'!<4@Z_;IF1>9*/8A$<Y5TJ[:-\_4_.<E(M#R!4
ML\7V!DI]W74VM<B%.K$D/88T8N[.9[2J%9H4ZSG)D66$*X++[RY6:;M]CF_R
MQTE81(N7<6Y,\ "S[R.!L3WVBS/BS6P^9FC77GFN.^@,=Y@F2I1D>R^=FS$Z
MNT1VX0&$6RV9R^T;)E?-FI\%Q'.>]YGS=<<6U*9\(-6C%BNYXR2F1][GKQT4
MV-AS"$IB-HDR,;O=Y!W=#Z]K1]UDTF)#MA,<S[QVAYZ!7[]E=M9E:_KE:[7
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MMB'XT&Z[8;N1P,9='%<J[- H&@]0%,7ME&:GDH[P +LMA?]8C&OQRZ_D 3I
MBM3'_Z*#;?E/ZH!^O,0&TUO0\7NEW5I9CCQ %,F)C2A J1'BJN_I768N1#-L
MSK"KN_U@HF,>)264O/AU>\8B3BYZU7Y&!)\PESS?B3V<VQWHOV_<PF7DI?
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M6ZJZ)YUAA[O435S\I!4RLB5!KD\R(FN%]U<N1P"_VV;8CW9N.P]M1:.&YN
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M,E];D5[:04(B+MSWP?=C[F]7?]/X:H;1<MYH^CGR$5M_WPB,;-E&,F.[!2Y
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MFOD:<DU?8KG-U(JYVQH?'OYRDQ^HXZ#X"4&7/A(I-(/2;&1Q"ZN7]B)K&#Q
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M%C.IM3C;9+EXB2I97_SV4O!"K=E])[CT" _@&ZYY%NENQESOHH(Z="%TOL4
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M+:WI0E^W-"AZ8SEMU6[?)M3+);J[2]6SW"$!7*&-O4%(M+R=[YPW1?H9Y<2
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MZ&4:=>8U2'=&@#\T/''!U/, +_-.<:3?L7T,X%AV88>;X5 B2IT>7O3*GY*
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M$T>AR=]\SPV$U-L>YTW^-U!+ P04    " !EB6=6G#'@?3_?  """ $ $P
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M)8I08)$_ XB!=D ^7OBS#$N&4GOPMB<=BR^]_NM*,AVT?62"&+A"$::7]C.
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MC'\/H6M7M][9>YGW"XQ7$*\\CJ_18'\$[I>DWF4]TD4,B%"D&4!8<Q #Z$N
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MC]O*O8)WWUM)%<Q'GO4B@^A73E%N,P!],EF1 9Q&GF$ 6_)AA4S@N87XW<,
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MGS" KTDG$5M;2?]D$QDQ7*'  '+Y)1D FTO3))TY*0CT"='Q%:;" /0V[)A
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M@"Z):X?,Y]T+SF6S6&G?[H];R#@O&8'5[<2?LG(95I(I7DH2$TRD$X>K>6U
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M@W-)D5H,<E6VM2KO%M7BD*PW-SQ$W!YO04XL\2#<?0/X8*$MW@7-Q[^PVQ.
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MM.8D-?,VLNUQ;=?L$ST.=N*N$(D^D8*L.D.<)V?*6Y"Z"VB/DED;(Z/=^PC
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M_LB'Z?ZC<P_#,"S58QJX\P/K(6#,>@C<\%",:#,<!KD)%IMT5R+8/)>:NT)
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M2VXO12G\%)D#73%\O$2O;591BOI01_DOO62*HT<92X;$Y0TS'R!<S&)YM=O
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M*3O>!*2@*US2]2#/4>UI3"*'Z2PN*"/)"_;S9AE-(NIZ8NV14'D6H(@ULZ+
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M]9O&SX/&+-(_6 4)1XL&JRV?$=!&V0 9OLGB5A8E2E9)$ ZK:"Y%;9P8P7*
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M^S4LKUUP?3O&&*CG?:L/75U>M;MY\(+[Y1;C2(>9IO^,KP 3EJ)H&1I+D\W
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M9*_UE06>/K1D&_O2D$$-6*\N]ML]OF/.H1_>G"_SN VPC?@.B1#.$\UIDC\
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MMRS1Z+O=A4=SUAE= HOE3C^B5Q.[(UZX912[7DFRL.YQ/1%W7)PL1256BZG
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MICK<BK:[ZTRT2O94_T+5N ^,U!@YXZ'H&QQSJ[6+T()B$\XT,;A)NM&(<4?
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M5(]?T/#SX$78ZV,CQSYS!#BXFB* HMPN.0)L: G17FLK'(N=)'W\D/UQ_A%
M9'QP'JC3S5/IEM(?$":7UV+CD4ATK=8FW>A;LMQF-/\@VFP'49_.8<$3-IEB
MJFL=P&JHG%;B93^">@3SQ2>$A6S;M^T4&@,*_%ET.7#;[K%*,7D!7<TR$/8B
M166J-GUR=&ENT[88U1'):#L"W,5T.S/,EE'[*8;[DN"$(\"F"?#1KQ?FL4>
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M<6T)G)L!7X1/\=/+83>']E4I]+_MKJGX.AL[W1R6^;#6\27WH8QFV>2!R1'
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M&82JH5U+?'=6]UIB%V+_WMO-8M=JX-L2Z%\):*FN O\1Q4W)'V[6:GK2W4<
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M7<Q:#YS3W1(42.MM*YR*C4DF*:$J3)\2D@U5H-T#?U%5#W;SJ+QO2V@(,/9
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M($60LRD;]*FZV_0%F_V^14(J57+XZ0^+K#\61T>>%Q9\W;&7GEZI6PD.24C
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M\EL\2VCAN%XJ**-Y*.TVQ/6SC1V[4<K<P[E5#DM]W0),IG5T0! N/!L'C)S
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MT(B^R$'BS:Q9O4)=V1]]BJ4>1%'&"P<S@16G:[ SZS,6;G33,5W'4ZI#>VW
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MW.Z=%\1)MI,&3C\_ 9'2Z53_H06,/W)[0UV^;\R%$5^X*\*__1^E&8O#T@L
MMS75!6#Z_(CR&;V57_DQ^SCO\,MY9IT^SO?K(S^-H_Y%AG8Z<I;:E!A&<\DZ
M^@)P/0@<N(2.7+A"NE;A"<I1>S8MJK\K5O]4&;^E.>T5K,J.$C$;KT36MC;R
M]HH&.6XWGO)LP&L:WV-@=G*]Z%AKKC/X2E:4#)S]S)R\OP+>925/]TB9F^O#
M$!N2<Q95M3\P3PI .D0(Z%[RM;:X5J"_3Y=NZ^SGPE/Q6IF$XVO0CD.:U@O
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MJD !C@Y_TPK[Q@^3=TO>R*/<Y2.72ENMJ=^?KVHZ5$#MRE6EW-/B@L'48:7
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M47V'8G,,]C!KGAY\C#NSJ2*GDM2Z%VX1"?&)"'+?2G<N=STY"T_+OZM&/+T
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M2;YZYA'I1;/!&?9ING;YTR/P>V3"VO5]R/C:\W@0RR&+7;Z1\_2,_X[7QN\
MP-'%#P! U&W>88 XX$@.'P2-J?W" 80^]X,&H&A.CVM;)SP[T.@6,;(U5'8M
MD /P+:4L"7]-G&"W]7RZ@YY,'H?VEM)'M"4?, )X/'+RP\4@HK$$T!GHQ)YY
M+,'_RG4R_H3JUMK%P=GV0<D4]%E768V-B!.IU[&?%XON^_KB*9?*M?UK/^?D
M3H<U_6R9WD2]6;[.CQ-KY[=];I?@+5;<K6$IFQIO*8N.4S7ZVZSWOW,$_6C>
M&..@AHK98XY5<0#/IE#88.W_ND;PSU?AK?ZUOF=9P=M?FEU[XB\P\^EJF_>O
MP(VO#D=TR3S<O_],^_R#[@_O#SH.U:3:\N?GFR.N"5YO8@F3L1'.2?<8F.^K
MD8+?X_L71/*%V=T^4'R(2;2G"*%X_E=)2_'QRN"FS$2FM*]+MX<0W@_NY&X2
M&+_/QH-[G]3=:P$9:*4E2>2D2ZXE]8T"*:9+?\@I&FP]?X)37^^:=I5:.!QZ
MS0N>!+Q,83IU9[7&7/0CD,0'0F@S:DOPX3\I^RJ!S&A+ O'U1N*MRZ85_M&[
MKNL(+&+6L&@OXV'K5?K:1!.V*[!(+2]/B;Y-@\\*-HX5^A*C76ICD&=$>01_
MCE!@$Z).8:K?J]:1_NK8^B3=/+&GA8%\G4V+]:[A0R>0[J*V3_'RJ4,NC'N[
M^L"R[/3&6M$HKJ0>VRR0R@U97=$=NOH?ZYG';?G2@"&7[2MCG&'C)?L@^/,=
M_A<YRHHVV)-7&[44;3*0XXN.2MU2?=ACI<" P.1*L!!CN(.6I\YWO;+&0:-2
MT ZG2^C8UP^NXA):\&CQ W?TI:9A;8)VQC0T<_4ZIOJB4AS5U/!KZ=I='T6^
M]?A=Z4LY81!$T$K(3[K2GM8SL.$F&\4]7O&G_EPRR[7DV+C,6'[=^S0K^DPY
MOVFT%!H4N[5Z'K@)^OQTZ97=F+IL_=V1_@MUWD=2.ZBQS[1^>C6Z_T+9VYE=
MM_JDS7,7GGO_=OP20CVB:FZE9FZF!*%D>$1^A   # 2L>I=J?Z<_Q(I\9U?%
M 8LBOZV4>)7<]5(NJ\=YJ);)%W[\^7!'/%)K_%8DL*:N:=M0$F=F,U"T0EN9
M+^WP<%38AF(WM#\6-)0,,:0&?TZ,MNF'#"6I!_PZ)L6-5VW&G+D6Z(.X$#]G
MS[ R#<1-O6HJ)@]>@66]&%P&^Q"R3N'>>*>US?[*N'X%.=W))_QB/?L\_FLT
M2_WA#D5+U(":MQ1$NX!XQ\QTG*5'YG*C?%VS+7T2MS@ #4K0MYW:B8F'/0@H
MXCB^6;GVDG^A<WZBN:E%@4/BR>I$7!VDSE92B,'/ 2 J&*<IS##;X,N-[1JI
MZ4)8)W[1C9(;_!"L^+OL JP8$2X-.C/:_["?^Q(I5!@,%TPDNXVD*^E=CQ$)
MA!EF7"8H.D4GHB]TVX&4K<A:,R+3W[/ &#AN.E-3$W*]Z@GY/=?HX(KN4."O
M1XKJ<_.@S@&I9@^(L!'3L+//H=V7GSMX"Z5["Q6*%96GWRU/';WW9#1G!6A?
MHFCS*#3]JX*BY6YZMC])ISW^4JGL?R+E2GU&:!<BUN-$_;..+@\=^DYBZ8P9
MV<4O:.7L (W'].PO/;?HVR7UD]J:;Q/;VP<?'_]=3^4-#;.@1L1';7PP.=T<
M2KO3E\R+JZ"8ST>*W'P,L,@T5M"9W*A"/9$UMTFZ\U:I\"HWQ.S%D^XK#EG/
MB8[RX_J/'UON W/>A^V$N>0(!QGR* ZF5_'G^D4XAW$YYP C2L'("/TRR Z4
M ^ K74\.*Y9-D3%/M130*[3;D*GMN@E W_?]5:DT :UWY%'GTRSZ5# FV5BF
MK86!>!8EMOS%1I9X"#H"%T#\6K>*7)LE#@>*<Y;#6OU_]LY=M*3Z1XU5?P>G
M<%MX<0 Q2+H'5M,=N6K+R.R"?V+W*B)>MLHVCA/20N *N>=GZJ()G</-/+@9
MU0^B4KX9U%45BZKYXS%"?%,C$,=.T]!$,2"ASA/:Z #9? $-R$A#9.HF=CMZ
M?F_PMXK,^H,RW&Z7NM@(.YND+"XZX-/O>MK<5-&3:C<S$67 4ANI,,L]3 !\
M\AK*=+,NDB,4C\_%:ROF2?Y,,8=2]R,=65_T3LA/_WI7%*K]S%@V L0X^M/X
M%%.QM.V!=VP_XV071L"9R6V1]IB^=B*Q"(+<[-$$"?BGX(F>/-_>][E<M-KR
M"I+UZ"]$HDSI+&YH_K<]WT18M%_=J K^>\$'(_*LWJY/0_^]M-ZK^$890\,H
M+EX$*(QHJ4696!$RRE2W/F^)WVHICW35P-]WNNP<TAC#S6-M[=<R-=%]X&\=
M)+_!)21'7_510YU,^^ I$G%]9("6G)!< /EE0"V67MF.]I".=W8^6SMI?(%A
MNI'(NF98%=!&(GO^MGF*5^6.W5UX(^H#7XS.IGEX&1+)'+*[=F+M1D]C4CYM
M/TZVSDOVBB%D:^_%Z_JD>X(J#$KY,S<+,?U")^((:/4PAU *UZYQ\))0G)KQ
M_%0: -[058 K?XMWL?EEQ='O &;EJ.(#_#0I>@]3X]R846@)I'2G/@])LYK-
M6'6=O@$_ ]X9[D(@N)XGS<YJQXC9FO>EF(K=-#WZ>ZE&4BYL0 A\?@ZURI9N
M,CI67HZ>!4_;/#45LA?_GQX4$D[[3V#@_Y6=9@0'>]0<8H(6>W9;'6;O(A 0
M]1>(8);/ <B(_GUNWIT#&%8QV.$ C#0&6_]"9/PW(NE8D]71O]$\4/)8W=NW
ME7=59]S@ *SBQD9,A4W_3ZJQ_7OU?L*D?XJ'\.T#H)Y[[N5.-_[%U8C"-(R$
MZ_=AEL;80_.=T&Z3V$^IFNW.'$#MMGBSS'ZY\,E!*3F=R:.&%.O UQS RA!Q
M\GG4\)[H*VU2[,0</=I/E>8I],U3P)@7V=YOFFQ;3?89^VXHS?!NRU-@R&7!
M]!->?X*T#+W8\H< =FWXH_\P@]RTKQ4W<\[B3R\\-5CDI6@#/)L  UY.QRIJ
MBW4I&D-U[U5&\AGHIE/1WJ7V6#LB4"\L8YF,/>V M\.>VO>[GJ%G9E\"MG^6
MJ'?M:I__I?T!J2J:NH"?AR!9G;@A -=_'%VP7"6^$6)DMZ3L:A4LR?/CEJV5
MQ<.4F]E8M)DSU5(V^,9\IB#K%G,.'G006\S,G,=TE+WR9?<SSE;'#]%BXXJ0
MGZ9ACQO!>/] Z6=;VJ^+5OWQ$-V7")J#5;:1N&^6(.EMA.(8ZUKI,OL*LR?2
MBY;,OSQYNA@9VAZ&S&CFGN?&Q]MNE;FFQW@*P-'?2T_&;3.-1R6??AUYL.7@
MQ1,^H]>'E@9&$.&F96/I#L5MRRP]:[UQ-#I$0?1X9<WS%DHEGW?\1\1VAOWQ
MIRA>$<$,0X\+1MAX/- 6+9%+='Y@9 JVK"P')ZY0G5)8OS)JL;0-WL]0MH+%
M Q9J/A&(.,G\T7X\N%9_)UOH'CSL#F:WVL]#:?0+D2$?ISX('F0Z#RA,EVN?
M2IM4_@J*>V LANPW9W:G:DD)DZP-VCR%Q_DIRJH"2\OS])ZD=4/"W?=($&3,
M;LBC_J%W-7T"^Z3"?0#A_7:VR2J0 7=GM$Q_FSL>K&=X/:57N[:$H=Z)\GO/
M#*(N)=9:264L/I\POK"J'+T(98LGJ?(J"EALDX2_35Z<;8=EG':$M8AAS4J7
MTK._8*_#9LGI./601[T-]B\^+YZVM\IZ5)4GK1'#>^7#@A*P0O?,N'[P<M=X
MEW>Q-GL@[H78[*,0Q0HW:T>QV[B7A?'IN4I:GS,KF)7=4A)TLPR=.EI+J V=
MG7%"N(*HV.GQH&+Z;FW-[P$-I.;Z%/0YN/*QK'6:KX7_VRRGI"L+.#=F"</^
M"WT<G4^/_>!DH4$C\4-'*CO=81,W47/?C(7&[)P-I<24"+I2FC79#K>I2_2#
MYA2"*AEI/S^1B875SJHRT'@40Z%GHB]JB(82Z.&:_H;M."W8[B%5=]2,WHQH
M&'\W.J^?GJ*;$53L9E::\7V;RT$1:JDT+N#96L(W@P<32BP5%)"DJ,8P79A&
MJIV.0^"GC7!AQ?G+&YZEMXM;B7:J$7KE[HI1BRAME3-CZ86HBG&<PBUZ2=3I
MF8,_;N B?)G3A?V+W1AX+2,@H]S&W4+^4:LZ_6N\?T+2$2?[DZ^/HBVB54SE
MHZFXY&#FN$JK/G.",>HGP,1<IP>\^R'\I[QMX;<\47,U4GB_<\^;347'CR%K
M6W8[VPU/W$IZ/78SN 0B==/??IG(]N@F32&UU9#=S=)*B24+&H3YU%!RKN%-
M**YEL?_C1EEU%>TA\_Z">]X!2=A0&<\SE0 SX4O*Z_M#QKLE-D[-<$)2X[7L
MDP?L-3,>)Y^#_#6<>UJ$Y/B#9UZ'H+NUG4FZ5>+ZJM]66OS"T]>IORT/-=I>
MQRO/WN[H9R\NMP5/V=^V"GA5YX7RM;=-@-)JN-RJET"KG[+( <M3_8)VS5C1
M.I7L49O8YV[,PH669XM10DB33IOS-[CY7EH7+NJ<_TY"T-F%Z"13P 691^\[
M%,'R?1$WF2D!;U=,?F%9.$<NTCF >-:%TL#%LL18AS%#+4F$*O],S;$3BV(I
M:V/V.^D4IPY;?X--Q;N"X0$94>ZJ9,7=@ YGR9N^7VK<0I5M@3DE/N2$)V'=
MH"-KKF&>646IU=4V:\SGGN(([^0H/#UT03[FVL/^0&J+H-OK(YL!W//)@DP2
M,K#ON,J478( V'G D;D&C_"MH4]V>":TRDY<^&%GI1@EP4QN P?^3"3<VMOM
M;#+YA1E&.V[GB]E7OSVF=C<1^,JI7@-":AXQUY%B#?'@UPO*''9"&QO3/;7-
MRO%8YW[7!HU(I\NV"2+WD5,E8WF\KSJ)_3Y*0<]+J%1CN,[7%V4G2[\X62.5
M/%GAC M29G'SH!B18X-X^:K(R 7_0'L#_XH+=:-\L5O!CTS"M0F;'P4OBJW+
M4D;YC;D]5NV->I*-E5A6C+O BZ$CP7-GK>:E>0KYKD18W9^_]A8N^IB<>FPG
M;+:I%-(7+Y,J>.Y6\H;#[=4!U&G[_.DI>[>5 :UQE\T)$!GG4_T>[7C],;*T
M/B?(9NTNW.I3[X_B_4] J9[CLM^_T.AK009;X/EF&?H0=?=W&IKO)/)<>ZN(
MRQ=HQ;WA+0-N[E?3<>>",YUV']/-0U"A5]@_PINFY!NRKOMD.;VNF0PW%4Y+
M7U10[+-/F[7SK]VOG48L3<V8):H8Z9'S@;D2@62MY>M"5.$I,_X$I\]"MJ8R
MM_\WRKLIJ[MP *\]2CB .]-#!_QR,+#-WU()O.O?4XE;6T?F9XV8T(4-<1Z1
M70M&N80AQ&W"2=_G77K(8;;<G'7]DPM^]E7E3%OYZDY69]TN8^BA-MS=X!;<
M55H!Y'JN]]A>TU[K4^I!P"#?:93_ZGO8;N/)F+4M_/7E![))"TX3$GV#<_;C
M7QK@4R)Z%>LJB7VNW%X7M6(C/V*4G$!_V6!0"%3L%G@6M9KN4^VOUVU+!CEO
M*NH:@QN^;@QEA:5=*@%>"7T4'^@N:&.++G'1R7%2#H7IQ+:)=<L)V=YZ6Q#/
MX #XD:@%N:7*8C=D$"WV6?!Y7DO!?9-;XZW"*_K;:_&G;.]9Y7I,T^['"OPL
MJK>4=W(W'I-]\%[LB]_ J+M>]Z/%7$BP8P76UC$P8/D1>RG#Q7UV-]"V.C3C
M.T9'J>66H8R^\RTS31N@6IX4TL)&:6"S=T%##Q)1VJ>3L&C0"Y%L)B>_M_40
MY !.5?9P 'LJ'  OBMX+0R6S)M0W-\Q9%TG2',"W&M95#J!#[E =FU1\9*+T
M'D\':EYOMI8#*#:?_2JZ@U9G/W?!L7E[PZ;9[S9(VU7K8T[/.8!VY4/YV*],
M.C L30B& S"6F!W;GA-@&3&#*N&SZF,+C%92P11,M%?A&8N_8JJU:-H9FA62
M^4)KS8IV@JBRY!M_VK<.O8#TK??SIUE:^T"TENV#DBYF^+9VZ=&$UNXK5\)C
M<;Q]GS\/$%+#I@M/QW?>A2LY:G[TY;&$.@DZJ648P[N':T6EX\H>8\/WC6\6
M;,BNH9P+2-K&8LS,!86GJE'*2%A_&_OB2(0G3579@CE-=6" XVA\Y[]!,K:W
MTSH6-O@2[UN]ZH#XOBJ'D>C)YYW,A[6-P*I 'BN'/ZSO+<M5Y*DRFW;B#MYM
M)0M$F.@C.K*]YS&2Q9.#)24L?<9'2L6+MYYP'@2B  Y!Q%8VWP@I8!::T]D#
M48O:+U5EQ@(^^_D:R5NHJ:W((>OE,Q;[17T;O.U3 P*7ILRT_>[Z=0?M1) [
M^O.T%B]=VRE1$+?ZWM6+E[[R;"= <Q&X;I,+$TSW&BQ<\Q>WT5JQ,2D2<EK"
M)Z]=8RQ1>N:)._CY)OPUEO=![!/&B8FY^:%.O,1<AX1'(7XH'Q9Z8F_W]I@L
M6=W0^$XRI)DPH1H7J;,P-+-S#I[H42_& <!)E$?[-QF\5?E(IP[]@T[(>N9]
M+%2'Q!TE[SH']9!HU/\SLUOWM554@*%KH64)E!(5?9J>H\L#HSRG##"2^*JF
MWO_,V!JQ<9AMW+SN4*C^^/.@;IGHD%@]1/L<U*[DSUF,WO7PLD<#UMB!*$>3
M&>*?7]Y]+NG62"\=M3OP*V@]QLS'+X?F*1RD-H<SN#] .O/DJD3S9!@J;'%F
MX,*<:!?5MX'>YGUTJ(#I"2:]KXOM3/VP ]8O?^A97H7]B%ZA@Y268'-$Z6XP
M$U?L"I7F42"W\G10W8,\JAC2"<VB"[D&#B3B:(1NV<IE>.5#U8*:$?Z0%D65
M[ X/V6BK<=SH.]%76J*A(FB'HI]"#7@D2%#\1ZN?7(Q=&F'+QOXV1D4"T@T.
MT$@O*/CY\PDX#6=69$\.Q1O;>%@?3+<[63<H=EW:!/)COH4(_ZRC'D)OM@ES
M9%\O(C*;%IGTIA3VGAFR1D@^P4100SMY%""U5@?B2Z-YJZ83O#5ES&>1-\"*
M\KGR3^_+Z@Q3,C/R@A0]#>C!)%&4;W),(RB.=8'Z8EPM2@E$M7:)DD1Z4GLZ
MW>T[9D6)(X:Z/M!*-[?ET8J4"J15EX?JDW.WQR&[H*2!C>\R\;-]/U;@KSK<
M*J[@;;!OE\LOOB)I9MQRHR2<&S&?:@,&I7ZM!MN&-F"(=B^NCMK 'G4JC!1[
MC2&T2;J$]#5KXYMD1';^WHAIE.,JABC:/<<WRVQF6GU(??E@NS(NJ^8W4DUE
MM_25+G.S-%/4R8R6.O2$R%B$^[&T;VFP!VF*J0,A@<<NFP4O[*&*5DZ70K,>
M%\5I618[4SQZS@_@QS,ZX8%<UHM#T'!AXEI1L:0*>O=U1Z#@4:'A[I5>('G'
M864*\A"GDSTA19;LTZQ^G#$VJ4PXZ._C;S0-JGARP[4[Q.O+07JZJ_N#,:J<
M\B-+J\\YY ?C!?'4[<J7QL?HZWBIZ$KF=+L$;X,.1@TODHA')EN,AE@&_RG3
MC/8'&NGL[,UN?[\0#6I!6Q%>3O><QWY.M1"9H,9H,[0NC]AW@K'7!=+OX"!%
MBM<&_2]= Q852CVI\^O>31N1W]+WHS+$WC0B8<*!PD)RMNV)^AF^^<>?#'3G
MW)<[I>JC#%$.JB]H7FQ58FE:$/IQS.1Y+>)$\(R5\\BZ9Q<%$ TF!P<WICF-
M;36XWN:?6VZ\"=9-A3FA8US#M8@-X;T77.$QI8P(+Z:5YC59$R&VY,#Y;DQD
MJ6NO:**AP470.R@&JH\NY)8OZM>.R5)5:YT+D5H-]ZP9VGES<=^0V'-0E>&N
M\.:.($Q5(:'#O:34[I4599:<"--\5=<B0?A2@3NI5OD]9^K=A-,?>KA+==LJ
MUFG1)>)E^\H> H403:=='V#!XX=9R3A;CR!OACTU#RM7'A;:Z?G+"L^3HCGX
M3IPW;89K<7W+2--U/]+<A6BA+0Y9L!RM"&ZY/KM_^Z41MKS6J<JM7P@="C2.
M.,B7988R#I.-\XS,V*2G#&\7IB7M_%%:9&9LLW2Q"[/,:<)0E;=,+9;F,TK(
M%0C?'["Y6FY"8'=(\O>?GZ@K:D.(O@EY,$SLT.HO[4OW6W@?X@[MNI$F:!9P
M.R#3R*([YZM^"HYKN$3[5.\/2^THO]G[:%^M0K#C>[$^8,*]I14O>+L&9D-(
M<= >)S:: 4S' =7\Y?1Z39Z!]^7C6<5,R_E*<9;^L.&-XC:ZUUH$B'[.FB$W
MV?$%<W,,(?+36!XF0OGXK+<0#M\0\4#RM0_II 3"WX%V^M^D?K5.LJA0\ZHT
M&XDR8@^'3<8_B##BB<F&%LTBO7O":C&T :?YT"YW_0ZG[(Y)RF_T@8&9=,H;
M3#L9F479=:QA?YAPW]:.%(,]3M2"S&;<B3Q1_C.*7*C_XU6@V^OG2HY0HJ(Y
M)?S25268C5W$,&Y(R;$%<WR7F!-9BA4WW52TK,?*P=EKF^J14ZI"Z6[+2I@"
M+:=VTO%6&=8=1EV7^ADW9NN"VWMZ%(Y>V6GG!A5%<;% 5'>EU2X((L&X?1(>
M6 P+P^PXU"Q?-M7)/M&Z'%J\3',MXW86.%BHU&=Z,>0[J*#?6W6=6>I,T()K
MY4O]Y$[UN-8+=/,8::IZISK?LL1 T=G/[LR \ %O!_I@=)'K\B]]70LU1/T$
MT=0TWC?O/@2HK=TM.ICUW29R;9/C'Z4%:Y#L@S]#$G/()2^CK=DKV4L)_@I'
M#.JQ$RT2FFF/GT?6BB S=%4#"OLE0#=S%OUZOV'W/$VC''KW(5$C[X:H,]B=
M."J(:V5O*ZMK,@ZQ#7J!$@XY%ZE[HVZ2T,2C[C!&\,..;O-Q'YH?)-XBY*H"
MH:&)D 2WFJN>7I%%1(V8G H!)4@38F.#,3S0'8CUVM?V4SQSG0,WVHUU+5C:
M95/(&M#8UH!]N]0E,H$#8)H7,D(J,OP?/_#7=G<15I5/)2]C+=E_PBX_RI-2
M&WD1EO%V16'@^SB7,-S&+G[*(PTGK'BMH15]3_\5NL9R<P0'C$ATZ:=,% *5
M6^.K2S][F\Q@Y4)DHW)L/=^$9:[),0+<$79D;41L%G8NEF 29WR&.+*M:C7O
MV3ECLV0MP2<(DP@@EAH^Y@L_DY49(T/&LT ^-&[WVDE%V2"*RQ]?:_-:X#MN
MS%6&/2V@KO0;2H!E$HA[$B7TGB&2BY)N)[WT -0D;3&CW48J"4\J(EQ5MS-F
M%J"U$+,ZX6;=VY^+(.DI+P/ $[2E#*V5T9W7-4V92JT5&H4V36F> FXUJ4W)
M,@]A@MDC5T'H  %P8((D$0(,P9J:[5MN7FHR;>BRO-K.-7! -!6R4_F76\XH
MF:P80VT.P'W[\$._.P\@Z/4_*B_=X;G" =A(M 2'#';][50_!W#P:L^3G0D;
M'_G/32+'E?L-7/==R\ZM.JNK5/HO$9H(C7$*M8W$>O-X>/A+'W"\GT*,6;PS
M]KB[>,IXQA^BKJ[7?([I3+R_ 8?#)6X@_!&'+P07(*7KC(924>!%0'%5L2,
M<)E7=00XHXX+R"163$R[WJO]<?.'>38F(\@5O>.T2-+.GMFG;,!7X2N'$$;S
M7Q^F^=</;_C_TLWC@/*6^^QK$-Q!=*4!:K2Y91^5 \;:DNK"FPSZ[RE5!L(-
M3WD:""_&+=@Q3RZ>:WMP;T'O#/+MJ:W*GR>A4ZL[W)Y#?:#)98CC1PKF[+2K
MZW2N^DU43=N9<]U-$;H_ \O#:S%\YYMJ [I=Q5<^]59]9<:RGT*DV7R5)C]S
MW_*L*)\<8H@>_$(P03$Q'H$< 'H#KX"A2>\=]\,P30Y1V5+8[[K?RM5-.MU1
MU<&W0H9V%C= .)8,8<ZDTV2+:\2$CCJ4X^,V #'B;(QZB?HFG,\!S.]M<@!O
M**!_24(Z)#GLC<Z]S6167:3?OOG+)BA$>J'2@V^1.OK;N3&P*(:FOG?L&X9I
MU++* 3S?P!D9M2P;'L*C4#)!@P,(G!Y:I8[\)D'ND!SI/5-EKG5%QES%KJ#Y
MD<RS:O.+.HO!(7(NKDK]KZ\-@N2H?+%YQ^AG( E2)^BZSPWY>?&A.P=VTJ>8
MH1;T+7TL_7C45'%/X92SW/8P6'GG58KLVWN(-B\(^Y\$^1MSU+#R30Z@;6VC
M%;7DOL..RNE+S X=QXJ^8[A59NPZQ3\.]7 :DZHEF0<W>I+P!)+OP$H^ROM^
MR=3,,B4CHP*+@XELNLPY>TYWA?B$0P//=05"0_T?5E\+0AC:W$6+CQ2FZOC-
MN#B7Y/]%046;K!L<P&_X0UAV<G>.-62?:@>&:FU!R]Y55.3N&;C@<]MWH/C1
MQDC[]>8^*7ZZ;G3$\7<ZK^91)YFN;?K7<M=)U1%R^= \J5$)FANB'LXC1>X>
M&[@ :'YGHE&UV3 0,O[T'_P4V'P;I)]YV/_@QW?(;Q+#&AR=+&N=V2BH'J^=
MC3LMFY%:_0,\WE2' V]'^6X+__77PB$&WZ$=@5C2<ZA-H]\&]JA$4FS>+PRI
M2BD2C>\HTL1S\L[H._*%B1 2C]\>&B^5&2C\77 Y!19:JZL;A[,^@8T\4QNG
M.U64]..';B)Z_>'C9@[@+ ?PCWX_V.4 KHRU_I-BVEO/\<4_P\7EF_.?&M26
MX1K+!_.7G$1:FQ7Y".NU>"L'F:YD^8YIB"5HS=S2#OOTI!Z8@[N.!]H'?RV:
M7[2Q37L^D?HJ0!.B-1&K,G>:+6HID@GC '@BCLI5Q.%@83J)#]A\PQ(\,I83
MWDW)SN2M^J2\NZ-;,W<-]K]M*QMHG">NN+N;APJMACSD<6[EB;CX]-=XOA<H
M'FK,'(A$OA.O?AP9H#<_JFU"0$&7AY6@\570/0QEG3T'E9H.)Q$^1V)E]V]-
M??^O8CYA7^  WH+C.(#H_0WV_;*T_7.7_'71/FM8L7=T9_"8EX3M,U)U2Z&$
MD+<PP5$)IOCH1F;)??%&:Q1L25%74:NJOB@[IQ3H7^E?EE,&3L]F8B&%H4$8
M754O>B$U)E.5D(7H0!V!#O@4SB'#1K8.(;^?"!Z:#POR_+P"426@]X+]$84K
M3OKOL$'AN)MV@TOPU>6*NVBKU3I_!"^3K\U8(.4>'1=MJ$B-LVL+3E&/C3#!
M0GD;[\Y\7M%8+I//O0];O9.5N#;[5O7*%]7%@8%/"6YNUC+0GW\5JR3B/P0_
MM+BV[:^'@A.Q*C5J^4I!A;^WD7//[8O;MP_CE-Q&<"=*^H1H5"09)]H/[SYK
MLZ)XJ>R-K^."G?#F&7\_Q[K:%V[63[KQ.5]:BGQL2R@A2I9!"AL.V;-VB+#X
M#__D0+9_L=F*A9=S!>\C_N'>_VC&(4;3W$"-SJ;]U9S%6G]E!LWSB<#VU%]&
M@.9-3C QG5*2=]E2DX8WJ'A1\#CAI*9L^9X:KMAYQA-ZRR=1;L9+177IH@EO
M?EE#.=]?(Z$ZQ=#T[UY6>7"R,@Q%-9B<WL8*]S4$?,^&!MM >K'5C\+JFE;#
MN2AS9;9.U2T%>.'P!^A^'W+W?^]TMWP/_GNG/+<%/OG7X)ZY)G5Q ^N'BFE!
MHC"QYC\W?CLS1OJB0:W<VRCF )9K(=_@?XA0NF8+L3,>$"CZ(70H5"8RT[ZQ
M!0VNKPWWL95LM/GCI5#K3I",Y,.S7Q5P_^(JC$_F+ =*-&KL*-"SCP-P'EIT
M%_ZW2][\F^5O_F\L!/Z7A<&9\7=E4F5J^;AWN9H@'.13[_GMKH$FF6FWV5NR
MR;V$%B>7XSNC]25V+6(:6AR ;B=I<^$M:G[P<*S+<!P>^4UR-YOF^9,Q;$*_
M?V@$?:6&<P(<P%#2TT-O,-A@.SK=.)1L%A&'^MKSVZ$AYAX& J7BS0@K#L!8
M_R3[S*$R'=UYA(X,/6F5XP PYX]R "="YUBEA0,,=1;SFS3SRJ$Z%QV#M6Z?
M-%IB9K(C@OE8XG.H'Z7)_[\A_^\TY+*J=EG3@1)M3U7IE-;RNIK)\/KZURRS
MK+ZE@=NR$V"_4N/1)9%9&]$C-NMA89?>\G&F_@=02P,$%     @ 98EG5DXG
MWVEN2P  [6T  !,   !I;6<R-#@T,C(V-S!?,34N:G!G[+P%5%W+EBZ\-A D
M$ @$#>X0W-V2X,'=@KN[)+"1A"0[.&$3G.!.<(<0W-TMN+O;YM^Y_>XYYW;G
M]KOW=O<8_WA]%J/&6%35FE6S9LVOOEE58]]-WOT 'LI)R4H!( 0  ,'_@+L9
MX!F BHR,@GP/%04%!0T-]3X&[@,,='0,(IQ'6+BDC\G)2!^3D%#0L-)34#%3
MDY P\#$RLW-P<W.3TPN(\',*LW)Q<_X4 D)#0\- QR!\\("0DY*$DO.??NZ^
M =BH(!L$9T00%8" #4+$!MVU N3P?MX#_>4!_L\#0D!$NH>,@HIV'QU>H>(A
M@ !"1$1 0KQW#PD)7NH++P>0L._A4')((#]2,4:A<L;E#(C\@DK]M*093W7H
M@(;+Q"40[3X^ 2'18UHZ>@;&)]P\O'S\ H+/GDM*2<O(RJFI:VAJ:>OHFIJ9
M6UA:6=NXNKE[>'IY^P2]>1O\[OT'2%3TIQAH[.>X^+3TC,RL[)S<O-*R\HK*
MJNJ:VN\MK6WM'9U=W<,CHV/C$Y-3TXM+RRNK:^L;FUN'1\<GIV?G%Y=7/_4"
M 8B@OSZ_U L;KA<"$A(B$LI/O4 (GC\K8"/=H^1 QI%003%V?D3%&8"*^S3R
M2TDS&C67Z@&>B<O0?7P:[D7:PY^J_46S?TRQP'])L]\4^UVO:0 #$00W'B(V
M( :<)PW71]TS4RX,4T_^=G4]O)L"\Y&^ _P&+H8(KKKN@ 7R*]1<*P26LCM@
M0.8.V)^Z Q[S#MP!(M1W0)/EC8TNP__:,FL'5HKR@/6:>'YC"6B4U/W\4_K,
MISQ,^%^OO1HJ>;T&II'R5T\[YOL%#\5Q_C"LE>#+3?+;:[%EY98\ZW-\%X,6
M7UO:<N\%SA>9!(CTS)@HN+RYV;20!9[;O&D^=(&XYY:)3E-M@,)OWTG!^[&>
M 3[?N0-"M6K'W>JH O=5RZHX64]P^G-K?*64J+*3C\;'EN0_?C;Q3C"3IW[+
M.O\Q.7M2&>&7O7AI4^N1N!4[_;:PC+_[PYHZS2NST06[B@4$WRS2<Z"<J=Y"
M'%G6\*7 DC^!W1UP/"QV?09N#_WCF(21/NU>VM+39F-9K?YX:R;[I"Q[%#'R
MA8&>PJO]KUE?K":\J7>6S#G-,"*K!#;%'_VJ%RI)3SN5A.F.9N4=ZM:4>#RE
MJONU+0/"7&R\5F1-=:C=O6:1-=4BOIU0#"+^P0)6,V(W)^&PVY3#'.JQ\BE'
MA4\^;]/G B4"+%1_A*4[N+:A:(W@7^\HY$RCU[\]PMA>LQQQ</UU!^2%#V;$
MC_7E(I\',1^Q:ZCL*<D%BJ@I05&SPZ[&%J$2N"[,W1JS![@D/U)L@(2_,Q"F
M"SKM#HASW[*FGBEB^'N+AP0NS"$ACG^>SDJ$,KV>.,NWFF5>,\=.=FZQQ 7Q
M_L&,Q)9W0'(DW-O*8-R!>U/9,OA+C[BR/T>^(XX3JT=QWE<IRC0YE'PR/\/M
MTK4JM:1!N9#RB>3(2]A]R9_VMS%(_[U745M'X^V((G.]O(>(033]V*ZG/"_W
M=89WZ(X<>9B$K&7F2JW'B,FJZ?R9?SDEBK*SOZI6C;=R2YFW]O2:YH?Y[3?)
M@6=V;JIIKO6)65&U]7H)/R6+JRT<I*+\2H#&XCAWS\<R:\QT2]I.&D)5=U;4
M+=Z@9,:)^**D;$Z6T]O"_+],-9:3KC5_NE\ID%]9DL42-5^9;L%"5%FPYCZI
ME&JW+$S>':5@*1\\SI3KSL1=]2F2I%#PS6OWYOX'@,XOA6259,F:TV[9\-I;
M$]M[MVZI*)'@]X-6_$RRH_:F:3ZL5'_ MT##M@2$R )\97?N :R_-@D/BVK9
M.'??4S4\:+JE*X5!&V62?L (/THV]7$J^A]-9__;6(QIG\Y16=.$B6BVS?-8
MN.N]H17?DAD /#.J)MP^UF!X3!>&]..6:.]AAZ&H^?LHWVOX>_C#,\H<QS+G
MR-(]2R+^//^#TK7P\86Z;<&F_:LSVM&"OO&E9/$DSSU2J=EU;I#IWYF6'Z_E
M.GR_^U;.^);N);T>ZWU&U.-Z%%ZH(ZV#;4#(R=Y=FA@H(@E(_Q)@Y"4!R?_G
M"F1KU:/8>T.(2KY'3J88VL2GQ=Z:D>^GW"(-(I6KP"O^OO+9,#2-*\$N[H!!
M27GQ>[@J_]=$LOZ1I<A<4*'72=;9WMHG6O_98ZA) ^(]DDJT_GOJ$^FVDR<-
M3R<4:VSY>?"2U\C+8J+$D8?H8T,[4$8M0Y9))@PD :?82D_/]3;/LW%/1D=/
MLZ^MX>C4 U2Y*Y3$=?Z< KO:6CYD1=/NXQ',EK;H7F17),\7A(L)$=@YQG02
MEQH4E];091Z_BDL/QKT>EFG6\,LX?)&B7%I1H9?_L<[+?H;8/$H\QW4$*=%5
MG,1\/C3'<)OWX?,']:I6]O;<PS/<D+JO]T\!OHF1+WE7:V]S#>5%,M^F\U3&
MF)+@1^D+41.!M!;(.Y\E4A4[W!P;S-:^_?0 H<_3D:B:TAB+@LR:_YM^LD]8
M<@7I?&'6YA&S9^W;S/(0SGSN[C?ARFBIF$+:96/N<VH*M160K7X=M]QG'$%O
M(OUO9QP(B01(PS.U2RMB]H4)F'7=^\K9)9Q*VP^K]M!",#B$0R*<DRLFY%_9
MWFOE/=9O(1DQDR3N1!05J\6B/\C4J[. 6&LN49/00K4PV=_Z'9C.D!X/^_/?
MXDP?]>C;&H@*%>^<RR;>5@Z8ZG0J/8\F=.J;M/07X$FY%SJ;C#=\PG"R75TA
M_VK%F\:+2.5^C45L7_M(QQ>:]4Q/J$],6%K1.%_EA 0JAE&,H>,$"D0O2:J[
M7SNMMKXJ4#:,2M9<@]7'",%[2U 9!52\<96V[4<QSLQBZ>T40?B=1/_[P9/*
MA7T\(RS2-H]:MT?AZ+IZ11L.?JWO^1#NBWX3.&G.Y].->1L2F;FZ6U'7 RNT
MB%%N&J%/3DN>J/S 7,(SRD3#N"87+'Z?[?S]CD@?X.1QYJGFY2D^]&7$X<<H
M\S[VFC>%N4PE!^O2"WN[(ZEAU_BIH8)3AAO#XG[>%FOF0_+YF1+. #)1Z5F@
M8W!"DO8TD??IF5X.SF".L9 ,@M$RBN<+DA!?&_X*7TXO5:L*8EDJ[^<,FX(Q
MUEC/482KJG2!KD/?PM:S6K<2"=I>_(DA)6<DVYIDCL1%\$>DH+!3O590Q0/1
MX;/V[RN%C;GW>GO./&1IU+\Q/_1O#0CH'.CI("R*9TKP7H'R6T*D/U1VYOSX
M)/H&,_CS^9GS;;KO+/J9$<9U!F(WDIG#^FKG>CRP7%3(6FQT&'/"&_M28[?<
M62__>^<1;FC =^RZ?(!_[2OKB8A!^78AA7;_./Z!R G_AT;OE^Q(1J9Y90)M
M/N[]V<;F2*YSAGH2N"DN<+MH+@OC>"\EG5V+41'!)E!BA)X\H__,V]F1JI8L
MNPL!5I^K;<Y3#E40[;+&3[DUE0D]0^SNHI-H>1+8DJVO^=K'?O?=V]<"ZSJS
ML1^U]'+3PO CET+B,.5RZ+\0G?,7+9VKC9SLIC@T5E8<<Y4-Q*AY""[3)Z<?
M9_.<IDE@[+HCM'"HX :+X_7XSF5_&;!S3\4T;/4X]Z-N*"FM*+5F?H.C+^?P
M)H*:"_%QD1P.H7D"DH^&1;AJ_<% \')U6<VU05:N0W30(S-F.PF_%$]"H5I7
M@X!1YC?'WQU96BNW&\V.M=QL0U:#O0C7Z3Z<$C/IJ==6UU=!I@XKK6DUI :H
MD1))!I%I^S*&7TM4)A7.[8++:$)7&.3,JB]E-Q,]"L"8UCZ!VU^U#69>5 I2
MINR,R+RSFYE!E1 FS4_)]#@[9S?X5C:C0#+8-!?%BU%X0@V!*,A]9QHMC3J;
M8DTA-K)6%_(E$. &]5R("NRR\: Z$*M^R&BL=@O817V3*X"UYNU[>'OS2C,\
MC"6[[L#W!G^PB[MO=3>,A[D#AY$?<;K"<NQDQK:B/$6Y'++Z%9^(3L,U^;.J
M:Y\L?'IJ.4_+>B+H=W.1L%!@+H^RJ0W"U$%!A9(\31_+0U7EO==+@AG3Z%#C
MU3!"^$WRT(W\I<1%+_J4RT?VQ18)#]4#AZV&;V9[;.TZGT4,_7B=)&$Z4^B>
M!NLKRJP@<")^K_4Z$@WYY"6F3+_XBOMISLZI@9"*ASSIT_'5"/,WCY@B1 ZL
M$&.:2IM&F5\+9= E#S\CK1UPHV?!,5=^\L6W,*AZG7"@1P/#)^K"5"+PJ'MG
M(,MFB&:&TALM3&1!T)^SIXHDP&"L8K7P1\3T; M_*$0LAL*^0# H[-UT^D?U
MD?5@@2^-%5&,-$>1P^9/!FX')5:NE9'.CC-[T;A-Q LXD2++[2_R >DEIH%Z
MZLR%S7,R4NC9])8,K$_8IAA;S9)NR?L;.1/;>=F SUY_ME%)?:BO'3;M$5%(
M_MOHZS?KP6?;FCF(H0?<KE/-+!5=HVD1?5SHWH5$)LJ&E$$[))&PH>WA JMQ
MOJ>.N.G--&#K6C!-9^:S0'\$M"VN^:H%C9'TRE<?V'8UD5R)NT<8-)S'9/M!
M9[G0-93$;V7M(TB8IICH]T0P!9?G_?D5GG0?>=TPF=@5I26\B)S?Z4.DHE"6
MQI0:[Z(FECW=5*&+RY',[?)FJ1BMM%VBBRE\'3V8@RX8P?<0;3TJ S/)MJYB
MM(#-/(I)?L;V ]4=H!TI5Z2V!5HJ5$;Y;*O+FD^Z_KY"#UW^'52';.P+=M7^
M8A1%W2<P_GCS\L)P \$+J7#9,FG5HJ\4YL:!F$/-^>K*($G<_WM2D8>58IT/
MP )M="&&IQ'@1O#)(W&<(4E<$*[A-OT=\!J\0969DW8'Z(A=+]\!$G@L "Z<
M"/S'I!#U/)@>JJ4>BELF1'(/,9?^:RJ*BL;2*'/60\*BW14"HB.Y3JR$L#KO
M=;+1)KL*ON"!7?;;'-8[@+J7^.QJ=SO<!TB&%+BC4[YF5EAMFN[L#.HSY"+L
M]U@7><(][E;#YM<:'Y-@@,RTPKQEZ+3%NRY R WR@ 3;]NAY?PE^]=D$:J))
MXWE_&'M*8GO4+>NE#:^@2[[A2[WI_$3&9 WQCADXHQ]Z =%>_T#[85QF[AGU
METXC;R2RI;1@6/_2DIX7ZP^HER)M* U&%^R )+S=G_VUQKVU3/<LZ\IQ$Z_'
M:LY.YLR1>(H:1-\K.95>@!\8BP1_<?XQ0TIUU.Y-6SJZ7.6$'6?VUC 8!9&Q
M/"#%86QNQ@9?"[KO;.OI*,P@8TT5P9E+DACAQ"!_+<"LL./IQ)-ZK_XT@O!
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M%U;=M>;/,J0\X&UK;^.071/,Y 3B[%Q41AR)[A @3Y(DR\^6QU"3!ML<RE-
M^'0^Y3>=2PS0SQ0">FEIP5OS2[*FP5X97GIVD#"T9QO.@Z/V.9-ILUSS>GDS
M)(HO\I ,]UV/8-P@"T@ FSV-EZI0CD&6$B=%*8*9TCY;SHJ+B VQ@:5\T^<6
MRUR=63EDN6>"=:83P."]Z2>Q9^U01[^VVTS+LX:9U^$BGNLC#J[Q/EN:6(]E
MJBK;R QIM>6JK<6J!:[GYZP0QO[>1H4DVU6GV(+8%5JN#2-X7 )V>0<,*@#R
M<*J$I (N2+D]O -2(="TC[=F=\!^^"V2VO3SIU_FU$NF:_B[3LAC $$(0RK"
MOT]EIQOSCIA;SL]#CD0R\G+2:3\\\T=QU<551DFT\N'-SKB(?EK!.U(9GW/.
M2/GL/=$2Y;+IS!H1$>Q4P+ZB>-?JM>*T79!'JB?#K"5^J[?>"SU! -%2]&+_
MY4=)P#E*3W_:ZYML5K/;IJM'H?>]MF03?;:KE814?AA)=)07*1/G*_G<DSY'
MN7"E>KX)W9$!>VH]P3364RI#]M!48[TO79OS#8\AP/$=@#UI^[@R-_?EM#:X
M4Y1_O&_%0IJU@,8BU"/IDH)-9;@\I+1E:8,GH8ZXQ=8Y*^^Y::7W8Y2YFI@8
M"7/ATXXJF^V<5$R];\PH[U;>PW:CMM3.+!9WFUV><MX!:/OA/FM[Y7TV(\JC
M^^4SC#?7,]<?Z>BX8'F2"E%W0&T!5M](_,DT V+_;GG?,\6#QK(,[:E9IKFM
M0GMTPJFGK=T0,WH4M'+RA$PYZ./0Y ]+293E:\^CZ)*'6,[EB>:K&0K+S0(%
M31L\3Y110*99AKI%N:1M%6.M91OO*9+2F_7I,&@8$)U,(SCJR,H;\4?VW;;1
M>_1F&.?7EA5#%VLY>#W>!UZB7&<J 9[;XW5;#(C0 P;HPM.J\FI?<042IEKB
M_&<XDEV+VFE[V[-5<@G-FA/X\<R'L\W,K(YT1J64JA(.F%@V&QNIF*I;PZOU
MIGF*E<>$AC)'P^+O;$67CX)FK[6X,JQ\BF(]%SLUAU<+S*.$:KB(^LK3.(N(
MKU-7E?C7>;:XX3/!8&I.P7))@8-[NZ.N830$6GCFB2JZ1W/,40X*ZG?5#2=M
M*VY%3\C54X&@5+Y]#CVS>/XYJ+L$=9+\J>!I43_<@@LXFQ.QR8SVB@LOXN69
MJ!VJ5%!G^*I-IC0Z!LK"BQ4#ZQZX[*U-B-?5E ;J%+TN>$9B)8\OC"EXH*@T
M.!Z#"_INY:.9GKHPI]UC=J]A/+FIOLHB!F.H:%@'4D3TCO^LP)?Z^5AYE[ 0
MPM1LQ:=S[)<O,.P3K#6(]-EA#UVP1)J+U=+\A9?.AK>TA96R61.\:?M.#VPU
MKX7>P$C$XD)3,=S[/'17'LDNBLC-:60E%9B+/\0QJ"_E)^WBR9<$O,<_9&SI
M*GW@MI6J3#KI-(4N,7IP/(RCODQW?,%.@]G$PU)85!K?D/*!9D3;^_S(.P\]
M;AP%A,O]BO\^ME[NE>O+#W!/,)E?&VA;/-EPF&=*:#B/T)^";6+.>@_U#3K[
M$]#G;@Z7F97558]4&#P1$3W>'=F.TM?K'-_[\/@RH'Z!/;3Z&W]SUP"I[5!.
M*I;HX8/@LCR;>&BZK9'LR$UFF3519->S-0')2<\],3:5D0;K./.*0Z]QU@+'
ME^/KBL\#TBN]=?'[UZ0TD'(%2*6/BFHAP.H-PM,+QVYZ4]K6FBIAD6I6&2G#
M19'#?6W\*]_ULZNO54W>CPRASAC0-J.'B4%L<>6N82D<78A!\2<^#(C^#</N
MQ$E"[>PMMGQQSF[A#Y]H]4N45P[[K"#P%\K$5"CA;VJ-:_+QCH][E-+LB]1)
MM/CCL!-B_ CTZB2K&!L2)TF.MG0E]BKNK8I[?1UK545)9C054ER\J'/%DG0S
M#TJ1@RA(./;%209O37XO(?/3</F8N%Y'_KVNFP$Q:C;6#Z.NHG*X:*GVHZR7
M1Y=5IP2#-#3#7X\&C"E-MLQ]TO $-M,J2AQOT9#,/1*GWX/SUG_7,/I).OD!
M<S)3#7P2Q#] T1S9+9\([E[]T=@@7?>NQWZPBV0E/S(,-_L(N58@RD!,]5!P
MWOK<DR6'XEJHQ6ZXX,/7G*?J#ZL%%DLF>&94Q$DX=5]:$XABVDZRFE_CE1_.
M"C^LG]=A^"(QB35RD/_J#BB[T<A?>+EY'HM_#BU!MX ,K7;G)1U&@*9E*1:_
M,A6E^?.C^Y(KCY0WW6_8+1^6-K*X?NZ4G7A0%K1:K8RY&[>#*7B6SZ%CL 7#
MFQ@^$\J.W565M:2!IA&EF%"&5KY15=0B:I=9JK-A0"3^7LEBO#ACR,]?6VU8
M/AM'@&D.CJO"TD_TP^NU$70_GO2:4NU?C%][S@YZ](BM6W2?G&_Q98 DX.3#
M&IEC+<H;V)4:=](C[]W8XUH>@[J#^G2.$]7XI$UCJ) U:^B&*[LHQ1MO-W0S
MV9NNT@O*4%5CW."/XF3\;:!)[@3>>NB@:?)(FV!7XI9RQGEF>H@N1[!*%?''
M'?X[H-%_J:S0[;KBL-26)6OV :OM)C8%1Z5)1(YA.>X.8>Y*& K/AMM_+>S_
M^EK2G+8_-UL>.7%"K5U&"LJP4B4NTV7?RAD9$OP2/+^I-_3[BN@OP+:S*YLU
M]J5B))[!H0A[JJA(_)$4@(G(Z$%<$B9]W[F#L#![PP>BD'5;K*#B?%]WMTY'
MY6VM5+77<<24'1DN]O'I\D_3WQ.''"',NQ;WM@!L)M*92BH2L *XMG? %78J
M8C?X\B+ZR/ @_:\ON5:IJ/79=T#*!S':.^"^\.^O4 CP\<_J?U;_WU@]4WN2
MG<Z2>O M/#\* CSYG<C*_^;W5@BZ#&G^5+_Q6/6*WQT__Z5-Y9F6YEE_61?W
M^MM@_&B;D]D9B>D:"GC=9_[HHYI>XP6DK+J,-(EZLJMR% &KE V LNQYN_,+
MI8?640J../I</-]4WSR_]K/;Q9C\'AW43'&MC)PDB7)5!KN^ S:D,G-2[P!-
M\ +X%O7?SA5_O:7X3R1-PQL:7:V9QK:SXI-PKNZIU:KY?HY$TT(;]7;GE.][
M^KG]Y#A?523QGO\C)Y7_:?J' H3><>Z$)+F]OK3X><)%N_)&/>_-S@'H8C G
M,BI%N/Y)(?\?SDX).:VF\T4S#FV^/I\(R>#496< $(F.A7+:I; $")<?O&LI
MDW;&YG-"-QKL8N;0P^MYSIZ YEKA]2(0:TXXY' 0WB4M")ZYB?Q*G9N+V/OK
M,0@$Z]3R]APN/!0@>PKV4;J^6%B6CDB9CX;!^"Y&RY617O[ORGWSEH@&$(K/
M%"W+F@$7-E:I"GG[IW2J=ZN$E7H\8?]4#JFQ[%3:E[T#P,0W5D>/KH?!"^UW
MP.-N48:1V:4I!X?PC(<<,*\,V,08W1T0;H]I!_;QUA3VPTL99SSQ/)DXXKFJ
M>)DW7^MG4?77)H=6Z,\S[H"F4!A/=%5K]&G4]S'P%,:.F"@#K*TI 29:T5-Y
M^I#AXZ7*KAF,4*P9I01RD=5$<.67E2^)PVCAJ2P4IPW6_2*:GZ&WWCNJC#UE
MR0RFL.$Y:(RMYA[J<5J8C]=TW-9*'=YA*5F9^O9N5(KK<LAG(,TP_/)>#FOA
M;<]-;].%##,-O+,R[NA-2K0DX:,0T:F\@3N [(J[4ZQ!9,IP1*#PBN',G>SX
M.NK6@6PX?IK\%3@S!*O$*Q#<Y&EK([89YTE]S)]=_&[/$-[=NDN1Y_:K03?;
M+A"1-X:M,Y=?KUICOT==LEVX1MX!;PC1%\KILJG"N;Q:P?SK8J\\#5]K+)L7
MZ9"TN<6_ <_&3//=H/+?;*>FI?'+.5VP-A"S:G>7P6A3\@P/UA"VH0=?%>2F
MC]H&B"+C(FX)'X]5V>KEW/2\"N<1434!%^J8:ZD6(#)NH7;RQ#@O]@GJ"$^J
M[-+MTI;941\MY8V93AL&W0%LG1^'H)L=AX;K%V72OS)FY[5H@RDL;8OXXMV!
M8ATY6:\@C#M_B?^'47Q24MM'M]GM!C%DW%=>Q:$N5W= <O.IMUC L8_CN8.M
M-]KMIMC^,CCT-U>2=?1T]"2[]EZ.\54)R,TW&]&28N'>Z:Q_ SM).3]L:@^G
M%&N@O[UQ/,RURJ)B^^L_Z;_UZN?%N3^S?V9G:FMH/S2D'I<2&\](\[__&Q%5
M'56] PJ";H_A4!H/0"$,J:A_/(#Z_1)*GM95TV0%,1/AKEEU_+KS]UJZ,7VS
MFU8':NJ Z)"4%_[6*CH/EHB='/#L'>:U+?7</QIIQDR:V<]*$W9U=2"*<'PN
MO%&Q=666@U:](AUGI'E29QSY 42^UN_"\8TZL@]P4%<&YXOM-\'>P%GR[Z J
M_TM2;6$SO5H9-HC^?LV5=[=1&X6PW35*Q-J^8E=PJ8LU?HT?K^SHQ58!N\QF
MBDVX-=*THZFDG#T=] Z8V+!6T1[VRI;5G"'9Y;H#/!BFFK*>4"\QKL+]UX!J
M\Q:CMP1K/'T;]TKHRO82[]2G0:/![:9OBPF8MRV['1NQE[[E_E2'U0-1*C54
MN /(1:DUR.<"\#@N3M.GNV[8'0]N6J8D7ZO)']X4N>&I^FHI50XDO7)X-]C)
M=:FI=$87<3.WT./VZO)<!_9<(\>N'-WQU'DR4*A$%<RE=+YOE7GKX_?E^FU]
MPJ7>Z2UR%<3M>YN1=9$V&(.]#"SG>#;^A>_&9T-+>MY#NRG)ZN,UDG*^IUVJ
M!PY#^K7B-_?&2C@&YL.X7ST9\/;MN=DC&X=,B\&C-R:BJ4.:6_SO8[X]0EB;
MTF=2V7PWOK;1R\.HX\)^/%]N\[,QJ\Z:SB_![0FWQ5F8M:'9MW> X6'Z5M5%
M$<SQA&"\\&#J=>RV2\1!8V('']W2QM4 %_DJI XY/&O&M+L$#O"71BG]T=>V
M<N3'.&7P/FS#N%-FXF7N@,])*7\1E1^&SS'V[(!..[='6JRU$4 $C%1T[H"9
MVI]U8K)O;W65=F\IP+UR$S#8_8FI@9)8X5?QW)J6-S2"_#]K5-V>,8HM4@^]
MNVDU@D<G.6>N.VV[E+.C::5-B[0_<XUO-L46Z8? &Y0$VS#<5XQPI;&L,3?&
MTTK%%AF&4&Y:J6_"+U3!WS72L"[?T]\>+2PJ3:G#M,Y1*MX=4YM VD29!SMN
MFHIO#Q86X8Z#YO%&;/4&O "G>_=%0I56P4X-A6)KAMY5DBXN7M-8N]PRE)R3
M*TS=H%G9/934FSN@6$=.^1/?$ZZ0ROL,::FI&>88F=H(6,K65JD8">&8UB-=
M:QV/=/NFY2TFI5<[-I5O8U^6P&?;JT['-/)FISK#G_#(4R-ILO'T/"R\YYG[
M^Z1"%JWD+(I#G)F(VLS0MLC-^B(X>]G_H@N=@$Y\:)SV6C54-W)6>XA*X2^Q
M]<!\]L)3H1K,8\Q[[!$U5U])'DN>R:01UB=_ )[H9)/2RR97T+J$T17BO3L3
M<>E(L-TH-B4_ZM]T6@C"; IE."28"IM3_;[4>W+,T2AVO:&R.WPQUN!Q?8:5
MWW7S0'X$7.?J  D</QL_Y9O1EV:X XP#.B:&LPNC%0P(RT?*X I_#OS5)NRO
MTF_7VT8K<)NV*>#T%TY/Z?QITR ,"+_?;U,9<P/O6@:8U\6PJ 3).N2\D9'H
MO(1 7THK2R^.%TO"2L'G';# )[I &QB3.7I6<3KF/($YG_/K49/;]C>F([#G
MZF59\^E:U$(+/G2DC4K?P$Y3A^9]:4R\9!<.7T_2E,"/@ C^PEH&(.]0XE$^
MU_,0^2I:"1BUYA,&L;&4\X4[X"DWX!N/=;E,?GO$<,U-?MPN=KVB#B<[AA9!
M,*\.>*\AHGTH-X?AL$L\%EP0P12<72=SP"&2*KQ,X@X0-H5/4<F?U_S.K,36
M0\#GG>D[@^ !0K@!(U6'Q+%_)1J9M6QQXU0-)*LYVU:WUY$TU5%]DK-S0V^,
M0<OZ2;\K\5T//=GG!WJCJE_WIJ+O -3^\#M %'R)=P>TAU](N8$OX=C=60SC
M*93D(!(["-FX X[7[X!(PQLK.%^PE(:'+6(WD#M@67=4&5GIAEI0[ ;.HU>T
MX"NUV"+1T!VP#B<K5$T7XQ6XH/]</ "/2;YSI=\! RDP2?!A.@P[B1P&M^(1
MTQT0:JLB_L?6R?_8^OO_T+KTW[8N]N];Q_Z;UL/_?>O/_]@Z]7]L_5_1O4?A
M1_6\I]=>JS.TNV/U4<!FTA0/Z?G;HA^W:W%N>T$%F-=*/UK">[7T)-7-C>7X
M^'NX,*)]XVVO\]&;+E<](*XG-$;C'6>*&2FNRE714[NXX"<C]24536]:/!'D
MDD,$?;%L.F&]8]S);OG%Y7KAEVZU AW7A3.'^>6TE2']QV%7:4JEVXQ#W#72
M]799(5L?SLM?"8C-1K =X]&FO+>W^*QGD#XY!U>>Z&)@J/;Q1,XG?8,XYRAH
M3NNU>3>X\. Z_)R(+'Q7S_P.T$N?E]ZS#\"KDI25HC^;#Q$;9XN!W=:0#V<J
M:#V/SCAKN5WM.,8K5&[(+$_QFX?S;&]0*BJ.+ZM2#4N"+Y&"(D6E\U$;.I8Y
M<GYC:%;7>8'1S4.L566^X),T%Q:/%(W(=Z>I"-LM\09#"V?.&$G)B%_#>R"Y
MM]%YVL?6KH[>\*D.]53Q7S@?W+X82[F0WIVXU9@[,=Q3E"2?/)>%Y6O7D^]'
MG'[\@CYG=5/.J_TATS+O>+3PM@0O=R;/FE/7IY,:!VXVW_LC%0D*#0KCA?8,
M^U\1I$<]\K(ZM%7>C@U+;-*6W@%RO;4'JSO[:Z@GAPPKLH1>"7< Z?)QIDW)
MU,*$]'GQ$>E&C]OR9MYURF42VR]=U!5ZX)76ZE],.FIZ8>[4<?QC[,.-M+N)
MV$AY7!IB?KJ#X0#AK:VD"!NM"0E/N0'LV/$W-Y;^75Y)X8V6M6L*Z_ANR6@:
M,N(1C]@-3;S+'5#H;7('^-&1#^=RCPT]X-[I8_N]8?+?<"0K_BR&7G[RW?44
M>7\!7;HY_6Q]E6-&T(WU^^A?-99<5,190/B*9+CLGFJON#*G[*XX]NV_AQ/5
M9FY/=IK!KU:SYMJ>>+3_# S]RPB7J4VI><]$7/HIKOJG?^V2DQ:<BZ&)C#J]
M[&+YA*"=);-<>:POA\BN;/"ZU$F)(M7(-6 PWC<%0G98:*:'BU]*: J5$-6A
MB?1DT)@)?JD5);&>39B*&986= OG%;YWP FUZIA7]@>\F$Q)RIG ;V#L5'1<
M=4/K(-BKO\PLT1&4F[-PV!4NB 6/8!K.*9+A0+#P-+R\^0X0@>-+XULX[90\
M^RRV7@X^'TS?90</6/U<@.%:J/AF85WNDM^>,%R_(#^>AJ^8RDCE?XK^'Q"-
M\8]@9V'Q[W+(?VNS>M19<^-Y:F:Q&N] *V_9"Y:BH1T'.-2'W%ANS#VP'6/J
M+-^^>,%G@J8V]'YYXY6F]!0;7'+A4Z&/SG< :ZPJ8OBY7M6RAI6\/1%?HN<8
M*2U>J/F2'M,'X8^)4_IA)?U.6'  'OVKONIRK*R]U5WRZK_40U7EOV-([Q$W
M86U6V:_Q? U[F2:CV(XR 2F\32J8O ,ZH!E5'.&7YEXU8N>#:Q6POP[W7V4P
M$3Q],,<DQO(@QCO38J_^E'U!0YM_G-ORC6>,LCSYFJ!&OA<WJ:RK(UYBXQ=<
M!-'T0NO?ON3=EQTJ)GZ5P<BF0J.('7#:"2NOL>FP!!N(X<&>K:6S3+!EY>^!
MUP3J^3)*.BNF?34FP;JYX,72\39F^AC2,$)9(?N9A1"2H3/[IQT)I!9,;TBI
MZBF;#A?[5$=OU'*T]1CL1?G7YI&/8&9V[#Y&(60IA8PFZGA;=$WDG3F+2=(V
M]F(M!Q;M0<;>6=,B%2.M6\0<.S3+(M(4X"A;S:\W0H6-^=E=(E.! OBJ_O2(
MA"@UHEF_J8]7* C)4%\NX\A55%];9!GZ>S;0^6]W T9-+QU_'>7H061<$.T_
M>[]!O1P4(<R3G<+>Z;#JZ;0DR[K*1H9&0>W0':;T[+1/% O+VF,"6^E!'5,K
M\M"Z@*HX!1<CO\7*3>NC?=V?P/O[Z4VNS>]L%L3R7]V%_47"VV>V=UQDGQ./
MRD['3'DV72I6>JI G_1D>Q=_&6; &N8,V_:XL?6#_.Z*5'_CBI_^CRN^ZB'6
M@[NB,DWN1DOVX%E!^$Z?DNRZ7.VU9/4=$"N?G@BNG6MZG/]4SZJK?KDQ9R&M
ME/GFF2WW]^E=LO9]F+=2NU_HX'C#\[2EG9Z03Q42DO 5Z(];U7BX9X,&%/+O
MJ>- G3H/V5$FXJ$0!?KTQ_9":0PLJ15/H0?2]Q]%E:0J*Q7#ESKE*%T*^RH/
M^(<<_^6K*NKE@(I^2.U9L=5(,[?5Q%%_[KVO5=^>T_@W]P:8H3B^R.U:)[D?
MU=,:6^723)7@ZD 'F=?NI36S=(YJ6:<4IW$^MK1U%2?5^,,V?M[AB[P"U-?O
M'-XK'9+; "62DNO9Y_#6FNQAN-Z;MU-B^S/@OTS0/[/_5V9S'K6/PQX]&$5[
MXL.^>2*23WW-I3[L/5S4..0@MCJ\L4Z^5^787EE_ MM).=]M^AXN(E9'?WOM
M>) ?*HWG\$;NONXIE]TO?$NU/K@;+G:L)D;D,=WRAG.;F6^XRD^Y--55Y$>;
M;B%P5S<-;\\;A$YS.O+OYPG*,3V>:*V,DJ&HE[4K:EH/V9+R>]=@\UL__^JK
MS\O57_J /92NSQ86I9-3YJ)AMU47ZI_^_S.>_TAV/F<9@+ARU=YRI8P4\X=-
MC<R<3#B_1;F&AZ(2_P; V+_O7$#83N&!;J/8";;J(+*;+F8D!L%#Z2Q=U")M
M[JZ57!U4 2(DUZ#.D]R)%R/#:TQO2BIU%B5(5-]_XF0@G,;D1$8CQ+.! +]O
M5_"P_ X2?]E, ?Z'$T+#:FCA#1UQ#H[ZB?'(3_YT9I&;<9QIX)LV"^[)'.H7
MFW-8"'4<TGH<]F0.]1-NQ9:9SD7PN/7;BFF1T(6;HY206^(OA3[%WJ:V8+3@
M+:08$4*W*[*QR-NX/&LQWACWLW^C8=+\=X![G1^/YIO*H6CO#E^5)LE?ROD@
MV3852\1H$PAAR&5@2(, OTK_]+%L9BH"9(EJPB%509:Z(1FVTLG!DU?8^Y )
MAQ.?9S;C24I,*2<*/<U(^1WP\*7!W.9EDS'71_?K1\_S+*7".>4#ZZJ%:I#8
MND;B@5V;/UA*"R*E843I03P3(7T>W@!HIZ4=&\)\5VXF;JQ^>T'0?<+& U\B
MYY7ZP.WAO[W!3?MGY3\K_Q.50;%0WJJ#SPZILFI#[Y2^[.J03_ED1??_!P>K
M6&NZN>ZZ++X8^NO+6'LZI.HI[3T6G[A*/\J*>&-[CW!33WCHG[TL)K5A^S+W
MI9[$3]=M[4X.K0K_,H 7X&M>8'7F4AG)O0^H77^HK GQ^=+O=0)SMV%/*!V"
M(=4HHANHC*OH[[]EXY$/I>&Y8:.Z WJ(9(F3?(_ +^^  <\^\.5Y]+'A8<$Z
MIBQ_X]OO^H>JOU+*1NZ_>1!CS$R^$>ICJ6K!\^7^^4.Q7"M0[F/I.I,G>[1A
M0R'1H[?6HS_)XO_@Y8O_IH3WKZQ6($FGL^$"#INFFC''3]U8*8\,6G<I31!B
M2$)3,4HQ[!%7^T')$]?/KN7Z7M1FE*:+YU)W<#X_>'.[Z$[ML.3I>P<D["WY
M"SW^_7A/7F.)\ZU]SAM'!_G(&^EI?V85%8<4F'?''0#&NE"I!5^ND]_>B"W^
M#+#^S/\S_\_\_RQ?-3?!:?8]B@M)RJ8XCOH?  SZS_RPQ/^SV*4@+8M;ROD5
MJ4A]/<))^H<$'MZ.B2WQ>XC,XI(Y$Q$H@3J5QA\K2\'$RZ7_:KH+1\B+V?YY
MYAO5:2J%)WCZ^-B-8Z]7'H6)DV HHTC^S4X+7IAZI\XC:Q/OISZ)5X-(H^IZ
MO_PI%O@0_EGR9\F?)?_C)7ETLWR"V+-(U'!O_)>"\E]=XD<6>\]65'YAMUHI
M[)M^WN/O*552]Y7LXB43+XO+F:W>^KS&6C)W&0)I&W:[Q+2 "0%;>$Y1'@18
MV7=O$)_9=/W6SC(D,R&>MRLE'4KL1"TD8;D9=*FQ,FKVJN[@?)MDL!P"]=+?
M18^X"9T][7<."M$\Q06%IFT1Q):6SE&(,^^N(E+LL32Q=!0-=51PSJ@[%\_/
M]+EEC3.\R(P;?'\PNQ*F#H _)J/MV+K$,:L,$(6I:ST;TS9[#*07O:0-BZ79
M][)G%]<RJ+$0P75 <O$%*U9 W6V;O:V)YUII&&V>J[PUKSY&P^%,K@;,C,[6
M!8J@$&#=>"SDG?:1NW9FV)Q4AV]*G9.>T[>.;E%EM#TLW;&AO?CKYR6UWOC2
M4"1/\W9T/*+-_?BZOP_9EK:QJCH;QP.X\_*L"_/.1X'?'@V0HFUK3PBV;EJB
M&4B^#O(STOMFJL0KQI@B]!GWNH4(,:E>2T,2,*4]C-:'HO'@O9'J+-%;!/ME
M@E@ZNU8BCY)YXSL^ZHR:#_H-V?N4S5=\I_MN:L2IU/,6*'(.<[$M2?,7(!*6
M\!1)SG^%T:A1VH8$K=' R#,8^KP>YA$] )A 'S@LF0^W3LS+]8Z\BWXMOV87
MJ>%G<K^J6VFN_95IIGNY,HJ(<<Z"[)+M1^L,,?.%)U*$K&C*;^Y]Z_<S490=
M< C.KA^E#6K5Y.T2W5@3,GN/RT],$E2U?XJ8_+DPCP&16&KL0=>H9-\*IS=!
MLASGHC@2Z]!$'0Y*(1E5$R]^9*EA9L'>M8G6)+[4B<D<KHLLH>AEFZTLKLON
M,;:>*;)^R(^PX!1Q0D2UQ.U]!X<8\:0TWA6V+L+W_+$B?N>DSL>F.7FJMJ7A
MZ%M\9],%:MZJY%26J#JQ-@?BWY J=\PL'40KQE7$40N* H:"F# ",25PR__.
M[T3MKN4*"]Y -WU2\V?R=/'4UI@J26L=?K@F_C"-?V-+0.D>2V"\6NFI_OX3
M%>V#T%7QN6_KT4$&DKB@WH4M>WM2_W>Z.,^8]XI=&_$ZT1,=F*J*4W/<15Q5
MRAO&[$V,HYY.57Y[75I"W97RDIA:Y**H% *LBE6Q=GRP9]%]W4;55DM9EM39
M&B%Z/H_>R8\H@ N=KMCM>&=>#3G-JN-J(1NUDE48SHM GF6D2&F(WV9(Q:A#
M[[(\V#)0XBR8ER>(?CO9(M#OA80]8!>D0ZU?8X")GLM&'=J>%L$1;7Q,S?4D
MLMI8J=M%AK0A/R_-_W&IU,Y66$&GTP^2&'X4E)% K&7]H7'].\#:^W&&2QO&
MU[8UTK@WY0EF_(A[>9&!<RWN>,,T*NWZ:?=89SX'G(<!73? 3>X)J%>^0 ;*
MB^$N,^Q=9!8F<HTP2]43VJMD'R3&RJEMFH/G,WS3MR2?+[,_[+44$D<E! H]
M8B<@B0"M)!Y)5Q?&_^UVVA\@B8?EMS.&5#2K- CP!T@:_<,9@_]]AK0_I+QS
M@C./$/RU/52=8/$H\8SPUA'9AC?3>E"&@DV>6RI:C.F87*2 HV["XQW&.V!&
M5^L6::=I_^H."!65]2 0?A6;4[!YFL^/%*)=;VLWP43C91ZIOA@8X4T=)C:-
M=_\B>&8GHG.KW5MCRN0#V0M[^VQG]*.0P^B B>B0T4^V0]KC,+J1K,"I>6G-
M./6($J&\1R&KWW\ BL,=B!1AJ0$\C4W9<P8L]5C"41P4)N,&]22/ZAR ?BG7
MD$ A9>0DO'?N2]IV^R]4)2C?* X246M&EI:\HS?)I7$-[SW+K#]43'"T=.56
M/"YGCU-G5JI4!'USRGATC+',3T3C9(7H &DW?&1]V &+90S6"'<+ZOZ4%@%Z
M0IC: WCK(Y-^:\[GC9\+W1V8^N+]O)H>1Z^+D+]=2D=\EI-3,%P.&$PK-6S%
M'VK.Z;4O1BVQ+THCC[OH5_=YE8AY*Y";-88CP#)F'"5!PR)T#ZDT%?%"G"9*
M&P,+_)?O"DZO;:=VEL+0/_$IQT74 GDH)JZ!?G'G[5*ZTWMM.!6A+3,\'1%E
M[9WJKQ=!%%\=M!/M'W2(;""^A+2_:Y5UV8%>N>\4EG=A"I>LI]IGQK+RHY"_
M0D%R5IGUBC$I#=SEWLX.7B+G9$03S]BQG'9J*WLK_)9Z@600>1=/;EFS+$BQ
MIA&GH$2O:%.X$BD,T;0(U(R2Z([T0QW%H$J&PIHZ7B [I#/2CM-86LKBHT]>
M8G@"__JV^.-/FJ0I$.9LPX44QI   I/ZCX&X>S0,DS5.G)-W #I;L?9MX-$6
M&L;W,729+S*4P5(CD2WF,ATJ[3X08"2ME.WFF6/VC$$<]>=9/?$1POHXA$9V
M]N(R#,YN-*)V%QMT,-YDO2KQY[U4*/W1BH0MU^L93](F"AK0: 1'NWAG)_(I
MWE,1DWY3%PIKBVOVWF!^TG<O%F4(30/YB80AP2)^TS+E4T@$%(:)TI\(%=$N
MPYP$W9!26KA!^9)FC76X/JFEO,><Y=_OQ2%K^<VU/AHTI7"G23QLS@YUF4L;
M-3O*EC"2 7/P[B^+,0@?#YIAG/T($G_LIBE\=5'J2KK[MI>5DC/W'JD9M=63
M:KMUUE3\^P(99)0& 3,*#9*//GJ7K<)6>QA _J\3]]2.]K;%B;DUI<\V'J=I
M]Y@*8_3GUVJ^>-A\]G5:+]"4&@4ELD/?%DX/I$5:>8<N8Q])XU@29QBEBZGI
MQ,)HAW>,=/P&8XGLZUCF#-ZA)%IFXSW*167JFAS&S>:SRH\_T33(?N]65Z>>
MLNO44B=6%R^I1<B_8O%QX:'UF2;8YOAMZU/)T- ZIMT!UP&)KC0>2K:W$/5L
MK _:HVFEY*T>'+6,.$GG8I:SJ0^QNOFB4^IB)5(T2=1=O*"X\5[I);6?6_BK
M;F<DCV647A @^6J#PF+,B-TTQ6YHH#;0U:5J::BKPU IQO?FP*B;9>(X*0GJ
M-7TSDI'^.M0ZCEOHQLR'MIJZ^XW*T4(>M[L+7F_[9RT; )LA[8$E/5R#%Z6*
MQ$J4!AXAG4J(EL(KA_T"N02MNIY19I'9[U'?9/=61KID6UTJSO(QIZ_2%_[\
M;#R9IK0Z;'4%1W*%H_MS8N6L/QJQ"V&T?X,B)J@YU[Y>PM0SI\,<M<::)C0#
MPWY.PTF&\@,Y8Z<PB5^:/P]#@96P6J9B,\;P\]GUW@^!12#AK\123Z,$UO%P
M7S*/S.OY+WDMAQ2-\Q[M&6DYFR1X/@D3->V@3K9"](%DV^?IS.OW.#KRQ3'K
M'.,R7@IT"#LGDOB$24GJIR)  FU[]"S017HY.(@0I.\KK2LW%F>E=C55;J'@
M($YLBA-8Y:5,UWK>W '3<"JY>@<\SG^UA"Y$7%7U24YN.B%U"Z0)<$QC^AVB
MMF*)>Z<^T&6BN0CN5/#%UO'4:5YOZF;O)G!&'Z!!J-D\?]=((<KP0<.@?'N!
MJ4OO XW:HP)G#@J!&<I9=K1+3V=QXG)-G8D=_+VSN;GH'6?O4AFM)SW^BK-F
MB>:N'8<8%O'Q-R9,T)J2NHHH=%<7D\^4%B&6-/8F7.WL,MR@0DGC31A#Z:BI
M=33VT\CNO0&J$A"2681R:>0'9#^[H'8L?LU#36@5$QJ?>(R'RW@4VR=<!,_
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MO7OWFYTT0/PTF(H (5X=/'8@.3N8[5B=?4:2F[@;^0SC]H%*2LN59#>2KR@
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MG6_JD5U9@4PYGUT8!U)[N!X&VZX^L&5Q^7'W935:G=9MH]2*#DE(?-K"/0^
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MI_*?VJ!?X%_@7^#_#0XNH67 -\M.5&78*]["F:^:_?DP^7Z,_A-02P,$%
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M3.EL(6_!'?,([\"O?>*#,6X>]FGW]8U+YX;@?CZ1YWO?^1E.SKCD'SPT!]Q
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MADM:*NZ7?UR2.[=U;C'DEE W;:0JS+$O(*6 ARZPV(:7H,^+10$YOL]-3R\
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MZ+C,IP3,SP4ND+\ZOPZ*_>K0Z/!.O_6RFG2.@(;9Y6?.W&=OJ@Q4#(&.C4X
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M$;Z$.[7KC)-$A^RC[>PZ&FKTDNR5UG[WWD*6+7"=  (6IME) <GMQHL2XHQ
M2G]<A!<).EJV,<.W_5_<!0_V-;W]>4>_44_Y5T-=4TO<7X]S[UWZK.-_'CQ_
MD]F)?^K!,@M3.>I%BNIK%((8=RFQ2(2^F-8DDJQC%=H-BMU&E3E#7[V=-6GV
M]=M6W<L[LDM;-7XA+"1$LG\:1/<^"H_0I6AZG#.4A8VIGJ%;J I;A9',?U&?
MNDN,9?2D6QHE845$$F6FKHYJ^:2'"X$&?,"#!G70,';3+;'P*08W<!'8!4PR
M:@CHB823$5T[<1+<^QVJ2^YU_ZZU]B,89TEP0<CK5^\"%I%G(&IK_#H%TD0M
M2XR5NDB'Z>]M14&9M,G;>6W)"4L:KE^WMCQ_NXNC"? -/O-GZ[<B7&\*5FHJ
M/'9=G\BZQ!-RPR[KO'!PEL47U"/[C!A7_[P50QZU)3PW95[NU.\>+?:[:'R!
M!EZP_3!)\*E($S@+%$M%73;TNBMX_-Q!Q>DYNVTV/\Q"K>:1'4+K5JOJOO.I
MX1'3_$: 688M//58"!@_Y:[52@]C31S.)VMXRZ5L8J$2W&Z^DMQ%>:.A5V+1
M( A0OLG%EJ?</-<^71C^-S[ 8UJ*[$UK*H5)+07$19C!22.7H)TZDX^Q1(8)
M._B8CS)1B)_")>8>F&)3M["#7/ZR:?SA\0\2KG\XMMA[QLR!/UO3UQ!X*T$+
MITO/7XKNT8#52[#I$#C/(Z^8D)/S]3@DEWK>K9K=TP-!B6O\V3-V,T4NR6N:
MJ]>QZ:\:W]Y SPLQ<TX STX K*X0G8*K3*0A&]UFQV%42_4*),==E.Z]."09
M"22T?I6=<OJ&8\-N\0];#DDX8647'A*KG3=WKLDJEC]#_#3DR>$X4FC'!L6Z
MY$;U67=Z;([K%@]N%=7^&$,J__DA:@N=,P\XO"Q/1^Y7BJ"3%WW>VI4SHVX.
MTJ,W;*HV%YI@YH-JP9[FXTUU]B3=/IT5OW782LQ_]7\=/)5A24*RTEV6%F*U
MD#PPO,=8NRII2'+V ?5>T'KK<4NY"_BU=5Z \G#L.6X@O'RN"\SN.LBK,%RE
ME"C<CI-(-%HLQM<YQNS/P0G")X#^';:UUP=Q(?EFA,/E/,,/Y/@\J\G@Y.D]
MID5?:/3=7('TX<-Y:)BPD'1*EK)H6JQ[AY<Q,_T$X+W L7X(3(@P.M*.N/ M
MA,EJ6S<9;!5@0@<NNNDXC(:DZJTK;NG8C^$4K2[-[P+'@S=6'[<UM#=D*^9!
MRXL*YN^7)HH73^"?!DQ[N8[CE*'.S%Q#%JC><%VY.Z2U$U/!D*&(T8HK(#F[
M@Z&1Y>N.!WJ7#QR;#@Z"+(-"0X*D,WZXFDLW?/[]>0CD$1O9$-6O3]-/!E;^
M.IZ:V87L[-MS^FQN>?O[0X^&]437D<E&MI8;G1+,2'* //P9577"76#:Q"1<
M*S<\)/&0D/$RB.8^\,7$*LA0I!??-+*9O CE/+=>H$ GD?(%@/1$$JS=9W$6
M4V748R.+)R76X,14Q-Q'E;'@>1%P"(?"X:C-VF-D!/"HJDHDGQT^FT&S;Z5#
MX=1LSI1YT0Q27/X2)_VO 'U7I8B_E*Y18<2].:=5/_\9O77E(&8>QLD][-VL
M5G/:TY[9L:?5&Z[,[%/W&[DZ2W\UTB/1L-!EQ.5,!YHA")V"V,EC09BJ32-E
M\@W?T,0F2/;-^>W$0'Y$27]X>"@L-^KC-:P+>EOV?DS#Y^5Q>(/CYBYGC+^A
M.($BL?C3'= VA2?=:*/<@W.TBQ?PME*OXW!U)X"8MTN$Y.+J5,/FY\^5E=+0
MRG4=1S*XR@M>')5J'UN:@])SMAO@OIBHHP/Z%;,X&L+"<GW*GIFCC))=0^^&
M-V(='1NH&K/D@.1%!$:?KQ:Z+G1*4L[Q$ZLHI0=X;&0F19$78][]T<OCNUX@
MK6!,/;-]XQ.R26<3394#4OLPBXB4>1'JE7S*"N$E'=_7Y/!*_%JJO@&IN=0R
M+,2EMVUTZVGNG(KT_220]*YW#O?CY9;_KEIVF<*?+ C2XPF=/)2I_@6V]6,I
MJD-+*2S@K[&JO1%>,VU4-=1Q\M _IZQ+IB_VG-I0>+F;,91G1/H%IOZ#=.I9
M@W"?N%,C(Z:7NOD[I>HH39\\HMT%ZJG^_\QP)OGI&U 6N@ZMFA*QNJ)6L@CR
M14VF\)BRCT6ZTZ1C[7@VU"'S@AK_PPE$<=07B?J%>)R5HMLW_+.:OW/Y6XH@
MVJ#&U$K?$P ;@ZUL_;4AILRU-^STQ9M9&AT0XEGNY'Z'8P(U5_)N)"!(V.IR
MHJ1B'IY#]TF I=ZC"+S]"<!W<(<?71W@?US9DH$)#Y=AMQWM]'O 1";I?P@X
M\CD3?F^%67D":&A.[(9N>+0=#WO,N([/=('4#XF5!7*YCW"*=\+PJ?C%0G@=
MGK#  SUFI\;WPR^M&LI3.HNULZK7!$ !B4^15N-^GYVWGJ43[[4VIM__(I*B
MH;='$)ZEIQX%'0_ +_E'&'A3SRX9Q>NKAI"1E\&&:M\\.VNIY_IM*,,M_CFY
MUE4L]:,[5V^';_@X%YE_#8K]E"[]V.Y5P35FIM$S(SZH<%E"A-71K8A+5-4$
M+4R+ZKY?D#O=<3'2T6&BQOLZJFT<I\B\LDX[7K=A20]'NYL]Y_=*F40D_8\3
M6>C;!8<:JM/9*- ^ 6$5A#>)*0[GC="FO&I2R?AWK4ZY,Z]HK7[]M=9FMIY#
MGC_F/"H6G38VPR75E'1K7.:!-\'UNS]$=T15RJGZ@2F+KOW/TG]7/3BW"<@"
M:D79:3653_0;1B8R/N34][U0S^NQ#0,:>O2H\%+F9S 8T2XS=1MT0K#!VQA*
M6I:,@Y9KX1<%B&$H]"@H:B 'S[$OD>*P(-2NJTI0ENNEPG@>4B'?87\[N< :
MH>P&#@;<BWZB$,X@V7RXWROIM.DM6BOZ_?UT$X]LB<;XK>(3P+E->@[5@^9%
MY4R0I2+Z#(P_B2LC[4?;G2E33FV4XVC*&(EAO'BTBX%- 2?]@MOF_#\-%765
M*S=F<?0,@DO6;^H)!2AGX9^2F;EPGSPXFRO#*'I1M:M<_WQX=4WB3@2?  '.
MVD]R&>%&8?G5-@[<Q:Q$P0+"/UYI3]+ Z"'(%-2/5YL<R/L(%06,FEN@ !?>
M%BC1^X_D((87FYE9)P"?.8&_J)F[,,RGUH[XMU$2<Q%/<*<9(N?3;G5TF:]V
MX^$#=YT/?LK^P=%>(7S3IE/7:G_3( @1F*@U/>"(4WC>,6_9%O:C9;0[,E2F
MD.WA\6C7T81/V@!U7 S"/N-X?':%]C!5P+1&V3>J:3'6B =/EGUQA!!^ ;PP
MZFK0BY% *L4C=A6P:B> ]6SX48JL0!P,']?@@5X.^.Z-_*WUMJC.?L,+O%3[
M"/.FYD [[P1P7ID9CPL_XM"P9A9&7 ^%HQ=<P#3MNK4"18>6]K9\Y:U_33/N
MI-TD6DG>J]SFNLJN/2&+U;<]72?$3(X0(4MPPX ]>(D(^1)Z<G?K,IHT!+=L
M)NH_W 7GSJ=&!I6NMT;\=ED-Y3)7SB[T,ZA,/9?>,US2*YTTL#+F9^2%G];K
M7IX\'*%Y, LV=YZOQ&T/;\^2./^^UHQK;0K.GE^>@;4;UG<9M)>G]RH]J#>3
MQ/1U_:,!FH0_14P'].B5HJLW\ V.GZR"7"?W1>9<G">U$#''Y\:U##SLQ_V]
MV_#C.(.[.W>:6_%X?'NN"Z:MK46ZN;DEW;PLW?QI: UJF03TS2U&AHL[AI-?
M3NEH+SU#3K3H\@:$0)O\';)&^K)4!0RK%)<B] ^G&J.CG0-X*O4*-W]M\18S
M*]9;YR>(+R 6ERZ!>[^@5<SZ%_ZK*BC#4UV.G;?H(Z2:*_\)WAYQ-4K$5+;X
M]4SHO%!+<W-#M .6'V0P:QP@,X']%M/*]55()!C2')0LP>!5I>GF=.M$&0+3
MCOD#6+_3"_J[FD KM-!$$ZRA[/A>APNH=@PD5<1>;#"<4;0N\.5:S&Q,G$FZ
M_3^]0OLG@*O'0Q(-_2G7*?M-R88L#&&J55.L9@+#B/1>WYPRVW78;BCRK3#,
M)]GD6_%X<'C/F.;[L@+G,0*0"U12;[$A\$%*;=ACVHSF974%SEZVN4)1BU +
MJG2!G1+;(*7FTT81L'K:>6YM,O?KH<VJ%S#'OH$8PC[+'OY'$MK\?+MZJRCK
M6FN!1I;NBX6&THJQ83%W^+P%'^52'FI++%-*22,7O=GB__-'9(7_@';BA#LR
M\03@4K4?X7-62:"V45BK_OA:MLR33HQ5D&.^_H FRG@CJ:0%W*UE6$EBE;/7
M[=0AU6P-'BDP7/%3FC7Q2*%V'7*5,:%3:"+"HW+6:>WXVIM-?9TB8UJ^H_W[
MA57:(TU^;7JZ76+!DYN2:::W]*T_G+JKRJF;0YE&EL13?O"XZ 81SO_5$9N*
M?>V1-+&MJK)L&>[+7?+-*U7<N>3^1,G3A_>5!MH1X92<3>*1/OW*RJ-.BL=_
M_,;1,8%-GCMKUTZI.<T3JZ%Z!;%HT^OCP="C5 VS^NQ=B_$G9VX/LF>G3R[?
ME&I.,B&W# *_[]"L:UMP'0W_:6*?-L7!VPG5E=M;G5RP,^S)+N^EG?]M;FQ.
M_LOY<8'0HV=)3M/NNF?J;P:VHBWC=#=TS&[3(K#,MTXI^'SKD9DC!PJC6L7U
M8U)N<GV.1@9D5"%*05_[O+'0)R!_Q=3QM\S?VU*'[6C=;X<575W/+*KT*I!-
M]G-A=C&HS8Z/GGRW\#I41P:O"TV5XI/0;DZ2X(F(I)0BR$"VC=:RN':3DA_@
M KGT2$6W4=7MX"%'Z^;T!>/FM^:5(>SF6S(PF6S^IUZBZ8J*4U9+R-EBF@T]
ML(PNXD MZX-ST.% .H+42PUX6UVCI']' 19-J F4*8(T0L'%<_HW1<I+$F1F
M[FC_TD7XJKH]PQU)'P]&79_ ^<'=F;G'9Z&MVVUH]PV]R89*ABQ%MK "*MR)
M"M+:/E6NN;&3L8&AY1#AU,U=MWEWMT'EWJ'Q^I% I8S[PZ\BS(XTCH>/57"4
M7XBDJ#,1PE031 SVW;]TT$B/$4>[&&86YG/OJN9&\2H71%AK'*2=W=#V0"GX
M5]QWBZ%KB/ &(1L2AH0/R7]9<HP[8N#GF?,%!&;^[YD:!F.EPT"@ QTUTBL@
MVL]L>!/VL9"9$8%/:'G<V2 .WSK/1+VN6MP19-J/-LKTO;1.#UY $$Z=["(S
M[1DEKI!ZQBAM7B"CJ]4G27/D@@<44P;+V6R<EYL,'@IP&<,F7M>[U@;>"49R
M0J9&[]=BV<4J,4IUGVG4+ J>P2M%TZ6FN,OD$3S$(I0QO23.*Q!Q9:K(++A3
MY@X*%OK@-QZK9?DFL.BOITVXW:7=JYSJ3RY.B_AIK24>R4=]?;?J:,B'H 73
M!0L$VB:?MYN$DGI.94/,M^V0+>W!A\1@IO^*A3!7+=*QEACB9MH]\C!=MJVI
MOJ.SZ:W=V\-E=:8(S8[Y(<(PM_VUP&D:T+AG%7Z_Y1L..V;(3Y?LTJJZNNO9
M-J;EC?NV*)R6 WL"Q#K-)?H]F^D,!F)M ^*4;<:#.OUA1[)4H<@LHY?'1&8!
MXP30XYAL\2-O_9X\';UULY,H]"GJRZ.<*=Z7VU*T]!XCZ&?*T+(_][\Y$W^*
MG2W\)W+3;>)5LV ZQY<DCH1A!SVO!:(9<M2-[MR5Q';S<D+):JY]8Q[9MVP\
M1"1NFJ-$-:1PUJ4D76>@U)G;P/GU5&[4Z,)I]0$LI2LNX;M'1".<B3@W=P+!
MXVJ4&)U HB4'5$_3D?83?GM# 82H:Q2'+/1@B4J.3\V"6W+5F;Y#E]ZZZ(=9
M*L(_74RG^/:VWQS)17T5%YS CG#!@FC^=.Y3@C-K33JRF,0:Q;I?(&JYJ=!X
MWOOO;5GTWVULKV])V!6EC964ASE<:"^FI3 1<!\)$88R?:O<D@*E15). &D1
M'HL2B3HO(^RHJH2%<TYNOE&*DWL<D%?TV!I8=^3U@,IJ;,>S3?K_0=*9QT/5
M_O_?YVZ5) EEK6S9RTZ82@@Q=K+,),D6DY"),7.79>SN"$5,]G4(,]9A8BQW
MB<F,=:PSDHQMIBPGQOBY?]]_SI_G<<YU7:_7^_FZWN=QG3P'MNS.*R9?PN/1
MLG8AY6F)ZPWT=._D[R3?<+]HRV95T<0OHV[X/TI1::%=(X5B&G&%_I2LDNF2
M<K[>W6EM<"]XS? E6'?>4.3&_L,!"3;K2TMMK2COR]T^$2#!BS4Y*WJM0",.
M&3 PX?UT/6R^<KC2LMVI^#=TM7TO$MDU=Y@/?.=B"P0^ O%S)W%1H-,S'GZ=
M1X!7NT-XQLP)ZU;V\2:&JK?K\.8,V)J0RUSUF+T]MA.T.&5]7N-)V%5D*W&_
M#>2CJDG_$<,.V#N$8%6N.)#38X".PX'.=Z 3W ;LV<>S+N384KWBM"(ZTZ)<
MAW9>K!4G]N^VRH)4X>!5U)X@<FA78764%67.[B>E3[8O'$8)$#_4?P=UOH8C
M/(^26IZ5!P-W\0,5\E2$4U1Y "5@+-L.(FD(HI6D*0;]>&GY]@NFMA9UB,.,
MW]TTWY?!W,.RV,8R3JV:68DTCUE'BL.-8:>7W09_O8B@=>9]L"CNS/2NA/3_
M\H2Z3<D-=B,:+5=>>TS>:PG<DY9M$M#O'F#"037TSN8LQ]13,%Z;S:LV\7P"
MID-O_BCVA13:Q,3*TV_GOKDL[9ONQ4!S[@@(2OSFGACZV2G+ *T2EO9D4I[B
M0^\YD*M_/7X7+ZW#.#U^+4[BN?04HXK.UL_6U"QUZ[C :#SMY!:^,O9+X RJ
MZS;(&R-,@[?;?C.^ ;@[-K!TT>Z]!4HM,3;L*_+)])'1L'Q!_(W7QHE\UG\Q
M=W_D>3>,6!O_68"I#]SWJ>R4/@QX-U&/!!*Y*JR=OSG\;'(W5XZ-2L(?HVKQ
MBY!MV!(N8OE[LAFE->=F?S8UU?\[;"J3;NPW?NKF@[M'*%J82?#VHV_T<54M
MU"1U_O%K?X;UU9^02TT4KC#\RI<YZ+#U8GQ)6/1CY: S%[:LKS$C@S$5T?&
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M;C_D&(&R>< CC AG-25'8>&PV^SG.;#0,B#;G,!:2L0-!/G>'#T[Y9>C]$]
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MBFEOZO^JTQIT)MW!'PH!K?!H.Z-?Z=%:2$&D(J,E..7ZEVQQ'9B@J6U)M=,
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M@,JL:A#*+)U"^;Q"O^WZ";]=M8*=2(D?9,OA3>!A [5&]8O;),U<0N2UR>E
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M.94AD%/-9Z_V).W=L3[,%5SS(VZVRP#F M$[??*P+B>O&KY@>].S,*F&]\N
M9["3M("(@DOLH%CO[AW1R@H('!FM;CZ^B97?L1B!/8R/MOFR30F,MBYL\C0-
M9C3B4O57;N.JZ*4VY8TI4C=HX3OU%\V\8[I&MX/TG'<+?!*['DOU5:<J59^D
M*[R0W;U\U4S;D3ZTN(6T-G#H]U(>3]?M!4]Y^;N0]NY&L;;'/=TX)$#NT/O/
M X6,.O2<-%*#<P]X.0\^"L L 7V6;H^TP&;Z>;](4;2A]CQ4 @'Y[RA'TQR'
M<4//BH!(!(T<J]7A3B).C0U6D?U^_701E0KJ"F\*W9;^&ZG"1.$/>#A"Y?U2
M,L/:('Z."8!F'/"\E+[ %5O11.@5S/XF(66!ZB(XJA<EL+7%\OD:X:(3$2F=
M@+A?-O""GE<=]>[)^F:JB0T!WY(QQE3,*V>15V?V^)A(F3%C#0#</7L"X\8R
M3\;B9J ]$"DV*O$*%:'-(,;9=2;[%T_[Y:(29+ZIJ!D>$2F4SQ/);GLVY3\0
M*HMZ;-:>$W&+C::KOT2>Y@Y)-_DF< 5_:L)!/2!!I 3B"8!AJ()OC6XMP\+!
M"6+HOSDF+W235/G["N%A@Y"HQ32Z[+>,K[+L*8*@&<N-H<E+7_I[L/S?,6G!
ME_F6YW\.VC@^9699ML#-:OZ,AB>1&.S,@NM*H;F%.69VO0[IQN*4^0G&0B]"
MSB8N4MJSN.>=A^>]V^\K"'<:);0O[D4Z^EH&Z-V#B!Z3?E!^4=M!@_#3^8U1
M>3^2)WG[PW_[N@\$)J$W6>6OM&>.]$*$1WWK@<FR"<#%@DWND3X*_Q\>)19
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M#*MAT*]P3^^CN^_,KNV.8@D<:S4(U\LCKM4 ; :7W!N"F\@7]G\;NH\YMTY
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MFD)CY\A.080E$_R90:88 P58I&*_]A&7:*>T.[#'$5*/]3@_%K*D+\X\88N
MXMG:K8S[Y*QBA4S:2WVC<L%/-KI99<H.OB^MRB\-290IV1?H2S7L5PZHPUPO
M_%JYBVWP&*RI&@F9!B&@(9A>XU#8J/^M\*!GW6:]QK8-99)6C9IV&6_/:5IY
M].4?3JIY!MIH43?)GNN'+&DX^"*:%X9K@/0,$<Z65\FD'(2(3QKE.&3PM7VY
M*KE<0_SN-NWRG[L[M'_QR0J9I[SQ-RV1W%G*P"5IJ)\'T"9,I[A05P2\I_/B
MI^:Q;03T^S>$IC1XV=$"/O3BC?>+)+]O;R0J?[6GG/J+HX&2.U8Z/[;]"%@"
M64UUPD>Z4LN.N.(YE]EFC*)4?3-(?&@$7^!9P.-WCS8YKG9&EY&3V,[',F#S
M3K8;T@J@QJ3_O[Y]>A.?1Q#2>E.6:F+?"B32[@0KQGGN5EM_;B2N/6U8Y0MI
M^DS"(-9JUFD//G<AX)*N7;Q7J+:W2IS'_OAZ J=9"GE=X%C@M/-2D6]+7E]&
MIM'GRD!P7PA3T^<.-$#5-N>F@]NRK1MQMR[&;BZ]P7+ X"5\K,RR[T6Z;H&R
M?PW62FPQO3X49G[.Y\,Q3>:>%+6Y?3)*X[@/6D#\U9.*_NB$1/7,\#/.?*!.
M6?+1-O%2&*G>4;B',(.2$+#QU*[WB.M,2&2KQP?,<F[L0B+D)\HP/&[1-"(B
M_3HM_UL]E/SI,!O;GPXHG6EF75OVE$$_J@Y,*SP-8&G8"RLRD)9X*KB$L>="
MU)@6N3/!G1PE@P] >0=6SI!_>?Z'AOTH^7'AA=#0Q<;&,=EGCPO/0=3[[+!G
M0+T6 NEIKJZK+M TY5 5FQ39JR3N\SWD!RDK1A/167^UN#U>V;*L-+>,^KF-
M_)!%0SD/P'SUK[NF7!.4HX?97>Z9?78^];Z1\S-'M+Z6DE>P,O!4KB2;YFUQ
MH\!LW.X#OUSUR/''NO;S\S/R@-?_SRA+[_>4=NIR!$E?9A"2]8.88HL]S9WR
MP#Z#N&AB';=.%^3W+Y0\[E0]?M;IC45GV7I,JV9JLJ>H'P<T$1@RY/VAD9/E
M^W':[XW+G5"WF7A&#H?7DXI-+#K#OCM!:0 EZE\J1L9WA3'\G(ZX&M2[UXTI
M]QDQD/.U@3M% FPGT@XDH=6A" \2<4;QM.7T0,LKRLLKX%5PW$^BZPIYG9/;
MJ0EQ!@@<WO19]?C"BTRK:#HH&B)RW!)D^\&J (Q:W8!C*'R T=$7D!:]'N<8
M-:U&^=G@*_G <XIM*[,\^J5W-;(Q)%)+Q2*Q=_Y'QW19;ROC^7$-&.T,H<\#
M4[1S17]WRL/1 F 06X;I\9DI.[M]#77+6AC)W0L1X"C/ " :=R*B<:XU!DB^
M/]*P*E7-8AUG46X'9J9(D+QM 6KL#PWTV/C3OJI?L=JXNLHXEE<BW\#-R(+8
MZ_7LEJY$EB<HS)ILFP7Z."0"-JW1KY<,_=BN>G6XP\V:IGG%0H2?EK2P@$G
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M#A0Q$;J+\6]NJW(AXLWUB0'J&;G/X&3E+*OM,JMGF;85CF7V4X%Y9",C4D;
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MNIM:LY)<PC=M<7^RH4W/7<^QOB/;%<ZZ<JFQ(XDF(:SK*1!U/!MUF]$[Z;Q
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M6:0O=15TCGT+:*9*;.IK5M:V>-.LA4U#.X0%/ ;A"9<B$*Z.C,+&4GBV>&Y
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M/0<+,8@-YU]6S;:EUM)21<>SS6/0/06H&,%#LXU>)2V[(*.;LZU"YR]F314
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MTA639U&2<Y,S:M%9C*!+F,69T,T($%\&ZWL/Y1N 72JG&1.CEFG/,1>33?!
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M\$%U]P8_^V+Q+?<?/VDFQM)HJU/L!5U> ,88$>EH)>9N!RALLO%@09%53B$
M47<:BO?#&M\G+CM.[!!5W^;N;/X1._\H6^O]^[*H_SWW\'Q=^=D?'IU.Q".F
M-_,]\?[G. 45&P=7/5P1T^Y=]6Z>KO._?[L='!1ZJ6S8^E)#D+A*SXK+34ZD
ML31G $S1[?F@RC9BP>A#VY<4XK/V2X>IOZT;>+YB'2VM?.%< "(4.DGB0&B7
MSL',/I'UG P61#ZEJDYJM3E;UU'>I3.1$1%0+^9@D:QHI-7##5I]$%OH@$Y+
M9,LL+6+S*3U$F8_&_,?%BQW%5T_#-\2-Z>PZ06R-\G^#RNPXL&$%);/-C_Y
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M6S&OF4P;_6U<>C1(@RR<N]J]PQEJ=?6 \>3<OA!Y0XN94W<U7:>^<S@X,UR
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M1D<+;@7=:)B]5=J%+61MT78FO9=M698RN:/95C]'<R.=Z],/S&R2"!/;6[%
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MI8"E<],$I<+[H8J,URP-JJ5@(D@&X,!4Z+&J9XTQ<ZS"C-L[9 6W06=1KMW
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M+5GR%XIP!N^?:WM_L7 L=&SA"2Q_U%!4J-3'K]0H]O3[J=4AK/*+Q?0X"]M
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MEV>!J%.I8FB3@5K4QC;_A1XK'Z1M'J96=7YD4PLI6/FF/EX;+W<G[8C+?A
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M8$Q%>G^6A)]4X=\=0[C3&=_]@L[;$#+'2J+R4#;[,6?T#6S:+<7!DV 1,"_
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M'ID8V%)1;JGE;M[U,M<HS7819VT;63K/4U-BD/*@[+J>X^%T:2O(1T+)@FB
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M\_EJCR&?N,'11T.&CM4?K[0AE9((D*8=&@M&[V+.[I!/S*Q"=DMH1AHV,0,
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M.A?5UFA7VX09D23-5YA=%K&JJQSU.RFZ+B4)(5XG41#46IA3,T01HRS4UB=
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MP_R%T6$C3JPHW5#3AYT(I2EQ<].E/FVNK.'L1[ZK#?OY?@PW'CRLN!DEU"M
M;U]D]>D\Z$0 X-YS%]$-.<:WQ[,TMWN3_-YZ[YC>F^=M%J89S1U=#C2W"%_'
M!_$XR]L6HX*#PR"PXZV6A[.A*ZA(M:=Q]5/H^ZAP,00Q-G*2N04%2DVS,<XL
ME+Y>3SN6S%,7'EF _#V:+KH_\M"^2-<(]WO#CY6?@6B$,(3G=MZ%9=53[52:
MT"^.Q+Y!K9!"'2$9I]OIR#.W2B&"HZQ=#:2:\FONG3QN+><RE[0O<N\F$%R'
MQCD .3P8=(2R?F H.+%*N*PYV\]976G:CIUDS72FOQYI7N")C!K$#NKOBS0U
MM]7?"LJ<I14\(FWZ[#I>8I>I93\WPQTF^7[=7'?369$ \_+/QRU5KH6 P;K.
MI?;-H:!.LB-[.M=TM#RC)%B\YKJ&C<)[B]C/,ZS-ZFM+UY<\[Z18=:"UF96;
M(6ZMRFP(H!WR3_.,5D]KP9PX)#2VA4N^O\[W9$-.P#$&S$V2S-L?=JR?[%*(
M(\__7X VI:_E.TH]K\%3*T;6?IY<*I2&(E\$+&]AM4;UP99:ACQ#@=CS72.^
MS$>,.XGO\IJ7BZ^GJL:PK P"8/ 1OB8+C0FH03=\^)9D136.9".40]>0*#/F
MIF+/=CKB,A-DW6?5BM^43*IH3A#D\J16@W<M ,)NS*[?V\)ZFA97G\B(E&$0
MT3_99[/"V80C/DM]EU\R^:ZH%^A6YQ:>_DS!(_M25 .J)I%\"97^?'38\S<V
M/V370-!7%%'.LE+O*[J3'\Q6EQ^J$%H+NI!"\M0HT:RSHV!3F97VP'O<7/=Q
M3#1-DRMH#8JL?%<+E6*@2BT]VEH;$TF79_PF"^7=2\<>E6OK>FJEIGBPOT*V
MJ0A*H]O7N+!KRW]7LVJ86[B.?#NX3\:UQ2'I;)5R1Y>.2J^3M?W8#X']F85-
M;Y='.>:Z'@LP5;>*;U^UU*_7M$N3/#_NY++F<JGF/(>W BEAC%@9KD%[]ZFI
M,<&NK%V^[EZ=XQCI&K4Q_V&@AU?H3;?^!_WU8G4O&81_(:$@X>%UDB=;^V;_
M .(XPM"*<>C@'<N8-P5R#P!N YUWIU&S2LVOF?IQOAOA"F@VLT<[-L/83.T'
M%&4S4A]AXGPL)[%V)I6"JZ:I8BXT N&0+#^7"0RL#HXN]V)2Q,,AW=C3$WQ;
M>?S:QHP,].,SYL93OD/=RL2PK1$\<II<\9,CW\IT3(A1GG6,B0,-S)KM/=T7
MN9:;NU/83<[ :C"I4AQGDG-WH9HH4,HN%6<3TS?V+H"OL::3]-ZV"A1Y?Y5)
M\:H>EB.Q>LSP6QODHV'C\GKA]=)RI97+=88]J(@&<D=Z%J/!R46VMC_'GN@E
MG6_&?-%6?K)2Q5I/&N]99W!Y[*O'LQ>\J_D7'U6_Y%.^T!IG=,_7'1$LQXUR
MW,JS5=K("$D'&0L/LD[7&D73WEMH,7+FN&[A!LPN-27(8;XI)Q&6/L1#=%K+
M\5KN<4 B/K,]W.U+[< @*S(U4"N++3:%[G^/OIL$1TA?ILF/;J#HTJU3+S(3
M!PXVR5_".0E.H4?F6!/WJ5!.XA[(8[R>JE4^NU)8%)AEG159,^OGVQU<H*R7
M*X,*5/QXZO'IIE_MM":BK_V](M3_\GT(V6#+74EL%T+&*(4GGP:6?X[Y<_@+
MSZNUQC1S Y2%.TYUWJ+++LWJ-=,GO-9[3+#6]/;1R V(*OJZWM(M$.AF@'SW
MEE149&10C5WTX!:L.S(-*PXTS><DLOJZ]0^#3J*UNK>DE]J_923$54^1-NME
M.N-$3'>2OA;4A5MUS%3(>VT7Q$<%VD6IQ/18.-V_!)HZU\%,SGROI9N?5)^W
MTY[O;R!6JL#,;JO5/;DR0H)?P'R>G7+_%EVCAW*!355ZE03HQBTHV[BYQVK
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ML3_06!\S[J".N4OL[5_VKBIVCO9AZ'1VXQ47M=M$EV/11,]K9T>(T'X*K#[
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M!?$;E,]DT!)1,UW3IULS^/<?R@LO&E+Y<4$1+61\U8Y7:_$9&N^+V!W_X=0
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MX0$/-1I^B@.#QH!("@R5'"XOM_Q?A6B..BM(OMO)L'0PB3_(M(NIP!"5Z48
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M&U9!F1S+^L%:=IA_EVUQM\B07$#/!H/%EW[-REI<>N-PP),J'=SN^M6V22?
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M1\9.KT.!G,1Y1D;SF@Q;A2)T&MK=8\;CV>E"*[!K=,Z9$HY)"[#].N;8W#\
MMKDBP,TZMU;QI=%+&[^G,<737?&\G@QAY3"7X*!"FR]5AWY $9% :CC@2=A-
M@<MA)?UW(],XKE50CZ?ZC?V_4:OVCB-:L"M0-%LNN0AC&4A(;YJ(I!*.N7E
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MS)GH\-!2I'3UA5'S(L.8D6U12H#/J^3J(+7XE#-"K.P=CJ@H2Z@'D89KF/_
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M/(=F#F&Q#"+2$*(<SU*,.Y"&]P.=>[@P4+F&Z,DY^7$TW$;P&^?/$8QJE6<
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M]7" '>9T(L<QE&7EQ^QY!6RS[XQA;"HX=QGK;=>!^UU6TC/=+?)=T=\D5NZ
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M@,+_6]31]%&D%,4FN@R$P$,N#'WR5!'FC'4TN1CY$U*;^;&LC2Y&C<!X97=
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M3WXL6CM55R]\/^34T5TH!WF53X>?H3;X(LA;G3.X+I)%Y^%!A\EI:GA0#W^
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M$,MO8)TA*SC,VH>^H\,6N58')WFGR">K*VJ+:?J?1(5Z!WILTM3X2+ECQB$
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M%UUUHX?-GWG[CKRFN_WZ^OJM+O"I)S-VYNSVQ--0U/;_C@"F.KB3W7LB9:A
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M)YCJPK#"7?S^S:7GQC'GK /H&F<P0[0?.:8%Y1PC)C(-+1U$QYU$O<9FM>4
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M[ R>'6:[0XRF7S>GE#5<;>4I#BE^_N]2B[$P]?PQF^%3\]]QGO$[YX6G H,
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MX5TO$GD:=OIJ3ZQ)M8CFW\\OJ8O<>EYU[JZ*AZ.CJ./-&KKH75#-RR<U?X%
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MBT\Q<EWQ68-"OM]Z1;<$YVIJ,<I*>'CFU,.9$QF[@BAD==N1?-8=Q!"F?I[
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MW 79"#K(T;PKTS9!=>LC?>8M%_E]G\S$22WV-_+,(Z?KBW_M.$Y^P_XIQYH
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M>HD#J5@Y9%B9J*]+*T<QMP3CL$BZAXHZ J#L:-];1[Z=F3 T_MQS^[_I!?L
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MX(N%7^BEI7VRGG=.VW>I1IH_C5,L"O)"W:I:1.3%+#F_2%0M]I<&?'9!!UP
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MAT]8HDJ^K)-K_-';"@A#P:BDE?A*&<^V[\B'JWK0FH5N.>],V7N9:DI %,O
MROOY=<P[BWW/APD.^_\Z]'>WC\&'E1^.+8+Z(\[G6BN+5L]6 PD\ _HMUO>D
M\I?'/(W<["XX^=_U=^$"NF+SW2?D3IC$&H]AU\\6Q)4Y7RS[FV&B7F#GQ!2F
M9?@(^JV=X&6'R9*WIIVL,^6/0:0 , ?<0ZU.XTMYSW53J_@7/XSHKQWX66]
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MC\.Z5(WQ)=YS"$E8_1*_/#T&<:7*]#)+9$W67;?]*U"L7/]4ZBO5CP2H#,9
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M53>=:6NG&VVTT%X?4+8.7M#N71#[YIJ8'WP2I;B/79S (<Q5Y;-)3D ?"YV
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MS2KS516YD8SC!B.7+&R.LCFQ=M>F/)B7#1V.+0UU#)>H5U4IN\2"JUI\>/8
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MJTDS[BIFP=\%3,R!RVSY$PR7=R(/ZR,TZO?M9?08[%<-XL![[I>A_NW))$9
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M HX\:Y[/)(VPZ*<^.5*&](=]A#H9!Z]]/:L<>\[CQ#TQG-H@Q L=J[,0WQI
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M0?.8 8B4P.4]BD4>8FIV@V*:Q8B"H@@"U2*F_0#'$.BE\+5!H/N>)U8]9^
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M2E[;!?/$A3[>NAC>]>B+O\MMO&_#WJ+_@7C082SL[G.".P$PXEC[%@)K%!*
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M<QWN7,[9"_S\V % W(EPFV@\Z_7C 9?\)C*J/ST<;D,-1+++6O@[)@<96N4
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MO1X*(*,26:+0"Y3,OKE%L;Y*VD!ONTJJZK'C]_3&G!O'!BS5WNQG35M/=HI
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M5'ZJ5/=Y6+HO;T#!/^.:XGW(]P13STH2SZR1%)X;L60N[@E_\,J729[CY_Z
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M2'83^6KUK:I3=29MD"Q)W9A0&^:SG-FAEM "R%'=82P^,A.5I,K1*4B[R<3
MQ("S[Z F1,B?#K+XQ\>)C_(TB\3NY<KZD9+=4A9./TQ<?RZRID9S9[H6R;#%
M'?:'&]^H3.J=ZC>,NB30,)MSO;$T\3,1=$V_4/2=MUW\(TT6U<Y[N_M<"W'>
ML.<'@R=5$\2WXO&(%6HF3SC[B_?KS31N2VO']K8B2;TC@'=QYK?61*4T>8\,
MC#RM7?#Z<XO"9Y(]3ZHFJEU%+$=KS5CGTND^*[,#:2&+0E )6M223@ 7U'X,
M"V@O:B'[$A>3AIOS RMI'::3F,%=E5,,!\J9^HI5$]1*GD9&R,_0Z1[J^!QH
MD:;LI^+CR##*+Z'!C@"G39DH73#!1'G/(%&<DQR]UU](KG:=@ 9$D26H+R9U
M%<CM*I=H-KV'F4G0&T3TJ4S^5?T;E)'J8@BZ9TI?S,^KN[TS'8R2X'4RJ?+>
MYM+_$Q%#P=".?\WIDY8OIUG";<Q:+(_!0'*,E$FM(\-"@@MZ3=4,E&A> A:J
MIVDQ-#O9S=6=?DW7["F98-3'@3M?<0DSZ#0ARAP;0:-KBR8K'EL*M6NFE=*=
M:&(#H@N?EBI51Q-$,]Z3I[LCG?5/4]YC4^Y1Q%$!;DN%TFKY]^H?*77V1 LR
MV[SX\FW^2;9,:,A[WD6\JGL$D*]\9-<]GOZT?JQ6UHIZO=*!Q_PWSH&J5@7$
M+CODXJ3E;-[Z](<6)],Q?:V'K=\N:Y*%+SY$@DX["6](M8()S^W*JHB2<7US
MR=) Q]_G+#E%[A2IL(O^:+\5[_.P')E &3T?\P.!2:2ZUE<R'M*B";B$K$>,
M4_CCMG:D2YK3."FWB(+'"F?H&+Q$UZDA$EMN@A>%L7H2:3'_K"!XE^+_P3?Y
M^HGNVY-WU'-#7&X>WJ-H?F&FP[Q!PM P9C%6DHA(UA?]1$;WNM@L&?=F<OD&
M@HM.4'"QNC>J>@B9*:*Z"X*3W(C:]06#\2:S85!/T&#M+!@N?GVRKC0EJN+Q
MA/\;KX1/8H3ISSB:7/,;$H+-IU./V=QYF8;^G =*Q6I40/ ]HK#NS-.K^YVR
MY,+R>M] HM[)4>LF6A1J?G5:>R19< 01$.4;[J?7E%W;]ZFO9DRI#T@K)NNP
MSCG50K;Z1=$] 7,VA*U8Z(F*=7A+##^YLY2,ZLK+H;XL,;GV+&2HUI3^6139
MM]M<#\W4Z_O]K4XKHK S<I7UI5MQ1- ^(EO^87%JH6;5^]*>\4K7##<X/J56
MMPZ"\#5CSRPK*W"^P<-C_<DGXQ.DQN"]35JP3]L]G^-9;$!JG71D",J_<QPG
M&*;7FG'IGGFZK@FK'>7:>T2Z'GIE>:_%-1]MFG9]N_1.J&\,8@Q4"+NDSP/K
M^I=A7D/S65X:V A8 B4<2L-?8?60M&SS2988Q!*8[T0I1'[(['65:FZ=U.6I
M&_0"URRP!9]!G/KH-'?UPEV_D[\?Y(+8CP !NS3^*HC]/K61K#<P,,.2NNS[
M@/8!P865S9.&]V27@M5)7>,0,)0O[UD+R;EQ(I2_2O^-]#(\6K >MZU$;.%M
MF.7..8>;TS(-19W]FIWKMB$KIZ,UU>R\NGTW,J-@3;76>[ 9CM)7_G8U;< -
M-F%QH^!ZB((]*BT-XKOV[L ZSD-41$99.CW<M<-?0$B!)[YL^6(4L*D4;#!V
M3F&G@R#QGXBX8TL9QR*JI ./102<ZEA*WL7%'V; R7/=>;;Z9RB-SJ5SM'R;
M%CR#O^Q:(YBKPML\?C><.C(0!11^N-<%85NR9 @LFU)0L6HJ8JPY'#?6?*E0
MHR]& D?)3%3LY(<H]^_TQ@AA)C>\*&<2O2J 4'U\G:*RFI^03NK9 *6ZC3\M
M6:%%G*F/2,*"H)EW441AZA]+>H:KP_![IPO#YI;[$N3\J')F-K4*OB4$3^QT
M9[7]<7X?<@0@2@1^HFSZE&EI.B&4?O4R771[6#=3#2V$>@?6,H68L<Y?U;8,
M8U!6H'<@ =996)?I'NXR#6='\Z*#&7IDKQ=JESW7EKN+A"8Z!2$:UIUD5OI5
M4,/J-+#P.!>%^N:OUG:_GM;0:+FII5/D\$][9CJ,';;TP56RDQR"8X?Y!K!!
M=?"[6VR0<%-*:%W]<;6 WSK_H6"0>0-$"7[@<"5-PME7S-R3IO9--+1C;FY.
MX6PQYJ7PD+R6I[AU#WH#6RB_^UO+9.AF\\7^Z_!&]#,,1OW/TJ>L:FZ(Q8[5
M[[=54/?W=RZF30,":XU?H"WB->]<4AE^;Q3J,PY)P^4G$PO/!:)$\9"!V-J_
MU=:_2^6+Q@L-QH ,QV.#1;&F#(2/\<\R&=: BNODH=D0X"FABRF'B\FJ<V8!
M29T7FZ9LU\-FMUZJ%IX<[[%MP]8C[J10=WKU739^UD[PRV[[Z^.]J=6RA]8#
M2_L,@3,&+_-&X]$&OI9LSHS(-EKZF<92AH5E0J> N; E#=*NEHYE\2)Z?)?>
M_4]SY_[/]/__?Z]ZE4Y>0LB$2G+(*&>2?4MX(1;2G/<JR6&.,2:S54)1>>>P
M%;%*:\X+&^4TS.%50DY;1FR3G/,<6<^8^:S77_']8;\^]WP^[K?'[7:[7AZ7
MR_/Y8W1YFK7T?4VNU/%5,Z<S5NUML]=1KQ/3FRCQ[NH-!U&"(.#V%)+3+2RK
M$\QDX.3F?-+* 85+8!(/N0MC 3KS#S0\2BV;XY R]15X*UZ8 J9C&9@ +_IY
MX1TMZ;T,Y7%$S#YEQ)L>;HR-[</N:Y:IAPKN&96IW(VQL+B8B[I^ .5)AJO=
M+;U7GO9LY9V'6Y'R6(E57T'.@YP[+K&X:F[6_:933)P.4!?,UT[S\\^/?E;S
M2+/TB5O'/YA8M=O,P)AGIH4\HP=FJ%1R9UR,1]ZA;]YQ"\EV5P.=%'5'*#ZN
MQI<V>O?R*2(E^8A ^W3_S:>2ZI[I\E>$:Q?TZO>>3I\4?\Y<5()\F#'G,%A]
M _)-5?/8_TK3@D(]SV;XY5:2[B$5\-Q*,QMS03.%.3G:([S*PFEP,-2.^!;I
MD;5EA4F[RC"Q7/W(=S[ (E>,967<](N>)W(.Q;/-!=#"E^2/V<_I]",193*R
M7&F1HCW;:]# E#I6SZLJ+O:=CU<(XV!ATB+9??7KX8A39S:?&7<#WZ33G,LO
M8>0O$73E"FZ^5[VMP_[]VFD2J,LJGX*KS.-V;M;CU#"!;1!B1M-9/'=+ZJ\
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MF'A<]AG3@=4#KLX)<=+UG]"9_DBF?*AFZ[9!WUZ'#D1^0/E?SX6&Z'T^6-:
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M,$JF<>T3H^[AMS&X% CU85-$*:@@' <3>,AM83BH0%).4YI,DP%B6\+/%E6
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MKBQKQQC^\H$>@-I6\QF3_G<C:B?P);7HJ?:MZW751#O?I&IKH3!^Q6^SU&9
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M3WIIDT\]R)E';MN20L&VBPR 2SB53XN1(LM*D3GPNC$1=C_BG^PS"3XNM@C
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MJKNA'ESPQ-M["C+I77S1DM%"Q?W^4UL;T?_Z F'L?E-[R7E0?OS7>8(.(@I
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M23:DH*=:K5H@O,L(A0++=57 /3S9/CTV%V&GX1AZ_LLI_>1(&WTK5F5C)3R
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MIUYK 5XW=9< ETHA JR*OLS 2-MHQCC7YW2/YMTY63<HK&HP^@.9[4,0XB@
M.-8TW5.^RTAO(YMC4@M/Z_, <FN] -B-<<SP1M/Z59-3<)C#<YX:N_0-;XZ7
M0DS3^/CC:?6_HS<]+60BV@?7H2SHA]5W06@1A(__@ITX/(H\=U2I#(1). :.
M<K0[ZP;'VS</-\46C/V>E?Q%MA_%ZQ6U1GS<6%,JG-5\H]'OX;N"7I=AZ?>8
M2#5U1'7OM-MU(R4 98\A]8A^&#_";B@4;T*79!^?@1[?ZYTZVX)QGYV'K Q-
MS+E98*;ZI-4+Q&X&$JY?)F8<]0_A=\CU_#%\AS)>(!GU/%X9_C10#_G,YRQ)
M8(5&ND88][$W96WT[@9DA.C%6HQ>)'F45F<:1JR^^CEEJ#Y44Q4Z_3C^#BG+
MS#O?RUK.BZZ\A;*3\'[SIMA*!^?P'A]E%9Q IG_G5WN[[)(9U)L7[-QV0$!=
M-]Z4ZYN,UP?C<_S'-A$Z%:CJ/-]Z$:I)M5.R;-;92E''9,V$/@O13(RC#B8]
M2TO $72S69X[O:OWS6.#I1W) QJR<10@(8^U],1:PT2FX2A+5L5LYF(2HTC-
M0^L<=)CGMXSVC@=Q:+WIFL36QT&.E>S/@TM:WY6D5)1?G:]^NK&=#R@'O(,?
M<ED7,,Z^5BIE]=T>(PQ*0B8G5O67+$9^^[N.A\I#98Q^7@^U$975J8;\T$)&
M519DPA::=?XRR9M27EMB9F=VRID$9:,*:N<$68@C'D4&''))0 _D24?F(GVM
M@A9"DK@!BXJ%L9@N[2--^U(.XD:+:-GBL"B-;T\@TSI>?^<VLWW^AOL<\"R'
MTPT[ Z7ZXP+,V*?;V)+]C!H3 8X]0TN$8P7-Y@.ENPA/0V-<\/235$T$Z%0%
M<3-ZR7FX*8"JE2,5T>J<+](N2>M_<@<L*U2=V6,A;-R>KUI\9D^R9*I9_L1+
MQN6-*2.G4JO<GOOUOX.'<XO=[+O-V]\L*5IA-+UZ.%&O[U?6_5%R=]3$E#"?
MK+1E'+0<V57_/WU"]^KONADPPO3"#%(6GLP4"5J(2]AWW[_B7GQ'ON)FGGYJ
MV48A?AW#0M^EDD#+\V<1070Y83.V?F\A"$7<MT&X5]04^J3H3G?<[%TBMZC1
M/ZW!]&*[CO-=D[%B]'([AB_.F.G5U+F^I>PY<4ZU'HF221Q)8=D5RMJPI>IE
MBURO+:J=J6C.>^OYR0^W H%.+S_12E/7]1B+M7'8(',[/N_^KIC,7LA1$4&\
MC]L3XY@5T O6G!<\[(0!\?7Y1E :QX0!$ID?V.\4Z$S[:^A>X0>/0!L8AD E
M[EQM_'2EX.Z9"ZW']=0K,. X.AY0EDOC7#GR'-*R)JRM[V@429CC CBR>MT+
M/-,65_H8)?@H[$SP_#DKBFK'>.JI:<AT5_E^U;7)BWL/LD-'B%S5B72JY$K^
M5<*/\3XR_TR9@UN54US+V.I7:]"9KOO*_'H&(W<7,XW][]RI+'W^4G5<W(!]
MP:F[7_"%KZJZK;@\+MV^PB%3_:R\:'*WG4[7,$:]EV"5?7R%6376\YEPVZFZ
M8.2#8\5ZN&KDT6R5F?"3M!'Z0)=_V#N.(=N_(&T-5Z.KX0*MY@NY>2:^B^%E
MLN=HVFK1V=@@U(>\)WGWPMGQ7^7-+>DAD:<H#7]$D 2Q@D,N@3OSC4ES21J%
MWG!>9L\N=]IBD3^IC2&C&FN(,*47&7A?;B!EE@<;Q7T;-;N ;.K7P/Y][V$M
M<\&$;"*$D 5.L9CT8LH2BN C?J1THLH!XQ67([9&D7<K,:7+U;X!L?*6H>WE
M3_4%8"(T7M\@INOK^T*^YSF^C(V);$8MMA;!"]33\6) @#6PP6+V[M+2B?X,
M&5@?6AQAMM 1(_"4P; )-V6A$R)7<3 SUE,TPZQUS[SB-*IB.<C?^#)%;OOY
M+4T/28-'+Q8GIG1Z.M<^]HLF=M&JU3X[!]_M(7._<@Y+DO(-HE58$>"]&57F
MHEA[IY7^0HN*5XO&06>E/K+ACTBB.LO(AP]?CX- 9J.5=1%L.._K9NND)$CK
M]&+>X];"B4?258SEH6)/37EAH]]_E=[:ULI&-[MDLCH9W&0T:HX/)@ ,0F@D
M%7@4O3.[:;F2AJM%R.NGKGMOV!4*N(S:M++V>W&P$ DBD<6AS4\]GK2!1BH2
MKXZJ4Y775O<> CZ,<3P#=@I@P$" &D.L@*W/,'E&-/D78E?CZ0Y'VP(1$7_T
M9""C+IVCN(C?I+11A^?;F[=CNZ(%RBS"I;4]VC\;6_2@ZPIZL$1H=?"<#+OE
M679RI,\4\N]]S#<"K90MO/H?Z(L@L7:?%(1ZP5T/+TCS2P@U]#=T<9]U\U'M
M>IF31]KW)BU N85R&_P78-%3V))Y(-M7^L-'/-X(8=:9;@Y6E.R9BNH-D3,?
M3DI*'ZPT"R[8/1GC\377=L[L2[:T>SI(/M*>S-K\8%Y\YQ:8H'XJIJ%VR8":
M?/U>G5N52!Q:N7$;Z0TGGBK,+>:C1E*7;<&RRMIL6>D;TF;\#34-'Y=$ JV/
MOW/(%XLVK@<X G=NXK>24G?)_?1_!N*J7LI;"^I;N<FZ42NTWB_L5X&/SP7)
M_D6K <LOMV<5T3.A=D.1II7+[0>ET9K8JO[PD J/P';GK+RP*N#?X*BK!6'+
M.[*2350-S;GQ]9#%W#7Q"D,-DVT"$!W-%J:T2Q^HL++0"S >CL+(@8KWZFY&
MB<((814J8&H?Z]K>,:J7R6?;Z'7NYI"ZN%A+XXH-]MKRJ)NIL;_=%Q_^(P54
M?)5T O#" _I.Z5T'6FR;+5PV:AWA6P-4,SHHZX=<*(1);-5JR;GW31ZS3W=!
M27,*K+D.I, X.I:U.')>P]/'R^/8]A]U-:E>),O.)!4IJ)<MT<_42INZBH4R
M.O\!GP-LISAEGFB*#KR@*UYUF!. @2<<"6+SEOJQICV<]6W4G3%?_=._%C]\
M@G?5?LM1S4N@OV*H.;IG1OLRP;<9P8Z9L]Q)&*V:D5);S<C@WG:<8C+6V/B-
MJN\/=VJ6TN,?)>$,OZ[O6Q7D5V<8*]VBU0N/":MZ=L+2H1>U/S#J7Q4V88=*
MU>6[>MV(U]7]]5WRC=JQ_-<]^8/W\6%[G@>#^3&G$QBQ^)1MEW;E5(07Z)_?
M_469H![6P"$73\:/' ]XN,/H@V%'QZ%(Z,=OEAHA1Y45?Y^9A[OU>0%MQIKO
MU4*!-8&X2+8C.5ZMGDH\$8 )GL(-IERTKH:'X"*T"$@H;I:PWY&WE=G[9MQ5
M<!8R?T.@QZ',0CTP##V8Z;C-#Q1$GRZJO<$$'6O)A)D$H4_%#Y6H$MI@0MF\
M%+GGNJLAVF2RMQPE<3>!5"K0612+]9F^\?USEX.$_3$3\_@CX]MX%<?*7E!.
M _-RK,<0AHQ8'Q$H&-PZ]I!%7GD!F0DD&;\GM;YO>$%0\[!^%7HOP;YPPE*R
M@=7([?+0GI+9_>#WKY6M.OCD6-_-BO.CY,^/7_KS^-;]JBWXJ1)K82WNT''>
MU3%1=92L^CG#&=ZZVR8;UCOQ9@^4./!+'2RNC/V'XHQ]Y5CA\H:9CLGL,>7Y
M4I'=LW?^?IUN'5#URL*JPO-H1*A+:6]8F\YJ'-']?TF7$>$LVVPVLGN>CZ,'
M9?53:"D'H!&"B>"<*7/=CHR>MJF4$_&QV-;YUXVL4:Z]\I_ES,<[F<?+']KI
MC7>$+FWG <K^#"U!P)S9-_68+9?D2WTXOG:A?CS48<Z+][.&M??HVL9ZT^3O
M=:C[T.\_#")5][KDXHYK?0N\_'U]T@-3;\<]0P0?T,\2[O(6!71 F1S16L05
MEOJO20#6L^Y;K=4CSNI><9SW")3,SU-W@$/7[2F/([;'[W6H-W\PACSY4K6U
M #OD.LEAR^#3"==F3?HDY0%'6R"7G<[82&"0#B8E.0?JP/M_,Y66S-AWALF*
M9?!PT];HVO6?C\I+MK>5TJ8\;M^YZ3(O:"&/S>SK+8;?/>+$C.H\JYQJ52I3
MPF$W3]VOICPOR'$QSRW6R%G9F=IAY91W2M-8[%KVY3;-&T:O_3W)QCVT_L P
MIRMX/CN>?W"JVODA'I>RA)R\[HB$:?3QN8_U.&*2DV6OE/H(>H@ZR-WLVXN-
M_]1 \3-&GM?M0SD,XXS-@K0!6&^))TF.1"2.WJ,A!@&+IZ9O^[!NLT$TR,LO
M^9"XWW9![P8#'CN#?*L.:#Z-XYF,6>L/A9B>]&L@D2!]61D"53TT0DNXHOG5
MG+H$Z\MN5N-^2L2U:P*1:61,</A\'V8@7,&E/WP[=2'EP-.$(]3/S"@4;4X!
M7^ HV#4>?%7>1NH?-SF/&$9+K)"T9!5X]G/.O"RV7A.X[_;.22?U$^S21-%V
M*)# #MC.W"\[$/["/JHCC203/V"DGX((B*5OG#<M6WF!T/_UDV@!(J^'>BG1
M+,<(EVH76AH%YSTIW\E/:4%+>AG;6\LUZ&15VLO'?_)BFM[M/\0]K1I=3!;*
M#TCH'NTYY&JKGCX!J=6,8/+8].?PZE(-L8@Q@[Z>79&@FK[DAC4E>5'U%M!S
MAR[&V!6)$GGE+U=>$4_>W_STA/"*7C<!T?ON(E)J,?W5Q^UEF1&RFG;(U83N
MLM'O0[-JM!!QF!O,RMC6B\,"60V,V/5K-EX/=RP)5$>;7#,B#?<[*MLQA'=\
M.\2]IEC96BDK\-.'(UFT'KUG!)3=HG(LWG(<AWXVV7#?;J-%0O\\(O2?KXE8
MO?X _O1IGIZ YF>_*%FBJY67ML&\0SZ;F2SE;M,C\<>BM[,>U L21T2SHBB9
MI@P::@L'HM-Z/B(<%] @J%C[F$X06,#N5#^]DM5^7FQQ9&[ENMW#FIWF'WV.
M^0P&=$GH!E02AU\#,7"FV]=HG0\WSL&73$<YSF%LWB7&V1>,;/[BIS*7YC!9
M_[*_%E6N-%P,,EIS"0D'36AB1I:2?XG^VEBKL$ZQ%_^2S/>7VR,-J[9,,^_R
MAH^,,E"\ ?P^]--#4:I^H@-VRUCW'14>:-,)Y1T+HM54.6)!%=4E\!3VGSQU
M+7Y?_R2R/<.H+:(>-$'L)?DD=?=?[+(6Y!_!J1L-U%=+H.#+PX_=HGWK=;I\
M%7F;@O>%V5';[0!T 994$*_/:DGC&-9"=U')'$<<('=C;(&MH.S3QLHL'EAL
M#*AV#YIRVIU/OEB_IY /R?S9Z8>!+.OGF(EA%;'JA-7YX_$*7@@OP(0UR/#?
MSH.]G8/O=+7KIX5&5%M^:VL>_4[5D&^/-=!4O%U18L"?)&:1Z?YAYG,;!2''
M $V<\$QJ"H'1QQOI6GQ \B$7'4GQ28XW&-D:B&+H9S1YY -ECQ3&$!YEJP=:
M8T1K1K&%1[J+7.AKO;:<:ZUOR"0)P0"3L/A!D[-ZZ$3DJ?CS"%VVP'8>=A5\
M@A5?0/>8-37;<]WVWPRZR^?V<]WL]]6=P!;!GIQ/TO7^"@_M.VZV]4M8*%44
M..\61],HQO[BXI#/."/52IA5C5!EL4K7:$7>>.3+18P1IXEIG8/3&?K(?N.7
M-HA%ABP$+3SY_M*5^#@MO&N<TOIX-D9TUO/.D?L*<!4L\2U+S./53%*7CUQ*
M??/.Q3MVSRU^&%*PMDSW.;Y2J/5\D4UJ9!YRI98( 6$5R^2[#:,+R:L]A8DN
MZQH].RTNV/P68<JC.]6\WKI:3Y>#&^J^K7>&@E#9;$.PE!<<Z=,HR#$E &;O
M .Q/W=2(Z]<8&;N2JPW #48R>XOOM3H=5C]0!9FVK"SZ?97]=>;*%C(;?<:8
MFXTW9=&2B;":U5W^ W$V"G5P 0AW9E$HQ<V$RE62>(?U>[Y66TP9/-TF?^:K
M3<>,/@11K>!P.6GAE871'ZOX3_,GRH#"3F&:*_M!;K:$!\>NJ&O3>V* ?FTP
M)7_W)A"'B(P4.9 IH BM.@2] P^#. I\90.1Q2YQFM:+L<SS$M^0SA@[.:OJ
M'A7F=]67Q;9!YA&_*IXGC?VY^&]IX1/-6_D7X5'N_6<7\U]3SAH>3. ]%"F^
MG0U+TEDB=4 */<32,9HYL!+[V^OARCCV/^T#5-@>N$3;0)3_28+QZ'82\)H-
M)<LUH];J6:/=\^((&SH>92*NNR$V!V_I=I&5 X)B0\*5$]\VEHRY025W_HD<
M%'6KK(7=D6RHQ%WX5982)!0XRA/*7<6![9>^!?S9S 6+Y[6$ 9@5:SY#=R-E
M-XO4_C2/;F-G2@4E1?!Y67EH"?K,S^#3B(;@5&BX6&-PQ'GIX..1S9T]%X([
M*?.3C=TF8D<ZAYOIW-<[GQ[/PT9U[U^S'R4*@Y[Y ?=WKZ;NUU6+-49L@_4
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MSOBJGSX.S-FCX$BM(!P@@4Y$/Y8A11\MQG3G'/D[SGR]7%0O&R?Y^%E'_C-
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M]-;W]E=C$\ WZ=S+<$<J'D%(CQ-0F*2YK89VDN42_ZH_\@:]H(^0UK^F]UE
M\B82]JZ6B@2D1II/J\S8-(7,L1G;BYBY:Y_&:-V N6CQ]?T'=Z".H!UIDJ3T
M ?E+5,MEOA6 BTR$^4!DE!X>'*5]:!ZOGO6W=;;>]\*?RA_9[G%[;@_J?"Z=
M:(LZ?W_ F99UY[2T.B7-94_2KH"+*UQ5*Y[7_MT7FV<[HXJ5_V+DC!"[O]/$
M@KUV"?$!4E-DQ;*&MG&KXZZ7\RHOB-8!#Z/4\6,0LIYY\MC6:J&ZO:$,)S M
M)R"NE+<9?2>$Y^F]Y+*JF>$A_5C0*GKE&E"' .*B#@\(L)-1KX)7F&CW)K44
MRR)^3N[7-J-N^/[]RZN'\GV:9U8<4>\3N/TU^1XT]&O"[Y)">URNH"&-D7I$
M2%^P^T@7FNT2#$(0%D\%[::[1#'ZOF&$;B\+TG(S?X$2+LC]P\*#))IX58?3
MBN.*PT2K)=[U\8GF'F8X,\1'R_8K:+4 U;B<6^;K>+."S$1<20&":FG"=53A
MD%)JR1F@+P#'$J^<JML<=9/R91,'O@F7_X C,G-;OG%U\!$C$R"L=D\:>_ZQ
M[1D@,<1U@4B_^UBITD;DS:20AP1\OGGZ$.\X*@X_$&^P9_EEXDF&+%]?!W>L
MV+1,22KOPTW2C[<NIM?;9PG3ZSE[*S*3I#5T,GTT%>&K3CZN*M@9XO@0U,QW
M8O_9JG)W#50C:29I5,X+B\B)%TK>(7A3W^XU- _:W%? 37VT=LBM1\<4OO!\
MNF5A&9##UJSF]E.O"?_1+%7RMT5I:D4Z^OKTQV?</S9W,T]LHZ>7-:FY!(SZ
MP;" +!5/^!DM3GM!0@SL:5A1PU9=A$U(J%@X:Z@?G ^S%2U&2G@5+3@HGG0H
MZ1YIG,\TNG/BU.JW4P$9;4)]Z-(] UP1(74GQ)P!O$VMS*D>Q&0$#_PZ:3F.
M*#UQP^<8E?#CM74=^7')A&&7B[G>],$NT<EIBXW?\>,7>;\"0\;7(B]P"]$,
MT>,K+/0K-! UCK3XB%I*5AK4XJ.^K8:5#JB_)T?-Q<DVFTK;DY%C=)'I8'Z[
M/JV+)/[QK([4P4]MCSL>O)D?YP#/6\SWB[5"[Y+F:.S#E##21 (MDO .[DXV
MML-'B\*529O]*%9CS(Z68-[NEA97>V0ADT-CWER?(^(M45H&Q^2B.%[^'>?3
MN ()X\[PX9XZOET 97Y6'Y3]XMS,D)H"CX.UT FP<.+Z'KW^W70E[\M^_&OK
MZ3KK-<NL"A4U4YOT1LK;HRZL$%E':N3^]/WP<F'V]^[;FX=D_)?&:YY//K?7
M&5]YX_9S9G!FC&RS=>IF.>[[)5[2,I;@FE67$6=OF5O]$]7<M'" [-(@S4X0
M[%(.P0+CJU@&&(ZH61$OUZ7RP0DNBX<':([7IH97F@94-CDV/)LU-?)N0D\S
MEQ>YY6R(>2D(7CM-.P.\6 H;TKH[&7V+YM!%9D$"H6M@7GA("PF<YA^\<@W2
M$;+\EM0XH/JUYU5D!=7+E/0GP'4>HA[7B/N <#\*2VD8EAW(937P_<DL2/&C
M^A$F$H_#!D$L<#WJ^V)J-_!2&4V%;'(<C2UC B4YBL6,RR4'K#%I]%YWE9Q5
M;A=]WMQ+RJ<&BQASY3U3#Q0KZ DAS5$$J,:D42++OSTB$$%NK?L^QQ.XU""B
M5F_)%OUN.Q4A]E9S>)!G;Q_H[ENI74:3_WK(ERS=_L(]4KFUMZ6]D=%R856:
M$]A41=J4DRHT".SOX6.5,+0:,,( G2&>Y@R\2KE-%%A(<CB\$'W=NL_HR4!5
M&])6LT"/?0 !S;8KM9C%Q(V1E,FW8 67[]LT.*PI7LF;8-=C8MK[S?C>.2A-
M7\J&B^]!3,X% DDM43(ZP<)YDR;J*$X[ XB?4CO. &O*B'Z;$L3$+\1*,I:N
M!%:/+O___Q&EM[U/B_J;K'EG]/";3PUQ-S'L!N@WZI^$W=JUI0SN_OO2^V(R
MXM,H]^F_HF> J9\[Q;7!9X!/HX*G_WJ>SZD[Z^<+0L <,'^6A8HG9%0\4.T-
M_-),4R?TQCS,UW9&#DV6S>DM'?Q A?O:'3?'HSC+JZ-4UE.X6RBV5^?,<HS?
M^=4VOR.DT1T"6U53?TUEVWE4I_A8H+VQS0^ML:9Z3,O9BT:3H>I]D/!IZ[4P
MCW$),\A(MS!'9>?X265;^8%(5*$N_ )H3YLL;D2VIRK5>$=?S5S3:J^&L8%N
M;.=P'?^""6BR#*MKU=>85OHLB"PL#;4'11*X2#T8M,OBP@Y7=2UGPXQ;YB.G
MEBF[GP<Q(*Y\(A0WBN7TG<WA%< 2"L,&EUG)P;89GQ9,6QI7H\XWK3N+5=[R
M%_#-FO)W,O/3FW;NRM3VD^I3QH]<,ILME914KB7N/<<'!E L/I1"DRPJ7;-Y
M&^Q2?,:MS"PM+;[8N G8B7\N*SF0#\NV3C7*<C["C.Y]F,0XLH;FH<VL"IX6
M0/>5[0C^K\[KY0#U015]BAM\XY#ERC:O?M^\B@VI)9OL&KG^ +58OSSB)]==
M_3-0_W*H*TM[YO-;AOP#"^@R5JUJH%5^=928_ *4&;;8KR7?W-)+ZD4VL;#.
M+__3RI7+*U?M\4$WX-*-FOK3'&+@)_V'VQISZ/?/VWLL=EW=7U7'IPEE^5IF
MY65Y\$BW?7ZRD2*%,XM0"JAFJO6N+OT!<QH08%X#8VMO3]0YU#1\]S"YJ<B!
M5K>1G"U?V(Q3)Z/5J3XY_O%RL3YNU66GV0[*4SL2)<C?+ V,$B7__E^-3:#X
M&4!H_SQGGXY"3R_;Z3NOQ(%^N$Z"=OFAAV< NY7E?_EKS@#G;!][!MC5?$ O
M=;U;BVQ?\J*#:.=WNFWU'O*2K\#T4X A:X4,E#=4G56J2K<TG7,NE<9"YK.:
M#A;]FGOB[*O%EORH:.&T2UMV;R32@=N!%1V7G9TO_'A"<_#@_1WK]EQ-M1?;
M4N,/&JSO']8K]1PX!HN5>I#5*IXO&B[I?IYK+,?,=&1#)E,[(%))G<W[%;Z?
M)Q$FD^#<:*%3[+FCY=-+7[M:K1G?OMK+;4X>-B2= 5YQ&[2V9.)R04S!X%O;
M/7>FN>U:D9JN1S1M\3@LYO!GLR$ZAC7$9\'9UE5W4;"TYRK\,?45*!VN39H@
MRB=B@.Z5P__S+?(,P+9[.*HI@'M\PD(3Z8GJJ20TM^*+6UORS?'R&,H6]P,F
MN7)*BAXZ/!QTK*/F&O40W!BGS^.-KV0\S-:4*S3XBIO!BG1_ZY-H/S'4N^FE
M<C6STRS$G9O?RMKW"<ZL0J^RQDR(@STTJV)<8G JI4H>\P$[=+!X0F?$$>3G
MV8F@>"U.F!V.FZY!=D5]V.)=&6AJG)8)/G'APX4I-*V0TG55EK.KKS>?VD[!
M0B[_<F\^8>ZR/=E/6"SE_&O>!UY4HH12]P@()EAF'XH#+LY!%Y_R:WY,ZJG'
M;#EZ(8,AY99>4R$8,=\)Q3F+ND*1IC:#9=]P'N".1G*GX=Y^_@SFK9<:O/=Z
MGLWHC@R7BI&UU&"D\9!ZI74*>Z'$='JOD8TPI^7US[(8\^2/L-0^!Q2;%U#\
M-?'&C=^[\<&5&VJ\V9P\>FAC2:MB2ZRLC(T1)V\I,EX@1#2^9D;J,_O7XQ(D
M&A+I&W6MZ,O^ F6IL272*7$SB7PZ[Q;.+=QS)WUZ9N&75<22XW)/MZ76O*&A
M.%<>1!EOJGQHZ[.U]>T\]]W_[[)>^>#H)NPUO1T"/C;7# [Y EGY=8?,<!HX
MU?NG* )@=080ED%0+N2? 8S7L._ %)_9PVX=2D["D(#B9 @+,_VK(@0+\2B&
M/3LQG 7>/9;+O)I>XLQO=C(0,5.$"?#E1&/^["OO<.1:VN7=WL,XO+#;6OL_
MEZQ%H@>UH =6A>*]?0^M\EMZ=K,J'UD4^*FIP Q=OL^2?4:& CX49OXM#FY=
M4A%#<\-&]W3GG0B5H.<3;*[;#?#',UJBD%84[^XAE 'LK26=T)^Y2/4RPG>Q
MH+<=]0I+G&%^7;HJIWL]6&BM3UC$[AE@\<VH:C'L>3V7:KVV)^HQG)?JY$?*
M[Y,DV,WP@7M[9X$Z1"CKCI(CIL'7]2[9#!..V<D=>2Y:I*$!P4+7G2+!JN9B
M,\)(0[&GOUIK9Y@6#0YV#V0\(99,BPXUZS /;[3]OC#,I23[FH+1A_72D*.W
M_P9\NBW^<$AIO3&K>]])HD)^:4DL\P>EL<(H)-RF:CJFVL(,V[.AO-5NM=&1
MXFQSF&^1#GQVY)RK@3;#V%M8YNYO?;'^CW!=&:$4YLI]FK(+\D/Q;B_?I[J[
M(TC^8 Y?*E)LVC\X7Y[360?J%49,4HY4V@1[!V[;LC=%F'8DULQNGIC-SCHE
MNUV)SEI ]#U N/<FJD? AE>_M!,G$G:J6(.\B(+GN,QVV"TU<BDG-%6FN+N]
MGKE7X/F#)\KU3='6B5</M<*(T&\)JZJ%)RXT5JJ'7P4UD6HW# :<]^259(&[
M\0C6E7%$$'$B[GR97@\L,]7QO-:SR*B^V3H#","?YU)\WT'+,CZ'3[RO6-S<
MT@RCR&;V/<"LL<PG#Q\/]R.X)7[+*SLM)C6;7Z36/G85FE.NN"GKD7_Q7I@7
M^Y'4V+*VI6VO.,'D9(L!9SDN39:%R[-[-#?>,5./9Y*:4  M4.^HRC553S"\
MJGAGV;_>]EV.I_?[:H!2L4VEM34YJ.G^U"E#,DW]6"K !HAE[O^NJ1^G9!0>
MS<V$'-XH4,@=EAI3:#/1! (5OFT?65=OS$<_X"CUF4]C4ZG4[<^OC*TX&7OT
MF_,T">&#2*C"D* 4"A4ILY>HNB X!&+Z25?'MUQ48')U^/ZS<>AB5?I#C+_#
MFQ>PY,[Q<^WTZYRW5U-JP*\5FM9I <*[\_)3X,%U:M[!1[I(CEK?Z#N@H6 L
M[2%$>94V6;H\5 M(C3G &I'F]I(K8>P.#23Y/8=5XXE8U[MMF;L=7FE^MB[F
M!%12X?V8?>9G,UY^XGN6JZ\"G\<OE;%4]J2]?GJ2:S(3O.<YM&@UI<(GZV36
M'2?>U(OW=^MJ[(S79>:8G;.=,KXQ:5"F.,*7_?QNS)+O(3!]P*0QR<W&@CXZ
M%F#O(.')$^J6K2_S)7 ;([^T<5O]R6BC"?#'_IIZY:,&,VL?ZXH#T*??*U<"
MG,6EM'""@W#-N$%Q8*?"" S%6?C\89S:UI[B=CO:^41HX!'C7,6C7$V^7W9H
M,\A'VA"(9(%(U+HR@.#O=8,N.!%V63,Y%GI?!X_+$^T2IAY_R@/O&9C'8QZK
M,=^WEY,7^57GKH0=6TY:[:5*,>S:K8G'SR)25(LN39=)82MHIJ2#1-K5KP:X
M_='*G6./^/A!)ZF-%<OW3RI'I1HTHF/MWL,F5@_ZL8F&ZK!% O85S7$.4(/?
MH?.>QZ6TJ*:UE2O#95#\). 3ECX'C&*8#61LL?F58L9FOK=^E%*HTGP&"$@O
M3<[*;C;>N1]VXN2TZ6I.Y&)8_AA0Y)#?!]F%I<=7]G>5HC%IA%U_"S.VT%ES
MZ2I,5=S?1@(+\@S #(STS$N(H=^C2@_.6NZQ+L'"!B+,JB_MKX<:>H2_Q+1K
M2\=HUYX! O>6WC;R_?5:7TS9U%1(SU<[03UP]?T]-X@B&6._+0[,(18<P3@'
M+?[MCZKC5H36Q.9>1M>RBBN>=LV=]USN2']($?((9PCR&NRY>]Z>U:,5J="/
M=.7&4Q3B!2HMPH]>^9]/3HXK.WDS48@L\#;ZUX*!,/Z_N8-_9OZ\AYHMJO2<
M& _[U]X)%X?WX?M^J&SK*0=5?;.S?&([ID@IOB*6Z=_#V'-/A:_EQY95VMSZ
MS/O9";CVJ(1M9=IJRM67'Z8J5>3XB&I&W5Z,_A#]2X5/%4?TK"#Z\SCNQ,JP
M_:JT$7HE%3%8Q$NVW#8E]+)Z%]WCU4('E&ZGEVS;1B3B58SM%)8@<T.SD,'F
MO<9X0\SFHM1]7*UMAR/=!K2:U]L HG'H$RJ2>\2IK1]+\*NGW5D+Z;$J^?(I
M0Y0HIF%7X=8>>WG7%;V&9/O.7K\KA,AFLE%_3N!GG!G^D DOUY)P.+9T'A3K
MIF>#3?+SXD.L[]W3%*[VKLDJOGR;(!\@$^BM>O]NFQ3GFB':>P0L+[TQ[G*$
M92;4J2VT.0M$9JU)XJT7"DT>O\2;O7R=];PW7(_<C4\-=]7X-:*&+5J=X/AM
M<I)0%]X23CBX_>-=C0E9DO#3([N15^M+*@1?85N 21AV+$DM\'TJJ16\], R
MJ]B"7F !?N>UID_C&#4)."T^$:3QDWEE,I10UVD.38WR;('U W#]J@6_/#A7
MTI+)4\[?LP(^HJ>87G]39B98+OWZ*'%T(TT\1YM@GKS"HG+C@UK*XSR/B417
M0P;R/_EHS4=5OUT1%"Z%,\#-'BN;[M(;!Y*6T6\KDV-1F([:S6G$P.,1-_KO
MG(!X-NGPV55_^6RUO6X3+6-7/M#&SQ/!#\IVZ^<V+N85S0]_"?$_5>ORS]-J
MF051;0G2?DJ/O(522B(Q2EQ?.^#6G2;RQ0\KTE7X"1HG2_^"^Y&K[&D6Z,4*
MTR?_*W7<B"MR/+8>9P#7C--J>WR9WNOJDD&1N,#0J_V9IZY?4'VO4\''Y)2/
M1 U-S7@A])^PJ6/?AF=G@,3"/@6Z*M3I>@,"//+[>\_X'X3KZ'U:[7'D;%A#
M1.,A(Y+6V7K^?.WT$;?_3$/EDXMN0<K>6L/R">!$S.<RG[A]GN"FF;\?>6*?
M#VX88?^N/9:^1\8NN-.9=$\>PC6HD;Z1)+LG,SW"L!.'7J[0/& /+YDAWHUT
MVMPU:1Q6N<,.P^HT-'<B?5\,>OF5\VWQ0F8V?:&-GTN-[L@/P%)T98"*+P*S
M(;_T@DK5)M/#K6O6=HNOS;<;61F*HA<-UH>IW80BIUSB;QESWN=:PU=T9ZOU
M<K3BG%_,=92:Q3,J'2]%S-PIO6U9H6?IM[2@D%5Z8J4;'0V_>KZCK.C/@GQ:
M@M2P(6X$-Y"5A+.='OVVO<Q*S2>FLO1'#&5C%B]SJXKY/=LQ:YAV+U!KP]<V
M'15)?Q#1:>&KCJR6H#>1-H<0L44R$D %LCEA)<FX08J984A <.9!4]KD4"6%
M7V\S()QU\I\1+SV;$2O4 _9<3S7U;$EBG5H>._KAH^BI; .T1(]#Y)<[J>*-
M*7D9L[+E^<?P:B35"XASJW^O%YGM_O/93SSVD3T\E"NP4+TN975)WG>O6)Q'
MSB>H@O=-].X:3P7GUA];N&-VZA P><>P$?^Y/6GTI?EH_;>7#[=A?8<8QA]S
M5:TKQV61DUD>-8[1J:!/Y[S*^/_)HQNT_W5A"<,T'.8,('BNX;<NHD'1;.?7
M,-TS0)U?*_W?)L#>_]MTA><B>VZV)O7(PM6I-4 _+"1,\&83!J'?2.I&Y[Q2
M3:]VA+WW$Y[M;?*75QY-=1%I2S>M-UC^_(OKU5.H,*0H%&$VB_AQCV!N@34_
M WQ82>0X ZC_A#BMQ-)G'CQ@Z"[8^I)56[@F*A4B?EW/<'#(5%FLO50"% ^1
M#([>+55KFD%S5=P>,9(U5"G5,C.?9R'0.EKJ5>NK=H[_QD&MA@7G!:Y,"XP$
ML]Q8@ALTHLS(A1NYHMUEZK&_?7)R[13T5)@ZW_TY;&\_85Q,3@H+0US7NK*%
M8-QO-G4$<U SAY;O33<5LN,0B\L2?FHKCC OW%ME7K$$J$"VE[N_6V/J/+HC
M@[N[IS!U?/?WF/%<I\5CJQ@CN5DTH[0Q?1\%$IJKL7&L3^D196R67.JW3+9$
MYF]D=&X6FI]$EU9(-G5(?LZ6RD#^]; LD!I1?YN2^X.%QJE#>4#5)J?W%]VB
MSF&W<F_!\/TH-BT&JK0EROC=?"N2QD-F6GOP6HMO.T\,(Z,AYB"SVQ44'E7N
MPZK0V90G*,J2+8P\3A@ D\QZOZT,'&N]+?$!7^SBO^,HD.E1LI5+877>.F[&
MI*&@S,WUIGI3L(H,PK-7//MELLH-^SGZ85XJ4 KM#) 9E$\?]=JM/@-@#$FA
M/5-8LX>S08RWG56 >!ZS>)9"MTH\UC:OI,K0R$BN@+B[,&G8S%GFQ\^26?GQ
M#BM8,-\SFVHG/.#^>\0BO$6</=<M0$5A"J>MEU(=&6&5KFP%_\(H%_AW8UW#
M,-K5!=$GUW6]V)32^QHA"/)&O59Z/&1L#+U!T^Z<;?H@*M+*&X:\BKF6TBZ:
M(994_ZOT S&7SG- 9Q0FD38)FWOIJV!DJ,&1J?1:.NYO?7N&J*!,F(#0)(@@
MWNDE&IZS//1U+89OP^?T44FKLW:>H1.G'7-ZNDWZQU5R8*3K8;5%SCV_+E^Q
MPL+]-!9J_'=IW=\>UDIR@I610\Z:15X/-24T5>QEN+2*P*(>_H[O#/L7 A=U
M?NWU>LM3)5IQ@2ND.M"S@RLT1[Q?>L;QRD=44HMJH]F3&\[E"42[Z>81VOI5
MTWK(_;LOV<P;>80L/R%6*\\1I4M#.13,1[\4/;5RX2#LVGK^T K3 ?:/VUT-
M3WMY9<G]0[[BZS=V1TN&!/@;M#<ZKU4?"E1-0*],*SI]7\2%0!5O_XB!S7I[
MZ,P\1_[S<V?B7A^_.J_Y_<]5BSL.-_DU"W[1_)6N:$Y!,[I-0ODU$'("TGZR
M#7"%P7>R@>FW@B0?J0\S#X3+F19:@)="&HYY;GI)+&),H@PQ1T65M+A5^<4#
MBB8U;80E'N0-2C",%"X+@/0(3Z-)H=4B&9R,;[<$%%I(R^7[QE+93K92*])N
M;=BJ/ZA;/R-^6(R7[D388B\G"CP,'CTQ_K9T[=-S7TCYY[>?GD;8Q</^4@Q/
M\^BB>F3JQ"H4I^E6SC">2V?%@,PZLM^MYQEWBVFJ;NN+%QY(/W -B,-FA9P!
MJ**@W=]W[.90UT.P2;V7FH_8(,$G*PG16N2;[]$+*QSN4-FA-+G![A^L7RPV
M8I[!?[YZE>^KJFL>OZ-<C!Q7_"LM4DT@?=OV-:C^W")0RX;):6WA[ Q^?NH[
MT'79"9-%JF!])+4?'NV1]Y(N9CO[M6_CMO/:C7794IZ-K)G]@@S0/\J()%>F
M.;@+$7$!XGJWN9N<\!K3=()E]1YAGC(M[ZL2R;!O+W*"U>RG5+(K)WDH'T!_
M83[W3SVNZ,;^:*4\/7T-@LHR4+Z0Y8 6Q-X$Q];8$+Y.[&UX\'3/7(VWJ_B4
M_)0M/GK(7ZXT?8B9F.@69V6: U4R21XK.@/L!D%F*<.4@)[+B#Z]8+T,4W;*
M*-6#R&G75L2'X(0+W$]I%Y)V\$QPF.$AI"HD,<;?Y*$U%CRHS"-M./P[8%4:
M1S1I:*B,P\UUVR!=#^U=:N%R@IQ&K/FGZQ(SE8Q5!<0*_@I0]FHO>UMUHN*8
MIX8JJ1,9>$1H3!F63[F/_XQ2N2$:;6!FW>@\+#5HC3$UWJ;FO?/AK,M6X/ !
M:CH]M$0?^^E&/T/=1/19*Z.U] ?DY\&#@T+7*JPFN_0):P'2"J+?[;T[>M_^
MJ.R/76YPEQ&6&3<63P6M5N8)*QJ?^SA'<D9"FK!8YAJ*W<'_0I#H&&)!=>':
MM]W[MM8WRFCU'#^.4-^^@''CBCZHOR!>S=Z?8ARRI3W=*!<6+#R,UX=:Q+8&
M5SG'DI2(6M4%Q'1MCZ:&W_Z*2VT>],\&DH8#+[#0&970J]NHNO2XKG]*[!1!
ML3W*,*%%ORXC]'MVU[GB[!\%F3]>&-[V8Q*Y@(Q_3>?SI31,761A/0?7!UJ*
MA?6F 2K#\?   OC6,V6V(U_.G.R*%6/E77*L]Y6/;5*6]L516WR"W]3^TM3?
MNT"E');-Q?\"7WBLH"EX%V[:8W_!A)-9=B0)O#SX$G2[GW>1[JHO7"CM6[VY
MGFZ;/JTN_6N'+J"YYB*C!&ND7#MM^*-6'.=(W!@FH"FM'AS[Y+*7F%\+$$J&
M=,+P.U%;MK?<&<;5-W6(\C3. X+7*R G<2ET<Q6T)UY,?:TS599I-*5UEZ8J
M<&LJA-]'UP C(W=87^-SO<)1=+H^JF'#"?%0MB<R,KP"MJIRDV_"QTQYRV._
MID*M+_*.'E<35+4$*V53P8$5#5<MR>R$^+B#!UTO]'_%) V2+]\/KOM395M%
M?A_M^[H ,A5;939-MN=5$16];2@5D%Q0UB[,K5IR!G"1P&X>4 3/F6H2)DR\
MTHO\P[+P*O=CV"QW[L)&TAJSAAE9,#$84A-B:E/$<M-U_F<+[S[ZZ?$C%UW?
MBF63=#_1[-[CY_6&'(VM6^7_<RI^_11)TU]/9ED $S3SC5Y6$S6CY9D4"SKH
M9+B58,(":Y:XTA4^HY;0$1[Y^X2",X#LP QN[C,YD&(&ZBG6:X8#IS.RG*4M
M*]0T!I?*ITL.>#XT?2*@N(":Q"XL0YY'EU4F/EY1<;UOC4PUZ54H5;,.KC!K
M8>!V31-B-E7A^:5NPV:)?CA8*>AMX:I!6$D_ URB.;3265$I*TQ PVZ="@I+
M6I="%51/6Z@C*L&ZXWLJGW1,^Q7[^QH&XOC5F:;%E'#>[%C"OU)NG3$F,2\9
M]][^O6C E%;!K^2JO&57?N1C46E**1!GV"PK*2J,WIOHP*V1[-M^$P+>.9LH
M_R51D2JEM<N'DE]4H_8ADQ8QMR4M;YII7[Z%FV;]A=H\??Y!O1\IQ?!6V/G3
M%N^^S6A#E7_HM>2<N_Z>3ZN4?FL!OCMX]Q[^A6P?_.>Z4GCL;:[+\>3"_SF<
M-PK/ /<F;B'F9*7/ (:;M6GMXQITG:)S(UOK:$?/G/B'$?'#(YW^40FQ!0^9
MM%,_GYFMD.]EG@&,2^FPX5^'_LC_!4:MR]3Y&EB^SFD;PE-ZXCI,#\3GLT8Q
M.FU^QJO<L=>;D+WW@SIR D"/KU"RQW/0MU3K,Q]D3"J9IL8\=F\[>8%B[WFP
MZ)\!G>^/?&>+LRZTTZ>B")W5+=.RM7NE^";RU6*T]]?$0Z>'M7+CA([!LJ],
MAK)H;LE@X,G0&> 7 M1P!CA]_W>O\PQ0'4:YB&W<$H7B2(;1_\*QQ!4NV.)@
MAVTEX8";_CEB#MFE%/BWWGGK-ZSZHWJ>#Q=EMB>J<(!+O:BX8B#7+NRQDR.T
M/<;8<&[/-(CM<DZ/:#YA8H^)%&:5"S[-H7/ ;4G[F4&1=W+/ (Q= 410_/%<
MS*93LG'AH_#@ROSAC"7O(A,*>>NR;H]>5T?+F_#9F-]6V&]2TIM*/>PC04>3
M VLO#R4V[*UGF=1&=V8^>G[CZVQ..%<ZXW86NH8T(VK%9&=CFVK0@IK\ ;<K
M)-&DW>KL\T(:QIS,!3,VE"4W>+2T1D1ES,!)5O_MZ$I;#5JFRKCP\S/^*<L$
MW8=KG*M%R!1DA0<RDTLI'M1U4B<Q;GTF[BUI[XCJP14'\]\?S 1O:4F2Q0?2
MF;WG(J(Z_=O>$KH*)OQ+-&4/771S^GHJ!9OTJG]=.M&@?RU.G.7IZKT)X]V^
MJ]QMZ:+(GZL*NH65%>>=#DAUUXV$K!O^23#<7_Z\._*T!TWF(X3]2Y?QMH)!
MB0QQ35CV+;;X7X1I#&["0[K8O!DR5V5[8-[YY&7C_.B=BOWZX&<8<CI-$G0N
MIT8#WX-_7:5RB;DX)TL/Q.N56UCXN+Y1HTE],RDL\4Y%=KW>W<;<3[$Y:HF=
M/-*XRG=D!+/I&<#GZ?I@. >OL>IG"2EG[7_+:XX:93(4LV5F)<4VDT?0YNSH
M69/]']W?/+[?&_AJ+CFD'QNT=9#EI9;NBVL[3JW6EYD0Y722S%Z1!8J%\7X+
MF:@-V?\ ^D^0DF;PO"O^8#5]C\%+MGH) "(XUY9R3H>VY'+[:F)FXVI\*!FB
M"XN:S650=>?NM3ZHR*WWQ- Z!(294<RCB^I!WABX_C1.!/&Z2*G7\'D.C]?+
M4AW\89)PVO='D^::_3K0S:8 '66,3&0[]#6J>1,'1N9E4I6<D&< 0MB@]$.N
M.2MJR-JG,T"#BEO$/UIFV2I?6Q-LV,3FW0S@G>_=W41"?^F<;!Q_[JD6FPA,
MN]LW+)CI3CJ*YQSI#RJ5CT[UIL'@ICR!<_U$2+<4@:Q<:8>6#PW&=VA9/?S4
MF"8P-"K_I8&FYX),<;=4WL$M88Q\2 -NU?IY\=),-H[6 ?8^V=ZVR1L5EA;3
M1R6+E"S2E8)H-Y+XL*;4U ](V"]#P=U-<LF/[N&D$+Y1"5?B\&.2:L6'Y)7F
M>6/5EBE'_TF_?=E#**MA!63NY4IW^6EE-+<^_S1^"\%;L[>[6]O,EW^NSWDL
M!5G7%#_[977ART1()*EC>66,C9F\F 0\23;_<V*_47]>6K"EWE@;%__]$UK&
M*8NH*.?S#./G&89R(\*;A@@?\]=ONI+$2M=L%,8K/_Z "U';?C9 ;B4=LBR+
MOYJ_**(?K+C_Z^"=<D2DJ[JB!?>>$TD <C<."(MQRH]MBA,AK207CT]W1,U6
MY7SQ_%K":GI:Z*4YJB]IF^Z5*Y$&$8X]Y=:5J 9C/_=A$3MFLWM4RM>CGD5*
MVVF!7,YW[!#TLN-(:$>0CF_E-C,:S%JMU[#UJFG/4IJ)ZGAZ1Z7#G%&)!/A^
MV\;NM 'DH?9B\4GW*5KKJG>+(4=F\W B78RJ@]NB>(<@J/KE'>"]);"A9TOR
M , [-?!"K$]M#O/=SAP)%KRU%2)L%+].54 !AT]LZ*-SY?O+\@N@5<[Y%OI7
M).4RM7&5)T5P?N<,P&Z_3P3?,EQG?F@?U2W&1+&YZW*M$2Q _X8"G &>'2P:
M:T_19&O@SZGZ!-0=JM>3W\KF;#"K88%+9X#8^#[7J5'K:>7\';40D/KQE[7'
MTR\.0?7?/ZB27>U]ZF/C-Q[Z_EE\,M6T9*N<;(5_$:+VM5'$,:Z,.Z!47=G,
M1DXXV[K+S/V9EN<CF]:+'XFN,.Z^B!0_SC/ :YI\%'O')[*KM[K-F)]0R6.1
MYWFSNE[VI08SB4OK)7>EZO^K+1"0Y\Y])D$DJ2'?O="]'F15;;I@V.R),M2M
M'K+(",@"2YL*Z(6_>?[=..?9KQ<G<KB-]YZJJ(8!-X7[&[&K:)[!2OC+ BD]
M%<F9"@GK"DN% I&R3"T!:M2)'/UC] T20WPTC]//,\!%FDT%-7KY\V=9G8&(
MX5B5=+;MN;S!L;^J?SMR,)2R:7GYP_R1==^[8-_'MA/FVGX7_Y& O:9?)YP!
M+O\E"S5ET&2H0>6C@3'@YI\]DMWX^5+0SRT1A?(6RJ@ 3:KI91SDGQ%/3X8]
M*])K@@.;%R$=M[:1K)*KQ4(B_^;ZV%['YF5V-/@J1\>;3VBI<$P _&ZC_5NO
M%^C?6X_K=$CBJS^>B+@^TN'&0:\.\_;[]RR[V<_I7:N/ZCKM'+WDM3#2-HPZ
MP4TU%FRKB-ORM&AQ2IE9%90B!W2_!.4JHT5YZTT_VT%-G7[IY\I=6D6^\[FM
M7B"*:W[YS4>YCAIA$_BBI<S[:^DU/-HLOXC+,L7-3(JUJ<E)D/,!C2V7XAYW
MF<Y,%A\ROZ#AZ61'LAN,BC1IBKL]5.,6\T#BT].+WV^M2MVZKF&CZW&.<8&^
MQQI'13=.6WM]0#<5C1J=T <IQ61KG\E.HRK<0*#KT=N#^6ZG=85BT\[G3Z-Q
MF90GI^\\,\(]3_.C+YK*]ON,!(B@KM$N3@0(=(=X1-7J*K4FS)>[A)Z8X ]"
M/-XT;'/;AH9Q]X?O[OV03Z#8GA;(5B")HZOF_852!BYEB1 !QJ_!'TK?8KCZ
MUM,631KJ6PV?UZ?*"NBF1WY$I@Q:Z/JW)6A.FBM4NR"F3=75T.LA216V9P"M
MUBB'3= -&*,<-?I._ZH';=[CA;^-"*4CW%/X&O%P"XHS3^LEG&.,G\L-/Q*6
MQB'H,EV2F-Z(6\,F+//.?!76CW- &6::Y#GGO.U3]!>Y9_F/E%_ZY7-'8 Y4
M?^SH=8X=\\-$_BXY _7S$(5 69R_O*)4&VJBA[#K# 9]4LC0IC0F!9>9PP+!
MAO3=W]XM6Q4T85)\6DX26N1Z\<)$J5!Y$FO+Y&2F45&?AZGJMR.N:HF .Z#.
M2UXC)N!YX]7'SQ1\5\UW6Y#+"].FI3#4X+$FSLEQV\*7BS*U!%&GHP* K#Y/
M1#\APX+=>KCM6HN(E\"+;94(/N9LNX,]Q90.YC/ XO3]/UYA2X9:):X"Z\K-
M?9Y=X-SFYSW8H3NZM@KS(I7NC3(>?-(OMIH]O$)Z1WI)#;VK%='<-J;FJRR[
M9#*K^S,!\'7:XQGEG?>Y+.+[[K,O_D1ZA'Q_PWI74#WPY9 .E4".I#-*GL"I
M893IUX\[2!N-!#^$SMPN4-+M! C)V;2>#(EZ8*%J5>.TZM1*OC*7Z.<H:S0Q
M\,14Y@E.R-A-1'7R^Q"B] CD 8KY=9WR<UFN(3(Y?Z<"94S%DL%&'<:I9A[M
M/3D+OTW(F.R9MWG!-ZHA,L87<]*^ZW TZL%&SP#?H)3(::!3!75[39>:()[\
M9TG]KV$=F96Z0B[8456U.PXM+)NX4HZ13W\^XR<;C4-_U(W#3$<$@<>C:B:\
M5)LKP=L-$0_!K![?I-J2UM1\I09.7LCZ*%!\NC6L*T<A1BI5SR3UY F9I4:%
MUH5K%B+X(SEY$B[I=Y><4\+(N8^G%:_^AM_4:JH>O8"TN4\--RXJ$'^-\WC7
M/I.N6&VD-F8F?_UAG]0WR,@0&G0)L3BQ=IIO2CD#4,41>UQ^F#U+_<ZI ^5"
M[0W4,^7)Q:VM<M%I9(922=9OEYA]UC=]51SGF86$Z[:TYD4Y42Z<8FMF>%52
ME<\ %\"^@2-==>X_[+=\%6.EVJ4YDN-EQI"Q<[/5)_=AS*Z3P\AHA?3Z)<B<
MA3Q-+CTI!2/VGDG[HK,T-3MNC*V4JRMFU9#_3[%G-S?;?Q%(P?E,7,OZE=X!
M;-I]'%>^%WKP K6:J)&5QB2]=3 5)$MKS;5:'OO+[!<2'A2@_)?+D+,I;>3V
MQ/O#[\4T9U#"S^XQG%+:;.=?,B>W4@NEH>>M_IP6W]KMWB5JZKMF3"DXGOJL
MI',>Y/YO_\B0U*R1D:/O@TA!<115\NVYE+NT3VY'+_"R&POKLRW!.<@,V?<L
M.J]K#C9G*.U=04K5VVR*"R7UKE;U,BG_^=<7U;BY%U[F8I)/'P\B:9TJ7N(4
MDY0+B512C]'R-,BZ]"9*>H?K-']OVEFT8@B1'@%_P-51B,V&KOWT?\Q2V9-_
MKZLUU_;KH4;B?HW9.VXS=R5=_]RP#VYOS#I?&)(N62]).]"_@@6;^I261X0<
MJ9E]K9(=^W.[DR_HWT@"55]KBQ!3+RS%'G/KC'4ZM?UF]>5\&U6#+)D]F-^8
M64/((UBL#J;-A?Z'W5C2ZZ8F10^+;GVTW@NE8]^[0<4QF%&.GK'"][]$S@ D
MVXGYHB_6K=,T<?*.07LP4K]Y1HMMNR67:T<J!D@=)[@U*7P?V1!^>F1Z5V+\
MWGD2=$</6KB<(O\.]MS'BSE<#D)X4R\-O#S-*K@SP1':\/TN(,;NLU??;5NK
MCIYFP8MP&ZAH04MO4_JPK6]D-8]GLG4W-3(2&GFE/%\+)=LTZ40#X9];?#!7
M]VG-&%0T"+DMK'H&\&J2]^RGL9-_6%Q)IKRAUN*K(6.BG8TDY>WHP4K=\)<-
M.H)Q>Z_+*_WX('9N#JH+!N/>?ON/QEAJ7AXVCP3L&+ORS*CUY >MJ\BV+$5T
M7UC7$M:GP@-P!\MF,U2NKM,9:-A?H'O"S&&N<62]HZ#,$J+/"?1,XL_>LU_#
M1-O2RB5(A%YI55^Y]BKJMDY E:&;K\IG2$O&1(EHTP,[+/>\7UEW#M/CG,>^
M[U?C!-Q^B>]:G'N='!0EC7HHWX]*%&3&X_+,TU0BWVGQ^@CPF.K8=4[.2M@O
M0J*E8J[M%VW5EK1F;/L]6]"(])5\GNV1*D,TU-\Z/=A=(IH^FMK^<K F4 FT
MJ]NN<Q$=QIT!$GX/!UU%1RJ/, \H011UE6U#V1$>0@8UK5R?77\:*S<H_!:<
MUZ!?7R?I4)Z0[5*!D814J44[\C R1%-[%Z@3=.GC\AT2O;C! 0[Z;VLH,M]/
M[ML7UX<>,8:>;<UIEQ4?IZITAA'JX?=N=*I4.$F,:;4[QJG\6VG';]3;@(ER
M]C!F>ITJRBTQC5+AW2^[)R'GZFN\WNB<.83\;MA'K1'D(7T/E!%P2T2QN;WL
M B%'E^4O;^$#8K>>!3EOP"K4'G4S&N4HR1_W"'4#3;I[&\UR5[*_P*SHNDOL
M^!/U%>@I"71\BNCO4-\$2O[O?W9;IX705CI5\#2ZEP"6BQZ3:SP#"-+9SP!U
M?U:.4V$Q'5*;S>G4\[2M !^QF*.P-.'HNSO4PS, [T]O0 E2XA)Q9?$WW?0+
M]$06U8"E-XOW+1RR4/^AJ^,^-)'A$?@#Y;DB'E#C00^/-ZOA94GH^NAEN] \
MY(@X2DLNI5$R^-*G?V[E:H%/HA$C[>-G (]&BLT98+:,J@&&/&'RHHN? <H^
M'BVP7*%_S2'K.:UYQ35+QS5.$M[ZT_D<G9Q&POSG0(L/5GY&?,P&-0OG7(#Z
ML^1ZDM@$+(#_-G<IG!@*<2>?.\OP6K:EF7L=),[MA=%@_Q_/?1-:Y[@(=YVN
M&C#^8ZM7>&.QWV!R;C+X"<.77]YG@*9/7MYP/]++U..WR(==]XA^:).IEK2&
MINB[MF)\01P1KTQX7%SVNMXL&O+W[AENW(]RIT3_BEX>5(5%$F\%E)\!W,>J
M4IP&:LJIL*S%+U. N^H/"OW6DS>0E)[$D@Q;FL8?V_V/1WUBIU5<"R(Y$ZLR
MK3O\>=\-+Y"[;#/&V"PJ#:$<N4$3'+(223497N%<2D+.G_:K=AM\5IHO^W#"
M[Y$\CVVL>H+)XD@90G;JWNI%C7#EDWEWI@HF5='UJ#FQ'\SU-8!3?EW%\-!%
M\_U#O NM9X\E?Q]N?&+FI#DU2.HDV-;&C-KES5I3DS&02*S;DV G24)F?T2E
M_>%5AKVYQ#/ 3W=F_N:Y\!]DQ!X?5/,3. ;%TFSL%@*TQ7(/[F!4[9J-.?*8
MDF;!"0MY,HT^8J::>Y/O= '&9P!U/;&AGJ22F/2"W.&5)F5/L?;3(IJ8FVQ%
MTIPI=85Y:2PZ<)G_G\$K*[@H*4F]HJ>-MP[:8I?YWE_GBA_\^YIH-ZQ]Q_\,
MT%C@H* O4J]#MGN4\?AM,T,KC'V,M,OZ>7*K+^3ND,'D#VC=.H_CCR@^W8MS
MO82M,P##P2^M4"BRE^OUI^H3-6IVMO#L>S"=/?WJ!>FMORUUD+<2)]IW=V9S
MV<$?QU]YYTQ<V9A')RHB^@G4-^ELO;MS9)51UPE?)6TB2WR&SHT 2.Z#+7BJ
M? IFV4DC?]3[CW=Z-O_<8NW3/%_[FBOC/Q"Z%H;5BR-G ##IY+_6HD)E>J_I
MJ>SO%/"=+G^1-#[L?-A:_WD?F(]^,:L$Y^MH3-F^I8Q_I3D\B%$G#"$_RX8H
M451 WA[T4=X"OEKN]V3H )4617 )ZRO2.LWJ 8*IT,&(YXX"K83_A[/WCFJJ
M"]=]8T5 !.D=D=Y1.@10$1 0(KT$B(J4@! ID2"!* I(EZ[4CQ)ZD1(Z00A%
MNG3I)"!(3Y 2(83+M\_=]]Z]SQEWG'O_F&.-D?5'QLJ8\WV>W\P[G[4-NT>&
ME<YLV+DT%\6P;] GXA<CT@[*'K2+4J=:/MGWP*&%.J<YSUU:(CEY-@TE"L7[
M%#YDB-%*Z)EZ&MZ-,HO.'3,V4$R#SFMB;I=+PM<M\NPRI$S+3?Q*1HNOJ,.A
MXU&AAG!!X655$YGN)^?4!396'.YGG-[%,VX=G3L)2.=A\(W3>"TUL<.#+FI]
MR3PY%8^-7W9 F4?2]P1IWP_35.GD%T'@QW*Q>XK-9E]IEVW74J!>#.W\>00'
MGL-GDZ(ILYUM5:B/+OK-K55!)@+37W:OQWD4X%X[J_!SCL .]#$-(4NV-G.?
M!^Y"=$0R8+Q57<V[&U(5!4Y?K#HMNBQ[""7/W6O7["Q+3@P4$ZP3TMX()QCV
M20@G/"*]RI#"J5YO9DS"W[V>&P;^\+XPO%U'MOW4+LE93$W<+)GVOJ^)6<:L
M\9"/3Z*/9UMO.>K0X_0M4.>N;-X)'U*_-H40J'3BF$KD6$:_K:../6S\DP%5
M%XCG55XJ<7Q'KQ3];GOUD;T1TQ[IA">X'6P&HT. #SN)EX8]G0*\D'S$\,-Z
MXGH]=[J^3+HBB/@/T/KF()PU+;1\J+]<<_E9:<_SR?J.-D^WBL^NC=N*>=>7
M[YA"GA%*A]11K^'"37!0R<:PW$W\%.!YP8;UT@)?LOX90$XPR7E?\OC$CM,.
M+I<[8?"R68BX$CR\>,VOV=M_J6W6Z9! A%=AQF4%PS;/-8H'4P5ECPN"Y3FL
M@4@"[] >KG7C2M=U/$1:S!8>; =YL'6A8P9_5R\(D+_@CP)A=*AV4ZW;A=,B
MXSF>&@3]#@FOM4@'6<Z*2JM?PL2AY*(XT5Y"O%%3_J^!E%7/'NWZ6JO2CPJN
M%#LR$H0J^S7]6J05LUH96BPU#29L[/JF4P4K:<;. +[M+K8>DXO32/W.@)=.
MY=O<".G14-;Z$?.Z-B'25<9H 8QK6%*,W.'^:2K0EAL"/71A_ AAA$.N04#*
M>86B&*>7V>Y97),>L_2?\_7#)"Y$';TMJ]O[AKJCO80^ V"LMPV*U@5N*.ZR
M(6%DD,I[O1S70-;%FNP8F"[F*(+'K#8<9\TO^4? <.)Y8\.X<"T_3_5 "F/Q
M7]B+L0T)=\:#/[;J6<G/RL#TFH;3LML)?XS'K3B@;+H+B45V&S-^?V-&CNPV
M[():9R0TN B6\2_T$A3F4TA (B=%ZVZ%==)S$=W>DP8Z3NB"Z<KJAZ^D#T*J
MC0Z.Z0YR'%"Y3,(P[6]OCANK:C<XHAJ&I<.T6',S&L(%OCS!J.]OG$C6_N%N
M2!O+LTY,R(V]+3O:THIN%*%0@X<A1%/4# Q$UB$>&4SB3].T)! ??]^UG_/@
M/@-LRQ"'<5A5=<_R/]"17D(KW5KG8?7TAI7U4ZCZAT2]>OD-VD-/$PW/>\9,
M1R!R@/XV/5/L(I7K:*FBZDUYD4[@:>B))9(=X;GCE\CB_LF [0P0(U,AE/HX
MDD KM^SLZY;0/>5X+TV:.N!H,^/.I%1^FHDYJ$F6@P5<]F=2L[J.SODBK"?Y
M33U!RPH0S>3!O-:>Q=P<N;JPUI'%TQBR(_51-J=AQ&\]MRED0_#*G,J=WI?K
M0)772SJO$D(2'UXV"[]WQ6=R2!Y3:E$*?"_6:IA8-.[H:BB5998J&</;G70[
M=R&2*=JR-M*.?XC^70WR*CW]>S1!F[L!_ZH!*>UN&4=/<%7%KYNCA]6656%L
M=FC#K,$^WW*[<KV57=-6R*]S%"*:@>*L&*ZT[FX%PF3&T$5.A=0?;325,LY9
MJX+"IK/#KI4+@AZA6GY,7-Q.]$)/\V@T?,YIW0 K#[;O@7F?7*-82?=["!FY
MDL2^O8EF9" $?#+V\':Z?#@5<9OFSE^6IIK\>"]FW5N@40C98I&>:D]1(-)\
M)W[/)CU"H%82+MO\$X_ZH65='V&E:AOL-F+YI.0M9E!N:YU(&SQ<O^3:_NM$
M6EEY<C:8!Z%*'^BILBTP77=('@E/O)%^V)Q=I<_//+7-<OKYH9=(65OMW2G2
MJT/(U%+7&M/>YA=CNWF9/W7A1G@O\9C3N C@PU1=B.C2S*&1,QQ7ZW#2;S3K
MZ87E>4^E4R%)&N19GX9HNW-@7O-4OE2,"C*;SUFPWF9/M+-)]_@-LOE5WXAX
M<9DU*80VC9$L\;I\3;[M-/P,X$DOY=8RK+6J_3[X=K--"^;Y(]/"!PFB2Y>^
MB])RN^A\HLO^*HMZ,3S]>H<0V%PYG;=T96*B*[D[4W.PIT,.8.SM_<R_J* &
M_@PXB@C(3QG:M(U1"HR"<N6DFS_$)G-O/]S/)O9FUZAC^G6(-'B^M\U-XY5>
M>:-(!ORI)'WZ]K.;2H'KV[6S/#P!,(PW,\IM7IUKEY>F*<&U/_5@X,MB^JV"
M9A\7&_+L\&*F,>K&^F; &< :,2KC0XZ(R*IW;Z-?86D:'6FE4PU2:1[!U,1N
MKO# R)+^[P -J5:G7\X 'MNRDPM"0O.HCN3Q@@AE2N><XE&= 8RYDUL_S4 Y
M-SK^??S?=SFH=G>LZB8$@XF-<R*N.NC@M3"$3= %:!O=K9&?B TW.27=JMH)
MSXH+)[:DF/XYX:@"K6U@MI31G6UKK$!;-K%/NV9&/F$6KQ+JUWNE;T'A=[R#
MV[#2^!O-X?#<+/]1V=K)Q@2^&SN>=Z\VW.64^5RF!1:&V;>%:#^/FZ[!KW45
M:RF1]?$J'_91'VEP1#?Y30-7S?GY=!VE?H/2&>.B>8@,MLK7]573B[2DF^>U
M[Z>3AS=\9=ZA(XBW61F?(3>EA<%Y-9]78,.XV@%)*XN-9N'E83W9Q, F4F*Q
ML=Q\N3,JB1!\G62NE/)P+YM5*+7G0CJ^ZO,9X!D.@62MLGFDO3!6*JFZ\:.S
M^TZ+T[MR/57WO<S-WB(]TV/4X];4)U5UK0D=9P"C!,+=[6?%,DV+X&>9#_VE
MH+Y!+V,?T +" JRA7,XORUW7_Y^G$GYO9HRUK:@1&(]_H5'KP(.]5H=:!V9L
MEET]-6@G>/#R,BM:3$VX4C3!!RJ\,N[).E_Y(@$L?$X=\2G:)X!SKX\F35TB
MK3F0K,.H3!2=*21C(/HGHOX1<?" &A509@!C"VV=H^.LT5RFU];,O5%G!$_W
M;Y77E4?,_SCJH>K9G &V+JE04WML!9A:+OV#-":^;EN"L?0@C@4^;@W&'/V4
M<_Z*_2@=/W??USF EAD\/V/?SC;1\MFMLZHPG7>$(Z*ZK%#2)YHG&LV>""Z$
M8^;,7[<F)L'J%2UG)C/RN)-^"6<XJ:J)5J29&1>4[626[;_Q_TE9(CN=W$,:
MDPKBT8C7/02]YC, QZ7EL&SBB>$4T/(?LM<PH0TW>'NXW=0C2WJL!90S^YO[
M]3NGTKG-%.L?9!/P_&WG;-V&.JS?>,MO%]@Y:KE /IX7_TZ!</]4+<EF[M2/
M0)'E;#X*$#MYI<6JO"+["B+[R8^GDZN8NE@IH\!,O<D^J:B&;2<C>*-"P)TN
M'F&=S/K3! H#>V9%>APKX@Q@3LIJ)031=/L+L,#@ C<*8[;.48U^W=LMF+=Q
MS"0;G\Y(-UN1G-MS^OF3=KAHY#%-BH,S7*-XX5=K,WX*-\R(E"=69"^= :YW
M^2D.:AG-?I&5V[FR4%CB;I?YJSNO9%.]=?H1=;K$?29YONM@"R^DGV5U4_^Z
MX2=9"K&V+,&+$X%FRR^\KGPQ/<W'?N1)L1$GFD&SMLJT4LTBK27 B0MMH&;0
M,)27E%69/-ECT&&@832C5T?;C6Y[_36AH'CTPSBD@UN[1P" =/B/-M@;7XF:
MPY&N+43(5LR)V_1F/P$2KLU$H;]NS1W>C?KYG-X7/4\^Z<#>K",I&GOC3Q;5
M4?2]Q3-VW74UD-J;[FG W6-;""=BD0I:.X2<<X76:3WJP(OZS?(PR)6!8YZ<
M/]@1*5[R'QC;&7SGW&[1:ZE##0HI]XA=!3G^GCRBJ01Z>QM$XD.G%%O%5I<K
MX**0/N1BS7>7ZH1[_.  KON5217;VE#0]-VAP$U-1]",T%)P/&_BW PB<H-'
M^R.5?F3[F\S*QA\-W0K;&3#-I_3N%'MQ&^-:%PW?8Q5'0=(:7KF85/A-/?QM
M&3"P"'%URH[9;M/ZV"O5LZ2_&*I@-W=?-H5D[VC[]XZ!<-7 *$XU25'PPLQN
M=@BA@B7O8V$LX7HX0U0[*4A:,8N1)_'YJ\9@.?GR:^</BE<0B_+N^\/+6^)3
M/#:X3A#2RU; J<,MN(XR)+K@7P_D>34[.<M$5=Z7/L\[F+L!#^UR404VQ1CT
M;*H.E#\=KWE<P]4[@#<7*PU/MHN]TZE7+J:P IEN^S>IM(WP!C$D$*$^$8?+
M?(#K'.O%-[3H>C.#(60/LQ3?PEG=0!B4K=IA_>)\.4RW]_JF3!DA8'I5Z@@5
M1A5&:I/\4\\ U]IBS[%:+TDP5I.QD]LJ3V+^TUN<AS_P>V=,CL.E%;:5$*D_
MS7@:"@M'^R)]"[0 D6U!#FECVD]WV_'$0*Z12_$[X8&YYTOJR>>LF5]*,N8V
ML5?UIWT9!EZ7 UFZ8VAC4L5^HVY2.R#5BQ^/'@5S_"2_^;VSMT,1*?-8X'6S
M?:N16SVF).4I_TG/?+#&F_^:KJE0V%\MNO+EH.N1T:IY8O@R$^?0<L<D?.R0
M^Q+I\X:L(4;R#&#?2YS>@?B5 !6? ;6X(5L;OM%)IWG'"RHY2PXOJ;5D:U5"
MM*QM5)Y>F>O;WF(G>1ON.6QW@<!&P*38K0%[^V+IQX6\5I(,!%Y!\89 \=,(
M7203ZED^\1!T7GEG% [?DM^4#KQ^0AYR<-7[L'8M>_KS*+XAE*DZWQ^D=EUG
M=ZZA> HOL)V'?RS 0!VELI%^8:I.)^(ZLR_:@/L5/3KRI[ "[^2$XT/"7+/V
M](3K=T&7@U#'PYUDR%\N,BH=/5EAD/%"K95M?N^Y][3>,Q%/:UF(A"9SS/2>
M]D8//>$,L&)-8#<>'(T-3"1=!=DN3-J3[:_ZOHU.?WU418K<5 S"ZR*%@X6"
M9['G9NS3&>#;8E@VT](E!NUW2# \=TZ99L&(S^C$^0SP7I#?LO]NS)*$D@UU
MFBI*_'L3^?#T,U89X9"GO:YB%YSL2?#@G-I5*!Y9@$[?O+O5+7+A_IJBW$W5
MU[%?T, C(93'"23LSYP,Y\M3BNLADLA>TZ;H;1:3B)P<UR;PDO@\?9J^7 W@
M()X!G$A:]Z/*-;&\+ ,2J[2;7K;/A!3W?VD=YF*E1MI@<=.EY@VQPQ8D^'DI
MV>5]5HZ$XD\A.FEBTM9.93_4S+B\$Y0_Z;A"KS8-\U&G%B\!!9<<]+LG!9B0
M$H1'90O=4D$:_Y)%6U/*X:JXA<R'BQX'-H377^9F7SY)?X'H#PF$DG8O3W00
M[B0UE-XN#>\P+8:P2 9DT?GF&4;S&29DLD%F]5-HL=:@+S.]*B]>#;]%$&+E
M&$+*.VQ/N<E]^U_)SN92W1ULI589T+%0]5%<"?-J4H*9I9IG*=0=6Y3[M46[
M$HH5&_&+8_I=GW(<EEP!/6PJR R"WNZ'P:$!=*#+/[XW,/+&JZI=#GSK@VF&
M6!J6JX_CK9+RS#(?=:/5/[D_R1!C4S5AMOYW'R Z$5J0YFF;+67&)F&1*?DU
M63VI4!(N,22K\&%ISI6V*W]9M5>U3\9!<6SJ7FZDY/=_>WJTY9&Z)Z@-J@"Y
MGD"OL"3':$QDZ1"H]4S=*B;$<:,Z#%YCU<:HH@L(?Z/)J]58+NY :!LQ#(<J
MO?\/,&&QH%B89%#4?CDM4.]@Q;^-:+%X\S>5X3TA+(]HUP>[@+0@GUMQ FIK
MZ5@_0G8'LWOS]QG@!N9C[=^>3@^Y+=R-D+3#*%72?/0Q:UK:3[([+6%\P"[D
M\^PL!D46.P.$M<!/3#P@O$C7' 08M\ 7U96BI? >YWB%%-<YG4<N7>:3N\_/
M-P)$D9S:[6++\Y'G8@S&S\L:E,DH,=Y N)I.87@>*>YNR[%IQN2ZY2D<OCH-
M13H1T[M1UVAB6ESQC,P4I=.4%AD2Q[?%FIWTO.F--F+"QAN..(R.2.M:9[$2
MO5OMK+%^>Q;'[%*F^C!NU)W=;MPTCLFQMW!H,$^.@<W.QEUQ8W"LJ_]Z1JE/
MA]_$'M;>TB[>1$FK1GI!D:3F3.<=780GF7<LL^:%9>26&.NSJ(V]S^*RSFU-
M/'*5T!>0T&-ZG6 #3VUX1FJ(4-DN-45$2Q9L=G]I/!&GSLT,;RLLQ84VA8:_
MVU>EP)9!; C"6*<\V1\\K@2Y:(/4(-)$[")5_$G6N";*,;QULA0?QSD_D\]_
M%;KT=I,C84Z:V=@Y?\-_Y'2:Q-BC#L+!KB J>^S6$T_$.M39J*W(3YXGNIW*
M['LF,I[UU7GV\]]#%N;MEP9O7\776Z^*;?_[LHMM4N4V[5*,M!M6G8@.[QPT
M(I@CQKIKR!%*(TO3^[.H&QY:'$27<'R1'QBR;7RW?VGW\#LI'+>I7:/KZKU<
M!&=DV6ASGJ3HEFPJ[:_U+$Z? 0BN78RA G18NG4MR:]8X@?URO=;6FH>,SW1
M%-02A ]1WZ[%'0=*-\<089'(2SR;Q_H?6T"!3QD._TG#)@=>R3.L4\=@5E;W
M-#?4)UX=M"99\; !C:]K<DCHE4MZ=YGB]!"%_32<^+WCQ*2JFROEVVBZ@Z_5
MF6JX*Z$69P"X778M[.9]TT[KTGXW8\/0-T.<CW8V++I&HK4JK=/8/Q1UM*I:
M6WI8+9 Y3IR0=\@C)VKK9X#:@CQ)BC@Q$+QQ3NL"S =!'+AZ1YH)16.]M4?C
M^P)L[NHQVV%Q^1M6,S'%M<[-36':ZH^69;GO@88@ -12">J2EBHY#_=&M#!O
M$<D_0K%=F@_LH@J0LKL$V,ABNL0ZC&P\B4^+:P8!TYW0JQ>I*R4P>-AZ:V5Z
MN$I'^=+K,D1!C($!1+ <672X!W1ACORGH^TZ$D8<!;T_]M_6QR_._&OEWF.E
M$#C"8A>#X1G \;UAVRC0>:DM&GN;-%$9!3]%Z9(85LL#2)=,)L,PE>YIVC'2
M^[U\<GFQX)F_.S"RL/:V*0ROS4:V08P=6I+T*<+95ZGB2.E1N Q(CW04MD(4
MZ>D<COJ$!"5:_Y#)_?<%<<M9($9T]?IK!7W9.*7.7/JPR-GO9H:^R8\=N'<R
MUI_^HI' \[7F)E7K1D3S>0R99OB6)'[K,#Y11YG&BC87Z_!=4RVEBTPJZLCG
MOZU:!G2*,C#,KDJ!625#U<V?F,4 "[($.,SC_Y@4J"/L-4N?%EJ<;J8NA[<7
MR;7 "HQ)*/P']6R<I\8)A,"?K1)+D>/;Q9V*]=_-!'4?^KB'+'>\026?[-9Y
MK#M[_JHX R@\7QFK(4\O:>J;RQ20>_"'Z"4RA<U[.;V2RX;RD(@91%?$>P2(
MU-;O_<0%2N/NQ:JB&]([NY_EXX1AGM(=%J\%/@DPM"TE8(6)E13I=<JYR;S&
M&$,!+=-,>OEE\VX*G)M[=W!Z,P+HL R[0=Z$$ >S0V1:P+ED1OR,6UI%M$!'
ML#(Y"#VSZ5'T\_>;KIUXUOA%.Q ]JEVVS<W3R'1"B<&\!W51&LYGC@^+PL^>
M 6Y"WVA5S/1\;#'':\?(4UR(DZG+)PY2[5B&L1;?I77N:20701/RA#U+9$K:
M%4NZ,I^4%G,Z4:.J!F;DCDLPR^-Z7GA-/<G-(D6 1V)/)XTSV@QMQFG)_<I/
M3++$;UD]:?-9H;GS]_7)S%\%8M/X=>4\JP*^Y_(W#S$\/F@]<[0YBZ8S>.Y7
M=(YA.5 G[WA-;%OA1%T'/RC6[4/]H7V90 QN207E("H@D?RTH!L>WM/V^JZ(
M8[VFF:71 ^&:YC0I<$%5UC.8]VT=#7WIR/"9I2R>HJ>-]6D\Z8$?S=S$0AZF
M<.&_/(PWOEY5(USU*+HB0= 9_O2WR=(@Y90"/A?RQQ17\OOE-DZ*^=A+U(MY
ME6X!5B0?J?X!R25=,SSZ^0^*5 G%AJCU?LD#"N1!";S;59(Q'#9Q8*0R;QMZ
M&L[J9S^9VK&[7!/VZ Q0QW-XLM03AC1>6OQP#CP4D67]'RXDV <*/3[[.CD$
M0F\/F7=CV7@C&@=%S]M#.;C+4]*+#9Q>'>HA&$[S52Y 7L;O.*RNHR69BTW5
ME7*)>WYJRZ:^$RG*2NL=)::6[&S/B#6(4!/6S3(DFZJ(GEF*N9>2N!Y',>VI
MYWAQOZ077>(WH)3?KT#@8V_5H@;?(0OTNPRTW&*W_ 'W:LN_QZ\._PW!V(2=
MLDJA*WP[G/AY1V@*TKW:$N3($VGT_ST#HWQ4GMZ55T6L_@02MYZQ^A63_>^?
M=MFGX05G@'&/3K86K>#6)J<#:O+=WTVU)[/HP[U+) \[<B])[MN".KF+<(T2
MN,S37\Z#@]2R5RW-.VY"IC#9X=FLA41JTI2Z2EB+"EZCN3F. 6$$)AN+9!QQ
M9Z0H6XUMQ-^_<Z*7G^"P<Z)QZ#^N-'B)X!\1S)_-22[LT>))Q8-PBQ_?FY.\
MVHH1*7NSG6GDIOJ)U=IQ)8WTS709;8<[LL6PO%D#]D2GA#3C3'3%K<H7HVTN
MYR7+3C]"B9'=EGS[0LF&OD- ><5!-M.&%G]M ^FQMBM):3)F:=O(NI48'EX)
M-+@$Y)X_#,VWF=\P!48$*?7,B%FM!_,B!<A!Q+39)W5$N?#86"4AS\/^J$PP
M>*IRM;XZNKU@O;0$$64^B9$*$C*H^S?CLS8PL&@_4W:1_=@Y,[/!INB?<:C9
M!\RK#K,<*=MBD_0>W_EFNQLV&9I>?DDEEKC[)LE)DCKJ5;[%9J^.+$B6I<*+
M..[$;WW,HU2*!+Y*48A]-0?$96I>S/G'/+4]F_B$,>8HA4JK31_7#HJIGIU'
M!IXFU?:C(B+PE8R,80K?%VLA[=OP'<')X:B\*=&Z,'&1L=4[;A>7W&^:A-ST
MH%^,&[>C_-M3GX-\,SY& +T/YB&[6C94"3"\&*7 BHQ@@C^Q\@KWB]U86ICE
MIG]EWP^;8=!;W*:7]AZ^V\_/]8)FW_40<OH5>>'D/CGP86W:CAPC4C=(=OY
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M,H/+PXI[WY''2=[FWZ05I<2?0_$U=$\Z.\R-I[KQ1(P$01*ZS=.Q[!TP+OX
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MBAI![D@Q^U2LX9_+L+]<B0+[%_XC?6!X.=H)XV<YE!C'+ %DW)(P$,LE4+5
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M<H;]#N;(R70DJ78LY?\@[;NCFMJZ?>.Q("(B7;I*)Q2E-^$HT@U(AU B(D*
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MCC3\=E[$I@ZS( A$/_[NHU9QZ4FGER/X<E'L1XO!FV^> IGM4[2&HQ2?V"U
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MO*)!ZQ:E%DUL1KO23_:J?T\RE49AJ*%(R)S+,8#G_Z2?%G3.?CUO,\FA[T:
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MWDUMR)-TSY^,#07[DX[,,. ;21,FN"O*6.NTU-2_J2-%@?]=*>1[7(-TTV.
MX1__#SKV?P8DU4GD5V'.<*3->,TJ_ Q2$_*LA?S:<>+=^V, ,UWT4HG0'\S;
M'0%<E.NH;_N7*N'(-$F%8X!705CIIDMR* ZI!)>/YZ</YM,2B(-A6M=1([-L
M+2Y-)C*^W5U:#&2WMA[D*?(%Z@C)+5H)S@M% <>C3@BMAT#(QS04KGAEUI,<
MD1VS1@>>:RRZHI3 [C@Q_<V3S6,\)?CLB"\>5#12M#:[*6%3LA:4V#&,4;^
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MSH/;./?8E=G^E 21#R;YG&R&LF*LK\TXUZ'^/9WC9C/>I12"DAG5]6/%<\_
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M5W>4BI>>NKJN: W=ENFNS-1K'1,C\P,UEO3/LCSI:NV$+&!Q@05M"GZBW2\
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MP]L/H6@$W)0&CWFR?6!-F"=([ULF%TXX#T+*W<:_$@B5F2([OMG2!EO%JQS
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MC79$GEA]X#/CCN377CVD^@ZJ2@=I/GF:&X^94D*M5U@*= UJX@ J-@@D@.
MC)M AY>>:>;[G0X6=$7([G2URI$!H5+FW:F?A4YXFN]XMW_J(T9?PU59DO;-
MU$L>7,-%C0W85&W[\&9G"KKS.I4:O'6F/JLQ,[5.-[M?:+5B<2T%?4<MC="<
M4FZ6[E.5WBCDET96,C1MB'Q7^(6O[0FM/CUGVN1E;_+Z=-V7X,FMHHB:$3YJ
MD*]@\)>WJ;Z;*39^#[1FF8@GD1J[O--MS_=PX1KTPA%G4'<)4$9E=7?6_01S
MO!--BW(_OM0J0[<LASQR"D()*A46< !BX: #M&>05FSX[?<3S#]#1;70?F5.
MRH5'12.\>D OK1:!?$R/:6Z=$OI43^LB\^@:E[@OMXHQ#4O"30DGNL74!_G'
M2=ZDHEB(5VD[91+I:)M!:;V$B/FJLR(6.+CZ+?SVPU9O.5R!G8Q\@%%XJ?]&
MV!3.OF=P(M5'6;#PY8N"&3*V]'6A69JG%HAT#=GLY]Q]RP(8]/FJ$>_Q%F8]
M8@ D+'.SO_^=MVVYM551X=7($M,@^!FRYOSY^M-5V=>**+T*#3$45NT+ Y?.
M!L'!^/ R,<&!9.78W_XLB/HC><8]I4T@\A)"WYT>OA<</]MVC(Q(ODU36<VG
M141*^XCOQ&Y)"3&3*7<7[M./5\THN8-P+- L_TF?B^)TVSW?9+&1A[7#++MR
MG^",8=V,Y*,\,+]E@CN/LJX37;1+.Z:0 ^ 5_SIH3X_E9HM@^%FZUG.@@&&Y
M<R^--'B7]KU1*>8Y767U/D2?-W!2U]E'<^HRC5!8QK2K^B6%0OCLF+LGJ''-
M="1P F=5Y9R=Y>"25NWN\!(=UOC[JYZBRXDW)T<*8[OZ5?TZ^]XV)MXV;2_5
MMGW\?A*EX:*A:V"!28D6M<\1'Y4F2J]X')#)W2I#57'N8EOZT0Z1)W!8R1/=
MD;)$X&5HO9LDK3*6(J&DO,SF *PP^,>C7@ZISH1PO6*PL7!ZQ<9NJGMO4_^W
M_/!7$C:4]6XD+\LHV2WYGBO(D,"2*^%3Z8X\3S=,67*[1)M<?</[ZM*H4O-*
MMGW<QAAN!K?7L7\?OY;G(8.=^)SJ=FS?DN13ASR+]!P\;TAI.P_=._&\56:E
ML2K.5U>2(B7(Q&T:53?0@@N+P.XNBU-GAUFWT2W-]3O7QS/K\96',04Z!6$3
M"*DN?3[$9I<X!]"='"^".L4R]IM&OG:385I,UPUOKQ^%9A%?_4*#Q\;D7VRA
M*^]0CC4FGUNADZ;(M^'\+[$MA\,^E]]F4 WNAH$MXG/T0Y5REK5]+4K*K(.N
MIRT%F-G'V20ZU15_7ILJS]&V]<%6X*R*\"FIG66X.+?AD32OUW:73O:2?=47
M\6FAM[+36E#2"VX)H"%^B7 3/$M8\_GI1O[76/R,+ %'VOP95SBB'B&/L1#9
M<<V GUNNKG_S?FRR_1>&O4/FX;N?1A['C0J&QR1'NPM4M%YEZ=.*DRM6"W&P
M9JL"@PK9MT%^PMT#+VTP<=4N ^=Z):0FU=;L##WGV]0BI5BJ].W6=%H>0?\(
M<TU/ZL[!>^#-Y<9P\<SG02J\', CA+D#M_-IDCS.0OSB?)L_6MW5QF[D(0:O
M2)!0\&QJ 9__8)ZY?RW >3V*_5.X%JWJ#SV5VS1&;1$4A2GN5-)G^-/74@.@
M?L7+0*F1K1;+69?A9L.2L8D*K>OF'A17\YZLB)$4<,]0)T/_>D_3U02)9I':
M4ETAB+Q;5D+U>;/1_%.OBZ]NSD3$B/C[;'G)W+K:F]N%%BH8-SM;=2UC9R+?
M6&+UFFTB2NE#=/0]%^OT,D-_(XM^560I!R $O.;-/7 P$:)VH^K)9Z'K,_QG
M(9&BPUM5O&!'-Y]G,57E:C)IUY5+2Q>SPKWGU1J=MD\^M!K* L5*";/4Z*J=
MK@VX_%%U5^..QNW!&%T["EEPW*"(VSP1T0]B@O';8(1O547\ #0(&@8)>ECB
M_FW*><+0#QZB:L)#AY,4*%,-H=.#46Q19@2LU$DKFBV' -Q&YBT6.UT4PZFG
M(Z3L49;>1=A]OK0;52@9BLC0&OD*,27<@ZD[=>J%01T'\#( S,R&TZ5Z26UQ
M0&7FLGO,3IL07 D;1#M 9\3[ T40D;W6N.+:7$G-<=/:7/B9Y0SQ\Z^5"U-(
M82_"3/TWB/L^-U\/=Q[$ AT]:XM(.WD?9-S%J,J[.8:QT<K!1>^<'?*+%?::
MKQ',-LTX />$69$T<$K.!46/_DQ%.>="DZN?U-;XC'L(SB'QNGH4N6&6<9#^
MJZT!!YMZHB+F=66X2E%W8>AQ$PVTG\0J"3;Y+0=92YVSAP[4K/Z96$TT]#M=
MV&73>\.]^<H;E^*BZ8+5P=TE]^2I\TP/NBE;)%SFXPB+AWYH6T]B6HMJ3 F+
MAX$[237+68](Q>-H7:GW4^,G*P<2ITH?9/SF_2PPP)11DG$^L IX-,IL3Y01
MSKP=0.N=T>_@3>3]XQGJ)2;"AO$ @V7&AIQ)#?6"(F?']8P[_4F&,_L-'EUL
MI?JX%4?'GF*UY;Q)WTM'^E[V--UYY[( 0IG<*ADH:"ELPQ;S=F/[UCPQ[P^6
M@.&N,JSF-5C'*7=!?TBW.NY^AJNE=4)^9.!<8NG5)8E>?AT]=SF2N''B$RS\
M++.V\X4I721;ZZ4G+N_3R':$+$S_#N$,VF?G:7W,ME/VGP3[T0<;<%9BV\-/
MWM.I"T^AZ"23.5>Z2<J'\Y,2"J57*L7,CP/?]M[BIB);*UR&KI40'D:7G8(?
M9F:":>NO(K78 UH;>D6I9=C<XO?>!(??F"D'RN@KMS4S"T*C)!\OB[4./JZT
MI@XU#+9%#EX\V\#T0+-Q69Y5+[&@TTQQXLP+J-N1844,]+.K.$Q\MMU-JFED
MO#WK2? 27"_Q:V-C"F^$N&@T5LWOL!RIN:O"X_,U( Z><C^?JIB:/G?*R64!
M&5TT!?01L$I%VI<U3O%-6MP![JC/I%=4E($D3Z*549?;>]_62\WB-^:WRMV3
MR?R5;-5E]\.7&]N .GA=':G7OKS.5X>RY*WEQXUC;=50:ETBI*#1W,*0(HD@
M!&;\,WA@7,YY(^<A U./;:0_<0;]6D2 J;O'V^L?#>2MHP-1Q6UQX1'J=1^7
MSV(KLB+ZA@.5Y"ME-['EKWU9ZS4#W[]1*!"@9QTWIF;OX5@2=,)*IW,$H<6/
MWK@^0WRE>^DA!26HWWV2I3,K9ARMS%(KN<TH?_4XOI/-:R$U@/LP)#)S?BLQ
M*?<1O_1;0ENM2'0 HW0-Z34@6?CIX-,Z]@$1R:>^J<92S%AR548-#+/(S-N2
MO)H,#N"UU->Q\D*+?D?$:'CE2.G,+UF6&@M)_?*C5ND%:?+W>XGY8D6S6K'E
MKR$E89K%,N<=TD15+:WSE5.+3RM[W6RU'6DH YV(K9A5=C*Z^<J#+1]FPD9#
MB*D@KP=!)Y4P5,L9G%@E9A%.V(8I7Y0)15,:-Z@66T]-!LY-H)MYKU6]G2LZ
M2 =U79098MTH6!&?;RH=7]JS?UX\L=R(G6CZOB\<76"A-/#EXW@%4?E-5\*W
M)![)ZFJ!B3*I =[DJ&=KI?3D[H&91;;TXM2EY!D.(+;9@(9WHX$Z$$%0QW#>
M0O,"BP)(ED,WN89/](_<\Q]K,8UX76,*=#+D=LK:(+5Z'*+=1:2A1W/D*"+9
M50BYF<$7S5XT\V[Q]5ZT+SP^%YD8A#KFHZ6M6>51@H1,(.PAK9=][CLQ;;JR
M7!AMWPA9)V+008G^.W=''V _:0,S9=_M%=;9I-/6FM7??1SUN_&AHA!AW3F:
MJ)+8\/4<6COH?3%57E?O[N[<E]E '(/VX598O( QOS5VY)>T!7NUDNPXC(RX
M7_JII%/".=Y.AC=+(U,7@5>'6.9Y$*#TL(8YE,KO6ETW@FFY'=(M.9<SH:"'
M*<F4/SK\^D$@4MD[/]W\2:#Q='W7U*4Z&N$Y>J4V.DM/PF0DR+U6L4^H'E+L
M;!$X=&<]?5/&T>S*,4_KW2<AK'(4!=9-C.$ 'G\V!4HQVSKU>;:D8K49SV?=
M^;ZQ![/J7W_' 16;G:5/N-!%.YJ2>>NJ2K$'+455QV*38,UZE4Y@5PZ@R*"T
M(RN3D9#5>HD)W%,;7P+J,$/H\%FI&!3##RC$- 664Q36!5: %^CC/GO4K\7'
MRR&4=6H8*+;U2BMNO5FUSNT2047=^\-'O"RN#6N]K%-^K?F>L,8K6R\OL1D/
MPS%+B_LQJH'?J=[]CLGE5AGB_*DK9[NM2H^M7[6\ON$?J%< '[B@6Z;D 8<Z
M\%GZA0^87@.2B@E>91\4]1!U$[ZM2_I2S2H/:<8FS*4JR%[E6TH.J#-+Y541
MGGI.$F1;\P*<\94WS$4]X[Y+GQ"1IM#8=VYU8AK)%^;W*;[?]/N;2XGI)A"G
M^X!9_^_5?\@=K!(7=A*;^6:6D+\HB;9_1!AW$8'7:YC0Z;!;+'E8OH]HJVS<
MNF7+\%QKM;A2A:AXP0[CMW$SO',[7'&AWZ_.(.LK=X93XC9J+7#*Q?SB1:1@
M(=.<\AGM2^PE1:+W@<Q]< J?S[KY2P34II7I- L_X;CBIH%#?T]" ,D%B("N
MNCVEU3>N9AE)D7A)8L+#5UW6!:G1NC"S&YE:3>(7?@M<UEH/JW1OBC:6+;9)
M$9U\8YQK"[$,B<^0M'VF\[7"VO^E0U.H\T /,0&<.IYV()2R/*7AD#)_<KCG
MNZI968T?2W'U2 (R9*/4WC#(X4Z-PNER^8D*_L"GC@+LB'*Z\8Q6!]IRY?Y0
MI+@C$]G5)J@KG\\Z24^GLJ3.LM0HX/6SX3K#X<8SX)C8KD;1*"P'(,X\B]!R
M&L:\FH_M>)T#<JVKB1JW8/=A<_O#A Y^8:KHOZR,%&+I9O]A+3W%!^?Q[NRL
M+7K7:(6R-#>939JQT+RI=*X_[(7$9[]3X\9UE*)!UWE;P6+M.-!$25Y^/WZ.
M\:W,TDYX_?B4\*=BEM%RC](^CUNAEOAOL4HC[^>_%V0Y%$>7GP&[J5DGR=RZ
M^7G"[!RD!R.V'&AEJ-H1=_7]X7_IH@!_0JR;,H,H356"RS2R:SO?U^QBYR72
MH_L6I<N-E;4E)(@V,-U#<K0[O;1I)$AGWQP<W-B$J3>5(^M]N1[[1O?K#B.)
M5I0]+8&2<O.^>+4NKK/G.O.(+6UUY3UX)<LA3IJ0-_2HIO73)R*%]N7IN/O7
MF(@[^F?[/!A(\FT_U7-W+)<PV7-IEZG(./_BDX5%5;GHF^/YI>994X0+/8T0
M^BWG?:!C/\BU];S%"K3$%CJ=WAJ;5ZTNZ10T('%O=+8^"Z=G^55B) I2H>P9
M+??SS"UE]>P!&_.<M OJ&2$[3P5W9,/7M61&GKP/N$"L>V/RB>]";5=2PZ&8
M^Q\]TCT]J"#;">=:RT';[14L<4 3Y2<O+TT8D-LIKVK/.[!/D<[2BG,D.!8F
MYJ5H'4JY^]1N>&3.2>P,P9XM560(HL+TV5&:^DQA.#<SA@_0Q1S D%$O!W 8
MS0$P&RT"O!FU%N# G;8@WZ2E[7M>64S0M'M'U3&?NBQB3+A@(40[Z9V*J!FB
ML/53W5!/'GC?@"U !6XLKU@. ;_)I+D@'Y*^B>6]F?&K,3W7\JR& \!B.("]
MD]\X@&F[-@Y U)A1A^( ;DM(L4[5<P S2^5CLN.FS@H%=N,UHV/0^K"6<6&L
M+ZEO"E21@P[>\9T<,%-0V0>#.(#WB<GL8V .@!Z(A$(X@"V!:@[@CW(D6_EY
M5IJ]^U^E+K()> Y@\<I##N"Y/0? <@7X6#DA223DP=$G2-HU,@<0G_\WH8<6
M+BHSK]#:>L6_3/U$UW\1>.#@V(RG;B4:K0Z6D/@>FM>EF,(")R-)/0P<WJVZ
M/K1P@QJ4'<:T>X1@/'D0.Z*$IF"B),".#^KKZN-N*J&G[\:=O_3ZJ%_W:6_A
MAW$WAT74[>P,+7ZU@__W]C=U<M)3&>C')$Z.![N"8>0(UYWTT=1,-8*]V;K#
MH[R4)D+?'7F%@_0QL'7<Y[^SE/H+PR(UZP97AW:V.&&;S(?(M!VF:O"%M&_X
MP"DY9M,F>.\:'\80R<?:"3 CD\' 3>F$2C^"B/QD=_$Z#D[X[R47$$J+']=!
M(]"M*]^']&Q<\:#A16*^L_H6U/A#J:$G!_!7!R7_A3+^R#]%_I[OGSK]5XVK
M%6W_O2D!(WG_-/P6_S5@=#F 'JGC; G$IDTRF Z*5MS6\U!?4@\>>=@X@EEI
M0E^TWWR$TQ##E _H82V4'?2!J!*)<ONI]@\'L\0/D"Q83**'9R'$WKXQ^&T1
MJ=/3P\/K]%/G,6?PY>YC6,R-:[VGKW>]OF!24A+WW@;Y3_))>J;!!@,/$<[S
M']T$^SZ>DYU$=2O7P(HJ=W/&S?I:7%M&H2TP;T-G1HWY(_0_=Y98J>%C)'2)
MO'7V(W?#)WTFU53D@Z=:A9\;R>+*N?(+(3=TZHXC#/T=9^>WQG\67?SW+W?^
MUZM,=*>N$98^GQ^A&URG*5([->72']P-AT$E!O6Z$EGR0E:8"G)'^>YN9F=5
M0J0X,UN]E$*5Z]$D=()B;>M&MCD 7I^LBV]+QBSOCX.*79=O_%QOKNN;VA-7
M-F4#OY8NWV#:(V_:+6\V2+&V]H-;"#7(?2:GV#-=4R'24W&6PW"J1G].T]A7
M'D9 (G5 @LHRIIW)H<MU$-W.CU0%Z<E[MN"PYDI@$TUHZ9)X3VPI">H,+'VD
MP:MDU+ZF&&0!Q%$>-N,KT44;7VP,I/VUM;+::8!OS !;VD%LU^!Y;@SY3KGX
M[&U3OR;3-AVUVUX%\5DOV(YNK^1HN=)\RPN-0TLU^L<EPLP5H!+F8>8V'C!H
M<(VKQ9:KD'^E@^2LRFNH5Y[E4EW+FF. @K-/CHR,BB<H?:4XU2*4FX.U265*
MX;IX;+IIJ9\4/TN@D'6+AHQM%LT;B !F4M#:2MHXF)'C?$NN^F.OK#E*#&GB
MLV+25_LITM3)G2=10J_/:2Q[?JS)^9+J!#:_(I5E^DN<T1- ON*?KA_+A)"U
M#B7EJ6F%\GU3-JEIJ."=".Q&#=7S4=J#O#3[/C"X?A-NSQK+.4@O1@X!>P]0
M6]Z1[L5K2VUCSB$'1Q3U:2+\;%G,8H$.V!/^YNT_=JEV<@"'?N%&KC>[']^V
M*.;! ?SZ$4G7*#8$/$9Z0LA;IW\$GJ,^,RN$89_# ?R\PL\Z%DOC #(BV@;1
MWL,_BY''G)$'1U:YPE78E[/_*A1J&0?XROZ,K^4 ?AJ_@"1B]%GP/1MD#69]
M[[@C<EI1BF4!&?[9>5PA/&%]%:W/?LZ08O**<@ "Q@Q[;EK]O,]5%L\!O$*+
M7SUG^B2! UAMT6$_)^@S^?BY_5;17P'B\YZ3?D@:7$5S-V5P)9W@  0M_UW]
MBA07-U%J@KV^2W56OR_2NLP!7-'95_M16&"9["/MW&;U!'(S2[_F1X*?^,9%
MY\XRY!)L</#<^6<DC__-5OI_8RB&^H\>2/X+0.? ^\>]_LVVG[ET7W!GU6+D
M8PBSEP'+T ,.'M=7^IU+G]<]"/D&=9#Y#\=>1#V.'6>_#8ML'4']1V 8[_=*
ML/16HY"_6B__/[,<SGON7_EY3>TO0'7V%7[LBXAE'^[F +KL$X6.F*ZU52W]
M4_9>2,^E,0[@-UB2_@I)BJUU(#\,8=S_E"(A85)@W]\GW'RU_YO";_W/8_N#
M]ZCE6_=%ZOK)/^7%707\"]:17+K";J04<0*R(UZ?F>\#/\A\;#;I$_:D2'^,
MT9LA*OIK1):BO_0;/^KNYKXHF9DTV./, 40'N9]"U'=J!^=0)'BV)M7LF?'T
M%SWB;O'%;XI<()IO(!>!GU([GUW*Z+V_KY'G_:8W,-:LM08!>X_= )&DQ(&7
MO*5XV1+,\IZ+<B-!.5)&>,P8;"TH\819$R%(21(KV1C16GHL/4WM3_N>L))*
MS]R[X+"@A &U F]39C'C H8.7LY*[_F@'Y?=P1"W_" 76X75/\,RJ,&'FV7-
M?4W9\*G7)B:DH^%55ENOX1XQ7W?NO[6L#>< O%/('H71IL1N<S>[F*CYIMJL
MXKCPJM2I #?<N;A21*'\U1Y<!0$1N_].VV$>$5]85,WX9">;M@7Q-S7%CVJ$
M]IFIV[:90]_00Q)U=:8M9+!M@LL&%OCH@99WOG7UQ!V'D/H41<TZ>^W@MU!D
MZ;)H_;GPCR1'QPD7_0$LT$B#Z)#$<J.)-,Q"^4^Y,!]:X[;( DR5'G%X@CJ2
M^B=<61TZ]N1]"WZA>B2EQ\0W_&T%5@%UV?';[[XB8L' _K@DM_5KEIO%8J[N
M&>_*[FC(0<L_V?BGN+G+%6^&W,^.\^VWN>_[SJ5BUW8^_X2">EHVA-2;MRC.
M2)V!R5D2,9)WB';#6*ACE?K!G8'7]8UUF6MF+ZD>?WIZS]F]$3,S>7W9)+T6
MU<G:I\*)DN5?V4((,?8%Q(E.(%_&MH;\EKG8I<:6)+DXA?*W:\HJOFY3\FZF
MEW\%A5QKEZA6.%5D:5K9NG"WMO'MPN_DW92'(:EERQG#B64E33_5-4>=W"@Y
M<G+6M5>9 ]#INS1<TF-S/R0NU2K")?+S,P5R2_J^TBN+L8CR[=JD)$(S.#N>
MZ"5+=#(/J34,X !HB4ODJ5%]6BCZ +DHPT2^PW$ '5I%' #2A@-HGV_@ #Y?
M.Q&*5)E)5F%N[]\-%SSXO9E'I:LM&244+DE+_>.W9?NL:\SDGL8"9UCA6C52
M<J [([Z@XUXFZ6MU .1AB5MW$<2^GDCU+'8G9[M7.[H/BIK3JF;:.I,3(T\.
M :59<O3>F,@K"/YND9C-VW3XRR =&-AP),_8NT!D)[C&K%2I>4FF9133ZCI0
M0<>(7N]4]S=VSY"B.:DP92R(+*'U:8=?64<H*J_S*:BD2#'6S\!;-';^C A1
M]S8EXC$O^@P'8#BJ#G-N5\F%AGY/FB?-6HRB\T,K'M5GD#^'0??3JCH'F3)R
MU$X_#N!H)AWU2G\ZAURO$K/6+$Q;4WFMW8F0FVU]&UHQS@1WL"\1%M*K,&3)
MGW>LQL:\Q5NZL77%15"1/VN^=8=I=+.T@L^9A\%L:8C^+3_',O4+M$\RIC-E
MAO(1;L*%JTLC)>G?2\VPI=KO6K]JR)D)OO-R?B=;-O,TT$T\VGGB]V9P68E-
M6DJBDQ6FV"S+SV7TBL$.8=X_[8I5#TI)?B29T6#HMV>7&:LQJ04BJ,/L7=V-
M1V$_C:A/VIC3-4O#BI?M'6XH$HAU(1FD L).,/'ZGZD&?J?1%][4:.N^"AWF
M %["+=AL;@_\8H#K]@R[*\UMF71N3WOP+'O+_@3KRC/XSK8^ZR(4Q:K)9PNT
M:.WOH=C\&H-LI_NBF1OLJ^2\C_H4"3RRK93;6FZZ< !SZ5+<V&DCCW!C*+02
MN='_ZP^!1@?"SSF DU/9!P?<6GTB:X$#4"SYNV[;8W.LMCBMQ0I^IM$6>7T9
MR=0EZN]Z&O\%Q'L5E3F659OA+\B_A^/?<1SZ$9Z)>PI'_@+;ZC_!X/V\BQ2"
M#SO^#7?R7T#\[.;^F9D?&??'?P+]GW <WF"[=TO\#XV'I%S M[64'NC7![4Q
M_ ;'#_YAE7ML!I?'BTEN,YTA],,JR:PCS_[ENO^UCN-"_"_,8R?3&NL)O>9R
M%Y[PYIS#X&@0]/==ZT_>RBI>T3T\^_2/]B=G%^X-_4"DP$ILO)H7%?4O^*2'
M7YU923XG^@?I&]/4B\*[+M7\U#BO?;8\>]R=CYHRK]X2MJN^ E[)&QZ3B*F[
M#9/VGSB9X?%]]^UN)^,!\P;]!(7X.OSAC/M%9L"=X6UWD;'Q/F0 !2355[HH
MZIP0HJ08[S%MS@]@\M\9TMI-^2Q;*KBL'=W'(]F5@$2ZFX9;ONBI13PRGQ9[
M@J1<PF_G"-J*B,<4!$)A(18?1]Y_&L4<)R!K@_(+D5 G0XVR20[@\439VL8[
MXPM5JHBVCGT5*43(C%UA9F(X3+.A@HEO;UQ/T#7]8%PRX0,4'\8*$:F_X+:2
MC_<J%:*^8<AGED)>F']J2E%PPO;R1#*J^V4%!B3E%-0+K>R*U]T8,1+CI#.:
M/H(O%=P&2D8*?8;OIXO>+(\T#%HS"O1:4Z^2)T;+#$:H6%JFISH\+=]_:V95
M5GK@82CL5E+3+<ROOW#PYN":SS]F*P5:+)N7?_\B M2C_3A^W\J4MF+)?)V/
M>/!5A2=RZ.*A3_4.%U69#Y&JSN/,J.,&0K05-G^&*X.48(WNK@!YE$@/5;XL
M DTN=Q(Q2G)=)$TTY2  5,\MP2&6C7@-"^":1LH4HX<AK[0&*S+Z\T:?4&7B
MP<2ZV[/]6\<#=),U.F<CLKH\"L4_N?0>T_)!L.J%I1XFM@^"(_=>%I3V%2W9
MVZX8X8M%FA,V%9+\,NTZKB7%7#([GW!&66'G=\5(<;-*06&0Q9)=W$)2'%K.
M.J'J5 IHUY)I3$?-NK,$,GK;@?*U([J>^R[(]HNM*M@Z[#3YPM+4XQ:Z,<,(
MYH-H'7X/98"^3RX#Q:J;<BD/HDB:-0V:#H1JE=AM3"T>F[S$ 5!$>_AC. !)
MMA0"/%/< 1)?=--G1LSJ*?.Y=^9>I5%QDTM[B>\6STO^(4T@7D^=FW1R-8"'
M>#U%PX-.J_7047TJ8S5?!QD@Y@Y=CLU-C23<>%<;H%6SMY0YS@A#=6MF[#3R
ML=]6[N9W<0!G?&=;U=IU_5UXJ*0>-T&'6N@W=(K4N?%!]TLLFX,,#@"BPKS"
MG\0"[=]C=]2)+_0D?W-W'BV@J_3"O_6$C6=3W2G89@JRCN5%BYR?=G-5*JQ?
M#U)[DNOY-:L;'20THJM_0:7 _=PC>E^ '(CGU@/_=T'B3C'FB<A-X8P'-H$R
M>DH7#(\71O?8#..ZA] 6Y89:N;>S!M4_C]#/V@8HRIA.U[I<@U4 /6X;VB?
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MRH!,8;5O9*6/?,1UX4PM:\KY$Y3;8*$5T_3H#I8"G8^:'-M\7U<XSP=%OV\
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MA42\N[!#X]A.!G=FN$)S?FC]0UV<8S,>3S"[QOKO(XTBM,A.KYTU8S&:+<-
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MQY8K=841!!MH8,$5F^DI&"$HDQ#R_J%GZ7(66>,6#"M?J.MLY^.?GO3Q:E>
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M?M9N+N%=TUP&9<2C>W>B],4AX*1J\B$ O+3"+4/U<""' (]T[CE+(/?EV4/
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MFL9X#E<$0R1^202/Q06+#<(KB(@]!]WH7V(>UPZ47%S:0!NR^5)#ZWC- U#
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M[[8A@^WI$]K"\#C,RQ6X=;I>9_&=M=V8@L(ZNW">M!S3QVUC(QNSMBM\=Q+
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MJWIWW\R"C-\UD;?,VCAG4&IH:B3T%8N;,#.Q!)7JF=\R<^RT#$Y[FO/!4ZC
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M);6U F @=<EJ.-FZ_,0HT68!HWM]G'!.](U+/!HH'?&$HMGD [=P!#<A9F\
M'@W;PW=*FNTQEGF;6KA_@F%R;?F&*]=P M;!SV98S/,H+Y%Z!'4FU(W[-8;_
M,"&UC[^/L1\:$/9T--:%$P^.-L/E*Z#AW@3WHGL;Z!*AFY^0>[%;J!MDK:*4
M5?)ZLP=USC6 >G'\5>)!8^>N@OIK:ZA\Y4[FH9TU+C'4(5N0ICA^-+E4K='?
M[1I[=&VM^EYP3_6=F$76;8IWAX[O0Y>N!\&OB>'/$]XV%-I:W?[RL2:WQF(Z
M./S5*!49JG&*17"4S61-#YFC;]H-D+.)>O,(7="Z\4:<P "W.QPK1+X7^E*
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M=I2U06-O75P71M6U<H0F]G9"%&OE_52?SL0+4=Y^MQH\S .83+920N[T$Y,
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MFSG>6AK\2N&F1G7%ZR%/E:S:Q?.6A8@X?^74$Z]5=.+6W,L4SJO>3H9:.3#
M:=KUZ@1<-5; SWKB+Y].M\,)GI)DGGV.NQIIBU3S#T-KMX ^'(QR4'B"?(YY
M&RP3_=,X 7FG/D]K/OT\>-"VIN\+/LUNHJOXZP1<3Y:#=+^%*PDMTO2-1U58
MTZ@ P"D;;B&BJ:*:(8U0D@Z^]1Q(Z>L)%_4G%/+H12HB V"X+P..I."3/X8R
M.R./']S7EW"Y,03W]<T+D"M5=!7H#FMBSE7@^3XEGI,$,TH@6DS>03SJ5HD/
MN#!Z!(S*T^P14&$"<N\P3PDS01[86,NH(+'<@FOPGH&/61O$FDC:Y1GMM[&Z
M0?>4UX6XY5VR2-D##*?<BEVV83$0XXPC4#K']D."UGW)/D ),\[0]U] J'>/
MFOTVVHY1_4"P!;7R5NOIT2$T]")">YR.DQ%:&L]LB)GZ>?4]P56P=??S/MNY
M.&^"F +'I?6/T+0=_4PO>YUA_1QN4VAE7/HFV<VXH&H/-[HF+=F3-5BF ^V>
M7?"I4HRM6#YL."@R-%S6)3QV+=>(N'C'XT'/]^=C!>3Q&<NM/Q&'H2(T]'[W
MGY&SV J9 ;9@0KX, +0IF8<CNH-<!1U%LZ[+, <PE+VBA@\16K#YFGCW%;:*
MI<Y::MR!#V'%G)J<GMY-=.63:PAU&739K]IK^4W*5#MY@&$.-8KTW(=[;R]T
M/8.FA,I_5BVLE^\?O?F4V[XOY"47:E@1K.=:16J*79WI]LWX%5;YL7&A=)#[
MN=TDJWOL%Y5'" ,">NNYQ%,PP/!%G [S+W_<9"D]!:BD,F_"#IJ3*\5:/%36
MZI:=8#U-$D%9$*&A"D&0>[2 ZN !4I)OQ28AV9/*,"\P-P,I<3V\2#@#5JU!
MH#)5L"*_4(SK4U$([^I@RJ<3[L$=-JT7[T ^LU$IFIVX$ $UKI>\7^(8!4>"
M#3@-Z()C<T2KWR+#%*,@MGGL!SV6JE*=W)^/'NO?OV[$$\<T!+>T'54@?H%=
MZPV^_2X!;%3 [GE;O\=)6\'=_.="GX?_-KI[>059G'&VVOQ^#>O&)4ZJ^JBA
MS5S,G%VZZFW..R/BC2T7D#<%3DOD+/+3?_CJ<#L!4SD<IDYPH,ET^ Z1(7LK
MI+_<]MG;;Q:ZBQTD#8)ADJ#1^3.-;EB#-[FH)&BM<[:\TELUU00X[,2 J]P@
MUX\D8!#35KHM-_4LG&@-J=5/$5SHP'0GA[^/K SQ7I\#4:ETPPJ_>=NX]%L6
MNZMBZQV"J0%.1*EI6QG:WI_W,:;N4T?KUQE2$_/FBBY^D4-2CDG$9?+N=8>
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ML\Q+F (,IJOWF]U^3N!O:QI41]JF;<MP#6JMRWT%)0;U(]2['D\N^Z33&F9
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M.[)DH<I5$+SCOOHD,-PA9]D,D5\).[IG;G6D7P+I:N=S=DVE65$@7+T]?,M
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M.IB!UAQBC%63G9M=QYH(4AVL%;-10L:=8F+6AT\V<%I_X25%>O1AB_GU$?)
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MLL(TQ7DW)-V?"OY"($*3^PVV8M2+* <.&$^S_>(.U/C?2@;^WH?K7.2NYV2
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MR,LZ%R^^I$\Z2]")&9_#+!E \L:B9J]NRJDIJ43C+P%U'6$)U!N=AZJHX67
MBL0O+9;7S0J"ACTF_2=E@%/KX(O_L7K_-N:W,?];C4DF"'2FJ>MN+#\4N"6
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M ^/0H+<P9^19.CB..F5O!^';4J[98'R'U^PZ"VRTMCF39CSGYHF*0Y5;WHE
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M/ZG(=U.PME#KVBC,3]Z[DKL++LEV7DO8\60& ?@5FU34XXRX)?%PS'.. )#
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M#(HRQ'QW[(G'HK]SI#K468A0<S[S_7>2L OOCYI[2I_?WP\5-;AQQU"QSDW
MH:;?$>I4:LGOY;!%#E V\DXNU5%$3IW+9J>YVI-,PTJ#Z\2M'79EY<N5G=*N
MZ]9HD?.58;!O>4I6/W\ZKV/Z\?.'5.PER'ZC8N0+.0FOH3C'L>Y3P&<WI-6
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M8U47_GC3YO#&T*5&9N0*&5RG4G91KM,3HRM62\"05TJ&D#T0U%,$YY*JN?K
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M(..PN4\7/;TF!PA\[9'-M?UN]""5KH\M6T9R*;,.P)<*!87@$,OQ*WL^<'$
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M/4Z4(^"@8 %,1 W"@"',5#=\!0VWGQL6P@J1(P[GS0X,2=DP-F/@Z2CF%F!
MT])@1\9WGJMQ'U)*9Q7@[$"U^ AWKH9>5Y^'[Y=$W)CU-_72>/&>*P]?Z9^5
M_T5RU]<+[\[V\J9^O%G@^ CU<RKQ.![#:J4522X7R7;: (R+;0RT/!3IED*U
M@8* UCY7V=& [WA*+W;OZ"^[+X(/ QBW [8C4[J/!Z(U&$U[_;KM?PY4.FSK
MZ7V?I^RM:%MTN3'%\,*5RMLL69^"ZQ^FWC@5("+"JBY?:^CL8MP_??K-]ZU[
M59YB=AU?RG"G^AW3:BICPZ2!+#7SH3>NJ17GLY3'J]6#INC9;4;-TF/7V)T!
M/2\)!S7">I'?S^#]^-0\5WX.S2VBG0G_(=]Y1@"[,B2L;)NK9.5$TN=2I@"V
MHSA?M%W?JW"5\JD>N<DB\_,?<,JD'7#+5A#PW]Q/+'Y^.&2%_-PMVW/:)E4_
MY-MS4/?XYL)/MK.?63R9[&A=4#>0N6QNEQT85N8BP<DV>G#KB7<><>/X!,\B
M/]71[IV6[HY>XP_DOAD/>Y^(T(#;"1JI[J4M!?!+.7(?WIR*^J5"U%#Y@*%J
M";F,0 (F"1?6JA=M9;KK#FH.7[ ^5UE]PEGK%]'7'9=^TGMP-\-\[\.F*P3F
M7.2,++@G7]D\\EF@@\Z3G[1\'ZJ:<MN9[D^SPV8,E&<H;V?00&L*'GFVG[F0
MS3[=KE%STO?Q!"+> _)RD7EC]Y!LI+N@J*USL$F#66-TF_,@Z^N.AT1! +\D
M]SKD%8$(F>HM(%ZJ?I^5Y;NO-*O]4L&"*"K!X<OPE$M "2*EG?>HBO0>=?&?
M QV9?-7,E0(;_MWH1/Y/7B10#\!,_LCDP7PP0/XA >P-A?S(%!EB_T,8_+L#
M@_0A'LU(?8%C5R: _=IE)H#MTL9 >9B&"-2VR!(2VA<J@/4-\XK^$L#>[Q%.
MW[YZ)+=F^\<ISH8 5HB$% F=W-F/3L_J2->6<!MB8QA DBV )9?LJ#D*8$^Q
MQ?^<2D%R;9'_Z@#\7YX?.;KV\ ([1J$Y)_;+B;P9A^//3AU(T%5'G#OLJWWQ
M2+O(WS\C<O_%IO4K]N?/.6+2'X^7Z+[8G$Y[<D5/7L4:O"EUOU8#[7[28^AT
MQ]@XV5"CADPT]M;XL1Q+*'I3(!/V7WEFE,O[:1/._;E- &,%4AK7D=NP?A)3
M7UD RR;A5%'_:P-5X]*-8*"N'?+T[WCRSE/1W2O82P C6J19(K:;[I_X%KCH
MZ]X<_6>)F<; 1(VC]:D*&]&4*L?;=ZQ/W3_1;FVW?:)\;;T!GW+RK'6M(2UP
MNNKGG.2E::N(G<<9#YKJ*JM'C!N>';OW]BWMO'KEZ^M7?WWU^O@3)*Z)>Z8<
MG5D<@+CQUWJPYN6,6Q*_/GD:]<IT[/<5Z:W#Z,TOV%W0Y2G3/J/^SGJKV-V:
M.7?V]KJMS*^:?-?VR6.=B9/LPQ[^$/7,\D]E5(LK9W9XF6HR?1]XG"D9*BL;
M10QZ\K[X?L_\>'C?W/>EL(QCS\$_&\)K6,L6J6Y1'F7[\1&K#ZN<1\L @OGC
MX7Z[' 5Q/<?L?6??/2<BLK4&941KV7MG9^QS[$)RS8>.I9P@+X9].?_?6GL2
M#C@*JG]F50/YK<J"C?12+^VGSJZ:$[UGCW6\$L#* WYI"^%<,;6B$2BXB#\5
M=1KNW3]X#I;F\[/BYX.6HB:'9O682EK0KZ-#>EL)UY)=K@<<'ZE3[*]<(5[Q
M,;ZN>][JF-B]9.11U>F&0]Q\]MK]]AG27]0TR%-$DRZCJ:*H&I9]\4[_I6VR
MR:VV%17]]GK'<%]%/8+>\66:8[&1;O7Z1#C_96)8WN% QYZK"RO%JRI&,KY$
M<_K-P-NC'[U>O],AKG6IG-0ZQ QW=491UV3[:0I41FG</9]#;RAQM.-)U*]]
M3B3F3R".)]:1R/LA[.5K?EA[(?L=;NHPT4?3GJV>&%0=DGXVL5AQKR/(<V:J
MR)M7?"^:%R+N)X#9+T:12'3 #V4>@03NXLG\^$]F?*X QKE$ZA5A4;;E(N [
MZP+8I+ 6+N&I_&3L+P(8%1T@@+W%4D:'>201 >P<GL1%V@A@C_BUBT1LRA+F
MW[A2*>Q4Q6BD#>TEY-:" -90PG-@P[=5\'$"V($?%0+8Z6BA$V;+$&I;C"J
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MD1YI:"JMJ9RWOQF@?4PL!(.L@)S,R"^I*_7;C(9"T!'=0/'ZDOL!QKB2>&D
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MK9,P!:M_1N)J@J[0F+K39SL&;'8%TN9>CISV1G/9396-\_=WW_"D^N5R2T(
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MDD1>F,*EFG-&DR@(\$"WA L,M)_-BZ-H#.H2.8^_3[/-P3 RF/&]"]?<%35
MH\C7-61:O1VM,Y7K_=Z*9K.QF,,",BL2N4T,1_GP(7"NZ^"&"'@>W99W="'O
M./< &RZ."[W)H78.Q/ A)];% <3*5@$XB \#Q"D(G%J;YO/-(3F@LH%5HN[H
MA0[7*'LEQ_E84CC,X,Q(1OY=/(<K[\W1-<73H9FW<W2;+U5%EKZU[_9)N:ND
M?,]36=W;DC9G4:*L8ORV].T&4ZD)P 7Y];OJF)6?USHX1+8P&BDB0RT284"R
M#+Y?VZ9!Q]1?OR)G=%U4GW"=\!E^I& WKH('(0P3( "F.Q'--&R#)X2T#JR*
MSQ)/<!W!&@ VX *J I5+Z"-@=G=#ED=<BSE;!=V5F;>W!</20['04>L_]=NK
M!S.[WDCH[VT)G96=Z3Z)E./>W4WBAGH!MC?YD*A<H"J*#WF BG21'VGQ8.^:
M=%$/$=U;B0X9? A+OJ/"MEM+IZ6)_)QKRVFVXR!?<7([#3YI*,P-:E#C'60W
MTS3"H)U9B;O!+PDBI,3>W,!G_06VB$2=]/O+3-?HKO8[P%(4UI3):[8>[G)O
M=,?O#W3(D X<YN ^=VN(&UL:O.MY;[,I6N"=G*YDVBL\3.XW^E'JI3!26GH[
MH;!@C1YB7[#I: ;L,O(!>->,B!1S+7E]&7T4A_D=N(4Y7G<:81+/'(TEC2(T
M3"[K(I@5=T][SSNT H;1HS>@X[N)WU(]O+P\PHH&?,-"1HM@Z\;<U\332]/2
M?,CS1!X#>3R5-9K U9M5.< []&.6&%OMU> B.\JU_A.O \CV)/-^6QQ?2\:K
MSCICS!D!S@C+VD^ZEPN=I^P];6R Z8JZ-TY7E3!_C?S0S^RFCGO,0I\2%'!0
M<XX53WNW8%WDLPE;I(L/>0J7YAW"WQ@E*.#ANR4KNL=]9NDBM*I3@DOH?217
M@4'L1-)6C+JI]\=Y\W@G.MY#KJ82%W0=0#9B^9"# U%EQGA11TG%8^VL1VFE
MHWWOE)T5Q8LX/,;EW+TG7QO(#M,8"<ZZ4FF*;@41&7)UAS7<X[<++VJ'C)08
M]Y3B/_IEQY6X7##RMQ\J9KTI.-CJ[5WRXWNWA=/K;X5#1*J5+3MSA5R%.\#R
MZ$H>2V6C.Z@3[-^!%>DS'.DZ,JYL-O/I/2 Z9H.8P(#-1_L\/"O@1PO("R 3
M*-UIHRB"5RO'$@VVNE,6LL1WD_+] SG+F)9TW>M,S"';2L&DN8G4628>P%_=
MD5YLJDI:7XM [:'(XSU'N5) 'BLSIJ*NA@D7^8MP&DQ:8R9'X8-+!3)\1D@C
M^2AXI9MX[,3X:;15<I>#WK/W] <!,^+.T[B[.]W34%TUIJ[AYJ;HF?R8$DO1
MF ZVG[@;1OGOMW99XI? K^*J)[5G_;1QHS36DF7?W(:VJUZYJD:UV,7<H5S5
MNPJW1Y<'K>1CTDXDN)NISI49/THI753H'XYX[?KK4F70%>WN2SFD U $_;#2
M=Z%K()&SQA-+7@UEYKAMLH%,FDC4](51]1S;]I"M-A4B;=,A>F6>G2?AH!G_
MAJL)[@$.H 54%=-%D0/0,;H.XS9ES(%P !<'?EZ"?7S%S/@D(Y "H/_O%PGM
MTY<!,VH^87#F(-7+QX-&.+7['@G#H=&#%!F0,-JMTQU)<N&JUG-RZC,Y?:R9
MMCY?83#E:Z> F;A[% K;]B#E.8DKN6=KP1)$3( SUH)>FXV.X$F4572\2!)2
MZW']<8CE-1?(>51ALJ,%C>PR$4F,VFMRLMC-1;K6<W:)[1;Q-VEE2O>"8J5#
MON7QJ/Y'G].53J\-190H- UFQV]^2K,J:8KMX%@XT6_/%U8%MULW111_E%^1
MQ6]QRC9?<C)IF'AJ+:)=1:TS5Y6SE<B'W(]/CG["N\R'1.3V78^_.6S+>AA9
M A9T!+F(4P=UK[(\AE>+/@6@&V9.7SN-=#1HKJO.D&^.=WR+"N=#A+*[0ZA<
MT2W>H<6=F]Q+( #DT?+JJ^(H9[FBG&\9",IEO#Z02.[V8%#D# NXMJ ?>R!Z
MG!JW,?.K-U)JD <[[=M-031GZH=;?IKEK/ N,C0<E4@ (D:$;LN'B'$1 LS/
M!!6_!6YUY:H"5>$!J'UXA=T,C=,807T>9-(#16*E3US?T05+&7K8MLVL<MNF
M6RY*](<7V,V#]X%?W8SKJ#=] TLJ'E2LK2U/E;2)+>AN'=IX]?7DWZ)=<Z#U
M/Z^0";&OQW1S$9T:2SV')%FR"7U^:6J]5(O2-$5&UU"9R>>ABHB2PZ_YD/$+
M:!$DQOW0]^&\5LEN*V]!JA97AAJF%,I&)]<ZT/3)?P_3,8W6\WF'N$1_X$J[
M R*ADB>-XT.8SA^K-:M^S3T$5I$60U") :ZD99VHN)IEG2?1Y2#5I"':/MX(
MQDMAC"=VH@M</CM/JKS^,;F8_A.ZH\7UH'\C/D1'88ZL5R7 K <Z^) X# <M
M)9AX&)S;57 TF)TQRI/]YRZPEE](GBZ*C!:,#S%_8@;O/<(582?:_' 9P4,]
MR,O0C.^D]2W>V?HA7176X9]N!F =(&(M<*T3H2]7,Y--IOFQG:_S#A\GXT1N
M RLH<:Z;0+BZ-#/#KF^. =&1'@(9$*M[7:Y9;RU^O6 6BU,':V>@1B5V<IF^
MWC;#$Q/MK_.9W^3,,F!%9\66W-0NG.JXW37<R1);Z-0A=964#$5ZZ'?GRIS)
M*F<K5M!NYTJ3R ZIY%?Z%'>HIR7-V-PRD;0B&[%\[QO;^7%12NMP1FS>T(:;
MMPXOL=!Y01-65$7V:N I#L]_XE[Q" L2;F50RQP78>28^:%UG%S*Y4"E':((
MSLURE%1?*Z+HU13(>]/[V[N6'*H:U4-2'@P4,%W)W0K*(5Q0-T5[F"(%'^N9
M1=# EM-LWYA<53!<.IH]A:6ACNOJL?1"]1N!32I;&'LCLPMV(;F@K]+1;LH0
M&_HH0R?GRR6SS0;Y^'^>HK7 .XR9:. =NER)6[9T/M")9B6/-^@S-/KX$ EO
M@OA0>3K*8]5[2[\^TZ9^9%W*1^[[EHW;$?^K&JW3A?D!V;$('X8*LL58%V%6
M&6RBF*%97CS*;,$<=P7$WGJQY \[R<>PO+7M[\S%S%E[ZPCMNW!+7[\?X67:
MNR3W@T9U76U][7OJUL6A\.PY,[M>G)=)7NH]TJHXJW9P \D#40*N:\A&=(F,
M'V#F1N;CFJ\#Z)4QMH@(*-KCQ8K7DQ92JK#MFC[Y#BA*]F>65<"= /AF1K8_
ML_5NWVVO-8M>S_%%']EZ>^;PF:H_E7Y. [;AW"NL-5'!9"#J>N-]V&%01]!-
MXAE[8)\W]2A/$>QKBV7FB8+$S2L<7N.?8!=\#QC?\6EI.R.G"N>]_VTV#35N
MH_FU>ZFW=WP*P<4\"$D4W<QC\,[BYC>MP;"=W[G!G*".Y#W<.P+//L8?!7MF
M!XYSK;-I,%0XY1+^#G#62:L[]@W@$4%0(@Q(H-DSPHM$3OS2N&9L6 EFVJL^
M*ZF$A3GJX)4)"U_RF*$]$M9A=,V]C*M=L.C[GF#F%IDA>CRNZU-)'%,W,T;U
M1-NUA%*;O\_.O[SKH6-V,MCUXKJB5=KR[0*=OMS<N^QOUL_32!;EKAK:'2J&
M4$=AN.>7%#)7FZ34EVMAW/NX>N>'/KYA1\Q+*U<:_&46+3S%^Z0SNFI%.:GS
M,9[,#03VYVXVY)U0?ZD1/U:;<TW/M XM:LA6TI-"-\9W/*&HAYM3T2=H)#[D
MX8?BI09H4-8B-^]3BQZ3&'M;X%Y745;R*A2@=EH2!JBG6^S].#UV;W<+*2J>
M#LGM*DAX./((<" JL$IXL1ZI\\[DY1F@,!/U&8:)\=E0.8LM_L;5RO]LT)07
M&U#Z<X4:5<+V:YR6MH^\Z?K=X;/#XZY/?:K6WBQFPL>+8QJPVK<G7]VI#G L
M2\AWL%*]2(I)U-)YF-)EH.Y!MSVY2,]'W7M=9N";87TG[91";TU\B;BVR51"
MIKIC/.'[0VE@=Z]M#MC,VC<0B3?GT#LO<O4 @8)V!1,KL#"5T3A=6=)B$$4"
M?)!E$QU<650#*&[S(?:#5;7.4O9A*-[QW;/S^C4C1>\9Y-JWC?4U2;/>XF !
MB1O*:+E.YLIS#JP>!Y1H2.@NV8<XFP4[T(6)E3X"IK-#?:-0PEP]5I7XI(F[
M+Z!UE?,U=?\S-D*20#^!;?K%<ZN^"5E0L"@M7 ^5R)(H8.[Z.S0.??1]BO)$
M28);;7#.5824$_X!X%+'(L;QS@^VR -QIDHLN;=9Q"Z39=386M?V1[(;H-0Y
M?K\:&MUB4C6!>S?>:=V:VE6OME3M_?VJ<M6IAHOYFX)>IYFIX:3OK5%"3W+?
MSS8YQMEP-SP[\..!G))0#%E!UT"Z_))QNL)(FD#ZET3EU51%E9W7E78_9&]P
M*?YAJFU:<*9@])SO]O/Z_A$Y)>\AEY);G5*]N]<<,W" 5CO,-705=*S%D4"1
M!"*,U;C[LEP&J&K?0^(&@>2"":X"H)^\TD#F&E8W<89U#!/4O]P496E44^H^
MU:'K/#-2X_O5#.G*,L,M^EZ8AKR:Z+@ZS"G\05"4?3KH-JR^D0V/@!_5M:[P
MOG.CP&HDD'I@$5994.S3<+R-^J"5DC+_X+",5%NL]>_BS/G7:KJ9>R)[POSN
M6@?/NMID=_9&O\MPZ_QI>-PU36YI9)/1\;6ZP $@?7"):,VK)UEH0 W@DJM+
MQGDU7]YEHW.,EW+/5L)LG:JQ,Z2_&UJ<I[*JEY=N7O[+XO*OCZ]NK.41R0^5
MEA$1%$1V5Y,Z0R>B0I-4<#(_^'6J[,CKTH[Q8*.YK\F]H<&.Y][>='_B==\?
MHS#Z%G_("]J5E74!7S0H%WS 9YGH.B?*8XP)+MM,6=H]L/"S*SCC.HMP_5F'
M3<G&T3,9,DK]%ZM]QUCG6_2,WQN_BYRTOB6M>*SB\"1E2#TGQ#S-U:6"2Y'K
ML*A*&RW1)ML*]SFDFX0.>OLEL G5KZ5,73X:GYA6V'X3IU"U_IG[YW]Z8]%/
M+38TDD37:& P8ZDU&PW3WQ5ZVXO/W4'_\N+39 QO.#+FAV218.9:_?R>M3-A
M07]0%VH2+VS 4&I62AM3/I%0=O3F/9DC*3(0X(/D"1G6S3$[)9&]#-ZO?[D'
MXU%EU[]4*]<W_?G"X3>S)RI3+9:OHMUG]FI"CGX_\9$8P77;1ODIOX]78R4=
MZ&/X9<YK9[U<N6]I7 <[N4*5<GE<%I<AG1-L&878%U-E$;C0*2*/$5&LR=_P
MN):F9+*N'!_[J+ICJ/VK^&E8VAE8P++QI72=-%;:G4)6(=-"U?C28^-+1B99
MJZ0?(C$MDDRT1/Q5%O$P&$03<IV70H$W YROV$@8S/?M7*WE#3:T[&B-(_NA
M.5]\?N"+N?W33O8CJ:;TK_0O0T7TE;DA]QJ?2Z::)G:P#L<#$1-&;K+9,HYZ
MV>.I#QCE11+AJI<NG8@>(S)O@LV\D(494,J/#_DKC=CQ O#E;@RA.)=\>095
M72C6"5QUWT'D098\S+3)'!?24OME//610[=*ZZ2%S]3,D]"9B<MZWZI!'Q]B
M:$#%O:FZAISM35UXU_0QSD!"N:T)@(D*$)'P\O(39WE-RPVI[]ZG7?ASZLM4
M12[9-_1AYC%?I%7[C=C&^HM'/H_5U354-]37U#0\__CQX\D*'Q^?NTE26$><
MN5N4D.?=X[0C%V^\47@3H]@=5_WFJ9AM%1_R+V@+!#HDGCA?^8(/>99*_*XA
MSX3'?3Q>",)CG+4;%-J9I=\-+.8L4I([2$I*O1^:O=<_V3/,LHF8CJ64J>"'
MJ[OXVI]\B ,'$<XU+%ET8%!GUXXL;S.B4FB%WN.,R")OA]RDU"]F6<Z[JW7]
M7U^G1IVUKL%U/7NI_=CQX@SW"D>S-*"F!"?5X9#J^>33F)<PD=E_=F%ALWZ5
M(F2J/#EN'+"##3(_=W$\V,^@34<Q%[O@"UH@5?B0W"9#WGY3@?.'_]7Y9<F1
MTBJTJX;AVBF*67Y%Z;#%:Y=\WG=B_+3.:Q;XN,LW_T%\\.7C5H_KP]6@@*J&
MK3"M"=X4O>VL8 &S_]QL+1?>SI,,[VJ?_P,7I2)TR_21QE!O@P41*UNZ)/4M
MY:O^>U^M2^7O8DUBW?>-9SYK.5.V'(*)#<0<Q&&M ,VX-WKR73H9T473V)!K
MRE'6R28CE3[D865Q=S<%Q\L%>Z_=@ZBIV5+^BPC @4-<AZ:4V4H9"ZLI682K
MPU):>H[Z=*E$JMGYXF6EJKCE'3?9B>7/CBZ;7Y>_+==OJP2MU^CNG6^;/M;"
M8 ,JH^$M:OXLN]Q#=X%]'R-)_17ZLK58\=KJI2$'Y)_)/F)>8D=3]\<>.Z=O
M;>VMY\$44)J6ZZ7CV*:UYWBERN5Z"5L']XSJ<I!H/*SAJ*+S_?+=%OJJAM2$
M2?Q$J-)?E:2H)8:DC61!EM6KT_=>81=0_SD>^3@T:]+)"8>(/<L4\=A?/&JF
MGC47\&8MT+3;5!L16$2WL3GP^MY'/F3UL[.#KW4KO9E.1&8M-O[@0V)TA6<%
M9-7K21,\M@7.3!9=>')B8M)^4?JW3[7]MB;O<@>//$D=7]R.K)@BU=:_</\M
MY>0(\YK-B3@[B67IO1Q,C'3[QL!^G*-3F-R^.CK<[E- J_[ZA)6BQ71[E<I#
MX=<'W2RJ'5;T%0L5%!NWA?X]")Q"O",?HA>0S#V2S8>\*$Z.X*E<U3=\_CY)
M\=2WP^I8DJ3UW&9*8E[S^<*TR0=SOB%+.O")RVHSIR.#ZF8T-^NJ M:JPBJY
M [(0P4<! MD#V=,&$4F#(&]#M3?G3]V@'J:<&A#^(LJ]S-%E;$=5^;.D%F0Y
ME='GM,9761&MH[YG0^5,*EP B$F.P:,M_V(A]2%7_3 9/N2P(8WZXY\=ZVT?
MJ#]AR?_N_GRF5KS8VLI[^9@2E]& !>MP'RP4][V9UO!PE."NNRR7WEC]V=:G
MD13J,CH50C3*0T[@#K1GA/S)J,!+,D-]'ES=O%HVL0!STOFS;N?BVQT%:M*(
M[Z_P.[^@O^,'$"L%*]GX/ZMAXQZ=&,C"8CZM$#S0WF2%A+:VCNA>D<YF5L ^
MHHXNP1+NJQC>_I0RWBL^A @\^>I-:Q,]PM*IFW9!VOJ^Y3J&>QXNP8<,. M6
M\XL<'_+%&R5HJ V\D$4X**G%A\A8HP[C';W([7@C#W&I4-CFG'F:F$_HXV*K
M$K%Z\Q)SG_-DU(0D8O> :^BWEKSO6T9;3;8A7LPL5)2NWI].6*@#/+K6^>AR
MET[X,FSN8S)I;'$+]JWD[$JJ%>-^3=RTJ>7M%[_;-E.\'MH;2%_OMQEM@3)1
M8I->T-QSG+QH7:,@YC)U5?CHFLN@^JK-_/76R>C5\1NCFZ./%X."GXF,*V==
M?A?3OG46MC7PGU._Q$44]ZXTU+I=]T:I8[J574BIEW;IDWFP8H4/"<*2/GQ;
MR1)93<C.3&=S*@2E3 _8Q(9N;(1),G4R(W6URKVS-!M+0=]K(QHS1_6ZFO97
MERQJ0K.*GFX95T\9O5F"WD8'DUJ'#$H>,2Y=<S]8=MZG5.D$*I)X](PI4IMW
M"I166,^.C^^_H,U5RC_KE6EKZU/L[.RU5*^H7'FA[H!.9!<C_US&2MUD^5#&
MR]W_,JU&S#EDVGN#B]'[@'-NXI[=ZMAN1:U4HW-#1CIU\-VN$BZ]<;<ZI17X
M;+/.6%K=:9K)X$/NZX40 QW; XC[0<?.T<SMJ$BF[]$%AZ1R$V_;;<U$\N)6
M5JIZQ16-W9&<UI:MR*\OR'*+KU_9DWQS7CT'LSNDH4!.6HAO/%Z5^4\7>#O9
M$RJ1QW*&HQGE=YLC+B8M77$VF][\M3'F9L?E=-V1?<_?'OV\E?=?A$3054Q9
M [6)@J#HK[H]=,BSK5B5Z4US\^)B,\[+KGEFNA?PQC_\#"90HQJP90&+?>3%
MH GT(8:N/+."J.\KO$R0^E0W(%S[Y)/FLW(O35A4W*"]KH7]C7'GN59:N*&[
M;+F%XYGX!R)BZ/^#O?>,:FIKVX7SV%"*"$@7LA61#J)T ]F*@(" ]$Y$1 @1
M$&D10K(M]+:E*@B1$D(+0:I2$B&4C4AO$J0D$9$FB4)80@B'/<YW?KS/.[YW
MCV^<\8WSX[P_9OYE)?.>U[S*&FO-^[AIVKE0,&WHC\7V]G'8>]*I&#/;IKP>
M[AY'OR2_?]=\O;N4'=EL^O&SI[N'FV)#GG2\?^D?QV6D+E; KO^;0%3'8&C.
MB0TRZDN.;P.5:(W1#KYIW^^%LO/?WA\#S9@>%_9XT@M15%!+Q>=*TO!)DDZ'
M)5_XZ!DG/'C+3Q9([/51B>9=.?U@7"G&1]PK)-GK"_S64N7:C .C9-&I_-X[
MDX _\6>"Q,(#+$XOO,M>5++03'&<S.N3KTF[R>Q#2P*'@@5GD7;!(*1.,"_,
M(Z;F)^42X&>:2=G.M5Q\'AE>W/Y\3%W]:E/R]MBU04@Y-WBVZR8UGC)_>&52
MRBF[ I#KC"K+?DUA!XI8C:,,2^?@.ZK'](HOPITBQ3*HR\._G$9,%J?/(^H4
M,X,^%=MO:OP3-SC[<:YAQ37".UY9ANL[V'R::JG0ZQ$N+]BL4,1)VD34Y-?5
MQ;ZZV]0\5=M4YT[(+FBB[LS<W?C$2M1J-P@T;'@9MBH9%M<@%0I_Z/9^)]HE
M@?/XSF2@M%O^U4/)(4$^%W^Y)-\;:;"8=$J-%-UU<]?>:V]@WYK7$LK_2TV]
M-"XZ_T9-1,/(C,<0?F9(2Z@Y6[7VJFKE4'#0Q!KLWP5C'Q0K1Y__M5J*6;@[
MSTEUQ72=8SES$X)^6]T'79S0+<C*CYXSEU<+MQBZ/KP/:JJ+@=*,!7"D*02\
M:3ZW#VMT (+#"T/KB (,]Q29#Q,\I];IN8HYR-+L1JK7[^S<Q/#RO=SUYD,_
M1IT:WKKBO+5;(2+!IG<O?S/B9Q)C<:1\"OHT<R/^POC'P/*!U]]:(G+52[WA
M;F*DC,ZY4<L2$8^_1O*?++JY\B[T71:,_K=_:_:?EF$$L*&/%]/4>>EF)Q1-
MND=JZ+1CKWX;BUA,GE2:-9FMNO)D\.'=,1>.]G<JJI] )&HL$6?Q?WR3Y6'&
MQP8U)F\(((TI1M(DEL#03'C_[.%K8UI5A(>KH<W4K>0"(^IHC,526-I<S$_+
M"YZ#:VTIU*C!^%)DLE7[2..Z@M540Z"%7' YW&TBNPE7MG)*C/\VJ;8]:65R
M1?BO&I^WIG8?3EXZ/=7X#[[*DIG;G>C@B#O8^LH5'97I@HX#>@_+M74W%(Y*
M**Y^+R\E!!Y]]66R>8HY&5V#4"\0MICEHOV&$A<$CYJ5+AL<0?,Q*_UEP7E7
M""(FZ90=NV4#^2XU.>.0TN7.89?ES*XI8:U0E]XS":/Z3L?,I>K:W)D;YI,$
MCDGY-ZK9LS ,&"&E7E3JBIRR9Q*:B!A\_R.\.4YUFP"/I!4$VS4]&835&V89
M-&::!Q4/>U DB67_!GS;?^?HAOA8([6QO I97KIZD)]*OX"3A75HRE>\I-=E
M1P6)#\45DLJI:);Y!<O!2_>J60#"52-IYGQVGGF5FEB+)W72;PFZ9K@+AF/J
MQ#N@<3#>FBV-8YRK+&<*[(0[(&2D]&W^9"!'B X5\1=S%E1+D:+WT\$)4EEU
M[CVK?*\G\CXF>/NKKE\[;[9\!1-/.E[?,KZQ#A&A77%??\C7[WGGQPQEYZ:N
M6W<[VVJK"1\B6FR%.?H+-=N-'#4S,B^ J<&N_<-JA?EPM%F9EWM]0E6#>5@R
M]X.\W7 H3]]G88YNC0$?&N;KBG@=O,6='KZ"V^-Y'68:SDI4R=MH_[5LC[<H
MU!60L+>XZ+$^+7^ZYLNK_#KSIIFHV67\H,X\OY'L=$<)E<HQ9'H2FN.KM=54
MC)N:F*3$TP9B^=4U WY6(S3+\^E6M9.9VU$%N*3NHRN<YC>#>N48FCU*6\?8
M"BJ .AZV^$ZWWWL?=+SP*5N^59,O%*F&IGSARSR4P-^!HIP2RE4612S;_-=*
M5(,!8KW4Y_9!*\$B7NOSTW21UJRR^>[6;/.^]L\X?=W("\[L'LM]T-6W-NWN
M=YL6ZR(LMT9<D:+I3R!R92M#Q&6N$',22^P7?WZAT:=H.8?:4"N1(<*W<M&M
M.VI$XK<TL%JITN+Y$$; ;SJ-\WQ 9!?KDS%=0]"?="[><CQPBZ"C%FE9-\X8
M"W>_U#/F6&L)!#D-V39<TFPF-9T(.1'QP_?:@-?2/[H"+.<:3.P1PW[/@JZK
M)R\Q0%OY::ITOD0296L>9J6B0T"D^NEKY^UPQ0;6!_#3\U81SL&P=UA]<!Q4
M,'$B$8A9J N?G9\Y#_B8*+@.C,*PZ_9L*/#B*_<(&1KX$SHZHDZ>++:TK$!=
M C!5WUHP<5LV\7-\$Q#]TMF8UIO#X6!^_^8\G=R(\QG!3? =SX&L)K%(K_"/
MF3'%D^=S/^:8:;2XYI%2_IG:D([TE9",A4'YMKMX\.>I[7O%19*]L C;^);2
MZO%@Z6E7F_^Y%I^<8V2K')&MT$A$5>.\<^7]'WHE+L_/)<HE*8[XI.EEG3--
M.%1\3I'W367YK=,"KT&:3V%"W,'Y-W8<,(#?->58L;")1F".8RNPSJK<8-0D
M2G,4I"XT,XD>[YA#<9#?PF9YNEJ:4XW.63T*W,M=D+:L(*K>WXQ^%\Z3P7AX
M+:?%%_T*\U]O&F^4%BOY<'PO[<$K2>Q(29XM+KZG^_99):<2TW95*X. ZF\M
M#79$"Y%,RF!6I7R?[0>LEELA(L.A0']()BZS]',%7M_M4M8C=P0MFS[?59 ?
MZ&:Q]&P>L*=$E;TI!9)MF7.QY4#RU;2O:N(>Y-'[ZHVI8BJ-TX_$LBN&CDSM
MA$4&1'R6SWJCVM_5T2OZ!'N")-5]\F4@F ([9((H2A0W:[8YX:]T+*UNMK_<
MHN6NY1VY6M=POI<:GUT3*+.6:C/?\UQ]H1;_]11#S3K3Q>@E$DR8L*FFN8EI
M*A(G.CCJ!#]?X):J E]7QFAM8/YG#D,3,!';V^'MV7OB/ZI07^;YT6#]"4N.
M$=->)KP98=*F6?QFTGW]W,^(:JN7W.'@II[F(B**PLYVK_Z55%>8:S$:-GNR
M9\9R9'-&0.YFG6G:F/4HX;<W;QI,(YYG3(Y.GVUJ=LHPS9Z4]VC5>B:\-K'^
M[Y&QHI]IW)WR.WSS;M\B]<>7/S3'G]7?4_@FH'"0T!SMG@$J"66OBL<#;*O^
M*LVZ7?IK7KG!+OURP$A+BWF1ZI)"*K67EIL7L<8V-U\ESD]A%(EX-#_2+5#.
MO&5RXZQ_37B)^'1)^-DQZ^30\\].X:P^I]WC-1O@?W #.BF5WDD^NCEPSI\8
MOMHP\?W<;1;UO*FAH<29IQHOW-P_GCKN>L16]OH;"Q7J'Q(@_K^SZ<))$,CW
M]\._A7-6=X+?8P_]+)0<5 PA2GDOWZX_(\-O LF53XURJ7P;\+9%/1:%-FB2
M=;S(K#AC:)%5^RD@7/F#>D.5<YCR"-Z*@Q=BB?+[BO_QOMDN:U'2N8:A:!KP
MJD1QK*PT:WTP"Z]P&JN<\JCD0I]_<1*79*3ZO].!_=^'RA!)X8"47E;N@Z;^
MWMPV;C%1 O^I,W422X%K-2^S#YJ6Z2+OE/7(3/MQ4NKV0;LG.S$K)I>'_?_N
M6_^_U1G^_Z>Y1);ZWOA5ZUPORXU_(OW9!^P&K#*<LED\E&O1+U"6-0&% N-!
M<GN?I]0NPT.K^R!BN=7'?IT5Z4KUB]@'Q63??O'R^D/G@R1UPTBKB^D<=\;F
MA5GLS\*S[WT>>LPH?T1\&>VT?G0Z] RI240P[YY$U%:%4Z$S[T1&-_W!&X+J
M>;L*MRS_=X[X[\ROO'J<F1/F]'+O@&OMO./9X;:JQCBGR]E2#U/N9L--HI]C
ME?.W[_RJQDYK.<>BY(8Y86IR4QPX72: ]KUXUKO(8W WL.BYM7JCXGLG7;NB
MCSIU/G]=._\JINB)V??&'9Y#(::74P ?-;J'G\"]SPI[53:K$O>QD!S1K[4=
M Z8N*%/U-&&"O[=OXK/VZHL3?EM)8:]DSQ5(U64K/OK$4;UX@%'_.^4,485^
M90"-\5$B)EW,&O<8ETV#/^R;S^Z+_EB<I+)V\K\Z!.G_ZSC\)RL^>7,?Q /O
M86^^Q!?D7>&3^'2BYNN9["-Q/V@)I\8&K[I,^3MFN,HEDKRFT H T2W#5*J:
MZOE.H;]AM&!=2+P6SO .UY23_CB:-6AQ_O::!E!2TU\-U#O8?9F!VS5E!LJ:
M.XA5]SUX_T#7\M%7_=N7G/OM;EP?.@%; J=P+X?H"K&,0I[??4324**]PHN[
MJY>8:1"<!2"C96+5W^YHOOVPJ6Q'\$J-VOS*_ 2W\J9=T_)3AKJRL^5WT,9_
MTBX"%GHI)A).W<[/ MXY)N45EV4Q>$.RZ3B)OE"+SX-6I;]44VV &XWS.R=7
MP8#FWUWB&C"=)C7[H.%(EWU01^J!29"I;E%ADM=3EKAQT^E<,3J'O+P/RMTB
M<.-7WF)^_3Q0SJ/V/[A+&=I0VKDIS+<KU9B%GI_[H+21?= )L=8#79WUV0<=
MT\5R(NJ^E>SZZ.^#BIK^?L7Z+5EC![.XAPC]/W29VD73#"5;^8SI+ZDC"@FF
MHYW=%JIO3C#>-E^Z;KTITGO>Y ]A,^7O2>137#[T&!F,"J1A "7=9(COKA<<
M<]*9?7FO#'T9!08PY0#C/9:7YP\B2H&Y:S*V13C&H!<T-L>W2=*M?&Z1L7:!
MN@YM3+\$E%:0T.EE'9UMJR_.K9G>0*9!47J7]T_JIM+B:'^)YQW-=UU+^O>0
M5!?^2T4V1RTE#0CT@&N7/"J=LNEXN,* I_?%'WA);X:"K4/((OY:_[0QU>([
M*C'Z34NP&2(<&O&/$R8;[(/N8F8(Z$NHHWOY*!^6<X=!\V,TE!,"N&-8UDL+
MN4\W!860\;!&YEQZ=5^1!^KW>/.TF5OC$(T%L/"O//0[VH!9SY03<S!O[B4M
M6<8>-LE[ECW Q^X&A.CIQY>-+C.WTX_5^Q)0M[ +AFGQ)^/I?#92&CW2QM'L
M?= S:O/C+<_+%BQ,'"H$=[74,R"*E$QO%=#Q5#%K?,O2:9B4TKH$_+&4TLEJ
M.BR:U.E<&*G\0M730R @2U/OLREX9IB80+&9IBM.5EPC2$YVW&&8MAMDX#R]
M5RVRRBH<_9_VKY@*I_BK(TU+?93#2HR<I1Y."B=E9*0LOS.=2M<*:E_$5/YC
MB4CB>T50>/J1;QC^,+"D&8O8 ZU??X(*8?I14FVZ<J%'VHSI^;L%$1K2RWG'
M<$RL&Y/;3I.QA6@B6%(K6Q 9//!U1250_]QX(,IQ8?8A>])3SNV*$Z;).5:#
M'$"41G\8!E3H)UB"E /@%IX!< 2@3N/$ZM0<N! L&I!7ABV%[[B.-JQ;^S6D
M@?GF\PFA=KNR!3IE3=1C3ZCM"^.C61<Y/O9\JIX0TU#E,%HJ(2&9D&>'C-*/
MN2EPQLIUG+#&G' (8##'%VWX8$)>695FJZ?+*[,*O/>NFE_M?!(XFA+S0>/E
MN%V68S'N_+JU]0_;E'<PE6Q<<#WY'\&CAY;A?L8<:^-C6H,3R:?V0?X8,90G
ML[!D]W=D_4(61J0&?0Q9U8G]5*C5"CR.IA7PT7(3VC1IV&,N [1HV/&5J0@R
MWP(K/D6U85? W:X^;=MI(O5[E0BVLLV1M4TC/SD(^&) :+?;5F\\$7*"N=-/
M)R=MR5A>GV0POSY>6+>TFPCSU+A%8NF-S5.JRA%2S;%;*@(JOULV3S5*-NQV
ME"TWWZ$ZEW?;,\[(/QHN\-CQ:&1)1(7[[#5:B*[0E(>+$E(-D.7>;X2RE=^^
MTE(>)5S+.9?U1NNL6ZI!ML\)O9AK(7:V%'S_";T90051O9^FW\\,1]Z*"+#6
MR' *^KC]CR1)S&\3W;V%4F&1N_8L%QH+\0=Q#.4ZQI$4[/J$$F+,'T/6=QC,
MO5N0W#)^34Q%Z8HG:\6<U#CE/]GR52OP%MS.,J8$9AX,IUNJ7;"<U5:I!Y)9
MD1T8?GEF-C9)VW7*$WA,Z*>E'T'"3,;"92*[9;4FUS=7V^]]IU#FP".!C0)V
M;$,%D]&:QH%@NXN]I=_RK!IVIA(U-JN.JX=++1:@57 )^-@*& 2?6&6AO3Q<
M<+]3.\![T89:??VWE;DP&<5!?%/J\J[>AR +S4PUXR/TKT7&.1K9?=<R;3-"
MTE509.%<Y<6H.6H <76>^1Q!WI29A#)]'NV#>OT/=G:RYS[H]?<W^Z"GTD/<
M*[ T+[Z]-Q"?&L0\T^F*AA0J@ 6C:,1#ZSC<0_5 -(MW>R$S@*0,B.*!S(52
M+T-6<-+6$,@-N&3EW,,NY&7);PWB^$D*8QJ;R4,GER.B,KR\EB-_ J_W^LK0
M8U#^S7:Y!?74<$:,32]7&V P9U'13':O*9, L/RZYD_Z%\H,;Q&%D#^Y0C&7
M>J@SG6Q+.#U?P&)'Q@'>-#G5@B/&:WW)O95#N6[4Y)W+RO'4LR^\HM5E'<9L
MS.B<'*PTU7JC+W8X@6@PAK,1E*35?0Y3]H%'^SGSK54Y$H[3'#2U0_"J1Z]3
M<19*^AIHB; -WA\4E-*[Z FEW?3<G$AS72-_8B7F'WD&-K8/0A ?YY$I&G%0
M<2V,;#<!*<VP2;@/$6=V!EXQG<)-H<(9 J:K#F_B.UIT8Z5O)G?+=35%>HE-
ME$QN$DP[J3&'#*4]QB%.6@@-02#=%N+;O+Z]:]!/(Z:A5=^RS%+#!L#L>YX^
M7/&G 1@>KOK,$)/$N-;T]-:D:C@0_^2\>&2.@<FF[/D?*"-J.A5R1<M+HQ;1
MSGN=)?"@,U=Z/%S4 &6N;TO<"AAY,H!3=L%64XZN*9NJ?1 EM2K29/3E-:H'
M]:(-1AT6,<S"=\%;#CA1Q=9;]>G*V$L1]>GG[%N"9ZW= [AC_PD=9ISS;AM[
M/.'I'(DY#(OZ2_H]M(GX_N^GZ$^U23(IOT]Q[!'TH43T,1*0S_P,5-&&N@2/
M QAZ^K/-%UI5A% '()1.%D4&7V624].>^M)3+]N.!W)T,9&7X%/LG<8ZCT_Y
M!-/B27*0X/3N[\-0FLX$!(&!,PF0N_N@DTM QS[H.#8)!YCYT;-8AY'7+-WG
M$VJ710"W(>/T[I'F9XNLQNY10$SC% _S,U<^V2%U,V-65C?5G[9X4LZQK,*B
MX,)/$[MB@D%#1;1>J+[59%5LMQU.XJ<%[J9A5(AU6&6W5MUNJ$;5P[(I735I
M=<<3%M^IBMV==D%]2B;K\ACBO]'LF/Q4X\M;O>KUE3?BCY3F;EL_JSIFYXC[
M;<V7_Y+>[>-?>'_]A.V5DB21D5VR%YGC.X7-E0'0DT%M<MZ,7RA-&DP(R.A_
M[URHGT1=ZG0B*;0,APTXN/15?@K(:9D=ZZSO+OKF[(168F619$<T&C9.@8V8
M0[U@7BSU,CN6Z53$VKC5#N7G2B %>W8V.@5/H73R._,4.F;%S%'6N?L@X=^
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M.+I.3@EZG4S1W3G=VR5U[!WF]O!*XSBZ=V>JRR9!5GB8I )4T9=2.;Y%J&M
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M ,8*>(1'&E\=UFHUA)JV,TEIVJE2%.<IE'JAUA0!K3"(L2,IHX0!2Q;9M.&
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MG6RF$=Q8M^.VRMP#PS=G+&,"T$\7>M>3"M68\[U0<>"GB2E3O%,P22J2LB&
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MG-@<D*;WI@1S%9&9';JRPLR<"C^>KG:86=WH5JK?==:%(G@X0TV.8C QF7V
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M+KY21'?.J' ]+V7&2VZ!$Q9[*5.\U61+U(_@MIS35EZW+D07M!!NRSTL\F:
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M]T#ST??Q",GEB?Z\FH#N B^&MR22_*,H_GU5"#T<MC^X>P1QD 7D8!M;0%L
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M%SSGC\$'/J7/\'G _$V]=;X6)2B\V7WU_V;7G4SXW=H-QA=$$O47<.(HG;%
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MZ^L>"A>V$1RFY4GI:>^], KI3]DWFQH#BI]0]A%!<$V":Z##$'Y8W4Q,]J>
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M'IC9UQ'3!89/[JO>_Q[#D[IHY#WX-QN(JI5.*SF0XK\W954;DJQ40C'*19?
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M>RAR(#2A0_A(TQO*WBX"!-,ZXM&/UG!L;NJ@[)@<WUB( H..>M#6/K;P 6-
M<-T;9VG1\Z[?2;<:IE M!;*R<U MI8MY,1B$S%^T;NA8SPMBZL][?K*,:^=E
MW 6T;I,['E%/HRXS=R+8F)911!4Z.CGG6T,UZU9';+>$=0/&=41R_$C42T^
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M!\=LK]* Z;VL@JX6Q&:4DL:7B!/(;$/FTYQ\(7,'\JJN^2]E993EZ>[]2')
M249#*UH;9M,C+5OMD;< >FY=5#1?-)I\[YW;66LXT.8NTKZ%:!-+^<AX:H,%
MU9:I!4E8CR=A=71R<KK'NRND&9,6&MX: GGC$D+87S/[QVR)Z)-HK[@@E>@Y
M:0+S1P?!(7I^*#ZG(([EQ@B@(S D] GGM7:^21U^NC[[YS.)P;2"LS_S0>1=
M_3-4($N?%Y8%OKC0BF]-&^\[4X5==6@)[P0P7=S?J^C2A5C6PQ&BV#R:$_9'
MJPLWU? 9?/KHG%<JLO/6&GC*H"L"-$DT#_9#PVK@UYS7XDN%489%R)4@7.P'
M"#(.R.Y<,#"3:1@A@ND.LM6T'+J7/.KU^W?JHP4-21D*\L-+6".[E0"C(E^*
MT3MO4[7,F]_L?LS_J1-5R:)[.(_GJU;6FE=,.L5WVE\KL*T:B.NVQ24\KXKU
M2RJWP^GHR-N6QI4:Y4N_4U"&]D(_#'5M6$(.WQ/-L "8E+.?K.-V8' T .6-
M "/_+*UU@H+C4U(9Q99 L"_S%@04WP+"1.^B!5?U3DYH"%4_JYWXRZ[3FA/Y
M@JU,OJIA;_UZS]Y;!:+(NVL.#' ,RKP*L#PZ)RBS8:;?(\V4?I63':=WD?H=
MJ*6:,TI>4T_0<\6"/^=8-!4!=_4Y2RXAO97T27_"O%H($T2>^2+<@:]P?WJR
MH->!^HRW=%&Y-:GDG7?-33EI&DOKIJF/Z$RM#G7UJ4VE:8EG8A36?B(GB?%+
M+;>'[K?19\:E,#!-?Y()7>A)NF*D82=F:"MQYS A0G8EE$HR#UV@6;X*RM4_
M?32'QLOT/F4T-M0@GXH@(_A8D%&4-9QV1S0103]_5H043.G)]*M%1HPJQ".>
MC+EGWVXBN_3T^(T!(GMW@09:@:@+@'-@Y.=5L/2'.Q!#%(F%HT)&@I@CR=85
M.?T9S4_DD(G1$X-;.<UZ:\[QHOE1FI-?R$:1=+-6A5M(Y=H@,6Z'=/LQ?-5=
M:U-GLK*I20^F[=SKB W+F)(J4X?#S99-2"E6Q$++W,14U;N"X6-K\KG3B;"^
M9H4#1\0RKS$Z;<M^D,5NDK+_B5DJE5XQ-[+.$)4?3V(=D- ?V+M:%7!G<!@B
M_SPUKM%%?[WWP RE_HIJU<)8:O"<W[R(L@(299+U>  5$U^>\*S5-4/ DX;_
M&S=WIUU2)".-0@H;&>MF)9+[!CA&['H%<X&$.-" K] R.YB^G1TG(@;SSP")
M)4"3 T,ED75^P0P<J6UJ60D/O5"%EM3G:1=&&8VP[OA5F\TCT)^;LO5 S-O$
ML2M >@GLQ21$OOEQ0K,GLJ^OHE+-PL;\AL4<:]7" 3(ZX))<EN;GAY6E/$_*
M"OQX7;9X?5;N,4U6WB'#>W3Y</P:OF+;\GM G^RC^9R,=Y["9*RU:;)WQN*,
M4\27=N4Z9BR+]Z +-/D2=8N^839/+F8&]': =YME&..CL\C-!>YHHF4Y7 ND
MMKH/"\"YKD"%40&50,O509"S\^V6LK3)T/H[V"8,TGB/GSF;AUU?YNY2>77$
MPSQFBXP00#D<-FA0A5!J'>-$X?+IU0@18%NZL!REE6U91U:F,?##/YL$7Y!#
M?UR'&(07N;F*;)R<='(UU]M+D!<(2+*&DCHV^2?QB9"1!2D905"=7_9!>&"I
MB'KF+?CY-O!9#U[4H.,H$K;5%)OA2C*0L%NX,4X:M(ME79X/H=GF7V^7>*OA
M,K*&]BP 9([9XO7 +%/ )(0)O</ =9WGCM&OMXR,$%R)T!LO'B$:Z\?HJ0.V
M=-\X5!CMF(T'<!GK.J>QU B@"^$OQ'D8L0EE302R.-4H9:0:/ZAI/"3E=W">
M]:P9<*:!3TMCBIR!W$_4^MX-+88C7;F]92[=3W!#A?D/?;8F#_<?RA =X*?F
M'>SB$$G//5^0\*>GF2FFA#(N!A)8+D#8 W*MSV[XDPQ[G6VQ#3&CE9MZQM4>
M_3G17DU"%>6].3<2LDTD<Y/F"V_TF J>_O&:U,MU]K&$A;Q52Q4W3-:B]EQ1
MTJJV1<"/_#.QBB4SR]PP4WSE2)6V[_E>,,/25Q0>(0P02G[JL^NPNP?3-[^'
MT;0^=US@T7JY<:7Q\+V.5%A-8^M"-E+*\T-+R@ T04@'_JQC^B\M!K_>\# 7
MXVZ'%9S:40$=D?NJD>X0!J3I_1KZ/%&L+&)*_)3QF,Z=*AB5[XC+^TB(J?^Y
MCGXK49@ UU7IUMZ9N]+JYC)FF]K30-/G<).JA)SO(]RV=AW]RG3*<<J^*;7^
M?&MQ<2EX#\-E/+>7EKNO&PT:GWGX$&X;]6O#/0O'N>C$:0$]9[<LE=0[:G]S
MAC=V@NR1=$BMPYJXU'<__O F;MQ>PO%T7)5!YLV 6K-/U ;TA@@6A02LF5 (
MX$>K.4/MA&@?5OFRT.[S:#ZD#9=,%\BQ.Q&^0KR"IBTUXPE,;%SQ!.%\N(0]
M\Q285\?@9CU3,>+IRR*DI>'8SL_8'H@:<(O.'9TO! @SV.G*T31GE+WOP25X
MP:GVRRLYF]WHF#GAA#%CIDS70&[<[N:K[&,V/K Q XY<Y^::R4T.OMLQO@L7
M"6&IHZ"T<+EG1^*K445- PW:0,)6$LW0*$_8/N%5!3@THTXMFDI E# )^?L(
M6\1!SN^W^USS'YR$ON6A'B[&=7<FS<(>+7O188NOJ_KX8Y)L,]10BHIT>K'\
M7O*J#'>EXYX'T*0QU%/ SU(#^(M6(DX"5%K'=_M RY/ ZD$G!9J@;GD>!4JT
M:6>V)4_&1GR? S7^=>Z?08/_%\< ./\T>'K#Q@MYX1O-4T?48O$UMJ>GPZ;X
M:D^R/V)/@]\2?@QX;^-^A?$33H-/C\7?M$_$CXE^#([?6=%U>)?"/C8:1?VL
M/V?P[H_AW1M$NX]5AU&YU#3M+T?3=._M&[N[JPM([>X65RBO/Q68UZM*KAY1
MI\K=&\DJCJ-T(4J%-N4JDDW[.A!2?+[S<F]6K?299PY@L'B,+F%*KBO:TZ>)
ME"DY8=8=?7Z^(QN(BJ=/#TVH^WQM65.*FE!1IQ2LI<WVU1117 ?3G__94$L#
M!!0    ( &6)9U9PSLU?+JD  +J^   2    :6UG,C0X-#(R-C<P7S<N:G!G
M[+L'5%-=URX:>T%$I"DM%GHQ(ATBL;R @(" ="$"(B4&I <)Q$*1_@H"KR!$
M>B=2 DI)I N(E% $I"2Q  %)$,(&4D[>[]S_G'.__SO_/>>>,<X==XP3LAC)
M7GNL-9^YUYSS>?9>X7[A+H!.F!J9&('V[-D#NL'[ W%G0-?__O:_]/I[D/_5
M,?9P/X $#^\1V7MMWYYSH+V">_8)[N%V@< @T)X#__D$T/_UVK-WW_X#!P\=
M/G*4CW<"_@1H[YY]^_;NWW?@P/[]O-Y(7C]HO^"!DV?5KAX4LG([="Y ^-*3
M%_F'SU^K;1>Q'J'+J+L'/CUR5%3LU&EQ63EY!44E#4TM;1U=O>M_&!H9WS Q
MM;EM:V?OX.CD<<_SOI>WCV]0<$AH&"K\T;/HF-BXY_$):>DO,S*S_GJ575!8
M5%Q26E9>45??@&]L>O>^N:.SJ[NG]V-?_RAI;'QB\LO4-)E"_?;]Q\_%I67&
M^N^-3>86L+WS-ZX]H'W_!?J_Q"7(P[5W__Y]^P_]C6O/WK"_3Q#<?^"LVL&3
M5ZT.N04(G;OTY+#PM1?YM>U'SJM;TT7< T>.BLIHD&49?T/[![+_,6!/_U\A
M^R_ _BNN:="Q?7MX%V^?( @&XG 4"A) _]:4GX\$(Q"[<BW-K9/2X;A-Y'>H
M">7P"27?IEJC%YW^Y9W'U+HES<1EU S%>W($]2?][ZS%PKZ)$C?955S0T@_.
M4]E6/QP;LMS.!1WNR>6"8*YGN*".RBXBJ[&0(YBLSXEJO<H%Q=C'8[:1+B+"
M(OTM&/@HI^9SV#]W&K/.BX>QV*AG7-!1W$DN:'VZ64GAN.W,#B=K,S2(2$_R
MF?^]21%@*;6:<4$#OC#R*1+Q)ZT+#-BBLKB@S/$1JRN!-?.3&\3*>IX9T1X6
M7! 6=P)#MJ7 .<Y6_]ZZFH2$?1FA'&(QV^7UVK^;.Q4PTEC;WF$<XHBXRG)!
MW_'!MV])5C9M\I"N_,3\T]QCF ZU4LS0Y',8O8(!X8)4*PL*'G]W(>*6,/9>
M^O]CCCFDM,K&F.VTZ,[_\\S@?X:^6/9&U]Z?M@,?G_K,&_+_/G79O\-N;VBX
MY_]X_?]X_?]X_?]#K^-[8ZM.SH69$4\<O''/TQ\P19L^[$\R!D_//I>B&5_+
M- E&2CO>"Y?-,GN;9B)S/UPF#)_4\G'%3+]%ZM-@FG.U2RL7E!J!W6'R++FJ
MF4N>W][C#6<>(A$W4I2.^,A5M42=C']O*'S+P<I0&/2OFKT^.77[ (Z-0<!V
MPHDU">_GCV$^JF)HNXY<$&F0O=\,M<,I6RPK2. [JE#P^/^Y\7P/? >9&$:A
MHT:(=!O,E#P3B;QNRA#H.H4.H[I ^X3S]@-W_T2UW'FZI"V3V8QGV8?.B='9
M7=8/A*81A+,D'-5()3-=V'N&@:#"66*EU..$K4=A[9#8.6' N?ABFHXF%R1F
M DF!.K0'GFUM3+ =@:H6?_S@E]:S9L*XZ=TMXC=[:77K#HR,$P^0])EHOS=^
M$3!M1$C]-;3LX&?OY]AN&S>A=B(,>/OET4!(<^WOTZ6GZ$SKGY:"J3%.]%$'
M]#E4=H6+A[S K'4V37S<I\V*?5M@VP?@@IP8&&G."&9/U*G6M^BKP R]],/6
M0[]Y#PI.&H4P'M-6[)1YA&26'F"-[N."5"A-F1:[RD T4+E[CS.*%7=:BCK'
M"@.2*<Y\'4Z1_.BK(44HSX&? 99'%P_]0?]TI7SFK^ R CS]E_WG\9U&YPUT
MN>R1G]#KITS0#NB6_<O&A>AWK>9.YINFP&4;ZW4#93'*2^> @?422C;^CNOY
M#/S/:TFRB&WWT^RWJ'3.T>K=@RBWHH3?S&?#>,5"F? H"7IO2NN-NK><PS4-
MX&.^C?PM#<G!M=@U^ZPY3+LWT4W":T8@F04O@[ VZH P2H@EJ\QQ:1WS38^C
MOX@K+UP0.W@5@DP:H@V8S8L]*94ZZ61T&CF^.A&X5),-X*&FE".PV9$!Q9K$
M92">F)-Y89 +FBGC=*EP00L-L+>Y TALSYP:B:0C$$%?ZUK!WO%A.D7_Q04U
M1M)(+&TNZ( ]^RGKIGO"$,_>AJ7<IZ=8QF2,-"K PV/:K#JL4]SS\3X@UV_Z
M(B9IDG'54*1U[T)?[Y;#IYWH9ECU0H41<[8C/&0^S*=R19AE.D29O"Q95V1'
M6P:>-[9Y)-9%^?',N +>PQD%@Z+D3(3! AQMECP#_PV8<OM[%B_;L2:M:T7-
MGGFE!H7'HGDAKEM=^*?7K\FFR>W>R6$P'P8Q-*V],.!<VHE-(0JRY#U\^X<7
M&SDR1")][A:+X!^SZ:-IR6_9] LWK5$>91_,!=F%;S\86-S6Z;'I Q+4LZ;R
M_UKP/+PS(!9;;3U0G,F_#?>8;$>52I11US.SG-[=M%3G@MHUW^!I8<_-2G*P
M\S$BK#RT.!?TE($.I]<[.;#NTN6?&5STL7J<I=>84KT %AMX%Q/^K674;8PE
MKYU9^,G9 2I;O#VTKOE-@28#K\/4$UDBSYA7V6^R!TP,-#'1>6JM:AUY8D!C
M8Y2X<TY61[@3/.%<:QL]*O_'IS_L0M<1F4[5/Q:9/KZ_/"P'@KB@8SKS<876
MC<IR>9 CYJX.GVI*)\O*JCUU2='G$PL/5S;I ;ZWS.Q6(FL<>]#ZV?T:BU3J
MM=9L,X$DN%W9#+[PM$FSB,ROM&0]4L8.N$38UKLXQ;LP^_1);SG#3$7W )G
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MRKNW>8O>FN@C,'UO?C&9$D\086DV7_J0MQ<(BP@O[8[TD/NFQ5%A'(6*_TQ
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M][8Y-T@_X/S7Z(/^X1&4 >6Z/[?OV/>\/W3(S:#^M?LVXG8BZB;Q>*&]5%)
M:%1_XLO;BMTS>6T^-OF'?NT:6_6<7.D+E"09U)3?O;A5*MI&4*I\V$DFF=2$
MKS<IMH7[M)L6I?VP^MX"CX?5:Z^H[5Z+&L\*P,:"!7Y]HS?/2CBO/9>6]]&
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MHB.ZH1 #B0]>!+ GU#)GH<[I?:177,^ :@>U8K@X&1?7PW9/T2)H:;01Y83
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M M4.#V((=.S,)VH.ZO]!YT]-,CC!,J?/L$Q=G&\WC@:SO<ACS=B8U6J68_Z
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MGB]I=5U82EA.>_$:J8M4"XY5H:C)271J5_J=!W_/8 \T#82,S6D1>]D'4UP
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MXO V+>(%?YT6<>8&G"@ORI'?'_KR\LE'](F0M:B"]_[OR3OG68;A6D3PS-A
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MV/2<7W+M [\E>\/)S^CH:T;WFV^%$?7+6J[_H4<^\54\_7%A#K<21^PVA[=
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M90$  JOPPW!?\7A$0TNB,B:8DMX[A7Y*-SCZ+F PXZF;NFN=(Z]^.NGJN?D
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M12Q%CS\!,AI?&_';)_ZC4&%-_B]02P,$%     @ 98EG5H #6B@>P   M-L
M !(   !I;6<R-#@T,C(V-S!?."YJ<&>TNP=8D]NV+AS%AHA([T:E=^F"0)8@
M(""$WB$"(B01$ %!#$217A4I$@1$"%4(2*\10EF"@/2F0(*"]$2* 4+R!]<^
MYS_;O>Z]^Y[SW/!,2$;&]\TYQASS'>.=S(\V09L#G#/4,] #'#ER!'"#_@.@
M30-T#C_]CUZ'-_F?WN,([3V ]=21P*-R#$<N 8ZR'F%@/4+K   !@"/'_U(
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MS++/TXNFM'VZ%NR0^?K\U8,<G9NBZ1VDYM,C&_E79,M1<[:DW#!8DY#27[M
MU>1"^N7 _^!USEF_8X'!(;O\?2JO_M9!>3+= NKO_@3_W=C^Q<'H?<BOP=$
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M)^C'"6<@[]I=/ ?37*+2+F7QL7<21FV5!Z:0<Z%/\<P67?<IVI\VM@YD.S=
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MP8$&6);##]  -OCA!H#7."4A&'@0-R-& PQ'18#!*Y]#'BZ5HAII@.>EUVF
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M%IO %,-?#'89*(\>YS!SR(C@,/OC^/^I^05S4\*;#T]V<6*I;ZC\-(!F:];
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MD2"!VL:KR!:$P+#U9TW7 O%)_)Y]T+>3F5#'SR+Q/SXO*?8<:1E>?R$/%%/
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MB0?ZLO#P<GEA_!Y'WW]<HSIZ_C]*QH%NBZ*#]%\!2HYBQ% ZQ^A1LQR(3X>
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MA.#;<BKP#N57]7($HTMX^LV*14?F2RS/6W:8>UP?$LYPD^PM&>AKR!B0P*L
M,6+(JY]^RWUP" C:;$?_*,W?V5'"4\Q\\5+T"$\")F(8SW>U(*);$N:,CL8+
MQ\_PN>C:"#7$*UK$GY]GJN"5J'S%] I0B+*4%'9'2IN..L-(<WJ6JI8N2989
M=\0N77_&J@'P]6NJP>V;C6U6>9-: \*A@7L;5T/9AO2F4YHR4H?<LV[5-_Q>
M&"^>_G\5H:GXX\<AX(0(Y6R3\OIN"?B:CM0P;'S>Y+W)N3O/(H9;\_,HQ^Y0
M=DKOG0B8$,B:LVN4.=M\7ZGJNJJ_-$?XD_'%4S1.B$5(J_,.D,Q[^1D$P=9V
MF=I]YWWB'U2=N<W$4$TW]<P;35>WH;%[H;Z_J$C@]+0G-EI0T\&V8Q(V9U.T
M/Q:%>Z)B8#%*2:APSRKAGD6Y!0Q"68E;:=P: G$>_"A>;?'P@G_9^GSNTI3B
M,X- K!0L,O9;=;)7:398[UI:T/ DXA6"A:&4KZ-B\H_A5 0GVEC(BXC'-D]V
M' 2&SUWHWCG6V[WTRX<?.<=?UVQ4X.U*D*VM+;_'DN;B3W>PVPB[E^?$?<V]
MU"]0MOAUL<:JT9OK#]_U<R<EAM[/D=]:NKAX:@GD<0XO(XWL>@7:9)J[[M>J
MO'2D)NH^VMB?0=I:!'W?Q1+:XZ_6X'+_I_2>OS\H*=./*9Q#PK4?JE/UKE3U
M2&A9/A^-E)04OYSQYKR+3^]@IY;X0?Q6'FNG\BR;MLOF10]XW:E._IM636-2
MH8).D,K0*Y2%H?<]*6ULTYK8Z WODAO"@I/Y%]6XFSW&.1P3)IM+#/:SXV=9
MXCOGIO(%ZB*R3:N,[T4!%><P.P'+EN9%CCSCF4A5776%-/U\8\CSA> 1<3VY
M]FXT^5O M1?9?A71/7]XM/)[GG2*RKL8>+)97\SZ3&R1,E^[4;M9 I5I<*>%
M$O1^<H2\2THC#]*Y/ 7=&S"X-C6:EH-UMR @5%^QXW1A&'!_'4?-(8B,#HS4
M3MJM' )^\Z)W=\G4P F7]J_HJ1]85L/,"5G=#LQZ8Z4)'72Y85GIL4- 1[XT
MF5YT8NC; Y%7(QKJ1"3[U[[:"Z=R+N*]5AI2+6S/]]VS+G*TQ<_BIR9 P,F9
MB>D.:>1HR92D)F:T99EB=**3O:I+P?SVP,4XB3=-\D(1U3>H;L"#1#=J6+E'
M^/6#9_0KL^&# L)M35D6(VV"87DM1F36[NR$J. KXUH7[?NND,,85G &5WKV
M4D="TKF=]B^]/OS)!3*7)04?$V8NMUN]6WPK)2T!2R^R8XWO.("+=DY4A.^R
M L_'4Z'!XC-R7;@ WGLE44_-4[*B.RF(,T1QHB_-2BR6G,[GOVJ&TA,G5G/Z
M6Q7$/R4'._IP\:S/,VV*,I0OU4KB][MWOY9M@,@IH8[4T)P6.918%^*<SB!-
M*%RE);ZGVXKR6#_2@%)\3SJY='W#0#:.9'7K=R'ZL,IM),,*I8')6;&RN Y\
M^4@HZSP[%ZC=41&C)EJB$?E5^\LN>S.X[5+<AUG.;,6%_GYO,T)AG(,%;:*0
M/F$]>PZZ-7B*_D7PG P= !G/"MPS1E#4/@6'FNYK4G%F60<"%]"SL:8ZG%C6
MI9$EVQK2EG:\TJ.S.TKQ[$:@>^^;H+6*J',P=:)HW''@IY<,6_?W$:_AC3[;
MU$DS=#;SBR"[V96@VI<W+UQZIN\%+^M#H:OKO[.F&E"G3,[XL)[SM2"L?RI^
MZ&MLX>NY@_%<$NF\*>VHZAC,E/'=L[', QP&5>XG,[X  7IB)5>;PTK-NT.5
MNWR09UU.]_/?Z%;IHYY5ZZU;/[[8.DORC.$P9+E9IIE+7)W[-F6L2#\$[!MC
M5,4-()L\5+^[%.XX@CKI_O!D9[Y00UO3D'^,[$["LL+RQX;46UR.YVEO1R>X
MW?1R=1^.M?M  GFJ4.U03MJ=$?_9>)TN+=[6T;:!N3!_/.PZZV^KP&244DZA
M^UY&9W9XAD9V7N?X8O>];YANA#"VR2XGP=*/CJ:/4B6[K-J4R5G1-&OGLV,[
M;5>&JC$VI#)K6Z^DC\S"]:@VE8])$#F(WW7QZ(<1Q(F%"/=2Z*<6,4K.":*C
M5]>$WFCY'S[!YY1RWID5 4NOG/^8UYW/#ANLMHR2];JZF%ZK7/Z:JKM]U\JQ
M)"8IP '[^>WWCER3$W^HA B2*HFO?]3SFG89(U7,,GGDC"WGH_T+)/)[#4^8
MI323:@5)G')>5OX'J0X!/UUA+4[)6/+SR4/ JC0!5?:=(4LKD.S/V*]B\ZS[
MYY$'VLO6Y-GY'W2N_;@?+[) WQ27X3LR?U.Z'!3]E/^#@MB/A5E/TN91SG_3
MPO*H182E#B_OG;5.N@PY)C(@9%GAK><&!L6QC-?=MP/S>F:-O^Z2WJB 7I^<
MF.@-"WMHTW0[VC;ORX.T]U2UW1U/1.>>1OBOS50YO_G?H),&H%^F8#?#O"S
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M\R==4YN825%>8]AP^=J\1Q*AO339*4@U.-ID,A1_XCTR1AY$VV,4H1K"$(>
M]"WLO]GWW^GV\ \H(I1N$=XJ_A=9_ F>C_U':@F#GV4_%R"$T0Z<G;$ A4T&
M5__IPJ10#=";/[;'#P'D3(KV(4!\[0CT$<N@#O[8H9RBLQ\=+BT8B1U-SZ0.
M\G-Z.=\'=V[_3!&"^L?:R_^DBY^) /[EKO]?-+D")X@?L<R1P3)0)Y96_A.=
M\B]\+&((K3H]+( ^^UT2EH,]:-<^</BW&CQ:F*J[C"%#?X,3)(\6=?R?204.
MRV@-OC3Y9T4LK;(FF=%:2CR:< B0^5-21+7[[_Q]>(R615I,#@%]CX[0,_F
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M'6+_RIH=N@D[3,">UJWS4 H,RG:9[D)DRUVW<^BX:O+RXFM+[5C>HY %GD.
M&ZQ.AYI2 ']_34-PGA]D1[&J(,*Y8(5$PT- HAJC-:*F(;!QO.A4!X>^7W47
MUW++Y_7D@HO1N'4E>4.G:_D2L$ L^JKRQMN.3.F-$G.NIVGILAOZW7GBN(I
M)--*A2Y&Q-*3/)S0AG$6EW%\0&#B&I>:=YW=]!A"&@]EK#J-$DG]LE-KNH>
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MBB01VY$2HXQOD;<'6^6K4Q Q+;)^%9.337H^6@AHC0?0OZ'6[L-RFKZG\*U
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M'G%JL;E)Y6?NY&,OFDAOZQ4]8VP%!_TFM_:IWYR<"1B8_FAYX,/U&4_/D9#
M0 ETA<@AI&<&4$$RAGX1PH44=WWM[@(S+T(9A:MQWTZ$) @N<BX6TE\\-NBS
MRO7/F?]*<WL#B7DZ?_%/I^X8C%!\CG,</HWPL.H9[O51B'SYIPIOLQ@>*.F]
MBT6N/]+R'CLR;^E!Q)TR=8KJ'^KWQ:0=15Q57](;7YN*;GE,EME,X>(KDA-T
M\G1JG6.=J[TWI?\:U=]EV"PS$>G*C0L6YH'F"FQYH'EQ3/=I.FQ'@F3$ ST*
MXHM4UW7_Q253[(WO.,#^+^EJP@,=^G&8QX6YP3W<O,'5MN"<D9?@@4H\*5V
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MQ-XWB@;#<1(>H>;Y'?9LG\WI'(NUYYOG![YN/^B*3,#532Q^>(!3<<KQR+G
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MB?^^,+L_T_OP@A&, L(BBB=%[&_[DU:2SU96X]B23S(X1O]TY>E8T[+C#VC
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M\QF1+C<SM/6W@'Y&#I$@KB\!I%!QR4HASKJF%%2=G^)6FD"$CZ\_<7P]8:M
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M/.@91!-RV<G21=@=LGF9M+EWVG%SU:@A=VVUM@X,Y%5?7B3JZ0XYCC_(6>2
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M*WH%G)=E,%K"5,JF'EFM5-K*'EZ%UH54A?-.J)5[?_J8T^+[VL$9%G#DYNJ
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M32)JO1/E 4^</NZUIF?@YGX1JQ_G=6),<W+)R+PIXK,BE>_"D)2Z+K.Q%'N
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M4L5^40A5WE_(*U>IKHIXFB!X+@YG'OVAQ+:8@="[QP'YW48^3ST,@:AG=C1
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MV+]_D,*"(N:;3L^Z-4EB_XKRU@;EA^/.0&TVS^8W[;1Q93F9\  S7D<=3.>
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MOF[.9OY="./:S+^M_MG]2^W3_F0 8DV5U/Q>VP\,I1!6N9[]$ \ 81AL1W)
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M\TB;JG:\-_N.\:#D\#.1RUT/5"K)<R66K99>YKGPCX.)/Q<;B])B:K+DB&6
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MIV97N^2PF?(M_LKTW,C7M6_/97>W_%[)?^3NM8,GGP1EYHZ\3F;9R%_9FV!
M\:_?W2MJRX _,MT\=NGU\__7GPWSPWL.?T8X=I7N[D8J?0B^>GO*^TKG@V;R
M:G?^=,A7^8<? H8G2"W6IU8N2O^1].QZ%3P5SC GK":UJ]J/CV/3@I43]$4
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MCKDI>J4F+(R^JFO3PM1N'5M7__*R]?MYLOZ$FX^"Q?W.L9/-$=F%[0F,4)8
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MRM)M &09X;RM9B+$ITAMP/W_,/:>44UEX=]H9BRHJ"@=!#**2 <+W9",.HJ
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MY/@#<R_?^RT^@Q!Y.W/5:KS&]GPY$W[QO.EG<*IJ7]@UM&LOO<[+)3K 0E2
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M'SX5[!T8E/.\62/C7%&N&IF8O8]$2L^S%$/L&, SP5XQY,+0 SSP9 +Q38\
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M7F45?D+C"%@&#(XM47\71 (<IYGPEAOY"B"539 '*ZQZB$_^:KKO6;- 9<Y
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M)K*ZPSF7)]>1&=@=$4],/^7]7W2]5U13V_?^S3GJ4:2#="$J E)CH0A&<BR
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M+%[<U,;Z!(W>B6S:%N,KY+Y51NZN',2C>9G8W2 J#1L)<,==!"W&FZ<T#/S
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MG3D TJ&CD\('XO?>DOAC+16QP4"&#\TOSE20LCQ:'O&T Z#TU"!,06%E0%'
M#'$R2><*N+]ZOO]X3XMS;I5@Z88=<4F[/'0040RH^UF> N;9R7=C#IY\=*;K
MP!>7]$07>O+KFTN-II^T;U8I.KY(]ADN5GG-GG*\6>K,@+.*L'L8Q0;L+8EF
M^NKWNN7"^N+2+ZUHML$4RWG<*,'_&\=Q-+I&"K.'\(*WYC3&D'I]J.'YB\9$
MXQ+>TM*%M..*%?EN;O>RPP7GR9T6Y&"#1,0.(AKLLX?J@'B>5@HS9OZ<%G>!
M;;^I,Z]\NW%M)S33>ZNW02G)4$!.O3R+*U3K*'[L^\_/$KVQVL#Q:X H)^CI
MDL=9_<*8?[4^DN^2=R)=P&6^N'(34X@HP",U6JR&+4(#@2+$9A>H:Z1\6^ZZ
MU50SI^:(5_<D!/8^\SRZD5LB X;W);FP2S3,HCV43R[&%B@[38<Y_V[8VP#"
M^'J;%43[N=4H9['9W)((:C?@!?? IOOFUE;5YCG;;$&=OE9LU]I.3Z)F^BM;
M/>H=H5L@<&1+HEO=&(SM#H9B%"=3UXOQKV9W-S *7+\5<GP3Y-0L2->GM>N-
M8? \M=V;-LE<[30JLI12=>>?$U>T>XP,0D0UV%-/RW9_#P@JL'8K=39-4;2<
MF%.T,+4^>_/GS#Q,]I,9YJ&50%^/YS5\YT9DKN]R;V)LKF*(>YZ96X![GO6M
MOI4*<4\\FLZO@8JJB4B@N6M+8G>G\FT-YG.HIYH0RT^'?,#M3E X?>;W[SX7
MD>;<NYHM(.9VC,N!.XY@T\,XO+;?1;T8K/1B#ON&QDB.:&^9X)0_T1I )PM-
M>4/[EE&_@9(9)'U(M9<#UQ>2Y_RDN#^[6+)"]1&JZ\0*TB>*7*?:3UZU\D38
M,IG9ET861K]JC,L[Y6FFC;>QIL[,]?514]#RY- A1:([0'[%@D&Q\UK9X<C0
MN5& RE/.0&+I7IWXBIZRCCQ>FX$<415R"0CSU@E9X[4.KZV-#9E/O8YX<\<I
MAYM@\]^0!.<0]3- S,]DII'@&/$"0$Y$G1*-;TG(KT1S4DO04#KWG+TG95Y,
MC*&S\'0GQ@M('L1<:NP H/%9:7_S:VU6S;8[D]?%DNXV[U9\<:3"6<%U.<%F
M6;W3X=M8+V9JL%*]XL)TQ5[_D0KM4XYR4:5V%=[C5:VSDRL:>V_&<,T:DLB-
M&M;%V#]_/+OA>3?>\WS%:GMM5<"\&97Y,3GNJ7/RQ2I+/L(9^@0$7QQ'(;YX
MTWH1R1ON+:#WA/E0\@:J;)XCY;5$E:O33)GEF=,I&S&#-3L7,E8_-K4VM621
MI7L2Y-F1.])ZS5-GFYA8$,T=^FN-:5Y!F.'!$I$J-836;P[F7878=*1+Z1<X
M)8UQX)[?CRT)Z:FEGWQELP_?-,H830^:Y8^TMCVI^8V3K+Y#7!WV0O]L[&9Q
MS)9$AA)U7\?A\W/TO]#;.W9#"VQUQ&8U.HQ.*5$&E.B I/LXHHLCQY0J(YX1
M^[4ZV/Q+4+J^LN3P.%(:I-H _Y)40<4'#<-"OZ?>_K-A^ TC@8]H8$M"@72*
MD,.EWA4ID[LD:<L=<B&-R]3]T% OZL1(T.@/7&:4W1@C^B7@#2%XE+]()Z8P
M 96*Z>R2LR.&;>D)E]A57T2G@?6/UA_7/9+WQI3M=6NO,WXP?W*PSF0UL2(U
M^MF#=$Q>U41EJ7MYA3(EV>S1VV(OEQIKT]Z?80DG3<)^CI^X0K,PBG2]4G"N
MS**L>.^-MCK_.N60WOPCR5[7A;#-M@YYHCO\*W4>)PZ4<#>83.M%IXI]J%!S
M#I.&D&7*!_#HJ69];#]KG+2WH.O6S:7+:C>0QULSFN#;E^5"^5'6DU$2,]EU
M?8)+Q$-OA:?FVG&\V)ZAVRR9& /X%[.(MDHOCO JD/F9\G0FS&/"S(TQE(RT
MK>GG7@#_O!=3O>1-*@ZL7=R(5IHL^-GD?N-"!/[0799>QQX1F]I$[MR2."@:
MF=6<8.H(-(1! 'U550S$Z?#QGW\1X\%XWO5;Z!1#ENJLK^_B,RCL,WFJH,?2
MFC%9NZZSB>9I)6LPVH=CM!BC,452$RTOQVIG.BO_6WE&-"G%I:841F.E60$U
M= 4(+=KSLTK4O4&_:X#2$3JGS#N-<;I)B-:WR%#I!>'I#WQ:;#DA_G>@'%;Y
MI=G9)C:8S)/&7FIXF3@[(1WSK:)_Y:DCK1MX9SIQN:V@R<L]%*OH8%5C$?7O
M2:\(E;&?B^<_ _=I=B:Z%S3'N!:>M;[G:"]*US?&@!'<M&9R24 RS9I^SM1V
M,&^?NI:LN].C0'><?D.=<2;-C/S6(%.D*S2 PI!FI,/"2Q 9V)(0R7WX?1&E
MA#(&2;>YR2#JZ2'!Y5&D^6;+TT7.S*V_&%L2MF=OA;Y\J30_^$W(;(^+9C$H
M8N-8%6(\G7V;=(XT)#(:)W,/@.14H3G-6W@=,*K,J9^!C"H8$_7Z1A_,!-U:
MF+<_SOUA60X589N?C=4QC9#WU2S>#U(#2=OG%UXA4JDJK&M#TI QAOI*70'Z
M.?</48J7+;GLX='*225*<\FIL[#X$Z0I?(U8QL\]@0J<AC5]<&V';T:KH3;B
M?6XO>%KT9!(U8\5.N1_J# 7D^4.0M1']#DLA0G26H.,#T%^](QW#H4Y3[  Q
MQ'<?8X+&V<CSO$U_\DY(X#KZU9">.BTF!B"!EORCSG*@X2W3''?N<WJ<*L?F
M=+;>)5]-@P_<#_@@]\((M[DR"P6UX]/E0:83Q5ZVYA:&3Z.,!8,AP<G1U>1K
MK<V5H-')&F7')S]//L^[!MZLTM1V^4BC1.<9[5IRK5O-K;#>GT$=)1]$SU52
M?Q/)G@<1=F_IC?ATA%R'S"SQQ!T>G<W9#BUT'5M^-<%2-%C](0C'N;2/K=7A
M#0P-I/OC L^VD6FARG+G9:J>]/&OMHU)EZ.]9TDCG(;>XKD'I&-A" 1)RE-H
M5.0M%A?A[TRH>*X&OW. 9_*UI#=\EX$2IM[F,8HA+<0''7M@X+#DIS'#1-U"
MQOPR K-%>[X+G,4MBMJHEDU905^3*K;A)XVP@J3:R38@)DMT>'JQ4"M5M&?1
M3#]SODYFQK<!,JK'XE#*8X^!'\;J:N,QTGNGQ:8VQRED/5.2K5/N;7^6D\2Z
M8C"]S)X]#**SM #\"CD.50;&\C#IUT5R6.)%**=6:,0$R#VP?8O^*N-'7TYH
M;E(-XS_ >E$'P^7T+ :E$%)+A=C4/U@=P_4, YFS S?2"]^E5BAKN]1S78KR
MC<*LO<*U";?LOC6I,Q?2HW%1'M&F8>YT]TJX8:G,+;L(PVI'W_IHX#U$CGE3
MF!N9ISV>YQ:D:Z434.I<H*<=(Y<,=Z*EYL51G[8.K1H+S$*46YN*ZTEOL3NB
M'6PL*.Q8[_&4YZ#]JXV$SYEXWD]7(+.W!A=7=QY5!$OWM\IFWY\]:EMGZC;B
M#3RK924C& :O6)DD'>C#W%J*N*WK\-IC^;? -((JK[@RKV[1& %D+B]8C,;\
MLNJ:P6).>_I85:%RHJJ&%-PO+V^@4Z,U\^TWM[OO^84%$:(]\6 /TMC@3H<\
M1)_+J@CB8:9P;-8VXGD>)DVK5]:/X-%=(@_=JR'^/AS#D8&P%L L'<?[H&C-
M0"7C<#500==&2K9B9O$X:^9"SA3] ^)%\,H\:#ZGE8G&J>%Z6@O8&#DO8@S$
MJA &O-47ZA?R<YXZU X!Z=SFOY"6E80[=F/A,5+X?>(NF,U=__3UGE)1-:'5
MI]C8/>TS/]Y>8)YI].-CQ4!ZN_OB2%?@IQ2J9GN'=A8NJ6ON\5P+[376(,M8
MS?"7STWV2-*DGHTS34?'&C5:&'?3P9:=KWC#KL,LW,'2V_/U:.=(6GB/1;OW
MO?L?D0M<2:&BU!RV!RU'V))P:0&QG1A)H000G$I'PH+!9;_-<I2B5>62^KEG
M8PZ)D(\OT/Y)E!/';2LF&14X 7G_C*T3&!]0TW%-7G+WGH,SHKTV@8!/#TM-
M:"KYBJ4,+;'G:.RU)(XL%SQ[E[<FV5D.+?P.T7C!P)A9Y=VBHM=UAF@9W\=%
M3F,1S%7K7\WZ>8\_>.]>XWQDR9([S[%P:P>%RN,D95QA\$H--SXSF+?0BU69
M'9K;DKA+EM5DH=2@XHJP>XO!%Z$D,=YV),]C]H3-PL?I5^ZXC!*/%OJ2M(>%
M@OAL^5!WQVG587!!*,_FOYW\@;\[K70/MM)RFC#$QT)2 ,R6-=%Q4NC5]#+;
M [K,JR'++1?.UNQ -\PR&AS'Q]XO;G@UOVQE8O5GOVZ\DTIO"\LXUYZOPE/6
MN^C\2OMYQ%>&W3O)U-XWI-?6AA_V70],MKOC%'UJ+Y+E7>K<P+P4J)S.E_OL
M%A8XH2BF(H]DW>DL^9W';3N\69[]Q=>#U[B:>T:=?RZZTVQ)?4-@6Z>WFE@>
MR=RS(%7LQ"$RV[A$;E3>8X)T+.3L9$TM1'44W P1:8\P3**O BFT,XU['D_Y
MA2DWHPXU%:WR@6EMJ:A[/,1T _\J0+U#- (1/>C&[%?X?4)S,)[I+P<NI))T
M(:F+0&Q:Q=V*+$^A,:_8IENI5;WE*'Y?S9'0V +=S(-I[TZ9H.^QE/Z[QXIH
M7,LF'1=:@5E%0##_8)$=B%]U$YB31C;LEK<DE%":QQC!3XEJ0 J%2U:VB8*+
M^F\-%'>P0!FUG=<CC&KVO!:]9KVDN(A& H_J?5OHQ?^%D!>I>!-UH/-@'.L:
MAS(M:J@BQDP^C&9E=>@#!HG,N#GL77\S=2UL4F&PN N*>CBJNO5"!Z.OC_G?
M"=C.V?UOB;[@C"4/(4-8L_9)S]RQ('G")3'L9+=KMW9TJ-VW[!>>EZ3C,.\_
M5QDAK8CABF%A[=HJX;Z7@/4@[V*YW!-=T@*/RUTGBUWOW[$K!Q?K0[\-9SRU
ME+[-],,$>3<%.F;@+B?#\X86_YSGX=DUF.W-W0)Z*FHO PI63T7::'6;9RN$
M_ UI&OZ6:#59U#/"H5,*K$-2_PYSB.>?3C(;=+N#R$"'XJ'CM$[,;9(*I%4%
MH7L1NU':$(6?!4I_O0TXLT7*M+^$BG-#:OHY96&M$W6UTT2KEWC9Q>V6S6:7
MW^JMV^OH.??.]VST48AG(J,"H^JF_?J:0<K<9#<L$]$PV5F$I\"#4X3;Y\D4
M=0TH#M2P@O"@V4^W#D"I523;V-*(I_B?F_BQJNP._O:EV<G?J*<@E?O6(,9<
M^DJ_U>17IO$M?K.W*K&)^ARSJE@*-? CP>!DIJ; T$YT8+-:=(PTCE42(F)!
MC;Y"6 I1.69^2X)B-LF^!DAVVNJ2=BX/\>(549H=T.UZ0DX/')N(9C!#\7&&
MMW8](EY.(.\2#<(4_3/M<M@C%6E\I^)2Y_+%WDJI_.]VT1KK:3&1JY/91D@#
MOCW-<*'PTTB*:[7-4B/N9B_#^\%!JV#8K,6C2)WM#QTSSA5%+P]8JEKJ5%9]
M[_),_?S^C5.*1W8[)X4,N"<8\&PR]97M()V@* #3Y:_=!,6 .;R^E YSXDFP
MI ;0XBGP6Z_J5!!_AR*Y5?08%:$>^B[C(E,K:!ZS#]?ZH78CK[Y4M_#ZV?S[
M_=AGVF^6LC)4U"PU#N_T\MGI=?'71>W.W(SM?Y-8Z? MB4YTED@:.B7 "#7
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M#GKA^[Q]<,V%V2DQQS^.WW_S+]XR-7*]QJ5LY?31Y3^6W1]/6.79NG8[#[Q
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MW-,MB1]_#_TW6X,ECFYA;5W\_XR*S"-@[3LFB5;BY-4$,!1#/>T/7V/4 K$
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M@.7BR\J"*B >*S(ORMW'>$FD40ZA'>U-I$F17$D@S###9"BZLV*L*;/JD^
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MRG(.A5N.+N5!#!!*7TE?/M^X1T9L*F$J%[#'! &5RJ4BT5E-8!]+[W'#4Y-
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M<./Z5J$NOD=ZIJ"1WXYE9=S/_I5R^$\#=3_'WC_]@M3OS!U68XOV,<WL.M\
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M:0?1E8KZ&0P+I;N/AZ\2J.\%#;LTCXGAUM/2/\1Y]*J33H64VPAG&;[&'C<
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M_JNC&&E?#4^/>HQLQY8)-ZD:N>=53?TQ64D>I&JC@R+$=N1D<Z70TUT6$\Y
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M/V.,B::8&'PW"A %HL44..]19E?$2K!L0*JU%2R V:S@@O='L:@$UMHKL-9
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MA"JO&7-/)[@T!Q* B(?(P'I?5V'J)XOH]4#']68G'>YT7*\=2KLY%&$4%BJ
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ML715:\8X$7UP&C'G<W%LK9%+"@166)U<4)[1_D8L^YKO\SAIS(PIY;DF*)D
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M@=7AW8,4\P$/7]W9P[\P=*EB/MQZ:T@ D*%B7LR'!H8<(=0GI24AO77+'OW
MR8K.)W"NK(Q@15K/4-[S0P;@.4<[G5>&.JF&;9KOS+O([1&!\G#%(',_0(N<
MS#5_/4U6,J^CZ*V47K\I?$ZKXVIT7([WM^H8RM/-B%7+*EC41'9!& &7B]92
M9+B/N5]23DPR!!D=C3 "1QG7TGQX4];-Y%%KG.<:#>#WJ$ZH%*A6.() $@-4
MRG^,U@)1F2A1/$C&>IO-V1-EUF'@RBJ+E09\DS9:,#D(F-Q,&T0ILT1Y%TGH
M;1F,/H03>^ U"<Z(X[F+I\2Y:0 H0.<,.%%!6!R3$*K'"613U[3.QF0[]_6[
M"DF7!G3BWUQ)&EJ0WU\^@ GTX.?;6<LX=SIV=6GH4J<=?-18@%G+N,];"9R
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MVBAU;\M?],:I[$$@E;% HK<$ 1F!CCY)Y+QBN8J\XS;ID,B0K7^K5'663Z,
M,&.N* >4R*$:AJPV"25.27)@>L?^%O@9BBRL55FYRP4<;G4,SH<N54A<*<&P
M!=,!>W ,!#"WM@K>:@,<SAS#LK<689_VX%;4;1@#'J044)#YM!!@.P*+#]!
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MD1V?/L3G V G!)_X^/*HCNAS;8\6'X1>N>]__3&M)J\VZ]*.9B^?%PVH+M0
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MXCKN/D4#^#>#V'?IAG2ZRF^JNI@<Q"*5#8AR<1)M7;3Y#2]O\4WN]10W $C
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M=^Z5#8 V -H : .@=0!H0^CPOH@&UZJKT<SO:JLIA*=_AG5K/ND6F=Z?37K
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M;"A,>[9NR+BH\<\2Q10&+LY-;I6'D=:B6I;XZ V#+;*\W![T;6)TG^(1;7M
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M#$^*3LB*A!,,8!9Z5X4Z/=1N\0>1#5B8%1EH[;754@\W)WAXLD>G_>[!YB$
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MCK5#(_H&[<3DN19_^])J__$2+? U$*/$TL0%*T8[E*RYLOU*\OS?J!O_ERK
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M_8&FU<^&M/KO:(]!6W%07TVNAC/7!6AV+7WF'#PA-+4DL=5_;:RITU#8+*9
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M^BAQ]-E!5+/9L;34:+,*F]PT<_+)TP)1,J^V8NEXB.(O.6A],NC7>Z]?^73
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M!T'V<4-.I67@:7U&\[D'O*7;R;Y8"@E&P&R8D]?&>>#I&BP;-#-582+2P+/
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M%IA=3T[DP>B,-TI=@U5GS IR(I:DAE$>7.18 \6XQR.<CG?%LQ_D8H3?PA.
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M'RCOEO=XJXYY6@6YO!;.7)O7/31W+FY" F*1KR1*SMRC2DT_H0-W<N+B[3S
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M2RITVVIM'.#@=(;4;?%I3+T@X&.)P'4M@@X=GN5Y_I:([IX<)C2A=D7S189
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M"(U(9TP1WR'5++$7-25($CO!+?0F6;U$YKDM2P.@4#FI2;.G26E( RS)2!'
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M30/Z2FY*_X*K+Q0,*]M.&L'WMC0?E\)TDTW0%Y&LOQNV$+&E)PDC[FEKTQA
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M'DG,9(KJ&NU^SBSFX,CCPI8XF:!6O/+<H'V?'#<RQ'_V6N/'%Z^3]PBHKYH
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M"$\U)0N\:5NS/.BM#Q):5\;%N#H4"[AEC.R^@F05,;JOPJ%@)3KS@M;9KJ+
M3#'9"-:R/.F[J">VI#"Y*&\4QYLV!Y2RN4?_*J3K0Q_*EX/Q"V-6C7;HG:'J
MJ.+6O=R.6,0NUJ%T9F\VH>]L$D"87-U#77+#Q[.BIE>_)JJ=7)JEX3"_A=Z1
MT*>M"!H03AGT+&)6<.@I6V/]^*&YUG_ISL+=.CC=8$Q(84G',$4M;J!^]=:Z
M3+M2/-[?:OAX:#7\NTK"-^0;0G)<3*<9V:8[]NH'Q?O(%"]RAYTMEZP,EWDR
M"Q\4,(H/&VD7)!$!6*%Y8U)+Z0?=3(ICW*B9G->3?="#(BBPKFHK%D4K]3[M
MMJH_J).$0D=/P(HOD8W BZ455TP3P@?^-XR.2J/,LP="(3A$-Y&AJ3I.EJ3=
MK':'"N[<$3\EC5'LT[ *6P\IM@6^P@AM?\<Q?9!/F ,UV;J6G,,/IOB362=O
ME_0P>OQK\G$,6B6BF8ET((0U7Y%.6=F,L(V&99.;BA4<ZUQI^TBC@+K46MYP
M#5CU+&N.-"DO+#=4@H62+1DWT*3ZGB5&),7)_"-;4WR0?"\V3<K3[IV>4-;2
M6)GX)"OPKWJ6E=;'L/:3?2I' $F?ST3+NU:9M83V[M@F^/D5*>]*U>8[<Y/3
M?G]1+1;Y:F6@,OD#^%W+X'=(OPF&#N^Y87V-TD,0O;3D$*T/[GAQNFE0&3XU
MX_6X$).SM'"83^W="8)B"Q1[1[:$/Q>,U1/S-.62WX9FPN2=SGH(\0'>-_1[
M?!]%3$W%00J>Z$[;#">#S?#[V@Q1!3_W.Q76Z!=S.E([MA,&$^*1F1#PW85$
MO%A+U EA+A7Z9 H(4[CQ+0,]X81)F:-@(:T1#4,,X5J./V0S_F=#LBU3/3&!
M[$1 2[WG0 V+[F7J"B]ZR:4*X%,=N%S@F*<Q T;*/7[7_+,4 0?&0VX,P 7U
M97#D*?)/R1V78.$X6W)(@ 9*M^?I=)@VK"PO."R7,\2SUK@;S^?_TV=?6XZ0
M%5V2T8*^E1_2/4@9CLD$J%4UN-6/GQ1JX\9WCGSQYFWC\7T<?UGS>QNHU >T
MQX#V^/M)EQ/RH;*J/<"U'__PYDK]L-ZP(4=^&Z-Q7J@"2#,Q[Y57A"4:V=XE
M]]]2B.["K/C7=\G_4.9KV'?[,-YS=)D?'NBUV!-@*9\[&>T@V"/A^>&Y>!7*
M93YEI8XIHK3"!]5*RJ@KVF.UE)?3.J._6Q[&KGD!@X1\D'['_>LK)52RTZL\
M[+H'KQPT(,<H;*VU 0RK3AD'0"NZ[ZCO;%#+L=\IF1]T0YV#&TWR3^X"&RH*
M6QV=/ 4\RY'VA9V76+!/E'>BR-GD+ZORM@)(95P@DXD%MO;^&.$=UVPP65;%
MVJSF]!X !J)OEO/5/..F4M.\6#B &!"!]4'BY^V52+$.]8X4O;0-, QO4>R1
M_%0U!A>]J [2Y/5J<N#M?_Z!=P#( _EO<EI*5D>LA,S'<='RJG @]!;HM1HO
MF-52<#FJ9238:%;9_2D&H1+1@WJI[B*Y,4BIXN8Z$C_C:))MPX5ZI(3SCW9I
MY]5J?V$*\GWD,WJO-YF@X^@9^3)W]67!BPPQ'VQR6, AH(>9N*,%;X*4-/3*
ME\#E12%#(/\++'OA4,5_51HE<@3KE3BL)X<=2DD.OR*Z74[RFWP"C,=X3KI^
M'\T"FA5&84JV4_" :V-L*MSC;>AQ%V79<BR4HX+TQ?? AAP=[O^4K/(5LL?V
MA3\PSO;[JYWOL"'06W4_>6//[\6L-IIBWD]>K:KQO.57)\?B2H/.ET&"WEWQ
MP-9IN_+1?#FF;?? YR_5"V^P:EC1_=X]@>LR?3I;\$ER_LERSNJ)90G]5 AD
M.K!/#C;$%TE\(G*W](T:<\\WFX8^FLU.T4E8:HER#1E<KBP<])<RAP]ZO4(6
M,%7V.7AK7GV&*5'HO8;982/'39-H9,.\X.-"C_Y1LJM'AV>DN5^_" )WF[\(
M$.(8*4-N%E)YM>!H(>G-$% TIA=9T1SC04CHQG7 P4QG9)K4;&:P;</Y+#:E
M4!Y+\L$$"3Q4TY+-5-A@*_2[HFJ8D'B2K1DUKG!2VT&NX__&(61'GML-X-IQ
M5TC6S6GSS1BOV?-&?(KSS?@G$GTTI!=5O:PT$>>6U7X;K.7&2A\=?NI='!UZ
MDPKR[8)6.6]HGF/SG:EI.?L?OO$S=Y>#Y#*<*UMFF9?8>2GX+,%;Z3:"":B$
MC[!/\&JD:::^():VT=*\^)_K-/E'5N#&^.8=FG)?Y!+,IL]),*P0K6=05L(4
M3Q.&3AG/OXPVG$F7CHU^7=5,(= 6,)LDY-*SA6WM=--E>S7U33Z6K81C-3+H
MH/17OX7U!V"=-/1@FIP9?^#)W53Y6&RW.68/,46?!ULGF1JI*7?WF,%"+]D>
MD(:$:OOILVC]VAKK0PM+\LY5*.!P\!/I0@2)]*BE7GX8VN&(*CVYO'YQ?<'2
MB62J!.5A?".H9&-$-?J^8Y7%#!P;7E8LR]IDM >D[?HE/9F!YB>@CCX\/N3_
M'J5JH0+8WL%+]J\[H.L<74(_=#=385TH!#+9=QDM#]FID!C2,U)3,J7!RM$Z
MM+JR+4D205'O7%9ZT.J/3*M?0#XE6N?$VLI\7&Z27UADBC,WF1M2?JKAY$E>
MPQ6-U"-M;8 ]I+I+35V-4<L?D5)B;(M7A)\&,@<AX*H C6U%IX].8$TN*&GF
M)@P@DTR8(/[-7JB,5;I$8^RHDXNDG#W432C @[&YGG/;1D?2YX*\^T*E""V6
M+R?3!5.(D=5G['HFBXJL!8_;M9)<M12[W;WF#@U;\=6BUGK%%@HEPE=MN3>T
M)J/7YG)#D#C)()"^=8'T-0@(CY,GUR_?7+[\WXN!1O!;WW]?@K,D(BQ!D0%=
M@O(\U/8:DJ\-ZAF::I*W"](*54.:867+:]GKNX&P)Y=B9@HIZG/P5Q\D_\3=
M@FXM)*J/P!?5N83K0[%&\!)(-\P*LG^39HU(D;$1\^-D\=IZH#*TJF@7YL#V
MXF/$IHZJL:.8K[.BK4E#KZ+8?5*2K4\F^BBON)!PE;,1SY-MR%3?-^4\DZI=
M%T&V8!_ES%*E_K)%:1YME"OECEL:U);8.#KS.-E8@,:[G <G1O+&0#W3U;%7
MST$0O/;!L]S4@QX;Y,@7DB-1(H9+934%)\&+:(^Z5LH"6=;BY)[BN B'/@^+
M :W0BN'^OOLFVZ9OLIJ>XFS3K"QI<6$A3]EHE!+TQM;L]M^25H D0#-=VS%8
M6B-75H8#]\&LU4B.OB*'?%GECA<PCG)KDHA30T&2C&XW .T&H-T M/O[R=,!
M:/>UUM[5>:WJ;,(!@-HHO,[UXRIGP&!+2B,7'M@>I#'$_6N4R%0U9];K+N-H
MD&UQXIL$_U2+9,UDHYP;-XBLLTB >J-,S2#61]=964WS_0M$8DGB_G)P?1!'
M[.4'/DC?9R0NV[II,Y_C^<&4_UXOS$8"5&*MND!R8RDE\[-6>P],IG=;R-[@
MZRS*D/C_]8G_;2_N@:W(9Z7X']C<?L>W;<4/?0TGETZ.1OL>[7O_[< +-8K[
M!:LM*NFI*;$2W(KUU,*WR,DMUH-#NI,FXR,/K)[L]"H/N^[!RUUM<>4"C&A=
M'W3S?G)T^"R""N_9>.$&1C<N#ED[P&ZJX%8'FNF-)4@S@+;1F]FNU*\D!6\[
M<W&YO 8[M(<,@Y=:!H5,VR)JN\MMY 1 H]/<>/2*3/&BD4@MCYMU*DVBI&6<
M='B3!A7PK1_&K]+<:Z=7>=AU#UX%_,.P$-7@M6<)3FU"R7652S_95LX5>(0%
M$QPY 6$9[AV3E5E6LT8I@S^C@UW2Z6#G4GAYN24B[^$HW )H5G'!>=#T0.!^
MJ_ZDP)8 T7MZ]$>;)E,L9Y.\*L=!70K_)@!A%M78MI)\46?EJ*W7:?+S?^^:
M?HDH3DX'BI/?]=2]X%I>=G-W[+4/ OZ1"7A0;]"RT7QJ;E\RIX<6:ZTFSYFM
M2<(GS.O+J/=LJ4!I4&NB]IQ#QZ[,;<R%75DY,Y(>%"@VAJZ]KH [9*@SD ,N
M(I,QY7V9S00GH(R2B^P#T(1,7YJM6,9*B8'GUR+]E+$:&>55MTV8AM L7]FR
MPJREWE'F!^BB)@4ZF'M&2KA923Y4.:-!]18_B&/V):N(-UEIPTR-\5\(-D+@
M)/F2>U4T"")EDQSXB)LL+QCA00H+AE\:-\<29G'#B=^ VDU(/D.^DUU3$X.\
M>&3R0@L_MS(#IJZ=?)#529-IIM1!C&,M\@]H$,4?CKVN$^@/</;C.E]*WP:N
MR,G'<A[>OG_ABDI]'&(IQ!(AJN(U?4E6G'#HZ2TVK]@PY-Z;FRQ-WJP1(^!P
M0E9WK+=4K+<+%X0&EU/OC,.)*C>'P+ILG2[-H\HG*OB8CT_;3OQ\??'JL@')
M< /Z/31+^)AQ6PGZ+QFY6* FL_6]^(Q>STU;-/(C)J :DWU=0[ P1+PQYH,G
MY[7)RH@G.!N#._WU=U>#!!DDR!< 5W5.RUP:!00:F@F[P4T==*[X_O)BWUZ3
M&#)#VIKI(DW-)TEE4>_^;L9@(A\#IS@''%0ZI\"W]9Y?6<5/>'G]BBN_<O'(
M[KRO0+%PRUO\E[X9FQIA4Q D['>'Z(E4X><%VOR@+RF>6O3_'R)%TJX(48.O
M%E-NZ4C7#D("-K!V6\.I1-^,9$2>ZP<EQ27'M2&!DI6&&0E 7%3SW>2GM)5M
M $# %[@;@UE9)6#)N1YE0S<P9?ET*JV!I;ELZ5Z7UF2,:JEK"45_@.[55S%8
M2H.<^X-#9W?)F2 $UH2X\B"PM254U2^&PLC9W:)(!4;(BQP,3=H695BX%5 ^
M2TVH6)\E'"LZRO@>QST]>:W7M<5&/$TWK<$[#CY'\QS_]$[OUF_V] Z8U4>*
M63T?,*M?,043%H<*O(F#8]H3GHUDLL7H'7!Q0AR]LYUS6J9(=.$IIFST0;#4
M-BB4=B]0,=7,\">6T#ZON=>0]$!DDF%R-$LFT! N7PWUU=M#558O"(55QO5!
M(Z9^$FZO&52:D&V@%$F*&;C0HI&6]RC%K2)BAB &&=P@X"O.R[^&Z:L>"YPM
MUH"E*Y44T"K[H+Q;4=LQQVS9[<A0C9QB5!I-#I+P&@:$FM8-YP*-S=&DWC10
MY-H&+J%O_$76EN,YLS?(YG"X-^.XN[HM''9#1@XJ]+$*+A\D(\\4@D$#5N-_
MM7F3B^FKTFDSU-X)L&N*(E?/4VJ<<#7WQUP !>M%Q<@H:!_ZM[;9U([$.T@N
M4!4I=THWPO5XBISHOL.K3T0FI%@[T<0VM_(&R<GESE;\6^E5JP+9'DKYD3VN
M(F-M+Q(KY Z2:W3U!3\!R34$]=0T]V.E+ZRC*VF0)J=WE]7=10R3TXWWN=E]
MU@9I84HG4@]15%$9B#KZ(*MK9'T$GLQ:@_5!&J4Q@DS)>[?D-A.C]:Q!F*/E
M+4(BN&YS)].8UH<EK6>A#]N<B-"TF232!$U5EAHO<&/A+1*7V4F[G; '3=3#
MI+</3\01)'M[D_91"OP8/5:#MX)YH4H#7)H22*8VFJY^4Y !MJ&66K 3VG0O
M\YN7P[>3F\QV,^X4HM@6I=P<G#-3X= X2J):4[-0[H>:B^*)2_\57E!Y1&."
M0RF.7O#0BDL@VQ)WDE[7W.*-=C8(-&@C%SDW6L;1W#!&!+,GI]:K[C18W<JR
MA&@KNZCF>$1F4)/Z@\1F$\YFYR#B)L#7CZMF94\QK*,-52EWN.VZ\8%5P2ZY
M_ 9O2[]AB*(/XO5W4A(KKC\5$A&?^APALH@1N8E\X.:I>R"RO&S.L<?V4P."
M[:;2M@H6L;3;-L(#U(DO U&X+8>L!Q[G#3W';G+AN@&Y62%V-M/1,,'O1C)X
MJK LW TKTX@MC\9FRJNS\0/>-W)(D6[?MD_UK#C/@A3H>%QQS0628-U-A4D$
MY]A;QR1;U1=8"7PH#?J>L]GLNDC6;J9\_H,#%W/+Y_\6MOL)"-#8 ."&W.PM
M[/86'LS<!W^D@7%!H7SH=,/*8LDJRL8BW 6*'A)QV6R/8M"YFY6VFJ^-C8R*
M:2;FH2W"I]/0UJJK4VUX#9V7:YZ=>^)U]'EM\L6HK1MEXH"&"0@ O;>ZT=-P
MYWS%"'UX-J /?]<-W5-MN&.O?Y"A#W+#W;^XX=<QF._DVQAVYX/7\%H$(0I1
M.1+NW) 2N_C<EA38[;KQ7\S-@IV"[VL:14XZN9=&67Z=1G7Q<=Q>J^PP8GN1
MCMC434"Z?-6A@+AS>G(_?Q^A]YH(739_F'IWO%@K^V0: /!6V=+59$3 O0!>
MJ";1DW#L.JS?,'+R"<05,6(C^0X?XO&F')R+.R":\,8<8ID5U8@#:K@$?,*K
M!M4G9&-)*X^=/H&#1'KP$NE5B4XK-;-W61[X, P <H*J;'*V_3FEM>W$IDFV
MJ' 7:_F7,_KUDR,PQ3##F3:M9IYU=BHD>+81GY^!CCS$I[CS@@\6<=.Y #""
MXEI!9@E]V:1J$-T6;MMI?*>FS?6G57].C>Y\@N:>)8L &\0(5X:'SVL2!&"Y
M'MCW$I_FA9(^! 6^S=:';LX8:_;DU \D3N$UM&!FOUV&8Y%5WLPT=F_-:+E,
MLAWRAF4UMKS&S(V!@R9H%)[?5(CISEL:5#><O?$XNL5HS_+3V5L$:R KU:"'
M1"TCFK@FL0O#ES0N@<S!'7J C-&&I6G\W@E%N+I=S:M:5J7;)VESD<=[<9#4
MY4$W5PT\T2MM"9^@SP*:7\4GQ<;3QCDZT^\O) .L[/9V-. 9L8.)<ZWPOG7C
M1$_?#>DW8',>*3;GV2/!YGRS6_'QV"7OY\8U0/=.P;BR "&8SE4U2:89ZP3X
M"[0M%W );N?BMD 7HUREJKW$WD@9W*D9TGO9*2GG^K*FJ8#@-]!7I'BX0V*+
M:G;_9\=V 0<5,%0\6NF!PMU??!8%F=JJ)-7&Z7\!;VG;1(X';^O/4"=D3K1F
M0W]P&65@O#%RRE=%L O#+0'@"IF>U9KJF/UH1VONF7207, FT#?&F<A_@MG5
M4C;;AD:DK/&Q33%)P>9*+$WMB\(8 ':.3#8&-* M45(ZN$:#"/JB(N@7VN %
M[U Z>'GMCI;(F<QS2GYND&-69]S]IVTBN$&:U-4:-<'[4[HR!:)1$JW2),GW
M$K7IUR=W-0'=$^QADJ\<*E\:'#%\$PTT38%JFE8J<VA@9+1J# ,E/I)KZK&4
M\8&/OP"#A$Y%7L1<<!D"CFJ =HE7P'8_C1/.--N9.D@R]/L%8;QV6&:600/4
M]Z5KXT0R2%>6I.CJUI@R.3[[,T_FA/Y7)QF\H%'&'6Y%8J$QD[\1+=4T#SBQ
MW;2UT1109 &^%A<'E_B*;I6X4TYV@]]_DM7V,<CV6?1$@(01CP0= 9B1BNX]
M4[C4 B*2?#07W?J9'ONZ:IJ #<2BRK1Q*Y0I_/X$'I.\0GL1JQ<EVP=;UXI]
M-=TWFV-M^9C$=^"N@-RR-^6+Z2H@OA0_EW&V'R@CUVP-$Q!P:5Z.T;>N"3OH
MC;'-?=N J$\=UI.;P(TS'\YD]MH?+BZN@O#>+_?=4PHC6E7"T.5?H*<,"\.*
M6%5^)]Q&2)% # &:LME ;T^5G6WS)>W!7.XVO!GK5VW[Q=4XW&"L%L 1CI49
MM_S.[?)O"!>GTITRM_+*?'KR[H#?T;R43[AN8L8T?9I7-W53OWLI>>QEM>+N
MQF;"1/3Q$KKEZV!&)$(>Q+U_^S+\WDM0*BY>ADJZRP\5K9;Q*$@=K(Z,F0%V
M3M5T2\5IE]X:Q;L8%BP>QS8U1IM3X?,P">]TBN&>FR(35/)Z(>I(]* 8T,L/
M,ADEJCCDT6,VA:<SRT+MOXOJ?4?(^0?[\;':C_"UK.6%@WPO8['3GDV4Z]OQ
MJD+#RF/N5/DL:,:#^QT=0H>6)7K[<! ZLC!"2G42G$&KZ.0"5L9M5D^LHQL/
M@@9.$\Y:>DU<F%YH @Z5-J3P#!/(,PZ),;"EV4>73;D,1J7TKJ0IL$:\E5J@
M6%EYF9RODG9) K/)/^XO:/;SY+;.5[22T >Y=O*TC,UI_]T %/P<*4\B%.D)
M+@5GT2PR,F??<V&Q*XAZT6+KHF8;JE*_IZN@N<9M+>8ZD,[3S@_TR\ZE F7$
MDZ$)]"8 HD/:=H>A/8"/GAVB+;"U%&6-:.GIM336<L==R/XY.3=_XS2)#9R[
M2$GC[=202*^;*[GE4 3&A1@$'5*;*H@QEFJ<9;0Y8-G175R;%\U!I&[B8?ZH
MQBYWQ0Z322WVDXDO7_/D\EJ+ B;D[:#3;A #HI^C5XZ;\<E>6.&&Y(56BBB7
MZUQFC\Q&O[G778??8.AM9+$^T\:C;Y$^"6_C?"ATU:D6^3BYR2U"+[=X03/I
ME+7!U$ "CKO\C-8)N7'M0F(N56GYN6P=742+#G;"$ASG-")DU\9Y39=*FUV\
M#WHQ2'BLZES3+]K$V 7QPC@>W:QM>G:#WR'NLFA[H#*G4,..JW+JR%D$5E?X
M%L?D+('M%V^7TSNT>G)43O3@T,)C\^S+Y@$ZN&V0JW'[YW0O&L@4_9]Y"#B&
MBY8=YT :L-MT.Z^< )?>WF'CIK#H;U[=ZBR:56/K+]D[8XH0.PJ\^+,]%7=J
M0')9Y;3O'(VR\D/=+E<2\OQ@N!/RK(R*_4<DGFE[<U4&]WV6"J;(MM3B@\^5
MI?E>Z.!^.C\8_-@?#EIFV>]Y[D56WC0M%LXYN._,M&UDDWV?%R;F]=^\K3LL
M?15806H6KR;5C>)BKW(HVT(/B4M"AMOV%@M;Y.9&2SSRE?C 04*Q+8,[\D9"
MQSZS$9/]%2M_:]SVQ"VWY9>W+KHJE=4<@5K6OAWWIK2=[=DL8#DL!5BT%TLO
M*C^YNK7S6"8B X8@[F"$_\%!W,^()&Y:)]*'DO56&E)76AX4B< *3Q+7QDS,
M@M3M6E(7BD^P4;2.+UZHOA8UES<6@E.)68J?>]L3-H)O%!(E2_#PP>D>$ P#
M@N'O)\\?"8+A :[]+5=MK[2,_%=E<^"E0NS!F$&R@4P$:_,BERX(@ 5"L9(W
M*(H0_%5DM^HJG>QUY65I9C0><4QK-K>G;9$L4!/(AOI@A^RD8'H\I^-]Y)YR
M&^VF72R"<)V+],#X[T8-[LA3(%21T5\3B8Q8EIX*-X$W,&&G_^,\'^4"3_]$
MIN(@^7]5FS1S"T"9N/OUQ\ ZSY?HAFU$+&<?48*)!<(6A=XGCTXHSWHXAM_Z
M,?S:Y6%W9/UV^ET,>_/!JXB7CD_D>S.J6ZB&HZ?(^!R=I\GU./]T!YCH1[X<
MC*U[AD]HMO:.32Z6U<:QB&JGXLO#J^^HIKKCF2Y][^+# ;\0K=J*.R//:32:
M.R'7G/41D_8P+XS@ZE>:_.C&MYZ V<1,N51+]>.=>I6LT!7K-1J#1M1+!1VZ
MI?&HH[8>,[>ICV$B\^X1"3IP3JK/\^6R#]B??%>Y.K\ Q1 \10MG6JUEL $(
MIN!Q#?&@R^/^I3Y[T81H4LT4V3!<6#@W:E><[ &OC@6;EEFQ%M@KEE@1K8V#
MMD;]CY;S=<,_968-6WZH$#.7!5**Y1VL;A@$[&,5L#X6^#EJ7YH]9FM('1(*
M9B&DY%/DBVONDNS!3*D%-2&':#B?Q'GW!2/:\#C[?4&+,*KL5ZE'.T.2] 0:
M:4[YHB43O,8<_@7)RI'#H(Q+P_*!L,B2HV/-II-X%/9&*ZW@C-##' H;HG/!
M("!_\PU!2@-!6MYR94FN .!T$&4=Z%KF37<PBZ6056,?V<2?OH)\BEP)K<8'
M2?J.2<J.<ZF.1MV7R^MAK (R=Z/AM; BS.70 @>(_0W@(!8.3>#FSQ<?))=2
M28<K@%X@3XDIWR_-V"P N3@Y8LR%("^.>.3TCT/9%'JOB<+AD?>P67"!9-+S
M__3TX)S>'JT^< M_.@O_PMW^='CPS'\2]H).@\#)YVQ8R2B%_'N.\XU&YX<:
M#I\6"<6$O 8RTUM2&,RZ!WZR5ID(.=XMO#, _M*@/L1S[]SF4+)AN%=#AGVB
M='^(<F_\TD;?F9F0TZY"1QZ/:X"7#=ILT&8VHO0Y8L&"NE +Q>I&*HA:5^7P
MN74-7=2 AFKO"<WZK*$C'Z9HJM\-J1431@OD2A/A3R-PE>>4BR%ITL1MNK;Z
M@Z;6ULZJE8=)//IXS^H%*0^(*P$48>(P"GG)()<2U%P6T3%><[78O>$<G53C
MN,CR13?)F-D%X<:C\D,=69Q>)&4GL?UU'-G_E?I)"M_"('_F&5&B^'Y/;%^*
M*NX.YLOD^):I,PL"FXJ92KE27(R'3^_TG99=@RQ_%++\UV0'/DN(#LF"X50^
MKE/YA9,%/YCRW^N%&1(#PS[\LIV52Q^/0"Z S,2SU/K2C'2XG5<P8JO;T@B"
M.Y_D&=J]7YM%V=8<K>AD < QX$%L2GB^:7B'<?]M^]]G&MALLS_K)9K3+X/"
M5'"E3T'_HX5TUUE93?/]"R88:!(NY7S]^L5F1F';<%+W310^!V-\Q$'55).\
M723S=49V:%5R.[$ 6TVKDB]SIZ:N7[ZY?/F_%Q*TB<N.;4CIZ/#PSXX5W>*=
M8W[I(7HQX/0&G-[?3P\'G-[76ONHCHKK^3;D( =W.;B!ABCT$FK$%?*X,_9F
M)3[WY.'B%S"V!/F#ERVR?[1J]/M0&;S\9:_#[XG,J4KOP;S?21GT> ["_>V)
M'I81) /184>)\J../HW<  7S&T?K +YS5)3+/Y8"7+D71ZPF9FE*QT&B*3GI
MMR>)J_?Z>R[$1[.F2LN2NL.PT<^-9_8/$-&'(%8&GQZO7,0%APLY%U,!$%$*
M2"6U)M5$BY\0(95,)L_%3VWDV@M*Y(U+'KF$\NS/_N;#R1]._A\>;MMVVNU>
MML$IKNWE+6\5%<ZA5N\BXYG=5!:?SJ[!'5F6HT--,GM^']]$BBOMM%@>.5!P
M=;N422]OCDW:<.:\-M4TU;BY+=EWM?@\%=]$S\_)%ND_Z6U]M9?:K$M4>M2Q
M'\)UX>989F4+?$F4&,Y5R&AKDVO6NS.@U6VU'XV'?RRK9)<D#Q(_,V:(TS0,
M1_O#Y!6CEUQQ]M$S6])(,DA:&(E[YSF]9([T?^5^2-APD+P,'[J9P]JZAWX[
MLP"R(XVMXK=Y*:U=]DDEK=&,VS:II\H%J")IJUHZ&/'*?+)"U%Y/[S 0\<C1
M=S-^=OZ?MS+YBHEQ<<3 V\AI&V&[B-F-16U(6J:+Q^-]9PO?8<-R=\89;WF
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MZN6[[R[L>NZ(.37(B<<J)WYQ,)V-@]97AA ?/CUY6>]&3SU"Q!W+IAVY;SU
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M<GH,MJQN3)%DD[EI;);559'[=X""/JR7F*SY@@N\%PY5M_D"-1,!P-0"ZC!
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MQVR'<)8NB5HJL;*7DE(3Q@1'-\W]NL&;)Y-^VW7:*N 7D:[Q2/2F6V[5HF_
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M#&^A4I:[U#RMN$-KL0A6'\<"&[43\9WGR -U!'-7*C*1H)B9IMST:*J,U4F
M@OBV'14X.H3]V@UA-6;LXQ$<KK!#0_@.63C)*F5#Y@DE5?6O'GP5]::*;E&$
MF3[Y\7U=WD2X:;C) &7;5=6C"DVZO?!T%VK*$L@TS!LH]48L&T>+\UNW.)\T
M2O]'&<[D'40X1%<H>"[/SV<OJOK83WC<(9_+#OD/D*5!A;1HF@&B9O\]A(.T
M!-<2RR_;DHPE<KP)R^K[&P^C3S69RHG9Q.,F;#BIBF#G&2\>C]V7%%DI09@G
MNQ0J#KO=]H^___WU]?5I7RY/+]HK):)I]7>C<4A$DFZ;QC4_,+!T(E5]/Y 4
M"C?@%)!1J6NI@."/S#!TWS I?C?K+9'H[\#S\$'X=<1_P.6'TT_FPP]*'T\T
M-4E7H9=HNT3$ ^E-VC$7 OCO1H5U<'7OJMV (9"2*99X9/9TY"@17155+9'[
M.@2"RH0= I+L!N,'F_.O9UPOLS?R0C!P0/UF#Q^<_'4^^]]Q$4U\_K_GLW.E
MP1M_^H>3OTKY%,&NK"_&4,A8Z:O7HGZ8F?70-55_*8%R#'+-=WGX^%YQ'U][
M^.3>ZGYT8X2)'5[7<\O@J,?X\-O'7Y'[2B/MD4BB^[:'</8A\D=4A\DMP,FT
MJ%%V0SPL;A^+ 7 E1ZN+*RX]A;P@OR@L8 \;Z$[;O-_L&7 L\GVA1;YO/[<B
M7UVN=PKI"E.W^?\>%I^[Y_XR/,;LX=GI[$W5O_M/:0E^6D?^A>B'W!%C+DOF
MSD<_=\G ?7X^_\?#=5\V5Q0GOY@E=M\-'6J4KI13!,EU\![/5N6%NHM=V)ZG
MLZ<E!"#@4RIC<L7+L39C.N/SV4T[&"QJ670EB,MOHK ,?1U<#0F_?ME5"_3"
ME#4UYWEU7(C^]_5E*6TPK=YG:LQQ4+BK.+M)\IP,GC>J%6,.H> /52O'O"\9
MD31A*XR2SB/R70-=\6(!MF5IIHBUO(*Y?A1?_X;ZV)L8= 0O%R2K)S^T+>?J
M;0Q8S*G\F'EB5+:NECH\H")!C7<Y0^FL:DYG+P7G)TYO'Q^#JI>H6"R7*(M5
M@ID#EWPGLG@H)614G=3C %6E\)+*Y,QG=?7?0W@9RF K!1>A^8QEC*P8(X4A
M15IN.RB:*@=GFG_5^PDO"838$K]A*N3/-4* ,$:XS!;3W C%KRVUL=+1K>]O
MM,8L^\J2<(,.ZP,_-(IW: 3Y&Q[\ :ZJ!<%PV7=->\W%-?0QN .#=ZQ^1BIY
M-&7/JHV]'$_Q$_\FI/>DH$6\SGI^+G-T-RSG\;#YMTS99^?SP'E3OV?V=@AK
M.6&D[OA2N+N+X Y.UEW:-U^RD_:41U6%8[67W61IK03<6:M*H?*Y$0?NW;$I
M]P[N! 2U"%?I>)+=:%.NW2<F%X.#U*&6PJ-X[<[8@P>CNDJN84"]%EXZS-LJ
MMH[B WT"N[//X^[?:&Z9T35>K9WER%N+_[0H)UPH@FBT>4?E6/;2Q#:B+,N9
M)3EE7(/)$:^EJ)0EC<USO=4O=AGI/1_V3F^IWVRBZ[,ZFC_>NKSA[GJ3R+6Q
M'']0?,&/439/L<[SV8L8&)Q;8* ,5":9ED %=^O4__@Y&?L!J^K*AJ^+!(OA
MCU^=/GGTA]_]:6\9!M.WK8N;/Z[K\KU?@E]SU+JO[';\U@FA+7_B0CM!+J__
M(X0Z$!%-+LLT\#"&Q]_\[M=8IY\T'9O-:9S0JL&,G'!>;[WO>&O?,N=^*K]Y
M\NCA-W_X^JMO'SW^YJMO'CWY'4W0>S261B/DUD(^K,]^SB-0*X6EP>,(F[\F
M>F=3=DM!"XN&5289$L[,R[*X@F#;JMR6C;"F--JF%W_KE$&TUPVF(ZF$#HUA
MID3K;8>>T?4:4AD-)#ZO2A4(\.):/OD0-VYX3?K_CQOXN(%_0QM8A7L,(9B$
M;R_E!.>.XY<J0=^O,OGPNNT!/>^A3*5:6BI1)+W(351Z,H><:MB\5I3P6-EE
MK/T$_G!?_O_LO6V3VT:2+?Q7$([="#L"W=>2Y;$]ON$(69)GO6N/]5@S.QOW
M&P@428Q @$8!W>+^^B=/9M8+0+ E>223+=67&8M-XJ6 ?*G,D^<8$0UFN;MD
MJA?SVB13/9.ILN4H")<'"89"].2*L(W&# U#?Y4?M#@HX#>@>%Q=N8W5G@;3
M@]."$;_8M2=[NYAGG^SM+$PQ(^@C$/$0#%U\ I8_Y(]YUIJ-%,18GG'==+=6
M^2B"=9;CSI7- (_30_4%!!3B[U7=N'(\PXBD(CAXF&A= 7>6;3I<$BC;3-^>
M--0+*GND&M!'4 -Z$K9MOX0I-9ZYU!W@TZ!"F2H]9XB&]Z_ID0+BI:PY)Z#=
MBE'LK@'ABS1[C([Y&DV> 9H!_'+T)_S&5X(P2 ^B*7$/CG?,M7V*6P]=T-EP
M/>?"[X6#J1.,M-:>+'VW-'+N&M!]%GJ,U1A8")99JFZ,C*\7');Y0EL3 #'A
M&- 'B \AJ7*VIIR:Q=@/C*3A26?WH_EOYF-VH-<2R6I-)K2NY?)U3=59=1T<
MQ0WP]9)'Z"WR3(![#LSWK]CR#S6?3QXL>;!_R8/U0$!QG;GN*Q$B-U8S;/8M
M(K.A[FL0'Z2$!H9)KU]_".UYLTPSUZ[F!V3@G3B8Z4&JCHU?J][:CBYZ-/"]
M]@C+?@M$#V3<J@!=-W/O$HT4JY-!,6\ZPDO^R=".Q+S:BZIV98H*SSKXHDF-
M7=U_=#C/#HC"W;*+3H[GDHP@.9YS.!X>C:MW'OA+[^T5;BWP%Y!KV8.L<B<Z
MBF0YA18;%OR1JZ2#Q7'DNKNR!: $<:3["#/6H;3"9CL@3?:413"X!*=1M&@H
M#S)<5"J,G@@3; #\!_"_HO3/??R(<E7G+X&F46(5\A0>@2KGMYX7B)DE<?9+
MJUZD8:T/<UCKJ\]_][!6BE,I3GTD<2K"6/SEIU^>/_OU^\<</KC]B]D56_<<
M(D"<;/HPZ3!W_'&'.)3(:9-+Z2=D8MS<_?*FGB-603O_R3D!RE0RPLE9*T//
M@$.@L#-[C;ZC+/72@DTJE7^DI7)/1P4C",7R5!1/$3-%S'NTYK2S6SOZMU F
MZ8VODK\TAT!I9OTHI88L^D(56F*(;<Q<(H"K-YFPO&NL,E5=+N<]2;9Y#MM\
MW!XP5=2/>S>KTS&FPQHFJA8Q[6!^ZZ($WB*,&-\Y,ONN[/&"LJV4>GX$J2=*
MD0THIM _>"[;N N;MDV)Y[URM"FXG7'T)L(/+HW2U+&U:]'F@(P5IE&7IK5&
M.@:_U'9;<_CZ<>C*[2CUF9JS6^;4D(%<NC$X$O=3ACLLGZ/K\6O\:@']%7'R
MUY:A"A1+1?ZM9QR% !GR8QBD SO0@L8301K'!4XR^=*+YU<//O\BNW5SODBL
MH8*5TN/+>9N3!SD;&J*4N3T3:V; :.DX9A.9J1O,\7Z#!]&#9N2R$V"'H2 M
M.2)#$RA#WFMC<3KOIVHR.+"K/[]#1S2_IW_!]?CJ>/(K%_R.)[]R*24Q3X L
MVI^PSD$)>&%W#C?JS>IT<RB/#-J69..>V^3HR )7@E>S"JMRD\$@T.J[HCH%
MN63M@2&21:4?:/E R,G2?C[MY\^_G_\+U)A;CF6_!AQQVLRGD)E"YCU:\T^^
M ]'_$JJ6\74\+:A!CA6Y*;(VIMT,6Y!7TNEP(#ONA#L*.3SH/3G(C:TJ.WO%
M<,VD.3HW]&-R)?R]?PGBF_\KE7&9:E[-2QDIG[Z\%S4YAW.UL<0((6$Q-[[8
M?!Q:MVME0EBJ88YB8S(%<%.;VY@C8!FZA<$ ;*]Q("8(N7M7S+MPO<*4(:<,
M^?P9,EY7_B<BS;;>3V6%4Z:<@F$*AO=HS3_Y[DF8%6;X5-T;(;+EBA'J.QC6
M]9AEG9,#.+C#$30G79-U21Y:<^';#BSA.UI73:KQ Q&@ME.?D3+22WHADA&>
MD_:1/NB[!C)KJT.D37[+.FS.LL0:JWJ]!OTQ3Z?QWQTG@*C<6MKO&14_3R9V
M28\[F=@Y3,Q9$X4Q&]JTHFF(0LRJ:%\"V%@>HHY'O*&K=_NB[A7Q>"H!OK[\
M+=HE/IR+4C+X6+9RO]RV%!OP"FOD>"(4^"] @9]V<BG"I0AWC]:<80)3,FXA
M03 ]JVN U4#94)BBA,F:F*9$O\Q[-ZAD=$+.% F$%6W1'"RTG=] 34S&<5A+
M+.6=E_2&)*L\X]:.[L'L#%Z\349W<$LYH]+WYXZ!OP3["*-F/ 90^=M,-9;<
M;P#C/HXP(1V*>(DHJB^?!8;)?0U6)IH'^ZSAT=F!:9!J$<'SON#2V@Z)4.0#
M)11YD A%[M,32^'DG.$DKA4Z'1A4(I0/:F?(YPN@G"/(V"@U:%.+VC" (571
M5YSW_;6P5?%;]BF^ZABU]+.?]/N_X@B.7>LS'"H7ZFRG,\O1Y;>1WO'U 065
M7$E"#X[>+\?<]FXOR2:7+5V8*[N> AM:[QO&WW&N&H>XZPS<X2S-IA5-CS'E
MI@1#5XN=B;&J!6:_*]GI3GX)C+V/B<QZ,J/FXJ;[R2NYK&"8).+.4[MYW_6P
MI?++Q=:@W@H\\$$*V[UI-2IYB4M>CXLUL#<O?]Y[_;C+LNO?7W>^K#<[6?J]
M3PG4VLA,V6+:YN#MV&-9T<>,;;50[EG%IP.NP\EX,/!Q#QZ7P?)W[<1LU5:9
MV?\'L^I'T.A2^O\USWCY4;!3P':]7C?F"BI>LX;;:,W8=_N"MBIEMD?Z7UC;
MT?4B*>!>ZO/_^*OKN[+D-LK7^.&^L[2R6W9GE@[3WQ@^@"^@K<RF:"<(6J07
M;N'$E?V]Y>SCQ<"\B/3A+^70K4S/=W:=/8ZW-#5[10 MZA)87E37Z/9&K ZS
M"(N7]3A]1SJ,^8"8K)Q6A<=S+0OX:9F/[AI_8]^KE\A;J$W!-+]<8E<U,6Q"
MBEU'][+?'BRYT@+:!N2M&]3W"J8?/G104% :8KD2V0=6S'.,11GIU@_1RI8H
MV#,)<G<L0,%>GJ^7=UA.S! =@[X&X22]39N""XUUO.895Q!=VZ#R/XQ;Y@H
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MHBSEY4D5-/_Z^W4.5NG>*GT'E6Z#:ZYH@)_,BE-83@,L[WHY[F%0_NI/OWN
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M#5Q^[?P[8>YZ(U)"DA*2E)#HEBVTDGB[T?6@39<RJO@J&>MXNSS#X^;=(/4
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M(%K.Y,GZA5/:L9UL.F.Y$\=3J+SD$T[W.^9(<XP9Y%E4_EG,MI,/N*3W,?F
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ME4)U*\F1)HN_IQ;_OH4%VNPIY4=<L(:R>H[Z-26\2#M[);PKNYX2T9NZ'V7
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M63.N"D-8XMY=VXO"E>W:5C?G_EJ.&?5T "D&K=&CKQDDR\GT,5!U$B\9R^7
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M:E_O.ON!ME60I@.%FQ1\8M7RR8D<&?+LC-@?"V@RS_[RTR_/G_WZ_>/L)//
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MD/C*G?>)V&RBPZ,ZP_/*LGCB]"DA9=C!*3Z^Q!*7O%;R6B<Y. %5O'$C 1O
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M-V08J!#IF+OZE#Z[>CL;DT$+_Z/H'TVS\^U(JQ25"YCJ>:BMN<Z>K<D##3H
M0<['1X# Q!I56J/5"%2-W!DM(HG))4?M_7SC2%Y%5IY^6-7@V]&1+,3DL)EP
MDR.6BZ:NY:JUD)I=GOXFW)P;? QG69G6T+LPD\T6Y+8"8A6LZC6<?33E8('C
M["2.A64YH@CP+Q6'\(A/:">094?0J.2;,=VU?S 2)6>DF%&HCUZ'XVO3J.M
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M]@(_ -\X*'?X8=<K_QT0&W&%/&AT!&"SWHIK[H3I;+C>19!:$OXX8C^7=$M
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M-HJ7W;5#Y$TUST&"&(0SA%H;6V79CT2]8TOCA%^T"@R/S#_,\S2!T!=VMGN
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MBY;3\:QT^UJ0C:0@15^"-N*MA.W $*(YE8I(//HZ'\/W:^'DS7H?CF&@<-%
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MSX6R5SB!0J&6Y\&>ADSP@L<]F=HM<([P(_C1Z#6MQP:LH3(\*I[3-Z;CTC>
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MY?UHU')?O'K.HKC,!N.HT@:1R.2X86(WHQ4XC3/1DA&O*J>2ANSLWR9'[%H
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MWL$-XW:GQ8-P;=?^U!VYQIZ"^-[0!!Y$ED0@/+:_^Y%0Z]=LJ[<4-6)Y(I[
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MN(Q&O^L.KF>%0TH1>_LY!'$MEE,1'XKCTHE95>'$)S&$A<4D$T6/K=@/PVX
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ML(T@<M:JQR[W)D6/;2D(B?AKY\U![7J_RI*6#@1N--9A?K!B%JBXH=JJ_@>
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M[8V1[K9L>53YA":%7"^9_XD<$7WP-\JM)EJBG>Z#AH2=5I1$<)S04)862+@
M+=(-!-3@O,F/X') Y\SB>7]=MD*20L]P**',8%VID_?Z]/G_//OZT>,O_<NM
M*LJM,)D<?MH'KC_9)I=!IF972M((%B%R"% ^WAM!>9-;\PYO1U.7Z$V$2.\7
M:T><@$J^&>E1R@#;$Y!$+>A<WK:4YFJU:(S,V)%M4^D?:+6-:P(M;>2O^_<H
MK.4FHX2BLO+(*]!FCO%Q.BCL#=JU:-S3Q-9J:D@GB\Y_RA>B["*M=JK.4#4B
M?=2]WR.#SCI$LQY#,^N3 *&A%)U!QS1'3>)-Q@F)'N*E9*-+=1E%DD3>VU"9
M4J,DM(Z*JV$D".?L9H9;Q)LFB;>81^0D(L_WN",(![CY#2:@ ,DDY1*X\? '
MN=$+!;N$IUXZRY5"5P:.D^R-8=.=_)Z/P0\4RO+#BZ>F >X)H\W\'YDMG]X+
MIT_U^0*5?@M1XLJM;$T'WRWL@9&F-X^G$N-7,K!A]FVDJ5-](C^\N1GE[;3G
MZ#OP^\[.B;\"[\.M0L=([D>TJ"9G%GT9:DZ$5(O#Q9;B"\AI>^EN^L)LY>QF
M; B^(WT!?I%1MAU??\2-!KV[Z00<$LN3>TU86Q8032HG]:]8O2RA>"2/0.HO
ML 6T:\I]U]<&2_;B*?H$*](I0,F,GH5M='R)VD3!O&2\.8>0M0@-;5++O5J0
M3F!S!*)+6IR',T?J!?FAF8,Q.=06"4ML +^M)0D3$O4Y=,^A^\.(EWYG.'L*
MZR6[IO\V'I=QJ0P/(1R&&EQ2V.'4LD74?5H.I"Z!5><C(,9G++?U,. (7#L7
M<GG1+4O@DK25174ENFDQ:/-1M?>PG$1%\R,-S;:<^41.TY&1:>'3KCMF-)X^
M!=LI.YC<JI"-R0,U)N_XM'JER%Z_"77W:W0UV:D!3CO=;][?' %_IX!^QG)X
M+_:<Q0 (B6-[)/S9=ITM@D\JV6ED J6[%6CD**QL,4!_6UBZ4W!8"0TH)\C@
M75D'-);.1QIK3F>CCGFH80]:M2#OV-1K!RRQ2E7@I\Q3<6ZR@Q?;B6+4Q*W]
M[5]#81Y2F17,^Y!(TSBD%O2,&U#.Z<<-JYA0Z89B;0DM=P-3%M;$?TC:K\C1
M$01[[/E0T,7 \#GR?6ELQ%UW5/H+'X]AGDM@6A(#KX,A)YSR@DH&(0ZRYMQ8
M^Y0BK\E!06.+I:=RZ:>B:Q58P<-/7IYINC/3H+T>K,O)A31^A1R*[\G?'FR"
M4)(GX@'WKG$WI3;R2?AQM?AG.E9)L&DF,&FT/3?RZ>T@[,#X<^4C@[<.#*)?
M%F7=P!?O ()O!*@9UJ#X^_P/+/?9/9KT6<^O8CMYYJZ42.I:3D@"&D@WK30*
MWV]H=OUWJKY>.M;ZYO'[]TYOUBPFVO&\M,WE.;4$OH]KKA]"D(8\&H0:WL2&
M?3* J_& M5BR'$)2#<9U$W,5E\DPOTY.)+-O55,MDER5BK6;EG247P*[$S6B
M2);!I,+:K-1P_TID?UC'Z3VJ&'[RGE0,_[!K\?W-"#PULJ@H!ESW3J)R^$^!
M@CGPG"3<I-R*9J12.\-QJA0BJ1,?2$BL"*LJA\^3GY[7-=%C[$)249!&.:[/
M)N&!FH1W'==W1#^^.TL6]+KM#H\VW2&XG[&-%'DU;>%FIU;\SK'E9#[\3P*@
MU^2J4R02\OP%,Q357/LF9GW3OCJ1&NG)&E"!V=B5!)&!DOLY4^;#Z8[Q"*Y=
MR?4X,$9KUVB8YJ.O[.U-9\TA8BI_RTV]K+D,GIJ]LP+3)>[)$6>(1(LP!',5
M>HIRH)I-1#YJ;.DO70Y%(@5=! 48[2DP;R:61P2X$=L87B'I:1\MJH7"@J9X
ME;030RI)Z&;K=?#NHL1VI'R--Y)2CQD$FIDY'QON(U-^$Y3OS .2!"$)?H9N
M$5$=;$.9DL/;GB@P$$_Y;7!35SK^4*]CM(6/>@?4^.5DR=%+/A_R^4"S&KJ>
MJK'O)7E$>]L*=,#LCRV2J0K0 P;.[['UJ&)5;[04T5]#$J-X@UT/+J/:"*0P
MV'NDNKU;!7O CJHW!V-;COM-U_MY6MW2@G,V5CEPAPUEQ<XYN&>?3$$S@UC7
MX35;-*!/TJM)EPF=NT U35([A:CXA1PJT%N!3''%)Q>L=N3&47Y&1M*7\=P1
M@D5!\]S476.!&,DY<;7X1\U=NZ)[,H>-(N (<GN%ICD+S2,ECL2$9+ T3Z@]
M%$,XWX[S<47 AB4O-3V:Z-V*3@VXR\X/7&.0=Y,,6WP36(M*JQ^3]ETJK''A
M]PVE']&9R9I)8"0O3A?>?W:351>FF?P=B._XQYSE/4JPB[%'16"(&D--=L;,
M%KPA-Q'G=X*-\:LP25;G$S6?J/E$92$84RV86,*P?6W_V6S2I!ZB$2]2L/2E
MZ\YG8Q2JJSB*4[PEY*&F-+:FF6MB3OE*Q-Y /%+?=;UCK4H,S71=<;&$0S^A
MC2>;X@=- 4(L@BG5R#0\]=/T4U>W^W//6RBK2!(>O6ER+9(T4N8/XU*ZY-C2
M1TP_/E"-= 3$S%*O;+T"6+V,H!=&$T3AOW159"N;K>P#L;*_<R(U]' G\I/,
M5$$$C?V>00SBW(;8AJ"W+;ETI11M_:ZN4=V%IW@@P5R.<4;QIJ-K38C>:[>:
M^JVJHW@VHA+MC.G@N&=H4^^8TX^;0*0_A\@=N:-W/E6>$^#94#Q00_&.3Z*G
MTG\GSL4M-CYHS'CO4H2&9C\B)27F@&X<Z&]RE17U3(TML]FS7&8_2_![JOMJ
M^'VC+S*%>=#/(AH_21(8?6QHE!+!?UT%+^MJ\:01_JT#Y3..G/H> L[^PEP@
M4:V3L>J0@U&.H'/>:F<2 "$;(>D9;PH/7?\:Y01P %PPU1@;IR:H9^VF7GDK
M)PV7;)%/S?"9VJ%I%IK/*YQU#J41 LF;.(J8N#AOV(-&$Q+BYY_0^H0)/"CT
M_BE%GF%?MP[N9#$STLR\PEYR_'QT,1$$9]+K^=-H1HKI:O%M%/J5-Y:0SC%A
MTZ*\]OMKT-?&CZG0*4"DZE:^RJF)H]6\12+)-JON2C2:;+N6WXQHU89E@S0C
MA4+2HGM!=Y>VCW^\KFU=PY3*EE7"2I1PGB[05O.$KEW)<O.'M^@H_*4*()J?
MFA+ QB8A4H0VS!=OC2$CBJP=Y5*IKS9&;.%]&%5GZ0;;;ZB--W31->EJF(J5
MV/ GARD9');!87]]_/C3]P0<]@ GG[A)J00_/20A3,_X)YI5%5'03SHX3P&N
M_=H=XR$BAE$=FF!EY7SP_EG/L <I2)U@E7X9I]+$=G\3R=$!<@\GQ.2@E6,Y
M.6R-#;^=5!.AC)F*L0QY?_\*2N;JS?FH'&9F:X.LOZ5^.* 7I@93*;9TYSW\
M([<W,"XH]=ZE$*[V!PW>06 MLA$R]*6MW$Z]- ,84LG54V^8(K^?B20B@04Q
M%(FYG1'GG/EI&K&-;6IN^,+A*J4!_0C$M P*(/ZIX.T3E5L1$#Z#>8[AW##.
M)<.L(PO.Z8/H]ITBD.+S7GQ4M!1%E-;92940P^@#>E=X_2C.A_C0YEJ3NJK_
M"1W_%:2"1;1:_HX*+6OR MNDJ<(0:)DHK0@,L*MI$"TJ?;T]#?",790=9OJ%
M-V<>Y[..*>.)C=CC1$Q!Q^,0"_%^IP8JG"[D/N@?RT;.*29IMW7T?.CD0^>!
M'#J_-P, SAI%O! !C*49VC*+".4=V3*P;$$0Q0%>Q>I4>;?/!_G^OTIFPXJ^
MY5F+H':1\:HSWFBB]*""L\=)XBD7,_*&?Y@;_AV?*"8ARSN;%>O3,QS@+X9'
MS^_1%#H6XL[;&0XP$R]$^N](^L'"PN%W,<!\C7\9+M8W[LS26&?H)-A.6WIG
M:(S53L$]W?KA[;A<P!)Z!N%R:7!&5$"<.VJ$4(1](%GQP?8CIA&S_'T,5U<"
M:5O/ (52%&J(9(M*8O7DV9-BHM]@>:O(7VZ.CY9]5ZZ29]%1FPP#]<>+=VD7
MB?+,#7"15Q!1&[HWYH5I4'[+'0I1O@.2U]]LY(9_AL;Z1_.KGM+[\"]3P#^6
M>LNJ;6G&FMZG,$F5@4G4?H?X"[DM>EJ *LY(?;^Q0XU7,D%_.VZ&H1EA$.Z>
MX $,+C:TX&8X1-"&E%_D5RMT-0,.Q50)06Z"&O<7/XVK:XEG@D.O3&96XVY7
MFLJ):PE#%4H*RDA*"9V;M&QYJ G\%%\;8*I%B$W'2$MQ;LFG/7M2,[%;/7>A
MW[^3,'L&[UTH\,J8=3D)S_L#UB>W14AD%IJ2FQ16_7AM,/M0NS3I)[^?NSXS
M;.4=^F!WZ+MGV&+FU3(IM91;XO6<^@;(^EK!UP#KON@,O[URM_4K04EUP0/E
M%.^#4X*YO0UX?_5NI-N.TJUE$)FQ^C2&M)>6 3F$0?M(:5Z5S#9MB2,%2_B^
M]G*4YA=",]LEY&.+?XY;UU/8$ZB\]8LIJ1LO6XGI9C64V=$$@W[$-R69<>26
M \ML[9J5(0*3\JF<84*F/0D# Z/R6^PHBJV!ZR)$3U0S9U 6/V,1VP1MY^"9
M0/5,A$H']37MT9Z<]@@PPS%O#O24OBQV-3!&+WO0^7S.YS/-ZM=NV-6$!2S7
M!#7MEYVE02PF+ G(= "Z'ZJ390";"%]BG6),C0%1K2IM;(V=R'W(39R*5PT%
MU^>,]0HX9>J2/90DS<%<WY+\Z@)>D4)K/X'*U%TLML[?>S7$_ W)ZY*T<?+1
M1'M+/P%A/.6=8&*0+(PJQM*CF_QT_1:F+4HJSS+H^55&J@+,)\D:+Y3K(LNJ
MY(\RA7%V]" 96S1S#1O#_YD0_8?N+GHBJTHV.9U^B;56LWPB%#%=6)>T5[*]
MSM#*#*W\Z^/'GV5HY5U-?JE8DP UT8(3^G\MCC[6493]1RB;I4UZYI3C=IN-
M:^#2ER)@ J("D+U-:'(96GD3"%#UT!&/GL!*YXZ?BR4@AL9O.Q]K$Z\P=TVL
M+!WRF7M)*:)N.4#'9>L]P8/8[]]TS0I=%Z;-9$*PI06(9=-5KR_C2%4B-!V]
M/^@:&HR!0BVTN3G6B0QW<O0PB'!C7S?IN'Q,4[,' %S1_V7O77OC-K*MX;_2
M.$" !*!T?$DF,Q,@@&(G,YDS.3'L9/+B_49U5ZL9L\D^9%-RSZ]_]MJ7JEUL
MMJQD$EMR^"6QI&ZR6*S:M2]KKP77@Q\0W"\&)5II=8_?G):>Y'*1<Z+^#9GZ
M_ACGUQQO?*A&])50K:.=L#IE"W^U*2Q9CBTVBN6>OUHJL6FG/'RP*?7!IP>]
MW!_<[')W4);K"@,A Z=\?7J)MUF[.QD[3<\8$X4S?&,#]@M,8.'(1.DA3U@]
M-7ILT:O^U]H[^/HJ08F"KF51HS7V9>>H/"F2+/JP]<%7F''SWI>89X,Z&]39
MH-+X7\0(^O4$:'K(0NNJ^7EHEESBB,VO %"(T&<7ZBJL<RB#X!4$$35IJ=9D
MFC4C?M3FP^;+/,_"(=XG[%K;B!UNNW#:.84RZIKM1Z1RLQ8?P6W7ZO9*&HHN
M7P'E8BIS:"G(JE"N]B30,.' B81!><UJ)1WO*ONJ;0S(E=!@0<'),).<EO3;
M$5-?Z?N6))88)ZX]9%WQ.2(8*/"6;$ &=?%-WP&O4O\BG=:T [HF''IKY195
MF'6B,LP&4-AB\6]$S79D-,WJ#4MD\E6#(?7GXKM3[SXJ<TV$'N/S"0_<M8>R
M-KA.%U8!L!K%)D7)^ZF+I:26*NOU?:7,O88:\I/)HAI2O= >;%X2JTJD9R?4
M!3>!5[YK)9:S+2V?>++)H<4-_?HM>LZ)S[WM!#Q??"/[#6]%FS\T3U9>]H%5
MA'U)-4&\E.E1W^TM[Y,;#X!*5-%>RX_RV0L9UFSC1F+%NR<%1WU]2AU@JB+F
MM$B,JIJ+-MHIW!G?J)GP%7 7A:-]JP2/O ]Y3N+<#XTY8K=:LA.+^=<:LC%>
MK-O^)WBPG-AL=HUFU^B!N$;WB"W+REEC_JN-4@2F Y]-IN=VE?R0?%VM7FIR
MO#N?UDF:W?:((]8<G#&ER0Q#FTW! S4%O_-9<]$CF8&3NFU^)5XLX^L9$4G=
M@&'XJKR2_$PDY1>:X<A/!,^*G% )RW00HU[F4W'/=YE#Y"Y:*(=.RNEGP\H8
MO#R!5R&UZM21:I]1WO&5_3TO*/,?)2W6F/2?TR HC&3J!.W7KV#]BAZB]DF<
M--W%,3E4Z69JQ"Z>8?^/C?()\BQOEC.00WL+R53VES8Q)"[K2HI"'Q#A5.[8
M3C;%I.CX%U)ZY '_;\+I@?$D7@^*',JM0_G%M32[U/,Y^D#.T??C4O_B#C+C
MG]YT8&L$* R'X4W;U:O9B9TWWP/=?.] K5Q3EZHO%>5V+2-O>A=6RY.2'!]N
MD"MC%T8EJ=& T3'AY3?T7>APT.[L(W\)-SJM,R0Z2XF[U#ZG-$_V$D_M[91W
M,]4Q*2W$QNPCD&!8U.4->]+<'6JH^3AZHVI-=*&WF1M!:O8E78D6"*?;:1;#
M"CKF\QD_0PQGB.&7CQ__:888OD^((84N>[5ZFB/XL6&E^E=[R04\HYB63H$@
M1-VG>OBEYIB7=CAUN>/X9YEH)I*^8K,0S@NSK62[>]$I' V"LP?"U$O65GFL
M1)[1E>-0>UX%47F:NE?C=+VRRZ> >]1&]6RD!C^H^-H(?)E_384J+;F+F8J:
M5$?2G!Y](X$[U ?B W'GEA2*"AX!G5PMP$DQEW!<E91S)W0=QHT!YN.94 >]
M'/*C.W(CQ#=3]:(KW--R07(9_U(UR:DE(_*8[K4<#$LEC1/N4+]#T:ZX98KU
M.%;!L<-4>QO?01[:FK>ZN[1YNF4>80GX*O1X:#T'T05-*S]L=8E& ;[F:H[D
MYV!B/FHLF#!*&92>ZHJ]Y\6/KSN81JTV2X=37S9+4ZAE!:Q,2(O,I6ATT;Z6
M;U>E6/>70]_CWQ,]1^>+EP$^4_S,"KE6[03*KS\I@:[F<72+_@10@XMH4&E@
MQ>2^(OLB@E[0RUUN2K0GS99AM@RS9:#Q?R?I 2O9\%$>&O8] HKAGM>(SFCR
M.+?L=)D'<Y0]>!MY@U$SG>B=AZ5B2J9%?^CW09J][3O1)2K$RUT.C"Z/?W>H
M,_=1]5+6Y;42UGIO"]IWWEVYQ3/Q3EMV^_T&]1//5G=9M7E53-4O$O \=99J
M\_IFH'>VN&Q7A[RLLD4?:+5W O0B,L-R?GMQ7(^ZX9/7)>1N$:X7<?69RSH6
MSAU+%.K;$T*SNCZ<+UXX(@1GH)VWE][XY)M^:QU'EA50F*KD(^0[AG*4T$)A
MF +-R_L!$KQ*[K0;]MFT@$\,[ 3T\<L@"]>8Y%;& -;1CL2/3=EU[4U]&'NT
M65^MNR"6&WQAVQTZ O*GV]<36O3:9'V$YHW54#W@KK7PARV+D'&H]@G+0@?Q
M'M1]20;7<*'1X69%:=P3;=0K=NVY8Z'PWG8&2=R&$GS2ZV'&X,\GYGQB'M/@
MY]EU.3YA8(>Z;SNO#<LI'FE+5%(7,R+,:AK1%S#.=/08U25L&AV_0(Q5W7+8
MPD0*^F(A=)H1+LNIE4S:*D,/CP8J;O:T6':TD&J(KM!N9?SNY!LH/-O].A,6
M8?QMVP=_!'ML.]\ZK)(UJMPMNW26B16.@($T,_'94X?1F#]]?(0*/P3"EXJY
MGS:YVK",U_L!*0Q).)5(X[E#%FAH*IGFB^6R[7 2LI*>.ZE&Y^+M%*^\!USM
M)&HCE*OP?P.2A XOG7EER6 O$L&L0KU/@3GLT+#D%\UT[!N[,Z9C)K*<3Y#W
M/Q\? *[BVVCD4H-"E-$6090(%E8;/:&/_DM4S2^9_H?L[XR_F#?I ]VDO_,I
M\!-'] >@(')\Z CR-$E_)=1\[+RQVS&NF%RB^W*J',3DF8F'G6,W/O2ET3IR
MK>=#8I*_F!]( ^0 DI^"J9:ZO?2<Y=9D+%YS6C:WB#7"GBLP\$#H[W5=7D)C
ME%5[^QU]ONW8OY->,@!C4VK%5'>-!SS6",?#N(-R;S%^%Z-9B3<](8.;X4^$
M6""1@%/H"REA<5Y57?B445XTI5& C9>$!Q%+;51PZ7"IEI"Y0KUL<^@9.LV1
M>UQ#^ T@.AW>D@T'7;%"XB8(674V"R6R5W0,0-V<)BA[^I:&#!MM3)3N_#3=
M[)5?AM L5@/#<UA(:Q43"7T8ZSKA+KY9V,IP"JG6J3C9XV)"L/E@%]'3Y<C@
M8-7-V$]+AZ-RR8&CYDZW&B&,5+-9B,JB+B*'!<+Y?&(5G5P_W]#^!-WHKF8:
MB<631X\?"9#IF^<7+&$MNVX-=IS%#_0FR*!U%$,=:&"<KV%]BBZP$]\ B=_O
MPR[I6^$ZZHLS(9R(^C*=)L89+^?;@GG[=&Q]]D*/Q\WB3C$@0[:#+&Z)Y>@;
M4\O969\!4C- ZLO'CS^? 5+OC=>Y!3R5SJ:RK[(>?Y,*\7;,R\K#8:B8 8S9
M:T[T]YRPZNJ9[ UVLZS)C5FH.=[!JP'@! 0"4F-F&VUT"[T_F%@3,^H#<>$Y
M)[K,^M:?M?U>2PRX^AE[/=N1",S2PK>L:<C23%*)\[*'=*SM)OT2DS)AC!,9
M?HPW99BX9E0U_&\_>]Y3O25#Y"//&)):"#KG@>80<[9O1Y4$]LJ/W/UC/]F<
M9+<3UXE^8]J@K4=N*L<OI3#K9,)?6O\M\TT/7K;4$^_C,?HWO8U6>QU= EZ<
M4.>OE]SN=[Z ?N-M3RG>_HG;24.EWI!3W/GH%7DZZ<!K*RLC!;E<D-I.Q0HB
M7((CSC)<B/G@;V<*XUM$"0V#)>\0ODRT1M&CHI%CX!+Z=VW#&%&F;'8S-?3*
MY9-.$H: Q@ _2NEJ,N%U0^>04<VPT><0PB"G>([FKED+ 4EYT.7YXD<_NHP<
MO.Y;KL5O=]*BVPI='EXBZU\!&1O LF)R7'F)/D%F]>R.Y[8;7HX#3C%]7D77
MPRB-I0M2F@\"IA4^&\-:^/,IUDQZ*8AT^&5D=YJ0_RF,2:E.=-=O+? 4"^4R
MTD*//C[>1UAYVG1'-Y,0R7Z\V=OBB5OSDVEF1J?V5LF^^0">#^#Y *;Q?\U^
M,R='/-ESJ6=853,23?-#PA5P))6Y&I^6(.^_#-Y<QX:W"><^P75,0K$"3D#A
MK)+UY=9YJ"E<L2C"T(>)).+1H:KZE?0[%+^E?3#Y# Q!\\<DAGV-XZ#<HL5
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M%-PG5L)ZT>F8A (EL(U#>1?& V@)T,X@APFI$_U8/1ZTXV@:2/'#&&:R/^P
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M!8[)/TZRBQBU$*/&ZO9&4E!F:\I5N=LKFQVCW$"-\49@(*,^*6TQ7[4[<ST
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M'^#D?__#,Z'@5,/H+6$1(^EH&U7[A>ULU?"O=UTEK=4,?A6F46XM>!Z6@94
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M BH$Y;+JQ%-?#!2,((6WXJ\R\;T,K.K3[?+\/L</3$[2!6$RW@0VF/0]F"@
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M?[J[$PZ/=?*&[/ZOI1 *](']GCT;%PN1,T;FA,L9TNAS:7 /X1^4/W%QU9@
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M1W+@*''=_#@F!N'U.LQ)F2H.@-T0^BEDD \!5G3=HH$EPHVE/A?QU/80=GE
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M?8YE]4(_=T2&\:_G-'S'QH&G>P9#2!:EP$7X92X'>>X?]^5&1L9I"!L+FQ7
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M<MGV&K]@+S:]=@PW.D&\\*R@>1YWS&3E<G3ZANNVOC:]W3VC5KAIUW4$Q_W
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M#-(.&K;;F*LL?2?E- HFL5*T79X-@P!&<U!,XC(EHHQ<,R0\R-!'N&ZB5&4
M\WK  RE^1#./9!NN939*FI8N4AH8%F;//*9VR\RU=QP3,6OU'WGUXRH7]P)5
M5O7PMY-\:F+W^"7;8DZ-S:'"PP@5WG%L^M.8K1%'./H=Q"T"8$Y^*AS9_)'S
M>-)W!*ZN1DI?4'GR*^YXH)."V:+RYCW&UO5#TV]HLQ?Z>>?WP<\(ZM^QB\&9
M]],<\AF)F= [?AOA>$.C9 +JT!923[I6H)YV:L-:PXG.C;6K"ZW1!.&+);&]
M>LY8S&;H@9JA=P"EL3(?EWFEF)4%3$X$A^T+N6WKP.$"^\W1D0:KA-;*[%?)
M@YOP5C720/0N?.ZT[:_*1B$5IK>6X  4@EJ.U8(T070;PN38*DZ;0A<4X]G0
M%YQXIJ2+QBYU09;D['\TFN/TQ+ /T8^V3WW#ME41S\;_TCO.-O'0"I2?X>*Q
MWT2/UESU2CIOKR#%N5+0C7.['U:'?#K-E1.XB;4I9:WD[?3;'0?+Z060&UH)
M_[%09U X8G9<8L!IFOJ<8WBW.?04A99-%!'/#IH8X-I-(P(\-:)?'A*!F$VR
MSSKH_!MI:).T5O(6'G*X(]]]3,5[SC!N]>,121MYF6DF36+P;U5@^>M#=7!7
MU;4-5XU?'=;[OWYZ_MF3/W_TQ9%Y!3:H+@]_7=?AC3>M?^(QJGVTV_&GZ,"C
M7?P%&] S>O9M_U=H1M("#Y/F-@V<QO#T\X\^1/N;36N<TZK!I)SQU-YZW_&I
M=<NT^]G\_+,GCS__\Y\^_<N3IY]_^OF3SS[BT_4-)#+C^>J60SZL!S_G__7E
M6^V[Y8(LR]9/&V[I?]3$12)_Y_"_JFOQ6WM.IHJ5%5IX_B=3<VKK(%E)85;=
M#HU&X[<Z_TA7+H.U#W6!;#IW<18+%6B1QDVZ02?@/48Q6L--8=3F:_I:!?]>
M1L9L;'(H(A_!#H!U@N("M&,Y)@C=-5S_-<NL\"RID3=N4O!/*1(Q3G/N/> D
MR?FKO@,$IU1Q)_FA6J7$HV _/_T"I%8\Z=)QR;SXJS9(FJT)DHI5)1EN L);
MJ</J*O*VW'ZNX_F BF//9<\G5VM-2U;*R,!7?"].G^Z%QC;VYWXAG4!V4$9K
M2Z]!_WOO("9_6'?^ T+<_.57(VY^@0,PG_Z_R?NZKHQ*XJ^;:D53>X_\@3^*
M'^"""O;].0VO^E>2+'-I<5ZW[A \:F8HCVD1;S]P$O-BSR6*6C1..&P=:J[V
M\!APVNZ&3MBY1E<>!Y]?/+P0)#\4YU!D#D7^(*&([>$HR)34F";R]7F!;KSO
MQU'+=-"2\=1U24!D%,0HD,/" 71#:0/\9; _(AG_5J.EP0'9+&=JUVB"XPNG
M.V[+UWPWOM'$33FN:#L1:[3;1M[;!'4$8]3I08UN2F]BJ=",[/>,AU%8 7Z\
M;JN5?F@5F M"P!0CCD!ZV@7->3@8N.8X=Z74T*-WEP1"!@6.Z4F4.GA4K8P,
M5<5'0(28.%A&1$)8]">4$O884JZAZX\*.<S$&  NZ6-4]E7H]Q +6/(T7FA7
MT'>N(TO^6F1SE; E7%Q>K\_J\C+4>*I^\7%U'LX+^3?WY+W!0NHQOSMFCXZ\
M2BCS,X7QJANN$J$47^N3+^9SXQ[9L/G<>!_GALK\B<$WUM9X="2CP5FAJ6/@
M5+HJO G+(9I]Z%YM=T;"*G_#CE_TRPV97>5#T1K+P6=Y+D,3:,@IVY/.+A-9
M2N*U5MI1]8"ZIQ6@UI;[$1D@M/-X]G4I.#@Y-/CF]C<PE4U8_W123(@YP>:L
M:!^SZC ,5SJX<(AI7=L_& SK4300TU2&(1V= B>2C?]Q4JL?I:_04WJ<OV)^
M]+NEKF8#>W\V^VQ@WYN!%==FWY]40#NRP-H9>I+'VBE(%+E6!I=(C0DQXU!]
MNT;&O&'OT^*9-^S[+NJ]B "$%WJ*OU(DFX^3D^QE;-3W=!-@":7HH^<V=I$C
M,<(#99SE,E5MG!3]1$D,V.FHE2,U,:MT%:G,I?6X9YNJ7G6A2?'.WV6G?QNY
M&UZ(-[7X.).@!)D!TY/TG\#&:-.%,/Z+YL&S[UYEJ#P3/Y"05<Q4Q/-F(IK7
M93V$J'$3D1T4S)'CQ\!ZT:3CKJ%5JZAT-E=,C=CN@/&AT))_VK6KJI0?)-E!
M+F"[4S#[)\5B#RX_F,I-V^\ C>./T<0'LB2-LJ!@21>I"5\X=DZBDSP:Y@:(
M^$VUTW878&G4(R37,6!0S"NA0:A[V%6D#"DOV^N(_ZD0<6,9,-2(ES"M"C0R
M];-)OD_F83;)[S6Y.26?23M(1:" [ W[RM%ZBA%E2=,ZPL*"XM64ZSP!Y:3'
M+_6'H7;CR;6Y$R%J;LT;\SXMDGECOB]?Z9OGSR[NB'/"Q\O54.\5G,2)EZJ_
M[$IM9(J>TK2#I/[3O//NTRJ8=][[/!)/=])D1Z 1EV-[C<(3-,N4]5).1FV^
MAMNOY%A'=9WIMFV?ET60@ L]9]D.J]K]"\VI\($OUCBMR?&/$NM>7]T)FL0J
M$S]9U"SGPI9UX>K(-=?1A6I[B6Y( W?_MS:"HX&9U5KDZ.=K"L<@Q2T5>^KN
MH8Y!AA#]X";Q:J?Z7HW2\F4]S5/"*([K+<OF:">V=@>?4/W.!Q_'[##R^2-+
M:'@:+-EKQ&)B-!3+=66_[X:E4H]Q=&4R*'Y0C$S70EJV@E*4Z4'NK,2>XN'D
M;\4'FJWX?;(HLQ5_7_[3"Z$1%5K8Y]A=WT62A2S))*0- G.F.S1,K:!_S4TZ
M]B[-%=D$(1T5L\2]\-U!=G!?PKKW2<=2K03B'XR$NZEB8DLR&-H052Z-#\+:
M]=5D)(:2W@G2(ID5J_IR6PR.'N9RD)PSOCO;@ONS+F=;\#YL@?09HB\ N^ZZ
MK(/R@K-.JQ9H)6MHY[MX> :T(2\#)#/20[VOS@S7DW=L%[\TBQ(MS"%)WT[A
M5]4-85\*9?2CADOO(CJ"$2849G,39T!S+^:T[I!XH=="YF)9UDY,G48RMT/,
M[1#OH!WBZ:.Y'>+!O*^Y'>+][I8Q;=_(?AM)6@H<K]MZ$-_4!=!70[7B=6S]
M^ZPA&:[+9C_^F-#1=^UVJ*_*?4)_3B1)^&#AK.1-U0?G52=:.FO?ODSERCR0
MOA;)R(26C7%R:I94'O@O3AYJTYF8=55;"D<;][4SO0M796>HMZ44,%,95@)V
MBQI8&&A5X:K./<"$@.[KM;&WI4P1,-756HF_("KDI7KY"7U+J8)9V .PNJ[.
MRNIXLE()56($A8D7CEN!)R<7DYAD>X&HRC$QC-.R6U;=<M@*[0#3$C3\)7%@
M5A7G)!B>+BZ5()V;+-_"!&N6_P!N3DC@66UB:V1ER&2K"@M2.QH*Q25IG/0/
MO7WF?G&BW,N9NT_>UH=R?/_7EQDS"#:QTHV<E,0YK9[DI7=_;)A;PZAA.9>1
M+BX,EJ,KM=,7%0V5)-W#JI$G;B0*,*)(7;T&.6G..6-\(Z.H;\0L*@0P@:ET
M#3V2%]GL.LR)]?!,SWW<.G_8P.W#,25?!='?TAV%.(T^E(2H(H<0_MJ470=L
M5]_G@'APMB9L7!2] 2#DDOF3#)I7,#;>,[3"Y6.%,S4LB>\V 4VB&)$KZRPW
M94VVX,K0?K3KN5K.4L/KQ%HG76!&#,YW"$*V,7"AYZB/V)ZYZET9R/SETBBX
MS76BWVX3@1[WE4E[!R/=Z(4Z;]L1W'I1(P4E@B_7:DN">&.?L8\<J.TN--)S
M!Q:N(/Y>O(TQJ'ZMXF?H(N'$D7KT?FHC$[*8^",&LM0O4IEY]B&+*]B-#?"8
M39F_:PS"1^I*YXL+FL52,VR1UY4SXB=>2R8PG/A>Z\-8+AA=F5Y?3LX2E7ER
M_JPPQ(M4J$[("MTI41>OE*EQ5;R],K9'\;'$[3I>Q?,Y,Y\S\SG#+JMLC,2"
MS#9-K' DBLXV?;*P8EO&T&!F2SJH<Y>Q67L+) 03EI<?^FDFO6EZ0NX5+V*W
MGWK$*_H!Y;E2*-NMCE>8-%[!C<F<K6'^9F:(OVH[L2.%" #VT7ZDD9^A63NL
MIE )*4LQS=_4)C6%"&2(D&VN1G9ZU&2L?06?'U>2/(!N#5;"./>1U-T%3M&S
M,2]96R,J3.1J.M(+7?6B,%=D:O%QEA)7-9 89;?%1/'<;@1^@N8_3Z9(H0WR
M'XHD$1E 8R?G/-5@XA#M>+$5BRS5H?3V(M539T2$OU:IQZC+=<4Z2'N$^T\F
MR3PS0*:TB2-)7!VG5 VO1/8,W(V3!.LC85(&%AXF^"/3RA9:!&RI?'E'RG%?
MG(HK6,D,=F/DS^U0H5P @ ,_UU+Z&[R+^="=#]V'<>B^8Y+K'Y3QP>>M4TP2
M!698;0(MZL@B+T,Z@L?NO<&94U;Z)"?%3 P^;]('NDE_?\]8V?FC-\P)!4<G
M(_L*2=2<YX5VV?__0UVMR'_]VS^_?_'URZ\NV-V83/46B)J-_T4X3=]^9Y%8
M7(F&3#B3KX/P/^YT\O/:R+\0_VXIF*EA1 ><Y8*=.Y+%Y<:L<;YXA0NI+1*?
M@BE\DM@P,LT1<AS+I\K_\U9S)P5.W_Z4F3+X',(>=%3XI#ADV)O,^<[8NQF!
MG!SVHQ?D%,5O>T-'PEME_(83!XHK8RV$31;P*%WV%-T/RTW$\M[D 8!RZKJF
MMY* Y'IOEP:Q2_-ZI!/ =":$>S>X>FM<%>N3B]/_223]T):_-._=N=/\\ $9
MFDU@K3S.7KJ+KB6AA@2:T)Z+(KE!0GE^)+E'ER9/%RO*@]'=4_$+&;GS>-@@
M8DPQ31=KN+$3Y^=A=24=K_N4OC1@/D^_#.=\\??V!D]3G-R-:?./'E+"#6\0
M<D9]YX7+$.IP?1@'M=8$<#JLE1)S>&W"]#%/%S=8,>ID^ =LL]!9'2^RE/F<
MW?09.S=CY[Y\_/3Q!R+>_0 GW^4@ #P"%1\?$$C 8'TA08:2"\X*6#?F))3<
M(_VNV[4J56%9M/**_BQ)+T;_DMEDTBD:D/ ?_#PT1_4.J6!)4D1II<(J]T!4
M48/.+?)T*K*D+'*Z0>&&LW^:#F.W@<\1.EIS23PF?D0UXSA2^]4^9!2$NJ,O
M9YF?&_Z23_K\EJFX^5R9(\N'8=S><2KC[RD72_X]+6YR5TO4B*/B926U]"ZJ
MDDZ; 8L"?)N"6IHYSS/OQ@>Z&W]G<_\#-VYS2 ><2%2OM4(/_UG!%N@>'%1!
M%Y%_,[!H.YUS=;BJ^EJ"-)>.16@E[H!K610>S?[0,Q99 _D<>R>";>!_$;]'
MQ>E5YC87YNK![N0,0J]%NO*RUF1+?NV1C-BX4-O+7/0;:!AG(KM*$L5)IZ'K
M!^:I&MNN\\4WJ)V]X8;)0NBJ'C^2"/CBV<7BINS)A2N73)ZMOE4"H-2'Z#WA
M"^149S+EO;H<DCEA@;2LPBS"S<*N:OU9DQ-\OKC%Z +N&,?+_6/1#=(WH%#O
MI18U\V*:O .5 I8NL\EWS.I%K#@OWJ12T7*Z8XO:\ 0S0.12.]:*CFFBQ&-V
M)!TX^V"SU9^M/F;U586J/) ,;(PD--SG1\&B;:Y:+JPG\-ZV74&UWJS#V_A1
M1]9P7[Y))P4%2VH(%Z68% #E:,^3P?S<* 5[#S?$45 XX?E_E,T /,OC M_Y
M"_VIKJ1U7LP(;B<9PX.TLSOI@YL-(Q@0C&XIXN4^E'Y8DZVO$CY C&@IL'%A
MP(_J:7U[M@3:9+4P/I1T>82T\$C/C2!E\2T'R11DUZ'L%G2V')\<R0#;M)"-
M?T;OH&-@:Y<F.27.OP(Q;)8D519I>6,2%S>B&C=Z=;C@K<RV<+<!MI&9IY71
MK@M%3J9S..EH_K/:FQ "5H5_S9BZ;,D< 4_&,\#(34'=LRBT.!XJ_3PTM&.
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M[2VO,-[B!=;F5^JZ+U\;E;+<]6S5]H(A08E*P"'Z%W#:ZA>0#.8(OY+'!["
ME@)2''BYN:[X^,9<TEOJJGG\Z"/>)RT[8^CFI"_12^^2RSW^OO3I4-B/>YTO
M\MTMP$4M!/A)GM3K8H&)J(P2<^<\L">?H7%QJ35462RXE()I4K]/;%Z16W!W
M#YF X\=>:P0@R9 BHUC,EXAP$;:@WO5I_TN!9:U/+GCNW^57P#DC'TJLRUXR
M3*5R)Y?R^3BLV76=7=?97TB4A'1$J1XTF\I71F=UD>/$/[:6M+^_?'5A#36?
MG$Y%.%%H28 ?Y9HY&3G*<>IQ!:!@7]F'3YNO9BQ2#:OXNFEO!#LG*#M5C.,4
M,T)BL;H2/ <O^GPZ=S+BX#E??#L1MW,B-DM_R/D91BV"WB?CPRD*=*>T\8F4
M[>@08%2AT>=.>#[',VQI<GGT=M@;E#3Z>GB]-A5TC4:P=?U&,AM;?$0N.YH^
MT1/4N:73$-=1:/]Q#D2TQH+Y)A[*8G6(6(G>)_5&KKC</566VH5E.B<6Z03-
MTE-V,.E-\Q,TX09*##UH>$0<JVS&0"'R"G8#<VGT;3WDN^7B^<NT61B]V>L[
M$%V#R\/13)Z<-:<'$=<Q0X09-GN8V@ME?O5#/O-10H:7HG(BLP)CKY"HU2 B
MXB%A*K4ZH^,O.TN]J3C9*K7+-0MZ>G!)A'H$SVJ9@@IXUR[@U7"*%?S.S(&E
M;(CT_4M.I9&94MJ2V*K!-3DL.;D%YC6L!+>,Y6&^SV@241XA9P_),0/2\G)P
MZV^RW./(E9(R1N)>@HYF^HC" 1SU$J9Z%=;<6J[D(^K3Y*W#F0F,8826E)0M
M,,_.&E#CINI'H0(0#1,&-J\Y-7?W]F>G:7::9J>)QO_LE#.2[%4-!OGCDO['
MU2=)0M $1I*S(I5T)@J$[CL9Q^ Z/A1-54&)9QN;_G*:F8)N,74/T<M9;*N>
M? /(U)O;8BP$26]RS97CB9"+KTT71\C9*U>3%?ZC]R'#E;(^5%]0C:$GNRS[
M2H+YCZOK6^?@V&$3AV(U[7,H*82%>J:'70G=OC2+9/9/RF=.=P!'SDJ8G+B3
MPA2()I,X%YF^@#A**K^4?=F[;"-]1B=1$(DZ&!MB!UND!G(Z0XD0UB<*1'ET
M.FF0GRQ)-^B4XS>;]]F\S^;]B-KO]A2S,G?AG[ JY>+S1Q]%-QD&\+)C#PO1
MY!0/S9X,T[^G4H?/:=,W@3UD[HJ[01@FD*G\#](LIC5SM=E7Y0Z-8 (WPU^R
M2^ZU,\]E]7PV+^LIAQ/>#TT?N$^:K'9\-@]KH,.C+IG^6I6\2NY/R$Z^\1?/
M%S^R(0L5YQ/UM\7I0#\F-4^?KO%@BJ^%.[U2*YA.5&+=GLA\QH&*#@W%7 Q'
MRSK<)B=NG 9]_KNE02="ACD;^MXMW6SY'[SE'^UK=@]U<Z=-&:-Z3JZD4)NM
M;VV;UB7R8D;3.>XW(2;IQBX\JJI64]TI3M2<<Q^[C]J-3]BD2(\6$.>W3&PG
M.IELOKU!,O"O90BU-KJIP'P:64MW("^?*MO=F(%>(E_#9UKJV-VWLY&9T3$S
M.N;+QT\_G=$Q[VOR8>&:MCF+;)0G'2H 6JO>FGM/\7OG<CT2<X,](S6-]6/-
MW8SVR)"K*\?EV62\E"/[K[HWR\B&>44N?<=9$FYJMD.@B&#/P@&/+]N5-;4(
M 760:R9?$=B(O2DJ1@V@?!!%3@*2+F_]Q]K"QX>19^?$X]*A,F>29X=S-DC:
M#0=YK5+@<JZ5MBYO"DN))ET8.(22$_:>9(5Z:-.$I1*R[S='5H/+O0WMVN7^
M[)*A^%F]*]63_G6Q^$9-XRO0Q!P6KY:;L!KJR/#V0U?EW&A(>9\NM9V*YHV$
M942QEHTQJY'#$U>DEK ]]%IU]>1$\%A9Q$QC[O2,3-8P&E[" ?1C#WQB3CDG
MWG6P^C)K_-M3LY5F:J*#3BFJ\X(]PZTD_[!.3O-H8.>+;U*7RK9\#9\>U63,
M;9J+7C/2H/K#/HD3FSTR7IRK;]9UB),]5L;%(+[AA?=,*KX@X4]V?ZJ]#ND=
M.>1XM47PW[A:H<N*!K*#PJ]4>+,W<4VGD.GM@.H#2W^I*FE+;7BQR -WE)7!
M,5?6"/++>C_N:3?X?-[-Y]V'1&;QDRIN-D$[5R^5"@8MS=\\OQBQ,*_5'X_,
MS58336EV=7BE?BJV$AB64*.OMN];VL4P26R]A9W?V&LF!2#OA0[VS $Q6X$/
MR>L%2M#M6"1#N>+/)@#0^U',[ AD3.UIBJ-=Q7,"&X[IAHT;57WLPW+H!+/*
MCXJ0%BQ_W6NF;8R(UWC)%S]\+SVNN/;^L$,'0LV>E399F%P$)VUOLTZ)RY/>
M82##,T3\:$*!"D*S60]]=$!;JY/Q)?EB:41LN^ CMXE$9^+V*"15P!/4(-\2
MMU=^W[ 9)+M+DRS6KV9P!:=]:T7ZL1=M$RQW4EU![M+5-W;+LRL!V,CY95XS
MQE36JI(+]K TZ-.KP3C8WG(%OK$XB<Q?AD>P6JB..Q*OI86@\5C*XO!Q<30(
M)4T]>BKV15>9L')6V3/ M7!)B(YEYK67=,-*I!\GWJ14)_F9_F\@ [$VP+!G
M9(K/ A>]8"P)A8Z 6LHD)+HY;'M%WF9,<8V47)=033.6)UT!G,C2!T^L=I=#
MA<J)R=&OAUI'+<^E=!A2($[CJQQ42$1LA,UZC\#$H,@WCL![+(T=[\:;TJBZ
MR72=6CFS2SX?Q@_C,'[W+CDGAU/K&%-?@I#_F[:C(36+9VW7#61P7R"I((TB
M64( $N]G2_D0SB^Q/B4.>CJ\@6)_PZ5/8\.6OR]I2MMMKS\E1K>87G#9AD3>
MPY573\%\DAY/P"!R]1/$<Y*NPMG;L;YR[3GFC"T89R+"!4]^C=H _4[R#V/N
MN114N&KQ'%3<IWT[V[$''U1\GQF"L0TS,,.T:4H^.?LVSUY<%&\Q9XK^X*PO
M9XN-OOZ&R<_9OC3BL\6-[EC\0X>X@VMB==6PB[U')M)<>AK!VP:0*G_6PH.$
MK=&1![)[[2$$HYD'.AEVB\?(4<UE1]]!6O22JX#X,3"<>%N^KJ( GUT[:1>R
MQS_9QQ,I0^GQ>F4;T(0.IWCY7S8=^-55:9(!6I^TOY'%I&<NKP)\S((?*--?
MZ?;<KVT/2V:5/$$.#V4%!'$HFV%[*2*Z/P]=U:^,[I_?W8Z9C$5^+XN]>/*E
M1RIF=&_"N,V?MD!=7K8^[>M5 GL[<S)6:,9OEIGH0+ROP/]YO0X\=5.=@#PV
MFKFZ%=F(XW4Q0@7=3+)H"W,V[:@ES1=GU?5@6EONVM$29+4B&I<<;9AW7E9-
MJ2&-VWQ;;'A_MK;3^I0Q_N 5';]EO76"4^\2X6)8S7[[?-[-YQUF]0<^:+3C
MJ&F1W!ZZ4I3CD1H(4=]#N-0XKY-Z75%';7K1_5;[JA1K"N&&IYY2"7<]-],A
M(!YQSMAL<K@<^&?NO[0.CZI]ZWFSSYC!&3/XY>.GG\V8P?<U^<DQ=#ZA]HI(
MI'"+DPZ_Y\C6 1F-?$JQ^'KHR&NBZ?FQ47B#7LL)'WG$0A.1"E:>;(SU?]@K
M^^=_)&"5=;GT&[[U#9+EVJX)1U):_=D%SH^,7S\COC+@@S;+PC!R@W,S+A^S
MJOJKMKL*47U=[II+ 4RE:U(>BIMJEGB.LF'*Z'$:9T) \F[8D?1&5'^*CD&:
M_D-V^[O@3-Y%*NB/<3K.KO##3F&?FM.7%,'WBY>A-D9Z[*F7+A87Z_0*U/3-
M;]B'\KL^U+QGYCWS3O/SSQ+G)_;/JH*.@ZDR<HZ/^1PC&?1R/XAL1O*/ %B@
M6\@YE;0>P[(<8BLRQ"65UJO/]^5<V9BWZ@/=JK\WIV]WOOA'6?75=O%J4VZ*
MQ7/ZQ=]#TQT6_ZB*!?[\'"-H%M^T8!5%WH=^3>[\/\NA*Q?_H$]C$+5\\X<J
M-&?_K!;_#$&_7%Y7*_IQJ_4#_.Z'=KL]+'[8D&O<DQ,*&?,H6?I56W:K\\5H
M6/S5?&0WFU:T>1A@$Y:#<.FI,2D2=]TV(%$?PZI+W$"X5LT*T0]F*!8?2TDC
M$]7);\R=K-',T)]?D"EB $JQ>+:IPGKQ=1S.]S(<'OZS35GQ1-YI()_,'OAL
MHF83Q:"1356'9!R8JC J4Z\D(_TN[!0LBM$NXC4"@L<,1[9_C8B1?0^U(=M0
M-LI\Y3+>7@X,.+Y]NWP-,F=I_,R*8E/RL 49#_)N3HW[:"(,E]JQ,**U0YFL
M"?^><P=W-XDGYAL?^6<H5XMOW?P\UZMFYHU',9I@O-BI0?;Y*-'WHBXA,A?:
MX89;GS*_[L;Y >=8%D>K BQB+)72<H&TN/7ZW!009P^WNZ"%>EUVKPVLXP3+
MKX7%4J"99=^'O:G1!VE^+5UG6'P)$UUC]K=$OU4N:>$D7EL;1/H MRJ /F'H
M>C QUMR8"_5@IBM'^JL+;]J&<;%;(S&505JMOZZ#^.> XP9(K O \WQQD;@E
MCL<FY1?K@+.A97(Q6L$Y-2-%FHT=V,EH+6X$.[LI.R$;/W[B5X%1"5_AE%Z'
MKN,]1+O-6JR47SY>>4/^/>.G 5E^PQ+M]6'QYX^FK][> "N -$ ,24H>R/.P
M9+=C\53T!![3[, 9<?0;O<C]V:SD"W/Q<ZO&[92C$&>01O\=14YRD_@<>%OQ
M(R(7O>?J.)K[6A$Y-,Q#UGJH&UU*];,3,CLALQ-RQ-O&6_>6+ :9!6>4XI[$
MED.\(_9']-:%4LRLW5N^E(HX\<]P%4 #=$-[/78^T_NMR"T@(]V;K3+#]KN-
M*!M(]GFKO;AF!;;:C,U:*W368%U<+]$NA^PO\4%4X@+'A#RP2_L U)^90)BR
M9*3AA#6'H\EKQZ,'8<5>M>XQ>OG9E-="*5"(=EV<2$LIH9[PPTVN$I8HH;6L
MS8+&3*WP,5<,LH[MO;3-^):1^!B1?2U=AK_+TB*]2-^$-R6 &L5;4VH**^ZJ
M/DPY'2KV8CSD.J/&4,ZCYWXA_OYEV-_ Z<E>R="/J/OAR<?P/!*8CD54V1&0
ME]R;A$!2GW$)>:S&(#*P=O^]BOZ1*XZ^GA=OF8+8\*2SP*AO=WZ>.CJ//#9W
MD,(Y\NJXLCI2II/65<FO.0[)URW)X@$,0\N%X94[,#LPP%,3JV1,;\ C  9P
M;E":"W@SO&6&MS"\Y4\?"+SE#[L6/]RZ6'*I!OX'\/:"WA>]L&&'5B;XE*D)
M%M(U'2<]EFVW:QF0OAX4EG*^0*="0GHX@7/C^S92%Y"87XJKN"PU=ZX'9:07
M<WV@[% PI%I@TX)#F2(ID>-R4ZXDX:&@>9&';]#,:8#ZE9[)ASP_HY!XSEM5
MS9*AX$O)AO&)S4J^.$SIX>C=ES72%2PBL[0+SN6^V0(]4 OT>^?2@R?U-KT@
MVG^@V69#H$2 0KOM?<QH9.@>!S(#6VO_67=EO^\&)J!*/1PW#!RGS7G%ZD+7
M$C[U:"\ON9]Z(3XZ?ON5]>8\:[>75:.:U#I6*>))WU!*E\G--Y5(^Z3>]]2;
M!+".-NS ,6^'_=$(Z"/'B<K8-Q)MFH($1ZI,^8.GT#NZX#QZV*OZD F%GR^>
M#['77;ID)-OM5<GQ-\X\UP?E:1-&! EUKD.*CZ6[OR]&[.,2)HNYC.VH!BRD
M$8%YUYB[N89*#[V-4IT<<55;K5P(P; <4DL7M,O5JS[#57(-8PX_9HL[6]Q?
M[./=ZMQ%KA+S<DX[>UU8U\P!JWQ\JMK2AY0[::7^5*/;C[,JK**3Y2FL.;+I
MV[H2M9M;74LF*>$;JSMY-U?R!G\Z[4^Z+[%#"<_R1O]]FQ,H\F/Q" *J^F?@
MW@]G2 BRAEM?H6LU\S_/%QEM9LI&W41B720.4S(H2_H4_F,;GXQD=]9774U&
M8M"\D4N'II?4)>"IO+ZT&$0 *2;%Z(WP"U158"DD,QL*'F%U-NS .!2,4B![
M&O&R)8TK)EUD'J&[D8]'\>+*+B/OE"G6Y.WK,S$]>YI0?X[+*3(ZL^_FT\O*
M//T!6:W^V'.S9TZ,;C<WCUB\DF1-A$PZ"=+J1D/?T%IM.Z5ETBT3E%!*OI6>
M-BL49#G 8FK6M<VU3A,?_80X:-#9J,OEV^)&GI<PT\G2W''BTM[4@MZDB)S+
M5;@HK9 *-"4L#\FC@\L2#95T;POQC<[<Z.7.Q_Q\S,_'O 167E%-":N<$<W.
MWLZ?((X=37KZSP 1./C#!W))7"516(R>JMX:L/THM'Z6V+2$DLSU['9A&7 \
M9V9+60"8[\ =>1F$>G$1+7:-5J,8O;EO1)TZ7[Q(_%T]O>Y2;6(Z4UQ<5H?K
MH&0/E^F3^(M2JO$QP>4U/$]@,@$\#QLW5&6SHRI^:62C?](+7(:KJO&!XOB0
M[0,F$Q"00O-:JY;?,;LC3 ]T WL?_F_ UWU<'/DFTM5 /HKE(/1CG9^9]+A;
M&6QDR,"!VJ5BT&B!V<!]JU=JQ*X/2G3F5H6N$Z.WH#NL000G9!!\& ;0AH1C
MK@=^YNPHU+6T,L[P.IVO?L*+*$J5QB\4_BHV?.NR V<)KXNH@GUT-U[8JXK#
M\PU3+(DX%2/3K( XF628SZ_Y_'H8Y]?[86K31MHZ=_L*99NQBOF4%]T*4)1M
MC/CI#"4!#(7LV9RAGS?B ]V(OS=_<83", &LG7D730.DR$O1=6L!N^ZVB\>/
MSOZG\,@LWJW]"+WZV9/SQQ_99KQN.;F]:V^ :M:#.92:HBD6JH_1L"B%RE="
MQBC_WO$M,6+ZC*A%UF \W^^!=$JRT\P;;!_!4!A!9@9!-)&L<9]/]"#N4<(Y
MQ=L)P6RMP"2=+]?HDYH%."JF:UEVP[)J$2K%?H[P;PUU28\FV#1.&\'9S)XT
MHM'9[8L9)1M!.^PY/\'>: 3.<1*MW,&P&-(?9+6U3 E/2.);4Y_7/UN$D!6C
M=)+S [4-$OX<N4K@+# 5*4G#\:3I*)]9U;5+GZH22*I- /)\&I533*%(C/L:
M.#6XY-:$$?C<W6GVLF;C/AOWL203-LC%%CTRLKU>!DZIXQ^.)/ZED&=':7A)
M''#<--T5<BK467R,OUC_TJWWL#ZF3V*4&,?V+*H@L67YMC&+>G2'_).S!9C1
MB#,:\<O'3S__0-"(#W#R,V,5;9QSJM"D9S47Z6E+8 BG!["'-EKD_#5,C'#V
M=H$S7.QMWJ &4UZ756U>&CNB4[YOAM#'[6X_ S0MV/L6@"!#+J:(B7W&F'X-
M781F%=/":]2"RER;)%9WA5WW_P;@XOD+PK.1>[?/I".$&^N$%/*:SZC+P^GK
MVMVYAS].%Z"!S=4Y/?]:1/ZDK:%?=M7.>Z6LL2(<9E9C0SR$1S&D87@CQ,5\
MD5LC**F3IGJD5T#,6A7Z$'L=?])\J-[QY.SI;5Z=/5Y\_ TF^G_;\\73IT_/
MGOSISW]Z]/030TMQ3_.RYM:71*1)$XAG>_7U,UPI-A4^^9R;"I]P@;'M5C)5
M/=V\7Q]TH$[A<)3*'2CZJ"5;#E6,+,A95V@,Y?1IC'.NN/M%H4*?/?IH*MKQ
MT>$[BX8XQ+C-(?&)\.,]$]TEM[?7B*NNRV7)^K89*04Z1K?MM6_I^5C$<[H(
M,.,PC$S*DAE.8Z?R-H2]0JG&>Y\LS#:HC;G=N7+[.LJ*^1A-O#6Y&O_RP)QX
MF5,FOXNV3Y+KZ7F@2%^+K&)J&^<94L[ 0S'6;HC-.\+9O J7]&WAV<9H7,O[
M4$< 051R9'-4]?T0_/[3=K14")=U MH[[4HS:<_"-LV"&]X"A"!%,N>U\7Z[
M0/\>&I6)'N[102--T<N9E6\.I&=?+L[JU]>HX&Y\;V$ZM"S?=9R@$W30^+#Z
M?^R]"W/;5I8U^E=0?9.Y=A7$T<//I+Y4R8[3[1YW[++<G9FY=:L+) XIM$&
M#1"2V;_^VVOO?5X@*,F=.*)D5,TC%DG@//=[KW4VHQO^Z;,B?V$S:Q D';*'
MF+0U?C+K=/OT/]+*K_#8ED-J7E.N'&*!"L15UB3@=#/)-[28AX='>+7\( WG
M0:*-AF>;+A0!X;2/@!!KAEW?\K& 52]VT=-6/^I++2J2#.:JF$#TDR%[G'40
MG=@XU!DL/5L(<UJ02@O5KHQ?:ONNTYR6*T'@5MA*\8K9?7.2G,Y(#T-:HPK
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MQOY-7N@+IGTK5<Z+0Z.$DTZ^3N0^1@XN(D1;<]"&.]_0M:O4WD4;@RXN?B+
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M#&GA8B%J_X!M@]O2@B8[#PH2?95;S:2=$"&20/@(;LD%^FL8U\O]2J5-TG;
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MGE5-KQM<KJ^'M12"^K45(*#(W5S=YBY9SV<U9133V<I#C8BL+;Q(NW717K/
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M<"^@1L4AJC<OW]'(E(^OG/L7&0@5U(G",L_A?C%!)0;?^*<2]#>I%()B'*=
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M@?,3].2'CET0?JMGV&8K#VT,'/JU6D)7AU0SASHXF2&79O9#O0^X>EX-P/U
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MN+-<@2W7_KJ.YMN5,, ':(\=90JL13&T&#+IV[KV#15,U"DC"2<2=4SF 77
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M/6H<?XU -Z+!;DYO?Z=ED>4;^.2C'L,=IP PQU_^]L/HA]V>B.&U%=A.%D5
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MRAIDBP[-T2#=)AF;.F.L*Y$'<M(4<1I89?APSI9TZE@Y+D_'9??BI-\]KPR
M.,7C#Z6,C RQ5RX$*N<+L<1D-=4)7HP&W9/[WI9FA73O/7>>N'XO\HZWO_][
M\$E>9\DU.2\SD>)M(]>:V'B?_"KS,%82K1/RCP;9 JT5XR9\X<0(-R_P4ZGB
M5"H5O,WF8T!^[5"M_;\O^F?=,\>W:[R@Z)]L[OE7O>>SX\V73[:[16FC P=$
MZ$/-1:J0!.&S=LW:E5:\KYOVW]V$RK[BJM<"F1640^"'][3S6!YBR&QP0!'2
MRLT%'!8/;;- /#[MGA_*"1[>V=U?0X%S/+M=V&^4V/UC)QOE&Q2;X"8N9L%5
MEN>PX:RSDA[SXGB+WC#9LA.CK[@*RWW4!Y;U#Y=M01S][0<E2<L:]6H![,?N
M6N*NVNJ<RF,J/0HN0LH,0#Q_#Z^&$I.]4H>I]'DC!S_/P/R%J\64RE)TU]WS
M-\JI?]'))JE(EBJF+![,"*H+9V"M**[R=G*IRJ30E^E<$RR@$;D,=#I.N4"S
M#1: VZA[#\F,>K6J0$:9^A>\=8'\'>M?0.@(()(\HDP<$BN_7%Q<=H//,WN5
ML"$X$ -@[6Y<.<<P&NPT*!7J-7/Q!>QC2W'T&O\LHZF^EA)B!-7=F'*>19;C
MGL4<B97>=$LN#?Z][99<7LNTE#JH]W6A8X11F5.-474/_@50C+.H&_R!J4?(
M'4J1@%XFKT52PGX)F-LV3PE E"TUDW.TEN&TBRPG;H-/S6.)@"2!3.E;$U#>
ML]R\]0T<FDQBV"E":8R;$BI+2:0#CDNR%>Z0JMX@NB<BE4NB#K4D:K@"T;:6
M1+40^&&<A^4<&#PP,]4-?@-.F,?$):,8.'>NO8%:,(7PIED8 M,$,[=QHVVI
M1>(NTC)MI3!T+,,,]_<ES6Y2CF)[R5(.!ZW_<.0OJ 23+$FR&^UAJPR%!>A0
MH54V'#4 M*9YIHH@M,8%2'#,* (-BD0WXGQ$:^%]6I? /U&;J/256GDRU,,H
M_]Q1?L>)&Y^,FOP)&.\T)9;L-<@9!5O/=3\2!]1HAY4I:&/-0%<82YD&4YFB
M48N\$7V>BSR+2C ,E4@DF77__1E,VHR,M2A#)RC<"NQ; 8CB"?!A4$1,_8A2
M&=:[P$IDQF9CVV$"=Y*#&:;,#V@K W!![\B9_S+R/[G*D6M6^Z>LJ.!F)E.-
MEEEB'>P&\Q5F3U ('M3LO ZV5QA++IO4>#ZT6R&7DT2&Y%HAEX:*(^,H0H\#
MNB70U9+A1B26-%5!B<:B\JM1UW4&=J;J/76##^M^HI\OKGX*+J[>!I^S11P&
MH]XHT,ZN\$W+0EK?+CT)@F^;?.6M!6;+WO[V>6'1X1YFYU#2!HL995QE(2;C
MQ"F&]K X$7DU,%'K +5B4&.KJ(B_$T02S/NY:<>$K$CF9*$CJ6=C8,C&Z1RG
MS86L.[;Z8I''H>P$ LRJ4%L_ZS]7M9LQ)K'CM]_P-,M*<>D&,[UMVZ0PD+*!
M1:MJ$LNH&UQLN1S9KV6A,JIWJ2MWR:6[LDGA0!:W$E?EGJ"4P'-3":>URL8#
M&>NU\'I0=&[2 +EN-I7TM594Z",8BJ"QA+:2%.W07(H(,PG$M8@3<AZOKFZR
M\)3VWV/MC<&&6/O\7<!:1SB],NQX"UPJV,&>401(#5=75#D23033+(OPG0!U
MKYUCK[%N+D6%<=7&42^DZA_R^2_QKE(9?SHI=/2K!:H1G2N/HA=:%[HHUNJ7
MV(8L60K HG.\D15AD+L  (_ 3V%'<!/U+Z.@1"ZG(B?+WX;,\29%YVF 0X6^
M&CBL<++"^>36UC;D)K8"#,4JA"M6%N%W32+(;0*#Z<$B W0GU@&;TADG-P[;
ML*0/BZZQ!8I01C(!U3-?KO*!)O=Y\#+H2!; *3K-RSKKW"4!<H4'Q$7--BG:
MV D6LZ4BS]XB@R]TI-9P&+JB-EIOT<\W/-&U5?-8?5%&E-T VR ) F^=ZE00
MP_AOP"96LWC1>'P%=(*,P.BL(C\\8A5NP[*?-?4>3Y*$!YY=-\!R[RRFS,)B
MN< W!I9''GREH8>/II6L@$]D.L5]36@%@$%Q@V"(JW7LA63;XVM0I-EN*,9
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MM.U9FA_ % U.+[K!?Z!O.2Y$U=SE/U!Q*D0C<09?_5_.A?\#%_[/O_2%^#=
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M5T,3H &(EYC@6_7'3):-I@3D/]1U(>]D*.=C@/JP[X!A4>8@*6F <XJ3/3"
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MMG0*K"?5C&;#,62UP2'I/A:;J)9R56"BF3K1;MGTH!\V?6]G.1UND6W\9<7
M+Y+_O\WC4M^4TU<*J#>V7@W&^JOD?V6<SN(@BN&=-M'OPZPNYB4_@'5JZCH%
M0 #//WC^'^_YQUWS_,]DOPS(?N>+R9[N?ET!714-_I:F:4\ ]MPZ/#PT8_VN
M4CK?P/J6=8.1O"B_S=ND?YN51.GZ?*]+IMJ*@#:#'"T?4^W%A&]4I1V/LS,K
MPOI5N?3TH15#L!U\>'UUSZN##VNK3]VJ<JS^SJ+9_-0?%K,VXG5 N+ISG^9
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M'39A=8"K;IFK$DP#6W%33-W ^R@X=CP[\"1+1?C;]YHS0$;H2D8H]NZX(^L
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M+[^24KP96>?3>WOX[?(B_LZ+/ZSS2R&EI"\HG]C/A1'@?\#_ALP9@/_U1Y?
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M=22NIN5;&^.GA1,-VU<^L/S;59S!QAL"@L8N][L!0>.WRV]MD,#$&&EBP&)
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M"T 6@"R83Q:$GW"?2<QW*::(A<Q!G+H1\N*0^X23*'1:*9'3(EGPO%% 6SO
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MN/H$,D[Z3N3 XVRXP('(=<^^;L@9YEY(L>LC#T<!8ESXR&<L1!X-2>()+'A
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M8\2PRU$8888B&C-BN['-DI6.?D\N^+)- (9Z:]VP0E  !APLVL&B>@F-K$Q
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M\02>@"<L-(&#SL,].@Z@*\#3"'C",65D!5D!-74( D@]I!YX.CT\05>  ^
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MY//#K_^Q*_G!^L<W!'3G-_Z9Q8\(?L8M[[+Q 7ZD=Y+K*^##E"'@ $X!''
M1^8 0K&R<"])<&9)>>TIJL))I>BU]KI8/LOY@IMV .Z,&PD' )*# ^@U"W
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MF<1[8WP^.8#^1?7N+NZM.\]!Q8L(6O3NHG>70[_HW47O@M[U,S]RHU0PY?&
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M>U4\-9+DD<:W>[&_)-07(34W@I^,A[\<^EF3>]',YZ&9HRC(DT"E+ \Q95V
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M/]P,>GD#E.N.]GW&D[[/Z,&^S^ B/-KU>>+,[, -UD<<CA-<#C"XE)0&P=C
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MZ#6\ZYHRW]+P >N:'I8"R$ E6"X:B:3G4]->#4(-5K_AI734^PWB [6C9UJ
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M8US*(@]2[KK[!0Q_QEQ\QLOF[R ;U6AH^'.0>LWV9K ;YV(NGF]\";?!H7U
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MP;B72):Y>>1E1>S+('X<<[&O33DIJS%VS]%J[",/H]*O^=I.BQUYTL+PZ>%
MUR3_,(7W'$*)#Z!\'H(0M?>Q4:0^F[$7)<)AD1@EV@\-&00G*@+;';9M0Y T
M\YI&/ME(T@CQ9R>Z:0W$H9E<6Y[34FS=,596HM:-9<:&7<K-9A9>$2E7OL==
M)E6&HZ]#T)<BSYGRXH"+),U4'CV&OGQC<+PN*_ET0/'Z39^*F38'316G=WZ*
M\\T87&VT+2"WVCE7ERT*]*05Z"3/8+LRNLE8B2.@?^-9$H[SYBC(8#\H6H\&
M',;$:2QF>P_4;@8"!/78\<?V<(EC;!JQ+BL:M]@U)8UM;C%N!%388D_TUG1[
MMQ;^O$:M:K^B*[=4_SN&C/ N[3A2HW6HS<=AEXIJ;DN!;P%<34BJA3)U9OI:
M."UVAG2+((O.R[IJ5 &'0[?IRELR#GI\5GPQ&IBGL5S-[4VEG*DK)_C(LI^T
M^!%$FJ)8WUG$8',!E9\;JFO#H[]"O\HPX%H/ZD94]X8/?3ATN6TUPNYNCN@_
MA]IM;&60;I9(@G.N!SHFRQ>+:V86EXK3*':3@"6QEZ/%Y3*N.&=YFL:^=",W
MB]3C3,=&V_L=?W]:\0G__,PLO1,.;,42E5B,JB]H5.&(L+*E7)1) ^VJP+,N
MB3W$9R>RR*--@B>VCH_?K%,[AD<+PZ1L<.Y>:]*N.S-T+')FQ]_;&>-4OUS>
M]$&W\;#Q_A.L%,3O- JL;J#/=;U=3R<.V<A<WU,^S$VX<'ZG"1J3<D7@?8:U
M:8?F[5"!F$YY#^^I>Z?Y&*D)/]W4=HQ&I5%-/P84=/)%ZUFT('PY(2U@]/(]
M[^F&K33\/>7DM]UUW1C7JY^_KG/SXMKX3K _W= :8YYB$$/'P*DC: <+I(E_
M/KR\6?3"+(73W[U./SA+S<35.]1TXQ%JNCE\- ?KWD[-(1 -FLFJY52)K6R(
MV-_V ?V>_37>VGA(SC31L8,#,D@@#0,&G*I?R920K+'41@<P2*)1=<Q\S\D<
M#\+"7%]^DHM4P!&-.:3[ X='[4(],F$S11H<P(=! _^]K[G'\4IWG%B- F.@
M]/)UV5YC7(MB63UZ\DHW(\FM4(=>QS8H&-P^TF$'U>X ^:=G@( NO"2.?@I/
MHB+U0'>8^L3,V&IZ)M;8KGF#T)^D\+E3;($HM_N[XO KCGE1:O@]0/5S"Z"=
M/JIA%,11FB8A\_,X86$J(L:#-&!^$J<\+B*O\/S'B*"]0+M>T0SN$ROR"<XO
MB*:W8;X:< F?G;3B&%L#HX$+B-([P6,BG#<:!**P8 <,<;71[N:K'FE.?THX
MT:PNV!9^Z2$?WKSZ?8!\.&9@[_36=7;\V@T:[/065-@S\8?-$)2A54N_19_J
MZZ<$Z[_C"K59<+!.B2YJ[?1.BBM*98"%@4M+C0FX0A=Z2YAZ.JNJ.ZC!$\CK
MIJGO**FZ]Z9E16,SM!:^Y>5:YR:/K1+\\MV2]0^LU;C^]<Z& .FMAX2C),S<
M$"3__2ZQ,*5H 2&U/49H(?HJW/.**C^G,88=ZIGN 0RQF$>9QKA6C\*$@T<1
M(!LP4J/=(;-0QU7 AFOK"DATWV,_]E$5>V#)WNO;2>GCVIQ*$IO]X$WT'7>6
M6DY:!"GNU'8-I\.[1J!JXP[N'Q_<F5:MUS2&U<PHU85I$O<*[T)%<C8;?VZ&
MU,EG(M.4AP4O0A9R'_X7N"%+99JR(BB$"/) 9DG^.+5?MZK:JC?ZF.&Y/"UK
M*CP_:\ILB3/:D_F:$XMI=2ZFU: B&W, R[:?CR!UPF'2$4>%/";3\7M%([W>
M=KJ];F*QU4KC'E!EUZ1!3Y8-AFUT(18HWCHG'6JKJMH![$L Q>N;,0K6[,."
M\SVGLR37PMR/3E.K2 ZP+K VQMSNIQ68^C/XX;_>K4M97QRVH">S]7*@&1^
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MP1/5MBL%B,GGE1@EPJS8&<0MB//+35.N:5++!%&J!U \$-Z=*"][4RT@#R3
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M13W4G[>T.>#P'$*(G>5A6W)=,RJD!>4LU!>II>VG%SP4>;Z 3P[&L#\JP##
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M(2%,L, ,I< "IV \=FERH 7WQ' L-U9VN*0*.YM3W4GB1IX*L#)J<#FMG9C
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M%V*Y))::D&@XDV!PM, HIV %0L"UT<P'+XC=J!'E"#84&07$YFZ[@HI$1FV
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M!&F??6=[V4ZSYX:%_YSG-(]OM>A2-+(_U&?()=J&NRFF5)U\K5M=%.6(2R1
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MXLF+)^^))HHG+YY\:)Y<&X\,1P0TT1:8]Q:,<AQ(($AP+[A%&Y76I;!"&2I
MV2B 61;!&H8@!(QR9V"GI"Z>O,= MA_O49KE#3Q*\_-\FJQX/OV6TN:E3UY_
MN-R0VT0,1NB%BAT>4.ZHMR$-9XQRB$J[W#Z9@78D@F9>2>:X1'YC!YCU2%@<
M E O#3!*&"BN&,08I+.&"VS,'J@8QJKTJRE U&.Q%T_<%TT,1NC%$P_%$Z.
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M=3YV']B_.)RQFWU)&;\/E]]%&@6"T@V83./7.S!*.8A8*XPHXM)L8*^WTL6
M-(B0QZ_W"C1'&*QWPE&!I.6T8&\7XW<:FLN07NXJC*Z/OTCITR3HSRVUO_/C
M4M$1*T)-<IB$* Y,,P**Y\@Z1X+RP%W0&^VYG^)D_SJ9^$_U:)3FXK^,9V9\
M5J<)V6G3A%GSKF[<:-+,I^%CNL=/HXG[X[LJ)-U?9N(]G8<'YK,/$W&L.F/B
MK;B:T(ZHO GN^8>3G8S\LPTF<5RM--*BX:U.JH52OGT6]%Q3POX)LZJZFCD^
ME\P.$.Y.FSP]W)@.MJ/U_K?ISSR/?#NY2.]\79T;GR#2Y1PJ7YVMAGFZ6O'Y
M#_I\3)E-'AL$0PG63?+^*A??;RMP&.Z9U*2+1=85\.ST]^*.O^</^OL=]-OQ
MB$7DH*U,CX6-!64B JZ4=9$1Z=#&=I"GA)D[?15,C[?%E ?*9M(%1FO;0 _\
M=8ZKCVL =!FF6<\)?4SUSWE"YIG)9*V:A6;61K]N0*E.)]33O#!1^?FT'I^U
M0!8G\^GL/)\ZG2642\B5H>^X^LDTZ9KSRS3.\V&)!LY'LV851KM_IW2UN[B8
M'M>-YAD49^=F5M7IOZ:ZF"1QC>H_$I6$]/48QI/9XO?V2=+355=F- ^KNRPO
M]K__UV>"L'[3W+Y+CFC5.<KG0G/S4,Y,I]?YO187R>B=OIZ&)(6PDM/-:]?3
M))]F%BY79\\^32#_>]LHZ>,PJ-8I0#+<)(LL\+W1@=OET .WKY]A($!Q&\!.
M0V2Q//7G\YM$XTMS%A8+?V!BTMR)&7TRUTV:?OQIX0GV/:"&PR_7D+>%Y8Q>
M\_$X9/ RT^L%H"\0L\G$XCS]GJ'1)8P\R\C^ #\=3[8B?+Y%YJ5GX_0ZOG4$
M7US^6*U[X./^SB[ZJ-XR)>M>IA^WN?_Z-G)@VLC!4;4 J>S55U9P5)EIMJ:+
MRTEF,,EP+DV^:-5FRZ13C/OGO)YF9A+<^3B]^]GUVI>CVN6%PV81N<VWN4CW
M\]6GR?2/9$4N'%?K^X96[&'CT1:\YMQ<9:Z1"'NHYDV(\U&ZP5421V)#9V$<
MIF8TNKZ=0*;KF:2TJ<F/FIC2.%36-.G8R55H#3@QI/7+'%?/,<O\;GOX3A*/
M9=0,HM0VS;^8!!6<!<E$P(@%9>1&\XRGA.\^N//@YZ/P/MZ/WIV._6H6]#$G
M6>R*X;4/48_GP9_.'OOD_X4/WVA.JV9^D2#B>B>!KC,0U;'.TMLR9A>.9B#T
MYY'QG&R*Z;WC9#2:?&JJ'^KQ3?2[^?'D!M3O1[MOL=[75]U:WG+TFK4@PZ-'
M<+\<SWY3:E8966U"ULU 7FQWS,^4O,8)>M/^"B-S/9G/TA4_!_]F<76,6KDM
M3T@C?&0NFW#2A$LS31YE;6_>VO:]J[JI;9WFQM<GJS-V;.);W(2A8X+%]UEP
MN]+XED^3G^7+1XECKBBZ_1_I[-+DF&C:W8/R8T5D7Q].'$OUU(?[PL9.]?7[
M.CLN#K EA?)1*9SJA4(&7P"-S76VY]T4D#21?_W7[S#ZKO=5''JIT!=8L>QT
M4&P0AX,I[+&Y6;_O8Z,_QEYP>S"JO(O;I,#VJX#MMI[S[2*0N4B/_BU%% IT
M'Y2]%RSNKVX*%K\R+%ZOQ&W6PN7]L> "QP6.7ZMN"AR_,CB^74AKOK6T6('A
M0S'U9Z\P^'3E7]3>CT+?B@<<X!KG[^NI#7NO"3$8M;Z@!OM0VV:IMU+;IH<6
MOGW3 54Z(,LC\( 5,*PM*!(X4.F4=U(*S-7]7!QI)(N2<+ Z&&!685!86<!6
M.HJ)L1%MY.+\W*8N_5I?A8VM=-VU3Z/D2-#=>RD+G/6@Q,VK)P?[+J!3#*#X
M\^+/A^K/B63!"TLAN6B>?+,CH'5R[YA[9C2)A"O_S/Y\+62[GN#\> _?)#6G
M3U_8=WC$< ^KV?43Z0;C7HJK[X\N#LD BJLOKGYHKEXPBKQ&!I1H&R!%!59)
M A(9*Q7E H7PS*Z^J\*T6!^1XLW[[<U[W/J\GVHZ0* YW=S1N/?N8OU4;F]9
M7,<V5?A #\UT1^G92*WV7(%VF +3(6D^4 O!1&(4=]SZC:F_PPI1174B .EP
MYI4'PR0#PSD3EF+)J-M+*)_@(_U 6<2"1J\2C7HF]L.:WQ<#. "A%W<\%'?L
M PXABEQ^6*(T/=<43%YH%UI'0Z@BP6]TC>G8';]()%ZDJ;LHCKK@5(_%7AQU
M7S0Q&*$71ST41RTU%3EF#CJB"$P9#9HS#,A(K:) 1FR6H^K847<61^='DK#B
MC/N,126;_A7%T5=% ,M*5H\LL*RJ%S:PFPU(G[R_4, DSH4FE0:%-0?KD!0$
M.:<XN\\&HJ7,4!8!(V^!:83 .&+ :NX<3H/(&;27*'JB QB79?4"1CT6^V'-
MS8L!'(#0BS<>BC=6SEG/.06I7?+&/$;05E- "@5)+'+4;+3WZ=@;OTPZN^IT
MUEY0ZH!1:EG0H&=B+VZZ+YH8C-"+FQZ*FV:.!6\,!]>N=?OH0%-$0%"EA9.1
M1*F?V4UW%4+G1YS(XHO[#$4E$_T51- W^^7T917KL;7'>C8(>DL;.K:])Y2&
M*_2B+V:_G5Y$(;TP1H*/3"2J$ EH)@D8)F)06%"$-C+;0\0,8^E!6)7.$<&#
MYB* EY019+'1E.XG)H_ZF];^U47T"L85?G%HL8%"!EZ/H10R,$ RP!"35 $)
M.6Z D0*=:4&,7#@?E9)^8X&^8S+P(DL"5':Z(;[PA%<(?ST3>^$)A2?TTU *
M3Q@<3R#4<\DD L^4 J8) QL0!HQ8<OU,.,$W]M]US!,Z2^LGA0H,"^&>?1/
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MC*Y$#PH_V+W7%7,3@N")%0@-C! +)G("U%I%L=<X:+-7?O#S9#[M)STH2'4
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M]V:Y<T_^<2"&4YC2@Q%*;X,G2 +"T0-+Y @T]Q$(Q2R7H)<T;,PWI#,(!^Y
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M0J09EFXS^2Y_UGEJ>>X8<<%&7KB,".$I*1@O%"^Q'N7]^/.OH33#:__6F16
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M:;,&'F8P,Y6:[JS&T!ZDND_4,MB%)WT1)WQS7)UOVQS&ME%L\UVKWVYJ/=W
M*>F;G!U>LBXL+%&+Q;0R2F-0P*KI3==;BO0O'T ^S]ZYY#=<FX@XGR^W>.+8
M7^ '91\:N9%C*++&N^Q?DPO??V6C/^/A&<*K6?+7U<QA5=ARTB=-O %^?*.
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M:"YR_B#ER "A -H)=:M?S"SR/\ =;F8JU_Q<-68Z;U:U^QV>\>-T;O[X)G'
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M/UPP\[H6AJ!Y]]?^MF1GO!!'E\":P%CM!2B)9G>]L:E[C)I.$[583"L3XOI
MCU@%@H9I=-H(L*1@5&V%V 2D5P4:2=T& \*S.N ]KT'NH1/"S%=U$\SY>M7
M;)JF]0AT 1/]L#@GO*A9F>O-G/ ]MY^[O%;XP]V%%X2'P43@62A<VW'_<?7V
M*OF/%R_>7"6O_(Y ?N_J$%W9K#2\(:Y9&+K['1[ES/4,SL:["M;]T+D:X\%)
MAK988,/!,&_=5[/+;C(ASYPB7Y(+82TLW0ZUP72,ZW6QFH5ZY]K<%Z(\[-SW
M:OI>W34_?)/\N8U>^MH'ZG(,_<AL+N1,[7I/:U"&T!G8\O*;X"A=S.N >CM)
ML^:Z*+,\P-'^)HMWU<[7\YO6 WC2 =(^#V=2S59!!/@5?   U;2.6^<]"A:
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M)H:=UX*JG3*-!Z1V'@$/5+AC#_# H-1<960'/ !XH$Y!&0\>&* ]__ZF&?F
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MQ\GR@(() 7%/&;(J:80-,3P$0AR3CY#(>33$((XXW>N,0D ,SU 15D9V0 R
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M_R_FI_RE+3_FKVE&(MAOHH^G+BX:1HX:BBGMR)%_(,WW98KPR7R5Q2ZT/[P
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M"JU0$,%()W%29K_;KG[Z?!9G;?RQMR1[P91[[3)_7*4(F+(2Y589V0%( )
M( % 8CA PF,BN8L&14T5XM%9I'50B'J=!"-4<R?VFL Z )"H=R4% (EJC!<
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MT:;T@Q+DF$N>>!.EQT]QI.DQ&_^1WLX)@3,\]/:.RH@Q0,G(3FZ??"#Z:)V
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M%Y33':*<[C>_G!<\*[IZ.GUTK=%KTK:K7OHNV[F*T)[F%\IDDKYNZ'J6',;
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MOMH!![R-Y#<PY'>P:L\J0=3*UB.SZC0S6_+PQO'PB;,G19>B7(2*&'<8BAD
MI(3'"!"3BX0R*9+$:$22C%,NC9%BJQ4:HXS$+)>(N<Z=E'.-A"*)JSF'+<:&
M9WI'!9QN@[R,_2CJ#W7KK/EOMTD?37WF]G(=>\&?[GJXJOE@3WV_)?&Z*DM1
M-]W5'3*+[^_+@26-X^,M NJ<-YXJ)ALP!N#20O[1*3Q".X[I>4<;4]AAB.*?
MK9MWTE)1U,S*8K[\I NG'DYUJSLV!0P6B,S[9]M5;)ZO*W%+5N5W:ZF+M;<[
M2#2XMV5%:VKU4$%?*=0]6EHZ:1U ><36:YQD>9Y(@;!V)62LP"C/F$3*]6W
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M-[1=#>!O+,QX-_A3,!-G>$&IX!)192V26"O$+* XDE,X@.1[7"6-*K^\:.7
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M"2QU-$05=N(^PHT\EFSKZ.,;RON-DB4>F@PD,2$CH,W[G8+MRG5C/PXC(^_
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M*[%D66QDIBB2N2&(4F:13+A%6.8)24BJ>$Z^FU@^=GOE$IG.1&D^V 'YW-/
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M\,D9 0KX$51XX9_'\Y][.%I65\X@H '47T>75;FX@(?X%77W7II:?#;=[2L
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MLK01Y2HBZJ8YMQ;'LNPK"RZ#FL1RGR/A6P8USIG6TR?P$M/,JZF386ZHZKR
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MNJ<)ZE^BO_]-5OKZ/_[E[W\[GU^4__$_4$L#!!0    ( &6)9U88]AY6Y"(
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M,WLL]RB1'=Q<!O>623(_-4T]Q7TU.JUZ2NAW/X69(E-'M_*C01I-+T:1<Y1
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M/O&K(@J);KH&WT/6:%#AIH^R][@LZ6_)?J';%0(OHN%Z!0:NRR%;^E4PP&@
M(T'3'<:(*%OMP;$@R1$-3%[.VVR?33R#B=>492L%W:HH@^8U7:N]-8^S1:-
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M<<H7XM3;3<N_]H,E7927+;27LO8Z9>[%FJE@78L%X3V5AVZJL2%U<-*IV'[
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M'3>2'6!<V,=>HH[OZ@E(=F<).C"1]B_.NB ;L[JW>BQAL#A Q;4TW0Z6#>4
M>^MT7BR%HN0*0RW5U8MN&E=5&J=S%-$9:CIO61QVDC@C0K-Q5>$@%EAU-,Z
M->LK3A<P:2;JVJC^=3CS"O ;B@XCR4KYZ-S)DQM@KQX$1?WFC#Z9.X_VSNYA
MK^H>L'LHC%?#M1:7G#P<A'_C86GO6&T%KMI'5U=?E>=&\=I()P3$TND2N%U4
MG:M_ON'(LSB/7BP*)HG80K_S-RG8&%(;&.C^ S#?HT<0(WW02MYALB8?<@O<
MXF1![YV+?9H.\$W*X>%F-A@/EB"BC=;QZBB&A%,Y R%)L_Y],*9:<>9<7-@B
M,_Q/G'YY@FIH5 B:EJF?U!B 90OL6LQPE$ Y][%A47_4XY]%FU@0NJ(F9H.R
MQ%&%NVU9D]E0#@EW)F+_RG-7_>N M!<6E!<LCF4MKMTDN?-C?!%GN )I03H@
MY-A/-/[I$FU;LC,(+915V!!VA]9MJ8?368L(.?<H0<]^K+F4U$7AGOOV8Q2#
M50%-7KLFVOSNC)(:N^''*(E6^:KE#F5;JBLZ:(0'T_Q,N\&H21@.*)PT8MEI
M OR54&W)AZ.U I+^O$X-=QN1,VC- ZE HIYUED,D=! X ]-"J%)TOWL4YLS8
M47WPW33#PDI*(,5R7$:I2W4&GX7*LK XU=&B*W]3C;W:-!D<C;:S0.FWGO +
M1NEUR<^)Y"_2)#BW@5+RJ&S[U+^Z=^JI>/Z'#E^@^NQ5Q=(9*2<6D'ID<*8#
M&0>(:BC'A+#8*G/^UC:Y?EE'O%HYP($]O=P&"_KIFPM<?BJ%%*XK1<(=% ,2
M:0,%>[!($[S)AM+!CJMP_9 __@L%V0S?@4)2,YM&"%LIJ[\>&9P;75ED%>JD
M*$X%P#Q6XM*F.:.HYLE; .#^",TMO/9T9T":>R/%(,\.*KI:RF#6AM(8(0+=
ML(@<XFY&"=% I=G;=B!VG\1U+0JXNE%OIML_OKV,H,)_-$UF2_3 WL>]@[%N
MY;/UP$7&E['TS#,U;I!T^5E^_TB^GE&TR $*=J:GFX<S@?[S&E/\%\$R0D^,
M9#JO1TFQ(G4&NG$TJ*YD,?[O 4R2HP<<H](K@DL3TI+8U;YCPSWIA?4@$;WW
M,1#>29&UI4?I Q:!B="1?(FJ6%FVU ,0+'\@5EW1MJ>["HB>T@>N)69+++HD
M#0PG#IH5S-9WG)O?'48@K(,D_(23<@TM#HY(@+K)!C0AU%Z3KE]8OA"1^27H
MEO3.M(&%/2#.IM*HI_=H+6RC.5VQ$5A^BM,P51/843O3 !9*4"&B)HTVM)^!
M:)AHN]\7M:$<'FX:!(8]N*.^KEX'W4HV*,3S**OL@4_5$Y+:)&?M UUXR@/'
MI#R<1T)EG#LSJWW825+$+:3/^L+J='UV^H-XRD]YPD_?#CL4-R"]9CVR,*<J
MMZCF0(T5J7LG:XI9=#J7_5!2K)$. D>7:/(;;G?"WJVCJ26Z:B;?HT!Y3>(J
M1QG.M!.DNC3;(J-[VQH:$&WOC"NA&OKG&\Z(Q-\-H$5^\$D$ML-OF 8DXSN.
M4@-T$0UF @,<XN@T?Q:/NY*ID=CR$JW4 'TS#DD%F&?XCK[<1CW#(GPVG8QY
MD)+JHH$<G;AQ56'W<H;99K58AMHD5[J(>4DMLU_U>QTX.=45?!:"DP)/3.=E
MK((*8%NZ,\II(T/Z_KAZWD[]Y@P8"X&5CIK2>Z??_9*1VN885#M4MF9QG+!I
M7AO)'%TJ5WR#>5$79R-EB&+[/<J6[&AO\C<_"9OHZNG#&5(C\H7'JD)AL;4*
MMB$8S=6YKVX:-Q=^]WCCQVP.I]^K/M3U['"_/([V1>XD9LMSR=LPG<]2/R$^
M.Z== K:C=<]/P?FN;WC5O[JWAFW,8:U'SVTHG1E'S38-<RM\H"\1TH?M$"@7
M6XA122T8Z8=-12+ZWP5=GU;Q]*K7T^A^7P#]\2IZBD*4A#0T:AFB[#5J<G/$
MVRMR.N3?P-*N/(!TL#9NJ<GA-B;UW=GZU[T.//MCNW#2;Q7*8*<BAC92;8>S
M'K=X+T4Y.(G9GBOO>9[<[:5 $<"C_H)@\[N#$EO#.(O94?B2;?F3,U*PZ)Y5
MG%PY\D3CLROK+S.BF?]RR8C8;:&;SMM%=K0R=B=N%DG+"7:.7_5MM:4ZHY7&
ML:&.8/H8BS@HS,Y!(=A#M4O1O;(,MR7HMHI\=KV^&2?1M[5,KR*<:2ESOV=/
M",7TJ7:Q8E4\V6VIKNY-?TZH[9Y&=+5$_6 5COIW5T9FHRY_7L]37(OV#$.N
MYHR>#>60-)/#B?EQG3E"-9QR@C.PC.(4_>CZ!1:24>VA4WV:JWVM\'!)]ZO4
MA4<'@7-+T]\1C:*%PHLGZ#@+Q&^&3>&/WU*_LA%,5#*LHHV_N9A@=5==["N1
MU+X.9CB\2='7'"7!9CH7+AURA5=^5,7*;R>H]Z20?3^P@-C?G6$KPYR?IK^#
M-E"QZ-.<A-'P':A(6I.=!$.GS(B]FD(#W99/+@01(K=1PD;>ZB5U*]I7W[PP
M090V6O!\FB[\1!BR,% 79]+$U1:P)ZY@0(CB)OA=2W&N6<JPU_1D<(SI(8X&
MZ&X:YR#=1E_S**2W<Y*0G;D#'0U0FC1P61 Z!ZY^(ZE-4<UT[D%3;EZT C-0
M.0=+/OTE;_"V ;2G=PXJLW:7.(;%&.&G%]M VE"Z!R]?K<!,Q/.':)&P8ZU)
M\<0MC;6 02\CU"K7;7,[UPS%,J<-:'NZ<U N_#1\\M,O+ 9FPV3[B&BPL *6
M':V3YEVQ12IN I$:L)94IZ',4+!,<(P7&SV89KJ;<,KG"@E]C! &?OK[O(:I
MF\A18*LHH;$D6 #K&S]@]Z7KN+IHW(0%?X;T$P\D>(/SM(:IG<!-0/?MN^$U
M9!:4;D(L>DU8 ]3X[BC[!-B+44A=6'.<!J@.HRW=23@?8$7RY2$ VP_!2IF6
M1MV^8 I\1-D2UT1D2>PFT/LH1AM#IS(0.0E,>P])A=5)XBBH)Q1C*)74D=2_
M.\E^>5>L2]D,1&X"ZU:T82D9<!OG!&P=.2A[.S(+6B=AWD0IR9@AA,)+E&;\
M!BBB(38"G*XQKT&%VR^/F[#E)T5KZ'1)KH)(+V&U@5<H;6!HI+@)(>>1/<M]
MBEN490TTW41. IN #LUAQ90A.<(UWY15T=E0N@I1V@!L@-*DN0E#$[-:CC1;
M V9)[294X'"9UP IWYQD^Q8M_& C'152$;0F.PR&WUTR0&HE<AX8XY8O DD[
M,AV5F]"XM[7%^FM+=1+*1Y0N4-J"I"7132 XR99QS4M9^^@DX^P!I"1 +#M[
M_:AL\%I?L:%T$N(=K :2C+W]6(.D2W$3@CZ:: U--Y'+P(J-/RV@>J*C0#!]
M4TLX?=C]2?VH9D'H*D!Z*ZP=E3;552A2)$3YU$0#E('.37A**,,:)&V:HS Z
M79+#<D;*RL.C _!052HF$Y6CT CR01:P"I4'-5B3INNEGURE^8)?@2-UL'WS
M#0B^V)*.ZNX\6VHWH>(56G2O/CI)G 0EQ^U0L>A2G(? AHUV'$JRJV"2C.;F
M# <(J@_\N(FID\I-:"C 2=AS>Z-G)D>!TR>3Z6W"8M=-W#>I0S60.0Q.AV0
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M(]3 PMJ4BI"S=50ZHAZBA(DX["%HV9F$"',;97D0-3/*FA&D*AH:->4>S-F
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M.!A"%#5$.M)73=P&<;*J00]Z#FSE/0/)CI=O978.;?-^EW8?#85L+ \$OWH
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MV+?F>OW<JVLQ!7\#$MR66Y P7^E9/O-,C$LT10!FT@!]2I+<F]S@54+SX#>
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MIPEG=OP-<Y@D-WF:L$':BSE Q;9-$Y#"'BK#7\GG[/^>8:?]]?]02P,$%
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M1KHZ=+?!1F#@$0[QK3N/L<6M9O)4VL" EL-[:RCR1^Z8H=CS[D:E^D$0V6R
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MZR7I>?O. (VD>.]0[.H>,4[)!TH)H_NN3]-O2AM#W"?@Z:1B#=,1RF,NTJE
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M^-G'XZ$,7(1)']NGQ*AXHV7#J)>QF(HX*Z#DL:[J"&IH6D8=JF=$5KS3,OH
M#:22BJ&6$0=H!^M;K-0R9:#:/0:50;5,(X"6 'ME52W3"K".K*^[:ID68-6[
ML>J[6J8?6,W'1DU8R[2"*O]/45O6LBL5H'P\2G59RV2#*EN;EJ:U3 Z LO:@
MPK:6R0-0(A^O#*YEV@&4V2%6G;5-=H!J@+[:K64: !;ONY;-M4P9@,)^ATJ[
MEHD!57(7%/2UC#E .=Q1C6#+<5R I7)Q76#+^$,5K_6UB"T3 K!@;5;/V#(]
M $O2-CF.JABRCJ)_.SX@*(7Z._]!\/<&I1&3+*-]:ZT&*9^?GW_(PCA!+PN<
M,)WR!RJ,'F_+=1_GP0M.\7)SS,F[#K\'W\BWV^*1OCY4LD6$3CA'>1 GV3MK
M;5A$J[>VJ-%^13W#7H,8T7<>!&UN=*/=="I0%S)L=RB0C+=&SAMN)Z-+TP]\
MH6=7N+?M02Z(9UP:]9"*^HD63R?568,,J=JA*@8Z(.O5[4S8]+;]N]L]/T=9
M2&+.C1L[J-]TZ4P'",W6B)PD"2ZC*CE,2NK+QWM4.[_#B[(WMBK8/,RT;VV0
MC^'SY22_9XK*%CU.@>!U HKW:RAD/$4B<"]6('Q3@>)N_R#47FC_<CV[[7>G
M=Q\H,>P? (70X)/"2N)UD*/;) BY@&%=916OKU9:=7/L*0;B+\D55]7X/[SV
M-;P#VP%YE4*X9/ ?S( P&/@J'OUK0.@)R&?DCL7A["0\%!:$F^+.J/Z HM--
M-2ZK!LI0'+HJ%$)<O%#M(:ZDG-V/.S@_=$%?NY:3&U?&HK.89!XZE-9!D]X\
MY207-U">,2N^@=+QWBGPAN_K7FY7/GE ]3C;+9IT#PY,,AC:,@QD&K^M&:]!
MJY_,M-.!/U@3"8 : :8BE5YH *HDCT @G8#A7SF@OI084-4#D+U DO.<V;8;
M:+ZCM!\8S[5F1]!\46I/,)KWIM%V508PR1\06;*PV0?Z(17@PK$0@%:;;R2C
M?05\5TWYS88V%!V#;EH'>*AFP$% N17J.8X8*/J]8 6'UO3_Z;B09#0,P-67
M0#K>9^"=\B/&4$HQ\;Q@KKE;GF%:BH\WZ)G_)#U)9I-=F%=QND8D9R&S]50.
MI8E?/>>5A65)1,M+7% !OM04,N''I</<WT EL<1CK1$NV!9=:40JB&@G&6G1
MRXB7<99ALF&GN/Y6R?=3.\<:=%7ID?A?0>G-YT>HUK=<!)UV#C2^R?__*=W:
MB.47(BH@,, O,9FC.-^KQUVXJ6Y):QLTX\E=5+6J&1":K>5%6V0PR\$F=2AD
M*=P1\_GV&#!EK!<O;(-;KV[[=P<D/2_0 SZ9S^,D9B4=M_F/0O*)QUHT@ZR"
M.-KFIHK,';7?79!*FD<KII9LN!.M:%6EH<WF#"ZI(G0PS &HDOH#!">SQYP*
MUY29[J/')'AT6\/: =X5:J,20!K&JR"1'V;I6+?"M>)P'(YR:VPQ\M/+ACL
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MYFM#R&7<#:O(5.2([,!2>NIDHUWX2,.P6!:\_/8Y6A$4QE7]H56"^&.?LO9
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M,EE@B7U=LWXL$P.6#-@S5\@R36 )A=K4(LO8PQ(+.^0G6:8#0.E0D %E&6F
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M9[]VNMU:OX5WZ&M<1S66IG>-P$3>+*!4Y[ 6[OZ!:P4F_L8,3NUW.;C]:O<
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MQ-,CXC6J 52OIR<$7C<+MCE8L4G-NCD:TO2\"]6?V?][I$KC?_U_4$L#!!0
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M&-I;C3!Q1P"8;Y)W9IXLGO$>&94I_M2SMQ<'#*$9U,D!"P8RREN"J<UM[>V
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M=W>/2-[#T/!=O:8 26ZDURDHR_K"DSNDV/NNR69#$KY/RM *=QF#31[$XAB
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MP8D@TAVE1X]B3)U][,U.)D,558^;.'_,#>T=!=M@J04/6OA)&QO:XVM5V0)
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MY26F0RK8&-E7Z4LW(>15KJ*@P(8KOP4P2&D\X^#"VP>2\^-IP2[0JF)]?[/
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MF2I0)&2E$[<%2:CRBLH4\ZYBT@.D>75R5_?Z3K.@1T=K#TAE,'0M?6,[>XP
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ME[+[.,^)I$%H,N][=IZ"9^D =Y(W5NW>QKTEJ][&AKJ*LMM66B[5P"*IQ))
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M(8_!"PMA85[%6C@.6%OU" YDR#E,M'UOM+J.M#J?BT:3N'25Q:-%P*?#ZCM
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M=OW]*B^")>W8G:J0A[A !!+17X5,IY&=!#9?BL,HNPZ6',"M%YC0<72#4J0
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MHU>]_"8(QR+C]61U,IDX^V^D.Y4498:V^\W>HF-/RX* 0\<'_Q4$.G3>:?S
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M8JV0&@==CJ%O 26TFL!9,E5.?^9Q?=+C)G%6"9I*%-<M>P=N,KRQP#^E0\-
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M%, 05?T<$VR4+%(/FR".%5K  BL6EX>4P,G./!YUTORS+SB/2FHE=DA7^8Z
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M)1H+4XZFS#[,;Y9D4;BG%;MNQWF(0RB.#9ERN9CO?%7?/>S@'C4HX)9DF-<
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MAV5<2QFNOY!!4ZW3+H\SY8>2I6+HA4,3Y?*:,7#&\?YDW1CC-B9;KWKD?-*
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MMAT,- D2]8F0_ JE\ZUVI&Z [.RD^4!+XJA5D=2Z;..LNS<M@E>IUI@*Y6N
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MM7J0RM1)R@*W9\$-3W8Z9S#\RGGHY#HU),E&TQR'$&JGZ5HZ13-/IPP)DIU
M;;5//&^KD_DM.,#$ED-GCF/"WA)WERQ$P##W!6<L2-+\4Y_NQY9D*B8L**!4
MLGDGTFD77['AO%P[05/Z]/QV HED$ MPZSCV?*<Q=I=OM]VZ-9)$L;/'&JN
M[ C9.FZ]+MLYY7@&%\'.Z6R7]&!O/NC(=2A(#IC[<BO*>@'^?< 2,'OJBZ2\
M>>GJX,VN@J6"=W&LZVE 'LOI^Z[X]"-?Q2O9IYQ'A[/2 S (EZ\T6486\$%)
M'];?XR7E<K0855@1)IJRO/\FYF^/VN2P9^L- <#T6. (P[ -$W%@*7S#8T,3
M!2C%D1?G5MR="H(%0'CHBB?41.@I(,X*;IT\'3 >>4#")#+0Z #IM9+$WX/
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MZSQ:@\/8!%%(5CQ10$W@5H(4VKSUCFH_B5H_7Q&&X5\K'\(C8(:W66#6!,
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MJ.VC8".0A97%.#<K<NEM160,E*[C;7*;\'"[S.9Q"]W()46B2)+/WF$%6I&
MU3(OR(V#_7($O7,QQ%!K8:OQ9 =GI+2=%OR>8[XYG\4:3_^*)XLG>K_Y_.G/
MJJ_N#<WF*RC6!OWC=.17-3I>D:I<#+*2- ?0'LMTO! '! (9W=]^%'SH5KP&
MK3Q4S+ROJ2I'FT<R9856.P^'6^T\-+3:^07KB$M==KY"T.M":(^M@$.8MC@?
M ]47YQ'#;2&8#EVD1PYTCO39VF([(LEI32<BY)8 NQ86A*<7&:-( #LJWM1'
M82[&].2:8QF0 EK$(C9@ODNG2:?\%Z[,*_%8ZTK+GSN]]4\7H5YK 7HC$6"_
MWM*%(-+9,U^=;=,(]JPXF1ZB6$(PQDX(9Y(RW(Z:-K&(DYG.R1R/8.6NEKT)
M:+G!MNLMIJ!?T$U"E](Q)_[-J(*GL:%)Q;X2%E:V@^K:#,RU?VRCS9MZH-?W
M.A&2_R>Q>"&AQ<P[DK[B,C0"V^-#"KSB "U8FP=PF4HN)ECCG$VDD:M9>7^3
M)?N:7<9ZL_B8M0D1],%M<!:(;WTV8.QW%N^S(,F\SN,9?8SB^%U/I>T(]#.)
MGLM&<Q3EQCEQR5TN25<4SE^"KY?V]> \A([@OW"QQICQZ=IS/:?TAYJ"@@G[
M<*0)^U!GPEH(A1:7$Z+Y)#FC&'/TV)@%FJ(FXHUGMX'8\5/95%><?<Z.$$W(
MM[^C70G4&N=$"5(5QYOJ#@P2^?0GU&CJ=S2D=-U.O8]1TI>6DI[@ /X+33S(
M5D8J/TH\7[5D'N1CQ67;0]E;)4W\+&Y"2!HL^JR=SH:<*#28TS[HF/LXZMH5
MHU()-%I)6&4MBO0\:KV8?/HS9>$L7B3;U$U]E9FL0.UC%'_,@)YW]=-= AN>
M! B08.DY>.+,<ZGYCISW)T$/@D00%\I&(@AKWCG>FKY !H],X&DUH:;7U*#V
MI2J[@GN2SMD(N=F"NUJUD4^GST'$P&2\X@G&IIQ@0I$TU@<C<1)HZAB?Q6CC
M^Y^1]L*)^7Q*ULBT,)]?_<RG1)W,09YE\M#ZE)A^\2K)8:-50I>G)-06!2CC
M8S;(X$MK;T<(5ED BUAGO6"<>E%66L'X=G-]I3%-L*!K&JZC&.!\L4:YA=I4
M11H==T&!> ?IC2W+Q:HB%>GZQQ]L>Z4L_?VP6/ZU^4([Q"MA8,=+*Z%3)ULY
M9:>6NR.&T+4$"YOB);62;_%S_YE4OD1F]=+*'BU:VCRQU8PS/DD+-NA;Q?6^
MI>?)8Q KCLZA-3*+0MVLQ6ZC8F8D8/?B$RJKM-S*2.RQ)Z0P.LY"H8V+F"W#
M <E9Z 3N]F1E5J6@S;=9F@48=2WERUV^@O<XI= D\<VG8SE:7,EOT]2Q!R.@
ME>5\=!<%'O3DV4'BMTU?A\'?@<Y@>Z:5R=0LS/"!]?"HQ 11#-TAYC'@M:7S
M%:0JIC>NX!O95IQ<*H0.6@MD0Z<PP @DT:JEH*<Z9Q"QPD@43F8D*TQD'R 5
M[:^*K50>%,C[#7R;\"6E80JXHQ(?$/U7=W1)HV>WU 2D*P%%-4RB](WEQ'W&
M6^,0M/+07-NSV!1;0:4WU W @1'$NWG,=GD+OE;:W=U=WB^FB\MOES<+,K\B
MMW>7O\SFW^^O?R.S^_OOEQ?D:G8SO3F?3:^)>?#^7<U&'K>1(UOZDS6VK(['
M1@]J> +C6QT1/7?'\Y+(<1>E/ZX22C4^ R1'?!,FXWJ[=MI4@NS'E:!+-/0$
M$2:H4 W6DO8?;W;:4P*:<EV 60+<$LTNIKI,R#=?<U[N5:9KK.Y I N:+I,(
MF7.+;%MMRTSA%.+.3(1M;\88CW2L()B$T]&TR9T4[&*,@M4WG.M!P'(#0WF>
M4W0;.&JG%U4OT^#Y9Q;K11^*9TVTK?FO]":N"N%-^U3@Q \L6BKH4'3X(,#G
M+0N6>&)K4-$6FZ_+(0U<JO+S2%Q1,ZYO--6.Y&9U(I/I7HD[;.?>T2Q4@*L'
M.AOUTAN<783^2M[>KK2$@V2#!5O0NH&B#JV&H(TG:.60*5-7*S6R"6!%V3=F
MD:L PWH61B9AI5B^=TF%?1]L(G%Q*._ZQ9:*V^:)UJ2'.E4MEL<A8J %7S1L
M7+\EC-YEKC0U&H3LIO-;$8QV_I %@HFP@!#1T'[+R2*>?Y?HM"GA:L@*%$1,
M7RS\H$I[M7<Q)_J%T*B]8DR)G4KFUK1<VM-2ZAV3@\I[C'&&?]^FLA_!@FM\
M.D *D8!TX ==<(#KODWX<Q32\&PG!!$39GB= M8=+EL;+3DM?@!,)-$<H6\\
M4ITM&7IGQ=?PX1*QQ%,YG?FF"@Q;'OMY#F'V6.W$&6; 9C M0:_UQ"$ NV8*
MW# ?OLL9_,G:A#EO';40E:^%;LCM#LM0K$]<1<O(:]O0-M@WUZ@Z(DQW<L\X
M!KG_']J?I_/55PZ=SW@"KCBGZ\ 0)@] F3QRQ/N7E,<@#6L01"CDHY.EJK%T
M+9-^71;!Z[E0=R-9=*>&NPG6](*OQ=8_-8DR>"62++'I3@A0)K]+VMZP0!
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MXK>,--@A'(6PI^$#P813I+*(1Y$(P@CLI$B/0QY6)\H=BG+K411H/7*;<$!
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MTT>KUJIJ>8Q>/41T'6^3)O^0]>7PG)5W)O5L%HJ9C5918)7MR&0J: UD&8@
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M]*:&K-2ZA_H^NK</D**110&[X-N';/K M]E7CFG,4#L2[S^IC_YU[XD1]^N
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MT"0IQ&U5M [)EV/WS]\S9;ZI]7^\A;P&F?4.TF2^/0^0)<QJ7S0 YP1T4!4
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MV^6EVF%?9#EPW@@15J?[3:YWLJF4,;]^4X_PJ#X8II&(9Q^JR/XV+/+ %,Y
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MVK+ S*)?@]OV0:N2+^I!7SK4\ E1Y+5,7Y(BLW'6HJ]-N8#6;?IM>!"MIXW
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M,9</G16DL0%16_$\(T=@ZQ,)@87Y VZ#P& ZBY>^E<2C>)7YJ_K($$F9/K6
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M_X4I7E'F%WER^358H63330R:78J])U ;H,,;LM7D/1"Y&)I<2*R6D.3>OW7
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M0>1P[U7P05MDN@'_OG).U=^FGN;R,3AO>1BBT!0 -@?P #4-" !S5H,543I
MJ-F")0<?/[F;.07N3(C8'V29E$?;)FJS*77],^"K4F'0O<:$[[!7:(9D^3#<
MM2J:?2!T Z6EHSL,CEWEBU,-TW)8?GVOU1$($?&O1;.W7G/8B;%\7&XK2$<\
MNJN&X)"?B-RKP'\S.H_=YK.505**0Y)U'#EZAA)W%:#)N:=.KQ#VCT:;8VJ
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MX/_]=W]_:K/_\8__:C]1_WE6(_SC_P%02P,$%     @ 98EG5L!Z(R8<?P
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M@Z*'V2H..-$R67$2>M8\9'0#L;D-YV'S9 +[QW%9P-6N\KBL>C_UJ$;]'S4
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MG/RHLNU,]':C3Z\XJ S9K/[K5%,IJT2PIU.UF&I*-WZ\NZ5QY.;OTQEXJPM
M:%?M-!T?,_BL1ZR1].NA^?M4' Z^%V-OAX?>_Q=B7PKM=A,;>?/#+V?FK;>=
M;)K)P0:)O(O](PY_0:&+5N@]O8 /?>5,6]RWL8RZCV<1-Y?DQ&[Y(?C/CNNI
M6>ZE:/'QA53.^-;=^D%UEM=QM*/Y:LJO1137R8<H]E#\SV_^]#.N]O,"NX#5
MUW]^\^,W'[($)I*_:'0"_%L1'G27H\&<(ID?@6S^&#0=.@46?_[^I+!@^X]*
M/'XX*3R8KJH2CA]/"HZN6ZS$X:<3Q*'MB2NQ^-,)8B%P_)70_/D$H6$Z%DM0
M_G*"H%#=ER4@?ST#DCM*2T#^=KJ =%RR)2:G):0R/;\%''\Y+3F5[F4NL3@M
M&;7IU"XQ."W!M.M++W$X+<&TZ[XO<3@MH;05,5""<%KB)SU.H<3B%*5.9EA$
M"<HI2IZ=X(L2C%.4.EFA'B4FIRAULB)*"DS^>HJB9RMPI83BM"1/:J!,"<5I
M":#<P)P2DM.21=D!0"4>IR63\F*-2D1.2T"E!3652)RB>-J(HBJ!.$61E!^W
M52)SBO(I/3"L1.2TI%-&!%H!QM].2RQMQ+N5$)R6.-J)LRMA."U1M!7;5X)P
M6L(G.Z*PQ..TA,]6\&()PBG*FYV0R1*,TQ(Y.0&:)2"G)7HJA(*6 (TG@?[C
M8P>?._C#B-E*JGS,.+MV%/@>67Y>O>^)5.^K )LP5\G:29X)2EGR[<9Q7O(P
M7A2D2?F70SQO\8<OU4J6ZRK;- C,Y!9@)#51ZCHP*+G/DHIZ"OS)MQH9F";1
MV!K)S85X,SL8F/Y#>5K)M$@5(<:\:2V-D45AD)>BCG9; Y-NYI-4)AGI[F:7
M)K<IG X&IG_I)%N<,Q;^!V/YZ@3X.ERDETX<[^'ZX)T(N;XFSDA>9#=Y</8X
M73[]/;2@L8F].)C N+"WFYGF0C+<9QY'4_I(FJ3:1^0BG]2LNT>I'.U2NYA9
M0IS!#0DB9"Q$G='8Q+2K%((/CN_=AI?.BY\Z[;0CHM9&I)>\$!DN1)#6JY$!
M&3#%&$X7]25T,S7BOWRYB\+-"L6[!QQ201)P%L(3J>,#-S?M6:Q*3P-@WX8X
MWV04[]G@-IH8F.(RW8*RFY\K:>XGZ#1#<;&GF&AB*8\X$6F(O&LG#G%=*\ Y
MVV4DFS(0MN_ZK%V1Z&B"P%[( <35;IT$/?J;+:C-GY.\]AJ+OKA]3)!7P6)P
MZ3$6*=6;F#K(H'&^P U35$R1.,3T#MJ8>L$CBN';K[JI369AD) V1)BY59KU
M"^'FR!-9XYBBHC0B\[:1Z&I@2:1@7Z%.U3+' UN^CT*72\927;41='%"U(44
MN8X&H!=0C$FJH!;Q%A*$J)<)!K.%;<>7PZ%:)8O#4%H:4]8/H)&[8K5UPL.?
ML.":5!6$F#H"5]/7\@'C,DU)9GLA:8K[:6-4]?H;!7>DL25:,V/TQJ458S*5
M"N_A=)C5K7H9.$GBKWVX?WI>KMT1S&I]8@5O1HQ"()CS.QDR,S.JQ7$LSJP>
MIGS[!RE>WO.+W?Y-/G1H4?CWM3KW4] LT)W1$ BVLL,#A^H5M1PANK^]2S(=
M+Y_EN*CZ;NN(\9RCEL/&]=/7,9+TP%H.E]B-WCB)# >OY2#UO>ODCW !X _6
M JC"O;K^>,OA4;P"1\(C2IU@'GCHO?JLATOZRN-'.EA^R)1O.FI$A>4@];WI
M).ZV'ZV%3(4],4->+$=)?,7Q8VHLAZ?/C:<4\&,Y?M)78#.8R')4U*X\41"3
MY6"-I>15P/UDJ?BI=@'*!&:- MA\*$U\%PK"O2S'9Y#ZUX@QLQPHZ5N/%]9F
M.49R=R ]SLYR:-1.%N=F^Y.E-YN84<M%$8X"TWSH: B_EHM9/!T 13Q*,G32
M<L#$![-S^/YL*11##I\P-/1TL),0HJCQIY8C).N9TA/D6F;^M13,(4=5(ECV
M=- 379+4L%W+X9$]J8<,AI8*[8-.&2=4>138YD,_:G>A4E#TZ2 W)%KAD.K*
M_H,I8[(2!'V/ I8=1,4--"]P^WE,W*;/J/;J?G6^Q%]8^=2^/!# MRCU72<X
M9U>;2]XOV)9E3*;JD4B_!Q23)-2,14EV-KZL/)'V(DM!8_3_0.VJ[Y*=9K(,
M4K='90E%AYE,OY'.7'H-]5YF,U(I'A&9GF87)'DX>#WFL #NL6"UGL/$Q0>"
MV\6T8-0W3$/VXCD_99" KWN&SW&QTK"5G.,<3R4-&:TFB;U>^7ZX2<D,EOL%
M-6#'9&VVNGBT8=;B:[8:VK7A12VT9+U9!F?\WZ$*Q&,QQ93AJB4K%9A?F,T-
M: #MN5PXB>]*SCMO:V#2OR(<](J\Q2N*G4U1:GRY[IP<P3XH#S/CI?+V36T,
M(^GV&L=>L&VLUD82B;ZB,&.F:*E^-ID7IXQ8%:#*;F_$+I' #5K QS1$U-L8
MR?T41B5H.4T6T F0%O<SF@CP%\</[Z(D68:'O[&3*XO[S>!2N_*#+&7:XUBM
MY\/MBQG)FNA41S'".!,$4C7.L7(%)SB(2)!7<0Z8W)37QT1>3Z#X!),\P!E>
MO^/SG/G)-A?_.7F,Q?U,)-!$08#CTE$(1!, Q@MOYX<^YDCX)/.W1K*SMM2+
M>81)[(-^]8(KR+DQC@-H38[7TL1U@=*<V^.=9UT-C38FLD3N<.SX'TX>/]Y^
MP,"8M:"3F?S-")B<@*&T6YF4TK T@P,R&'F\Q>T-3/XFBN&F"?.H&W=/2GR"
M^ )44,H"%V@-;5;..V,Y*B.8W!WAP:6UG)-(JBJ*FM,",70W<;3+(Y,RF%B!
M;106Q)"W Y) "5R>L1/%(,4X\?X6]$$2E D]XXA<2.4)YVJ2XWS1&( PS6(3
M+^ Z7C-K6;!:FS:ABHQI=;,IPWHUAIL69.GG:"YFYKX&L#IVBI8EZS$5&*&:
M:0I*LX_E 0%"(U+3A]$PVE@.C;3UA_ZFCFEET0K;SSEL(=I@[\H\@!O"WRM#
MSA@1);/B1B-R>+8UR7I4%7@\A_59'LZDQ/0%ACS+H>IU"4B8#;7"-L=+0.$@
M2F!L>;"<TH&4M>-:CIG2R>3:E+4"=>QGL6G#MCQWG=*Y$UG.+0],[743=LST
MEH.D<-+86M(84;K!+.!1.F\<SXGEB<=Z'34E7XU6 (_\RE-7Q,<("3_F TJ1
M&/2&RQ_YT>0X[;3"U3R(JR-';51OX2BO%*P G.)='.-U0M=J:.Q] N'TC?0:
M*]B;'Z/XIV-YGE#=<RM*C5I&(R,UXHL9Y"A?1KN7*"1Y2MY]9C%G;A\C@8V'
M[&(U(2NYV-=_X:Q(80##R[N*=B Z2BRC:&B2I$!@$V;)82=)X?35%M+X%)'<
M1=$GA 5,6BACJX6)N.KF(>,2 +VM21H GHS(K2_:\$-#(]-MTQI<O'G.Z"*O
M[R)-8_\Y2S&?7D5* 4^:!M=&]'<@B[K[VN-'-O6SFIK8(LDX_%E$VHO 9;?3
MMLO7ZS5R@8U>9 F<K"2!3SV##([)[38LBCAV-URBE_$L0EQ$J4VG 36G/&54
MBVXFXL[IE<^X^/+[F&+=^4/WJRS&/!6!0E0$6I ?ET0= D44Q:Z?,%\D]1C(
MB"S8+-;#W2Q&X_GL$N$H&C:),XZVL_^(W)S6"W_358;2*-TBRJ%F<P+U0<:<
M_RI:43_-O!Z4QS#!U0(R;A%K=>$DN!3##EM/R+SXL?F2G;5MRA6.$<"B'PR^
MBDIE@THZK*;:YK+P?LORI/ P?"U_"%Q1:!=F\<(%X37/JL$D$.4QYL.+"L$1
MYYON<T/D'>>VG,LH? 6U@[C'/X<^\S69XB#S62:AHH&K9(PQGT7FV_"0Q>X6
M.-)RS7T8J#;&?!:9Y\4:M$;Z$*,P2(8<?.>[^((@-D300^X1CB[T$U+D6XII
M]AYWA%6FD5/-!M>I\\/B]O>*+SNU\!O^PM2&TF??JUU!J^@_4?SUU0\"3"))
MYF"XZW\B5+/8Q(C8HWCZG(YAY[!&S6LS8QJ(UG[*>21::W V+-(&__+C#T=E
MS_ORXX_&?;ETYUZS-B/7KS;&.ZUYA*NH^^*:+QNZKBY[L5+RE%&I:]6HI&0A
M1&S?9Q5#WG;B6?X&4LICWXAJI3L0[:49MO.17SVWW]4\!HXON<J6 M7/@^BX
M3NCJ)#(]BZ=R))GB@,JM.,;SO:,ZF-.\D3V^,\;Q+EO^Y%-!WJZ1UABO[8[A
M($G[_^T%2/HLT4,++'^G.91\2LO8&"_'CHQ^!#$4EK^M4Y"T%4,TQGA.-JNL
M&-(4QHKX.)7"(7U(BQ=7<BK%0]B\O4<DRQAO<^;!Z?OA)8B<&>-USC' I1J#
M8WG)8 G:8@8 35$5>-[0J,<CE5JP]7:F_N)6$=]4(F6]P: _4I2@HA*UT]0+
M>T9BE:"==2"%R*X2M+-T+Q\I5F(VQL/]8T!-8XQ:">5IRON](^!*V$:M&3AO
M[+1$W)4XGK!>,"BJK\3O-)4'6FA@:= _:P9Z @8K0$=PR5Z'1W'=<@,4*WRT
MJ@HT?&910O;22;8W0?16X3/SY"P@\^ I X=X]6$&%_O/";8K%-6#P\W"3?U7
MN/>%!1Q[#*0M\!L^ZB+DD51,=&LD+;Y;HI?9G"$E+8F@YW8Q4VJ,1@I51K:A
M-,4;Z%Q936E/;L-7N,<T[ EO('T/<@YV3LQSX?MYKK52J0/:C^)'0'G32H!;
MZTCC!%K&-9*VH%3/DE7TB$!"P3=7@]96D9ZC.,JGC!2:A:O8]7/O%7H)$)&B
M0F_!?L"EU-5$BI6"YV,9%?[S<!)#CW+[8OM&$"69L$S\X&$UOM>O1;ZCYS0W
MK9(DDKGL?M %\<_7[Z %AAO^XZ[!8YHIL$:2PE^A_']KAZLP:(E+E\L.,(OE
M+5QB6DJ WR#_E9,]4*JK-GJLA2V3[,_XFBCHB7C#VU[R6GL:*0X9SL0[0V=?
M7 /D]HL1<'R@(C@Q 1P7G D;_OI".7<]!C!>@K;B=&6:[](\+%>,EM-=7^*,
M0F]N2"[]Y*"^0\V"6> +*H0/^<SJM?P^&J^KEYS"E^NJGL<RA(/\1.P*#ULG
MWCFDW ?]8I+N/6LU8K#Z, ^J(D@?+A%YTNITU%A]G*@DC4-*B02A$9=LUUE
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M9&_1#MTB0^/%DO4L08.LH/*RRMZ*#JHR@0K96E[N0<]-K_((;A1 (YR[<!:
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MQ7"*$A71L:V Q&#$NA%<HY1&MP$JQ0@R6ZN #^-C[%BV4<J"'S->S#"Z4:J
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M\(\OC_AA+&5NS=^FG P]/J[UJY'49H2)/#AQNB>/YAR2)#FYV-=_X>8ODQ[
M\/($^1H[#2<BCT_.N[_+=DP":?X^@S//Q9'1V$1NI3#U/3_(<&WE)URA&FX+
ME%R_YP6I;^ 6SRMQ%.^CROK4#RA^VL*U?[&G#\ Y"F-^<38 "I_4"+N9J'L6
M(&\#6#]D\4N4<"L]4EJ:GS"__"&UK3;[<9TSWD<I2AZ</18_V!'?@AY&BL:E
MP)26ZTL0=GU^'49J4R/YX)]3:>\KH[&!:>,T\.G^,RA%0([NUJDEQ.)G$9;H
M:&@7#F+WG>!]%JOU&!/__:=JUDF6S_SWGSASOTV2#,YD[(>N_^*PLNSR^VCC
M*4\H!+64W [((RSB*D.KMVBUC;+$";W5&WQ]_^2_LYF,ZA!327-^R)?F&K\/
MG%2"W.\VT>M'].YNBTG!?QTFA/_UY=>GQ2^MB1S^KFU'FX2#C["S31"0CMO6
M:(7-C:@)KU'P"G=HSO5O')>4FN<R+'X?$V$\<.W?14FR#)^< "7+]5T$ZAC[
MV1J[O;YW8K"['JGME&%4L"F<\U",V5CC"[HT<X++/ X<Y%-8+%D[=3JLMB8J
MPU:S("IVD%LXO=^R)"TJ9RW7*^<]3S-R&[HQ+A%UA?+_96S_L#'U/<TM;Y=%
M"&P\7+Z0##[AIC!RTG9&U$7;W,I5XXIZQ2<OG, )Z3R-T]I$RH#L.8H]/\PK
M)SZSF$"GF3;P+IUD^XA(\#8E$3NUB;9OWP!80-CA8A=E]$^W6A@1+6/_E9R_
MPT6(R[O]"[0YE-SYSC.^3_P.<U+O;R1#!RA1*$F+(WD1Q7'TAHT=C,6PVVNC
M"2PC5@?S$7EY-3@VA7#;:]2N7PIUI_K6+4X7Y6)_Q8;*9T1=1IC;KWZZQ8=U
M&?X+1&O^I%IM-?,3%V%7&[:E/1#?'+:H.>&>S5U8'?3)%!O04_%KK\.UQ*0I
M9EMML_D<XF,$<C3P<PP ;1:=-MJ^7F@W$JR?T5*C6!'M_"2)8F*!HDL1C1;:
MOKS,TB0%RL<6N>8NYZ(4;2["/B9,D,V)U*98: K_0@'(A0]1G*ZCP&<%R2L/
M8]S*DT/NNP_.GOQ3R63"[&Q\6>45^PCLYWJ]1BX6'9@W3;\QC"PRCV&X 1D6
M1.W+*.&E:F&U-J2N)UC_!M4[O'['"DSF)UL,\W+-D=C%_?2)T8X?_]L),I8J
MR6BD\<J/XSVLCPQ?JE=4!LIH:>9- 5 63"47/;#?XV IBL)7%).8'5P= K,_
MQB:KCF*D4&"(2C=):?RJ\X>K+,;7&>W.ZS6$Z4@O3JQ.HPP(-4+&OMPJU# ;
M$KW6#GFQ;^W]@V>:6?V[L2GV8<6(@"HII17]8M_Z92+G>/S#7LJ8,%"GD199
M&-9B+]2<.)@Z1(SH$WMQ88<)5O'8HC 8RY^3<0.2&OR+&FIC+^GPXW3JR% %
M2'N!D0T?K$,D$SUD^4$31!RQ":H3X&,Y4/RPY(IO*X<:60Z;0(UMJ77V91@4
MZ2/-^"W[UB]]H=>"Q^Q%08+;BL/;+'_0+F:TDF%TEN,D:2"DZF#VEG=3D&<X
M 8R6)RZ0E&4XX92G0D"<&JGRMM@QDC',$2SV?<8.A#T5;)B$-*HY<HQD%'-$
ME\OG!T8S6Y[00Y),F7A;GG!#EL,)X\K'P.EHCJ(PO'V,#")'@PX[AKZ Y:\G
M?K@Z 9X%+G\[27*A/CDH$/GY)!'I\<:A- Z<AMV5BQKG\42)TFG84-BGC?^8
MHT3)5G.!+$K"QR4E4-9K>S(8M1^YE."<IK(F\^:F1.C4=0WV$Z 2H=.4HQDO
MDDI0M$K1QP4*ZZ%4"<T)"]+MEULE)*<I24L^*2O-_V?IN<>[M1*\$Q:J55_"
ME9"=L(3=\Y5=B9RMF<"5D&,\W2LQ.@T3/Q<CB5>")5IZI/!F =.CP8OU7K$$
MYX0%<-8KRA*:TQ3#>[_7+&'3*J(?)W.Z4WH"6@*G59"?4]51C-Q3MMLY\7ZY
M/EAME^O5%CV1X4C\,5!5XB?$I71TR>J/,"-IDYX789@Y027)%I(M9Q'"KL:7
M]#ET\N(00%& ."7WC'P_ XNI3P//+TDR+ W2\[])=C*1HB_:[4#,]S%AO*!X
MD3:N7<8R!)T,D=9E%L?\0U&V,##!9;I%,8Z77!7QDHQI=MN92,*W!2(M SLK
MZ90Q8T9CX_Q%-&]6ZSD(,GU>YK&NB!-X&-0'+NKUHS74?ZXJJ1Q:HOM-:^3V
M<4,END,M+Z*G=@*K6UIK/.QQ$Q!%.#B!<%@Y;%BRB-V1GGUNM"XXH\9[3F^R
M>'6_.E_B+^2] FX.$\I?WD]KD6 5AV!-JV.+*@11V5Y&DF@6E/&41NY7,L=D
MD:5P%+$\P!"H!9T,+ ._25NN%W&,'TX3&9E=08G>UD3]JL,4DOP1@'/X2_V)
M&+?,@^HH)DP/@9,DRS6A%FZE*$I#$THQBO%[J":5<_> UT-3"14/^?G<X3\.
M4X9_?+D#42BX#E.?6@:1UF+T*>7?HFYUYV<3&XRWI\&*L=U;8# 6=-)7>HAU
M3]"JK\KT, (P".>8_^33P?&844@8%)LM\_L8JQ16S8/+N.AMM='$KX2EY]P<
M.$R5<XA=JT;0PR1-U)F\##UTVANQD^*7L]@MC?<8P9V:JPF'J_=B?VA36.06
M;T[LD?]#\BF&WD/@A,+RE*-\2C<ETD426@L3<E6% Z<4:J.-/N8=$9M'M (U
MWWE!6>J[R6WH<JK$<3M,5!-NA=6HY?HV]/Q7W\N< +\T(%D)L-RX]5]6$>=&
M[S."/L"!X281IVA7LX$I0!FEONGMC*N!#TZ\C G_]8B9H4P=(*4.,CL;\GE&
MH5A^[[;3EZ+>CY.4Y$4!AH[BU%_[T)ELNAO%+U%,C@B;?I7ZFX58TGK ZV&<
M]+EDHDF_8]8<=:/0&T J:@/,@5;RE)"R=%*TU@9X+K1W$GFR >9WF .@M<<$
MLJC6NYA=@N*U(]-37]$DDF8ASB7OY"E[_@VYZ2IZB)+$)Q&9'MH1<SN-;N0[
M&^=_$N>2TV$FTQ>? E$O PLI]290WA[]S3:MSP=["QDK$78SI2W32BM3&I@S
M1Q?(+6."V_4[=NP7*3.K'Y/BU^0'OL5:<:RY+%KBNA!U,V6^S3E./8 [/\7W
MZ(W\Q#8K276>RP[EB127ZT.>MDLG")!WL;]VW&VSK<H6*HT[GSTFMWO/+6[U
MU5?)L9 '"Q,EOS8JN[$^/2*-,S<E"[]!]-+A[2;&<EVKN=.;KVCYCNLQ@B%?
M4?P<S26PANOR;N2+5'4SVUOR@>V(;@0B\?R_]H'#\2%C5+K^7/L@4',,'THW
M"%RU-@,EX>#M%D[I.%/M1:AG<$]%6R*7K^7!_D)O<2,LF\+6[:6L,7W1;?*S
MO:B10L1-0T+@LS][:8_J6F\&<8]!G/8!RHJ2.\@6_$@"6\]C_VB$ W+-D(!3
M0HI6ZE@93OL.FS8S ]M#-4;IH%F9&^149TK A;VUN8:*^&JA(986I^HI@;4$
M$?N(; #/XH;D6%ZH2HY-<4U[MD(SE%TIQB=9BF9/?L6PUMM7%4TGWRK#4"Q_
M5C_T8 KBV.PKF*9X!JD.CE-#1>WD-0)#+*UGIDA%'(7;OJ)Y>FA)J"[;EO1B
MJ#FYZ^RPKPA<#])2C< =(V/(+(PQJBQ+%FK[4JQHCBQJ2:):TZT< 64IXT63
M'[3F(SYVT,31WF/4YYO]%<G%K!Y6/DHUOF,GJIZ![;;6[-.-)(VI65?";\CY
ME(S+'Z6HGY5G5RWZ?Y1Z@%:29/L9@:UU OOJ6IPG#:,4##QBJ#JO+48I'CB;
ME(R/*"F-%=$:)/]7/\J28)\?L:)4B1-4!HUD#B4D!,DZ+B/X6)C4IG\;KJ-X
M1V:W7#=*BB[#8"\L,:%I4../:0\F%2([*F4!8?4UL*A;(+1P@VU$BR1!:<*O
M'L!J;3+.2Q^%LO5VYF9;'#\W#JY,>ILB@L=<KEYWB[PL0-':![Q<N!W2+7S)
M\7[+DI1<!6D$?UF72%?7B).\5-=(C%XB4LZJ8<D\BCOC<.5=.F0OV=F E?L;
MJ; 1^Z\.K@UYYSO/N'"6SWQO2V\[4:JMFD#"2++5;C']Q)AIT[IM)II<>5J7
M:QXE4C..*O;6]ZRY^N@M83"D:EF"%@<&L\+!\MV)+)*#G/I8,!B6Y#;>AR;;
M6!0Z<+MT9T)/:R33Q0#[$3,=PZRF(@8FK+S6)C*D@W07Q4Z\+YXL%85+\AK4
MBS2-_><LQ2=V%>5R#P-W]7&T<8#:":R!^R,[7Q>_@]ED5Z*J:XUF^B L@6"P
M VH;$RE</<_/!>('Q_=N0Y")_!1+QU2\6*T-3/P1VSM"Y%T[<8AK:RY<-]ME
M@4.J::Y]UV>=*XF.L\B4SI@^I>&\-#L)^;Q9<(4J_UJ;580C2I?!;Q2!UL*G
M8OV$8PI&MCX%'E\8+\%4V@<+@>8ID0>,1/+^2=GO%+D\C;=;%P4QC*,I8FSA
M0SR98\A5#2TFK,$GL(=:.L:;J3G*8(ST!@(MV-9G=SJ(K:M^C_$*Z)AHJ6,.
ML/2IG1;R81HEQGC_,QLJ&@R;C$EDC&<N]B!(L\*,\63#O#/YX&'/(_="''?F
MO^*<4->[ER#:(W2!0J":%*>(2@YR+6F^S+'$O#W?VR3)\IB&SPDF-O.A2"H>
MV H*++4?<FF1U#TXO5:2)B1$X[F622L1%#$<.*@)"^1ABWNG%J/Y,?6//Y47
M"D^'Y>JN?IMR,FP76.U7 Z13\8$5<K>A_WO&+[S';*[-^W(1..Y7(#C@=,FR
MBK4"EO@)I=N(XY*1ZSC1GG_R0W^7[9B[WOQ]CL4:6>>X<PFW><7P@4W!\2R>
M]7-[UN5U"BH"\GY%^)$!\A8@5CD;] M^>7 %=T:M%CT;LPF^/@O^PBDXR6@\
MU9EUWOEGMO'[,9W9B@(.PEYR_?Z"7*Q>X"P-(+\] J7H/M+2W[4%S']'.&5D
M (H&7E;!Y*=$E3X!2^'-SZ-!>(L)'#N\CW[R]29&Z#8$Y1:NDHEIE_=Y*Z&=
MCFYYGS\F*8MW)G$F %;EL1$_>"X#.;.CUGC#/\VE4/^@Z01Y>DQA#8NJ/JN2
MI8$G;2M3Y>FN6WSL6[NL[:ARH4G:=.Q#BF'^*^FD926R- I)O\FID_!F"LN-
M[;NCVX=0WR26%<B^$R]G]^)C8W?D,(\?-BUPEL:$3< /QS426E_'8Q1>V)(8
M[0L"/4*Z9MAK+8T/G.2JU['[]F7\/_ZS41HM+0U^/*(-XIKK+<U#?^S;TSH]
MMN70FZF*+^$VL#8-^KA;HE+ P+Y$X$?$C5I>D3'2C%L2$5W+7+QPH?<AL>4Y
M&OJXHJ'[GI\N(>2YA74[$YG?.4*PB*4\N0WSG,&_Q%&B/3"4\R53V3Y8";SK
M_*3DO!X+#_6!CI ^;J)XC?PTPQ4V@1N_O_AY!<1J(T>B%O%WCQ!,8YSIRY^.
M$:[BX&!+U:AP=;]SA&#5]KSE#!TUL$;QZW,$EFDCI5Y<8X"K<0;'"'"Y J,8
MJTUBCC /O5$-L(UA<SK"33@*+OWEA^^/$=O:-6X 6]FO'R&P-;*Y#5-0=1+?
M%3Z'&^5[I@V&(P3IZE<IQ@@[>LEUV]2)TWF8;N>W$U1+BN4A4"/L0@_SC-9P
M@Y]SD$.T<7(OD\58CV\;TAIM<-Z:01:@46(+\HOA.O3..R%MQ+(\B&!^>R"M
M=8T137 6G?2:V,:(2CCMTZ/9/C=%C,)I;="XECU+B[#/=[\4S'#CU( _"VVZ
M3(FVEI6?[]9PC)&3E*N??73<(8-OK=#GD47"X87<.SM^+L-6(VT9#%=OT6H;
M90D0V1-Z!7P0"O.,M!7T^-/L3(9J Y@H?'D.-!SE'=7LTZXJ@%-LVP.HK?L5
MS#.!3<+\]V)?_X63#%!A ,/+XW(92D,3J8,")TF*>&?N="D-S68ZHK))=CN-
MI53Q]?H AVKGL%DUI961ZNUP_:,J8?H=_@CF#^S#Q>LQGP5P*97?QTAD<#&5
M^AGB[ &[_1Q]_,P;)K]F8&H@3TK)7:-\2MNY_QR^DHPPI6@,G[J/PO)?-0\B
MFRFH#F&B=FB%))L^FVWF2).GE:.Z=MD5555RK_8C*&'Q*_)NHO@FPU8\[/YV
M0F:DDOHX!A:[?$'8"!EN\'O-,*'GSQ<T-C#MDBMQCE6CR1A*YST0*589:XQ&
M6M_D]STF'D#^#T[N!63QB$UPVID!Y0MC;.?J#3ZXAS_TM2%(#'!,&YM[P0N=
M.%EDZ3:*_3_8SZRT?V?<3:Y+"0]9[&YA7CVV6C#,,6UX:;A-MR@&XHT1-$BN
M4/$?I8_J"B5N[).F8X65RD_@F."%V6.&X&S0<ETSCN=*]3BIJF4^J>V4=<4=
MLH=X,D+)Y]IQM_]!#O78:1GWF BEQ1!?'3_ QD58' F_&)G_=CYW3-"9?K]I
M JSJ"H(CX+N(OB;0BW-=F4P_645P=NJ_8ZO_?93^!Z6/R(TV(;Z ZU&\# "G
M^;8V%M7R$>?WR1+^03M8,CUF<S:4"-R(*PNM<=W-F@/T,@KSBLJYLZ$@)=91
ME>]OVA5/M\U5.;H5O9:69T,^9],W KNZT[!91+?KD[,7*[9+CY&HR]XT^V*G
M;,7F:&X]RWF9A'>P3C$"7YR]U"/TWS7.%>7T60S-B-[!ZF@J>][LQ9OJGM,3
MD\_;$'L!U>=*9%RNLAZYT[QKV/()R\]G,2F.F7V]Z7^T%T2:GY6&@_V<35ZM
M%_B%+4\U,,X-H-4];?L.C,GXN$J.O;56Y$^_3!B![75/YL4"V($,MN_#F(Q
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MF2_B759QNXK/_>'HJW*@F3!V CJX2R<I"A1X1O!LJ12?M1R?61;(\X*7$0>
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M!>$O8_3Q"&LF@-%829O3"!(K4%ZIQ-)Q*FVBM*TQCDPP6@7<5$8G(L5IRPX
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MB_$B?78QO8?]BX1]?!?VCRY^6^A_?-E\=!) XIC)E+#-K2XY\0-ND1>HPR7
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M_]2E?Z?''K9[OZR-H?:)1U#?O);O>FWW&2*:-M7.%/I*K$D"L+3)2]O%B12
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M!AW)%_]KK)/Y_(^X4Y4V)5>_V[VZBA8>_74+.7D5A?^_;BVO'EG+F9%<+5?
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MA!902JO0PQ/$9A(UP@A;@SS1[*2WAFDZPS*G&):Q9+[NAFX'WQZ,.P_&DR?
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M75#=F!HYP'J>GZ;:9-X WP-/1 7ZKI *<$7XAPLD@OX^P!VI2-9@ CL7S7O
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MN\]@^QMM]LH\CE[;:6.7#-N?@,ZRE,X)\12K2#1(/ ED$A9Z+0= -XJX)9*
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MH L KUQ;6P':"M (6,\OR(?SJXOI;$8^O)E>3M^>=7??;@)IA7S'=V?*-R^
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M9M";5O<;G"V)519;N#MD9&2/='0GV+USW<+L>1> #()]<?;>%,T'/@^2JDF
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MV^U5P_92;GLE-]31[J>DCPX&_2.O[>W2.6E') USVZI@@J)9EYX:!4HJLP*
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MWDX9_JE$Y%;+['XMH#L(-2?5(^M&@$X'*/Q )>R@IA*M,XD1S\98157PV.W
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M0'&E%W"*>IO"$3B!B0_P&>D4J"@=!F@M  F0BJW-J2;6]N&V=6ZXHY)\4U_
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M ^HO>ADDO=G?8=C81Q&7#T4)!FP3C:T\0$8Z2C'8,>1T%*>C^+X?Q>B-43-
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MZT]F3;GY^W]\_<FR7U5___]02P$"% ,4    " !EB6=6$HLWSJ]I  "0@P
M$@              @ $     :6UG,C0X-#(R-C<P7S N:G!G4$L! A0#%
M  @ 98EG5MBHK5'GU   ,L\! !(              ( !WVD  &EM9S(T.#0R
M,C8W,%\Q+FIP9U!+ 0(4 Q0    ( &6)9U;Y*>-OY)   +.J   3
M      "  ?8^ 0!I;6<R-#@T,C(V-S!?,3 N:G!G4$L! A0#%     @ 98EG
M5O/DTVZRHP  Z<$  !,              ( !"] ! &EM9S(T.#0R,C8W,%\Q
M,2YJ<&=02P$"% ,4    " !EB6=6ED%M1@SU  !(#P$ $P
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M-#@T,C(V-S!?,BYJ<&=02P$"% ,4    " !EB6=656^IN^<; 0!H*P$ $@
M            @ %!6@@ :6UG,C0X-#(R-C<P7S,N:G!G4$L! A0#%     @
M98EG5D12F;XO\0  'P ! !(              ( !6'8) &EM9S(T.#0R,C8W
M,%\T+FIP9U!+ 0(4 Q0    ( &6)9U8[UTHE8W8   VR   2
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M-#(R-C<P7SDN:G!G4$L! A0#%     @ 98EG5MF@:[3<-@8 1,]. !$
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M%P!S8VQX+65X,C-?,2YH=&U02P$"% ,4    " !EB6=6'J@^*@X(   _/P
M#P              @ $GBA< <V-L>"UE>#,Q7S$N:'1M4$L! A0#%     @
M98EG5HX0A0,?"   )3X   \              ( !8I(7 '-C;'@M97@S,5\R
M+FAT;5!+ 0(4 Q0    ( &6)9U:A=)I?; 8   LW   /              "
M :Z:%P!S8VQX+65X,S)?,2YH=&U02P$"% ,4    " !EB6=6J>ATO3E"  !^
M80( #@              @ %'H1< <V-L>"UE>#1?,BYH=&U02P4&     !L
,&P# !@  K.,7

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
